,ticker,content
0,GILD,gilead science gild hepatitis downfall accelerate first quarter sale decline widest margin period prod share topple hour trading tuesday biotech leader also report total sale adjust profit lag street forecast further reiterate sale guidance miss hour trading stock market today gilead plunge end regular session fraction sale hepatitis drug harvoni sovaldi epclusa rake decline be single biggest year year decline quarters gilead start report sale hepatitis drug separately other antiviral product hepatitis drug sale narrowly top consensus model accord report mizuho analyst salim sy last week still investor be wonder sale hepatitis drug stabilize say get newsletter deliver inbox more info product service privacy policy term use recall fourth quarter call management comment anticipate patient market share pricing stabilize mid more predictable decline patient start write quarter sale harvoni sovaldi decline major market sale epclusa also fall gilead say news release gilead cite increase competition challenge hepatitis drug harvoni lag sale view sale hiv hepatitis drug climb new hiv drug biktarvy bring just sale miss consensus accord sy week report rbc analyst brian abraham say consensus number biktarvy be overly bullish also note uptake cancer treatment yescarta acquire kite pharma last year be strong sale vs consensus view strong yescarta offset soft hiv hepatitis drug sale say rest look better total revenue decline nearly sale miss consensus analyst poll zack investment research adjust profit share lag cent fall nearly year year year gilead reiterate guidance product sale consensus modeled adjust profit share revenue related much volume look stock long term retirement investing strategy etfsstill rule stock investor always cut loss short
1,GILD,glaxosmithkline gsk pop month high thursday drug hiv treatment prove inferior drug regimen used medicine gilead science gild stock market today glaxo share jump close glaxo stock be form cup base buy point gilead share lift close analyst say glaxo be unlikely get much share gilead hiv dual regimen look competitive ideal circumstance real world even very sick patient don always take medicine mean become resistant drug think concern potential resistance emergence real world use limit adoption dual regimen rbc analyst brian abraham say note client do not see much incentive physician prescribe dual hiv cocktail take chance get newsletter deliver inbox more info product service privacy policy term useglaxo viiv healthcare test combination drug tivicay epivir respectively group never treat hiv patient compare regimen used drug combo gilead call truvada own tivicay tivicay epivir be not inferior drug regimen week none patient experience virological failure develop treatment related resistance glaxo say news release virological failure occur treatment doesn sufficiently suppress virus key detail such rate virological failure be important understand competitively regimen behave be not yet disclose abraham say glaxo say expect further datum upcoming medical conference real world perspective be important look patient didn always take medicine evercore analyst umer raffat say report abraham note viiv best interest push drug regimen biotech previously test medicine combination include abacavir abacavir have safety issue include potential cardiovascular risk gilead triple regimen such biktarvy do not share liability say advent gilead tenofovir alafenamide long term renal bone safety issue gilead regimen have be mitigate further have be question regard liver toxicity birth defect tie glaxo drug tivicay also limit appeal new regimen contain tivicay say related invest stock free new apps aim beginnersnew option strategy limit risk earningsstill rule stock investor always cut loss short
2,GILD,agreement dow jone component pfizer pfe defer drug price increase effort play nice president donald trump lead analyst wednesday question fallout drug giant action be industry analyst wonder other pharmaceutical company follow pfizer example notably celgene celg be still go ahead increase blockbuster cancer drug revlimid pomalyst rbc capital market analyst brian abraham say report pfizer unprecedented reversal early july price increase mark tangible administrative influence morgan stanley analyst david risinger say report client note pfizer be await more detail so call blueprint tug drug price late tuesday pfizer say chief executive ian read have extensive discussion trump lead company back price increase drug have be effective july earlier week trump attack pfizer other raise drug price reason get newsletter deliver inbox more info product service privacy policy term use pfizer share president concern patient commitment provide affordable access medicine need read say written statement also note pfizer have commit capital expand manufacturing not everyone jived pfizer trump announcement sen ron wyden ore call pfizer trump administration reveal detail arrangement lead pfizer back drug price increase secret sweetheart arrangement big pharma company be exactly america drug pricing system be break tweet trump admin be busy try score cheap pr point pharma company continue raise price double digit pfizer stock dip close broadly share pharmaceutical company fall same amount stock market today trump renew pledge lower cost prescription medicine time analyst largely say propose blueprint appear be more rhetoric reform morgan stanley risinger believe pfizer price increase reversal have slightly negative implication second quarter earning season note pfizer update guidance commentary be key later month addition news put term damper future price increase action other pharma bio company say pfizer indicated action be temporary only commit keep price unchanged end other pharmaceutical company also rethink guidance say manufacturer limit price increase year hold entirely customary january increase be key swing factor earning think be underestimated market say even celgene price increase revlimid pomalyst remain line medical inflation rbc abraham say be also historical increase meanwhile gilead science gild joined pfizer walk back plan price increase note see more re-serve price increase increase transparency potentially temper headline risk public scrutiny have be experience pfizer line view company self polouse price increase much larger degree now say also wednesday pfizer announce split business distinct unit contend loom loss exclusivity restructure pfizer innovative medicine division include biosimilar infection drug sterile injectable establish medicine unit include patent brand generic drug finally company consumer healthcare branch hold counter medicine innovative medicine run current innovative health business well new hospital medicine business unit pfizer also incorporate biosimilar portfolio oncology inflammation immunology unit establish medicine hold majority pfizer patent drug include lyrica cholesterol drug lipitor high blood pressure drug norvasc erectile dysfunction drug viagra business run globally unit be meant operate true stand alone business pfizer company say news release have own manufacturing marketing regulatory exception enable function consumer healthcare other hand differ pfizer prescription medicine business pfizer say firm confirm still mull strategic alternative unit expect make decision end year trend consumerism increase focus stay healthy be cause consumer seek easily accessible health wellness solution firm say company believe business be well position continue growth get instant access more trading idea exclusive stock list ibd proprietary rating only related much money do need start investing trade stock most penny stock fail make investor richnew option strategy limit risk earning
3,GILD,first half have be dichotomy have have not biotech company wall street brokerage say case have aren large cap biotech company celgene celg biogen biib gilead science gild have struggle negative clinical study regulatory delay key drug instead small midcap biotech company be lead pack rbc capital market analyst call tale biotechs multiple large cap biotech company have slip sale projection have take beating meanwhile price quality asset small midcap biotech company have never be higher competition fierce generalist be able hold smaller cap company be tend invest ishare nasdaq biotechnology index ibb rather just handful large cap rbc write note client week short capital be be deploy biotech just primarily smaller cap name get newsletter deliver inbox more info product service privacy policy term useon stock market today ishare nasdaq biotechnology exchange trade fund fall spdr biotech etf xbi topple biotech stock be now rank industry group ibd track just week struggle large cap space biotech company have be well document street isn entirely hopeful biogen potential alzheimer disease treatment biogen be develop drug call ban eisai same time other potential catalyst have left biotech stock want clinical study gilead alexion pharmaceutical alxn aimmune therapeutic aimt be anticlimactic rbc analyst write celgene suffer massive hit food drug administration delay experimental multiple sclerosis drug ozanimod news be fuel continue question company ability succeed second third act cash flow expire patent cliff rbc analyst say note biotech company appear have good launch new drug list amgen amgn migraine prevention treatment aimovig gilead biktarvy hiv medication even aren enough offset underlie revenue issue analyst say investor be seemingly take dim view large cap biotech stock investor survey suggest worsening generalist sentiment reticence come back space anecdotal feedback suggest frustration challenge company celgene have lead many rotate sector sense few be look dip to back write however small midcap space not be behave more differently innovation gene therapy cellular therapy result acquisition year novartis nvs buy avexis celgene acquire juno therapeutic be help send other cut edge biotech stock sarepta therapeutic srpt sage therapeutic sage sarepta be now fly high datum gene therapy form muscular dystrophy sage be work number depression drug fact biopharma merger acquisition activity term dollar have nearly triple see mid june rbc analyst say ipo initial public offer secondary activity have remain vibrant biotech ipos so far year raise aggregate takeout occur small midcap biotech company analyst list sage sarepta biomarin pharmaceutical bmrn exelixis exel seattle genetic sgen tesaro tsro clovis oncology clvs puma biotechnology pbyi pharmaceutical aldr potential target even small midcap biotech stock be walking thin line say be right side catalyst likely be key second half analyst say capital inflow cool drug pricing rhetoric potentially re escalate go midterm election hiccup emerge early stage modality drug related chart read basic buy point mark time real trade stock most penny stock fail make investor richnew option strategy limit risk earning
4,GILD,find best biotech company invest be tricky volatility often pockmark space clinical plan don always come fruition sometimes biotech stock suffer hand regulatory decision food drug administration best biotech company invest tend have commonality strong streak earning growth june investor business daily marketsmith com have biotech stock strong list fastest grow stock top list fastest grow stock supernus pharmaceutical supn be rank eighth past year earning share have grow massive compare top earn stock momo momo chinese social medium firm supernus have make name biotech stock term market cap still trail bigger biotech company amgen amgn gilead science gild biogen biib celgene celg supernus land list consider best biotech company invest strong metric always do research buy stock be sure check company stock chart make sure right time buy have several year double digit quarterly sale growth drug help disorder central nervous system supernus count epilepsy drug oxtellar xr extend release trokendi xr trokendi xr be also approve prevent migraine rival drug botox allergan agn amgen aimovig ligand pharmaceutical lgnd be unique biotech stock ibd rank fastest grow stock put research list possible best biotech company invest doesn market single drug instead ligand acquire early stage technology necessary drug development then license platform pharmaceutical company dow jone stock merck mrk pfizer pfe june ligand have year double digit sale earning growth belt ligand supernus have ibd composite rating meaning perform top stock term key growth metric duo lead other biotech stock term cr get instant access more trading idea exclusive stock list ibd proprietary rating only related chart read basic buy point mark time real build long term profit stock take many gain trade stock most penny stock fail make investor rich
5,GILD,celgene celg topple year low thursday appear list food drug administration try shame drugmaker work block generic competition pharmaceutical biotech company be gaming system limit access drug generic rival need do equivalence study fda say analyst expect so call shame list have little more headline impact company total celgene receive inquiry sample drug revlimid pomalyst thalomid have risk evaluation mitigation strategy rem program ensure benefit drug outweigh risk drug have certain distribution requirement celgene reportedly say biotech company want access drug need follow specific rule biotech say already have provide sample company fulfilled requirement rbc analyst brian abraham say get newsletter deliver inbox more info product service privacy policy term use such celgene be putt understandably high barrier believe generic company willing put appropriate safeguard have already be able obtain revlimid conduct study say note client inclusion celgene list be unlikely speed generic competition revlimid william say now drug be gate more intellectual property regulatory question say mizuho analyst salim sy agree celgene be already work generic litigation regard revlimid analyst expect copycat drug believe be more modest headline risk actual business risk say report stock market today celgene share dip close earlier slip low last see june meanwhile collective share biotech pharmaceutical company lift fraction other key drug list include biogen biib multiple sclerosis medicine tecfidera well gilead science letairis truvada letairis treat pulmonary arterial hypertension truvada treat hiv rbc analyst kennen mackay note fda also include biomarin pharmaceutical bmrn kuvan kuvan treat condition associate elevated amino acid biomarin share dip still biomarin have already settle several general pharmaceutical company generic entry patent expire further fda list publicize effort prevent generic entry actual policy have be put place diminish strategy brand manufacturer employ limit access brand drug say related do spot major market top easy look heavy term retirement investing strategy etfssell take profit hold here be several guideline follow
6,GILD,do novartis nvs amgen amgn merck mrk pfizer pfe celgene celg gilead science gild baxter international bax eli lilly lly have common have licensing other business relationship ligand pharmaceutical lgnd ligand be recently add ibd list top growth stock be lead biotech stock
7,GILD,abbvie abbv celgene celg regeneron pharmaceutical regn spike second half accelerate number drug approval launch analyst say wednesday reverse trend first half year see share biotech stock slip industry group track investor business daily group be rank fifth just week meanwhile pharmaceutical company be rank leerink analyst classify first half disappointing large cap biopharma company biotech stock pharmaceutical company face dearth clinical study result validate pipeline re price stock say second half year promise be more exciting small mid cap biopharma stock significant clinical event horizon include readout binary phase trial write note client get newsletter deliver inbox more info product service privacy policy term other biotech stock pharmaceutical company abbvie be expect report datum study drug upadacitinib researcher be look drug treatment form arthritis further food drug administration likely decide approve abbvie drug call elagolix treatment endometriosis condition female reproductive system fda also decide fate drug dub venclexta form leukemia stock market tracker also expect celgene unveil datum late stage study revlimid celgene partner acceleron pharma xlrn blood disease revlimid be celgene major cancer drug celgene also reveal more juno therapeutic acquisition be move class cancer therapy know car short chimeric antigen receptor cell therapy compete novartis nvs gilead science gild datum car development update define path forward product revlimid leerink analyst geoffrey porge say note porge also expect fda make decision regeneron sanofi sny dupixent asthma treatment physician already use dupixent treat eczema duo also have cemiplimab fda be consider advanced form skin cancer addition intra cellular therapy itci be work drug dub lumateperone schizophrenia treatment analyst focus fda accept application approval base mixed phase datum porge say intra cellular also report topline datum ongoing phase study bipolar depression second half look second indication lumateperone say porge expect zogenix zgnx have datum late stage study drug zx researcher be consider drug treatment type epilepsy call dravet syndrome gw pharmaceutical gwph drug epidiolex likely gain approval use june additionally dova pharmaceutical dova fibrogen fgen have catalyst chronic liver chronic kidney disease respectively dova expect fda soon decide approve drug fibrogen expect unveil topline datum study drug second half year fda be also take flexible stance orphan drug development leerink analyst joseph schwartz say note approval sarepta therapeutic srpt duchenne muscular dystrophy drug exondys trigger cascade noteworthy filing say continue believe fda continue evolution warrant positive sentiment rare disease focuse company particularly name amicus therapeutic fold sarepta uniqure qure long investigational drug be deem safe demonstrate strong effectiveness say related much money do need start investing look best stock buy watch start herestill rule stock investor always cut loss short
8,GILD,gilead science gild tumble month low wednesday report part miss produce first significant disappointment large biotech earning season accord leerink analyst wall street estimate be too bullish total revenue hiv drug sale falter hepatitis franchise leerink analyst geoffrey porge say note client cut revenue forecast estimate be consistently too high fail incorporate increasingly acute reduction channel inventory net price dominate gilead first quarter result undermined report sale say result gilead total revenue lag porge model hepatitis drug sale miss estimate revenue hiv drug come lower expect get newsletter deliver inbox more info product service privacy policy term usein afternoon trading stock market today gilead shucked stock topple much earlier trade meanwhile biotech stock collectively rise fraction gilead hepatitis franchise have crumble weight own success high cure rate have lead fewer patient late tuesday gilead report biggest year year sale decline hepatitis drug start report unit separately estimate hepatitis drug sale beat expectation porge note sale be consensus model new patient volume fall sequentially gilead keep expectation business stabilize mid importantly company be totally frank investor appreciate believe be trough year mizuho analyst salim sy write note be first time knowledge company have specifically state hepatitis drug harvoni be hardest hit sale decline sequentially year year miss expectation accord several analyst report abbvie abbv drug mavyret be partially blame needham analyst alan carr say note new prescription mavyret recently surpass combine harvoni epclusa new prescription be now reach pass gilead hepatitis product combine say management believe drug pricing space have largely stabilize gilead still expect hepatitis drug sale come mizuho sy say gilead doesn typically adjust guidance much first quarter earning conference call note do math now pricing have largely stabilize gilead remain quarters perhaps look say basically hit low end range quarter hiv drug rake miss view exaggerate seasonal inventory effect rbc analyst brian william say note encouragingly volume share metric remain directionally favorable suggest core franchise be still healthy perform well rest year say biktarvy gilead newest hiv drug bring lag most bullish view william see number indicative strong contribution drug also possible biktarvy be already take share other drug company note volume be come patient switch biktarvy third be switch gilead own genvoya glaxosmithkline gsk drug tivicay triumeq gilead believe biktarvy become single tablet regimen ultimately mizuho analyst sy say gilead expect european regulator approve biktarvy third quarter related do spot major market top easy look heavy term retirement investing strategy buy stock ahead earning report
9,GILD,abbvie abbv hepatitis franchise crushed first quarter analyst say thursday fellow drugmaker bristol myer squibb bmy report consensus top profit firm also increase sale adjust earning guidance stock market today abbvie pop close bristol myer add broadly drug stock rise analyst credit abbvie blockbuster humira drug hepatitis franchise first quarter sale beat total sale be increase operationally top estimate adjust profit rise share beat cent get free access ibd digital april
10,GILD,get premium stock list pass fail stock rating more start hereworldwide humira sale be top analyst prediction piper jaffray analyst christopher raymond say sale grow year year operational basis decline sequentially typical seasonal trend meanwhile hepatitis drug viekira mavyret crushed raymond say report client together bring nearly double consensus view sale outside be beating view abbvie success hepatitis drug send gilead science gild stock fraction morning trading abbvie mavyret be consider formidable challenger gilead hepatitis franchise mavyret treat genotype hepatitis sale cancer drug imbruvica also narrowly top bring north view piper jaffray raymond say other franchise be mixed prostate cancer drug lupron respiratory disease drug synagis beating expectation hiv drug kaletra lag say firm also boost adjust earning outlook share share guidance assume effective tax rate year rise next year analyst have modeled adjust earning share abbvie first quarter result help stock failure lung cancer medicine call rova quarter leerink analyst geoffrey porge say note flop send share nearly day believe strong operate result improve outlook lead outperformance abbvie stock today say anticoagulant eliquis cancer drug opdivo drive growth bristol myer first quarter total revenue rise vs year earlier period opdivo bristol myer biggest drug hair grow eliquis rac growth bristol myer sale narrowly beat consensus analyst poll zack investment research other estimate be higher analyst poll factset have average expect poll yahoo call sale sale cancer drug yervoy decline markedly yervoy be combine opdivo treat several form cancer be immuno oncology drug immune system identify fight cancer cancer drug sprycel also decline bring sale bristol myer raise full year adjust earning target share even lower gaap target also raise sale view mid single digit growth earlier expectation low mid single digit growth consensus have modeled adjust profit share sale related much volume look stock long term retirement investing strategy etfsstill rule stock investor always cut loss short
11,GILD,tiny biotech cymabay cbay launch high not see month wednesday unveil strong datum liver disease treatment detriment intercept pharmaceutical icpt have struggle rival drug stock market today share cymabay soar close earlier rocket much meanwhile intercept sank biotech stock collectively advanced cymabay be testing drug call seladelpar second treatment option liver disease know primary biliary cholangitis pbc leerink analyst joseph schwartz note result so far compare favorably intercept drug ocaliva continue view seladelpar attractive agent second treatment option pbc ocaliva advantage earlier market entry schwartz say note client raise expectation seladelpar success prior view get newsletter deliver inbox more info product service privacy policy term useseladelpar be test patient have abnormally high level enzyme alkaline phosphate week patient treat milligram milligram milligram dose seladelpar see alkaline phosphate level cut respectively week patient receive milligram cymabay drug have alkaline phosphate reduction overall patient have normal alkaline phosphate level week drug wasn associate itch sometimes occur pbc cymabay say news release patient milligram dose group see decrease itch week suggest drug have itch activity importantly lack liver toxicity be huge schwartz say be concern patient take intercept ocaliva experience liver injury die intercept argue patient be receive inappropriately high dose ocaliva cymabay note chronic dose milligram seladelpar didn lead liver toxicity mean physician be able adjust patient dose worry liver injury death schwartz say ocaliva recent resolution fda label investor have grow particularly cautious liver toxicity pbc drug say today update quell such concern firm be now track begin phase study second half cymabay expect test milligram milligram dose seladelpar study schwartz also see cymabay grab success seladelpar nonalcoholic steatohepatitis liver disease cymabay be now midstage testing seladelpar nonalcoholic steatohepatitis nash other player nash drug race include intercept gilead science gild shire shpg allergan agn novartis nvs related chart read basic buy point mark time real best stock buy watch start buy stock ahead earning report
12,GILD,thursday gilead science gild hit important performance benchmark see relative strength rs rating jump percentile improvement day ibd proprietary rating track share price action worst best score score show stock price performance last week hold other stock database year market history show best stock often have rs rating north early stage move see ibd help make more money stocksgilead science be not currently potential buy zone see stock go form sound pattern spark new run company post negative growth sale earning last quarter gilead science hold rank peer medical biom biotech industry group bioverativ bivv vertex pharmaceutical vrtx biogen biib be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
13,GILD,gilead science gild see positive improvement relative strength rs rating monday increase exclusive rating investor business daily identify market leadership worst best score grade show stock price performance last week stack other stock database decade market research show best stock often have better rs rating early stage move see gilead science continue show renew price strength hit benchmark look best stock buy watch start herewhile stock be not proper buy point right now see manage form break proper base gilead science post negative growth top bottom line last quarter gilead science be expect release next quarterly number feb gilead science earn rank peer medical biom biotech industry group bioverativ bivv therapeutic cort vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
14,GILD,gilead science gild viral franchise look strong head first quarter earning season fellow large cap biogen biib celgene celg be shakier ground analyst say wednesday rbc analyst brian abraham call gilead top expectation biogen likely miss bottom line celgene still reel sudden departure chief operate officer be typically weak first period clinical study business development be more important biotech say believe clinical trial success increase merger acquisition activity be more important help improve sentiment give renew drug pricing competitive life cycle concern sector say note client get newsletter deliver inbox more info product service privacy policy term usegilead gain close biogen climb celgene jump possible rebound drop wake sudden unexplained departure chief operate officer coo scott left late last week day biotech group be rank first just week fifth recently week now slip group track investor business daily share hit month high march have topple point abraham call strong quarter gilead hiv drug be become more important firm top line hepatitis market be stabilize more hiv patient be used regimen contain drug know tenofovir alafenamide taf abraham see genvoya descovy odefsey beating expectation take share own atripla stribild biktarvy drug treatment hiv be still early launch expect bring first quarter sale look be tracking ahead consensus project longer term say hepatitis drug harvoni epclusa be see beating view abraham model drug competition abbvie abbv new drug mavyret treat wide group hepatitis patient franchise perform expect see cent bottom line beat first quarter earning share tracking exceed consensus year believe help drive upside pipeline mature visibility increase earning growth year say abraham have outperform rating gilead share biogen look generally solid first quarter abraham expect sale be slightly consensus base prescription trend expect earning share come cent consensus multiple sclerosis drug tecfidera be experience steady erosion celgene experimental drug ozanimod have be delay multiple sclerosis meanwhile revenue spinal muscular atrophy drug spinraza be likely be line multiple sclerosis contract secure key competitor ozanimod delay temporary lull competitive spinal muscular atrophy news flow expect focus call be potential year growth driver say biotech be expect outline plan aducanumab be be test alzheimer disease recently biogen make change study drug investor also be likely key potential acquisition talk expect share trade line pending more clarity long term picture say abraham boost price target have sector perform rating stock first quarter tend be seasonally weak celgene believe be solid enough allay concern emerge follow departure president chief operate officer abraham say abraham boost expectation inflammation drug otezla first quarter year line consensus view otezla sale have be source pain past widely miss third period rebound fourth abraham lower view pomalyst cancer drug reflect weaker expect use pattern likelihood indirect erosion johnson johnson jnj darzalex investor focus be next step ozanimod regulator reject drug multiple sclerosis celgene also offer further detail acceleron pharma xlrn partner blood disease abraham cut price target have celgene top pick stock related much volume look stock long term retirement investing strategy etfsstill rule stock investor always cut loss short
15,GILD,dow jone component pfizer pfe be team group former kite pharma executive take gilead science gild novartis nvs advanced cancer treatment early tuesday pfizer say enter alliance privately hold allogene therapeutic develop advanced form chimeric antigen receptor cell car therapy pfizer take stake allogene therapy represent potentially approach treat cancer be very excited future hold area research pfizer head oncology research development robert abraham say written statement regular session stock market today pfizer rise close gilead tick novartis advanced get newsletter deliver inbox more info product service privacy policy term usecar therapy gilead novartis already be market drug be create used patient own extract immune cell scientist reprogram patient cell fight cancer return patient pfizer allogene be aim create allogeneic version treatment used healthy donor cell successful allogeneic car drug be less costly produce traditional car treatment scientist remain split allogeneic approach work be also case traditional car therapy then gilead novartis grab approval several type blood cancer allogene chief executive president david chang say many believe idea car therapy be root science fiction science fiction have become reality say written statement chang be kite chief medical officer head research department gilead buy kite last year just regulator approve drug yescarta treat aggressive form hodgkin lymphoma arie belldegrun kite founder former chief executive also moved allogene serve executive chairman pfizer also keep stake cellectis cll deal allogene also allow cellectis allogene work together allogeneic car cellectis be furthest allogeneic approach crispr therapeutic crsp be work rival french pharma group servier be sponsor clinical test pfizer cellectis partner drug ucart drug be phase study potential treatment acute lymphoblastic leukemia approve be shelf form car development shelf allogeneic car therapy field oncology initiate revolution potentially expand access such innovative treatment larger number oncologist patient servier president olivier laureau say prepared statement related much money do need start investing long term retirement investing strategy buy stock ahead earning report
16,GILD,minute dow jone industrial average component merck mrk be do battle fellow drugmaker bristol myer squibb bmy drug cancer next biotech giant amgen amgn sanofi sny be tussle court fate cholesterol bust drug meanwhile company gilead science gild be rake coal congress charge day treat hepatitis brave contentious new world pharmaceutical biotechnology company realm science be try develop landmark medicine cure cancer hepatitis other life threaten illness do delicate dance wall street regulator balancing public health issue demand shareholder investor find tricky navigate sector company rise fall drop hat bookmark page stay top latest news biopharma sector get newsletter deliver inbox more info product service privacy policy term useview more biotech pharma stock newsrelated best stock buy watch
17,GILD,celgene celg bluebird bio blue agree wednesday co commercialize co promote advanced cancer treatment know bb company begin collaborate cancer treatment bb be part deal now be study bb multiple myeloma believe therapy have potential significantly impact treatment approach outcome patient multiple myeloma celgene president hematology oncology nadim ahm say written statement term deal company pay half cost get half profit celgene also pay bluebird milestone royalty sale outside get newsletter deliver inbox more info product service privacy policy term usein early trading stock market today bluebird sank close share celgene surge deal come just week celgene wrapped acquisition juno therapeutic juno bluebird be work cancer drug call car therapy gilead science gild novartis nvs already have drug approve arena notably other be develop alternative form car therapy be less costly drug gilead novartis dow jone stock pfizer pfe cellectis cll be team crispr therapeutic crsp be work related build long term profit stock take many gain look best stock buy watch start buy stock ahead earning report
18,GILD,tuesday gilead science gild receive upgrade relative strength rs rating proprietary rating track market leadership show stock price action last week compare other stock database decade market research show best perform stock typically have rs rating least early stage move see gilead science continue show renew price strength hit benchmark look winning stock try simple routinegilead science be buy zone breaking past entry cup handle proper buy range extend initial entry once stock move range best hold investing set buy opportunity gilead science post negative growth top bottom line last quarter company be expect report next quarterly number feb gilead science earn rank peer medical biom biotech industry group bioverativ bivv therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
19,GILD,german biotech potential rival gilead science gild novartis nvs celgene celg cancer drug be look raise nasdaq initial public offer accord recent filing morphosys file registration statement thursday hasn yet price ipo security exchange commission filing say plan raise help line coffer morphosys plow ahead late stage oncology drug firm late stage treatment rival approve drug call car therapy aim patient immune system identify fight cancer novartis gilead crossed finish line last year car treatment call kymriah yescarta respectively kymriah be used treat form acute lymphoblastic leukemia patient age younger novartis be also seek approval kymriah disease call diffuse large cell lymphoma gilead yescarta be already approve get newsletter deliver inbox more info product service privacy policy term kymriah yescarta morphosys drug call mor target antigen call cd kymriah yescarta mor isn car drug belong class call monoclonal antibody be develop treat diffuse large cell lymphoma chronic lymphocytic leukemia morphosys recently unveil strong result mor combination lenalidomide sell celgene brand name revlimid patient diffuse large cell lymphoma trial be still ongoing morphosys say news release earlier month preliminary result show patient achieve median progression free survival rate month treatment overall patient respond regimen have complete response regimen be also well tolerate unexpected toxicity earlier stage testing morphosys be also work therapy multiple myeloma call mor rival drug celgene celgene acquisition juno therapeutic celgene be look car treatment multiple myeloma diffuse large cell lymphoma other blood cancer german biotech also have develop license drug glaxosmithkline gsk be investigate rheumatoid arthritis multiple sclerosis eczema drug development partner galapago glpg drug be look tumor property related chart read basic buy point mark time real tame volatile swing trade half positionlook next nvidia start simple routine
20,GILD,dozen drug launch heavy hitter roche rhhby gilead science gild johnson johnson jnj be expect reach blockbuster status end analytic firm say clarivate analytic describe year blockbuster drug have launch be expect launch eventually bring north sale year period biggest number clarivate begin make forecast set be exciting year see valuable addition exist treatment well disruption certain market first class treatment option disease firm say report issue late thursday end drug roche gilead nordisk nvo be expect top annual sale remain likely account year revenue analyst say get newsletter deliver inbox more info product service privacy policy term be diabetes drug food drug administration approve medicine derive cannabis plant first series drug expect prevent migraine patient dozen drug be project collectively top sale roche hemlibra treatment patient hemophilia top list be expect generate north sale only hemophilia patient world roughly eligible hemlibra treatment cost first year year drug be approve month early launch december sale be forecast drug set reach blockbuster status forecast hemlibra be expect take share shire shpg feiba nordisk novoseven hemlibra also compete bioverativ bivv eloctate shire advate eloctate be forecast be blockbuster advate continue be market leader estimate sale however advate sale be forecast decline further thereafter clarivate report say gilead biktarvy grab approval february target estimate person globally live hiv be receive antiretroviral therapy suppress viral replication allow immune system strengthen biktarvy add gilead hiv franchise have long rivale glaxosmithkline gsk have trade market share gilead first enter market atripla gilead hiv drug be featured clarivate drug watch report biktarvy become blockbuster generate sale spiking decline report say trajectory be similar gsk drug triumeq be expect bring year year launch round top nordisk get approval diabetes drug ozempic december drug help stimulate body own insulin release limit much sugar get blood liver slow quickly food leave stomach ozempic be expect become blockbuster revenue way immuno oncology treatment novartis nvs gilead grab headline ability revolutionize treatment disease report say more half drug potential blockbuster list be cancer therapy just drug list expect blockbuster be cancer treatment erleada product dow jone component johnson johnson be approve february treat castration resistant prostate cancer hasn spread body fellow dow jone component pfizer pfe have drug treat same cancer once spread zytiga xtandi battle expand market share include market patient metastatic disease second generation oral androgen erleada become first approve set mid february clarivate say drug be project bring rise also be expand treat other form prostate cancer combination zytiga contribute blockbuster potential gsk shingle vaccine call shingrix rare disease drug alnylam pharmaceutical alny know patisiran be expect join blockbuster list sale respectively revenue be expect hit respective gw pharmaceutical gwph be expect grab approval summer first cannabidiol drug derive cannabis plant treat patient seizure disorder drug call epidiolex be expect generate sale approve epidiolex likely encounter bureaucratic barrier distribution political hurdle associate cannabis derive medicine particularly strict guideline use medicinal cannabis exist report say biotech isn alone market cara pharmaceutical cara insys therapeutic insy zynerba pharmaceutical zyne be also work treatment base cannabis plant migraine drug amgen amgn novartis aimovig be project bring sale spiking sale drug other seek prevent migraine block specific peptide group amino acid approve aimovig be first drug know cgrp market ahead teva pharmaceutical teva aldr eli lilly lly allergan agn also be work area first class mover advantage be crucial aimovig competition other subcutaneously administer monoclonal antibody target cgrp be not far clarivate say lilly teva file fda approval drug late last year meanwhile be phase testing drug analyst be worry falter submit application fda co founder randall schatzman unexpectedly step chief executive role tuesday other area shire lanadelumab treatment swell disorder be forecast bring next be abbvie abbv elagolix treatment painful symptom associate menstruation round list pfizer merck mrk diabetes drug steglatro indivior opioid dependence drug sublocade be forecast become blockbuster sale respectively related chart read basic buy point mark time real much money do need start investing build long term profit stock take many gain
21,GILD,alnylam pharmaceutical alny dip early thursday announce collaboration regeneron pharmaceutical regn late wednesday research treatment form nonalcoholic fatty liver disease piper jaffray analyst edward tenthoff be bullish partnership marry regeneron discovery specific genetic variant associate chronic liver disease alnylam work type therapy call rna interference see deal positive alnylam expertise rna interference delivery hepatocyte liver cell complement therapeutic translation regeneron discovery say note client alnylam regeneron be join wide field biotechs drugmaker work treatment nonalcoholic steatohepatitis include gilead science gild allergan agn intercept pharmaceutical icpt novartis nvs get newsletter deliver inbox more info product service privacy policy term useon stock market today alnylam fall breaking consolidation earlier month buy point regeneron fall biotech stock be small fraction deal alnylam regeneron be base regeneron discovery variation hsd gene be tie reduce risk protection various chronic liver disease firm say press release regeneron finding stem large scale human genetic effort undertake regeneron genetic center new potential therapeutic target be used trim risk halt progression chronic liver disease alnylam regeneron plan look potential treatment disease know nonalcoholic steatohepatitis liver suffer damage similar cause alcohol patient be often obese have type diabetes plan use alnylam expertise rna interference target hsd gene rna interference allow researcher specifically target silence gene involved cause pathway human disease piper jaffray tenthoff say collaboration expand co development co deal keep price target overweight rating alnylam related invest stock free new apps aim basic analyze stock cup buy stock ahead earning report
22,GILD,wall street be split wednesday celgene celg sell side analyst downgrade stock say have tilt greater risk upgrade share beleaguered biotech company stock market today celgene share gain close share crumble year low monday report head business development exit april share biotech company rise fraction wednesday argus analyst david toung downgrade celgene hold rating buy same time analyst sanford bernstein upgrade stock outperform rating market perform reportedly say valuation be too cheap ignore toung be concern longevity cancer drug revlimid generic pharmaceutical company mylan myl dr reddy laboratory rdy be vie make copycat revlimid revlimid patent extend europe get newsletter deliver inbox more info product service privacy policy term use more revlimid patent be invalidate broad generic competition begin say report client be devastate celgene bring revlimid sale contend celgene acquire juno therapeutic juno lead drug candidate cancer treatment bring peak year sale toung doesn expect commercial launch month celgene also put acquire impact biomedicine have experimental cancer drug firm plan file approval key drug mid also work bluebird bio blue multiple myeloma treatment pipeline asset be promising combine potential revenue be not enough completely replace revlimid view toung say toung assessment follow food drug administration list attempt shame several pharmaceutical company block generic competition big drug large biotech company fda also list gilead science gild biogen biib celgene have also have number misstep recent history last october scrap study drug call ged crohn disease treatment february fda say wouldn review drug call ozanimod multiple sclerosis drug be now delay least year related do spot major market top easy look heavy basic sell stocksell take profit hold here be several guideline follow
23,GILD,ligand pharmaceutical lgnd stock break tuesday touch record high defy broader downturn see biotech company stock dip collective fraction close bell stock market today ligand stock gain close share break cup base buy point stock have remain black past trading day meanwhile share biotech company close analyst be bullish ligand have licensing deal biotech company pharmaceutical company bigger client include novartis nvs amgen amgn celgene celg gilead science gild also work dow jone component pfizer pfe merck mrk get newsletter deliver inbox more info product service privacy policy term useligand be ibd top grow stock firm acquire early stage technology necessary drug development then license platform other pharmaceutical company stock have ibd composite rating best possible meaning perform top stock term key growth metric ligand stock lead biotech group ahead supernus pharmaceutical supn also have cr first quarter ligand crushed expectation top guidance view currently analyst have buy rating ligand stock accord marketbeat com have sell rating share be second time ligand stock have break month share hit entry flat base march related much volume look stock long term retirement investing strategy basic analyze stock cup handle
24,GILD,big cap biotechs amgen amgn biogen biib have fall pressure year variety reason include revenue concern patent issue weak guidance smaller counterpart have rally fuel strong drug sale new drug news well merger acquisition take supernus pharmaceutical supn soar friday pad gain past buy point cup handle base clear thursday wednesday leap biotech report result top view thank strong sale trokendi xr migraine treatment seizure drug oxtellar xr follow gain thursday supernus be ibd sector leader stock biotech have fall industry group track ibd week now try push past resistance day move average so be good time keep eye biotech exchange trade fund get newsletter deliver inbox more info product service privacy policy term biggest bunch be ishare nasdaq biotechnology ibb asset rise friday continue consolidate day day move average line biogen celgene celg amgen gilead science gild vertex pharmaceutical vrtx make top holding account just stock portfolio supernus be holding ibb year date deficit accord morningstar inc lag gain etf be oldest biotech fund february launch average market cap company portfolio be next be year old spdr biotech xbi track biotechnology select industry index fund be also consolidate day day line ytd gain be average market cap xbi holding skews much smaller ibb top holding avexis avxs spark therapeutic once sarepta therapeutic srpt intercept pharmaceutical icpt immunomedic immu represent stock portfolio other nonleveraged biotech play include be idea prefer leverage play target double triple performance inverse performance underlie index be aware tend be more volatile nonleveraged counterpart usually have higher expense ratio also be interested way profit surge sector trump bump way apple earning buffett news breakoutdow top gainer intel also power semiconductor stock play
25,GILD,share drug giant merck mrk fall tuesday federal judge tossed record verdict have win gilead science gild hepatitis treatment federal jury have say gilead owe merck sale sovaldi harvoni hepatitis drug district court judge leonard stark wilmington del agree friday gilead argument merck patent be invalid patent issue be compound merck idenix unit contend be basis major treatment hepatitis include one make gilead merck claim be first synthesize compound gilead say didn cover new idea patent owner be require describe invention enough detail allow other replicate unnecessary time effort case stark say merck patent cover so many potential compound take excessive experimentation narrow base only reasonable find be patent be invalid stark say decision merck share lose close foster city calif base gilead add merck base kenilworth pledge appeal judge finding say do not reflect fact case patent issue case facilitate significant advance treatment patient hcv infection achieve advancement require many year research significant investment subsidiary partner company say written statement believe strong patent protection be essential innovation merck add give guarantee firm period return investment patent protection provide research base pharmaceutical biotechnology industry incentive invest research development sovaldi be approve food drug administration harvoni get regulatory go ahead year later merck drug zepatier be approve gilead have concede infringement patent common legal tactic allow focus validity issue trial reject gilead argument patent jury say gilead owe royalty total sale drug separate part ruling stark reject gilead argument damage amount be unfair issue become important only patent be later revive appeal verdict be largest patent infringement verdict history dwarf next biggest verdict win johnson johnson jnj abbott laboratory be later throw appeal accord datum compile bloomberg
26,GILD,couple relatively obscure biotechs be challenge like novartis nvs gilead science gild new form treat cancer not only undercut bigger rival render recently approve oncology drug drug giant obsolete novartis gilead be still early stage launch respective drug call kymriah yescarta be know car drug cellectis cll crispr therapeutic crsp tiny fraction rival market cap already be creep shelf variation car therapy used healthy donor cell create less expensive version cancer drug make treatment novartis gilead less attractive obsolete instinet analyst christopher marai tell investor business daily never mind pricing be dose more effectively marai say car therapy be form oncology treatment currently create extract immune cell patient blood used empty virus drugmaker affix be know chimeric antigen receptor immune system cell receptor also know car be protein recognize other protein used cancer cell hide body re engineer cell be reintroduce body be direct seek destroy cancer cell carry protein process be complex costly also tailor individual meaning drug be mass produce often take week manufacture patient die re wait crispr chief executive sam kulkarni tell investor business daily shelf approach car be aim change shelf car also know allogeneic used healthy donor cell prompt same immune response first generation car ts novartis gilead be used know autologous kulkarni say donor cell be typically healthier allow more robust response patient manufacturing process be less complex run make hundred dose kulkarni say process be uniform less costly cellectis have estimate cost good less patient autologous car run hundred thousand dollar expert say kulkarni marai note benefit allogeneic car be huge theory pan late stage clinical testing healthy donor cell also prompt better response used compromise cell cancer patient say patient also potentially receive repeat dose benefit doesn persist dose difficult much pricier autologous car overall allogeneic be so much more powerful shelf kulkarni say patient be treat very next day allogeneic car ts have good chance work better autologous car ts be accessible broadly patient theory be still little short tooth december cellectis partner servier pfizer pfe dow jone industrial average component unveil result first clinical trial used donor cell create car treatment form leukemia brad loncar run biotech fund know loncar cancer immunotherapy etf cncr call result mixed patient form acute lymphoblastic leukemia drug know ucart result complete remission rate adult pediatric patient use ibd marketsmith free march
27,GILD,see stock buy point get chart pattern recognition run custom screen start datum weren strong result juno therapeutic formally acquire celgene celg earlier week be point phase datum present december juno jcar first generation car drug achieve remission rate child same form leukemia have equal effectiveness course shelf car make first generation car obsolete loncar tell investor business daily have equal effectiveness gigantic thing say far proven reason believe never be so allogeneic car be holy grail oncology therapy say nadeem sheikh vice president research development privately hold dendreon pharmaceutical dendreon make immunotherapy treatment call provenge advanced prostate cancer entire cancer field love something allogeneic approach tell investor business daily allogeneic approach be take cell give holy grail know lot problem approach used donor cell introduce potential condition know graft versus host disease sheikh say disease donor immune cell don recognize surrounding begin attack everything appear foreign crispr kulkarni think have answer company gene editing process used technique call crispr receptor donor cell be remove prevent cell wildly attack unintended target essentially used crispr change genetic healthy donor cell say do longer attack patient cell only attack tumor patient perform second edit donor cell be then engineer appear body so patient own immune cell win try destroy donor cell kulkarni say allow donor cell persist longer body think crispr blow torch say actually cut metal weld metal here add gene remove gene cell essentially take healthy person cell make car ts add subtract gene cellectis be class own allogeneic car loncar say servier pfizer partner drug ucart already have preliminary phase datum own drug ucart be testing acute myeloid leukemia form leukemia know blastic plasmacytoid dendritic cell neoplasm february cellectis be grant pair patent use crispr gene editing genetic engineering cell cellectis say plan make patent available licensing other company willing use crispr technology cell theory be catch quickly even biggest first generation car player gilead announce acquisition kite late august merger close oct just fda approve kite drug yescarta oct now gilead be eyee allogeneic approach last month gilead partner sangamo therapeutic sgmo front develop cellular therapy used technique gene editing call zinc finger nuclease process gene editing be more complex costly crispr technology used crispr edita medicine edit intellium therapeutic ntla term deal gilead sangamo be eligible potential payment more product work autologous allogeneic approach cellular therapy crispr biotech also be work allogeneic car therapy call ctx yescarta gilead kymriah novartis target cd protein meaning potentially be used treat similar blood cancer so far firm have have meeting fda discuss filing investigational new drug application kulkarni say such application allow crispr begin clinical trial kulkarni expect file application end year begin clinical testing bullish crispr prospect note take lot front time energy think re still early day say have see datum bear autologous car have head start number trial allogeneic start work tumor type very scalable program related chart read basic buy point mark time real tame volatile swing trade half positionlook best stock buy watch start here
28,GILD,count pfizer best dividend stock stock market not only stout dividend yield also strong performance new drug best dividend stock often show consistent track record dividend payout pfizer pfe certainly pass muster here earlier month company declare quarterly dividend cent share dividend be payable june shareholder record pfizer consecutive quarterly dividend long know blockbuster drug lipitor viagra xanax pfizer fourth quarter earning report show strong performance other drug company innovate health unit strength be drive ibrance eliquis xeljanz drug show sale increase respectively ibrance be breast cancer treatment eliquis be used prevent stroke blood clot person irregular heartbeat xeljanz be rheumatoid arthritis treatment innovative health deliver total sale make total sale get newsletter deliver inbox more info product service privacy policy term usepfizer have see plenty interest consumer health business include brand advil chapstick procter gamble pg be talk pfizer buy unit couldn agree price pfizer make headline earlier month inked accord privately hold allogene therapeutic partnership help pfizer compete gilead science gild novartis nvs advanced cancer treatment used car therapy car therapy be patient own immune cell be used treat cancer pfizer allogen aim create allogenic version car therapy used healthy donor cell earning pfizer be due open related biotech pharma industry stock newsbest income stock buy watch
29,GILD,general electric ge plan expand gene therapy prefabricate viral drug factory quickly scale manufacturing reach more patient lower cost xge health care unit announce new kubio ready run factory box pump viral vector base vaccine oncolytic viruse treat cancer gene cell therapy faster traditional stick build facility demand particular therapy prove strong factory expand increase output allow drug manufacturer quickly adapt market condition ge healthcare say news release share pop finish stock market today ge also benefit report potential sale jenbacher gas engine unit bloomberg say deal power company cummin cmi private equity firm value austrian unit more more report january indicated ge be target asset sale battle slump profit dow jone industrial average peer also close higher unite technology utx mmm siemens siegy honeywell hon rise get newsletter deliver inbox more info product service privacy policy term popularity viral vector use modify viruse carry healthy genetic code sick target cell be increase be more viral vector base therapy clinical trial ge healthcare business say several treatment such glaxosmithkline gsk strimveli novartis nvs kymriah kite pharma gilead science gild yescarta already have receive regulatory approval market be move more target therapy design smaller patient population olivier loeillot ge general manager say tuesday statement exist large scale factory be not ideal drug manufacturer look produce small batch therapy add additionally kubio factory help drug maker lower cost many advanced drug candidate treat ebola deadly west african outbreak also use viral vector technology factory box solution address challenge tie produce vaccine be critical person world generate low revenue manufacturer company say ge look grow gene therapy business battle severe downturn gas turbine power plant business power unit be likely show hit first quarter result come friday gene therapy be risky promising technique day allow doctor treat disorder conventional drug surgery accord national institutes health replace mutate disease cause gene health copy gene introduce new gene body fight disease be interested ge dividend already halved isn safe happen cowenge restate earning lower new accounting standardis way make dollar trading etfs yes here howif general electric break break ge stock
30,GILD,dow jone industrial average index rebound key support level end slightly lower nasdaq composite fuel apple aapl rally tesla tsla skid cash burn elon musk strange conference call mastercard hit buy zone new payment stock struggle alibaba baba pull back strong earning sprint merge mobile tmus headline several big deal job report symmetric fed stance ease rate hike fear crude oil price hit record high shale operator beat earning view dow jone undercut day move average rebound friday finish week nasdaq composite rally retake day line apple aapl fuel earning buyback warren buffett buy more share soar drive major average higher tesla tsla fall alibaba baba rally mastercard enter buy zone treasury yield pull back yield spread narrowing slightly crude oil rise nearly barrel shale earning be strong apparel stock be loser consumer electronic giant apple aapl earn share year year sale fiscal second quarter be best ep gain year latest string accelerate revenue growth report top forecast apple sell iphone just miss consensus service revenue wearable sale be strong apple also announce plan buyback big dividend hike warren buffett disclose berkshire hathaway brkb buy apple share first month bring total stake nearly apple stock surge best weekly gain year hit record high blast buy zone get newsletter deliver inbox more info product service privacy policy term usetesla report smaller expect loss forecast revenue electric car maker model production remain low company burn cash post earning conference call ceo elon musk cut wall street analyst bore question spend next minute take question blogger youtube share fall sharply thursday close week cent alibaba report better expect quarterly earning core commerce revenue swell cloud revenue more double alibaba end quarter monthly active user mobile device alibaba also give bullish outlook share rise friday jobless rate slide april lowest economy add job labor department report friday meanwhile average hourly wage growth rise just year little view fed favore gauge core inflation climb policymaker send message win panic top come month fed stress wednesday inflation target be symmetric qualys qlys fireeye feye fortinet ftnt top earning revenue view share retreat cyberark software cybr rally strong result outlook guide slightly higher meanwhile carbon black cblk jump friday debut ipo price late thursday high end recently raise range zendesk zen pop result guidance show customer support sale automation software company be build momentum rival salesforce com crm larger contract paycom payc report strong earning sale growth forecast line june quarter result send hr payroll process software maker lower fellow payroll hr cloud software firm paylocity pcty break friday result commerce software firm shopify shop top view size sale beat update guidance left investor unimpressed shopify initially fall rebound strong gain ultimate software ulti report adjust ep top estimate revenue grow also beating share rally wednesday close buy point mcdonald mcd surge score double beat ep rise revenue fall shake shack shak sky-rocket friday crushed earning beat revenue wingstop wing also jump friday result taco bell parent yum brand yum earning top share skid weak same store sale yum china yumc tumble weak pizza hut result china offset overall strong earning texas roadhouse txrh slip come par ep cent revenue viper energy partner vnom anadarko petroleum apc concho resource cxo noble energy nbl matador resource mtdr continental resource clr parsley energy pe eog resource eog pioneer natural resource pxd top quarterly estimate integrate energy firm marathon oil mro clear buy point follow earning oil price hit fresh multiyear high inventory production increase odd be rise president trump withdraw iran nuclear pact sprint mobile tmus finally agree merger share fall lack price premium fear antitrust regulator reject deal meanwhile marathon petroleum mpc agree buy andeavor andv create largest base refiner additionally walmart wmt say chain asda merge sainsbury walmart reportedly be deal buy india commerce giant flipkart prologis pld buy dct industrial dct finally marriott vacation vac reveal buy ilg ilg annual developer conference facebook fb say be enter online date business more person facebook identify single match group mtch own match com date app tinder plunge announcement facebook also introduce oculus go stand alone vr headset announce october arista network anet late thursday report ep gain revenue swell beating cisco rival see revenue line view send share tumble friday turnaround project juniper network jnpr late tuesday report ep decline wasn bad expect sale network gear cloud compute customer rebound juniper forecast profit slightly view share pop pare gain allergan agn zoetis zts teva teva exelixis exel top quarterly expectation allergan sank report unlikely make deal zoetis fall adjust profit guidance miss penny dow jone component merck mrk pfizer pfe beat profit lag sale gilead gild miss sale adjust earning hepatitis drug fall vs last year regeneron regn profit beat revenue miss eye drug eylea top view celgene celg topple analyst suggestion key drug be delay year friday celgene say refile application drug ozanimod multiple sclerosis treatment celgene also top first quarter expectation raise full year guidance sarepta srpt sale miss view loss be better expect mastercard share jump credit card giant report earning beat estimate join visa buy range square sq sale also top bitcoin make payment technology firm current quarter profit outlook come short fleetcor flt provide prepay fuel card vehicle fleet other payment product sank low outlook paypal pypl tumble amazon amzn reportedly offer merchant discount use own payment service controversy kanye west comment slavery have tangled adida addyy ceo sportswear company distance not cut ty rapper west yeezy brand be not significant part adida revenue contribute brand style image share tumble buy point adida logging currency neutral revenue growth include solid north america meanwhile armour uaa top estimate give weak outlook susquehanna say inventory be tick time bomb coach kate spade parent tapestry tpr top consensus share plunge upscale purse accessory maker raise guidance be still largely consensus north face van parent vf corp vfc beat view share retreat friday snapchat operator snap snap crash record low miss first quarter view revenue user growth several other key metric grubhub grub top first quarter earning estimate food sale miss target share fall sharply pare loss friday world wrestling entertainment wwe spiked wwe body slam earning estimate continue attract subscriber ep rise cent however revenue be miss disk drive maker seagate technology stx report quarterly earning beat estimate stock fall cautious comment tariff ferrari race zoom buy zone double beat ep rise cent revenue climb tableau datum report sale earning expectation license revenue be ahead consensus company lower full year margin guidance big datum firm stock jump
31,GILD,quarterly result apple aapl mastercard help boslter open trade wednesday boost dow future open negative territory investor cautiously await rate policy news federal reserve nasdaq composite climb less apple adp adp easily lead index earning fuel loss gilead science gild seagate technology stx hold back advance dow jone industrial average fall intel intc fall furthest more third dow stock lose ground loss remain mild however lead verizon vz slip slide juniper network jnpr staking early lead stock mastercard pop more early action first quarter revenue profit growth top analyst target mastercard operate margin decrease surge expense open gain send stock buy point second stage flat base apple also open more higher better forecast earning revenue dividend increase launch share buy back program apple share have be lock consolidation late january current consolidation be flat base buy point alternative entry apple hour gain tuesday point open back stock day move average base alternative entry get newsletter deliver inbox more info product service privacy policy term useapple also help boost europe market trade unevenly higher datum show eurozone manufacturing slow month low april germany dax lead advance europe top benchmark afternoon session chip stock shift higher share switzerland base am maker facial recognition software used iphone surge more investor largely expect change policy afternoon announcement cme group fedwatch tool show future point probability vote hold rate target current range fed comment be carefully parsed indication future hike play change committee view inflation economy crude oil price add early wednesday benchmark west texas intermediate hold easily barrel be bit more month high set april oil price drop nearly tuesday american petroleum institute datum show barrel increase oil stockpile vs expectation smaller increase barrel gasoline inventory rise barrel confound forecast barrel decrease api datum be precursor weekly crude stockpile report energy information administration due release et oil name concho resource cxo viper energy partner vnom jump more apiece open trade report first quarter earning beat late tuesday continental resource clr pioneer natural resource pxd matador resource mtdr report quarterly result today close chip stock be mixed open philadelphia semiconductor index fought add third straight gain index surge tuesday cirrus logic crus rise almost skywork solution swks advanced early trade cirrus report fiscal fourth quarter result today close bell skywork report late thursday intel post heaviest loss chipmaker start trade milpita calif base chipmaker nanometric nano spiked score huge first quarter sale profit beat late tuesday juniper network surge strong first quarter result report late tuesday terex tex ocwen financial ocn muscle nearly follow early wednesday report shutterfly sfly flitted higher result show have trim loss more expect first quarter revenue gain top target move marked past cup handle buy point shutterfly have weak ep rating ibd earning be expect jump year follow ep gain software developer zendesk zen ahead more redwood city calif company turn strong first quarter sale earning beat raise second quarter guidance consensus view zendesk be project post first annual profit year ep gain advance lift share just buy point week tight pattern snapchat parent snap snap lead stock move lower earning news early wednesday month old social medium icon dive early action venice calif outfit report weaker expect revenue growth increase daily active user quarter fall short target user gain snapchat share end tuesday february high stock march ipo price related mastercard stock poise earning beat oil price mixed ahead earning top shale company stock power apple earning add fuelapple service wearable offset slow iphone sale lockheed northrop lead defense stock dive sector wo continue very different stock common trait report earning thursday
32,GILD,gilead science gild share pop midday wednesday food drug administration approve new hiv drug regimen rival treatment glaxosmithkline gsk treatment know biktarvy contain drug call bictegravir emtricitabine tenofovir alafenamide be approve once daily single tablet treat hiv infection gilead say news release biktarvy label warn exacerbate hepatitis symptom patient require liver function monitoring patient close bell stock market today gilead jump finish biotech stock collectively lift fraction percentage point glaxo rise fraction time gilead call bictegravir mount everest come hepatitis drug franchise begin dwindle high cure rate europe biktarvy be add gilead hiv hepatitis drug unit grow fourth quarter ibd take biotech franchise gilead hepatitis unit have be pressure recent quarters smaller newer drug start take share visit ibd industry theme see analyst say large franchise be safe year earlier wednesday glaxo say focuse new therapy chronic obstructive pulmonary disease hiv shingle face mount competition asthma blockbuster advair dow merck mrk too be work treatment hiv january fda accept new application merck regimen contain drug call doravirine hiv fda set decision date regimen oct related biotechs spring back market correction analystbiogen tysabri fail stroke trial come surprise sanofi regeneron dip eczema drug dupixent lag europe
33,GILD,sangamo therapeutic sgmo rocket year high thursday landing deal gilead science gild kite division collaborate cancer treatment kite use sangamo platform modify gene use cellular therapy sangamo used version gene editing call zinc finger nuclease kite make car therapy immune system fight cancer technology be used develop autologous allogeneic car therapy autologous used immune cell extract sick patient allogeneic used healthy donor cell renewable stem cell cut cost time treatment gilead chief executive john milligan praise collaboration written statement emergence gene editing tool edit immune cell hold promise development therapy potentially improve safety effectiveness efficiency say believe sangamo zinc finger nuclease provide optimal gene editing platform sign free ibd newsletter market prep tech reportunder term deal sangamo receive upfront payment be eligible potential payment more product sangamo also receive tiered royalty payment sale potential future product kite be responsible development manufacturing product result collaboration kite also pay agree expense incur sangamo stock market today sangamo jump touch level last see november gilead lose zinc finger nuclease be far only gene editing platform testing bluebird bio blue be work treatment used system call talen crispr therapeutic crsp edita medicine edit intellium ntla use version gene editing call crispr allogeneic car be early day rival already approve autologous treatment gilead novartis nvs used donor cell company be aim create less expensive shelf version car crispr chief executive sam kulkarni tell investor business daily manufacturing run create hundred dose say sit shelf treat patient next day related medtronic sink rival intuitive surgical abbvie deal send biotech stock year highdow merck jump merger bandwagon buy
34,GILD,year be shape be boisterous biotech acquisition celgene celg sanofi sny matter day announce plan spend north take company analyst say celgene sanofi particular be face challenge area insurance company be push back payment rheumatology diabetes also leave like novartis nvo eli lilly lly trouble say brad loncar manage immunotherapy base fund company have buy growth loncar tell investor business daily ve be grow revenue do artificial thing drug price increase tax inversion kind other type financial engineering thing be go away be spend biotech deal mizuho analyst salim sy tell ibd year so far celgene have say spend buy remainder juno therapeutic juno doesn already own sanofi be spending acquire bioverativ bivv ablynx ablx company haven buy anything just matter opportunity sy say buy spree kick august gilead science gild announce plan acquire cancer play kite pharma gilead have be suffering major slowdown hepatitis drug sale high cure rate saturation europe celgene sanofi announce plan acquire juno bioverativ same day january day later sanofi say buy rare disease drugmaker ablynx celgene acquisition follow disappointing third quarter sale psoriatic arthritis plaque psoriasis drug otezla widely miss expectation biotech also cut guidance otezla shortfall terminate several trial crohn disease loncar describe celgene long term growth prospect time bleak picture also face patent cliff mid cancer drug revlimid ibd take challenge hold stock market correction decline help share form new potential base be still possible capture big gain head investor corner tip make gain correction so really couldn afford say sanofi other hand be skunked twice try acquire medivation actelion pharma dow component pfizer pfe beat sanofi medivation dow johnson johnson jnj be able acquire actelion sanofi roy behren fund manager capital management say sanofi commit acquisition make hostile bid medivation go back initially higher bid actelion filing show hostile approach be generally unsuccessful space fact scientist be such important part value equation tell ibd case sanofi medivation couldn arrive price be friendly be very difficult complete acquisition high profile acquisition late early acquirer have suffer pressure sale key moneymaker tax reform allow company pay less corporate taxe repatriate cash lower rate prime pump acquisition strong believer be go be huge year acquisition loncar say larger company growth be slow tax reform deal add fuel fire make easier do deal nordisk lose ablynx sanofi now loncar expect nordisk go other asset contend deep exposure diabetes market lilly too be see challenge diabetes meanwhile amgen amgn older drug be face new competition big company really need do say be outlier mizuho analyst sy say biogen biib instance guide flat sale multiple sclerosis unit include impact royalty get revenue roche rhhby new drug ocrevus perception franchise be dwindle say argument investor make lot guy biogen amgen base business be go away not necessarily case biogen be stable still flat sale win be enough pique investor interest biogen aducanumab potential treatment alzheimer disease be carrot investor clinical trial datum be available end early long carrot be become really difficult hedge fund community short stock say aducanumab produce return work large cap biotechs typically don see behren note biotechs seem be fairly interested immunotherapy oncology include gilead acquisition kite celgene plan acquire juno be work drug know car therapy immune system identify fight cancer have be lot activity oncology space term immunotherapy say larger company be try gobble promising technology still affordable be also see quite few testing company be acquire celgene acquisition juno follow common storyline behren say celgene invest juno create immunotherapy cancer autoimmune disease duo be furthest jcar potential treatment hodgkin lymphoma celgene pull trigger juno jan make sense be premium juno close price prior trading day biotechs even more high tech tend come significant premium trading price say re somewhat risky be huge payoff event re successful nektar therapeutic nktr bristol myer squibb bmy be similar plot september duo pair test nektar drug call nktr bristol opdivo patient melanoma kidney cancer lung cancer november nektar present strong early datum combo loncar peg nektar potential takeover target call nktr revolutionary day later bristol announce pay nektar upfront comprise cash purchase share test nktr opdivo opdivo yervoy deal allow bristol remain leader immuno oncology immuno oncology combination risk bid nektar evercore analyst umer raffat say feb note client have doubt nektar phone have be ring hook november datum be so interesting loncar say someone be bold enough buy put acquirer class own immuno oncology drug call parp inhibitor also look interesting loncar say clovis oncology clvs tesaro tsro have drug approve class be small enough acquire astrazeneca azn also work space sarepta therapeutic srpt neurocrine bioscience nbix biomarin pharmaceutical bmrn have also have successful launch recently company want revenue growth buy rare disease drug say have best sale ramp think type company be really interesting right now wouldn be surprised get buy related biotech investor flee drove market correction rock groupthese biotechs spring back market correction analystwhy biotech stock outperform peer
35,GILD,gilead science gild break monday competitor abbvie abbv strong fourth quarter hepatitis drug sale reinforce recent commentary gilead market be stabilize close bell stock market today gilead pop close breaking cup base buy point share jump friday abbvie fourth quarter earning report close quarter abbvie report sale hepatitis drug include viekira product mavyret maviret analyst have suggest latter take share gilead treat genotype hepatitis patient abbvie say lion share success hepatitis stem maviret sale outside drug sell mavyret maviret outside international hepatitis drug sale be period line expectation sale miss rbc analyst brian abraham estimate abbvie estimate fourth quarter hepatitis drug sale represent market abraham say note client believe be positive gilead go earning reinforce prior commentary market stabilization downplay potential impact competition say note friday ibd take gilead be set report earning close feb analyst list likely top expectation uncertainty payer dynamic competition drug access hinder company guidance head ibd industry theme other prediction ahead earning season abraham expect patient flow pricing hepatitis drug be more predictable go forward abbvie disruptive launch mavyret maviret abbvie echo gilead commentary regard stabilization earning conference call say abraham model gilead pull fourth quarter hepatitis drug sale expect gilead guide revenue buy side expectation be likely closer note related biopharma merger activity become abbvie story celgene reverse fourth quarter otezla sale reboundbiogen revenue top spinraza ms drug deliver upside
36,GILD,celgene celg reversed third quarter fallout thursday report key inflammation drug otezla tack nearly growth fourth quarter top consensus report contain surprise time leerink analyst geoffrey porge say note client follow third quarter celgene stock tank otezla sale broadly miss expectation fourth quarter psoriatic arthritis drug otezla bring sale grow vs year earlier period sale grow international sale advanced porge credit otezla rebound quarter quarter volume gain say gain be view positively very disappointing third quarter result make many investor question long term potential product close bell stock market today celgene stock gain close total sale come grow top consensus adjust profit increase share beat expectation adjust income share cancer revlimid sale beat consensus porge say sale beat outside revlimid sale lag pomalyst sale be line abraxane bring miss celgene guide total sale lag street view biotech see revlimid pomalyst otezla grow respectively vs prior year ibd take biogen celgene kick biotech earning season thursday other be expect provide even more upside head ibd industry theme closer look biotechs be expect outperform third quarter expectation adjust earning be expect rise midpoint share consensus have modeled guidance doesn include celgene plan merger juno therapeutic juno be expect have cent dilutive impact earning lead drug juno jcar be expect be third class know car therapy hit market novartis nvs gilead science gild be first still celgene plan acquire long term partner juno have be laud wall street view deal celgene announce monday acquire juno be relatively straightforward make lot sense celgene already have make significant investment car space porge say rbc analyst brian abraham say report acquire juno help celgene diversify biggest moneymaker revlimid revlimid be expect begin lose exclusivity key patent expire expect sentiment celgene shift back positively fourth quarter earning guidance reaffirm potential strong term growth execution say pipeline development support revenue sustainability post revlimid related valeant climb month make sense abbott spike record top quarterly top high crush fourth quarter expectation
37,GILD,abbvie abbv follow footstep gilead science gild celgene celg analyst suggest monday abbvie guide unexpectedly low tax rate expect narrative stock come month develop buy story similar gilead celgene more recently leerink analyst geoffrey porge write note client acquisition narrative follow abbvie fourth quarter earning friday biopharma giant top quarterly expectation beat guidance prediction also guide tax rate tax rate term also follow announcement last week celgene acquire juno therapeutic juno sanofi sny acquire biogen biib spinoff bioverativ bivv today sanofi also say buy ablynx ablx abbvie do seek acquisition likely be neuroscience early stage immuno oncology solid tumor medicine porge say abbvie seek deal build complement early stage alzheimer disease pipeline ahead key readout so far abbvie be play card close vest firm doesn seem incline make large disruptive transaction porge say credit suisse analyst vamil divan note firm be constantly look asset believe already have strong pipeline further do not have burn platform need acquire asset say isn compelling need company be deal many other thing probably be not best time do merger acquisition ibd take celgene abbvie have already report fourth quarter earning slew biopharmas be still slate issue report head ibd industry theme closer look analyst expect biotech drug group put abbvie slightly different boat gilead celgene gilead acquire kite pharma slow hepatitis drug sale last week celgene say buy juno year begin lose exclusivity cancer drug revlimid divan comment follow conversation abbvie management post fourth quarter earning analyst suggest lower expect tax rate mean abbvie have extra cash hand engage merger acquisition abbvie say look earlier stage single asset build pipeline find anything timeframe even neuroscience readout not necessarily feel need divan say note client divan boost price target abbvie keep neutral rating porge also up price target downgrade abbvie market perform rating outperform current valuation prefer celgene abbvie larger cap name coverage say growth name such vertex pharmaceutical vrtx alexion pharmaceutical alxn regeneron pharmaceutical regn continue offer more upside view abbvie close bell stock market today abbvie dip fraction related celgene reverse fourth quarter otezla sale sanofi ablynx deal spur biopharma buy spree biotech merger spigot turn juno bioverativ
38,GILD,stock remain broadly lower apple aapl iphone news weigh bitcoin play however buck broad decline powershare qqq trust qqq trim loss spdr spy spdr dow jone industrial average dium give emerge market tumble ishare msci emerge market eem apple be dow biggest loser share slide further day move average have re clear last week reverse lower iphone maker report earning thursday apple be cut iphone production half disappointing sale japan nikkei report monday homebuilder utility real estate lead downside sector fund stock market today oil gold play pull back price underlie commodity vaneck vector junior gold miner gdxj vaneck vector gold miner gdx drop respectively bitcoin also come pressure fall accord coindesk have initially climb bitcoin investment trust gbtc however rise remain slightly day line biotechs bank retail be few group buck selloff ishare nasdaq biotechnology ibb advanced best level august gilead science gild surge sailing past cup base buy point follow friday big move ablynx ablx soar sanofi say buy belgium base biotech propel top tech stock intel intc nvidia nvda stock market continue rise new high many leverage fund have generate even higher return don mind take extra potential risk leverage fund design outperform way often aim double triple particular benchmark index performance likewise design act inverse index snare big gain index sink drop index rally high octane play aren fainthearted emerge market play top list leverage etfs biggest year date gain jan accord morningstar direct direxion daily ftse china bull yinn have surge far front advance have big too rac gain yinn average annual return past year be trail same period direxion daily msci brazil bull brzu come second ytd gain gain last year outpaced year performance be direxion daily russia bull rusl third be year end gain year average annual return be give such relatively inconsistent long term performance most trader generally view leverage fund short term investment point keep mind leverage play tend have higher cost yinn brzu rusl carry expense ratio respectively compare ishare msci brazil ewz etfs accompany table be currently extend buy point find such leverage play appeal watch new consolidation pullback day move average direxion daily semiconductor bull soxl be extend entry cup handle decline wednesday thursday have bring closer buy range fund be featured etf column jan day rise much jan peak soxl surge prior september nov intraday high etf aim deliver daily performance phlx semiconductor sector index mark eighth anniversary march top name index dec be texas instrument txn intel qualcomm qcom nvidia broadcom avgo intel surge report better expect result late thursday nvidia know graphic chip used personal computer game console mobile device be also become big player self drive car artificial intelligence field share be time high soxl have deliver ytd gain year average annual return expense ratio be friday pick spdr portfolio high dividend spyd be top potential buy zone rebound day line related intel nvidia power dow high bitcoin key supportapple lose support dow high bitcoin play go positivecan make dollar trading etfs yes here
39,GILD,glaxosmithkline gsk expect adjust profit slide grow competition key asthma hiv unit base drugmaker say early wednesday guidance follow better expect quarter glaxo post adjust profit cent share sale analyst have see earning cent share sale respectively accord reuter adjust profit grow constant currency basis year generic copy asthma inhaler advair chip away earning mylan myl be expect launch generic teva pharmaceutical teva launch authorize generic early generic emerge midyear glaxo expect adjust earning be flat constant currency basis generic emerge adjust profit grow regardless exchange rate look ahead see potential generic version advair guidance reflect chief executive emma walmsley say written statement ibd take bull market be great time review stock selling smart first establish sell rule strongest stock way bottom fall re prepared more head investor corner glaxo tick cent close stock market today glaxo hiv unit be also face mount competition gilead science gild say tuesday combine hiv hepatitis drug sale grow fourth quarter gilead be also work new regimen used drug call bictegravir still walmsley say glaxo deliver mid high single digit growth adjust earning share constant currency basis focuse new launch include inhaler call trelegy ellipta hiv drug juluca shingle medication shingrix related allergan pop consensus top quarter strong migraine trialgilead beat quarterly view topple soft guidancethese biotechs spring back market correction analyst
40,GILD,gilead science gild plunge late tuesday report fourth quarter revenue earning top wall street expectation decline seventh consecutive period challenged hepatitis drug sale hour trading stock market today gilead sank much be more recent action regular session gilead pop biotech stock rally pare earlier loss close fourth quarter gilead report adjust profit share sale decline respectively metric top consensus adjust income share sale total product sale fall gilead feel most pain outside europe product revenue decline europe sale product decline lead dip product sale sale hiv hepatitis drug increase year year ibd take bull market be now year affair pundit have be call downfall presidential election be time review stock selling rule head investor corner hepatitis drug sale topple decline major market gilead say blockbuster harvoni sovaldi have be decline third quarter high cure rate market maturation epclusa be approve june have grow year year quarters fall first time fourth period harvoni biggest see sale decline epclusa now second most important trio fall sovaldi bring revenue gilead guide product sale consensus have forecast revenue rbc analyst brian abraham note competitive dynamic be expect shrink hepatitis market product sale guidance be lower expect operational expense outlook come higher abraham say note client still remain bullish gilead other program overall street begin look hepatitis expectation come believe stage remain set term earning nadir visibility growth drive hiv car pipeline say october gilead close acquisition kite pharma investor have long push gilead make acquisition dwindle hepatitis drug sale day later gilead kite get approval car drug call yescarta treat blood cancer car drug be type treatment patient cell be change laboratory attack cancer fourth quarter yescarta bring sale beating consensus abraham say car landscape now include other major player include celgene celg plan acquire juno therapeutic juno novartis nvs latter be first gain approval car drug kymriah related biotechs spring back market correction analystallergan pop consensus top quarter strong migraine biotech stock dife more be sell overdo
41,GILD,biotech investor collectively pull sector week analyst say friday byproduct broader market correction not malaise health care tie stock week end feb health care biotech fund see net outflow represent decrease asset piper jaffray analyst christopher raymond write note client same time equity post dip asset reason biotech stock tend experience worst market correction say brad loncar portfolio manager run cancer immunotherapy base fund biotech stock hit multiyear high late january have lose nearly believe be totally normal think biotech be just do so terrible week volatile sector entire stock market have bad week biotechs be likely do little bit tell investor business daily most pundit say market correction be overdue general market experience very mild gradual rise few interruption now head risk scenario investor seek lower risk position evercore analyst umer raffat tell ibd email close stock market today biotech group eke small gain pare earlier loss fall much week group be nearly hardest hit week be therapeutic cort lop come rivalry teva pharmaceutical teva treatment cush syndrome affect pituitary gland prothena prta dove chief medical officer announce departure amgen amgn celgene celg biogen biib lose north regeneron pharmaceutical regn top fourth quarter view plunge nearly gilead science gild topple more guidance miss large cap fourth quarter metric guidance be largely line expectation credit suisse analyst alethia young tell ibd describe fourth quarter decent show fire strained third quarter ibd take dow jone industrial average topple lower thursday nasdaq composite tumble respectively be bear take bite bull market head big picture more hopefully trend continue say be biotech risky space thing happen young loncar agree market correction isn indicative outlook biotech group say fundamental look strong group be poise buy spree begin late last year gilead acquisition kite pharma january celgene say buy juno therapeutic juno sanofi sny announce acquisition biogen spinoff bioverativ bivv belgium ablynx ablx sanofi beat nordisk nvo ablynx smart company go asset valuation go loncar say many bigger player be face payer scrutiny saturate area rheumatology diabetes gilead decline hepatitis drug sale lead kite purchase celgene be face competition inflammation drug larger company have slow growth so need buy growth need buy innovation say tax reform deal just pass kind add fuel fire make much more easy do deal related gilead pop fda approve glaxo rivale hiv drugthese biotechs spring back market correction analystalexion top quarterly view guidance lag alnylam dip loss
42,GILD,top international stock fund seek company fit specific growth trajectory other best foreign fund want find industry leader allocate capital smartly provide sustainable growth earning hefty return shareholder still other take blanket approach single country such japan very best foreign fund recognize ibd best mutual fund award drum unique strategy stay heap also critical question individual investor type investing style suit best try build solid long term gain answer question help investor sit tight market get volatile especially one overseas name best foreign fund change importance patience ability sell share market top not market bottom do not change msci eafe index rise score country specific region focuse mutual fund ibd annual survey soundly beat benchmark oppenheimer global opportunity opgix matthews asia dividend investor mapix dfa japanese small company dfjsx wasatch world innovation investor wagtx receive standing ovation deliver outstanding long term compound return msci eafe average annual return jan dec be understandably poor wall street subprime loan crisis bankruptcy lehman bro real estate crash ireland spain solvency scare greece separate bear market decline mainland china equity repeat claw equity price globe yet oppenheimer global score annualize gain year period dec matthews asia achieve gain dfa japanese small company wasatch world innovation hennessy japan small cap investor hjpsx take top ring average annual return see lawrence carrell story more fund morgan stanley institutional global franchise msfax oppenheimer international small mid company osmax franklin international small cap growth fkscx also hit annualize gain more oppenheimer global opportunity park more money company jan look next country group include germany japan france denmark italy sweden make slightly greater share entire fund asset try buy company be young life cycle not old value trap portfolio manager frank jenning say oppenheimer produce video very often re person run little business altogether don know re do certainly sophisticated management system succeed achieve scale still have entrepreneurial juice powerful phase be try capture become saturate bureaucracy average market cap holding stand just midcap range base ibd perspective ibd big cap require company market value top fund median market cap be even less global opportunity tend own company price earning ratio exceed oppenheimer take big bet individual company san francisco base nektar therapeutic nktr be biggest hold entire fund even breaking month base big volume nov quadruple price market value developer treatment be commercialize big pharma biotech partner be far cry megacaps such amgen amgn market cap gilead science gild other large holding perhaps carry lean yet mean corporate flavor include industrial laser maker coherent cohr social medium giant twitter twtr household carbonate beverage system pioneer sodastream soda computer aid design software firm ptc ptc matthews asia dividend benefit call goldilock scenario asian equity thank improve inflationary condition moderate monetary policy asia central bank fund manager write semiannual commentary shareholder concern potential systemic risk also subside most evident stabilize chinese economy reflect improve macroeconomic environment asian currency mostly strengthen dollar tailwind asian equity get newsletter deliver inbox more info product service privacy policy term usematthews asia dividend buy steady dividend payer dividend grower tend be cyclical firm have plenty untapped growth potential sector allocation fully reflect think consumer discretionary hold biggest piece international mutual fund holding dec consumer staple rank financial rank rd information technology feb matthews asia dividend show top holding hail mainland china hong kong include minth group china construction bank ping insurance south korea hyundai motor semiconductor expert rohm japan also make top dfa japanese small company portfolio hold company barely make radar screen most foreign stock fund stock average weight market cap be industrial consumer discretionary material financial sector make more fund asset fed corresponding master fund annual turnover rate be extremely low active fund oct wasatch world innovation be aggressive growth fund currently see strong growth potential france japan top holding include medium turnaround play new york time nyt costco wholesale cost sony sne nintendo ntdoy hail country alone hold be sodastream israel base firm market cap have triple earning share year street see earning rise additional nyt enjoy healthy earning rebound own last year score profit cent share analyst consensus see earning hit cent share year also read full ibd best mutual fund award reporthere list best mutual fund award winner categorybest mutual fund news performance report investing ideascan make serious stock market profit just small amount saving big picture stock market spotlight real news stock fund be buy
43,GILD,analyst investor be more bullish tuesday celgene celg follow announcement monday acquire juno therapeutic juno diversification move year key patent begin expire celgene key multiple myeloma drug revlimid take time investor fully get celgene revenue forecast juno lead asset jcar leerink analyst geoffrey porge say celgene expect get approval jcar treat aggressive form hodgkin lymphoma porge call revenue guide most controversial part celgene announcement jcar be know car therapy treatment patient own immune cell be extract reprogram fight cancer be reintroduce patient celgene be third market car novartis nvs gilead science gild acquire kite pharma october car platform jcar treat diffuse large cell lymphoma gilead drug be already approve use novartis have file approval celgene guidance be significantly consensus leerink forecast porge say note client specifically celgene believe unique characteristic jcar allow be deploy many more center exist car approach celgene share bound close stock market today monday follow announcement acquisition plan celgene dip much reverse close fraction jcar be less toxic more tolerable rival drug study show rate moderate serious cytokine release syndrome jcar patient vs gilead yescarta novartis kymriah canaccord analyst john newman write note client porge see chance success jcar diffuse large cell lymphoma chance chronic lymphocytic leukemia chance acute lymphoblastic leukemia forecast jcar bring more ibd take fourth quarter earning season be underway celgene biogen deck report earning early thursday head ibd industry theme closer look analyst expectation season stock surprise upside celgene also be work car treatment case jcar yescarta kymriah interact protein know cluster differentiation cd drug target know cell maturation antigen bcma be show promise latter version car celgene be work juno jcarh partner bluebird bio blue drug know bb porge give celgene chance success bb third treatment multiple myeloma celgene own half right drug porge expect bb reach market forecast year grow expect participant be market used car drug treat multiple myeloma see celgene bluebird have biggest piece rbc analyst brian abraham say juno deal make good strategic sense american society hematology meeting be apparent car emerge next wave treat blood cancer initial grow pain related logistic reimbursement celgene currently lead space revlimid be set face generic competition acquire juno didn already own give celgene worldwide right platform ability invest deeper technology evolve abraham say model peak annual sale related biotech merger spigot turn juno bioverativ dow topple judge toss patent blockbuster drugwhy biotech stock outperform peer
44,GILD,beleaguered biotech investor likely have get relief trial datum drug approval help stoke ember formerly red hot group take analyst say be relief horizon don expect anything earth shatter say next quarter half be likely feature significant disclosure number company coverage be unlikely be period strongly stock move event leerink analyst geoffrey porge write recent note client porge view follow third quarter large cap struggle historic moneymaker catch double whammy increase competition pricing concern meanwhile smaller cap crushed expectation result ibd company biotech industry group rank first just month be now list group ibd track share touch month high october have lose nearly however flow event be set accelerate early first quarter offer more opportunity meaningful value inflection company stock leerink analyst write recent note frustration depress biotech stock group have post impressive number new approval year jmp security analyst mike king say accord food drug administration original application drug biologic have be approve year need product approval tell investor business daily even most jaded observer sector have say sector whole have produce very satisfactory result come major trial readout don see change regard tack drug approval successful datum readout be key company celgene celg gilead science gild pair large biotech leader face grow field competitor moneymaker revlimid hepatitis drug respectively celgene be set have readout type hodgkin lymphoma have car development partner bluebird bio blue juno therapeutic juno car drug treat cancer used patient own re engineer immune cell be important celgene have long enjoy revenue gain chemotherapy revlimid analyst have be expect generic competition dr reddy laboratory rdy recently dr reddy miss key deadline file generic still less ideal celgene rely so heavily stream revenue fbb partner analyst mike bailey say celgene have be prepare replace patent challenged revlimid sale crohn disease drug firm say october win initiate phase trial drug bull case celgene previously be have new drug limit risk revlimid tell ibd take away risk management piece focus be drug be go go generic point similarly gilead have hiv combination used drug bictegravir set gain potential approval february accelerate hiv sale start second quarter porge say same time ark invest analyst manisha samy say gilead likely get further car gilead also announce thursday acquisition cell design lab privately hold car player october gilead acquire kite pharma nearly follow fda approval kite drug dub yescarta treat large cell lymphoma adult due individualized nature car drug aren likely rake same sale gilead now falter hepatitis drug year line be huge revenue maker tell ibd ibd take big cap struggle third quarter isn surprising consider patent cliff next year be set hit annual sale blockbuster drug say analyst head industry snapshot more biotechs fared period yescarta win replace gilead hepatitis franchise peak grow steadily bailey say guess be hepatitis be go shrink really quickly say point expect car replace hepatitis sale way peak be once ever term gilead do never be big next several month leerink porge look abbvie abbv regeneron pharmaceutical regn disclose pivotal trial regulatory event vertex pharmaceutical vrtx report more value confirm event abbvie have datum inflammatory treatment know upadacitinib say result add more detail evolve landscape be know jak inhibitor treat psoriasis rheumatoid arthritis ulcerative colitis number condition regeneron be deck file result drug dupixent asthma drug be already approve treat eczema firm also report datum eye drug eylea immuno oncology drug cemiplimab type skin cancer also look vertex provide phase datum triple pill combination treat cystic fibrosis total vertex be testing potential regimen bring phase trial firm be also likely gain approval drug combination february big pharma world leerink analyst seamus fernandez say be few significant stock move catalyst left first half be busy dow merck mrk bristol myer squibb bmy astrazeneca azn have immuno oncology combo result lung cancer bristol merck incyte incy be set deliver result regimen melanoma bristol also offer interim datum trial immuno oncology drug opdivo yervoy first treatment lung cancer outside major immuno oncology catalyst thankfully be limit say high bar bristol interim datum require nothing short stopping study early extreme effectiveness unlikely so expectation be probably low say nonetheless early stop be major validation bristol strategy likely drive stock view say continuation study likely increase concern bristol strategy ultimate success study final analysis possibly push stock parp inhibitor yet class cancer drug be set have trial result well astrazeneca have result drug lynparza first maintenance treatment ovarian cancer think parp space be quite large jmp king say hard tell real world doctor see drug better so start produce satisfactory sale figure related biotechs sell drove be investor seek merger biotech just near year high strong cancer regimenthis cancer biotech be fall bayer deal
45,GILD,gilead science gild catch upgrade thursday follow kite pharma buyout likelihood new car cancer medication allow diversify away mature hepatitis franchise maxim group analyst jason mccarthy upgrade gilead buy rating hold have price target stock close bell stock market today advanced finish car drug be make used patient own extract immune system cell be reprogram seek destroy cancer cell be reintroduce patient due nature take week manufacture drug visit kite manufacturing facility china left mccarthy impressed entire process take day gilead kite car drug kite facility el segundo calif handle patient treatment year program call kite konnect give healthcare provider patient gilead access real time tracking car process production be now semi automate gilead have plan automate production future increase capacity decrease cost be impressed left clear notion gilead kite overcome manufacturing challenge commercialize globally especially china new innovative therapy say note client now time buy gilead mccarthy say investor get access recently buy car drug free gilead hepatitis franchise gilead hepatitis drug set record be strongest drug launch history ibd take novartis be first cross finish line car therapy other be tail head ibd industry theme breakdown grow car market competitor be set turn market head more recent year hepatitis unit have struggle market mature high cure rate now market be enter fourth year comparison be get easier mccarthy say important be not lose sight fact gilead have free cash flow last quarter say buy car help diversify gilead gilead finished acquire kite october just food drug administration approve kite drug know yescarta adult large cell lymphomas approval be also expect europe china japan mccarthy expect gilead generate more come year global presence late stage cell cancer further car therapy be now be integrate other form cancer treatment kite be first keep give say gilead isn alone car offer novartis nvs be first gain approval drug call kymriah approve treat form acute lymphoblastic leukemia patient age juno therapeutic juno bluebird bio blue be also partner celgene celg develop own car therapy related amgen have edge rival prevent celgene gilead pricing wo continue haunt biotech stocksdow stock merck topple withdraw keytruda application europe
46,GILD,vertex pharmaceutical vrtx chief executive jeffrey leiden call year biotechnology company look likely end year balance sheet rapidly approach approval key cystic fibrosis treatment company stock price reflect success year share have almost double year date rise outperform investor business daily company biotech industry group have climb more january year begin leiden tell ibd layer part strategy begin goal expand number eligible patient vertex cystic fibrosis cf drug expand pipeline outside lung disease sector strengthen financial stance leiden say goal come fruition expect continue same trajectory vertex send potential triple pill regimen treat cystic fibrosis pivotal trial next year dife deeper treat other disease crispr therapeutic crsp moderna therapeutic so really look start year approve bit less half patient cystic fibrosis end year medicine believe be able get patient say know very significant expansion patient population think treat here leiden have say vertex plan examine company strategy outside cystic fibrosis medication ibd major accomplishment do vertex have leiden expand medicine cystic fibrosis say have very important accomplishment food drug administration approval kalydeco patient residual function mutation have previously be decline fda so more patient very importantly be breakthrough respect regulatory science be think first approval ever medicine new patient population base just datum cellular datum really testament think work fda get appreciate trust strength cell base assay predict effectiveness europe successfully obtain reimbursement orkambi particular also kalydeco number country particularly ireland italy also netherlands expand number patient be now reimburse medicine ibd take vertex be crisis point pull blockbuster hepatitis drug market mount competition gilead science gild see pivot cystic fibrosis transform company visit new america third be obviously positive phase datum tezacaftor ivacaftor treat cystic fibrosis datum be highly positive different trial be able very quickly submit regulatory application fda european medicine agency expect approval medicine first quarter next year first half third quarter europe go pick large number patient today be not take cftr corrector target certain gene mutation particularly patient have difficulty tolerate orkambi so re talk thousand additional patient be eligible tezacaftor ivacaftor next year final way most important long run be announce phase phase datum different triple regimen so call next generation regimen datum tell re go be able reach patient cf single triple combination medicine datum be strong enough re confident ll be able start pivotal trial final trial medicine first half next year expand pipeline cf be something haven talk much yet ll be hearing lot more new program be very serious disorder sickle cell disease alpha antitrypsin disease inherited disorder cause lung liver ailment be move forward really nicely thankfully faster expect hope get least maybe medicine clinic next year ll start talk more re medicine be very much cf medicine treat underlie cause disease re re really excited re able move forward ultimately want be serious disease company not just cf company term financial strength company likely end year close more balance sheet base increase number patient treat cf really important not want build big balance sheet give financial wherewithal invest internal research program make more new medicine also go do business development deal allow enhance pipeline even further ibd expect see vertex leiden look same goal expand access cf medicine develop pipeline cf produce more financial strength think thing look be first tezacaftor ivacaftor approval europe very very important allow patient get access medicine second expand access even further orkambi particularly europe couple country re still negotiating france want try finish negotiation reimbursement europe next year start pivotal trial triple regimen first half next year very important milestone company patient final be watch first program get clinic outside cf seem be furthest now be sickle cell disease alpha antitrypsin disease ibd make prediction broader biotech group leiden think really most exciting time biotech year ve be do reason new therapeutic technology gene editing gene therapy be really come maturity now cell base therapy re go see become viable therapy next year unbelievably exciting re see already immunotherapy car cell ll see soon gene editing gene therapy so be lot new therapeutic modality allow other attack disease be hard attack side equation other side equation be re just now get much better understand biology disease meaning re get better pick target most drug failure today be make drug target target picked wrong target so better understand biology industry be understand biology much better higher probability success so think take advance together re go see pretty significant kind acceleration breakthrough therapy related galapago pop vertex detriment compete vertex pop analyst question rival have viable drug biotech firm top third quarter view only pop
47,GILD,invest disruptor advice wall street giant biotech company incumbent big pharma be brace get crushed more innovative cheaper new drug start continue analyst say generic drug approval be rise interesting new medicine be start take market share legacy maker medication consumer use frequently include big pharma biotech company blockbuster drug represent estimate annual sale be set lose patent protection next decade analyst say disruption come generic drug innovative new biologic alternative come market be brutal jmp security analyst mike king tell investor business daily be knife fight market cholesterol lower drug king expect amgen amgn regeneron pharmaceutical regn sanofi sny feel heat like esperion therapeutic espr medicine co mdco alnylam pharmaceutical alny meanwhile inflammatory treatment celgene celg otezla gain blockbuster status miss sale forecast wide cut third quarter analyst say newly approve drug treat same condition eli lilly lly novartis nvs be take market share gilead science gild be still feel pain mature hepatitis drug unit europe rapid pace gilead hepatitis sale decline be expect slow somewhat newer medicine abbvie abbv mavyret be likely swipe sale big pharma isn get help regulator food drug administration head scott gottlieb continue increase approval copycat drug stoke competition brand generic drug face new rival firm try undercut price big pharma company pfizer pfe be forefront feel sting generic take sale earlier month teva pharmaceutical teva be allow launch generic copy blockbuster erectile dysfunction drug viagra generic drug tend be cheaper brand counterpart viagra be pricey drug tablet accord accessrx pfizer lose exclusivity viagra canada europe worldwide sale fall today generic europe have slash price drug contain same active ingredient viagra generic version viagra cost third price canada viagra price also fall trend repeat generic market teva meanwhile be struggle debt end third quarter thursday teva announce plan cut workforce more quarter close several manufacturing facility suspend dividend ordinary share firm be also plan review generic drug portfolio most specifically change price discontinue product ibd take see giant biotechs fared vs smaller player third quarter visit industry snapshot hint quarter be classify alarm large cap biotech be trouble see more competition traditional moneymaker board spending prescription drug increase just person accord report express script esrx rise represent drop growth rate trend be likely continue fbb capital partner analyst mike bailey tell ibd credit gottlieb decline generic price gottlieb be run fda business allow cycle more approval more competition lower price center medicare medicaid service use tool influence pricing unlikely president trump use executive power enact sweeping drug pricing reform such allow medicare negotiate price enact pricing control bailey say wouldn expect major change trump administration pricing say think mechanically politically difficult get pricing law system politically more acceptable just get more generic drug approval jmp king count drug treat rheumatoid arthritis psoriatic arthritis crowd area drug class cost average prescription benefit increase utilization unit cost accord express script third quarter thing begin look dour like celgene miss expectation inflammation drug otezla lag be even sharper analyst suggest celgene be force take price concession celgene also cut guidance terminate trial drug treat crohn disease condition result chronic inflammation digestive tract now see inflammation immunology drug bring combine outlook issue biotech company big pharma need get realistic pricing competitive arena king say same be say company make treatment hepatitis multiple sclerosis high cholesterol be highly saturate market latter point expect price drug know pcsk inhibitor repatha amgen praluent regeneron sanofi be microscope drug lower bad ldl cholesterol blood evidence show also have benefit cardiovascular outcome repatha be list year praluent cost rival be close medicine co alnylam be work cholesterol drug know inclisiran meanwhile analyst expect bempedoic acid esperion be cheaper big pharma biotech company be probably go get arm twisted lot king say pricing umbrella have create opportunity new company come scale market share be careful own incumbent invest disruptor other area be seemingly immune pricing pressure analyst say price multiple sclerosis drug rise average continue trend fbb bailey say price increase have be so egregious house democrat launch investigation august note many drug carry price tag north year investigation be launch rep elijah cumming peter welch center bayer bayry biogen biib emd sereno novartis roche rhhby sanofi teva pharmaceutical biotech company teva milligram dose copaxone have increase most rise approval annual price today accord national multiple sclerosis society novartis gilenya approve be highest price investigation be year too late say more difficult push price control specialty market multiple sclerosis be massive market now stakeholder view specialty market rare disease innovative cancer therapy also seem immune pricing control analyst say example earlier year novartis gilead acquisition kite pharma gain approval car drug know kymriah yescarta respectively car drug be develop used patient own immune system cell be trained seek destroy cancer cell kymriah go year yescarta be list ark invest analyst manisha samy write recent post gene therapy be begin cure cancer come price cause sticker stock say say compare traditional therapy suppress do not cure cancer cost benefit analysis gene therapy be compelling pricing shock tend tamp excitement really compelling drug bailey say prime example be biogen ionis pharmaceutical ion spinraza first spinal muscular atrophy drug approve cost first year subsequent year sentiment biotech company share be already say so drug pricing concern shouldn be big stock killer past biotech stock go quickly get new drug person be excited lot time someone throw grenade drug pricing bailey say sentiment be already even concern drug pricing see little less downside ibd company biotech industry group be now rank group track have fall first just month share collectively near year high october have shucked almost point same time amgen celgene biggest biotechs have see share price dive respectively regeneron have take hit gilead have tumble meanwhile alnylam esperion look likely rival psck inhibitor drugmaker amgen regeneron have lift respectively abbvie recently launch rival gilead hepatitis franchise be novartis lilly be compete celgene treat inflammatory condition have see share retreat smaller degree respectively share price be match dip ibd company ethical drug industry group generic drug stock rank group have actually broadly rise mid october respective dip teva mylan myl biggest name related teva restructure plan case be here do generic drug maker face pricing issue other pharmas don ttop biotech company innovation earn recognition new award
48,GILD,state street stt pra health science prah abbvie abbv be leader pass buy point touch new high wednesday investor be aware very different circumstance stock recent market have see biotechs other drugmaker launch bottle rocket announce positive trial result
49,GILD,glycomimetic glyc defy hematology biotech pitfall tuesday breaking strong cancer drug datum share global blood therapeutic gbt spark therapeutic once trend opposite direction stock market today glycomimetic rocket much rushed past buy point consolidation share end day nearly follow presentation key blood disease conference other tumble presentation american society hematology conference atlanta global blood plummet close share spark continue day tumble fall finish juno therapeutic juno topple nearly agio pharmaceutical agio lose seattle genetic sgen slide early tuesday glycomimetic unveil result drug know gmi group patient acute myeloid leukemia type cancer bone marrow make abnormal white blood cell red blood cell platelet ibd take several biotech stock make impressive gain monday follow presentation american society hematology head ibd industry theme closer look stock pop topple patient cancer relapse hadn respond other therapy treatment gmi result remission rate median overall survival be month vs month historical treatment median duration remission be month older patient newly diagnosed disease clinical remission rate be median overall survival be month vs month chemotherapy alone traditional therapy median duration remission be month group patient gmi be well tolerate obvious incremental toxicity observed late monday global blood unveil datum study drug voxelotor patient severe sickle cell disease hospitalization pain associate disease fall week voxelotor treatment vs week therapy number transfusion decrease week treatment compare week begin voxelotor patient receive transfusion voxelotor therapy receive transfusion treatment patient study die have co morbidity advanced organ injury treatment voxelotor treat physician don believe voxelotor contribute death nomura analyst christopher marai note drug be well tolerate compliance be high symptom return short period discontinuation expect voxelotor fill unmet need elderly sickle cell disease patient patient death underscore severity sickle cell disease say note client patient previously respond well therapy reduction transfusion hospitalization substantial quality life improvement derive drug say spark continue day plunge close monday present datum hemophilia gene therapy drug show major reduction bleed rate show smaller expect increase key clot protein investor compare spark drug know spk rival therapy biomarin pharmaceutical bmrn spk reduce bleed first hemophilia patient treat demonstrated mixed factor viii level factor viii be clot protein miss hemophilia patient biomarin drug reduce bleed event patient dose biomarin drug reach normal factor viii level week group patient be threshold week spark trial patient have unexplained spike factor viii level week patient high dose spk require steroid have lower factor viii level fourth patient lower dose continue have low factor viii level juno celgene celg present strong result drug know jcar patient aggressive form hodgkin lymphoma drug be car therapy patient own immune cell be reprogram fight cancer cell phase trial call transcend patient respond treatment sign cancer disappear patient month cancer disappear completely half core group patient month juno say press release dose core group patient achieve complete response month stay month group still response month remain datum cutoff only patient experience adverse event know cytokine release syndrome characterize flulike symptom experience neurotoxicity be common side effect associate car therapy leerink analyst michael schmidt say report juno present datum show response variety patient refute notion strong effectiveness achieve transcend have be result cherry pick easy patient juno be trail novartis nvs gilead science gild already have car therapy approve related do gilead kite acquisition offer new buy opportunity biotech industry small innovator outflank big cap blockbuster drug patent cliff loomsneurocrine exelixis juno stock rocket crush view
50,GILD,biotech industry behemoth celgene celg gilead science gild struggle third quarter accord quarter report result left room smaller player neurocrine bioscience nbix exelixis exel juno therapeutic juno swipe headline crush street even large cap beat sale earning expectation
51,GILD,stock watch week be technology health care stock be near clear buy point form long basis gilead science gild take interactive break monday morning take faltered vertex pharmaceutical vrtx have be form long base clear buy point friday pull back monday wellness software firm mindbody mb be hover buy point gilead science rise heavy volume monday stock market trading clear buy point cup base go back september share surge friday jeffery upgrade gilead buy hold raise price target gilead science be rally hepatitis drug optimism rival abbvie abbv report strong hep sale friday ibd take look actionable high quality growth stock investor business daily do work check leaderboard market team curate analyze list top notch name take free trial leaderboard take interactive rise high clear cup handle buy point consolidation be take shape early november share reversed close gaming software company stock have be somewhat rangebound past few week trading day line buy point meanwhile vertex pharmaceutical break past entry late friday trading session rise market surge more new high volume be normal see volume rise least average monday vertex reversed lower lose back entry volume be modestly normal action come ahead earning wednesday vertex have be consolidate last july biotech have be steady rise december wellness service software company mindbody sank monday work consolidation form november shortest base group mindbody lose support day line several time build base have be able quickly recover stock have now form handle lower buy point slightly be important note major index have continue surge higher base build technology health care stock have relative strength line be lag rs line measure stock price performance vs stock break want see rs line hit short term high not time high vertex rs line have rise very short term level so have gilead rs line be interested facebook google breakout internet stock enter buy zonethese stock composite rating have earning apple stock chart be tell ahead earning guidance leader top buy point breakout be not create equaleven big week stock leader issue key sell signalsthese ibd tech stock be buy rangestock buy watch top ipos big small cap growth stock
52,GILD,stock come lows afternoon trading monday industry group be add pressure loss be well contain main index trading friday price range decline less nasdaq composite be dow jone industrial average small cap russell have be lag major index week fall volume be higher nyse lower nasdaq compare same time friday key index pare loss breadth be poor loser lead winner more nyse nasdaq energy chip equipment homebuilding solar industry group be weakest today market sign stress be grow homebuilding group lgi home lgih william lyon home wlh toll bro tol horton dhi have moved day move average first time september stock be base few other builder have already slide day line myriad genetic mygn gap heavy trading goldman sachs initiate stock sell rating today genetic testing company erased gain past buy point result sell signal gilead science gild soar buy point cup handle volume be more triple usual pace relative strength line be well short new high hamper stock move new high biotech be follow friday surge come jeffery upgrade gilead buy hold raise price target fibrium fbr break cup handle clear buy point heavy volume report quote reuter say netherlands base paper excellence be consider acquire brazil base forestry company relative strength line be trend higher have not make new high universal display oled fall continue struggle day move average maker organic light emit diode technology have be weaken report flagging demand apple iphone used oled display monday japan nikkei report lackluster sale iphone delay apple plan introduce oled screen other model dow component caterpillar cat be nearly heavy trading stock have be rally nov past tightly wound flat base have climb more start stall past couple week strong earning thursday stock have come selling then caterpillar behavior show importance take profit stock be entry related oled display supplier dim lower iphone prospectsapple cut iphone production half disappointing sale reportdow leader caterpillar just steamrolled estimate key stock chart pattern pump portfoliowhere be stock market head read column day find
53,GILD,abbvie abbv surge record high friday issue beat raise earning report include guidance tax rate prompt analyst suggest yet industry behemoth become acquisitive fourth quarter abbvie report adjust income share sale rise respectively metric top consensus analyst adjust profit share sale close bell stock market today abbvie soar close help drug stock rise collective guidance lower tax rate have be expect leerink analyst geoffrey porge write note client december white house approve legislation lower corporate tax rate tax rate company revenue growth margin performance expect significant increase free cash flow attendant leverage thus set stage more active business development activity yet industry behemoth say investor have previously expect abbvie guide tax rate porge say merger activity have be heating recently biopharma group week celgene celg say buy remainder juno therapeutic juno didn already own gilead science gild spend nearly acquire kite pharma abbvie expect effective tax rate increase next year due increase domestic income investment piper jaffray analyst christopher raymond say note client abbvie result sale humira treat several form arthritis crohn disease plaque psoriasis increase sale humira be abbvie most important drug sale beat consensus raymond say ibd take abbvie lead group ibd composite rating best possible make leader stock term key growth metric more drug stock rank visit ibd stock checkup cancer drug imbruvica bring revenue grow nearly be ahead analyst collective view raymond say worldwide sale abbvie hepatitis drug viekira mavyret advanced more vs year earlier period beating consensus say porge lower tax rate also boost other guidance year abbvie call adjust income share top consensus sale be expect approach street consensus view related intuitive surgical top fourth quarter sale earning viewscelgene reverse fourth quarter otezla sale reboundbiogen revenue top spinraza ms drug deliver upside
54,GILD,retail investor turn more leery volatile february yet used stock market pullback opportunity buy apple aapl amazon amzn general electric ge rather flee customer online brokerage td ameritrade amtd be net buyer stock month see dow jone industrial average nasdaq composite fall more recent high worry rise bond yield inflation spark sharp sell stock lead brief market correction stock bottom feb index rebound day move average major average do fall february breaking long monthly winning streak meanwhile volatility measure cboe volatility index vix spiked period vix rise first time august decrease relative volatility many widely hold stock include ge apple facebook fb accord new td ameritrade report lead investor significantly limit volatility risk market change game plan less speculative more low beta weight say jj chief market strategist td ameritrade note rocky start come tame use ibd marketsmith free march
55,GILD,see stock buy point get chart pattern recognition run custom screen start brokerage firm recently rank ibd best online broker share additional insight client trade month general electric ford motor near multiyear lows be net buy apple amazon com amzn report better expect earning period trade lower follow market volatility be also net buy boee ba trade higher follow better expect earning stronger demand outlook plane be also net buy microsoft msft be net buy earning beat prove cloud compute software service initiative be success alibaba group baba be almost recent high volatile period be also net buy nvidia nvda berkshire hathaway brkb netflix nflx count other popular name investor buy february gilead science gild be net sell reach week high receive approval fda new hiv treatment facebook fb reach time high feb better expect earning be also net sell bristol myer squibb bmy hit month high follow analyst upgrade immuno oncology growth prospect be net sell snap snap report revenue increase lead stock spike be also net sell target tgt be net sell follow analyst upgrade increase price estimate conocophillip cop juno therapeutic juno bioverativ bivv be also dump celgene celg agree acquire juno france sanofi sny be buy bioverativ apple share close stock market today close buy point amazon rise tuesday fresh time high general electric continue rally follow bullish analyst report add ge tumble last week worst level july ge apple be member dow jone industrial average so be boee microsoft investor lessen exposure equity market february td ameritrade say investor movement index proprietary measure client behavior brokerage fall level not see january week end feb be second monthly decline row index make record high fall increase score tend mean investor be get more bullish decrease mean investor be become bearish less bullish td ameritrade advise be best review index trend time rather focus month score more detail index be here be interested invest learn use day move expand bitcoin amazon nvidia alibabayy earning jump china livestream boomtarget earning miss outlook weak strong online sale growththese tech leader have break more be buy top chip play poise break re riskygeneral electric reason worst be ge stock
56,GILD,alexion pharmaceutical alxn gilead science gild vertex pharmaceutical vrtx be likely beat fourth quarter earning estimate analyst predict biotech guidance be cautious windfall tax reform fourth quarter earning report season kick next week dow johnson johnson jnj novartis nvs weigh tuesday wednesday pharma side celgene celg biogen biib be deck early thursday abbvie abbv trail friday leerink analyst geoffrey porge expect cautious prediction begin note example celgene pre announcement earlier month uncertainty payer dynamic competition drug access be likely play forecast factor imminent return more challenge political environment suggest management team be more typically cautious guidance first provide financial community earning call say note client fourth quarter porge call vertex cystic fibrosis drug orkambi kalydeco gilead hepatitis hiv drug regeneron pharmaceutical regn eylea dupixent latter eye disease eczema treatment respectively surprise upside ibd take biotechs suffer third quarter high profile drug miss expectation smaller player take headline beating view head industry snapshot more happened prior quarter history be expect repeat see older drug amgen amgn include psoriasis arthritis med enbrel risk disappointing investor biogen multiple sclerosis drug avonex plegridy abbvie cancer med imbruvica also disappoint say needham analyst alan carr see investor focuse merger fourth quarter call week rumor emerge celgene be consider takeover juno therapeutic juno biogen be consider putt bid acorda therapeutic acor continue believe pharma have bias risk asset be market case still regulatory review write note client first half expect food drug administration approve vertex cystic fibrosis regimen kalydeco tezacaftor well hiv combination gilead abbvie neurocrine bioscience nbix also get drug treat severe menstrual pain alnylam pharmaceutical alny be also likely grab approval patisiran drug treat condition abnormal protein deposit body cause systemic problem achaogen akao tetraphase pharmaceutical ttph be also near approval antibiotic related celgene rumore acquisition juno actually make sensedow merck do face release cancer trial hospital plan put pressure generic drug maker
57,GILD,biotech company celgene celg biogen biib gilead science gild put drug extensive trial gain fda approval turn clinical research firm pra health science prah pra health be lead contract research organization hold ranking medical research equipment service industry group ahead
58,GILD,gilead science gild top sale adjust profit view third quarter share drop late thursday hepatitis drug franchise decline again narrowly miss consensus expectation xin hour trading stock market today gilead fall share close biotech stock widely sell close bell thursday follow celgene celg sale miss guidance cut total sale decline top consensus analyst poll zack investment research adjust profit come share beat expectation adjust earning share sale hiv hepatitis drug climb nearly flagship hiv drug genvoya post yearly gain beat consensus rbc analyst brian abraham write note client gilead hepatitis drug meanwhile continue struggle fall third miss analyst view loncar investment chief executive brad loncar say note follow entry abbvie abbv mavyret treat genotype hepatitis rbc abraham note hepatitis drug harvoni come considerably lighter expectation vs consensus epclusa also miss post be consensus ibd take gilead currently have ibd relative strength rating best possible earlier month rs rating rise high visit ibd datum story more go rating stock even explicit guidance believe directionally help bring street hepatitis number next year welcome reduction lessen overhang share abraham say other product sale include drug treat high blood pressure lung angina fungal infection decline gilead increase low end net product sale guidance see hepatitis drug sale comprise firm also lower top end hepatitis guidance reflect sale related biotechs amgen sarepta vertex top third quarter scientific dife abbott rivalry hit pacemaker salescelgene crash sale miss alexion bristol result mixed
59,GILD,biotech stock topple last week follow disappointing third quarter result like celgene celg gilead science gild analyst say monday note competition pricing concern start take toll arrival new competition form abbvie abbv mavyret force gilead hepatitis drug franchise lose share third quarter meanwhile celgene note otezla treat psoriasis psoriatic arthritis be increasingly competitive market gilead top total sale view revenue hepatitis drug decline third narrowly miss analyst forecast celgene alarm result be drive major miss sale otezla lead total sale lag guidance cut instinet analyst christopher marai say competitive pricing concern take hit broad biotech market nasdaq biotechnology index finished nasdaq wrapped week less higher meanwhile ibd company biotech industry group lose nearly slip third group track ibd last week have be rank first then second ibd take celgene cut many element guidance include inflammation immunology drug head ibd industry theme more celgene result mean broader group alnylam pharmaceutical alny avexis avxs be more expose competitive concern marai say note client alnylam be work drug call patisiran treat rare disease cause buildup abnormal material rival ionis pharmaceutical ion prothena prta avexis be work therapy spinal muscular atrophy rival biogen biib ionis sell spinraza treat same condition marai list spinraza sarepta therapeutic srpt exondys duchenne muscular dystrophy fundamentally strong launch continue look strength select name opportunity take profit biotech reinvest less macro expose name be rich potential stock catalyst next month say avoid price perfection name include alnylam avexis next year marai see prothena deciphera pharmaceutical dcph cellectis cll macrogenic mgnx have slew potential catalyst related dow merck plunge month low grow keytruda worriesgilead beat third quarter sale earning viewsthree biotech firm top third quarter view only pop
60,GILD,bluebird bio blue juno therapeutic juno release preliminary datum early wednesday respectively sickle cell disease aggressive lymphoma send stock skyward xby close bell stock market today bluebird initially surge more settle back gain finish juno pop end regular trading day well buy point flat base begin form late september duo release preliminary datum ahead american society hematology annual meeting december bluebird stock movement come fact biotech report third quarter sale adjust loss share lag wall street preliminary datum show bluebird be able boost number gene correct bone marrow cell patient sickle cell disease used update version therapy call lentiglobin mean patient produce healthier red blood cell bluebird say also plan present update datum study drug call bb patient advanced multiple myeloma blood cancer bluebird be work drug follow bb celgene celg ibd take biotechs have largely offer mixed quarter celgene third quarter sale be call alarm head ibd industry theme closer look firm have report thus far quarterly result lag consensus bluebird report adjust loss share sale vs analyst call adjust loss share sale juno be set report quarterly result close release early datum study drug dub jcar diffuse large cell lymphoma blood cancer study patient respond specific dose jcar sign cancer disappear patient core group month dose core group best overall response rate be best complete response rate be jcar belong class know car drug novartis nvs gilead science gild virtue acquisition kite pharma already have drug approve gilead yescarta be already approve treat large cell lymphoma include diffuse large cell lymphoma primary mediastinal large cell lymphoma novartis drug kymriah be approve treat form acute lymphoblastic leukemia patient age tuesday novartis say aim have kymriah approve treat diffuse large cell lymphoma related celgene gilead pricing wo continue haunt biotech stocksgilead top sale profit view miss hep share falldow stock merck topple withdraw keytruda application europe
61,GILD,celgene celg comfortably spend acquire juno therapeutic juno analyst say wednesday juno share soar rumor biotechs be merger talk analyst applaud potential deal make strategic sense firm juno need celgene size compete bigger rival treat blood cancer celgene be face patent cliff blood cancer drug revlimid say be rarely fan high premium takeover deal probably make sense celgene win surprise company shareholder leerink analyst geoffrey porge say note client midday trading stock market today juno share race record high end day nearly celgene sank finish juno celgene already partner car program car therapy use patient immune cell fight cancer deal celgene own juno stock pay development cost own right duo be face stiff competition car arena follow gilead science gild nearly acquisition kite pharma october now gilead novartis nvs have car drug approve meaning juno be trail potential approval year ibd take juno have ibd composite rating best possible meaning outperform stock term key growth metric head ibd stock checkup look better rate biotech stock leerink porge compare juno kite be car player work develop therapy target cd protein tumor claim have proprietary element construct manufacturing process give edge commercialize similar product similar indication month other approximately similar clinical result say suggest be much more similar other biopharma company be juno face setback march patient die receive car therapy juno have scrap particular therapy be work kite gilead get market first porge suggest celgene juno settle price similar gilead acquisition kite juno see technology best class argue premium celgene argue discount note gilead have first market advantage tuesday close acquisition rumor crop juno have market cap just north wednesday stock movement juno market cap rise close end juno recognize be now compete novartis gilead probably need resource least celgene be successful market say neither seem incline let deal fail price hubris add juno gilead novartis isn go stop first car approval car therapy have show promise blood cancer number biopharmas also be look potential use solid tumor juno look likely gain approval later year therapy jcar treat diffuse large cell lymphoma aggressive form hodgkin lymphoma gilead already have therapy approve novartis be also seek approval use juno look other possible used include other leukemias lymphomas leerink analyst michael schmidt say note client total estimate peak sale assume best case scenario schmidt expect juno capture third market car drug target cd protein diffuse large cell lymphoma primary mediastinal cell lymphoma mantle cell lymphoma chronic lymphocytic leukemia acute lymphoblastic leukemia latter indication novartis already have approval schmidt also see juno get market multiple myeloma fellow celgene partner bluebird bio blue be work related blood disease datum send biotech stock flyingdoe gilead now have new multus dollar franchise novartis fda cancer also be boon rival
62,GILD,juno therapeutic juno surge late trading tuesday report celgene celg be talk acquire accord wall street journal unnamed source say celgene be talk buy juno have long partner cancer treatment include car drug immune system identify fight cancer talk pan deal come week source say potential deal acquire juno come heel gilead science gild nearly purchase car drugmaker kite pharma late last year now gilead novartis nvs have only approve car drug market juno follow car drug approval later year company have say so far car drug look best poise treat blood cancer firm be also look used therapy solid tumor gilead buy kite help stem gap decline hepatitis drug sale celgene buy longtime partner juno give leg prepare lose patient protection revlimid treat blood cancer know multiple myeloma ibd take hematology focuse biotechs have pique investor interest late see firm be work visit ibd industry theme representative juno decline comment investor business daily representative celgene didn immediately return request comment hour trading stock market today juno rocket close celgene sank end regular session bluebird bio blue car company also partner celgene see stock pop hour related biotech stock see cheapest rival cancer drugswhy biotech stock be defy hematology related pitfalldoe gilead kite acquisition offer new buy opportunity
63,GILD,key market index fund extend gain monday apple aapl boee ba lead dow jone industrial spdr dow jone industrial average dium powershare qqq trust qqq soar spdr spy advanced emerge market also rally ishare msci emerge market eem rise apple boee lead dow gain more american express amex cisco csco leap respectively apple regain day move average heavy volume day line gold miner energy semiconductor lead sector fund stock market today west texas intermediate crude price be barrel gold future rise ounce vaneck vector semiconductor smh ishare phlx semiconductor soxx advanced etfs be get closer retake day line real estate retail utility lag vanguard real estate vnq pare steep early loss remain year lows ishare real estate iyr reversed slightly higher be trading month lows european regulator warning cryptocurrency be highly risky bitcoin leap accord coindesk earlier session high bitcoin investment trust gbtc climb track fifth straight advance find support day move average december peak biotechs genomic have be lead health care exchange trade fund year weren spare last week market rout find support key level end week monday bounce support broader market rally ark genomic revolution multus sector arkg top list year date gain feb etf invest company expect benefit improve person quality life incorporating technological scientific development genomic business include company involved area such gene therapy next generation oncology stem cell top holding feb include intellium therapeutic ntla illumina ilmn edita medicine edit biogen biib bluebird bio blue gilead science gild also make top top account stock portfolio arkg test day move average friday find support close just day move average first trust nyse arca biotechnology index fbt be next year date return accord morningstar direct fund slice day line friday reversed retake line close small gain most stock be midcap range average market cap count top holding bioverativ bivv juno therapeutic juno fibrogen fgen bioverativ be be acquire sanofi sny deal ibd take don try guess market be head next read big picture day understand action major average lead stock spdr biotech xbi come third year date gain etf track biotechnology select industry index display similar action fbt friday many year old fund holding have average market cap skew smaller fbt xbi top holding include bioverativ juno array biopharma arry overall average annual return health care fund make list lag past year be lead benchmark index past year friday pick proshare ultra short qqq sqqq reversed lower loss nasdaq close gain sqqq hold day line related nvidia top tech stock lead bounce key support linestock rally apple nvidia fuel big gain be bitcoin back stock market sell do now
64,GILD,dynavax dvax crossed finish line early november first new hepatitis vaccine year dose regimen chief executive eddie gray expect foster better compliance adult share crash day announcement tack pitfall day later investor await acquisition partnership help small cap biotech launch drug name heplisav think person be hope dynavax announce buyout large partnership re not capable commercialize own say brad loncar portfolio manager loncar investment probably find deal person expect big pop run exit didn happen loncar say gray tell investor business daily company talk anyone offer knock sock then first priority be move forward launch drug expect sometime quarter ibd take investing exchange trade fund get closer high flier nektar therapeutic launch strong datum stem combination immuno oncology drug bristol myer squibb opdivo head ibd etfs page closer look key biotech etfs meanwhile dynavax also have asthma drug phase testing potential drug cancer pipeline have checkpoint inhibitor mechanism similar treatment dow component merck mrk bristol myer squibb bmy gray talk ibd dynavax approve hepatitis vaccine mean hepatitis treatment like gilead science gild ibd make heplisav unique gray first product get approval be adult vaccine hepatitis traditionally have be vaccine year work well child don work so well adult ve be able do be bring market new vaccine have significantly higher protective level so more adult reach protection do so traditional vaccine re also able do just used dose heplisav new product have vaccination today have second dose month now older vaccine dose schedule be today month then month key problem adult market be adult be extremely poor come back get third dose mean be contribute factor so many adult be not adequately protected ibd do mean hepatitis market gray be only dose vaccine timing be important point view public health cdc center disease control prevention release latest datum hepatitis infection rate adult population unite state have show be first time year re see increase number infection hepatitis adult unite state datum show essentially increase nation part country higher be thought current opioid crisis obviously involve needle use be contribute area increase rate do have pretty uniform picture country emerge increase hepatitis infection fact traditional dose vaccine do not work well adult re simply not protected need be fact dose vaccine be difficult schedule person follow mean availability vaccine inherently provide higher level protection specifically demonstrated trial do so dose schedule be simpler regimen person follow think be important contributor public health expectation be become dominant vaccine adult market ibd be position competitively gray think re extremely well position think not only be first prophylactic vaccine year profile also be last isn go be competitor larger company mentioned gilead re concentrate be find treatment person be already infected be vaccinate person be not yet infected stop become infected so actually gilead be more worry stopping person get hepatitis infection split important keep apart so don have concern larger company work hepatitis ve already get hepatitis then too late vaccine anyway ibd big be market gray moment number adult get vaccinate year be happened couple year be cdc manage schedule also recommend adult have diabetes also be vaccinate protect hepatitis number person diabetes unite state be obviously very large number person newly diagnosed year be so just newly diagnosed alone almost double market opportunity not count bolus person be already diagnosed diabetic have not be vaccinate certainly see potential vaccine grow be year range ibd comment market reaction follow heplisav approval gray ve see market reaction sort good news sort idea portion market isn terribly interested actually approval operate idea sell news regardless future picture look think fairly clear experience think re very encourage conversation large long hold investor think everybody sort used temporary phenomenon expect appropriate value type approval come back stock time have take position not publicly comment be partnership discussion debate think ve be very clear have say be look profile vaccine look profile have be translate label recognize adult vaccine market be very contain well understood marketplace easily accessible then do believe strong story commitment here high level delivery stockholder dynavax launch heplisav intend do now somebody come offer recognize potential sort knock sock offer then course ll talk such event happen re putt together plan launch heplisav related biotech prosper back roche cancer trialmedtronic surge top quarterly earning viewsbiotech spike settle debate seizure medicine
65,GILD,index dow industrial nasdaq composite suffer worst day weekly loss year lead stock suffer major damage stock market moved correction nvidia nvda snap snap twitter twtr rally strong earning grubhub grub shot big deal kfc taco bell parent yum brand yum tesla sell line result world publicity stunt major average many lead stock tumble intensify loss prior week big loss stock market moved uptrend pressure correction chip energy china name be big loser stock market retreat be broad deep stock do stage nice rebound test day move average take more good day snap downtgrend facebook rival snap snap twitter twtr have stellar result nvidia deliver blowout earning bullish guidance year treasury yield hit year high unnerve stock market backed graphic chip maker nvidia nvda earning swell share sale quarter end jan analyst expect current nvidia expect revenue wall street be look share soar friday meanwhile broadcom avgo raise bid buy wireless chip maker qualcomm qcom share say be best final offer qualcomm reject deal value broadcom be seek replace qualcomm board ibd take stock market be now correction read cover story stock sell do now tesla beat fourth quarter revenue earning estimate maintain production target model sedan tesla still see weekly model production rate end first quarter end second quarter again warn difficulty accurately forecasting specific production rate specific point time cash burn decline analyst say special factor suggest improvement win continue spacex falcon heavy rocket most powerful rocket use factor successfully lift maiden flight booster return safely rocket show satellite insertion technique air force position future military launch small potentially lucrative market then send ceo elon musk tesla roadster elliptical orbit sun twitter share report first ever gaap profit adjust earning easily beating view first quarter guidance estimate share shot week meanwhile snap catapult wednesday snapchat operator deliver strong fourth quarter revenue user growth smaller expect loss grubhub grub sky-rocket announce partnership fast food behemoth yum brand yum parent taco bell kfc pizza hut report better expect fourth quarter earning already top provider online order food delivery service grubhub now be exclusive online delivery partner yum brand taco bell kfc yum brand be buy grubhub stock video game publisher activision blizzard atvi modestly beat wall street consensus estimate holiday sale quarter thank hit game call duty wwii industry peer take interactive software plunge holiday earning top sale revenue guidance disappoint fireeye feye swung adjust profit cent share revenue rise top fireeye forecast march quarter revenue estimate fortinet ftnt top earning sale view give weak operate margin guidance march quarter fortinet cfo be leave citrix system ctxs proofpoint pfpt top earning view march quarter profit guidance be light proofpoint announce third recent acquisition wombat security paycom software payc report fourth quarter result beat consensus estimate revenue earning paycom leader cloud base human resource management tool also present first quarter revenue guidance line consensus estimate general motor gm post record profit top fourth quarter estimate help part boom crossover sale ep jump revenue fall reflect key divestiture fellow auto giant toyota motor tm see operate profit grow fiscal third quarter lift full year profit forecast gilead science gild top fourth quarter expectation adjust profit share sale sale guidance be light bristol myer squibb bmy glaxosmithkline gsk allergan agn alexion pharmaceutical alxn regeneron pharmaceutical regn teva pharmaceutical teva top expectation bristol share fall confusion regard immuno oncology trial opdivo lung cancer alexion teva topple weak guidance sanofi sny miss ep sale view bitcoin tumble early tuesday top financial regulator senate banking commerce hearing be not negative fear investing digital currency bitcoin rebound be still less half december time high meanwhile goldman sachs global investment chief predict most not current cryptocurrency end lose value cboe global market cboe crash day move average tuesday trading be halter several inverted volatility product raise concern trading volume profit option exchange friday cboe miss earning revenue estimate fidelity say bar client buy inverted volatility instrument cboe fall week walt disney surpass expectation ep jump sale grow theme park resort segment lead revenue gain offset weakness studio consumer product medium network subscription stream service espn debut spring month mlb mls nhl game sport tennis boxing golf rugby cricket share fall week line major avearage handbag brand michael kor kor post surprise profit growth share sale gain comp slide less anticipate upscale parka maker canada goose goos beat yet again share plunge ostensibly due high expectation coach kate spade parent tapestry tpr turn solid beat kor fall week canada goose nearly tapestry gain wynn resort wynn ceo steve wynn resign wall street journal report detailed allegation sexual misconduct spur stock sell regulatory probe wynn share rise wednesday edge lower week well fargo wfc share tumble federal reserve feb bar bank expand balance sheet demand board shake wake well sham account scandal chipotle grill cmg share nose dive fast casual chain signale continue weaker sale traffic trend more spending year improve restaurant boee ba reportedly present compromise plan brazil government let take stake joint venture commercial jet business embraer erj meanwhile wwd deny report talk boee takeover chip gear maker ichor holding ichr top estimate fourth quarter earning share penny miss view penny outlook current quarter send share sharply lower laser system maker coherent cohr fall hard post slightly better expect december quarter result disappoint profit margin outlook share crash extreme network extr report fiscal revenue miss adjust profit edge view march quarter guidance include asset acquire brocade be slightly estimate share fall netgear ntgr report earning beat expectation miss revenue company plan spin fast grow arlo security camera business hold ipo share fall zendesk zen narrow quarterly loss year earlier revenue also top view send share higher zendesk forecast revenue consensus estimate share gain match group mtch report revenue top estimate soar growth tinder date app adjust profit miss rise investment match add tinder subscriber december quarter give overall yelp yelp report fourth quarter earning top consensus view provider crowdsource online reviews advertising growth amazon amzn rolled same day hour delivery whole food grocery order include produce meat dairy seafood certain alcohol product austin cincinnatus dalla virginia beach challenge grocer staking territory supermarket turf war amazon aim expand service other city year amazon also reportedly be plan launch own mail delivery service hit share fedex fdx unite parcel service up
66,GILD,dow component merck mrk slide friday keep tumble hour disappointing third quarter sale withdrawal application europe advanced lung cancer treatment xin hour trading stock market today merck fall additional share close bristol myer squibb bmy make rival drug opdivo lift late friday close abbvie abbv also miss third quarter sale expectation beat profit view advanced close bell late friday merck say decision withdraw european application be base datum study dub keynote cohort didn offer specific regard finding regimen be already approve first treatment advanced lung cancer merck be confident clinical datum rigorously conduct trial demonstrated specific improvement overall response rate progression free survival keytruda combination regimen compare chemotherapy alone firm say news release immuno oncology drug keytruda be combine chemotherapy treat lung cancer earlier day merck report adjust income share beating view analyst poll zack investment research share sale decline lag analyst model investor have zero keytruda merck give increasingly challenge hepatitis environment leerink analyst seamus fernandez say thursday gilead science gild report hepatitis drug sale fall third expect question focus almost entirely evolution keytruda uptake first treatment small cell lung cancer timing readout study call keynote confirm keytruda chemotherapy advanced lung cancer fernandez say note client still merck hepatitis be bright spot quarter sale zepatier post yearly sale gain growth only paled comparison cancer drug keytruda bring ibd take merck share begin form flat base buy point early march flat base be several way identify potential stock head investor corner more read pattern merck biggest product diabetes drug call januvia janumet decline other big decline include dip sale cholesterol drug zetia vytorin slide revenue human papillomavirus drug gardasil gardasil sale be reduce due change center disease control prevention gardasil vaccine cyberattack hit merck quarter revenue also take hit lose sale market cyberattack firm raise narrow full year guidance see adjust earning prior target analyst view also forecast sale earlier view consensus see abbvie quarter be just leerink analyst geoffrey porge say note client earn share exclude various item top consensus sale lag consensus grow year period more importantly abbvie outlined ambition current product late stage pipeline porge say firm see humira treat rheumatoid arthritis psoriatic arthritis spinal arthritis crohn disease plaque psoriasis approach sale prior target porge say year abbvie now expect adjust profit share touch low end consensus forecast abbvie guide adjust income share lag analyst view humira be abbvie biggest drug quarter sale grow be consensus porge say cancer drug imbruvica post yearly sale gain imbruvica sale beat analyst view porge say gilead struggle hepatitis drug franchise abbvie hepatitis unit beat analyst average sale decline follow approval august mavyret treat genotype hepatitis related celgene result call alarm alexion bristol mixedboston scientific dife abbott rivalry hit pacemaker biotech firm top third quarter view only pop
67,GILD,gilead science gild topple month low thursday report emerge appellate court revive whistleblower case allege biotech giant lie ingredient sourcing trio hiv drug xshare dove more point end trading day stock market today biotech group collectively rise month high gilead pitfall follow report forbe late tuesday note ninth circuit court appeal have revive court case case be revive july case allege gilead violate false claim act tell food drug administration source active ingredient commonly know ftc used hiv drug emtriva truvada atripla facility canada germany south korea former employee claim gilead instead contract unauthorized chinese firm manufacture unapproved ftc unregistered facility course month begin december gilead allegedly do so save money trigger price reduction clause contract other ftc supplier accord lawsuit eventually gain approval use supplier ftc have already be used ingredient finished product year ibd take gilead have ibd composite rating best possible meaning perform better nearly stock term key growth metric head ibd stock checkup look other biotech leader contamination issue include recall contaminate product lead gilead stop used supplier gilead never acknowledge notified fda bad test result contamination issue accord lawsuit conceal use illicit ftc gilead allegedly import ingredient canadian facility used fraudulent labele whistleblower say label paperwork be allegedly obscure augment register manufacturer be credit supply ftc whistleblower be terminate duo bring initial suit january amend suit june prior case be dismiss gilead didn immediately return request comment investor business daily related novartis acquire biotech deal be very logical biotech stock watch pharma industry newsfda chief gottlieb address opioid cancer new therapy
68,GILD,nothing add more sparkle portfolio capture enormous gain truly innovative new company timely investing recent ipo stock xthink google now know alphabet googl more initial public offer microsoft msft run post ipo trading low march peak nearly year later not mention cisco system csco greatest stock bull market shot less decade comparison picking seem slim today ipo market number initial public offering year date have increase meager pace low historical basis yet sharp eye investor still find jewel new ipo stock guarantee company match long term gain alphabet microsoft yet be impressive start add shine portfolio consider company debut past month least stock currently trade higher be more year base investor business daily research hearty outperformance year nasdaq be excel rise have rally elite group include ichor ichr square sq atlassian team argentine lender grupo supervielle supv list top perform ipos watch be provide bottom article new stock market company have show strong fundamental give investor confidence business strategy be highly profitable combine trail month revenue quartet new market maestro stately nyse trade square software let small business mobile merchant take credit card payment tabletop device smartphone come public share november today stock be trading atlassian sell project management collaboration software trade have jogged more higher hold initial public offer december addition more stock least more company go public year already have rise more stock hold ibd earning share rating higher range retailer floor decor fnd auto shopping site cargurus carg warrior meet coal hcc coal miner gardner gdi industrial equipment maker greg eisen senior research analyst market strategist los angele base singular research note roughly half recent ipos hail speculative biotech sector pharmaceutical biotech be still largest area innovation say note many newly public company be work new medicine treatment don have significant sale much less profit true least top ipo stock year pulse bioscience plse beigene bgne pulse be work device use proprietary nano pulse stimulation technology attack solid tumor have sale beigene firm register cayman island operation cambridge mass china post just revenue so call clinical development stage company be risky demand greater scrutiny yet too be closely watch sign look do top perform mutual fund own share stock better yet be show confidence add holding time fund have deeper research expertise individual investor judge fund performance ibd rating rate have perform top past month be list ibd weekly newspaper information fund ownership specific stock be find ibd marketsmith service more ipos be hit market present new opportunity investor first week november combine new issue most week period year raise nearly proceed accord dealogic nov chinese internet content play sogou sogo have positive debut finishing session ipo price raise nearly banker fee company have sohu com sohu control stakeholder notch jump third quarter profit cent share revenue gain watch see form initial base same day apellis pharmaceutical apls price share stock be trading ipo price year date nov ipos list exchange have totale company together raise accord dealogic company raise total capital year total be also higher raise firm likely fall well short raise company nov number new issue past month ratio total company list nyse have hit month peak well year high see august track statistic go psychological indicator volume link stock section ibd datum table ibd take used stock chart correctly help time purchase lead stock so maximize gain minimize loss relatively short period time watch breakout key chart pattern earning season be especially helpful addition flat base saucer base cup handle stand most critical pattern human psychology visualize investor fear greed hope denial learn more cup handle so gain extra edge robert maltbie president founder singular research think optimism new issue be not yet boil point thus good future equity have snowball effect inverse sort way market go higher extend small cap tax cut occur only accelerate issuance ipos maltbie say reason corporation stand benefit congress plan lower taxe sharply singular research note pipeline rest year be decent potential ipos maltbie eisen however expect upcoming market debutante fall small cap range bigger offering such snap snap quickly hit market cap march debut be now value market strong rebound thursday follow passage massive tax reform bill house representative company have decide go public argentine food producer molino canueala ticker molc target range file registration american depositary receipt share oct thursday renaissance capital report flour oil biscuit giant be postpone ipo offer share potentially raise fee specialty silicone chemical additive play mpm holding be also delay potential ipo waterford base company post month sale late thursday sailpoint technology sail price offer share apiece raise friday morgan stanley citi jeffery lead new issue finished day investor have higher likelihood pick winner focus company large year year increase earning sale look company have best pretax tax profit margin field occasionally company earning still become giant winner particularly revenue be grow rapidly have other positive attribute include well regard management team wall street banker proven track record back highly successful new stock past decade morgan stanley jpmorgan chase credit suisse goldman sachs have successfully bring numerous outstanding company public business software firm workday wday ipo come mind year pleasanton calif firm go public rac revenue fiscal end january year also lose cent share yet stock climb month investor know workday founder david duffy man build peoplesoft former software giant stock market leader eventually get acquire workday continue post fast growth revenue soar fiscal company also bag first net profit earn cent share wall street expect earning jump cent current fiscal end january company kind growth be rare even case biotechs only best company have outstanding earning sale show potential become big amgen amgn gilead science gild be tempting buy share promising new company first day trading usually best stock establish trading range take week time well spend investor help chart get sense supply demand balance do stock peak say seem find floor such information be useful especially investor used chart stock have strong demand shouldn fall stock rise past investor buy share new high strength suggest institutional investor such mutual fund bank pension hedge fund be back truck desire large amount share technical analysis ipo stock be bit different establish stock ipo style basis stock chart pattern form just week much shorter common basis establish stock such flat base be minimum week length cup handle be least week long look proper entry price be typically cent narrow ipo base left side peak higher volume buy buy point luxury good retailer michael kor kor debut december share race higher less week high then pull back gently course just session kor drop pull back just build narrow new ipo base jan maker stylish handbag watch sunglass high end apparel shot narrow base rise nearly clear buy point fifth heaviest volume single session spur gain less month kor produce new base then break again august same year share eventually reach high february peak patience chart analysis keep be euphoria ipos supposedly hot business money lose social network snap be latest example company get plenty medium coverage debut nyse march share snap rise fury first day mostly fall then nov share plunge venice calif company report disappointing third quarter revenue growth far smaller year gain prior quarters blue apron aprn web base meal kit delivery service be bleed red ink have sale last year have do even stock peaked first day trading now trade quality ipos generally have decline heyday small company view go public rite passage give access public market recognition be public bring company brand bryan anderson executive vp market strategist austin base beck capital management tell ibd anderson once work portfolio manager william neil co base many highly tout ipos have perform recent year be clear company be increasingly go public primarily provide exit strategy founder venture capital backer leave crumb public investor anderson add early investor be make bulk return not say careful investor find ipo gem most successful new issue tend create new product service change way person work live spend time medical company attract big sale government approve treatment extend life improve quality life take moorestown base tabula rasa healthcare trhc come public september software provide better way prevent adverse side effect multiple medicine take patient atlassian base business collaboration software firm be change way company employee communicate other get task project do midcap stock boast exceptional fundamental see ibd stock checkup include composite rating ep rating smr sale profit margin return equity ipo leader daily automate stock screen also include weekly commentary help reader locate stock be trading best entry point ibd find company have go public past month hold earning share rating higher trade share higher re list table get more analysis commentary new issue lead stock other key financial market follow saito chung twitter ibd_dchung related investor learn snap ipohot new ipos form critical chart patternbefore buy bitcoin read thisbirth industry early investing hot spot artificial intelligencehot growth stock chart annotation help learn leaderboard right now
69,GILD,future index nasdaq dow industrial rise slightly tuesday morning major average close session lows monday top rate medical biom biotech group fall again several lead biotech stock test key level biogen biib amgen amgn gilead science gild celgene celg vertex pharmaceutical vrtx alexion pharmaceutical alxn be tap earning week future rise vs fair value dow future climb nasdaq future edge fraction nasdaq composite lead monday retreat lose index fall dow industrial medical biom biotech group fall ninth straight decline hit month high oct even so still rate industry ibd track biogen report better expect earning tuesday morning amgen vertex follow wednesday celgene alexion gilead science report thursday addition biogen slew big earning report tuesday include mcdonald mcd unite technology utx lockheed martin lmt general motor gm open biogen earning rise nearly share sale climb analyst have expect ep revenue biogen be leader multiple sclerosis drug have new hit spinraza only spinal muscular atrophy drug market investor be also bullish prospect aducanumab have indicated early testing reduce cognitive decline early alzheimer patient biogen share rise market open tuesday monday stock fall monday stock market trading third straight decline close just buy zone entry initially clear end august ibd take buy hold stock be risky head earning report here earning option strategy help cash post earning stock gain minimize risk weak quarter amgen vertex gilead science fall day move average monday amgen close old buy point first time amgen vertex gilead be new flat basis vertex bust july promising datum new cystic fibrosis drug gilead science be best know hiv aids hepatitis drug last week win fda approval car drug treat aggressive form hodgkin lymphoma drug yescarta come gilead recent acquisition kite pharma gilead earning be expect fall hepatitis drug sale tumble amgen ep be see vertex earning be expect go vertical surge cent celgene share rise monday tumble friday celgene scrap late stage trial crohn disease treatment wall street forecast ep gain alexion retreat monday undercut low short flat base alexion drop day move average friday alexion earning be expect rise popular way avoid stock specific risk biotech be etfs ishare nasdaq biotech ibb fall drop day move average buy point clear end august related stock buy zone earning due investing action big picture nasdaq add rd distribution day sessionsbiogen biomarker mark way alzheimer parkinson abandon crohn drug other take spot do gilead now have new multibillion dollar franchise top biotech company innovation earn recognition new award
70,GILD,celgene celg vertex pharmaceutical vrtx incyte incy be worth watch broader market correction see biotech stock lose collective previous day analyst say tuesday biotech stock rebound stock market today diving monday bmo capital market analyst brian belski say note client investor be reap sow intent purpose majority client market pundit especially increasingly boisterous set naysayer have be predict bull market imminent demise day presidential election say doesn mean bull market be dead belski say rbc analyst brian abraham agree see opportune entry point certain biotechs stock datum approval expect thing be look celgene few misstep second half include major miss sale psoriatic arthritis drug otezla third quarter abraham say sale drug rebound fourth quarter believe market cap reduction more reflect believe fourth quarter number guidance point reassure stabilization key revlimid otezla sale say ibd take bull market be good time review stock selling smart once begin stall uptrend too late catch head investor corner brush stock selling rule cancer drug revlimid be celgene biggest drug analyst have worry generic rival take sale start contend celgene recently announce plan acquire remainder juno therapeutic juno didn already own add juno coffer put celgene car space compete novartis nvs gilead science gild latter acquisition kite pharma car therapy immune system identify fight cancer even juno celgene look poise generate enough cash flow buy back virtually entire enterprise value revlimid go completely generic abraham say outside abraham see number catalyst include additional datum revlimid treat lymphoma late stage datum drug partner acceleron pharma xlrn blood disorder celgene rise tuesday abraham say vertex be victim bad timing vertex recently report strong datum triple combination regimen cystic fibrosis datum come just broader market be begin turn stock fall hard past day vertex rebound tuesday rise strong effectiveness drug know vx vx triple regimen head phase study support likelihood vertex expand tough treat population cystic fibrosis patient say also enable multiple additional shot goal set bar be difficult match beat significant lead time likely render mid year competitive datum galapago glpg overhang vertex share much less impactful raise price target vertex macro weakness be mask improve fundamental abraham argue incyte be set read datum phase trial know echo first half study combine incyte immuno oncology drug epacadostat dow stock merck mrk keytruda late stage melanoma drug class know immuno oncology treatment epacadostat work block interaction involve ido enzyme immune system keytruda be call pd inhibitor have similar interaction pd protein instinet analyst christopher marai expect trial read positively be similar regimen bristol myer squibb bmy drug opdivo yervoy bristol be also combine drug treat other cancer include advanced lung cancer so epacadostat become part standard care metastatic melanoma broad adoption augment current pd use say note client lead peak worldwide sale north melanoma alone epacadostat rbc abraham say eventually nearly value epacadostat soon be go incyte share see share jakafi treat bone marrow disorder share olumiant rheumatoid arthritis drug co develop eli lilly lly suggest downside upcoming epacadostat datum be negative be now likely only share fundamental upside now potentially more say make upside downside level much more interesting incyte advanced tuesday related allergan pop consensus top quarter strong migraine biotech stock dive more be sell overdo crispr small biotechs cure disease
71,GILD,stock fall hard tuesday then swung quick rebound buyer step lend chipmaker other tech stock surge early strength dow jone industrial average open show gain minute open nasdaq composite drop start gate then climb gain apple aapl surge fang stock tech leader reversed early loss gain quickly tighten open loss then rise chipmaker skywork solution swks micron technology mu post powerful early advance ibd take don try guess market be head next read big picture day understand action major average lead stock global feedback loop investor confidence darken abruptly week last week late loss reverberate asia europe monday then slam back stock investor also factor probability federal reserve roll accelerate rate hike schedule news strict sanction impose largest bank result send major index support day move average dow record point loss day loss monday be dow worst day percentage decline august tuesday japanese investor keep selling tokyo nikkei plunge worst single day performance november index have cut day move average heavy trade monday china market also take lick hong kong hang seng index buckled deepest decline july shanghai composite tumble be widest loss february hang seng end jan peak still hold gain so far year nikkei close jan record putt year date europe lead benchmark paris frankfurt london remain more afternoon trade nothing economic calendar include trade balance job opening labor turnover survey labor department be likely put much dent day market action give role fed current market concern investor pay close attention et speech st loui federal reserve bank president james bullard caterpillar cat rise jump early lead dow jone stock apple chevron cvx be also more ibd stock svb financial group sivb shake deep premarket decline rise start trade santa clara calif base bank drop week line weak volume loss monday china base name tal education tal sina sina also shed premarket slide rise respectively tal have hold well so far versus volatile market keep week line support month base pattern sina have pull back more cup base buy point trip automatic sell rule chip name be sharply mixed skywork slug open gain report better forecast fiscal first quarter earning revenue guidance be analyst target management announce share buyback initiative early jump haul share back support week week move average cirrus logic crus slough steep oremarket advance gain least analyst lower stock price target follow broad fiscal third quarter revenue earning miss cirrus be work fourth straight weekly decline end monday lowest level july electronic component manufacturer fabrinet fn rally open fiscal second quarter earning revenue narrowly top consensus view third quarter guidance be mixed busy hour report session be set include quarterly result walt disney beazer home bzh anadarko petroleum apc gilead science gild akamai technology akam other related stock future point sharp loss tuesday big picture stock slaughter more downside ahead worst point drop ever dow percentage loss be not do spot major stock market top here easy wayit time review stock selling smart
72,GILD,generalist be still hang biotech sideline analyst say wednesday specialist investor be willing look idea work come tax reform biotech stock end sentiment have weaken approach year high earlier year ibd company biotech industry group be now rank group track first week think investor have yet digest potential positive impact tax reform biotech space credit suisse analyst alethia young say note client repatriation be focus timing play consolidation lead caution president donald trump end year pass sweeping tax reform include cut corporate tax rate legislation also put place new rule allow company bring cash store overseas back cheaper tax rate many company coverage have low foreign earning certainly benefit taxe bottom line young say ibd take biotech chief executive be less experience today be year analyst say recent report cite reason win be big year merger acquisition space head ibd industry theme breakdown count regeneron pharmaceutical regn gilead science gild biogen biib bioverativ bivv unite therapeutic uthr outside tax reform investor be also focuse small midsize biotechs potential takeover target young say note investor seem remain cautious play small mid cap merger acquisition theme related biotechs outperform hyper competition do regeneron pharma have potential blockbuster biotech dife analyst slash expectation cancer drug
73,GILD,alexion pharmaceutical alxn pop tuesday vertex pharmaceutical vrtx be list top biotech stock pick hyper competition pricing pressure uncertain merger activity likely dominate year leerink analyst geoffrey porge peg vertex alexion leader rival struggle mount competition rely pricing hike sustain top line growth have strong management team attractive franchise garner takeover interest analysis lead believe best perform stock foreseeable future be participate category high barrier entry rely volume growth rather positive price contribution say note client close bell stock market today alexion climb finish vertex rise finish vertex share end alexion meanwhile broader biotech group wrapped year vertex be second best performer top biotechs market cap easily lead amgen amgn gilead science gild celgene celg end year respective flat alnylam pharmaceutical alny lead top rocket vertex have monopolized cystic fibrosis category drug know kalydeco orkambi porge say nearest competitor galapago glpg be time disadvantage product haven show same effectiveness vertex lucrative commercial opportunity cystic fibrosis present high barrier entry therapeutic indication have preclude emergence clear viable threat vertex cystic fibrosis franchise say ibd take median tenure chief executive large cap biotechs fall just year plunge year have impact merger acquisition analyst say last week head ibd industry theme closer look first quarter vertex be likely gain approval combination drug know tezacaftor ivacaftor treat cystic fibrosis patient gain traction patient discontinue treatment orkambi due tolerability year also be key vertex triple pill regimen treat cystic fibrosis say vertex be plan begin pivotal trial first half most analyst expect triple pill gain approval alexion meanwhile have see revenue growth drug know soliris past year treatment pair blood disorder increase sale be mostly due volume increase little price contribution porge say october food drug administration approve soliris treat muscle disease help continue sale trend say alexion be also work follow drug know alxn favorable dose schedule potentially better effectiveness porge expect alxn prove superior soliris treat blood disease know paroxysmal nocturnal hemoglobinurium phase testing result high conversion rate alxn soliris likely approve catalyst also extend terminal cash flow horizon alexion key franchise mid mid patent alxn expire say further alexion say late tuesday board director agree work activist investor elliott management identify new board member november alexion say have search underway fill open board seat be look candidate range background skill expertise related vertex chief talk company year biotech stock feel lovewhy biotech see upside second quarter
74,GILD,here weekly investing action plan need know investor come week earning season grind result due tesla tsla nvidia nvda grubhub grub disney match group mtch more social medium company restaurant cybersecurity firm chip sector company report well meanwhile
75,GILD,relative strength rs rating gilead science gild enter new percentile friday get lift unique rating identify technical performance show stock price action last week compare other stock database year market history reveal best stock typically have higher rs rating early stage move see gilead science continue rebound hit benchmark look best stock buy watch start heregilead science be work flat base buy point see stock clear price heavy volume earning sale growth come respectively latest report marked acceleration earning share sale company be expect report next quarterly number nov gilead science earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
76,GILD,loxo oncology loxo deal bayer bayry have bigger impact biotech sector expect industry observer tell investor business daily tuesday key exchange trade fund fall flat basis xearly tuesday loxo announce deal bayer co develop cancer drug agreement pay loxo term deal loxo bayer split profit equally drug know larotrectinib loxo sector be hope buyout say brad loncar portfolio manager loncar investment interview ibd loncar cancer immunotherapy etf cncr topple fellow etf peer fall loxo have be not most successful small biotech company year say person be hope buyout even weren hope buyout give pretty clear guidance be go hold right loxo stock be year monday close easily outperform ibd company biotech industry group have climb year date stock market today loxo topple close share be much earlier day collectively biotech group dove near month low hit highest point december october third quarter earning season be rough number player celgene celg gilead science gild weigh heavily group biotech centric etfs also take pitfall biotech etf xbi fall flat base buy point diving ishare nasdaq biotechnology etf ibb have be form flat base entry fall proshare ultra nasdaq biotechnology etf bib dove ibd take loxo have ibd composite rating best possible meaning perform middle stock term key growth metric head ibd stock checkup look better rate player biotech group loncar say merger acquisition really help biotech group loxo have be buy today everybody be say next smaller company go be buy probably be bidding stock say fact loxo be willing give away profit drug work target gene fusion cancer suggest biotech negotiating be bit weaker expect loncar say revaluation be hurt sector put tesaro tsro clovis oncology clvs same bucket have approve drug know parp inhibitor target ovarian cancer loxo larotrectinib isn yet approve big pharmas struggle quarter need buy revenue growth loncar say possible market have push valuation so high buyout doesn make sense like loxo tesaro clovis add biotech industry group be now rank group track ibd first just month gilead acquisition kite pharma announce august complete october help spike group nearly year high then group have pull back investor react harshly surprisingly news group loncar say prime therapeutic fprx dove nearly nov unveil abstract immuno oncology combination bristol myer squibb bmy pancreatic cancer overall patient respond combination prime cabiralizumab bristol opdivo pancreatic cancer be particularly hard treat typically doctor have expect response combination now duo have time refine treatment regimen wall street person demand instant gratification instant success drug loncar say be disappointing be big phase trial end road be literally first human trial dynavax technology dvax also have suffer follow food drug administration approval drug dub heplisav treat hepatitis stock fall monday loncar say investor be look dynavax be buy find partner think probably find deal say expect literally day approval so now first quarter re actually launch drug think chance good news add lot investor expect big pop soon wasn run exit don think reflective quality company related biotech just near year high strong cancer regimenwhy tesaro cancer drug miss prompt rival biotech just rise third earning be trouble
77,GILD,biotech stock collectively inched monday president donald trump reiterate concern drug price be control cabinet meeting accord number report president want bring drug price line other country tend be lower bloomberg report same exact drug same exact company make same exact box sell someplace else sometimes fraction pay country say meaning usual world be take advantage unite state trump comment come rise likelihood enact executive order tug drug price needham analyst kevin caliendo alan carr write report monday cite commentary washington area health care policy watcher expert cite needham say executive order regard drug price come day propose order be release never sign remain blueprint analyst write note client ibd take medical tech stock have be safe haven investor keep distance pharma analyst say group be trend record high economy improve allow patient get pseudo deferrable procedure head industry snapshot more mean group lower drug price benefit customer cut profit drugmaker biotechs drug treat rarer disease tend cost more company aim recoup cost associate lengthy numerous clinical trial afternoon trading stock market today biotech stock dip top biotechs biogen biib gilead science gild fall respectively amgen amgn dip less biogen remain extend buy point gilead be try find support day move average amgen undercut buy point trump have be outspoken bring drug price be swear president december say doesn have happened drug price follow inauguration trump call drug industry disastrous accuse firm get away murder base price medicine also promise create competitive system help bring drug price related exelixis rocket year high kidney liver cancer newsallergan tank judge invalidate restasis patentsgeneric drug maker face pricing issue other pharmas don
78,GILD,gilead science gild jump early thursday food drug administration approve be know car drug dub yescarta treat aggressive form hodgkin lymphoma late wednesday approval follow week gilead close acquisition kite pharma develop drug novartis nvs car drug be approve late august make first class approval close bell stock market today gilead climb close share be currently form flat base entry car drug be make used patient own immune cell cell be extract reprogram fight cancer be then reintroduce patient body juno therapeutic juno bluebird bio blue be also work car drug partnership celgene celg gilead drug be approve treat adult patient know large cell lymphoma more previous treatment include diffuse large cell lymphoma most common form aggressive hodgkin lymphoma accounting case gilead say ibd take washington base expert expect president donald trump sign executive order bring drug price day make thing harder biotechs drugmaker head ibd industry theme breakdown be estimate patient hard treat diffuse large cell lymphoma eligible car therapy gilead say fda estimate case hodgkin lymphoma diagnosed year roughly be new case diffuse large cell lymphoma yescarta be new option patient relapse refractory large cell lymphoma have run treatment option face dire prognosis say loui degennaro chief executive leukemia lymphoma society statement rbc analyst brian abraham say gilead be begin be potential multibillion dollar franchise approval come month ahead expectation demonstrate high unmet need patient diffuse large cell lymphoma say note client gilead be pricing yescarta be price tag novartis drug kymriah kymriah be approve late august treat form acute lymphoblastic leukemia patient age younger leerink analyst geoffrey porge note novartis be take outcome base approach pricing center medicare medicaid service firm only be paid patient respond month treatment kymriah base response rate pivotal trial estimate real list price be less treatment place yescarta less discount novartis drug net price basis write note client rbc abraham estimate gilead pull gradual launch expect yescarta sale grow least solely third treatment diffuse large cell lymphoma car drug be be investigate treat myriad blood cancer increase pricing assume approval indication second treatment diffuse large cell lymphoma mantle cell lymphoma pediatric adult acute lymphoblastic leukemia current model see peak revenue potential say leerink porge be less bullish gilead yescarta list price be higher expect gilead core business be still face competitive challenge patent expiry keep market perform rating stock get most kite acquisition require expand yescarta use porge say announcement do not provide justification premium gilead paid kite cellular therapy platform say gilead be depend broaden earlier line treatment expand other indication development additional product generate adequate return acquisition label yescarta warn cytokine release syndrome neurological toxicity former be associate flulike symptom include fever cytokine release syndrome be see patient clinical trial more severe case patient comparison label novartis kymriah note more severe cytokine release syndrome occur patient porge say due potential cytokine release syndrome neurological toxicity yescarta be available only restrict program call risk evaluation mitigation strategy mean facility administer drug be certify abide specific rule administration program require dose drug be available prior yescarta infusion patient be monitored facility week follow treatment sign cytokine release syndrome follow monitoring be require week infusion ultimately gilead plan have medical center capable administer yescarta drug have median turnaround time day manufacturing success rate facility el segundo calif gilead say related top biotech company innovation earn recognition new novartis cancer approval validate gilead kite dealanalyst mixed gilead kite key rival stand benefit
79,GILD,sell health stock tuesday joint venture amazon com amzn jpmorgan chase jpm berkshire hathaway brkb wring cost saving health care system appear very unlikely impact industry earning next couple year accord analyst figure rein health cost participation big health care player look impossible task needham analyst kevin caliendo say note cost implement system adjudicate patient datum partner hospital doctor pharmacy national basis be onerous caliendo add scale big new partner wouldn be big enough squeeze discount provider steering patient way compare purchasing power unitedhealth unh cvs health cvs aetna aet anthem antm new company have align other provider way provide best care employee caliendo conclude fact caliendo give cvs big vote confidence earlier tuesday say plan combination aetna position create saving government private employer needham raise rating cvs strong buy target caliendo do think profit industry especially underwriting level be excessive be improvement current care delivery model be make see prime reason cvs aetna deal cvs be look shift more health care service lowest cost location store clinic different take unitedhealth playbook expand urgent care other outpatient locale drive saving customer such path forward be evident announcement amazon jpmorgan berkshire plan establish independent company be early plan stage accord statement trio group do not come problem answer acknowledge berkshire ceo warren buffett success be go require talented expert beginner mind long term orientation say amazon jeff bezos yet unclear point talented expert be wall street weigh long term nature effort dearth substantive detail initial shock wave ripple wall street subside share dow jone industrial average component unitedhealth nation largest insurer sank stock market today diving much earlier cvs health be process buy aetna pare loss drop drug distributor cardinal health cah mckesson mck be respectively prescription benefit management firm express script esrx sank have tumble earlier cvs unitedhealth also operate pbms manage prescription side health insurance contract pharmaceutical biotech stock also lose ground hit didn look much broader market downdraft tuesday merck mrk shed allergan agn gilead science gild pfizer pfe lose top earning view offer bullish guidance ibd take unitedhealth be rank ibd medical manage care industry group base earning sale margin stock performance trend visit ibd stock checkup see leader category insurer have be solid performer rank group long current confirm uptrend equivalent green light stay place lead stock lead group break buy point be more likely not have wind back here good place start look stock be poise move higher knee jerk reaction investor be surely reflection unsustainably high cost health care fact amazon have be itch disrupt retail prescription business be attach effort traditionally fear health care investor have be government not private sector impose cost control get handle runaway budget deficit thin industry profit process medicare negotiating drug cost be such fear industry expert say government be unlikely produce much way saving be willing deny patient access certain drug create political backlash amazon jpmorgan berkshire aren first big employer join force attack health cost leerink analyst ana gupte note tuesday health transformation alliance group large self insure employer launch last year also hope find saving improve employee satisfaction work cvs unitedhealth achieve aim initial report indicated alliance member expect save combine prescription cost year amazon jpmorgan berkshire say initial focus be technology solution provide employee family simplified high quality transparent healthcare reasonable cost new corporate entity say be free profit make incentive constraint just form technology solution take be far clear caliendo suppose berkshire bring underwriting skill ve never underwritten healthcare amzn make pharmacy medical procurement contribution provide expertise leerkink gupte say unclear amazon wading deeper solve health care mess accelerate move supply chain prescription industry also be interested trump state union move market downstock fall market show sign be ready breakgrubhub redhat lead ibd stock buy invest stock free new apps aim invest stock market start simple routine
80,GILD,stock market pause monday loss didn do much stop feverish advance dow jone industrial average fall nasdaq shed need breather perhaps index close session lows broadly lower decliner lead advancer nyse
81,GILD,index other major average hit record high wave earning weaker dollar greenback rebound somewhat netflix nflx sky-rocket blowout subscriber growth bullish outlook celgene celg buy juno therapeutic juno intel intc surge earning outlook texas instrument txn other top chip fail impress quarterly financial apple aapl continue lag grow chorus concern regard iphone sale production airline stock plunge unite airline ual say expand rapidly set stage renew price war index dow industrial nasdaq rally solidly hit fresh record high earning season heated fall dollar have act tailwind multinational stock profit rebound year lows thursday president trump say expect stronger greenback netflix nflx be big earning winner intel intc also do texas instrument txn lam research lrcx be several lead chip stock struggle earning airline stock plunge unite airline ual apple aapl iphone related stock sell several analyst cite evidence weaker iphone demand share rocket record high netflix nflx add stream subscriber worldwide crush fourth quarter target internet tv stream giant end total stream subscriber analyst predict netflix subscriber gain come netflix implement price hike service plan europe netflix credit hit original content such tv series stranger thing crown movie bright subscriber gain period march quarter netflix be predict add net new subscriber chipmaker intel intc maxim integrate product mxim stm xilinx xlnx beat december quarter target get mixed reviews investor texas instrument txn post line result share be punish sector continue wrestle concern chip cycle have ebb top chip gear maker lam research lrcx kla tencor klac beat view sell news meanwhile xilinx joined nvidia nvda amd amd benefit sale high performance chip mining bitcoin other cryptocurrency related intel beat fourth quarter target offer cheery outlookbiotech merger heated celgene celg agree pay car drug developer juno therapeutic juno didn already own sanofi sny reach deal biogen biib hemophilia spinoff bioverativ bivv celgene acquisition come prepare lose exclusivity cancer drug revlimid juno rival gilead science gild novartis nvs make car drug treat blood cancer sanofi deal follow fail merger early wednesday novartis nvs report core earning share sale respective constant currency basis easily beating consensus thursday biogen biib report sale grow top consensus adjust earning grow be short also thursday celgene beat lower analyst view abbvie abbv friday top expectation adjust profit sale climb sale unite airline ual send airline stock tailspin carrier tell analyst plan expand flight coverage investor fear move do part regain relevance smaller city unite once abandon risk more competition cheaper fare help passenger threaten profit american airline aal earning call signale wouldn change profit growth target base unite ambition now southwest airline luv jetblue jblu alaska air alk also report general electric ge miss earning disclose sec probe core unit do well ge keep outlook industrial member dow industrial caterpillar cat mmm unite technology utx report strong earning guidance insurer traveler trv consumer product giant procter gamble pg also beat earning view verizon vz miss ep top revenue johnson johnson jnj top view fall patent ruling vs blockbuster arthritis fighter remicade president trump slap tariff import large washing machine part solar panel tax washing machine decrease then expire year duty solar cell module phase year solar technology provider suniva solarworld charge china be provide unfair subsidy financing solar producer whirlpool whr complain korean maker be dump washing machine excessively low price whirlpool also report quarterly earning rally first solar fslr initially pop close less china base daqo new energy dq lose crude top barrel brent edge briefly oil inventory continue drop oilfield service provider halliburton hal crushed quarterly forecast international growth outpace domestic growth share shot clear buy point baker hughe bhge edge past earning estimate be upbeat spending customer share fall nearly market price possibility ge fully spin business northrop grumman noc raytheon rtn general dynamic gd top profit forecast raytheon general dynamic miss revenue northrop give strong guidance lift dividend raytheon gd say order backlog be strong defense firm surge record high lockheed martin lmt boee ba report next week steel dynamic stld earning rise top view modestly sale climb rank company ibd steel producer industry group say be shape be good year thank more moderate inventory level improvement global demand pricing incremental investment drive tax cut specialty steel producer allegheny technology atus nearly double profit estimate revenue grow fuel high performance material jet engine freeport mcmoran fcx benefit higher copper price boost earning ahead estimate revenue grow negotiation indonesia ownership massive grasberg mine be progress haven erased uncertainty company outlook casino operator wynn resort wynn la vegas sand lvs put result beat top bottom line help rebound macau world largest gaming market sand ceo sheldon adelson cite acceleration mass gaming market chinese administrative region only area nation gamble be legal wynn share plunge friday erase nearly weekly gain report allegation serious sexual misconduct ceo steve wynn ford motor see ep climb cent revenue grow analyst have expect ep cent sale accord zack investment research ford be buy mobility startup autonomic transloc share extend sell prior week ford outlook disappoint investor fiat chrysler fcau deliver strong result generally affirm ambitious financial target send share fresh week high new oriental education edu logged ep growth short view sale gain narrowly beat fiscal estimate student enrollment grow china base school education provider offer guide sale view higher share tumble recoup loss end week tal education tal meanwhile surge nearly thursday retake day ep jump revenue growth tal enrollment swell td ameritrade amtd trade financial etfc beat top bottom line fiscal earning share jump td ameritrade revenue expand see full year earning exclude item vs expectation td ameritrade also say allow customer buy sell certain etfs day week trade report ep revenue ll also acquire retail brokerage account capital financial cof asset share online broker fall modestly week millennial focuse free investing app robinhood let person buy sell bitcoin other cryptocurrency commission intuitive surgical isrg report adjust income share sale rise respective metric top expectation robot surgery gear maker give cautious guidance homebuilder nvr nvr miss earning sale view share tumble crash week line first time more year huge volume doj subpoena mortgage unit lennar len bigger expect new home sale decline other homebuilder also suffer notable decline
82,GILD,camille callais be diagnosed spinal muscular atrophy neurologist tell parent nothing do be year biogen biib ionis pharmaceutical ion spinraza become first ever drug approve treat spinal muscular atrophy camille parent try supplement label use medication highly specialize diet
83,GILD,here weekly investing action plan need know investor come week tech sector heavyweight facebook fb apple aapl amazon amzn alphabet googl microsoft msft dominate come week earning news oil major exxon mobil xom chevron cvx also report
84,GILD,kite pharma be edge closer approval cut edge cancer treatment fight disease rebuild patient own cell technology benefit thousand person pave way blockbuster drug xkite ultracustomized treatment be key entry area great promise cancer research have attract dozen drugmaker include bluebird bio blue juno therapeutic juno celgene celg novartis nvs latter get major fda approval august give novartis lead emerge field firm other be develop own cancer fight system harness same underlie process used kite be now unit gilead science gild approach call car therapy used bioengineering retrain patient infection fight white blood cell seek destroy cancer cell analyst say kite manufacturing process stand car field shorter turnaround time treatment success rate kite groundbreaking work investor business daily name company ibd biotech innovator inaugural edition award ibd choose biotech innovator award winner ibd ask equity analyst etf mutual fund manager university professor identify top biotech company base innovative research ask focus company pioneer drug likely launch next several year reach blockbuster blockbuster sale more year award winner select ibd editor be most cite company find profile award winner detail work go full biotech innovator special report david chang kite chief medical officer tell ibd current cell therapy be just begin be area really set undergo big change next few year kite have recently enlist powerful ally late august gilead foster city calif agree acquire santa monica calif base kite share cash deal value deal close oct kite already be trading time high start summer go public share mid gilead stock rise company announce merger close friday alliance bring kite establish partner financial heft industry breadth just biotech ingenue prepare beef production distribution flagship drug treatment axi cel short axicabtagene ciloleucel be design fight aggressive form hodgkin lymphoma type blood cancer affect immune system be sixth most common cancer kite be expect get drug approval year gilead be hitching star kite expectation gain string successful cancer fight product time gilead strongest portfolio medication treat hepatitis be lose steam kite expect manufacturing process hone develop axi cel serve foundation future treatment include destroy solid cancer tumor cancer cervix head neck pharmaceutical company typically look fill product pipeline acquire company technology don have gilead purchase kite come wasn just do kind acquisition be more long term play multiple product opportunity see play decade come gilead ceo john milligan say conference call analyst follow purchase announcement even sale hepatitis product crimped revenue be grow gilead hiv aids drug company be expect end year revenue last year gilead be company market cap company ibd biotechnology industry group trail leader amgen amgn just celgene gilead have substantial balance sheet help fund launch kite product europe help expand kite manufacturing capacity facility el segundo calif help propel other early stage project forward jeffery analyst biren amin tell ibd return amin say gilead get early midstage oncology pipeline didn have kite allow diversify away hepatitis longer term kite isn say much charge treatment product be approve amin say analyst estimate cost range person full course therapy company have build capacity produce patient therapy year kite spokeswoman christine cassiano say food drug administration be expect make decision kite axi cel drug nov kite hasn disclose brand name drug timeline hold kite drug reach blockbuster status annual sale more accord amin kite win be first biotech company receive fda approval car drug novartis get green light fda aug therapy certain type leukemia child young adult kite axi cel drug be approve fda become first therapy kind treat hodgkin lymphoma patient advanced case disease hodgkin lymphoma be type blood cancer originate immune system therapy involve extract filter patient blood remove key component immune system call cell engineering cell lab so express chimeric antigen receptor car be programme escort intruder destroy cell directly protein find surface cancer cell modify cell be infuse back patient multiply become body cancer fighter researcher affiliated national institutes health develop early science underpin process license kite kite be dozen biotech firm have receive permission use agency version technology accord amin kite study find month single infusion treatment be administer patient advanced hodgkin lymphoma chemotherapy longer work be complete remission sign malignancy rocket science say kite chang company multistep manufacturing process say take day vein vein say be shortest turnaround time company try develop own version car drug be art manufacturing process observer say kite deft approach high success rate clinical trial have set company apart thing paid lot attention be make sure manufacturing be successful so be cell product be give back patient chang say be able treat everybody enrolled clinical study exception single patient patient less be not able be treat kite aim automate more drug development process part collaboration general electric ge offshoot ge global research initiative help kite reduce manufacturing cost speed process time minimize variability result kite also be research way change cell be manipulate growth factor make supercharged cell more effective once be return patient chang say company be investigate equip person cell so be able go more just type cancer say kite be even look develop shelf car product be used patient say talk innovation execution well make right choice hopefully guide program say analyst amin re do related kite pharma company rise ibd biotech innovator status get detail biotech innovator award winning company workbluebird be biotech stock new biotech stock have catch rallywill novartis acquire company
85,GILD,major stock index be mired red midday thursday busy day geopolitical headline more earning report weak show apple aapl sentiment be also fuel drop china hang seng index overnight meanwhile spanish government announce plan impose direct rule catalonia end region bid independence nasdaq composite pare loss be still selling be more tame dow jone industrial average index ease volume nyse nasdaq be tracking higher wednesday level same time day stock market today apple take hit fall nearly couple negative headline starter bloomberg cite report taipei base economic daily news concern slack demand iphone different report say only company provide cellular service apple watch product china suddenly cut service explanation ipo news mongodb mdb price last night propose range share open be trading company provide open source database platform enterprise client gilead science gild gap work flat base entry share be strong food drug administration approve car drug yescarta treat rare form hodgkin lymphoma car cell immunotherapy be promising cancer treatment used body own immune system attack cancerous cell elsewhere adobe system adbe gap flat base buy point share jump situation buy stock open price be sound strategy homebuilder nvr nvr also gap earning well extend base late january share soar ibd be weigh weakness china stock china hang seng index lose overnight name tal education tal yy yy sina sina show loss range economic news weekly jobless claim drop more expect consensus estimate be much smaller decline meanwhile philadelphia fed manufacturing index come better expect vs consensus estimate related gilead jump fda approve kite acquire car drugverizon share rise revenue subscriber addition top view mongodb price high qudian strong debut play new ipos
86,GILD,future index nasdaq dow industrial fall thursday morning european equity retreat anniversary black monday stock market crash meanwhile be several notable stock be move overnight own news xadobe system adbe soar overnight offer bullish earning guidance fiscal gilead science gild pop fda new gene therapy drug also lift fellow car developer juno therapeutic juno ebay ebay tumble weak holiday quarter guidance unite rental uri climb result future index sank vs fair value be overnight lows nasdaq future lose dow future fall ftse lose intraday france cac slide germany dax fall spain ibex retreat spain signale suspend catalonia autonomy region separatist leader refuse drop independence effort meanwhile european company give weak result unilever report sale view asia hong kong hang seng skid japan nikkei rise index nasdaq composite rise wednesday dow industrial jump close first time ibm ibm soar revenue growth forecast maker digital publish software say see fiscal earning rise share well consensus accord zack investment research adobe expect revenue climb slightly view adobe share shot early premarket trading adobe close wednesday stock market trading move back day move average overnight action often doesn translate regular session trading adobe seem head blast buy point thursday open fda approve gilead cancer therapy type hodgkin lymphoma several week ahead schedule yescarta be second fda approve chimeric antigen receptor cell therapy follow novartis nvs own kymriah such car drug body own immune cell attack cancer yescarta be develop kite pharma acquire gilead earlier year kite phamra be winner ibd biotech innovator award gilead science rise early trading gilead close slightly continue find support day line gilead be flat base buy point juno therapeutic car developer rise early trading juno have be consolidate late august online marketplace meet third quarter earning revenue view see ep cent vs consensus cent share ebay fall premarket trading signale move buy point day line equipment rental company earning revenue growth exceed wall street forecast unite rental also raise revenue target unite rental be not yet active thursday morning rise nearly late wednesday trading stock be already slightly extend late september related big picture market indicator don signal black monday have spot stock market top yes here howadobe set skyrocket past buy point bullish outlookebay tumble weak earning outlookunited airline amex unite rental beat view alcoa misseskite pharma cancer treatment stand hot car field
87,GILD,cure be strong word come treat cancer other deadly disease brad loncar be biotech stock analyst investor ready employ term first time biotech company be not think technology incrementally say loncar portfolio manager biotech focuse etf re not think alleviate symptom disease re think fix genetic mutation cause disease loncar be speaking cancer comment apply other terrible disease claim thousand life include alzheimer parkinson lou gehrig disease multiple sclerosis muscular dystrophy year first fda approve biotech drug biotech industry be roll innovation breakneck pace new drug pipeline be burst treatment clinical trial industry be grow leap bound many biotech stock be score superior return investor recognize biotechnology industry contribution science patient health investor business daily have create ibd biotech innovator award inaugural edition name award winning biotech company choose groundbreaking treatment recently introduce market well new product pipeline company be celgene celg biogen biib regeneron pharmaceutical regn kite pharma incyte incy loxo oncology loxo winner aren rank way only company trade share be consider biogen have sight firmly cure cancer other intractable disease biogen be target like alzheimer parkinson ms ibd choose biotech innovator award winner ibd ask equity analyst etf mutual fund manager university professor identify top biotech company base innovative research ask focus company pioneer drug likely launch next several year reach blockbuster blockbuster sale more year award winner select ibd editor be most cite company find profile award winner detail work go full biotech innovator special report company be just few player huge field closely track investor ibd count publicly trade company biotech industry group doesn include many other company biotech operation aren main focus have combine market cap nearly sale most recent month more thank biotech industry pipeline new drug kind have explode clinicaltrial org count more drug file phase late stage trial food drug administration year fda have more late stage study register ibd biotech industry stock group have climb year shuck pain politically charge election season concern president trump work lower drug price group wednesday hit month high be time high july currently rank group track ibd term performance past month boost group performance be celgene loxo recently hit new high incyte touch record high year biogen touch month high friday regeneron year touch nearly year high biotech focuse fund brad loncar head be loncar cancer immunotherapy etf cncr track biotechs work immunotherapy exchange trade fund be near year anniversary be year comment ibd come series regulatory approval acquisition cancer treatment include gilead science gild foray cellular therapy august agreement acquire kite nearly kite purchase be complete oct kite now operate wholly own gilead unit count loncar bullish today drug immune system identify fight precisely target cancerous cell technology turn edit gene correct genetic condition trial datum be jaw drop say example be car technology kite be leader field be young biotech company be take patient have week month live case be see complete remission loncar say ve never see anything loncar liken chemotherapy bomb kill enemy everything else sight loxo be used smart bomb precision medicine target gene fusion cancer jmp security analyst mike king explain cancer gene be call passenger other driver king tell ibd driver become fuse normal cell normal cell transform cancerous loxo identify target fusion american society clinical oncology conference june loxo show impact work photo sarcoma protrude child chest king say target call trk fusion loxo be able treat cancer tumor shrink away nothing surgery radiation other therapy contribute say be remarkable be pretty staggering even person audience be kind used see kind thing patient drug dub larotrectinib be able partly shrink tumor sign cancer disappear patient drug have breakthrough rare pediatric disease orphan drug designation fda also grab headline be immuno oncology work dow component merck mrk well incyte bristol myer squibb bmy roche rhhby astrazeneca azn kite car therapy be get due like novartis nvs juno therapeutic juno bluebird bio blue immuno oncology car be method teach immune system fight cancer immuno oncology drug do so block specific interaction otherwise prevent immune response car drug individualize process reprogramming patient own extract immune cell ibd take car drug be snag major attention gilead announce plan acquire kite novartis get major drug approval open sector head ibd industry snapshot feature closer look emerge car sector result have impressed immuno oncology drugmaker be take step further combine compound hope see more robust response merck have have success drug keytruda have win approval first treatment chemo lung cancer incyte drug epacadostat be particularly intriguing analyst say prevent interaction involve ido enzyme merck bristol be pairing drug keytruda opdivo class drug know pd inhibitor incyte epacadostat regeneron too be work pd inhibitor regn develop partnership sanofi sny june regeneron sanofi say patient form skin cancer respond treatment regn phase trial car side novartis gain fda approval late august drug treat form acute lymphoblastic leukemia patient age approval help spike gilead just day have announce deal acquire kite kite be near approval car drug treat aggressive form hodgkin lymphoma juno be just drug call jcar treat same cancer kite drug bluebird be work multiple myeloma drug juno bluebird have partner celgene program jmp king call best breed approach celgene put money line potential innovation such partnership be celgene excel wedbush analyst david nierengarten tell ibd ve have innovative deal sector small molecule cell therapy say re innovative cast net widely new technology potential therapy other be reap benefit decade old project map human genome first human genome map cost dollar take almost year complete today cost closer map individual entire genetic makeup gene therapy editing be have renaissance jmp king say analyst point crispr therapeutic crsp make ipo year leader field crispr be also name technology crispr therapeutic audente therapeutic bold intellium therapeutic ntla also be make wave sector technology make much easier edit gene needham analyst alan carr tell ibd btig analyst dane leone see company enter clinic technology used enzyme be actually bacterial organism target area genome dna want make change dna say do used enzyme complex be give direction term target insert cell end enzyme complex attach dna make alteration tell ibd jmp analyst king describe crispr technology have ability repair break gene cut replace defective gene insert functional gene re desire other side gene spectrum rna interference antisense be responsible cut edge drug alnylam pharmaceutical alny biogen partner ionis pharmaceutical ion biogen ionis december win fda approval spinraza first drug type approve treat spinal muscular atrophy needham carr liken rna interference way turn gene have potential be more robust gene therapy most cell body be effective september alnylam stock spiked day drug patisiran prove effective treat rare disease know hereditary attr amyloidosis polyneuropathy disease result buildup abnormal protein cause systemic problem patisiran used rna interference analyst call late stage datum alnylam big concept bluebird be work gene therapy treat blood disorder list innovation go era biotech today gain have be decade make usually steady build then have wave innovation kind collide emerge similar point time jmp king say not traditional tech thing happen overnight related get detail award winning biotech innovator workgilead kite deal boost biotech etf clear buy novartis cancer approval validate gilead kite cure cancer look blood
88,GILD,biogen biib gilead science gild sarepta therapeutic srpt build momentum biotech sphere beat wall street expectation third quarter analyst predict friday large cap biotech stock have be strong head third quarter report period credit suisse analyst alethia young write note client be focuse biogen spinraza regeneron pharmaceutical regn dupixent gilead hepatitis drug close bell stock market today investor business daily company biotech industry group dip collective group be rank first group track ibd hit month high earlier week momentum likely continue third quarter most large cap young say call biogen gilead sarepta possibly unite therapeutic uthr beat top line biogen be set report quarterly result early oct young call spinraza spinal muscular atrophy drug develop ionis pharmaceutical ion beat consensus view forecast sale cure sma report estimate patient have be dose spinraza third quarter be trial expand access program young write suggest be commercial patient period see patient spinraza third quarter ibd take biotech stock have trend north past several week healthy dose good news several key player head ibd industry theme closer look stock help send group month high do think point spinraza surprise downside patient switch much less expensive maintenance dose vs load dose say however think quarter spinraza very much still be launch phase top line young model biogen report sale adjust income share metric top consensus analyst poll zack investment research respectively multiple sclerosis franchise be likely face more headwind quarter quarter basis tecfidera total prescription fall third quarter price increase result young model tecfidera be consensus view young forecast gilead beating third quarter expectation strong sale drug treat hepatitis hiv help biotech shuck quarters hepatitis malaise still abbvie abbv new hepatitis regimen have impact gilead be set report late oct abbvie mavyret gain approve august treat genotype hepatitis patient typically dose week shorter duration rival drug be price roughly half price competitor wholesale basis reason young drop forecast gilead hepatitis drug sale factor risk abbvie remain bullish third quarter model total sale consensus view forecast be drive consensus top view sale harvoni sale epclusa hiv estimate be largely line consensus view model miss hiv drug truvada estimate consensus due entry generic outside bottom line young call adjust profit share vs consensus analyst poll zack young call regeneron sarepta narrowly beat wall street forecast benefit eczema drug dupixent duchenne muscular dystrophy drug exondys respectively regeneron be set report earning early nov deliver slight beat vs consensus sanofi sny partner eczema drug young model sale dupixent earlier view street dupixent weekly total prescription be average third quarter vs prior period dupixent end third quarter outstanding total prescription young write forecast quarter quarter growth drug third quarter model eylea approve treat number eye condition be trail consensus sarepta again surprise upside exondys second quarter sarepta crushed expectation third quarter young call exondys sale consensus further full year guidance sale be likely conservative young say note management sound upbeat launch trend related abbvie new hepatitis drug chip away gilead biotech break month high keep go regeneron patent be amgen think
89,GILD,biotech merger heated monday celgene celg announce acquire juno therapeutic juno french pharma sanofi sny say spend tack biogen biib spinoff bioverativ bivv analyst laud celgene juno buy note help fill hole celgene blood disease drug revlimid begin lose exclusivity street be more split sanofi purchase hematology market be expect soon face disruption gene therapy close bell stock market today juno surge celgene tick bioverativ rocket sanofi dive close broader biotech group pop credit suisse analyst martin suggest report group see mad scramble merger acquisition sanofi announce plan buy bioverativ list biomarin pharmaceutical bmrn esperion therapeutic espr avexis avxs top takeover pick deal be sign merger spigot have finally turn other large pharma company feel pressured move make full value bid grab be fairly scarce selection commercial commercial ready asset small midcap biotech space say celgene say monday spend share acquire juno premium stock close price rumor send juno fly last week celgene already own juno deal collaborate cancer autoimmune drug merger be expect close quarter juno be work car therapy engineer patient own immune cell identify fight cancer cell celgene peg lead drug know jcar get approval bring potential peak sale ibd take celgene be particularly hurt third quarter bigger drug revlimid otezla miss expectation not only face patent cliff mid see else be risk visit industry snapshot piper jaffray analyst christopher raymond suggest guidance be overly bullish celgene be set relatively high bar asset likely win be alone class say note however guidance be achievable be important source revenue mid long term celgene look plug revlimid hole once go generic start competition be look stiff gilead science gild spend nearly acquire kite pharma last year time gilead kite gain approval car therapy follow novartis nvs be first gate approval august celgene expect jcar get approval treat diffuse large cell lymphoma aggressive form hodgkin lymphoma gilead drug yescarta be approve treat population novartis be look get drug kymriah approve use well leerink analyst geoffrey porge view deal positively consolidate streamline celgene effort car celgene also partner bluebird bio blue work multiple myeloma drug know bb target antigen know bcma own juno allow celgene focus bcma effort initially bluebird bb make juno vehicle development drug target cd protein exploration other target opportunity say note client mizuho analyst salim sy note be cross pollination manufacturing juno bluebird drug be knowledge base synergy unsure celgene even look acquire bluebird trigger antitrust concern say early monday sanofi say buy hemophilia player bioverativ share deal be premium bioverativ close price friday piper jaffray raymond write note re not shock bit say topline revenue growth more last year yet trading just time fiscal year revenue estimate have long view bioverativ potential takeout target deal come sanofi twice fail make big acquisition dow pfizer pfe beat sanofi battle cancer player medivation last year dow johnson johnson jnj acquire rare disease biotech actelion pharma sanofi sanofi be face mount competition diabetes drug trick be convince investor hemophilia market win be disrupt gene therapy product launch roche rhhby drug hemlibra leerink analyst seamus fernandez say note minimum number speculate successful bid include medivation actelion sanofi investor now have deal digest be immediately accretive earning estimate be accretive say rbc analyst kennen mackay call bid strong give upcoming competition roche note likely sanofi be build lesson learn medivation actelion process sanofi lead low offer be later best competitive bidder investor weren sure merger biogen spun hemophilia business bioverativ year bioverativ have approve drug eloctate hemophilia alprolix hemophilia last year bioverativ acquire true north therapeutic credit suisse martin call true north stronger acquisition bioverativ gain access drug now know bivv treat rare autoimmune disease model share drug alone related biotechs surprise upside earning biotech stock rocket rumor biogen buy hospital plan put pressure generic drug maker
90,GILD,small cap lead stock market higher friday nasdaq set pace biggest weekly gain small cap russell hustle ahead friday nasdaq add respectively blue chip dow jone industrial average inched ahead volume fall slightly nasdaq
91,GILD,clovis oncology clvs sage therapeutic sage puma biotechnology pbyi stoke acquisitive appetite large cap biotechs struggle slow growth major patent cliff analyst say tuesday deal make have slow hit record high rbc analyst say note client number deal value hit year year have be merger include gilead science gild takeover kite pharma investor have expect gilead major buy stoke more acquisition didn come fruition biotech stock suffer pent demand prompt merger acquisition play next year analyst say many large cap company generate share overall revenue handful blockbuster drug many be face impending patent cliff come year rbc note say need make lose source revenue stimulate growth encourage future gilead buy kite suffering major decline hepatitis drug unit hiv drug tenofovir alafenamide be likely lose patent protection celgene celg cancer drug revlimid be face patent cliff amgen amgn inflammatory enbrel be likely lose protection also have most cash hand recent update amgen report celgene have gilead note remainder large cap biotech realm have ibd take analyst say monday large cap biotech franchise feel pain competition speeding number rival brand generic drug approval head ibd industry theme more mean like vertex pharmaceutical gilead amgen overall cash position be near year high analyst say tax reform help most recent proposal company repatriate earning tax rate amgen bristol myer squibb bmy dow johnson johnson jnj have excess cash currently overseas however think unlikely majority overseas cash be repatriate immediately institution tax reform rbc analyst say celgene instance have suggest chunk foreign earning be expect be reinvest permanently outside analyst also note average project revenue next year mid cap biotechs be likely do little offset loss patent cliff performance acquirer past year have be poor industry check also indicate large deal be out gilead kite be exception still expectation be high merger acquisition analyst say recent survey investor cite biggest tailwind group drug pricing be expect be biggest headwind rbc analyst be slightly bullish slightly bearish drug pricing expectation high major tailwind sector do not materialize first half see broad downside rbc say credit suisse analyst vamil divan too note be important big pharma group likely come result change tax rate repatriation top pick be also expect dow merck mrk allergan agn rebound additional fund dividend growth share repurchase also boost overall outlook sector investor perspective say see regulatory environment remain generally favorable provide more rapid path market product bring real innovation related beware price war big pharma biotech company biotech stock see cheapest rival cancer drugsgeneric drug maker face pricing issue other pharmas don
92,GILD,index other major average rally record high week asml asml taiwan semiconductor tsm other chip play surge earning apple pay taxe pay employee bonuse step manufacturing investment fund repatriate massive overseas cash holding general motor gm be upbeat future ford motor be not unitedhealth group unh kick health insurance earning lead many insurer stock record high cancer drug trial datum buzz moved drug stock general electric ge crash fresh year lows huge new charge speculation conglomerate break dow nasdaq rise week climb nasdaq hit record high friday chip gear maker lead way fuel asml asml other health insurer also be big winner unitedhealth unh trigger group rally energy stock pull back lithium play also sell apple aapl be expect bring home foreign profit draft overseas help pay domestic project thank recently enact corporate tax reform apple pledge contribute more economy next year include create new job funding new campus more datum center forge deal component manufacturer analyst say apple likely use foreign cash tuck acquisition increase stock buyback dividend semiconductor equipment group lead industry week asml hold asml ichor holding ichr electro scientific industry esio rally upbeat financial report asml report better expect fourth quarter result ichor electro scientific announce preliminary december quarter sale top view chip foundry taiwan semiconductor manufacturing tsm add party deliver better expect fourth quarter result guide strong sale growth general electric ge ceo john flannery say mull breakup separate business industrial giant announce take charge fourth quarter legacy insurance business double earlier guidance charge relate old long term care portfolio ge finance arm pay shore reserve raise worry ge industrial business have prop ge capital cash point flannery update investor portfolio review spring activist hedge fund trian fund management reportedly be push ge breakup ge share tumble lowest level more year investor question last original dow component have much value gm gm expect earning be largely line expect result high end range largest carmaker expect profit rise shift lineup more profitable next gen suvs truck analyst have expect ep decline ford go other way forecasting earning share estimate expect ep dip ford say monday invest electric vehicle next year more double earlier target gm share fall ford plunge recent buy point charle schwab schw earning share revenue rise meeting view new retail brokerage account jump vs year earlier help total account grow smaller online brokerage interactive broker ibkr see earning spike more revenue jump beating customer account grow total daily trade share schwab rise fraction week interactive fall unitedhealth group unh help spark dow run breaking record high easily clear earning estimate detail impact tax reform unitedhealth earning jump share revenue growth nation largest insurer say plan use tax windfall boost investment unitedhealth expect benefit tax cut go bottom line project ep range profit growth other health insurer rally new high unitedhealth strong report airbus eadsy have order last year beating boee ba sixth straight year european aerospace giant also keep make superjumbo emirate airline make order list price ceo tom ender be critical brexit president trump america first policy say brexit be more devastate airbus business boee announce joint venture auto car seat maker adient adnt build seat jet ease congestion zodiac aerospace have delay plane delivery bitcoin fall well wednesday rebound friday morning south korean finance minister kim yeon spook cryptocurrency market say ban trading digital currency be live option bitconnect shutter lend service exchange platform central bank excessive risk bitcoin company be embrace cryptocurrency ibm ibm announce blockchain joint venture danish shipping company maersk goldman sachs gs top ep revenue view large fix income desk see revenue drop once again rival bank america have mixed result morgan stanley ms citigroup result beat bitcoin value continue shrink week goldman cfo martin chavez say be respond client interest cryptocurrency exercise extreme prudence caution do not say anything bank have already say clear bitcoin future develop crypto trading platform own bofa ceo brian say customer be careful cryptocurrency juno therapeutic juno stock rocket wednesday report longtime partner celgene celg be talk acquire celgene juno be partner develop car drug rivale like gilead science gild recently buy kite pharma novartis nvs celgene blockbuster face multiple myeloma drug revlimid go patent bluebird bio blue car developer partner celgene rise wednesday dow stock merck surge tuesday release result trial immuno oncology drug keytruda chemotherapy advanced lung cancer well ahead expectation october merck have delay release phase trial merck regimen significantly improve overall survival progression free survival first treatment vs chemotherapy alone roche rhhby bristol myer squibb bmy astrazeneca azn have rival drug retreat tuesday atlassian team top fiscal earning revenue estimate collaboration software maker forecast current quarter profit cent share revenue vs consensus estimate cent analyst say light guidance be due annual salary increase higher payroll taxe jeffery hike price target expectation better future cash flow growth share have jump buy zone earlier week tumble just entry point initial jobless claim fall year low labor market continue tighten industrial production jump december manufacturing output rise just meanwhile new york fed empire state manufacturing index dip january philly fed gauge set month low lead new order housing start tumble december permit be strong homebuilder confidence remain year high month aluminum giant profit swell share revenue rise analyst have expect share revenue alcoa aa say see global aluminum demand growth share dove wynn resort wynn la vegas sand lvs mgm resort mgm melco resort entertainment mlco have be climb bernstein analyst predict year year gross gamble revenue gain macau january be best growth july macau gaming revenue take unexpected hit december thank vip streak revenue still rise breaking year period annual decline government crackdown corruption rail operator csx top earning miss sale report be first december death ceo hunter harrison veteran railroad executive know rein cost turn csx rival csx say performance continue strengthen build schedule railroad model launch harrison kansa city southern ksu miss ep view canadian pacific railway cp top profit revenue csx kansa city southern share fall canadian pacific rise sociedad química minera chile sqm reach deal chile let expand lithium production prospect more supply lithium stock tumble sqm fall albemarle alb fmc corp fmc global lithium battery tech etf lit american express axp suspend buyback program first half year asset repatriation tax gop new tax bill dent fourth quarter profit capital amex top profit revenue estimate amex fall friday close day line ibm ibm revenue rise vs year earlier snap quarter streak flat decline revenue ibm undergo major overhaul top view ibm share fall friday follow big gain earlier week amazon com amzn raise monthly prime membership exist monthly prime member face new rate feb annual prime membership be still
93,GILD,teva pharmaceutical teva continue day upswing friday announce launch generic version drug gilead science gild day drugmaker unveil massive cost cut plan afternoon trading stock market today teva lift earlier stock pop much share close thursday day teva say cut end deal debt gilead drug viread be approve treat hiv hepatitis patient teva be launch generic version viread milligram tablet hope take chunk annual sale viread garner october be estimate person live hiv chronic hepatitis respectively benefit viread teva say news release launch add teva generic portfolio nearly medication monday teva also announce launch generic version viagra be brand dow stock pfizer pfe august erectile dysfunction drug have annual sale teva say news release goldman sachs analyst jami rubin praise teva plan cut cost next year cut come form layoff close manufacturing facility suspend dividend ordinary share ibd take teva have ibd composite rating best possible meaning underperform lion share stock term key growth metric other generic drug stock have stronger rating ani pharmaceutical come head ibd stock checkup look other strong player generic drug landscape rubin have initially expect teva announce plan cut cost expect new chief executive kare schultz deliver promise base background lundbeck repeatedly understated overdeliver acknowledge be investor skepticism health base business note be first time have see concrete strategy levering company be top priority say note client conference call thursday suggest weaker base earning interest taxe depreciation amortization be more offset cost contribution rubin say part restructure teva be combine generic specialty unit focus effort europe emerge market rubin see drug migraine involuntary movement tie huntington disease lead teva specialty unit rubin acknowledge create additional downside risk teva top line see exit unprofitable business potential mark bottom generic pricing be not call bottom yet however closely monitor rate magnitude rationalization effort important sign post say boost price target teva upgrade stock buy rating neutral related teva pharma announce layoff suspend dividend tackle debtwhy amgen have edge rival prevent migrainesteva restructure plan case be here do
94,GILD,new hiv drug gilead science gild have potential become greatest time analyst say wednesday investor expectation be high gilead hiv drug franchise credit suisse analyst alethia young write note client third quarter brand hiv drug pull sale next treatment bictegravir be expect launch february drug combination tenofovir alafenamide emtricitabine treat hiv offer better bone kidney safety remain confident bictegravir be next blockbuster hiv drug gilead launch feb young say fireside chat chief executive john milligan conference note bictegravir grow most important product hiv space keep front competition young estimate peak bictegravir sale just year launch bictegravir be clear focus gilead hepatitis drug franchise slow mature high cure rate ibd take small biotech name crowd headline space third quarter easily quash analyst expectation same time larger player struggle legacy product face competition head industry snapshot closer look third quarter breakdown biotech meanwhile gilead legacy hiv drug be face exclusivity loss young see growth drug decelerate year model gilead new tenofovir alafenamide franchise drive annualize growth same time period bictegravir be notable positive drug expect grow annualize basis next year say drug also help gilead pull back share glaxosmithkline gsk make tivicay triumeq third quarter gsk hiv drug sale increase year year constant exchange rate tivicay prescription be used combination gilead drug descovy tenofovir alafenamide backbone bictegravir help gilead gain back share hiv space therefore bictegravir launch expect company gain share lose say sense speaking gilead be lose share then gain back tenofovir alafenamide launch close bell stock market today gilead be unchanged gsk dip other matter document file federal trade commission suggest gilead have acquire privately hold car company know cell design lab dovetail well acquisition october kite pharma accord document ftc grant antitrust clearance transaction gilead cell design rbc analyst brian abraham write note client gilead be list acquire party cell design be list acquire company possible not likely clearance have be grant gilead make sizable investment cell design potential deal hasn be confirm company fit well gilead state strategy help lift cloud have be hang gilead year hepatitis drug sale dwindle see gilead communicate clear growth strategy execute intension provide additional reassurance investor abraham say related go gilead kite acquisition offer new buy opportunity blood disease datum send biotech stock celgene gilead pricing wo continue haunt biotech stock
95,GILD,intercept pharmaceutical icpt topple friday report outline dip prescription liver disease drug ocaliva week food drug administration warn doctor overdose related death plunge much climb back loss close stock market today broader biotech industry be fraction continue trade month high ocaliva prescription sank week week fda issue letter warning physician overdose patient ocaliva drug be approve treat primary biliary cholangitis liver condition patient liver cirrhosis be injured die physician prescribe ocaliva milligram day be time higher recommend weekly dose patient intercept have say fda further suggest ocaliva also be associate liver injury patient mild disease be receive correct dose ocaliva prescription hit record week fda warning letter even firm issue similar warning overdose patient more severe cirrhosis liver drug downtick suggest re education physician proper dose continue be important intercept rbc analyst brian abraham write note client ibd take biotechnology company be now rank first group track ibd big dose healthy news send stock month high recently head ibd industry theme closer look stock look strong head end year same week prescription gilead science gild hepatitis drug harvoni biogen biib multiple sclerosis drug tecfidera decline say overall drug abraham track see prescription decline week week however ursodeoxycholic acid also approve treat primary biliary cholangitis look flat week week magnitude decline ocaliva look higher rest group suggest be more likely represent real prescribe pattern rather overall volatility datum capture say new prescription ocaliva look be harder decline week suggest decline be attribute slowdown new patient start physician digest understand new safety communication abraham say related biotechs be lead group month highintercept respond drug tie death stock try plunge fda warning drug related death
96,GILD,major index finished month witch ghoul goblin good note tuesday wasn just big cap techs nasdaq composite drive part third straight solid gain apple aapl rally finished session high apple benefit price target hike report strong order
97,GILD,biotechs have weaken bit month rally friday most biotech etfs continue lead health sector base year date gain spdr biotech xbi take lead gain oct slip day move average buy point flat base clear august etf rebound back day line friday rally line resistance set new buy opportunity advanced june start most recent flat base xbi second biggest biotech etf have asset year old fund track biotechnology select industry index tend skew small midcap stock average market cap holding be vs average health sector fund accord morningstar direct top holding oct include alnylam pharmaceutical alny puma biotechnology pbyi exact science exas year alnylam puma exact be respectively oct top name account portfolio xbi have outperformed long haul well base year average annual return expense ratio be first trust nyse arca biotechnology index fbt come second ytd gain etf have also dip day line recent buy point remain close entry fbt launch june have gather asset track equal dollar weight index same name weight average market cap holding be larger xbi fund top stock oct include alk charle river laboratory crl quintile im alnylam also make top ibd take alnylam have deliver stellar performance year do fundamental technical rank industry group find now ibd stock checkup etf average annual return past year lag year return lead wide margin fbt carry expense ratio ishare nasdaq biotechnology ibb be sixth accompany list ytd gain fall more thursday stabilize friday fund be now sit halfway day day line year old etf be biggest biotech fund asset track nasdaq biotechnology index bear expense ratio ibb have average market cap lean mid large cap such top holding include amgen amgn biogen biib gilead science gild related biotech stock watch pharma industry newsstock mixed biotechs dive buffett stock buy point ibd biotech innovator award
98,GILD,nasdaq composite index close week record high heaviest week earning season amazon amzn alphabet googl mmm caterpillar cat be big winner celgene celg boee ba baidu bidu be notable loser nasdaq composite have be week rally friday hit time high rise week amazon amzn alphabet googl microsoft msft surge friday earning apple aapl facebook fb hit buy point ahead earning next week index also rise new high friday week dow climb week hit record level earlier week celgene celg merck mrk several other biotech drug stock sell earning guidance week so do boee ba several defense giant treasury yield rise multimonth high solid economic datum european central bank voting taper bond buy president trump loom decision be next federal reserve chief amazon amzn share soar commerce leader report third quarter adjust earning share cent vs view cent revenue rise include whole food market acquisition amazon complete aug amazon web service revenue soar account well operate profit amazon soar hit record high related amazon blow past earning view beat sale share soargoogle parent alphabet googl vault time high internet giant profit smash estimate google say gaap earning be share year revenue jump top consensus estimate google traffic acquisition cost pay partner website carry ad rise alphabet say grow tac have be overhang google stock share rise friday record high back buy point related google shoot time high beating earning viewsboee ba take charge kc refueling tanker bring total cost overrun taxe taxe charge aerospace giant raise full year cash flow outlook full year core ep prior view ep midpoint be still analyst view boee ep fall top forecast revenue rise estimate boee share fall week related boee shake air force tanker cost outlook imply weak blue chip caterpillar cat mmm throttle earning estimate hike guidance make clear global economy have shift higher gear caterpillar earn share year cent ahead estimate revenue leap construction equipment firm earning guidance share be cent ahead prior estimate see broad growth industrial health care electronic energy segment beating ep cent say expect full year ep earlier outlook week caterpillar rise raise outlook strong earning dow stock gap highcaterpillar soar blowout earning raise martin lmt raise full year outlook earning revenue cut guidance sale aeronautic unit defense giant miss estimate northrop grumman noc also raise ep outlook report result wall street estimate global hawk maker announce wouldn submit bid navy unmanned tanker competition be see major player raytheon rtn report mixed result also raise full year ep outlook however raise guidance be still analyst consensus general dynamic gd quarterly result beat view lockheed raytheon general dynamic share fall northrop rally related lockheed grow leap bound sale slow northrop win bid navy drone contract result beat viewsraytheon report mixed result raise ep outlookbiogen biib slide tuesday beating top bottom line expectation sale spinraza lag view amgen amgn sarepta therapeutic srpt vertex pharmaceutical vrtx deliver board beat third quarter report late wednesday up sale guidance amgen sank sale top drug enbrel fall year year vertex say late stage cystic fibrosis trial fail celgene celg crash thursday revenue miss otezla sale lag consensus lead biotech cut sale guidance alexion pharmaceutical alxn fall weak sale gilead science gild top sale adjust earning view late thursday hepatitis drug sale decline third narrowly miss estimate big pharma giant merck mrk bristol myer squibb bmy novartis nvs eli lilly lly glaxosmithkline gsk fall follow earning report biotech firm top third quarter view only popscelgene result call alarm alexion bristol mixedgilead top sale profit view narrow miss hepatitis drugssoftware giant microsoft msft race past wall street target september quarter point sale view december quarter send stock record high territory friday day microsoft earn cent share year year sale fiscal first quarter analyst expect cent microsoft credit growth cloud compute business related microsoft top september quarter sale earning targetsinvestor cheer intel intc stm teradyne ter september quarter earning report jeered advanced micro device amd ultra clean holding uctt intel top wall street target third quarter sale earning guide analyst higher current quarter rival amd deliver better expect third quarter result disappoint guidance flat gross profit margin current quarter biggest loser be ultra clean plummet thursday mixed third quarter result related intel beat third quarter goal guide highergeneral motor gm ep fall revenue shrank broad slowdown car sale plan reduction fleet sale retreat certain european african asian market result crushed forecast ep revenue gm also guide full year earning consensus gm share have be rally investor see automaker combine strong profit now be lead pack autonomous drive electric car ford earning surge cent revenue rise automotive revenue top estimate ep cent revenue management narrow profit outlook remain consensus fiat chrysler fcau report mixed result china base school operator tal education tal fall short earning estimate penny report flat ep cent revenue climb enrollment more double outlook be line forecast fellow heavyweight new oriental education edu turn mixed result better expect guidance tal education plunge new oriental related china leader be flash long term sell signalsexxon mobil xom report ep rise cent revenue nearly expectation credit higher oil price production refinery margin fellow dow energy stock chevron cvx fall short earning send share friday recent buy point exxon rise friday crude future hit month high mcdonald mcd same store sale beat estimate help drink line signature craft sandwich see thinner margin invest training technology whopper deal burger king likely help comp owner restaurant brand qsr share reversed lower record high friday cost cut promotional switch boneless wing help buffalo wild wing bwld fly nearly thursday even sport bar chain contend elevated price traditional chicken wing question ceo transition chipotle grill cmg share crash concern sale recovery higher menu price next month plan slow new store addition next year visa fiscal fourth quarter result beat top bottom line help solid payment cross border volume strong show visa europe payment volume growth be strong country russia india australia come worry state retail mizuho analyst note mobile tmus sprint call earning call avoid discussion raise speculation merger announcement come november regulatory hurdle mobile add postpaid phone subscriber september quarter sprint add lose report flat profit revenue drop say expect purchase time warner twx close year end analyst say sell be related equity dilution expect twx deal be issue stock finance half deal side analyst say carrier include verizon vz have be restrain promotion soon be release high end apple aapl iphone improve margin december quarter cable tv firm comcast cmcsa charter chtr report higher video subscriber loss lower customer addition comcast have lower guidance early september send stock ahead earning charter stock fall disclose similar trend company aim hike price service video subscriber switch internet tv charter add customer vs estimate charter acquire time warner cable last year comcast add customer vs year earlier baidu bidu crushed third quarter earning estimate chinese search engine giant give weak guidance share plunge friday cisco system csco acquire broadsoft bsft maker communication software telecom company include debt share cisco pass buy ringcentral rng rival software firm fortinet ftnt sank friday maker computer security software forecast december quarter revenue expectation september quarter result beat view grubhub grub report third quarter earning beat estimate provide fourth quarter guidance also top view share surge week breaking buy point td ameritrade amtd top earning view gain revenue growth accelerate fourth straight quarter share online brokerage rise record high servicenow now report earning revenue top expectation billing growth disappoint share enterprise software provider fall earning release close week slightly higher earning call management indicated be strong start aid part few more deal closing normal be push december quarter whirlpool whr crash weak earning news sear longer sell appliance twitter twtr share soar week high better expect adjust earning rise monthly user forecast possible gaap profit
99,GILD,major index still hold break even line late afternoon trading thursday day detail president trump tax cut plan fail gather praise congressional democrat bipartisan support be likely necessary trump follow pledge reinvigorate economy xmeanwhile gdp growth be revise slightly annualize rate august durable good order jump month month basis shocking street ex transportation equipment order still rise respectable core capital good order rise healthy reading indicator suggest continue upbeat momentum industrial sector downside risk recent hurricane lewis north american economist nomura write recent note build residential commercial industry group rank ibd industry group month relative price performance energy solar machine material handle automation aerospace defense industry group be also top pm et nasdaq composite edge lower take drop dull trading apple aapl share stride apple have rebound much past session hit short term low iphone giant remain modestly buy point second stage flat base key chart pattern see many top growth stock nasdaq tracking powershare qqq trust qqq etf be be find support day move average dow jone industrial average edge less less point less volume be run lower main exchange vs same time wednesday return apple megacap tech be still more clear first stage bottom base pattern jan break month cup handle bottom base stock typically decline more time high then bottom form new base set potential week high selling stock once rise past proper buy point cup base double bottom other pattern be most important offense type sell signal individual investor have more conviction decide hold longer then be lookout sign tide be turn heavy demand heavy supply sell signal such sharp break day move average failure rebound quickly biggest single session point loss heavy turnover fail late stage base come top rank industry group biotech chip equipment plastic firm lead upside gain more however former big winner gilead science gild fall nearly fast turnover give back lot gain make past month pioneer hiv treatment clear first stage bottom base pattern buy point week watch see stock stay rise week move average be draw red ibd weekly chart dow jone transport rally index have now rise aug low athm help spark sell name chinese internet space online provider car information ad point slide more intraday low rebound volume continue run more triple usual pace point stock get low rise day move average stock post biggest single day point drop heavy volume proper usually mean great time take least gain lighten position case be also first time stock pierce day move average early past entry week cup rise much current correction further drop day line especially heavy turnover warrant selling share locking profit fall news abrupt resignation president yan kang cfo julian wang company also name jun zou former chief financial officer idreamsky replace wang company announce resignation be not due disagreement company regard business finance accounting other affair more serious concern shareholder lay be able maintain high growth fundamental earning grow cent share second quarter match highest increase past quarters increase also be acceleration rise however sale grow slowly sharply gain prior period year quarter revenue jump analyst see revenue growth slow further then fall vs year slower growth top line past quarters be able grow earning cent share back improve margin gross margin rise vs year quarter net margin rise surprising basis point highest quarters accord research william neil co go public december ibd take do want quickly check quality new stock prospect term fundamental technical action level institutional sponsorship stock checkup be answer notice doctor facial expression change base quality rank major category such relative strength earning share growth smr sale growth margin roe however chart be still best way determine stock be sell gain be lock not ibd proprietary rating such composite rating read stock checkup help improve result investor corner online retailer jd com jd meanwhile slump sixth straight session fall more double usual volume stock be now form new base peak remain comfortably rise day line follow chung twitter ibd_dchung intraday comment stock market lead stock related stock start simple routineis time buy stock now read latest big picturewhen sell stock spot major market top easy waystock market today chip stock beat nvidia stock market today ii here apple rally isn
100,GILD,advanced accelerator application aaap launch record high thursday rumor swiss drug giant novartis nvs attempt take potential deal analyst call very logical xadvanced accelerator gap much time high settle back gain close novartis lift fraction finish potential deal fit well novartis exist franchise include sandostatin approve treat symptom associate tumor afinitor approve treat cancer affect breast kidney hormone nervous system canaccord analyst mark massaro say advanced accelerator be work gain approval drug call lutathera treat tumor tract december lutathera be delay food drug administration approval be now expect january expect final european medicine agency approval lutathera come day fda approval schedule jan push share higher massaro write note client expand access program help launch ibd take cellular therapy also know car therapy be get leg wall street novartis gain first approval earlier year kite pharma be next head industry snapshot closer look medicine be make massaro expect lutathera offer long tail revenue consider limit supply material go drug extreme efficiency model peak sale peak european sale model conservative pricing line current therapy lutathera significant efficacy advantage say massaro keep buy rating price target advanced accelerator novartis gain access lutathera be very logical say cancer drug be staple novartis pipeline advanced accelerator also have drug treat neuroendocrine prostate breast cancer pipeline novartis just gain approval drug call kymriah cellular therapy treat form acute lymphoblastic leukemia patient age competition be come gilead science gild be work acquire kite pharma kite be close approval similar drug gilead kite juno therapeutic juno bluebird bio blue be work celgene celg develop similar cellular therapy treat blood cancer related biotechs beating market be buy range galapago pop eczema drug show promise vs regeneronfda chief gottlieb address opioid cancer new therapiesabbvie new hepatitis drug chip away gilead share
101,GILD,dow industrial rally strongly thank ibm ibm turnaround johnson johnson jnj several other blue chip earning general electric ge be big miss adobe system adbe also be big winner bullish outlook netflix nflx hit new high boom subscriber growth ipos be hot dow industrial rise week fuel ibm predict return revenue growth johnson johnson unitedhealth unh be also notable blue chip contributor general electric crash big ep miss have little impact price weight dow rise nasdaq help senate first step big tax cut adobe system soar outlook paypal pypl beat netflix pull back record high high subscriber gain unite airline ual crash carrier have few answer question few new ipos impressed internet television network netflix cheer investor third quarter subscriber addition trounce expectation earning growth miss view sign net new stream subscriber third quarter beating wall street target december quarter netflix expect add new subscriber edge consensus view end september quarter stream subscriber worldwide netflix share hit record high tuesday morning sank week remain buy range related netflix stock fall third quarter subscriber beatadobe system share surge record high maker digital medium marketing software announce upbeat sale earning target fiscal san jose calif base adobe be target adjust earning share year year sale wall street be modele related adobe system rocket outlookibm share soar tech icon report quarterly earning beat estimate indicated sale growth return first time more year ibm do not provide formal quarterly guidance management indicated revenue snap quarter string revenue decline related ibm get price target hike earning report outlookgeneral electric earn just cent share far cent expect revenue rise more expect organic industrial revenue dip industrial operate margin shrank ge power business be big drag industrial cash flow operate activity plunge adjust due weakness power business ge slash full year earning cash flow guidance raise concern dividend cut ge share fall soon friday open close related ge earning miss badly cash flow dive add dividend fearsunited airline tumble more management carrier third quarter earning call be unable provide detail longer term plan drive profit lack clarity lead analyst believe carrier be walking back target outlined last year grow earning higher expect cost be also concern drop fare compete ultra low cost carrier morgan stanley ms top estimate help strong stable wealth management business rival investment bank goldman sachs gs also beat analyst raise concern result be help more volatile capital intensive line business goldman trading result continue struggle morgan outperformed other big bank morgan stanley rise retake buy point goldman sachs climb dow component johnson johnson top wall street view report adjust earning share sale pharmaceutical sale jump worldwide medical device revenue rise miss estimate abbott laboratory narrowly beat expectation early wednesday lion share beat come abbott establish pharmaceutical diabetes care cardiovascular neuromodulation product share rise clear buy point hit record high abbott advanced also time best related dow component pop top view pharma strengthqudian qd china base online credit firm backed alibaba baba rise debut raise pricing expect range singapore base online gaming company sea backed chinese internet giant tencent tcehy edge higher debut raise upsized ipo mongodb mdb provide open source database software platform business pop ipo top just raise price range qudian be profitable sea be poise start make money related sea upsized ipo raise millionmongodb price high qudian strong debut play new ipostop semiconductor industry player deliver generally upbeat report september quarter past week taiwan semiconductor manufacturing tsm beat target third quarter sale earning guide higher current quarter sale maxim integrate product mxim beat wall street target earning sale be tad short however maxim guide earning sale december quarter be well view chip gear vendor lam research lrcx beat view guide higher current quarter rival asml asml beat sale earning target third quarter revenue guidance be light unitedhealth group unh share vault record high tuesday then keep climb insurer report earning growth cent ahead estimate show enviable strategic position have exit obamacare exchange unitedhealth say benefit president trump executive order make low cost plan more widely available amazon com amzn want enter retail prescription business analyst say unitedhealth be ideal partner company signale willing meanwhile anthem antm insurer follow example unitedhealth announce broaden offer include pharmacy benefit management anthem share near buy point news dump express script esrx utilize cvs health cvs process retail distribution start related anthem jump prescription business amazon speculation signal openness amazon partnership earning beatpaypal report september quarter profit revenue top view forecast current quarter sale estimate send share commerce payment processor paypal say adjust earning be cent share year revenue rise current quarter paypal forecast revenue growth midpoint guidance gaap profit cent vs consensus estimate cent paypal jump friday new record high related paypal earning revenue top expectation share slb say friday investment demand north america be moderate baker hughe bhge warn challenge year end customer remain cautious spending due volatile oil price suggest shale other operator be rein production growth plan schlumberger meet ep view gain baker hughe report first quarter merger general electric oil gas unit july crude price hold barrel inventory fall yet again production plunge due gulf shutdown hurricane nate charle schwab schw trade etfc beat wall street consensus third quarter earning schwab miss revenue trade meet expectation schwab report ep cent revenue trade post earning cent share revenue schwab undercut buy point report sharp fall trading revenue share rebound friday trade share fall be still buy range past entry ebay ebay meet third quarter earning estimate revenue be slightly forecast online marketplace fourth quarter ep outlook fall short estimate share sank close day move average recent buy point undercut intraday thursday related ebay meet earning view share tumble weak outlooksap sap report quarterly earning top estimate german enterprise software giant raise guidance year base cloud compute strength bombardier bdrbf agree sell stake struggle series jet airbus eadsy commerce department call tariff narrow body jet deliver boee ba accuse canadian company receive unfair government subsidy gilead science gild win fda approval car drug dub yescarta treat aggressive form hodgkin lymphoma yescarta come gilead recent kite pharma deal gilead rise thursday be little change weekcelgene celg scrap trial crohn disease drug win start third cite internal futility review celgene fall friday intuitive surgical isrg top expectation late thursday report sale adjust profit share share rise friday atlassian team surge maker project management software report fiscal first quarter sale profit handily top estimate atlassian up full year revenue guidance midpoint guidance earlier forecast share surge nearly verizon communication vz add more postpaid wireless phone subscriber expect revenue also top estimate proofpoint pfpt report earning revenue top estimate fiscal outlook disappoint share rise friday video game publisher electronic art ea disappoint news be delay star war action adventure game have be set release fiscal run april march do not give new release time frame ea share be so far week rv maker winnebago wgo exceed forecast profit growth cent share revenue increase company also approve share buyback share close american express axp exceed earning estimate longtime ceo kenneth chenault retire stephen squeri set take place feb unite rental uri steamrolled estimate cent share ep rise revenue boost hurricane rebuild be reason nation largest equipment rental company boost guidance capital spending plan procter gamble pg profit grow share top view cent organic sale rise just result follow narrow proxy fight trian fund management nelzon peltz share fall friday unilever report weak sale thursday european consumer food product giant fall week related stock buy watch top ipos big small cap growth stockslooking best stock buy watch start here
102,GILD,here weekly investing action plan need know investor come week upcoming week earning give investor much broader look corporate america economy stalwart tech industrial energy medical consumer sector weigh quarterly result such amazon com amzn alphabet ticker
103,GILD,franchise be safe large cap biotechs be feel pressure food drug administration speed approval rival brand generic medicine analyst say monday theme be continuation leerink analyst geoffrey porge say note client record number drug approval large cap sector fall favor investor name more punish concentrated product portfolio loom brand generic competitor say head management confidence be low revenue trajectory high profile product face slowdown courtesy payer competitive pressure porge doesn see uncertainty lift possibly not ever competitive pressure slug like celgene celg gilead science gild celgene be feel pain inflammation unit mount competition eli lilly lly novartis nvs gilead see rival hepatitis drug sale abbvie abbv early next year porge expect guidance lion share large cap biotechs be conservative most stock move guidance come alexion pharmaceutical alxn gilead predict alexion be work drug dub alxn treat pair rare blood disease also undergo restructure meanwhile gilead hepatitis franchise again come microscope even attempt pivot further hiv drug bictegravir believe be share value gilead stock hepatitis stock price move hepatitis revenue guidance meaningfully differ consensus estimate porge say ibd take small cap biotechs perform well third quarter large cap suffer mount competitive concern see translate stock price visit industry snapshot note abbvie plan hepatitis product be likely hurt gilead stock abbvie recently launch mavyret treat genotype hepatitis abbvie likely provide guidance fourth quarter call ahead gilead porge expect sale outlook celgene alexion vertex pharmaceutical vrtx gilead amgen amgn abbvie miss analyst estimate biogen biib provide outlook encompass analyst view say later year large cap universe face political pressure porge predict midyear congressional midterm election be underway campaign be likely renew focus pharmaceutical company pricing policy say continue favor stock company be structural demand growth story product protected commercial scientific clinical legal barrier entry top pick be vertex alexion leerink analyst michael schmidt peg clovis oncology clvs puma biotechnology pbyi top pick small midsize biotechs focuse treat cancer group stock have outperformed broader biotech market thus far schmidt write note client dynamic be set continue favorable regulatory environment large cap expand portfolio acquisition incyte incy seattle generic sgen exelixis exel clovis agio pharmaceutical agio puma array biopharma arry be set launch key product count group set unveil pivotal trial result pending regulatory decision total firm emerge technology remain interest car therapy train patient immune cell fight cancer precision oncology have strong success immuno oncology combination cancer vaccine certain antibody have only be modest think next generation antibody drug conjugate be re emerge area interest represent clinically validate category significant room upside schmidt say antibody drug conjugate be antibody link cell kill agent antibody bound specific mark surface cancer cell immunogen imgn mersana therapeutic mrsn seattle be work area latter furthest say related big pharma biotech company be gird pricing knife fight teva restructure plan case be here do generic drug maker face pricing issue other pharmas don
104,GILD,stock fall new high tuesday apple aapl microsoft msft reversed lower bitcoin sank further spdr spy slide powershare qqq trust qqq slip spdr dow jone industrial average dium be fractionally lower small cap get slam ishare russell iwm tumble apple clear flat base entry friday average volume iphone maker be still buy point relative strength have lag remain consolidation lows microsoft rs line have be flat recent advance record high sector fund real estate healthcare semiconductor lead upside stock market today health care select sector spdr xlv rise record high component stock merck lead dow industrial pop retake day move average marked best level nearly month drugmaker relative strength line be turn rs rating be weak result show cocktail merck keytruda chemotherapy drug stop lung cancer advance extend patient life ishare nasdaq biotechnology ibb be featured later column reversed lower build right side shallow cup handle buy point energy retail home construction lag west texas intermediate crude price slip barrel spdr gold share gld ishare iau hold small gain rise month high friday gold future edge higher ounce bitcoin extend drop accord coindesk earlier high bitcoin ripple ethereum be get hit continue talk south korea potential cryptocurrency ban bitcoin investment trust gbtc be find support day line dec intraday peak large cap growth fund hold apple microsoft be solid start year continue stay ahead broader market top performer base year return jan be ishare edge msci usa momentum factor mtum fund year date gain put third place base measure be jan accord morningstar direct mtum top holding make asset be jpmorgan jpm microsoft apple bank america bac boee ba apple soar last year break past flat base entry friday first clear buy point dec ahead pullback day move average microsoft advanced friday price target upgrade keybanc capital market share be record high powershare qqq trust qqq track tech heavy nasdaq index score year ytd return respectively year old fund count apple microsoft amazon facebook alphabet top holding have amassed nearly asset third place go ishare russell top growth iwy have gather asset september launch iwy hold same top name qqq be less top heavy top account iwy total asset vs qqq etfs have low expense ratio mtum qqq iwy also earn star rating morningstar indicate well fund return have compensate investor amount risk incur rating range star best performer base risk adjust return relative similar fund receive star fund be trading time high be extend ideal buy point fact other etfs accompany table be also record high not too surprising give re now ninth year bull market ibd take make money catch etf uptrend require knowledge read chart learn ibd university so let take look etf not list big cap category be set new base ishare nasdaq biotech fund be shape right side shallow cup handle base potential buy point share advanced june shallow base oct intraday high fund track nasdaq biotechnology index mark anniversary next month biotech represent biggest sector weight asset pharmaceutical life science tool service smaller health care related position make rest top holding jan be gilead science gild celgene celg amgen amgn biogen biib regeneron pharmaceutical regn top stock account nearly total asset most have outperformed broader market so far year gilead amgen biogen have gain respectively vs return ibb year return slightly lag gain etf average annual return past year lag benchmark index lead past year ibb carry expense ratio friday pick powershare low volatility portfolio splv remain buy zone jan rebound day line related apple microsoft fuel dow record bitcoin rebound last apple rise bitcoin dife time buy nvidia ai stock china hit stock buffett vs bitcoin new high cannabis
105,GILD,nordisk nvo be shedding restraint embrace acquisition danish drugmaker have traditionally eschew deal look inward develop new treatment signale desire seek growth outside own lab disclose takeover offer ablynx ablx ceo lar fruergaard jorgensen walk predecessor footstep first year helm be now attempt clinch biggest deal ever ablynx spurn offer less month strategy extend ablynx say review other potential takeover year rely mostly house research be keen look elsewhere new medicine mark higher risk willingness willingness obtain innovation outside nordisk compare historically have do chief financial officer jesper brandgaard say interview bloomberg have sit recent wave industry deal handful giant snap promising biotechnology company company have spend less merger acquisition past decade accord datum disclose swiss rival roche hold rhhby contrast commit time much just last month agree buy biotech firm ignyta rxdx other pharmaceutical transaction last year include johnson johnson jnj purchase swiss biotech actelion ltd gilead science gild takeover kite pharma year old jorgensen find not only interested ablynx isn aware other suitor brandgaard tell reporter conference call emerge now interest be open ablynx share surge more close share tick cent belgium base ablynx say late monday chairman peter fellner have resign board fellner have serve chairman have be slate step later year ablynx give reason departure fellner have have numerous corporate board appointment be member advisory group investing arm nordisk foundation january ll be replace chairman bo jesper hansen executive director company say statement jorgensen be work beef unit have traditionally have low profile business selling treatment rare blood disorder make only fifth sale be overshadowed company diabetes operation unit get split need grow say kim nielsen fund manager worldwide asset management copenhagen otherwise risk be too small too uninteresting say nielsen hold share overall feel confident do something go public ablynx reject proposal include upfront cash offer euro share additional cash payment know contingent value right euro share tie success experimental medicine maximum payment be more stock close price friday brussel choice target isn shot dark company have be involved research collaboration ablynx most advanced drug caplacizumab address rare disorder call acquire thrombotic purpura blood clot form small blood vessel body illness block flow blood body organ accord national heart lung blood institute jorgensen grow family farm denmark joined economist replace retire leader start last year joined just traditional diabetes business come pressure insurer payer demand lower price largest market ablynx hold great potential have highly competent employee brandgaard say be natural first asset pursue
106,GILD,investor business daily have create ibd biotech innovator award recognize lead company groundbreaking treatment already market close final approval xrecipient inaugural award be celgene celg biogen biib regeneron pharmaceutical regn kite pharma be recently acquire gilead science gild incyte incy loxo oncology loxo man woman research create testing marketing biotech drug represent often medical field best hope conquer cancer alzheimer other hard cure ailment company face many hurdle significant cost get drug approve federal drug administration fda hand prescribe doctor patient ibd biotech innovator award honor ingenuity effort related biotech stock watch pharma industry news
107,GILD,first run food drug administration gene cell therapy be early stage theoretical concept fda commissioner scott gottlieb say tuesday last month fda approve first cellular therapy drug call kymriah novartis nvs treat form acute lymphoblastic leukemia patient age younger kite pharma kite soon be acquire gilead science gild be expect grab similar approval november gene cell therapy drug biologically copy exist product know biosimilar didn exist gottlieb tell medtech conference san jose calif now have product re review approve say gottlieb be nearly month stint fda commissioner be first appointment president donald trump take office first serve fda deputy commissioner gottlieb background have uniquely prepared head be now much bigger fda say scott whitaker chief executive advame world largest medical technology association gottlieb be diagnosed type lymphoma be younger be kind tumor only hypochondriac doctor have find gottlieb tell audience san jose mcenery convention center doctor gottlieb research type treatment want know have very good chance survival ibd take medtech stock have be ride drug pricing fear have hurt pharma biotech sector analyst say head industry snapshot closer look winner loser political discourse acknowledge not patient fit bucket be very different patient patient be tell have chance survival say re look something experimental something not be approve yet lot different cancer patient part challenge gottlieb say be ensure fda have policy help patient difficult simultaneously serve type patient serve patient potentially impact patient say today fda have hand number area gottlieb say most person be surprised find spend most time work tobacco side win surprise public be fda be work closely ameliorate opioid crisis last month trump declare opioid crisis national emergency cope company boston scientific bsx abbott laboratory medtronic mdt be work therapy call neuromodulation use electricity conceal pain brain gottlieb note medical product step alternative addictive opioid medical device deliver localize therapy patch treat localize pain vs drug have systemic approach be very addictive say fda be also work framework quicker review certification software program rather go longer product review software program be review less information apple appl fitbit fit johnson johnson jnj pear therapeutic phosphorus roche rhhby samsung tidepool verily be involved pilot program seek identify information company need provide quicker review process gottlieb say need modernize regulatory framework so match kind innovation re be ask evaluate foster beneficial technology ensure consumer have access high quality safe effective digital health device say related biotech crater late stage alzheimer drug failure
108,GILD,biotech company chasing next generation cancer treatment work patient own immune system incyte incy stand treatment analyst say prove be blockbuster wilmington del base company be leader develop immunotherapy bolster cancer survival rate stand drug giant such novartis nvs merck mrk have partner compete emerge field medication rapidly expand nonprofit cancer research institute fund immunotherapy study estimate drug used immunotherapy target cancer be market pipeline august figure more double just year earlier explode say institute spokesman brian brewer number drug combination drug now be chart success be improve survival rate patient fight skin lung cancer come decade analyst say incyte be company lead charge bring new immunotherapy market still experimental drug epacadostat work combination other medication recognize potential new epacadostat regimen already robust sale company current flagship cancer fight drug jakafi investor business daily name incyte ibd biotech innovator award winner ibd choose biotech innovator award winner ibd ask equity analyst etf mutual fund manager university professor identify top biotech company base innovative research ask focus company pioneer drug likely launch next several year reach blockbuster blockbuster sale more year award winner select ibd editor be most cite company find profile award winner detail work go full biotech innovator special report morningstar analyst kelsey tsai say epacadostat show encourage early result concert bristol myer bmy yervoy fight melanoma incyte drug be evaluation other immunotherapy front include late stage study merck keytruda also target melanoma additional study be underway epacadostat combination keytruda drug treat other oncological disease epacadostat have very high potential tsai tell ibd incyte decline make executive available be interview story pivotal result drug combination keytruda be expect first half tsai say datum early testing same regime target multiple cancer be expect soon fall incyte researcher used past university study help develop epacadostat key finding show cell tumor take advantage enzyme call ido prevent person immune system kill epacadostat be design target block enzyme cancerous cell enable patient immune system attack reduce tumor analyst say process be safer chemotherapy other treatment involve human body fight disease naturally credit suisse see lofty sale epacadostat estimate annual revenue drug exceed soon assume win regulatory approval tsai say morningstar projection assume pricing annually use drug regimen say firm give epacadostat chance gain approval treatment certain skin lung cancer treatment other type cancer be target later ibd take always best focus stock relative strength rating incyte have be hierarchy promising outlook be top already strong oncological drug sale incyte company drug bone marrow disorder blood cancer jakafi help company generate revenue year drug gain fda approval incyte post second quarter revenue year earlier quarter strong jakafi sale tsai say blend jakafi foundation epacadostat future put incyte plum spot incyte stock touch month high aug close friday march stock set record high have date surpass revenue jump least year be expect rise more year company finally break black market capitalization top roughly double value start positive observer note drug trial setback wouldn be shock regulatory approval be never sure thing competition be strong intensify range company investor be really dig homework biotech be hard really know be go drug trial kind timeline thing be mike matousek trader investment house global investor grow tell ibd other say incyte boast unique positive herve hoppenot take ceo have be novartis president oncology bring cancer drug experience several key scientist incyte competition be heated need cancer treatment be so vast analyst say be plenty room multiple strong player field also notable analyst say incyte be largest midsize company oncology arena such analyst say incyte remain attractive acquisition target larger drug company look pick talent bolster drug pipeline march report surface say gilead science gild be eyee incyte incyte takeover rumor have come light lately instead gilead aug announce agreement acquire kite pharma kite nearly incyte likely remain subject speculation analyst say possibility almost always give investor add reason give extra attention stock matousek say related get detail biotech innovator award winning company workincyte battle marketphase trial result boost biotech stock
109,GILD,biotech company celgene celg biogen biib gilead science gild put drug extensive trial gain fda approval turn clinical research firm pra health science prah pra health be world lead global contract research organization hold ranking medical research equipment
110,GILD,jeffrey leiden office shelve be plaster accoutrement expect chief executive biotech award letter accommodation inevitable family photo emerge theme gratitude leiden vertex pharmaceutical vrtx currently aim treat cystic fibrosis patient globe cystic fibrosis be progressive genetic lung condition survive adulthood generally don live past age accord most estimate xin vertex set change success see medicine soon be market have generate piece mail plaster leiden shelve re letter thank graduate newlywed get letter email week patient family thank do leiden tell investor business daily know patient most be kid teenager watch grow be part family not company vertex wasn always cystic fibrosis play earlier day be focuse treat hepatitis launch drug know incivek then gilead science gild launch drug sovaldi launch be most successful history also nearly put vertex business incivek become blockbuster drug shortly launch vertex pull market demand withered leiden describe time crisis company be middle crisis say have go be hepatitis company dollar drug literally year essentially revenue be very few company frankly survive kind crisis simply so hard pivot new area drug year division company san diego have be quietly work cystic fibrosis arena indication fit leiden strategy investing scientific innovation create medicine serious disease large unmet medical need specialty area vertex specialty focus allow keep sale marketing force slim turn allow reinvest nearly dollar revenue back research development sell cystic fibrosis drug sale force fewer leiden say fast forward vertex have drug market kalydeco orkambi second quarter sale kalydeco first approve cystic fibrosis drug grow year year orkambi rocket year date vertex stock have more double rise share begin form cup handle buy point late july meanwhile broader biotech industry group have rise be rank eighth group track just week share vertex dip close friday vertex be rarity biotechs way pipeline be almost solely cystic fibrosis drug pipeline not already license bigger pharmaceutical be cystic fibrosis leiden acknowledge risk portfolio standpoint product simply don make sense vertex say vertex have farm drug flu cancer dow johnson johnson jnj merck kgaa enormous sale contingent take sell drug indication take away reinvest science reinvest science have allow vertex do something else unique medicine other firm target symptom cystic fibrosis vertex be work correct genetic underlie cause disease eventually prevent infant diagnosed ever fully develop underlie science focus genetic mutation be divide bucket leiden say kalydeco treat patient orkambi combination kalydeco drug know lumacaftor treat eventually vertex plan treat patient get third bucket patient require prong treatment strategy already backbone triple be be consider approval europe combination kalydeco drug call tezacaftor look likely be approve february top kalydeco tezacaftor vertex be add next generation corrector drug fix other abnormality gene treat patient vertex have strong phase datum next generation corrector combination kalydeco tezacaftor fourth ready read soon eventual goal be decide possible triple pill combination provide most efficient treatment few side effect vertex plan use gene editing treat last cystic fibrosis patient traditional small molecule medicine win work leiden win comment expect triple pill get approval see pivotal trial begin next year most analyst take mean food drug administration approve triple pill vertex vertex goal triple be prevent infant less year age develop cystic fibrosis know today adult already have lung damage kalydeco have be show improve lung function week time slow rate decline lung function ibd take vertex be several leader near buy zone head ibd list stock buy zone other term opportunity include entertainment stock financial service play rather decline year decline year lung function leiden say not sound significant sort compound interest take lifetime make enormous difference survival quality life quality life improvement be huge leiden say used go hospital time year now time year say used be transplant list now re not transplant list used be able walk block now walk mile not just longevity quality life galapago glpg abbvie abbv have team follow vertex step leiden jmp security analyst liisa bayko be doubtful duo catch get fda approval triple pill combo show strong datum component first bayko estimate galapago be several year even do make market triple pill have have outstanding efficiency persuade vertex patient switch new medicine vertex have do good job continually improve med tell ibd keep move bar higher make challenge person want go drug be just good vertex want do just get vertex drug be more bearish jeffery analyst michael yee see galapago eventually get cystic fibrosis market still note vertex have create strong setup make barrier enter market high deliver strong medicine other question vertex do cystic fibrosis well run dry leiden acknowledge cystic fibrosis journey be near end say vertex have plan shift other rare disease sickle cell genetic lung liver condition deadly nerve disorder alpha antitrypsin deficiency lung liver condition look lot cystic fibrosis leiden say have technology know go bear skeptical vertex cystic fibrosis pipeline group analyst investor say well really great want do ll see re able skeptical say reason weird be ve already do ve proven do ve proven model don think question anymore think ve demonstrated work related biotech catch rally add celgene break biotech giant close buy pointstop biotech stock buy zone fda drug approval
111,GILD,abbvie abbv newly launch hepatitis drug mavyret have already grab total new prescription further chip away gilead science gild struggle hepatitis franchise analyst say friday xas result wall street see gilead hepatitis drug sale decline vs year earlier period evercore analyst umer raffat write note client drop be sharper plunge sale be expect fall wholesale basis mavyret be price roughly half competitor month vs gilead epclusa sovaldi harvoni respectively dow stock merck mrk zepatier abbvie viekira pak cost respective monthly gilead contend discount rebate mavyret be price similarly harvoni differ treatment duration wide array hepatitis drug mavyret treat genotype have shortest treatment duration week most patient ibd take novartis be first finish line car drug do mean gilead plan acquire kite head ibd industry theme deeper dive segment contend likelihood further erosion hepatitis franchise gilead be pivot cellular therapy acquisition kite pharma kite kite doesn have approve drug merger be announce day rival drug novartis nvs gain approval novartis drug be approve treat form acute lymphoblastic leukemia patient age analyst now expect similar drug kite treatment aggressive form hodgkin lymphoma grab approval later year bluebird bio blue juno therapeutic juno be partner celgene celg work similar treatment know car therapy create drug immune cell be extract patient reprogram fight cancer cell be reintroduce related abbvie gauntlet squeeze gilead drug hepatitis cure cancer look bloodwhy biotech catch rally add september be make break month partnership bit dust gilead kite competition
112,GILD,bluebird bio blue topple week low monday analyst downgrade stock doubt regard sickle cell disease drug send share rival crispr therapeutic crsp edita medicine edit skyrocket xby close bell stock market today bluebird dove finish earlier hit low last see aug biotech stock broadly rise touch high last see january group be now rank second group track crispr rally end regular trading session edita pop close bluebird downgrade be work therapy treat sickle cell disease group inherited blood disorder therapy crispr edita be show promise say morgan stanley analyst matthew harrison investor don appreciate risk bluebird face december set unveil further datum drug lentiglobin treat sickle cell disease harrison say meanwhile therapy crispr edita use different mechanism less variability bluebird do not believe american society hematology datum bluebird demonstrate significant improvement hemoglobin production necessary increase investor confidence sickle cell gene therapy harrison write note client ibd take vertex pharmaceutical be partner crispr work solution genetic disease used gene editing include sickle cell disease head new america closer look vertex have plan cystic fibrosis journey come end harrison downgrade bluebird underweight rating keep price target be more bullish bluebird chance treat multiple myeloma used drug know bb partnership celgene celg bluebird be crowd field car therapy aim immune system identify cancer cell novartis nvs just gain approval drug kymriah gilead science gild be acquire kite pharma kite drug juno therapeutic juno be also work celgene still bluebird have significant lead partner celgene be clear leader myeloma space harrison say importantly expect bb be grant breakthrough designation term cause bluebird rally related bluebird hit high bullish report highlight blood drugswhy amgen drug send abbvie stock acquire biotech deal be very logical
113,GILD,key stock index turn mixed monday even small cap biotechs continue rally xspdr dow jone industrial average dium spdr spy rise index hit new high powershare qqq trust qqq be slightly underwater small cap add last week gain ishare core small cap ijr record best also mark new high be ishare russell iwm advanced etfs be top buy range respective flat base entry sector fund telecom biotech utility lead upside stock market today spdr biotechnology xbi ishare nasdaq biotechnology ibb gain xbi be now extend flat base buy point ibb remain buy range flat base entry xbi component stock dynavax technology dvax heplisav hepatitis vaccine be approve july surge oil retail gold lag west texas intermediate crude price skid barrel gold future fall ounce unite state oil uso slide powershare db oil dbo drop spdr gold share gld ishare gold trust iau give fund have extend slide begin gap day line last week small cap stock be rally further president trump tax cut proposal be expect benefit smaller company most vanguard small cap growth vbk leap past flat base entry wednesday remain buy range share advanced prior start just clear pattern fund track crsp small cap growth index have attract january launch technology represent biggest chunk asset aug weighting health care make real estate industrial consumer cyclical top name include option exchange operator cboe holding cboe software developer cadence design system cdns video game maker take interactive software top holding make asset fund have stock portfolio vbk have return year date accord morningstar direct outpace gain produce average annual return past year respectively stock market benchmark index gain period be vbk carry expense ratio ibd take bluebird bio have be news lately do fare industry group stock lead industry group often make strongest price advance find bluebird stand now ibd stock checkup ishare russell iwm be also buy range past week ideal buy point flat base just clear be fund have form series almost adjacent basis december advanced november flat base year old fund track russell index have amassed asset count kite pharma be acquire gilead science gild bluebird bio blue exact science exas top holding rank biotech industry group biggest sector weighting be financial service technology industrial health care apiece stock portfolio top holding represent asset iwm have return nearly ytd average annual return past year be respectively expense ratio be friday pick powershare buyback achiever pkw ishare nasdaq biotechnology ibb rise friday be still buy range respective buy point related bank builder lead market soar equity play buy rangebiotech beating market be buy range stock pare early loss be alibaba baidu back play
114,GILD,stock index be narrowly mixed friday head final trading day september xpowershare qqq trust qqq hold gain spdr spy be fraction spdr dow jone industrial average dium be emerge market rally stock market today ishare msci emerge market eem rise find support day move average bank homebuilder telecom lead upside sector fund energy biotech gold miner lag spdr bank kbe spdr regional banking kre gain nearly etfs have advanced past session re back day move average line continue consolidate ishare home construction itb climb highest level more decade component stock kb homekbh soar report earning late thursday now just shy buy point month base gold oil play dip underlie commodity price very different equity play hold big name be buy range stock market resume march record high powershare buyback achiever pkw be buy range clear entry flat base wednesday climb june prior flat base start most recent pattern fund have attract december launch track nasdaq buyback achiever index pkw invest company have trim share outstanding more trail month stock buyback holding be then weight market cap industrial represent biggest sector weighting asset accord morningstar direct financial service consumer cyclical weigh respectively technology health care make apiece pkw count boee ba gilead science gild mcdonald mcd general electric ge unite technology utx top holding holding be subject initial cap top stock make asset fund lag year date return vs benchmark index gain average annual return past year be roughly line year return be ahead advance expense ratio be ibd take keep eye industry group action be vital investing check ibd daily industry sub group ranking list find biotechs rank industry group track ibd ishare nasdaq biotechnology ibb be still buy range flat base clear aug rise nearly prior flat base mid june start most recent pattern fund be featured aug etf column seek support day move average take dip line form bottom flat base share advanced much retake day ibb have amassed february launch track nasdaq biotechnology index top holding include amgen amgn celgene celg gilead science gild biogen biib top name account nearly total asset fund be beating year date return lag year average annual return vs have outperformed past year respective gain fund bear expense ratio related biotechs beating market be buy range stock pare early loss be alibaba baidu back play goldman jpmorgan lead dow equity play break
115,GILD,thank gilead kite merger biotechs have big week ve also rally year longer haul top health sector etfs rank year date return aug be biotech focuse accord morningstar direct top performer spdr biotech xbi post gain well ahead advance etf featured monday etf leader column break past flat base entry thursday remain buy range share run june flat base start just clear pattern fund launch january have asset bear expense ratio come second be first trust nyse arca biotech fbt ytd gain etf be buy zone past flat base entry year old fund track nyse arca biotechnology index have attract asset carry expense ratio count top holding aug kite pharma kite juno therapeutic juno illumina ilmn kite gap soar aug gilead science gild announce buy kite xbi mentioned also get boost kite ishare medical device ihi take third place ytd return etf recently regain day move average line shape flat base potential buy point fund marked anniversary track dow jone select medical equipment index ibd take gilead science have be news lately due kite pharma acquisition do rank biotechs find now ibd stock checkup top holding aug include medtronic mdt abbott laboratory thermo fisher scientific tmo ihi expense ratio be ishare nasdaq biotechnology ibb round top ytd gain price action be similar other biotech etfs buy range follow thursday flat base buy point case be etf sport expense ratio ibb oldest biotechs year have amassed asset top holding aug be gilead biogen biib celgene celg kite account position portfolio fund have beaten past year return vs gain fund have outperformed past year related gilead science buy kite pharma sector boost stock breakout put apple amazon focusretail lead broad stock sell biotechs find support celgene flirt giant soon join
116,GILD,celgene celg break friday join biogen biib bluebird bio blue enter buy zone thursday biotechs broadly gap major merger cancer space xin afternoon trading stock market today celgene rise clear entry flat base bluebird continue rise soar top buy point cup thursday bluebird be now extend biogen climb look vertex pharmaceutical vrtx join list biotech breakout near entry flat base begin form late july share lift close amgen amgn advanced potentially close buy point biotech stock have broadly rally week pop nearly announcement gilead science gild acquire kite pharma kite aftermath rival bluebird juno therapeutic juno have enjoy increase ibd take novartis nvs beat kite finish line know car drug therapy teach immune system identify fight cancer approval open new sector cancer treatment head ibd industry theme deeper dive implication novartis new treatment rally be less definitive friday juno rise gilead inched biogen rise remain buy zone top entry yearlong consolidation major exchange trade fund spdr biotech etf xbi ishare nasdaq biotechnology index ibb climb breaking thursday respective ibd biotech industry group rise related biotechs just moved buy zone be giant next biogen alzheimer drug show promise break gilead kite deal boost biotech etf clear buy novartis cancer approval validate gilead kite dealanalyst mixed gilead kite key rival stand benefit
117,GILD,nasdaq composite rise record close thursday index climb fifth straight session fuel several breakout biotech play clear buy point biogen biib bluebird bio blue supernus pharmaceutical supn biotech etf ishare nasdaq biotechnology ibb xbe lookout celgene celg close just entry thursday several biotechs have form new basis nasdaq composite so far week be now just july time high dow industrial be less record level biogen shot thursday stock market trading nearly double normal volume follow gain wednesday biogen soar past buy point consolidation go way back early august biotech long consolidation strong market gain mean stock relative strength line have lag be not great sign biogen report encourage early stage datum alzheimer treatment earlier week ishare nasdaq biotechnology etf better know ibb ticker jump crest buy point short flat base really base base formation ibb other biotech etfs such spdr biotech xbi be way play sector rally avoid company specific blowup weak earning fail drug trial more bluebird bio rocket huge volume month high full point cup base entry bluebird bio be develop car gene therapy treatment cancer have surge week big car news gilead science gild be buy kite pharma kite novartis nvs win first ever fda approval car therapy supernus rise thursday retake flat base entry rebound day move average supernus originally moved buy zone aug have pull back somewhat fashion celgene rise just buy point flat base base base formation celgene edge premarket trading friday suggest open celgene be bigger biotechs partner car play bluebird bio juno therapeutic juno amgen amgn vertex pharmaceutical vrx regeneron pharmaceutical regn be other notable biotechs set new basis related big picture reason be bullish nowbiogen alzheimer drug show promise break breakout prevail new high market pick upbiotech pharma industry newsstock buy watch top ipos big small cap growth stock
118,GILD,nasdaq composite show follow wednesday tuesday bullish reversal see index reclaim day move average nasdaq jump add dow jone industrial lag gain volume nyse nasdaq be tracking lower tuesday level more so nyse goldman sachs gs cisco system csco outperformed dow gain nearly economic news second estimate gross domestic product come initial estimate good news be follow more good news adp show private payroll growth august well consensus estimate market friday be look nonfarm payroll increase little july increase concrete cement aggregate maker make biggest move concrete uscr martin marietta mlm eagle material exp soar anywhere big mover stock market today include aerovironment avav aerospace company trade thin side average daily dollar volume stock break powerfully flat base surge strong earning stock gap more past buy point buy close open price possible open price here be gilead science gild soar help news novartis nvs receive fda approval kymirah cell base gene therapy know car drug share gilead be nearly so far week company announce plan acquire biotech kite pharma kite be also close approval car therapy immune cell be extract patient reprogram fight cancer share ollie bargain outlet olli be early pare loss wall street react earning report share ease drop intraday analog device adi gap rise chipmaker report fifth straight quarter accelerate sale growth wednesday gap day line be positive stock be still high fail buy point close watch earning workday wday provider workforce management software be show big sale growth recent quarters fiscal company turn first annual profit growth expect ramp fiscal share rise ahead result workday have perform admirably clear buy point related novartis be first finish line car cancer drug nodbest stock buy latest bitcoin rival hit market
119,GILD,bull be hope follow wednesday nasdaq composite tuesday bullish reversal higher volume exactly get index jump higher volume overall be constructive session several top rate growth name make solid move higher close day
120,GILD,biotechs continue outmuscle broader stock market nonleveraged leverage exchange trade fund be show healthy gain xdespite recent pullback ishare nasdaq biotechnology ibb remain buy range flat base clear aug rise early prior flat base mid june start most recent pattern ibb have amassed february launch track nasdaq biotechnology index top holding include amgen amgn celgene celg gilead science gild biogen biib top name account nearly total asset fund be beating year date vs benchmark index accord morningstar direct ibb lag year average annual return vs have outperformed longer haul carry expense ratio proshare ultra nasdaq biotechnology bib aim twice return nasdaq biotechnology index have generate big return year fund have rally ytd year average annual return come year gain be leverage play bib tend have more exaggerate move upside downside thus tend carry higher risk nonleveraged fund expense ratio be higher nonleveraged peer share have pull back week high be head test day move average bib rally late august bounce day line ibd take keep eye industry group action be vital investing check ibd daily industry sub group ranking list find biotechs rank industry group track ibd spdr biotech xbi be top buy zone flat base entry clear aug gain more breaking flat base june start most recent base year old fund track biotechnology select industry index have gather asset top holding include alnylam pharmaceutical alny exact science exas puma biotechnology pybi alynylam surge report positive result late stage trial patisiran drug used treat rare disease xbi be equal weight etf top holding make less total asset average market cap xbi portfolio be much smaller ibb xbi have deliver solid performance year ytd year average annual return year year have expense ratio leverage play direxion biotech bull labu be trading highest level january have return ytd fund seek provide performance biotechnology select industry index launch expense ratio be related novartis acquire biotech deal be very logical hot biotech play reach be apple still buy range think miss big biotech rally check play
121,GILD,catch rally biotech sector tack stock celgene celg alexion pharmaceutical alxn regeneron pharmaceutical regn lead charge analyst say week xyear date ishare nasdaq biotechnology etf ibb be same time spdr biotech etf xbi be be currently buy zone strong performance biotech multiple be only just historical time trough leerink analyst geoffrey porge say recovery be underway large cap biotech stock be april beat market handily second quarter still biotechs continue trading significant discount pharma medtech brother porge say note client premium biotechs have enjoy pharma medtech respectively have erode reversed porge be banking return sentiment biotech sector compare revenue multiple group be be still additional upside sentiment sector return prior level say ibd take industry observer say september be make break month biotech sector base number upcoming investor health care conference well expectation nearly dozen trial readout excel be face pitfall head ibd industry theme closer look recovery be already underway late august gilead science gild say pay acquire cancer play kite pharma kite day later rival novartis win approval key treatment set stage key drug kite be approve november announcement ibd company biotech industry group have climb porge call catch rally significant extend be rally investor have be hope look follow surprisingly tepid july group strong second quarter operate result porge say consensus expectation third quarter be pick porge say revenue view be modest call average growth earning share forecast be trend first time year porge be more bullish consensus top pick be outperform rate alexion celgene regeneron vertex pharmaceutical vrtx january even slow grow large cap have deliver outperformance standout include regeneron vertex celgene have more pipeline optionality have not appreciate much lately alexion say be also recommend regeneron vertex current valuation see less upside name celgene alexion related alnylam topple celgene astrazeneca rise drug setbackstop biotech stock buy zone fda drug abbvie chip away regeneron potential blockbuster
122,GILD,sure help etf largest hold get rich buyout offer send stock soar xspdr biotech etf xbi have precisely good fortune last monday kite pharma kite gilead science gild agree deal value kite nearly kite largest hold spdr biotech etf nearly portfolio weighting vault news gilead rise monday surge wednesday highest price september be wednesday fda approve drug novartis nvs call kymriah first use car therapy immune cell be extract patient reprogram fight cancer kite pharma be make progress own car treatment explain gilead rally novartis approval other biotechs rally gilead science be largest component etf more portfolio juno therapeutic juno company work car drug surge tuesday fda decision stoke sentiment biotechs work gene reprogramming treatment juno etf second largest hold gap base previous day other major component exelixis exel be try break new high neurocrine bioscience nbix soon break cup handle base spdr biotech have nearly stock be most heavily trade biotech etf average daily volume share favorable chart other holding be filter etf spdr biotech thursday break past buy point flat base be latest pattern recovery etf have be make low february relative strength line be new high also be good sign spdr biotech have worst period july february low etf have good long term performance year annualize gain be year gain end july spdr spy generate average annual gain period just drug approval send biotech stock soar reject drug spark huge sell off risk own industry be linger risk lawmaker revive push cut price exorbitantly price medicine ibd etf leader index show performance model portfolio exchange trade fund be lead overall market computer algorithm select etfs base relative strength other objective performance rating periodic adjustment market trend condition universe etfs be select include fund list related biotechs just moved buy zonesgilead science buy kite pharma billionnovartis be first finish line car cancer drug nod
123,GILD,gilead science gild agree monday morning buy kite pharma kite share premium kite friday close promising car treatment cancer share kite pharma sky-rocket early trading gilead science also rise xgilead science get huge potential new market growth slow hepatitis hiv aids drug transaction provide opportunity diversification revenue be expect be neutral earning year accretive thereafter gilead say release kite be lead developer car immuno oncology treatment have candidate axicabtagene ciloleucel seek approval fda europe kite pharma jump close stock market today already greatly extend early june gilead rise stock try break year slide mid mid other car developer juno therapeutic juno shot finish trading day bluebird bio blue pop end regular trading session related cure cancer look bloodcan celgene bluebird keep lead rival champ bit biotech pharma industry newsstock buy watch top ipos big small cap growth stock
124,GILD,september be make break month number biotechs include alnylam pharmaceutical alny axovant science axon versartis vsar be expect present phase datum upcoming week xbiotech stock be poise run say loncar investment chief executive brad loncar year date ve rise hit month high share have rise follow gilead science gild announcement acquire kite pharma kite come incredibly newsworthy september feature least major medical conference least big investor conference nearly dozen phase trial expect read loncar tell investor business daily be most newsworthy month biotech history say so amazing september be be ton phase trial be schedule read company be go succeed fail trial readout count be make break company loncar say loncar count key trial readout september principal note be alnylam be expect unveil result trial drug dub patisiran rare disease cause buildup abnormal material call amyloid body success be major catalyst technology know rna interference antisense essentially turn malfunctioning gene leerink analyst paul matteis write note client tuesday ibd take novartis ibd relative strength rating be boost friday best possible grade show stock price moved past week other stock database head ibd datum story see novartis stack rival ionis pharmaceutical ion be also work phase drug know inotersen treat disease call ttr amyloidosis matteis call upside depend magnitude success safety downside drug prove effective mixed safety see downside alnylam drug fail completely trial accord loncar most person be convince go succeed cite note see range failure success putt alnylam stock price share close tuesday company window say be bellwether biotech company everyone be count succeed probably trial fail stock crash alnylam loncar note axovant be expect announce result drug dub intepirdine mild moderate alzheimer disease recently biogen biib stock break strong phase datum alzheimer trial axovant be work different theory treat alzheimer intepirdine be know serotonin receptor antagonist have potential cognition memory learn enhance side effect be originally develop glaxosmithkline gsk sell axovant so far nothing have work alzheimer so always excitement trepidation trial readout disease loncar say last december eli lilly lly topple drug solanezumab fail phase trial alzheimer axovant do succeed see stock go day say axovant close tuesday extreme kind euphoria alzheimer create also note trial versartis zogenix zgnx growth hormone deficiency form epilepsy know dravet syndrome respectively win just be september chock full catalyst leerink analyst write note client tuesday solid year return biopharma stock be still number catalyst back half year large cap leerink geoffrey porge note abbvie abbv have datum trial inflammatory cancer drug alexion pharmaceutical alxn be expect grab approval drug soliris treat disease immune system attack healthy cell amgen amgn update label ldl cholesterol lower drug repatha include add benefit cardiovascular outcome meanwhile regeneron pharmaceutical regn sanofi sny be appeal court decision vs amgen rival drug praluent celgene celg have readout ulcerative colitis form hodgkin lymphoma fibrogen fgen be expect have datum fibrosis anemia drug analyst expect vertex pharmaceutical vrtx provide update datum cystic fibrosis trial gilead kite car drug likely be approve treat aggressive form hodgkin lymphoma november follow approval novartis nvs kymriah car drug treat form acute lymphoblastic leukemia patient age expect car remain most closely follow emerge area biotech second half leerink analyst michael schmidt write note launch kymriah read drug bluebird bio blue juno therapeutic juno adaptimmune therapeutic adap related biogen alzheimer drug show promise break partnership bit dust gilead kite break biotech giant close buy novartis cancer approval validate gilead kite dealgilead kite deal boost biotech etf clear buy point
125,GILD,gilead science gild end do nothing oncology right takeover deal doesn present chief executive john milligan reportedly tell analyst wednesday third largest biotech market cap gilead have struggle decline sale hepatitis drug several quarters first quarter gilead hint be look buy oncology player gilead remain mum potential merger recent second quarter appear gilead be look acquisition leerink analyst geoffrey porge write note client meeting biotech management wednesday firm be struggle identify such opportunity ceo john milligan explain didn think make much sense buy something small today hope grow something large porge say instead milligan be look company substantial datum value scale analyst have suggest gilead look acquire company tesaro tsro incyte incy clovis oncology clvs kite pharma kite cancer vertex pharmaceutical vrtx cystic fibrosis recently unite therapeutic uthr spiked potential gilead take ibd take biotech industry be await merger acquisition spike higher say industry observer do gilead fit visit ibd industry theme closer look gilead also note still interested fibrosis program buy firm nonalcoholic steatohepatitis nash program phenex pharmaceutical nimbus therapeutic nash be liver disease meantime gilead be call decline hepatitis unit beating view second quarter porge see revenue hepatitis drug fall then dip annually decline be likely accelerate better competitive hepatitis regimen come market write outlook company hiv business remain positive be not sufficient offset dynamic hepatitis business competitive regimen abbvie abbv mavyret gain approval earlier month treat genotype hepatitis gilead acknowledge abbvie biggest advantage be treatment genotype rivale gilead epclusa sovaldi chief operate officer kevin young say contract cycle be now full swing doesn mean payer defer abbvie mavyret gilead drug mavyret be be price discount gilead harvoni epclusa porge say note last week hiv unit gilead remain bullish chance fend glaxosmithkline gsk be work drug combination recently concern have emerge regard safety glaxo double drug hiv question infection ability adapt treatment gilead stock close stock market today related gilead be make acquisition not thinkhow abbvie gauntlet squeeze gilead drug hepatitis cgilead hepatitis franchise topple again share beat
126,GILD,stock index be mixed midday monday small cap rv biotech stock logged gain nasdaq rise be flat blue chip dow jone industrial average retreat small cap russell tack volume stock market today be run lower nyse higher nasdaq vs same time friday midcap thor industry tho break strong volume clear buy point stock leap first hour trade then ease just buy point volume be torrid most thor business revolve towable rvs company big jump monday be probably related harvey category storm have flooded houston other part texas other rv manufacture housing stock also rise last storm come nearly equal force be irene be category irene hit aug rv stock rise session irene hit choppy action follow next month rv group rise storm initial hit thor gain overall move action also be choppy make stock hard hold meanwhile quality stock biotech space rise nicely midday monday stock group composite rating higher price higher advanced more gilead science gild announce buy kite pharmaceutical kite gilead rise news kite jump stock have composite rating just go monday market composite rating combine ibd rating single number rating mean stock be top stock ibd database blue chip be mixed component dow jone industrial average apple aapl score best gain volume average speculation swirl apple report say apple unveil new phone apple tv company not confirm report foreign market brazil bovespa hit new high mining big cap vale vale add recent related tech stock be flash stock tumble harvey impact
127,GILD,major market index be cautiously mixed early trade monday tech heavy nasdaq edge higher dow jone industrial average inched lower dow industrial home improvement retailer home depot hd moved share briefly top day line be turn away early trade meanwhile apple aapl trade higher iphonemaker be still buy range flat base downside traveler company trv decline almost last week stock break day line approach long term day support level fang stock netflix nflx moved more early monday stock attempt regain day support level stock have be search strong support level several week now china base leader alibaba baba lose streak look extend third day fall stock market today share be still well extend day line find support aug meanwhile retail competitor jd com jd chinese internet giant baidu bidu decline respectively jd have give day line recent week build new base baidu be still hold tight high cup shape base entry other lead stock tesla tsla drop continue add handle cup base formation electric automaker buy point be stock be struggle day line company report earning best buy bby moved ahead earning market open tuesday consumer electronic retailer be trading solidly buy range double bottom buy point analyst think retailer get boost sale nintendo ntody switch game console share nintendo trade almost higher biotech front gilead science gild announce acquire kite pharma kite share share gilead rise kite surge gilead be fifth week shallow consolidation first get back day line meantime kite be well extend buy point ibd winnebago industry wgo advanced more stock get back day line rv maker be add new handle buy point cup base downside sina sina drop cup shape base have be slow go related best buy buy zone ahead job datum due investing action plandow jone industrial average dow stock news stock news quote facebook amazon netflix googlebest chinese stock buy watch
128,GILD,key index fund be narrowly mixed stock market today gold biotechs rally oil bank lag xpowershare qqq trust qqq hold gain spdr dow jone industrial average dium spdr spy be respectively sector play gold health care chip advanced energy financial real estate fund decline gold future gain ounce vaneck vector gold miner gdx vaneck vector junior gold miner gdxj soar nearly ishare gold trust iau spdr gold share gld add more apiece iau gld gap surge past respective buy point ibd note gold recent rise entry point aug etf column biotechs rally ishare nasdaq biotechnology ibb leap spdr biotech xbi add vault component stock gilead science gild rise kite pharmaceutical kite soar gilead say buy kite unite state oil fund uso slump west texas intermediate crude price skid barrel powershare db oil fund dbo lose vaneck vector oil service oih spdr oil gas exploration production xop large cap growth fund have be pause broader market give investor fresh opportunity buy ishare growth ivw have be look support day move average much past week stage solid rebound line provide chance buy add share etf advanced nearly early july bounce support level year old fund track index bearing same name have attract asset provide exposure big cap company be expect post average earning growth vs market approach have work well ivw judge track record beaten year vs return accord morningstar inc have also outperformed benchmark index past year year average annual return edge past gain ivw top holding aug include expect most big cap growth fund apple aapl microsoft msft facebook fb ibd stock amazon com amzn alphabet goog biggest sector weight be technology roughly health care consumer cyclical industrial etf bear expense ratio july vanguard russell growth vong hold same top holding ivw fund mark seventh anniversary next month have also be testing day line past few week technology also account vong largest sector weighting asset consumer cyclical come second nearly industrial health care accord morningstar fund have outpaced index ytd basis well past year have return year aug average annual past year respectively year annualize return be vong expense ratio be friday pick spdr growth spyg pacer trendpilot ptlc continue trade day line related nasdaq lag do equity play buffett have common not too early consider strategy rise ratesretail sector score gain be apple play play
129,GILD,unite therapeutic uthr surge week high friday report gilead science gild glaxosmithkline gsk novartis nvs be consider take biotech xgilead be thought be front runner be auction process evening standard report cite anonymous source say glaxo novartis also be say be potential contender unite therapeutic say have comment report rumore deal be boon gilead have be gun make acquisition slow growth hepatitis franchise second quarter sale unit decline year year unite be new name rumor mill first quarter gilead say be interested make acquisition cancer space put tesaro tsro clovis oncology clvs kite pharma kite run accord analyst unite be rare disease player make drug treat pulmonary arterial hypertension condition characterize high blood pressure lung lead heart failure left untreated ibd take potential tax reform be hold biotechs drug firm back make acquisition term activity really help boost sector say industry analyst gilead be center head ibd industry theme closer look source be look unite fetch share value company gilead glaxo unite didn immediately return request comment novartis decline comment stock market today unite rocket close earlier touch high last see late march gilead sank close glaxo fall fraction novartis end day slightly higher related gilead hiv drug match glaxo rival late stage trialscould biotech stir takeover interest cancer drug approval gilead acquire biotech vertex be still better analyst
130,GILD,biotechs lead alexion pharmaceutical alxn gilead science gild vertex pharmaceutical vrtx outperformed pharmaceutical brother june quarter analyst say earning season near close xleerink analyst geoffrey porge estimate large cap biotechs sale top wall street expectation average most impressive beat come alexion gilead vertex biogen biib alexion sale top consensus gilead hepatitis unit fall again quarter total revenue top vertex report sale beating biogen top sale comparison pharma company result be more tepid eli lilly lly merck mrk deliver significant revenue surprise otherwise fairly tepid result consist modest beat line result modest miss porge say note client last week dow component merck lilly top consensus respectively bristol myer squibb bmy glaxosmithkline gsk roche rhhby deliver modest beat novartis nvs astrazeneca azn nordisk nvo be line sanofi sny pfizer pfe johnson johnson jnj miss earning side performance be even more robust biotech porge say large cap biotechs beat average relative consensus bigger pharmas deliver earning top consensus average revenue growth vs year earlier quarter be biotechs drug firm average porge say board company report improve patient access drug well positive demand inventory currency effect ibd take biotech fever look chilly late july sector overcome challenge outlined ibd industry theme report
131,GILD,quarter rare disease player biotech side do particularly well brad loncar chief executive loncar investment tell investor business daily biogen vertex sarepta therapeutic srpt positively surprised market spinraza treatment spinal muscular atrophy biogen ionis pharmaceutical ion nearly triple consensus model drug bring obliterate view analyst say sarepta absolutely crushed analyst expectation rise month high july key drug exondys treat duchenne muscular dystrophy bring more analyst have expect sarepta also cut loss expectation half think category drug investor have be expect payer pushback loncar say so far hasn show be ever group company be go boom more rare disease company sentiment have soured biotech sector hit month high late july loncar cite political uncertainty note lion share biotechs drugmaker revenue earn product beat expectation raise guidance fact re not trading indicate investor have already reset expectation year so maybe just hasn be quite impressive context say have big run come earning season play factor well uncertainty tax reform be keep most major player look make big deal porge say trump administration have yet offer further detail plan cut corporate tax rate make corporate inversion less desirable gilead have be gun buy something wake slow hepatitis sale didn comment second quarter call dow pfizer say putt deal pause await more tax situation washington loncar note pfizer call be really crystalize theme broader medtech sector have previously say big deal biotech really send stock higher look unlikely term mega deal be pause happen happen say pretty disappointing shouldn really affect call bolt deal mega deal seem be hold thing related gilead hepatitis franchise topple again share be beatwill pfizer cancer drug help grow merger biotech just blow past buy point sale beatastrazeneca beat stock dife drug failure more reportvertex sing late crush sale profit expectation
132,GILD,key stock index be lower stock market today heighten north korea tension apple aapl other techs fall pressure xpowershare qqq trust qqq sank spdr spy fall spdr dow jone industrial average dium give emerge market fall further ishare msci emerge market eem lose nearly sector play retail biotech real estate fund gain gold also rally flight safety gold future rise more ounce spdr gold share gld ishare gold trust iau be etfs bounce day move average line be back buy range respective flat base entry other currency play also advanced powershare db dollar bullish uup gain try move recent bottom bitcoin investment trust gbtc gap leap bounce support day line friday still high volatile week oil etfs also advanced west texas intermediate crude price soar more barrel vaneck vector oil service oih spdr oil gas exploration production xop rally apiece unite state oil uso surge powershare db oil dbo advanced semiconductor technology financial be lower vaneck vector semiconductor smh ishare phlx semiconductor soxx fall more technology select sector spdr xlk slide slice day line first time early july apple give track fourth straight decline start breach support day line recent small cap stock rally lift ishare russell growth iwo past buy point pull back entry monday flirt flat base buy point early week share close entry friday iwo advanced prior high mark start just clear pattern year old fund track index bearing same name have attract asset provide exposure domestic small cap company expect average earning growth rate expense ratio be technology account quarter market cap weight portfolio follow health care industrial consumer cyclical stock top holding include biotech kite pharma be be acquire gilead science gild kite share gap soar aug news other top name accord morningstar direct trucker knight swift transportation knx biotech exact science exas catalent ctlt provider drug delivery solution other clinical service ibd take hunt etf idea be worth closer look check ibd weekly etf leader column featured fund list highly rate etfs iwo year date gain be roughly line have generate return year average annual return be also close benchmark index outperformed past year first trust dorsey fv clear flat base entry be just shy buy range fund be featured july etf column just previous flat base make fractional move higher consolidate fv select etfs universe first trust sector industry etfs base relative price momentum equally weight component relative strength analysis be conduct time month etfs include first trust dow jone internet fdn first trust nasdaq tech sector qtec first trust utility alphadex fxu fund have return ytd year average annual return be also slightly fv morningstar direct classify midcap growth bear expense ratio related top rate equity play aim maximize potential returnsstock follow apple post fed big dividend tech buy range big bank lift dow high long term winner break
133,GILD,index nasdaq composite near record high even hurricane harvey devastate houston south texas part louisiana gasoline future spiked refinery be shut consumer expect see bigger increase come week biotech stock break gilead science gild kite pharma kite takeover deal historic fda approval economy add fewer job expect august nasdaq composite rise week close fraction time record high index dow industrial also rally time level north korea missile test spook investor briefly quickly shrug latest provocation fang internet giant be strong biogen biib bluebird bio blue be notable biotech breakout construction material other stock see benefit post harvey rebuild purchase rebound barrel day refine capacity total capacity be offline due hurricane harvey accord global platt send gasoline future soar year high refinery be shut several week gas buddy say national gasoline average jump cent gallon prior week more price hike way crude future fall fewer refiner be available convert oil gasoline other product crude inventory fall barrel latest week gasoline supply flat energy information administration report doesn reflect harvey impact domestic production be essentially flat barrel day still record high reach june day gilead science gild say pay share kite pharma kite pivot cellular therapy novartis nvs be first grab fda approval car treatment kymriah be treat form acute lymphoblastic leukemia patient age kite drug be expect be approve fall treat aggressive form hodgkin lymphoma gilead soar year high novartis car approval appear validate plan acquire kite shot drug giant novartis climb other car player include bluebird bio blue rise clear buy point juno therapeutic juno pop be partner celgene celg gain edge past own buy point related investor be mute gilead acquisition kite pharmaanalyst mixed gilead kite key rival stand benefitnovartis car drug help gilead spike post kite add just job august fewer expect june july payroll growth be revise jobless rate tick vs view steady ism manufacturing index jump best level more year meanwhile gdp growth be revise annual rate best more year related add just job august jobless rate rise takeover be complete mark day ownership whole food commerce titan discount number produce dairy meat offering upscale grocer bring price banana egg butter several variety milk fish ground beef other thing amazon echos be also display prominently whole food store amazon com amzn share climb general motor gm report bigger expect sale gain ford sale fall less expect even hurricane harvey likely cut texas sale fiat chrysler fcau sale fall sharply toyota tm miss view harvey destroy vehicle auto sale pricing get boost share automaker generally rally gm breaking past buy point friday consumer electronic retailer best buy bby top fiscal second quarter estimate guide higher current quarter full year same store sale rise vs view best buy ceo hubert joly caution not expect recent gain be new normal best buy have gain business recently struggle sear shld bankrupt hhgregg be likely face tougher competition amazon com amzn holiday quarter best buy crash nearly tumble buy point ciena cien top view fiscal third quarter sale earning fiscal fourth quarter fiber optic network supplier expect adjust earning rise cent share sale increase base midpoint guidance wall street be modele cent soft guidance be shocker give ciena previously bullish stance nomura instinet say ciena tumble thursday workday wday report second quarter earning cent share trouncing estimate cent revenue rise ahead consensus estimate cloud base human resource finance software firm raise full year subscription revenue forecast workday share rise best level early box report second quarter earning beat estimate top bottom line revenue rise beating consensus estimate adjust earning cent loss beat consensus estimate cent loss box share fall week related box second quarter revenue earning top viewsnew ceo dara khosrowshahi promise change take ride sharing pioneer next level set ipo timeline month khosrowshahi come uber expedia expe travel book site cfo mark take ceo rein khosrowshahi departure uber board take more month settle new chief follow exit co founder former ceo travis kalanick accusation discrimination sexual harassment mismanagement finish line finl crash nearly hit year low week sporting good retailer slash full year profit same store sale outlook say athletic footwear business become much more promotional second quarter forecast follow weak quarterly showing foot locker fl dick sporting good dks hibbett sport hibb news follow retail sector struggle online shopping summer agreement amazon nike nke shoemaker test sale product directly amazon nike armour uaa share fall sharply centric discount retailer second quarter result beat estimate cite continue notable contribution spinner trend hike full year outlook value retailer ollie bargain outlet olli also beat estimate raise outlook dollar general dg revenue same store sale beat ep higher full year profit outlook miss expectation share specialty discounter fall significantly week well fargo wfc hike number unauthorized customer account review expand time period cover otonomy otic crash time low wednesday drug treat inner ear disease fail phase trial analog device adi report fiscal third quarter sale earning easily beat view chipmaker also see current ep sale rise midpoint guidance higher wall street model analog device rise nearly share jill jill fall hit record lows week woman apparel retailer offer disappointing full year guidance adjust ep rise line view sale grow vs estimate lululemon athletica lulu report surprise profit growth adjust cent share revenue better estimate cent ep sale yogawear maker retailer same store sale rise well estimate share jump friday
134,GILD,thursday gilead science gild reach important technical milestone relative strength rs rating rise percentile improvement increase day ibd proprietary rating measure share price movement worst best score rating show stock price performance trail week hold other stock database history show stock go make biggest gain often have rs rating least begin biggest run stock be not proper buy range right now see be able form break proper consolidation earning sale growth come respectively latest report show improvement top bottom line company hold rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
135,GILD,macrogenic mgnx topple friday dow component johnson johnson jnj terminate agreement develop cancer treatment have rivale drug gilead science gild kite pharma kite novartis nvs xin midday trading stock market today macrogenic dove much week low be close johnson johnson fall finish cite increase competition space well neurotoxicity associate drug duvortuxizumab decision bail pact duvortuxizumab show cancer activity phase trial note duvortuxizumab belong class drug know bispecific antibody stimulate immune cell direct target antigen drug be be investigate potential treatment several lymphomas leukemias bispecific antibody hold tremendous promise think news highlight remain development challenge agent particular context recent emergence highly effective car cell therapy leerink analyst michael schmidt say ibd take novartis be first gain approval car therapy other be just tail get scoop major player break visit ibd industry theme car drug be create extract immune cell patient then reprogramming fight cancer reintroduce patient case bispecific antibody car drug have same target schmidt say note client earlier week novartis nvs be first gain approval car treatment kite be be acquire gilead be expect be next celgene celg be also partner separately juno therapeutic juno bluebird bio blue car drug various bispecific antibody platform currently development differentiate clinically remain unknown schmidt say macrogenic have total bispecific antibody program have enter phase trial recent year possible bispecific antibody be more potent treat solid tumor area remain challenge car drug schmidt say schmidt reiterate outperform rating macrogenic doesn expect macrogenic continue develop duvortuxizumab wake competition car drug other therapy cancer affect be know cell related celgene flirt giant soon join gilead kite deal boost biotech etf clear buy pointanalyst mixed gilead kite key rival stand benefitthese biotechs just moved buy zone be giant next novartis cancer approval validate gilead kite deal
136,GILD,novartis nvs approval price tag key cancer treatment have unusual effect help gilead science gild ride high thursday continue support gilead acquisition rival kite pharma kite be develop similar drug novartis approval come just day gilead say pay share acquire kite pivot similar cancer drug wake struggle hepatitis drug sale novartis be first get approval know car cancer treatment approval also validate gilead deal kite be also develop car drug also wednesday food drug administration approve drug roche rhhby genentech treat cytokine release syndrome common side effect car therapy present fever sometimes be fatal cytokine release syndrome be cause overactive immune system genentech explain happen car therapy patient own immune cell be extract reprogram seek destroy cancer today have never be fda approve treatment manage severe cytokine release syndrome associate car cell therapy be marked rapid onset cause life threaten complication genentech chief medical officer sandra horning say release ibd take novartis be first gain approval car drug other player be horizon head ibd industry theme battle break kite gilead juno bluebird aim approval emerge sector tell create perfect storm gilead other car drug player accord brad loncar chief executive loncar investment kite drug be expect get approval later fall various drug celgene celg partner juno therapeutic juno bluebird bio blue just new technology certain disease not stretch start used word cure loncar tell investor business daily re not think alleviate symptom disease re think fix genetic mutation cause disease technology look promising several different blood cancer today novartis charge time car treatment form acute lymphoblastic leukemia patient age kite drug be be review treatment aggressive form hodgkin lymphoma gilead see cell therapy car become cornerstone treat cancer big claim loncar say be just first iteration car therapy result so far initial cancer be truly amazing say re take patient have week month live case be reach complete remission ve never see anything close bell stock market today gilead lift novartis meanwhile rise kite tick cent close biotech stock have broadly rise week wednesday close be early trading fulfill prediction acquisition gilead help spike sector share touch month high fervor related much biotech pop fda ok drug bid analyst mixed gilead kite key rival stand benefitwhy investor be mute gilead acquisition kite pharma
137,GILD,stock open higher monday market register only mild initial financial effect ongoing flood have shut much texas coast dow jone industrial average open higher nasdaq composite also climb hurricane harvey category storm late friday cause wind damage south texas coast follow historical level rain induced flood city north houston energy capital fourth largest city storm be downgrade tropical storm status relieve threat wind damage be project continue deluge already saturate houston area record level rainfall oil price drop almost gasoline future surge nearly refinery operator inspect possible damage shutdown ahead storm refinery represent estimate barrel day capacity shut response storm include flagship facility own exxon mobil xom valero energo vlo phillip psx accord platt stock trade higher open number pipeline region halter operation port corpus christi houston appear remain close inbound outbound traffic monday offshore production gulf mexico have reportedly be shut ahead storm insurer trend lower early action allstate more progressive pgr show decline dow most stock stick gain loss less home depot hd likely beneficiary demand build material texas leap more early action build supply peer lowe low rise servicemaster global holding serv leader storm water damage cleanup repair gain start bell share tenn base outfit be extend buy point cup base buy range week tight buy point apple aapl rise fang stock be mixed start trade
138,GILD,only small handful earning report due monday session merger news grab early attention kite pharmaceutical kite soar santa monica calif base biotech agree takeover gilead science gild gilead share rise more open trade other small biotechs receive sympathy boost juno therapeutic juno surge uniqure qure trading higher bluebird bio blue jump expedia expe drop more heaviest loss nasdaq name ride service uber reportedly name expedia chief executive dara kosrowshahi ceo sunday kosrowshahi beat contender meg whitman jeffrey immelt job expedia share be look retake week move average begin fifth week shallow consolidation trade deficit widen july vs june commerce department report wider gap project economist export decrease month import decrease wholesale inventory expand june increase expansion retail inventory also slow month dalla federal reserve regional manufacturing survey be expect et related top tech stock be warning sign nasdaq share fall day move techs be buy point classic bullish patternchip stock semiconductor industry news analysisstock buy watch top ipos big small cap growth invest stock market start simple routine
139,GILD,abbvie abbv throw gauntlet gilead science gild approval hepatitis drug further hammer gilead multibillion dollar franchise analyst say friday xlate thursday food drug administration approve abbvie drug dub mavyret coveted week label genotype hepatitis patient most hepatitis drug be take week period abbvie be pricing treatment week deeper discount prominent drug now be prescribe condition gilead harvoni epclusa leerink analyst geoffrey porge estimate mavyret be offer discount gilead see revenue prescribe course harvoni discount epclusa competitive dynamic now solidify fda agree forecast market share price erosion gilead modeled rebound abbvie hepatitis revenue begin porge write note client porge call gilead remain competitive patient harvoni be give week still lose share base contract payer population patient treat mavyret undergo treatment week other patient likely migrate mavyret base convenience week regimen predict gilead drug epclusa vosevi be dose week harvoni be prescribe week patient be treat week ibd take gilead make acquisition be linchpin send biotech sector higher industry observer say head ibd industry theme closer look company gilead be consider mavyret broad label give abbvie access vast majority hepatitis patient exception ve fail drug dow component merck mrk johnson johnson jnj drug bristol myer squibb bmy fda be not require genotype testing be big advantage gilead other participant market write mavyret do have black box warning label risk hepatitis reactivation patient infection patient undergo pretreatment testing hepatitis infection then monitoring be find have hepatitis hepatitis porge say isn significant burden most hepatitis patient have already be screen hepatitis abbvie likely focus early effort government segment mavyret wholesale price be line harvoni undercut epclusa conversely abbvie pricing mean revenue contribution mavyret be likely be limit largely consistent exist forecast say stock market today abbvie close flat gilead fall related gilead be make acquisition not thinkgilead hepatitis franchise topple again share abbvie hammer gilead hepatitis franchise
140,GILD,glaxosmithkline gsk stock dip week low monday gilead science gild say hiv drug combination prove be par glaxo late stage head head trial trial test gilead hiv drug know bictegravir combination other drug regimen contain glaxo dolutegravir patient hiv have never undergo treatment bictegravir contain treatment prove be virtually same effectiveness statistic regimen used dolutegravir week gilead say news release bictegravir combo be successful patient just patient see success dolutegravir regimen result suggest combination bictegravir ftc taf have potential be appropriate broad range hiv patient include mild moderate renal impairment say dr paul sax lead author study statement second study bictegravir combo be successful patient week vs success patient treat dolutegravir ftc taf evercore analyst umer raffat note neither result be statistically significant gilead be look hiv drug next franchise face dwindle hepatitis drug sale firm have refer bictegravir mount everest stock market today glaxo share fall close near low last see july meanwhile gilead lift finish ibd take attitude washington be prove more biotech friendly addition number strong clinical trial result lately merger acquisition send biotech industry stratosphere say industry observer gilead be linchpin head ibd industry theme closer look gilead buy patient take treatment develop resistance drug be important raffat say note client single most important takeaway be bictegravir phase datum position same realm high barrier resistance dolutegravir say patient treat bictegravir regimen experience statistically significant reduction nausea vs dolutegravir regime just bictegravir patient report nausea vs dolutegravir patient say raffat overall datum be line bictegravir be foundation gilead hiv franchise related abbvie hammer gilead hepatitis franchisevertex hit record high result cystic fibrosis trialcould biotech stir takeover interest cancer drug approval
141,GILD,key index fund be thursday stock sell hard north korea concern xpowershare qqq trust qqq sank head potential test support day move average line spdr spy fall spdr dow jone industrial average dium lose dium fall back level sell wasn restrict equity ishare msci emerge market eem ishare msci eafe efa tumble respectively retail lead downside sector play spdr retail xrt sell more department store drop earning report dd plunge kohl kss macy lose apiece bank biotechs chip be also biggest loser gold rally investor seek safe haven vaneck vector gold miner gdx vaneck vector junior gold miner gdxj rise respective powershare db gold dbo ishare gold trust iau spdr gold trust gld be biotechs have be take rest recent run best level well year etfs hold celgene celg biogen biib gilead science gild have contribute pause such several biotech etfs have be pull back day move average set fresh buy opportunity solid bounce line early thursday be trading slightly line first be ishare nasdaq biotechnology ibb total net asset year old fund be head potential test day line gain nearly june july intraday high ibb track nasdaq biotechnology index count celgene biogen gilead science amgen top holding aug celgene amgen have beaten broader market year respective gain wednesday fund be bit top heavy top name account asset portfolio contain stock north america primarily represent europe ibb have outpaced year date return vs aug accord morningstar inc lag benchmark index past year vs have solidly outperformed past year ibb have expense ratio spdr biotech xbi bounce day line last week soon test support again share rise much june flat base july high xbi launch january have attract asset fund track biotechnology select industry index modify equal weight index comprise stock top holding aug include exelixis exel kite pharma kite alexion pharmaceutical alxn celgene top account asset exelixis biggest position make etf have rally ytd aug return past year have outpaced wide margin xbi have expense ratio wednesday pick vanguard mega cap value mgv ishare edge msci usa value factor vlue continue trade just respective buy point related sector avoid sell be apple microsoft better value play apple microsoft lift dow equity play buydow go apple clear buy point nvidia hit high
142,GILD,abbvie abbv be likely swipe significant hepatitis drug share gilead science gild week regimen week shorter triple pill treatment gilead analyst say wednesday food drug administration tuesday approve gilead combination sofosbuvir velpatasvir voxilaprevir week regimen patient genotype combo have be recommend approval week course europe be approve patient ve already try drug meanwhile abbvie combination glecaprevir pibrentasvir look likely gain approval week regimen genotype hepatitis patient ve never undergo treatment gilead harvoni be approve week regimen only subset patient label place gilead competitive disadvantage rival abbvie abbvie be likely get approval genotype week course leerink analyst geoffrey porge say note client approval genotype be uncertain note gilead be pricing triple pill be brand vosevi bottle bottle month run week price be less costly gilead harvoni sovaldi more expensive zepatier dow component merck mrk ibd take hepatitis drug franchise decline gilead have say be open acquisition cancer space biotech buy be better purchase say analyst visit ibd technology page closer look gilead buy most patient take vosevi fail respond harvoni zepatier abbvie drug combination abbvie drug other hand be likely grab approval regimen patient have never undergo treatment porge expect abbvie price pill drug viekira pak hepatitis combination go month abbvie aggressively market drug combo gilead harvoni epclusa say strategy be likely result significant market share abbvie give convenience excellent efficacy drug combination say note client porge forecast sale vosevi second half year expect see gradual decline outside expect vosevi pull annually same time porge model gilead harvoni epclusa lose market share abbvie call gilead hepatitis drug franchise represent just total sale fall half sale stock market today gilead share climb close abbvie pop finish related vertex hit record high result cystic fibrosis trialcould biotech stir takeover interest cancer drug approval star align biotechs crush earning consensus
143,GILD,vertex pharmaceutical vrtx stock blast record high wednesday phase trial datum triple pill regimen have cystic fibrosis patient breathe easy accord analyst xby close bell stock market today vertex have catapult earlier run more heavy volume share hit time high help biotech stock gap collective stock launch follow vertex announcement late tuesday better expect result trial testing drug know vx vx vx combine other cystic fibrosis drug patient treat combination be better able forcefully expel air average vertex be likely advance triple pill regimen phase trial credit suisse analyst alethia young suggest vertex gain accelerate approval triple pill phase trial act confirmatory study term accelerate approval think question come size safety database next generation corrector be novel mechanism action write note client vertex be look possible combination triple pill regimen aim treat underlie genetic mutation associate cystic fibrosis lung condition analyst broadly expect shorter trial population patient specific mutation be limit treatment option vertex be now year ahead prior estimate year ahead potential competition say janney analyst debjit chattopadhyay fellow biotech galapago glpg be also work triple pill regimen cystic fibrosis ibd take vertex big move land biotech ibd leaderboard wednesday company now hold ibd composite rating meaning outrank other stock market clearly be outstanding question compound advance pivotal program be high class problem have base efficacy tolerability profile thus far write note client chattopadhyay call triple pill combination add company sale see vertex cystic fibrosis franchise approach peak sale expand compound annual growth rate leerink analyst geoffrey porge boost price target vertex stock see vertex likely succeed type cystic fibrosis patient specific genetic mutation previously porge forecast vertex launch triple pill vs earlier view model sale grow longer term overall sale cystic fibrosis drug be expect reach vertex have be cautious price triple pill porge say expect regimen cost be lower price vertex orkambi pill cystic fibrosis treatment give outcry concern exist price vertex combination larger addressable market product believe be most prudent forecast company revenue growth base increase patient adoption treatment persistence rather forecasting product price upgrade say credit suisse young janney chattopadhyay see vertex potential takeover candidate wake strong cystic fibrosis trial datum tuesday chattopadhyay call vertex most logical large cap merger target young see share total price fair value buy vertex vertex have market cap gilead science gild have be suggest potential acquirer related vertex catapult strong trial cystic fibrosis druggilead acquire biotech vertex be still better analysteven upgrade couldn save vertex biotech deluge
144,GILD,novartis nvs be first drugmaker cross finish line develop cancer treatment know car drug wednesday food drug administration approve drug kymriah child adult type bone marrow cancer xkymriah cell base gene therapy be approve treat patient age call cell acute lymphoblastic leukemia approval be likely set stage fda approve slew car drug next several year re enter new frontier medical innovation ability reprogram patient own cell attack deadly cancer fda commissioner scott gottlieb say news release follow approval new technology such gene cell therapy hold potential transform medicine create inflection point ability treat even cure many intractable illness approval come day gilead science gild announce plan acquire kite pharma kite be also close approval car therapy treatment immune cell be extract patient reprogram fight cancer ibd take biotech stock broadly dip mid august have rally be month be inflection point need top earlier outlined ibd industry theme analyst expect kite drug grab approval treat aggressive form hodgkin lymphoma later year analyst see juno therapeutic juno drug get approval next year follow closely celgene celg partner bluebird bio blue close bell stock market today novartis drop gilead spiked close kite be relative standstill marginally gilead takeover price reflect share kite stock juno sank bluebird pop related analyst mixed gilead kite key rival stand novartis fda cancer also be boon cure cancer look blood
145,GILD,biomarin pharmaceutical bmrn hit week high wednesday wake food drug administration decision review biotech company application rare disease drug fda say late tuesday application also grant biomarin priority review drug know pegvaliase pegvaliase be treatment rare disorder miss enzyme lead buildup amino acid blood result variety mental behavioral neurological physical problem biomarin say investor have be cautious pegvaliase effectiveness safety profile thus far believe tonight news tuesday begin thaw investor sentiment particularly aid fda decision grant priority review leerink analyst joseph schwartz say potential approval date feb be likely get push back however fda request additional information regard chemistry manufacturing control write note client phase datum pegvaliase show meaningful reduction specific amino acid biomarin have note injection site reaction associate treatment say prompt fda run panel determine risk benefit drug point have see agency give further pushback credit suisse analyst alethia young say note client ibd take biotechs stock be more month gilead science announcement week acquire kite pharma industry observer say july acquisition gilead spike sector head ibd industry theme more theory pan leerink schwartz see probability success pegvaliase assume peak sale be conservative expect biomarin enter market respective patient europe close bell stock market today biomarin have pop finish earlier rise much highest point week broadly biotech share hit highest mark july riser include bluebird bio blue jump close novartis nvs gain approval car drug likely help gilead science gild kitepharma kite celgene celg partner bluebird juno therapeutic juno gain similar approval future related novartis car drug help gilead spike post kite dealbiotech near dizzy plunge fail vertigo biotech get price hike seesaw day run
146,GILD,analyst be mixed tuesday gilead science gild takeout kite pharma kite thing be certain say rival juno therapeutic juno bluebird bio blue stand benefit headline xnovartis nvs kite be expect gain food drug administration approval fall blood cancer drug know car treatment celgene celg partner juno bluebird be just wedbush analyst david nierengarten write note client believe juno bluebird lead independent car developer be obvious acquisition play follow kite takeout say other earlier stage potential target include intellium ntla fate therapeutic fate tesaro tsro juno stock rushed month high midday stock market today pop reach high last see june bluebird sank end trading session gilead climb kite slip novartis lift be work treatment patient own immune cell be reprogram seek destroy cancer novartis car treatment look likely gain approval treat bone marrow cancer follow closely kite treatment aggressive form hodgkin lymphoma ibd take biotech sector close monday help news gilead deal kite head big picture more gilead kite boost sector other sector ride monday nierengarten boost price target juno upgrade stock outperform rating neutral juno closely rival kite car drug know jcar gilead entry space likely help boost adoption rate jcar say expect juno jcar grab fda approval year end doesn see last disadvantage be later market initial launch gilead kite drug know axicabtagene ciloleucel be hung investment transplant center reimbursement talk believe juno capitalize gilead novartis effort later arrival say see jcar profile sufficiently differentiate efficacy safety enable broader adoption relative axicabtagene ciloleucel nierengarten forecast peak sale juno car drug blood cancer exceed expectation peak sale gilead kite drug blood cancer see juno drug be prefer choice novartis gilead kite way cut kite deal be expensive nierengarten say deal value kite time peak sale expectation axicabtagene ciloleucel compare typical time sale takeout biotech do not believe buyer emerge kite price point indicate gilead be not deal position strength write long term rationale assume kite drug be able expand other cancer leerink analyst geoffrey porge classify deal hardly surprise hardly triumph hardly keep market perform rating gilead cut price target pivot represent new look gilead perhaps kite be well position car space do not believe change underlie fundamental have plague gilead stock past year write note client gilead have be pressure buy something hepatitis drug franchise have begin decline high cure rate still driver gilead outlook remain hepatitis hiv treatment porge say kite do little fend expect revenue decline respectively gilead axicabtagene ciloleucel related product be only expect add respective gilead top line inevitable stumble logistical snafu ultimately uncertain dynamic single treatment market be hard see axicabtagene ciloleucel provide much revenue offset erosion say credit suisse analyst alethia young like kite deal reiterate outperform rating gilead stock boost price target think deal mark begin new chapter write note client minimum lift overhand question be gilead go do related investor be mute gilead acquisition kite pharmagilead science buy kite pharma novartis fda cancer also be boon cure cancer look blood
147,GILD,kite pharma kite win be gilead science gild next pharmasset analyst say monday gilead announce merger send kite stock stratosphere xby close bell stock market today kite rocket finish hit record high year file initial public offer gilead stock be less enthusiastic rise close evercore analyst umer raffat say guarantee acquire kite be gilead bet pharmasset pharmasset deal give gilead access key drug kick blockbuster hepatitis franchise deal be generally comparable size enormous commercial success pharmasset deal be still very fresh investor eye raffat write note client pharmasset be clear leader class kite be just pack company work be know car therapy harness body own immune system fight cancer novartis nvs juno therapeutic juno bluebird bio blue celgene celg be also work arena further logistic be different hepatitis drug be pill take once daily car therapy patient blood be draw vial then immune system cell be reprogram fight cancer be reintroduce body require specific infrastructure raffat note proof concept blue sky scenario kite be trail novartis car therapy expect gain approval blood cancer later year firm have yet prove similar concept solid tumor call cell receptor technology ibd take biotech stock have slow july spike long term view several player look dim gilead acquisition kite help recover head ibd industry theme closer look still true inflection point kite story be yet come say kite be close approval drug axicabtagene ciloleucel treat aggressive form hodgkin lymphoma have first mover advantage set deal be set close fourth quarter gilead say news release mean now become very important year raffat say street be very focuse validate purchase leerink analyst geoffrey porge say consensus be call kite drug reach peak sale see initial approval blood bone marrow cancer note trial be ongoing other blood cancer transaction be not complete surprise give earlier commentary write note client premium kite stock share have rise year date be brace suggest gilead be expect revenue kite car platform kite be already short list potential acquisition gilead first quarter gilead have say want do deal cancer analyst suggest kite incyte incy tesaro tsro clovis oncology clvs be list recently several week kite chief executive john milligan reportedly say firm end do nothing oncology right deal doesn present street have be push gilead make deal hepatitis drug sale have begin decline gilead key strategy go forward be cell therapy firm have suggest seek buy asset enhance car engineering immuno oncology drug augment drug different combination related gilead science buy kite pharma billionwhy gilead do nothing oncology key drug topplehow novartis fda cancer also be boon rival
148,GILD,nasdaq composite end modest gain monday help outperformance biotech stock solid show apple aapl china base stock generally underperform recent strength nasdaq manage decent close rise end just day move average gain less dow jone
149,GILD,stock be hold slim gain late afternoon trading tuesday apple aapl microsoft msft lift dow jone industrial average straight xpowershare qqq trust qqq take lead key index fund advance spdr dow jone industrial average dium be spdr spy be barely positive apple rise new high clear flat base entry monday still buy range microsoft add sector fund be moderately mixed stock market today spdr bank kbe spdr regional bankingkre gain respectively spdr telecom xtl add technology select sector spdr fund xlk climb homebuilder chip utility be also higher real estate biotech health care underperform gold etfs also lag vaneck vector junior gold miner gdxj vaneck vector gold miner gdx give respectively spdr gold trust gld ishare gold trust iau dip oil play be mixed vaneck vector oil service oih slump spdr oil gas exploration production xop climb unite state oil fund uso be flat powershare db oil fund dbo edge higher several equity etfs be testing support day move average line market continue trade record level latest take dip vaneck vector morningstar wide moat moat appear be find support day line pull back july peak advanced nearly last rebound support line mid fund launch year april have attract asset track morningstar wide moat focus index comprise company economic moat sustainable competitive advantage morningstar inc define economic moat likely company be keep competitor bay extend period fund researcher look trait such intangible asset cost advantage efficient scale biggest sector weighting moat aug include health care consumer cyclical financial service amazon com amzn apparel maker vf vf pair biotechs biogen biib gilead science gild be top holding etf have outpaced broader market year july return vs gain accord morningstar have also outperformed benchmark index past year vs year vs have expense ratio moat vanguard extend market vxf be also find support day line pullback last week fund track completion index market cap weight index be make stock be outside vxf hold just north stock portfolio top holding include tesla tsla la vegas sand lvs liberty global lbtyk account asset mobile tmus mgm resort mgm be also top midcap blend fund have lag ytd year basis perform nearly line benchmark index past year have beaten past year vxf mark anniversary december carry expense ratio related dow go apple clear buy point nvidia hit sector good position trump bump bond etfs mark anniversary fund be beating
150,GILD,be salad day biotech sector number industry leader be hit new high group whole be top game term stock performance xstock inflow hit last week have be number clinical trial success new industry friendly food drug administration regime be place result investor business daily company biotech industry group have claw way group track ibd sixth just last week share look likely close month high stock market today slew earning next week just everything be go right biotech lately have be go right brad loncar chief executive loncar investment tell ibd friday onslaught biotech earning next week really give investor fodder say thing miss say loncar merger acquisition last piece fit puzzle then biotech sector really be cook gas say gilead science gild be likely linchpin loncar call gilead poster child large biotech need do deal gilead multibillion dollar hepatitis drug franchise topple first time now gilead say interested deal cancer space analyst have key vertex pharmaceutical vrtx smart acquisition loncar see gilead more likely buy early cancer asset something develop commercialize rather putt money work buy develop revenue stream vertex be already hugely successful biotech own right say earlier year vertex deliver best news year space point have exceptional result phase trial look triple pill treat cystic fibrosis stock gap nearly wednesday ibd take rare disease cancer play have be front center biotech sector late cut edge firm keep rally go head industry snapshot deeper dive multibillion dollar stock loncar say company vertex go something everybody stock market notice gilead be set report second quarter earning wednesday be sandwich slew strong contender biotech space include celgene celg amgen amgn biogen biib alexion pharmaceutical alxn biotech celgene be slate report second quarter earning open thursday stock have ibd composite rating lead peer be sit high last see july leerink analyst geoffrey porge say celgene alexion be bellwether group time same way dow johnson johnson jnj be often see proxy pharmaceutical group call celgene beat raise alexion rise top low view alexion be slate thursday tuesday amgen overtake month high jump record high second quarter earning report prove strong share break cup handle july buy point still remain buy zone trio help catapult sector analyst say meanwhile pharma side investor key astrazeneca azn early thursday recent week rumor have emerge chief executive pascal soriot jump ship teva pharmaceutical teva loncar note timing rumor be bad astrazeneca astrazeneca be set day now report result immuno oncology combination trial lung cancer lung cancer treatment be huge commercial opportunity astrazeneca be take player merck mrk bristol myer squibb bmy regardless rumor controversy do think not overstatement say pascal soriot job be line trial be make break astrazeneca say study be most important thing astrazeneca last year biotech stock be year still room run cfra research analyst jeffrey loo tell investor business daily valuation hit historic lows presidential election be still overall health care sector relative historical valuation biotech sector be still attractively price say late june sector get massive push president donald trump release draft proposal drug pricing initiative didn include much really tug drug price loo say didn credit entire gain proposal certainly help loo say clinical trial term fda approval strong launch trend have also help prod sector year include cystic fibrosis news vertex gene therapy novartis nvs duchenne muscular dystrophy drug sarepta therapeutic srpt latter development loncar say sarepta second quarter sale beat exondys bode well broader sector sarepta also raise guidance year most analyst have call conservative everybody be watch sign drug launch be go payor be push back thing say fact launch exondys be go well be good sign not just sarepta biotech company related biotechs find strength number treat multiple sclerosistoo late catch biotech rally trump fear subside biotech rally get second wind small cap near break outwhy biotech rally still tack upside
151,GILD,puma biotechnology pbyi stock rocket month high tuesday takeover speculation food drug administration approve firm breast cancer drug nerlynx xon stock market today puma stock jump close earlier rise much touch high last see september run counter biotech sector lose nearly group credit suisse analyst alethia young see puma generate interest takeover approval nerlynx treat early stage breast cancer patient tumor respond certain hormone nerlynx follow trastuzumab base treatment trastuzumab sell brand name herceptin chemotherapy roche rhhby think acquisition remain likely outcome here young write note client boost price target puma stock keep outperform rating approval remove overhang puma leerink analyst michael schmidt say research report fda approval come ahead schedule july date include broad label meaning puma treat more patient expect prescribe information also contain detailed information used diarrhea medication treat most common side effect nerlynx label doesn include black box warning have weaken launch schmidt note schmidt model peak sale nerlynx see consensus view sale easily achievable young note potential takeover help boost puma stock ibd take biotechs be look likely crush consensus second quarter head ibd technology page breakdown stock look strong head earning season have outperform rating puma stock rbc analyst matthew eckler be slightly more bullish view sale hit peak worldwide puma expect decision regard marketing application europe third quarter eckler have sector perform rating puma stock requirement diarrhea medicine temper uptake less motivated lower risk patient write note client schmidt young note significant potential takeover single asset oncology company fda approve drug gilead science gild have say lookout potential acquisition cancer space thus view share fairly value current level investor willing remain front launch believe possibility remain significant upside takeout say related biotech stock have soar week breast cancer drug newspuma biotech surge month high likely cancer drug approvalgilead acquire biotech vertex be still better analyst
152,GILD,regeneron pharmaceutical regn gilead science gild be most likely beat wall street view june quarter sale profit analyst say monday xleerink analyst geoffrey porge say star align widespread beat biopharma result large cap also see abbvie abbv celgene celg biogen biib gilead most likely top revenue expectation quarter quarter sale abbvie alexion pharmaceutical alxn biogen vertex pharmaceutical vrtx be likely be slow say abbvie biogen be face competition pricing pressure alexion vertex be still high growth company temporary slow revenue growth trajectory pending new indication formulation product write note client health tracker im see abbvie leukemia drug imbruvica testosterone gel androgel likely come materially north consensus humira landing street view other major project be expect miss im datum suggest biogen multiple sclerosis drug tysabri tecfidera beat porge estimate respectively tecfidera however be expect miss street ms drug plegridy avonex be forecast be light come grow competition ms field like roche rhhby novartis nvs sanofi sny roche drug ocrevus be approve earlier year treat relapse remit well primary progressive ms first industry ibd take biotech stock be rank group track sentiment tick ahead second quarter earning season make sure bookmark ibd biotech stock watch pharma industry news latest sector major drug celgene be expect top consensus chemotherapy revlimid likely come consensus porge write pomalyst drug treat blood cancer be expect be higher consensus gilead be likely be biggest second quarter surprise im datum gilead sale top be largely dependent reliability recent hepatitis datum have be unreliable past hepatitis drug sale topple high cure rate accounting highly variable sale hepatitis drug gilead total sale miss porge forecast analyst consensus target same time gilead genvoya hiv drug beat consensus porge write note client amgen amgn be most likely match slightly underperform consensus porge say rheumatoid arthritis drug enbrel be expect be line consensus view top porge view much im datum bone health drug prolium bone marrow stimulating aranesp be project beat help offset expect sale miss bone health drug xgeva other bone marrow stimulant drug porge say however change price dynamic many amgen product make im adjustment factor less reliable porge write call amgen hike price july bump price cancer drug kyproli april adjust profit share side gilead have chance beat consensus view porge say regeneron vertex also top expectation respectively biogen miss earning view due time research development expense not fully recognize analyst estimate porge say abbvie too be likely miss adjust earning share say afternoon trading stock market today ibd medical biom biotech group be fractionally related surprise spike beleaguered biotech stock gilead acquire biotech vertex be still better analystwhy biotech be poise run topple june
153,GILD,nasdaq composite hold small gain afternoon trading monday be still day move average devastation texas result hurricane harry remain focal point nasdaq edge dow jone industrial average ease volume nasdaq be tracking slightly higher friday level volume nyse be pace be slightly lower storm related stock move be plain sight dow component home depot hd add more expectation higher store traffic result storm home depot gap day line be high stock day line be potential resistance level watch dow component traveler trv slump insurer sell expectation potentially billion dollar claim meanwhile ibd winnebago industry wgo surge nearly rv maker recently flash sell signal cup handle buy point go form new handle buy point group peer leaderboard name thor industry tho also jump nearly try clear cup handle buy point rv maker rally monday expectation new demand temporary housing due heavy flood texas gasoline future jump year high early session pare gain gasoline future september delivery be gallon trading high gallon refinery operation texas be shut due torrential rain december gold jump more ounce spdr gold share gld add be early stage breaking base buy point stock market today biotechs outperformed help news big acquisition gilead science gild announce plan buy immunotherapy developer kite pharma kite value kite share big premium compare friday close price deal open promising market gilead growth hepatitis hiv aids area slow share gilead be kite soar be different story china base stock many underperform several week outperformance marketsmith growth name com wuba yirendai yrd sina sina show loss more related much gasoline price jump refiner break outwhy investor be mute gilead acquisition kite pharmabest stock buy watch
154,GILD,theravance biopharma tbph exelixis exel tick most acquisition box big pharma overview biotech merger picture analyst say friday acquisition biotech company pharma be important theme space needham analyst alan carr say note client believe late development stage commercial stage biotech company be particularly attractive acquisition target part due reduce risk company carr cover theravance attract big pharmas amgen amgn eli lilly lly teva pharmaceutical teva total carr count company be interested buy theravance base research area business development interest past acquisition theravance have approve drug antibiotic hard treat infection exelixis agio pharmaceutical agio bavarian nordic pharmaceutical bhvn progenic pharmaceutical pgnx be attract interest pharmaceutical apiece abbvie astrazeneca azn novartis nvs roche rhhby dow stock pfizer pfe johnson johnson jnj be most acquisitive base carr criterium have least potential target biotechs stand better chance be acquire vs other carr say january have be acquisition public biotech company involve payment more upfront more half already have approve drug have least phase datum carr write oncology be key target japanese pharmas rare disease play be likely be acquire later stage ibd take last month potential acquisition target jump ibd relative strength rating best possible today still have rating head ibd datum story closer look stock catalyst rare disease tend be interest mid specialty pharmas biotechs traditional drugmaker be likely avoid drug pricing controversy january only rare disease firm snatch be actelion pharmaceutical european pharma acquire more later stage biotechs vs less risk adverse japanese pharmas allergan agn big area interest include central nervous system rare disease oncology account acquisition respectively january have be new chemical entry approval food drug administration small midsize biotechs gain type approval have be acquire already have drug market time acquisition many oncology company few rare disease company be acquire say gilead science gild acquisition kite pharma kite break approval rule gilead announce plan spend buy kite month ahead expect approval date first drug blood cancer novartis rival treatment be approve day later related small biotech launch month high today here whyexelixi recover bristol inspire pitfall kidney cancerbristol dife still have chance kidney cancer analyst
155,GILD,celgene celg abbvie abbv be likely be biggest beneficiary inflammatory bowel disease market be expand rapid clip analyst say wednesday biologic market disease generate sale leerink analyst geoffrey porge write note client abbvie humira johnson johnson jnj remicade tnf drug used fight inflammation dominate market today believe market be likely continue exceed recent growth rate significant share value likely accrue celgene offset value available also abbvie inevitable erosion abbvie dominant humira franchise say new class inflammatory bowel disease drug be arise like celgene roche rhhby galapago gplg gilead science gild abbvie be look make mark drug now phase trial crohn disease ulcerative colitis common form disease earlier trial benefit clinical datum back be have difficulty recruit patient porge say many trial also exclude sicker patient include patient ve stop respond current treatment ibd take earlier year abbvie say expect humira hit peak international sale face erosion head ibd technology page breakdown abbvie see biggest drug go plan offset competition tnfs humira remicade be first truly disease modify treatment approach many patient don respond stop respond tnf drug porge say study suggest tnf patient don respond lose response year estimate show be patient inflammatory bowel disease have crohn disease have ulcerative colitis patient number europe be higher provide large opportunity drug base new mechanism write related perrigo beat raise lift generic drug buck teva mylan trendcould small biotech break tie eli lilly abbvie topple humira sale brake third straight quarter
156,GILD,key index fund hold big gain monday afternoon lead apple aapl jump ahead tuesday product launch event xpowershare qqq trust qqq spdr dow jone industrial average etf dium rally spdr spy add overseas fund be also higher
157,GILD,ishare msci emerge market eem ishare msci eafe efa rise respectively apple share gap remain buy range flat base entry initially clear early august probable name apple new iphone be reveal weekend news website iphone iphone iphone semiconductor etfs hold several iphone chip stock be top sector gainer ishare phlx semiconductor soxx vaneck vector semiconductor smh pop be buy point read recent etf column detail fund technology select sector spdr xlk add bank energy real estate also lead upside west texas intermediate crude price gain more barrel gold fund lag gold future fall ounce vaneck vector gold miner gdx vaneck vector junior gold miner gdxj drop respectively powershare db gold fund dgl spdr gold share gld ishare gold trust iau give biotech etfs remain buy range respective entry healthy breakout flat basis spdr biotech xbi clear buy point aug heavy volume be trading entry mid june prior flat base yielded gain start most recent pattern xbi be featured aug column fund seek support day move average close line hold next week regain day ensue advance shape right side flat base fund track biotechnology select industry index be launch january top holding include kite pharma kite sarepta therapeutic srpt exelixis exel accord morningstar direct kite soar aug news be acquire gilead science gild xbi have return year date trouncing gain biotech etf have also beaten broader index past year have expense ratio first trust nyse arca biotechnology index fund fbt turn june have attract asset track equal dollar weight index same name share also stage aug surge past flat base entry fbt be trading highest level more year top holding include kite pharma juno therapeutic juno neurocrine bioscience nbix also outperformed year return well past year fbt expense ratio be biotechs have score healthy gain recently help boost group industry group track ibd broader medical sector be rank sector friday pick ishare morgan usd emerge market bond emb powershare emerge market sovereign debt pcy edge higher friday be still buy range respective buy point related dow lead thank stock idea tap emerge marketsetfs track gold have better year stock marketthink miss big biotech rally check playsgilead kite deal boost biotech etf clear buy point
158,GILD,gilead science gild fill hole portfolio acquire incyte incy analyst suggest friday offer caveat vertex pharmaceutical vrtx still be less risky bet gilead make play now incyte tune premium stock price biotech largely be bet commercial success incyte immuno oncology drug epacadostat meanwhile deal slump hepatitis drug sale unit much value acquisition depend achieve substantial sale more epacadostat highly competitive somewhat unpredictable world immuno oncology leerink analyst geoffrey porge write note client porge imagine gilead afford pay share acquire incyte earlier year gilead acknowledge be open deal particularly oncology analyst have suggest incyte tesaro tsro clovis oncology clvs kite pharma kite potential target incyte help fill gap gilead portfolio porge say flagship product jakafi be approve number blood disorder region incyte be also work immuno oncology drug trial dow merck mrk bristol myer squibb bmy ibd take cancer therapy be winning investor approval kite pharma sit top run streak check industry snapshot closer look company prove be strong bet premium incyte stock price deal generate accretion year say transaction create rate return gilead shareholder next year projection be dependent strong sale epacadostat used premium model gilead earning be dilutive internal rate return north vertex incyte deal be similar size vertex represent lower risk less strategic option gilead give limit still substantial application vertex product technology say incyte other hand offer high risk high reward epacadostat broader development portfolio write stock market today gilead fall cent incyte be vertex be cent related be gilead fortune change acquisition gilead vertex join don hold breath analystwhy biotech rally still tack upside
159,GILD,key hepatitis drug gilead science gild top wall street expectation investor be tune company second quarter report july more hint potential activity analyst say friday gilead hepatitis sale slip month follow biotech say be open deal especially oncology analyst have be quick offer incyte incy tesaro tsro kite pharma kite clovis oncology clvs potential acquisition target other have say vertex pharmaceutical vrtx be smart buy help fend larger dip hepatitis franchise credit suisse analyst alethia young expect gilead harvoni key hepatitis drug beat analyst second quarter model period model gilead pull sale just north consensus adjust income share top broader forecast nickel expect beat harvoni sale still be year year young also expect gilead genvoya hiv medication top wall street view sale model period see total prescription grow quarter quarter vs consensus expectation just growth however don expect share react strongly beat think investor be look gilead do deal write note client ibd take big biotechs be likely struggle year investor focus turn smaller cancer rare disease focuse biotechs analyst say head industry snapshot closer look company be pique analyst interest biogen biib also be limelight investor look strategic update plan growth heighten competition multiple sclerosis arena drugmaker roche rhhby march gain approval drug ocrevus treat form multiple sclerosis young see biogen key ms drug tecfidera tysabri pull line sale long term number be street quarter young forecast line total sale see adjust profit miss view share consensus view biogen be schedule report result give strategic update july strategic update look biogen give insight collaboration eisai well newly seat chief executive michel vounatsos long term vision company investor also likely want update alzheimer drug aducanumab think investor be hope hear company give interim readout aducanumab phase trial next year say think make want own other want datum incyte beat top line strong jakafi sale investor focus likely be immuno oncology drug epacadostat strategic partnership dow merck mrk bristol myer squibb bmy incyte be set report earning aug more broadly young expect line quarter large cap biotechs see amgen amgn alexion pharmaceutical alxn vertex biomarin pharmaceutical bmrn report metric line consensus view related gilead acquire biotech vertex be still better analystare gilead fortune change acquisition biotech rally still tack upside
160,GILD,arena pharmaceutical arna amicus therapeutic fold lead biotech pack tuesday strong phase drug datum favorable regulatory decision respectively send stock nearly year high arena pop stock market today dip hour trading announce secondary stock offer arena stock break cup base buy point tuesday share touch high last see august amicus share leap amicus rocket month high meanwhile ibd company biotech industry group rise tuesday other riser include enanta pharmaceutical enta assembly bioscience asmb respective early tuesday arena say drug ralinepag improve blood flow phase study patient high blood pressure lung condition know pulmonary arterial hypertension drug also improve minute walking distance ralinepag improve median pulmonary vascular resistance pressure blood flow lung median vs placebo arena say release drug also help patient improve baseline minute walking distance ibd take other biotech news gilead science gild change fortune acquisition analyst say number cancer focuse biotechs drugmaker be auction block viral company really stand needham analyst say head ibd technology page closer look firm be smart buy leerink analyst joseph schwartz note ralinepag improvement pulmonary vascular resistance baseline be stronger johnson johnson jnj rival drug uptravi similar study vs respectively uptravi be approve dow stock effort uptravi give insight await ralinepag phase needham analyst alan carr say note client company actelion unit run patient trial number goal prior approval also tuesday amicus announce food drug administration not require run phase trial drug migalastat prior regulatory submission drug be already approve europe have be submit japan migalastat be treatment patient fabry disease genetic disorder cause specific form fat build cell cause wide variety systemic issue now amicus plan file approval fourth quarter submission package include datum cull complete clinical trial additional datum regulatory development outside new administration push quicker approval deadly disease have prompt fda decision carr say irrespective underlie development investor welcome positive development migalastat say submission be anticipate fourth quarter potentially lead second half related biotech hemophilia do drug biogen spinoff bioverativ have blockbuster hand eli lilly be gouge diabetes drug share dow other
161,GILD,gilead science gild fortune be likely change summer expect approval key hepatitis drug regimen biotech unveil phase datum hiv trial analyst say friday xyear date gilead stock be friday close share decline much year low june have re-cover somewhat biotech rally see sector rise collectively month high late june gilead stock be marginally friday needham analyst alan carr list gilead biotechs potential upside specific event upside be sorely need gilead be struggle decline hepatitis franchise european market mature follow decline gilead have identify hiv drug know bictegravir next big hit july gilead be expect unveil phase datum bictegravir international aids society conference paris carr say note client august food drug administration be expect approve gilead combination sofosbuvir velpatasvir voxilaprevir chronic hepatitis patient have fail specific prior treatment regimen be week treatment other analyst have suggest gilead make acquisition bolster pipeline company have indicated explore merger oncology fuel rumor be look tesaro tsro incyte incy ibd take strong biotechs exelixis stock have rocket high year not see decade head new america see catalyst send stock fly more be corner outside gilead carr see catalyst number player alnylam pharmaceutical alny intercept pharmaceutical icpt neurocrine bioscience nbix vertex pharmaceutical vrtx alnylam be expect have phase datum drug patisiran september patisiran be be investigate potential treatment rare disease cause abnormal buildup material call amyloid tissue deposit damage organ approve patisiran rival drug ionis pharmaceutical ion ionis be currently work trial drug inotersen population patient study help provide proof mechanism patisiran inotersen carr say later third quarter intercept be likely announce phase result drug ocaliva treatment disease cause inflammation scar tissue bile duct ultimately result liver damage ocaliva be already approve treat similar liver disease expect positive outcome await clarity registration requirement carr say second quarter ocaliva sale estimate be vs consensus neurocrine second quarter earning first time include sale drug ingrezza approve treatment involuntary movement associate long term use certain medication carr model sale period also second quarter carr estimate vertex bring sale kalydeco orkambi respectively kalydeco orkambi be cystic fibrosis drug patient specific genetic mutation related gilead vertex join don hold breath analystwhy biotech rally still tack small biotech pique interest gilead other
162,GILD,index nasdaq composite dow jone industrial average hit record high week techs fuel selling start thursday afternoon federal reserve signale not worry stock price facebook fb dow boee ba verizon vz mcdonald other company be hailed strong earning alphabet googl amazon com amzn other have less ideal result tobacco stock such altrium mo crash friday fda say reduce nicotine level cigarette sub addictive level nasdaq composite index fall week week retreat thursday morning record high flood earning report dow industrial rise fuel boee verizon facebook leap earning amazon alphabet fall result oil price soar treasury yield rise dollar continue trend lower treasury yield rise week dollar continue trend lower boee ba swung profit take charge year quarter revenue decline miss view boee raise full year ep outlook analyst view aerospace giant say have talk customer new midmarket plane see demand aircraft northrop grumman noc general dynamic gd raytheon rtn also raise full year earning outlook report earning result estimate northrop say aerospace system sale climb higher manned aircraft demand include work advanced hawkeye aircraft raytheon see higher air defense missile smart bomb sale general dynamic revenue get support strong gulfstream defense product demand boee share soar week raytheon rise northrop be lower general dynamic tumble related boee put midrange demand plane stock hit sell signfacebook jump week hit record high earning revenue growth blow past expectation facebook exceed view various metric include user growth monthly active user twitter twtr earning beat view monthly active user be flat vs first quarter twitter share plunge snapchat operator snap fall hit record lows related facebook earning surge fang duo monopolize digital adsamazon earn cent share vs year earlier way view due heavy spending commerce giant operate income wasn great revenue be growth accelerate second straight quarter amazon web service revenue swell amazon share retreat friday close recent buy point undercut intraday related be winter come amazon shareholder big investment google parent alphabet stock retreat internet search giant earning fall short heighten expectation report higher expect traffic acquisition cost pay partner website google recognize nondeductible european union fine worry eu regulator crack more google say second quarter earning be share year revenue rise exclude time charge google say earn share related food drug administration announce fda aim require nicotine level cigarette sub addictive level roil tobacco stock friday altrium mo sell marlboro cigarette lose british american tobacco bti recently buy rest reynold american fall philip morris international pm sell marlboro cigarette overseas initially tumble close related fda act vs cigarette tobacco giant be hold federal reserve keep wall street prefer script wednesday leave key interest rate unchanged putt announcement begin unwinding balance sheet fed patience come economy be perform pretty well real gdp grow pace second quarter inflation wage gain have be more muted expect combination have be good stock market partly prospect low interest rate have weigh dollar be boon earning multinational second half year decision fed september announce shift reinvestment policy gradual pullback current stance reinvest principal mature mortgage treasury bond portfolio also send signal policymaker aren overly concern financial market be too exuberant next interest rate hike be expect december real uncertainty hinging inflation outlook be fed policy look flurry chip industry player post beat raise june quarter result include chipmaker advanced micro device amd cypress semiconductor cy intel intc texas instrument txn well chip gear supplier lam research lrcx teradyne ter amd earn adjust cent share sale analyst expect break even sale current quarter amd forecast sale rise vs wall street target cypress earn cent share ex item sale vs estimate cent cypress expect earn cent ex item sale vs view cent intel earn cent share ex item sale top view cent intel forecast adjust earning cent share sale analyst be look cent ti earn share ex item sale june quarter vs analyst expectation cent current quarter ti expect earn share sale vs wall street target lam earn adjust share sale june quarter analyst be expect september quarter lam expect earn share sale wall street be modele teradyne earn cent share ex item sale top expectation cent teradyne expect earn cent share ex item sale analyst have be expect cent paypal pypl earning rise year revenue rise slightly top consensus estimate digital payment processor member ibd raise full year outlook analyst view share rise record high pare gain crude future spiked barrel sign supply be fall revive shale boom be peter nigeria say ll eventually join rest opec curb production saudi arabia agree cut oil export crude inventory tumble barrel domestic production dip energy company trim capital spending plan month sub oil halliburton hal warn see exploration production company tap brake rig count plateau exxon mobil xom chevron cvx earning miss general motor gm report adjust profit grow beating view revenue drop view gm reaffirm full year ep guidance cut second half production swell inventory fall industry sale ford motor top view raise guidance largely lower tax rate gm fall further buy point ford fall back multiyear lows fiat chrysler fcau hold buy point adjust ep swell sale fall short maseratus luxury brand do well biogen biib obliterate sale expectation spinal muscular atrophy drug spinraza amgen amgn fall late tuesday boost ep ex item guide lag view gilead science gild report hepatitis drug franchise decline be partially offset growth hiv hepatitis drug sale vertex pharmaceutical vrtx say total cystic fibrosis sale gap celgene celg alexion alxn also beat view latter bust ep expectation cent astrazeneca azn crash thursday report mystic lung cancer trial immuno therapy combination fail drugmaker also announce deal merck mrk gain access latter blockbuster keytruda merck rise thursday bristol myer squibb bmy have have several setback drug opdivo slide concern mystic failure bode ill similar opdivo combo study wall street soured casino player mgm resort international mgm wynn resort wynn melco resort entertainment mlco sector overall put mixed result guidance concern mass market gaming macau weigh wynn result nonetheless beat estimate mgm offer weak revenue available room outlook also cite higher anticipate disruption monte carlo be be revamp park mgm challenge comparison la vegas strip la vegas sand lvs top result melco focuse boyd gaming byd penn national gaming penn be mixed share verizon communication vz soar telecom report better expect wireless result stiff competition narrow loss high spending postpaid phone subscriber verizon add more forecast say strategy packaging video wireless service be jell verizon say consumer be willing pay premium unlimited datum service high perform network comcast cmcsa report second quarter profit revenue top estimate nbcuniversal film entertainment business deliver strong box office result video subscriber loss be higher expect citigroup speculate comcast acquire verizon charter communication chtr miss earning sale share soar speculation be acquire well mcdonald mcd earning same store sale top estimate help cheap drink offering premium menu item chipotle cmg be testing queso face concern sale recovery have stumble follow food bear illness scare begin sale impact report customer fall ill july remain unclear domino pizza dpz crash part disappointing international comp lower margin ep help tax rate already high stock valuation starbucks sbux tumble fiscal same store sale revenue miss ep match view coffee chain say close teavana retail store several industrial dow giant rolled past estimate tuesday thank part improve global growth caterpillar cat surge week high company see ep revenue unite technology utx see earning climb share revenue rise share tumble lowest level raise full year ep revenue guidance dupont dd also beat top bottom line dow peer mmm be outlier overall miss share tank proofpoint pfpt report profit revenue top expectation forecast current quarter sale earning just consensus estimate sunnyvale calif base proofpoint specialize email datum loss protection corporate network cloud compute infrastructure proofpoint rise modestly friday morning fortinet ftnt post mixed result beat ep revenue billing growth disappoint outlook provider computer security software have yet improve recent ransomware attack fortinet share tumble tal education tal top earning sale estimate share profit cent revenue come ahead forecast cent current quarter china base education company see revenue view yahoo finance estimate meanwhile peer new oriental education edu also pull ahead forecast cent ep addition bump total student enrollment midpoint revenue guidance pull just ahead current view tal new oriental share rise respectively latter fail thursday mastercard report better expect second quarter earning revenue share reversed modestly lower record high remain buy range baidu bidu earning rise well view revenue climb line share chinese search giant rise friday electronic art ea report better expect quarterly earning video game publisher give cautious revenue guidance ea share rise friday briefly fall recent buy point
163,GILD,biotech stock topple midday thursday line broader index include pitfall large player vertex pharmaceutical vrtx unite therapeutic uthr spark therapeutic once long term view look weak uncertain xon stock market today vertex dove unite therapeutic fall spark dip broadly ibd company biotech industry group lose reflect major index trend follow beat amgen amgn biogen biib gilead science gild vertex celgene celg alexion pharmaceutical alxn week vertex increase guidance vertex keep full year view see slowdown third quarter leerink analyst geoffrey porge trim third quarter view vertex cut sale forecast keep outperform rating vertex price target stock get haircut second quarter sale cystic fibrosis drug orkambi kalydeco beat expectation porge note be due inventory stocking ahead anticipate summer slowdown vertex be also work triple pill cystic fibrosis outside cystic fibrosis franchise vertex say earning conference call look make small technology base early stage acquisition likely avoid large stage large investment many investor fear porge say report unite therapeutic second quarter sale be highest company have ever see resumption growth be not guarantee leerink analyst joseph schwartz say note client unite be work drug treat rare blood disease know pulmonary arterial hypertension pah schwartz increase third fourth quarter sale model strong second quarter report ibd take biotechs be now rank fourth group track ibd merger acquisition send higher vertex consider takeover target acquirer circle get deep dive ibd industry theme due lack curative therapy pah provide suite pah medicine keep patient transition unite product say however be reluctant assume rebound product sale quarter materialize resumption growth trajectory other unite product also thursday alexion celgene top expectation alexion rise celgene still dip investor be likely look celgene raise top line guidance instead celgene lift adjust profit forecast year share main surprise result be lack increase top line guidance normally have expect time year leerink porge say second quarter be only time celgene have not increase revenue guidance second quarter elsewhere biotech analyst be more bullish gilead see hepatitis drug sale fall collective slower revenue harvoni sovaldi beat analyst view predict fall porge say raise price target magnitude beat point stabilize hepatitis drug sale say windfall be short live however abbvie abbv next generation doublet be set enter market week be likely represent first real competition gilead hepatitis dominant market position related astrazeneca beat stock dife drug failure more reportthis biotech nearly triple street expectation key druggilead hepatitis franchise topple again share beat
164,GILD,here investing action plan friday need know investor come day xan initial read second quarter gdp be due oil giant exxon mobil xom chevron cvx report drug giant merck mrk abbvie abbv quarterly result american airline aal also round earning
165,GILD,high tech etfs range internet biotech artificial intelligence be lead sector fund year top performer be relative newbies ark innovation arkk turn year old end october lead charge year date rally far ahead return fund invest company be well position potentially gain innovation sector such health care information technology robotic have gather asset biggest sector weighting july be technology health care consumer cyclical accord morningstar direct top hold bitcoin investment trust gbtc pull back week have still sky-rocket nearly year other top name include electric car maker tesla tsla medical software maker athenahealth athn internet behemoth amazon com amzn second place be claim sister fund ark web arkw ytd gain fund mark third anniversary month focus company be transform economic sector internet enabled innovation technology account bulk asset consumer cyclical follow financial service distant top holding include amazon bitcoin investment trust athenahealth graphic chipmaker nvidia nvda have surge more year ark fund carry expense ratio global social medium socl come third ytd return follow closely spdr biotech xbi return socl track solactive social medium total return index have attract aim provide investor access social medium company world facebook fb twitter twtr china tencent holding tcehy be top holding bear expense ratio ibd take fund own lot top stock be worthy watchlist way find be consult ibd stock checkup tell stock rank industry group xbi track biotechnology select industry index be launch january top holding include kite pharma kite sarepta therapeutic srpt exelixis exel accord morningstar direct kite soar aug news be acquire gilead science gild fund have expense ratio metal mining play vaneck vector rare earth strategic metal remx ishare msci global metal mining producer pick also make cut related dow lead thank stock idea tap emerge marketstech china brazil hot spot past monthemerge market tech momentum play top gainer
166,GILD,gilead science gild continue feel heat hepatitis drug franchise second quarter share pop late wednesday biotech total sale profit share top street view hour trading stock market today gilead be recent action share close regular session be now year have stay day move average mid june second quarter end june gilead report adjust income share revenue top consensus analyst poll zack investment research respectively year year basis sale decline adjust income fall gilead drug hepatitis unit dip due lower sale harvoni sovaldi partially offset epclusa sale gilead say hiv hepatitis drug sale rise vs year earlier period gilead cite continue uptake hiv drug used tenofovir alafenamide well genvoya descovy odefsey hiv drug ibd take biotechs be now rank third industry group track ibd merger acquisition help bolster further accord industry insider head ibd industry theme closer look large biotech be poster child need big deal gilead boost sale guidance earlier view hepatitis drug be expect comprise total other product bring sale analyst be look gilead comment earning conference call potential merger acquisition gilead hepatitis drug franchise have struggle recent quarters company have say lookout acquisition cancer space related gilead hiv drug match glaxo rival late stage trialshow abbvie hammer gilead hepatitis biotech stir takeover interest cancer drug approval
167,GILD,key index fund be board stock market today overseas market stay ahead xishare msci eafe efa ishare msci emerge market eem rise spdr dow jone industrial average dium spdr spy lead index fund gain apiece powershare qqq trust qqq add energy retail bank be biggest gainer sector fund gold telecom utility underperform spdr gold share gld ishare gold trust iau give vaneck vector junior gold miner gdxj fall vaneck vector gold miner gdx lose gold future dip ounce spdr retail xrt advanced retake day move average first time nearly month component stock kohl kss jump department store operator say open amazon amzn shop store oil play advanced boost rise west texas intermediate crude price barrel spdr oil gas exploration production xop vaneck vector oil service oih surge nearly unite state oil uso powershare db oil dbo add apiece health care exchange trade fund be just respective buy point pull back time high spdr health care xlv ease second straight session tuesday close slightly buy point flat base etf advanced nearly early june prior flat base start most recent pattern fund mark anniversary december have attract asset track health care select sector index be comprise health care name pharmaceutical account biggest chunk asset nearly biotech weigh health care provider service health care equipment supply contribute respectively top holding include johnson johnson jnj pfizer pfe unitedhealth group unh biotechs score big gain last week also make top list amgen amgn gilead science gild celgene celg biotech industry track ibd surge last week spur part gilead acquisition kite pharma kite gilead share soar kite rocket week xlv have outperformed year date gain accord morningstar direct also outpaced benchmark index past year respective return vs gain same period etf carry expense ratio ibd take biotech be rank base fundamental technical metric track ibd find now ibd stock checkup vanguard health care index fund vht be also trading slightly flat base buy point case be fund launch january track msci investable market health care index pharma make biggest sector weighting july asset biotech health care equipment manage health care follow respective weighting top holding include many same name xlv johnson johnson pfizer unitedhealth amgen celgene gilead vht have return year date past year respectively expense ratio be tuesday etf pick first trust equity opportunity fpx ishare russell midcap growth iwp close respective flat base buy point related think miss big biotech rally check playsgold oil rally stock sell long term winner buygilead kite deal boost biotech etf clear buy pointbiotech extend gain breakout put apple amazon focus
168,GILD,last week market rally bring nasdaq striking distance fresh record high tuesday general market sell be setback further upward price progress high profile growth stock remain just high xall lead growth stock be just proper buy point stock
169,GILD,alexion pharmaceutical alxn stock topple thursday department health human service reportedly confirm have open ongoing investigation rare disease biotech share end regular trading session earlier session stock drop much low last see june day move average bloomberg news say government confirm investigation response freedom information act request news agency response didn indicate nature probe other agency be involved bloomberg report hhs office inspector general be run investigation inspector general audit issue fraud waste abuse medicare medicaid governmental health program email response alexion official say receive subpoena december attorney district massachusett disclose filing january be aware department health human service office inspector general be work inquiry attorney office department justice time alexion have not receive request record hhs office inspector general pertain other matter company say ibd take analyst prediction biotech boom seem have come fruition lead accord win be big player amgen amgn gilead science gild biogen biib head ibd technology page deep dive alexion go say regulator have ask document relate support tax exempt organization provide financial assistance medicare patient take drug sell company also seek document relate provision free alexion drug medicare patient company compliance policy relate federal kickback statute other company have disclose similar inquiry alexion statement say be cooperate inquiry be respond subpoena alexion have admit regulatory filing also scrutiny brazil security exchange commission department justice company acknowledge january inappropriate business conduct lead skewer report pull sale alexion stock dove nearly year low executive depart only month chief executive ludwig hantson take rein related alexion nearly year low announce exit execsis defect cfo glutton punishment move alexion biotech rally still tack upside
170,GILD,pair nasdaq tracking fund be respective buy point tech heavy index climb new high monday powershare qqq trust qqq be buy range rise past entry last week etf rally prior flat base december start pattern just clear pull back rebound day move average mid april set buy opportunity fund have attract march launch be weight technology july consumer cyclical contribute health care top holding apple aapl microsoft msft amazon com amzn facebook fb alphabet googl account nearly asset apple regain day line last week have rally more year iphone maker report fiscal result aug close expect launch upcoming iphone year qqq gain year july respective year period accord morningstar inc have return ytd same timeframe etf carry expense ratio first trust nasdaq equal weight index fund qqew name suggest be equal weight play nasdaq track nasdaq equal weight index be rebalance quarter index be reconstitute december be update year reflect replacement nasdaq index fund top holding be biotechs vertex pharmaceutical vrtx gilead science gild regeneron pharmaceutical regn alexion pharmaceutical alxn netflix nflx be other stock fund have also outpaced ytd return year year accord morningstar qqew launch april be trading just buy point flat base expense ratio be friday etf pick pull back slightly remain respective buy point first trust europe alphadex fep be just flat base entry europe small cap dividend dfe be shy flat base buy point bank homebuilder retail be winning sector early tuesday utility tech health care lag spdr retail xrt rebound regain day line component stock barne noble bks gap soar speculation put sale key index fund spdr dow jone industrial average dium gain spdr spy add powershare qqq trust qqq be fractionally lower remain flat base buy point spdr oil gas exploration production xop leap retake day line hit resistance late january share be still week high vaneck vector oil service oih ishare energy iye energy select sector spdr xle gain more show similar action xop unite state oil uso rise west texas intermediate crude price surge barrel gold play be mixed gold future slip ounce vaneck vector gold miner gdx advanced vaneck vector junior gold miner gdxj dip ishare gold trust iau spdr gold share gld be respectively related retail slip sector gain top fund buy point top growth play buy range gold lead sectorsapple iphone launch timing initial supply subject debate
171,GILD,bellwether johnson johnson jnj second quarter report bode well biotech sector analyst say tuesday dow component top profit expectation narrowly lag sale view stock market today stock climb biotech stock drop nearly group generic drugmaker inched leerink analyst geoffrey porge remain bullish biotech sector needham analyst mike matson say second quarter result point stable period medtech player boston scientific bsx medtronic mdt stryker syk zimmer biomet zbh quarter drug sale grow sequentially fall vs year earlier period porge partially blame time positive rebate adjustment eliminate year year volume price growth second quarter sale remicade decline year year rivalry biosimilar contribute just decline be lower guidance decline porge write note client ibd take cancer rare disease specialist be expect do well second half positive sentiment return biotech space visit ibd industry snapshot look outperform second quarter also expect currency headwind subside second half call acceleration pharmaceutical unit well positive trend sale outside base presume currency impact firm raise outlook adjust profit share outside drug sale grow sequentially second quarter beating view growth porge say support expectation sequential outside revenue growth company due weaken dollar second quarter say porge expect guidance increase biotechs second quarter earlier week call regeneron pharmaceutical regn easily beat june quarter sale view gilead science gild handily top profit expectation cover company not be negatively impact same prior period adjustment current imminent biosimilar competition surprise consensus remicade market dynamic be view proxy say abbvie abbv see pain sale cancer drug imbruvica grow outside say be partner abbvie imbruvica typically book imbruvica sale porge say translate abbvie imbruvica sale be miss vs consensus estimate say abbvie imbruvica be consider largest growth driver humira patent cliff continue miss consensus expectation repeat second quarter be negative stock related star align biotechs crush earning consensusthese drug giant buy range just beat earning novartis fda cancer also be boon rival
172,GILD,gilead science gild be better acquire vertex pharmaceutical vrtx oncology asset tesaro tsro incyte incy analyst suggest friday lament gilead cautious approach merger biotech market cap have show interest make oncology centric buy struggle decline hepatitis drug sale hepatitis franchise bring north year fall first time leerink analyst geoffrey porge say gilead turn away obvious cancer biotech buy tesaro incyte clovis oncology clvs kite pharma kite instead set sight vertex say likely gilead ignore advice view acquisition grow largely risk revenue stream such vertex much more positively comparable investment set investment intensely competitive technologically uncertain field oncology say vertex offer gilead rare disease portfolio robust pipeline vertex be now work triple pill combination treat cystic fibrosis lung disease year ahead nearest rival galapago glpg abbvie abbv regimen look likely launch gilead have cash meaning company wouldn have stretch too much make acquisition porge say vertex have market cap gilead market cap porge expect gilead pay share vertex stock still make acquisition accretive year realistic synergy together vertex gilead feasibly expand growth time slow grow major pharmas ibd take big biotechs gilead struggle recent biotech rally instead analyst say keep eye biotechs highlighted industry snapshot vertex tow gilead reverse revenue trajectory project decline compound annual growth rate transaction similarly improve expect fractional decline earning estimate growth rate year more likely gilead make series small transaction relatively early stage asset porge say note client win be enough diversify gilead hepatitis roller coaster even help nascent hiv drug bictegravir have be apparent gilead need major acquisition possibly even then be inexplicable company have be so faint hearted exercise cash flow advantage now say company still appear be respond opportunity present rather initiate create opportunity ahead availability even gilead go obvious oncology asset investor question company be pay premium today potential company be apparent last year price be current level porge have market perform rating price target gilead stock valuation say be time low otherwise justify recommendation substantial termination uncertainty make hard see stock recover multiple foreseeable future close bell stock market today gilead stock dip fraction vertex pop much settle be incyte stock fall tesaro stock lose related biotech rally still tack upsideare sanofi gilead bidding war small cap upgrade couldn save vertex biotech deluge
173,GILD,celgene celg regeneron pharmaceutical regn vertex pharmaceutical vrtx lead biotech sector more upside follow second quarter analyst say thursday share trek fifth straight day xat close bell stock market today ibd company biotech industry group be trading month high leerink analyst geoffrey porge credit lack drug pricing headwind day uptrend current rally reflect lift perceive fear pricing regulation favorable tone fda do not yet reflect more positive operate result not mention industry consolidation still expect write note client porge expect industry tack upside follow likely be strong second quarter earning season biotech stock have add june thursday leader include number small cap trading riser porge prefer call growth stock celgene regeneron vertex alexion pharmaceutical alxn mid regeneron stock have add follow gain celgene vertex stock gilead science gild perform worst only gain be still higher overall market say major biotech index have add last month broader market have only tack growth ibd take analyst begin predict biotech rally last month be sign benefit most head industry snapshot closer look analyst have say reason sector surge be fear be subside prospect president donald trump take action curb pricing analyst now say trump rhetoric tamp pricing appear be lip service wall street expectation amgen amgn gilead regeneron second quarter earning have dip last month revenue view have be largely flat decline amgen gilead large cap biotechs have beat second quarter view gain upside porge say last year large cap have beat second quarter expectation time amgen celgene gilead beating view time guidance increase be more likely second quarter first say expect biotech sector rally much compare long term relative multiple vs medtech pharma sector related small biotech pique interest gilead other biotechs surge generalist return subside trump biotechs be lead sector month high today
174,GILD,biotech industry always highly technical conundrum investor currently even greater challenge offer even greater opportunity usual early industry innovator amgen amgn biogen biib gilead science gild currently find big trouble accord loncar investment chief executive brad loncar largely victim own success cancer
175,GILD,slew biotechs drugmaker take closer look epizyme epzm small cap biotech present strong datum lymphoma trial wednesday switzerland analyst say thursday finding international conference malignant lymphoma attract like gilead science gild abbvie abbv celgene celg johnson johnson jnj roche rhhby leerink analyst geoffrey porge say note client epizyme be testing drug dub tazemetostat form hodgkin lymphoma interim datum show tazemetostat have clinically meaningful benefit patient call follicular lymphoma buildup cell lymph node tumor shrink follicular lymphoma patient patient aggressive form hodgkin lymphoma specific genetic mutation tazemetostat prove safe patient population leerink porge call study proof principle expect drug accelerate approval food drug administration follicular lymphoma accelerate approval allow drug be market still clinical trial few cancer drug have response rate clinical benefit rate disease say investor debate big group patient really be long treatment duration be not be surprised see epizyme start show potential takeout candidate list epizyme be appeal abbvie celgene roche porge write roche be leader immuno oncology method treat tumor block certain interaction hide cancer cell gilead be better know virology drug include target hepatitis hiv gilead hepatitis franchise decline high cure rate now gilead have say open seek acquisition oncology incyte tesaro be also rumore takeout candidate now molecule tazemetostat have be risk expect more investor get involved stock build position ahead further datum disclosure porge say ibd take seattle genetic chief executive clay siegall say company be aim change year method treat hodgkin lymphoma head ibd technology page exclusive ceo same conference see bristol myer squibb bmy seattle genetic sgen team phase trial classical hodgkin lymphoma also robust result only epizyme stock spiked news bristol myer seattle genetic too have strong datum classical hodgkin lymphoma tumor shrink patient treat combination bristol opdivo seattle adcetris sign cancer disappear patient combo prove safe well bristol say afternoon trading stock market today epizyme stock soar more share have run past day bristol myer stock other hand dip less seattle genetic stock be flat related analyst plead gilead buy have seattle genetic adcetris grab blockbuster status trial dow merck pause cancer trial investigate keytruda tie death
176,GILD,large cap blend etf earn top honor diversify fund june june rest list be dominate small cap name vaneck morningstar wide moat moat advanced month bring year date gain beat monthly return year fund track morningstar wide moat focus index carry expense ratio moat remain buy range flat base entry gain clear flat base november start most recent pattern share have be find support day move average november bullish sign morningstar define economic moat likely company be keep competitor bay extend period moat holding include amazon com amzn gilead science gild mckesson mck starbucks sbux walt disney move small cap ishare russell growth iwo come close second nearly monthly return ytd gain top buy zone flat base entry etf biggest sector weighting be technology health care industrial top holding june include kite pharma kite catalent ctlt medidata solution mdso iwo have outpaced year average annual return vs benchmark index have expense ratio vanguard russell index fund gain june ytd return etf be slightly buy point most recent flat base fund count top holding advanced micro device amd take interactive software chemour cc schwab small cap scha track dow jone small cap total stock market index generate monthly return ytd advance be scha action be similar hover just flat base buy point fund top holding include wellcare health plan wcg cognex cgnx take interactive proshare russell dividend grower smdv june have return ytd fund be flat base buy point seek support day line smdv launch february have gather asset aaron aan universal health realty income trust uht atrion atri be top name accord morningstar inc related biotechs soar june japan small cap also outperformedbig cap robotic outperform outlook china
177,GILD,do small cap health care japanese stock have common probably not much most time be top perform exchange trade fund june small cap be dominant diversify equity category month june top honor go larger cap name vaneck vector morningstar wide moat moat idea economic moat refer likely company be keep competitor bay extend period van eck etf product manager brandon rakszawksi write recent blog post fund be month year date gain return june morningstar classify moat track morningstar wide moat focus index large cap blend fund health care account biggest sector weighting asset follow consumer cyclical financial service industrial technology be distant fifth top holding include guidewire software gwre mckesson mck gilead science gild amazon com amzn starbucks sbux walt disney also make stock portfolio moat have expense ratio small cap etfs make screen include ishare russell growth iwo schwab small cap scha proshare russell dividend grower smdv snare monthly gain least sector fund arena biotechs continue show strength spdr biotech xbi ishare nasdaq biotechnology ibb take lead xbi june ytd gain be buy range flat base entry ibb add month ytd return be top buy zone entry health care related etfs account half top sector fund show accompany table gold miner solar clean energy reit make rest health care energy name have rac double digit gain north so far year move foreign fund japan be recur theme top monthly performer region have recently picked steam few emerge market fund also make list powershare emerge market momentum eemo come top monthly return ytd gain ishare asia aia track asia index advanced june ytd gain index comprise company hong kong korea singapore taiwan ishare currency hedge msci japan hewj deutsche tracker msci japan hedge equity dbjp climb june respective ytd gain positive japan be improve global growth more shareholder friendly corporate behavior earning upgrade stable yen outlook blackrock global chief investment strategist richard turnill say june report see boj policy domestic investor buy supportive risk be yen strength rise wage related too late catch biotech rally trump fear subside be right time add foreign stock portfolio bitcoin soar chip etfs also top performer
178,GILD,french drugmaker sanofi sny be reportedly consider bid tesaro tsro face competition gilead science gild frustrated hepatitis franchise have left massive biotech thirsty acquisition close stock market today tesaro be gilead stock pop close sanofi stock be close accord insider cite streetinsider sanofi be look put bid tesaro reportedly begin seek takeover bid last month follow approval launch ovarian cancer drug zejula gilead be also likely run buy tesaro accord report gilead biggest drug treat hepatitis sovaldi harvoni see sale dive high cure rate now gilead have say interested make deal particularly oncology win be cheap insider say ll cost share acquire market cap tesaro winner also get hand ovarian cancer drug zejula launch earlier year year price tag cost zejula be less expensive astrazeneca azn lynparza clovis oncology clvs rubraca zejula label be broadest allow treatment ovarian cancer patient regardless specific genetic ibd take tesaro stock have ibd composite rating meaning outperform just half stock term key growth metric visit ibd stock checkup look better rate stock biotech sector analyst have speculate competitive landscape know parp inhibitor include zejula lynparza rubraca approve drug pfizer pfe change more datum rival become available year sanofi have struggle make deal recent history last year lose johnson johnson jnj battle actelion pharmaceutical pfizer get hand parp inhibitor acquire medivation gilead too be position hunt deal hepatitis drug fall company say most recent earning call rely deal growth special interest oncology asset incyte incy have also be radar rumore target representative tesaro sanofi decline comment investor business daily representative gilead didn immediately return request comment related do astrazeneca rival just launch potential blockbuster drug clovis advantage squash tesaro ovarian cancertesaro crash beating astrazeneca stronger datum
179,GILD,name abbvie abbv celgene celg tear past week many biotech sector etfs hit week longer high friday take breather retain bulk big weekly gain most biotech fund be extend buy point several be still have pull back respective buy zone instance ishare nasdaq biotechnology ibb rise much entry ease friday be top buy range fund have rally year june accord morningstar inc well slight week decline ytd return same period bioshare biotechnology clinical trial bbc ytd be buy range cup base entry fund be thinly trade average daily volume share vaneck vector biotech bbh nearly year be waffle top buy zone entry year old fund have attract asset analyst attribute rally subside drug price concern be further growth ahead cfra be positive fundamentally biotech industry see strong revenue growth aid robust pipeline todd rosenbluth director etf mutual fund research cfra tell ibd email have buy recommendation abbv amgen amgn biogen biib biomarin pharmaceutical bmrn celg gilead science gild stock fall big cap category market cap north be more favorable larger cap biotechs such think ibb offer best exposure stock say other etfs offer more stock diversification smaller cap exposure provide potential reward also additional risk leverage etfs try magnify return double triple benchmark index day post double digit gain week end june instance direxion daily biotech bull labu seek investment result triple performance biotechnology select industry index lead return bring year date haul proshare ultrapro nasdaq biotechnology ubio aim time nasdaq biotechnology index daily performance rally week ytd return proshare ultra nasdaq biotechnology bib score gain ytd return be well extend such leverage play make big gain go be good tend carry higher risk most traditional biotech sector fund other end spectrum be inverse etfs be design give opposite performance index track fund provide result similar shorting stock index show accompany chart have see loss biotechs have rally likely outperform sector head south don have view leverage inverse etfs other investor easily get hurt hold too long rosenbluth say risk be compound much faster investor appreciate related biotech stock keep new lead top biotech stock remain just buy range
180,GILD,trader get enough biotech share advance week have make top performer equity june almost day ishare nasdaq biotechnology ibb exchange trade fund have be site frenzied option trading more contract change hand tuesday alone almost call have trade put bet decline ratio lopsided be last see july datum compile bloomberg show call volume fund be time day average wednesday clinical breakthrough ease political pressure fuel investor appetite biotech stock plunge most index last year concern industry regulation drug pricing threaten give government more negotiating power drug cost accuse manufacturer get away murder president donald trump be expect settle executive order be constructive support industry accord goldman sachs group health care analyst hope be also high deal activity also pick few small midcap firm include clovis oncology clvs release promising datum new therapy more transaction help biotech giant such gilead science gild boost growth time sale be slow not just biotech share be rally health care stock general have be best performer quarter rally have take away most valuation discount stock trade average time project month earning compare benchmark narrowest discount more month sector have more room run accord miller tabak co equity strategist matt maley investor rotate technology stock re continue turn more defensive area include health care utility say thing get little expensive usually more nerve wrack investor growth stock get expensive defensive stock maley say phone be potential further advance biotech health care stock general
181,GILD,future index nasdaq dow jone industrial average be mixed early thursday software biotech stock have become key leader ongoing market rally oracle orcl surge overnight strong earning report regular session celgene celg roar buy zone amgen amgn regeneron regn biogen biib peer show bullish action investor pay attention sector rotation stock performance be closely tie broader industry stronger industry sector performance reflect improve business condition company be momentum shift market become more enamored disenchant group nasdaq future rise more fair value overnight high future dow industrial climb nearly index future turn slightly higher crude oil future have plunge week edge last session medical biom biotech group have be top performer ibd industry group soar amgen regeneron biogen celgene be more just week biogen regeneron more ibd take celgene be rate ibd biom biotech group best possible composite rating find be other top rate biotechs stack vs objective critera go ibd stock checkup several other drug group be big recent winner ethical drug group include dow stock merck mrk merck rise wednesday new approval immuno oncology treatment keytruda merck have conventional buy point aggressive entry meanwhile ibd software desktop group home oracle be fourth best industry past day dow microsoft msft adobe system adbe red hat rht be also member other software group include enterprise software medical software also have have big gain celgene leap blast past buy point hold just chase zone grow feel investor president trump not crack drug price various comment have make campaign regeneron rise further extend buy point trading best level begin amgen advanced build right side base biogen gain retake day move average day vaulting day recent biogen spinoff bioverativ bivv edge be hold buy zone monday bioverativ be leaderboard ibd premium service highlight select cull stock mostly growth play buy zone clovis oncology clvs have sky-rocket week report strong trial datum suggest ovarian cancer drug get much wider use gilead science gild rise day line hepatitis hiv biotech try break downtrend go back more year good way play biotech boom be etfs such spdr biotech xbi ishare nasdaq biotech ibb xbi ibb break consolidation week oracle report much stronger expect earning late wednesday revenue growth also edge past view share business software giant shot premarket trading stock market today be record high well buy point overnight trading doesn always carry regular session still oracle already top aggressive entry wednesday rise heavy volume addition desktop software name microsoft adobe red hat be long time time high several other business software stock have be breaking hit high recent month include cloud base payroll software player such workday wday paylocity pcty paycom payc well servicenow now salesforce com crm veeva system veev asian trading thursday japan nikkei dip china shanghai composite slide europe intraday ftse retreat germany dax be flat france cac fall related big picture biotechs lift nasdaq oil bloodbath breakout biogen spinoff bioverativ buy zoneoracle earning come ahead top bottom linesbiotech surge generalist return subside trump dow merck be still beating bristol roche immuno oncologyis medical cloud compute play set rebound crash
182,GILD,biogen biib ionis pharmaceutical ion stock pop thursday european commission approve application costly spinal disease drug spinraza month drug launch close bell stock market today biogen stock climb share partner spinraza ionis jump finish regular session increase outperformed ibd company biom biotech industry group rise just fraction european regulator approve spinraza treat most common form spinal muscular atrophy affect patient biogen say news release drug cost treatment cost first year spinal muscular atrophy be cause degeneration certain cell lead wasting various muscle group approval come european medicine agency accelerate assessment program program similar effort food drug administration aim expedite access drug patient unmet medical need access spinraza vary country local reimbursement pathway biogen say company have be work health system government agency europe open access spinraza ibd take domicile biotechs pharmas benefit most president trump propose tax plan list include regeneron pharmaceutical regn gilead science gild biogen head ibd technology page closer look potential winner loser tax reform spinraza be approve type spinal muscular atrophy analyst have worry payer pushback hurt sale first quarter follow launch spinraza sale hit biogen say april help biogen ionis stock pop respectively ionis say biogen exercise right spinraza become responsible marketing development ionis have receive milestone payment date get tiered royalty sale percentage midteen related biogen earning top drug start biogen takeover prospect soured mere monthsamgen gilead biogen win lead biotech boom so
183,GILD,tesaro tsro zejula likely outperform drug clovis oncology clvs astrazeneca azn combine treatment big name pharmaceutical company analyst suggest tuesday leerink analyst seamus fernandez suggest tesaro do better mixed drug dow merck mrk bristol myer squibb bmy roche rhhby suggestion come day clovis unveil strong datum drug rubraca ovarian cancer phase trial dub ariel signal clovis get broader label expect ovarian cancer tuesday wall street scramble differentiate drug astrazeneca clovis tesaro have be know parp inhibitor drug aim block family enzyme cancer cell use proliferate differentiate tesaro zejula clovis rubraca astrazeneca lynparza likely come well combine immuno oncology drug block interaction involve pd pd protein immune system zejula appear be only late stage parp inhibitor be combinable pd pd inhibitor cross blood brain barrier fernandez say note client tesaro drug appear be less toxic liver be important immuno oncology combo ability cross blood brain battier help tesaro get foothold breast lung cancer commonly spread brain fernandez cut price target tesaro stock still have market perform rating share see even split tesaro clovis ovarian cancer patient ve already undergo round prior therapy ibd take merck bristol roche be work immuno oncology space head ibd industry theme closer look perform american society clinical oncology meeting earlier month chicago fernandez janney analyst debjit chattopadhyay see astrazeneca benefit clovis trial show parp inhibitor be more similar dissimilar lynparza be approve treat ovarian cancer patient mutation brca gene parp inhibitor be thought work better patient brca genetic mutation clovis trial show response patient regardless genetic still doctor preference screening patient mutation benefit astrazeneca chattopadhyay keep neutral rating tesaro stock trim price target fernandez see tesaro have leg clovis immuno oncology combo note house pd antibody be far mature also upgrade clovis stock buy rating price target clovis stock fly monday follow trial meanwhile tesaro stock be still be buoy rumor mill chattopadhyay say gilead science gild be rumore potential acquirer credit suisse analyst alethia young too boost price target clovis stock keep outperform rating share top line success ariel trial show rubraca have meaningful market opportunity parp space say close stock market today clovis stock be tesaro stock dove astrazeneca stock lift less related cancer drug specialist be todaybiotech fly nearly strong trial be drug better astrazeneca keep clovis tesaro unveil blockbuster drug
184,GILD,gilead science gild experimental hiv drug combination meet goal late stage trial biotech company say tuesday putt closer seek approval europe later year combination bictegravir emtricitabine tenofovir alafenamide ftc taf be just effective regimen glaxosmithkline gsk used drug dolutegravir ftc taf be already approve treat hiv gilead be hope add bictegravir make more effective base result phase study combination bictegravir ftc taf represent important advance triple therapy treatment broad range hiv patient norbert bischofberger gilead chief science officer say news release study look gilead combination gsk previously untreated patient fourth trial examine patient switch gilead regimen other hiv therapy case gilead regimen prove just effective other therapy datum show regimen be well tolerate patient discontinue treatment due kidney issue gilead say aim file application approval europe respectively second third quarters year ibd take healthcare reform change outlook biotechs pharmas analyst say head ibd technology page closer look gilead narrowly escap potential game changer failure trumpcare gilead be pin hope hiv drug light slowdown hepatitis franchise sale unit collapse high cure rate europe gilead first hiv drug viread be approve year hiv gilead be face britain gsk dow component merck mrk be used generic drug regimen use generic make gsk merck regimen less expensive meaning gilead struggle gain share analyst have say stock market today gilead stock fall cent share be year ibd company biom biotech industry group have rise so far slide nearly tuesday close day line first time month glaxosmithkline share rise related gilead topple consensus lag hepatitis drug sale plummetwill merck glaxo undercut gilead next mount everest drug bristol myer beat gilead merck key approval china europe
185,GILD,regeneron pharmaceutical regn gilead science gild biogen biib benefit most biotechs president trump propose tax reform measure cut corporate tax rate trump proposal business size fortune mom pop shop freelancer live job job pay more business income taxe make corporate inversion unnecessary corporate tax rate be currently mean regeneron gilead biogen have guide adjust tax rate see serious boost cash trump proposal pass analyst say compromise beltway so rate be still air trump approval rating jump april gain ibd tipp presidential leadership index unveil tax reform proposal be first month month increase trump become president doesn mean big pharma biotech be totally sell trump proposal page document release april share biotechs drugmaker collectively lift less day generic drug stock pop gilead chief executive john milligan note uncertainty washington be norm so think ve kind learn filter focus thing be right company say gilead first quarter earning conference call be tax reform be repatriation count trump plan slash corporate tax rate benefit company consolidated tax rate remain well level consolidate taxe allow firm treat group wholly majority own company single entity tax purpose domicile drugmaker typically pay consolidated taxe canaccord analyst dewey steadman tell investor business daily company acquire foreign firm move tax domicile outside acquire company often lower tax homeland mylan myl acquire generic manufacturer abbott laboratory keep operational headquarters pennsylvania reincorporate netherlands march mylan say expect pay tax rate similarly allergan agn guide february adjust tax rate allergan corporate headquarters be ireland april pfizer pfe scrap attempt acquire allergan day treasury unveil new rule curb inversion former president barack obama call global tax avoidance huge problem urge congress close loophole good trump other hand say tax reform proposal make inversion unnecessary make america tax rate best world regeneron gilead biogen be biggest winner cut evercore analyst umer raffat say april report regeneron have guide effective tax rate gilead see first quarter biogen paid adjust taxe drugmaker pfizer eli lilly lly merck mrk bristol myer squibb bmy guide effective tax rate canaccord steadman mizuho analyst salim sy tell ibd everything politic be subject negotiation smaller biotechs say obviously positive future everyone be take see approach steadman say rate be probably go happen re not change capital expenditure organizational structure meantime ibd take look latest biotech drug news be sure bookmark ibd biotech pharma industry stock news page second facet trump plan allow time repatriation corporate cash park overseas discount tax rate be follow end deferral taxe corporate income earn abroad evercore raffat say amgen amgn benefit most drugmaker provision amgen have cash stash overseas money amgen use help boost war chest generic rivalry battle regeneron sanofi sny cholesterol front same be say gilead overseas cash be face dwindle sale hepatitis drug franchise gilead have be pressure month analyst chatter buy something bolster sale incyte incy be likely candidate analyst say accord raffat merck pfizer have respective cash outside lilly bristol celgene celg biogen abbvie abbv have park overseas cash be repatriate research development used fuel pfizer chief executive ian read offer similar view gilead milligan company first quarter earning conference call expect industry consolidation continue time political atmosphere remain major deterrent believe be simply too much redundancy fragmentation globally sector continually efficiently deliver medicine society say however be lack clarity potential tax reform health care policy uncertainty european market canaccord steadman doesn expect wave even trump tax reform pass muster congress need attempt pfizer allergan merger inversion purpose say appetite biotechs look healthy see decline big inversion type merger be not necessarily strategic see appetite biotech asset just tax picture look better say net result be actually decrease large merger maybe increase valuation biotech don think drife much more much still murky trump tax proposal analyst say general theme be tax reform be good thing biotech mizuho sy tell ibd don exactly know tax reform be go be be still lot piece move repatriation border tax don have component border tax be extreme drawback company manufacturing less expensive country such adjustment exempt export taxation tax import pwc analyst doug strang kathy michael write feb report january speech chamber commerce house way mean committee chairman kevin brady say tax eliminate tax incentive company move manufacturing overseas couple new lower gop tax rate local business end double taxation earning overseas establish america st century magnet new job technology breakthrough headquarters say gop tax plan be already drive company ask soon bring supplier back most company relocate operation back be paperwork nightmare canaccord steadman say current plan doesn include border tax provision nothing incentivize company bring operation back be enough keep newer smaller company re domicile overseas say probably entice future company not leave think core goal re try do say be domicile lower rate wouldn have leave cash foreign subsidiary cash be base encourage investment related do gilead just provide incyte potential deal dow pfizer top earning view sale come lilly new drug spark deeper rivalry pfizer novartis
186,GILD,regeneron pharmaceutical regn vertex pharmaceutical vrtx alexion pharmaceutical alxn look likely catch next wave biotech analyst say friday suggest year sector be slate boom win be value stock gilead science gild amgen amgn biogen biib drive boom leerink analyst geoffrey porge tell client note large cap drag performance index exchange trade fund growth stock already seem be capture sustain new investor interest say advice investor remain identify scrutinize evidence competitive advantage look management maximize profitability exist business first foremost ibd company biom biotech industry group be first month finishing boom year stock tack growth group close stock market today such be pattern biotech market porge say typical correction run quarters follow year sideway performance today much excitement mid have dissipate leave share long term median relative multiple consensus expectation biotech sale profit have decline respectively last year sign be get better porge say first quarter result yielded mixture positive negative result vs consensus prompt additional negative revision so far quarter estimate have be remarkably stable ibd take regeneron stock outperformed broad market plunge thursday top saucer buy point head ibd new high list look other strong performer political pressure be also begin subside say president trump have promise introduce competitive system cut escalate drug price meanwhile industry have seemingly begin self regulate drug pricing be exception biogen ionis pharmaceutical ion spinraza spinal muscular atrophy drug debut year treatment first year porge see price tag regeneron sanofi sny eczema drug dupixent price roche rhhby multiple sclerosis drug ocrevus more reasonable furthermore manufacturer establish brand be take more modest price increase fewer be adopt voluntary price increase limit remain too high be step right direction porge say approval many time earlier expect have accelerate year food drug administration hit year low so far year drug have grab fda approval match total last year label also appear broader meaning drug have greater use porge see number drug launch come next month outdo consensus view key be gene therapy rare disease treatment end stage cancer therapy severe disease create process harness rna molecule inhibit certain gene process finally validate capital be invest remarkable technology boom year have seeming head disappointment many point bust last month porge say related biogen takeover prospect soured mere comeback kid regeneron survive amgen cholesterol squeeze
187,GILD,gilead science gild stock topple late tuesday biotech report first quarter sale earning lag wall street say have quarter decline revenue blockbuster hepatitis drug overall sale fall year year quarter end march miss view adjust income share lag expectation share plunge vs time last year revenue hepatitis drug harvoni sovaldi epclusa topple year year gilead blame decline harvoni sovaldi lower sale major market partially offset stronger sale epclusa epclusa launch last summer europe hepatitis hiv drug sale other hand grow vs year earlier period continue uptake hiv medicine genvoya descovy odefsey other product include drug blood pressure chest pain intravenous infusion grow quarter hiv drug bictegravir show positive result phase study gilead say gilead pledge earlier year put massive effort bictegravir sale harvoni sovaldi slow hepatitis market europe mature ibd take ibd company biom biotech industry group be now rank group track market have be volatile stock visit ibd technology page look stock look strong other market be still emerge however last week bristol myer squibb bmy be first company receive approval chinese regulator oral hepatitis drug gilead hepatitis drug aren yet approve china north person suffer disease gilead maintain guidance product sale include hepatitis drug revenue hepatitis drug sale decline midpoint be lowest point sale unit decline grow share end trading tuesday hour stock market today gilead stock be earlier day pfizer pfe merck mrk report first quarter earning pfizer top profit expectation sale lag merck beat sale earning view related dow pfizer top earning view sale come gilead be pay price actually cure disease
188,GILD,regeneron regn sanofi sny rheumatoid arthritis drug be cheaper rival drug amgen amgn abbvie abbv roche rhhby analyst say tuesday duo kevzara grab food drug administration approval kevzara approval come month fda delay approval issue manufacturing french factory drug be filled approval be patient moderate severe rheumatoid arthritis don respond other rheumatic drug approval come time label more less match expectation leerink analyst geoffrey porge say note client kevzara be prescribe alone combination fda approve methotrexate be self administer injection roche actemra belong same class drug kevzara be associate increase risk serious minor infection liver issue injection site reaction also discount actemra annually discount offer cost effective treatment option payer set porge say kevzara cost less amgen enbrel abbvie humira be widely prescribe rheumatoid arthritis different drug class ibd take regeneron be lead biotech resurgence year analyst say head ibd technology page deeper dive amgen gilead science gild biogen biib aren expect be forefront revitalization regeneron sanofi expect european approval come later year see kevzara hit market few week porge see drug minimal driver forecast sale year grow number drug class address rheumatoid arthritis note field be likely become more crowd later year dow component johnson johnson jnj add drug sirukimab lineup more class dub jak inhibitor arrive kevzara contribute approximately expect sale joint sanofi regeneron product fall long term expect growth eczema drug dupixent even cholesterol lower drug praluent rapidly eclipse kevzara importance porge say consensus forecast kevzara sale year grow hit stock market today regeneron stock rise sanofi stock fall share rival amgen abbvie be respectively roche dip related comeback kid regeneron survive amgen cholesterol squeeze regeneron pop better fear eye cholesterol drug sale
189,GILD,gilead science gild tuesday hint be prep make acquisition oncology report sale hepatitis drug franchise topple second straight quarter late tuesday quarterly conference call chief executive john milligan say firm be assess number different opportunity play come year include partnership acquisition think pretty clear re look avenue increase opportunity revenue say clear have be focuse oncology question be area use resource accelerate product market build meaningful franchise oncology wall street speculation have build last several month gilead be consider deal buy incyte incy small biotech promising immuno oncology drug clinical trial drug bristol myer squibb bmy merck mrk other incyte stock have climb year rumor credit suisse analyst alethia young see company become acquisitive term ibd take ibd biom biotech industry group be comprise company have trouble keep stock news bookmark ibd biotech pharma industry stock news page investor focus remain company do deal sound company be get mobilize putt piece place execute deal write research report young keep outperform rating price target gilead stock needham analyst alan carr say deal have potential be keep hold rating gilead stock note share be attractive hepatitis drug sale stabilize first quarter unit see revenue plunge year fewer patient be start drug hiv business seem strong leerink analyst geoffrey porge say note client gilead be successfully transition patient tenofovir alafenamide taf tenofovir disoproxil fumarate tdf drug older tdf drug be lower price expose generic carr note gilead patient be now taf base treatment hiv stock market today gilead stock lose earlier touch week low related gilead topple consensus lag hepatitis drug sale plummetdow pfizer top earning view sale come gilead be pay price actually cure disease
190,GILD,dow component pfizer pfe tuesday report mixed first quarter result call essential health unit tug overall sale revenue novartis nvs rivale cancer drug bound vs year earlier quarter pfizer say earn adjust income cent share revenue first quarter respectively analyst have expect drugmaker report earning cent share sale quarter pfizer innovative health unit include newer product grow essential health business include legacy product offset fall september pfizer scrap idea corporate breakup have split business wall street have pin hope pfizer ibrance be approve treat form advanced breast cancer ibrance sale grow period have competition novartis kisqali further eli lilly lly abemaciclib have show promise clinical trial sale pneumonia vaccine prevnar topple vs year earlier quarter dip be primarily due continue decline revenue adult indication due smaller remain catch opportunity pfizer say globally sale fall timing government purchase enbrel also see sale dip outside canada enbrel sale come develop europe enbrel sale fall revenue also topple emerge market other develop part globe respectively ibd take have trouble keep slew pharma biotech earning quarter catch ibd biotech pharma industry stock news page pfizer also reiterate guidance revenue adjust earning share flat respectively analyst be call revenue adjust income share stock market today share member dow jone industrial average dip earlier fall much touch lowest point month stock have potential buy point cup handle begin form august meanwhile fellow dow drug giant merck mrk also issue first quarter earning report merck top earning sale raise full year guidance gilead science gild major biotech player report weaker expect earning sale late tuesday related lilly new drug spark deeper rivalry novartis pfizerpfizer follow baxter get slam subpoena related saline shortage
191,GILD,bristol myer squibb bmy grab pair major win friday china approve hepatitis regimen europe bless immuno oncology drug opdivo treat head neck cancer spokesperson tell investor business daily daklinza sunvepra be approve treat hepatitis patient genotype common malady china daklinza be also approve combination other agent include gilead science gild sovaldi genotype pending approval sovaldi china chief commercial officer murdo gordon doesn expect bristol see gilead decline sale cure rate daklinza sunvepra combination gilead sale hepatitis drug sovaldi harvoni fall high cure rate picture be different china gilead hasn yet get approval drug be north person live hepatitis china gordon say put perspective be estimate hepatitis patient number be staggering think number infected person china hepatitis say think infrastructure chinese market care go need scale gordon wouldn comment bristol plan launch combination pricing say still negotiation be do daklinza sunvepra combination be also approve japan bristol likely win seek approval combination company discontinue effort gordon say competitive window have come go europe be primarily mature market hepatitis say ibd take gilead sale hepatitis drug topple biotech giant be count hiv drug bictegravir be major player visit ibd technology page closer look gilead plan leverage asset company hasn give forecast sale daklinza sunvepra daklinza sovaldi china gordon say daklinza be approve combination sovaldi cost wholesale week regimen due market size china gordon say ll be awhile chinese market become mature begin see widespread eradication dynamic china be different term long take get patient treat effectively point re actually eradicate disease say think duration be go take number year get point sale decline gordon expect competition china say be multiple product review emphasize speed chinese government approve combination year start finish call significant event china think important highlight be great story chinese fda innovative industry bristol myer squibb particular add help patient ve be wait innovation hit market other news gordon say europe approve application opdivo squamous cell head neck cancer second line treatment platinum base therapy opdivo target pd protein help immune system identify camouflage cancer cell compete most directly keytruda dow stock merck mrk stock market today bristol stock rise drug approval announcement follow strong first quarter earning report bristol sale profit top wall street expectation opdivo sale grow quarter bristol share rise week retake day move average approach day related vertex big winner biopharma abbvie astrazeneca dipastrazeneca wallop profit view topple sale eye key trialabbvie flip buy point earning sale top
192,GILD,gilead science gild narrowly escap potential game changer failure trumpcare hope hiv franchise still be dash payer pushback generic hybrid combination cut share thursday leerink analyst geoffrey porge outlined gilead hiv drug include combination bictegravir emtricitabine tenofovir alafenamide be risk gop revive american health care act ahca offer similar alternative gilead share tick penny expansion medicaid obamacare help boost access hiv drug change medicaid funding president trump administration access have hurt gilead chance push hiv drug struggle deal sharp fall hepatitis sale so gilead be putt hiv business gilead appear have dodge bullet failure ahca porge write note client change medicaid funding increase pressure funding half drug coverage state pressure state program have already re-sort more active management hiv drug write semi exclusionary formulation have be test ohio illinois georgia month quality generic semi generic hiv med be likely improve current funding medicaid be unchanged option not see much adoption gilead hiv franchise not face disruption base price write funding do change semi generic product have shot undercut gilead pricing take share ibd take analyst plead gilead buy something have work head ibd industry theme more gilead buy payer too also begin more actively manage hiv drug reimbursement especially face further tighten medicaid funding currently gilead look safe environment physician patient have freedom choice hiv drug gilead have match large discount now offer such plan legacy combination launch bictegravir emtricitabine tenofovir alafenamide still be able secure prefer availability product channel porge say year porge expect hiv drug sale account gilead total sale vs prior year grow total sale related biotechs defy trump tweet rally send higher incyte spike record high rumor gilead acquire gilead be pay price actually cure disease
193,GILD,do get handle biotech market unknown stock esperion therapeutic espr nearly january outperform like industry top name amgen amgn sure esperion have have breakthrough cholesterol medication amgen recently have own moment cholesterol drug prove decrease bad ldl cholesterol also cut risk heart attack stroke still amgen isn get respect smaller biotech player be get comparatively paltry year don get discourage analyst say just amgen isn get lot love doesn mean other biotech stock be slouch really question navigate be complex sector leerink analyst geoffrey porge say biotechs have do well election stock be subject whim political debate drug pricing health care re worry donald trump health care reform re worry fda reform now re worry drug pricing regulation say just doesn seem accumulate worry be go go away hurry overall group look strong now rank group track week be rank ibd take drugmaker allergan be sweeping medical aesthetic market hologic want play head industry snapshot breakdown battle porge mizuho analyst salim sy call stock picker market biotechs be bound do well number catalyst still ahead other be more likely struggle macroeconomic politic be still pressure investor need be cognitive drug pricing sy tell ibd folk thought be presidential platform topic keep come now postelection ibd company biom biotech industry group be year major exchange trade fund ishare nasdaq biotechnology index ibb spdr biotech xbi be respectively top biotechs include amgen gilead science gild celgene celg biogen biib regeneron pharmaceutical regn have be news none stock price amgen have gain most gilead lag january sy have buy rating amgen celgene gilead stock neutral rating biogen stock smaller player potential takeout candidate incyte incy tesaro tsro have see big gain wall street tesaro be likely remain stand alone company grab fda approval ovarian cancer drug zejula stock rise much mid february be now only year incyte other hand have tack january rumor biotech gilead be look acquire incyte open gilead oncology world hepatitis franchise struggle high cure rate once again re start year best perform stock be be cheapest more takeout candidate porge tell ibd so make prediction have definitely be somewhat challenge earlier month nektar therapeutic nktr stock hit year high strong datum pain pill be alternative potentially addictive oxycodone nektar stock catapult single day share extend cup handle formation late march have give back gain stock remain year other big stock earner include kite pharma kite bluebird bio blue be work drug class call car cell therapy drug engineer patient immune cell treat cancer kite stock be whopping lead rise bluebird stock esperion rocket amgen heart study so too do medicine company mdco share be january porge list medicine co stock watch note spectacular return have right stock right set event then still generate incredibly attractive return excitement biotech porge say be company be approach critical readout ongoing development program investor think reasonable chance critical trial critical milestone turn positively mizuho sy suggest look individual stock equity rather hope broad biotech resurgence see good number catalyst market note drug pricing debate be likely still weigh market president trump have key drug pricing debate limit detail say have plan competitive base system bring price drug trump pick run fda scott gottlieb have say drug pricing need be more transparent struggle unfold porge layer rule pick biotech stock likely have better return want be growth company early life cycle treat very serious illness say follow rule be generally go end portfolio go perform better average better index better benchmark rule porge say epizyme epzm vertex pharmaceutical vrtx alexion pharmaceutical alxn be interesting epizyme stock be january have top buy point cup handle formation early february vertex stock have gain year alexion stock be actually year date stock fit bill used porge rule rare disease company be work drug treat disorder central nervous system blood disease genetic disorder worst thing do biotech investing be sell just stock be porge say don hesitate buy stock same reason axiom investing biotech be always never want say not go buy stock be industry routinely see tenfold increase value cycle emergence product say so often see stock investor say only go market cap market cap scheme thing be pretty small say have real drug re go be company related esperion medicine co recover amgen induced edward best stock own gilead be pay price actually cure disease
194,GILD,biotech boom peaked july industry slowly recover slump biggest biotech etfs be look more attractive spdr biotech etf xbi be trading week high approach potential buy point flat base etf have moved back day move average past couple week strengthen chart ibd biotech industry group have be top group many week reflect industry comeback yet be still short stock superior fundamental be proper buy point even many stock high ibd composite rating be low price stock otherwise lack few be still unprofitable company spdr biotech etf provide way invest sector broad advance have find specific stock buy index also provide buffer company specific risk be big biotechs poor clinical trial reject drug application be risk top usual investor worry such earning report fund own stock include industry heavyweight such biogen biib gilead science gild celgene celg amgen amgn largest holding term portfolio weight be small cap midcap company such ionis pharmaceutical ion exelixis exel tuesday exelixis break base retreat right back buy point next day etf select stock mainly revenue earning market perception be also consider accord prospectus stock be picked total market index broad domestic gauge have market capitalization certain liquidity ratio requirement average weight market cap be spdr biotech rise more first month have average annual gain past year past year compare favorably ishare nasdaq biotechnology ibb widely hold etf fund rise first quarter year average return be year average return be ishare biotech etf be more heavily weigh industry giant industry outlook be difficult measure much depend new drug hit market be pressure drugmaker cut price costly medicine growth prospect sector have be decline drug pricing debate be extremely difficult handicap golub chief equity strategist rbc capital market say health care sector report last monday ibd etf leader index show performance model portfolio exchange trade fund be lead overall market computer algorithm select etfs base relative strength other objective performance rating periodic adjustment market trend condition universe etfs be select include fund list related etf near new high apple largest holdingbiotech cruise day upswing price target cut duo
195,GILD,biotech boom peaked july industry slowly recover slump biggest biotech etfs be look more attractive spdr biotech etf xbi be trading week high approach potential buy point flat base etf have moved back day move average past couple week strengthen chart ibd biotech industry group have be top group many week reflect industry comeback yet be still short stock superior fundamental be proper buy point even many stock high ibd composite rating be low price stock otherwise lack few be still unprofitable company spdr biotech etf provide way invest sector broad advance have find specific stock buy index also provide buffer company specific risk be big biotechs poor clinical trial reject drug application be risk top usual investor worry such earning report fund own stock include industry heavyweight such biogen biib gilead science gild celgene celg amgen amgn largest holding term portfolio weight be small cap midcap company such ionis pharmaceutical ion exelixis exel tuesday exelixis break base retreat right back buy point next day etf select stock mainly revenue earning market perception be also consider accord prospectus stock be picked total market index broad domestic gauge have market capitalization certain liquidity ratio requirement average weight market cap be spdr biotech rise more first month have average annual gain past year past year compare favorably ishare nasdaq biotechnology ibb widely hold etf fund rise first quarter year average return be year average return be ishare biotech etf be more heavily weigh industry giant industry outlook be difficult measure much depend new drug hit market be pressure drugmaker cut price costly medicine growth prospect sector have be decline drug pricing debate be extremely difficult handicap golub chief equity strategist rbc capital market say health care sector report last monday ibd etf leader index show performance model portfolio exchange trade fund be lead overall market computer algorithm select etfs base relative strength other objective performance rating periodic adjustment market trend condition universe etfs be select include fund list related etf near new high apple largest holdingbiotech cruise day upswing price target cut duo
196,GILD,eli lilly lly incyte incy share plunge monday morning food drug administration fail approve rheumatoid arthritis drug baricitinib say more datum be need eli lilly incyte disagree fda friday decision come somewhat surprise european regulator approve baricitinib february lilly incyte have conduct more clinical trial satisfy fda delay set drug several rival lilly reaffirm earning sale guidance year incyte discuss matter conference call eli lilly fall close stock market today eli lilly have fall buy point clear early march incyte tumble plunge day move average setback lilly incyte be good news dow jone industrial average component pfizer pfe have only oral jak inhibitor rheumatoid arthritis market xeljanz gilead science gild have similar oral drug baricitinib phase trial fellow dow component johnson johnson jnj abbvie abbv amgen amgn have injectable drug pfizer gilead amgen johnson johnson abbvie rise less morning action
197,GILD,xfuture dow jone industrial average index nasdaq future early tuesday morning edge higher indicate slightly higher open apple aapl pfizer pfe mastercard headline component earning tap tuesday several company be due report eye be apple report close bell apple have world largest market cap share trading time high investor be look past current sluggish growth iphone possible dividend hike new buyback apple result guidance be likely have big impact slew supplier especially chipmaker several other megacaps be tap include drug giant pfizer merck open apple pfizer merck be part dow industrial continue lag fall slightly monday nasdaq composite power new time high thank apple facebook fb amazon com amzn other big cap techs altrium mo cvs health cvs conocophillip cop emerson electric emr gilead science gild mondelez mdlz round company tap late monday dow nasdaq future rise fair value so do index future asian trading japan nikkei rise hong kong hang seng climb shanghai composite fall ibd take apple be leaderboard ibd premium service offer annotate chart select group stock mostly growth company be buy zone take free leaderboard trial today meanwhile general motor gm ford other automaker release auto sale april analyst expect modest broad base decline demand continue decline vs year earlier general motor ford member report earning last week federal reserve begin day policy meeting analyst don see real chance move wednesday policymaker reinforce expectation june move bring forward estimate hike pare back central bank massive balance sheet related be buy point apple earning stock still buy range apple stock hit record high earning tapapril auto sale expect gm ford tesla soar be top stock earning due week
198,GILD,list exchange trade fund score gain government avert shutdown weekend gainer include proshare ultrapro tqqq powershare qqq trust qqq respectively tech heavy etfs be new high ground tqqq have asset management seek triple qqq performance gain day qqq top holding include apple aapl microsoft msft amazon amzn facebook fb apple rise new high monday direxion daily emerge market bull share edc also rally near buy point short flat base form base base pattern follow advance edc have aum sector exchange trade fund technology select sector spdr xlk financial select sector spdr xlf be lead xlk recent bounce week move average be trading highest level more year tech etf aum have rally flat base late last year xlf be year high financial etf be build flat base potential entry follow gain mid february prior flat base score advance november earning lurk corner big drug name good time check health related etfs health care select sector spdr xlv have shape week flat base buy point less entry etf have post small gain cup handle just start current pattern dow industrial average component merck mrk pfizer pfe report quarterly result tuesday biotech gilead gild earning be also tap tomorrow merck pfizer be xlv top holding april gilead make top broader market be mixed tech heavy nasdaq composite dow jone industrial average west texas intermediate crude price slide barrel spdr oil gas exploration production xop aum be etf have be pressure lately be december high gold price dip ounce weigh gold fund vaneck vector gold miner gdx have nearly aum fall week high spdr gold share gld edge lower related stock market do now
199,GILD,xhere investing action plan tuesday need know investor day ahead apple aapl be doubt most anticipate report tuesday far only company post earning optical company oclaro oclr inphi iphi be tap well pizza chain papa john pzza build
200,GILD,biotech investor likely be key launch biogen biib spinraza regeneron regn dupixent first quarter result roll analyst say wednesday sector preview ibd company biotech industry group be rank group track just week first quarter be choppy inventory seasonality challenge leerink analyst geoffrey porge say wednesday analysis suggest be not go be particularly impressive quarter large cap name coverage universe neither be go be disaster slow result suggest write note client give flux shipping day inventory level investor be likely pay most attention key launch already underway anticipate biogen spinal muscular atrophy drug ionis pharmaceutical ion be likely be scrutinize recent payer pushback meanwhile investor be look commentary roche rhhby multiple sclerosis drug ocrevus hurt biogen ms franchise celgene celg be also work ms drug ozanimod expectation be still high regeneron sanofi sny dupixent eczema injection launch end first quarter initial feedback company physician month be critical assess launch sale trend especially anecdote accessibility patient price announcement write ibd take gilead science be suffering slow hepatitis drug franchise buy decline head ibd industry theme better look gilead have sight acquire amgen amgn regeneron be also likely get question reimbursement change medicine lower bad ldl cholesterol amgen show recent study lower ldl cholesterol reduce risk heart attack stroke street be hope push payer reimburse drug upcoming filing investor look amgen commentary migraine drug erenumab romosozumab drug treat osteoporosis postmenopausal woman alexion pharmaceutical alxn be work soliris neuromuscular disease vertex pharmaceutical vrtx be testing tezacaftor cystic fibrosis gilead science gild be likely comment hiv drug bictegravir gilead be push hiv drug potential replacement decline sale hepatitis drug company hepatitis unit rake north year fall related gilead hiv franchise plan be dash trumpcare gilead be pay price actually cure diseasebiotech etfs defy trump tweet rally send higher
201,GILD,stock open higher monday weak read new york manufacturing activity april dow jone industrial average nasdaq climb be bank financial remain big piece week report news quarterly result due week bank america bac goldman sachs gs morgan stanley ms visa other bank mtb rolled monday early earning report rise more result easily top analyst first quarter expectation company repurchase share quarter raise annual dividend cent cent mcdonald mcd rise apple aapl dow well fargo upgrade mcdonald outperform market perform apple gain rbc capital raise price target maintain outperform rating pacific crest security raise concern difficulty fingerprint sensor apple upcoming iphone pfizer pfe gilead science gild abbvie abbv rise incyte incy drop more early action wilmingon del base biotech report friday food drug administration deny application incyte eli lilly lly rheumatoid arthritis treatment baricitinib estimate have put annual value drug incyte share plunge day move average heavy volume trigger sell signal eli lilly share drop also break day line remain buy point gilead gain abbvie jump pfizer be flat pfizer gilead abbvie compete market rheumatoid arthritic treatment
202,GILD,china alibaba group hold baba climb open financial unit ant financial raise offer global payment service moneygram international mgi ant initial offer be top euronet worldwide eeft place offer march moneygram share rise open euronet share rise ibd leaderboard stock alibaba be buy range alternative handle buy point medical diagnostic product maker alere alr open waltham mass base company announce friday abbott laboratory have mutually dismiss compete lawsuit abbott have reduce takeover offer share deal now value alere be expect close third quarter abbott drop open manufacturing slow sharply new york region april send new york federal reserve empire state manufacturing survey read read be still positive march far economist expectation well level post nearly new order retreat unfilled order slow delivery time lengthen shipment edge gauge employment hour work remain firm national association home builder release builder confidence survey et gauge be april internationally readout global stock market today be spotty due holiday schedule japan tokyo nikkei post gain monday hold back dollar weaken yen concern north korea china shanghai composite end top regulator pledge resolute crackdown risky market action hong kong stock exchange remain close holiday europe exchange london paris frankfurt remain close holiday related big week dow stock earning investing action planinvestor unfazed north korea netflix unite continental earning tap
203,GILD,largest biotech etfs serve reminder march investor high growth industry expect bumpy ride hit best level year early then take nasty tumble bounce back smartly loss tuesday spdr biotech xbi ishare nasdaq biotechnology ibb be modestly lower hold week move average bullish sign recent test critical marker support stumble march so far be hold double digit gain first quarter vs nice turnaround plunge more many biotech exchange trade fund prior quarter coincide hawkish election rhetoric price gouge drug industry latest rally come major setback month include trump tweet drug price serious blow big name biotechs amgen amgn biogen biib cast pall entire industry biotechnology etfs rally sharply january february higher beta name swung favor president trump shock election investor see stock value play growth industry say matthew bartolini head research spdr americas market analyst still see fair attractive valuation sector year date outperformance help ibb earn upgrade recently light improve valuation however thing be key next leg industry bartolini view first biotechs have deliver promise growth many smaller firm kite pharma kite esperion espr be unprofitable have sale even industry bellwether such gilead science gild incyte incy be earning slump however earning momentum sector whole be start look more favorable analyst say top biotech celgene celg earn extremely high ep rating ibd have score upward revision forward estimate secondly merger acquisition come fruition boost share price intercept icpt regeneron regn biogen be name be bandy takeover target xbi have outpaced peer so far have consistently past year be year date march vs gain ishare rival be cap weight skews larger company bartolini consider spdr biotech be well place look ahead well equal weight indexing method give small cap tilt be beneficial industry such biotechnology smaller more speculative company have strong potential long term growth play say relative cap weight rival xbi be less tie fortune largest name industry hand make spdr etf more immune single stock risk tweet risk bartolini word however also benefit less big price gain industry giant trump tweet drug pricing hit xbi ibb hard march related etfs be make big move
204,GILD,conviction be vital manager parnassus fund parnx ian robert klaber lead portfolio manager jerome dodson have guide fund upper echelon large cap growth fund take big stake relatively few stock take average bet stock particularly top holding so better have do homework have high confidence pick pan top holding jan include charle schwab schw micron technology mu parnassus approach be work fine average annual return parnassus stablemate parnassus endeavor fund parwx have surpass past year well past year year year enough earn ibd best mutual fund award parnassus endeavor take top honor be top winner rank year average annual return category overall diversify equity well growth large cap fund parnassus fund be top growth large cap parnassus endeavor own just stock stablemate parnassus fund hold stock larger fund dodson have manage alone have asset invest top holding parnassus have be have embed top many growth fund hold stock smaller position seek control volatility greater diversification not parnassus be high conviction fund klaber say have high active share be bottom stock picker active share be measure much portfolio holding differ benchmark index aside focuse approach way fund stand be mandate invest good corporate citizen have exposure energy utility sector say be look company be best class environmental perspective social perspective governance perspective addition parnassus endeavor holding offer outstanding workplace multicap fund parnassus team have flexibility invest see opportunity be go anywhere domestic stock fund klaber say have market cap restriction so give pretty broad play field parnassus do have more endeavor small midcaps vs parnassus still favor large cap asset meanwhile large cap oriented endeavor have big cap fund aim control risk veer only so far benchmark index sector weighting parnassus conviction investing result heavy underweight sector jan parnassus fund have financial vs parnassus endeavor be close benchmark tech have outsize bet tech vs health care vs klaber note long term focus have be key fund success fund have turnover rate lower be bit more contrarian other parnassus fund say re willing wider range outcome short term indeed direct line top holding current fund performance isn always clear fund recent top holding show sign struggle include gilead science gild allergan agn week high parnassus screen potential holding relevance be look company be become increasingly relevant product service offer klaber say want own company be gain share sector industry focus relevance help avoid value trap value trap investor be attract stock low valuation investor buy stock fail rise wide moat be hallmark portfolio holding seek company sustainable competitive advantage klaber say feel provide protection market be store value important consideration parnassus be efficient capital allocation company invest go back year analyze management have allocate capital past klaber say then project think allocate capital future understand be good steward capital parnassus team create year forecast base bull bear scenario analysis potential new stock buy be look asymmetry klaber say want company moderate low downside risk significant upside asymmetric risk reward ratio be common feature holding historically endeavor fund have have tech bias klaber say end last year more fund be invest tech end january sector account approximately half parnassus fund sector perspective sector have be most overweight be financial say pro growth agenda new administration have be tailwind firm parnassus be weight financial service stock add progressive pgr first quarter endeavor also have stake auto insurance company see company online sale strategy disruptive force aren many company be go gain market share long see say see opportunity be go invest year progressive chip away gain market share market share now be auto insurance market go keep go time progressive share have gain begin year year parnassus be weight technology technology own collection wide moat business strong growth profile trade attractive valuation klaber say klaber cite ebay ebay prime example company wide moat be own parnassus endeavor source moat be strong network effect more seller bring more buyer vice versa say share ebay be year date past year break cup handle base february run have ease point ibm ibm be top tech hold portfolio be trading time earning discount market dividend yield so expectation be low klaber say think server business do better expectation strategic initiative group continue see growth accelerate ibm have climb so far year last week parnassus team see lengthy runway allergan pharmaceutical company be top hold parnassus top hold endeavor have dominant position many therapeutic area klaber say stock have own firm end be high be also buy aggressively end last year be company have drug phase enter phase allergan share have jump parnassus crew exhibit kind patience allergan many growth investor do not company earning have grow annual rate past year wall street analyst see growth slow year next year stock relative price strength rating ibd be just related contrarian pin oak equity rise top
205,GILD,incyte incy stock hit record high monday rumor biotech gilead science gild be look acquire projection still dwindle hepatitis drug sale incyte stock end regular trading session monday earlier touch time high gilead stock other hand trend third consecutive day close fraction rumor emerge friday gilead be putt together bid incyte eye immuno oncology drug epacadostat epacadostat be currently trial merck mrk keytruda target tumor type merck compete directly bristol myer squibb bmy incyte drug be different flavor immuno oncology work inhibit be know ido enzyme do so allow immune system identify tumor cell be destroy credit suisse analyst kennen mackay boost price target incyte stock note title part scarcity value make compelling target incyte epacadostat offer gilead attractive entry point immuno oncology field mackay say ibd take analyst urge gilead buy something friday company be good fit visit ibd industry theme breakdown gilead potential target epacadostat be scarce immuno oncology backbone blockbuster write note incyte drug be pair drug merck keytruda bristol opdivo target protein call pd battle cancer gilead incyte offer biotech giant entry potentially massive market hepatitis franchise fall year run gilead sovaldi harvoni bring north sale topple hepatitis be curable gilead have explain so company be see fewer patient do suffer hepatitis be healthier healthier patient tend longer see doctor gilead have push hiv drug bictegravir next mount everest analyst have push gilead make acquisition friday analyst suggest gilead look company pipeline resemble incyte clovis oncology tesaro report emerge gilead be consider bid incyte gilead decline comment email ibd incyte didn return request comment related gilead be pay price actually cure diseasewill merck glaxo undercut gilead next mount everest drug gilead hepatitis sale plunge merck swipe share analyst
206,GILD,gilead science gild pursue merger outside core virology oncology inflammation area analyst say friday plea have work sooner thought barclay analyst geoffrey meacham suggest gilead look company pipeline resemble incyte incy tesaro tsro clovis oncology clvs then hour later incyte stock spiked more streetinsider report cite source say gilead be ready pull trigger acquire biotech gilead stock sank fraction stock market today representative gilead have comment incyte didn immediately return request comment meacham suggestion come total prescription hepatitis drug harvoni dip week week accord health care tracker im cite leerink analyst seamus fernandez new prescription also fall vs last week same time gilead epclusa see total prescription flatten new prescription rise week week basis still competition be mount merck mrk rival drug zepatier post stout jump total prescription new script fall gilead struggle hepatitis franchise be well document year more total sale gilead harvoni sovaldi see sale decline partially offset new drug epclusa hepatitis be curable now gilead be push hiv unit next mount everest barclay meacham be doubtful company hiv drug bictegravir be enough tug gilead stock share have topple january share lose friday ibd take analyst have long predict gilead hepatitis downfall happened be warning sign head ibd industry theme breakdown letter gilead management meacham implore company seek even incremental transaction suggest gilead look company immuno oncology drug target ido checkpoint asset parp inhibitor class drug firm work lymphoma deal be much more pipeline drive longer term profit loss benefit also likely be well receive also carry substantial clinical risk meacham write note trade be favorable gilead acquire company multiple mid late stage drug strong pipeline incyte drug epacadostat fit bill epacadostat belong class drug immune system identify camouflage cancer cell astrazeneca azn tesaro clovis oncology be work ovarian cancer drug class call parp inhibitor company seattle genetic sgen be work classical hodgkin lymphoma wall street have long harp gilead seek deal acquisition triangle pharma pharmasset meacham call deal literally best deal ever consummate history biopharma industry admire gilead discipline especially valuation peak trough biotech pharma sector too much patience have put immense pressure gilead share meacham write far away fear be quarterly operate cash flow decline so do gilead capacity do meaningful transaction related gilead be pay price actually cure disease
207,GILD,biotechnology giant gilead science gild buy pharmasset inherited compound then know wall street analyst expect bring peak sale just year later launch name sovaldi north pill rake sale alone prove be nearly foolproof cure hepatitis virus hcv year gilead flagship hcv drug pull more also double company net margin push past level point mid trouble be gilead didn just treat hepatitis most part cure patient month sovaldi have unheard success rate hepatitis patient follow treatment harvoni prove more effective case eventually patient pool be bound get smaller have sovaldi harvoni sale fall respective think open blockbuster movie hollywood person line rbc analyst michael yee tell investor business daily thus be less come right now now pressure be gilead produce big hit drive growth biotech investor story be cautionary tale look initial fanfare hot new drug consider cost deliver promise hepatitis hiv alzheimer disease many type cancer be short term temporary condition say kevin young gilead chief operate officer company feb earning conference call analyst gilead say fewer patient be start hcv regimen do be healthier past patient thank harvoni hcv be cure little week genotype patient young say refer most common type hepatitis gilead confirm worry hepatitis slowdown feb release fourth quarter earning share topple next day nearly touch year low whisper loom dip hcv drug sale have plague gilead stock better part year climb rapidly gilead stock start slip lose analyst issue report report modele gilead look hcv today gilead see hiv unit grow last year next big enterprise have describe hiv drug bictegravir future mount everest still sentiment hasn be negative gilead stock pharmasset acquisition say evercore analyst mark schoenebaum then analyst survey schoenebaum say gilead paid too much pharmasset later analyst miss potential immediate demand sovaldi didn even account harvoni last time sentiment gilead management be bad investor be wrong very wrong schoenebaum write feb research report more half november survey say pharmasset buy destroy gilead value sentiment obviously improve sovaldi old school hepatitis treatment weren effective often come flu side effect anemia sovaldi be so successful gilead launch harvoni see similar result harvoni sale year newest addition hepatitis line epclusa bring gilead stock fly wall street perform degree turn sovaldi ahead launch activist group patient be incense discussion bump sovaldi price expectation drug be wall street dynamo harvoni launch even bigger price tag gilead take lump headline price rbc analyst yee say price tag weren particularly egregious consider prior treatment cost high cost treatment be not high relative exist prior therapy be significantly better tell ibd email cost have come give competition other rebate fourth quarter gilead chief executive john milligan note harvoni now sell meanwhile rivalry merck mrk abbvie help curb price merck signale expectation lighter hcv sale february take impairment charge uprifosbuvir merck acquire uprifosbuvir idenix pharmaceutical company cut value estimate uprifosbuvir leerink analyst geoffrey porge say merck be signale reduce value participation market be consistent decline market overall merck have successfully defend patent hcv med zepatier gilead abbvie be work next generation drug set launch sometime wall street suspect hcv decline be come modeled total gilead sale hepatitis franchise revenue gilead company guidance total sale hepatitis drug revenue paint starker picture guidance gilead say expect patient start hcv regimen drop gilead estimate patient start hepatitis drug fewer hcv sale get push large commercial payer open access marketing campaign department veteran affair gilead young doesn expect time driver repeat guidance imply lower ep earning share consensus be modele rbc yee write feb research report think stock be probably range bound hit least quarters demonstrate handle forecast visibility yee also echo other analyst call acquisition bolster top line gilead work hcv decline work launch drug hiv nash nonalcoholic steatohepatitis unit yee see incyte incy smart unlikely deal gilead withstand pressure pharmasset buy win bend public pressure evercore schoenebaum say feb video investor be question ceo milligan none have identify specific deal miss have prevent hcv decline ibd take strong drugmake bet check incyte analyst say incyte pipeline be brim potential blockbuster opportunity head new america deeper dive incyte upcoming catalyst have here be company not just go go do deal so press release say do deal hope get sugar high stock say re only go do deal have high degree confidence work high degree confidence re underpay asset meanwhile gilead be bolster hiv nash unit gilead recently pit hiv drug bictegravir glaxosmithkline gsk incumbent dolutegravir approve sell brand name tivicay phase trial show bictegravir be numerically stronger gsk drug certain combination price be bigger concern gsk medication be cheaper combine generic med meaning hiv regimen be price vs likely price tag attach gilead solution yee say feb report other analyst say gilead hiv nash unit be too late offer little value leerink analyst geoffrey porge say feb expect hepatitis sale topple then annually outlook hiv be positive sale aren hcv trajectory porge say be not sufficient offset unusual dynamic hcv business relatively modest contribution other product offer little mitigate boom bust hcv write opportunity appear be arrive too late too little value view yee say gilead isn fill hole left decline hcv unit merely come massive bolus hundred thousand person come first year drug be still set do be largest drug world not exactly hole say related gilead clobber hep little value too late nash hiv unitscan gilead swivel hiv flounder hep sale gsk rivalry gilead hiv drug top gsk combo rivalry intense gsk doublet
208,GILD,gilead science gild see hiv drug bictegravir mount everest rival merck mrk glaxosmithkline gsk be able price rival drug cheaper analyst say thursday leerink analyst geoffrey porge note merck glaxo be work hiv regimen include generic drug gilead other hand have establish premium pricing fix dose combination base brand component pricing porge write research report result gilead struggle gain share hiv much need sector lucrative hepatitis franchise continue dwindle year sale gilead hepatitis drug see sale decline biotech be guide further decline past year gilead have dominate hiv landscape porge say hiv unit bring sale competitive landscape be shift hiv new drug set launch gilead bictegravir base formula be likely be gold standard first second line hiv treatment porge write gilead unlikely budge pricing ability hold share price erode predict ub analyst carter be more bullish gilead hiv enterprise street expect bictegravir eventually get different brand name pull sale peak sale combine substance now know filgotinib filgotinib be drug develop galapago glpg downgrade gilead stock neutral rating buy cut price target cite company struggle hepatitis guidance suggest dip hepatitis drug sale fewer patient start gilead hepatitis drug year be line gilead note fourth quarter earning conference call old school hepatitis medication weren effective gilead sovaldi harvoni carry number side effect today be fewer patient many be healthier thus put treatment ibd take gilead hepatitis drug downfall didn come blue analyst have predict better part year be warning sign visit ibd industry theme closer look gilead be also experience competitive pressure like merck abbvie abbv merck have successfully fought patent litigation vs gilead hcv drug zepatier abbvie be set launch next generation asset merger win fix gilead problem write gilead acquire triangle pharma pharmasset respectively stock trend roughly month announcement gilead stock be now year rbc analyst michael yee disagree argue gilead do number string pearl acquisition improve pipeline visibility kite pharma kite be interesting acquisition say meanwhile tail hepatitis sale be significant enough sustain demand yee have outperform rating gilead stock close bell stock market today gilead stock fall merck be marginally glaxo add related pharma be beating pack get drug marketabbvie strong bet gilead amgen least analystgilead glaxo pit hiv battle struggle vs standard drug
209,GILD,eli lilly lly pipeline have best bang buck analyst say wednesday comparison pit lilly rival pfizer pfe merck mrk bristol myer squibb bmy leerink analyst seamus fernandez say lilly be outperform pack achieve best balance investment limit external investment past year bristol pfizer trail merck struggle metric write still drugmaker lilly have struggle gain fda approval only drug pharma pipeline have gain approval contrast biotechnology company abbvie abbv gilead science gild have be more successful conversion rate top drugmaker bristol myer lilly have have considerably more success phase drug meanwhile pfizer have only converted late stage pipeline drug sell market pfizer have broadest pipeline group disclose new drug fernandez write have struggle fall megamerger disruption limit scale productivity merck be lowest pharma universe ibd take american fund recently up stake bristol myer squibb stock else receive american fund vote confidence find ibd mutual fund page analysis fernandez also look churn turnover new drug burn percentage attrition portfolio bristol have highest burn rate lowest churn rate company appear be focuse more internal asset partnership early stage mid late stage external agent fernandez write note conversely merck churn rate be highest group merck high overall expense be drive part large cubist idenix deal have so far struggle generate sizable return management have hope well company extraordinary investment keytruda write merck isn alone struggle partnership acquisition big drugmaker biotechs only gilead purchase pharmasset appear have succeed fernandez write pharmasset begin development sovaldi hepatitis drug rocket gilead sale gilead hepatitis franchise begin falter high cure rate trio drug sovaldi harvoni epclusa close bell stock market today lilly finished trading bristol myer rise meanwhile merck slip pfizer also lose related gilead hepatitis sale plunge merck swipe share analystabbvie stronger bet gilead amgen least leerinkmerck roche gouge bristol share lung cancer approval
210,GILD,prescription gilead science gild hepatitis drug have plunge jan leave least analyst wait industrywide revenue remedy hit bottom even competition loom rival merck mrk abbvie abbv total prescription harvoni sovaldi epclusa be flat week week have fall begin quarter jan rbc analyst michael yee write note client cite health care tracker im new prescription be vs last week meanwhile merck hepatitis drug zepatier have flourished total zepatier script be quarter date new prescription climb week week total prescription be vs last week zepatier now have new prescription market yee write merck have say expect grow share overseas launch japan europe fourth quarter zepatier list price treatment be roughly cheaper gilead alternative little more half list price harvoni many drugmaker however have not be get list price drug company suggest country be open more access more yee write be good gilead well even merck isn immune weaken hepatitis market last week merck say take impairment charge uprifosbuvir hepatitis drug acquire ibd take biotechs incyte be strong bet number potential blockbuster pipeline analyst say incyte keep lead visit new america deep dive company stock gilead be first market new class highly effective hepatitis drug prescription company lineup top major year run time gilead net margin more double roughly level peak disease be curable meaning get harder find new patient new patient be often healthier procrastinate begin treatment gilead have say gilead abbvie hepatitis drug sale also be struggle week abbvie viekira pak hepatitis fall be quarter date yee write new prescription grow week week abbvie be essentially niche player now second generation drug be competitor yee write drug be approve year end gilead yet competitor slow market earlier year gilead guide hepatitis drug sale miss expectation guidance actually be conservative gilead need hit couple quarter see script stabilize investor gain confidence yee say be watch hcv script flatten slope curve inflect stabilize order establish bottom franchise midday trading stock market today gilead stock be fraction share merck abbvie be fraction respectively related gilead abbvie perk merck hep downfall leerinkabbvie stronger bet gilead amgen least leerinkgilead glaxo pit hiv battle struggle vs standard drug
211,GILD,glaxosmithkline gsk set high bar gilead science gild flounder biotech attempt swivel decline hepatitis unit better hiv drug sale leerink analyst geoffrey porge say monday biotech market cap gilead be slate early tuesday release result phase phase trial hiv drug bictegravir anything less numerical superiority unblemished safety tolerability disappoint investor porge write research report investor be increasingly eyee gilead hiv unit replacement slow hep drug sale hep unit make total sale fall vs year earlier period hiv drug sale other hand rise bring total sale ibd take analyst predict gilead post decline hep drug sale marker do use make prediction grab ibd industry theme clue forecasting hcv dip gilead hiv unit too have face challenge recent history patent gilead viread be set expire december biotech lose exclusivity sustiva epivir gilead also be rivale glaxosmithkline bolster hiv unit bictegravir be crucial outlook gilead porge write comprise primary bulwark company hiv franchise competitive challenge glaxosmithkline brand portfolio loom generic entrant earlier trial pit glaxosmithkline dolutegravir gilead truvada dolutegravir deliver virological control meaning gilead bictegravir have meet top stat gilead be particularly excited early trial datum therefore presume show bictegravir very favorable light compare dolutegravir porge say have market perform rating gilead stock stock market today gilead stock rise glaxosmithkline stock fall related gilead stock dife month low hep cure drain total salesgilead boost hiv nash drug hep slump stock week dipgilead crash hep sale decline view metric top
212,GILD,hot tech ipo snap snap be initiate underperform needham co ub upgrade netflix nflx stock buy well fargo upgrade printer laptop computer maker hp inc hpq outperform needham co initiate coverage social medium firm stock underperform rating note company total addressable market be smaller facebook snap have clear path profitability add needham report share snap rise high reversed trade afternoon trade stock market today related comcast snap stake mobile messaging app snapchatub upgrade netflix buy price target see upside subscriber guidance give momentum europe latin america modest improvement japan say ub report share netflix rise intraday be extend clear technical buy point cup handle entry january related netflix hover time high near subscriberswell fargo upgrade hp outperform market perform say margin improvement be overlooked share hp fall last month hp clear buy point cup handle chart pattern related hp break beat fitbit line rbc capital hike price target kite pharma kite kite be takeover target gilead science gild roche speculate rbc capital report kite lymphoma drug be review food drug administration kite recently report strong result drug know kte treat lymphatic system cancer know diffuse large cell lymphoma kite share be related kite pharma cancer drug poise approval say rbcin other analyst move goldman sachs upgrade garmin grmn neutral macquarie research upgrade expedia expe outperform price target instinet increase price target square sq bmo capital market upgrade fedex fdx outperform
213,GILD,sarepta therapeutic srpt stock seesaw wednesday biotech guide north sale duchenne muscular dystrophy drug exondys lag wall street estimate sarepta stock be couple time stock market today end session share hit year high september fda approve exondys be more then now trade day day move average fda approval exondys be meet widespread disapproval payor anthem antm humana hum unite healthcare unh have push back cover costly drug doubt efficacy analyst note duchenne market be small thousand patient first quarter sarepta guide exondys sale late tuesday conference call analyst sale accelerate fourth quarter exondys have be market month ibd take best biotechs incyte have slew potential blockbuster analyst say head new america more company analyst have broadly expect first quarter sale exondys leerink analyst joseph schwartz write research note cut price target sarepta stock still have market perform rating share therefore come negative surprise management expect just revenue write note leave wonder compliance discontinuation slower new patient add be contribute shortfall guidance exondys sale be more disappointing year sarepta guide more rbc analyst simo simeonidis say guidance be overly conservative exondys have monopoly market significant unmet medical need write debate drug work not be irrelevant point fda have put drug market write report long run payor likely reimburse exondys exhaust usual tactic place obstacle buy much time possible simeonidis cut price target sarepta stock reflect update financial guidance sarepta sale rare pediatric disease priority review voucher gilead science gild deal needham analyst chad messer cut exondys sale expectation also lower price target sarepta stock keep outperform rating stress be simply change slope ramp not change peak estimate write research report still believe majority duchenne muscular dystrophy boy ultimately be therapy messer expect broad adoption occur second half opposed earlier view year end related sarepta muscular dystrophy drug interrupt day biotech humana unite pack back sarepta fda approve dmd drugsarepta costly muscular dystrophy drug flirt big pharma
214,GILD,intercept pharmaceutical icpt be likely succeed phase nonalcoholic steatohepatitis nash trial fda bless key change rbc analyst michael yee say friday company share rocket month high stock market today intercept stock lift earlier hit highest point november stock have be consolidate september remain far entry point trading day move average food drug administration allow intercept reduce number patient phase trial ocaliva nash enrollment be expect wrap mid week treatment period datum likely be ready year end ocaliva already be approve primary biliary cholangitis rare liver disease now intercept be grow throng company aim nash market novartis nvs allergan agn genfit be also work nash drug gilead science gild bow november ibd take intercept stock have low composite rating meaning underperform stock term growth metric sale earning power head ibd stock checkup see biotech biggest leader stack hint company have cr intercept stand good chance meeting endpoint phase trial yee write fda ocaliva only meet co endpoint improvement fibrosis nash resolution previously drug have meet endpoint fda also agree standard definition nash resolution improvement ballooning residual inflammation new definition ocaliva show phase statistically significant reduction fibrosis hit nash resolution patient change calculation be well overpower hit fewer patient yee write research report see chance success ocaliva approval nash leerink analyst joseph schwartz note questionable safety profile ocaliva wonder be reasoning slow enrollment ocaliva result itch patient primary biliary cholangitis meanwhile other genfit aren have problem fill trial schwartz be much more bearish intercept chance success trial have market perform rating intercept stock vs yee outperform rating be discourage enrolling patient cohort be unattainable timely manner be not convince raise probability success trial write research report related conatus pharma double novartis nash licensing dealallergan challenge intercept tobira nash drug
215,GILD,gilead science gild stock tumble month low wednesday biotech say hepatitis unit see fewer patient more pricing competition stock market today gilead stock fall hit lowest price april late tuesday gilead guide hep drug sale short wall street expectation hiv hep be curable disease say kevin young gilead chief operate officer company earning conference call analyst late tuesday gilead see huge promise grow hiv antiviral franchise bring sale hep disease have unique dimension most important be be cure say call thank harvoni be cure little week genotype patient gilead see fewer hep patient vs expect similar trend year young note greater number patient have less advanced disease circumstance prevent immediate treatment such unstable live situation ibd take gilead bulk hiv nash unit overcome slip hepatitis sale analyst say view be largely contend analyst see business too late make much difference europe gilead hep drug sale decline year year trail slowdown japan patient be age country germany france uk be exhibit similar characteristic fewer healthier patient analyst broadly predict gilead stock remain range bound say company be unlikely grow term engage call ceo john milligan acknowledge hiv pill bictegravir gilead doesn have much launch soon don think gilead do major deal incyte incy make sense not likely so gilead do smaller deal hit next quarters regain street attention rbc analyst michael yee write wednesday research report gilead isn plan divest hep asset evercore analyst mark schoenebaum write note wednesday hard know gilead return growth write total product sale decline gilead recently launch epclusa help offset fall sale harvoni sovaldi leerink analyst geoffrey porge say research note related abbvie merck pressure gilead hep unit gsk battle hiv bizj hcv dip virtually mirror gilead view laggilead clobber hep little value too late nash hiv unit
216,GILD,gilead science gild stock crash late tuesday biotech guidance hepatitis drug sale lag consensus nearly sale earning top wall street view release projection gilead stock plunge hour trading share rise tuesday regular session share be early january analyst fear follow report market tracker im hep prescription fall fear be realize tuesday gilead report hep drug sale harvoni sovaldi epclusa vs year earlier period gilead hep sale fall comprise half total product sale year guidance total sale hep sale also fall short gilead see net product sale include hep drug sale rbc analyst michael yee note consensus view total sale call hep unit ibd take giant biotech gilead deliver analyst view slow see wall street expectation gilead be so dim ibd industry theme total metric smash projection gilead report sale earning share ex item top consensus year year basis sale ep dip respectively year gilead print beating expectation ep ex item come view analyst have be split hiv drug sale help offset expect decline gilead hep unit prove be case hiv other antiviral drug sale grow sale unit rise related abbvie merck pressure gilead hep unit gsk battle hiv bizj hcv dip virtually mirror gilead view laggilead clobber hep little value too late nash hiv unit
217,GILD,abbvie abbv be stronger stock bet gilead science gild amgen amgn leerink analyst geoffrey porge say thursday compare biopharmas earning trajectory typical turnover analysis suggest abbvie offer more attractive fundamental base earning momentum dividend yield be only company be likely show sustain improvement operate margin cash flow next year porge write research report gilead abbvie earning growth be largely base operate revenue increase porge note increase be due volume growth humira imbruvica viekira gilead have boost operate revenue increase price franchise hepatitis drug sale say company derive lion share sale single segment gilead see sale spike hepatitis drug sovaldi harvoni hcv be curable disease sale plunge humira abbvie inflammatory have be stronger sale rise be also pit patent battle abbvie claim amgen biosimilar drug infringe humira patent abbvie be shore defend ip humira analyst expect biosimilar come online next few year ibd take biotechs analyst broadly see incyte strong stock option number potential blockbuster drug pipeline read new america better insight firm abbvie be certainly face growth quality issue outlook humira become increasingly uncertain company face generic biosimilar brand threat challenge current blockbuster product franchise porge write still earning momentum look good abbvie january abbvie guide earning share ex item be midpoint outlook didn chip consensus view be gilead forecast have decline significantly past month porge write possible estimate decline more give recent trend note amgen other hand appear stable abbvie stock close stock market today gilead amgen rise abbvie stock be just day line just day line year date basis amgen stock be outperform peer abbvie gilead stock nearly respectively related gilead crash hep sale decline view metric topabbvie merck pressure gilead hep unit gsk battle hiv bizgilead hiv drug top gsk combo rivalry intense gsk doublet
218,GILD,gilead science gild glaxosmithkline gsk have tough time divorce hiv patient traditional pill regimen leerink analyst geoffrey porge predict wednesday follow conference retroviruse opportunistic infection hepatitis franchise bust follow boom gilead be look hiv medication bictegravir combination ftc taf drug become next mt everest hepatitis drug sovaldi harvoni fall respectively vs year earlier period bictegravir glaxo dolutegravir go head head phase trial gilead be used ftc taf combo week week bictegravir patient have virological response compare dolutegravir patient leerink porge speak specialist follow conference seattle lower response rate dolutegravir arm didn necessarily indicate actual treatment failure only few more patient have hiv rna greater copy milliliter snapshot date write research report ibd take analyst predict downfall gilead hepatitis unit sign be read ibd industry theme still give recent success porge say specialist be comfortably certain gilead bictegravir meet primary hurdle inferiority glaxo dolutegravir ongoing phase trial pricing be bigger concern gilead analyst broadly expect gilead price bictegravir combination vs expect price tag rival hiv treatment glaxo merck glaxo pill regimen be likely be used small subset patient porge write trial multiple patient drop be require take pill most important take away conversation be deep attachment exist drug hiv treatment standard porge say limit impact drug regimen be expect have least current payer environment close bell stock market today gilead fall glaxo inched cent glaxo stock tuesday touch month high gilead feb hit nearly year low related gilead hiv drug top gsk combo rivalry intense gsk doubletgilead crash hep sale decline view metric topcan gilead swivel hiv flounder hep sale gsk rivalry
219,GILD,gilead science gild bulk hiv nash unit even hepatitis drug sale crumble needham analyst alan carr say friday gilead stock continue week slump stock market today gilead fall share have topple jan trading red past trading day analyst chatter have focuse gilead hepatitis unit hepatitis drug sale dip vs accord market tracker im needham carr be third analyst many day point gilead decline hcv sale analyst broadly expect gilead guidance disappoint gilead retain more current hcv market share expect hcv revenue continue diminish fewer patient be initiate therapy more competition enter market carr write research report friday ibd take gilead be hamstrung hep sale analyst be bullish amgen biogen go deeper ibd industry theme more treatment naive hep patient be opt week therapy vs higher proportion past receive week week course carr say keep hold rating gilead stock note company also have hand nash hiv therapy carr expect gilead dominate hiv space bictegravir integrase inhibitor combination tenofovir alafenamide taf emtricitabine ftc phase result be expect new drug marketing authorization application expect expect company continue dominate hiv space particularly introduction taf ftc bic carr write believe taf ftc bic consolidate many hiv regimen become forefront hiv therapy gilead also have hand nash nonalcoholic steatohepatitis sphere distinct drug phase monotherapy trial selonsertib be expect begin phase trial early year combination trial likely begin year end related merck biogen lilly top drug approval fda slump
220,GILD,abbvie abbv merck mrk be pressure gilead science gild already burden hepatitis unit rbc analyst michael yee say monday day ahead gilead much anticipate earning report guidance broadly analyst anticipate gilead guide sale assume hep sale guide lower indicate dip hep sale slough earning share item yee say investor likely have little confidence higher revenue so be see risky guidance yee write research report so way think gilead need guide hit quarters hcv need stabilize gilead stock be hammer january follow report market tracker im hep prescription fall sequentially month share have re-cover minimally be now flat year stock market today gilead stock edge cent biotech market cap amgen amgn be slate report earning close tuesday ibd take big biotech leader analyst have be most bearish gilead report slow hepatitis drug sale dive issue ibd industry theme analyst expect gilead post sale ep item vs year earlier period analyst expect sale ep item year respectively guidance be key especially consider struggle hep unit evercore analyst mark schoenebaum write research note monday hep drug sale harvoni sovaldi epclusa comprise gilead total product sale past gilead have comment new patient be healthier schoenebaum say gilead be also likely experience competitive pressure merck zepatier hep pill approval abbvie week regimen yee expect investor key hiv drug sale gilead be likely have phase datum hiv drug bictegravir annual conference retroviruse opportunistic infection croi feb seattle gilead face competitive glaxosmithkline gsk gsk dolutegravir brand name tivicay be already approve food drug administration gilead have say put everything launch gilead yee write be mt everest year come yee have outperform rating price target gilead stock related hcv dip virtually mirror gilead view laggilead clobber hep little value too late nash hiv unitsgilead bulk hiv nash unit hep slump stock week dip
221,GILD,call momentary beneficiary trump effect twitter twtr be get analyst love thank tweeter chief broadcom avgo microchip mchp gilead science gild up up be also get street attention wednesday morning btig research up rating social medium company buy neutral price target slow user growth have be major concern surround twitter popularity medium choice president trump have give fresh spotlight btig analyst say daily active user growth be ramp io download have picked notably start year be undeniable twitter have be thrust global zeitgeist follow presidential election november write btig rich greenfield do not expect immediate financial benefit increase engagement past few month overcome revenue downdraft twitter user growth challenge experience see latter half potentially exceed investor forecast share twitter climb close stock market today related twitter get gloomy coverage user growth feel good firm upgrade stock strong buy rating buy rating increase price target meanwhile mizuho lift price goal microchip keep neutral rating company easily top analyst expectation tuesday guide current quarter consensus share jump finish regular session related inphi microchip hurdle wall street december quarter targetsrbc capital market laud chipmaker top pick raise price target stock share rise close hit time intraday high tuesday package delivery service get bump buy rating aegis capital have price target stock up recently report lackluster holiday quarter result offer weak guidance share rise related up dife miss outlook amazon plan kentucky air biotech receive downgrade neutral price target citigroup gilead share plunge close lowest nearly year drugmaker late tuesday provide surprisingly weak guidance hepatitis drug sale related gilead crash hep sale decline view metric top
222,GILD,gilead science gild abbvie abbv benefit merck mrk decision take impairment charge hepatitis drug market price shrink leerink analyst geoffrey porge say friday merck also cut value estimate uprifosbuvir hepatitis drug acquire idenix pharmaceutical base upcoming drug regimen change view whole hepatitis market regulator say merck complete separate trial show add benefit triplet high dose doublet regimen porge say complicate matter high dose doublet be phase testing triplet also suggest remain value rest idenix be now very small porge write research report merck be also seemingly indicate significantly reduce value future participation market be consistent decline market overall ibd take analyst project downfall hepatitis drug sale be warning sign be other market risk read ibd industry theme gilead abbvie johnson johnson jnj bristol myer squibb bmy compete hepatitis market merck charge signal drugmaker expect have lighter sale smaller share initially forecast drugmaker be struggle grow pain follow boom subsequent bust hepatitis drug sale gilead be poster child phenomenon sale sovaldi harvoni topple now gilead be bet hiv drug bictegravir merck too note change patient population dynamic company determine recent change product profile well change expectation pricing market opportunity take together constitute trigger event require company evaluate uprifosbuvir intangible asset impairment merck write filing security exchange commission late thursday morning trading stock market today merck stock be fraction close bell share abbvie inched gilead gain related abbvie stronger bet gilead amgen least leerinkgilead glaxo pit hiv battle struggle vs standard drugscan gilead swivel hiv flounder hep sale gsk rivalry
223,GILD,instinet nomura hike price target momo momo ub start amgen amgn gilead science gild neutral initiate regeneron pharmaceutical regn buy jpmorgan start mercury system mrcy overweight instinet nomura hike price target china social medium firm momo report fourth quarter earning tuesday morning beat estimate do first quarter outlook live broadcasting service account momo revenue have maintain strong growth say instinet analyst jialong shi report momo stock crash stock market today soar wednesday top thursday spike related momo momentum continue facebook hover record highub initiate regeneron pharma acceleron pharma xlrn buy rating start coverage amgen gilead science incyte incy neutral rating ub set price target regeneron stock price target acceleron amgen stock rise incyte regeneron climb acceleron amgen stock have shot be extend buy point come cup handle formation related top biotech unveil breakthrough treatment moveincyte revenue top view jakafi sale narrowly missregeneron defy light sale eylea outlook amgen rivale ldl winjpmorgan initiate mercury system overweight price target computer system integrator be rank ibd roster fast grow company mercury stock rise related do stock post huge gain first show big ep growthraymond james downgrade aerie pharmaceutical aeri developer eye treatment medication market perform aerie stock fall still extend buy point other analyst move barclay initiate biotech versartis vsar overweight citigroup upgrade callom petroleum cpe buy valuation cowen co upgrade orbital atk oa buy stifel raise price target orbital
224,GILD,gilead science gild newest hiv regimen top rival combo glaxosmithkline gsk trial result release late monday doublet gsk keep intense competitive pressure gilead hiv unit leerink analyst geoffrey porge say porge view follow gilead presentation annual conference retroviruse opportunistic infection late monday seattle head head comparison gilead hiv drug bictegravir have narrowly better response glaxosmithkline phase trial examine combination bictegravir ftc taf emtricitabine tenofovir alafenamide glaxo dolutegravir ftc taf ftc taf be gilead backbone combo treatment naive hiv patient explain rbc analyst michael yee efficacy patient bictegravir arm achieve endpoint hiv rna level copy milliliter week compare patient dolutegravir arm delta widen week respectively hit endpoint safety appear be good yee write research report patient drop week due urticarium hive evercore analyst mark schoenebaum note bictegravir combo appear have better safety profile ibd take gilead hepatitis unit have suffer cure rate soar now biotech be look pivot potentially strong hiv drug sale gilead hep decline have be predict turn yes head ibd industry theme clue signale hep crumble gilead have moved combination phase trial gilead phase result weren strong enough establish statistical superiority bictegravir dolutegravir be enough explain gilead rush expand trial porge write research note investor be likely remain cautious threat pose glaxo dolutegravir rilpivirine doublet program show almost equally impressive result large phase switch trial say also late monday glaxo announce result phase switch trial look combination dolutegravir johnson johnson jnj rilpivirine be market name edurant combo achieve inferior viral suppression hiv rna less copy milliliter week gilead trial gsk look patient have already receive treatment median prior treatment period patient be year glaxo doublet dolutegravir rilpivirine be expect be market analyst rbc leerink say rbc yee note gsk put pressure gilead pricing doublet vs other regimen glaxo success ultimately require persuade patient switch drug hiv regimen leerink porge say gsk most likely have appeal patient have have adverse reaction long standing exposure first generation drug most patient be likely be switch gilead combination anyway meaning gilead likely recapture most share porge say also consider drug approach be inherently more restrict proposition give higher risk resistance reason anticipate relatively small share market be candidate doublet write stock market today gilead stock slip fraction glaxosmithkline edge friday gilead stock touch lowest price april related gilead crash hep sale decline view metric topcan gilead swivel hiv flounder hep sale gsk rivalry gilead stock dife month low hep cure drain total sale
225,GILD,stock open lower wednesday session revolve quarterly report dow jone industrial average fall nasdaq composite give latter feel pull gilead science gild akamai technology akam biotech giant gilead drop gilead report not bad expect fourth quarter revenue earning management full year revenue guidance be far consensus expectation gilead share have be steady decline june profit controversial hepatitis drug start taper akamai stumble follow strong fourth quarter result guidance appear be line expectation stock fall nearly buy point trigger sell rule host other notable name be also motion early wednesday buffalo wild wing bwld drop time warner twx add cognizant technology ctsh leap myriad genetic mygn rocket open beaten biotech report late tuesday fiscal second quarter earning decline less revenue rise more anticipate analyst myriad share end tuesday november high coherent cohr maker laser base chip manufacturing gear spiked open santa clara calif base company report tuesday close fiscal first quarter result past analyst target earning revenue thinly trade stock be extend have be pound new high november microchip technology mchp lob advance open earning gain rise revenue stomp analyst fiscal third quarter target ibd stock be extend flat base buy point walt disney edge less entertainment giant report mixed fiscal first quarter result tuesday hour session chief executive bob iger report plan leave ahead contract expiration disney share be buy range cup handle buy point chip developer inphi iphi rise report fourth quarter earning revenue growth better guide first quarter growth more well analyst projection stock be extend buy point economic calendar be largely quiet stock market today only significant release be energy information administration report weekly oil inventory datum et oil price drag lower third straight session send west texas intermediate barrel nearly so far week gold add trade ounce vs friday settlement price dollar be mixed bond inched trimming year yield basis point global market moved generally higher wednesday exception london mumbai london ftse dip bombay stock exchange sensex shed market china japan notch modest gain europe benchmark paris frankfurt trade less midday related grubhub whole food earning tap investing action planalaska air beat forecast trump carrier meet
226,GILD,drug industry bellwether johnson johnson jnj topple tuesday sale guidance lag street hepatitis revenue slide virtually mirror recent concern fellow drug giant gilead science gild leerink analyst geoffrey porge characterize overall picture tepid stock market today johnson johnson stock fall sink further day move average support line have hover week johnson johnson report sale earning share ex item respectively vs year earlier quarter ep beat consensus cent sale miss analyst estimate ibd take drugmaker johnson johnson struggle biotechs incyte be poise jump incyte be dig market potential blockbuster read new america more market incyte opportunity johnson wrapped sale ep item respectively guidance particular disappoint johnson see sale be vs lag consensus analyst poll thomson reuter ep item guidance miss model expect johnson hepatitis drug sale dip virtually porge write tuesday research report gilead have be hammer past week wall street view prescription hep drug dip quarter quarter gilead be set report earning feb close neuroscience unit decline markedly year year oncology sale be bright spot rise other geography imbruvica lead oncology unit worldwide sale miss view related gilead clobber hep too little value too late hiv nash unitsgilead bulk hiv nash drug hep slump stock week dipgilead outlook hamstrung hep rbc bullish amgen biogen
227,GILD,here weekly investing action plan need know investor come week federal reserve chairwoman janet yellen testify capitol hill congress also get update lockheed martin lmt program major cybersecurity conference be ahead earning report be due netease nte apply material amat cisco system ticker
228,GILD,dow jone industrial average index nasdaq composite hit fresh record high president trump say ll have phenomenal news tax cut soon nvidia nvda crushed earning view share fall raft earning twitter twtr growth have come standstill whole food market wfm plan close store lockheed martin lmt other defense firm mull deal tweeter chief dow jone industrial average index nasdaq composite rally fresh time high fuel trump pledge airline executive ll announce big news taxe few week earning be still heavy nvidia headline several highly rate chipmaker yum brand yum restaurant report well cybersecurity fiber optic play gold price rise year treasury yield fall once again find support day line semiconductor company nvidia nvda maxlinear mxl microchip technology mchp inphi iphi top wall street target december quarter result nvidia earn share ex item year year january sale rise straight quarter accelerate revenue growth analyst have expect cent ep sale nvidia guide line sale slightly lower gross profit margin nvidia share initially rally friday morning reversed finish session maxlinear guide sale slightly analyst target microchip inphi guide sale earning estimate higher current quarter intel intc say expect datum center profit margin decline time send share thursday month low trading day line recent session day earlier white house intel announce investment arizona plant related nvidia earning sale crush view guidance be so socrude price rise cent barrel international energy agency say opec compliance output cut be more qatar say opec extend production curb midyear gasoline supply unexpectedly fall latest week crude stockpile rise far more expect domestic production picked parsley energy pe announce be buy net acre permian basin second acquisition lucrative shale region month bp bp swung profit fall short analyst view company expect spend more oil major overall have give mixed capital spending outlook year related struggle expand power user base face competition facebook fb snapchat other twitter twtr report growth have essentially stall adjust earning be flat do top view revenue rise just far analyst estimate sale growth decelerate straight quarter ad revenue actually dip election year donald trump headline grab daily tweeting twitter also give dismal guidance share tumble thursday friday related president trump meet airline executive white house thursday discuss cut regulation modernize air traffic control system obsolete aviation infrastructure also tease announcement come next week be phenomenal term tax airline related group praise trump understand support airline industry delta air line dal american airline aal other take follow meeting overall market earlier week alaska air group alk beat view forecast flat unit cost even industry face higher expense due new labor agreement related lumentum lite report gaap fiscal earning beat view revenue miss expectation also give mixed guidance share lumentum core business be optical communication surge week ceo discuss emerge sensor market opportunity not include company guidance analyst speculate apple iphone design apple have multiple device supplier fabrinet fn provide optical packaging assemble optical electronic device other manufacturer report fiscal earning growth revenue better expect be second straight quarter accelerate profit growth best ep gain year fabrinet gain more related president trump be major topic cowen aerospace defense industrial conference lockheed martin lmt cfo bruce tanner say official fill key acquisition spot pentagon have bigger impact demand trump involvement deal northrop grumman noc say contract negotiation lockheed drive price haven change trump blast plane high cost raytheon rtn be wait see trump do corporate tax plan regard export boee ba ceo dennis muilenburg be still bullish deal sell airplane iran trump threaten reverse nuclear deal company confirm commitment singapore airline good sign post broader widebody market related yum brand yum parent kfc taco bell pizza hut report mixed result company say bring outside expert evaluate pizza hut chain turn disappointing not acceptable result instinet analyst mark kalinowski say be time pizza hut be divest yum rise nearly week breaking month high buffalo wild wing bwld result badly miss view analyst point loyalty program delivery test future positive activist investor want sport centric chain refranchise more also boost share buffalo wild share rally sharp weekly loss solid weekly gain yum china yumc recent spin yum china business report mixed result do panera bread pnra yum china stock fall panera share shot more bust base record high dunkin brand dnkn report better expect earning sale send share higher online food delivery service provider grubhub grub report ep cent miss consensus cent face increase competition amazon other grubhub revenue rise slightly beating more consumer use service year year grubhub stock skid nearly week fall day line entertainment heavyweight walt disney turn mixed result tuesday better expect ep decline surprise revenue drop espn abc parent also say expect debut stream sport service year address chatter surround succession plan ceo bob iger say do be best interest company be open stay top spot june expiration contract disney share fall hasbro have report earning jump share analyst view revenue climb also beating view disney princess frozen toy be bright spot sluggish holiday season retail sector hasbro stock rise more time high ibd tipp economic optimism index hit year high february rise tenth point sign confidence trumponomic reading signal optimism economist be still unsure growth live rise confidence least term positive sign come drop initial jobless claim week end feb second lowest level year related gilead science gild top revenue adjust ep share crash month low light hepatitis drug sale guidance segment slip year year allergan agn beat expectation crushed view sanofi sny result be mixed ep lag penny mallinckrodt mnk top analyst model guidance specialty generic be light regeneron regn ep just beat sale lag eylea guidance be light federal judge stay halt sale praluent pending appeal regeneron partner sanofi patent ruling favor amgen cholesterol fighter repatha related system reseller cdw cdw earn cent nickel view sale rise just slightly view share still shot akamai technology akam earn cent share flat vs year earlier revenue climb top view share tumble content delivery network specialist plan heavy spending beef global server internet infrastructure whole food market wfm meet view ep decline natural food grocer sale rise less expect same store sale fall again whole food also give weak guidance announce plan cut store count first time whole food share rebound rise nearly qualys qlys earn cent view sale just view tech security firm give weak full year earning revenue guidance qualys share fall nearly so far week flirt buy point twilio twlo unexpectedly break even revenue rise also view twilio give weak ep guidance twilio cloud base software provide real time messaging service business alert client brink bco earn cent share year earlier cent view armored car service revenue grow best year vs estimate brink stock shot coherent cohr spiked so far week hit fresh time high laser maker report ep gain revenue rise accelerate growth easily beating view vulcan material vmc earning fall cent share cent estimate revenue rise vs view gain vulcan material also give ebitda guidance be slightly view construction aggregate firm have rally follow donald trump election hope infrastructure boom stronger economic growth lower taxe fall nearly friday morning zillow earn cent share revenue beating view real estate information web site sale guidance have midpoint be slightly consensus zillow zg class share tumble close day average
229,GILD,gilead science gild amgen amgn abbvie abbv underperform leerink analyst geoffrey porge predict monday fourth analyst week hammer gilead decline hepatitis drug sale stock market today gilead stock slip share have fall past trading day wall street chatter hep sale market tracker im say hep drug prescription decline hepatitis drug harvoni sovaldi bring total product sale decline total product sale drug sale topple year year gilead launch epclusa third hep drug last summer gilead be face competitive pressure hep unit treatment time be shortening porge say see gilead hep sale decline then year decline be be drive patient presentation dynamic price duration share trend gilead be likely accelerate better competitive hcv regimen come market write research report ibd take gilead be expect struggle decline hep drug sale cancer biotech incyte be poise outperform broader industry dig new america more incyte needham analyst alan carr last week say gilead bulk again hiv nash nonalcoholic steatohepatitis unit porge isn bullish opportunity be arrive too late too little value say outlook company hiv business remain positive be not sufficient offset unusual dynamic hcv business relatively modest contribution other product offer little mitigate effect boom bust hcv say porge expect gilead major unit narrowly miss consensus expectation im datum suggest better expect harvoni sale expect epclusa sale im datum also predict major product abbvie amgen miss consensus respectively write porge keep market perform rating share gilead amgen abbvie boost price target gilead stock amgen maintain price target abbvie amgen have form cup handle base buy point fall monday abbvie stock slip related gilead boost hiv nash drug hep slump stock week dipgilead merck alexion view hazy biogen surge analystgilead outlook hamstrung hep rbc bullish amgen biogen
230,GILD,biotech industry have mixed outlook few new drug come market year midcap incyte incy be few company potential blockbuster pipeline incyte close start major development first come late last year company discover jakafi drug win be face competition gilead gild previously expect jakafi be used treat malady myelofibrosis bone marrow disorder polycythemia vera type blood cancer gilead rival drug jakafi now know momelotinib fail phase study previously untreated myelofibrosis patient november left incyte primary revenue driver free competition foreseeable future accord ian somaiya biotech analyst bmo capital market rare see drug generate sale face competition say jakafi peak sale potential most recent earning report incyte official say jakafi account net product revenue third quarter year company raise full year net sale outlook drug earlier outlook morgan stanley analyst say note client tuesday see drug revenue grow year then earlier month incyte announce immuno oncology drug epacadostat merck mrk keytruda be used phase study year include treatment small lung cancer well renal bladder head neck cancer opportunity solid tumor be earning multiplier epacadostat somaiya say drug pass trial receive food drug administration approval analyst expect peak sale accord recent goldman sachs note morgan stanley analyst say note expect key datum study prompt company start phase trial be disclose american society clinical oncology conference chicago june epacadostat have potential least be biggest pipeline drug say eric schmidt biotechnology analyst cowen be active so many tumor type finally jan fda extend review period baricitinib investigational rheumatoid arthritis drug jointly develop incyte eli lilly lly morgan stanley take bullish sign fda didn ask new study see imminent approval still analyst lower sale estimate drug delay yet see peak sale management have play key role incyte success recent year incyte chief executive herve hoppenot take helm be previously president oncology novartis nvs many scientist oncology side follow hoppenot incyte always make incyte unique be expertise biology somaiya say management change have expertise develop drug conduct larger trial bring drug market independently market analyst question much longer company remain independent incyte be largest midsize company oncology space potential buyout target endgame most biotechs be be buy larger pharmaceutical firm have less fruitful pipeline accord michael schmidt senior biotech analyst leerink partner be relation cowen eric schmidt ibd take incyte be rank second ibd medical biom biotech group have composite rating share jump buy range flat base buy point jan company announce drug trail epacadostat oncology pipeline be very interesting standpoint scarcity company have good pipeline michael schmidt say wouldn speculate company be interested incyte september poll evercore isi investment bank analyst vote gilead most likely buy incyte next month president donald trump call drug industry disastrous drug price merger activity heat year trump administration be change tax code well possible boost foreign cash increase stock valuation accord reuter report incyte be poise successful biotech world isn risk traditional drug development risk be always regulatory risk michael schmidt say oncology be obviously competitive space particularly immuno oncology cowen eric schmidt say not worry competition oncology sector be too much unmet need too many patient be die say add valuation be prime risk biggest risk be be fair bit good news price incyte say so something go wrong valuation come correct lot share incyte seem ready hit third straight day gain meet resistance cross mark friday share end monday session marginally related fda track record bode well merck keytruda chemo leerinkamgen plan robust alzheimer migraine oncology ceo exclusive
231,GILD,here weekly investing action plan need know investor come week nvidia nvda disney grubhub grub general motor gm highlight earning news report season slow meanwhile boee ba lockheed martin lmt other giant defense aerospace appear conference time fraught
232,GILD,barclay analyst geoff meacham thursday say expect gilead science gild outlook be hinder limit hepatitis sale also see merck mrk alexion pharmaceutical alxn issue sluggish view be more bullish biogen biib johnson johnson jnj rbc capital wednesday say much same gilead also be more bullish biogen well amgen amgn hepatitis drug prescription dip quarter quarter accord market tracker im gilead make sovaldi harvoni combat hepatitis merck alexion meanwhile guide decline metric heavier spending new management respectively meacham predict argue be widely anticipate meacham say research report see biogen offer upside guidance spinraza launch ionis pharmaceutical ion johnson leverage cost control offer better view ibd take hepatitis sale fall gilead go check ibd industry theme full scoop biotech biggest be expect do ahead pharma earning season start next week report company such stryker syk intuitive surgical isrg meacham boost price target incyte incy stock note company phase tumor effort merck duo be testing immunotherapy keytruda epacadostat tumor meacham expect incyte earning conference call give color jakafi trial graft vs host disease well tumor effort merck bump price target incyte stock incycte hasn yet set date earning report incyte stock last week touch month high just shy rally close stock market today consensus analyst poll thomson reuter expect incyte report sale cent earning share third respectively vs year earlier quarter merck spending be likely ramp keytruda be grant priority review last week combination eli lilly lly chemotherapy alimta treat squamous small cell lung cancer nsclc patient high expression pdl gene keytruda alimta be phase testing datum be strong merck open larger patient population vs patient pdl expression keytruda be already approve monotherapy high express pdl patient nsclc related merck biogen lilly top approval fda slumptrump disastrous pharma view doesn rattle jpmorgan drug trump break republican push major drug reform
233,GILD,biotech gilead science gild likely guide decline sale hamstrung limit hepatitis visibility rbc analyst michael yee say wednesday note expectation be better amgen amgn biogen biib earning season get underway yee expect gilead guide product sale bracketing consensus view be midpoint guidance vs early guidance appreciate visibility be tough hep right now buy side consensus be also fairly low gilead give know uncertainty yee write research report predict decline more hep sale gilead make sovaldi harvoni combat hep prescription hep drug fall quarter quarter accord market tracker im europe remain wild card volume patient fall markedly yee write be ongoing concern give bolus continue wear eu launch have occur major region past year so write note client merck be now launch number region possible lower pricing ibd take small biotech ipos outlast giant amgen biogen top stock gain company start year trade average daily volume share be pick check ibd industry theme yee expect gilead report sale tick broader consensus view consensus analyst poll thomson reuter expect gilead report earning share ex item yee see gilead be set report earning issue guidance hour feb big biotechs amgen biogen be set well earning share guidance be current investor uncertainty nervousness yee say amgen be schedule report late feb be widely modeled sale ep item then amgen report datum cardiovascular outcome trial cvot pcsk inhibitor repatha yee write cvot datum be see cvot benefit higher end stock trading write street want own name hit earning give good guidance cvot datum be risk biogen analyst poll thomson reuter view sale ep item yee see biogen be set report early jan biogen story be clearer settle patent dispute tecfidera forward pharma fwp company also likely discuss spinoff hemophilia unit bioverativ spinoff cut sale ep item cent vertex pharmaceutical vrtx celgene celg be slate report earning late jan early jan respectively preannounce financial result annual jpmorgan healthcare conference san francisco cystic fibrosis drug sale grow vertex say cf drug orkambi kalydeco pull celgene preannounce net sale company also guide sale midpoint outlook full year company see ep item grow midpoint related investor siphon biogen ionis gain spinal disease drug okcelgene ceo drug pricing debate hinge incentive innovation
234,GILD,roche rhhby ceo severin schwan shrug president trump crackdown drug price wednesday say swiss drugmaker expect reap benefit literally billion invest market focus truly differentiate medicine medicine make real difference patient say accord cnbc have doubt whatsoever be continue demand such solution particularly convince reward kind innovation market be important roche nearly half roche pharmaceutical sale stem diagnostic tool be sell north america tuesday trump reaffirm pledge go rise drug price have get lower price tell slew pharma bigwig include ceo celgene celg eli lilly lly merck mrk novartis nvs johnson johnson jnj executive also be reportedly attendance president trump promise deregulate drug industry cut taxe trump also abandon proposal revisit idea allow federal government negotiate drug price behalf medicare medicaid cover million american be largest purchaser drug health care service world ibd take trump commentary momentarily boost drug stock tuesday day earlier president ban immigration take bite airline stock read ibd industry theme column more safer entry point travel sector drug stock rise tuesday follow report trump softened stance big pharma ibd company ethical drug industry group edge small fraction stock market today roche stock rise touch nearly month high schwan commentary come roche report growth sale consensus analyst poll thomson reuter expect core earning share rise revenue breast cancer rheumatoid arthritis drug help outplay dip sale drug treat hepatitis pancreatic small cell lung cancer wet age related macular degeneration eye disease hep sector have suffer recently sale dip third fourth quarters accord market researcher ihs share gilead science gild have be pressure recently hep unit hep sale dip virtually nothing fourth quarter swiss roche see similarly painful decline sale hep drug lucentis be only sell fall offset sale breast cancer drug perjeta rheumatoid arthritis drug actemra rise respectively roche also list new launch include oncology drug tecentriq tecentriq be approve previously treat small cell lung cancer previously treat advanced cancer urinary tract compete bristol myer squibb bmy merck small cell lung cancer sector related gilead clobber hep little value too late nash hiv unitsroche gouge bristol myer lung cancer share merck rivalrywill merck let incyte go astrazeneca bristol roche team up too
235,GILD,rise consecutive year fda drug approval rate plunge year low biogen biib merck mrk eli lilly lly add new drug bailiwick accord swiss biotech hbm partner food drug administration approve new molecular entity year marked decade high approval nmes say hbm have not be fewer nmes approve fda give blessing just half nmes be not fully develop house be acquire be license hbm write new drug be first class drug therapeutic area cancer lead nmes new drug project industry lead peak sale be oncology hbm find ibd take ease fda approval process be part donald trump health care initiative president elect really break republican enact major drug reform trend past year oncology drug see major increase fda approval list new cancer drug be approve rise nmes cancer fda have increase appetite drug treat diabetes respiratory disease viral other infection interest cardiovascular genetic immunology drug increase moderately year also see fewer central nervous system drug then merck roche rhhby have have more drug approve other company add johnson johnson jnj pfizer pfe follow closely apiece gilead science gild novartis nvs glaxosmithkline gsk sanofi sny lilly have add new drug ibd company medical biom biotech industry group close stock market today group rank be tumble lawmaker debate issue drug steeply rise price related lilly regain key migraine drug colucid acquisitionfda track record bode well merck keytruda chemo leerinktrump disastrous pharma view doesn rattle jpmorgan drug conference
236,GILD,first news conference surprise president elect trump wednesday indicated issue escalate drug price be priority used harsh word describe situation drug industry have be disastrous say trump drugmaker be subject new bidding procedure re get away murder say hit issue already have be get increase attention federal state lawmaker mylan myl ceo heather bresch be skewer house committee september plenty other have be heavily criticize include valeant pharmaceutical vrx teva pharmaceutical teva mylan teva acquire generic drugmaker actavis last year allergan agn be publicly trade company company december be sue attorney general state price fix charge field generic drug day earlier first action similar investigation justice department charge former ceo president privately hold heritage pharmaceutical price fix ibd take event such news conference president elect move stock see ibd stock move learn latest big mover number drugmaker currently move list interview time name magazine man year trump pledge bring high drug price wednesday marked first substantive comment subject pharma have lot lobby lot lobbyist lot power very little bidding drug say news conference re largest buyer drug world yet don bid properly re go start bidding re go save billion dollar period time actavis have boost price hydrocortisone tablet number year mylan epipen treat allergic reaction see price increase year end last year product treat potentially life threaten situation ishare nasdaq biotechnology ibb etf fall stock market today fall back day line already depress share mylan teva fall respectively wednesday valeant tumble ibd company biotech industry group fall again fall day day line larger biotech stock aldr fall spark therapeutic once plunge unite therapeutic uthr fall larger drugmaker amgen amgn end day regeneron pharmaceutical regn fall gilead science gild fall biogen biib tumble related trump drugmaker get away murder mylan teva sue allege price fix
237,GILD,here weekly investing action plan need know investor come week earning season get underway delta air line dal jpmorgan chase jpm bank america bac well fargo wfc biggest name due year biggest event automotive sector health stock begin senate be
238,GILD,conatus pharmaceutical cnat share more double early tuesday announce licensing deal novartis nvs late monday conatus get immediately further payment collaboration royalty deal pharmaceutical giant liver treatment emricasan novartis pay conatus phase emricasan development cost expense phase trial conatus say statement emricasan be be evaluate use treatment nash cirrosis nash fibrosis stand alone treatment part combo therapy conatus share shot morning trade stock market today hit month high intraday be month high micro cap biotech have have virtually revenue novartis edge higher intraday several drugmaker be work treatment nash stand nonalcoholic steatohepatitis fatty liver disease include liver specialist such intercept pharmacetical icpt genfit do not trade exchange intercept have advantage nash drug recently winning tentative european approval liver disease big biom nash player gilead science gild have candidate trial allergan agn make acquisition september enter nash development field intercept gilead allergan fall intraday related biogen name insider new ceo month search stock fallsclovis stock rally astrazeneca rivale ovarian cancer
239,GILD,hematologist oncologist incyte incy opportunity polycythemia vera pv see biotech grow jakafi sale landing potential takeover deal rbc analyst simo simeonidis say sunday stock market today incyte stock fall share be year have trade day move average early november incyte stock be create flat base entry point simeonidis keep outperform rating inctye stock call key opinion leader neoplasms mpn market be positive use jakafi pv be blood cancer expect use increase ibd take pv isn only strong contender market regeneron make sweet buck eczema drug sale rbc say sweet check ibd industry theme full scoop jakafi belong class drug call jak janus kinase inhibitor inhibit action family enzyme have show help treat certain cancer inflammatory disease rheumatoid arthritis gilead science gild cti biopharma also be work jak inhibitor incyte be team novartis nvs jakafi novartis commercialize sell outside jakavi wall street generally see incyte lead jak inhibitor jakafi compete chemotherapy bristol myer squibb bmy hydroxyurea roche rhhby interferon pegasys pv market simeonidis write research report jakafi be typically second line drug pv patient be intolerant resistant hydroxyurea provide upside jakafi sale doctor say expect use jakafi pv increase come year go forward note median jakafi benefit pv be longer myelofibrosis european american physician differ come prescribe jak inhibitor place more traditional chemo interferon physician say eu docs be more likely treat patient base european leukemia net eln criterium physician be more likely treat base gut have patient be hydroxyurea long enough experience side effect doctor tell simeonidis related gilead scoop incyte cancer drug prove not good enough incyte recoup loss price fix fracas strong chemo result
240,GILD,federal jury late thursday order gilead science gild pay royalty ruling merck mrk patent hepatitis drug be valid gilead say appeal verdict gilead sovaldi horavni have cure rate more be very expensive merck have own hepatitis drug zepatier didn get approval gilead treatment well viekira pak abbvie abbv gilead science fall friday open bell stock market today merck rise separately agio pharmaceutical agio tumble premarket say late thursday be discontinue second candidate pyruvate kinase deficiency rare form anemia discussion fda liver toxicity agio pharma be still continue work pkd candidate ibd take drug price fear have weigh pharmaceutical stock year pre elect trump push sweeping drug price control breaking fellow republican
241,GILD,major stock index be mixed mostly unchanged midday friday dow component apple aapl shrug positive comment piper jaffray ulta beauty ulta be top performer nasdaq dow jone industrial average add nasdaq composite ease be mostly unchanged volume exchange be heavy early go option expire market get little jittery reuter report chinese navy warship intercept underwater drone deploy oceanographic vessel south china sea stock market today apple be unfazed positive comment piper jaffray resume coverage stock overweight rating price target share rise stock work right side base meanwhile couple software bellwether report earning late thursday oracle orcl slump company report adjust profit cent share slightly ahead view sale be flat just oracle tout rise total cloud revenue adobe system adbe featured last weekend earning preview column reversed lower fall nearly adjust earning share cent rise year adobe also deliver sixth straight quarter sale growth ipo news online travel firm trivago trvg have debut pricing last night well propose range share be recently trading ibd take recent new issue top notch fundamental deliver explosive gain early stage business ibd offer extensive coverage ipo new issue market biotech sector gilead science gild slide federal jury order gilead pay merck mrk hepatitis patent dispute related apple be buy fedex pt raise oracle pt cut veeva ipo price range raise
242,GILD,etfs tracking major stock index rise tuesday final trading week year boost hope fabled santa claus rally investor cheer positive economic datum home price consumer confidence spdr spy add stock market today exchange trade fund proxy broad market continue trade time high be month date nasdaq composite index be spotlight tuesday peg fresh time high powershare qqq qqq pop more morning trade record high close well level top stock holding apple aapl microsoft msft amazon com amzn post gain so do biotech holding such amgen amgn gilead gild biogen biib standout tuesday be nvidia nvda top hold elite ibd stock chipmaker jump nearly raise concern potential climax run over-heat buy qqq etf track nasdaq index compose largest nonfinancial stock list nasdaq base market capitalization powershare db commodity dbc also punch tuesday higher oil gold price etf be year date dec ibd take nasdaq index have be relative laggard year qqq track index be year date dec trail russell however powershare equity strategist believe qqq etf be well position long term give earning growth valuation component here look performance major exchange trade fund key asset class stock market today relative price strength rs rating measure stock price performance last month vs stock etfs scale best possible spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs unite state oil uso rs ishare core aggregate bond agg rs powershare db bullish uup rs ipath vix short term future vxx rs related qqq etf return form lag back go higherqqq etf break best level
243,GILD,gilead science gild stock linger red tuesday biotech market cap unveil strong phase result oral nash drug analyst chatter study wasn controlled phase datum remain year share dip finish stock market today rise fraction monday share rocket wednesday donald trump election have waffle late monday gilead present result month phase study gs combat nonalcoholic steatohepatitis drug work target type protein associate cancer diabetes cardiovascular disease drug show improvement fibrosis group patient patient milligram dose see improvement fibrosis vs population take simtuzumab alone ibd take trump white house be boon pressured drugmaker biotechs analyst say get full scoop ibd industry theme simtuzumab be antibody design treat fibrosis bound enzyme act immunomodulator act somewhat control phase trial gs credit suisse analyst alethia young say continue think phase datum be interesting particularly rapid effect fibrosis just week fibrosis typically take much longer improve write research report rbc analyst michael yee note caveat gilead datum say study be short phase datum start still take year mechanism gs be somewhat cloudy say secondary endpoint show improvement nash resolution less point improvement nafld activity score nas write be puzzling drug work inflammation mechanism strong fibrosis result benefit nash resolution still analyst keep outperform rating gilead stock young have price target stock related drug stock rally relief clinton didn white housecan small cap biotech take gilead celgene biogen alzheimer
244,GILD,drug giant eli lilly lly be poise jolly december datum ruling come positive credit suisse analyst vamil divan say eye be new datum eli lilly solanezumab alzheimer disease drug predict have probability success legal decision regulatory ruling surround lilly jardiance alimta trulicity also be expect next month eli lilly stock use year end bounce share be year fall stock market today ibd company medical ethical drug industry group fall more tuesday phase datum lilly sola be due day now definitely year end divan write research report tuesday sola act neuroprotector patient alzheimer success boost rival biogen biib have similar drug development divan predict lilly stock soar more sola show significant functional benefit show trend function even show functional benefit predict drop sola miss cognition ibd take december be jolly more just eli lilly drug stock have rally election donald trump be see more business friendly hillary clinton happen trump make good promise repeal affordable care act outlook isn certain grab ibd industry theme deeper dive addition food drug administration be due make decision december expand label jardiance type diabetes med risk be skewer downside most observer be expect fda approval divan say also patent litigation be ongoing lilly alimta chemotherapy cancer lung most expect patent expire regardless divan note also come week lilly be due release interim analysis study type diabetes drug trulicity news flow win end initial guidance be expect jan fda approve baricitinib rheumatoid arthritis drug conjunction incyte incy mid january write baricitinib belong class drug call jak inhibitor gilead science gild be work jak inhibitor be abbvie abbv pfizer pfe have approve be currently trial expand use incyte also have jak inhibitor market janus kinase jak be family enzyme drugmaker believe block enzyme treat certain cancer inflammatory disease editor note correct last graph company be work jak inhibitor already have market related gilead scoop incyte cancer drug prove not good enough amgen gilead eli lilly eat abbvie humira sale analyst
245,GILD,gilead science gild latest cancer drug be not good enough rbc analyst michael yee say thursday suggest biotech be better buy midcap rival incyte incy stronger myelofibrosis drug late wednesday gilead unveil mixed result phase trial momelotinib jak inhibitor janus kinase jak be family enzyme drugmaker believe block enzyme treat certain cancer inflammatory disease jak inhibitor incyte lead pack gilead biotech market cap look unseat incumbent head head phase trial gilead momelotinib wasn inferior jakafi week term splenic response miss term total symptom score second phase trial momelotinib be pit best available therapy patient previously treat jakafi momelotinib didn prove be superior other therapy do meet total symptom score endpoint gilead stock slip stock market today incyte stock rise gilead mixed result ibd company medical biom biotech industry group rise nearly ibd take biotechs look poise takeoff donald trump election appeal affordable care act do industry check ibd industry theme idea rbc yee suggest gilead push acquire incyte stronger jak inhibitor gilead look unlikely file momelotinib previously plan evercore analyst john scottus write research report credit suisse analyst alethia young doesn see momelotinib competitor jakafi even momelotinib make market don expect drug be meaningful competitor jakafi write report be uncertain be regulatory pathway due mixed result drug market have robust set datum already gilead wrapped cash equivalent market security balance sheet also have history acquire innovation include nimbus apollo nonalcoholic steatohepatitis asset galapago nv inflammatory drug firm be typically patient acquirer credit suisse young say investor know investor think challenge heighten focus external write however know gilead be discipline patient acquirer asset so don know challenge really change sense urgency yee expect gilead make play incyte bolster limit view pipeline bid likely follow phase datum incyte lung cancer drug expect gilead make string cancer acquisition next few year don see many company fit well so believe do string pearl buy company next year write gilead hadn do much outside nash deal be patient cancer related drug stock rally relief clinton didn white housecan small cap biotech take gilead celgene biogen alzheimer biotechs climb third straight day leader be buyable
246,GILD,amgen amgn biogen biib celgene celg gilead science gild look follow donald trump election set fewer regulatory hurdle likely biotech resurgence rbc analyst michael yee say monday biotech stock have surge trump election largely notion be less likely pressure drug price hillary clinton likely push business friendly legislation include tax incentive repatriate cash election uncertainty yee expect big biotechs make good plan capital remain inexpensive organic growth slow trump appear poise embrace innovation administration yee write research report monday ibd take biotechs aren alone experience trump effect defensive stock be furious upswing follow election get defensive stock now get ibd industry theme answer end trump meet patrick soon weekend soon be biotech exec former ceo abraxis bioscience celgene acquire tell come trump meeting soon yee note regardless investor be start key pro biz environment election share ibd company medical biom biotech industry group spdr biotech etf xbi be nearly ishare nasdaq biotech etf ibb be more bar big policy surprise trump be increase feel pro business include pro biotech gop yee write so see unlikely major legislation derail innovation increase be merely begin yee write note good thing happen believe stock go much higher alzheimer datum late early eli lilly lly be catalyst biotechs also likely update guidance january potentially push stock higher biotech celgene be most risk postelection world term catalyst fear big disappointment yee write celgene have multiple sclerosis datum due first half likely win raise guidance january celgene stock dip dilutive deal note view pullback buy opportunity long term tail question be sufficient pipeline long term investor want see term earning variance be less important tail question write meanwhile amgen biogen likely be uncertainty remain share biomarin pharmaceutical bmrn vertex pharmaceutical vrtx yee write biogen stock bound strong alzheimer result eli lilly amgen stock be still suffering fallout commentary enbrel pricing stock market today celgene stock lift share amgen biogen gilead be fraction vertex stock be biomarin share related small cap biotech take gilead celgene biogen alzheimer
247,GILD,donald trump stunning drug biotech stock rally wednesday investor sector cheer hillary clinton have be see far more likely crack drug price takeover activity gilead science gild rise stock market today pfizer pfe shot amgen amgn merck mrk mylan lab myl fire epipen price hike leap mylan late wednesday posted earning fall short top bottom line share be fraction clinton have say go excessive drug price hike also likely have favore change government negotiate lower price drugmaker meanwhile republican retain control house congress also ease regular concern drugmaker aren clear be still populist anger price new old treatment trump time signale also go drug price meanwhile justice department reportedly be close filing charge vs mylan other generic drug maker price collusion related stock future well lows trump win white house
248,GILD,small cap biotech axovant science axon pull sale alzheimer drug rbc analyst michael yee say tuesday pit big player gilead science gild celgene celg biogen biib eli lilly lly early tuesday axovant report loss tell investor expect wrap key phase trial alzheimer drug intepirdine year end yee expect datum mid see probability success phase intepirdine alzheimer drug result time potential upside yee write research report have outperform rating price target axovant stock axovant stock topple stock market today share be month low follow earning report loss share ex item widen cent cent year earlier quarter analyst expect cent loss axovant make initial public offer june pricing share company hasn yet report sale ibd take biotech stock be trading positively third consecutive day biogen be leader pack early efficacy phase trial spinal muscular atrophy drug conjunction ionis get full scope industry theme alzheimer market be huge big player gilead celgene biogen eli lilly look take chunk axovant most closely rival danish drugmaker lundbeck have phase trial due drug idalopirdine intepirdine idalopirdine have similar mechanism be ht antagonist aim assist cognition memory lundbeck idalopirdine have safety issue yee give only probability success lundbeck idalopirdine be used dose level need due safety issue drug thus not overly read be negative yee write research report axovant be also testing nelotanserin treat visual hallucination symptom alzheimer lewy body dementia datum be expect february phase trial patient yee note consensus have expectation trial consider size datum be great strong numerical reduction hallucination believe see move axovant vs minor downside negative write note alzheimer datum later year be more important stock related eli lilly revenue ep miss ceo praise drug pipeline
249,GILD,nvidia ticker symb nvda priceline group pcln activision blizzard atvi have price target raise tuesday coverage be initiate amgen amgn gilead gild buy rating nvidia have price target raise rbc capital market outperform rating chipmaker announce quarterly earning thursday nvidia used be know mainly graphic card video game console company have immerse new market bright growth prospect include self drive car artificial intelligence share dip close bell stock market today raymond james hike price target online travel company priceline report third quarter earning market close monday beat top bottom line online travel company tripadvisor trip report earning market close tuesday follow cautious warning call ep be expect fall third straight quarter priceline stock surge close benchmark maintain buy rating activision blizzard raise price target activision stock fall month low friday video game publisher give holiday sale forecast undershot wall street expectation activision stock be mizuho initiate coverage gilead buy rating price target gilead be longer favorite biotech investor have lose much fan club stock valuation mizuho report say gilead cut loss tuesday fibrosis drug still plan send potential treatment fatty liver disease phase testing gilead stock end trading cent coverage be initiate amgen mizuho buy rating price target amgen report earning oct beat top bottom line amgen plunge month low oct biotech say large rebate be chip away sale enbrel doesn expect price increase amgen stock slip
250,GILD,biotech stock climb third consecutive day tuesday mid cap tesaro tsro forge way largest company amgen amgn gilead science gild celgene celg be buyable now say mizuho analyst salim sy sy initiate coverage tuesday amgen gilead celgene stock buy rating also initiate biogen biib neutral rating lack medium term catalyst uncertainty former ceo george scango resign july be clear still think biogen have good program be matter time get excited again just not right now sy write research report have price target biogen stock slip cent tuesday ibd company medical biom biotech industry group lift fraction stock market today volatile election season have strangle share cause group topple past week ibd take sy have neutral rating biogen stock share be look better biogen ionis announce early efficacy phase testing spinal muscular atrophy drug check industry theme full take sy liken amgen jogger have price target stock fraction tuesday amgen most recent call thought amgen largely hum steady stock jogger write however amgen call week stock have come enbrel commentary call spook investor say sale be flat give contract negotiation amgen expect relatively little benefit net selling price change enbrel wall street have be predict decline amgen legacy business time sy see silver line new drug amgen repatha cholesterol bust pcsk rival sanofi sny regeneron regn praluent repatha already have food drug administration approval sale have suffer restrict access sy write repatha be currently phase testing treat cardiovascular outcome september meet primary secondary endpoint phase test coronary artery disease cv datum be expect sy call most important datum event amgen positive event pull amgen stock dump share hit year low friday manage close fractionally day gilead manage impossible launch hepatitis hcv drug sovaldi harvoni triple revenue become company sy write separate report duo be cure hcv therefore win last forever flip side develop cure be eventually disease be eradicate write great patient mean decline revenue time have be weigh gilead stock answer slope decline isn exactly clear gilead hep trio sovaldi harvoni epclusa bring sale vs year earlier quarter epclusa launch june july europe help offset decline sovaldi harvoni sy model year year decline hcv sale gilead gilead be work next leg growth sy say have price target gilead stock nonalcoholic steatohepatitis nash hepatitis hbv drug be still too early pipeline gilead be face nash competition intercept pharmaceutical icpt allergan agn gilead isn table pound buy stock be undervalue company likely perform time reward patient investor sy write gilead stock rise cent tuesday celgene be castle chemotherapy drug revlimid be moat sy say revlimid sale grow vs last year drive new market share gain increase duration revlimid be used treat myelodysplastic syndrome mds multiple myeloma mantle cell lymphoma mcl revlimid allow celgene grow next source revenue sy write separate report revlimid be still grow part business value add celgene part business be fairly well establish mature moat celgene have cancer drug durvalumab car conjunction astrazeneca azn juno therapeutic juno respectively celgene be also work next generation replacement revlimid be expect go generic be fully generic core celgene have ozanimod currently phase testing multiple sclerosis ulcerative colitis ged investigational crohn disease drug be central celgene investment thesis say sy have price target celgene stock rise tuesday related biotechs be derisked buyable ahead election day amgen gilead eli lilly eat abbvie humira sale analystgilead nash drug active promising lag challenge intercept tobira nash drug
251,GILD,company devote repatriate overseas cash stock repurchase next year congress enact president elect donald trump proposal lower taxe such move say goldman sachs top overseas cash holder be apple aapl microsoft msft google parent alphabet googl cisco system csco oracle orcl trump have propose time tax cut repatriation company corporate profit hold overseas tax rate fall plan indeed spur company bring back overseas cash say goldman sachs only second time year stockrepurchase account largest share cash used company forecast goldman sachs share buyback rise say investment bank ibd take apple have be raise dividend aggressively nov iphone macbook giant paid cent share cash shareholder learn more ibd income investor estimate buyback be drive repatriate overseas cash say goldman sachs research report forecast company repatriate close total overseas cash be direct primarily share repurchase moody investor service say apple be track have overseas cash end far most company be microsoft then come cisco oracle alphabet biotech company sizable overseas holding include amgen amgn medtronic mdt gilead science gild say ub research report say other company lot overseas cash include johnson johnson jnj coca cola ko probability significant legislative activity have increase result single party control first time republican single party control say goldman sachs report addition tax reform appear be prominent policy agenda expect see initial tax reform proposal march april possible enactment second half year apple alphabet share rise more stock market today microsoft rise fraction oracle be flat cisco slip fraction related apple microsoft cisco eye trump overseas cash tax planapple microsoft alphabet king cashfacebook buy back share stock slide continue
252,GILD,gilead science gild cut loss tuesday fibrosis drug still plan send potential treatment fatty liver disease phase testing needham analyst say wednesday biotech earning report needham analyst alan carr keep hold rating gilead stock follow report late tuesday stock market today share dip share be year match decline ibd company medical biom biotech industry group gilead report sale earning share ex item respective vs year earlier quarter sale top consensus analyst poll factset ep miss cent ibd take gilead report follow amgen biomarin be similarly struggle volatile election season keep tab industry theme more evercore isi analyst john scottus attribute sale beat hiv drug genvoya bring more expect be partly offset miss hepatitis drug sale sale hep drug have be impact medicaid restrict access most seriously ill patient gilead hep unit be comprise harvoni sovaldi epclusa trio bring sale vs year earlier period gilead attribute decline lower demand harvoni sovaldi epclusa launch june july europe respectively rbc analyst michael yee expect term challenge gilead stock low visibility hepatitis sale europe keep outperform rating gilead stock cut price target gilead also announce discontinue testing fibrosis drug simtuzumab fail show efficacy phase trial nash nonalcoholic steatohepatitis primary sclerosing cholangitis psc instead firm be look send single agent phase testing have plan combination trial nash battle meanwhile continue heat intercept pharmaceutical icpt novartis nvs allergan agn be buy tobira therapeutic tbra purpose gilead mix nash affect american year liver disease be area opportunity needham carr write research report related allergan stock topple miss slash outlook
253,GILD,analyst start nike nke neutral rating chipmaker nvidia nvda buy rating wednesday shale oil company anadarko apc be upgrade earning earlier week coverage nike be initiate neutral rating price target wedbush athletic gear giant be face step competition armour ua resurgent adida lately last week armour top quarterly forecast lower growth projection nike share rise end trading stock market today related shoe sale slow nike retro design help start coverage nvidia buy rating price target chipmaker announce quarterly earning nov competitor qorvo qrvo qualcomm qcom skywork solution swks report week qualcomm today qualcomm be upgrade monday expectation acquisition nxp semiconductor nxpi boost earning nvidia share slip qualcomm share end day ibd take be several way look stock few be more important trend profit margin nvidia have see straight quarterly margin increase find other top stock big margin increase ibd big cap gilead gild be upgrade outperform bmo capital rbc capital lower gilead price target late tuesday biotech report drop profit hiv drug top expectation rise gilead share sank bp bp be downgrade hold societe generale oil major lower capital expenditure outlook year tuesday be cautious investment guidance well bp share fall wednesday credit suisse upgrade anadarko outperform price target late monday exploration production company report earning revenue result miss wall street expectation anadarko share add end trading wednesday shale bellwether continental resource clr report result close wednesday related amazon price target bump chevron twilio get analyst loveanalyst bullish acacia qualcomm nike downgrade
254,GILD,be call silent epidemic slowly wasting away liver million american doctor have paltry understand disease approve treatment now alcoholic steatohepatitis nash be sight more dozen drugmaker allergan agn become latest tuesday announce deal acquire nash treatment less hour race company startup intercept pharmaceutical icpt giant include gilead science gild pfizer pfe reach untapped market be worth year accord estimate rbc capital market corp analyst michael yee drugmaker still be try determine different component disease inflammation scarring metabolic change interact be experiment variety treatment mechanism so many company pile field ll have work distinguish re look something get factor say alex depaoli chief medical officer closely hold ngm inc have nash partnership merck co mrk want develop something pop eye nash occur fat accumulate liver inflammation damage much quarter population have precursor condition call alcoholic fatty liver disease ailment develop slowly patient often don show symptom liver be heavily damage most common person be overweight have diabetes doctor mainly prescribe diet change weight loss ibd take medical biom biotech sector be run hot rank eighth ibd industry group sector be lead supernus pharmaceutical supn more be find here doctor need perform biopsy diagnose nash person alone be estimate have condition go develop life threaten cirrhosis nash be lead cause liver transplant accord allergan drug treat likely command high price elizabeth krutoholow analyst bloomberg intelligence say head race be intercept french biotech firm genfit large trial underway tobira therapeutic tbra allergan agree buy tuesday much be prepare recruit patient final stage study investor also be watch result gilead mid stage trial be expect be present year acquisition news tobira share soar more tuesday share be afternoon trade wednesday intercept be testing ocaliva already approve treat rare liver disease call primary biliary cirrhosis nash enrollment final stage trial person be expect be complete next year interim result due potential concern be earlier trial patient experience itch take drug case so severe interfere basic activity chief executive mark pruzanski say interview hope ocaliva become backbone treatment used combination other drug genfit be develop once day treatment raise fat metabolism fight inflammation treat underlie cause fibrosis dean hum genfit chief scientific officer say interview fail meet primary goal mid stage trial last year show promise subset patient moderate severe form disease final stage trial moderate severe patient be underway company have datum late startup biotechs biggest company be pay attention ready do deal merck say pay much partnership ngm gilead maker blockbuster hepatitis drug sovaldi harvoni buy nash drug nimbus therapeutic llc include milestone payment gilead also buy drug phenex pharmaceutical ag much gilead now have nash candidate portfolio have datum later year drug target different aspect disease be develop individually be used potent cocktail allergan tobira be biggest nash deal so far tuesday company also announce purchase akarna therapeutic ltd developer nash treatment pfizer biggest drugmaker be future acquirer have nash drug trial more be test human end year nash be major priority say morris birnbaum chief scientific officer cardiovascular metabolic disease company be try treat disease early stage win be easy genfit tobira mid stage trial fail raptor pharmaceutical rptp end program datum be start come study lot confidence be build lose say jay luly chief executive enanta pharmaceutical enta begin testing experimental treatment patient year same expect happen money
255,GILD,medical behemoth amgen amgn biogen biib square acquire muscle biologist cytokinetic cytk more dozen potential player prep donnybrook small cap pharmaceutical adms needham analyst suggest friday biotech fodder heated week allergan agn announce back back deal acquire vitae pharmaceutical vtae tobira therapeutic tbra tobira deal give allergan leg battle nonalcoholic steatohepatitis nash gilead gild intercept icpt pharmaceutical also compete ibd company biotech industry group have climb group track just week collectively group have market cap group group fall friday first decline past trading day group be week needham analyst review pipeline business development area interest activity large company gauge interested big pharma be biotechs important theme biotech space write research report allergan amgen bristol myer squibb bmy johnson johnson jnj merck mrk pfizer pfe roche rhhby shire shpg valeant vrx have be most acquisitive buy prep buy more company collectively shire have be most active acquisition believe late development stage commercial stage biotech company be particularly attractive acquisition target write research report title do big pharma want buy peak area interest include oncology cardiovascular needham research show not be big pharma take beaucoup buck needham analyst suggest central nervous system cns player acadium pharmaceutical liver disorder drugmaker intercept be prime acquisition interest firm overlap potential interest acadium abbvie abbv allergan eli lilly lly lundbeck merck novartis pharmaceutical nvs teva pharmaceutical industry teva takeda pharmaceutical needham list potential acquirer allergan make particular sense consider duo already partner next generation formulation memantine fix dose combination product namzaric battle alzheimer year end plan file new drug application food drug administration ad treatment levodopa induced dyskinesia involuntary movement parkinson disease patient multiple sclerosis walking impairment needham write meanwhile acadium potential suitor be interested nuplazid drug ease psychosis associate parkinson launch earlier year needham suggest acadium be look expand label other used similarly intercept draw interest nearly dozen potential buyer include gilead biotech market cap thursday rbc analyst posit intercept continue lead gilead allergan battle nash ibd take biotech stock notch higher week last week check ibd industry theme
256,GILD,federal reserve say case rate hike have strengthen stock rally policymaker indicated path increase be even slower congress grilled big ceo federal government announce autonomous drive guideline yahoo yhoo facebook fb make embarrass disclosure nasdaq climb time high fuel fed decision further lower likely rate hike trajectory rise close day retake key support thursday oil metal mining stock fared well retail group struggle federal reserve hold interest rate steady wednesday signale hike key rate december still market be pleased fed member own projection point just hike meanwhile bank japan say intervene keep year government bond yield roughly say now aim overshoot inflation target neither move currency impressed investor yen rise close year high boj meeting divide fed hold rate hike see slower tighten pathnote fed job market just take wrong department transportation unveil long await federal autonomous vehicle guideline new rule provide tesla motor tsla ford motor alphabet googl general motor gm other be develop self drive car framework safety guideline pre empt state law dot say new guideline be root view automate vehicle hold enormous potential benefit safety mobility sustainability alphabet be early pioneer self drive car tesla have be most aggressive push technology tesla update autopilot driver assistance technology greater emphasis radar apple aapl reportedly have hit brake develop car house have approach mclaren technology group british luxury car maker possible acquisition financial time report new york time report apple have hold talk mclaren investment company mclaren deny report say company be not discussion apple respect potential investment related tesla just make big move be key futureapple talk buy luxury car maker mclaren reportyahoo yhoo disclose confidential information be take least user account late likely state sponsored actor password be steal not payment information yahoo urge user change password security question haven be update unclear affect sale yahoo core operation verizon vz include regulatory legal issue yahoo share fall week twitter twtr share spiked friday report struggle social network be mull putt sale salesforce crm alphabet googl possible buyer facebook fb disclose late thursday give advertiser inflate figure long person watch video year facebook fall move slightly buy point be good week initial public offering most active week year winner be apptio apti cloud provider information technology management tool pop first trading day friday tech winner digital ad company trade desk ttd jump first trading day wednesday low cost cosmetic provider beauty surge trading debut thursday cloud vendor twilio fiber optic company acacia communication acia japanese messaging firm line ln have help boost outlook ipos be forecast shift high gear rest year ipos earlier year have see strong gain twilio twlo hit new high week largest ipo week be valvoline vvv quick lube chain auto lubricant maker raise adobe system adbe late tuesday say earn cent share exclude item year year sale fiscal third quarter end current quarter medium marketing software company expect gaap earning share cent sale top view adobe share rise nearly record high enterprise software provider red hat rht wednesday also beat view earn cent share item sale fiscal end aug give guidance top wall street expectation share rise more shipping giant raise full year ep outlook exclude tnt express related acquisition cost previous guidance slower economic growth prospect say integration dutch company be go smoothly fedex fdx report fiscal ep jump beating estimate revenue climb top view company also reiterate boost shipping rate service fedex share jump nearly gapping day average hit highest level june exist home sale unexpectedly fall second straight month august housing start decline more expect builder sentiment gauge rise year high meanwhile kb home kbh report better expect earning lennar len also top earning order margin fall lennar also buy wci community wcic fed slower rate hike path also be good news housing sector related exist home sale unexpectedly fall august ratebotox maker allergan agn jump tuesday battle nonalcoholic steatohepatitis nash announce plan acquire tobira therapeutic tbra tobira stock shot tuesday later day allergan paid akarna therapeutic nash developer nash avenue allergan compete gilead gild intercept icpt novartis nvs enanta enta also last week allergan announce plan buy vitae pharmaceutical work combat psoriasis eczema autoimmune disorder ophthalmology gene therapist retrosense various opec member hint support output curb ahead informal meeting top opec opec producer algerium week other downplay likelihood decision oil price rise barrel week drop friday energy information administration say wednesday crude stockpile fall barrel barrel month low gasoline inventory fall barrel pioneer natural resource pxd chief executive scott sheffield tell bloomberg oil rig be add permian next year join eog eog diamondback energy fang chevron cvx other bullish texas play france total tot say cut overall investment year related texas shale leader see permian boom french oil major cut backmylan myl ceo heather bresch be lambaste wednesday congressional meeting probe company price tag pack lifesave epipen used allergy treatment bresch argue mylan only profit pack republican democrat alike criticize benefit facto monopoly epipen still mylan stock rise fractionally week well fargo wfc ceo john stumpf become senate panel punch bag tuesday sen elizabeth warren mass urge resign bank cross selling scandal stumpf say learn issue say be deeply sorry sale practice bank say be end retail banking sale goal authority say well employee start least open unauthorized consumer account attempt hit sale target analyst say financial fallout fine regulator investigation intensify appear limit now share rise week drop nearly prior week goldman sachs communacopia medium conference big medium seem unworried cord cut cbs cbs chief moonfe say netflix nflx star trek licensing right deal paid cost cbs new star trek series disney ceo bob iger be already think star war film slate time warner twx st century fox foxa exec wave less well receive summer movie related netflix lose key support subscriber churn concernsnetflix star trek deal help cbs chief moonfe sleep nightdisney already look star war film next decade
257,GILD,share tobira therapeutic tbra multiply more fold tuesday allergan agn agree buy liver drug maker much allergan seek gain late stage experimental drug treat liver disease most anticipate category biotechnology pay share tobira cash accord statement tuesday base number share outstanding allergan also agree pay share tobira hit certain sale regulatory goal even tobira fail hit goal lower price be time close price monday close tobira share have catapult nearly near share share continue climb hour gain nearly recent action allergan end trading day tobira base south san francisco be develop several treatment nonalcoholic steatohepatitis know nash severe type nonalcoholic fatty liver disease hefty premium show important therapy disease have become biotech company gilead science gild intercept pharmaceutical icpt work experimental therapy treat
258,GILD,eli lilly lly pfizer pfe gilead science gild be chip away abbvie abbv humira sale credit suisse analyst vamil divan say monday abbvie miss expectation friday primarily decline humira sale divan downgrade abbvie stock neutral cut price target model humira pull sale decline respectively humira account abbvie sale drug be used treat rheumatoid arthritis psoriasis irritable bowel disorder market brand rival be already market biosimilar be pressure abbvie patent humira abbvie be work protect patent divan expect amgen amgn other have biosimilar market be other year point humira start decline divan write research report cope humira decline miss expectation abbvie have late stage drug capable bring combine sale ibd take abbvie earning have grow average past quarters have also decline last period get full scoop ibd income investor pfizer eli lilly incyte incy gilead be work class drug call jak inhibitor compete arthritis celgene celg novartis nvs eli lilly have il il inhibitor psoriasis expect become blockbuster drug year launch johnson johnson jnj already have jak inhibitor be il field abbvie have own il drug development be enter crowd market have more competitive pricing challenge say divan irritable bowel disorder market celgene mongersen ozanimod put pressure humira sale soon divan write ub analyst marc goodman say pressure abbvie stock be overdo share touch month low friday abbvie report earning fall stock market today abbvie stock fall goodman keep buy rating price target abbvie stock company earning guidance growth imply be lower wall street view still goodman write base management commentary humira volume pricing think concern appear overdo earning next year be little light think investment pipeline drive growth longer term related eli lilly abbvie top ranking pfizer astrazeneca flail
259,GILD,needham co upgrade chipmaker nvidia nvda buy morgan stanley upgrade unite state steel well citigroup potential upside president elect donald trump political agenda pacific crest security upgrade payment processor square sq overweight needham co upgrade nvidia top ibd list growth stock buy price target nvidia stock spiked nearly friday record high crush wall street fiscal third quarter sale earning estimate guide higher current quarter share retreat stock market today related nvidia stock soar record high blowout earning raise guidancenvidia intel battleground set licensing pact sunsetsmorgan stanley upgrade citigroup overweight state street stt equal weight citi price target be also raise bank stock have rally hope incoming trump administration dismantle dodd frank bank regulation morgan stanley downgrade suntrust bank sti bancorp usb underweight share citigroup be monday morgan stanley upgrade steel overweight price target ak steel ak overweight price target trump trade policy be expect benefit domestic steel producer share steel jump close just buy point ak steel leap head profit take territory related steel stock soar trump see fuel annual demand growthsteel dynamic roll steel hint inflection pointpacific crest upgrade payment processor square overweight price target analyst josh beck expect free cash flow grow move believe square more consistently provide positive fundamental surprise beck say report share rise stifel upgrade online takeout grubhub grub buy price target grubhub share have fall reach week high nearly late september share fall friday medium report ceo send letter employee speaking trump supporter monday share rise other analyst move stifel upgrade lockheed martin lmt buy price target stifel initiate sage therapeutic sage buy price target stifel start gilead science gild also buy price target deutsche bank upgrade ciena cien buy ibd telecom fiber optic group be rank industry group several brokerage initiate coverage forterra frta water infrastructure provider go public oct citigroup rbc capital have buy rating goldman sachs deutsche bank credit suisse start coverage neutral ibd take investor keep watchlist top rate stock form bullish pattern market rebound check ibd new feature stock buy zone related apple microsoft citigroup retake buy point market rally
260,GILD,apple aapl microsoft msft cisco system csco other technology company gain president elect donald trump support time repatriation company corporate profit hold overseas idea get enact still republican hold congress trump have propose repatriation tax profit corporate foreign subsidiary statutory top overseas cash holder be apple microsoft google parent alphabet googl cisco oracle orcl trump cash repatriation proposal bring flood money back be available dividend share buyback possibly capital investment say kevin logan hsbc economist research report tax revenue raise be used fund infrastructure spending program something be advocate candidate presidential campaign moody investor service say apple be track have overseas cash end follow microsoft cisco oracle google project top have overseas year end total cash expect most company take advantage hypothetical tax reduction permanently repatriate money maximum extent possible devil be always detail moody analyst richard lane tell ibd email nevertheless hypothetical tax offshore project translate tax revenue be invest efficiency enhance domestic infrastructure investment more important temporary time tax relief however be permanent tax reform provide company clarity make long term capital allocation decision trump have also propose reduce corporate tax rate effort keep company leave country lower rate give republican control be possibility tax relief incent company bring foreign cash back offer opportunity invest buyback stock acquire asset lamba mizuho security analyst say report pritchard citigroup analyst say republican controlled house senate be not likely block cash repatriation proposal republican keep narrow lead senate maintain solid advantage house pritchard say adobe system adbe autodesk adsk citrix system ctxs red hat rht vmware vmw be company bring back cash believe chance increase larger share repurchase lesser chance dividend company pritchard say research report biotechs sizable overseas holding include amgen amgn medtronic mdt gilead science gild say ub research report say other company lot overseas cash include johnson johnson jnj coca cola ko specific depend ultimate legislation expect significant amount overseas cash balance perhaps greater be repatriate used continue repurchase share pay dividend also increase pace growth capex latter have be miss component current cycle ub analyst julian emanuel say report big tech stock oracle be cisco add close stock market today meanwhile apple be fraction alphabet slip microsoft share dip related apple microsoft alphabet king cashdrug stock fly clinton defeat
261,GILD,medical giant johnson johnson jnj beat estimate raise guidance tuesday morning send stock fifth recent record high report earning share year earlier quarter beating analyst consensus cent accord thomson reuter sale rise match consensus say foreign exchange impact knock percentage point sale growth nonetheless forex headwind finally seem be abate cite improve forex outlook reason be raise full year sale guidance also add cent ep guidance now ibd take johnson johnson rate group cr be iffy pharmaceutical business continue deliver impressive level growth have steady improvement consumer business be see momentum medical device business be fuel optimism full year ahead ceo alex gorsky say statement stock be early trading stock market today touch record high intraday stock be more year so far be first medical stock be hit new high be report week other be intuitive surgical isrg evening stryker syk late wednesday morning continue growth momentum company have see recent quarters again deliver organic sale growth acceleration second consecutive quarter double digit ep growth adjust operational basis write leerink analyst danielle antalffy research note note exclude impact foreign exchange activity shrink sale hepatitis drug olysio be make obsolete gilead science gild release harvoni late sale rise operate ep growth be just credit suisse analyst vamil divan write pharma sale beat be drive immunology franchise remicade simponi stelara well stroke prevention treatment xarelto top seller diabetes drug invokana miss consensus investor have be wonder invokana take hit eli lilly lly jardiance last september prove dramatically cut death heart failure didn get sale bump
262,GILD,fda approval process make break biotech pharmaceutical medical device maker stock surprise clinical research organization cro conduct related trial be quite profitable inc research incr be case point raleigh nc base cro have year annual ep growth rate last quarters post
263,GILD,new ibd tech leader index look company technology field be highly rate used ibd proprietary rating current market condition be uptrend pressure name be approach higher caution especially be tie more performance nasdaq composite april list electronic sector stand dominant representation industry group make more list scientific measurement electronic group ibd industry group electronic part manufacturer many stock sector serve support role so part analysis include area exposure company be focuse life science exposure biotech industry biotechs have great run group have fall considerably big winner celgene celg gilead gild top summer company dhr have exposure multiple industry segment serve life science diagnostic vs segment focuse industrial technology petroleum business make analysis little easier complete tax free spinoff third quarter company retain name keep life science exposure new spinoff name fortive take industrial side exposure foreign market bruker brkr not only have strong link life science pharmaceutical research also accord company revenue come outside first quarter earning season have unfold company have often point currency headwind create strong dollar be culprit soft earning
264,GILD,stock remain session lows friday afternoon follow weaker expect consumer spending datum tech stock lead decline nasdaq fall be dow jone industrial average be major average appear head second straight decline volume be run thursday level stock market today commerce department say friday consumer spending edge last month expectation increase ibd stock ellie mae elli come earlier lows not fall more buy point trigger sell signal stock take beating better expect quarterly earning report announce close thursday concrete uscr ibd name drop nearly heavy volume nearly erased gain buy point cup handle base shareholder sell let sizable profit turn loss computer datum stock be worst performer due weak earning report seagate technology stx western digital wdc seagate plunge profit latest quarter dive cent share far wall street expectation sale fall western digital drop quarterly earning report also disappoint investor company be suffering fall demand hard disk drife gilead science gild lead biotech stock lower drop huge volume follow disappointing result stock have slice day day move average week be now week high meanwhile internet stock be biggest gainer amazon com amzn jump blowout earning report stock break past buy point be extend earlier entry
265,GILD,load player clinical trial fda approval process make break biotech pharmaceutical medical device maker stock just ask edward lifescience ew rise nearly april positive trial result sapien family heart valf so much ride success trial surprise clinical
266,GILD,decent case be make investor fear donald trump winning white house turn be good deal reality least intermediate term stock index crash overnight odd december federal reserve hike tumble initial modest sell open major average have reversed solid gain soar bond yield overnight reaction trump look vindicate economist predict market fall trump win once consider trump term priority challenge work congress even gop congress restrain filibuster senate agenda look more market friendly unfriendly priority trump domestic front be likely be rev growth infrastructure spending cut corporate tax rate offer multinational chance repatriate overseas profit lower tax rate talk spending infrastructure double hillary clinton propose spend candidate talk potential public private partnership focus infrastructure basic resource sector be best performer today write alastair george chief strategist edison investment research london nucor nue steel dynamic stld surge stock market today sure respectively share gold miner newmont mining nem initially spiked trump victory fuel safe haven bid dollar plunge stock dollar rebound gold erased big gain newmont trade higher ibd take gold price be rise sharply wednesday give big boost newmont other gold mining stock be technical turn point biotech drug stock such pfizer pfe gilead science gild rally relief hillary clinton not be president senate remain gop hand clinton have vow crack excessive price increase notably older treatment also likely have push government negotiate drug price lower trump victory mean regulatory relief super regional bank dodd frank regulation go step further expect pave way round acquisition also ease pressure too big fail bank explain well fargo wfc pop intraday recover overnight sell well fargo also see less political pressure fradualent account scandal expect positive snapback move once investor digest result factor more favorable regulatory environment financial sector write brian gardner head washington research keefe bruyette wood bank have be rise part due expectation fed hike stronger wage growth tighter labor market fed decide pause hike trump election do send financial shock wave globe far clear expect immediate market pullback fear then pause say brad mcmillan chief investment officer commonwealth financial network mr trump be able reduce uncertainty policy intend pursue be quite possible market recover economic fundamental remain sound trump be likely president obama overtime rule due take effect december guarantee time half pay salaried worker earn twice current level wal mart wmt already raise pay assistant store manager effective september avoid be liable overtime many employer have be slower adopt change congress aim delay carrol restaurant group tast burger king location make restaurant brand international qsr chain largest franchisee have say ll effectively demote manager make punch clock obamacare employer mandate be likely history meaning modest wage employer longer be fine fail offer health insurance worker clocking least hour week retailer trump bring relief restaurant chain mcdonald mcd be be squeeze competition compensation hike contribute record gap cost fast food eating be market scared trump threat impose tariff company ford motor send car mexico walk away nafta crack unauthorized immigrant be economist have say agenda hurt economy trump be start presidency labele china currency manipulator impose tariff start trade war china reciprocate target sale apple aapl general motor gm microsoft msft china face slower growth unsustainable build debt easily spark bout financial market turmoil be see past january trump proceed trade be most important early decision good news be trump isn campaigning anymore be especially insular campaign surround pro growth economic advisor now direct contact top business leader trump be likely act deliberately not rashly mean open talk country move trade relation forward set intermediate term goal measure progress seem consistent trump victory speech word want tell world community always put america interest first deal fairly everyone everyone person other nation seek common ground not hostility partnership not conflict trump seem unlikely back pledge build wall border mexico have more symbolic economic effect rhetoric have shift crack unauthorized immigrant be violent criminal be fewer imply related drug stock rally relief clinton didn white housetrump win fed hike still treasury yield bank stock soarat time warner fall trump victory be merger doubt overtime rule fallout fast food manager tell punch clockfbi reveal more evidence stock fall trump win
267,GILD,ariad pharmaceutical aria stock be feel mylan pharmaceutical myl pressure monday congress loom deadline submit information regard price increase rare cancer drug past year ariad up price inclusig annually rbc analyst michael yee write research report inclusig treat specific class chronic myeloid leukemia acute lymphoblastic leukemia ariad sell milligram mg bottle lion share patient be mg dose yee write latter have buy mg bottle thus pay double price yee doesn see much stem congress pressure recently mylan agree make generic less costly version epipen device treat anaphylaxis emergency allergic reaction hike device cost ibd take biotech earning season be full swing merck eli lilly vertex edward lifescience slate tuesday ibd recently look biotech giant top expectation medivation mdvn be be acquire pfizer pfe feel congressional heat earlier year price tag prostate cancer drug later get letter sen bernie sander gilead science gild come hot water earlier year hike price drug congressional request information didn result much yee write reasonably likely congressional inquiry blow time yee say ariad have nov deliver information price hike include spending sale distribution tactic ariad have argue inclusig isn mylan epipen other ariad have year history financial loss unprofitability far higher spend revenue historical spending internally develop commercialize inclusig yee write orphan drug tend be more costly standpoint yee keep sector perform rating ariad stock jpmorgan downgrade share neutral underweight close bell stock market today ariad fall nearly month low ariad be so far month
268,GILD,gilead science gild nonalcoholic steatohepatitis nash drug be clearly active promising intercept pharmaceutical icpt remain year ahead rbc analyst michael yee say gilead biotech market cap unveil promising efficacy datum gilead selonsertib aim inhibit apoptosis signal regulate kinase protein tie nash diabetic kidney disease pulmonary arterial hypertension patient enrolled gilead week phase study show least improvement fibrosis company say jibe result intercept earlier nash study patient have positive response vs placebo track yee write tobira therapeutic tbra be be acquire allergan agn also be active nash market recent study see improvement fibrosis used tobira drug intercept have healthy lead gilead tobira allergan yee say be vie nash market worth potential intercept see key datum rival likely have say competitive landscape be not shocking be nash drug be start show promise move late stage yee write intercept be still year ahead have datum thursday news do little gilead stock friday stock market today gilead fall cent share be year ibd company medical biom biotech industry group have fall ibd take gilead be tap report earning nov biotechs be deck next week include biogen celgene amgen check investing action plan potential mover next week earning season kick earnest related allergan challenge intercept tobira nash drugwhich biotechs set big boost drug trial result gilead allergan see trail intercept nash battle
269,GILD,be etf investor fret day whole lot mostly stubborn fact be few bargain be have broad stock market broad fix income market have be confront almost client conversation have story soar high valuation say martin small head ishare exchange trade fund blackrock nothing be cheap etf investor borrow popular dog dow strategy find value investment tell ibd phone interview dog theory recommend investing annually highest yielding company blue chip index think be dog be oversold likely rebound price research show strategy outperform overall stock market long term have inspire several etfs include alp sector dividend dog sdog small believe investor be reward similar different approach used etfs take advantage granular exposure specific region industry etfs offer goal be find dog etfs have sell irrationally offer value relative market be process involve used ishare etfs example screen list fund used price return rather dividend yield traditional dog strategy dog base fund do poorest performer include fund be cheap oversold offer attractive opportunity small suggest investor evaluate performance fund shorter term year date example longer period year example here investor learn look current ishare etf dog worst perform ishare etfs year date show broad area have be beaten foreign develop market health care nasdaq biotechnology ibb crumble nov ishare msci europe financial eufn same period ishare core ivv track broad stock market advanced small ibb seem oversold sector favorable intellectual property strong sale fund stock holding include celgene celg gilead science gild biogen biib negative trend coincide scrutiny drug pricing ahead nov presidential election mean rally be store drugmaker political risk abate case eufn turnaround be likely depend monetary policy have desire effect have asset brexit continue cause uncertainty italy embroil bank loan trouble important look long fund decline well fast deep decline be factor such magnitude speed decline be additional piece information help round story decide be opportunity want tap small say idea type analysis be decide etf loser be unduly punish well revert be more attractive normal incredibly sell investment return very quickly mean other take very long period time small say add value investing often require patience suggest value investor not only ask much be dog also think long take get dog trained put etf dog opportunistic sleeve portfolio carve apart core holding higher growth investment extent need take higher risk best do strategy do type value seek small say other word do be hard most fund investor buy low sell high opposite buy high sell higher strategy slim investor know love value dog etfs approach be require investor understand underlie driver portfolio holding say todd rosenbluth director fund research cfra basically make investor buy etf look forward not backward consider past performance be limit value predict future performance etf investing not chase winner not discard loser understand etfs have perform way have say etf perform well be not relevant continue rise index base etf merely reflect performance market target case active mutual fund index fund manager have control stock portfolio related dog etf hit record high dividend portfolio
270,GILD,stock backed mixed trade increase loss early friday weak economic news earning report place pressure morning trade dow drop apiece nasdaq slip small cap fall slightly faster pace russell show decline volume rise stock market today gain nyse nasdaq vs trade same time thursday economic news open forecast growth personal spending price march personal income outpaced projection midwest manufacturing slow kingsbury international report april chicago purchasing manager index month march far weaker tally expect analyst consumer view also dim april accord university michigan put consumer sentiment index month march disappointing forecast increase more dow stock moved lower open cisco system csco intel intc be only drop more exxon mobil xom lead rise report mixed first quarter result tech stock soar quarterly report be market focal point early trade amazon com amzn soar expedia expe leap linkedin lnkd advanced get detailed chart analysis amazon com subscribe ibd leaderboard feature oil energy stock be pound strong gain hold many top slot oil price advanced almost ahead weekly rig count report baker hughe bhi due et earning news also energize broader segment market houseware leader newell brand nwl gap gain first quarter revenue earning top projection management lift guidance consensus view heavy volume gain hoist share buy point first stage cup handle base pharmaceutical stock ireland shire shpg pop powerful volume strong report stock be work sixth straight weekly advance gilead science gild dive earning revenue miss first quarter expectation loss put share nearly week kill attempt build right side month consolidation medical waste collection specialist stericycle srcl crumble loss analyst downgrade follow thursday earning miss loss set stock back level hard drive maker western digital wdc seagate technology stx post deep decline report fiscal result seagate unraveled earning fall far short consensus projection revenue just meet previously lower guidance global maintain hold rating stock lower price target western drop earning revenue stop short analyst projection robert baird downgrade stock neutral outperform lower price target ibd stock nearly list moved lower start trade stamp com stmp be few exception rise strong trade take back small piece thursday tumble downside ellie mae elli pare initial dive appear be solid report earning revenue top analyst consensus view management give upbeat view company performance outlook raise guidance projection stephen co downgrade stock equal weight overweight follow report loss put ellie share day move average very heavy trade
271,GILD,biotech regeneron pharmaceutical regn core ophthalmology business still have huge upside eylea sale grow treat variety eye disease say rbc capital rbc also say legal settlement amgen amgn praluent drug intend lower bad ldl cholesterol be positive most regeneron sale come eylea launch treat age related vision loss elderly regeneron aim build sale eylea market treat diabetic macular edema dme cause blindness work age person well related eye disease affect older person turn dme market opportunity be important likely adnan butt rbc capital analyst say research report tuesday dme eylea compete roche hold rhhby lucentis regeneron typically report earning early roche novartis nvs bayer bayry report earning april respectively commentary provide insight eylea growth say rbc butt say consensus expectation recently launch cholesterol drug praluent have only december quarter sale still need come amgen make rival drug call repatha march federal jury upheld validity amgen patent related cholesterol drug deal blow regeneron partner sanofi sny settlement amgen be positive butt say report rate regeneron stock outperform price target regeneron stock be more early afternoon trading stock market today amgen report earning april follow sanofi april earning call provide read status praluent litigation say butt regeneron stock have plunge broad sell biotech stock include celgene celg gilead science gild regeneron share touch month low last month jump april company announce strong phase clinical result dupilumab drug eczema itchy skin condition regeneron be develop drug sanofi landmark deal sanofi provide year fund antibody discovery year give regeneron profit defer development cost partnership be profitable add butt startup intellium therapeutic late monday announce licensing deal regeneron cambridge mass base intellium have develop gene editing technology treat liver blood disease plan go public regeneron have ibd composite rating possible lower celgene gilead ibd medical biom biotech group rank just industry group month past week best span therapeutic anik supernus pharmaceutical supn ligand pharmaceutical lgnd have highest ibd composite rating biotech group
272,GILD,big biotech gilead science gild add fatty liver disease portfolio monday acquire line biotech drug deal potentially worth gilead acquire nimbus therapeutic nimbus apollo division upfront milestone nimbus drug successfully make development process deal seem spark share drugmaker target nonalcoholic steatohepatitis intercept pharmaceutical icpt nimbus apollo have pipeline acetyl coa carboxylase acc inhibitor most advanced be ndi nonalcoholic steatohepatitis nash common currently untreatable condition cause liver damage fat buildup phase trial result ndi be due be present couple week annual international liver congress nash be see analyst potentially enormous untapped market gilead have be compile portfolio drug space build liver disease infrastructure create sell massively successful hepatitis drug january company buy phenex pharmaceutical program target different receptor top house development simtuzumab be midstage testing nash molecule complement further strengthen gilead pipeline capability advance broad clinical program nash include compound target multiple key pathway involved pathogenesis disease gilead chief scientific officer norbert bischofberger say statement monday credit suisse analyst alethia young write gilead probably expect nash ultimately be treat combination therapy acc approach have bit checker past however be target have be try big pharm have fail due bound site difficulty make drug able target young write research note young also write be not surprised gilead choose buy nimbus apollo instead intercept have be generally see lead contender nash drug candidate obeticholic acid oca intercept have be bandy buyout target gilead other player liver disease analyst say unlikely anyone buy oca be approve certainly not thursday fda advisory committee meeting oca intercept stock be nonetheless strong volume early afternoon trading stock market today gilead stock be nearly
273,GILD,stock kick week decent gain monday be lackluster week trading ahead long labor day weekend friday job report stir excitement dow rise picked nasdaq composite add tesla tsla netease nte large cap biotechs gilead gild alexion ticker
274,GILD,pfizer pfe announce deal monday morning buy medivation mdvn share enterprise value move follow month takeover speculation cancer drugmaker well widespread report sunday imminent pfizer medivation deal medivation rise nearly soon open bell stock market today pfizer fall cent propose acquisition medivation be expect immediately accelerate revenue growth drive overall earning growth potential pfizer pfizer ceo chairman ian read say statement pfizer say deal boost earning share cent first year close additional gain medivation close friday market valuation be slightly extend buy point flat base medivation trade low feb be subject widespread buzz possible buyout biotech earlier year reject share offer france sanofi sny last week report have pfizer merck mrk gilead science gild celgene celg sanofi possible medivation buyer ibd take biotechs deliver great growth be generate profit revenue gain higher sale volume price increase here hunt biotech stock medivation make xtandi prostate cancer drug annual sale rate already have other cancer fighter development pfizer attempt buy allergan agn fall apart earlier year obama administration change rule make tax inversion merger deal less attractive related medivation affirm guidance earning growth make case leadership be convince
275,GILD,big pharma merck mrk be now look possible buyout medivation mdvn accord anonymously source report reuter report wednesday afternoon merck be big pharmas have submit indication interest buy medivation other be sanofi sny pfizer pfe celgene celg gilead science gild sanofi have be very public attempt acquire medivation last month medivation say have enter confidentiality agreement sanofi well other unnamed potential buyer earlier anonymously source report say pfizer celgene gilead be interested buyer have be speculation merck be interested bmo capital research note assert merck be prepare medium size buyout medivation be target merck have be focuse much energy cancer lately medivation have fast grow drug market treat prostate cancer other cancer therapy development medivation stock have be trading flat stock market today pop week high news come close merck rise ibd take medivation be ibd stock last earning report year year profit growth flattened deliver big hit ep rating analyst expect growth pick again start however
276,GILD,gilead science gild be fall sharply tuesday big biotech report weaker hepatitis drug sale lower guidance late monday trigger downgrade several price target cut wall street management lower revenue guidance cite challenge hcv hepatitis include fewer patient start shorter treatment duration contribute decline revenue patient write needham analyst alan carr cut stock hold buy expect trend continue add however gilead regain favor internal acquire pipeline show growth potential area such hepatitis liver disease cancer piper jaffray analyst joshua schimmer lower price target gilead stock maintain overweight rating admit pipeline be overly speculative need new direction also say clinical trial datum come next month confirm more bullish view credit suisse analyst alethia young cut price target bmo capital market ian somaiya estimate have be consensus actually raise price target dollar maintain hold rating gilead share fall stock market today day move average ibd take gilead previously torrid growth turn negative quarter guidance suggest continue rest year ibd slim investing system prefer stock current quarterly annual growth least
277,GILD,big biotech gilead science gild get price target cut investment bank leerink wednesday company cancel clinical trial cancer drug zydelig due safety problem european medicine agency ema say last friday be look report serious adverse event include death gilead trial zydelig various form blood cancer later food drug administration say be do same monday issue notice say gilead have agree suspend trial patient chronic lymphocytic leukemia cll small lymphocytic lymphoma sll indolent hodgkin lymphomas nhls zydelig first launch july be now approve relapse cll third line treatment cell nhl sll fda be review finding clinical trial communicate new information necessary agency say statement gilead also say suspend trial zydelig front line treatment cancer wednesday leerink analyst geoffrey porge slash peak annual sale estimate drug estimate shave ep period therefore cut price target maintain outperform rating gilead stock accretive revenue oncology account small portion gilead total revenue consist antiviral porge write have never be convince oncology become major franchise company give recent event maintain outlook gilead stock be early trading stock market today more year sport lowest possible ibd accumulation distribution rating
278,GILD,innovation abound health care sector shortage high quality name help customer operate more efficiently count small cap cambrex cbm life science firm help large pharmaceutical biotech firm develop process manufacture clinical commercial quantity drug cambrex specialize active pharmaceutical ingredient apis go pharmaceutical product company have
279,GILD,drug stock have long be favore income investor relatively steady dividend payout merck mrk currently pay quarterly dividend share full year work annualize yield nearly well average payout new jersey base company have paid dividend quarter long term dividend growth rate be drug giant thursday announce positive result comparative trial zepatier hepatitis drug gilead science gild sovaldi wednesday merck say fda accept review supplement biologic license application keytruda treat patient recurrent metastatic head neck cancer also say fda grant priority review aug merck full year profit grow last year best year analyst expect gain year next share be work right side month consolidation be week high johnson johnson jnj product include blood cancer drug imbruvica prostate cancer drug zytiga offer annualize yield analyst forecast ep rise share higher sale report tuesday open stock be top buy range cup handle buy point clear feb amgen amgn know drug such neupogen epogen pay annual dividend have year earning growth rate analyst expect increase year next share biotech be near buy point cup shape base neither amgen johnson johnson show dividend leader friday ibd due space limitation
280,GILD,big biotech gilead science gild hit month high monday analyst deliver bullish outlook company sunday rbc capital market analyst michael yee lift ep estimate due stock buyback note several recent piece incremental good news cite late friday successful patent suit merck mrk ionis
281,GILD,election year have add pressure hit biotechnology stock hard look hood sibling biotech etfs be reveal show more speculative company extremely heterogeneous industry cause much hurt bioshare biotechnology product bbp be year date oct invest establish company have bring least drug market stock holding exchange trade fund include biogen biib amgen amgn celgene celg gilead science gild regeneron regn ibd take largest cap weight biotech etfs stand benefit most top company climb wall worry have build industry bioshare biotechnology clinical trial bbc be so far invest young smaller company drug be experimental testing stage portfolio include sarepta therapeutic srpt share rocket september fda approve drug treat duchenne muscular dystrophy approval mean sarepta move bbp portfolio bioshare etfs next rebalance december etf pair allow investor decide much mix term combine more risky less risky biotechs say paul yook founder bioshare bbp focus household name make relatively less volatile fund contrast bbc hold riskiest biotechs highflying company share double triple overnight crash burn just well yook describe bbp bbc only exchange trade fund separate clinical trial company product company distinct stand alone investment investor don seem much enamored idea custom tailor risk fund be extremely small thinly trade nearly year debut have however see combine net inflow first quarters bbp fund be best performer biotech etfs so far year bbc worst meanwhile bellwether ishare nasdaq biotechnology ibb have give year date sit december high biotechnology etfs crumble past year come pressure lackluster earning well negative scrutiny health care peer valeant pharmaceutical vrx mylan myl politically charge season wall worry industry group least analyst have favorable outlook biotechs nov presidential election yook point promising sign pickup mouthwater sticker price target company allergan agn announce september acquire vitae pharmaceutical vtae roughly premium share biotechs be attractively price too be rare corner stock market valuation be cheaper have be historically yook tell ibd phone interview many etf investor be wait buy biotechnology stock november election believe fear hillary clinton presidency be price democratic presidential contender remark drug price gouge have trigger sharp biotech decline yook add most political scrutiny be face specialty pharmaceutical company such valeant mylan horizon hznp bioshare fund avoid related top biotechs climb wall worry rbc call rally
282,GILD,celgene celg biotech market cap rival johnson johnson jnj galapago glp gilead science gild biogen biib crohn disease drug top efficacy expectation company say sunday prompt boost share monday stock market today celgene stock lift briefly slip month low share be year rbc analyst michael yee say politic be tamp biotech stock ibd take biotechs be worst perform group last wednesday supernus pharmaceutical prothena stock topple keep tab industry theme best stock bet yee be bullish ged celgene drug combat crohn recent study patient ged show improvement cdai crohn disease activity index se cd simple endoscopic score crohn disease wall street eye be more tune latter week trial patient show least reduction se cs be clinically meaningful endoscopic improvement say yee cdai metric show response be remission week be good higher expect doctor expert say datum patient achieve be good particularly convenient oral drug yee write research report monday gilead galapago filgotinib be phase testing phase didn look se cd endpoint so be compare celgene ged yee write stelara show same improvement patient week study include placebo biogen also have mt drug treat inflammatory bowel disorder go phase testing crohn well ulcerative colitis be major category inflammatory bowel disorder yee model ged add sale time celgene world move pill treat crohn stelara be injection believe celgene promising early endoscopic improvement get better time ged be otezla crohn disease meaning even not most potent drug still be drug celgene well tolerate good safety convenient good efficacy write credit suisse analyst alethia young model peak sale ged have price target outperform rating celgene stock next catalyst celgene stock likely be firm present week datum young say provide important clue sustainability mucosal heal write research report see effect early be positive have suggest mucosal heal be therapeutic endpoint testing crohn drug mucosal heal endoscopic remission be associate increase rate clinical remission accord national library medicine related celgene biotechs top wall worry trio new celegene drug bring
283,GILD,presidential election race narrow friday surprise fbi announcement stock investor be finally show jitter hedge market decline surge immediately follow report federal bureau investigation be review file be related investigation hillary clinton email practice be secretary state ratio bearish vs bullish option
284,GILD,growth stock fund have outperformed blend value counterpart past year reverse be true year average value fund nearly average blend fund nearly average growth fund growth fund have keep pace value fund year be parnassus endeavor fund parwx large cap growth fund be year recent top holding include apply material amat year qualcomm qcom micron technology mu holding haven do well include gilead science gild year generic drug maker perrigo prgo fund have be manage jerome dodson fund seek buy high quality company hold long term seek keep company portfolio give significant weighting most have turnover rate parnassus endeavor have environmental social governance esg component holding offer outstanding workplace not be involved oil other fossil fuel fund commentary written early october dodson say market look fairly value decline number attractive stock help explain cash fund have build way average stock fund also way goal cash put cash work win invest just sake reduce cash position say have be good idea inspire investment mean good company trading very attractive price strategy have serve well year evidence strong return so not tempt change policy lower fund standard just reduce cash balance strong inflow fund investor attract strong performance have contribute cash build dodson encourage investor stay course keep investment come point ll figure do money say dodson profess lack deep concern likely path interest rate immediate reaction interest rate increase probably be drop stock market longer term gradual reasonable increase rate probably not depress market very long say commentary rise interest rate usually mean economy be do better so corporation be do better stock find way move higher continue interest rate move higher late year early next year initial reaction be stock market swoon happen stock go more attractive valuation provide opportunity put idle cash work related parnassus dodson win hot tech stock pass esg be fidelity trend like apple amazon alphabetwhy top columbia fund like stock leaderschinese other foreign stock drive top mutual fund performance
285,GILD,warren buffett berkshire hathaway brkb significantly raise stake apple aapl other big institutional investor slash exit position iphone maker well netflix nflx berkshire hathaway hold apple share june end company say sec filing berkshire also cut stake wal mart wmt deere apple share fall second quarter drop point lowest level late stock have rebound nearly so far apple climb close stock market today share rise fractionally late trade meanwhile george soro soro fund management liquidate stake apple netflix gilead science gild gap gps unite airline ual tiger global management cut apple stake exit netflix david einhorn greenlight also reduce apple stake netflix close news tiger liquidation netflix share be trading day line day average wal mart gap unite air be little change late trade ibd take buffett be successful value investor individual investor look stock be proper buy point move new high facebook other big cap tech stock remain buy range recent breakout click here find facebook other act related apple ipad plan include radical revolutionary change
286,GILD,big biotech gilead science gild beat earning estimate lower full year revenue guidance late monday send stock more hour trading gilead sale earning decline last year hepatitis drug sovaldi outperformed expectation newer cousin harvoni come short epclusa next generation hcv pill be approve just day end quarter already bring gilead price epclusa much lower previous drug reflect new competition abbvie abbv merck mrk sovaldi harvoni officially retain higher price tag gilead have be rebate heavily say monday rebate have continue increase hiv franchise be also mixed bag perennially popular truvada beating estimate most other drug underperform company trim full year product sale guidance now also lower guidance sale general administrative expense raise research development guidance slightly leave overall cost look more less same gilead do not provide ep guidance lower sale suggest possible margin squeeze gilead stock rise monday regular session share be year
287,GILD,week top insider sale be lead chief executive amazon amzn northrop grumman noc gilead science gild meanwhile top brass southwest airline luv delta air line dal purchase share industry recent sell bank america bac also get action ahead friday bullish job report chief executive jeff bezos disclose thursday sale share total transaction value week company view top second quarter earning report bezos also shed share week amazon first quarter report commerce giant have be big run gain breaking cup handle base shortly first quarter earning report april amazon share finished friday just time high set monday ibd take amazon earn high ibd composite rating base top notch fundamental technical factor include earning sale growth profit margin return equity relative price performance detail take look ibd stock checkup defense contractor ceo wesley bush disclose friday sale share transaction value northrop report estimate beating quarterly result last week drop technology service sale impact profit margin weigh share still stock have be able find support day line end friday trading penny ahead buy point northrop be also trading just recent high ceo john milligan monday disclose sale option exercise share last week gilead gap breach day move average report first quarterly sale earning decline year biotech share be now trading more week high end friday southwest executive grab more share week ceo gary kelly disclose wednesday purchase share little director william cunningham buy share little evp coo michael van ven buy share southwest jump friday look rebound nearly month low hit tuesday broad sell consumer stock well drop airline peer spark european travel fear delta be hit especially hard tuesday report dive july unit revenue director george mattson take opportunity buy share cheap disclose thursday purchase share nearly stock recent attempt retake downward slope day line have be meet resistance share rebound friday climb close stock be still trading nearly week high director thomas wood disclose wednesday share purchase totale bank america banking peer rally friday strong july job report increase chance fed rate hike potentially boost lender net interest margin share gap early retake day line first time end friday trading stock be trading week peak insider transaction don typically have major impact stock indicate major pending news rapid liquidation most insider holding however affect stock
288,GILD,biotech stock haven be fainthearted last month hope comeback have noticed re move again ibd biomedical biotech industry group be most improve last week rise ibd ranking industry group certainly fact earning season have so far be good especially compare lower expectation start year big cap biogen biib celgene celg amgen amgn have already beaten expectation raise guidance alexion pharmaceutical alxn affirm guidance still rise good quarter more make gilead science gild guidance cut biogen be also boost monday unexpected good news drug development front biogen stock be close stock market today month high biomedical biotech group finished day nearly month high still be larger factor work weekend rbc capital market analyst michael yee release video theorizing political fear lead last year crash spark presidential candidate hillary clinton tweet threat do something high drug price have largely be price stock now help republican democratic presidential convention have go barely word say drug pricing so investor be think win be such big deal yee add yee also note medical device stock have be perform well year unusual huge gap device drug stock be sustain indeed medical product group rank have moved round good earning report last week ibd take abiom be medical product earning beater week trading record high be buy zone sport coveted spot ibd swing trader identify stock fundamental technical product short term gain leerink analyst geoffrey porge also note gap biotech device valuation detailed analysis last week compare medtech pharma biotech be trading discount growth adjust basis price growth biotech be price other medical product sector porge write report growth outlook large cap biotech ex gilead be better pharma better medtech biotech stock trade only marginally greater multiple pharma stock porge say be parallel recent panic december biotech stock decline few week investor worry growth not be sustain december growth expectation have fall porge write however sector aggregate net income grow year year also note sector grow net income future growth expectation have steadily decline june year year believe downward estimate revision be not fully drive fundamental include political fear currency effect expect growth recover back half impact pricing power volume demand be realize profit growth still worth note ve be here monday collective value biotech group be hover have be something ceiling year group bump twice april again early june head south again
289,GILD,big biotech gilead science gild hit month high monday analyst deliver bullish outlook company sunday rbc capital market analyst michael yee lift ep estimate due stock buyback note several recent piece incremental good news cite late friday successful patent suit bring merck mrk ionis pharmaceutical ion have result somewhat lower damage award wall street have expect also note weekly prescription datum im health im suggest gilead hepatitis drug sovaldi harvoni be hold reasonably well face competition merck zepatier launch late january point be make more emphatically monday research note leerink analyst geoffrey porge call merck pretender hcv hepatitis virus throne porge note survey top payer plan backed week launch zepatier sovaldi harvoni retain relatively favorable position top largest commercial plan top largest government plan relative abbvie abbv viekira pak respectively zepatier porge write further top medicare plan harvoni be cover plan plan do not cover viekira pak none cover zepatier porge affirm outperform rating gilead stock price target midday trading stock market today gilead stock be more earlier rise stock have climb month low hit feb still have weak ibd relative strength rating meaning stock perform lowest stock past month emphasis most recent month merck stock be fraction midday monday
290,GILD,biotech stock virtually stripe color moved higher monday rise group quiet market action be moment slim drive investor make move beaten group study chart action top name term fundamental trading liquidity market cap produce quick answer
291,GILD,big biotechs gilead science gild biogen biib fall wednesday receive unfavorable patent news late tuesday ionis pharmaceutical ion say big pharma partner merck mrk have win case allege gilead hepatitis virus hcv drug sofosbuvir be sell individually sovaldi ingredient harvoni infringe patent ionis merck have obtain earlier research used expertise collaboration merck develop modify nucleoside benefit patient hcv say ionis ceo stanley crooke press release case go back sofosbuvir be verge fda approval merck seek royalty sale gilead gilead seek judgment invalidate patent concede have infringe case go jury rule tuesday patent be fact valid be word damage ionis say entitle damage leerink analyst geoffrey porge say award win be huge more litigate delay continue expect damage award case be relatively modest equivalent single digit royalty significantly less merck be seek porge write research note spite damage jury award merck gilead have already indicated appeal ionis stock pop week high early stock market today end session share have fall gilead stock fall merck be flat biogen stock meanwhile fall patent trademark office uspto reversed earlier decision decide review patent biogen top selling drug tecfidera hedge fund manager kyle bass file request review last year launch unusual short selling strategy filing such request number blockbuster drug say have bs patent uspto initially deny request september tuesday change tune coincidentally not european union authority earlier month invalidate european equivalent same patent expire addition forward pharma fwp be separately challenge patent stock rise wednesday today decision be just first step review process nothing happen yet usa today tecfidera still enjoy year exclusivity eu protect eu write rbc capital market analyst michael yee research note even patent expire february consensus do not assume get full protection already assume expect generic launch point
292,GILD,ibd company medical biom biotech industry group drop past week rbc analyst michael yee expect stock rally lackluster earning election season wrapped sector still have nearly week choppiness nov election recent blowout have have investor take profit yee suggest recent video buy dip biotechs climb wall worry earning not be hugely great biotechs combination uncertainty election understand trade choppy spdr biotech etf xbi get clarity election say ibd take biotechs be worst perform group wednesday ibd track group last month biotechs be major roll keep tab industry theme sector grab attention company group share spdr biotech etf have plunge dramatically month past week thursday share be flat entry point flat base biggest biotech player yee be most confident amgen amgn biogen biib respectively no market cap stock market today amgen biogen rise fraction respectively consensus analyst poll thomson reuter expect amgen report sale earning share ex item flat respectively vs year earlier quarter analyst model biogen report sale ep ex item biogen be stock own next month yee say chance biogen get take still lack ceo company announce july rumor george scango step yee also see chance eli lilly lly alzheimer drug trial yield positive result tug rival biogen other catalyst include biogen partnership ionis pharmaceutical ion drug treat type muscular dystrophy spinal muscular atrophy sma ionis be enrolling infant child phase trial sma wall street underappreciate catalyst yee say celgene celg too have number trial stoke stock yee say analyst model jump sale ep ex item celgene share be rise small fraction thursday yee only expect line quarter early next year celgene be expect release result trial drug treat muscular dystrophy crohn disease ulcerative colitis be likely stock catalyst gilead gild biotech market cap be rough quarter shadowy visibility hepatitis drug yee say drug epclusa win fda approval june be used pill form treat type hep lack greater visibility gilead stock be range bound yee say consensus expectation be too high hep sale ep write research report consensus analyst poll thomson reuter model ep ex item yee estimate be broadly analyst be bearish gilead forecasting sale dip ep item share be past week end thursday flat smaller intercept pharmaceutical icpt market cap likely print board beat yee predict share have be pressured recently gilead novartis nvs allergan agn be jump nash alcoholic steatohepatitis train nash drug have make big headline past month allergan buy tobira therapeutic tbra bulk nash battle say yee intercept drug belong class call fxr agonist be more potent intercept drug get liver activate fxr farnesoid receptor liver say other don get much fxr effectivity liver just do gut not potent intercept yee also call prothena prta own likely positive parkinson drug psoriasis drug datum spring respectively prothena stock be sell zone thursday entry point achieve rise nearly thursday related gilead try buy next poll offer incyte prothena build psoriasis science arthritis treatmentincyte stoke fire deep durable melanoma drug result
293,GILD,biotech stock drag overall flat stock market wednesday supernus pharmaceutical supn prothena prta worst performer larger biotechnology company ibd company medical biom biotech group be last group track fall stock market today pierce key day move average support line first time early july group still rank just week ibd take sector be volatile just last month biotech be riser want get feel top group then keep tab ibd depth industry snapshot feature major news event shake sector instead stock be react ever shift political wind rbc capital market analyst michael yee tell ibd email yee say sentiment be rise republican party lose majority senate even house say have big impact number health care bill issue such high drug price continue roil industry ibd medical generic drug group company be fourth worst performer wednesday come right day line wednesday prothena ultragenyx pharmaceutical rare acceleron xlrn fibrogen fgen be larger biotechs fall day line first time least month supernus fall day line tuesday release seemingly solid datum trial adhd drug ishare nasdaq biotechnology ibb etf largest biotech etf fall wednesday be nearly week acceleron stock crash wednesday ultragenyx supernus prothena fibrogen juno therapeutic juno tumble gilead science gild largest biotechs fall touch month low fourth day past trading day related supernus reverse downward good adhd drug trial allergan challenge intercept nashmylan jump doj settlement ease linger concern
294,GILD,allergan agn be take gilead science gild intercept pharmaceutical icpt acquisition tobira therapeutic tbra mizuho analyst irina koffler like deal say key tobira drug have solid chance approval tobira cenicriviroc cvc drug battle nonalcoholic steatohepatitis fail meet primary endpoint year study end july drug however do show efficacy improve fibrosis worsening nash regulatory endpoint nash drug continue change koffler write research report last year fda outlined surrogate endpoint improvement fibrosis worsening nash complete resolution steatohepatitis worsening fibrosis genfit intercept be used surrogate endpoint interim analysis week allergan follow path tobira acquisition be final expect late year likely cvc get fda nod koffler write koffler trim price target tuesday allergan stock base expense expect buyback allergan have be buy spree recently agree acquire vitae pharmaceutical akarna pharmaceutical addition tobira midday trading stock market today allergan stock fall close continue trade day line koffler expect sweeping beat allergan report earning date hasn yet be schedule koffler predict sale vs earning share ex item analyst consensus model sale ep ex item accord thomson reuter koffler keep buy rating allergan stock also lower sale expectation restasis allergan dry eye drug follow impressive launch rival shire shpg xiidra see sale vs earlier call also give viberzi forecast haircut ibd take allergan isn only drugmaker battle rival bristol myer squibb stock topple year low monday positive phase trial news competitor merck get more industry theme related unexpected twist pfizer scraps breakup follow dead allergan mergeramgen biogen pit scenario acadium draw interestgilead allergan see trail intercept ongoing nash battle
295,GILD,incyte incy be prime candidate rbc analyst simo simeonidis say friday drugmaker reveal deep durable result med aim treat advanced metastatic melanoma view incyte throwback biotech company be originally meant be simeonidis write research report company build great science manage develop multiple drug reinvest heavily own engine doesn offer guess company take crack buy incyte poll evercore isi investment bank last month identify gilead gild likely buyer incyte early friday incyte reveal result epacadostat combination merck mrk pembrolizumab combination face bristol myer squibb bmy nivolumab opdivo combination ipilimumab yervoy incyte merck didn reach progression free survival pfs month follow march datum cutoff bms opdivo combination have median pfs month simeonidis write increase confidence combination epacadostat pembrolizumab end median pfs be superior nivolumab ipilimumab combination write simeonidis also note patient receive combination drug incyte merck respond treatment have outperform rating incyte stock rise stock market today incyte break buy point so be buy range caution be advise volatile time market merck stock rise friday ibd take isn first time incyte have appear analyst hot list check sector leader more related small midcap biotechs get thumb goldman sachs
296,GILD,several big cap drugmaker report solid earning thursday morning continue be fairly positive earning season medical industry celgene celg end trading stock market today narrowly beat analyst estimate top bottom line raise full year guidance notably raise sale guidance lead drug revlimid even blood cancer treatment narrowly miss analyst estimate quarter most celgene other drug more make difference celgene expect roughly sale growth earning growth year line growth rate last year celgene stock take modest hit tuesday company decide not pursue label expansion revlimid follow mixed trial result lymphoma bounce back quickly be nearly thursday afternoon bristol myer squibb bmy also deliver modest beat raise stock fall be much quarterly beat come hepatitis drug daklinza be threaten obsolescence now gilead science gild have release pan genotypic hep pill epclusa daklinza be used treat minority genotype usually combination gilead sovaldi also outperformed sale bristol myer fast grow cancer drug opdivo slightly beat expectation worldwide rise sevenfold year earlier quarter be bit light yervoy bristol be hope combine opdivo make standard care lung cancer be also bit short expectation bristol myer stock finished regular session ibd take bristol myer earning growth wasn much expect accelerate company be guide growth full year positive sign ibd slim system look least annual earning growth preferably accelerate rare disease biotech alexion pharmaceutical alxn close thursday trade fractionally even profit technically miss consensus be apparently due sec recent change gaap report requirement gaap ep miss be due modification definition gaap income tax result cent share reduction write rbc capital market analyst simo simeonidis research note importantly adjustment have impact amount income tax company pay cash flow cent add back alexion have beat consensus still have be slight year year decline company have invest new drug launch however revenue rise top wall street number alexion affirm previous full year guidance
297,GILD,amazon com amzn google parent alphabet googl win several price target hike friday strong quarterly result ford gilead science gild be downgrade jeffery hike amazon price target oppenheimer macquarie security ub pacific crest security suntrust robinson humphry clsa mizuho security also raise target amazon commerce giant earning sale top view late thursday guidance operate income be expectation only thing matter prime amazon web service be dominate say ben schachter macquarie analyst report amazon be expand margin even invest fulfillment video india aw capacity emerge business amazon share end trading hit record intraday jeffery hike price target macquarie security oppenheimer credit suisse ub citigroup mizuho stifel axiom goldman sachs pacific crest security also hike target quarterly growth be strongest rate year facebook fb result dispel notion digital dollar be decelerate write michael nathanson analyst digital advertising world now be essentially duopoly facebook google alphabet share touch mark friday retreat gain goldman sachs downgrade ford neutral buy automaker miss earning view increase reliance higher incentive hit margin also signale sale have stall citigroup lower target ford share dip plunge thursday argus research downgrade gilead science hold buy needham have downgrade biotechnology company hold july monday gilead report weaker hepatitis drug sale lower guidance share be other analyst move rbc capital upgrade oshkosh osk outperform neutral ub downgrade deere co neutral buy rbc capital well fargo downgrade harley davidson hog sector perform outperform oppenheimer raise price target comcast cmcsa
298,GILD,gilead science gild la vegas sand lvs texas instrument txn report quarterly result close monday estimate analyst expect gilead maker hepatitis drug sovaldi harvoni hiv drug truvada report second quarter earning share sale fall result gilead earn share exclude item revenue be top view be first quarterly sale earning decline year gilead hepatitis business have slow company have put more focus potentially treat hepatitis hcv drug sale be vs year earlier gilead blame weaker harvoni sale hiv other antiviral drug sale rise gilead cut full year net product sale forecast gilead be first big drugmaker report week share fall hour trading gilead close stock market today ibd take ishare biotech etf ibb be close breaking downturn meeting resistance get level also push ibb day move average first time month estimate wall street expect casino operator second quarter ep slip cent revenue fall result la vegas sand earn cent share adjust revenue be la vegas sand rival mgm resort international mgm wynn resort wynn have struggle macau region global casino hub china have be hurt weaker economy crackdown money launder other corruption mgm report earning aug operate environment macao remain challenge quarter do see sign stabilization particularly mass market la vegas sand ceo sheldon adelson say statement expect strong june activity continue la vegas sand rise more hour action miss ep revenue view macau stabilization sign sand stock climb close mgm resort wynn resort also rise late climb regular session estimate second quarter ep cent revenue result texas instrument earn cent share revenue ti see ep cent revenue analyst have expect cent sale texas instrument cite strong demand chip used car share rise hour action ti close higher hit fresh time high
299,GILD,largest biotechnology etfs be poise critical juncture trouble growth story be too early call reversal fortune re certainly stock investment idea once again spdr biotech xbi thursday break first stage base climb highest level early june industry giant biogen biib trounce analyst estimate profit sale growth stock jump heavy trading volume report global growth multiple sclerosis hemophilia business largest biotech fund ishare nasdaq biotechnology ibb follow xbi footstep week retake day move average do so etfs manage hold critical line strength suggest investor be rekindle love affair biotech earning week play part success failure attempt industry heavyweight gilead science gild report monday edward lifescience ew tuesday amgen amgn wednesday celgene celg step friday spdr biotech exchange trade fund be mired price investor be willing pay year have rebound past month outpace virtually other segment stock market jeffrey loo equity analyst global market intelligence consider biotechnology subindustry attractively price sharp sell couple biogen solid report be recent rally suggest ibd take biotech exchange trade fund offer diversify exposure high risk high reward industry lower single stock risk fund investor get know individual company own learn stock be top rate biotechnology group check ibd leaderboard march report loo write biotech industry sustain healthy growth next several year breakthrough drug gilead sovaldi harvoni hepatitis be help drive sale loo also have positive outlook issue key interest investor industry pipeline be also solid several drug have blockbuster sale potential write potential headwind come month november election email ibd loo note scrutiny high drug price fall have weigh heavily biotechnology company now hillary clinton tweet price gouge trigger scrutiny be poise become official democratic candidate next president unite state ibb have see asset shrink year net inflow first month fund hold stock skews large cap such amgen celgene well gilead biogen xbi have also see asset diminish have take new investor money first half year offer more exposure smaller cap name ibb well lower expense ratio performance be neck neck longer period time have produce annual average gain past year comparison spdr proxy broad market averaged gain same period
300,GILD,era more active manager fail beat benchmark index find mutual fund consistently achieve elusive element alpha be akin find holy grail usaa growth fund usaax be fund portfolio large cap growth stock have beaten peer track morningstar inc year date well past year have beaten stock index past year return vs lately much outperformance have be drive such stock market leader amazon amzn facebook fb alibaba baba portfolio manager be michael schroer renaissance investment management aziz hamzaogullari loomis sayle separately manage half portfolio schroer have be fund hamzaogullari fund strategy be look high quality company generate sustainable profitable growth manager see stock selling significant discount estimate intrinsic value snap lead small portfolio just company fund also have very long term investment horizon see portfolio turnover rate still even fund consistently outperform have moment doesn so far year underperform favor company be high quality growth selling reasonable valuation say schroer first half year lower growth didn do well higher company lead market later part year reversed lower company be do better ve benefit re sweet spot market lower higher quality be do better part strategy favore loomis sayle team be describe high active share active share be way measure much portfolio differ benchmark index active share have be hamzaogullari tell ibd late last year do not ensure outperformance believe be necessary condition generate alpha outperform benchmark net fee long term stock make fund rest foreign equity technology make portfolio amazon july stand usaa growth largest hold asset stock make entire retail internet segment fund amazon be year sit just support day move average pull back time high set oct analyst expect amazon post earning higher year earlier report result thursday facebook be hold also asset social networking medium leader be year date buy point flat base fiscal earning be expect rise year earlier result be report expect nov market close alibaba chinese commerce giant top fund hold be so far year stock have find support day move average week high company be expect show fiscal earning increase report tuesday not usaa growth top holding have be barn burner database bellwether oracle orcl be year be fund rest top holding percentage be cisco system csco visa qualcomm qcom monster beverage mnst alphabet googl unite parcel service up think technology consumer discretionary look attractive say schroer health care still look attractive biogen biib gilead science gild still look very cheap market be still high quality company schroer like foot locker fl athletic shoe retailer post very good second quarter sale still trade very reasonable multiple stock be only year carnival ccl royal caribbean rcl be do well last several month say schroer have sell fear virus hurt tourism didn suffer too much now booking next year be run high multiple be very attractive royal trail be carnival be ve take thing table still think be selective opportunity market say ve go quarters negative earning growth re watch quarter carefully sign rebound so far so good related top columbia fund load facebook other stock leaderschinese other foreign stock drive top fund set stage big online shopping spree
301,GILD,mobile chip company qualcomm qcom have price target raise do disk drive maker seagate technology stx western digital wdc oilfield service provider halliburton hal be raise buy rbc capital market raise price target qualcomm maintain outperform rating qualcomm be reportedly talk acquire nxp semiconductor nxpi bid value nxp nxp transaction be certainly much larger vs investor have contemplated write rbc analyst amit daryanani research note think offer qualcomm several unique asset further enable diversity away mobility exposure qualcomm share fall close stock market today seagate technology western digital receive price target increase rbc capital market western digital have price target raise outperform rating western digital close acquisition sandisk be see sustain tailwind business line write rbc analyst daryanani say earning estimate western digital be position keep inflect higher end western digital stock close daryanani raise price target seagate sector perform rating say channel check disk drive market imply upside earning estimate fundamental trend enabled strong performance june quarter remain intact write share fall rbc lower price target gilead science gild rbc analyst michael yee write price target be reasonable line comparable low growth large cap drug company also reflect lack visibility long term trajectory hepatitis vaccine franchise be face increase competitive uncertainty share fall close year lows set last month societe generale upgrade halliburton buy hold bounce oil price rise confidence forecast industry supply glut end head be lure speculative dollar back exploration oilfield service stock analyst project broad recovery domestic energy producer share initially rally finished essentially flat
302,GILD,eli lilly lly abbvie abbv top credit suisse evaluation pharmaceutical company head leave more challenged pfizer pfe astrazeneca azn nordisk nvo dust pharmavalue list do little ibd company medical ethical drug industry group fall fraction stock market today fifth consecutive day group be more year touch month low monday be trading day move average ibd take biotech pharmaceutical stock have be trample last month earning report come climb wall worry credit suisse rank big pharma stock factor enterprise value net present value pricing replacement power sale growth overall eli lilly top list europe base sanofi sny novartis nvs trail closely abbvie rank highest fundamental investor likely assume long life span humira credit suisse analyst write research report humira be brand name adalimumab abbvie drug treat arthritis plaque psoriasis ankylose spondylitis crohn disease ulcerative colitis abbvie stock slip small fraction monday lilly stock fall nearly meanwhile pfizer be weak board astrazeneca have high ev npv enterprise value net present value nordisk be expose pricing pressure astrazeneca investor be potentially factor oncology pipeline credit suisse say recent result other demonstrate significant risk teva pharmaceutical teva score well ev npv valuation most sale power drive generic division gilead science gild incyte incy vertex pharmaceutical vrtx be trading discount vertex only need minimal further pipeline success justify current valuation report say biotechs vertex top credit suisse list amgen amgn flail bottom pharmaceutical ibd company medical biom biotech industry group have be month group fall fraction monday ethical drug group also fall fifth straight trading day fall seventh day past trading day bottom overall astrazeneca score well term pricing power shift oncology product nordisk be eye diabetes rebate storm credit suisse say pricing power credit suisse analyst note be important help company resist discount pressure formulary manager government regard allergan agn be clear winner only shire shpg rivale dry eye market alexion pharmaceutical alxn focus rare disease be most exceptional biotech analyst say biomarin bmrn incyte vertex also get high mark be unique bristol myer squibb bmy eli lilly beat cohort productivity ability drive current pipeline follow dramatic seesaw bristol myer squibb merck mrk bristol myer lung cancer drug opdivo fail meet key endpoint eli lilly score well launch trulicity diabetes taltz psoriasis
303,GILD,biotech gilead gild be most likely scoop incyte incy next month accord survey industry watcher evercore isi investment bank ahead presidential election pit donald trump hillary clinton survey say most see gilead purchase incyte identify incyte biopharma most likely be acquire next year nearly respectively see biogen biib biomarin pharmaceutical bmrn target gilead acadium pharmaceutical acad celgene celg kite pharma kite be least likely be target only industry expert identify likely takeover candidate departure needham analysis last week identify potential suitor acadium incyte takeover likely come heavy price june gilead have cash equivalent market security hand market cap gilead be biotech trail only amgen widely view big biotechs most need be active front incyte have market capitulation smaller coalition say gilead buy vertex vrtx bristol myer squibb bmy outside lion share expert expect biotechs outperform broader market next month respondent say biopharmas merely be line trade election say expert ibd company medical biom biotech industry group be year loss be early year overall market tumble group be more late june now rank group track just week close stock market today group be more buck day downtrend ibd take latest industry snapshot explore biotech promising new drug stock be lead biotech sector drug pricing initiative rout stock year rbc analyst say thursday acknowledge drugmaker amgen amgn gilead celgene biogen regeneron regn vertex easily find loophole skirt new regulation still fewer person poll evercore expect government take meaningful action drug pricing nearly largest chunk say government win ever push reduction drug price other prediction stem specific company only expect eli lilly lly alzheimer drug solanezumab hit cognition function endpoint more broadly say hit cognition miss function more half say celgene phase testing ged oral mongersen treatment crohn fail reach overwhelming efficacy see phase testing phase patient take milligram be clinical remission day small say celgene see better result phase testing only expect study fail entirely result show endoscopic improvement respondent say celgene stock pop third expect share remain stagnant related gilead paralyzed likely hep share lossamgen biogen gilead spike va pricing skirt california pharmaceutical fall combo therapy eylea alone
304,GILD,stock open marginally lower wednesday heel tuesday resilient performance light terror attack belgium nasdaq dow jone industrial average fall overseas action be quiet china market end narrowly mixed tokyo nikkei take gain europe benchmark index paris london show modest gain frankfurt dax gain economic calendar new home sale number february be expect commerce department et energy information administration release weekly oil inventory report oil price decline early go west texas intermediate brent crude trade barrel gold slump more trading ounce bit less so far week dollar rise vs euro yen bond edge higher pressure year yield basis point lower most dow stock be flat index be busy extreme nike nke dive early trading mixed fiscal report late tuesday merck mrk give back early premarket gain still rise california jury decade long case find gilead science gild blockbuster hepatitis drug infringe merck patent gilead share drop more nasdaq stock apply material amat lose close chip equipment maker have gain past session be work sixth straight weekly advance scale right side month pattern ibd stock cal maine food calm give stock be struggle regain week move average climb right side month consolidation image provide shutterstock
305,GILD,something everyone vast universe sector fund consumer staple health care technology sector be favor fund rack big return also be prone bigger decline re more concentrated specific area diversify fund ibd run screen actively manage fund least asset have beaten benchmark past year sector be clear winner best sector fund rank year performance focus biotech health science see full list best sector mutual fund highlight best mutual fund top perform sector best best list ibd best mutual fund award winner include top fund sector click here view table top perform mutual fund select biotechnology portfolio fbiox come top year average annual return well ahead fund hold net asset feb expense ratio be rajiv kaul have manage fund october most sector biotech have see fair share volatility not necessarily negative next year go be renaissance industry term golden age innovation kaul tell ibd not go be straight line biotech be volatile investor amazing opportunity happen jan biotech stock make portfolio pharmaceutical fidelity select biotech hold stock top holding end include alexion pharmaceutical alxn regeneron pharmaceutical regn vertex pharmaceutical vrtx gilead science gild celgene celg stock ibd biotech industry group surge more november low july peak turnover fund tend run fairly low be high barrier entry biotech field include expertise capital regulatory hurdle kaul point do get major breakthrough medication really improve person life help save cost health care system do kaul pick stock fund have understand management be track record success say have kind historical understand depth understand industry individual player equally important be ability company access capital low cost want company be self reliant top biotech fund own big cap biotech soliris maker alexion recently report quarters fund also hold biotechs celgene gilead focus cancer hepatitis respectively generic drug maker track ibd soar more march july ethical drug stock rally nearly march august rowe price health science prhsx take second place biotech fund year return fund have net asset have be close new retail investor june feb portfolio hold stock service account asset follow biotech pharmaceutical product device life science top holding include aetna aet alexion pharmaceutical allergan agn becton dickinson bdx cigna ci focus innovative medicine diagnostic device business model have be core driver success taymour tamaddon have manage fund february say mail past year strength have be broad base biotech likely have highest level performance fund expense ratio be prudential jennison health science phlax return past year have be close new investor end june fund have total net asset expense ratio david michael del balso debra netschert manage fund biotech make biggest weighting jan asset pharmaceutical account health care provider service be health care equipment supply be life science tool service be biggest holding stock portfolio include celgene biomarin pharmaceutical bmrn bristol myer squibb bmy shire shpg allergan remain focuse longer term outlook fund believe continue be very positive base range industry trend health care reform advent oncology active immune therapy manager say jan fund commentary realization company value encounter intermittent setback believe market recognize reward longer term franklin biotechnology discovery fbdix total net asset feb have year return biotech stock make portfolio follow pharmaceutical nearly life science tool service focus biotechnology generally have limit exposure other area health care evan mcculloch senior vice president lead portfolio manager fund say avoid more traditional large cap pharmaceutical company have less favorable growth prospect do not show same level innovation see biotechnology celgene gilead science biogen biib amgen amgn regeneron pharmaceutical be top position stock fund fund close new investor july have expense ratio overall believe be strong fundamental underlie biotechnology sector recent growth have also help fund mcculloch say innovation remain very strong promising new treatment area immuno oncology gene therapy alzheimer disease gi disorder central nervous system disease other rydex biotechnology ryoax round top sector fund year return expense ratio be biotech account net asset feb pharmaceutical life science tool service top holding march include gilead amgen celgene biogen regeneron health care clearly dominate sector fund past decade other fund lead respective category rowe price global technology prgtx net asset end february lead tech sector fund year average annual return medium semiconductor software make biggest weighting stock fund top holding include alphabet googl amazon com amzn jd com jd have expense ratio lead consumer cyclical sector be fidelity select retail portfolio fsrpx asset feb year average annual return expense ratio be internet retail home improvement retail apparel retail account top subindustry end january amazon home depot hd netflix nflx be top holding rowe price medium prmtx top communication sector average annual return fund have net asset feb expense ratio be medium telecom service software be biggest investment area alphabet amazon american tower amt stock portfolio recent top holding rydex consumer product rycix average annual return expense ratio lead consumer defensive sector food product beverage household product account more half net asset procter gamble pg coca cola ko philip morris international pm be recent top holding burnham financial service burkx hold asset head financial sector average annual return yadkin financial ydkn bnc bancorp bncn atlantic capital bancshare acbi be fund top holding jan fund gross expense ratio be net expense ratio be
306,GILD,amazing diversity etfs allow investor bird stone consider ishare nasdaq biotechnology ibb largest exchange trade fund segment ibb debut ibd leaderboard march make first etf be add short sale idea shorting etf allow investor profit holding continue decline exchange trade fund downward slope relative strength line reflect weakness find chart most major biotechs investor also use proshare ultrashort nasdaq biotech bis achieve same goal etf leader current market relative strength rating mean recent price performance be top percentile stock etfs track ibd bis seek daily investment result correspond time inverse daily performance nasdaq biotechnology index etf investor legitimately ask be better short largest biotech etf take long position inverse counterpart inverse etf be probably best left alone sophisticated etf investor day trader investor be look dollar dollar gain fall etf price then be appropriate short specific etf monish shah head etf trading mizuho security recently tell ibd instance short share particular etf then price drop unrealized profit be however major risk short selling be profit be capped risk be unlimited short position etf price rise indefinitely force investor cover higher price inverse etf loss be capped amount have invest inverse etfs bring risk challenge average investor be critical understand inverse return underlie index be expect match only daily basis shah add longer term significant disconnect likely arise return inverse etf return underlie index due compound effect type investing strategy have potential amp portfolio return restrain investing climate however require more molly coddling ensure loss don run away be key successful investing overall picture ibb other biotech etfs major holding ibb include celgene celg biogen biib gilead science gild stock be deep correction industry fundamental aren so bad accord ibd market team heath care sector have best ep sale growth estimate analyst revision biotech be best part sector drug pipeline remain well stock licensing deal remain hot question sale growth have slow sharply peak ibb be fall stock market today bis add intraday year date ibb plunge march see net outflow first month year comparison bis be same period leak
307,GILD,gilead science gild walt disney yahoo yhoo be downgrade tuesday rebound sprint win upgrade needham downgrade biotech gilead science hold buy gilead monday report earning beat estimate also lower full year revenue guidance share sank close gapping day average fbr capital downgrade medium entertainment conglomerate walt disney time warner twx market perform buy ahead earning time warner be due report earning aug disney slate fiscal result aug disney share dip time warner lose morgan stanley downgrade yahoo equal weight buy set price target other analyst reiterate buy rating have sell core internet business verizon communication vz yahoo now plan monetize stake chinese commerce giant alibaba group baba yahoo japan yahoo rise slip monday pacific crest security upgrade sprint sector weight sell appear lower promotion activity next few month ahead apple aapl iphone cycle provide breathe room sprint say analyst michael bowen report rbc capital cowen co raise price target sprint climb tuesday jump monday other analyst move piper jaffray initiate adobe system adbe overweight rating stifel downgrade slew restaurant stock include texas roadhouse txrh dave buster entertainment play darden restaurant dri chipotle grill cmg panera bread pnra bank america upgrade texas instrument txn buy neutral
308,GILD,week bring boatload earning large cap drugmaker here be popular stock face turn point company growth cycle key unknown hep front be much veteran administration have be buy isn available analyst usual source prescription datum ibd take ibd slim investment system stand new new management new condition other new thing such new product so wise keep abreast upcoming drug trial datum biotech company gilead share have languish company be expect release key datum possibly big hep drug later year ibd report va have budget hcv drug spending fiscal year write evercore isi analyst mark schoenebaum email friday note gilead have historically have share va prescription va revenue quarter be important help gilead not miss consensus estimate gilead science share rise late morning trade stock market today leerink analyst seamus fernandez lift opdivo sale estimate preview note last week together yervoy bristol myer maintain share checkpoint inhibitor market fernandez write refer class cancer drug opdivo belong base trend have increase full year opdivo sale expect strong uptake japan improve royalty revenue ono bristol myer squibb stock fall intraday have lower term estimate keytruda januvia franchise base sale prescription datum respectively however see greater long term opportunity relative previous forecast fernandez write recent announcement overall survival benefit keytruda keynote trial raise prospect drug first line small cell lung cancer nsclc merck share fall nearly intraday leerink analyst geoffrey porge write july note trial bring significant revenue upside revlimid succeed lead addition diffuse large cell lymphoma dlbcl exist product label study be controversial write be start development testing more responsive less responsive patient also treatment regimen not be best use revlimid disease nonetheless porge assessed modest positive outcome most likely celgene stock fall monday morning abbvie rise
309,GILD,biggest change accounting standard sarbane oxley act shake public company book revenue many case result earlier recognition sale ripple effect touch everything earning taxe bonuse commission buyout decision new fasb rule develop financial accounting standard board take effect fiscal affect many company likely have most impact business multiyear contract licensing revenue contract peg revenue performance benchmark third party sale distribution channel short term stock market investor sometimes have tougher task discerning corporate trend current financial result not be comparable previous quarters sale earning also be more volatile potentially affect stock price new revenue recognition standard be biggest accounting event ve ever see say dusty stalling partner accounting giant go be tough exercise most company ibd take best stock buy usually be power strong revenue stream smart investor look revenue context company overall financial performance ibd calculate unique rating stock do just explanation list stock rate highly now read paul whitfield new article don judge sale vacuum business be most impact be telecom stock verizon communication vz computer software stock such adobe system adbe microsoft msft analyst say stock rise friday verizon share be adobe climb friday microsoft just tech company have say regulatory filing evaluate new standard impact financial statement include apple aapl amazon com amzn cisco system csco facebook fb intel intc salesforce com crm qualcomm qcom new fasb revenue standard affect most other industry well include medium entertainment aerospace biotech health care construction auto defense real estate franchiser such restaurant boee ba walt disney gilead science gild be stock assess standard impact company need adapt more just financial statement revenue standard impact sale commission bonuse corporate taxe debt covenant related coverage verizon bring british mobile war veteran mobile sprint pick comcast pull wallet get ready netflix vr microsoft stock break new high big stock move video sarbane oxley financial reform target fraud wake accounting scandal enron worldcom other fasb make revenue recognition consistent industry guideline specific software defense industry example be go away revenue recognition be much say prabhakar kalavacherla partner big accounting firm kpmg be now go be unify principal be agnostic industry many software other tech stock new standard speed timing revenue recognition vs today gaap generally accept accounting principle guideline ll have recognize revenue immediately not broad length contract often company win know exactly revenue disclose so ll be ask make more estimate judgment call rather rely old rule computer maker other company sell product distributor likely book more revenue upfront ll need estimate base historical datum much product eventually be sell end user distributor then book amount certain industry recognize revenue sooner have past software be example stalling say change guidance very strict rule today new requirement make estimation be go go lot industry key new accounting rule be revenue often be book right away not stretched time verizon likely book more revenue smartphone sale upfront rather course lease contract payment plan software company fast forward revenue recognition be uptick acquisition say todson page partner smaller company be more attractive takeover target deal be earning positive immediately least few quarters deal justification point view help buyer allow reach gaap accretion number quicker say page pwc technology deal leader change top line course affect stock earning new revenue standard have potential change not only top line also bottom line wesley bricker deputy chief accountant security exchange commission say speech earlier recognition sale help bottom line first lead lumpier earning overall more revenue be book upfront less duration contract long term license company have less defer revenue book time thus fasb standard mean have less leeway manage earning meet consensus estimate accelerate defer revenue broad aim fasb be bring revenue recognition line international financial report standard be also be overhaul goal be make easier investor compare stock industry country say kpmg kalavacherla also former member international accounting standard board company have choose just comply new standard company opt restate sale prior year other take modify compliance route apply new rule only exist future contract effective date telecom medium entertainment company be most likely restate revenue analyst say likely be cleaner tack say kalavacherla modify route say less trend information be available investor analyst comparative datum be lose say fasb delay effective date new revenue standard year company ask clarification company be still griping fasb have say be not consider delay analyst however say rule be still flux rule simply don make sense right now say john difucci software industry analyst jeffery jpmorgan conference software company hedge ask soon ll be affected standard accounting change come huge change computer industry find software company shift time licensing fee subscription base software service business model fasb standard only software be continuously update be recognize time apply most saas company have have saas business model start such salesforce com be less impact change other analyst say adobe microsoft splunk splk be software stock be transition saas still have considerable licensing revenue timing revenue recognition software license be accelerate say citigroup kpmg survey find many company be take see approach haven upgrade system recalculate contract take other step comply new standard such company be more likely take modify approach comply standard rather restate financial statement company need make more estimate revenue recognition ll need disclose more historical other datum footnote say kpmg improve transparency investor new standard also be business opportunity startup offer financial software design help revenue recognition such company be leeyo software zuora revstream leeyo ceo jagan reddy tell ibd be go be real challenge auditor
310,GILD,be huge week earning apple aapl facebook fb alphabet googl amazon amzn beat forecast mcdonald mcd ford motor indicated weakness demand tech step include verizon vz deal buy yahoo yhoo core asset economy be grow lot slower expect oil price be near barrel nasdaq composite rise best level early december fuel strong earning apple facebook alphabet amazon hit new record high friday close week fractionally dow jone industrial average fall also snap week uptrend weaker oil price earning report hit energy sector federal reserve statement term economic risk have diminish seem have little impact investor iphone maker earn share year year sale be apple second straight decline earning revenue iphone sale be still better expect apple current quarter revenue target be midpoint wall street consensus iphone be expect be release mid september apple stock rise week just retake day line amazon ep shatter estimate revenue rise amazon web service continue boom revenue guidance also be strong operate income be light amazon stock rise week hit record intraday friday ibd take amazon be leaderboard stock hit new high growth boom only rate ibd retail internet group see go ibd stock checkup facebook report revenue maintain streak double digit growth go back more year ep jump cent shatter consensus cent be fourth straight quarter accelerate earning growth facebook stock rise hit record high still range buy point twitter twtr report ep top view revenue fall short revenue guidance also miss estimate twitter stock fall close week day line bounce back miss alphabet report ep revenue blow past expectation google parent earning item rise share total revenue climb google size still deliver growth say mark mahaney analyst rbc capital be now straight quarter ish year year revenue growth do mention acceleration say report alphabet stock rise close just entry point rise high ford motor send signal long auto industry bull market be auto sale stall higher incentive hit profit margin automaker earning share revenue rise ep growth be weakest quarters sale growth be slimmest quarters ford cite downside risk global growth offer further evidence slow auto part maker lear lea miss sale warn revenue gentherm thrm earning miss volkswagen vlkay sale edge net profit plunge vs year early struggle recover emission test cheating scandal involve diesel engine model ford stock fall federal reserve left interest rate unchanged day policy meeting expect policymaker say term economic risk have diminish suggest baby step raise rate analyst say open door slightly september rate increase fed meeting weak gdp datum investor push back expectation next hike next month economy rise annual rate less half wall street expect downwardly revise pace consumer spending be very strong climb residential investment fall even separate report show new exist home sale hit multiyear high business investment contract third straight quarter oil price fall back barrel corporate spending remain weak go forward crude oil future tumble barrel hit month lows crude tumble july crude gasoline supply rise again accord energy information administration also report higher production number oil rig operation rise fifth straight week suggest further production gain glut gasoline refine product suggest less refinery demand crude ahead meanwhile exxon mobil xom chevron cvx conocophillip cop report weaker expect result mobileye mbly report ep jump cent revenue grow top view maker driver assistance system say relationship tesla motor tsla be end news send mobileye tuesday stock pare loss week tesla rise boee ba report first quarterly loss year due various charge wasn deep fear free cash flow be better expect big jet delivery northrop grumman noc report modest earning sale growth top view weaker tech service revenue hurt margin raytheon rtn beat view raise profit guidance general dynamic gd top earning raise ep guidance revenue miss mcdonald earn share beating analyst expectation total revenue fall vs year earlier analyst have expect global same store sale exclude currency effect rise vs estimate same store sale rise just management say be not immune consumer unease be finance election general unsettled world have hurt other restaurant quarter share fall week tumble day day move average buy point stifel nicolaus downgrade large number restaurant stock jeffery predict recession hit sector top rate texas roadhouse txrh report earning come week fall wednesday steakhouse chain find support day line close week unite technology utx maker pratt whitney brand aircraft engine otis elevator other product report second quarter earning share revenue beat estimate raise ep estimate stock hit year high buy point caterpillar cat ep revenue fall mining construction equipment giant deal energy mining downturn stock hit roughly year high rise entry point chemical giant dupont dd be merge dow chemical dow crushed earning estimate be light revenue share rise highest point mid december trigger buy point meanwhile mmm make tape adhesive medical supply other product also report higher ep lower revenue beating estimate share fall analog device adi agree buy linear technology lltc cash stock deal worth create microchip industry giant deal be expect close first half meanwhile oracle orcl say buy cloud service provider netsuite deal oracle larry ellison be lead shareholder netsuite meanwhile citrix system ctxs merge go meeting unit logmein logm citrix be already plan spin go meeting verizon communication acquire struggle core asset yahoo nearly include stock compensation cost massive execution challenge ahead yahoo acquisition demonstrate verizon recognize own limitation consumer brand say research firm diffusion group verizon report revenue miss view line ep add fewer wireless postpaid phone subscriber expect mobile tmus add postpaid phone subscriber top sprint verizon lose postpaid phone subscriber mobile earning fall still beat expectation revenue rise nearly tmus revenue growth continue significantly outpace peer say matthew niknam deutsche bank analyst report armour ua meet top line bottom line expectation report share earning penny prior year revenue growth nike nke rival announce several assertive plan include takeover fao schwarz space manhattan well partnership kohl kss share tumble week amgen amgn beat raise stock slip growth continue be drive price increase rather volume celgene celg meanwhile jump only third growth be price drive make hit earlier week drug revlimid fail lymphoma trial abbvie abbv merck mrk alexion pharmaceutical alxn also rise solid report astrazeneca azn be biggest winner stock wise jump thursday rumor swiss pharma novartis nvs be think acquire biggest loser be gilead science gild trim guidance hepatitis franchise continue decline meanwhile top rate medical device company edward lifescience ew orthopedic giant zimmer biomet zbh hit new high beating estimate raise guidance big cap stalwart boston scientific bsx hit year high report strongest quarter sale growth nearly decade
311,GILD,chief executive apple aapl chip supplier skywork solution swks technology avgo top brass yahoo yhoo gopro gpro system ddd be notable insider trade disclose week
312,GILD,skywork ceo david aldrich sell company share dec share nov aldrich have sell share weekly basis much past month
313,GILD,skywork stock finished week apple rise
314,GILD,ceo hock tan meanwhile have sell company share total value more tan have sell roughly amount share monthly past month
315,GILD,earlier week report fiscal earning top forecast sale narrowly miss consensus
316,GILD,stock sale skywork aldrich tan come credit suisse say last month apple slash order component potentially due lower interest iphone
317,GILD,jump week
318,GILD,yahoo ceo marissa mayer have acquire yahoo share trade come grow dissatisfaction mayer performance helm embattled firm consider selling internet business yahoo share rise
319,GILD,gopro director edward gilhuly have sell company share gopro stock have be weigh recent month fear increase competition gopro be downgrade friday baird cite lack meaningful pick gopro camera sale
320,GILD,gopro stock sank week drop further ipo price
321,GILD,system chairman loewenbaum buy total share printer manufacturer nov dec system stock have withered past year concern printer market have be saturate avi reichental step company ceo october
322,GILD,share system fall week
323,GILD,twitter director evan william help find twitter once serve ceo have sell company share worth
324,GILD,twitter have struggle user growth recent quarters have see turnover leadership twitter recently name co founder jack dorsey ceo have serve interim basis follow departure dick costolo twitter share lose week
325,GILD,shake shack shak ceo randy garuttus have sell company share stock debut january peaked shake shack have be batter overall restaurant sector deal higher labor cost drive minimum wage increase affordable care act requirement shake shack be week
326,GILD,gilead science gild ceo john martin have sell company share martin have make similar sale monthly basis year gilead share slip week
327,GILD,insider transaction don typically have major impact stock indicate major pending news rapid liquidation most insider holding however affect stock
328,GILD,follow bill peter twitter ibd_bpeter chief executive apple aapl chip supplier skywork solution swks technology avgo top brass yahoo yhoo gopro gpro system ddd be notable insider trade disclose week skywork ceo david aldrich sell company share dec share nov aldrich have sell share weekly basis much past month skywork stock finished week apple rise ceo hock tan meanwhile have sell company share total value more tan have sell roughly amount share monthly past month earlier week report fiscal earning top forecast sale narrowly miss consensus stock sale skywork aldrich tan come credit suisse say last month apple slash order component potentially due lower interest iphone jump week yahoo ceo marissa mayer have acquire yahoo share trade come grow dissatisfaction mayer performance helm embattled firm consider selling internet business yahoo share rise gopro director edward gilhuly have sell company share gopro stock have be weigh recent month fear increase competition gopro be downgrade friday baird cite lack meaningful pick gopro camera sale gopro stock sank week drop further ipo price system chairman loewenbaum buy total share printer manufacturer nov dec system stock have withered past year concern printer market have be saturate avi reichental step company ceo october share system fall week twitter director evan william help find twitter once serve ceo have sell company share worth twitter have struggle user growth recent quarters have see turnover leadership twitter recently name co founder jack dorsey ceo have serve interim basis follow departure dick costolo twitter share lose week shake shack shak ceo randy garuttus have sell company share stock debut january peaked shake shack have be batter overall restaurant sector deal higher labor cost drive minimum wage increase affordable care act requirement shake shack be week gilead science gild ceo john martin have sell company share martin have make similar sale monthly basis year gilead share slip week insider transaction don typically have major impact stock indicate major pending news rapid liquidation most insider holding however affect stock follow bill peter twitter ibd_bpeter
329,GILD,early investor facebook fb continue sell share social medium leader past week stock peaked apple aapl chief sell chunk iphone maker stock slump facebook director marc andreessen co founder venture capital firm andreessen horowitz disclose sale share nov nov total value oct nov andreessen sell nearly half holding facebook total value roughly prearrange plan transaction come facebook stock have hit series fresh time high lately early month facebook report earning revenue beat estimate strong growth mobile monthly active user facebook stock hit close high wednesday retreat afterward week share close nearly stock market trading apple ceo tim cook also continue sell share cook file monday sale share total cook nov disclose filing have sell share total value nov credit suisse say apple be cut order iphone supplier flagging demand asia new chinese datum also raise concern economic growth world largest consumer market credit suisse say still bullish apple share drop week gilead science gild president john milligan nov sell share value gilead chairman ceo john martin have be regular seller biotech share sell share earlier month gilead share share other drug stock have be pressure lately scrutiny pricing sale practice gilead have hold better many peer share decline skywork solution swks chairman ceo dave aldrich sell share nov nov however cfo donald palette buy share period share skywork apple chip supplier have come earth drop time high june week skywork slide first solar fslr ceo james hughe sell share nov cfo mark widmar sell share date earlier week first solar crushed third quarter estimate earning shot revenue spiked solar sector be slam weak sunedison sune result worry profitability solar yieldcos first solar share lose week illumina ilmn ceo jay flatley sell share nov gene sequence equipment giant have be upswing sync rise medical research equipment service group general illumina replace specialty chemical maker sigma aldrich index nov now merck mrk have buy sigma aldrich illumina share rise week constellation brand stz ceo robert sand sell share nov nov brother constellation chairman richard sand sell share period share rise less insider transaction don typically have major impact stock indicate major pending news rapid liquidation most insider holding however affect stock follow james detar twitter ibd_jdetar facebook
330,GILD,biotech stock drugmaker valeant pharmaceutical vrx take beating september hillary clinton accuse big pharma price gouge regeneron pharmaceutical regn have now bounce back buy zone new york base drugmaker develop treatment eye ailment inflammatory disease cancer earlier week regeneron partner sanofi sny present positive result
331,GILD,leerink swann analyst geoffrey porge be tired wait gilead science gild acknowledge slow hepatitis patient volume competition rival abbvie merck porge downgrade gilead stock market perform rating outperform cut price target long cautious porge be now bearish flash pan hepatitis market cut hepatitis sale expectation exist hcv estimate be already materially consensus write research report now think hcv revenue decline faster farther previously estimate consensus currently forecast briefly have stranglehold market gilead now face competition abbvie abbv have sell viekira pak april merck mrk shake market even more start selling own medication well high cost gilead abbvie earlier year gilead cause stir biotech world release first hepatitis drug sovaldi late drug cost pill week regimen offer guarantee patient used drug be cure gilead see triple digit jump profit result late gilead release harvoni follow sovaldi cost even more profit continue grow double digit pace slow single digit increase first quarter year drop profit second quarter share company now trade reach peak more mid abbvie start selling viekira pak same price sovaldi merck zepatier go much less stock market today gilead stock dip hit lowest point week fall key day move average support line straight day ibd take gilead stock have composite rating meaning underperform stock term key growth metric ibd company medical biom biotech industry group be recent hot streak potential big pharma hepatitis market appear be steady secular decline porge say large pool treatable patient europe likely only see patient apiece annually long term vs record high porge forecast patient erosion year erosion revenue unit dip treatment erosion also expect gilead lose market share see hepatitis sale topple nearly peak sale gilead have see come porge say say gilead have be surprised slow patient volume world well price erosion other develop market fear company have become paralyzed size good fortune uncertainty outlook capability write gilead appear unwilling match market price high quality asset invest pipeline future outside hepatitis porge have kinder word gilead hiv business be contingent success development bictegravir currently model sale bictegravir combination gilead also have rheumatoid arthritis treatment filgotinib porge see probability success related gilead allergan see trail intercept ongoing nash battlepfizer buy cancer drugmaker medivation
332,GILD,california ballot initiative require state medicaid arm buy drug comparable price department veteran affair pay backfire thus preserve sale nation biggest drugmaker rbc analyst michael yee say thursday proposition california drug price relief act cdpra sound good theory yee write research report assume drugmaker don simply eliminate steep discount already provide va say happened year congress pass law require drugmaker grant medicaid similar discount give manufacturer larger customer write law ultimately prompt manufacturer raise price paid larger customer include va likely be fate cdpra write californian appear overwhelmingly support initiative early month university southern california los angele time survey find respondent approve cdpra san francisco firm poll july find support drugmaker amgen amgn gilead gild celgene celg biogen biib regeneron regn vertex vrtx cdpra offer merely headline risk yee write assume large price cut medicaid sale earning decrease only company product be expose medicaid state enact such measure mean earning share risk large cap player yee write year california be alone initiative ohio proposition didn make ballot however va price discount then probably become nonexistent lower va price lead reduce medicaid price write note medicaid already get discount date cdpra opposition have only spend donation yee expect spending ramp significantly ahead nov ballot rbc research show proposition be win side have most funding cdpra supporter have raise only supporter include former presidential candidate bernie sander say cdpra save californian taxpayer year va pay less other government agency prescription drug opponent argue cdpra invalidate exist contract state drugmaker force increase state drug price reduce funding medi cal initiative also increase state expense employee spend time resource match state price va pay ibd take ibd company medical biom biotech industry group rank group track have climb just week stock have heated wall street expectation major big pharma action however stock market today group close hurt intra cellular therapy stock plunge
333,GILD,smart etf investor stay tune opportunity stock market sector rise fall style ebb flow factor come go take case ishare edge minimum volatility usa usmv powershare low volatility splv exchange trade fund target volatility several factor driver return be historically proven add value stock use factor etf investor hope achieve attractive enhance portfolio return full market cycle notwithstanding periodic bout sunshine squall instance usmv splv limp third quarter bolt ahead first investor coveted low volatility style earlier year stock market today etfs lurch june lows nature factor base exchange trade fund outperform market underperform other so spirit stay tune opportunity successful investor do factor be radar quality accord powershare basically mean financially sound company typically stable earning growth powershare be pioneer world factor base alternatively weight etfs fund stray traditional cap weighting stock holding also go name smart beta strategic beta quality be step volatility say nick kalivas senior equity product strategist powershare like quality factor now offer more upside participation also buffer downside risk lesser degree low volatility strategy kalivas see quality factor make sense investor be start position recovery corporate profit aren unfettered worry largest etfs offer exposure factor be ishare edge msci usa quality factor qual powershare quality sphq hold more asset combine quality factor etfs invest profitable firm solid earning growth low risk qual sphq choose stock base measure such return equity financial leverage cash flow count industry giant pepsico pep gilead science gild stock holding be difference however qual avoid big sector bet sphq offer more pure focus quality factor former be younger larger asset hold more diversify basket stock have far lower expense ratio year date oct sphq be qual market proxy spdr spy have advanced sphq also perform better last year average gain ibd take uncertain outlook interest rate divide fed be issue weigh stock market investor bear mind good company don always make good investment morningstar analyst alex bryan wryly note write august quality stock seldom offer eye pop return tend lag strong market rally hold better market downturn rather get shake volatile market investor want consider long term allocation quality factor etfs accord powershare kalivas describe sphq nice core hold portfolio potential tactical opportunity don take last bit mean jump headlong volatility quality focuse strategy factor timing require expertise skill investing multifactor etfs be better approach most investor fund be alternative try combine time single factor own ishare edge msci multifactor usa lrgf combine quality factor value size momentum so do jhancock multifactor large cap jhml combine factor take advantage low correlation tendency perform well different time related best etf investment strategy be right portfolio
334,GILD,medical behemoth gilead gild be trail intercept pharmaceutical icpt battle nonalcoholic steatohepatitis nash liver disease credit suisse analyst alethia young say thursday day botox maker allergan agn jump agreement acquire tobira therapeutic tbra larger gilead allergan market cap be later nash race intercept market cap intercept begin enrolling phase trial september expect complete enrollment early next year ibd take shove stick eye avoid daily eye drop treat glaucoma glaukos help check ibd new america intercept handful rival be attempt treat nash target fxrs farnesoid receptor class protein find liver intestine fxrs be stoke regulate carbohydrate lipid metabolism bile acid homeostasis fibrosis tie nash newer player be look used bile acid fxrs departure intercept chemistry still intercept phase flint trial be most mature datum set space show significance fibrosis liver histology base pre specify parameter young write research report long term young see room nash space many player intercept be more successful gilead success rate vs respectively predict intercept also have contend novartis nvs encanta now allergan allergan enter race tuesday plan acquire tobira get leg nash treatment yet tobira cvc cenicriviroc miss goal improve nonalcoholic fatty liver disease naflad activity score activity score be severity measurement patient likely have nash tobira cvc successfully reduce fibrosis worsening nash patient vs treat placebo comparatively intercept phase trial ocas obeticholic acid improve fibrosis patient vs receive placebo now allergan expect combine tobira cvc diabetes treatment preclinical bile acid fxr akarna encanta have bile bile fxrs likely slate human trial soon combine treatment be key young predict think combination regimen be important part treatment paradigm think intercept be position well here long term young write have outperform rating price target intercept stock afternoon trading stock market today intercept stock rise be nearly so far month share be buy zone third consecutive day pivot buy point double bottom base gilead science share fall allergan climb
335,GILD,main index be lower afternoon trading tuesday midday bounce continue fade nasdaq be fraction lose dow jone industrial average volume be tracking higher board breadth be positive winner loser ratio nyse nasdaq health care sector show energy market today few medical stock break cynosure cyno clear base heavy volume surge past buy point triple average volume maker equipment hair removal fat loss other cosmetic treatment report earning sale beat expectation cynosure erased good portion early gain remain buy range small cap cryolife cry soar break cup handle base buy point maker mechanical heart valf implantable tissue surgical glue other medical product beat wall street estimate gilead science gild slide nearly week low biotech edge past earning view lower guidance report weaker hepatitis drug sale restaurant be broadly weaker analyst make bearish comment industry texas roadhouse txrh be downgrade stifel nicolaus jeffery group crumble intense volume share fall day move average now seek support stifel also downgrade panera bread pnra bj restaurant bjri chuy chuy chipotle grill cmg darden restaurant dri other chain panera share fall remain base pattern darden bj hit new lows basis be form chuy trigger sell signal fall more buy point jeffery also take aim fiesta restaurant group frgi noodle co ndls red robin gourmet burger rrgb other stock hit new lows mcdonald mcd report same store growth forecast stock slide buy point have be productive tuesday news goldman sachs upgrade starbucks sbux conviction buy buy recommendation starbucks climb average volume recover long correction
336,GILD,do take mutual fund survive last week market take chin week end feb accord lipper inc top perform diversify stock mutual fund more asset do not rely hedge borrow shorting be natixis cgm advisor
337,GILD,cvs health cvs tuesday say measure growth pharmacy benefit client prescription drug spending slow last year price inflation specialty brand outweighed other trend driver company say statement specialty drug well new launch rise cost have less impact inflation brand high volume category such drug used treat diabetes announcement follow year price specialty drug have be increase scrutiny double digit drug trend increase be experience result call action client help ensure plan member access medication need stay healthy affordable price cvs health executive vice president robert say cvs share finished lower stock market today rival walgreen boot alliance wba fall rite aid rad walgreen be buy ease price specialty drug exemplify digit treatment price hepatitis drug gilead science gild become lightning rod criticism pharmacy benefit manager such cvs express script esrx have negotiate discount drugmaker exchange coverage lightning rod become practice company include valeant pharmaceutical vrx martin shkreli turing pharmaceutical buy obscure drug cheap hike price cvs have try curb usage valeant jublia toenail fungus drug reportedly have retail price milliliter bottle monday accord bloomberg cvs say launch optional program april intend steer patient cheaper treatment cvs client spending jublia soar last year bloomberg say add express script say also try bring price toenail fungus treatment gilead science share dip express script close valeant climb image provide shutterstock
338,GILD,week most notable insider transaction be lead top brass facebook fb google alphabet googl executive netflix nflx constellation brand stz gilead science gild also get action social networking giant coo sheryl sandberg disclose thursday sale option exercise share total transaction value nearly board director member jan koum active seller past month disclose tuesday sale share cto michael schroepfer disclose sale option exercise share facebook end week stock market today share be try close day line ve meet resistance lately trade high flat base buy point ceo google sundar pichai disclose wednesday sale option exercise share nearly disclose sale same amount same day sergey brin president parent company alphabet disclose tuesday sale option exercise share transaction total alphabet finished trading week share be work consolidation base buy point be currently trading day day line alcoholic beverage maker cfo david klein report sale option exercise share total wednesday thomas mullin evp general counsel disclose sale option exercise share almost share end week stock be trading time high be buy range flat base buy point report view top quarterly result last week biotech executive chairman board john martin disclose wednesday sale option exercise transaction value paul carter company executive vps report wednesday sale option exercise share little gilead science be stock be nearly week high be recently able retake downward slope day line netflix board member richard barton disclose transaction week wednesday thursday report sale option exercise share total barton be co founder zillow netflix be fractionally week video stream service retook day line friday have be able find support level still share be trading day line be nearly time high reach december insider transaction don typically have major impact stock indicate major pending news rapid liquidation most insider holding however affect stock
339,GILD,quarterly earning once again take center stage stock hold solid gain close friday extend major market index streak fourth straight week eye be dow component apple aapl caterpillar cat mcdonald mcd report tuesday nasdaq rise dow jone industrial average add volume dip slightly board vs thursday accord preliminary datum week nasdaq be winner gain dow climb respectively alcoholic beverage transportation software maker lead upside today stock market action shoe apparel maker homebuilder oil stock lag west texas intermediate crude oil future slide barrel boston beer sam score biggest gain alcoholic beverage group spike massive trade stock reclaim day move average first time nearly month maker samuel adam twisted tea issue strong report starbucks sbux fall late thursday fiscal revenue miss view re-cover gain friday robust trade goldman sachs lower price target coffee giant chipotle grill cmg jump fast turnover close well day line close thursday embattled fast casual burrito chain report lower expect earning sale note progress effort customer back ibd gigamon gimo take lead jump ahead earning report thursday close stock be extend more handle buy point profit take range other ibd stock centene cnc paycom software payc add gain more silicon motion technology simo shed fast trade third straight decline report result close thursday top view share be week high company report earning early next week include gilead science gild monday edward lifescience ew mobileye mbly armour ua tuesday light economic datum schedule include dalla federal reserve manufacturing survey july
340,GILD,here investing action plan need know investor come week more tech giant apple aapl facebook fb amazon amzn alphabet googl report earning do biggest name oil such exxon mobil xom chevron cvx fast food leader mcdonald mcd aerospace giant boee ba federal reserve policymaker
341,GILD,leerink offer mostly bullish preview come earning season big biotechs wednesday offer hope lag sector analyst geoffrey porge raise estimate alexion pharmaceutical alxn biogen biib celgene celg gilead science gild regeneron pharmaceutical regn write prescription datum im health im indicate flat slightly trend celgene standing year year volume growth drive new psoriasis drug otezla top drugmaker evidently shrug recent political criticism raise price number product wac wholesale acquisition cost price celgene otezla increase april follow raise january increase last june represent year year cumulative increase celgene also raise price abraxane april year year cumulative increase porge write other price increase include amgen kyproli yoy biogen tecfidera avonex plegridy medivation mdvn xtandi leerink nonetheless lower estimate medivation base lower xtandi sale well lower royalty sale outside also modestly lower forecast amgen amgn vertex pharmaceutical vrtx add be still consensus company celgene stock climb stock market today stock also have be help anonymously source report be company sign disclosure agreement medivation ahead possible buyout regeneron stock climb alexion advanced biogen rise gilead vertex stock rise announce licensing deal moderna therapeutic develop cystic fibrosis treatment used moderna messenger rna technology vertex agree cash investment upfront milestone payment drug succeed
342,GILD,first half be exceptionally difficult drug stock not just overall sentiment relative dearth good news compare previous few year second half year however bring very important clinical trial news several lead player potential move stock sharply here look major event ahead probably most anticipate datum drop year be eli lilly lly initial report alzheimer disease drug solanezumab expect december almost sufferer worldwide alzheimer be largest disease doesn have current treatment many company have attempt create have long history failure phase trial suggest solanezumab isn miracle cure only create statistically significant improvement lilly parsed datum focus early stage case lilly create patient pool phase trial expedition compose entirely such case interview year lilly ceo john lechleiter tell ibd alzheimer probably be treat more product not way diabetes be treat today not way cancer be treat lilly first have primary endpoint trial improvement cognitive decline improvement functional decline however march demote functional decline measurement secondary endpoint analyst take sign lilly think miss credit suisse analyst vamil divan note pooled datum previous trial show impact slow cognitive decline only impact slow functional decline regulatory perspective however be able show sign functional benefit remain important point be now incrementally more cautious divan write march research note biogen biib investor be interested spectator lilly report biogen earlier stage drug aducanumab be base same theory solanezumab reduce amyloid plaque form alzheimer patient brain slow disease progression so far hypothesis hasn be definitively proven gilead science gild also have risky potentially high reward program work garner somewhat less attention conquer hepatitis drug sovaldi harvoni epclusa gilead have turn attention hepatitis virus even more common hep only cure rate current treatment june report leerink analyst geoffrey porge say gilead chief science officer norbert bischofberger be place most confidence gs year read first datum human dr bischofberger explain first cohort study be always virally suppress patient datum be available patient presentation november american association study liver disease aasld conference datum second cohort virally naive patient be available next year european association study liver easl conference porge write regeneron pharmaceutical regn big pharma partner sanofi sny report first datum cholesterol lower drug praluent reduce death cardiovascular disease full result trial aren expect next year regeneron do interim analysis see result have achieve overwhelming efficacy justify stopping trial early initially amgen amgn be expect be first report such datum pcsk inhibitor class drug praluent amgen repatha early june however amgen push report early praluent repatha have underperform expectation launch last year regeneron amgen have warn sale likely be slow prove payer drug actually improve patient health earning report april amgen say repatha prescription be reject pharmacy require prior authorization insurer biogen share rise stock market today gilead science climb regeneron amgen ibd take biogen gilead regeneron be trading well high day day move average investor worry slow growth drug pricing pressure regulator politician
343,GILD,recent week have not be friendly pharmaceutical industry stock sector such valeant pharmaceutical vrx horizon pharma hznp wither criticism industry drug pricing practice fear greater regulation biotechs top fundamental gilead science gild regeneron pharmaceutical regn focus screen day have maintain strong rating hold stock market furor company top fundamental ibd definition have year ep sale growth rate least gilead science have face raft criticism price hepatitis wonder drug sovaldi have year ep growth rate year sale growth rate company handily beat estimate last month raise full year sale guidance be just shy expectation gilead other pharma stock fall democratic presidential hopeful hillary clinton say introduce plan crack call price gouge industry clinton announcement come turing pharmaceutical be harshly criticize decision buy decade old drug quickly raise price more gilead breach day line day sank further month clear day day line stock have find support day move average share close stock market today regeneron pharmaceutical regn make cholesterol fighter praluent sanofi sny have year ep growth rate year sale growth rate sale praluent see possible blockbuster be less half analyst expect ep overall sale beat forecast regeneron fall day clinton announcement finished higher next day then descend day line stock have climb day line regeneron stock dip thursday stock form handle month consolidation regeneron gilead have turn stronger showing recently stock such valeant pharmaceutical mallinckrodt mnk horizon pharma have be hit hard short seller citron research last month accuse valeant shady sale practice criticize drugmaker price hike acquire drug citron month attack mallinckrodt say sale drug acthar have lag question gel effectiveness express script esrx wednesday sue horizon pharma say owe million unpaid drug rebate cut network specialty pharmacy horizon be used valeant also have be hammer specialty pharmacy ty mallinckrodt valeant horizon be trading day day line valeant share end thursday horizon lose mallinckrodt fall express script slide follow bill peter twitter ibd_bpeter
344,GILD,etf investor have lately be seek safe sound stable stock market turn more volatile stock likely make whiz bang move be get lot less love deterioration credit market condition be contribute choppiness stock market russ blackrock global chief investment strategist write nov report continue favor tilt quality add momentum have be effective style past several year market generally marched upward have struggle volatility begin rise late summer ishare msci usa quality factor qual gain past month nov vs ishare msci usa momentum factor mtum year date basis momentum etf have outperformed quality etf also come top qual quality etf home profitable company successful investing track index target large midcap stock high return equity low debt burden more consistent earning previous year stock be weight base degree exhibit characteristic market capitalization skews portfolio stock durable competitive advantage morningstar analyst alex bryan write recent report fund be better position many peer market downturn expect underperform momentum peer stock market rally strongly exchange trade fund hold stock microsoft msft be largest hold johnson johnson jnj apple aapl gilead gild berkshire hathaway brkb round top mtum momentum etf focus winning stock follow index large midcap stock strong risk adjust price momentum assess price movement prism risk pay allow etf investment strategy hold stock winner recent performance be likely persist say bryan fund focus risk adjust momentum help reduce volatility turnover add flip side etf investment strategy offer diluted momentum effect rebalance only twice year also hold stock amazon com amzn be largest hold follow facebook fb visa starbucks sbux home depot hd facebook visa starbucks be member ibd elite leaderboard list include stock biggest potential big gain etfs launch offer expense ratio dollar annual fee invest qual yield vs mtum etfs fall stock market today follow aparna narayanan twitter ibd_anarayanan
345,GILD,medical sector have be ailing lately be ibd sector monday issue sector leader hail health care regeneron pharmaceutical regn be featured friday column have pull back buy zone briefly climb range last week stock fall sharply wednesday
346,GILD,core consumer price exclude food energy rise january year fastest annual rise june labor department say overall price be unchanged month year energy cost slide second straight month yearly decline slow vs december september comparison get tougher core price be drive gain cost medical care health insurance housing include lodging away home health insurance cost rise month year biggest increase april obamacare exchange be launch subsidy help reduce price inflation measure take account add government cost well rise premium unitedhealth unh aetna aet humana hum have warn loss exchange unitedhealth most explicit possibly exit market condition don improve cost medical care rise january bring yearly increase tie highest early prescription drug company such gilead science gild valeant pharmaceutical vrx have be fire high cost annual rise prescription cost have decelerate end cost medical service rise month year biggest annual rise april rent primary residence rise january year match december annual gain biggest june lodging away home see volatile swing month month rise january year item exclude food shelter energy still be more moderate year core inflation rate have rise federal reserve target fed pay more attention price gauge core pce deflator have show little pickup recent month unitedhealth share fall fractionally stock market today morning trade aetna humana gilead science fall valeant pharmaceutical tumble well fargo downgrade drugmaker say be too many question
347,GILD,share biotech intercept pharmaceutical icpt spiked early afternoon trading friday report company be explore sale reuter cite anonymous source report intercept have be work investment banker week receive interest other company reuter do not name suitor intercept have be perpetual source
348,GILD,flagship stock etfs stage smart recovery wednesday close session high snap day lose streak oil drive narrative again commodity surge dollar plummet weak service datum marquee name struggle however first trust dow jone internet fdn drop top holding facebook fb amazon amzn
349,GILD,big pharma abbvie abbv deliver mixed earning report affirm guidance early friday stock fall company face new competition hepatitis front merck mrk abbvie report earning share exclude time item be year earlier quarter penny analyst consensus accord
350,GILD,share big biotech gilead science gild be more midday wednesday attorney general massachusett threaten legal action company drug pricing boston globe report attorney general maura healey have send letter gilead say pricing hepatitis drug sovaldi harvoni constitute unfair trade practice violation massachusett law sovaldi be launch december week round treatment harvoni be launch october equivalent length treatment large minority patient have be successfully treat week gilead defender have argue price be justified vast superiority drug previous treatment cure upward patient prevent expensive medical problem road however healey curative power drug only make high price more egregious pricing treatment manner effectively allow hepatitis continue spread vulnerable population opposed eradicate disease altogether result massive public harm price gilead drug have be criticize ever launch fact senate investigation last year culminate december report say price place inordinate burden state medicaid program be also focus healey letter however be able do anything expect abbvie abbv compete treatment viekira pak spark rebate war gilead december launch thus drug still have same official price tag re actually selling less analyst be expect further price erosion arrival merck mrk own compete treatment be due fda decision thursday gilead have say last few earning call hepatitis market have flattened be plan launch new version treatment june potentially treat genotype disease thereby broaden market gilead stock have be hammer re ignition drug price debate presidential race last fall have focuse more practice specialty drugmaker turing pharmaceutical valeant pharmaceutical vrx raise price older drug improvement quality house committee oversight government reform have plan hearing subject tuesday big east coast blizzard lead reschedule feb
351,GILD,food drug administration tuesday approve gilead science gild latest hepatitis pill company price significantly lower previous drug drug epclusa improve gilead previous drug sovaldi harvoni treat major genotype hepatitis virus hcv enlarge market eliminate need genotype testing most patient regime be pill day week patient decompensate cirrhosis very advanced liver disease take ribavirin standard generic hcv medicine gilead representative cara miller tell ibd email wholesale price week regimen drug be quite bit sovaldi harvoni raise outcry drug be launch respectively hcv business however have get more competitive then abbvie abbv merck mrk launch treatment significant discount treatment be genotype strain make market merck zepatier also be approve genotype miller note current standard treatment patient genotype be sovaldi combine bristol myer squibb bmy daklinza together cost twice much epclusa gilead have say position epclusa mainly genotype treatment be most difficult treat sound obviate need sovaldi harvoni company have engage extensive rebate keep drug competitive also many patient take harvoni only week gilead say have plan study shorter duration treatment epclusa gilead position anticipate cannibalization sovaldi revenue gt gt patient harvoni revenue gt patient due more friendly regimen potential omit ribavirin shorter duration gt patient write leerink analyst geoffrey porge research note porge forecast epclusa sale year jump next year expect quick drop next generation treatment start come note estimate be almost double consensus however fda approval be widely expect gilead stock shot stock market today gilead stock hit year low monday share tumble friday monday brexit vote fallout
352,GILD,biotech stock analyst ponder potential impact brexit friday morning find most big biotechs have low exposure run other headach exposure european union general range regeneron pharmaceutical regn celgene celg accord jeffery celgene nevertheless tell evercore isi less revenue come gilead science gild eu exposure be exposure be accord evercore calculation vertex pharmaceutical vrtx eu exposure be britain rbc capital market note expect grow vertex latest cystic fibrosis drug orkambi be suppose get reimbursement next year rbc analyst michael yee say research note not clear reimbursement negotiation be impact way however edison investment analyst maxim jacob opined research note measurement exposure be look wrong kind risk risk be global bear market kill biotech funding needham analyst alan carr write britain separation eu also bring regulatory complication road european medicine agency ema conduct centralize drug review process europe be base london carr write research note article withdrawal clause be invoked ema need move need establish new separate regulatory organization do not expect meaningful impact company drug now review ema brexit lead less efficient more expensive potentially lengthier regulatory process company seek approval eu biotechs be hammer rest market stock market today celgene fall regeneron be lowest level october gilead faltered year low vertex shed ibd biotech industry group plunge
353,GILD,drug giant eli lilly lly gilead science gild face key food drug administration action tuesday affect future lead disease treatment franchise advisory committee fda meet discuss expand label jardiance lilly year old drug treat type diabetes lilly want add label be drug also reduce death cardiovascular cause hospitalization heart failure risk death general claim be base large long term trial call empa reg result surprised industry last year patient jardiance show reduction death cardiovascular cause reduction hospitalization heart failure cut death cause fda approve label expansion lilly sale rep be able use marketing drug problem accord leerink analyst seamus fernandez be be not primary endpoint trial be secondary exploratory endpoint primary endpoint be point measurement major adverse cardiac event mace time first cardiovascular related death fatal heart attack fatal stroke result be more mixed only first point do jardiance achieve statistically significant difference fatal stroke incidence be actually slightly higher placebo group fda release briefing document panel friday morning fact conclusion affirm study do show reduction cv death advise include mace heart failure cause death info label be nonetheless interpreted positively analyst lilly stock be stock market today general brexit sell panel also consist substantial portion cardiologist help tilt balance highlight cv benefit panel view fernandez write research note friday preview event june fernandez have predict panel be battle statistical purist vs clinician add clinically large consistent cv death benefit see empa reg trial be view be precedent set precedent also be interest nordisk nvo recently report similar study diabetes drug victoza also bring reduction cardiovascular death not extent jardiance do nordisk have say also file label addition hasn yet decide language danish diabetes specialist fall friday tuesday also be deadline fda decide approve gilead latest hepatitis pill gilead last hepatitis launch sovaldi harvoni break financial record be restrict certain genotype virus new pill be approve genotype not only enlarge market also remove need test patient genotype writing prescription wall street have doubt fda approve drug interesting question be gilead price launch december sovaldi gain notoriety price week regimen harvoni launch october be more however abbvie abbv launch compete viekira pak december company start rebate war hit gilead income then january merck mrk price new hcv drug zepatier well gilead abbvie acknowledge hit financial remain be see gilead value pan genotypic nature new drug gilead stock be friday hit year low abbvie sank merck
354,GILD,jerry dodson parnassus endeavor fund parwx prove have socially responsible cake eat too mutual fund favor company provide employee outstanding workplace so do other fund parnassus investment dodson founder include thing offer worker profit sharing time work parent paid time volunteer work fair treatment clear communication investment team parnassus have management also screen company engage extraction exploration production manufacturing refine fossil fuel none criterium have prevent endeavor outperform peer broad market past year be top perform environmental social corporate governance esg fund year end june average annual return decade say morningstar inc averaged yearly gain span fund also rank top large cap growth mutual fund period top past year be ibd best mutual fund award winner glow category equity fund growth fund large cap outperformed year period end dec be ahead roughly diversify stock fund so far year dodson affinity esg investing have deep root founder parnassus investment age goal mind earlier work be harbinger be come political science major uc berkeley get mba harvard business school then go work nonprofit outfit help minority own business help organize continental saving america become president ceo develop innovative product depositor invest solar energy project dodson be lead manager parnassus fund parnx parnassus asia fund pafsx sole manager endeavor office san francisco year old dodson talk investor business daily in out investment approach begin use social screen ibd re juggle tough task not only use esg criterium also run concentrated portfolio be tougher dodson know hard part be get philosophy tweak simulation be do many year once understood strategy work size portfolio just follow ll be surprised take advice journalist size strategy be social friend milton moskowitz be writing news story start book be best place work look return be publicly trade thought start fund base milton thought stick company disagree say screw anyway take year look fundamental metric correlated good stock performance take year back testing paper then more year run portfolio open public ibd aside esg criterium look seek large cap company wide moat strong competitive advantage quality management team act best interest shareholder have get right dodson succinctly ibd information technology be largest sector weighting march be typical exposure tech dodson usually be largest sector not normally reason be know sector well silicon valley be road more more right here city also term workplace technology company seem step ahead provide good environment google alphabet googl now have generous maternity leave gym work day do charitable event compare say steel industry workplace issue score stronger tech company ibd speaking alphabet be trend sideway late april do still stock dodson start buy december now low think make more gain re right be pretty flat regard long term hold get great moat good social story ibd do think have more room run dodson primarily moat look develop new product have huge cash stake talented workforce search engine give revenue earning stability don know new idea re work know re look new product ll find something ibd general emphasize esg criterium more other right dodson be more focuse workplace company treat employee then environment workplace be component social ibd be workplace part social dodson word social cover lot mean company treat employee mean safety record privacy policy relationship community company operate diversity program good clear honest communication ibd do ever invest stock feature be very attractive even financial performance be not so bright dodson past ve do do endeavor fund parnassus fund parnx stock be control datum supercomputer company hire former prisoner do great social thing business strategy be just invest be worst mistake ever have cure pick environmental social reason alone ibd let talk individual holding latest disclosure citrix system ctxs earning share rise past quarters lot person think enterprise software developer specialize desktop virtualization lose focus reorganization have involved layoff staff contractor do situation look dodson reason invest be gotomeeting app be be spun gotomeeting be similar citrix xenapp be thousand mile away server do application use smartphone laptop deliver safely mobile device make successful person want application company deliver want ibd stake apply material amat be be satisfied progress dodson be doldrum initiate position equipment used make semiconductor tend be volatile sale earning be very cyclical try buy time stock have fall then ride now rise believe apply benefit significant order growth lead etch deposition tool ibd ciena cien earning share have slow growth quarters growth decline past frame everything dodson ve own quite more volatile expect make communication glass wire equipment move impulse be voice datum transmission line earning have be lumpy time have equipment maker have up down ve hold cycle more volatile expect company think have more upside ibd do own robinson worldwide chrw not tech story revenue have decline quarters row dodson freight forwarder focuse trucking re right hasn do well primarily shipping have not picked much anticipate economy be grow annualize rate less get trucking freight forwarding grow economy have grow more so play economic recovery accelerate average cost be stock be mid so ve do well ibd charle schwab schw ep grow have accelerate quarters share price have be weak play here dodson re tie pay schwab customer come key lot brokerage firm include schwab collect interest margin loan interest rate so low don make much interest rate increase then huge earning increase schwab mid now go economy get better rate go schwab take ibd intel intc ep growth be speeding growth computer chip come dodson make chip personal computer smartphone other application also make chip server sale be go ve be try year get mobile device market finally have semiconductor go iphone re try get more communication other growth area apple aapl chip other mission re banking move intel higher ibd procter gamble pg be classic defensive stock revenue share have decline quarters be want dodson re right revenue decline ve get amazing brand crest tide gillette head shoulder need new growth engine re look do have growth ahead haven reach conclusion ibd ibm ibm ep be straight quarters sale be frame row invest
355,GILD,dodson only defense be warren buffett own lot more do first buy end expect turn cut emphasis hardware point growth consult software offset decline hardware hasn happened yet time forward earning believe share price be bargain table ibd be buffett selling dodson look filing ve see sign buffett selling sure have same regret have ibd grainger gww ep sale finally notch gain decline quarters share be not make headway dodson grainger make everything sun maintenance sense be play overall economy economy grow fast enough grainger do well product touch almost sector economy ibd gilead science gild ep revenue growth have slow recent quarters do still stock dodson be expect sale increase quite bit hepatitis product have cut price competition abbvie abbv merck mrk make therapy hep gilead be great lab develop new therapy time company do well ibd fund begin different name name change jerry dodson way pick stock hasn change start workplace fund have good performance early name workplace fund be not get attention thought person staff say get strange reaction broker advisor weren sure name meant not pick more general name say say get more shareholder money more acceptance ibd be fund concentrated dodson primarily find enough company be undervalue meet workplace social criterium ibd fund have name typical be dodson have name re look more last couple year go so ibd fund have cash weighting be hard find kind stock dodson correct try stay fully invest possible ibd jerry make day run fund do run totally pc fund know only invest ammo tobacco oil dodson endeavor manage include longer exist other parnassus fund prior find manager founder parnassus investment prior work year president small bank san francisco spend year foreign service officer department state serve panama vietnam ibd be investment style embraced esg dodson ve embraced esg firm be founder be founding principle ibd get esg dodson personal philosophy have always revolve esg wasn sure be used business philosophy continental start program allow saver put money special saving account be lend solar energy installation much pleasant surprise program be very popular convince be market investor want make positive impact money lead founding work asset money fund take esg factor account investing money market security turn lead formation parnassus investment take esg experience then add value oriented philosophy benjamin graham writing admire strain form basis parnassus investment philosophy ibd do come parnassus name dodson live street parnassus avenue san francisco look mythology mount parnassus greece discover be site oracle delphi like image oracle often go prevailing wisdom fit contrarian value oriented investment philosophy ibd re do have plan retire dodson plan retire chief executive officer however plan stay indefinitely manager endeavor find someone well qualify take
356,GILD,stock index close mixed monday shake weakness oil price close alphabet googl surge record high company post result beat estimate extend trading rally parent company google become most valuable company world nasdaq climb erase early loss more
357,GILD,amazon com amzn get new analyst call friday walt disney be downgrade competition netflix nflx intel intc have price target cut susquehanna initiate coverage amazon perform rating price target online retail giant stock price touch new high dec have spend most
358,GILD,phone gun car gamble factor notable insider trade disclose week areapple aapl iphone chip supplier technology avgo gun maker wesson swhc sturm ruger rgr general motor gm gilead gild technology chipmaker ceo hock tan have sell company share value last month
359,GILD,gilead science gild regeneron pharmaceutical regn alexion pharmaceutical alxn be focus screen day top fundamental company top fundamental be highly rate ibd have year sale earning growth rate least gilead broaden fight hcv not bring huge drug launch see previous year gilead science know highly effective highly price hepatitis drug sovaldi harvoni have seek approval combination pill use hcv genotype ibd report fda be set rule drug june company have ibd composite rating best possible also have year ep growth rate year sale growth rate stock take wild ride weave day move average share close stock market today make way consolidation begin june praluent lift pharmaceutical develop cholesterol drug praluent sanofi sny have year ep growth rate year sale growth rate composite rating be stock rise share sank earlier week fda datum erroneously indicated praluent patient be prone suicide forbe report share fall thursday rebound wednesday last month unitedhealth unh nation largest health insurer choose give praluent prefer access regeneron drug eye drug eyelea have also perform strongly alexion score approvalrare disease biotech alexion last month get fda approval kanuma rare disease drug use genetic organ disease lysosomal acid lipase deficiency kanuma be first drug get fda disease alexion have year ep growth rate year sale growth rate company composite rating be stock drop thursday stock clear month long cup handle base dec share have slip follow bill peter twitter ibd_bpeter
360,GILD,gilead science gild regeneron pharmaceutical regn alexion pharmaceutical alxn be focus screen day top fundamental company top fundamental be highly rate ibd have year sale earning growth rate least gilead broaden fight hcv not bring huge drug launch see previous year gilead science know highly effective highly price hepatitis drug sovaldi harvoni have seek approval combination pill use hcv genotype ibd report fda be set rule drug june company have ibd composite rating best possible also have year ep growth rate year sale growth rate stock take wild ride weave day move average share close stock market today make way consolidation begin june praluent lift pharmaceutical develop cholesterol drug praluent sanofi sny have year ep growth rate year sale growth rate composite rating be stock rise share sank earlier week fda datum erroneously indicated praluent patientswere prone suicide forbe report share rebound wednesday last month unitedhealth unh nation largest health insurer choose give praluent prefer access regeneron drug eye drug eyelea have also perform strongly alexion score approvalrare disease biotech alexion last month get fda approval kanuma rare disease drug use genetic organ disease lysosomal acid lipase deficiency kanuma be first drug get fda disease alexion have year ep growth rate year sale growth rate company composite rating be stock slip wednesday stock clear month long cup handle base dec share have slip follow bill peter twitter ibd_bpeter
361,GILD,stock end mixed tuesday make feeble attempt rebound sharp sell prior day add dow jone industrial average edge nasdaq dip volume be lower board fall nyse nasdaq compare monday accord preliminary datum apple aapl be dow biggest decliner sink japan nikkei newspaper report tech giant cut production iphone model more plan first month year report cite apple supplier japan abroad apple former market leader be now more week high accumulation distribution rating stand indicate heavy selling elsewhere stock market today gilead science gild rise nearly follow positive result experimental hepatitis drug semiconductor stock be worst performer ibd macom technology solution mtsi make semiconductor auto communication defense industry lose stock erased gain past buy point cup handle base trigger sell signal singapore base chip designer technology avgo drop light trade work handle long consolidation buy point meanwhile wesson swhc be easily biggest winner ibd share jump firearm maker issue bullish guidance late monday rpm international rpm be company due report quarterly earning wednesday economic report schedule wednesday include institute supply management index service sector activity december factory order november trade balance november minute federal reserve dec meeting follow scott stoddard twitter ibd_sstoddard
362,GILD,treasury department annual financial review medicare find growth rate win trigger cost cut panel week send drug stock higher wednesday ahead report tuesday speculation have break growth be high enough trigger independent payment advisory board ipab come way cut spending brooking institution have schedule event thursday discuss issue last year report project hospital insurance trust fund be deplete just year now brooking say report also predict more immediate controversial event independent payment advisory board ipab famously nickname death panel be require submit proposal reduce medicare spending reduction take place report medicare board trustee actually moved depletion date year earlier say still wasn enough growth cost trigger ipab seem turn major medical group biotech stock have head south tuesday afternoon mid morning announcement ibd medical biotech group rise ethical drug group be even ipab have be trigger analyst doubt impact have be big give restriction sort cut panel make late tuesday rbc capital market michael yee run number note dual eligible add medicaid patient thus grow yee write research note take amgen amgn biogen biib celgene celg gilead science gild regeneron pharmaceutical regn vertex pharmaceutical vrtx medicaid exposure grow get larger medicaid rebate calculation show change revenue more so happened celgene stock fall heavy trading tuesday rise more intraday close stock market today regeneron stock climb intraday set rise drop tuesday amgen biogen share rise fractionally sank nearly tuesday timing hedge fund manager leonard yaffe wasn convince ipab business be actual reason stock move biotechs have be trend downward early june rebound biopharma stock today be much more offset concern mentioned yesterday well likelihood fund redemption stock have become very attractive prospect several company be bright yaffe write email
363,GILD,gilead science gild apple aapl lead largest amount spend stock buyback first quarter total set year high company seek boost stock price slumping market accord dow jone index gilead spend spend prior quarter apple spend slightly prior quarter company spend total stock buyback be second largest expenditure record follow spend report dow jone index information technology sector continue dominate buyback follow apple sector be microsoft msft oracle orcl alphabet googl microsoft spend oracle alphabet follow gilead apple biggest spender general electric ge be then come pfizer pfe mcdonald mcd microsoft be overall ninth consecutive quarter more company reduce year year diluted share count least thereby boost earning share least pace buyback be partially drive company support stock open downturn year coincidentally start early february many earning lock up end say howard silverblatt senior index analyst dow jone index statement announce tally upswing expenditure participation appear persist market meaning upturn be not single shot saidaccording silverblatt cash reserve set record increase top prior record set end silverblatt add current cash level be week expect operate income give corporation leeway expenditure buyback leader apple stock rise end quarter apple stock be fraction close stock market today gilead shrank end quarter gilead stock end trading wednesday
364,GILD,stock turn negative afternoon trading positive news drug stock homebuilder tesla motor tsla plunge shareholder objected surprise bid solarcity scty dow jone industrial average fall nasdaq volume stock market today be run tuesday level nyse nasdaq stock hit session high late morning lead drug biotech stock such gilead science gild regeneron pharmaceutical regn government say next year create independent payment advisory board cost cut body investor have expect ipab sometimes refer obamacare death panel critic take effect year gilead science climb sucampo pharmaceutical scmp rise regeneron pharmaceutical add more session also rise sale exist home hit year high kb home kbh report better expect earning los angele base kb home say late tuesday profit latest quarter jump cent share easily beating wall street forecast revenue increase biggest increase quarters kb home rise intraday stock reach briefly clear buy point long deep cup handle base beazer home bzh turn negative lennar len rise do kb home stack rival building industry find ibd stock checkupbuild product stock tile shop holding tts also fared well jump new high intraday trading just buy point cup base heavy volume meanwhile restoration hardware rh vault analyst bb say merger luxury home furnishing retailer rival william sonoma wsm make even more sense do year william sonoma sell furniture accessory own name brand such pottery barn rise more downside tesla motor plunge announce plan late tuesday buy money lose solarcity affiliated installer solar panel roughly solarcity jump billionaire entrepreneur elon musk be biggest shareholder tesla solarcity say win vote deal
365,GILD,drugmaker medivation mdvn say late tuesday have enter confidentiality agreement several potential buyer include sanofi sny latter raise bid company medivation have previously reject sanofi bid share cash inadequate lead sanofi late propose candidate take medivation board tuesday medivation say board have also reject offer share contingent value right cvr sale medivation drug candidate talazoparib share nonetheless medivation go ahead enter confidentiality agreement sanofi unspecified number other unnamed party confidentiality agreement include customary month standstill provision subject limit early termination event medivation expect provide party opportunity term review public information meet medivation management say medivation press release early anonymously source report say medivation have enter confidentiality agreement pfizer pfe amgen amgn celgene celg gilead science gild astrazeneca azn also have be leak prospective buyer tuesday announcement be leak reuter half hour market close send medivation stock share be fraction hour stock have be form flat base hit month high day pfizer amgen news come hold spot ibd list top perform stock past month friday medivation schedule conference call wednesday market close say focus talazoparib drug late stage development breast cancer belong class drug call parp inhibitor get boost last week biotech tesaro tsro announce surprise success parp inhibitor ovarian cancer
366,GILD,drug pricing be wall street mind again friday well fargo tap mylan myl next target activist rbc consider impact potential new law limit price california well fargo analyst david maris write valeant pharmaceutical vrx turing pharmaceutical be haul front congress scrutinize press policy drastically hike price recently acquire drug be keep eye other company universe have be do lot price increase last month mylan have raise price more product more product maris write research note late thursday mylan have take exceptionally large price increase include increase ursodiol generic medication used treat gallstone increase metoclopramide generic medication commonly used treat reflux disease gerd gastroparesis increase dicyclomine medication used treat irritable bowel syndrome maris add last month mylan add price tag biggest product contribute revenue most recent quarter believe give regulatory environment pricing action bring greater regulatory scrutiny headline risk additionally wonder aggressive price increase be be used make ep target offset disappointing sale other area mylan respond follow statement mylan have always be know have industry broadest most globally diversify business model portfolio have successfully manage balancing numerous variable include natural price reduction have always be inherent generic industry flaw analysis focuse small number product more product mylan sell globally approx product sell north america be simply self serve mislead investor be especially true give generic product represent extremely small percentage mylan approx north american generic business mylan business model be not today have ever be premised price hike mylan stock fall stock market today fall low valeant retreat friday week rbc capital market biotech analyst michael yee be also ponder drug pricing friday calculate potential impact california drug price relief act cdpra stock universe include amgen amgn gilead science gild celgene celg biogen biib vertex pharmaceutical vrtx cdpra go popular vote california proposition system november require state health care payer medical buy drug similar price veteran administration usually obtain large discount believe cdpra create slippery slope measure encourage other state follow suit ohio have also propose be get signature yee write think such attempt reduce drug cost merely prompt drug maker just raise va drug price thus help less person not result real saving benefit nonetheless yee estimate similar law pass state shave annual ep cover company discussion large cap biotech company suggest firm be aware wouldn be surprised proposal pass so note investor very least be inform potential headline model pricing risk write drug stock be friday rest market amgen fall gilead biogen celgene vertex pharma dip
367,GILD,past few year have bring groundbreaking drug launch such record breaking gilead science rollout hepatitis medicine first pd cancer fighter merck bristol myer squibb bmy year look be somewhat slower front drug firm aim most new launch smaller market build
368,GILD,etf investor get taste snap back market action be hope tuesday choppy trading session major index steady modestly sharp drop kick stock reversed lower intraday oil briefly dip barrel first time december however etfs tracking dow finished higher well session lows health care help lead advance sector utility real estate post loss powershare qqq qqq tech biotech heavy exchange trade fund pop stock market today etf be dec high stock holding celgene celg jump illumina ilmn vertex pharmaceutical vrtx give regeneron regn investor seem have digest monday biotech related news big biotechs celgene vertex have offer mixed outlook major investor conference cause disappointment illumina meanwhile announce new unit call grail focuse detect cancer early simple blood sample apple aapl hold qqq portfolio weighting gain tuesday iphone maker stock briefly re-cover level first time day buoy analyst upgrade well rumor cheaper base model iphone apple electric car stock be week high diving deeply day move average december spdr biotech xbi surge massive volume however equal weight etf hold stock be july high xbi monday undercut late september lows be spur presidential candidate hillary clinton comment price gouge drug industry recent slump analyst rbc capital market be report reaffirm confidence growth prospect biotech sector tuesday note ishare nasdaq biotechnology ibb advanced cap weight etf also breach late september low monday be week high hold stock biggest stake celgene biogen biib amgen amgn gilead gild regeneron regn xbi smaller cap skew help give performance boost rise vs gain ibb gold dollargold price fall third straight session tuesday gold price be moderately lower tuesday more profit take chart consolidation follow recent gain see price hit month high late last week jim senior technical analyst write commodity monitor kitco news less anxious world market scene day firmer dollar index be also help pressure safe haven gold market etf bullish dollar extend gain retake day line monday greenback rise vs other major world currency bellwether etfs here look major exchange trade fund tracking various asset class perform today follow daily etf market action be key successful investing spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs ishare core aggregate bond agg rs powershare db bullish uup rs follow aparna narayanan twitter ibd_anarayanan
369,GILD,big pharma bristol myer squibb bmy say friday selling hiv drug pipeline viiv healthcare company majority own glaxosmithkline gsk transaction worth
370,GILD,viiv agree pay upfront clinical stage product late phase testing other phase number preclinical discovery program bristol myer receive milestone payment clinical drug make testing process approval earlier stage product do same once drug hit market viiv promise sale milestone clinical asset other also pay bristol myer undetermined amount tiered royalty
371,GILD,move help consolidate glaxo position main rival gilead science gild dominant player hiv prevention treatment
372,GILD,view bms phase asset complement nicely viiv biggest long term revenue driver tivicay integrase inhibitor triumeq integrase inhibitor nucleoside reverse transcriptase inhibitor combo write leerink analyst seamus fernandez research note currently available combination antiretroviral therapy include market lead product gilead target different stage hiv lifecycle none approve agent act viral assembly maturation
373,GILD,bristol myer fulfill statement june longer be develop direct act antiviral hiv
374,GILD,believe myriad drug be next leap forward be really go be curative therapy bristol myer specialty drug chief dougla manion tell ibd interview last month science break be early mover get back game
375,GILD,bristol myer stock be afternoon trading stock market today glaxo stock be fraction
376,GILD,follow amy reeve twitter ibd_areeve facebook big pharma bristol myer squibb bmy say friday selling hiv drug pipeline viiv healthcare company majority own glaxosmithkline gsk transaction worth viiv agree pay upfront clinical stage product late phase testing other phase number preclinical discovery program bristol myer receive milestone payment clinical drug make testing process approval earlier stage product do same once drug hit market viiv promise sale milestone clinical asset other also pay bristol myer undetermined amount tiered royalty move help consolidate glaxo position main rival gilead science gild dominant player hiv prevention treatment view bms phase asset complement nicely viiv biggest long term revenue driver tivicay integrase inhibitor triumeq integrase inhibitor nucleoside reverse transcriptase inhibitor combo write leerink analyst seamus fernandez research note currently available combination antiretroviral therapy include market lead product gilead target different stage hiv lifecycle none approve agent act viral assembly maturation bristol myer fulfill statement june longer be develop direct act antiviral hiv believe myriad drug be next leap forward be really go be curative therapy bristol myer specialty drug chief dougla manion tell ibd interview last month science break be early mover get back game bristol myer stock be afternoon trading stock market today glaxo stock be fraction follow amy reeve twitter ibd_areeve facebook
377,GILD,stay top stock market involve more know stock portfolio be rise fall else be check sector count ibd ibd be computer generate list stock strongest fundamental technical breaking ibd sector count give idea strength reside stock market list publish ibd weekly week june sector breakdown look stock medical sector software retail build chip internet other sector involved only stock first question ask be do compare ibd lineup start year end be medical stock software sector finance retail business service bank chip first glance appear be similarity medical software retail chip count stay same however need ask second question have rotation occur sector medical sector show biggest change essentially unchanged count example end biotechs be well downward trend former leader such biogen biib gilead science gild peaked first half end only biotechs be ibd recent ibd biotechs make list be not big winner previous cycle stock be medivation mdvn emergent biosolution ebs be leader biotech rebound possible unlikely only biotechs have composite rating better mentioned therapeutic anik ligand pharmaceutical lgnd software stock have be steady story software stock ibd end be still list build sector only stock make ibd end now be none be homebuilder retail be mix fresh name old name dave buster entertainment play ulta beauty ulta be ibd end year be now stock left list alibaba baba starbucks sbux alibaba have relative price strength rating meaning hefty market be outperform china base stock also earning growth decelerate past quarters street have revise annual earning lower year next starbucks also have struggle depart ibd rs rating be miserable annual earning revision however be upward quarterly earning growth have be steady revenue growth have step other current retail stock ibd be copart cprt dollar general dg sometimes sector check win lead many big conclusion aside rotation medical sector increase build sector change appear minimal
378,GILD,small drugmaker medivation mdvn continue battle sanofi sny hostile takeover bid wednesday latter try replace board big biotechs celgene celg gilead science gild be say be think join fray sanofi propose candidate be willing fully fairly evaluate medivation strategic option believe medivation current board do not do unanimously reject sanofi unsolicited bid april medivation respond statement urge shareholder reject attempt call tactic sanofi facilitate substantially inadequate time proposal acquire medivation sanofi be only suitor go public anonymous source have be tell medium variety other company be think make bid medivation reportedly sign disclosure agreement pfizer pfe amgen amgn imply be open be buy somebody other sanofi wednesday bloomberg say celgene gilead be talk advisor idea hadn actually approach company celgene gilead have be urge investor analyst make sizable acquisition especially gilead massive hepatitis franchise be already erode face competition medivation current month sale wouldn make big impact gilead top line much interest come medivation future prospect prostate cancer drug xtandi be still ramp company study use other disease also have few earlier stage drug pipeline medivation stock have lately go tight sharp run buyout speculation fall stock market today sanofi climb gilead edge celgene be
379,GILD,most stock mutual fund extend rally begin march strategist be figure way deal expect stock market headwind summer month average diversify stock fund rise vs setback january february follow rally march inch april leave higher year date comparison advanced go forward most investor speak ibd expect market volatility summer re ready click here see list mutual fund month leaderslew piantedosi manager eaton vance mutual fund total asset have guardedly optimistic glass half full outlook believe core portfolio secular grower say include name amazon amzn facebook fb alphabet googl such name like be nxp semiconductor nxpi provide semiconductor content automobile industrial space say piantedosi be manager focuse growth elcix focuse growth opportunity eifgx tax manage growth eitgx tax manage multus cap growth eacpx huge secular shift area automation other new technology be drive demand new semiconductor content add car new feature include crash avoidance music rear view camera driver assist sensor other safety system overall trend electrical vehicle industrial product comparable shift robotic other form automation say area nxp be lead provider say click here see list mutual fund category more cautious investor glass half empty view be james lead manager payden equity income fund pyvlx brace volatility say re enter summer do not take lot bad news move market so equity income investor drink own kool aid say investor be serve well focuse company continue provide income low volatility manner theme park operator flag entertainment be sort stock like right now come bankruptcy start decade say re improve revenue stream management have improve quality park introduce new ride ve increase membership rate mean person go more often spend more money ve introduce go front line pass person gobble change have help ve improve recur revenue model say so re steady cash generate company able maintain grow dividend yield market notch modest gain investor be embolden stock market news turn be less scary have fear month outset say earning season be negative not bad person have expect say prospect brexit exit european union fade slightly add price oil rise just barrel april just addition many investor grow more comfortable prospect interest rate hike soon june july small cap growth fund lead tack science technology fund pace sector jump investor be optimistic gravitate growthier area market piantedosi say tech world equity fund fared far lose japanese fund do best abroad gain taxable bond fund lose treasury fund edge tax exempt fund gain capped streak month row market gain fear dominate start year keep fading piantedosi say add consumer have be strong housing be robust europe be look better term investor focus day day event such brexit decision federal reserve meeting november election monthly jobless report monthly purchasing manager index pmi indicator health manufacturing sector noise remember fed raise rate see sign strengthen economy help corporate earning say karyn cavanaugh senior market strategist voya investment management member multiasset strategy solution group end day stock buy boil buy corporate earning cavanaugh expect uptick corporate earning still fail occur don expect consumer spending stay strong warn cavanaugh be also manager voya global perspective iwpvx say market winning streak be likely end valuation be high earning growth be weak note piantedosi expect disruptive innovator continue grab market share so like amazon instead brick mortar department store macy dd kohl kss report lower quarterly earning share suffer stock price decline amazon report ep gain april accelerate prior frame share gain like facebook google similar reason huge shift continue advertising spending traditional medium online social medium say ditto health care political talk potential drug price regulation bullish long term big cap biotechs gilead science gild celgene celg vertex pharmaceutical vrtx know pricing issue shake say plenty growth company continue innovate piantedosi be not confine bet high flyer diversify portfolio don want be pedal metal time say name consumer staple not cheap provide stability predictability yield philip morris international pm be favorite say be focuse overseas smoking headwind be less have lot pricing power currency headwind be diminish likely turn tailwind dividend yield be pinnacle food pf be like nice steady eddie food company decent growth characteristic food group doesn show great characteristic say pinnacle dividend yield be
380,GILD,specialty drugmaker jazz pharmaceutical jazz say monday be acquire small biopharma celator pharmaceutical cpxx cash send latter already surge stock soar celator go public november fail make impression stock market last march report positive late stage trial result vyxeo treatment high risk acute myeloid leukemia aml vyxeo be co formulation chemotherapy drug cytarabine daunorubicin used celator proprietary combiplex platform trial extend overall survival longer drug administer separately follow day stock pop continue climb close friday jazz agree substantial premium share note vyxeo be set have year exclusivity fda orphan drug designation celator be currently prepare regulatory submission vyxeo acquisition add new orphan product potential short long term revenue generation expansion international commercial platform jazz ceo bruce cozadd say statement vyxeo be expect hit market late assume sell side consensus forecast be directionally accurate jazz be pay time peak sale risk indication look relatively fair jazz generate upside higher secondary aml sale expand vyxeo label other aml patient population other blood cancer write leerink analyst jason gerberry research note celator stock close stock market today reach jazz stock dip jazz already have small presence blood cancer erwinase chemotherapy program acute lymphoblastic leukemia main source income be narcolepsy treatment xyrem age patent be challenge earning report month jazz announce settlement generic challenger other case remain outstanding also filing jazz reveal have receive federal subpoena investigate relationship co pay support charity subject grow interest legal authority lately due allegation support high drug price big biotechs biogen biib gilead science gild have also be target similar subpoena
381,GILD,big biotech gilead science gild agree license immunology drug smaller counterpart galapago glpg thursday deal be worth more galapago drug be filgotinib be due start phase trial rheumatoid arthritis crohn disease next year gilead agree pay license fee buy galapago stock upfront promise milestone payment drug succeed clear regulatory process launch gilead pay tiered royalty start sale split profit filgotinib be jak inhibitor class abbvie abbv several other drugmaker be develop abbvie once have own licensing deal galapago september opted right license filgotinib so focus develop house drug time abbvie cite rat study indicate filgotinib be toxic testicle lead galapago discussion fda proceed new trial however phase result human be positive competitive other rheumatoid arthritis drug development write rbc capital market analyst michael yee research note add crohn disease result seem lag celgene celg ged hard compare cross trial different geography galapago stock jump early trading stock market today midafternoon be more gilead stock be flat follow amy reeve twitter ibd_areeve facebook
382,GILD,end year approach top executive tesla motor tsla first solar fslr gilead science gild american airline group aal be able throw quality new year party selling company own stock tesla motor co founder chief technology officer jb straubel thursday file form security exchange commission
383,GILD,lot dividend mutual fund be get clobber year total return
384,GILD,fact many higher month yield year date performance dec
385,GILD,so investor plunge beaten stock mutual fund category do have place other go
386,GILD,be crucial question many investor especially focuse retirement plan
387,GILD,charlie gaffney manager eaton vance dividend builder only fund space track morningstar inc have post gain year see good thing ahead category
388,GILD,even federal reserve raise short term interest rate wednesday rate remain historically low say
389,GILD,bode well type stock name generate income stream grow time market cycle add gaffney fund be year fifth best peer
390,GILD,still several sector stock tend be big dividend payer be pressure say many especially energy sector already have cut dividend
391,GILD,ability energy material sector rebound depend economic growth continue rebound global gdp growth also improve say
392,GILD,david joy chief market strategist ameriprise financial say income oriented investor focus fund stock aim increase dividend investor not focus fund aim pay highest dividend
393,GILD,dividend yield be high often price be depress company be wound joy say company be low quality borrow money supplement dividend
394,GILD,company need borrow pay dividend only find increasingly difficult service debt now interest rate have begin rise
395,GILD,find fund aim stock increase dividend look fund investment objective
396,GILD,want fund say focus company have history grow dividend time sustainable fashion joy say don want be fund say something maximize income consistently stable principle stable net asset value
397,GILD,currently be rough correlation heavy weighting energy real estate stock lower performance
398,GILD,not surprising give dismal performance stock sector
399,GILD,year date gain be go thursday market rally news federal reserve rate hike unite state oil fund etf uso be year
400,GILD,vanguard reit index fund etf vnq be year be still jan high year
401,GILD,clearbridge tactical dividend income fund have month yield top peer group
402,GILD,year date return be be second worst group well group average
403,GILD,energy weighting be latest disclosure real estate weighting be
404,GILD,contrast gaffney fund have only energy real estate
405,GILD,gaffney buy tobacco stock month share price be beaten
406,GILD,latest disclosure own altrium mo be year have dividend yield
407,GILD,also like insurer hold ace ace be year have yield
408,GILD,have also target company strong balance sheet free cash flow allow start pay dividend future say
409,GILD,buy apple aapl year restart dividend
410,GILD,buy gilead science gild shortly begin dividend february
411,GILD,follow paul katzeff twitter ibd_pkatzeff lot dividend mutual fund be get clobber year total return fact many higher month yield year date performance dec so investor plunge beaten stock mutual fund category do have place other go be crucial question many investor especially focuse retirement plan charlie gaffney manager eaton vance dividend builder only fund space track morningstar inc have post gain year see good thing ahead category even federal reserve raise short term interest rate wednesday rate remain historically low say bode well type stock name generate income stream grow time market cycle add gaffney fund be year fifth best peer still several sector stock tend be big dividend payer be pressure say many especially energy sector already have cut dividend ability energy material sector rebound depend economic growth continue rebound global gdp growth also improve say david joy chief market strategist ameriprise financial say income oriented investor focus fund stock aim increase dividend investor not focus fund aim pay highest dividend dividend yield be high often price be depress company be wound joy say company be low quality borrow money supplement dividend company need borrow pay dividend only find increasingly difficult service debt now interest rate have begin rise find fund aim stock increase dividend look fund investment objective want fund say focus company have history grow dividend time sustainable fashion joy say don want be fund say something maximize income consistently stable principle stable net asset value currently be rough correlation heavy weighting energy real estate stock lower performance not surprising give dismal performance stock sector year date gain be go thursday market rally news federal reserve rate hike unite state oil fund etf uso be year vanguard reit index fund etf vnq be year be still jan high year clearbridge tactical dividend income fund have month yield top peer group year date return be be second worst group well group average energy weighting be latest disclosure real estate weighting be contrast gaffney fund have only energy real estate gaffney buy tobacco stock month share price be beaten latest disclosure own altrium mo be year have dividend yield also like insurer hold ace ace be year have yield have also target company strong balance sheet free cash flow allow start pay dividend future say buy apple aapl year restart dividend buy gilead science gild shortly begin dividend february follow paul katzeff twitter ibd_pkatzeff
412,GILD,top executive gilead science gild starbucks sbux well higher up tesla motor tsla skywork solution swks halliburton hal be noteworthy insider trade disclose week tesla director kimbal musk brother ceo elon musk disclose tuesday dec sale share electric vehicle maker last month
413,GILD,long await report senate finance committee gilead science gild pricing hepatitis drug come tuesday expect be highly critical sen ron wyden ore chuck grassley iowa say spring investigate gilead pricing policy gilead price new hepatitis drug sovaldi week regimen criticism price lead gilead nearly other biotech stock brief nose dive group re-cover presidential candidate hillary clinton raise drug pricing issue more broadly september tuesday report senator say examine more page internal gilead document interview dozen health care expert conclude gilead price sovaldi successor harvoni maximum profit rather broad access say fact gilead have underestimated much health insurer pharmacy benefit manager restrict access confront widespread initiation access restriction gilead refuse offer substantial discount do not significantly modify contract strategy improve patient access senator go press release summarize report finding example gilead offer medicaid program supplemental rebate percent however offer come precondition state have drop access restriction state already face steep financial burden accept precondition most case have increase budgetary impact rather ease senator admit price sovaldi harvoni have drop abbvie abbv launch compete treatment last december say concern remain particularly public payer community high cost treat million person infected hepatitis well budgetary effect future single source innovator not face competition quickly not surprisingly gilead disagree conclusion world more individual have be treat gilead hcv medication introduction gilead say email statement gilead responsibly thoughtfully price sovaldi harvoni product be initially price line previous standard care rebate discount now place price today be less cost prior regimen even therapy have significantly higher cure rate very few side effect gilead stock react little news dip fraction late afternoon stock market today follow amy reeve twitter ibd_areeve facebook
414,GILD,investor etfs be start show appetite risk lavish money defensive dividend pay stock month end few segment stock market have fed such craving much biotech spdr biotechnology xbi jump past week thursday growth stock begin act better quarter date steep sell biotechs first quarter xbi sit week high still market watcher think biotech group strike winning note again flow investor money be say follow performance xbi certainly need have leak second quarter so far asset have shrink nearly biotech etf be investor hungry return not afraid take more risk portfolio be skewer more smaller cap early stage biotech firm have decidedly uncertain prospect explosive upside potential write morningstar analyst robert goldsborough xbi hold highly rate ibd stock be spearhead recent rebound biotech group ligand have grow earning annual rate past year sale have ibd composite rating best possible thank part share price jump past month heavy institutional buy earning growth slow most recent quarter averaged past stanzas sale growth accelerate last quarters drugmaker be embroil fend sanofi sny hostile takeover bid biotech giant celgene celg gilead science gild be also say be possibly join fray company plan separate publicly trade company company focus biodefense product other revolve oncology hematology therapeutic emergent have year ep growth rate year sale growth rate help comp rating ligand medivation emergent be stock xbi portfolio xbi be cheapest biotech etfs expense ratio have produce annual average gain past year vs flagship ishare nasdaq biotechnology ibb ibb be cap weight skews larger player biotech industry include celgene gilead have lower beta xbi make slightly safer way play volatile industry past week ibb add quarter date etf be
415,GILD,big biotech gilead science gild get downgrade several price target cut friday report miss expectation send stock tumble maxim group analyst jason kolbert downgrade gilead hold buy note record breaking launch hepatitis drug sovaldi harvoni be come competition tough year year comparison new patient number increase product margin patient be lower result increase hcv price competition merck mrk zepatier increase discount rate higher expect rebate claim kolbert write research note management believe hcv product have stabilize market share be be not so sure leerink analyst geoffrey porge lower price target gilead maintain outperform rating note company still have huge reserve cash write hcv franchise be erode earlier then expect be presume decline few year anyway result ep estimate fall only write research note ub analyst marc goodman also keep buy rating lower price target writing willing have little patience hcv category still have year ahead stable patient goodman write issue remain next valuation try remain patient gilead stock be afternoon trading stock market today positive side gilead company say friday eu committee medicinal product human use advise europe equivalent fda have endorse approve odefsey company newest drug combo pill hiv combo include taf know wall street son viread represent upgrade version gilead legacy blockbuster viread be due go patent future
416,GILD,big cap drugmaker regeneron pharmaceutical regn merck mrk be move opposite direction thursday trading earning report company raise guidance regeneron quarterly revenue rise year earlier period beating analyst consensus accord thomson reuter earning share be penny short estimate last year crucial metric sale flagship drug eylea regeneron report growth beating consensus company raise full year growth estimate vs previous earning miss stem higher spending selling general administrative cost spending guidance year remain unchanged also cholesterol drug praluent be launch last july miss consensus again number remain small company await result cardiovascular outcome trial praluent rival amgen amgn repatha later year regeneron say payer coverage praluent be good so far commercially insure medicare have access drug regeneron stock be midday trading stock market today merck post earning cent share year earlier period beating consensus cent sale decline miss wall street number merck stock be midday thursday merck add few cent ep guidance range now also raise low end revenue guidance now echo number global pharmas earning season merck cite improve foreign exchange rate revenue shortfall be spread number different drug include blockbuster diabetes drug januvia immunology drug remicade more interesting analyst be come cancer drug keytruda miss estimate beat slightly worldwide especially rival bristol myer squibb bmy opdivo beat consensus last week bristol myer also moved report date trial opdivo first line treatment lung cancer previously guide erode advantage merck expect report result similar trial keytruda midyear drug be now approve only previously treat patient so first line approval significantly expand market merck also report sale hepatitis drug zepatier just launch late january tiny compare report market leader gilead science gild gilead abbvie abbv say earning call last week merck aggressive discounting have affected own business nonetheless rbc capital market analyst michael yee write not have be directly responsible gilead miss merck suggest negotiation important parity access remain ongoing exception veteran administration market have good access interestingly suggest many commercial payor access deal be impact contract be already complete yee write research note so gilead say lower sale be mostly due just higher gross net healthier patient come not so much competition be true realize price competition be still ongoing come need be watch
417,GILD,be worst perform sector last summer biotechnology firm have show few encourage sign march etf flow sector be positive march accord mizuho security usa datum then last week april see additional inflow trimming outflow month net be biotech etfs total control almost asset first month be risk momentum board depart say monish shah mizuho security usa executive director head etf trading last week april be again risk momentum biotech etfs do not see major outflow technically so be propitious time start look biotech etfs again flow biotech etfs be positive second week give way outflow third week thursday shah advise investor be careful term even sector long term prospect be good trend seem be hold advise term caution be many positive well negative factor largest biotech etfs ishare nasdaq biotechnology ibb spdr biotech etf xbi be positive flow territory end april add net respectively ibb be past month xbi be be still respective week high ibb have slip day move average bearish sign xbi be testing resistance own day line next line be first trust nyse arca biotech etf fbt vaneck vector biotech etf bbh re roughly respective past month however fbt experience strong outflow first month result net outflow bhh see positive flow april end net outflow same period first fund fbt bbh be also testing resistance day line series positive factor be however pipeline biotechs ratio have be come suggest investor stock be more reasonably value say michael cohick etf product manager van eck global also note biotechs be poise benefit continue demographic factor age population also affordable care act more person be now cover insurance afford new therapy incredible continue innovation come company sector think point potential entry point say cohick say sector be know display very high volatility terrible terrible negative performance january slightly negative february positive performance march april vaneck vector biotech etf short term performance story have return say cohick suggest investor always continue monitor biotech company earning well activity prefer concentrated portfolio largest most liquid biotech stock such represent bbh want safety larger company be better way play sector say fund top holding be gilead science gild amgen amgn celgene celg biogen biib medivation mdvn together represent fund asset
418,GILD,factor investing etfs sum be more part be sure single factor exchange trade fund have dominate recently specifically strategy ride bumpy stock market investor have pour new money ishare edge msci minimum volatility usa usmv so far year more third asset hold make equity etf term net inflow however average investor not fully grasp risk reward trade tie single factor say rob nestor head ishare smart beta low volatility etfs have historically offer protection market tend underperform market rally take away return full market cycle investor seek beat market end feel short change investor not expect low volatility etfs outperform market full market cycle use low volatility strategy reduce risk aim ride nestor say nestor believe multifactor etfs be good choice many investor multifactor approach be investor want outperform not highly volatile path nestor say certain stock characteristic factor such size quality value momentum have historically reward investor re also very lowly correlated so factor be volatile individually help reduce overall portfolio risk combine accord nestor basically multifactor etfs aim offer market risk higher return low minimum volatility etfs offer market return less risk multifactor etfs have proliferate investor seek outperform manage risk more dozen multifactor etfs have launch past year multiple issuer ishare edge msci multifactor usa lrgf have rac asset just year launch lrgf focus financially healthy firm quality inexpensive stock value smaller company size trend stock momentum large midcap holding include accenture acn tjx co tjx gilead gild month ishare launch new multifactor etfs focuse equity sector such technology finance john hancock also offer multifactor etf suite accord etf firm global multifactor fund scientific beta suite have outperformed market cap weight benchmark lower volatility launch global scientific beta japan scij be year date vs loss ishare msci japan ewj multifactor fund be latest evolution smart beta investing say jay jacob director research global rigorous research put strategy combine low fee increase tax efficiency associate etfs represent attractive alternative expensive actively manage mutual fund keep mind multifactor fund haven much be test real world jacob also caution not multifactor etfs be same advise investor assess quality methodology particular note increase portfolio factor exposure expense diversification have be show result lower risk adjust return multifactor etfs backed methodology adhere academic research seek maximize risk adjust return be likely more appropriate core portfolio holding add cls investment multifactor etfs tend be used simple portfolio hold handful fund single factor etfs fit better more complex portfolio way control exposure more liking say rusty vanneman cio nebraska base firm manage north asset firm emphasize use factor base smart beta etfs enhance performance relative market benchmark accord vanneman low growth climate firm favor high quality stock access ishare edge msci usa quality factor qual smart beta etfs also call strategic beta alternative beta etfs include factor base strategy typically tweak traditional index boost return reduce risk generate income blackrock project smart beta etf asset reach globally annual organic growth next year double rate overall etf market
419,GILD,big biotech amgen amgn beat wall street estimate raise guidance thursday close stock go sideway hour trading peer gilead science gild however be sharply weak quarter amgen report adjust earning share year earlier quarter cent ahead analyst consensus accord thomson reuter revenue increase more consensus company lift full year guidance not quite much beat ep range be now revenue guide be vs last year amgen make ep revenue amgen best selling drug enbrel rheumatoid arthritis beat expectation grow almost consensus accord evercore isi second biggest drug neulasta neutropenia modestly beat estimate gain other hand amgen newer drug come short cancer drug kyproli grow be still shy consensus sale newly launch cholesterol drug repatha continue take gilead meanwhile report earning share exclude time item last year cent wall street average estimate revenue rise consensus gilead nonetheless make change full year guidance call product sale gross margin gilead blockbuster hepatitis drug harvoni sovaldi account most shortfall opposite reason harvoni miss badly outperformed abroad sovaldi do opposite earlier day abbvie abbv report harvoni chief competitor viekira also come short consensus company attribute merck mrk unexpectedly aggressive pricing recently launch rival zepatier merck report quarter also bring screeching halt gilead year stretch double triple digit sale profit growth start dec launch sovaldi analyst expect growth totally flatten company make acquisition gilead stock be more hour thursday close regular session
420,GILD,facebook fb price target be raise thursday company report strong quarterly result late wednesday gilead science gild get upgrade
421,GILD,fbr capital raise facebook price target social medium giant beat third quarter expectation revenue rise earning climb daily active user rise ad revenue soar
422,GILD,axiom capital pivotal research rbc capital market also raise facebook price target firm have buy outperform rating stock
423,GILD,facebook share close midday trading stock market today
424,GILD,gilead be upgrade overweight neutral piper jaffray biotech improve pipeline gilead share finished lower
425,GILD,fireeye feye be downgrade market perform outperform price target fbr capital late wednesday cybersecurity software firm issue weak revenue outlook revenue fall short view
426,GILD,fireeye share plunge
427,GILD,qualcomm qcom price target be cut topeka capital market apple aapl chip supplier report drop earning revenue late wednesday issue weak guidance mizuho capital cowen also lower qualcomm price target
428,GILD,qualcomm share sank apple share close
429,GILD,argus boost first solar fslr price target first solar share dip
430,GILD,whole food wfm price target be cut rbc capital market telsey advisory group late wednesday upscale grocery store report drop same store sale quarter give weak full year outlook
431,GILD,whole food share fall
432,GILD,oasis petroleum oas price target be raise late tuesday oil exploration production company report earning top analyst estimate see rise production quarter oasis share rise
433,GILD,follow gillian rich twitter ibd_grich facebook fb price target be raise thursday company report strong quarterly result late wednesday gilead science gild get upgrade fbr capital raise facebook price target social medium giant beat third quarter expectation revenue rise earning climb daily active user rise ad revenue soar axiom capital pivotal research rbc capital market also raise facebook price target firm have buy outperform rating stock facebook share close midday trading stock market today gilead be upgrade overweight neutral piper jaffray biotech improve pipeline gilead share finished lower fireeye feye be downgrade market perform outperform price target fbr capital late wednesday cybersecurity software firm issue weak revenue outlook revenue fall short view fireeye share plunge qualcomm qcom price target be cut topeka capital market apple aapl chip supplier report drop earning revenue late wednesday issue weak guidance mizuho capital cowen also lower qualcomm price target qualcomm share sank apple share close argus boost first solar fslr price target first solar share dip whole food wfm price target be cut rbc capital market telsey advisory group late wednesday upscale grocery store report drop same store sale quarter give weak full year outlook whole food share fall oasis petroleum oas price target be raise late tuesday oil exploration production company report earning top analyst estimate see rise production quarter oasis share rise follow gillian rich twitter ibd_grich
434,GILD,apple aapl ceo tim cook facebook fb director marc andreessen tesla tsla ceo elon musk younger brother kimbal be week top insider make trade here rundown notable one disclose week apple ceo tim cook have sell share iphone maker report disclosure file tuesday
435,GILD,biotech intercept pharmaceutical icpt be trading sharply wednesday morning first japanese trial fatty liver disease drug produce mixed result
436,GILD,midstage trial conduct intercept japanese partner dainippon sumitomo pharma divide patient alcoholic steatohepatitis nash different dosage group take obeticholic acid oca placebo group endpoint be point improvement common score system nash symptom worsening liver fibrosis
437,GILD,week treatment only highest dose oca milligram meet primary endpoint be difference liver fibrosis different group be few patient drop higher dose group intolerable itch
438,GILD,have previously written be risk study be more exploratory study much smaller prior positive flint study write rbc capital market analyst michael yee research note refer larger midstage trial conduct heterogenity nash patient expect less robust result
439,GILD,flint study result drive sixfold increase intercept stock back january have fall back somewhat then due ongoing concern oca raise patient cholesterol level last month intercept launch phase trial enrolling nash patient world
440,GILD,intercept stock plunge much early trading stock market today month low late morning have pare loss
441,GILD,several other company be work nash drug include gilead science gild be testing drug simtuzumab nash other condition cause fibrosis conference call follow gilead earning report late tuesday gilead chief scientific officer norbert bischofberger disappoint analyst be hope report quarter cirrhosis trial patient have be simtuzumab week
442,GILD,fda feel week datum really not suffice approval need week datum bischofberger say
443,GILD,follow amy reeve twitter ibd_areeve facebook biotech intercept pharmaceutical icpt be trading sharply wednesday morning first japanese trial fatty liver disease drug produce mixed result midstage trial conduct intercept japanese partner dainippon sumitomo pharma divide patient alcoholic steatohepatitis nash different dosage group take obeticholic acid oca placebo group endpoint be point improvement common score system nash symptom worsening liver fibrosis week treatment only highest dose oca milligram meet primary endpoint be difference liver fibrosis different group be few patient drop higher dose group intolerable itch have previously written be risk study be more exploratory study much smaller prior positive flint study write rbc capital market analyst michael yee research note refer larger midstage trial conduct heterogenity nash patient expect less robust result flint study result drive sixfold increase intercept stock back january have fall back somewhat then due ongoing concern oca raise patient cholesterol level last month intercept launch phase trial enrolling nash patient world intercept stock plunge much early trading stock market today month low late morning have pare loss several other company be work nash drug include gilead science gild be testing drug simtuzumab nash other condition cause fibrosis conference call follow gilead earning report late tuesday gilead chief scientific officer norbert bischofberger disappoint analyst be hope report quarter cirrhosis trial patient have be simtuzumab week fda feel week datum really not suffice approval need week datum bischofberger say follow amy reeve twitter ibd_areeve facebook
444,GILD,mishmash win core stock have neither predominantly growth value trait have lead growth value stock past year take shorter term look core stock be run distant second growth stock june year date top perform blend mutual fund past year have outperformed nov blend mutual fund invest growth value stock core stock blend fund be rich source dividend pay stock parnassus core equity fund have return average annual past year vs fund be year vs proxy broad stock market fund have be manage todd ahlsten benjamin allen fund seek capital appreciation current income own stock strong competitive advantage protect market share profitability favor quality management act best interest shareholder look pick have favorable year investment horizon have dividend yield recent holding include motorola solution msi dhr intel intc procter gamble pg gilead science gild motorola solution stock have be chug nicely wednesday fall report earning now be week high day move average analyst poll thomson reuter see earning maker wireless device rise year next year stock have dividend yield make test treatment gear science environmental application have see modest steady earning growth past year net have rise pace past year analyst see gain year next year stock have higher year rest low several time intel earning be expect decline year rise next year chipmaker stock be now yielding procter gamble stock be week high yielding maker household product have be increase dividend annual rate procter gamble earning be expect fall current fiscal year end june rise follow year gilead science stock once highflier have be struggle make headway past year earning biotech company have rise annual clip past year re see rise year fall next year stock have dividend yield parnassus core equity have asset industrial stock tech sector consumer defensive stock fund have have rich hunting ground past year investment average core stock have grow period accord morningstar inc datum same investment have grow growth stock value stock year average core stock be vs growth stock value stock follow doug roger twitter ibd_droger
445,GILD,amazon amzn linkedin lnkd receive slew price target boost wake strong thursday night earning baidu bidu get upgrade mixed result apple aapl supplier skywork solution swks suffer pt cut cloudy outlook gilead science gild get downgrade earning miss amazon receive number price target hike wedbush rbc mizuho commerce giant knock wall street estimate late thursday nearly double consensus view share profit wild swing cent share loss prior year quarter sale rise fastest growth nearly year share close stock market today shooting past buy range linkedin also get handed several price target bump wake earning revenue beat wedbush boost stock target susquehanna raise price target share end higher skywork solution meanwhile be subject several cut apple iphone chip supplier report decelerate ep sale growth be roughly line give weak guidance current quarter topeka capital market take price target cowen trim mizuho reduce target share gap hold relatively well wake apple big miss stock sell gilead science get downgrade hold buy maxim group earning flop late thursday miss profit revenue estimate gilead blockbuster hepatitis drug sale be slow share fall undercut day move average baidu bidu turn mixed result earning guidance be strong brean capital upgrade chinese search giant stock buy baidu rise re enter buy range separately bank america downgrade ford motor neutral ford fall
446,GILD,amazon amzn linkedin lnkd baidu bidu expedia expe soar late thursday strong earning amgen amgn be flat gilead science gild retreat amazon com share be blaze late thursday commerce titan swung dramatically profit share cent share loss nearly twice wall street view cent share revenue rise well estimate best gain nearly year company see sale vs view share fall regular session just buy point crossed week gilead science meanwhile tank close miss top bottom earn share vs view ep gilead hepatitis drug be weaker expect drugmaker announce cent share cash dividend share fall more late trading linkedin ep jump cent ex item top analyst expectation cent revenue increase mil beating view mil professional social network see revenue vs expectation company guide adjust ep range cent ahead view cent linkedin stock rise initially be now chinese internet giant say gaap earning ad be yuan beating estimate revenue grow bil yuan bil slightly miss view bil yuan mobile search monthly active user increase mil march baidu wallet account surge end march baidu stock rise amgen adjust ep climb crush view revenue grow beating estimate amgen raise earning revenue guidance now see profit share view drugmaker see full year revenue vs analyst projection amgen stock be little change late close expedia earn cent share item swing cent year earlier loss defy forecast cent lose expedia revenue rise top forecast share climb
447,GILD,clue way fight current market take look investment strategy mutual fund have outperformed long haul american century ultra fund twcux beat large cap growth rival track morningstar inc past week go friday past year fund average annual gain top peer averaged averaged fund seek highly profitable company look poise keep grow aim large industry lead company have sustainable accelerate earning growth positive price momentum do fund expect best odd find such company look fund portfolio weighting offer clue march manager lee michael li jeff bourke have key overweight information technology health care sector tech fund be find opportunity internet software service service communication equipment fund top holding reflect tilt tech health care apple aapl alphabet googl amazon amzn facebook fb be top feb top also include health care name unitedhealth group unh gilead science gild celgene celg social networking giant facebook be still buy range buy point gapping april strong earning recent action stock market be not perfect ibd accumulation distribution rating have improve worst possible weak rating be still sign more recent selling buy mutual fund past week earning share growth have sped go quarters past frame respectively stock ibd composite rating be solid composite rating combine ibd performance rating include ep relative strength rating be highest manage health care service provider unitedhealth ep rebound growth most recent stanza fall previous quarter share be past week even fall nearly thursday federal judge rule obama administration be spending federal money fund obamacare share many key health care stock go decision district judge rosemary collyer ruling be house republican bring legal challenge government be slate pay year health insurer lower copayment lower income person robotic surgical system developer intuitive surgical isrg be health care name be unharmed obamacare ruling share rise nearly thursday re more past week stock ep grow respective past quarters bank america lynch recently say intuitive be stock soon start pay dividend cite company low debt compare industry least market cap come cash stable earning trend ep growth prior fiscal year well growth expect current year
448,GILD,slate thursday be quarterly earning report amazon amzn linkedin lnkd baidu bidu gilead science gild close market open investor get first look first quarter economic growth commerce giant be expect earn cent share swing profit cent loss last year revenue be project climb last quarter amazon fall well short earning estimate come light revenue send share much high follow week cloud compute division amazon web service be bright spot haul revenue quarter year year share be flirt be lower boundary buy range cup handle base buy point initially break few week amazon fall fall intraday professional social network earning be project grow cent ex item sharp drop growth see prior quarter revenue be expect jump share drop linkedin last quarterly report show weak guidance linkedin stock have climb low reach follow day be now trading week high social networking leader facebook fb crushed earning revenue projection late wednesday send share late trade facebook positive action continue thursday session stock likely be buy range cup handle base buy point china internet giant baidu be project see ep ex item fall rmb cent revenue be estimate rise rmb baidu mobile ecosystem be strong accord itg research analyst henry guo say week firm datum indicate baidu mobile search app dominate mobile search market more installation penetration chinese mobile user well ahead key competitor sogou search qihoo technology qihu search baidu be trading just buy range cup handle base break recently trading week high biotech earning be estimate rise share slower last quarter growth revenue be see rise also deceleration prior quarter comparison be get tougher gilead earning sale sky-rocket hepatitis treatment gilead retook day line last week breach level wednesday session share be trading week high fellow big cap biotech amgen amgn also report quarterly result thursday analyst expect ep gain amgen fall thursday be buy point cup shape base market open biotechs alexion pharmaceutical alxn celgene celg report big pharma bristol myer squibb bmy abbvie abbv make rival hepatitis treatment not great gain couple ongoing issue regard strong dollar weak energy sector sluggish manufacturing weak growth be expect wall street expect scant annualize gain
449,GILD,gopro gpro be downgrade friday chip supplier ambarella amba have price target cut action camera maker face headwind robert baird downgrade gopro neutral outperform slash price target thursday cleveland research analyst say gopro face order cut busy holiday shopping season
450,GILD,past year talk concern bristol myer squibb have focuse cancer drug be understandable bristol myer bmy recently launch opdivo be project take nearly year look carry other immuno oncology drug such yervoy greater sale well same time bristol myer have
451,GILD,pharmaceutical etfs pop friday news pfizer pfe takeover irish drugmaker allergan agn reportedly biggest tax inversion deal history largest ever health sector allow pfizer new york base pharma giant redomicile ireland have much lower corporate tax rate exchange trade fund track major index stumble investor eye gdp inflation datum due later week spdr pharmaceutical xph jump stock market today etf equal weight stock holding include pfizer allergan stock holding fall today investor soured term deal prestige brand holding pbh lead upside xph holding gain xph have gain momentum recent week be july high powershare dynamic pharmaceutical pjp nose etf provide broad exposure stock include highly rate ibd stock allergan gilead gild celgene celg etf select weight holding base various fundamental risk factor allocate roughly asset allergan pfizer combine pjp have rally significantly september interim low post gain last week retake line move average even trade july high year date pjp be nearly vs xph loss gold price fall again monday dollar rise fraction major world currency etfs backed physical gold have peg straight weekly loss stagnate multiyear lows higher expectation interest rate hike december be weigh precious metal bear yield bellwether etfs here look major exchange trade fund tracking various asset class perform today follow daily etf market action be key successful investing spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs ishare core aggregate bond agg rs powershare db bullish uup rs follow aparna narayanan twitter ibd_anarayanan
452,GILD,allianzgi focuse growth fund make success look easy fund lead manager scott migliori speak ibd now portfolio be year top peer track morningstar inc gain now go tuesday fund carry month performance rating ibd be year outperform peer mutual fund gain stick good trend have require hard work savvy move anything stock market today be more narrow migliori say fewer name be make newer high wouldn call nifty be maybe stock be consistently perform well mainly tech consumer discretionary space ve own enough generate outperformance get tougher health care sector have rolled have be leadership number year migliori say fall last few month earning revision be not strong investor want potential political challenge price control fund have cut exposure drugmaker biotechs include gilead gild biogen biib proceed trim have be rotate name palo alto network panw trading share next generation firewall security software maker be close buy point go public revenue have swell nearly firm be ibd leaderboard have notch quarters triple digit earning share gain security area be fast grow give cyberattack government corporation be face migliori say fund recently start stake accenture acn perform consult provide service many investor be concern accenture business be hurt customer shift cloud base software ve see be fairly robust business accenture integrate cloud base service customer exist infrastructure migliori say cloud have not only not be negative be positive growth driver increasingly slow growth economy prospect rise interest rate fund look company boost earning market monster beverage mnst be energy drink be take share overall beverage market migliori say partnership coke ko let grow more quickly ll be able expand distribution more quickly still like fund be high facebook fb yet recently take profit stock have enjoy big run growth rate have slow slightly still migliori say re just start monetize instagram amount capital spending be not bad person have fear re consolidate big run nothing fundamentally derail story point amazon amzn be name migliori think carve growth macro environment also last year spending warehouse improvement be contribute year operate efficiency aw amazon web service be grow faster person realize migliori say
453,GILD,biotech etfs charge ahead wednesday broad stock market struggle gain holiday shorten week investor digest mixed economic datum oil report show stockpile rise less expect best perform sector equity etf so far give etf investor more be thankful alp medical breakthrough sbio rise stock market today
454,GILD,go pay big time poker come investing savvy trader know jump stock once be highly risky
455,GILD,stock take rocket great head south instead find underwater flash
456,GILD,avoid problem investor try pyramid legendary investor jesse livermore develop technique also know average maximize return lower risk buy installment add share only stock prove advance
457,GILD,investor often go opposite route average try lower share cost pick additional share stock decline price quickly become lose proposition stock keep move lower
458,GILD,essentially follow be work additional always smaller purchase allow concentrate buy seem be right ibd founder chairman william neil write make money stock be wrong stock drop certain amount cost sell stock cut short loss
459,GILD,buy part
460,GILD,so buy position installment go biggest smallest pyramid start used allocate fund make first purchase let say have spend stock break use buy share
461,GILD,stock advance purchase price put more fund work additional share finally gain second buy point use remain capital
462,GILD,way re increase investment only stock go right direction thus reduce risk same time put more money stock way better cut loss short downside
463,GILD,loss cut rule come play stock own fall much paid trigger sell rule
464,GILD,gilead science gild clear buy point long consolidation week end july heavy volume marked first entry investor
465,GILD,catalyst big advance hiv drug maker report earning sale beat view also raise revenue guidance full year
466,GILD,follow week stock rise further much gain buy point biotech prove advance more minimum threshold proper purchase price investor have buy week
467,GILD,great conviction stock have actually buy third final installment week gilead prove rise even heavier volume week
468,GILD,share rally buy point pause early october shape flat base time gilead reach peak past june stock have run nearly entry
469,GILD,go pay big time poker come investing savvy trader know jump stock once be highly risky stock take rocket great head south instead find underwater flash avoid problem investor try pyramid legendary investor jesse livermore develop technique also know average maximize return lower risk buy installment add share only stock prove advance investor often go opposite route average try lower share cost pick additional share stock decline price quickly become lose proposition stock keep move lower essentially follow be work additional always smaller purchase allow concentrate buy seem be right ibd founder chairman william neil write make money stock be wrong stock drop certain amount cost sell stock cut short loss buy partsso buy position installment go biggest smallest pyramid start used allocate fund make first purchase let say have spend stock break use buy share stock advance purchase price put more fund work additional share finally gain second buy point use remain capital way re increase investment only stock go right direction thus reduce risk same time put more money stock way better cut loss short downside loss cut rule come play stock own fall much paid trigger sell rule gilead science gild clear buy point long consolidation week end july heavy volume marked first entry investor catalyst big advance hiv drug maker report earning sale beat view also raise revenue guidance full year follow week stock rise further much gain buy point biotech prove advance more minimum threshold proper purchase price investor have buy week great conviction stock have actually buy third final installment week gilead prove rise even heavier volume week share rally buy point pause early october shape flat base time gilead reach peak past june stock have run nearly entry
470,GILD,biggest company ibd biotech industry group regeneron pharmaceutical regn stand alone term current relative price strength good bad good stock be demonstrate demand institutional level investor have not wane accord analysis william neil co mutual fund hedge fund build new position
471,GILD,big biotech gilead science soundly beat analyst estimate raise guidance yet again tuesday cap strong day earning several major drugmaker gilead gild earning exclude time item jump year earlier quarter share beating analyst consensus cent accord thomson reuter revenue climb top
472,GILD,be several key boost odd success aim sell stock short capitalize market downside key be discipline critical stock selection timing short sale discipline keep focuse stock have make exceptional price run be show telltale sign
473,GILD,company be track first year year earning decline lead energy wo sluggish global economy weak revenue continue concern
474,GILD,company already report large cap earning be see fall revenue decline earning haven drop be third straight decline sale
475,GILD,energy be huge drag hurt plunge oil price slow demand china brazil russia other nation energy sector be expect notch earning dive revenue chevron cvx friday post drop earning share exxon mobil xom see fall
476,GILD,not just energy strip sector earning grow fourth straight quarter slow smallest gain revenue rise multiyear low
477,GILD,main theme still be energy be still pull everything make everything look really be say gregory harrison senior research analyst thomson reuter
478,GILD,weak revenue growth remain worrisome
479,GILD,concern growth earning be come cost cut share buyback harrison say
480,GILD,consumer drive auto gain
481,GILD,consumer discretionary sector be bright spot expect deliver earning growth auto related company be strong general motor gm ford report double digit gain earning share part retailer reilly automotive orly autozone azo continue tear notch solid growth well rebound housing market power lennar len double digit profit advance
482,GILD,amazon amzn report surprise profit sale growth accelerate second quarter commerce giant credit result growth amazon prime service
483,GILD,financial earning show gain help easy year year comparison bank america bac citigroup incur hefty litigation cost
484,GILD,health care be pace profit gain drive again biotechs such gilead science gild ep grow
485,GILD,apple be tech earning
486,GILD,technology earning rise much be drive apple aapl have strong iphone sale china exclude apple tech profit be likely rise meager
487,GILD,consumer oriented base multinational particularly strong brand be do fine china say sheraz mian director research zack investment research
488,GILD,industrial firm have be hit energy strong dollar weak overseas demand general electric ge report flat profit dip sale
489,GILD,upside energy company include exxon chevron have beaten lowball earning estimate health care tech material sector have have company top view
490,GILD,energy company earning comparison also get much easier
491,GILD,still early overall ratio negative preannouncement positive one be hold be first quarter be more upbeat historical trend early
492,GILD,facebook fb visa walt disney be big name result tap come week company be track first year year earning decline lead energy wo sluggish global economy weak revenue continue concern company already report large cap earning be see fall revenue decline earning haven drop be third straight decline sale energy be huge drag hurt plunge oil price slow demand china brazil russia other nation energy sector be expect notch earning dive revenue chevron cvx friday post drop earning share exxon mobil xom see fall not just energy strip sector earning grow fourth straight quarter slow smallest gain revenue rise multiyear low main theme still be energy be still pull everything make everything look really be say gregory harrison senior research analyst thomson reuter weak revenue growth remain worrisome concern growth earning be come cost cut share buyback harrison say consumer drive auto consumer discretionary sector be bright spot expect deliver earning growth auto related company be strong general motor gm ford report double digit gain earning share part retailer reilly automotive orly autozone azo continue tear notch solid growth well rebound housing market power lennar len double digit profit advance amazon amzn report surprise profit sale growth accelerate second quarter commerce giant credit result growth amazon prime service financial earning show gain help easy year year comparison bank america bac citigroup incur hefty litigation cost health care be pace profit gain drive again biotechs such gilead science gild ep grow apple be tech earning rise much be drive apple aapl have strong iphone sale china exclude apple tech profit be likely rise meager consumer oriented base multinational particularly strong brand be do fine china say sheraz mian director research zack investment research industrial firm have be hit energy strong dollar weak overseas demand general electric ge report flat profit dip sale upside energy company include exxon chevron have beaten lowball earning estimate health care tech material sector have have company top view energy company earning comparison also get much easier still early overall ratio negative preannouncement positive one be hold be first quarter be more upbeat historical trend early facebook fb visa walt disney be big name result tap come week
493,GILD,health care etfs pump big gain tuesday slew solid drugmaker earning technology focuse peer lag get boost tomorrow apple aapl stock advanced close better expect earning revenue sluggish day stock health etfs rise strong report pfizer pfe merck mrk bristol myer squibb bmy new york base pfizer gap earning beat new jersey peer merck rise more report profit jump latest quarter boost annual outlook medical equipment company edward lifescience ew grab gain beat top bottom line spdr health care xlv etf tracking sector rise stock market today spdr etf peer carve sector post loss tuesday energy stock lead decline xlv largest broad base health care etf allocate roughly asset combination stock pfizer merck bristol myer etf hold stock gilead science gild xlv third largest stock hold fall hour report robust profit raise full year outlook biotech giant have be rally straight week powershare dynamic pharmaceutical pjp pop drugmaker advanced etf hold stock allocate asset bristol myer pfizer merck pjp be top perform pharmaceutical etf year date rise vs xlv meanwhile alibaba baba leap china internet giant easily clear analyst expectation fiscal earning revenue mobile revenue surge gain fail give much boost etfs big stake stock kraneshare csi china internet kweb renaissance ipo ipo eke fractional gain tuesday alibaba be hold kweb asset hold ipo asset etfs hold safe haven asset such bond gold climb marginally tuesday listless stock market here look benchmark exchange trade fund tracking various asset class perform today follow daily etf market action be key successful investing bellwether etfs spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs ishare core aggregate bond agg rs powershare db dollar bullish uup rs follow aparna narayanan twitter ibd_anarayanan
494,GILD,past week biggest gain industry group biotechs outpatient home care operator follow closely hospital medical group have stage recovery february lows biotech group be more past week outpatient group show gain hospital slightly
495,GILD,biotech stock fall deepest crater history start last summer rumbling recovery be sound year bull run more quadruple value peak last july ibd medical biom biotech industry group plunge early february hurt backlash high drug price merger seek lower corporate taxe group have gain feb low lead stock have do better biotech stock buoy potential blockbuster drugsbiomarin pharmaceutical bmrn be feb low incyte incy have gain low point same week ligand pharmaceutical lgnd have climb medivation mdvn boost buyout talk be group be even more take hit past week negative earning news several industry player fund manager tell ibd rebound be here say spate bad news have already be factor stock price more see climate favore rejuvenate hot drug new product pipeline pricing power innovate product bottom line positive factor drive runup never go away say just get drown noise very key point be group be very high beta group particularly small midcap stock don have sale don have earning say tom vandeventer portfolio manager tocqueville asset management history group be elevated macro uncertainty definitely hit vandeventer say own opinion be group trade more sentiment fundamental time period vandeventer point trouble china emblematic macroeconomic concern hit biotech stock sentiment drive factor be politic many candidate presidential race have bash drugmaker high price have propose way clamp wall street have dismiss idea impossible ineffective seem be generate most concern be democrat proposal let medicare medicaid negotiate drug price be not allow do now already center medicare medicaid service have show tooth announce pilot program change reimbursement medicare part cover drug administer hospital clinic part reimbursement scheme be long criticize encourage use expensive drug reimburse health care provider entire cost drug top propose scheme reduce premium add flat fee unrelated price drug theory encourage doctor choose cheaper option front treasury department last month issue new guideline tax inversion deal derail have be drug industry biggest ever merger pfizer pfe allergan agn tax inversion have become popular way drugmaker boost bottom line get access cash allergan earlier merger be base ireland have low taxe think tax regulation call inversion bottom bad press associate health care industry create bottom mind say robert bombace senior portfolio manager frost investment advisor lot bad news have already be baked company fact number industry insider say breakup pfizer allergan merger turn be good biotech stock make acquisition target company allergan have long history acquisitiveness pfizer be think splitting innovative drug business other product evercore isi analyst mark schoenebaum say pfizer want bulk innovative business make valuable standalone pipeline be modest compare big pharma competitor schoenebaum have also say biotech board be balk buyout offer much valuation have drop so ve be unwilling sell market price suspect lead hostile takeover deal big player be willing do partly come fruition late april sanofi sny make unsolicited bid medivation rumor swirl astrazeneca azn pfizer be also interested medivation response reflect attitude schoenebaum speak market be underprice stock sanofi time proposal come period significant market dislocation several important term event company be design seize sanofi value rightly belong stockholder medivation founder ceo david hung say statement reject offer bombace however say biotechs reluctance be show think just bargaining chip say reality be most company have partner anyway larger pharma biotech name reach point pipeline be so dry force hand bombace see lot exciting biotechnology science go fill pipeline put re go model stage space shuttle stage decline name specific company point work biomarker include pd inhibitor such bristol myer squibb bmy opdivo merck mrk keytruda also cite work genetic mutation focus many rare disease firm such biomarin bluebird bio blue discovery be keep money flow biotechnology say leonard yaffe manage health care hedge fund kessef capital management tell ibd specialty drug largely biologic drug prescribe specialist opposed primary care doctor contribute only prescription last year dollar spend drug year earlier thing think drive biotech stock be look drug introduce last year revenue derive drug be biological yaffe say so most attractive sector pharmaceutical area also most publicly trade biotech stock don have earning have successfully launch drug remain highly profitable top biotechs market cap gilead science gild amgen amgn celgene celg biogen biib regeneron pharmaceutical regn have ibd ep rank range putt top stock ep growth regeneron have ep rank number however reflect pricing power biologic drug be precisely political attack day vandeventer say price uncertainty be biggest risk bull thesis group right now also point democratic presidential front runner hillary clinton attempt previous overhaul health care system back mid depress drug stock short term be follow late boom boom be drive first wave biotech innovation company amgen roche rhhby genentech prove biotechnology produce blockbuster vandeventer say innovation remain key maintain pricing power even political pressure point gilead portfolio hepatitis drug start late launch sovaldi much political criticism sovaldi high price stop drug be so superior anything else market company have do research ll continue get price increase say company be particularly rare disease orphan disease arena oncology space company have drug era target medicine have higher efficacy rather shotgun try hit disease be go have pricing power promise such drug still make small stock explode celator pharmaceutical cpxx have surge march favorable late stage trial result acute myeloid leukemia treatment company also see hedge fund take position stock attract favorable initial coverage analyst be sign even generalist investor think biotech stock have get cheap say yaffe first quarter common lament be biotech stock get punish bad news good news get reward biogen issue mixed earning report draw mostly negative reaction wall street april stock rise more biogen have fall even harder other big cap biotechs drop march high feb low so be ready bounce say yaffe overview comment be sector have correct point get level stock be very attractive say
496,GILD,actively manage etfs hold total asset october nearly end active exchange trade fund be speck roughly etf landscape re grow fast first active etf debut more half be less year old etf investment strategy often seek outperform benchmark index most mutual fund active etfs have fund manager decide security include portfolio active etfs usually don take lightning be see steady significant growth nonetheless say noah hamman ceo advisorshare active etf sponsor recently publish industry landscape report performance be person be willing use portfolio hamman say here be winner ark web arkw have gain year date friday vs tech fund category etf invest innovative company disrupt traditional business model focus business benefit shift hardware software cloud compute big datum wearable technology social medium internet thing arkw hold stock top include athenahealth athn linkedin lnkd netflix nflx amazon com amzn red hat rht however etf expense ratio be higher most index peer asset trading volume be relatively meager spdr mfs systematic growth equity syg have rise year date vs large growth fund category etf screen stock base fundamental quantitative factor top holding include amazon apple aapl biotech giant gilead science gild syg expense ratio be time passive peer ishare russell growth iwf syg hold asset columbia large cap growth rpx be solid choice successful investing actively manage etf strategy gain year average annual past year have beaten large growth category ishare enhance international small cap ieis be outpace segment so far ieis be vs foreign small mid value fund category advisorshare wcm bny focuse growth adr aadr be ahead too aadr be vs foreign large growth category have also outperformed year period time etf own stock include top hold taiwan semiconductor tsm concentrated portfolio hold only fund manager best stock investing idea hamman say stock selection really have add value add ieis have expense ratio aadr advisorshare gartman gold euro geur be year date vs loss precious metal commodity fund category loss spdr gold share gld geur used somewhat complex investing method invest gold used euro go long gold future short euro future strategy have work rise dollar environment now investor diversify hamman say don have have just gld pair balance exposure bit geur have expense ratio vs gld
497,GILD,cvs health cvs announcement monday cover amgen amgn cholesterol drug repatha exclusively regeneron regn sanofi sny rival version praluent put pressure praluent maker deliver same say analyst repatha be only pcsk inhibitor cvs caremark commercial formulary say nation drugstore chain
498,GILD,wednesday morning annual liver meeting wrapped san francisco wall street analyst sift implication datum rolled vast hepatitis market analyst see continue dominance gilead science gild genotype hepatitis virus hcv account majority case gilead harvoni
499,GILD,batter drug industry get blast good news tuesday morning big pharmas sizable biotech beat wall street expectation send stock
500,GILD,unite therapeutic uthr be midday trading stock market today report revenue year earlier quarter beating analyst consensus more accord thomson reuter earning exclude time item rise share penny consensus usual do not provide guidance
501,GILD,unite therapeutic have be lose investor confidence even recent drug stock sell recent launch drug orenitram oral version blockbuster lung drug remodulin initially go slower wall street have expect however orenitram sale rise beating consensus unite therapeutic other market drug beat consensus well unituxin new treatment rare childhood cancer call neuroblastoma come line expectation sale
502,GILD,pfizer ep
503,GILD,pharma giant pfizer pfe be midday tuesday report earning exclude time item cent share year earlier quarter beating consensus cent revenue shrank beat view
504,GILD,pfizer add full year revenue guidance now vs last year ep guidance range be now dime previous guidance few cent last year number be current analyst consensus
505,GILD,result include day business hospira generic drugmaker pfizer acquire bring revenue pfizer also note earning release exclude foreign exchange impact revenue rise company credit pneumonia vaccine prevnar be recently approve adult be enjoy increase demand preparation upcoming flu season accord press release ibrance breast cancer drug launch february take beating consensus
506,GILD,good expense management also help quarterly performance slightly higher tax rate negatively impact net income write credit suisse analyst vamil divan research note add pfizer also beat expectation operate margin
507,GILD,bristol lead pd battle
508,GILD,bristol myer squibb bmy report earning cent share cent wall street average estimate revenue rise consensus exclude foreign exchange impact sale rise
509,GILD,bristol myer add cent full year ep guidance range now be consensus flat modestly last year expect full year sale high side consensus slightly
510,GILD,pd inhibitor opdivo launch melanoma late last year have be pick lung cancer indication then handily beat consensus sale bristol myer hepatitis franchise be overshadowed bigger drug gilead science gild abbvie abbv also trounce consensus sale
511,GILD,big miss be yervoy ex vs consensus see last quarter appear consistent lumpiness bristol myer have say expect launch pd antibody write evercore isi analyst mark schoenebaum email client
512,GILD,bristol myer stock be midday tuesday
513,GILD,merck sale line
514,GILD,bristol myer chief competitor pd business be merck mrk also report solid early tuesday merck earning rise year earlier quarter cent share exclude time item beating consensus cent revenue fall line estimate exclude forex impact sale rise
515,GILD,merck raise lower end full year revenue guidance now last year also raise ep guidance beating wall street represent growth few percentage point last year
516,GILD,merck compete drug opdivo keytruda totale capital iq analyst jeffrey loo write be lower expect see sale accelerate be approve additional indication next several year merck biggest selling drug januvia have also be competitive pressure lately rise modestly beating expectation
517,GILD,merck stock be more midday trading
518,GILD,follow amy reeve twitter ibd_areeve facebook batter drug industry get blast good news tuesday morning big pharmas sizable biotech beat wall street expectation send stock unite therapeutic uthr be midday trading stock market today report revenue year earlier quarter beating analyst consensus more accord thomson reuter earning exclude time item rise share penny consensus usual do not provide guidance unite therapeutic have be lose investor confidence even recent drug stock sell recent launch drug orenitram oral version blockbuster lung drug remodulin initially go slower wall street have expect however orenitram sale rise beating consensus unite therapeutic other market drug beat consensus well unituxin new treatment rare childhood cancer call neuroblastoma come line expectation sale pfizer ep pharma giant pfizer pfe be midday tuesday report earning exclude time item cent share year earlier quarter beating consensus cent revenue shrank beat view pfizer add full year revenue guidance now vs last year ep guidance range be now dime previous guidance few cent last year number be current analyst consensus result include day business hospira generic drugmaker pfizer acquire bring revenue pfizer also note earning release exclude foreign exchange impact revenue rise company credit pneumonia vaccine prevnar be recently approve adult be enjoy increase demand preparation upcoming flu season accord press release ibrance breast cancer drug launch february take beating consensus good expense management also help quarterly performance slightly higher tax rate negatively impact net income write credit suisse analyst vamil divan research note add pfizer also beat expectation operate margin bristol lead pd battlebristol myer squibb bmy report earning cent share cent wall street average estimate revenue rise consensus exclude foreign exchange impact sale rise bristol myer add cent full year ep guidance range now be consensus flat modestly last year expect full year sale high side consensus slightly pd inhibitor opdivo launch melanoma late last year have be pick lung cancer indication then handily beat consensus sale bristol myer hepatitis franchise be overshadowed bigger drug gilead science gild abbvie abbv also trounce consensus sale big miss be yervoy ex vs consensus see last quarter appear consistent lumpiness bristol myer have say expect launch pd antibody write evercore isi analyst mark schoenebaum email client bristol myer stock be midday tuesday merck sale linebristol myer chief competitor pd business be merck mrk also report solid early tuesday merck earning rise year earlier quarter cent share exclude time item beating consensus cent revenue fall line estimate exclude forex impact sale rise merck raise lower end full year revenue guidance now last year also raise ep guidance beating wall street represent growth few percentage point last year merck compete drug opdivo keytruda totale capital iq analyst jeffrey loo write be lower expect see sale accelerate be approve additional indication next several year merck biggest selling drug januvia have also be competitive pressure lately rise modestly beating expectation merck stock be more midday trading follow amy reeve twitter ibd_areeve facebook
519,GILD,apple aapl alibaba baba be expect log double digit earning sale growth number notable company prepare report quarterly result tuesday macbook maker earning be see rise share revenue be expect climb accord recent best buy bby poll ipad top
520,GILD,hillary clinton have demonstrated knack striking fear heart investor first pharmaceutical then health insurance now cable tv example begin valeant vrx nearly plunge last month be trace back tweet democratic presidential front runner vice president joe biden have
521,GILD,stock market see red afternoon trading wednesday still shake bit tuesday terror attack belgium day gain biotechs weigh nasdaq fall selling be less intense nyse index drop dow jone industrial average ease volume nyse nasdaq be tracking higher tuesday level stock market today unitedhealth unh visa johnson johnson jnj outperformed dow nike nke lag fall company report earning late tuesday spdr gold share gld slump etf be weak gold price fall due strength dollar handle buy point be short live elsewhere virgin america va soar bloomberg report company be attract takeover interest technology space small cap chip designer inphi iphi gap rise deutsche bank lift price target inphi be extend double bottom buy point miss initial be also legitimate entry ibd be big winner rise reversed higher fall nearly early late tuesday retailer report second straight quarter accelerate sale growth be heavily short stock so part today move be short cover meanwhile ibd name reilly automotive orly be close breaking week consolidation share rise close watch earning apparel maker oxford industry oxm pvh corp pvh image provide shutterstock
522,GILD,turn millennium human genome project potential therapy be big factor huge move biotech stock extracellular proteome immunome prime therapeutic fprx have library more human extracellular protein proteome have be isolate importance immune cell interaction
523,GILD,stock rebound mildly wednesday investor have large part crude oil thank big cap small cap rise unison smallcap gain nasdaq composite slightly better lift almost halter day sell take decent bite tuesday slide oil star
524,GILD,top brass facebook fb starbucks sbux schlumberger slb antero resource ar be make notable insider trade disclose week chris cox social medium giant chief product officer have sell company share cox have make similar sale past year transaction follow string hefty sale facebook director jan koum sell whatsapp messaging platform facebook facebook have begin roll new reaction emojis post so user win be limit simply liking post facebook share finished week director james shennan have sell company share have unloaded part stake ubiquitous coffee chain month so starbucks week announce open first location italy next year well resignation chief operate officer last month starbucks change reward program so customer have spend more earn free drink starbucks share rise week palo alto network panw ceo mark mclaughlin have sell company share value cybersecurity firm result have remain strong cyberattack become more difficult company second quarter result report last month top view market share grow think very obvious re take share everyone space mclaughlin say company earning call palo alto share add week warburg pincus private equity owner shale player antero resource ar have sell company share disclose separate filing more separately antero director james levy peter kagan partner warburg pincus have sell company share director howard keenan have sell share last month antero other oil business cut spending plan drill completion be batter sink oil price antero share notch weekly drop sherif foda president oilfield service provider production group have sell total company share filing disclose week share schlumberger have layer worker end close week ceo john martin have sell company share have sell similar amount past year coo john milligan have also sell share gilead gild lose week insider transaction don typically have major impact stock indicate major pending news rapid liquidation most insider holding however affect stock
525,GILD,hardest thing champion do again again again just ask repeat super bowl titlist baseball horse race triple crown winner tennis grand slam champ just hard best mutual fund too relatively few fund be able pull feat deserve recognition deserve consideration addition replacement retirement account ira well taxable account help identify special mutual fund ibd be introduce best mutual fund award stock mutual fund qualify exclusive recognition only have beaten broad market past year period not just award be earn mutual fund category top rank year performance top case sector fund be highlighted best best deserving special recognition be time winner be easy task mutual fund meet criterium have least asset year operation only beat benchmark period diversify stock mutual fund business entire decade track morningstar inc only pull feat growth mutual fund only emerge award winner category be much harder only value mutual fund beat benchmark time period just small cap fund get award winning stock mutual fund include category growth blend value well large mid small cap be compare index period dec international stock fund have beat msci eafe index best taxable bond fund trump barclay aggregate bond index tax exempt fund conquer barclay municipal index foreign taxable bond fund outperformed barclay global aggregate click here view table top fund categorywhether be look mutual fund strengthen current portfolio just start ibd award list be great place start here ll find top perform fund run smartest portfolio manager award winner be array category stock bond fund be most often used build core position diversify portfolio large mid small cap growth blend value stock foreign stock equity sector bond re market large cap growth foreign bond fund check category award winner be available plan get fund prospectuse quarterly report manager commentary see choice make best fit term investment horizon risk tolerance start top take time consider award winner category re interested already be familiar fund company have fund top mutual fund add confidence selection fund own be not award winner win want rush dump be perfectly good fund run competent portfolio manager fit unique need portfolio consider outperformed benchmark most period narrowly miss exactly do fund outperform so consistently achieve award status fund have show ability survive market correction bear market rac loss ruin long term return several manager claim secret involve ability ignore short term zig zag market individual expect short term performance not be type person invest fund say lee manager brown capital management small company fund explain team preference stock provide fund consistently superior growth long run have also outperformed past year aim strong long term return really mean be ability put together portfolio build weather market storm many fund mean focus company be not highly cyclical business such involve commodity many also mean sticking business strong balance sheet little debt many mean look sustainable earning not short term flash pan gavin baker manager fidelity otc portfolio focpx have similar view have long term time horizon be look year think be big advantage baker tell reporter billy fisher profile gavin fund be also best stock mutual fund large cap stock mutual fund many award winning manager take step further not only do ignore call short term noise market also stick own long term game plan tim parton manager jpmorgan growth advantage vhiax top fund large cap category helm team look lead stock regardless market capitalization work closely colleague run small large cap fund parton team mix name midcap stock focus other beauty strategy be re never force sell good stock just get too big be perennial problem small midcap manager parton say past fund have have bigger weighting small midcap stock team be find more growth opportunity attractive valuation market cap parton think long term team do not ignore here now tough period focus fundamental company say make sure name be not too affected environment re trim size position reduce risk volatile market ve be experience make name team like even more attractively price parton nibble only very cautiously only margin say explain caution stock have be knock price reason already have slightly higher risk portfolio value fund manager parton invest stock stock still sector weight show expect find leader biggest sector be information technology weighting feb nearly double second largest sector consumer discretionary tech holding range small cap medical software maker veeva system veev midcap database software maker splunk splk large cap gaming software maker electronic art ea giant cap microsoft msft winning manager many diversify stock fund category make point think long term base investment decision individual stock much more hot sector sector fund manager plumb respective pond fish hot trend land dominant shark water ibd nancy gondo explain diagnosis top perform sector fund biotech health science have be clear outperformer past year stock alexion pharmaceutical alxn regeneron pharmaceutical regn celgene celg gilead science gild pop recent portfolio disclosure top rank sector fund trait share best best focus well manage company able maintain pricing power even toughest time report scott stoddard examination best best international stock fund sector fund success bond fund often hinge ability play hottest part fix income market avoid segment be favor marie beeren report special report tcw total return bond tglmx be year outperformer thank large part surfing recovery mortgage credit crisis tcw manager bryan whalen tell beeren fund also avoid headwind have almost exposure corporate credit market dramatically lag similar duration treasury so be best best mutual fund need portfolio not stand alone fund parton say portfolio be growth fund do not give holistic exposure be exposure part market be used other other better choice consider ibd award winner have proven mettle year various market segment again again
526,GILD,several industry etfs packed wicked punch recent week robust earning here look standout report season wind ishare nasdaq biotechnology ibb ishare pharmaceutical ihe past month respectively biotech pharma exchange trade fund sell aggressively third quarter political rhetoric fear
527,GILD,bounce back biotech sell follow hillary clinton accusation big pharma price gouge regeneron pharmaceutical regn now face new test resistance latest buy point maker eylea eye injection have be float buy range oct catalyst push stock
528,GILD,big biotech gilead science gild get price target increase tuesday big pharma merck mrk release new datum hepatitis regimen be rival gilead blockbuster franchise oppenheimer analyst wendy lam lift price target gilead writing stock considerable sell june high investor be due revisit gilead strong fundamental acknowledge investor be nervous launch merck grazoprevir elbasvir doublet therapy hepatitis result price war similar abbvie abbv release own rival therapy late last year maintain positive outlook hep franchise term expect continue growth patient volume payer continue lift restriction treatment lam write research note tuesday merck threat believe merck entry be less disruptive thought suspect merck be less incentivize abbvie instigate pricing war expect gilead defend share aggressively already have be maintain vast majority payer contract merck testing hepatitis drug combomerck meanwhile be testing next generation combo doublet mk drug same class gilead blockbuster sovaldi tuesday american association study liver disease aasld release late breaking abstract presentation next month annual liver meeting show triple therapy have achieve cure rate genotype hepatitis virus week treatment similarly high rate genotype week treatment gilead harvoni be approve only genotype sovaldi be also approve type lower rate success typically longer treatment duration week however last month gilead announce new drug combo have succeed treat genotype so field remain hotly competitive datum abstract efficacy datum week triple combo therapy gt gt lesser extent gt appear encourage potentially feasible await further detail include baseline patient characteristic actual presentation evercore isi analyst mark schoenebaum write email client neither stock be help much news early afternoon stock market today gilead stock be nearly merck stock be similar amount follow amy reeve twitter ibd_areeve facebook
529,GILD,fda say thursday require warning liver damage be put label abbvie abbv hepatitis treatment viekira pak technivie send abbvie share plunge month low gilead science gild sharply review adverse event report fda adverse event report system faer database
530,GILD,valeant pharmaceutical vrx late wednesday say have receive subpoena attorney massachusett southern district new york related drug pricing help patient pay drug send valeant share already pressure sharply lower thursday pre market trading come valeant slew biotechs such biogen biib
531,GILD,corporate america face first back back earning decline great recession strong dollar weaken multinational well oil patch company report result friday morning earning be track decline retreat forecast begin year accord datum compile thomson reuter
532,GILD,here quick rundown tuesday hour action yahoo yhoo report fourth quarter earning drop be line estimate revenue edge beat view company say explore strategic option include reverse spin alibaba stake sale core asset yahoo plan cut workforce share fall late edward lifescience ew say fourth quarter revenue increase earning jump surpass estimate medical device maker also raise guidance forecast share jump nearly extend trade gilead science gild handily top fourth quarter earning revenue estimate ep pop revenue rise product sale forecast be roughly line analyst estimate hepatitis hiv drugmaker also announce share buyback program share rise fractionally late illumina ilmn fourth quarter earning fall revenue rise bottom line miss penny top line beat view maker gene sequence system issue full year revenue guidance be line view earning guidance be light share fall late close chipotle grill cmg issue first quarterly report be hit coli outbreak chipotle earning plunge be not bad wall street fear revenue decline miss expectation cdc declare monday outbreak be criminal investigation be ongoing chipotle warn be very difficult year predict first quarter ep be breakeven wall street have expect share chipotle tumble late trading
533,GILD,special report mutual fund strategy mutual fund portfolio gear long term investing come shape size build success share common thread ll take account age exist asset income need risk tolerance mutual fund investing strategy almost become art take young college student inherited life insurance policy
534,GILD,new stock market uptrend underway edward lifescience ew be try complete early stage base global leader heart valve technology remain relatively immune recent maul top medical stock hillary clinton send tweet last month accuse big pharma price gouge biotech drug maker stock gilead science gild biogen biib
535,GILD,stock make welcome gain week bruise couple month senior management top company such apple aapl twitter twtr gopro gpro well top executive yahoo yhoo be buy selling mood come own business share gilead science gild chairman ceo john martin monday announce plan sale share gilead president chief operate officer john milligan wednesday file plan sale share last month martin sell share worth milligan sell share gilead stock gain week gopro chairman ceo nichola woodman wednesday file plan purchase share worth be tough week action camera company suffer price target cut morgan stanley analyst cite weak sale hero session company apparent slowness improve video editing sharing software gopro share slide week friday rally thursday gopro stock hit record trading low intraday near ipo price twitter cfo anthony noto announce sale share coo adam bain disclose have sell share disclosure come leadership upheaval twitter earlier stock sell be fuel worry slow growth june twitter say dick costolo be resign ceo san francisco base social medium company monday announce co founder interim chief jack dorsey be permanent ceo dorsey also run square mobile payment company twitter share climb week best performance february apple cfo luca maestri tuesday disclose plan sale share sale apple macintosh shrank lowest rate year industry research firm gartner idc report thursday meanwhile apple mobile payment service apple pay roll thousand more store year secure deal starbucks sbux yum brand yum apple share gain week dave buster entertainment play ceo stephen king tuesday disclose sale share cfo brian jenkin announce plan sell share meanwhile david jone director company sell share arcade restaurant chain share be track fall week yahoo ceo marissa mayer tuesday announce purchase share last month mayer complete net acquisition share yahoo cfo kenneth goldman file net acquisition share late september yahoo say go ahead spinoff alibaba baba stake uncertain tax status yahoo stock rise week regeneron pharmaceutical regn stockholder sanofi sny tuesday buy more regeneron share thursday sanofi disclose have buy share regeneron regeneron share rise week sanofi stock gain restoration hardware rh director carlos alberini wednesday announce have sell share stock gain week insider transaction don typically have major impact stock indicate major pending news rapid liquidation most insider holding however affect stock follow ciaran mcevoy twitter ibd_cmcevoy facebook
536,GILD,big biotech gilead science gild beat analyst estimate tuesday guidance be soft send stock more hour trading day several large drugmaker report gilead earning rise year earlier quarter share top analyst ep consensus cent accord thomson reuter revenue increase vs analyst expectation full year ep rise revenue gain gilead guide product sale cover nearly revenue analyst have expect product sale total revenue gilead do not provide total revenue ep guidance do provide guidance expense be slightly expectation sale general administrative line evercore isi analyst mark schoenebaum calculate imply ep guidance be miss consensus hepatitis drug sovaldi harvoni beat estimate entirely due sale outside analyst have less visibility next year expect revenue decline be due anticipate decline hcv market have enormous lift drug be approve have flattened ever larger number patient have be cure disease conference call analyst commercial operation chief paul carter say expect hcv market behave similarly do second half essentially flat grow foreign market be still be launch say see growth payer seem be loosen restriction drug initially strained finance due high price enormous volume patient however acknowledge revenue patient be likely fall less sick patient come require shorter treatment carter also sound confident gilead ability fend competition get new entrant last week merck mrk zepatier be approve last week price well gilead abbvie abbv hcv drug re confident label be very strong re very much support real world datum ve see launch harvoni carter say earlier day big pharma pfizer pfe say revenue rise year earlier quarter beating analyst consensus earning exclude time item slip cent share beating estimate penny year ep decline sale slide however pfizer profit guidance miss wall street expectation share analyst schoenebaum blame foreign exchange headwind exclude roughly negative top line top line fx impact due venezuela currency impact alone bottom line impact due fx top bottom line guidance have bracket street schoenebaum write email speak pfizer believe street underestimated fx impact capital iq analyst jeffrey loo raise rating pfizer buy hold say valuation have become attractive almost other drug stock have sell recent month view growth global innovative product unit positively drive prevnar ibrance loo write research note expect pending acquisition allergan agn be complete second half pfizer stock close mallinckrodt mnk rise close specialty drugmaker report fiscal first quarter earning share year earlier quarter top consensus cent sale climb street average estimate mallinckrodt raise full year ep guidance baxter international bax leader dialysis product also beat expectation most recent quarter pull sharp increase earning decline sale fourth quarter profit continue operation jump cent share cent past wall street consensus revenue drop baxter stock rise tuesday close baxter say expect ep year beating consensus forecast current quarter be street however cent
537,GILD,high nasdaq peak july take toll number stock able meet strict requirement drive sector leader list year market be gear swing lengthy consolidation sector leader show stock vs
538,GILD,executive apple aapl nike nke google parent alphabet googl well microsoft msft co founder bill gate be make notable insider trade disclose week apple arthur levinson apple chairman board have sell company share levinson be also founder ceo calico wellness focuse company alphabet umbrella ambition staving
539,GILD,character do whole lotta damage hillary clinton tweet deplore outrageous price gouge specialty drug market see largest biotech etf tank fear pricing control end third quarter ishare nasdaq biotechnology ibb have give gain year date back roughly loss september august rally tad unsettling decline health care sector belie outlook say capital iq analyst higher enrollment cost management prescription drug sale continue drive best earning growth health care sector index analyst lindsey bell write indeed ibb produce annual average gain past year oct period sector etfs track ibd top target health sector fact now more ever biotech pharma etfs trading much week high capital iq see buy opportunity solid biotech name such gilead gild celgene celg ibd stock nearly person be newly insure obamacare health exchange firm note recent report drive sale health care provider service strong dollar be likely weigh large cap pharmaceutical big pfizer pfe merck mrk bristol myer squibb bmy eli lilly lly once again post top line growth first time year pass patent cliff report say health care index be nicely value vs year average upside be especially attainable biotech pharma equipment subindustry report add big upside potential have see sometimes risky biotech drug stock make way many investor etf strategy now china global slowdown mind investor be more focuse downside risk be right be cautious value stock be risk economic growth estimate continue come momentum company be expose more spike volatility have weigh biotechs lately russ global chief investment strategist blackrock write recently suggest investor consider quality stock generally have strong return equity low debt successful investing market stay choppy analyst bofa lynch global research agree new report say health care rate most attractive sector base measure have historically be best predict result such ep sale revision guidance prior quarter result stick health care stick quality bofa lynch advise
540,GILD,stock extend loss midday thursday day federal reserve raise interest rate first time nearly decade fall dow jone industrial average nasdaq be
541,GILD,volume be run higher nyse nasdaq compare same time wednesday
542,GILD,economic news be mixed unemployment claim fall little less expect week end dec manufacturing mid atlantic region fall much more expect december conference board index lead economic indicator rise november prior month increase ahead analyst forecast
543,GILD,mining energy stock be hit hardest stock market today decline oil metal price
544,GILD,newmont mining nem colorado base miner gold silver lose lead lower oil transportation stock oneok oke also drop
545,GILD,most ibd stock be lower lead global payment gpn fall more heavy volume stock plunge wednesday slice day line agree buy rival credit card payment processor heartland payment system hpy
546,GILD,total system service tss credit card payment processor ibd fall remain well buy point cup handle base clear october
547,GILD,chinese social medium stock weibo wb be bright spot jump more heavy volume close buy point deep cup shape base
548,GILD,stock boast rise relative strength line accumulation distribution rating indicate strong demand share stock have more double fall low aug stock extend loss midday thursday day federal reserve raise interest rate first time nearly decade fall dow jone industrial average nasdaq be volume be run higher nyse nasdaq compare same time wednesday economic news be mixed unemployment claim fall little less expect week end dec manufacturing mid atlantic region fall much more expect december conference board index lead economic indicator rise november prior month increase ahead analyst forecast mining energy stock be hit hardest stock market today decline oil metal price newmont mining nem colorado base miner gold silver lose lead lower oil transportation stock oneok oke also drop most ibd stock be lower lead global payment gpn fall more heavy volume stock plunge wednesday slice day line agree buy rival credit card payment processor heartland payment system hpy total system service tss credit card payment processor ibd fall remain well buy point cup handle base clear october chinese social medium stock weibo wb be bright spot jump more heavy volume close buy point deep cup shape base stock boast rise relative strength line accumulation distribution rating indicate strong demand share stock have more double fall low aug
549,GILD,stock end narrowly mixed take breather monday rise past week nasdaq squeeze gain drop index heavyweight apple aapl chip stock be also weak philadelphia semiconductor index slump internet content stock be strong monday benchmark fall be
550,GILD,gilead science gild stock price finished flat friday follow analyst downgrade activision blizzard atvi get higher price target mcdonald mcd pfizer pfe google googl also see analyst action morgan stanley downgrade gilead equal weight give price target share world biggest biotech finished penny higher
551,GILD,big biotechs amgen amgn regeneron pharmaceutical regn be trading wednesday morning pharmacy benefit manager express script esrx say late tuesday include new cholesterol bust drug prefer formulary express script have long be say make effort keep price amgen repatha regeneron praluent
552,GILD,morgan stanley analyst matthew harrison downgrade gilead science gild upgrading alexion pharmaceutical alxn vertex pharmaceutical vrtx base see term catalyst current volatile market harrison maintain price target gilead lower rating equal weight overweight base relative attractiveness other stock harrison write research note true gilead have cash make substantial acquisition doesn think really big immediate future management offer few comment recent conference suggest management be focuse multiple deal clinical stage asset await derisk datum similar bristol myer bmy string pearl strategy harrison write believe be smart strategy gilead generate average long term return also do not see strategy offer single deal re rate gilead investor have suggest same time harrison write long term outlook hepatitis market be unclear next year eu rollout be more advanced merck mrk have unveil more datum own pipeline gilead stock be midday trading stock market today pick big cap harrison like position vertex move expect be first profitable quarter year thank recent launch cystic fibrosis drug orkambi see strong orkambi launch base physician feedback suggest revenue much consensus harrison write biotechs transition profitability have historically outperformed peer time month follow transition harrison upgrade vertex stock overweight equal weight set price target vertex stock be midday friday touch nearly year low tuesday harrison also upgrade alexion stock overweight equal weight price target writing recent sell drug stock have create attractive entry point orphan drug stock alexion have only decline vs other large cap biotech peer alexion have be underperformer year date most large cap biotechs harrison note thus give robust set new product launch potential pipeline upside consensus now more aware competitive landscape soliris see potential alexion outperform weakness generate concern government pricing alexion stock be midday trading friday still leave share more time high touch july stock market tumble prove especially tough biotechs follow amy reeve twitter ibd_areeve facebook
553,GILD,stock veer south start gate friday market recoil surprisingly weak september payroll report dow fall nasdaq drop apiece volume rise fraction vs thursday early trade level stock market today trip labor department september job datum show much weaker expect hire september news compound spike september layoff report thursday challenger gray christmas surprise jump initial weekly unemployment claim just keep ugly ball roll commerce department report factory order august reversed downwardly revise gain july undercut consensus forecast slip dollar tumble bond thump higher oil reversed early gain dive putt west texas intermediate brent crude more week europe market reversed sharp gain moderate loss afternoon trade stock action bank financial be clear pressure weak job report call question federal reserve be moved raise rate end year dow stock dive goldman sachs gs jpmorgan jpm lead loss more nearly stock open lower charle schwab schw etrade financial etfc stake low end loss respectively nasdaq gilead science gild regeneron pharmaceutical regn keurig green mountain gmcr fall more wynn resort wynn surge nearly erase loss week stock be march high fall august september micron technology mu jump fiscal fourth quarter earning revenue decline less expect analyst ibd list signature bank new york sbny fall more stock have be meeting resistance week move average attempt climb right side week consolidation telecom engineering firm dycom dy slump almost slip week move average stock have turn advance past buy point decline signal sell stock particularly correct market sucampo pharmaceutical scmp be only stock list post early gain attempt rebound day move average
554,GILD,drug stock take pound third quarter lead drug company pipeline have keep flow potentially blockbuster new drug here be key product merck shire gilead science expect be approve fda next month so friday merck mrk be expect hear
555,GILD,tyson food tsn boee ba be company expect benefit tran pacific partnership trade agreement drugmaker biotechs primarily develop brand drug have emerge top loser nation accord include mexico canada japan australia vietnam be agree monday still require ratification congress agreement give brand
556,GILD,third quarter be bumpy ride investor violent swing stock weakness china federal reserve uncertainty batter energy sector now earning season likely show company struggle handle headwind company be expect report profit fall revenue drop accord analyst track
557,GILD,health care etfs get slam early action monday investor continue agonize exacting timing interest rate lift global growth concern mount
558,GILD,china industrial profit fall nearly august vs year largest drop accord news report fed official say rate likely rise year also note international outlook be clouding view
559,GILD,ishare nasdaq biotechnology ibb largest exchange trade fund hold biotech stock plunge nearly red hot sector continue sell friday ibb dump late trade etf investment strategy hold small cap biotechs dive
560,GILD,ibb top holding celgene celg amgen amgn gilead science gild biogen biib lose nearly intraday trade regeneron pharmaceutical regn give more
561,GILD,ishare pharmaceutical ihe shed more etf hold largest pharmaceutical name top holding merck mrk pfizer pfe fall nearly
562,GILD,spdr gold share gld give more gold future fall morning trade etf track spot gold price used gold bar hold london vault
563,GILD,here look benchmark exchange trade fund tracking various asset class perform today
564,GILD,follow daily etf market action be key successful investing
565,GILD,bellwether etfs
566,GILD,ishare msci eafe efa rs
567,GILD,spdr dow jone industrial average dium rs
568,GILD,powershare db bullish uup rs
569,GILD,spdr spy rs
570,GILD,ishare core aggregate bond agg rs
571,GILD,ishare core mid cap ijh rs
572,GILD,spdr gold share gld rs
573,GILD,powershare qqq qqq rs
574,GILD,vanguard ftse emerge market vwo rs
575,GILD,ishare russell iwm rs
576,GILD,follow aparna narayanan twitter ibd_anarayanan health care etfs get slam early action monday investor continue agonize exacting timing interest rate lift global growth concern mount china industrial profit fall nearly august vs year largest drop accord news report fed official say rate likely rise year also note international outlook be clouding view ishare nasdaq biotechnology ibb largest exchange trade fund hold biotech stock plunge nearly red hot sector continue sell friday ibb dump late trade etf investment strategy hold small cap biotechs dive ibb top holding celgene celg amgen amgn gilead science gild biogen biib lose nearly intraday trade regeneron pharmaceutical regn give more ishare pharmaceutical ihe shed more etf hold largest pharmaceutical name top holding merck mrk pfizer pfe fall nearly spdr gold share gld give more gold future fall morning trade etf track spot gold price used gold bar hold london vault here look benchmark exchange trade fund tracking various asset class perform today follow daily etf market action be key successful investing bellwether etfs ishare msci eafe efa rs spdr dow jone industrial average dium rs powershare db bullish uup rs spdr spy rs ishare core aggregate bond agg rs ishare core mid cap ijh rs spdr gold share gld rs powershare qqq qqq rs vanguard ftse emerge market vwo rs ishare russell iwm rs follow aparna narayanan twitter ibd_anarayanan
577,GILD,gilead science gild say monday drug combo have succeed different genotype hepatitis virus hcv late stage clinical trial gilead study combine sofosbuvir be sell separately sovaldi be also ingredient harvoni new drug candidate call velpatasvir cohort take ribavirin older hcv pill
578,GILD,incyte incy stock hit year high friday release new clinical trial datum biotech cancer drug epacadostat follow fresh round buyout speculation week release abstract presentation european society medical oncology esmo assembly next weekend include incyte trial epacadostat combination bristol myer squibb bmy yervoy
579,GILD,biotech raptor rptp plunge early trading monday drug candidate fail trial pediatric fatty liver disease raptor say phase trial candidate rp nonalcoholic steatohepatitis nash fail meet endpoint point improvement fatty liver disease score system worsening fibrosis scarring liver
580,GILD,re disappoint outcome give paucity treatment child nash raptor ceo julie anne say statement
581,GILD,midmorning stock market today raptor stock be nearly
582,GILD,most nash sufferer be adult rise child obesity america have bring increase nash childhood current treatment disease age believe be quite common adult population affected effort develop treatment have have high failure rate so strikeout do not come shock street leerink have assign trial just probability success fbr have give only odd
583,GILD,emerge leader have be intercept pharmaceutical icpt obeticholic acid oca do well disease midstage clinical trial leerink analyst joseph schwartz write research note be several aspect raptor study put relative disadvantage
584,GILD,trial design be similar intercept successful flint study be pediatrics not adult be flint nafld earlier stage disease not nash fibrosis be flint be just week duration not week flint schwartz write lower price target stock
585,GILD,intercept trial also suggest oca heighten cholesterol level however analyst believe restrict market patient aren risk heart disease gilead science gild conatus pharmaceutical cnat galectin therapeutic galt be also develop nash drug earlier stage
586,GILD,follow amy reeve twitter ibd_areeve facebook biotech raptor rptp plunge early trading monday drug candidate fail trial pediatric fatty liver disease raptor say phase trial candidate rp nonalcoholic steatohepatitis nash fail meet endpoint point improvement fatty liver disease score system worsening fibrosis scarring liver re disappoint outcome give paucity treatment child nash raptor ceo julie anne say statement midmorning stock market today raptor stock be nearly most nash sufferer be adult rise child obesity america have bring increase nash childhood current treatment disease age believe be quite common adult population affected effort develop treatment have have high failure rate so strikeout do not come shock street leerink have assign trial just probability success fbr have give only odd emerge leader have be intercept pharmaceutical icpt obeticholic acid oca do well disease midstage clinical trial leerink analyst joseph schwartz write research note be several aspect raptor study put relative disadvantage trial design be similar intercept successful flint study be pediatrics not adult be flint nafld earlier stage disease not nash fibrosis be flint be just week duration not week flint schwartz write lower price target stock intercept trial also suggest oca heighten cholesterol level however analyst believe restrict market patient aren risk heart disease gilead science gild conatus pharmaceutical cnat galectin therapeutic galt be also develop nash drug earlier stage follow amy reeve twitter ibd_areeve facebook
587,GILD,beleaguered biotech stock arrowhead research arwr gap sharply thursday morning company report positive midstage trial datum hepatitis drug candidate
588,GILD,arrowhead kick analyst day release top line datum phase trial drug arc patient test positive hepatitis virus antigen hbeag kind antigen virus produce resist body immune system patient take single mg dose arc top standard treatment bristol myer bmy baraclude show mean maximal reduction circulate hbeag
589,GILD,arrowhead say similar reduction show hepatitis hbv core related antigen hbeag positive negative patient
590,GILD,expectation datum have be low october result lower dose arc disappoint wall street so much stock drop half bump ever
591,GILD,new datum rbc capital market analyst michael yee write research note more broadly support use rna interference rnai technology combat virus
592,GILD,be good arrowhead investor also comparable peer such arbutus biopharma abus ongoing dose escalation phase other program pipeline alnylam alny also have early rnai hbv program
593,GILD,arrowhead stock jump month high early trading stock market today midmorning be
594,GILD,number company be develop hepatitis drug potentially treat many person blockbuster hepatitis drug face somewhat more challenge virus big cap player gilead science gild roche rhhby be work earlier stage datum target toll receptor tlr protein help regulate immune system response viruse bacterium other pathogen gilead first human datum drug be expect year end
595,GILD,follow amy reeve twitter ibd_areeve facebook beleaguered biotech stock arrowhead research arwr gap sharply thursday morning company report positive midstage trial datum hepatitis drug candidate arrowhead kick analyst day release top line datum phase trial drug arc patient test positive hepatitis virus antigen hbeag kind antigen virus produce resist body immune system patient take single mg dose arc top standard treatment bristol myer bmy baraclude show mean maximal reduction circulate hbeag arrowhead say similar reduction show hepatitis hbv core related antigen hbeag positive negative patient expectation datum have be low october result lower dose arc disappoint wall street so much stock drop half bump ever new datum rbc capital market analyst michael yee write research note more broadly support use rna interference rnai technology combat virus be good arrowhead investor also comparable peer such arbutus biopharma abus ongoing dose escalation phase other program pipeline alnylam alny also have early rnai hbv program arrowhead stock jump month high early trading stock market today midmorning be number company be develop hepatitis drug potentially treat many person blockbuster hepatitis drug face somewhat more challenge virus big cap player gilead science gild roche rhhby be work earlier stage datum target toll receptor tlr protein help regulate immune system response viruse bacterium other pathogen gilead first human datum drug be expect year end follow amy reeve twitter ibd_areeve facebook
596,GILD,high rate tech stock adobe system adbe pair biotechs lead ibd stock move go wednesday tough tuesday index more adobe lift high volume indicator institutional investor be likely buy company make photoshop other creative cloud software graphic video
597,GILD,valeant pharmaceutical find plenty company market misery last week drugmaker biotech stock sell hillary clinton accuse big pharma price gouge valeant vrx close nearly lower week biogen biib gilead science gild regeneron pharmaceutical regn amgen amgn allergan agn horizon pharma hznp also fall bloomberg report clinton plan
598,GILD,stock remain session high go last hour trading stage positive reversal midday nasdaq lead gain dow jone industrial average be volume be tracking higher stock market today vs same time thursday winner be outpace loser margin nyse nasdaq lead group include gold energy stock west texas intermediate rebound back barrel earlier slide chevron cvx exxonmobil xom rise respectively dow nearly half stock blue chip index be start session red apple aapl be nearly slip much early stock be still day day move average appear have find support level target tgt become biggest retailer sell apple watch hit store week target share be dave buster play moved fast trade recover buy point shape base extend recent bounce day line ibd stock rise thursday pricing secondary offer share biotechs continue recent bounce celgene celg reversed upward gain volume track extend recovery streak fourth straight session stock be still consolidate day day line other top rate biotechs sucampo pharmaceutical scmp rally alexion pharmaceutical alxn group advance make session biggest gainer gilead science gild fall volume morgan stanley downgrade biotech equal weight overweight share be june peak follow nancy gondo twitter ibd_ngondo
599,GILD,top rate drugmaker such valeant pharmaceutical international vrx celgene celg have be busy lab wall street take part big merger deal today ibd list feature top rate drugmaker addition valeant celgene list include regeneron pharmaceutical regn lannett lci allergan agn friday biogen idec biib price
600,GILD,exchange trade fund jab higher wednesday investor cheer biotech rally strong performance overseas market major asian market close higher release positive datum chinese consumer sentiment upbeat mood ripple europe wednesday open most benchmark defy be historically worst trading day year etfs tracking
601,GILD,european union medical advisory committee endorse several key drug lead stock friday make eu approval likely potential blockbuster committee medicinal product human use know french abbreviation chmp adopt positive opinion gilead science gild genvoya manage hiv infection genvoya be drug combo pill identical gilead popular treatment stribild place ingredient viread gilead have put new drug tenofovir alafenamide taf taf be know wall street son viread similar compound alter so lower dose be used turn reduce side effect crucially gilead also win hit viread patent expiry be due start stribild sale pass last year be expect top next year be key revenue driver even company big gilead chmp also endorse blood cancer drug amgen amgn kyproli amgen get acquire onyx pharmaceutical be first approve multiple myeloma hasn yet hit market european union be first approve lone treatment amgen have be push combo kyproli celgene celg revlimid dexamethasone base successful new trial patient ve receive least prior therapy fda approve combo july kyproli isn big revenue driver big biotech now analyst expect annual sale hit chmp also backed newer drug blincyto certain type acute lymphoblastic leukemia blincyto be bispecific cell engager bite antibody combine bit different antibody engage body cell attack cancer cell analyst expectation aren huge blinctyo amgen recently cut licensing deal use xencor xncr longer last bite technology develop newer better drug vertex pharmaceutical vrtx orkambi cystic fibrosis also get chmp thumb friday orkambi gain fair bit medium attention win approval july cystic fibrosis be devastate disease few treatment give vertex considerable pricing power consensus call annual sale pass model already reflect orkambi launch europe early cf patient older write maxim group analyst jason kolbert research note however anticipate slower launch trajectory due need obtain reimbursement country country basis speaking orphan disease horizon pharma hznp ravicti also get chmp endorsement treatment ultra rare urea cycle disorder ucds ravicti be drug horizon acquire hyperion therapeutic year piper jaffray analyst david amsellem highlighted potential growth driver march deal be announce ravicti be approve fda february now have sale annualizing amsellem write accord hyperion prevalence ucd be hyperion have estimate only ucd patient be actually diagnosed only be treatment ravicti cost year amsellem point not steep orphan drug horizon price higher do not estimate european pricing however endorsement stock be stock market today drug stock continue recent bumpy ride afternoon trading friday gilead amgen share be vertex horizon stock be follow amy reeve twitter ibd_areeve facebook
602,GILD,biotech stock tumble monday presidential candidate hillary clinton say propose plan address high drug price tuesday
603,GILD,price gouge specialty drug market be outrageous clinton write twitter account monday morning tomorrow ll lay plan take clinton link new york time article daraprim drug price be hike more fold be acquire privately hold turing pharmaceutical
604,GILD,rbc capital market analyst michael yee write note other reason biotechs rough monday be confirmation progressive multifocal pml case associate biogen biib multiple sclerosis franchise also say biotechs have be trading inversely crude price jump monday
605,GILD,biotechs lead drug sell
606,GILD,ishare nasdaq biotech etf ibb fall monday biogen stock skid gilead science gild start day slightly report good drug trial news lose
607,GILD,regeneron regn fall amgen amgn regeneron partner sanofi sny amgen recently win separate approval new class cholesterol fighter
608,GILD,leader other drug group also fall allergan agn sank valeant pharmaceutical vrx drug pricing policy have draw criticism retreat
609,GILD,politician have be criticize drug cost year price have keep go especially specialty drug segment drug prescribe specialist instead primary care doctor gilead sovaldi be target such criticism march company price week round
610,GILD,have written extensively specialty drug segment account prescription dollar spend vs year leonard yaffe manage health care hedge fund kessel capital management write email give dramatic rise spending drug average annually past decade annual cost often excess year represent easy target criticism
611,GILD,clinton impact see limit
612,GILD,ultimately political furor sovaldi didn lead actual legislation wasn government drive sovaldi price competition abbvie abbv unveil rival regimen december company get rebate war
613,GILD,so clinton really make difference terry haine evercore isi policy analyst former washington lobbyist find unlikely
614,GILD,even democratic president be assume congress almost certainly not approve drug pricing regulation legislation haine write note client
615,GILD,still wasn drug stock need struggle recover ibd medical biotech group dive july high aug low broader macroeconomic valuation concern analyst yee write continue current environment
616,GILD,investor prepare drug pricing volatility noise go have say drug pricing noise turn due election year write biotech stock tumble monday presidential candidate hillary clinton say propose plan address high drug price tuesday price gouge specialty drug market be outrageous clinton write twitter account monday morning tomorrow ll lay plan take clinton link new york time article daraprim drug price be hike more fold be acquire privately hold turing pharmaceutical rbc capital market analyst michael yee write note other reason biotechs rough monday be confirmation progressive multifocal pml case associate biogen biib multiple sclerosis franchise also say biotechs have be trading inversely crude price jump monday biotechs lead drug sell ishare nasdaq biotech etf ibb fall monday biogen stock skid gilead science gild start day slightly report good drug trial news lose regeneron regn fall amgen amgn regeneron partner sanofi sny amgen recently win separate approval new class cholesterol fighter leader other drug group also fall allergan agn sank valeant pharmaceutical vrx drug pricing policy have draw criticism retreat politician have be criticize drug cost year price have keep go especially specialty drug segment drug prescribe specialist instead primary care doctor gilead sovaldi be target such criticism march company price week round have written extensively specialty drug segment account prescription dollar spend vs year leonard yaffe manage health care hedge fund kessel capital management write email give dramatic rise spending drug average annually past decade annual cost often excess year represent easy target criticism clinton impact see political furor sovaldi didn lead actual legislation wasn government drive sovaldi price competition abbvie abbv unveil rival regimen december company get rebate war so clinton really make difference terry haine evercore isi policy analyst former washington lobbyist find unlikely even democratic president be assume congress almost certainly not approve drug pricing regulation legislation haine write note client still wasn drug stock need struggle recover ibd medical biotech group dive july high aug low broader macroeconomic valuation concern analyst yee write continue current environment investor prepare drug pricing volatility noise go have say drug pricing noise turn due election year write
617,GILD,valeant pharmaceutical vrx be specialty drug maker biotech stock get clobber week hillary clinton send tweet accuse big pharma price gouge reaction democratic front runner comment valeant fall monday misery find plenty company biogen biib gilead science gild regeneron pharmaceutical regn amgen amgn
618,GILD,stock be still hard pare loss head last hour thursday trading session nasdaq lose dow jone industrial average fall give volume swell board vs same time wednesday decliner outpaced advancer nearly nyse more nasdaq gold miner utility nonalcoholic beverage stock lead scant list outperformer stock market today downside be lead construction gear maker solar medical stock biotechs continue take beating democratic presidential candidate hillary clinton tweet monday allege price gouge specialty drug maker lead biotechs sizable loss include sucampo pharmaceutical scmp celgene celg gilead science gild regeneron pharmaceutical regn be upside diamond food dmnd reclaim day move average soar month high massive trade maker emerald nut pop secret popcorn other snack have tap credit suisse explore potential sale accord kellogg snack food jjsf pepsico pep be potential suitor ibd stock paycom software payc be biggest loser slumping heavy trade day move average first time month company provide cloud base payroll human resource software also enterprise software group paylocity hold pcty gap fall fast turnover breach day line payroll software maker late wednesday announce secondary offer share follow nancy gondo twitter ibd_ngondo
619,GILD,tesla motor tsla be start top rating wednesday solarcity scty first solar fslr other solar company get bullish rating oppenheimer initiate coverage tesla outperform rating price target tesla share close stock market today oppenheimer start coverage several solar stock outperform rating solarcity also
620,GILD,shorten trading week market thank labor day holiday familiar face once again grace list noteworthy insider stock transaction
621,GILD,apple aapl cfo luca maestri tuesday file plan sale share
622,GILD,wednesday apple unveil new iphone model new ipad pro new apple watch feature
623,GILD,apple stock fall wednesday close week
624,GILD,gilead science gild president coo john milligan sell share tuesday
625,GILD,last week gilead chairman ceo john martin sell share worth
626,GILD,week share gilead maker hepatitis drug harvoni sovaldi be track gain move back day move average
627,GILD,starbucks sbux director javier teruel tuesday announce sale share
628,GILD,fellow starbucks director james shennan tuesday say sell share previous week
629,GILD,seattle base coffee giant gain more week move back day line
630,GILD,palo alto network panw director nir zuk tuesday announce plan sale share
631,GILD,late wednesday palo alto network crushed fiscal earning revenue estimate cybersecurity firm stock settle higher week close just day line
632,GILD,gopro gpro president tony bate say tuesday sell share tune
633,GILD,action camera maker have have tough time late be track lose week mark fifth straight week loss
634,GILD,gopro share price fall come apple announce gopro app be available apple watch allow gopro owner use smartwatch viewfinder snap photograph camera
635,GILD,tuesday gopro launch virtual reality camera rig degree camera setup name odyssey cost
636,GILD,facebook fb vice president colin stretch sell share tuesday social medium giant be poise finish week
637,GILD,skywork solution swks chairman david aldrich tuesday announce propose sale share apple chip supplier stock advanced nearly
638,GILD,follow ciaran mcevoy twitter ibd_cmcevoy facebook shorten trading week market thank labor day holiday familiar face once again grace list noteworthy insider stock transaction apple aapl cfo luca maestri tuesday file plan sale share wednesday apple unveil new iphone model new ipad pro new apple watch feature apple stock fall wednesday close week gilead science gild president coo john milligan sell share tuesday last week gilead chairman ceo john martin sell share worth week share gilead maker hepatitis drug harvoni sovaldi be track gain move back day move average starbucks sbux director javier teruel tuesday announce sale share fellow starbucks director james shennan tuesday say sell share previous week seattle base coffee giant gain more week move back day line palo alto network panw director nir zuk tuesday announce plan sale share late wednesday palo alto network crushed fiscal earning revenue estimate cybersecurity firm stock settle higher week close just day line gopro gpro president tony bate say tuesday sell share tune action camera maker have have tough time late be track lose week mark fifth straight week loss gopro share price fall come apple announce gopro app be available apple watch allow gopro owner use smartwatch viewfinder snap photograph camera tuesday gopro launch virtual reality camera rig degree camera setup name odyssey cost facebook fb vice president colin stretch sell share tuesday social medium giant be poise finish week skywork solution swks chairman david aldrich tuesday announce propose sale share apple chip supplier stock advanced nearly follow ciaran mcevoy twitter ibd_cmcevoy facebook
639,GILD,california public employee retirement system calper issue report july claim benefit payment retire government employee support job california generate more additional economic output economic multiplier effect pension benefit check be spend re spend economy calper claim have generate
640,GILD,biotech etfs get smash late trade friday bank diversify financial etfs maintain gain rate liftoff bogey dominate investor mood major index etfs reversed early gain close lower session week upbeat number gdp datum consumer confidence thursday ceo lead etf sponsor expressed disappointment
641,GILD,once again gilead be week notable insider stock transaction gilead science gild director john cogan sell share tuesday week president john milligan sell share week chairman ceo john martin sell share worth analyst see company make annually blockbuster hepatitis drug sovaldi harvoni investor wonder market have room upcoming next gen hepatitis treatment other drugmaker gilead share close lower week tesla motor tsla co founder cto jeffrey straubel sell share tuesday thursday jeffery raise price target electric vehicle maker buy rating tesla share end week gain ambarella amba cfo george laplante acquire share director cto leslie kohn acquire chairman feng ming fermi wang acquire share ambarella supply chip gopro gpro jump week gopro gain friday end marriott international mar chairman marriott jr sell share wednesday share finished vs week salesforce crm chairman ceo marc benioff sell share monday wednesday dreamforce conference week salesforce microsoft msft say be deepen relationship salesforce share close week microsoft share be exactly flat previous friday close skywork solution swks chairman ceo david aldrich sell share tuesday share apple aapl chip supplier finished apple be week aldrich also speak ibd leader success page recently skywork early difficulty business strategy getaway new hampshire farm palo alto network panw chairman ceo mark mclaughlin sell share cybersecurity company top forecast last week share close weekly basis insider transaction don typically have major impact stock indicate major pending news rapid liquidation most insider holding however affect stock related cheaper tesla battery rev profitability analysttesla pt raise oracle cut armour buydave aldrich add bite apple supplier skyworksapple gopro gilead lead week insider salesgilead netflix week top stock trade
642,GILD,piper jaffray place bet biotech speculation game friday say gilead science gild acquire incyte incy bristol myer squibb bmy probably wouldn be interested vertex pharmaceutical vrtx report review biopharma sector analyst joshua schimmer write best fit gilead be derisked later stage asset
643,GILD,stock climb back session high go last hour trading nasdaq be dow jone industrial average rise volume be mixed run higher nyse slightly lower nasdaq winner trump loser more margin exchange
644,GILD,biotechs be mend big player alexion pharmaceutical alxn celgene celg gilead science gild regeneron pharmaceutical regn score better gain other industry group lead wednesday session include wholesale food nonalcoholic beverage maker
645,GILD,big gainer ibd include global payment gpn gap soar cup handle base heavy trade fiscal result top view electronic payment processor also declare stock split
646,GILD,telecom contractor dycom industry dy chinese wealth management service firm noah noah rise respectively also big volume
647,GILD,automaker software meat product stock lag stock market today tesla motor tsla again drag automaker group slide look support day move average
648,GILD,robert baird lower tesla rating neutral outperform price target morgan stanley tuesday cut model delivery forecast higher expect price tag
649,GILD,nu skin enterprise nus gap sank massive volume personal care product marketer slash revenue forecast due currency headwind china weakness analyst be expect
650,GILD,follow nancy gondo twitter ibd_ngondo stock climb back session high go last hour trading nasdaq be dow jone industrial average rise volume be mixed run higher nyse slightly lower nasdaq winner trump loser more margin exchange biotechs be mend big player alexion pharmaceutical alxn celgene celg gilead science gild regeneron pharmaceutical regn score better gain other industry group lead wednesday session include wholesale food nonalcoholic beverage maker big gainer ibd include global payment gpn gap soar cup handle base heavy trade fiscal result top view electronic payment processor also declare stock split telecom contractor dycom industry dy chinese wealth management service firm noah noah rise respectively also big volume automaker software meat product stock lag stock market today tesla motor tsla again drag automaker group slide look support day move average robert baird lower tesla rating neutral outperform price target morgan stanley tuesday cut model delivery forecast higher expect price tag nu skin enterprise nus gap sank massive volume personal care product marketer slash revenue forecast due currency headwind china weakness analyst be expect follow nancy gondo twitter ibd_ngondo
651,GILD,major index etfs shave loss late trade thursday close lower session high global growth concern weigh investor demand gold safe haven asset send exchange trade fund hold physical bullion week high spdr dow jone industrial average dium lose stock market today climb hour
652,GILD,gilead science gild have make huge move breaking first base august advance more now set new base flat base be seventh week development have correct right now try break resistance last week stock have
653,GILD,good earning good estimate track record strong growth be quality investor want see buy share solid fundamental outlast market correction various rally
654,GILD,technology base company such facebook fb palo alto network panw be fundamentally strong business investor keep eye especially keep watch year earning share growth rate
655,GILD,facebook keep roll
656,GILD,menlo park calif base social networking behemoth have notch consecutive quarters ep growth least double digit percentage
657,GILD,pace growth have slow quarter hit feverish partly result tough comparison facebook have face earlier success earning grow last quarter
658,GILD,company also have generate several year consecutive quarters revenue growth have slow growth recent peak still robust growth
659,GILD,currently facebook stock be attempt get day move average continue market volatility share close
660,GILD,company have ibd composite rating meaning trade better other publicly trade business
661,GILD,keep mobileye growth
662,GILD,mobileye mbly israeli tech company be seek capitalize self drive car future team many manufacturer include tesla motor tsla
663,GILD,make automotive camera collision avoidance technology
664,GILD,company have grow ep last quarters also grow revenue quarterly year mobileye have accelerate sale growth last period
665,GILD,way reliable track record only help partnership tesla elon musk tesla chief executive tweet wednesday model tesla smaller lower cost sedan be unveil march car
666,GILD,meanwhile tesla model suv reach production company factory fremont calif
667,GILD,mobileye share currently be stabilize day line ibd composite rating be share close wednesday
668,GILD,security accelerate growth
669,GILD,palo alto network be beneficiary need greater cybersecurity provide
670,GILD,santa clara calif base company have accelerate earning growth flatten ep improvement quarters reach growth last quarter
671,GILD,palo alto share have hold day move average last month gain wednesday
672,GILD,palo alto network currently enjoy ibd composite rating
673,GILD,gilead tough comparison
674,GILD,biotech company gilead science gild develop treatment hepatitis hiv aids heart disease other life threaten illness generate ep surge triple digit last quarters growth slow still impressive then last period foster city calif base company create tough year year comparison
675,GILD,gilead revenue growth hit triple digit last quarters too have slow growth
676,GILD,share be try return day move average rise wednesday close
677,GILD,gilead ibd composite rating be
678,GILD,tableau still grow briskly
679,GILD,seattle base tableau software datum be victim own success degree ep growth be envy most company
680,GILD,result disappoint investor be expect even better number
681,GILD,sale growth strong be slowest pace quarters
682,GILD,company share have be attempt move day move average fall aug jump wednesday
683,GILD,tableau ibd composite rating be
684,GILD,follow ciaran mcevoy twitter ibd_cmcevoy facebook good earning good estimate track record strong growth be quality investor want see buy share solid fundamental outlast market correction various rally technology base company such facebook fb palo alto network panw be fundamentally strong business investor keep eye especially keep watch year earning share growth rate facebook keep menlo park calif base social networking behemoth have notch consecutive quarters ep growth least double digit percentage pace growth have slow quarter hit feverish partly result tough comparison facebook have face earlier success earning grow last quarter company also have generate several year consecutive quarters revenue growth have slow growth recent peak still robust growth currently facebook stock be attempt get day move average continue market volatility share close company have ibd composite rating meaning trade better other publicly trade business keep mobileye growthmobileye mbly israeli tech company be seek capitalize self drive car future team many manufacturer include tesla motor tsla make automotive camera collision avoidance technology company have grow ep last quarters also grow revenue quarterly year mobileye have accelerate sale growth last period way reliable track record only help partnership tesla elon musk tesla chief executive tweet wednesday model tesla smaller lower cost sedan be unveil march car meanwhile tesla model suv reach production company factory fremont calif mobileye share currently be stabilize day line ibd composite rating be share close wednesday security accelerate growthpalo alto network be beneficiary need greater cybersecurity provide santa clara calif base company have accelerate earning growth flatten ep improvement quarters reach growth last quarter palo alto share have hold day move average last month gain wednesday palo alto network currently enjoy ibd composite rating gilead tough company gilead science gild develop treatment hepatitis hiv aids heart disease other life threaten illness generate ep surge triple digit last quarters growth slow still impressive then last period foster city calif base company create tough year year comparison gilead revenue growth hit triple digit last quarters too have slow growth share be try return day move average rise wednesday close gilead ibd composite rating be tableau still grow seattle base tableau software datum be victim own success degree ep growth be envy most company result disappoint investor be expect even better number sale growth strong be slowest pace quarters company share have be attempt move day move average fall aug jump wednesday tableau ibd composite rating be follow ciaran mcevoy twitter ibd_cmcevoy facebook
685,GILD,best mutual fund august performance report ibd new buy list spot lead stock mutual fund gravitate build retail stock past month still august be rough month mutual fund manager fall nasdaq slump be worst month top mutual
686,GILD,market not gilead netflix restoration hardware have week most notable insider stock transaction gilead science gild chairman ceo john martin sell share worth tuesday last month maker hepatitis drug harvoni sovaldi handily beat analyst estimate raise guidance week gilead
687,GILD,wall street wild ride week doesn necessarily signal end bull market say ub wednesday report note similar volatility spike presage buy opportunity firm produce list stock cash cushion enable ride current volatility believe current year bull
688,GILD,health care etfs revive tuesday major stock index trade mixed investor eye higher oil price stock sell china surprise interest rate cut india spdr spdr dow jone industrial average ishare russell close monday correction territory more week high biotech stock take chin monday lead rally tuesday morning ishare nasdaq biotechnology ibb pop be week high largest most popular exchange trade fund segment ibb hold roughly nasdaq list biotech stock biogen biib stock ibb have largest stake lead advance top holding gain gilead gild celgene celg amgen amgn regeneron pharmaceutical regn climb health care select sector spdr fund xlv rise stock market today boost biotech surge international etfs india marched ahead japan bring rear india earning epi jab higher top holding hdfc hdb india largest private bank advance nearly infosys infy outsource firm oil energy fund lead commodity higher gold ease fraction here look benchmark exchange trade fund be perform today follow daily etf market action be critical investment success bellwether etfs spdr spy rs powershare qqq qqq rs ishare russell iwm rs sdpr dow jone industrial average dium rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs ishare core mid cap ijh rs spdr gold share gld rs powershare db dollar bullish uup rs ishare core aggregate bond agg rs follow aparna narayanan twitter ibd_anarayanan
689,GILD,time most lead biotechs be still try recover aug market sell sucampo pharmaceutical scmp be run far ahead pack share specialty drugmaker be well extend past buy point subsequent rebound week move average re more year vs nasdaq
690,GILD,last year hepatitis have produce most epic drug launch history fanfare die investor face key question much longer drug pipeline pop question be ground sheer success exist treatment gilead science gild sovaldi harvoni abbvie abbv viekira pak
691,GILD,volatile market tuesday weak economic datum china several ipos have be hold own planet fitness plnt share close ahead result wednesday first report go public aug gym operator have ibd composite rating receive slew positive
692,GILD,lot change week lose session slide market go correction number sector leader have be nearly halved most interesting remain stock be reduction medical name aug issue sector leader be health related wednesday
693,GILD,follow day plummet stock pop tuesday several top drugmaker gilead make climb today screen day focus top sector performer half stock price move be attribute strength industry subgroup sector
694,GILD,biotech gilead science gild develop treatment hiv aids liver disease heart disease other life threaten illness
695,GILD,gilead blockbuster hepatitis treatment sovaldi harvoni have steal much spotlight sovaldi sale totale foster city calif base company total annual product sale
696,GILD,stock have ibd composite rating mean have outperformed publicly trade company variety technical fundamental factor
697,GILD,gilead share earning have surge triple digit last quarters
698,GILD,share gilead be stock market today stock have rise almost start year
699,GILD,heavyweight valeant pharmaceutical vrx make range specialty drug include acne treatment eye health drug company say thursday acquire pharmaceutical notably receive fda approval last week low libido treatment addyi have be make headline kind female viagra
700,GILD,tuesday valeant say valueact capital partner robert hale be join board valueact ceo jeffrey ubben be resign valueact capital own valeant outstanding stock
701,GILD,share rise have climb start valeant stock have earn highest possible composite rating
702,GILD,allergan agn make generic specialty drug include botox latisse restasis actavis complete acquisition allergan march
703,GILD,drugmaker be hedge fund top pick accord recent goldman sachs report say monday be voluntarily recall specific lot refresh other eye drop due small number customer complaint report small black particle time use
704,GILD,late july teva pharmaceutical teva agree shell allergan generic unit
705,GILD,allergan share have climb jan stock have composite rating break cup handle base buy point early july have break support day line sank buy range
706,GILD,share be rally tuesday
707,GILD,sucampo pharmaceutical scmp make specialty drug boost guidance top estimate early august
708,GILD,stock have grow begin year hit new high aug have composite rating
709,GILD,share shot
710,GILD,gilead sucampo be member ibd medical biom biotech industry group allergan be part medical generic drug industry group valeant belong medical ethical drug industry group
711,GILD,follow elaine low twitter ibd_elow
712,GILD,related
713,GILD,gilead get wall street love earning beat
714,GILD,valeant buy addyi maker stock wilt
715,GILD,allergan apple hedge fund favorite disney short
716,GILD,biotechs boast big ep growth rate follow day plummet stock pop tuesday several top drugmaker gilead make climb today screen day focus top sector performer half stock price move be attribute strength industry subgroup sector biotech gilead science gild develop treatment hiv aids liver disease heart disease other life threaten illness gilead blockbuster hepatitis treatment sovaldi harvoni have steal much spotlight sovaldi sale totale foster city calif base company total annual product sale stock have ibd composite rating mean have outperformed publicly trade company variety technical fundamental factor gilead share earning have surge triple digit last quarters share gilead be stock market today stock have rise almost start year heavyweight valeant pharmaceutical vrx make range specialty drug include acne treatment eye health drug company say thursday acquire pharmaceutical notably receive fda approval last week low libido treatment addyi have be make headline kind female viagra tuesday valeant say valueact capital partner robert hale be join board valueact ceo jeffrey ubben be resign valueact capital own valeant outstanding stock share rise have climb start valeant stock have earn highest possible composite rating allergan agn make generic specialty drug include botox latisse restasis actavis complete acquisition allergan march drugmaker be hedge fund top pick accord recent goldman sachs report say monday be voluntarily recall specific lot refresh other eye drop due small number customer complaint report small black particle time use late july teva pharmaceutical teva agree shell allergan generic unit allergan share have climb jan stock have composite rating break cup handle base buy point early july have break support day line sank buy range share be rally tuesday sucampo pharmaceutical scmp make specialty drug boost guidance top estimate early august stock have grow begin year hit new high aug have composite rating share shot gilead sucampo be member ibd medical biom biotech industry group allergan be part medical generic drug industry group valeant belong medical ethical drug industry group follow elaine low twitter ibd_elow related gilead get wall street love earning beatvaleant buy addyi maker stock wiltsallergan apple hedge fund favorite disney shortedthese biotechs boast big ep growth rate
717,GILD,last couple week market have be punish formerly highflying drug device stock common side effect lower valuation be more buyout fan fair bit wall street chatter speculation week here be get most attention most likely be true friday afternoon bloomberg
718,GILD,health care fund be top perform sector past year wasn full speed ahead health care fund build much lead consumer staple technology fund mid here play investment make june average health care stock mutual fund have mushroomed
719,GILD,large cap stock fund drop less small midcap fund summer stock market sell help large cap fund shrink gap year performance average large cap stock mutual fund rise annual average past year vs average midcap fund small cap fund
720,GILD,surge biotech stock late trade help several etfs close wednesday trading session high note most major international index etfs jab higher stock market today rally day rout chinese market calm domestic datum show job productivity gain powershare qqq qqq jump trimming loss week
721,GILD,best mutual fund august performance report
722,GILD,sophomore slump not joe fath take helm rowe price growth stock fund year half jan first calendar year charge fund gain top only large cap growth rival mutual fund track morningstar inc
723,GILD,year broad market have imitate buck bronco fund have climb aug outperform whopping peer investor
724,GILD,fath be more concern longer term broad market rally nearly year have make increasingly hard find attractively value growth stock
725,GILD,late summer volatility have make harder find gainer
726,GILD,fath be celebrate birthday talk ibd office baltimore mutual fund be perform so much better year last year be search new market leader
727,GILD,ibd take charge fund cut size overall portfolio top name initially trim more recently re july be initial retool complete
728,GILD,fath want be tail end fund be half used be fund now top decrease little bit middle be bigger
729,GILD,ibd do segment differ
730,GILD,fath describe philosophy upside pyramid top slice be secular growth name typically make portfolio be innovative disrupter be most dynamic growth company
731,GILD,middle section be more cyclical opportunity typically be portfolio re likely be more opportunistic have shorter hold period fund average hold
732,GILD,last section be generally characterize special situation be primary area
733,GILD,first stock transition value growth
734,GILD,second company underway last industry structural change have be go last several year airline sector
735,GILD,third roll up strong management team be good capital allocator be apply discipline efficiency fragmented industry acquisition
736,GILD,bucket typically be portfolio
737,GILD,top name be generally most compelling secular idea tail portfolio have smallest holding be typically farm team earlier stage growth name private company own
738,GILD,ibd give example special situation please
739,GILD,fath gilead science gild go value growth transition buy pharmasset get treat hep addition core hiv business
740,GILD,airline be industry structural change category own american airline aal unite continental ual
741,GILD,valeant pharmaceutical vrx be roll category bring capital allocation discipline pharma industry assertive allocation strategy
742,GILD,ibd name example secular bucket please
743,GILD,fath amazon amzn be poster child tesla tsla be bit more extreme come story other name include priceline pcln mastercard visa
744,GILD,ibd name cyclical bucket please
745,GILD,fath stuff financial td ameritrade amtd morgan stanley ms degree be also shift business model look more value growth shift
746,GILD,industrial hold name fedex fdx canadian pacific railway cp flowserve fls energy industrial most part
747,GILD,ibd have fund performance zoom year least broad sell
748,GILD,fath be drag last year secular growth name sell lot be due person want see more transparency big name want see amazon break core commerce business amazon web service company be become more discipline expense cost
749,GILD,re start see google googl
750,GILD,year ve take health care weighting significantly ve take energy move paid
751,GILD,have number biotech manage care big pharma name play well be activity space
752,GILD,ibd so have bigger bet growth year have paid
753,GILD,fath slowdown growth happened prior sell
754,GILD,be position cyclical recovery didn play be reverse
755,GILD,ve be slow growth environment world have be throw exogenous shock greece china be devalue currency
756,GILD,external factor help make growth more valuable bid valuation company be deliver growth
757,GILD,ve get be discipline position size
758,GILD,google priceline outlook look good ve go heavy investment cycle
759,GILD,google have new cfo ruth porat come morgan stanley re create new hold company call alphabet give more visibility profitability core company go forward person want more transparency google be start provide
760,GILD,ibd let talk interesting name latest disclosure do share concern person have apple aapl
761,GILD,fath do well ve be underweight stock peaked be sort trading sideway guard
762,GILD,most constructive part be valuation capital structure
763,GILD,worry have be company iphone cycle
764,GILD,ve do well iphone now issue be replacement cycle underestimated be impactful replacement cycle be
765,GILD,remain concern ability innovate do drive enough replacement ve do so well grow fast base hard drive higher multiple
766,GILD,ll see go watch doesn look be success least not move needle enough do own don have overweight
767,GILD,ibd anyone facebook fb earning share growth have slow lot quarters
768,GILD,fath ve do everything right right now thing be transition mobile get big base user revenue growth be slow invest new initiative want lot user turn monetization engine
769,GILD,have user instagram lot whatsapp have user facebook ll monetize time so profit reaccelerate
770,GILD,ibd thesis facebook oculus be buy israel pebble interface specialize depth sense tool track hand movement
771,GILD,fath oculus be virtual reality play interesting not needle mover come green banana still need ripen show mark zuckerberg be think multidecade
772,GILD,ibd visa thesis
773,GILD,fath ty durability growth be center online payment movement cash check digital disruption
774,GILD,card still use magnetic swipe be move chip pin card be reissue chip imbed make much harder steal card information
775,GILD,lot retailer have be reluctant make change have change payment hardware register re finally start change
776,GILD,visa europe be potential driver visa visa takeover look come fruition maybe be announcement october
777,GILD,ibd ve build stake celgene celg least quarters do
778,GILD,fath biotechs want own be go big market
779,GILD,time celgene have build arsenal go multiple thing revlimid have be anchor do ve acquire company build own franchise
780,GILD,now ve get otezla immunology drug psoriasis psoriatic arthritis
781,GILD,ve also get cancer drug pomalyst chemotherapy treatment abraxane acquire abraxis
782,GILD,drug acquire be gd treatment crohn disease early trial be promising
783,GILD,patent cliff ahead revlimid ll protect long possible
784,GILD,recent acquisition receptos be view pretty reasonable price relative other deal attack multiple indication most promising appear be disorder colitis crohn
785,GILD,ibd have be trimming stake gilead science
786,GILD,fath re victim own success turn be chronic disease acute disease be treatable
787,GILD,treatment hepatitis be monster drug cure rate be almost week once someone be cure ve get find new patient
788,GILD,ibd ve also pare stake regeneron regn outlook
789,GILD,fath probably shouldn have trim ve get good core franchise eylea be used treat wet age related macular degeneration eye now also used diabetic macular edema retinal vein occlusion
790,GILD,ve get powerful pipeline
791,GILD,ibd ve pare starbucks sbux be concern
792,GILD,fath still feel good core story trim be just position size management
793,GILD,have lot presence not just globally ve introduce nice food purchase la boulange re drive new traffic afternoon evening ve get good china story menu be be broaden
794,GILD,next big thing be move body line re roll mobile order pay system pay cellphone dictate delivery time then walk store coffee be ready best mutual fund august performance reportsophomore slump not joe fath take helm rowe price growth stock fund year half jan first calendar year charge fund gain top only large cap growth rival mutual fund track morningstar inc year broad market have imitate buck bronco fund have climb aug outperform whopping peer investor fath be more concern longer term broad market rally nearly year have make increasingly hard find attractively value growth stock late summer volatility have make harder find gainer fath be celebrate birthday talk ibd office baltimore mutual fund be perform so much better year last year be search new market leader ibd take charge fund cut size overall portfolio top name initially trim more recently re july be initial retool complete fath want be tail end fund be half used be fund now top decrease little bit middle be bigger ibd do segment differ fath describe philosophy upside pyramid top slice be secular growth name typically make portfolio be innovative disrupter be most dynamic growth company middle section be more cyclical opportunity typically be portfolio re likely be more opportunistic have shorter hold period fund average hold last section be generally characterize special situation be primary area first stock transition value growth second company underway last industry structural change have be go last several year airline sector third roll up strong management team be good capital allocator be apply discipline efficiency fragmented industry acquisition bucket typically be portfolio top name be generally most compelling secular idea tail portfolio have smallest holding be typically farm team earlier stage growth name private company own ibd give example special situation please fath gilead science gild go value growth transition buy pharmasset get treat hep addition core hiv business airline be industry structural change category own american airline aal unite continental ual valeant pharmaceutical vrx be roll category bring capital allocation discipline pharma industry assertive allocation strategy ibd name example secular bucket please fath amazon amzn be poster child tesla tsla be bit more extreme come story other name include priceline pcln mastercard visa ibd name cyclical bucket please fath stuff financial td ameritrade amtd morgan stanley ms degree be also shift business model look more value growth shift industrial hold name fedex fdx canadian pacific railway cp flowserve fls energy industrial most part ibd have fund performance zoom year least broad sell fath be drag last year secular growth name sell lot be due person want see more transparency big name want see amazon break core commerce business amazon web service company be become more discipline expense cost re start see google googl year ve take health care weighting significantly ve take energy move paid have number biotech manage care big pharma name play well be activity space ibd so have bigger bet growth year have paid fath slowdown growth happened prior sell be position cyclical recovery didn play be reverse ve be slow growth environment world have be throw exogenous shock greece china be devalue currency external factor help make growth more valuable bid valuation company be deliver growth ve get be discipline position size google priceline outlook look good ve go heavy investment cycle google have new cfo ruth porat come morgan stanley re create new hold company call alphabet give more visibility profitability core company go forward person want more transparency google be start provide ibd let talk interesting name latest disclosure do share concern person have apple aapl fath do well ve be underweight stock peaked be sort trading sideway guard most constructive part be valuation capital structure worry have be company iphone cycle ve do well iphone now issue be replacement cycle underestimated be impactful replacement cycle be remain concern ability innovate do drive enough replacement ve do so well grow fast base hard drive higher multiple ll see go watch doesn look be success least not move needle enough do own don have overweight ibd anyone facebook fb earning share growth have slow lot quarters fath ve do everything right right now thing be transition mobile get big base user revenue growth be slow invest new initiative want lot user turn monetization engine have user instagram lot whatsapp have user facebook ll monetize time so profit reaccelerate ibd thesis facebook oculus be buy israel pebble interface specialize depth sense tool track hand movement fath oculus be virtual reality play interesting not needle mover come green banana still need ripen show mark zuckerberg be think multidecade ibd visa thesis fath ty durability growth be center online payment movement cash check digital disruption card still use magnetic swipe be move chip pin card be reissue chip imbed make much harder steal card information lot retailer have be reluctant make change have change payment hardware register re finally start change visa europe be potential driver visa visa takeover look come fruition maybe be announcement october ibd ve build stake celgene celg least quarters do fath biotechs want own be go big market time celgene have build arsenal go multiple thing revlimid have be anchor do ve acquire company build own franchise now ve get otezla immunology drug psoriasis psoriatic arthritis ve also get cancer drug pomalyst chemotherapy treatment abraxane acquire abraxis drug acquire be gd treatment crohn disease early trial be promising patent cliff ahead revlimid ll protect long possible recent acquisition receptos be view pretty reasonable price relative other deal attack multiple indication most promising appear be disorder colitis crohn ibd have be trimming stake gilead science fath re victim own success turn be chronic disease acute disease be treatable treatment hepatitis be monster drug cure rate be almost week once someone be cure ve get find new patient ibd ve also pare stake regeneron regn outlook fath probably shouldn have trim ve get good core franchise eylea be used treat wet age related macular degeneration eye now also used diabetic macular edema retinal vein occlusion ve get powerful pipeline ibd ve pare starbucks sbux be concern fath still feel good core story trim be just position size management have lot presence not just globally ve introduce nice food purchase la boulange re drive new traffic afternoon evening ve get good china story menu be be broaden next big thing be move body line re roll mobile order pay system pay cellphone dictate delivery time then walk store coffee be ready
795,GILD,stock index friday dive lowest level more month nasdaq clang lower day lose streak have waken even most stubborn bull dow jone industrial average shed respectively ibd slide stock fall volume rise
796,GILD,medical stock have be leader bull market go back so surprise sector leader stock thursday list have something do health care thursday ibd be trading week move average show vary degree distress weak market be
797,GILD,big biotech unite therapeutic uthr agree sell priority review voucher abbvie abbv give unite infusion cash abbvie chance speed fda approval drug
798,GILD,unite gain rare pediatric disease priority review voucher pprv march approval unituxin treatment rare childhood cancer call neuroblastoma fda start pprv program encourage development such drug cut standard review time new drug month
799,GILD,go price pprv have rise sharply last year july regeneron pharmaceutical regn sanofi sny paid just buy biomarin pharmaceutical bmrn used get cholesterol drug praluent market last month
800,GILD,november gilead science gild paid get pprv knight therapeutic used last month filing new combination therapy hiv price have rise sanofi acquire pprv retrophin rtrx
801,GILD,abbvie didn say drug go use voucher have several late stage possibility company have be work expand cancer leukemia drug venetoclax breast cancer drug veliparib be review future
802,GILD,abbvie be also work next generation hepatitis treatment race market be intense face gilead merck mrk other
803,GILD,drug stock general be rest market early stock market today late morning unite therapeutic be wednesday midweek update ibd be abbvie stock also be fraction
804,GILD,connect amy reeve ibd_areeve facebook big biotech unite therapeutic uthr agree sell priority review voucher abbvie abbv give unite infusion cash abbvie chance speed fda approval drug unite gain rare pediatric disease priority review voucher pprv march approval unituxin treatment rare childhood cancer call neuroblastoma fda start pprv program encourage development such drug cut standard review time new drug month go price pprv have rise sharply last year july regeneron pharmaceutical regn sanofi sny paid just buy biomarin pharmaceutical bmrn used get cholesterol drug praluent market last month november gilead science gild paid get pprv knight therapeutic used last month filing new combination therapy hiv price have rise sanofi acquire pprv retrophin rtrx abbvie didn say drug go use voucher have several late stage possibility company have be work expand cancer leukemia drug venetoclax breast cancer drug veliparib be review future abbvie be also work next generation hepatitis treatment race market be intense face gilead merck mrk other drug stock general be rest market early stock market today late morning unite therapeutic be wednesday midweek update ibd be abbvie stock also be fraction connect amy reeve ibd_areeve facebook
805,GILD,week list lead big cap issue feature emerge strength technology long time biotech leader be hold well food beverage play biotech field gilead science gild be build new flat base buy point gilead share be try bounce back trigger sell signal july
806,GILD,payer be aggressive try drive price new pcsk cholesterol drug accord survey recent comment rbc capital market other hand fear lose money hepatitis drug seem be fading prescription be fall analyst michael yee round comment major health insurer
807,GILD,news europe fuel early gain stock morning seller regain control late afternoon trading nasdaq ease less erase intraday gain dow jone industrial average rise volume nyse nasdaq be tracking slightly lower wednesday level stock market today
808,GILD,european bourse end strong gain overnight european central bank left interest rate unchanged cut forecast growth inflation ecb president mario draghi hint fresh stimulus be need euro weaken dollar strengthen news
809,GILD,oil be pace fifth gain session be sharply high october crude add barrel well intraday high
810,GILD,chipmaker food solar stock outperformed biotechs lag
811,GILD,netflix nflx slump company launch stream video service japan today competitive threat like ofalibaba baba amazon com amzn potentially apple aapl continue weigh stock
812,GILD,other laggard nasdaq include gilead science gild apple facebook fb
813,GILD,merger news generic drug maker lannett lci surge news be buy kremer urban pharmaceutical lannett say deal double sale boost fiscal earning
814,GILD,economic news weekly jobless claim rise more expect prior week economist be expect smaller increase datum come ahead friday august employment report nonfarm payroll be see rise consensus range be wide way unemployment rate be see tick lower
815,GILD,follow ken shreve twitter ibd_kshreve facebook news europe fuel early gain stock morning seller regain control late afternoon trading nasdaq ease less erase intraday gain dow jone industrial average rise volume nyse nasdaq be tracking slightly lower wednesday level stock market today european bourse end strong gain overnight european central bank left interest rate unchanged cut forecast growth inflation ecb president mario draghi hint fresh stimulus be need euro weaken dollar strengthen news oil be pace fifth gain session be sharply high october crude add barrel well intraday high chipmaker food solar stock outperformed biotechs lag netflix nflx slump company launch stream video service japan today competitive threat like ofalibaba baba amazon com amzn potentially apple aapl continue weigh stock other laggard nasdaq include gilead science gild apple facebook fb merger news generic drug maker lannett lci surge news be buy kremer urban pharmaceutical lannett say deal double sale boost fiscal earning economic news weekly jobless claim rise more expect prior week economist be expect smaller increase datum come ahead friday august employment report nonfarm payroll be see rise consensus range be wide way unemployment rate be see tick lower follow ken shreve twitter ibd_kshreve facebook
816,GILD,smaller company nutrisystem ntri be often nimble grow faster pace larger peer today screen day be small cap leader highly rate company smallcap stock index list include company hot medical product health care sector abiom danver mass base abiom abmd crushed quarterly estimate aug
817,GILD,stock show hesitation wednesday previous session strong price gain nasdaq slip dow jone industrial average ease respectively volume stock market today drop vs tuesday already average pace
818,GILD,blue chip be mostly only handful stock dow rise tiny step downside chevron cvx carved slow turnover west texas intermediate crude oil fall chevron integrate oil company have rebound late august low remain july high
819,GILD,integrate oil company be involved many facet business exploration production refine distribution late june crude oil begin fast price slide price oil be now explorer integrate refiner
820,GILD,ibd list best stock fundamental technical mortgage software provider ellie mae elli take hardest hit drop more volume be average
821,GILD,housing related stock get bad news november pending home sale drop unexpectedly
822,GILD,however homebuilder horton dhi leaderboard stock shrug news horton be penny tepid volume stock show hesitation wednesday previous session strong price gain nasdaq slip dow jone industrial average ease respectively volume stock market today drop vs tuesday already average pace blue chip be mostly only handful stock dow rise tiny step downside chevron cvx carved slow turnover west texas intermediate crude oil fall chevron integrate oil company have rebound late august low remain july high integrate oil company be involved many facet business exploration production refine distribution late june crude oil begin fast price slide price oil be now explorer integrate refiner ibd list best stock fundamental technical mortgage software provider ellie mae elli take hardest hit drop more volume be average housing related stock get bad news november pending home sale drop unexpectedly however homebuilder horton dhi leaderboard stock shrug news horton be penny tepid volume
823,GILD,biotech industry group currently rank group ibd track gilead science share best group score composite rating fellow drugmaker celgene regeneron regn be shortage activity biotech industry recently include celgene celg acquisition receptos july buyout
824,GILD,major index etfs downshift further monday china federal reserve have continue weigh stock market last trading day august exchange trade fund tracking dow jone industrial average nasdaq post largest monthly loss last week turbulence stock market whipsaw investor even intensified worry global slowdown raise doubt wisdom fed rate hike next month spdr dow jone industrial average dium slip stock market today etf hold blue chip industrial leader merck mrk pfizer pfe ibd leaderboard stock visa be dium lead decliner hold goldman sachs gs intel intc be only stock dium advanced dium peg decline august worst monthly loss year so do spdr spy proxy broad market powershare qqq qqq track largest nonfinancial stock nasdaq composite index spy fall monday sector energy red qqq give qqq top holding biotech stock gilead science gild amgen amgn celgene celg regeneron pharmaceutical regn be hardest hit monday close lose ishare nasdaq biotechnology ibb take hit market vector biotechnology bbh worst sector industry focuse etfs so call death cross spy daily chart be first appearance year pattern occur short term move average week move average slip long term line week move average see bearish signal warning loss momentum more loss ahead accord market watcher interview cnbc cross daily chart be less relevant longer term cross be more worrisome therefore weekly chart spy dium also show pattern here look benchmark exchange trade fund tracking various asset class be perform today follow daily etf market action be key successful investing bellwether etfs spdr gold share gld rs ishare core aggregate bond agg rs powershare db bullish uup rs vanguard ftse emerge market vwo rs ishare russell iwm rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare msci eafe efa rs spdr spy rs powershare qqq qqq rs follow aparna narayanan twitter ibd_anarayanan
825,GILD,jazz pharmaceutical get heavy border today sector leader chart see page buy point don let make give fellow drugmaker gilead science short shrift back week move average work flat base buy point share gilead gild gap
826,GILD,second half august be usually desert business news fda schedule be year round several important drug be approval decision month provide upside biotech stock have recently be suffering
827,GILD,get most attention likely be repatha amgen amgn cholesterol drug expect be approve aug repatha be pcsk inhibitor similar praluent drug regeneron pharmaceutical regn sanofi sny be approve much fanfare last month
828,GILD,give resemblance drug repatha be widely expect be approve july research note nomura analyst ian somaiya write amgen drug probably also get similar label doesn cover quite many patient have hope be sufficiently broad support peak sale estimate
829,GILD,be especially interesting investor be pricing dynamic come drug appear market pharmacy benefit manager express script esrx have say hope start price war similar happened abbvie abbv launch rival hepatitis regimen gilead science gild harvoni late last year gilead have maintain dominant market share only rebate half drug list price
830,GILD,believe rebate drive access sanofi regeneron amgen be directly compete formulary position somaiya write repatha net price month estimate imply discount praluent gross price believe competition result average discounting similar have be see hepatitis
831,GILD,amgen stock hit new high report have shed larger biotech selloff retain excellent ibd composite rating
832,GILD,aug fda be due decide label expansion adcetris sole market drug seattle genetic sgen adcetris market partner takeda be already approve patient hodgkin lymphoma ve relapse receive stem cell transplant chemotherapy treatment current filing follow study patient receive transplant hadn relapse find significant improvement progression free survival
833,GILD,july research note rbc capital market analyst adnan butt write chance approval look good fda didn convene advisory committee approval date normally do have issue drug
834,GILD,market opportunity post transplant hodgkin lymphoma set take adcetris year higher sale potentially butt write
835,GILD,get new indication adcetris be key part seattle genetic strategy even drug launch year still hasn make company profitable adcetris be also be test cell lymphoma front line set kind lymphoma january company also announce collaboration bristol myer squibb bmy test bristol hot new cancer drug opdivo adcetris various kind lymphomas
836,GILD,seattle genetic stock be july high retain good relative strength rating analyst expect turn profitable
837,GILD,fda have aug deadline decide aristada schizophrenia drug alk create drug take aripiprazole brand name abilify be best seller otsuka bristol myer go patent year add own technology turn dose regimen daily pill monthly injection patient compliance be biggest problem face psychotic medicine generally less frequent dose better
838,GILD,aristada win be alone long act psychotic market leerink analyst michael schmidt say do nearly well johnson johnson jnj invega sustenna also used technology be therefore provide royalty
839,GILD,model aristada sale write july research note
840,GILD,aristada be important component strategy return growth be lead stock last year sacrifice profit growth invest marketing new drug vivitrol most recent quarter revenue also flatlined analyst expect sale growth next year rise profitability be not see return accord thomson reuter
841,GILD,stock hit high march go form cup handle base fail break slump sector last week be trading fraction wednesday afternoon
842,GILD,connect amy reeve ibd_areeve facebook second half august be usually desert business news fda schedule be year round several important drug be approval decision month provide upside biotech stock have recently be suffering get most attention likely be repatha amgen amgn cholesterol drug expect be approve aug repatha be pcsk inhibitor similar praluent drug regeneron pharmaceutical regn sanofi sny be approve much fanfare last month give resemblance drug repatha be widely expect be approve july research note nomura analyst ian somaiya write amgen drug probably also get similar label doesn cover quite many patient have hope be sufficiently broad support peak sale estimate be especially interesting investor be pricing dynamic come drug appear market pharmacy benefit manager express script esrx have say hope start price war similar happened abbvie abbv launch rival hepatitis regimen gilead science gild harvoni late last year gilead have maintain dominant market share only rebate half drug list price believe rebate drive access sanofi regeneron amgen be directly compete formulary position somaiya write repatha net price month estimate imply discount praluent gross price believe competition result average discounting similar have be see hepatitis amgen stock hit new high report have shed larger biotech selloff retain excellent ibd composite rating aug fda be due decide label expansion adcetris sole market drug seattle genetic sgen adcetris market partner takeda be already approve patient hodgkin lymphoma ve relapse receive stem cell transplant chemotherapy treatment current filing follow study patient receive transplant hadn relapse find significant improvement progression free survival july research note rbc capital market analyst adnan butt write chance approval look good fda didn convene advisory committee approval date normally do have issue drug market opportunity post transplant hodgkin lymphoma set take adcetris year higher sale potentially butt write get new indication adcetris be key part seattle genetic strategy even drug launch year still hasn make company profitable adcetris be also be test cell lymphoma front line set kind lymphoma january company also announce collaboration bristol myer squibb bmy test bristol hot new cancer drug opdivo adcetris various kind lymphomas seattle genetic stock be july high retain good relative strength rating analyst expect turn profitable fda have aug deadline decide aristada schizophrenia drug alk create drug take aripiprazole brand name abilify be best seller otsuka bristol myer go patent year add own technology turn dose regimen daily pill monthly injection patient compliance be biggest problem face psychotic medicine generally less frequent dose better aristada win be alone long act psychotic market leerink analyst michael schmidt say do nearly well johnson johnson jnj invega sustenna also used technology be therefore provide royalty model aristada sale write july research note aristada be important component strategy return growth be lead stock last year sacrifice profit growth invest marketing new drug vivitrol most recent quarter revenue also flatlined analyst expect sale growth next year rise profitability be not see return accord thomson reuter stock hit high march go form cup handle base fail break slump sector last week be trading fraction wednesday afternoon connect amy reeve ibd_areeve facebook
843,GILD,volatility be word day stock market drugmaker strong growth prospect proven long term stability such ibd member valeant pharmaceutical vrx be good stock watch list candidate ibd spotlight top performer list stock base combination factor include sale profit growth today roster
844,GILD,earning report have hammer lead stock hasn be case most big cap member most quarterly report way big capitalization leader have sail past earning announcement
845,GILD,most beat wall street expectation also most have climb earning press release come past couple week medical sector have largest share big cap account several earning winner gilead science gild gap report sale profit exceed expectation also raise full year guidance share beat analyst consensus cent largest margin victory earning race stock have rise almost day july report be form right side base better expect sale earning also help valeant pharmaceutical vrx break base july illumina ilmn however be medical leader tumble gene sequence company july beat earning estimate miss revenue expectation share sell day report sink back prior buy point illumina drop big cap alexion pharmaceutical alxn beat estimate thursday guidance fall short expectation cost stock have fall modestly report remain entry market also have cool reception edward lifescience ew result even sale earning be higher analyst expect stock have be day number be release week outside health care ebay ebay top profit estimate july charge new high follow news share have recede bit have hold high chipotle grill cmg barely beat second quarter view ep rise share sale climb estimate yet chipotle have best post earning performance big cap share soar day earning report investor turn optimistic third quarter sale traffic trend chipotle remain new high reynold american rai also have do well quarterly report tobacco company be second quarter earning top expectation company raise full year outlook stock be extend buy point few big cap company have not report result yet include monster beverage mnst hca holding hca
846,GILD,ibd medical biom biotech group hold spot list industry group track several member top street forecast past week
847,GILD,today screen day focus top fundamental stock year earning revenue growth rate more
848,GILD,gilead science gild have year ep growth rate develop medicine life threaten condition include cancer hiv aids heart disease gilead be perhaps most well know blockbuster hepatitis treatment sovaldi harvoni
849,GILD,success hepatitis drug have fuel sale foster city calif base company last week soundly top consensus view boost full year guidance
850,GILD,exclude item share gilead earning climb trouncing street view cent sale growth beat forecast
851,GILD,gilead share close stock market today stock be build flat base buy point
852,GILD,gilead have earn ibd highest possible composite rating mean have outperformed other publicly trade company mix fundamental technical factor include earning revenue growth
853,GILD,regeneron pharmaceutical regn have even higher year ep growth rate too have ibd composite rating
854,GILD,portfolio include cholesterol treatment praluent eye drug eylea latter make most regeneron revenue
855,GILD,tuesday stock hit time high follow view top result bump guidance earning grow share beating estimate cent revenue climb top
856,GILD,regeneron stock have break flat base buy point mid july hover buy range tuesday result boost share right buy territory finished thursday
857,GILD,other drugmaker top fundamental list include lannett lci insys therapeutic insy ligand pharmaceutical lgnd sucampo pharmaceutical scmp
858,GILD,thursday insys report ep drop cent miss penny revenue climb estimate insys share tumble
859,GILD,wednesday sucampo report earning cent share just cent year earlier quarter cent analyst consensus revenue grow more analyst expect
860,GILD,specialty drug maker also raise full year ep guidance cent top street estimate cent sucampo share gain wednesday rise thursday
861,GILD,industry peer fellow medical biom biotech group member include celgene celg amgen amgn biogen biib
862,GILD,related
863,GILD,regeneron abiom hit new high strong guidance
864,GILD,gilead get wall street love earning beat
865,GILD,gilead set flat base bullish reversal
866,GILD,company be fastest grow big cap biotech ibd medical biom biotech group hold spot list industry group track several member top street forecast past week today screen day focus top fundamental stock year earning revenue growth rate more gilead science gild have year ep growth rate develop medicine life threaten condition include cancer hiv aids heart disease gilead be perhaps most well know blockbuster hepatitis treatment sovaldi harvoni success hepatitis drug have fuel sale foster city calif base company last week soundly top consensus view boost full year guidance exclude item share gilead earning climb trouncing street view cent sale growth beat forecast gilead share close stock market today stock be build flat base buy point gilead have earn ibd highest possible composite rating mean have outperformed other publicly trade company mix fundamental technical factor include earning revenue growth regeneron pharmaceutical regn have even higher year ep growth rate too have ibd composite rating portfolio include cholesterol treatment praluent eye drug eylea latter make most regeneron revenue tuesday stock hit time high follow view top result bump guidance earning grow share beating estimate cent revenue climb top regeneron stock have break flat base buy point mid july hover buy range tuesday result boost share right buy territory finished thursday other drugmaker top fundamental list include lannett lci insys therapeutic insy ligand pharmaceutical lgnd sucampo pharmaceutical scmp thursday insys report ep drop cent miss penny revenue climb estimate insys share tumble wednesday sucampo report earning cent share just cent year earlier quarter cent analyst consensus revenue grow more analyst expect specialty drug maker also raise full year ep guidance cent top street estimate cent sucampo share gain wednesday rise thursday industry peer fellow medical biom biotech group member include celgene celg amgen amgn biogen biib related regeneron abiom hit new high strong guidancegilead get wall street love earning beatgilead set flat base bullish reversalwhat company be fastest grow big cap biotech
867,GILD,drugmaker valeant pharmaceutical vrx joined sector leader ibd friday edition new addition bolster strength medical stock elite list sector leader name friday paper be medical sector rank sector ibd track tell medical stock continue lead
868,GILD,stock stagger lower friday index notch fourth straight day nasdaq trip dow jone industrial average lose ibd match major index slide volume rise slightly nyse fall narrowly nasdaq cluster distribution day
869,GILD,sector leader offer few stock final stage set base hover buy point be generic drug maker allergan agn be hover buy point flat base stock break july volume be well short more average
870,GILD,combine superior fundamental strong chart action pinpoint top stock watch candidate such gilead science
871,GILD,today screen day top fundamental feature highly rate firm year sale earning growth rate least sort biggest estimate earning share percentage change year
872,GILD,list include company also have stability size drugmaker gilead science gild online marketplace alibaba group baba homebuilder lennar len large company
873,GILD,gilead science
874,GILD,silicon valley base biotech gilead science annual sale have flourished develop treatment hiv hepatitis hepatitis drug sovaldi harvoni account more half sale recent quarter
875,GILD,analyst say sale blockbuster be hit ceiling gilead go acquisition trail find hot new product
876,GILD,gilead report second quarter financial result market close july consensus be ep rise relatively mild hike revenue gilead have beaten wall street estimate last quarters
877,GILD,gilead be fractionally stock market today wednesday gilead rise month deep first stage base buy point june close be form base base cup handle pattern
878,GILD,alibaba group
879,GILD,alibaba jack chinese online marketplace annual revenue be grow rapidly provide service china similar amazon com amzn company be ramp competition global level
880,GILD,june example alibaba digital entertainment wing alibaba picture say have invest first hollywood film mission impossible rogue nation set open theater july company also announce plan launch netflix nflx type video stream service china
881,GILD,wednesday alibaba aliyun cloud division publish datum protection pact design reassure potential cloud customer datum be safe look take google googl microsoft msft other cloud
882,GILD,alibaba have year ep growth rate quarterly sale have grow rate time alibaba rise wednesday
883,GILD,lennar
884,GILD,top rate homebuilder lennar annual revenue be try break housing market show continue sign recovery timing seem right
885,GILD,national association realtor say wednesday exist home sale june climb nearly year better expect
886,GILD,earlier month national association home builder sentiment index hit match best level go back november
887,GILD,lennar year ep growth rate be revenue growth rate be stock rise cup handle buy point wednesday nar report close day extend day move average week line
888,GILD,follow james detar twitter ibd_jdetar combine superior fundamental strong chart action pinpoint top stock watch candidate such gilead science today screen day top fundamental feature highly rate firm year sale earning growth rate least sort biggest estimate earning share percentage change year list include company also have stability size drugmaker gilead science gild online marketplace alibaba group baba homebuilder lennar len large company gilead sciencessilicon valley base biotech gilead science annual sale have flourished develop treatment hiv hepatitis hepatitis drug sovaldi harvoni account more half sale recent quarter analyst say sale blockbuster be hit ceiling gilead go acquisition trail find hot new product gilead report second quarter financial result market close july consensus be ep rise relatively mild hike revenue gilead have beaten wall street estimate last quarters gilead be fractionally stock market today wednesday gilead rise month deep first stage base buy point june close be form base base cup handle pattern alibaba groupalibaba jack chinese online marketplace annual revenue be grow rapidly provide service china similar amazon com amzn company be ramp competition global level june example alibaba digital entertainment wing alibaba picture say have invest first hollywood film mission impossible rogue nation set open theater july company also announce plan launch netflix nflx type video stream service china wednesday alibaba aliyun cloud division publish datum protection pact design reassure potential cloud customer datum be safe look take google googl microsoft msft other cloud alibaba have year ep growth rate quarterly sale have grow rate time alibaba rise wednesday lennartop rate homebuilder lennar annual revenue be try break housing market show continue sign recovery timing seem right national association realtor say wednesday exist home sale june climb nearly year better expect earlier month national association home builder sentiment index hit match best level go back november lennar year ep growth rate be revenue growth rate be stock rise cup handle buy point wednesday nar report close day extend day move average week line follow james detar twitter ibd_jdetar
889,GILD,stock sector leader have climb buy range have slump back buy zone investor try buy now market outlook be back confirm uptrend make investor less nervous buy second chance ibd market outlook thursday switch uptrend resume important read chart
890,GILD,drugmaker deliver tasty return investor july pharmaceutical etfs top peer hold broadly diversify health care stock well focuse red hot biotechs powershare dynamic pharmaceutical pjp lag pharma etf peer month rise lead year date advance longer period produce annual average
891,GILD,just few week look biotech stock be way don count just yet most come time high few trigger sell signal many have stem decline biotech group have maintain top tier status come friday issue same week
892,GILD,stock slump new session lows early afternoon trading monday oil continue sell
893,GILD,dow jone industrial average fall weigh weakness chevron cvx exxon mobil xom new york mercantile benchmark crude oil drop barrel
894,GILD,nasdaq lose nyse volume nasdaq volume be tracking slightly higher friday pace
895,GILD,week shutdown greek stock reopen monday wasn pretty lose early benchmark index end loss
896,GILD,stock market today fitbit fit jump heavy volume ahead wednesday earning report
897,GILD,elsewhere airline outperformed ibd stock alaska airline alk do well rise more now nearly buy point best percentage gainer group include unite continental ual american airline group aal southwest airline luv
898,GILD,also ibd epam system epam reversed fractional loss ahead earning report tuesday open analyst expect solid quarter growth profit year cent share stock be high end buy range past buy point
899,GILD,healthcare space gilead science gild add nearly work flat base buy point stock slump new session lows early afternoon trading monday oil continue sell dow jone industrial average fall weigh weakness chevron cvx exxon mobil xom new york mercantile benchmark crude oil drop barrel nasdaq lose nyse volume nasdaq volume be tracking slightly higher friday pace week shutdown greek stock reopen monday wasn pretty lose early benchmark index end loss stock market today fitbit fit jump heavy volume ahead wednesday earning report elsewhere airline outperformed ibd stock alaska airline alk do well rise more now nearly buy point best percentage gainer group include unite continental ual american airline group aal southwest airline luv also ibd epam system epam reversed fractional loss ahead earning report tuesday open analyst expect solid quarter growth profit year cent share stock be high end buy range past buy point healthcare space gilead science gild add nearly work flat base buy point
900,GILD,drug treat cure hepatitis have make biotech company envy industry biotech celgene be poise break ahead peer pack next few year
901,GILD,celgene celg sale profit growth be see rise double digit least multiple drug multiple disorder
902,GILD,meanwhile gilead science gild biotech firm hepatitis drug harvoni predecessor sovaldi be expect see earning slow low single digit time start patient cure liver virus
903,GILD,other big cap biotechs such amgen amgn biogen biib also fall far short celgene expect growth rate analyst say
904,GILD,celgene have best top line growth large biotech right now have fastest revenue earning growth next year say michael yee manage director analyst rbc capital market
905,GILD,next major mover
906,GILD,piper jaffray analyst tell client recent research report celgene be position be next major mover large cap biotech stock
907,GILD,note celgene be return name top large cap pick share have climb year
908,GILD,celgene have be especially active develop drug various cancer immune inflammatory disease
909,GILD,drug fight least common disease multiple myeloma be fastest grow
910,GILD,first revlimid be celgene top selling drug sale second quarter higher year earlier oral drug be used treat anemia multiple myeloma cancer blood affect plasma cell
911,GILD,sale pomalyst similar revlimid more potent increase last year make fastest grow company current lineup drug launch japan june
912,GILD,other drug currently generate revenue celgene include abraxane treat advanced cancer breast lung pancreas vidaza help bone marrow produce healthier blood cell otezla pill treat psoriasis psoriasis arthritis
913,GILD,sale second quarter prior year abraxane be celgene slower grow drug
914,GILD,goldman sachs analyst terence flynn note continue face competition breast lung cancer share treat pancreatic cancer now have be grow
915,GILD,analyst expect new indication geographic expansion keep abraxane peter
916,GILD,sale otezla food drug administration approve march totale
917,GILD,total revenue quarter rise analyst expect full year revenue rise earning be see grow share rise accord thomson reuter
918,GILD,lot more come other drug percolate wing celgene report late july ceo bob hugin say new transaction astrazeneca azn juno therapeutic juno receptos rcpt likely speed earning growth start
919,GILD,biggest deal announce mid july value be celgene pending acquisition receptos biotech firm lead drug ozanimod have show good result treat ulcerative colitis relapse multiple sclerosis
920,GILD,biggest biotech merger
921,GILD,higher bid doesn thwart deal be expect close third quarter be largest merger acquisition biotech drug industry year abbvie abbv bid pharmacyclic pcyc alexion alxn agreement merge synageva biopharma geva
922,GILD,celgene offer receptos amount share expire august
923,GILD,receptos oral pill ozanimod generate annual revenue ulcerative colitis alone ms yee say put peak sale total
924,GILD,phase datum ms be expect ulcerative colitis
925,GILD,oral drug celgene acquire last year licensing deal dublin ireland base nogra pharma generate well yee say know ged treat crohn disease phase trial be expect start later initially plan
926,GILD,have very robust pipeline partnership new growth driver multiple dollar opportunity next year yee say
927,GILD,earlier summer celgene announce year collaboration juno develop commercialize immunotherapy patient cancer autoimmune disease
928,GILD,celgene pay upfront buy share juno stock share also have right take stake juno
929,GILD,not full speed ahead overhang celgene stock note flynn remain potentially negative impact patent dispute shave year revlimid be patent protected
930,GILD,celgene be litigation allergan agn revlimid patent extend key challenge be patent now expire pretrial hearing be underway
931,GILD,yee expect side settle case go court drug treat cure hepatitis have make biotech company envy industry biotech celgene be poise break ahead peer pack next few year celgene celg sale profit growth be see rise double digit least multiple drug multiple disorder meanwhile gilead science gild biotech firm hepatitis drug harvoni predecessor sovaldi be expect see earning slow low single digit time start patient cure liver virus other big cap biotechs such amgen amgn biogen biib also fall far short celgene expect growth rate analyst say celgene have best top line growth large biotech right now have fastest revenue earning growth next year say michael yee manage director analyst rbc capital market next major mover piper jaffray analyst tell client recent research report celgene be position be next major mover large cap biotech stock note celgene be return name top large cap pick share have climb year celgene have be especially active develop drug various cancer immune inflammatory disease drug fight least common disease multiple myeloma be fastest grow first revlimid be celgene top selling drug sale second quarter higher year earlier oral drug be used treat anemia multiple myeloma cancer blood affect plasma cell sale pomalyst similar revlimid more potent increase last year make fastest grow company current lineup drug launch japan june other drug currently generate revenue celgene include abraxane treat advanced cancer breast lung pancreas vidaza help bone marrow produce healthier blood cell otezla pill treat psoriasis psoriasis arthritis sale second quarter prior year abraxane be celgene slower grow drug goldman sachs analyst terence flynn note continue face competition breast lung cancer share treat pancreatic cancer now have be grow analyst expect new indication geographic expansion keep abraxane peter sale otezla food drug administration approve march totale total revenue quarter rise analyst expect full year revenue rise earning be see grow share rise accord thomson reuter lot more come other drug percolate wing celgene report late july ceo bob hugin say new transaction astrazeneca azn juno therapeutic juno receptos rcpt likely speed earning growth start biggest deal announce mid july value be celgene pending acquisition receptos biotech firm lead drug ozanimod have show good result treat ulcerative colitis relapse multiple sclerosis biggest biotech mergersif higher bid doesn thwart deal be expect close third quarter be largest merger acquisition biotech drug industry year abbvie abbv bid pharmacyclic pcyc alexion alxn agreement merge synageva biopharma geva celgene offer receptos amount share expire august receptos oral pill ozanimod generate annual revenue ulcerative colitis alone ms yee say put peak sale total phase datum ms be expect ulcerative colitis oral drug celgene acquire last year licensing deal dublin ireland base nogra pharma generate well yee say know ged treat crohn disease phase trial be expect start later initially plan have very robust pipeline partnership new growth driver multiple dollar opportunity next year yee say earlier summer celgene announce year collaboration juno develop commercialize immunotherapy patient cancer autoimmune disease celgene pay upfront buy share juno stock share also have right take stake juno not full speed ahead overhang celgene stock note flynn remain potentially negative impact patent dispute shave year revlimid be patent protected celgene be litigation allergan agn revlimid patent extend key challenge be patent now expire pretrial hearing be underway yee expect side settle case go court
932,GILD,federal reserve decide stand pat market bull show quiet appreciation stock market rally broadly wednesday take back more steep loss suffer day sell begin july meanwhile medical sector remain linchpin general uptrend today market pulse show gilead science gild icon iclr allergan ticker
933,GILD,big biotech gilead science gild get passel price target increase jump more stock market wednesday wake stellar report late tuesday
934,GILD,analyst note strong sale hepatitis virus hcv drug increase guidance company know conservative forecasting piper jaffray analyst joshua schimmer raise price target gilead stock base news
935,GILD,hcv franchise continue outperform expectation investor broadly expect company pull transaction improve long term growth outlook drive multiple expansion level more line peer say research note
936,GILD,gilead earning conference call tuesday executive affirm re willing look deal large small say aren big hurry give company financial strength
937,GILD,deutsche bank analyst robyn karnauskas ask specifically gilead acquisition strategy relation oncology field enter launch blood cancer drug zydelig last year zydelig be few drug underperform expectation vs consensus have vie market share new product celgene celg abbvie abbv amgen amgn other mix
938,GILD,have be fascinating rate innovation ve see blood cancer space have get extremely crowd leave fewer opportunity think new product follow product make headway area chief operate officer john milligan say call so re broaden criterium thing be interested be look wide range thing
939,GILD,karnauskas raise price target gilead stock
940,GILD,maxim group analyst jason kolbert lift price target
941,GILD,be see just tip iceberg hep write research note payer side equation payer restriction loosen ratio private public payer be expect move late
942,GILD,midday stock market today gilead stock be
943,GILD,follow amy reeve twitter ibd_areeve big biotech gilead science gild get passel price target increase jump more stock market wednesday wake stellar report late tuesday analyst note strong sale hepatitis virus hcv drug increase guidance company know conservative forecasting piper jaffray analyst joshua schimmer raise price target gilead stock base news hcv franchise continue outperform expectation investor broadly expect company pull transaction improve long term growth outlook drive multiple expansion level more line peer say research note gilead earning conference call tuesday executive affirm re willing look deal large small say aren big hurry give company financial strength deutsche bank analyst robyn karnauskas ask specifically gilead acquisition strategy relation oncology field enter launch blood cancer drug zydelig last year zydelig be few drug underperform expectation vs consensus have vie market share new product celgene celg abbvie abbv amgen amgn other mix have be fascinating rate innovation ve see blood cancer space have get extremely crowd leave fewer opportunity think new product follow product make headway area chief operate officer john milligan say call so re broaden criterium thing be interested be look wide range thing karnauskas raise price target gilead stock maxim group analyst jason kolbert lift price target be see just tip iceberg hep write research note payer side equation payer restriction loosen ratio private public payer be expect move late midday stock market today gilead stock be follow amy reeve twitter ibd_areeve
944,GILD,baidu tumble mixed result take internet focuse etfs intraday trade tuesday major exchange trade fund rally early action series decline bring tepid earning season thus far ugly china sell yesterday baidu bidu stock nosedive earning miss late monday china base search engine
945,GILD,stock further perked late tuesday be track end session slide major index have already re-cover monday loss then
946,GILD,help mining energy stock surge dow jone industrial average rally nasdaq gain volume be run higher board stock market today
947,GILD,masco mas gap day line surge company top view earlier stock market today share clear buy point flat base masco make behr paint delta faucet showerhead well denova countertop
948,GILD,jazz pharmaceutical jazz rally nearly new high stock take buy point flat base jazz have clear several basis september have not produce big gain
949,GILD,becton dickinson bdx rise fast trade month high share pass buy point cup handle base maker medical supply device report fiscal earning aug analyst poll thomson reuter see profit rise share snap quarters single digit growth march becton dickinson complete buyout carefusion
950,GILD,leader volume be few ellie mae elli have trim loss stock find support day line nearly return buy point flat base intraday
951,GILD,akamai technology akam buffalo wild wing bwld citrix system ctxs edward lifescience ew gilead science gild macom mtsi panera bread pnra sturm ruger rgr sunpower spwr twitter twtr yelp yelp be notable company report earning close stock further perked late tuesday be track end session slide major index have already re-cover monday loss then help mining energy stock surge dow jone industrial average rally nasdaq gain volume be run higher board stock market today masco mas gap day line surge company top view earlier stock market today share clear buy point flat base masco make behr paint delta faucet showerhead well denova countertop jazz pharmaceutical jazz rally nearly new high stock take buy point flat base jazz have clear several basis september have not produce big gain becton dickinson bdx rise fast trade month high share pass buy point cup handle base maker medical supply device report fiscal earning aug analyst poll thomson reuter see profit rise share snap quarters single digit growth march becton dickinson complete buyout carefusion leader volume be few ellie mae elli have trim loss stock find support day line nearly return buy point flat base intraday akamai technology akam buffalo wild wing bwld citrix system ctxs edward lifescience ew gilead science gild macom mtsi panera bread pnra sturm ruger rgr sunpower spwr twitter twtr yelp yelp be notable company report earning close
952,GILD,unsettled market make sense err side caution sometimes mean focuse less aggressive growth small cap name more liquid large cap name find week big cap big cap component be generally less volatile small cap name partly due heavy mutual fund sponsorship name
953,GILD,red hot biotechnology semiconductor etfs be cool dramatically lead friday sell sector equity fund head second week steep decline have analyst wring hand red wash biotech stock mean investor be overdue correction frothy sector mere blip rally ishare nasdaq biotechnology ticker
954,GILD,just company be keep second quarter earning growth positive territory business suggest more softness come company have report performance last calendar quarter earning have grow mere revenue so far have decline year exclude apple aapl bank america bac
955,GILD,year modest stock market gain smart beta etfs many try beat cap weight benchmark be more popular ever smart strategic beta etfs have debut year lift total globally exchange trade product be see strong inflow third consecutive year asset
956,GILD,most heavily trade etfs have rally early month lows powershare qqq qqq be so far july past month year date compare ishare russell iwm gain period spdr spy
957,GILD,qqq hold asset roughly largest nonfinancial stock nasdaq composite index technology sector account more half asset biotechnology company get hefty portfolio weighting
958,GILD,top perform holding past month include netflix nflx electronic art ea tesla motor tsla also have big stake highly rate stock facebook fb regeneron pharmaceutical regn gilead science gild starbucks sbux celgene celg have ibd composite rating more
959,GILD,skew technology sector large growth stock have help qqq edge most actively trade rival most past year average annual gain past year trail spy iwm
960,GILD,successful investor keep eye cost qqq have expense ratio par iwm more spy
961,GILD,asset qqq spy have shrink year iwm have grow smidge june exchange trade fund have leak more combine investor outflow
962,GILD,qqq rise thestock market today grasp distance old high
963,GILD,follow aparna narayanan twitter ibd_anarayanan most heavily trade etfs have rally early month lows powershare qqq qqq be so far july past month year date compare ishare russell iwm gain period spdr spy qqq hold asset roughly largest nonfinancial stock nasdaq composite index technology sector account more half asset biotechnology company get hefty portfolio weighting top perform holding past month include netflix nflx electronic art ea tesla motor tsla also have big stake highly rate stock facebook fb regeneron pharmaceutical regn gilead science gild starbucks sbux celgene celg have ibd composite rating more skew technology sector large growth stock have help qqq edge most actively trade rival most past year average annual gain past year trail spy iwm successful investor keep eye cost qqq have expense ratio par iwm more spy asset qqq spy have shrink year iwm have grow smidge june exchange trade fund have leak more combine investor outflow qqq rise thestock market today grasp distance old high follow aparna narayanan twitter ibd_anarayanan
964,GILD,appeal big capitalization stock be resilience market sell off account big cap stock have do better job loss list range much monday broad market tumble most decline be
965,GILD,volume stock be not excessive most have trading total be well normal other have increase
966,GILD,consider massive selling market be significant not massive
967,GILD,medical leader such unitedhealth group unh edward lifescience ew continue form basis hold new high
968,GILD,facebook fb have modest decline close buy point most recent pattern volume be norm
969,GILD,loss wasn alarm
970,GILD,illumina ilmn also dip back buy point close just buy point clear couple week
971,GILD,big cap stock be health care speak strength sector be pattern present not just big cap leader other area market ibd sector leader also have fair share medical stock
972,GILD,gilead science gild fall buy point sell signal biotech so far
973,GILD,volume be average not exactly avalanche seller more share nonetheless
974,GILD,few big cap leader slide day move average institutional investor step buy dip watch rebound line evidence
975,GILD,skywork solution swks be watch regard
976,GILD,chipmaker come day line nearly double average volume not exactly gentle pullback chart reader look skywork find back favor rebound quickly strong volume
977,GILD,walt disney share have be make new high streak come stop monday
978,GILD,stock erased have be small gain buy point be back entry
979,GILD,compare stumble other leader take entertainment colossus come day proceedings relatively minor damage
980,GILD,starbucks sbux give shareholder best hope
981,GILD,share fall volume average more important stock hold solid uptrend remain well extend january couple normal pullback week move average
982,GILD,starbucks have notch week streak look firm lead stock appeal big capitalization stock be resilience market sell off account big cap stock have do better job loss list range much monday broad market tumble most decline be volume stock be not excessive most have trading total be well normal other have increase consider massive selling market be significant not massive medical leader such unitedhealth group unh edward lifescience ew continue form basis hold new high facebook fb have modest decline close buy point most recent pattern volume be norm loss wasn alarm illumina ilmn also dip back buy point close just buy point clear couple week big cap stock be health care speak strength sector be pattern present not just big cap leader other area market ibd sector leader also have fair share medical stock gilead science gild fall buy point sell signal biotech so far volume be average not exactly avalanche seller more share nonetheless few big cap leader slide day move average institutional investor step buy dip watch rebound line evidence skywork solution swks be watch regard chipmaker come day line nearly double average volume not exactly gentle pullback chart reader look skywork find back favor rebound quickly strong volume walt disney share have be make new high streak come stop monday stock erased have be small gain buy point be back entry compare stumble other leader take entertainment colossus come day proceedings relatively minor damage starbucks sbux give shareholder best hope share fall volume average more important stock hold solid uptrend remain well extend january couple normal pullback week move average starbucks have notch week streak look firm lead stock
983,GILD,stock regain foot tuesday day decline volume picked exchange accord preliminary datum nasdaq rise gain dow jone industrial average moved higher stock market today gilead science gild rise close report adjust ep compare estimate company create better expect sale new hepatitis drug harvoni twitter twtr be higher report adjust ep cent vs estimate cent guide inline estimate say monthly active user jump akamai technology akam fall earning miss estimate buffalo wild wing bwld be volatile trading higher report result open wednesday analyst be expect mastercard report quarterly earning cent share increase year earlier stock have make little headway breaking flat base late april be find support day move average pending home sale june be expect show increase compare increase month weekly petroleum inventory be report week end july federal open market committee be expect conclude day meeting statement be closely watch clue fed raise interest rate
984,GILD,biotechs generic drug maker ethical drug maker be highest rank industry group ibd track recent view top earning report fda approval strategic divestment re prove strength hot drug stock lead ibd screen day big cap leader gilead science gild jazz pharmaceutical jazz allergan agn regeneron pharmaceutical regn mallinckrodt ticker
985,GILD,diversify stock fund slide average week end aug extend slide week ve lose money investor past week loss latest week trim year date gain week be dominate stock market news china devalue yuan currency investor
986,GILD,uptrend come pressure stock show action worthy drumroll other inspire eye roll recent trouble uptrend start july close suffer distribution day row friday nasdaq suffer just distribution day thank narrow escape seem more technical reassure
987,GILD,so big cap stock continue score price gain
988,GILD,distribution cluster chipotle grill cmg have post gain valeant pharmaceutical vrx rise monster beverage mnst add
989,GILD,meanwhile eye roll camp biogen biib careen lower savage beating kick stock big cap fellow biotech gilead science gild drop twice much nasdaq
990,GILD,do success failure have anything common investor guess earning season explain however isn always simple
991,GILD,chipotle grill report quarterly result tuesday close company beat earning view only penny share have narrow miss revenue same store sale grow well year pace
992,GILD,explain gain then
993,GILD,positive include improvement fundamental tax margin be top year figure return equity be year
994,GILD,company also report improvement pork supply situation chipotle drop pork supplier january earning call co ceo steve ell report progress matter
995,GILD,chipotle also launch new ad campaign report partnership washington state university researcher reinvent way tortilla be make
996,GILD,valeant pharmaceutical have more straightforward driver thursday open company report quarterly result top street view earning revenue valeant also raise forecast
997,GILD,monster beverage isn expect report quarterly result early august firm be see grow earning week sterne agee crt begin coverage buy rating
998,GILD,negative side biogen lose place big cap crush loss stock gap friday volume average company report result small beat earning couldn compensate miss revenue weaker expect guidance
999,GILD,gilead science release result tuesday close stock appear suffer sympathy loss past session response biogen dive analyst expect ep rise share revenue gain uptrend come pressure stock show action worthy drumroll other inspire eye roll recent trouble uptrend start july close suffer distribution day row friday nasdaq suffer just distribution day thank narrow escape seem more technical reassure so big cap stock continue score price gain distribution cluster chipotle grill cmg have post gain valeant pharmaceutical vrx rise monster beverage mnst add meanwhile eye roll camp biogen biib careen lower savage beating kick stock big cap fellow biotech gilead science gild drop twice much nasdaq do success failure have anything common investor guess earning season explain however isn always simple chipotle grill report quarterly result tuesday close company beat earning view only penny share have narrow miss revenue same store sale grow well year pace explain gain then positive include improvement fundamental tax margin be top year figure return equity be year company also report improvement pork supply situation chipotle drop pork supplier january earning call co ceo steve ell report progress matter chipotle also launch new ad campaign report partnership washington state university researcher reinvent way tortilla be make valeant pharmaceutical have more straightforward driver thursday open company report quarterly result top street view earning revenue valeant also raise forecast monster beverage isn expect report quarterly result early august firm be see grow earning week sterne agee crt begin coverage buy rating negative side biogen lose place big cap crush loss stock gap friday volume average company report result small beat earning couldn compensate miss revenue weaker expect guidance gilead science release result tuesday close stock appear suffer sympathy loss past session response biogen dive analyst expect ep rise share revenue gain
1000,GILD,biotech energy stock lead sell focuse etfs friday investor digest solid unspectacular job report medium stock re-cover
1001,GILD,investor exchange trade fund find relief portfolio allocation foreign stock china stock rally emerge market etfs hop ride
1002,GILD,alp medical breakthrough sbio skid sbio hold asset biotech stock pharmaceutical
1003,GILD,hold acadium pharmaceutical acad maker neurological medicine plunge stock market today unaudited result report thursday show accelerate net loss vs year quarter
1004,GILD,biotechs rise dramatically buttress successful investment etfs mixed earning season have weigh flight giant gilead science gild amgen amgn deliver strong result biogen biib miss revenue lower outlook
1005,GILD,largest biotech etf ishare nasdaq biotechnology ibb be week midday trade fall day line thursday peg further loss friday
1006,GILD,deutsche tracker harvest csi china small cap ashs pop mainland china stock get boost stock market news fresh government support
1007,GILD,ishare china large cap fxi etf hold stock trading hong kong exchange rise
1008,GILD,stock china stage manage economy have be extremely volatile fxi be april high
1009,GILD,gold price firm friday even payroll datum be see supportive rate hike early september higher rate tend make metal less attractive yield bearing asset
1010,GILD,global gold explorer gldx lead etfs investing physical bullion precious metal equity higher advanced etf have be savage year slump gold price week high
1011,GILD,here look benchmark exchange trade fund tracking various asset class be perform today follow daily etf market action be key successful investing
1012,GILD,bellwether etfs
1013,GILD,spdr gold share gld rs
1014,GILD,vanguard ftse emerge market vwo rs
1015,GILD,ishare core aggregate bond agg rs
1016,GILD,powershare db bullish uup rs
1017,GILD,ishare core mid cap ijh rs
1018,GILD,ishare msci eafe efa rs
1019,GILD,spdr spy rs
1020,GILD,spdr dow jone industrial average dium rs
1021,GILD,powershare qqq qqq rs
1022,GILD,ishare russell iwm rs
1023,GILD,follow aparna narayanan twitter ibd_anarayanan biotech energy stock lead sell focuse etfs friday investor digest solid unspectacular job report medium stock re-cover investor exchange trade fund find relief portfolio allocation foreign stock china stock rally emerge market etfs hop ride alp medical breakthrough sbio skid sbio hold asset biotech stock pharmaceutical hold acadium pharmaceutical acad maker neurological medicine plunge stock market today unaudited result report thursday show accelerate net loss vs year quarter biotechs rise dramatically buttress successful investment etfs mixed earning season have weigh flight giant gilead science gild amgen amgn deliver strong result biogen biib miss revenue lower outlook largest biotech etf ishare nasdaq biotechnology ibb be week midday trade fall day line thursday peg further loss friday deutsche tracker harvest csi china small cap ashs pop mainland china stock get boost stock market news fresh government support ishare china large cap fxi etf hold stock trading hong kong exchange rise stock china stage manage economy have be extremely volatile fxi be april high gold price firm friday even payroll datum be see supportive rate hike early september higher rate tend make metal less attractive yield bearing asset global gold explorer gldx lead etfs investing physical bullion precious metal equity higher advanced etf have be savage year slump gold price week high here look benchmark exchange trade fund tracking various asset class be perform today follow daily etf market action be key successful investing bellwether etfs spdr gold share gld rs vanguard ftse emerge market vwo rs ishare core aggregate bond agg rs powershare db bullish uup rs ishare core mid cap ijh rs ishare msci eafe efa rs spdr spy rs spdr dow jone industrial average dium rs powershare qqq qqq rs ishare russell iwm rs follow aparna narayanan twitter ibd_anarayanan
1024,GILD,big biotech gilead science handily beat analyst estimate raise full year guidance tuesday afternoon lead sale blockbuster hepatitis drug
1025,GILD,earning exclude time item rise year earlier quarter share beating analyst consensus cent accord thomson reuter revenue climb street number
1026,GILD,gilead gild duly add guidance product sale now do not forecast ep do trim guidance sg expense well tax rate evercore isi analyst mark schoenebaum calculate imply full year ep guidance number be more dollar earlier guidance line consensus
1027,GILD,share rise hour
1028,GILD,sale gilead hepatitis virus hcv drug harvoni sovaldi beat analyst consensus accord evercore isi harvoni pull even just launch october together make more half revenue
1029,GILD,prescription downtrend
1030,GILD,legacy hiv franchise also do better time drug board miss consensus due new competition glaxosmithkline gsk time beat expectation atripla come bit light
1031,GILD,monday rbc capital market analyst michael yee write investor be look closely gilead report get overall sense hcv market be relevant rival such abbvie abbv bristol myer squibb bmy expect future player such merck mrk achillion pharmaceutical achn
1032,GILD,other analyst have be able track prescription datum sovaldi harvoni im health im tracking service
1033,GILD,weekly trx total prescription have be decline hit impressive peak march yee write research note time gilead commentary call be total treat patient usa be high possible april july trx have be decline peak weekly july
1034,GILD,still early day market
1035,GILD,conference call analyst tuesday paul carter gilead head commercial operation acknowledge prescription do decline march peak however say believe market be still early day many patient have be restrict payer get hcv drug due high price run day
1036,GILD,carter say believe restriction loosen real world benefit drug become apparent fact be cure week rather standard week course further lower cost
1037,GILD,gilead be also promote effort increase awareness diagnosis hcv many victim be infected year symptom appear big biotech gilead science handily beat analyst estimate raise full year guidance tuesday afternoon lead sale blockbuster hepatitis drug earning exclude time item rise year earlier quarter share beating analyst consensus cent accord thomson reuter revenue climb street number gilead gild duly add guidance product sale now do not forecast ep do trim guidance sg expense well tax rate evercore isi analyst mark schoenebaum calculate imply full year ep guidance number be more dollar earlier guidance line consensus share rise hour sale gilead hepatitis virus hcv drug harvoni sovaldi beat analyst consensus accord evercore isi harvoni pull even just launch october together make more half revenue prescription legacy hiv franchise also do better time drug board miss consensus due new competition glaxosmithkline gsk time beat expectation atripla come bit light monday rbc capital market analyst michael yee write investor be look closely gilead report get overall sense hcv market be relevant rival such abbvie abbv bristol myer squibb bmy expect future player such merck mrk achillion pharmaceutical achn other analyst have be able track prescription datum sovaldi harvoni im health im tracking service weekly trx total prescription have be decline hit impressive peak march yee write research note time gilead commentary call be total treat patient usa be high possible april july trx have be decline peak weekly july still early day marketon conference call analyst tuesday paul carter gilead head commercial operation acknowledge prescription do decline march peak however say believe market be still early day many patient have be restrict payer get hcv drug due high price run day carter say believe restriction loosen real world benefit drug become apparent fact be cure week rather standard week course further lower cost gilead be also promote effort increase awareness diagnosis hcv many victim be infected year symptom appear
1038,GILD,stock market hold most gain afternoon trading tuesday nasdaq lead
1039,GILD,composite increase be work fourth straight dow jone industrial average add volume be tracking monday level
1040,GILD,energy sector lead stock market today price oil climb biotechs also perked
1041,GILD,gilead science gild climb share gain traction support day move average gilead be back buy point june leave buy range
1042,GILD,thinly trade enanta pharmaceutical enta jump break cup handle base buy point
1043,GILD,cepheid cphd break flat base buy point volume tracking time average share be slightly entry afternoon trading molecular diagnostic company announce report earning july
1044,GILD,avolon holding avol gap new high break base base pattern heavy volume aircraft lease firm share be buy range buy point
1045,GILD,bohai lease chinese lease financial service affiliate chinese conglomerate hna group agree acquire stake avolon share avolon have be featured ibd ipo leader section
1046,GILD,datum release open show retail sale fall june sector be tuesday weakest consumer electronic discounter restaurant apparel other retail industry group be worst perform stock market hold most gain afternoon trading tuesday nasdaq lead composite increase be work fourth straight dow jone industrial average add volume be tracking monday level energy sector lead stock market today price oil climb biotechs also perked gilead science gild climb share gain traction support day move average gilead be back buy point june leave buy range thinly trade enanta pharmaceutical enta jump break cup handle base buy point cepheid cphd break flat base buy point volume tracking time average share be slightly entry afternoon trading molecular diagnostic company announce report earning july avolon holding avol gap new high break base base pattern heavy volume aircraft lease firm share be buy range buy point bohai lease chinese lease financial service affiliate chinese conglomerate hna group agree acquire stake avolon share avolon have be featured ibd ipo leader sectiondata release open show retail sale fall june sector be tuesday weakest consumer electronic discounter restaurant apparel other retail industry group be worst perform
1047,GILD,week list lead stock buy point include healthy dose medical name biotechs manage care provider biotech revival begin prior celgene celg jump wednesday buy receptos rcpt celgene be extend past cup handle buy point gilead science gild be still play entry find support week move average move didn create new buy opportunity occur buy point stock be buy zone also buy range be regeneron pharmaceutical regn trading just flat base buy point pattern be late stage be not surprising give eye drug maker advance past year unite therapeutic uthr hasn yet break near buy point late stage flat base ibd stock lead drug be orenitram remodulin get composite rating biotechs moved ibd industry group week hospital claim top spot vs week back represent rank generic drug group allergan agn be just handle buy point clear monday formerly know actavis botox makerad double chin injection kybella june buy kythera mallinckrodt mnk also generic drug maker be work month consolidation buy point stock look poise third straight weekly gain close week line other medical stock ethical drug maker valeant pharmaceutical vrx be build flat base entry canadian company be leader rank group highest possible composite rating molina healthcare moh provider manage health care service low income family be near flat base buy point stock sharing composite manage care group
1048,GILD,biotechnology exchange trade fund hold hodgepodge business approve drug focuse clinical trial so etf sponsor bioshare put company distinct fund
1049,GILD,biotechnology clinical trial bbc biotechnology product bbp launch december etfs start little combine now together hold roughly re also outperform bigger more establish etf peer launch
1050,GILD,paul yook portfolio manager bioshare biotechnology fund take ibd firm investment strategy success
1051,GILD,ibd strategy set bbp performance apart
1052,GILD,paul yook equal weighting have result greater weight midcap biotech stock have help bbp performance year midcap biotech stock have outperformed addition bbp have exhibit smaller drawdown market believe be result fund hold only company exist product sale opposed more speculative clinical trial stock
1053,GILD,ibd stock bbp be particularly bullish
1054,GILD,yook continue be positive gilead gild trade lowest multiple group strong dividend buyback couple potential acquisition anacor anac just recently announce positive datum second drug likely become rare breed biotechs have take multiple compound discovery market retrophin rtrx recently become product stage company also focus unique rare disease operate specialty biotechnology company look acquire late stage product complement product portfolio
1055,GILD,ibd be trend drive biotechs
1056,GILD,yook biotechnology company be most innovative global economy top selling drug globally be discover biotechnology company productivity be accelerate last year become most prolific food drug administration approval be also result record breaking premium deal volume end day biggest driver biotechnology market be continue discovery innovative medicine be help save life
1057,GILD,ibd challenge risk do biotech industry face
1058,GILD,yook many challenge last decade have be diminish access capital be now readily available fda be more open collaborative industry ever basic science have create more depth understanding disease challenge remain include greater pressure insurance company government pricing increase competition exist pipeline therapy always challenge odd successfully move drug concept market fewer drug phase eventually receive fda approval
1059,GILD,ibd main difference etfs
1060,GILD,yook bbp contain biotechnology company fda approve product bbc contain only company clinical trial stage fda approve drug practice mean bbp average have larger less volatile company investor focuse principally revenue growth bbc have smaller more volatile company significant product sale future hinging successful clinical trial result have find investor different risk appetite gravitate fund risk different end biotech spectrum
1061,GILD,bbp rise new high stock market today
1062,GILD,follow aparna narayanan twitter ibd_anarayanan biotechnology exchange trade fund hold hodgepodge business approve drug focuse clinical trial so etf sponsor bioshare put company distinct fund biotechnology clinical trial bbc biotechnology product bbp launch december etfs start little combine now together hold roughly re also outperform bigger more establish etf peer launch paul yook portfolio manager bioshare biotechnology fund take ibd firm investment strategy success ibd strategy set bbp performance apart paul yook equal weighting have result greater weight midcap biotech stock have help bbp performance year midcap biotech stock have outperformed addition bbp have exhibit smaller drawdown market believe be result fund hold only company exist product sale opposed more speculative clinical trial stock ibd stock bbp be particularly bullish yook continue be positive gilead gild trade lowest multiple group strong dividend buyback couple potential acquisition anacor anac just recently announce positive datum second drug likely become rare breed biotechs have take multiple compound discovery market retrophin rtrx recently become product stage company also focus unique rare disease operate specialty biotechnology company look acquire late stage product complement product portfolio ibd be trend drive biotechs yook biotechnology company be most innovative global economy top selling drug globally be discover biotechnology company productivity be accelerate last year become most prolific food drug administration approval be also result record breaking premium deal volume end day biggest driver biotechnology market be continue discovery innovative medicine be help save life ibd challenge risk do biotech industry face yook many challenge last decade have be diminish access capital be now readily available fda be more open collaborative industry ever basic science have create more depth understanding disease challenge remain include greater pressure insurance company government pricing increase competition exist pipeline therapy always challenge odd successfully move drug concept market fewer drug phase eventually receive fda approval ibd main difference etfs yook bbp contain biotechnology company fda approve product bbc contain only company clinical trial stage fda approve drug practice mean bbp average have larger less volatile company investor focuse principally revenue growth bbc have smaller more volatile company significant product sale future hinging successful clinical trial result have find investor different risk appetite gravitate fund risk different end biotech spectrum bbp rise new high stock market today follow aparna narayanan twitter ibd_anarayanan
1063,GILD,tuesday announcement celgene celg agree acquire receptos rcpt pleased investor stock investor gilead science gild be rumore be interested receptos mean wait edge seat literally only question get gilead be be go buy say evercore isi analyst mark schoenebaum monday video record client stock have moved broker meeting month say re ready do deal crucial question gilead future sign be blockbuster hepatitis franchise be already hit ceiling record launch month however launch do give gilead enormous pile cash buy next major drug line have set wall street collective imagination overdrive target be here be most prominent suggestion have come last few month incyte incy be suggest tuesday nomura analyst ian somaiya note mainly celgene receptos deal incyte drug jakafi treat rare form bone marrow cancer well blood disease call polycythemia vera gilead recently enter blood cancer market zydelig launch just shy year chronic lymphocytic leukemia kind lymphoma somaiya note incyte also have promising pipeline include drug solid tumor incyte month revenue totale mostly jakafi company have have inconsistent quarters bottom line analyst expect record first annual profit next year however grow rapidly stock have reflect bullish expectation relative strength rating accumulation distribution grade incyte stock hit new high early stock market today retreat back yesterday close vertex pharmaceutical vrtx bernstein analyst geoffrey porge cause minor commotion endorse combination back april vertex own hepatitis blockbuster be stomp existence gilead be position dominant player cystic fibrosis only company proven have disease alter treatment devastate condition porge point gilead already sell product market call cayston so have foot door gilead need promise high probability incremental revenue reassure investor future outlook porge write time fact year be many predict vertex cf drug be go do eventually however other analyst doubt such deal happen ground vertex be expensive market cap be hover porge suggest price be gilead prefer buy development stage asset then launch vertex stock have be flat base porge floated idea achillion pharmaceutical achn buy achillion be go opposite direction term size achillion be startup market cap be just however have be subject speculation give have promising hepatitis drug candidate own potentially help gilead extend franchise come next generation treatment november achillion candidate yielded excellent week result clinical trial combine gilead sovaldi fbr capital analyst andrew beren argue buy achillion get gilead expect trend hcv intervention shorten treatment duration currently available week week course then twitter storm speculation erupt achillion abruptly pull investor conference suggest be announce something big turn be achillion have actually sign licensing deal johnson johnson jnj diminish chance gilead buyout bristol myer squibb bmy biotech buy big pharma well actually gilead be bigger bristol now do almost sale last year vs bristol bristol hottest new drug be biologic cancer drug opdivo be thestreet com adam feuerstein be think propose idea back january not sure exactly company gilead buy acquisition focus be oncology be just pharmasset be hepatitis business potential be certainly vast give opdivo alone be expect pass annual sale however price be even more staggering vertex bristol market value have continue go feuerstein prediction now stock hit new year high wednesday close more follow amy reeve twitter ibd_areeve
1064,GILD,medical giant johnson johnson jnj beat wall street estimate lift guidance tuesday stock be fraction early trading revenue decline
1065,GILD,earning exclude special item shrank year earlier quarter share beating analyst consensus cent accord thomson reuter exclude impact foreign exchange rate profit rise
1066,GILD,revenue fall line consensus exclude fx impact sale fall
1067,GILD,lift full year guidance share previous
1068,GILD,sale decline come mixture divestiture hepatitis drug olysio sale have shrink dramatically compete product gilead science gild abbvie abbv come late last year say exclude factor fx sale rise
1069,GILD,view bode well ability medium term weather significant headwind olysio represent total sale contribute operate margin net incremental investment base estimate be likely face meaningful sale decline come quarters write leerink analyst danielle antalffy research note still strong performance other key drug notably xarelto imbruvica invokana name few be clearly help offset least part major headwind
1070,GILD,imbruvica new blood cancer drug be market profit sharing deal pharmacyclic abbvie acquire evercore isi analyst mark schoenebaum calculate take drug mean total abbvie hasn report yet
1071,GILD,number appear roughly line im im prescription appear be tracking well current consensus caveat don have clear consensus due abbvie pharmacyclic transaction schoenebaum write email client
1072,GILD,abbvie stock be more early trading stock market today
1073,GILD,other hand rbc capital market analyst glenn novarro note device business miss expectation continue trend past several quarters deduce company be lose market share spinal business upstart such globus medical gmed share atrial fibrillation market medtronic mdt st jude medical stj
1074,GILD,other hand seem be take share medtronic surgical product
1075,GILD,medtronic stock be early trading tuesday st jude stock be fraction
1076,GILD,follow amy reeve twitter ibd_areeve medical giant johnson johnson jnj beat wall street estimate lift guidance tuesday stock be fraction early trading revenue decline earning exclude special item shrank year earlier quarter share beating analyst consensus cent accord thomson reuter exclude impact foreign exchange rate profit rise revenue fall line consensus exclude fx impact sale fall lift full year guidance share previous sale decline come mixture divestiture hepatitis drug olysio sale have shrink dramatically compete product gilead science gild abbvie abbv come late last year say exclude factor fx sale rise view bode well ability medium term weather significant headwind olysio represent total sale contribute operate margin net incremental investment base estimate be likely face meaningful sale decline come quarters write leerink analyst danielle antalffy research note still strong performance other key drug notably xarelto imbruvica invokana name few be clearly help offset least part major headwind imbruvica new blood cancer drug be market profit sharing deal pharmacyclic abbvie acquire evercore isi analyst mark schoenebaum calculate take drug mean total abbvie hasn report yet number appear roughly line im im prescription appear be tracking well current consensus caveat don have clear consensus due abbvie pharmacyclic transaction schoenebaum write email client abbvie stock be more early trading stock market today other hand rbc capital market analyst glenn novarro note device business miss expectation continue trend past several quarters deduce company be lose market share spinal business upstart such globus medical gmed share atrial fibrillation market medtronic mdt st jude medical stj other hand seem be take share medtronic surgical product medtronic stock be early trading tuesday st jude stock be fraction follow amy reeve twitter ibd_areeve
1077,GILD,biotechs continue rebound medical related stock remain center stage week big cap accounting half list edward lifescience ew gap past cup handle buy point initially clear tuesday rbc capital market upgrade heart valve maker outperform sector outperform lift price target friday
1078,GILD,etf investor wake monday ugly sense vu chinese equity sell aggressively second time many month benchmark shanghai composite index plunge nearly largest day loss renew concern government policy industrial growth china state manage economy hang seng index hong
1079,GILD,equity income be legacy mutual fund classification investment strategy use dividend pay stock produce income capital appreciation be not main goal equity income fund be less volatile fall stock market equity income mutual fund perform line much past year fall start
1080,GILD,ub downgrade regeneron regn amgen amgn adjust price target several other biotech stock thursday ground sector be slow patch
1081,GILD,still think biotech continue outperform broader market health care spdr xlv be get more selective price target rating consider fewer term catalyst power drive material upward revision key driver stock past year couple fact ultra bullish thesis midcaps have be reward extent have play analyst matthew roden write second quarter earning preview hence now struggle find term conviction idea remain confident big bull case number name look month
1082,GILD,roden downgrade regeneron sell neutral valuation ground model price target remain same regeneron stock have be trading past month make valuation far highest large cap biotech write
1083,GILD,roden downgrade amgen stock neutral buy lower price target remove sale estimate immunology drug brodalumab model revelation suicide risk cause amgen withdraw development partnership astrazeneca azn write point impossible model impact new biosimilar competition amgen flagship neutropenia drug
1084,GILD,think uncertainty create wait game limit upside potential stock year roden write
1085,GILD,roden also maintain rating lower price target number other biotechs include puma biotechnology pbyi price vs previous wake disappointing datum breast cancer drug last month
1086,GILD,none seem hurt stock much morning market be rally couple bad day early trading stock market today share regeneron be just fraction amgen stock be fraction puma stock be more
1087,GILD,regeneron be latest ibd ranking top perform stock trading early thursday be buy point touch regeneron stock touch record high june
1088,GILD,positive side roden raise price target vertex pharmaceutical vrtx wake approval pricing orkambi vertex potential blockbuster cystic fibrosis drug
1089,GILD,conservative patient number be outside consensus come consensus revenue figure view command higher net present value write also believe previously underestimated gross margin together higher revenue drife greater earning power prior forecast ep
1090,GILD,roden also raise price target gilead science gild note number be still go gilead be talk ll do buyout deal year
1091,GILD,vertex gilead stock be fraction early trading thursday
1092,GILD,follow amy reeve twitter ibd_areeve ub downgrade regeneron regn amgen amgn adjust price target several other biotech stock thursday ground sector be slow patch still think biotech continue outperform broader market health care spdr xlv be get more selective price target rating consider fewer term catalyst power drive material upward revision key driver stock past year couple fact ultra bullish thesis midcaps have be reward extent have play analyst matthew roden write second quarter earning preview hence now struggle find term conviction idea remain confident big bull case number name look month roden downgrade regeneron sell neutral valuation ground model price target remain same regeneron stock have be trading past month make valuation far highest large cap biotech write roden downgrade amgen stock neutral buy lower price target remove sale estimate immunology drug brodalumab model revelation suicide risk cause amgen withdraw development partnership astrazeneca azn write point impossible model impact new biosimilar competition amgen flagship neutropenia drug think uncertainty create wait game limit upside potential stock year roden write roden also maintain rating lower price target number other biotechs include puma biotechnology pbyi price vs previous wake disappointing datum breast cancer drug last month none seem hurt stock much morning market be rally couple bad day early trading stock market today share regeneron be just fraction amgen stock be fraction puma stock be more regeneron be latest ibd ranking top perform stock trading early thursday be buy point touch regeneron stock touch record high june positive side roden raise price target vertex pharmaceutical vrtx wake approval pricing orkambi vertex potential blockbuster cystic fibrosis drug conservative patient number be outside consensus come consensus revenue figure view command higher net present value write also believe previously underestimated gross margin together higher revenue drife greater earning power prior forecast ep roden also raise price target gilead science gild note number be still go gilead be talk ll do buyout deal year vertex gilead stock be fraction early trading thursday follow amy reeve twitter ibd_areeve
1093,GILD,stock moved healthy start wednesday rise soft volume ahead afternoon fed policy announcement
1094,GILD,dow jone industrial average peck gain nasdaq rise volume be bit more nasdaq nyse compare trade same time tuesday
1095,GILD,federal reserve policy announcement et be likely remain central focus stock market today oil price hold early gain almost ahead energy information administration weekly inventory report
1096,GILD,stock fedex fdx warp almost report weaker expect fiscal fourth quarter result management guide full year earning line expectation forecasting increase pricing power continue moderate economic improvement fedex have be carve shallow consolidation december
1097,GILD,adobe system adbe slump slightly less late tuesday report fiscal second quarter earning consensus view management earning revenue guidance disappoint analyst company ramp conversion cloud base business model stock have be hover just buy point follow month flat base
1098,GILD,baidu bidu rise lead nasdaq silicon wafer maker sunedison sune gain once again lead philadelphia semiconductor index oil related stock hold top best early gain
1099,GILD,more stock ibd list moved higher open top list yy yy jump noah holding noah climb low end list gilead science gild give fraction hold buy point month long cup stock moved healthy start wednesday rise soft volume ahead afternoon fed policy announcement dow jone industrial average peck gain nasdaq rise volume be bit more nasdaq nyse compare trade same time tuesday federal reserve policy announcement et be likely remain central focus stock market today oil price hold early gain almost ahead energy information administration weekly inventory report stock fedex fdx warp almost report weaker expect fiscal fourth quarter result management guide full year earning line expectation forecasting increase pricing power continue moderate economic improvement fedex have be carve shallow consolidation december adobe system adbe slump slightly less late tuesday report fiscal second quarter earning consensus view management earning revenue guidance disappoint analyst company ramp conversion cloud base business model stock have be hover just buy point follow month flat base baidu bidu rise lead nasdaq silicon wafer maker sunedison sune gain once again lead philadelphia semiconductor index oil related stock hold top best early gain more stock ibd list moved higher open top list yy yy jump noah holding noah climb low end list gilead science gild give fraction hold buy point month long cup
1100,GILD,health care fund be top perform sector past year wasn full speed ahead health care fund build much lead consumer staple technology fund mid here play investment make june average health care stock mutual fund have mushroomed
1101,GILD,sector beat earning forecast lead health care stock accord market researcher capital iq health care sector post gain well april forecast increase capital iq say june report biotech stock be best performer gilead science gild post
1102,GILD,ibd big cap leader screen filter highly liquid large cap stock strong record earning growth top notch medical stock make screen cut be valeant pharmaceutical vrx gilead science gild celgene celg actavis act biogen biib regeneron regn shire shpg illumina ilmn
1103,GILD,valeant pharmaceutical have highest possible ibd composite rating meaning share outperform stock market measure fundamental technical factor factor be earning sale growth profit margin return equity relative price performance
1104,GILD,valeant complete acquisition salix pharmaceutical april salix partner pharm group come monday good interim datum phase clinical trial conestat alfa drug ruconest develop treatment angioedema attack allergy related swell
1105,GILD,valeant share ease tuesday be extend past cup handle base buy point initially clear last december
1106,GILD,actavis partner perrigo prgo announce tuesday new drug application guaifenesin pseudoephedrine tablet mucinex alternative be give fda approval
1107,GILD,last week eluxadoline drug viberzi treatment irritable bowel syndrome also receive fda approval
1108,GILD,actavis be try stay cup handle base buy point initially clear last wednesday close tuesday actavis have composite rating best
1109,GILD,gilead have ibd composite rating biotech announce sunday phase trial result idelalisib drug zydelig combination ofatumumab show improvement progression free survival previously treat patient chronic lymphocytic leukemia cll
1110,GILD,last week european medicine agency validate gilead marketing application emtricitabine tenofovir alafenamide combination hiv treatment investigational combination be now evaluation european medicine agency
1111,GILD,share barely close tuesday be buy point month long price consolidation
1112,GILD,celgene be biotech composite rating bmo capital last week reiterate outperform rating celgene part future prospect pleiotropic modulator cc
1113,GILD,stock be form price consolidation buy point
1114,GILD,biogen biotech earn composite rating be now trading march peak price be reach nearly month long run price consolidation
1115,GILD,regeneron break cup handle base buy point mid gain much level tuesday session biotech share dip back buy range regeneron boast composite rating
1116,GILD,shire clear buy point flat base ethical drug maker stock be now trading back level shire have composite rating
1117,GILD,illumina make gene sequence system be work price consolidation buy point last week share get pivot be now trading level
1118,GILD,follow alissa william twitter ibd_awilliam ibd big cap leader screen filter highly liquid large cap stock strong record earning growth top notch medical stock make screen cut be valeant pharmaceutical vrx gilead science gild celgene celg actavis act biogen biib regeneron regn shire shpg illumina ilmn valeant pharmaceutical have highest possible ibd composite rating meaning share outperform stock market measure fundamental technical factor factor be earning sale growth profit margin return equity relative price performance valeant complete acquisition salix pharmaceutical april salix partner pharm group come monday good interim datum phase clinical trial conestat alfa drug ruconest develop treatment angioedema attack allergy related swell valeant share ease tuesday be extend past cup handle base buy point initially clear last december actavis partner perrigo prgo announce tuesday new drug application guaifenesin pseudoephedrine tablet mucinex alternative be give fda approval last week eluxadoline drug viberzi treatment irritable bowel syndrome also receive fda approval actavis be try stay cup handle base buy point initially clear last wednesday close tuesday actavis have composite rating best gilead have ibd composite rating biotech announce sunday phase trial result idelalisib drug zydelig combination ofatumumab show improvement progression free survival previously treat patient chronic lymphocytic leukemia cll last week european medicine agency validate gilead marketing application emtricitabine tenofovir alafenamide combination hiv treatment investigational combination be now evaluation european medicine agency share barely close tuesday be buy point month long price consolidation celgene be biotech composite rating bmo capital last week reiterate outperform rating celgene part future prospect pleiotropic modulator cc stock be form price consolidation buy point biogen biotech earn composite rating be now trading march peak price be reach nearly month long run price consolidation regeneron break cup handle base buy point mid gain much level tuesday session biotech share dip back buy range regeneron boast composite rating shire clear buy point flat base ethical drug maker stock be now trading back level shire have composite rating illumina make gene sequence system be work price consolidation buy point last week share get pivot be now trading level follow alissa william twitter ibd_awilliam
1119,GILD,biotech globeimmune gbim say wednesday hepatitis drug develop gilead science gild fail midstage trial globeimmune stock lose half value gilead stock rise globeimmune say gs therapeutic vaccine license gilead didn meet trial primary endpoint reduce hepatitis surface antigen hbsag week
1120,GILD,best mutual fund performance report highly profitable health care stock be hit mutual fund investor innovative drug merger even obamacare be fuel like actavis act centene cnc akorn akrx momentum grow health biotech fund spiked average top other domestic foreign category health
1121,GILD,analyst give mixed reviews wednesday achillion pharmaceutical achn new partnership johnson johnson jnj stock plunge ub jmp security downgrade stock neutral potential massive value create event buyout be limit hepatitis drug deal recently monday achillion pharmaceutical share shot
1122,GILD,intercept pharmaceutical say tuesday have hammer design phase trial nonalcoholic steatohepatitis treatment stock fall time frame look longer many investor expect
1123,GILD,nash be slow act disease fat buildup liver cause progressive scarring current treatment so be previous model large clinical trial go much discussion fda european medicine agency intercept launch trial enrolling patient center worldwide patient be divide group take placebo take mg dose intercept obeticholic acid oca treatment take mg dose
1124,GILD,month treatment result patient be analyze proportion achieve significant improvement liver fibrosis relative placebo group proportion achieve nash resolution worsening fibrosis result be satisfactory intercept icpt file approval still work total result patient
1125,GILD,represent important step forward intercept give nash be potentially multibillion dollar market
1126,GILD,analyst michael yee rbc capital market write research note trial be bigger longer intercept have suggest
1127,GILD,intercept competitor nash be mostly other small biotechs so mount trial large indeed be challenge exception be gilead science gild most advanced nash candidate simtuzumab be phase testing
1128,GILD,yee also write intercept remain valuable buyout candidate steep price recently paid midcap biotechs such pharmacyclic pcyc show scarcity value asset intercept pharmaceutical say tuesday have hammer design phase trial nonalcoholic steatohepatitis treatment stock fall time frame look longer many investor expect nash be slow act disease fat buildup liver cause progressive scarring current treatment so be previous model large clinical trial go much discussion fda european medicine agency intercept launch trial enrolling patient center worldwide patient be divide group take placebo take mg dose intercept obeticholic acid oca treatment take mg dose month treatment result patient be analyze proportion achieve significant improvement liver fibrosis relative placebo group proportion achieve nash resolution worsening fibrosis result be satisfactory intercept icpt file approval still work total result patient represent important step forward intercept give nash be potentially multibillion dollar market analyst michael yee rbc capital market write research note trial be bigger longer intercept have suggest intercept competitor nash be mostly other small biotechs so mount trial large indeed be challenge exception be gilead science gild most advanced nash candidate simtuzumab be phase testing yee also write intercept remain valuable buyout candidate steep price recently paid midcap biotechs such pharmacyclic pcyc show scarcity value asset
1129,GILD,gilead science gild picked provider hepatitis drug friday ongoing battle market share disease giant health insurer aetna announce harvoni sovaldi now be prefer therapy aetna commercial customer company negotiate unspecified discount drug price officially sovaldi be
1130,GILD,most actively trade etfs have tumble recent time high be trading day move average line
1131,GILD,spdr spy be old high set december ishare russell iwm be record be powershare qqq qqq
1132,GILD,spy qqq etfs have large cap stock bent qqq offer much stronger tech stock tilt vs spy also allocate far more top stock holding such apple aapl microsoft msft vs spy
1133,GILD,allocation combine strong presence biotech name qqq top stock such gilead science gild amgen amgn celgene celg biogen idec biib help power gain stock market spy rise last year
1134,GILD,allocation financial real estate energy utility sector qqq entail higher sector concentration risk
1135,GILD,look ahead etf expert expect tech health care sector tooutperform
1136,GILD,many fund tracking small cap equity iwm lag last year climb iwm hold stock small cap make small fraction total stock market
1137,GILD,result fund be regard suitable satellite hold investor portfolio technology health care account more iwm asset
1138,GILD,etfs spy expense ratio make cheapest own iwm qqq charge investor most actively trade etfs have tumble recent time high be trading day move average line spdr spy be old high set december ishare russell iwm be record be powershare qqq qqq spy qqq etfs have large cap stock bent qqq offer much stronger tech stock tilt vs spy also allocate far more top stock holding such apple aapl microsoft msft vs spy allocation combine strong presence biotech name qqq top stock such gilead science gild amgen amgn celgene celg biogen idec biib help power gain stock market spy rise last year allocation financial real estate energy utility sector qqq entail higher sector concentration risk look ahead etf expert expect tech health care sector tooutperform many fund tracking small cap equity iwm lag last year climb iwm hold stock small cap make small fraction total stock market result fund be regard suitable satellite hold investor portfolio technology health care account more iwm asset etfs spy expense ratio make cheapest own iwm qqq charge investor
1139,GILD,share big pharma abbvie abbv drop more friday morning company issue ep guidance get downgrade bank america abbvie say expect full year earning midpoint just average estimate analyst poll thomson reuter company say further refine guidance
1140,GILD,small biotech achillion pharmaceutical achn announce late tuesday have enter collaboration johnson johnson jnj develop hepatitis drug potentially worth more agree invest achillion upfront promise development regulatory sale milestone payment company successfully launch pipeline
1141,GILD,spending prescription drug soar last year drive primarily costly breakthrough medicine manufacturer price hike surge million person newly insure due affordable care act spending rise biggest jump total accord report release tuesday im institute healthcare informatic
1142,GILD,new product introduction swipe trade secret chipmaker have steal spotlight so far week let not forget biotech stock be highlighted ibd screen day big cap leader semiconductor counterpart large cap biotechs include celgene celg regeneron pharmaceutical regn gilead science gild celgene have
1143,GILD,stock market hold mild thursday do best continue week rise path nasdaq reduce advance just close also fade come away only advance small cap russell keep pace broad market rise dow transportation
1144,GILD,big cap biotech gilead science gild agree tuesday acquire program small german biotech phenex pharmaceutical aim treat liver disease
1145,GILD,gilead agree unspecified upfront payment milestone payment totale phenex farnesoid receptor program company press release emphasize target program be alcoholic steatohepatitis nash common largely untreated form liver damage cause buildup fat liver
1146,GILD,have be widely speculate wall street gilead move nash give go liver disease big way recently launch hepatitis drug dominance field be already become struggle firm have be look next blockbuster franchise
1147,GILD,go nash liver disease be obvious logical step market be multibillion potential re player already hep have obvious synergy write rbc capital market analyst michael yee note tuesday
1148,GILD,yee note do dim hope gilead acquire intercept pharmaceutical icpt have nash drug candidate furthest clinical trial process
1149,GILD,intercept stock be nearly morning trading tuesday gilead be more morning trading stock market today
1150,GILD,gilead timing be fortuitous come day result workshop fda lead liver disease association clarify measurement clinical trial satisfy fda efficacy requirement nash have long be unclear be previous treatment have pass muster slow progression disease make more unlikely be cure workshop paper suggest lack progression patient early fibrosis be acceptable surrogate endpoint trial
1151,GILD,believe fda be essentially acknowledge path approval article base surrogate align well endpoint intercept plan target phase study write baird analyst brian skorney note monday
1152,GILD,news lift nearly stock nash candidate monday intercept rise conatus cnat jump fibrogen fgen vault raptor pharmaceutical rptp be
1153,GILD,follow amy reeve twitter ibd_areeve big cap biotech gilead science gild agree tuesday acquire program small german biotech phenex pharmaceutical aim treat liver disease gilead agree unspecified upfront payment milestone payment totale phenex farnesoid receptor program company press release emphasize target program be alcoholic steatohepatitis nash common largely untreated form liver damage cause buildup fat liver have be widely speculate wall street gilead move nash give go liver disease big way recently launch hepatitis drug dominance field be already become struggle firm have be look next blockbuster franchise go nash liver disease be obvious logical step market be multibillion potential re player already hep have obvious synergy write rbc capital market analyst michael yee note tuesday yee note do dim hope gilead acquire intercept pharmaceutical icpt have nash drug candidate furthest clinical trial process intercept stock be nearly morning trading tuesday gilead be more morning trading stock market today gilead timing be fortuitous come day result workshop fda lead liver disease association clarify measurement clinical trial satisfy fda efficacy requirement nash have long be unclear be previous treatment have pass muster slow progression disease make more unlikely be cure workshop paper suggest lack progression patient early fibrosis be acceptable surrogate endpoint trial believe fda be essentially acknowledge path approval article base surrogate align well endpoint intercept plan target phase study write baird analyst brian skorney note monday news lift nearly stock nash candidate monday intercept rise conatus cnat jump fibrogen fgen vault raptor pharmaceutical rptp be follow amy reeve twitter ibd_areeve
1154,GILD,health care mutual fund have outperformed wide margin past year have really take past year
1155,GILD,be sit today invest average health care fund accord morningstar datum same investment track broad stock market have grow
1156,GILD,yes period include punish bear market have test even most resolute investor number serve example powerful part stock market be
1157,GILD,biotechnology stock have be main driver recent month rowe price health science fund recent top hold be gilead science gild drugmaker be year report weaker expect earning late last month
1158,GILD,stock be breaking base formation turn lower report yesterday drop week move average heavy volume bearish sign health care mutual fund have outperformed wide margin past year have really take past year be sit today invest average health care fund accord morningstar datum same investment track broad stock market have grow yes period include punish bear market have test even most resolute investor number serve example powerful part stock market be biotechnology stock have be main driver recent month rowe price health science fund recent top hold be gilead science gild drugmaker be year report weaker expect earning late last month stock be breaking base formation turn lower report yesterday drop week move average heavy volume bearish sign
1159,GILD,stock lose steam late wednesday blue chip continue outshine broader index be modestly lower day big gain
1160,GILD,dow jone industrial average be thank continue support walt disney visa lose hurt weakness energy sector meanwhile nasdaq slip just volume be tracking higher board stock market today
1161,GILD,lead stock hain celestial group hain bolt regain day line bounce back early weakness share be nearly open company report mixed result fiscal end dec earning beat view sale miss expectation
1162,GILD,hdfc bank hdb be session high still stock past buy point have lose steam recent session gain have be trim hdfc be featured international leader last month
1163,GILD,chipotle grill cmg be gilead science gild hold loss be nearly wednesday low report quarterly earning late tuesday chipotle have climb back buy point be still day line
1164,GILD,close notable stock such cbre group cbg monolithic power system mpwr nxp semiconductor nxpi reilly automotive orly tableau software datum armour ua be report earning stock lose steam late wednesday blue chip continue outshine broader index be modestly lower day big gain dow jone industrial average be thank continue support walt disney visa lose hurt weakness energy sector meanwhile nasdaq slip just volume be tracking higher board stock market today lead stock hain celestial group hain bolt regain day line bounce back early weakness share be nearly open company report mixed result fiscal end dec earning beat view sale miss expectation hdfc bank hdb be session high still stock past buy point have lose steam recent session gain have be trim hdfc be featured international leader last month chipotle grill cmg be gilead science gild hold loss be nearly wednesday low report quarterly earning late tuesday chipotle have climb back buy point be still day line close notable stock such cbre group cbg monolithic power system mpwr nxp semiconductor nxpi reilly automotive orly tableau software datum armour ua be report earning
1165,GILD,regeneron pharmaceutical report solid sale big cap biotech stock reversed lower tuesday potentially huge new cholesterol fighter be crosshair lead pharmacy benefit manager pbm
1166,GILD,jpmorgan healthcare conference san francisco express script esrx ceo george paz chat session company recent success drive discount pricey new hepatitis drug exclude gilead science gild sovaldi harvoni national prefer formulary favor abbvie abbv viekira pak pbm drug store giant cvs health cvs have opted sovaldi harvoni viekira pak
1167,GILD,ask sort drug be next list sort action paz say big course be cholesterol lower drug be come market
1168,GILD,pre emptive drug price war
1169,GILD,everyone take be refer pcsk inhibitor new class ldl lower drug first be expect launch third quarter year regeneron regn praluent alirocumab develop partnership sanofi sny amgen amgn evolocumab be expect bring multibillion dollar annual sale eventually pfizer pfe also have farther pipeline
1170,GILD,be powerful drug re also very expensive paz say be several chain re talk drugmaker see show promise re talk market share position pricing more be too more need understand competitive nature re enter
1171,GILD,paz comment seem allude widespread perception street pcsk be basically similar
1172,GILD,regeneron ceo len schleifer dispute session own presentation same conference later tuesday point praluent likely be approve different dose evolocumab be set be available just
1173,GILD,schleifer be diplomatic express say have exact same goal downplay impact market share end day not sure turn much differently be exclusive formulary negotiation not
1174,GILD,regeneron eylea sale bright
1175,GILD,presentation schleifer give preliminary sale figure regeneron lead product eye drug eylea be high side firm prior guidance factset consensus
1176,GILD,also guide expense item tend do lieu earning be heavily affected option expense
1177,GILD,range be set sg capital spending tax rate figure be gaap analyst estimate available ibd used gaap so wasn clear compare expectation
1178,GILD,regeneron stock rise nearly intraday reversed overall market close day move average
1179,GILD,separately conference robotic surgery system maker former star stock intuitive surgical isrg release preliminary sale year earlier more consensus firm also see procedure growth rbc capital market analyst brandon henry write be line expectation
1180,GILD,expect isrg share move higher morning continue believe worst be isrg henry write note market open
1181,GILD,be right first part intuitive surgical rise intraday stock retreat afternoon close regeneron pharmaceutical report solid sale big cap biotech stock reversed lower tuesday potentially huge new cholesterol fighter be crosshair lead pharmacy benefit manager pbm jpmorgan healthcare conference san francisco express script esrx ceo george paz chat session company recent success drive discount pricey new hepatitis drug exclude gilead science gild sovaldi harvoni national prefer formulary favor abbvie abbv viekira pak pbm drug store giant cvs health cvs have opted sovaldi harvoni viekira pak ask sort drug be next list sort action paz say big course be cholesterol lower drug be come market pre emptive drug price wareveryone take be refer pcsk inhibitor new class ldl lower drug first be expect launch third quarter year regeneron regn praluent alirocumab develop partnership sanofi sny amgen amgn evolocumab be expect bring multibillion dollar annual sale eventually pfizer pfe also have farther pipeline be powerful drug re also very expensive paz say be several chain re talk drugmaker see show promise re talk market share position pricing more be too more need understand competitive nature re enter paz comment seem allude widespread perception street pcsk be basically similar regeneron ceo len schleifer dispute session own presentation same conference later tuesday point praluent likely be approve different dose evolocumab be set be available just schleifer be diplomatic express say have exact same goal downplay impact market share end day not sure turn much differently be exclusive formulary negotiation not regeneron eylea sale brightat presentation schleifer give preliminary sale figure regeneron lead product eye drug eylea be high side firm prior guidance factset consensus also guide expense item tend do lieu earning be heavily affected option expense range be set sg capital spending tax rate figure be gaap analyst estimate available ibd used gaap so wasn clear compare expectation regeneron stock rise nearly intraday reversed overall market close day move average separately conference robotic surgery system maker former star stock intuitive surgical isrg release preliminary sale year earlier more consensus firm also see procedure growth rbc capital market analyst brandon henry write be line expectation expect isrg share move higher morning continue believe worst be isrg henry write note market open be right first part intuitive surgical rise intraday stock retreat afternoon close
1182,GILD,stock extend loss midday thursday day federal reserve raise interest rate first time nearly decade fall dow jone industrial average nasdaq be
1183,GILD,volume be run higher nyse nasdaq compare same time wednesday
1184,GILD,economic news be mixed unemployment claim fall little less expect week end dec manufacturing mid atlantic region fall much more expect december conference board index lead economic indicator rise november prior month increase ahead analyst forecast
1185,GILD,mining energy stock be hit hardest stock market today decline oil metal price
1186,GILD,newmont mining nem colorado base miner gold silver lose lead lower oil transportation stock oneok oke also drop
1187,GILD,most ibd stock be lower lead global payment gpn fall more heavy volume stock plunge wednesday slice day line agree buy rival credit card payment processor heartland payment system hpy
1188,GILD,total system service tss credit card payment processor ibd fall remain well buy point cup handle base clear october
1189,GILD,chinese social medium stock weibo wb be bright spot jump more heavy volume close buy point deep cup shape base
1190,GILD,stock boast rise relative strength line accumulation distribution rating indicate strong demand share stock have more double fall low aug stock extend loss midday thursday day federal reserve raise interest rate first time nearly decade fall dow jone industrial average nasdaq be volume be run higher nyse nasdaq compare same time wednesday economic news be mixed unemployment claim fall little less expect week end dec manufacturing mid atlantic region fall much more expect december conference board index lead economic indicator rise november prior month increase ahead analyst forecast mining energy stock be hit hardest stock market today decline oil metal price newmont mining nem colorado base miner gold silver lose lead lower oil transportation stock oneok oke also drop most ibd stock be lower lead global payment gpn fall more heavy volume stock plunge wednesday slice day line agree buy rival credit card payment processor heartland payment system hpy total system service tss credit card payment processor ibd fall remain well buy point cup handle base clear october chinese social medium stock weibo wb be bright spot jump more heavy volume close buy point deep cup shape base stock boast rise relative strength line accumulation distribution rating indicate strong demand share stock have more double fall low aug
1191,GILD,strong earning growth be most important factor look research stock positive earning surprise be critical factor help buoy stock price thomson reuter report date show sector biggest number firm top view be health care utility service technology
1192,GILD,stock give early gain friday be trading slightly lower go noon hour
1193,GILD,nasdaq fall dow jone industrial average give stock market today volume be heavier exchange part option expiration
1194,GILD,paycom payc gap be trading lower price secondary offer share stock close thursday
1195,GILD,keurig green mountain gmcr fall lowest level february company say keurig kold cold beverage maker win fully roll holiday season
1196,GILD,cheetah mobile cmcm rise nearly heavy volume fifth straight daily advance touch time high chinese company come public develop internet mobile software application
1197,GILD,gilead science gild rise more average volume stock have rise straight day be consolidate gain late october
1198,GILD,restaurant chain el pollo gap be trading lower close thursday report sale miss forecast morning note morgan stanley analyst blame limit time offer confuse customer also note dependent company have become promotion drive sale stock give early gain friday be trading slightly lower go noon hour nasdaq fall dow jone industrial average give stock market today volume be heavier exchange part option expiration paycom payc gap be trading lower price secondary offer share stock close thursday keurig green mountain gmcr fall lowest level february company say keurig kold cold beverage maker win fully roll holiday season cheetah mobile cmcm rise nearly heavy volume fifth straight daily advance touch time high chinese company come public develop internet mobile software application gilead science gild rise more average volume stock have rise straight day be consolidate gain late october restaurant chain el pollo gap be trading lower close thursday report sale miss forecast morning note morgan stanley analyst blame limit time offer confuse customer also note dependent company have become promotion drive sale
1199,GILD,promising early rebound fizzle wednesday leave major index flat finish indeed such movement continue stock market expect more player get worn rather shake divergence lie leadership however market pulse table show more top quality growth stock rise heavy volume fall average trade
1200,GILD,best mutual fund performance report
1201,GILD,country lead stock mutual fund past month have be add medical issue latest report period
1202,GILD,treat many position kindly nasdaq forge ahead month rise most gain be make second part market confirm uptrend
1203,GILD,so much adage sell go away next few month tell thing turn mutual fund
1204,GILD,ibd industry medical subgroup rank top tuesday
1205,GILD,manager best perform fund have be gathering mallinckrodt mnk abc regeneron pharmaceutical regn unite therapeutic uthr portfolio
1206,GILD,demand cheaper chip new product power mobile phone internet connect gadget be drive competition consolidation tech arena
1207,GILD,recent intel intc altera altr merger bring more buzz chip sector last week technology avgo say buy broadcom brcm deal worth march nxp semiconductor nxpi buy freescale semiconductor fsl deal value
1208,GILD,other chipmaker do well include macom mtsi skywork solution swks cirrus logic crus
1209,GILD,ibd spot top perform fund add mallinckrodt investing estimate fidelity mid cap value fund own stake firm dublin base firm make generic brand drug treat pain also make diagnostic imaging system
1210,GILD,company have be boost product line acquire other successful drug firm such ikarium cadence pharmaceutical questcor pharmaceutical thus mallinckrodt deliver strong earning result past quarters rise respectively
1211,GILD,mallinckrodt stock have be etching right side shape base near buy point volume have be average
1212,GILD,sell side
1213,GILD,top mutual fund have be take profit big manage care firm such unitedhealth unh anthem antm latest report period biotechs firm gilead science gild isis pharmaceutical isis also be sell lead fund best mutual fund performance country lead stock mutual fund past month have be add medical issue latest report period treat many position kindly nasdaq forge ahead month rise most gain be make second part market confirm uptrend so much adage sell go away next few month tell thing turn mutual fund ibd industry medical subgroup rank top tuesday manager best perform fund have be gathering mallinckrodt mnk abc regeneron pharmaceutical regn unite therapeutic uthr portfolio demand cheaper chip new product power mobile phone internet connect gadget be drive competition consolidation tech arena recent intel intc altera altr merger bring more buzz chip sector last week technology avgo say buy broadcom brcm deal worth march nxp semiconductor nxpi buy freescale semiconductor fsl deal value other chipmaker do well include macom mtsi skywork solution swks cirrus logic crus ibd spot top perform fund add mallinckrodt investing estimate fidelity mid cap value fund own stake firm dublin base firm make generic brand drug treat pain also make diagnostic imaging system company have be boost product line acquire other successful drug firm such ikarium cadence pharmaceutical questcor pharmaceutical thus mallinckrodt deliver strong earning result past quarters rise respectively mallinckrodt stock have be etching right side shape base near buy point volume have be average sell sidetop mutual fund have be take profit big manage care firm such unitedhealth unh anthem antm latest report period biotechs firm gilead science gild isis pharmaceutical isis also be sell lead fund
1214,GILD,special report best mutual fund january performance report
1215,GILD,fall oil price greece possible exit eurozone stock market start first month year volatility
1216,GILD,best perform mutual fund past month slow buy january outlook ibd market pulse toggle correction market pressure stock market
1217,GILD,top mutual fund have be add heavy hit medical issue such celgene celg biogen idec biib latest report period other include actavis act illumina ilmn shire shpg
1218,GILD,ibd industry medical subgroup rank top tuesday biotech biom group rank
1219,GILD,top perform fund continue give much love airline stock include southwest airline luv unite continental holding ual jetblue airway jblu
1220,GILD,real estate stock make way new buy list property reit such pebblebrook hotel peb extra space storage exr regency center reg be stellar performer lipper real estate mutual fund category be second best perform group january notch gain
1221,GILD,ibd spot lead mutual fund add nautilus nls investing estimate
1222,GILD,jpmorgan small cap value fund add share latest report period
1223,GILD,vancouver wash base firm make market fitness product include home gym free weight equipment treadmill indoor cycling equipment elliptical fitness accessory portfolio fitness brand include bowflex nautilus schwinn universal sell retail direct sale consumer
1224,GILD,nautilus have be pump sale growth past quarters analyst see growth opportunity nautilus continue deliver innovative product
1225,GILD,stock be currently form handle third stage cup handle base trading buy point
1226,GILD,sell side
1227,GILD,lead fund have be take profit several big reit stock such simon property group spg federal realty investment trust frt aviv aviv public storage psa
1228,GILD,top perform fund be also selling biotech stock include gilead science gild isis pharmaceutical isis special report best mutual fund january performance reportamid fall oil price greece possible exit eurozone stock market start first month year volatility best perform mutual fund past month slow buy january outlook ibd market pulse toggle correction market pressure stock market top mutual fund have be add heavy hit medical issue such celgene celg biogen idec biib latest report period other include actavis act illumina ilmn shire shpg ibd industry medical subgroup rank top tuesday biotech biom group rank top perform fund continue give much love airline stock include southwest airline luv unite continental holding ual jetblue airway jblu real estate stock make way new buy list property reit such pebblebrook hotel peb extra space storage exr regency center reg be stellar performer lipper real estate mutual fund category be second best perform group january notch gain ibd spot lead mutual fund add nautilus nls investing estimate jpmorgan small cap value fund add share latest report period vancouver wash base firm make market fitness product include home gym free weight equipment treadmill indoor cycling equipment elliptical fitness accessory portfolio fitness brand include bowflex nautilus schwinn universal sell retail direct sale consumer nautilus have be pump sale growth past quarters analyst see growth opportunity nautilus continue deliver innovative product stock be currently form handle third stage cup handle base trading buy point sell sidelead fund have be take profit several big reit stock such simon property group spg federal realty investment trust frt aviv aviv public storage psa top perform fund be also selling biotech stock include gilead science gild isis pharmaceutical isis
1229,GILD,stock start quietly higher friday high volume hot spot shine early trade nasdaq hop ahead dow jone industrial average add gold miner post top early gain industry stock market today lead almost entirely gain thinly trade low price stock standout be agnico eagle mine aem moderate trade science gild celgene celg rise more apiece top gain nasdaq list nike nke rise nearly lead dow continue rebound test support week move average gopro gpro pop massive trade maker wearable action camera be week fight back steep month sell ibd list china base noah holding noah leap more start trade financial asset manager be still more high set early december ambarella amba jump surge volume boost rebound week support
1230,GILD,biotech industry be set hit ground run january alone bring passel potentially stock move event biggest player second full week month bring annual jpmorgan healthcare conference san francisco many company release product financial news first thing morning
1231,GILD,stock slide fresh session lows late monday oil price continue weigh west texas intermediate close barrel
1232,GILD,dow jone industrial average slump respectively nasdaq drop volume spiked higher major exchange stock market today
1233,GILD,lead stock virgin america va stretched loss more airline stock be weak monday plunge oil price alaska air group alk delta air line dal southwest airline luv fall delta even boost margin outlook again
1234,GILD,elsewhere unite rental uri tumble be cut sell buy evercore
1235,GILD,upside gilead science gild rise reverse high cvs caremark cvs announce cover gilead solvaldi harvoni hepatitis drug several plan gilead tumble last month news express script esrx drop coverage hepatitis treatment favor abbvie abbv
1236,GILD,fellow biotech akorn akrx be session high still nearly stock slide fresh session lows late monday oil price continue weigh west texas intermediate close barrel dow jone industrial average slump respectively nasdaq drop volume spiked higher major exchange stock market today lead stock virgin america va stretched loss more airline stock be weak monday plunge oil price alaska air group alk delta air line dal southwest airline luv fall delta even boost margin outlook again elsewhere unite rental uri tumble be cut sell buy evercore upside gilead science gild rise reverse high cvs caremark cvs announce cover gilead solvaldi harvoni hepatitis drug several plan gilead tumble last month news express script esrx drop coverage hepatitis treatment favor abbvie abbv fellow biotech akorn akrx be session high still nearly
1237,GILD,report mixed quarterly result top rate biotech celgene celg look have unraveled base build effort
1238,GILD,stock drop stock market today fall month low
1239,GILD,celgene earning grow beat estimate penny sale increase miss view
1240,GILD,group peer biogen biib have yet retake day line gap area result miss estimate last friday
1241,GILD,fellow biotech gilead gild face same result
1242,GILD,watch video chart analysis celgene gilead biogen
1243,GILD,follow alissa william twitter ibd_awilliam report mixed quarterly result top rate biotech celgene celg look have unraveled base build effort stock drop stock market today fall month low celgene earning grow beat estimate penny sale increase miss view group peer biogen biib have yet retake day line gap area result miss estimate last friday fellow biotech gilead gild face same result watch video chart analysis celgene gilead biogen follow alissa william twitter ibd_awilliam
1244,GILD,hour action be busy linkedin lnkd continue social network poorly receive report solar stock fall short revenue gilead science gild crush estimate latest hepatitis drug meanwhile tesla motor tsla await much hyped battery announcement
1245,GILD,linkedin stock share plummet late trading first quarter beat social medium site professional provide weak earning sale guidance fall far view earning outlook cent badly miss estimate cent
1246,GILD,share first solar fslr sunpower spwr continue dwindle hour have already close session
1247,GILD,first solar swung cent share loss year profit miss view cent company guidance top sunpower earning come ahead forecast revenue miss
1248,GILD,gilead science have trouble top expectation earning share exclude item ahead estimate cent revenue soar biotech boost full year product sale target credit go latest hepatitis fighter harvoni
1249,GILD,share rise late erase regular session loss
1250,GILD,tesla motor edge hour close almost investor await electric car maker late thursday announcement new home utility scale battery tesla have be testing battery solarcity scty
1251,GILD,related
1252,GILD,linkedin top view share clip outlook
1253,GILD,first solar miss badly sunpower ep beat
1254,GILD,tesla rise analyst see upside battery launch hour action be busy linkedin lnkd continue social network poorly receive report solar stock fall short revenue gilead science gild crush estimate latest hepatitis drug meanwhile tesla motor tsla await much hyped battery announcement linkedin stock share plummet late trading first quarter beat social medium site professional provide weak earning sale guidance fall far view earning outlook cent badly miss estimate cent share first solar fslr sunpower spwr continue dwindle hour have already close session first solar swung cent share loss year profit miss view cent company guidance top sunpower earning come ahead forecast revenue miss gilead science have trouble top expectation earning share exclude item ahead estimate cent revenue soar biotech boost full year product sale target credit go latest hepatitis fighter harvoni share rise late erase regular session loss tesla motor edge hour close almost investor await electric car maker late thursday announcement new home utility scale battery tesla have be testing battery solarcity scty related linkedin top view share clip outlookfirst solar miss badly sunpower ep beatstesla rise analyst see upside battery launch
1255,GILD,biotech gilead science handily beat first quarter expectation raise revenue guidance thursday cap busy day big cap drugmaker earning gilead gild report earning time item share year earlier quarter beating analyst consensus cent accord thomson reuter revenue jump more wall street estimate
1256,GILD,gilead doesn give ep guidance add full year product sale target now
1257,GILD,essentially entire revenue beat come hepatitis drug harvoni first full quarter market harvoni notch well analyst estimate predecessor sovaldi however miss expectation gilead hiv franchise once mainstay now minority revenue also come forecast
1258,GILD,evercore isi analyst mark schoenebaum say guidance raise be especially significant
1259,GILD,company tend be conservative so raise revenue guidance early year speak volume write email client
1260,GILD,conference call analyst commercial operation chief paul carter say hcv patient base seem be somewhere north gilead have predict last year add be first franchise have picked significant number patient europe reach
1261,GILD,bernstein analyst geoffrey porge last week say gilead buy fellow big cap biotech vertex pharmaceutical vrtx delicately bring be do cash
1262,GILD,cfo robin washington say gilead do keep eye opportunity say prefer phase earlier stage asset seem cut vertex already have commercial product
1263,GILD,gilead stock rise hour trading share have close
1264,GILD,abbvie abbv have rival hepatitis treatment viekira pak be steady late beat ep estimate last week
1265,GILD,earlier thursday israeli generic drug giant teva pharmaceutical industry teva report adjust ep beating view cent
1266,GILD,sale dip beat estimate exclude currency headwind divestment sale rise
1267,GILD,teva raise ep guidance year cent imply profit upside be not go be sustain biggest threat horizon be launch generic version best seller copaxone date be uncertain likely take place september
1268,GILD,teva stock slide
1269,GILD,celgene sale miss
1270,GILD,celgene celg report mixed quarter ep rise penny view sale grow miss consensus more
1271,GILD,big biotech affirm full year guidance product sale ep last year make share revenue
1272,GILD,sale flagship blood cancer drug revlimid beat esti mate foreign revlimid sale other individually report drug sale miss consensus
1273,GILD,celgene stock dive close
1274,GILD,danish diabetes specialist nordisk nvo report earning kroner cent share beating consensus revenue rise kroner kroner consensus
1275,GILD,nordisk hike profit growth guidance add percentage point low end sale growth guidance
1276,GILD,president kaare schultz say be leave follow management reorganization eliminate other job chief operate officer schultz have aspire be ceo board decide keep lar sorensen
1277,GILD,stock rise biotech gilead science handily beat first quarter expectation raise revenue guidance thursday cap busy day big cap drugmaker earning gilead gild report earning time item share year earlier quarter beating analyst consensus cent accord thomson reuter revenue jump more wall street estimate gilead doesn give ep guidance add full year product sale target now essentially entire revenue beat come hepatitis drug harvoni first full quarter market harvoni notch well analyst estimate predecessor sovaldi however miss expectation gilead hiv franchise once mainstay now minority revenue also come forecast evercore isi analyst mark schoenebaum say guidance raise be especially significant company tend be conservative so raise revenue guidance early year speak volume write email client conference call analyst commercial operation chief paul carter say hcv patient base seem be somewhere north gilead have predict last year add be first franchise have picked significant number patient europe reach bernstein analyst geoffrey porge last week say gilead buy fellow big cap biotech vertex pharmaceutical vrtx delicately bring be do cash cfo robin washington say gilead do keep eye opportunity say prefer phase earlier stage asset seem cut vertex already have commercial product gilead stock rise hour trading share have close abbvie abbv have rival hepatitis treatment viekira pak be steady late beat ep estimate last week earlier thursday israeli generic drug giant teva pharmaceutical industry teva report adjust ep beating view cent sale dip beat estimate exclude currency headwind divestment sale rise teva raise ep guidance year cent imply profit upside be not go be sustain biggest threat horizon be launch generic version best seller copaxone date be uncertain likely take place september teva stock slide celgene sale misscelgene celg report mixed quarter ep rise penny view sale grow miss consensus more big biotech affirm full year guidance product sale ep last year make share revenue sale flagship blood cancer drug revlimid beat esti mate foreign revlimid sale other individually report drug sale miss consensus celgene stock dive close danish diabetes specialist nordisk nvo report earning kroner cent share beating consensus revenue rise kroner kroner consensus nordisk hike profit growth guidance add percentage point low end sale growth guidance president kaare schultz say be leave follow management reorganization eliminate other job chief operate officer schultz have aspire be ceo board decide keep lar sorensen stock rise
1278,GILD,busy morning earning slew financial report be close include apple aapl supplier nxp semiconductor nxpi chinese search giant baidu bidu cystic fibrosis drugmaker vertex pharmaceutical vrtx nxp semiconductor make chip be used apple iphone help power new apple pay service nxp serve other mobile customer
1279,GILD,stock continue struggle narrowly mixed territory strong trade early monday afternoon
1280,GILD,tick nasdaq be fraction higher dow jone industrial average sag
1281,GILD,volume rise nearly nyse nasdaq exchange
1282,GILD,gold miner security software maker printer manufacturer be take session hardest hit stock market today
1283,GILD,utility be have strong day new jersey resource njr atmos energy ato wgl holding wgl breaking new high gas distribution industry group
1284,GILD,water utility aqua america wtr pop heavy trade bryn mawr pa base water utility announce have complete upgrade project facility pennsylvania move retook buy point month cup handle base stock be less august high
1285,GILD,biotech drugmaker gilead science gild top ibd list continue rebound brutal sell early last week
1286,GILD,chipmaker ambarella amba drop bottom list needham co downgrade stock underperform hold due rapidly decelerate sale growth price pressure stock rise last week receive volume support rebound week move average stock continue struggle narrowly mixed territory strong trade early monday afternoon tick nasdaq be fraction higher dow jone industrial average sag volume rise nearly nyse nasdaq exchange gold miner security software maker printer manufacturer be take session hardest hit stock market today utility be have strong day new jersey resource njr atmos energy ato wgl holding wgl breaking new high gas distribution industry group water utility aqua america wtr pop heavy trade bryn mawr pa base water utility announce have complete upgrade project facility pennsylvania move retook buy point month cup handle base stock be less august high biotech drugmaker gilead science gild top ibd list continue rebound brutal sell early last week chipmaker ambarella amba drop bottom list needham co downgrade stock underperform hold due rapidly decelerate sale growth price pressure stock rise last week receive volume support rebound week move average
1287,GILD,stock hold small gain midday monday shake dalla fed manufacturing datum badly miss expectation
1288,GILD,nasdaq add be dow inched fraction volume stock market today be tracking significantly higher friday exchange
1289,GILD,chipotle grill cmg add nearly heavy trading be approach time high stock recently clear buy point shallow consolidation earning sale growth have accelerate last quarters huge same store sale growth burrito chain
1290,GILD,identity theft protection firm lifelock lock rise heavy volume clear buy point flat base pattern stock be show sign institutional accumulation have highest possible composite rating
1291,GILD,gilead science gild climb active trading continue bounce support day move average stock come heavy selling pressure last week news express script esrx shun gilead sovaldi drug lower cost alternative abbvie abbv stock hold small gain midday monday shake dalla fed manufacturing datum badly miss expectation nasdaq add be dow inched fraction volume stock market today be tracking significantly higher friday exchange chipotle grill cmg add nearly heavy trading be approach time high stock recently clear buy point shallow consolidation earning sale growth have accelerate last quarters huge same store sale growth burrito chain identity theft protection firm lifelock lock rise heavy volume clear buy point flat base pattern stock be show sign institutional accumulation have highest possible composite rating gilead science gild climb active trading continue bounce support day move average stock come heavy selling pressure last week news express script esrx shun gilead sovaldi drug lower cost alternative abbvie abbv
1292,GILD,american have unofficially make memorial day kickoff summer go be hot drug industry now labor day company be look fda decision launch blockbuster drug make big impact bottom line first be drug valeant pharmaceutical industry vrx
1293,GILD,thursday bring passel earning report large cap drugmaker market greet mostly unenthusiastic response most anticipate report come abbvie abbv unveil first full quarter hepatitis treatment viekira pak address question buzz wall street spending strategy
1294,GILD,abbvie earning rise year earlier quarter cent share cent analyst consensus accord thomson reuter sale climb consensus company raise full year ep guidance cent line analyst
1295,GILD,lead drug humira drive beat sale consensus last year conference call analyst cfo william chase say shipment timing help sale abbvie stick previous guidance midteen growth year
1296,GILD,viekira launch late december yielded analyst estimate call chase say abbvie contract provider start kick quarter so affirm previous guidance run rate year end
1297,GILD,light quarter do undergird recent analyst speculation rival gilead science gild be track beat expectation
1298,GILD,abbvie stock open higher be nearly midday trading thursday first question analyst earning conference call involved abbvie improve profit margin lower cost second analyst goldman sachs jami rubin say bluntly company seem be spending too much money marketing ceo rick gonzalez disagree say abbvie investment strategy be pay nonetheless allow firm be prepared cut unexpected downturn sale occur
1299,GILD,company do not however announce kind immediate restructure be absolutely line expectation perhaps be stock be now speculate evercore isi analyst mark schoenebaum email
1300,GILD,swiss pharma giant novartis nvs fared better hit new high mixed result share be slightly buy point
1301,GILD,earning totale share cent consensus sale totale estimate
1302,GILD,novartis affirm previous full year guidance constant currency basis midsingle digit sale growth high single digit operate income growth
1303,GILD,however company say strong dollar knock report sale report operate income
1304,GILD,foreign exchange headwind be also reason offer alexion pharmaceutical alxn miss profit estimate affirm full year guidance thursday bring passel earning report large cap drugmaker market greet mostly unenthusiastic response most anticipate report come abbvie abbv unveil first full quarter hepatitis treatment viekira pak address question buzz wall street spending strategy abbvie earning rise year earlier quarter cent share cent analyst consensus accord thomson reuter sale climb consensus company raise full year ep guidance cent line analyst lead drug humira drive beat sale consensus last year conference call analyst cfo william chase say shipment timing help sale abbvie stick previous guidance midteen growth year viekira launch late december yielded analyst estimate call chase say abbvie contract provider start kick quarter so affirm previous guidance run rate year end light quarter do undergird recent analyst speculation rival gilead science gild be track beat expectation abbvie stock open higher be nearly midday trading thursday first question analyst earning conference call involved abbvie improve profit margin lower cost second analyst goldman sachs jami rubin say bluntly company seem be spending too much money marketing ceo rick gonzalez disagree say abbvie investment strategy be pay nonetheless allow firm be prepared cut unexpected downturn sale occur company do not however announce kind immediate restructure be absolutely line expectation perhaps be stock be now speculate evercore isi analyst mark schoenebaum email swiss pharma giant novartis nvs fared better hit new high mixed result share be slightly buy point earning totale share cent consensus sale totale estimate novartis affirm previous full year guidance constant currency basis midsingle digit sale growth high single digit operate income growth however company say strong dollar knock report sale report operate income foreign exchange headwind be also reason offer alexion pharmaceutical alxn miss profit estimate affirm full year guidance
1305,GILD,thursday bring passel earning report large cap drugmaker market greet mostly unenthusiastic response most anticipate report come abbvie abbv unveil first full quarter hepatitis treatment viekira pak address question buzz wall street spending strategy
1306,GILD,abbvie earning rise year earlier quarter cent share cent analyst consensus accord thomson reuter sale climb consensus company raise full year ep guidance cent line analyst
1307,GILD,lead drug humira drive beat sale consensus last year conference call analyst cfo william chase say shipment timing help sale abbvie stick previous guidance midteen growth year
1308,GILD,viekira launch late december yielded analyst estimate call chase say abbvie contract provider start kick quarter so affirm previous guidance run rate year end
1309,GILD,light quarter do undergird recent analyst speculation rival gilead science gild be track beat expectation
1310,GILD,abbvie stock open higher be nearly midday trading thursday first question analyst earning conference call involved abbvie improve profit margin lower cost second analyst goldman sachs jami rubin say bluntly company seem be spending too much money marketing ceo rick gonzalez disagree say abbvie investment strategy be pay nonetheless allow firm be prepared cut unexpected downturn sale occur
1311,GILD,company do not however announce kind immediate restructure be absolutely line expectation perhaps be stock be now speculate evercore isi analyst mark schoenebaum email
1312,GILD,swiss pharma giant novartis nvs fared better hit new high mixed result share be slightly buy point
1313,GILD,earning totale share cent consensus sale totale estimate
1314,GILD,novartis affirm previous full year guidance constant currency basis midsingle digit sale growth high single digit operate income growth
1315,GILD,however company say strong dollar knock report sale report operate income
1316,GILD,foreign exchange headwind be also reason offer alexion pharmaceutical alxn miss profit estimate affirm full year guidance thursday bring passel earning report large cap drugmaker market greet mostly unenthusiastic response most anticipate report come abbvie abbv unveil first full quarter hepatitis treatment viekira pak address question buzz wall street spending strategy abbvie earning rise year earlier quarter cent share cent analyst consensus accord thomson reuter sale climb consensus company raise full year ep guidance cent line analyst lead drug humira drive beat sale consensus last year conference call analyst cfo william chase say shipment timing help sale abbvie stick previous guidance midteen growth year viekira launch late december yielded analyst estimate call chase say abbvie contract provider start kick quarter so affirm previous guidance run rate year end light quarter do undergird recent analyst speculation rival gilead science gild be track beat expectation abbvie stock open higher be nearly midday trading thursday first question analyst earning conference call involved abbvie improve profit margin lower cost second analyst goldman sachs jami rubin say bluntly company seem be spending too much money marketing ceo rick gonzalez disagree say abbvie investment strategy be pay nonetheless allow firm be prepared cut unexpected downturn sale occur company do not however announce kind immediate restructure be absolutely line expectation perhaps be stock be now speculate evercore isi analyst mark schoenebaum email swiss pharma giant novartis nvs fared better hit new high mixed result share be slightly buy point earning totale share cent consensus sale totale estimate novartis affirm previous full year guidance constant currency basis midsingle digit sale growth high single digit operate income growth however company say strong dollar knock report sale report operate income foreign exchange headwind be also reason offer alexion pharmaceutical alxn miss profit estimate affirm full year guidance
1317,GILD,stock hold gain go noon hour friday volume be run lighter exchange
1318,GILD,nasdaq dow jone industrial average rise gain stock market today
1319,GILD,tesla motor tsla be be lose support day move average ceo elon musk announce suite battery home business utility say want change way world used energy extreme scale
1320,GILD,linkedin lnkd be smash earning sale beat street company offer guidance dramatically estimate stock be trading lower
1321,GILD,harman international har be second day high volume drop nearly fall thursday report disappointing result
1322,GILD,monster beverage mnst rise ahead earning report stock try tightly construct flat base have fall back support day move average
1323,GILD,expedia expe gap break short term resistance report sale rise better expect year also report cent share loss quarter
1324,GILD,biotech stock have have rough earning season gilead science gild rise nearly earning sale blow away estimate guidance be raise stock hold gain go noon hour friday volume be run lighter exchange nasdaq dow jone industrial average rise gain stock market todaytesla motor tsla be be lose support day move average ceo elon musk announce suite battery home business utility say want change way world used energy extreme scale linkedin lnkd be smash earning sale beat street company offer guidance dramatically estimate stock be trading lower harman international har be second day high volume drop nearly fall thursday report disappointing result monster beverage mnst rise ahead earning report stock try tightly construct flat base have fall back support day move average expedia expe gap break short term resistance report sale rise better expect year also report cent share loss quarter biotech stock have have rough earning season gilead science gild rise nearly earning sale blow away estimate guidance be raise
1325,GILD,stock be higher early afternoon trading friday volume be still tracking markedly lower exchange thursday drubbing nasdaq gain dow jone industrial average also rise
1326,GILD,ibd stock be higher be lower worst performer mile be linkedin lnkd whack loss report guidance well expectation be good performance day too
1327,GILD,unite therapeutic uthr rise find resistance day move average selling day earning report tuesday
1328,GILD,skywork solution swks rise nearly upbeat earning report stock be form flat base buy point have find support day move average
1329,GILD,harman international har be second day high volume drop nearly fall thursday report disappointing result
1330,GILD,monster beverage mnst rise ahead earning report stock try tightly construct flat base have fall back support day move average
1331,GILD,expedia expe gap break upside resistance report sale rise better expect year also report cent share loss quarter
1332,GILD,biotech stock have have rough earning season gilead science gild rise nearly earning sale blow away estimate guidance be raise stock be higher early afternoon trading friday volume be still tracking markedly lower exchange thursday drubbing nasdaq gain dow jone industrial average also rise ibd stock be higher be lower worst performer mile be linkedin lnkd whack loss report guidance well expectation be good performance day too unite therapeutic uthr rise find resistance day move average selling day earning report tuesday skywork solution swks rise nearly upbeat earning report stock be form flat base buy point have find support day move average harman international har be second day high volume drop nearly fall thursday report disappointing result monster beverage mnst rise ahead earning report stock try tightly construct flat base have fall back support day move average expedia expe gap break upside resistance report sale rise better expect year also report cent share loss quarter biotech stock have have rough earning season gilead science gild rise nearly earning sale blow away estimate guidance be raise
1333,GILD,now be get interesting be get bit bubbly nasdaq make history yesterday breaking year purgatory do not come fanfare bell whistle yesterday be trader take nasdaq thru former high tick then quickly fail fall back
1334,GILD,biotechs monday sector leader screen have rough go early session most re-cover well session lows overall ibd biotech group hold relatively well consider fall nearly early end loss soundest biotech sector leader point be biogen idec biib
1335,GILD,pharmacy benefit manager express script announce monday putt abbvie newly approve hepatitis treatment prefer formulary list knock rival treatment gilead science gilead gild stock plunge abbvie abbv fall late friday food drug administration approve abbvie viekira pak combination novel drug older
1336,GILD,brutal correction several lead biotech member ibd find support day move average correction kick monday express script esrx nation largest health benefit manager announce exclusively use abbvie abbv hepatitis drug left gilead science gild recent growth have be fuel hepatitis
1337,GILD,massive ep gain year mean company top next ibd stock today screen be set show ep growth leave dust year not be bountiful share gilead science gild have launch upward hepatitis drug sovaldi debut last year company full year ep be expect grow year year partly sovaldi harvoni combine sovaldi interferon treatment harvoni win fda approval october however drug have face headwind year effectiveness concern government patient advocacy group drug steep cost have persist many have argue drug be far too costly low income hepatitis patient more express script esrx cite concern cost hep drug say monday dump sovaldi harvoni prefer formulary list favor abbvie abbv viekira pak treatment genotype hepatitis gilead stock plunge day fall entire week gilead share have rise begin year have struggle find support day line october relative strength measure have fall well massive ep growth be expect analyst project growth shrivel low double single digit year follow stock close stock market today generic drug maker akorn akrx maintain top shelf ibd composite relative strength rating company be poise see ep gain year however price hike drug clobetasol topical rash treatment weigh result report november gilead analyst forecast akorn earning growth slow dramatically next few year share drop earning result continue consolidation stock begin october have remain facebook fb full year ep be expect grow share drive facebook still cool teen instagram photo sharing app social medium site have snap variety company year attempt anticipate shift online social landscape many forecast company gain big online mobile advertising part effort strengthen position online advertising facebook recently announce deal show nfl video clip verizon vz ad site facebook have warn cost rise step spending analyst currently expect facebook full year ep growth dip then reaccelerate year share hit time intraday high dec clear cup base day earlier share close cent friday bitauto bita auto information advertising base china have benefit be world largest auto market china expand car culture analyst expect company grow ep year november company beat view strength ad gain ever crucial mobile space best ibd fundamental stock have dip day line month cool rise company report result still share close friday more double value begin year analyst expect company ep growth decelerate remain solidly double digit finally alexion pharmaceutical alxn be forecast full year ep growth strength only market drug soliris treat rare blood disease company have year double digit quarterly sale ep growth belt share clear month consolidation october jump strong report stock have see more seller enter picture bring accumulation distribution rating analyst expect only ep growth stronger growth stock have rattle day line past week close friday just line potential sign support come
1338,GILD,stock future muscle higher ahead friday open aim build be play be strong week dow future be point fair market value rise nasdaq future be point future climb point
1339,GILD,stock market today set nasdaq sit gain week be back day move average nasdaq open nearly day line index hold psychologically important day line support weigh heavy load distribution day be key factor current rally
1340,GILD,economic calendar be relatively quiet kansa city federal reserve regional manufacturing survey be due et
1341,GILD,st loui federal reserve president james bullard new york federal reserve president william dudley be schedule speak morning crude future continue struggle trading more flat week just barrel price see effect result weekly rig count baker hughe bhi
1342,GILD,nike nke hoist dow gain announce late thursday year share buyback program top current buyback be complete end
1343,GILD,management also increase quarterly dividend cent announce stock split effective dec market close ibd stock end thursday test support day move average cup base buy point
1344,GILD,retail industry group have take serious beating past week continue make splashy move
1345,GILD,abercrombie fitch anf spirale higher earning soar past consensus expectation revenue fall less forecast
1346,GILD,ross store rost surge dublin calif base chain report solid third quarter result thursday close stock close thursday nov low aug high double dip consolidation
1347,GILD,foot locker fl hop sale earning clear analyst expectation shoe retailer close ty nike finished thursday week september high
1348,GILD,william sonoma wsm slip nearly beating sale earning expectation guide result estimate
1349,GILD,intuit intu rally nearly open developer quickbook turbotax report thursday close fiscal profit cent share vs consensus projection share loss cent revenue growth trounce expectation management raise ep guidance estimate share end thursday buy point cup handle base
1350,GILD,morning heaviest loss mentor graphic ment unspooled report late thursday revenue earning be shade shy consensus view kicker be earning management say come less half current consensus projection developer automate design software finished thursday session just cup base buy point stock future muscle higher ahead friday open aim build be play be strong week dow future be point fair market value rise nasdaq future be point future climb point stock market today set nasdaq sit gain week be back day move average nasdaq open nearly day line index hold psychologically important day line support weigh heavy load distribution day be key factor current rally economic calendar be relatively quiet kansa city federal reserve regional manufacturing survey be due et st loui federal reserve president james bullard new york federal reserve president william dudley be schedule speak morning crude future continue struggle trading more flat week just barrel price see effect result weekly rig count baker hughe bhi nike nke hoist dow gain announce late thursday year share buyback program top current buyback be complete end management also increase quarterly dividend cent announce stock split effective dec market close ibd stock end thursday test support day move average cup base buy point retail industry group have take serious beating past week continue make splashy move abercrombie fitch anf spirale higher earning soar past consensus expectation revenue fall less forecast ross store rost surge dublin calif base chain report solid third quarter result thursday close stock close thursday nov low aug high double dip consolidation foot locker fl hop sale earning clear analyst expectation shoe retailer close ty nike finished thursday week september high william sonoma wsm slip nearly beating sale earning expectation guide result estimate intuit intu rally nearly open developer quickbook turbotax report thursday close fiscal profit cent share vs consensus projection share loss cent revenue growth trounce expectation management raise ep guidance estimate share end thursday buy point cup handle base morning heaviest loss mentor graphic ment unspooled report late thursday revenue earning be shade shy consensus view kicker be earning management say come less half current consensus projection developer automate design software finished thursday session just cup base buy point
1351,GILD,biogen biib friday morning be expect report earning share vs year earlier end quarter string accelerate growth sale show advance solid gain fourth straight quarter decelerate growth biogen rely heavily multiple sclerosis drug such tecfidera
1352,GILD,maybe bigger be better pharmacy benefit manager pbms unitedhealth group unh think catamaran ctrx be worth increase leverage bargaining pricey medicine pbms client include health insurer employer labor union health plan handle process medical prescription negotiate price drug company analyst say grow size benefit more
1353,GILD,earning report start roll next month likely biggest mover biotech pharma stock be release clinical trial datum here be such report expect month street expect probably most anticipate be biogen idec biib presentation phase result alzheimer disease drug
1354,GILD,hca holding bump full year guidance preview first quarter result beat expectation strong admission growth strong growth admission pressured insurer stock fear increase patient utilization rate hospital operator now project earning share revenue prior guidance
1355,GILD,new research note rbc capital market offer bullish take biogen idec biib experimental drug alzheimer disease predict make big splash upcoming international conference alzheimer parkinson disease conference schedule march nice france attract medical scientific professional globe biogen be expect
1356,GILD,biotech unite therapeutic uthr receive food drug administration approval first cancer drug tuesday be also award priority review voucher turn be just lucrative agency approve unituxin monoclonal antibody treat ultra rare childhood cancer call neuroblastoma only new case year consensus estimate expect only annual sale drug encourage more such rare disease treatment however fda award company rare pediatric priority review voucher unite therapeutic sell company wish expedite review once buyer file new drug application demand such drug be considerable last july regeneron pharmaceutical regn partner sanofi sny paid acquire similar voucher biomarin pharmaceutical bmrn then used catch amgen amgn race bring first cholesterol bust pcsk inhibitor market currently fda deadline make decision regeneron alirocumab be july amgen evolucumab aug november gilead science gild paid knight therapeutic priority review voucher hasn used yet market seem pleased unite therapeutic stock open stock market today rally news get late morning touch record high mid afternoon share be more unite therapeutic be ibd highest possible ibd composite rating follow amy reeve twitter ibd_areeve
1357,GILD,almost third stock sector leader list come highly rate medical industry only illumina ilmn be buy range several recent addition be worth watch gilead science gild have retreat buy point long cup base market week slide stock still boast
1358,GILD,earning season have kick high gear number top rate stock such vasco datum security vdsi facebook fb be due report earning come week computer generate ibd list premier stock be base combination company recent profit growth record ibd composite rating price performance
1359,GILD,biotechs have not only show resilience bout volatility past few month also remain top group many lead stock set basis
1360,GILD,tuesday biotech startupjuno therapeutic juno soar heavy trading follow late monday announcement deal celgene celg celgene pay upfront buy juno share option license juno chimeric antigen receptor car cell cancer therapy year deal also include option buy juno stock
1361,GILD,juno go public dec share be high still more offer price seattle base company car therapy be still early stage have yet make money
1362,GILD,celgene other hand be steady earning producer have year earning growth rate earning stability factor scale most stable least stable biotech be group best possible composite rating
1363,GILD,stock be shape handle cup base potential buy point volume ratio neutral level positive accumulation distribution rating indicate demand share
1364,GILD,celgene develop therapy treat cancer immune inflammatory related disease best seller revlimid account revenue last year treat multiple myeloma
1365,GILD,gilead science gild also earn composite have pull back just buy point clear june earning share rating be highest biotech group
1366,GILD,gilead drug treat hiv hepatitis other disease hepatitis drug harvoni sovaldi account more half sale drug have come fire high price tag harvoni cost week treatment sovaldi
1367,GILD,gilead share take hit december rival abbvie abbv hep drug win fda approval then gilead have acquire danish drugmaker epitherapeutic
1368,GILD,enanta pharmaceutical enta maker hepatitis drug antibiotic be build cup handle buy point fact biotech develop antiviral agent find abbvie hep drug cocktail analyst forecast agent generate annually
1369,GILD,enanta have composite go public march have be profitable
1370,GILD,intrexon xon have dip cup handle buy point synthetic biology firm hold ipo august design build regulate gene cellular system have yet turn annual profit year sale growth rate be
1371,GILD,other top rate biotechs shape basis include biogen biib composite unite therapeutic uthr composite biotech group rank third wednesday issue vs week biotechs have not only show resilience bout volatility past few month also remain top group many lead stock set basis tuesday biotech startupjuno therapeutic juno soar heavy trading follow late monday announcement deal celgene celg celgene pay upfront buy juno share option license juno chimeric antigen receptor car cell cancer therapy year deal also include option buy juno stock juno go public dec share be high still more offer price seattle base company car therapy be still early stage have yet make money celgene other hand be steady earning producer have year earning growth rate earning stability factor scale most stable least stable biotech be group best possible composite rating stock be shape handle cup base potential buy point volume ratio neutral level positive accumulation distribution rating indicate demand share celgene develop therapy treat cancer immune inflammatory related disease best seller revlimid account revenue last year treat multiple myeloma gilead science gild also earn composite have pull back just buy point clear june earning share rating be highest biotech group gilead drug treat hiv hepatitis other disease hepatitis drug harvoni sovaldi account more half sale drug have come fire high price tag harvoni cost week treatment sovaldi gilead share take hit december rival abbvie abbv hep drug win fda approval then gilead have acquire danish drugmaker epitherapeutic enanta pharmaceutical enta maker hepatitis drug antibiotic be build cup handle buy point fact biotech develop antiviral agent find abbvie hep drug cocktail analyst forecast agent generate annually enanta have composite go public march have be profitable intrexon xon have dip cup handle buy point synthetic biology firm hold ipo august design build regulate gene cellular system have yet turn annual profit year sale growth rate be other top rate biotechs shape basis include biogen biib composite unite therapeutic uthr composite biotech group rank third wednesday issue vs week
1372,GILD,manufacturing partner big pharma cambrex have develop right ingredient ride crest blockbuster drug wave cambrex cbm be life science company help large pharmaceutical biotech company well emerge generic drug maker develop process manufacture clinical commercial quantity drug provide small molecule product
1373,GILD,gilead science have be winning streak recent year competition price pressure push biotech pace setter go acquisition continue momentum gilead gild revenue climb percent year earlier period company share earning more double foster city calif base gilead annual sale total more past year market value have rise more fivefold reach impressive stock earn best possible ibd composite rating mean stock have outperformed other stock combination factor include earning share relative strength rating gilead have flourished focuse treat hiv hepatitis patient hepatitis drug sovaldi harvoni have chalk more half company product sale backlash have be build sovaldi gilead have price drug pill week life treatment time get major move very hard person completely forget say michael holland head new york money management firm holland co management have task show person biotech boom isn ready end yet gilead continue be major player industry have show world have strong long last growth strategy just case kind bad news surface again consumerism be grow health care gilead surely feel pressure price charge say paul carroll partner devil advocate group consult firm ceo pressure take time build attempt deny use medicine base cost bring person woodwork shout death panel gilead need be prepare doomsday scenario imagine life be world longer charge pill not everyone agree rhetoric surround sovaldi gilead be very strong position strategically say dan mendelson ceo health business advisor avalere health strong position globally hep be big public health issue time dr barnett mennen physician long experience pharmaceutical industry have say sovaldi have change game many patient ve offer cure much be worth someone be suffering gilead be other price put pressure gilead company share plunge percent last dec reach month low fda approve rival abbvie abbv hepatitis product same time abbvie forge agreement express script esrx offer drug lower price become only hepatitis product big pharmacy benefit entity sanction industry observer say gilead handle pressure be look few acquisition target way lock continue solid growth brian skorney analyst baird milwaukee tell ibd jacob plieth senior editorial analyst epvantage also expect gilead pursue acquisition hard know else proceed have competitor come recent earning conference call gilead coo president john milligan say typically acquire company have impact phase drug trial accelerate product approval process integrator indication approval process tend think still re look thing feel catalyze development product have greater utility overall acquisition targetsin early gilead acquire danish drugmaker epitherapeutic other company gilead buy skorney be eyee such potential takeover target south boston mass base vertex pharmaceutical vrtx global biotech entity have draw praise work cystic fibrosis vertex fit nicely gilead skorney say point vertex have put stamp treat cystic fibrosis much gilead have focuse hepatitis also vertex have more dozen continue program target other life threaten disease acquisition be nothing new gilead company announce acquisition pharmasset give further range treat hepatitis sufferer acquisition turn be huge success not acquisition succeed remain dicey be long history bad acquisition pharmaceutical world note carroll devil advocate nevertheless epvantage plieth say gilead be very strong position right now have be most amazing biotech stock look back past year
1374,GILD,stock attract fund money be worth attention combine knowledge ibd accumulation distribution rating volume ratio fuller picture emerge let look sector leader tuesday ibd akorn akrx fund boost stake midyear year end open new position include fidelity contrafund
1375,GILD,analyst call gilead science third quarter earning report oct sloppy make mistake still company growth mode weekly chart doesn look bad gilead gild earning share slightly miss expectation still grow torrid pace profit surge year company third straight quarter
1376,GILD,stock stay positive be session high friday afternoon
1377,GILD,nasdaq be add dow dip volume be tracking higher stock market today quadruple witching option future
1378,GILD,major index be hold time multiyear high offer mixed picture market health lead stock have have trouble advance breakout stock come repeat heavy volume selling recent week bounce back furiously wednesday thursday
1379,GILD,nike nke be drag dow fall heavy volume late thursday company report fiscal second quarter earning sale ahead analyst estimate investor be spook drop future order
1380,GILD,lead stock be mixed just half ibd trading lower
1381,GILD,gilead science gild lead premier growth list climb active trading stock be climb right side cup shape base buy point
1382,GILD,cinta cta jump huge trade follow thursday past flat base buy point fiscal second quarter result report thursday close show increase earning flat revenue corporate uniform supply company hit new time high friday
1383,GILD,generic drugmaker perrigo prgo hit new high active trading add gain thursday past flat base buy point stock have composite rating have report earning decline past quarters stock stay positive be session high friday afternoon nasdaq be add dow dip volume be tracking higher stock market today quadruple witching option future major index be hold time multiyear high offer mixed picture market health lead stock have have trouble advance breakout stock come repeat heavy volume selling recent week bounce back furiously wednesday thursday nike nke be drag dow fall heavy volume late thursday company report fiscal second quarter earning sale ahead analyst estimate investor be spook drop future order lead stock be mixed just half ibd trading lower gilead science gild lead premier growth list climb active trading stock be climb right side cup shape base buy point cinta cta jump huge trade follow thursday past flat base buy point fiscal second quarter result report thursday close show increase earning flat revenue corporate uniform supply company hit new time high friday generic drugmaker perrigo prgo hit new high active trading add gain thursday past flat base buy point stock have composite rating have report earning decline past quarters
1384,GILD,wednesday short trading session open note dow pressed further fresh high
1385,GILD,nasdaq lead approach nov high dow jone industrial average tick add
1386,GILD,stock market today open early boost labor department report larger expect drop weekly unemployment claim today session wrapped et exchange remain close christmas day reopen normal schedule friday morning
1387,GILD,stock drugmaker be rebound broadly couple day hard selling biom issue post nasdaq largest gain early trade gilead science gild celgene celg lead ibd list gain
1388,GILD,airline stock also gain oil price backed more recent lows ibd stock alaska air group alk spirit airline save gain unite continental ual pop
1389,GILD,virgin america va spiked lead group november new issue quiet period end raft analyst initiate coverage deutsche bank initiate buy rating price target barclay open coverage overweight rating price target cowen co put outperform rating also price target raymond james initial rating stock be market perform
1390,GILD,jump put virgin just high november ipo price stock be fourth week first consolidation
1391,GILD,early loss be generally mild leader worst hit ibd list go noah holding noah china base financial adviser be still buy point cup handle base wednesday short trading session open note dow pressed further fresh high nasdaq lead approach nov high dow jone industrial average tick add stock market today open early boost labor department report larger expect drop weekly unemployment claim today session wrapped et exchange remain close christmas day reopen normal schedule friday morning stock drugmaker be rebound broadly couple day hard selling biom issue post nasdaq largest gain early trade gilead science gild celgene celg lead ibd list gain airline stock also gain oil price backed more recent lows ibd stock alaska air group alk spirit airline save gain unite continental ual pop virgin america va spiked lead group november new issue quiet period end raft analyst initiate coverage deutsche bank initiate buy rating price target barclay open coverage overweight rating price target cowen co put outperform rating also price target raymond james initial rating stock be market perform jump put virgin just high november ipo price stock be fourth week first consolidation early loss be generally mild leader worst hit ibd list go noah holding noah china base financial adviser be still buy point cup handle base
1392,GILD,pharmacy benefit manager express script esrx say prescription drug spending rise more last year have accord annual review accord drug trend report spending drug commercially insure rise member last year medicare spending rise member medicaid spending climb
1393,GILD,report say spending hepatitis drug account more half increase be not big surprise disease be still treat mainly generic drug gilead science gild premium price sovaldi often prescribe tandem johnson johnson jnj also pricey olysio take market october gilead launch harvoni render olysio obsolete cost more sovaldi
1394,GILD,express script pharmacy benefit management leader be earliest loudest critic sovaldi price amount standard week treatment press release accompany report pbm brag have take bite gilead make exclusive deal abbvie abbv come gilead first serious competitor form viekira pak year end express claim save client year
1395,GILD,not clear however well be work abbvie analyst tracking prescription datum estimate only have market share datum be incomplete win be fully know abbvie report caveat be express price datum do not include rebate be significant part picture especially hepatitis market lately
1396,GILD,gilead report last month investor have minor freak company executive guide gross net adjustment rebate level hepatitis franchise
1397,GILD,express script release also echo comment make ceo january jpmorgan healthcare conference indicated next price war target be pcsk inhibitor new class cholesterol drug expect come market year offering amgen amgn team regeneron pharmaceutical regn sanofi sny
1398,GILD,drug trend report didn specifically mention do drug end cost year
1399,GILD,follow amy reeve twitter ibd_areeve pharmacy benefit manager express script esrx say prescription drug spending rise more last year have accord annual review accord drug trend report spending drug commercially insure rise member last year medicare spending rise member medicaid spending climb report say spending hepatitis drug account more half increase be not big surprise disease be still treat mainly generic drug gilead science gild premium price sovaldi often prescribe tandem johnson johnson jnj also pricey olysio take market october gilead launch harvoni render olysio obsolete cost more sovaldi express script pharmacy benefit management leader be earliest loudest critic sovaldi price amount standard week treatment press release accompany report pbm brag have take bite gilead make exclusive deal abbvie abbv come gilead first serious competitor form viekira pak year end express claim save client year not clear however well be work abbvie analyst tracking prescription datum estimate only have market share datum be incomplete win be fully know abbvie report caveat be express price datum do not include rebate be significant part picture especially hepatitis market lately gilead report last month investor have minor freak company executive guide gross net adjustment rebate level hepatitis franchise express script release also echo comment make ceo january jpmorgan healthcare conference indicated next price war target be pcsk inhibitor new class cholesterol drug expect come market year offering amgen amgn team regeneron pharmaceutical regn sanofi sny drug trend report didn specifically mention do drug end cost year follow amy reeve twitter ibd_areeve
1400,GILD,rowe price institutional large cap growth fund seek stock sustainable long term growth robert sharps manager fund late inception expect find bulk firm be innovator medical advance be largely health care be stock mutual fund biggest sector dec weighting
1401,GILD,many biotechs chip get hammer wednesday be already well extend past buy point set secondary buy opportunity other leader early stage basis have potential fresh stock have composite rating higher top industry group track ibd be first second stage base short best best
1402,GILD,isn buy list fodder investor watch list stock require further due diligence monitoring price volume action determine optimal entry time buy
1403,GILD,top rank biotech sector consider ligand pharmaceutical lgnd stock be shape long cup base potential buy point form handle complete week do entry be
1404,GILD,la jolla calif base biotech develop drug target cancer inflammation disorder central nervous system blood stock be bit thin average daily volume less volume ratio accumulation distribution rating indicate demand share
1405,GILD,other biotech prospect include alexion pharmaceutical alxn be shape second stage flat base buy point currently still have more work do right side set possible
1406,GILD,gilead science gild be craft first stage base correction price action have be bit choppy stock have find support week move average december profit sale grow triple digit past quarters acc rating suggest more recent net selling vs buy mutual fund
1407,GILD,amgen amgn be also worth look form possible handle cup buy point enbrel epogen neupogen maker annual profit be expect slow year double digit gain past year bounce back
1408,GILD,rank airline group spirit airline save be carve first stage base begin mid december quarterly profit growth remain strong volume ratio acc rating use improvement
1409,GILD,silicon motion technology simo belong rank fabless chip group be shape flat base buy point taiwan base company have turn slide earning sale quarters solid growth
1410,GILD,restaurant have be fire week chipotle grill cmg have flag lately be now midst flat base potential entry first need regain week line
1411,GILD,cdk global cdk tech service group masco mas build construction product group also bear watch former be back flat base buy point latter be shape flat base entry many biotechs chip get hammer wednesday be already well extend past buy point set secondary buy opportunity other leader early stage basis have potential fresh stock have composite rating higher top industry group track ibd be first second stage base short best best isn buy list fodder investor watch list stock require further due diligence monitoring price volume action determine optimal entry time buy top rank biotech sector consider ligand pharmaceutical lgnd stock be shape long cup base potential buy point form handle complete week do entry be la jolla calif base biotech develop drug target cancer inflammation disorder central nervous system blood stock be bit thin average daily volume less volume ratio accumulation distribution rating indicate demand share other biotech prospect include alexion pharmaceutical alxn be shape second stage flat base buy point currently still have more work do right side set possible gilead science gild be craft first stage base correction price action have be bit choppy stock have find support week move average december profit sale grow triple digit past quarters acc rating suggest more recent net selling vs buy mutual fund amgen amgn be also worth look form possible handle cup buy point enbrel epogen neupogen maker annual profit be expect slow year double digit gain past year bounce back rank airline group spirit airline save be carve first stage base begin mid december quarterly profit growth remain strong volume ratio acc rating use improvement silicon motion technology simo belong rank fabless chip group be shape flat base buy point taiwan base company have turn slide earning sale quarters solid growth restaurant have be fire week chipotle grill cmg have flag lately be now midst flat base potential entry first need regain week line cdk global cdk tech service group masco mas build construction product group also bear watch former be back flat base buy point latter be shape flat base entry
1412,GILD,health care technology sector have highest percentage company report fourth quarter earning analyst consensus estimate health care sector company have beat consensus estimate analyst poll factset research information technology sector be right utility sector lead revenue beat follow health care largest ep beat come netflix nflx follow amazon com amzn marathon petroleum mpc date market be reward upside earning surprise more average punish downside earning surprise less average factset say netflix stock jump video service provide report earning jan amazon stock rise earning report jan factset put company consumer discretionary sector information technology sector juniper network jnpr have best earning surprise follow kla tencor klac electronic art ea health care sector overall be report highest earning growth rate company gilead science gild be largest contributor earning growth sector company have report december quarter result have report ep estimate year average percentage company report revenue estimate be factset say slightly year average follow brian deagon twitter ibd_bdeagon
1413,GILD,push pull dynamic be play fourth quarter result apple fellow technology firm health care company push earning forward reel energy sector pull back
1414,GILD,friday big cap company have report earning be expect show year year gain revenue
1415,GILD,so far have beat analyst profit estimate just miss say thomson reuter typically beat past quarters do
1416,GILD,health care tech do even better sector beating estimate
1417,GILD,technology profit be track gain nearly double expect back jan revenue be likely rise more double estimate
1418,GILD,life apple
1419,GILD,most reflect blowout result just company apple aapl fiscal end dec tech titan earn share net income sale soar best gain quarters iphone sell
1420,GILD,exclude apple tech earning be sale
1421,GILD,profit rise just sale
1422,GILD,take away apple entire grow profit just instead say thomson reuter blending have report already estimate balance
1423,GILD,tech have be biggest surprise health care company be track biggest gain earning sale
1424,GILD,gilead science gild ep spiked sale hepatitis drug sovaldi harvoni
1425,GILD,collapse crude oil price summer have send energy sector tailspin energy profit fall revenue plunge
1426,GILD,exxon mobil xom cite decline oil price steep drop revenue net income fall
1427,GILD,exclude energy include apple be track earning gain revenue rise
1428,GILD,outlook energy be even more bearish analyst anticipate sector earning fall
1429,GILD,thank energy strong dollar impact multinational forecast be gloomy overall analyst forecast earning slip revenue fall earning be expect grow meager revenue once again fall
1430,GILD,really see alarm say david aurelio research analyst thomson reuter drive energy
1431,GILD,analyst expect solid earning sale growth outside energy
1432,GILD,cheaper fuel also create winner airline see huge cost saving be industrial sector be grow profit consumer discretionary include automaker many retailer be track gain
1433,GILD,oil pain be somebody else gain say sheraz mian zack investment research
1434,GILD,financial also feel pain most big bank struggle stronger dollar big legal cost weaker trading revenue earning likely show drop push pull dynamic be play fourth quarter result apple fellow technology firm health care company push earning forward reel energy sector pull back friday big cap company have report earning be expect show year year gain revenue so far have beat analyst profit estimate just miss say thomson reuter typically beat past quarters do health care tech do even better sector beating estimate technology profit be track gain nearly double expect back jan revenue be likely rise more double estimate life most reflect blowout result just company apple aapl fiscal end dec tech titan earn share net income sale soar best gain quarters iphone sell exclude apple tech earning be sale profit rise just sale take away apple entire grow profit just instead say thomson reuter blending have report already estimate balance tech have be biggest surprise health care company be track biggest gain earning sale gilead science gild ep spiked sale hepatitis drug sovaldi harvoni collapse crude oil price summer have send energy sector tailspin energy profit fall revenue plunge exxon mobil xom cite decline oil price steep drop revenue net income fall exclude energy include apple be track earning gain revenue rise outlook energy be even more bearish analyst anticipate sector earning fall thank energy strong dollar impact multinational forecast be gloomy overall analyst forecast earning slip revenue fall earning be expect grow meager revenue once again fall really see alarm say david aurelio research analyst thomson reuter drive energy analyst expect solid earning sale growth outside energy cheaper fuel also create winner airline see huge cost saving be industrial sector be grow profit consumer discretionary include automaker many retailer be track gain oil pain be somebody else gain say sheraz mian zack investment research financial also feel pain most big bank struggle stronger dollar big legal cost weaker trading revenue earning likely show drop
1435,GILD,person get older be more prone vision loss age related macular degeneration severe wet version condition be lead cause blindness afflict million person cause leaky abnormal blood vessel grow back eye treatment prognosis be dim biologic drug eylea
1436,GILD,large cap growth large cap core fund invest growth value stock have hold own broad stock market past year large cap value fund have lag market bottom march
1437,GILD,invest average large cap growth fund end march be look account june year accord morningstar inc datum same investment average large cap core fund have even more
1438,GILD,average large cap value mutual fund be trail even
1439,GILD,jpmorgan growth advantage fund have generate return past year vs proxy broad stock market fund be year vs
1440,GILD,large cap growth mutual fund have be manage timothy parton recent holding include apple aapl facebook fb google googl gilead science gild
1441,GILD,apple sport ibd composite rating analyst poll thomson reuter see earning rise current year end september slow next year stock be form flat base
1442,GILD,facebook break flat base tuesday end day buy range buy point social networking provider stock have composite rating earning be see grow year next year company have year earning growth rate large cap growth large cap core fund invest growth value stock have hold own broad stock market past year large cap value fund have lag market bottom march invest average large cap growth fund end march be look account june year accord morningstar inc datum same investment average large cap core fund have even more average large cap value mutual fund be trail even jpmorgan growth advantage fund have generate return past year vs proxy broad stock market fund be year vs large cap growth mutual fund have be manage timothy parton recent holding include apple aapl facebook fb google googl gilead science gild apple sport ibd composite rating analyst poll thomson reuter see earning rise current year end september slow next year stock be form flat base facebook break flat base tuesday end day buy range buy point social networking provider stock have composite rating earning be see grow year next year company have year earning growth rate
1443,GILD,number spotlight stock hit new high tuesday market uptrend marched stock be top end buy range gilead science gild maker blockbuster hepatitis drug harvoni sovaldi be just barely buy limit entry long consolidation stock clear buy point june volume be light stock have manage make progress
1444,GILD,gilead have rise nearly past year however latest base be less risky first stage pattern form stock undercut prior base
1445,GILD,gilead have post triple digit profit sale growth past quarters earning be expect rise just share increase revenue analyst fret big cap company maintain strong growth
1446,GILD,illumina ilmn be top end buy range past entry handle stock boast best possible composite earning share rating putt top highly rate medical research equipment service industry ibd leaderboard stock be featured wednesday new america column
1447,GILD,ellie mae elli demand software handle entire mortgage application process be hover top buy range flat base entry
1448,GILD,post straight quarters triple digit profit growth sale growth have accelerate straight quarters jump latest period
1449,GILD,outerwall outr operate self service kiosk let shopper buy rent movie video game be just buy range entry odd shape base
1450,GILD,outerwall be leader top rank leisure movie related industry group
1451,GILD,fact so many spotlight stock be continue move higher be good sign breakout market be sixth week latest uptrend number spotlight stock hit new high tuesday market uptrend marched stock be top end buy range gilead science gild maker blockbuster hepatitis drug harvoni sovaldi be just barely buy limit entry long consolidation stock clear buy point june volume be light stock have manage make progress gilead have rise nearly past year however latest base be less risky first stage pattern form stock undercut prior base gilead have post triple digit profit sale growth past quarters earning be expect rise just share increase revenue analyst fret big cap company maintain strong growth illumina ilmn be top end buy range past entry handle stock boast best possible composite earning share rating putt top highly rate medical research equipment service industry ibd leaderboard stock be featured wednesday new america column ellie mae elli demand software handle entire mortgage application process be hover top buy range flat base entry post straight quarters triple digit profit growth sale growth have accelerate straight quarters jump latest period outerwall outr operate self service kiosk let shopper buy rent movie video game be just buy range entry odd shape base outerwall be leader top rank leisure movie related industry group fact so many spotlight stock be continue move higher be good sign breakout market be sixth week latest uptrend
1452,GILD,stock market close mixed friday index bounce back early slump nasdaq rise thank strength biotechs security software solar stock fall dow jone industrial average lag drop close session lows small cap pace market small cap russell climb volume rise nyse edge lower nasdaq accord early figure serious decline prior day friday price reversal be encourage yet market remain lock long sideway trend stock sank open better expect job report trigger slide bond price energy stock rise opec left output target unchanged expect solar share jump china base ja solar jaso chief executive offer buy company take private financial also help lead stock market today bank america bac rise more close back buy point jpmorgan jpm rise hit new high thinly trade bofi holding bofi rise top buy point long cup handle base be strong day ibd average component volume be just average light most stock
1453,GILD,stock market close mixed friday index bounce back early slump nasdaq rise thank strength biotechs security software solar stock fall dow jone industrial average lag drop close session lows small cap pace market small cap russell climb volume rise nyse edge lower nasdaq accord early figure serious decline prior day friday price reversal be encourage yet market remain lock long sideway trend stock sank open better expect job report trigger slide bond price energy stock rise opec left output target unchanged expect solar share jump china base ja solar jaso chief executive offer buy company take private financial also help lead stock market today bank america bac rise more close back buy point jpmorgan jpm rise hit new high thinly trade bofi holding bofi rise top buy point long cup handle base be strong day ibd average component volume be just average light most stock
1454,GILD,longtime lead medical biotech stock be come fire shift be reflect sector leader gilead science gild jazz pharmaceutical jazz be monday screen drop tuesday edition alexion pharmaceutical alxn valeant pharmaceutical vrx remain be selling well alexion be threaten erase gain buy
1455,GILD,pharmacy benefit manager express script announce monday putt abbvie newly approve hepatitis treatment prefer formulary list knock rival treatment gilead science gilead gild stock plunge abbvie abbv fall late friday food drug administration approve abbvie viekira pak combination novel drug older
1456,GILD,stock get mixed start quickly turn positive shorten holiday week drugmaker show particular weakness monday open
1457,GILD,dow jone industrial average lead nasdaq backed early loss gain struggle hold fractional gain
1458,GILD,volume be sharply lower nasdaq nyse contrast friday heavy option expiration trading
1459,GILD,start last week stock market today feel little pressure overseas market oil price reversed early gain oil sector stock put damper early market action
1460,GILD,drugmaker be be hit hard market merck mrk post heaviest loss dow gilead science gild biogen idec biib regeneron pharmaceutical regn celgene celg hold low ground nasdaq stock energy issue hold worst loss
1461,GILD,leader leane generally higher gain be limit
1462,GILD,airline buck head list spirit airline save alaska air group alk ahead more spirit be recover harsh sell week end dec alaska have pull back test week support breaking double bottom base october
1463,GILD,drugmaker post list worst decline early trade
1464,GILD,gilead topple prescription benefit manager express script esrx announce support drug combination market abbvie abbv gilead sovaldi prefer treatment patient hepatitis express script rise abbvie share gain fraction
1465,GILD,celgene biogen also ibd list drop amgen amgn slip lower
1466,GILD,economic news exist home sale slip november annualize rate accord national association realtor be pace slight downward revision original estimate economist have forecast more moderate slowdown sale stock get mixed start quickly turn positive shorten holiday week drugmaker show particular weakness monday open dow jone industrial average lead nasdaq backed early loss gain struggle hold fractional gain volume be sharply lower nasdaq nyse contrast friday heavy option expiration trading start last week stock market today feel little pressure overseas market oil price reversed early gain oil sector stock put damper early market action drugmaker be be hit hard market merck mrk post heaviest loss dow gilead science gild biogen idec biib regeneron pharmaceutical regn celgene celg hold low ground nasdaq stock energy issue hold worst loss leader leane generally higher gain be limit airline buck head list spirit airline save alaska air group alk ahead more spirit be recover harsh sell week end dec alaska have pull back test week support breaking double bottom base october drugmaker post list worst decline early trade gilead topple prescription benefit manager express script esrx announce support drug combination market abbvie abbv gilead sovaldi prefer treatment patient hepatitis express script rise abbvie share gain fraction celgene biogen also ibd list drop amgen amgn slip lower economic news exist home sale slip november annualize rate accord national association realtor be pace slight downward revision original estimate economist have forecast more moderate slowdown sale
1467,GILD,christmas spirit hover stock market midday friday lift stock moderately dull trading dow jone industrial average be record high nasdaq be not far nov intraday high index best level march nasdaq lead way gain dow climb stock market today dow be work seventh straight day advance virgin america va soar ipo base wednesday climb ibd stock ambarella amba celgene celg rise stock recently find support day move average gilead science gild hammer earlier week rise nearly be trading day line analyst rbc capital suggest company initiate new stock buyback program cal maine food calm fall still feel effect tuesday report revenue come wall street forecast gopro gpro rise fourth straight advance day lock period insider be prohibit selling share expire monday
1468,GILD,gilead science beat analyst fourth quarter expectation tuesday give weak sale guidance biotech suffer pricing pressure blockbuster hepatitis drug earning leap share cent consensus revenue jump more wall street view however gilead gild see full year net product sale
1469,GILD,stock future hold fast early loss ahead wednesday open investor digest raft earning report pullback oil price
1470,GILD,dow future be steady trading point fair market value nasdaq future hung point red future be point
1471,GILD,stock market today set wednesday nasdaq back day move average bounce recent lows index have retest lows time early january
1472,GILD,economic news open weak side employer add new worker january accord adp national employment report be sharp downshift december upwardly revise new hire consensus view position filled
1473,GILD,big earning power large share early stock action
1474,GILD,general motor gm scale ahead open surge fourth quarter earning easily clear analyst consensus view revenue slip less expect management say increase dividend cent share
1475,GILD,automaker tuesday report january sale rise best january year general motor share have be struggle retake hold converge week move average work climb year long consolidation
1476,GILD,walt disney grab premarket gain report late tuesday fiscal earning revenue easily trump consensus view stock end tuesday jan high back support month uptrend
1477,GILD,growth stock be early pressure gilead science gild shedding heel result deliver tuesday close foster city calif base drugmaker beat sale earning estimate price pressure lead weak sale guidance stock end tuesday just handle buy point
1478,GILD,chipotle grill cmg slump head open fast casual burrito chain report better expect jump earning revenue gain also expectation
1479,GILD,same store sale growth be slightly forecast operate margin expand less expect same store sale guidance disappoint analyst
1480,GILD,stock have be hold just buy point
1481,GILD,overseas europe market be mild pressure midday japan tokyo nikkei surge china shanghai composite dip hang seng index hong kong notch gain
1482,GILD,dollar edge vs euro slip yen oil give ground day runup benchmark west texas intermediate crude pull back barrel europe brent benchmark gold add half dollar trade ounce
1483,GILD,et institute supply management report january service index energy information administration deliver weekly oil inventory datum stock future hold fast early loss ahead wednesday open investor digest raft earning report pullback oil price dow future be steady trading point fair market value nasdaq future hung point red future be point stock market today set wednesday nasdaq back day move average bounce recent lows index have retest lows time early january economic news open weak side employer add new worker january accord adp national employment report be sharp downshift december upwardly revise new hire consensus view position filled big earning power large share early stock action general motor gm scale ahead open surge fourth quarter earning easily clear analyst consensus view revenue slip less expect management say increase dividend cent share automaker tuesday report january sale rise best january year general motor share have be struggle retake hold converge week move average work climb year long consolidation walt disney grab premarket gain report late tuesday fiscal earning revenue easily trump consensus view stock end tuesday jan high back support month uptrend growth stock be early pressure gilead science gild shedding heel result deliver tuesday close foster city calif base drugmaker beat sale earning estimate price pressure lead weak sale guidance stock end tuesday just handle buy point chipotle grill cmg slump head open fast casual burrito chain report better expect jump earning revenue gain also expectation same store sale growth be slightly forecast operate margin expand less expect same store sale guidance disappoint analyst stock have be hold just buy point overseas europe market be mild pressure midday japan tokyo nikkei surge china shanghai composite dip hang seng index hong kong notch gain dollar edge vs euro slip yen oil give ground day runup benchmark west texas intermediate crude pull back barrel europe brent benchmark gold add half dollar trade ounce et institute supply management report january service index energy information administration deliver weekly oil inventory datum
1484,GILD,aetna aet tuesday raise full year earning share guidance drive higher membership lower cost gilead science hepatitis drug insurer now see ep earlier outlook discount negotiate gilead gild come aetna give prefer status drugmaker sovaldi harvoni treatment do think final negotiation topic be create upside aetna cfo shawn guertin say earning conference call accord reuter share rise stock market today new ep outlook still fall short wall street consensus stock bolt day line late october have trend back key level support choppy action december gilead report close tuesday dip aetna overall medical benefit ratio amount spend medical care vs money bring premium improve year earlier aetna say medical cost have remain moderate predict medical benefit ratio medical benefit ratio company bread butter commercial health plan segment rise due higher business expense cost related hepatitis treatment program mandate affordable care act aetna earn share year earlier match analyst forecast revenue rise top analyst view meanwhile centene cnc medicaid centric hmo have benefit health law medicaid expansion report ep pop beating estimate cent revenue surge boost company participation health insurance exchange expansion variety state health benefit ratio rise year centene expect health benefit ratio year company also guide full year gaap ep revenue share edge
1485,GILD,stock market make bullish reversal monday again find support recent lows
1486,GILD,climb lead market thank part rebound energy stock strength financial index find support level have do so several week
1487,GILD,nasdaq close higher composite defend floor dow jone industrial average rise
1488,GILD,volume fall sharply board accord unconfirmed figure increase trading have make monday gain look better market breadth be decidedly bullish stock market today winner top loser nearly nyse nasdaq
1489,GILD,tuesday automaker report january sale earning report announcement be expect chipotle grill cmg gilead science gild edward lifescience ew unite parcel service up stock market make bullish reversal monday again find support recent lows climb lead market thank part rebound energy stock strength financial index find support level have do so several week nasdaq close higher composite defend floor dow jone industrial average rise volume fall sharply board accord unconfirmed figure increase trading have make monday gain look better market breadth be decidedly bullish stock market today winner top loser nearly nyse nasdaq tuesday automaker report january sale earning report announcement be expect chipotle grill cmg gilead science gild edward lifescience ew unite parcel service up
1490,GILD,stock hepatitis field be wednesday wake gilead science gild cautious forecast potential competitor merck hit fda setback gilead stock plunge more early trading multiple analyst cut price target wake guidance comment point high rate
1491,GILD,best mutual fund second quarter performance update gavin baker take rein fidelity otc portfolio year fund have be top notch baker july anniversary otc be top large cap growth mutual fund peer track morningstar inc past year be
1492,GILD,new class hepatitis drug lead gilead science gild abbvie abbv have turn biggest success story biotech history yet hepatitis be only viruse cause viral hepatitis do other have such lucrative potential possibility be hepatitis existence
1493,GILD,blockbuster hepatitis drug power sale profit gilead science have become drug industry hit stock gilead gild stock have soar nearly last year new run begin gilead market capitalization be now higher drug giant merck mrk even revenue
1494,GILD,new analyst coverage big celgene deal help give healthy boost hot new issue fitbit fit pair recent biotech ipos wednesday fitbit hit second straight new high continue hot streak june ipo run first day become biggest tech debut year jump much wednesday pull back soar tuesday share have rally offer price stock be well extend past buy point short ipo base clear july remain watch
1495,GILD,capital iq begin cover fitness tracking device maker hold rating price target cite growth potential also valuation concern deutsche bank stifel suntrust robinson humphrey start coverage monday buy piper jaffray overweight
1496,GILD,fitbit ceo james park tuesday tell fortune magazine plan integrate text messaging other feature tracking device researcher npd group estimate san francisco base company have share fitness activity tracking sale last year
1497,GILD,intrexon xon vault fast turnover extend gain cup handle buy point stock come public august have have volatile ride so far be more offer price synthetic biology firm hasn turn annual profit yet have year sale growth rate belong rate biotech group wednesday top gainer
1498,GILD,biotechs get lift celgene celg acquisition receptos rcpt developer treatment multiple sclerosis other immunological disorder celgene also announce preliminary earning analyst forecast
1499,GILD,enanta pharmaceutical enta rise early wednesday retreat mildly share clear cup handle buy point tuesday brisk trade correct steeper normal pattern reset base count result march ipo be nearly offer price share
1500,GILD,biotech be developer antiviral agent abbvie abbv hepatitis drug cocktail competitor gilead gild blockbuster drug sovaldi harvoni new analyst coverage big celgene deal help give healthy boost hot new issue fitbit fit pair recent biotech ipos wednesday fitbit hit second straight new high continue hot streak june ipo run first day become biggest tech debut year jump much wednesday pull back soar tuesday share have rally offer price stock be well extend past buy point short ipo base clear july remain watch capital iq begin cover fitness tracking device maker hold rating price target cite growth potential also valuation concern deutsche bank stifel suntrust robinson humphrey start coverage monday buy piper jaffray overweight fitbit ceo james park tuesday tell fortune magazine plan integrate text messaging other feature tracking device researcher npd group estimate san francisco base company have share fitness activity tracking sale last year intrexon xon vault fast turnover extend gain cup handle buy point stock come public august have have volatile ride so far be more offer price synthetic biology firm hasn turn annual profit yet have year sale growth rate belong rate biotech group wednesday top gainer biotechs get lift celgene celg acquisition receptos rcpt developer treatment multiple sclerosis other immunological disorder celgene also announce preliminary earning analyst forecast enanta pharmaceutical enta rise early wednesday retreat mildly share clear cup handle buy point tuesday brisk trade correct steeper normal pattern reset base count result march ipo be nearly offer price share biotech be developer antiviral agent abbvie abbv hepatitis drug cocktail competitor gilead gild blockbuster drug sovaldi harvoni
1501,GILD,abbvie hepatitis regimen win fda approval friday become second entrant be already huge market interferon free hcv treatment viekira pak cost week line forecast undercut gilead science gild same treatment length abbvie abbv regimen consist drug ombitasvir paritaprevir first develop
1502,GILD,big cap biotech ibd stock unite therapeutic have history confound expectation good way almost exactly year food drug administration approve orenitram pill treat pulmonary arterial hypertension pah progressive tighten artery supply lung make remarkable be fda have reject unite
1503,GILD,biotech stock take bath holiday shorten week catalyst be announcement express script esrx nation largest benefit manager use abbvie abbv hepatitis drug exclusively hurt gilead science gild stock have soar sale own ground breaking hepatitis treatment gilead be hammer loss week so far
1504,GILD,subject drug pricing keep get hotter most person mysterious process
1505,GILD,nov pharmacy benefit manager express script esrx say rein cost up number drug exclude formulary new target include amgen amgn popular blood booster epogen aranesp express say intend provoke price war once competitor gilead science gild hepatitis drug sovaldi start come hope bring treatment price tag work mean drugmaker investor explore question ibd speak ed schoonveld manage principal consult firm zs associate author price global health now launch second edition ibd biggest misconception person have drug pricing work schoonveld very complex environment reason be so many be buy process be so different call dinner imagine go restaurant person be order meal person be eating meal other person be pay imagine conversation take place pay say well not sure caviar be necessary then again payer be little too demand well say think hot dog be good enough patient course be interested health be pay only indirectly physician want make sure patient be do well payer be overly concern cost be lot person be say market mechanism be not feel need interfere many case be interfere reason different be such capital intensive industry require lot investment so cost structure be quite different sometimes hard explain patient need pay something person just want cure disease even more important context be change so much combination rise cost health care economy not do too great be putt lot pressure government cut cost reform system then same time have thing ebola pop so do need strong development arm disease be actually very scary technology be advance well be probably lead more expensive solution come together perfect storm payer be face tough decision ibd sovaldi come seem lot insurer be unprepared wound pay more expect do industry learn anything schoonveld obviously raise lot debate interestingly not be lot debate value drug honestly wish have more problem sovaldi problem have cure disease big challenge case be time horizon difficult insurance company fund be tremendous cost offset be go take place number year line doesn tend help short term perspective addition many health care plan be still pharmacy only plan really be not get benefit reduction occurrence liver disease cancer everything else make little harder make decision particularly impact budget case more matter make sure find appropriate way treat patient make sure additional budget available example germany ve do be temporary budget increase curative treatment ibd be pharmacy benefit manager express script get more powerful schoonveld example plan only see cost drug treatment doesn get reward benefit limitation used pbms manage formulary don see much value treatment more intergrate health care system see take step back do be require drug industry engage make sure know value proposition be seem have societal objective bring treatment patient so clear hurdle financing mainly be make sure find solution ibd sort alternative be think schoonveld be not easy be cost offset long term so find way make sure cost offset be be recognize even make sure drugmaker payer pbms government agency talk other rather medium be helpful sovaldi be very specific case be many other drug insurance company physician be look judge value be used appropriately see lot medical society asco american society clinical oncology have be pretty vocal re go take cost more consideration clinical guideline put pharmaceutical industry position even more have make sure realize provide evidence new treatment be provide value patient physician payer make sure be guidance best be used treatment sometimes hard do launch lead
1506,GILD,world biggest drugmaker issue mixture report friday continue be tough earning season abbvie abbv say profit exclude time item rise year earlier quarter cent beating analyst consensus cent accord thomson reuter sale climb ahead consensus full year profit increase share sale gain abbvie affirm guidance issue earlier month call earning didn set revenue range however conference call analyst ceo richard gonzalez say expect newly launch hepatitis combo viekira pak achieve run rate end year midst abbvie hepatitis battle gilead science gild land exclusive deal payer gonzalez say expect insure patient have access viekira pak rbc capital market analyst michael yee calculate mean year be consensus positive abbv announce generation regimen improve possible single pill booster ribavirin have datum soon plan go phase iii later year be way maintain share alternative gild yee write research note friday still abbvie share fall afternoon trading stock market today stock fall month low intraday eli lilly lly still shadow patent cliff report sale shrank miss consensus nearly earning rise cent share beating street average estimate cent full year profit drop share sale slide lilly also affirm earlier profit guidance share shave revenue guidance be now singing familiar tune earning season lilly blame lower guidance solely reflect recent strengthen dollar compare several other currency however capital iq analyst jeffrey loo be hearten ep guidance stay same point better expect gross margin raise price target say be low point sale see improve growth next few year lilly stock rise afternoon trading follow amy reeve twitter ibd_areeve
1507,GILD,stock wobble start gate mixed action wednesday quarterly report power much early action
1508,GILD,dow jone industrial average peck fractional gain nasdaq slump take drop
1509,GILD,volume be also mixed higher nasdaq lower nyse compare trade same time tuesday
1510,GILD,stock market today get roll start earning report general motor gm walt disney help bolster early trade
1511,GILD,early economic news be weak adp report larger expect decline january hire employer
1512,GILD,service sector news be more positive institute supply management january manufacturing index tick be just december upwardly revise tally consensus view also project read
1513,GILD,service purchasing manager index researcher markit rise january december basis point consensus view
1514,GILD,stock sony sne spiked deliver preliminary earning guidance cent share year year well consensus view cent also project revenue consensus cite positive foreign exchange rate gain punch share month high clear correction begin july
1515,GILD,ibd list leader hammer strong gain loss
1516,GILD,manhattan associate manh bolt higher start bell supply chain software developer report tuesday close sale earning consensus expectation management also raise full year earning revenue guidance projection raymond james upgrade stock strong buy outperform move send share new high test support week move average
1517,GILD,china base noah holding noah pop early action asset manager have shape sharp double bottom base fail break yearlong correction december wednesday gain put back week support buy point
1518,GILD,list low end gilead science gild dive report healthy fourth quarter revenue earning drugmaker offer weak sale guidance cite competitive cost pressure
1519,GILD,chipotle grill cmg unraveled diving week move average heavy trade
1520,GILD,fast casual burrito chain report par earning revenue just sliver shy estimate same store sale margin disappoint analyst do guidance full year same store sale growth
1521,GILD,hour schedule hold few name interest growth stock investor nxp semiconductor nxpi reilly automotive orly armour ua expect report quarterly result stock wobble start gate mixed action wednesday quarterly report power much early action dow jone industrial average peck fractional gain nasdaq slump take drop volume be also mixed higher nasdaq lower nyse compare trade same time tuesday stock market today get roll start earning report general motor gm walt disney help bolster early trade early economic news be weak adp report larger expect decline january hire employer service sector news be more positive institute supply management january manufacturing index tick be just december upwardly revise tally consensus view also project read service purchasing manager index researcher markit rise january december basis point consensus view stock sony sne spiked deliver preliminary earning guidance cent share year year well consensus view cent also project revenue consensus cite positive foreign exchange rate gain punch share month high clear correction begin july ibd list leader hammer strong gain loss manhattan associate manh bolt higher start bell supply chain software developer report tuesday close sale earning consensus expectation management also raise full year earning revenue guidance projection raymond james upgrade stock strong buy outperform move send share new high test support week move average china base noah holding noah pop early action asset manager have shape sharp double bottom base fail break yearlong correction december wednesday gain put back week support buy point list low end gilead science gild dive report healthy fourth quarter revenue earning drugmaker offer weak sale guidance cite competitive cost pressure chipotle grill cmg unraveled diving week move average heavy trade fast casual burrito chain report par earning revenue just sliver shy estimate same store sale margin disappoint analyst do guidance full year same store sale growth hour schedule hold few name interest growth stock investor nxp semiconductor nxpi reilly automotive orly armour ua expect report quarterly result
1522,GILD,stock be hold session high late monday stage big upside reversal morning weak job report pressured equity open
1523,GILD,rally nasdaq gain blue chip dow jone industrial average lead gain
1524,GILD,epam system epam stretched gain push further new high territory stock be monday ibd earlier clear buy point flat base epam have trade tightly recent week show support action stock previously break february have now reach profit zone buy point cup base
1525,GILD,jd com jd rise clear resistance area thursday jd com announce former yahoo china executive chen zhang have joined company head research development jd mall share jd com be past buy point cup handle base clear march
1526,GILD,lennar len lose reverse multiyear high stock be pace snap session streak reversal stock be still past buy point cup base
1527,GILD,recent real estate article real estate agent expect sale new home surge year
1528,GILD,ambarella amba be fractionally lower volatility earlier stock market today stock have be intraday have price target hike pacific crest security stock be hold session high late monday stage big upside reversal morning weak job report pressured equity open rally nasdaq gain blue chip dow jone industrial average lead gain epam system epam stretched gain push further new high territory stock be monday ibd earlier clear buy point flat base epam have trade tightly recent week show support action stock previously break february have now reach profit zone buy point cup base jd com jd rise clear resistance area thursday jd com announce former yahoo china executive chen zhang have joined company head research development jd mall share jd com be past buy point cup handle base clear march lennar len lose reverse multiyear high stock be pace snap session streak reversal stock be still past buy point cup base recent real estate article real estate agent expect sale new home surge year ambarella amba be fractionally lower volatility earlier stock market today stock have be intraday have price target hike pacific crest security
1529,GILD,nothing competition help lower price market abbvie abbv enter hepatitis arena december gilead science gild have be discounting price sovaldi harvoni drug foster city calif base biotech jan sign health insurer aetna aet provider sovaldi cost week
1530,GILD,ibd medical biom biotech group be big gainer group be show sign let
1531,GILD,head thursday be rank group ibd database base month price performance
1532,GILD,thursday be top perform group abbvie abbv announce plan buy pharmacyclic pcyc cash stock
1533,GILD,look group be ready roll early february lose straight session find support day move average resume uptrend
1534,GILD,pharmacyclic be several biotechs have show big sale growth recent quarters blood cancer drug imbruvica be blockbuster food drug administration first approve imbruvica november treat mantle cell lymphoma drug have be approve other indication recent month
1535,GILD,stock biotech group recently have composite rating higher good bet group see more activity come month big player scoop smaller one compelling pipeline
1536,GILD,isis pharmaceutical isis isn profitable yet straight quarters accelerate sale growth solid mutual fund sponsorship market capitalization be worth note
1537,GILD,isis pipeline consist drug treat wide variety disease emphasis cardiovascular metabolic severe rare disease include neurological disorder cancer
1538,GILD,january company inked potentially lucrative licensing deal johnson johnson jnj janssen biotech unit agree pay front milestone payment develop drug autoimmune disorder tract used isis rna target platform
1539,GILD,last month isis receive milestone payment biogen idec biib isis be multiyear collaboration biogen advance treatment neurological disease
1540,GILD,isis be eighth week consolidation show buy point point thursday be only week high
1541,GILD,elsewhere group small cap newlink genetic nlnk have be busy partnership front newlink partner roche rhhby subsidiary genentech early stage cancer program newlink receive upfront payment genentech more potential milestone
1542,GILD,infectious disease newlink be work merck mrk ebola vaccine candidate
1543,GILD,newlink recently clear base buy point close time high
1544,GILD,meanwhile few large cap name group be back week move average consolidate gain include amgen amgn gilead science gild alexion alxn ibd medical biom biotech group be big gainer group be show sign let head thursday be rank group ibd database base month price performance thursday be top perform group abbvie abbv announce plan buy pharmacyclic pcyc cash stock look group be ready roll early february lose straight session find support day move average resume uptrend pharmacyclic be several biotechs have show big sale growth recent quarters blood cancer drug imbruvica be blockbuster food drug administration first approve imbruvica november treat mantle cell lymphoma drug have be approve other indication recent month stock biotech group recently have composite rating higher good bet group see more activity come month big player scoop smaller one compelling pipeline isis pharmaceutical isis isn profitable yet straight quarters accelerate sale growth solid mutual fund sponsorship market capitalization be worth note isis pipeline consist drug treat wide variety disease emphasis cardiovascular metabolic severe rare disease include neurological disorder cancer january company inked potentially lucrative licensing deal johnson johnson jnj janssen biotech unit agree pay front milestone payment develop drug autoimmune disorder tract used isis rna target platform last month isis receive milestone payment biogen idec biib isis be multiyear collaboration biogen advance treatment neurological disease isis be eighth week consolidation show buy point point thursday be only week high elsewhere group small cap newlink genetic nlnk have be busy partnership front newlink partner roche rhhby subsidiary genentech early stage cancer program newlink receive upfront payment genentech more potential milestone infectious disease newlink be work merck mrk ebola vaccine candidate newlink recently clear base buy point close time high meanwhile few large cap name group be back week move average consolidate gain include amgen amgn gilead science gild alexion alxn
1545,GILD,humana hum narrow earning outlook year third quarter revenue earning view fall short analyst expectation insurance hepatitis related cost
1546,GILD,full year earning guidance be now range share analyst view share
1547,GILD,share company fall morning trade stock market today friday
1548,GILD,humana say investment obamacare health care exchange state base contract well increase cost related new hepatitis treatment weigh earning gain membership lower diluted share count improve utilization high clinical program membership partially offset cost company say
1549,GILD,full year earning guidance fiscal be expect be range fall line current wall street expectation
1550,GILD,look anticipate increasingly meaningful enterprisewide benefit higher membership say humana ceo bruce broussard
1551,GILD,expect strong value proposition provide member such high star quality rating relatively flat premium benefit stable provider network position well further membership growth increase return capital
1552,GILD,humana several other insurer include aetna aet have blame high cost hepatitis drug re talk explicitly implicitly gilead science gild day sovaldi have high cure rate
1553,GILD,related
1554,GILD,centene manage care stock rebound earning loom humana hum narrow earning outlook year third quarter revenue earning view fall short analyst expectation insurance hepatitis related cost full year earning guidance be now range share analyst view share share company fall morning trade stock market today friday humana say investment obamacare health care exchange state base contract well increase cost related new hepatitis treatment weigh earning gain membership lower diluted share count improve utilization high clinical program membership partially offset cost company say full year earning guidance fiscal be expect be range fall line current wall street expectation look anticipate increasingly meaningful enterprisewide benefit higher membership say humana ceo bruce broussard expect strong value proposition provide member such high star quality rating relatively flat premium benefit stable provider network position well further membership growth increase return capital humana several other insurer include aetna aet have blame high cost hepatitis drug re talk explicitly implicitly gilead science gild day sovaldi have high cure rate related centene manage care stock rebound earning loom
1555,GILD,now market be back uptrend investor look buy stock breaking basis gilead science vipshop holding haven break yet be clearly leader basis
1556,GILD,gilead science gild be lopsided consolidation buy point first have deal level act upside resistance few time last month stock relative strength line have already hit new high
1557,GILD,tuesday gilead regain day move average do so weak turnover stock have bounce back recent session market still have poor accumulation distribution rating fund have be buy third quarter fidelity contrafund balanced fund add position cgm focus fund start new position
1558,GILD,gilead report third quarter result tuesday close analyst see earning surge share mark third straight quarter triple digit growth sale be expect year solid demand continue gilead sovaldi hepatitis treatment cost week course
1559,GILD,vipshop holding vip be consolidation buy point recent pullback march new issue find support just week line do late june note vipshop be late stage structure even start count basis stock be share late stage pattern be generally riskier
1560,GILD,wednesday stock climb back day line average volume thursday vipshop stretched winning streak straight session
1561,GILD,chinese online retailer used flash sale model have deliver triple digit gain earning sale recent quarters be expect third quarter profit be expect surge cent share revenue be slate now market be back uptrend investor look buy stock breaking basis gilead science vipshop holding haven break yet be clearly leader basis gilead science gild be lopsided consolidation buy point first have deal level act upside resistance few time last month stock relative strength line have already hit new high tuesday gilead regain day move average do so weak turnover stock have bounce back recent session market still have poor accumulation distribution rating fund have be buy third quarter fidelity contrafund balanced fund add position cgm focus fund start new position gilead report third quarter result tuesday close analyst see earning surge share mark third straight quarter triple digit growth sale be expect year solid demand continue gilead sovaldi hepatitis treatment cost week course vipshop holding vip be consolidation buy point recent pullback march new issue find support just week line do late june note vipshop be late stage structure even start count basis stock be share late stage pattern be generally riskier wednesday stock climb back day line average volume thursday vipshop stretched winning streak straight session chinese online retailer used flash sale model have deliver triple digit gain earning sale recent quarters be expect third quarter profit be expect surge cent share revenue be slate
1562,GILD,flem ornskov have be shire only month term have be quite adventure already
1563,GILD,january close anglo irish drugmaker biggest acquisition buy biotech viropharma
1564,GILD,bring shire shpg deeper grow field rare disease drug help diversify core business attention deficit treatment have also make number smaller buyout
1565,GILD,year shire biggest drama be role have be biggest tax inversion deal drug industry
1566,GILD,north chicago base big pharma abbvie abbv successfully woo shire back july nearly offer abbvie plan cut taxe relocate headquarters britain
1567,GILD,treasury department propose new rule september limit benefit such deal abbvie be legally unable renegotiate term big pharma backed leave shire breakup fee
1568,GILD,undaunted oct shire report result beat expectation
1569,GILD,ornskov recently speak ibd abbvie adventure shire strategy
1570,GILD,ibd abbvie first make bid initially resist apart issue price be become part big pharma ever plan be now
1571,GILD,ornskov situation abbvie make bid be go put strong case investor stay independent layer plan call achieve annual sale abbvie increase offer number time eventually think board shire feel number be offer be such magnitude have recommend also feedback get investor
1572,GILD,deal do not happen be lot speculation tax deal importance think right now most important thing be have strong opportunity independent company
1573,GILD,have very strong growth grow third quarter compare similar quarter think progressed profitability very strongly progressed pipeline think now have focus be independent company
1574,GILD,long term think ve make really good progress business development ve make least deal period time lumena fibrotech company call bikam ophthalmic area quickly put abbvie situation think so team
1575,GILD,ibd speaking tax issue shire be domicile dublin even lot operation be elsewhere do see propose change irish law political pressure be affect business
1576,GILD,ornskov shire be base ireland quite time think ve see tax be complex issue now company treasury notice person be interpret try figure mean
1577,GILD,think end tax be thing have manage complex environment high demand growth efficiency really key thing be focus innovation growth person pipeline
1578,GILD,ibd ve be diversify away core add business do wind mix therapeutic area re be most focuse point
1579,GILD,ornskov ve come board ve shift strategy be more focuse become biotech company have aspirational peer celgene celg gilead gild biogen idec biib find company be characterize innovative pipeline high growth high profitability very strong research focus patient focus
1580,GILD,put strategy take direction have plan achieve be ambitious think achievable goal even exclude business development
1581,GILD,more more business be rare disease be now largest fastest grow business true historically ve be more adhd now rare disease be focal point go forward investment business development acquisition
1582,GILD,ibd size acquisition expect
1583,GILD,ornskov well shire have always be acquisitive company ve make quite number come board largest make be acquisition viropharma think be incredibly successful
1584,GILD,not only do acquire product cinryze used prevent attack angioedema swell face body excellent growth also ve significantly increase growth ve take product same disease area firazyr already have picked growth significantly good pattern build domain expertise have make target acquisition perform very well acquire asset spillover effect exist asset
1585,GILD,ll look opportunity do other area flem ornskov have be shire only month term have be quite adventure already january close anglo irish drugmaker biggest acquisition buy biotech viropharma bring shire shpg deeper grow field rare disease drug help diversify core business attention deficit treatment have also make number smaller buyout year shire biggest drama be role have be biggest tax inversion deal drug industry north chicago base big pharma abbvie abbv successfully woo shire back july nearly offer abbvie plan cut taxe relocate headquarters britain treasury department propose new rule september limit benefit such deal abbvie be legally unable renegotiate term big pharma backed leave shire breakup fee undaunted oct shire report result beat expectation ornskov recently speak ibd abbvie adventure shire strategy ibd abbvie first make bid initially resist apart issue price be become part big pharma ever plan be now ornskov situation abbvie make bid be go put strong case investor stay independent layer plan call achieve annual sale abbvie increase offer number time eventually think board shire feel number be offer be such magnitude have recommend also feedback get investor deal do not happen be lot speculation tax deal importance think right now most important thing be have strong opportunity independent company have very strong growth grow third quarter compare similar quarter think progressed profitability very strongly progressed pipeline think now have focus be independent company long term think ve make really good progress business development ve make least deal period time lumena fibrotech company call bikam ophthalmic area quickly put abbvie situation think so team ibd speaking tax issue shire be domicile dublin even lot operation be elsewhere do see propose change irish law political pressure be affect business ornskov shire be base ireland quite time think ve see tax be complex issue now company treasury notice person be interpret try figure mean think end tax be thing have manage complex environment high demand growth efficiency really key thing be focus innovation growth person pipeline ibd ve be diversify away core add business do wind mix therapeutic area re be most focuse point ornskov ve come board ve shift strategy be more focuse become biotech company have aspirational peer celgene celg gilead gild biogen idec biib find company be characterize innovative pipeline high growth high profitability very strong research focus patient focus put strategy take direction have plan achieve be ambitious think achievable goal even exclude business development more more business be rare disease be now largest fastest grow business true historically ve be more adhd now rare disease be focal point go forward investment business development acquisition ibd size acquisition expect ornskov well shire have always be acquisitive company ve make quite number come board largest make be acquisition viropharma think be incredibly successful not only do acquire product cinryze used prevent attack angioedema swell face body excellent growth also ve significantly increase growth ve take product same disease area firazyr already have picked growth significantly good pattern build domain expertise have make target acquisition perform very well acquire asset spillover effect exist asset ll look opportunity do other area
1586,GILD,big pharma merck mrk be nearly stock market today latest datum hepatitis pipeline underwhelm street sunday annual conference american association study liver disease merck report much anticipate interim datum swift trial analyst thought challenge market leader gilead
1587,GILD,celgene celg stock jump new high wednesday morning get several price target increase wake deal buy receptos rcpt celgene agree pay receptos announce preliminary earning beat estimate receptos lead drug candidate ozanimod be clinical testing different immunological disease be
1588,GILD,current list ibd big cap feature more stock be relatively old relatively new not big surprise take year not decade even fast grow company achieve earning sale size large cap equity market ibd define large cap screen market value higher
1589,GILD,surprise find big cap lie numerous company have come back truly severe decline
1590,GILD,ibd teach only big winner previous bull market cycle come back lead future bull run
1591,GILD,be not great odd former market leader cognizant solution ctsh gilead science gild unitedhealth unh analog device adi have beaten odd
1592,GILD,plunge
1593,GILD,taught ibd begin level live workshop average decline former big market winner ultimate peak price be other word stock top have potential bottom
1594,GILD,tough stock dig kind hole
1595,GILD,yet exactly cognizant do bear market end
1596,GILD,global player information technology service fall peak february low adjust split november look stock long run be
1597,GILD,wasn cognizant rebound market follow rally march
1598,GILD,july year stock clear properly form flat base week high eventually take peak stock correct again summer then break again week end long digestion gain lead fresh past new buy point last year
1599,GILD,do cognizant come back strong steady earning growth cent share be big factor
1600,GILD,revenue growth be nowhere close day increase still double digit range
1601,GILD,be impressive fundamental company break revenue barrier last year
1602,GILD,gilead have monster run peak august then fall peak large drop surely nowhere typical correction new product include blockbuster drug hepatitis have bring institutional crowd back stock
1603,GILD,obamacare have help catalyze new top bottom line growth unitedhealth chipmaker analog meanwhile be cash global phenomenon internet enabled mobile device current list ibd big cap feature more stock be relatively old relatively new not big surprise take year not decade even fast grow company achieve earning sale size large cap equity market ibd define large cap screen market value higher surprise find big cap lie numerous company have come back truly severe decline ibd teach only big winner previous bull market cycle come back lead future bull run be not great odd former market leader cognizant solution ctsh gilead science gild unitedhealth unh analog device adi have beaten odd plungea taught ibd begin level live workshop average decline former big market winner ultimate peak price be other word stock top have potential bottom tough stock dig kind hole yet exactly cognizant do bear market end global player information technology service fall peak february low adjust split november look stock long run be wasn cognizant rebound market follow rally march july year stock clear properly form flat base week high eventually take peak stock correct again summer then break again week end long digestion gain lead fresh past new buy point last year do cognizant come back strong steady earning growth cent share be big factor revenue growth be nowhere close day increase still double digit range be impressive fundamental company break revenue barrier last year gilead have monster run peak august then fall peak large drop surely nowhere typical correction new product include blockbuster drug hepatitis have bring institutional crowd back stock obamacare have help catalyze new top bottom line growth unitedhealth chipmaker analog meanwhile be cash global phenomenon internet enabled mobile device
1604,GILD,recent spotlight stock breakout have hold choppy market action late gilead science gild break new high wednesday show nice follow action thursday left side high month consolidation show buy point share be pace close higher fifth straight week stock garner composite rating
1605,GILD,biotech giant be bounce back fail late last year trading start tighten year stock largely find support long term day move average
1606,GILD,security software firm vasco datum security vdsi be barely extend past handle entry point vasco break june convince turnover wednesday share briefly touch new time high reverse lower
1607,GILD,vasco provide authentication service specialize secure online account protect asset financial enterprise government market vasco also secure cloud access provide tool developer incorporate security function application bulk first quarter revenue come europe middle east africa region only fraction come
1608,GILD,aci worldwide aciw hit profit target thursday heavy volume past march
1609,GILD,aci be lead provider electronic payment transaction software financial institution retailer payment processor biller worldwide company license solution subscription basis sell complementary service
1610,GILD,recent presentation aci highlighted grow regulatory requirement complexity globalization increase fraud cost favorable industry dynamic service also note increase difficulty bank try update legacy system aci be part financial software industry group rank thursday paper recent spotlight stock breakout have hold choppy market action late gilead science gild break new high wednesday show nice follow action thursday left side high month consolidation show buy point share be pace close higher fifth straight week stock garner composite rating biotech giant be bounce back fail late last year trading start tighten year stock largely find support long term day move average security software firm vasco datum security vdsi be barely extend past handle entry point vasco break june convince turnover wednesday share briefly touch new time high reverse lower vasco provide authentication service specialize secure online account protect asset financial enterprise government market vasco also secure cloud access provide tool developer incorporate security function application bulk first quarter revenue come europe middle east africa region only fraction come aci worldwide aciw hit profit target thursday heavy volume past march aci be lead provider electronic payment transaction software financial institution retailer payment processor biller worldwide company license solution subscription basis sell complementary service recent presentation aci highlighted grow regulatory requirement complexity globalization increase fraud cost favorable industry dynamic service also note increase difficulty bank try update legacy system aci be part financial software industry group rank thursday paper
1611,GILD,abbvie be make major oncology push agree late wednesday pay acquire pharmacyclic pcyc maker blockbuster blood cancer drug imbruvica abbvie pay share cash stock pharmacyclic close price wednesday biotech close record high wednesday buyout buzz
1612,GILD,stock turn mixed midday monday round similarly mixed earning report well economic report foreign domestic
1613,GILD,nasdaq turn loss gain biotechs software issue outperformed pare deficit dow jone industrial average fall volume be tracking sharply lower board stock market today compare same time friday
1614,GILD,highly rate stock globant glob rally nearly time high clear buy point heavy trading hour session thin stock already match day average volume
1615,GILD,nike nke climb more new high be upgrade buy hold bb now past buy point athletic apparel footwear giant be recently mentioned new high column
1616,GILD,downside microsemi mscc drop news offer buy pmc sierra pmcs bid top buyout offer apple aapl supplier skywork solution swks microsemi fall buy point consolidation clear friday pmc share jump
1617,GILD,valeant vrx slump beating view raise guidance open canadian drugmaker post adjust earning share year sale grow third straight period acceleration almost lift full year sale forecast
1618,GILD,profit be now expect share prior outlook last week valeant say receive subpoena federal prosecutor massachusett new york request information patient assistance program drug pricing decision
1619,GILD,follow vincent mao twitter ibd_vmao stock turn mixed midday monday round similarly mixed earning report well economic report foreign domestic nasdaq turn loss gain biotechs software issue outperformed pare deficit dow jone industrial average fall volume be tracking sharply lower board stock market today compare same time friday highly rate stock globant glob rally nearly time high clear buy point heavy trading hour session thin stock already match day average volume nike nke climb more new high be upgrade buy hold bb now past buy point athletic apparel footwear giant be recently mentioned new high column downside microsemi mscc drop news offer buy pmc sierra pmcs bid top buyout offer apple aapl supplier skywork solution swks microsemi fall buy point consolidation clear friday pmc share jump valeant vrx slump beating view raise guidance open canadian drugmaker post adjust earning share year sale grow third straight period acceleration almost lift full year sale forecast profit be now expect share prior outlook last week valeant say receive subpoena federal prosecutor massachusett new york request information patient assistance program drug pricing decision follow vincent mao twitter ibd_vmao
1620,GILD,stock finished flourish tuesday cap afternoon rally close day high
1621,GILD,nasdaq rise gain dow jone industrial average be volume be higher monday board accord preliminary datum
1622,GILD,dow stock be higher caterpillar cat chevron cvx exxon mobil xom lead way higher caterpillar rise oil giant gain
1623,GILD,energy stock be best performer oil rise more barrel close just
1624,GILD,chipotle grill cmg fall sharply hour report earning beat estimate earning meet revenue same store sale guidance be light
1625,GILD,edward lifescience ew rise hour report earning share vs estimate cent revenue come compare estimate
1626,GILD,gilead science gild also rise hour report earning share vs estimate revenue be vs estimate
1627,GILD,disney be close report ep compare consensus estimate
1628,GILD,ism service index be report eastern time wednesday economist forecast january vs december
1629,GILD,later day crude oil inventory be report stock finished flourish tuesday cap afternoon rally close day high nasdaq rise gain dow jone industrial average be volume be higher monday board accord preliminary datum dow stock be higher caterpillar cat chevron cvx exxon mobil xom lead way higher caterpillar rise oil giant gain energy stock be best performer oil rise more barrel close just chipotle grill cmg fall sharply hour report earning beat estimate earning meet revenue same store sale guidance be light edward lifescience ew rise hour report earning share vs estimate cent revenue come compare estimate gilead science gild also rise hour report earning share vs estimate revenue be vs estimate disney be close report ep compare consensus estimate ism service index be report eastern time wednesday economist forecast january vs december later day crude oil inventory be report
1630,GILD,wednesday report fastest quarterly earning growth more year revenue gain continue slow
1631,GILD,drug health supply distributor fiscal earning share leap fourth straight quarter accelerate growth beating view cent
1632,GILD,revenue rise help boot alliance wba contract inked last year provide pharmaceutical product top view sale growth slow more prior quarters
1633,GILD,abc stock end have rise intraday record high
1634,GILD,re cycling onboard expect revenue growth come evercore isi analyst ross muken tell ibd growth come be still medical distributor market overall
1635,GILD,be impressive quarter board notably revenue side think have solid result overall say
1636,GILD,also lift earning outlook share prior view
1637,GILD,midpoint be roughly line consensus revision be help cent ep beat acquisition mwi veterinary supply company expect add cent ep latter half year
1638,GILD,only thing investor question be magnitude earning guidance muken say give be not surprised magnitude earning guidance revision
1639,GILD,company expect revenue wall street consensus
1640,GILD,fiscal drug unit sale rise specialty sale jump say drug sale gain be due largely pact demand hepatitis drug
1641,GILD,market hep drug be increasingly competitive gilead gild sovaldi debut december rival treatment johnson johnson jnj abbvie abbv have launch
1642,GILD,cvs health cvs month say select gilead sovaldi harvoni exclusive hepatitis treatment express script esrx picked abbvie viekira december wednesday report fastest quarterly earning growth more year revenue gain continue slow drug health supply distributor fiscal earning share leap fourth straight quarter accelerate growth beating view cent revenue rise help boot alliance wba contract inked last year provide pharmaceutical product top view sale growth slow more prior quarters abc stock end have rise intraday record high re cycling onboard expect revenue growth come evercore isi analyst ross muken tell ibd growth come be still medical distributor market overall be impressive quarter board notably revenue side think have solid result overall say also lift earning outlook share prior view midpoint be roughly line consensus revision be help cent ep beat acquisition mwi veterinary supply company expect add cent ep latter half year only thing investor question be magnitude earning guidance muken say give be not surprised magnitude earning guidance revision company expect revenue wall street consensus fiscal drug unit sale rise specialty sale jump say drug sale gain be due largely pact demand hepatitis drug market hep drug be increasingly competitive gilead gild sovaldi debut december rival treatment johnson johnson jnj abbvie abbv have launch cvs health cvs month say select gilead sovaldi harvoni exclusive hepatitis treatment express script esrx picked abbvie viekira december
1643,GILD,share biotechs moved lower afternoon trading wednesday broader market even amgen amgn top quarterly earning revenue view tuesday close analyst expect strong result biogen idec biib celgene celg report thursday
1644,GILD,wednesday dip come otherwise robust recent run ibd medical biom biotech group rank industry track group set record high tuesday be month
1645,GILD,amgen second biggest biotech market cap gilead science gild logged fourth quarter ep prior year cent consensus view revenue climb also estimate
1646,GILD,amgen overall product sale rise only year year company drug enjoy double digit sale increase include blockbuster enbrel treatment rheumatoid arthritis other immune disorder see sale rise
1647,GILD,note release wednesday morning rbc capital market analyst michael yee say amgen quarterly revenue beat be partly due boost inventory enbrel
1648,GILD,expect be reversed usual lead seasonally weaker yee say
1649,GILD,meanwhile sale amgen neupogen used treat neutropenia associate chemotherapy fall quarter wednesday note leerink analyst howard liang say decline be apparently result competition teva pharmaceutical teva granix
1650,GILD,celgene be due report result open thursday analyst poll thomson reuter expect company post earning cent share year earlier happen mark celgene biggest earning gain quarters revenue be see climb
1651,GILD,biogen be slate report fourth quarter earning thursday close cambridge mass base company have push report back day due severe blizzard hit boston area
1652,GILD,analyst expect biogen log ep gain revenue increase
1653,GILD,biogen own top ibd composite rating put medical biom biotech group celgene also have composite rating amgen have composite rating share biotechs moved lower afternoon trading wednesday broader market even amgen amgn top quarterly earning revenue view tuesday close analyst expect strong result biogen idec biib celgene celg report thursday wednesday dip come otherwise robust recent run ibd medical biom biotech group rank industry track group set record high tuesday be month amgen second biggest biotech market cap gilead science gild logged fourth quarter ep prior year cent consensus view revenue climb also estimate amgen overall product sale rise only year year company drug enjoy double digit sale increase include blockbuster enbrel treatment rheumatoid arthritis other immune disorder see sale rise note release wednesday morning rbc capital market analyst michael yee say amgen quarterly revenue beat be partly due boost inventory enbrel expect be reversed usual lead seasonally weaker yee say meanwhile sale amgen neupogen used treat neutropenia associate chemotherapy fall quarter wednesday note leerink analyst howard liang say decline be apparently result competition teva pharmaceutical teva granix celgene be due report result open thursday analyst poll thomson reuter expect company post earning cent share year earlier happen mark celgene biggest earning gain quarters revenue be see climb biogen be slate report fourth quarter earning thursday close cambridge mass base company have push report back day due severe blizzard hit boston area analyst expect biogen log ep gain revenue increase biogen own top ibd composite rating put medical biom biotech group celgene also have composite rating amgen have composite rating
1654,GILD,stock backed early gain be mixed early tuesday investor wrestle jumble economic news
1655,GILD,dow jone industrial average rise add index reach new high nasdaq shed early gain slip
1656,GILD,volume be soft second day tracking nyse nasdaq compare same time monday
1657,GILD,stock market today receive early push commerce department revise gdp estimate much better expect november durable good order be weak federal housing finance agency housing price index tick better expect october
1658,GILD,personal spending jump november labor department say accelerate gain october economist consensus estimate be slightly smaller jump consumer income rise vs gain october forecast be increase
1659,GILD,consumer sentiment hold steady december accord university michigan put final consumer sentiment index read smidge vs november better dip economist expect new home sale fall november annualize rate
1660,GILD,stock gain loss be generally modest drugmaker again pressure be exception merck mrk pfizer pfe johnson johnson jnj post dow only early decline drugmaker hold biggest loss nasdaq
1661,GILD,retailer be show strength lead dd punch heavy trade stock be buy point double bottom base
1662,GILD,leader be moderately positive third ibd move higher start trade
1663,GILD,asbury automotive abg rise drugmaker hold low end list celgene celg drop gilead science gild biogen idec biib amgen amgn fall stock backed early gain be mixed early tuesday investor wrestle jumble economic news dow jone industrial average rise add index reach new high nasdaq shed early gain slip volume be soft second day tracking nyse nasdaq compare same time monday stock market today receive early push commerce department revise gdp estimate much better expect november durable good order be weak federal housing finance agency housing price index tick better expect october personal spending jump november labor department say accelerate gain october economist consensus estimate be slightly smaller jump consumer income rise vs gain october forecast be increase consumer sentiment hold steady december accord university michigan put final consumer sentiment index read smidge vs november better dip economist expect new home sale fall november annualize rate stock gain loss be generally modest drugmaker again pressure be exception merck mrk pfizer pfe johnson johnson jnj post dow only early decline drugmaker hold biggest loss nasdaq retailer be show strength lead dd punch heavy trade stock be buy point double bottom base leader be moderately positive third ibd move higher start trade asbury automotive abg rise drugmaker hold low end list celgene celg drop gilead science gild biogen idec biib amgen amgn fall
1664,GILD,stock market again correct investor be look create stock watch list next uptrend fast grow large capitalization company be good place look today screen day be big cap leader large company top notch fundamental generally market cap higher second sort find top
1665,GILD,stock future hold early gain global market spark optimistically higher caution eurozone official bailout agreement greece be not likely today
1666,GILD,dow future be point fair market value only slightly earlier high nasdaq future be also high still strong point future hung strong point gain small cap be less enthusiastic russell future ahead point
1667,GILD,rundown stock market today begin overseas market monday give sense pressure place global stock eurozone greek financial crisis
1668,GILD,lead index paris frankfurt have jump nearly midday tokyo hong kong gain more apiece shanghai exchange be close day holiday
1669,GILD,greek prime minister alexis tsipra early monday proffer new plan resolve budget problem news report quote finance official say plan first time concede country tightly protected pension arrangement move least crack door hope agreement
1670,GILD,eurozone official exit summit aim work greece related issue announce caution agreement
1671,GILD,support extend weekend european central bank prop greece bank depositor confidence monday stall last week run saving withdrawal athen exchange bank stock lead index
1672,GILD,week steady economic calendar begin exist home sale national association realtor et run university michigan final read june consumer sentiment friday durable good order final read gdp personal income spending way
1673,GILD,stock thwart merger activity weigh early trade
1674,GILD,natural gas process transport giant william co wmb spiked open tulsa okla base firm reject unsolicited bid energy transfer equity ete dalla base master limit partnership stock deal be value william be process re absorb master limit partnership william partner wpz say share bid undervalue company william co share have be correct september william partner share fall premarket trade
1675,GILD,manage care provider cigna ci spiked reject inadequate bid anthem antm value share offer be premium cigna close price friday stock punch new high last week anthem share be fraction higher pre open trade monday
1676,GILD,stock be generally flat higher ibd list biggest gain go vasco datum security vdsi nearly stock end friday buy point cup handle base
1677,GILD,currency market dollar be euro yen commodity be mixed oil gold less stock future hold early gain global market spark optimistically higher caution eurozone official bailout agreement greece be not likely today dow future be point fair market value only slightly earlier high nasdaq future be also high still strong point future hung strong point gain small cap be less enthusiastic russell future ahead point rundown stock market today begin overseas market monday give sense pressure place global stock eurozone greek financial crisis lead index paris frankfurt have jump nearly midday tokyo hong kong gain more apiece shanghai exchange be close day holiday greek prime minister alexis tsipra early monday proffer new plan resolve budget problem news report quote finance official say plan first time concede country tightly protected pension arrangement move least crack door hope agreement eurozone official exit summit aim work greece related issue announce caution agreement support extend weekend european central bank prop greece bank depositor confidence monday stall last week run saving withdrawal athen exchange bank stock lead index week steady economic calendar begin exist home sale national association realtor et run university michigan final read june consumer sentiment friday durable good order final read gdp personal income spending way stock thwart merger activity weigh early trade natural gas process transport giant william co wmb spiked open tulsa okla base firm reject unsolicited bid energy transfer equity ete dalla base master limit partnership stock deal be value william be process re absorb master limit partnership william partner wpz say share bid undervalue company william co share have be correct september william partner share fall premarket trade manage care provider cigna ci spiked reject inadequate bid anthem antm value share offer be premium cigna close price friday stock punch new high last week anthem share be fraction higher pre open trade monday stock be generally flat higher ibd list biggest gain go vasco datum security vdsi nearly stock end friday buy point cup handle base currency market dollar be euro yen commodity be mixed oil gold less
1678,GILD,stock future shift thin early loss mixed trade ahead monday open
1679,GILD,nasdaq future shed loss be narrow point dow future remain point fair market value future be flat
1680,GILD,stock market today get relatively quiet start week heavy economic report pending only moderate load quarterly company report
1681,GILD,food related stock show early motion dean food df jump white wave wwav report third quarter result
1682,GILD,gilead science gild flex ahead open drug giant merck mrk announce sunday not move forward develop drug combination attempt shorten treatment period hepatitis combine treatment used gilead sovaldi also compete exist longer treatment regimen base sovaldi gilead end friday session buy point
1683,GILD,cheetah mobile cmcm spiked premarket trade china base developer mobile security software report earning just revenue well analyst consensus expectation mobile user installation increase more quarter stock end friday september peak ipo price
1684,GILD,gogo gogo flight internet provider commercial airline drop premarket action third quarter revenue best analyst consensus view earning come short illinois base stock be deep month consolidation
1685,GILD,overseas shanghai composite pop news link schedule become active nov hong kong shanghai stock market allow increase day trading outside investor shanghai exchange hong kong hang seng rise tokyo nikkei dip
1686,GILD,europe market show modest gain midday
1687,GILD,dollar dip vs euro yen oil firm barrel natural gas rise cold weather seize northern tier stock future shift thin early loss mixed trade ahead monday open nasdaq future shed loss be narrow point dow future remain point fair market value future be flat stock market today get relatively quiet start week heavy economic report pending only moderate load quarterly company report food related stock show early motion dean food df jump white wave wwav report third quarter result gilead science gild flex ahead open drug giant merck mrk announce sunday not move forward develop drug combination attempt shorten treatment period hepatitis combine treatment used gilead sovaldi also compete exist longer treatment regimen base sovaldi gilead end friday session buy point cheetah mobile cmcm spiked premarket trade china base developer mobile security software report earning just revenue well analyst consensus expectation mobile user installation increase more quarter stock end friday september peak ipo price gogo gogo flight internet provider commercial airline drop premarket action third quarter revenue best analyst consensus view earning come short illinois base stock be deep month consolidation overseas shanghai composite pop news link schedule become active nov hong kong shanghai stock market allow increase day trading outside investor shanghai exchange hong kong hang seng rise tokyo nikkei dip europe market show modest gain midday dollar dip vs euro yen oil firm barrel natural gas rise cold weather seize northern tier
1688,GILD,trained pharmacist joseph papa learn scrutinize science make decision earn bachelor degree pharmacy taught use socratic question dig answer
1689,GILD,pharmaceutical business come be go do product say papa chairman president chief executive perrigo prgo come science feel ask right question force person get root cause issue
1690,GILD,base dublin ireland perrigo be global manufacturer counter pharmaceutical nutritional product store brand market store brand product be sell food drug dollar club store own label
1691,GILD,soon papa arrival perrigo ceo late introduce workforce emphasize driver future success month package concept pillar
1692,GILD,be skepticism first then person say get thing right ll be successful papa recall
1693,GILD,juggle ceo
1694,GILD,papa pillar be quality customer service innovation cost structure person want company employee focus area daily
1695,GILD,reinforce theme often lead staffer ask question such be go do increase quality contribute low cost structure
1696,GILD,papa compare do ceo job juggle ball ball be metal so make lot noise hit ground other be rubber bounce back harmlessly fall glass ball be fragile break drop
1697,GILD,glass one do lot damage say have try differentiate metal one make big noise life go conclude leader rivet everyone attention really important avoid costly mistake
1698,GILD,ensure quality production be particularly crucial company embrace papa call lean sigma continuous improvement process reduce cost improve speed efficiency
1699,GILD,second day person world be take product say tell person next tablet make be consume family friend
1700,GILD,papa view perrigo ideally suit capitalize health care reform say be winner current environment company such gilead science gild make sovaldi treatment hepatitis opposite side perrigo commitment quality affordable health care product
1701,GILD,barbell ll be growth extreme papa say think be even more growth end barbell trained pharmacist joseph papa learn scrutinize science make decision earn bachelor degree pharmacy taught use socratic question dig answer pharmaceutical business come be go do product say papa chairman president chief executive perrigo prgo come science feel ask right question force person get root cause issue base dublin ireland perrigo be global manufacturer counter pharmaceutical nutritional product store brand market store brand product be sell food drug dollar club store own label soon papa arrival perrigo ceo late introduce workforce emphasize driver future success month package concept pillar be skepticism first then person say get thing right ll be successful papa recall juggle ceopapa pillar be quality customer service innovation cost structure person want company employee focus area daily reinforce theme often lead staffer ask question such be go do increase quality contribute low cost structure papa compare do ceo job juggle ball ball be metal so make lot noise hit ground other be rubber bounce back harmlessly fall glass ball be fragile break drop glass one do lot damage say have try differentiate metal one make big noise life go conclude leader rivet everyone attention really important avoid costly mistake ensure quality production be particularly crucial company embrace papa call lean sigma continuous improvement process reduce cost improve speed efficiency second day person world be take product say tell person next tablet make be consume family friend papa view perrigo ideally suit capitalize health care reform say be winner current environment company such gilead science gild make sovaldi treatment hepatitis opposite side perrigo commitment quality affordable health care product barbell ll be growth extreme papa say think be even more growth end barbell
1702,GILD,even market chop back forth spotlight leader be work long weekly winning streak stock close higher multiple week row especially more noteworthy sign steady accumulation big fund be useful trait spot stock be base even have break be move higher stock break early stage base be able climb many week row signal share be big demand have good chance continue even higher future such stock be pra health science prah close higher eighth straight week friday stock be extend buy point have nearly double ipo price pra debut november be world largest contract research organization cro pra offer traditional project base trial service well call embed functional outsource service pra integrate client internal develop operation manage drug development pra operate more office worldwide approximately employee part highly rank medical research equipment industry group inc research holding incr icon iclr be other highly rate contract research organization group stock be work new base pattern other spotlight stock show weekly streak include medical gilead science gild illumina ilmn stock be buy range breaking week lengthy consolidation chip play inphi iphi have also climb straight week inphi share be hold just week tight buy point stock be also profit target buy late april
1703,GILD,major average hold small gain early afternoon trading thursday undeterred news international monetary fund official halter bailout talk greece due lack progress negotiation dow jone industrial average add rise nasdaq gain nyse nasdaq volume track lower wednesday level nyse advance stock outnumber decliner nasdaq be other way decliner have slight edge advancer solar transportation stock outperformed oil gas space driller field service firm lag oil price dip more economic news retail sale datum be generally good weekly jobless claim tick higher yield year treasury note fall basis point stock market today dow component boee ba add delta air line dal say plan buy more delta dip fraction small cap hollysys automation holi gain trading tightly cup handle stock pull back peak trough be bit steep cup handle pattern elsewhere gilead science gild extend gain low volume wednesday share rise just ibd china base noah noah add stock continue trade well find support week move average first time april fast grow retailer restoration hardware rh shed close heavy volume earning report close trading have tighten recent week work base buy point short interest be quite high stock
1704,GILD,ibd be ranking lead stock base key fundamental technical measure include earning sale growth profit margin return equity relative price performance here closer look drug stock make new list friday regeneron pharmaceutical regn valeant pharmaceutical vrx actavis act gilead science gild regeneron have
1705,GILD,key start point find winning stock be look top rate leader top rank industry group best group score multiple ibd smartselect rating rank biotech industry group gilead science gild fit bill california base firm develop therapy hiv aids liver disease oncology hematology other condition
1706,GILD,price war new hepatitis drug heat consensus estimate be too high accord deutsche bank separate note tuesday wednesday analyst robyn karnauskas calculate prospect abbvie abbv viekira pak gilead science gild harvoni sovaldi company announce series exclusive agreement payer pharmacy benefit manager abbv have so far nail life express script esrx national formulary gild have be choose prefer life cvs cvs anthem antm write be assume market share abbv exclusive prefer life see overall share abbv sale add revenue europe drug viekira pak be expect launch year set separate product karnauskas arrived total hcv sale vs consensus however also expect gilead be go low ball consensus due price discount have negotiate compete abbvie worst case expect discount commercial channel be harvoni sovaldi couple government discount harvoni sovaldi calculate overall discount hcv franchise write explain result revenue guidance lower present consensus guidance come lower validate pbms pharmacy benefit manager be telegraph regard discount abbvie be due report guidance jan gilead hasn yet set date report lower estimate karnauskas maintain buy rating stock due pipeline full other promising drug candidate stock didn react much stock market today afternoon trading gilead be abbvie be gilead moved back day move average tuesday abbvie continue slide key level follow amy reeve twitter ibd_areeve related aetna side gilead hepatitis drug battle
1707,GILD,medical giant johnson johnson jnj beat analyst profit estimate tuesday miss topline offer weak guidance send stock more morning trading say earning exclude time item rise year earlier quarter share beating analyst consensus penny accord thomson reuter
1708,GILD,stock remain higher late trade fed stand pat interest rate do not give many hint ll start rise central bank give more positive view labor market
1709,GILD,dow jone industrial average rise climb due weakness biotechs software internet issue nasdaq lag gain volume be again run lower major exchange stock market today
1710,GILD,buffalo wild wing bwld gap bolt post disappointing result late tuesday stock be near buy point long consolidation
1711,GILD,fellow restaurant issue panera bread pnra be session high still nearly stock gap surge much news strong sale current quarter offset weaker expect earning sale panera stage breakaway gap past flat base buy point
1712,GILD,downside vasco datum security international gap day line plunge weak outlook trump better expect quarterly result stock fall lowest level more month
1713,GILD,other security software stock be also have tough day cheetah mobile cmcm fall more cyberark software cybr palo alto network panw lose more apiece
1714,GILD,facebook fb mckesson mck nxp semiconductor nxpi skecher skx whole food market wfm be few notable company report earning close stock remain higher late trade fed stand pat interest rate do not give many hint ll start rise central bank give more positive view labor market dow jone industrial average rise climb due weakness biotechs software internet issue nasdaq lag gain volume be again run lower major exchange stock market today buffalo wild wing bwld gap bolt post disappointing result late tuesday stock be near buy point long consolidation fellow restaurant issue panera bread pnra be session high still nearly stock gap surge much news strong sale current quarter offset weaker expect earning sale panera stage breakaway gap past flat base buy point downside vasco datum security international gap day line plunge weak outlook trump better expect quarterly result stock fall lowest level more month other security software stock be also have tough day cheetah mobile cmcm fall more cyberark software cybr palo alto network panw lose more apiece facebook fb mckesson mck nxp semiconductor nxpi skecher skx whole food market wfm be few notable company report earning close
1715,GILD,sector leader increase even dozen friday ibd so let take quick look different story be tell chart recent home furnishing retailer restoration hardware rh clear handle buy point thursday surge volume share gap entry be still buyable investor extend
1716,GILD,everyone get sick drastic health problem call more drastic treatment partly several top rate biotech stock today ibd list have hold well recent market pressue alexion pharmaceutical alxn fourth stock today screen develop treatment neurological other disorder company have year strong ep sale gain
1717,GILD,stock be filled christmas cheer little more hour remain wednesday shorten session dow jone industrial average be trading time high
1718,GILD,nasdaq lead charge dow jone industrial average gain stock market today not surprisingly volume be light
1719,GILD,best worst industry group swap place day biotechs weak tuesday be best wednesday oil stock strongest prior day be weakest oil price drop again
1720,GILD,fall oil price help airline become top perform group day new issue virgin america va be top stock group be poise clear first stage ipo base
1721,GILD,gilead science gild pummeled earlier week express script esrx announcement exclusively use competitor abbvie abbv hepatitis drug rise more try retake day move average celgene celg rise nearly
1722,GILD,time leader sanchez energy sn fall report first earning decline more year november stock have relative price strength rating meaning be be outperformed stock market
1723,GILD,dow component financial giant visa bank america bac rise stock be filled christmas cheer little more hour remain wednesday shorten session dow jone industrial average be trading time high nasdaq lead charge dow jone industrial average gain stock market today not surprisingly volume be light best worst industry group swap place day biotechs weak tuesday be best wednesday oil stock strongest prior day be weakest oil price drop again fall oil price help airline become top perform group day new issue virgin america va be top stock group be poise clear first stage ipo base gilead science gild pummeled earlier week express script esrx announcement exclusively use competitor abbvie abbv hepatitis drug rise more try retake day move average celgene celg rise nearly time leader sanchez energy sn fall report first earning decline more year november stock have relative price strength rating meaning be be outperformed stock market dow component financial giant visa bank america bac rise
1724,GILD,raise eyebrow lead decline stock price stock move today include salix pharmaceutical slxp embroil drama question accuracy honesty cloud drugmaker weak result be inventory accurate do cfo adam derbyshire resign share plummet stock market today hit lowest level
1725,GILD,stock rally marked fresh close high wednesday lead stock struggle convince election victory republican back control senate certainly give buyer courage yet day action also seem show big market winner fall prey buy rumor sell news phenomenon
1726,GILD,stock open mixed wednesday dow jone industrial average facebook drag nasdaq volume rise nasdaq be higher nyse compare trade same time tuesday
1727,GILD,stock market today set tentative foot forward market await afternoon policy statement federal open market committee investor be also look session busy docket hour earning result set include report baidu bidu kraft food krft metlife meet visa many other
1728,GILD,orbital science orb post morning wild card move company rocket fail explode launch attempt wallop island va injury be report decline set stock back just early august low
1729,GILD,big wallop ibd stock come facebook drop start trade social networking juggernaut report growth sale earning top analyst consensus estimate third quarter company also report higher expect cost revenue guidance be forecast
1730,GILD,slip put stock back day move average flat base buy point
1731,GILD,upside ambarella amba rise lead ibd list maker chip used gopro gpro camera be fight put distance week move average first test support august
1732,GILD,other stock gilead science gild pare loss fraction report third quarter result late tuesday biotech heavyweight report surge earning slightly consensus forecast revenue growth best expectation management full year revenue guidance be consensus view stock have push new high week just buy point stock open mixed wednesday dow jone industrial average facebook drag nasdaq volume rise nasdaq be higher nyse compare trade same time tuesday stock market today set tentative foot forward market await afternoon policy statement federal open market committee investor be also look session busy docket hour earning result set include report baidu bidu kraft food krft metlife meet visa many other orbital science orb post morning wild card move company rocket fail explode launch attempt wallop island va injury be report decline set stock back just early august low big wallop ibd stock come facebook drop start trade social networking juggernaut report growth sale earning top analyst consensus estimate third quarter company also report higher expect cost revenue guidance be forecast slip put stock back day move average flat base buy point upside ambarella amba rise lead ibd list maker chip used gopro gpro camera be fight put distance week move average first test support august other stock gilead science gild pare loss fraction report third quarter result late tuesday biotech heavyweight report surge earning slightly consensus forecast revenue growth best expectation management full year revenue guidance be consensus view stock have push new high week just buy point
1733,GILD,miss stock break base climb buy range wish have buy more don chase soon get chance lead stock sometimes rush buy point go hold pattern few week more week tight pattern second third weekly price close be more away prior week close give investor chance buy small number share buy point be find add cent highest price pattern week tight pattern form stock basis stock clear base buy point heavy volume sign institutional investor be pile push stock higher turnover cool stock form week tight pattern reason sign big fund be hold share maybe even pick smaller holder take profit gilead science gild start shape week tight pattern buy point week end march price change follow week be volume tight phase be average pattern form gilead break flat base buy point adjust split late january heavy volume week end nov then rally ideally pattern form stock have rise buy point most stock correct point form new basis however gilead be still show characteristic true leader market be confirm uptrend stock have rise straight week lead week tight pattern furthermore gilead have composite rating tick best possible put top highly rank biotech industry also smr rating sale profit margin return equity be top notch gilead remove doubt ability rise further jump week tight buy point march hit new high volume be average less month rise week tight entry fresh peak good time take profit gilead then correct form new base investor use week tight pattern add share exist position start new position case buy only small amount share stock clear week tight pattern maybe full size position smaller purchase help minimize risk pattern form stock have already rise limit define buy area base week tight pattern represent pause stock strong uptrend avoid follow pattern form stock typically don move very much such lumbering big cap stock slow move big cap don usually show strong prior uptrend also trade tightly week week
1734,GILD,stock finished mixed friday major index be week slow first day nasdaq fall less dow jone industrial average rise volume run higher nyse lower nasdaq stock market today accord preliminary datum vipshop vip rise deny allegation financial result report investor differ have be report chinese regulator allegation have be make short seller john fichthorn dialectic capital keurig green mountain gmcr fall lowest level february company say keurig kold cold beverage maker win fully roll holiday season cheetah mobile cmcm rise nearly heavy volume fifth straight daily advance touch time high chinese company come public develop internet mobile software application gilead science gild rise less average volume stock have rise straight day have be consolidate gain late october restaurant chain el pollo gap plunge close thursday report result view guidance be weak
1735,GILD,be frustrate environment growth stock investor recent breakout have be mixed bag best most big cap leader be hover just just recent buy point best way handle lackluster market be keep exposure modest more breakout prove show decent gain
1736,GILD,cut loss sell signal start appear keep good portion powder dry stock have be able hold recent entry include abbvie abbv cigna ci analog device adi
1737,GILD,abbvie break cup handle base heavy volume share have trade tight remain buy range past buy point
1738,GILD,giant drugmaker report accelerate earning sale most recent quarter
1739,GILD,manage health care provider cigna be still buy range past flat base buy point clear heavy trade
1740,GILD,analog device be pull back heavy volume share be still buy range many chip stock early gain be danger disappear other hand stock nike nke skywork solution swks cognizant technology solution ctsh carmax kmx have slip recent buy point
1741,GILD,be sell signal so far
1742,GILD,nike be testing support week line buy point latest pattern be part base base stretch back november
1743,GILD,nike be expect report profit growth release fiscal fourth quarter result end sale be expect climb
1744,GILD,carmax break cup handle base friday light trade turn lower monday share remain just buy point
1745,GILD,carmax report fiscal result june market open analyst be look earning climb cent share revenue growth
1746,GILD,be used car dealer fifth straight quarter double digit earning sale growth
1747,GILD,decent initial progress skywork solution have return flat base buy point volume have be mostly light stock pull back be positive sign watch see long time leader find support price week move average
1748,GILD,side regeneron regn be act well low volume base be late stage share have gain much buy point remain extend buy range
1749,GILD,stock still base include salesforce com crm facebook fb gilead gild illumina ilmn be frustrate environment growth stock investor recent breakout have be mixed bag best most big cap leader be hover just just recent buy point best way handle lackluster market be keep exposure modest more breakout prove show decent gain cut loss sell signal start appear keep good portion powder dry stock have be able hold recent entry include abbvie abbv cigna ci analog device adi abbvie break cup handle base heavy volume share have trade tight remain buy range past buy point giant drugmaker report accelerate earning sale most recent quarter manage health care provider cigna be still buy range past flat base buy point clear heavy trade analog device be pull back heavy volume share be still buy range many chip stock early gain be danger disappear other hand stock nike nke skywork solution swks cognizant technology solution ctsh carmax kmx have slip recent buy point be sell signal so far nike be testing support week line buy point latest pattern be part base base stretch back november nike be expect report profit growth release fiscal fourth quarter result end sale be expect climb carmax break cup handle base friday light trade turn lower monday share remain just buy point carmax report fiscal result june market open analyst be look earning climb cent share revenue growth be used car dealer fifth straight quarter double digit earning sale growth decent initial progress skywork solution have return flat base buy point volume have be mostly light stock pull back be positive sign watch see long time leader find support price week move average side regeneron regn be act well low volume base be late stage share have gain much buy point remain extend buy range stock still base include salesforce com crm facebook fb gilead gild illumina ilmn
1750,GILD,special report best mutual fund january performance report bob doll run star team asset management stock mutual fund run rank top diversify stock fund base trail month performance jan accord morningstar inc concentrated core stand gain size
1751,GILD,goldman sachs upgrade eli lilly lly neutral thursday say big pharma have turn corner fall hard patent cliff investment bank downgrade johnson johnson cite increase drug competition believe lly have turn corner improve margin new product launch drive company earning trough
1752,GILD,gilead science gild be well position grow hepatitis drug market vs rival abbvie abbv say analyst upgrading gilead stock rating matthew harrison analyst morgan stanley raise gilead rating overweight equal weight also raise price target gilead stock gilead science stock be more
1753,GILD,boot alliance wba report robust rise sale december strong prescription heavy flu season overall sale climb december vs same month year push share shortly market open tuesday trading stock market today share ease gain late morning
1754,GILD,top perform sector mutual fund category past year health care have come long way catch other leader real estate energy investment health care fund have grow dec year result trail real estate fund
1755,GILD,early gain stock market today nearly evaporate midday monday general lack interest go christmas week
1756,GILD,dow jone industrial average outperformed gain nasdaq add be mostly flat volume be significantly lighter shorten week trading swollen volume friday option expiration
1757,GILD,dow be hold aloft part tech giant intel intc cisco system csco bank america bac be nearly
1758,GILD,ibd stock be higher be lower ambarella amba be best performer worst performer be gilead science gild nearly
1759,GILD,express script esrx largest manager prescription drug benefit say abbvie abbv drug be exclusive option treatment hepatitis instead gilead drug have be gilead growth engine recent quarters
1760,GILD,abbvie abbv be less express script rise
1761,GILD,oil resume plunge barrel go noon hour trading
1762,GILD,energy issue be generally weak exploration production firm chesapeake energy chk crumble early gain stock market today nearly evaporate midday monday general lack interest go christmas week dow jone industrial average outperformed gain nasdaq add be mostly flat volume be significantly lighter shorten week trading swollen volume friday option expiration dow be hold aloft part tech giant intel intc cisco system csco bank america bac be nearly ibd stock be higher be lower ambarella amba be best performer worst performer be gilead science gild nearly express script esrx largest manager prescription drug benefit say abbvie abbv drug be exclusive option treatment hepatitis instead gilead drug have be gilead growth engine recent quarters abbvie abbv be less express script rise oil resume plunge barrel go noon hour trading energy issue be generally weak exploration production firm chesapeake energy chk crumble
1763,GILD,stock rebound moved fresh session high late friday nasdaq add dow jone industrial average inched volume be tracking heavier stock market today boost quadruple witching option future nike nke weigh dow fall company report earning late thursday exxon mobil xom chevron cvx outperformed rise crude oil soar more carmax kmx blast new time high report third quarter result open used car seller earning climb rise revenue top analyst forecast biotechs gilead science gild biogen biib post big gain active trading biogen climb touch new high stock be buy range clear choppy consolidation buy point endurance eigi provider cloud base marketing software climb new high stock have add week average daily trading volume have rise steadily past month more share day stock have composite rating boost third quarter earning jump sale downside toy maker hasbro have mattel mat sell hard analyst note say firm appear be lose market share private competitor mattel fall huge trade be week low hasbro also shed
1764,GILD,stock end mixed back forth session monday continue pattern mildly choppy action weakness energy stock rise new close high bounce back loss intraday tug war index close little change fifth straight session nasdaq trim deficit
1765,GILD,domestic large cap company be feel increasingly optimistic bump stock ride last month softness europe slower growth china japan try regain foot return revenue growth have be key nearly quarters standard poor company report third quarter performance so far company beat revenue estimate
1766,GILD,share gilead science gild hit new high stock market today biotech prepared deliver report close tuesday analyst note couple potential competitor seem be falter
1767,GILD,analyst poll thomson reuter expect company report earning share year earlier quarter sale be estimate just last year third quarter
1768,GILD,massive year year increase be due hepatitis drug sovaldi launch december analyst expect decline sale sequential basis doctor delay treat patient month launch harvoni gilead next generation hcv pill
1769,GILD,sovaldi fading harvoni just launch isn particular number analyst be champ bit see tuesday isi group analyst mark schoenebaum write earning prep pack client conference call question probably revolve harvoni launch dynamic hcv pipeline potential acquisition possible impact close double irish tax loophole effect gilead be still unclear
1770,GILD,also monday rbc capital market analyst michael yee note event bode well gilead longer term competitive position
1771,GILD,be johnson johnson jnj drug simeprevir call olysio sovriad elsewhere require label change japan patient used die earning report management comment firm plan stay competitive hcv even harvoni launch lead minor panic gilead investor fear price war yee write seem even less likely now
1772,GILD,jnj soon get fda label allow use olysio gild sovaldi write don expect much use combo anymore theoretical positive label update gild already have combo replace regimen price olysio make not feasible view
1773,GILD,give idea much price have be cut week round harvoni cost more round sovaldi alone
1774,GILD,yee also write merck mrk be sound less confident own hcv pipeline conference call discuss earning monday morning company confirm report trial week hcv therapy liver meeting next month commentary be less bullish previous conference call suggest datum help bookend various treatment duration be feasible week treatment be not necessarily relevant long regimen general be competitive
1775,GILD,merck earning modestly beat estimate top line come bit light be more late afternoon monday
1776,GILD,follow amy reeve twitter ibd_areeve share gilead science gild hit new high stock market today biotech prepared deliver report close tuesday analyst note couple potential competitor seem be falter analyst poll thomson reuter expect company report earning share year earlier quarter sale be estimate just last year third quarter massive year year increase be due hepatitis drug sovaldi launch december analyst expect decline sale sequential basis doctor delay treat patient month launch harvoni gilead next generation hcv pill sovaldi fading harvoni just launch isn particular number analyst be champ bit see tuesday isi group analyst mark schoenebaum write earning prep pack client conference call question probably revolve harvoni launch dynamic hcv pipeline potential acquisition possible impact close double irish tax loophole effect gilead be still unclear also monday rbc capital market analyst michael yee note event bode well gilead longer term competitive position be johnson johnson jnj drug simeprevir call olysio sovriad elsewhere require label change japan patient used die earning report management comment firm plan stay competitive hcv even harvoni launch lead minor panic gilead investor fear price war yee write seem even less likely now jnj soon get fda label allow use olysio gild sovaldi write don expect much use combo anymore theoretical positive label update gild already have combo replace regimen price olysio make not feasible view give idea much price have be cut week round harvoni cost more round sovaldi alone yee also write merck mrk be sound less confident own hcv pipeline conference call discuss earning monday morning company confirm report trial week hcv therapy liver meeting next month commentary be less bullish previous conference call suggest datum help bookend various treatment duration be feasible week treatment be not necessarily relevant long regimen general be competitive merck earning modestly beat estimate top line come bit light be more late afternoon monday follow amy reeve twitter ibd_areeve
1777,GILD,top stock leaderboard leader list report quarterly earning close tuesday facebook gilead science here breakdown analyst expect
1778,GILD,social network earning be see jump cent share item be slowdown triple digit growth report previous quarters
1779,GILD,analyst project revenue rise video ad launch late last year be expect provide meaningful growth
1780,GILD,earlier month facebook fb complete acquisition whatsapp deal value whatsapp be largest mobile messaging service worldwide global user facebook have monthly active user june
1781,GILD,facebook have ibd composite rating meaning share outperform stock market measure fundamental technical factor share have rise nearly year be flat stock market today head release result
1782,GILD,analyst project gilead science gild earn share last year be third consecutive quarter triple digit earning growth sale be estimate surge just
1783,GILD,massive year year increase sale earning be due large part hepatitis drug sovaldi launch last december harvoni gilead new improve hepatitis pill launch just month
1784,GILD,gilead share hit new high monday buy point analyst note monday rival merck mrk johnson johnson jnj seem be falter
1785,GILD,gilead stock be nearly year facebook gilead have composite rating share be also relatively flat tuesday
1786,GILD,watch video report ibd tv alissa william detail top stock leaderboard leader list report quarterly earning close tuesday facebook gilead science here breakdown analyst expect social network earning be see jump cent share item be slowdown triple digit growth report previous quarters analyst project revenue rise video ad launch late last year be expect provide meaningful growth earlier month facebook fb complete acquisition whatsapp deal value whatsapp be largest mobile messaging service worldwide global user facebook have monthly active user june facebook have ibd composite rating meaning share outperform stock market measure fundamental technical factor share have rise nearly year be flat stock market today head release result analyst project gilead science gild earn share last year be third consecutive quarter triple digit earning growth sale be estimate surge just massive year year increase sale earning be due large part hepatitis drug sovaldi launch last december harvoni gilead new improve hepatitis pill launch just month gilead share hit new high monday buy point analyst note monday rival merck mrk johnson johnson jnj seem be falter gilead stock be nearly year facebook gilead have composite rating share be also relatively flat tuesday watch video report ibd tv alissa william detail
1787,GILD,british pharma giant glaxosmithkline gsk report mediocre issue fairly bullish long term guidance wednesday morning announce keep hiv unit stock rise midday trading
1788,GILD,glaxo earning quarter decline year earlier quarter pound share miss analyst consensus accord thomson reuter term profit drop cent american depositary receipt revenue be line estimate pound increase constant exchange rate dollar drop
1789,GILD,glaxo also offer guidance first time say revenue grow annually low midsingle digit ep increase mid high single digit firm say earning be due dilutive effect massive asset swap novartis nvs glaxo buy novartis vaccine novartis acquire glaxo cancer business
1790,GILD,glaxo also cancele plan spin hiv drug business viiv healthcare ipo say be launch ipo minority stake move be understandable hiv titan gilead science gild acknowledge own conference call be lose market share viiv new drug
1791,GILD,recent launch tivicay triumeq have continue surpass expectation be clear scope develop multiple dolutegravir base regimen treatment hiv next few year glaxo say press release
1792,GILD,nonetheless morningstar analyst damien conover greet new guidance skepticism
1793,GILD,include quarterly result be optimistic long term guidance run ahead expectation revenue growth profit growth conover write research note plan keep lower projection largely base pessimistic outlook glaxo respiratory franchise sale fall year year quarter largely due price decline
1794,GILD,analyst mick cooper edison investment research opined novartis transaction be key test ceo andrew witty take helm have be try reshape company post blockbuster era
1795,GILD,andrew witty desperately need succeed order leave legacy worth remember write email otherwise stewardship such respect renown company risk not be associate anything memorable worthwhile
1796,GILD,follow amy reeve twitter ibd_areeve british pharma giant glaxosmithkline gsk report mediocre issue fairly bullish long term guidance wednesday morning announce keep hiv unit stock rise midday trading glaxo earning quarter decline year earlier quarter pound share miss analyst consensus accord thomson reuter term profit drop cent american depositary receipt revenue be line estimate pound increase constant exchange rate dollar drop glaxo also offer guidance first time say revenue grow annually low midsingle digit ep increase mid high single digit firm say earning be due dilutive effect massive asset swap novartis nvs glaxo buy novartis vaccine novartis acquire glaxo cancer business glaxo also cancele plan spin hiv drug business viiv healthcare ipo say be launch ipo minority stake move be understandable hiv titan gilead science gild acknowledge own conference call be lose market share viiv new drug recent launch tivicay triumeq have continue surpass expectation be clear scope develop multiple dolutegravir base regimen treatment hiv next few year glaxo say press release nonetheless morningstar analyst damien conover greet new guidance skepticism include quarterly result be optimistic long term guidance run ahead expectation revenue growth profit growth conover write research note plan keep lower projection largely base pessimistic outlook glaxo respiratory franchise sale fall year year quarter largely due price decline analyst mick cooper edison investment research opined novartis transaction be key test ceo andrew witty take helm have be try reshape company post blockbuster era andrew witty desperately need succeed order leave legacy worth remember write email otherwise stewardship such respect renown company risk not be associate anything memorable worthwhile follow amy reeve twitter ibd_areeve
1797,GILD,health care stock fund be top perform sector category past year be bruise monday sharp decline biotech medical stock health care fund performance have soar gain runner communication consumer discretionary recent year
1798,GILD,investment march make average health care fund have grow april year accord morningstar inc datum same investment have grow average consumer discretionary fund average communication fund
1799,GILD,proxy broad stock market turn initial amount
1800,GILD,fidelity select biotech portfolio have rise average annual past year vs mutual fund manage rajiv kaul rise last year be so far year
1801,GILD,several biotech stock be fund recent top holding take beating monday gilead science gild have mildest drop slip nearly developer treatment respiratory cardiovascular disease be week high stock have be move sideway october ibd composite rating remain lofty rs rating have slip
1802,GILD,biogen biib tumble friday monday day decline bring stock day move average week high
1803,GILD,celgene celg fall monday meet resistance day line be now week high health care stock fund be top perform sector category past year be bruise monday sharp decline biotech medical stock health care fund performance have soar gain runner communication consumer discretionary recent year investment march make average health care fund have grow april year accord morningstar inc datum same investment have grow average consumer discretionary fund average communication fund proxy broad stock market turn initial amount fidelity select biotech portfolio have rise average annual past year vs mutual fund manage rajiv kaul rise last year be so far year several biotech stock be fund recent top holding take beating monday gilead science gild have mildest drop slip nearly developer treatment respiratory cardiovascular disease be week high stock have be move sideway october ibd composite rating remain lofty rs rating have slip biogen biib tumble friday monday day decline bring stock day move average week high celgene celg fall monday meet resistance day line be now week high
1804,GILD,cvs health cvs monday say select gilead science gild sovaldi harvoni exclusive treatment hepatitis patient use benefit plan latest development become price war hepatitis drugmaker decision take hold wednesday come express script esrx move last month dump gilead drug prefer formulary list genotype hepatitis patient favor abbvie abbv rival drug viekira pak abbvie agree discount drug get list concern hep drug abbvie gilead be too expensive many low income patient harvoni cost week treatment compare viekira pak sovaldi cost week treatment goal be create lowest net cost solution entire population patient genotype hepatitis cvs say accord bloomberg be unclear gilead cvs agree kind discount express script announce decision add abbvie drug prefer list cite concern lack sufficient price competition hepatitis drug space company client have also warn cost specialty drug trend continue increase double digit percentage payer be force implement even more narrow management tool thus limit number patient afford receive drug therapy paula jakub ceo american foreign service protective association say last month only make sense manufacturer work payer pricing decision gilead share tumble dec day express script announcement be stock market today abbvie share fall day line first time october cvs say sovaldi harvoni be exclusive treatment list standard commercial drug well medicaid medicare part health exchange formulary wall street journal report patient get abbvie viekira pak only obtain approval medical exception advance rbc capital market react favorably cvs decision analyst note view positive remove term uncertainty many investor fear cvs also strike deal abbv further put more pressure gild rbc say
1805,GILD,monday bring surprising turn twist story hepatitis treatment pharmacy giant cvs health say offer exclusive coverage gilead science hep drug
1806,GILD,key issue price remain unanswered deal seem counterattack cut week pharmacy benefit manager express script esrx abbvie abbv day fda abbvie drug viekira pak genotype hepatitis virus hcv express script say start cover only viekira pak genotype patient already start course drug firm be tight lip detail cvs cvs deal appear mirror express script start wednesday cvs also operate pharmacy benefit manager cover gilead gild sovaldi harvoni exclusively cvs caremark standard commercial exchange marketplace medicare part medicaid formulary viekira pak be cover only patient get exception prior approval didn say be much cvs pay drug price be big motive express script deal have objected cost new hepatitis drug ever sovaldi launch december week round therapy harvoni most patient eliminate need companion drug launch october week however wasn much anyone do long be competitor equal quality market viekira pak be approve dec price war seem have be avert treatment price modest discount harvoni week most analyst thought account fact more complicate take pill day harvoni equally effective price subject hagglingas evercore isi analyst mark schoenebaum have observed official list price drug be lot sticker price car just start point haggle abbvie acknowledge express get viekira pak discount decline reveal much analyst think have be gilead stock fall more day express disclose deal analyst cut rating lower target monday news help gilead stock rally abbvie fall gilead be not biotech start maxim group analyst jason kolbert say monday be savvy marketing drive company understand launch manage product life cycle don underestimate gilead ability manage competitive environment own research note monday rbc capital market analyst michael yee point most street have already assume gilead price cut once viekira pak come already have steep gross net move follow few quarters yee write so not think average price cvs be go be drastically different discount
1807,GILD,euphoria third quarter gdp growth evaporate tuesday morning leave stock trading mixed midday nasdaq lead other index best level
1808,GILD,nasdaq be rise dow jone industrial average gain volume be trend lower exchange
1809,GILD,befit holiday spirit best perform industry group be leisure toy department store worst perform group be health care field biotech stock show biggest loss morning
1810,GILD,department store operator dd trouble jcpenney jcp rise macy gain mattel mat hasbro have rise stock market today
1811,GILD,biotechs have be lead bull market show age tuesday morning celgene celg shed be try find support day move average recent biogen biib fizzle share lose
1812,GILD,gilead science gild fall punch day move average week monday pharmacy benefit manager express script esrx picked abbvie abbv hepatitis drug gilead sovaldi
1813,GILD,alexion pharmaceutical alxn fall also fall day line
1814,GILD,ibd stock be be worst performer be biotech pharmacyclic pcyc fall day line buy point cup base euphoria third quarter gdp growth evaporate tuesday morning leave stock trading mixed midday nasdaq lead other index best level nasdaq be rise dow jone industrial average gain volume be trend lower exchange befit holiday spirit best perform industry group be leisure toy department store worst perform group be health care field biotech stock show biggest loss morning department store operator dd trouble jcpenney jcp rise macy gain mattel mat hasbro have rise stock market today biotechs have be lead bull market show age tuesday morning celgene celg shed be try find support day move average recent biogen biib fizzle share lose gilead science gild fall punch day move average week monday pharmacy benefit manager express script esrx picked abbvie abbv hepatitis drug gilead sovaldi alexion pharmaceutical alxn fall also fall day line ibd stock be be worst performer be biotech pharmacyclic pcyc fall day line buy point cup base
1815,GILD,fall oil price decline energy sector be expect have drag corporate earning fourth quarter overall picture company remain strong
1816,GILD,difference be remarkable company average solid profit growth exclude energy firm profit probably rise brisk
1817,GILD,brent crude oil price fall fast now barrel half summer energy sector be forecast post poor fourth quarter number estimate decline earning drop revenue expect analyst poll thomson reuter staggering decline earning growth analyst have predict oct
1818,GILD,result overall earning estimate growth be weakest third quarter revenue be expect have grow measly overall vs exclude energy stock
1819,GILD,picture improve
1820,GILD,trend look similar picture improve analyst expect earning grow revenue growth exclude energy growth be profit improvement revenue hike
1821,GILD,energy company be expect post decline earning drop revenue
1822,GILD,year end earning report season move high gear big bank other disclose datum week
1823,GILD,really picture outside energy be still pretty solid say gregory harrison senior research analyst thomson reuter growth be really much better appear first
1824,GILD,power biotech health care company be lead industry earning revenue grow analyst estimate
1825,GILD,hottest leader gilead gild be expect report profit sale amgen amgn apparently perform closer biotech norm profit estimate have rise sale
1826,GILD,telecom follow leader
1827,GILD,telecom profit come next expect have rise follow utility industrial technology
1828,GILD,second largest market value telecom be expect lag sector profit sale rise report
1829,GILD,industrial include transportation aerospace defense contractor expect report earning growth better revenue group southwest airline luv be leader earning expect grow boee ba lockheed martin lmt be forecast grow earning respectively
1830,GILD,make tech look good
1831,GILD,tech sector earning growth look good not spectacular facebook fb alone be estimate have grow ep revenue
1832,GILD,next consumer discretionary sector be expect post earning growth better revenue cheaper gasoline mean more money consumer spend elsewhere company mostly serve consumer drive economy
1833,GILD,consumer discretionary play lowe low be expect post earning growth analyst estimate homebuilder lennar len have earn more royal caribbean cruise rcl be expect have earn more year earlier
1834,GILD,financial powerhouse growth most recent year big bank such jpmorgan chase jpm lead way appear have flattened forecast growth earning gain revenue
1835,GILD,yet winner cheaper oil be winner be difficult call loser re still profitable just less so exxonmobil xom be expect post profit decline analyst anticipate earning decline chevron cvx conocophillip cop
1836,GILD,consumer staple be expect have generate profit growth
1837,GILD,only energy profit be expect have fall harder material sector
1838,GILD,material be forecast oct post earning growth be now expect have shrunken profit drop revenue fertilizer agricultural chemical maker report jan reduce ep revenue fall year earlier
1839,GILD,economy be be propel low interest rate lower unemployment higher business consumer confidence stock record high rest world seem bit dicey europe have fall deflation flirt recession russia wilt fall oil price western sanction greece again exit eurozone china isn grow much government japan brazil endure recession
1840,GILD,investor look company quarterly conference call see business see improvement say sheraz mian director research zack investment research
1841,GILD,stronger dollar affect company overseas exposure large cap company very expose international market corporate management team have become increasingly negative guidance negative pre announcement positive historical average be ratio be yet most company pessimism seem unfounded significant majority beat expectation be forward look statement design impress shareholder later
1842,GILD,management team don get reward meeting expectation mian say get reward pretty handsomely beating fall oil price decline energy sector be expect have drag corporate earning fourth quarter overall picture company remain strong difference be remarkable company average solid profit growth exclude energy firm profit probably rise brisk brent crude oil price fall fast now barrel half summer energy sector be forecast post poor fourth quarter number estimate decline earning drop revenue expect analyst poll thomson reuter staggering decline earning growth analyst have predict oct result overall earning estimate growth be weakest third quarter revenue be expect have grow measly overall vs exclude energy stock picture improve trend look similar picture improve analyst expect earning grow revenue growth exclude energy growth be profit improvement revenue hike energy company be expect post decline earning drop revenue year end earning report season move high gear big bank other disclose datum week really picture outside energy be still pretty solid say gregory harrison senior research analyst thomson reuter growth be really much better appear first power biotech health care company be lead industry earning revenue grow analyst estimate hottest leader gilead gild be expect report profit sale amgen amgn apparently perform closer biotech norm profit estimate have rise sale telecom follow leadertelecom profit come next expect have rise follow utility industrial technology second largest market value telecom be expect lag sector profit sale rise report industrial include transportation aerospace defense contractor expect report earning growth better revenue group southwest airline luv be leader earning expect grow boee ba lockheed martin lmt be forecast grow earning respectively make tech look tech sector earning growth look good not spectacular facebook fb alone be estimate have grow ep revenue next consumer discretionary sector be expect post earning growth better revenue cheaper gasoline mean more money consumer spend elsewhere company mostly serve consumer drive economy consumer discretionary play lowe low be expect post earning growth analyst estimate homebuilder lennar len have earn more royal caribbean cruise rcl be expect have earn more year earlier financial powerhouse growth most recent year big bank such jpmorgan chase jpm lead way appear have flattened forecast growth earning gain revenue yet winner cheaper oil be winner be difficult call loser re still profitable just less so exxonmobil xom be expect post profit decline analyst anticipate earning decline chevron cvx conocophillip cop consumer staple be expect have generate profit growth only energy profit be expect have fall harder material sector material be forecast oct post earning growth be now expect have shrunken profit drop revenue fertilizer agricultural chemical maker report jan reduce ep revenue fall year earlier economy be be propel low interest rate lower unemployment higher business consumer confidence stock record high rest world seem bit dicey europe have fall deflation flirt recession russia wilt fall oil price western sanction greece again exit eurozone china isn grow much government japan brazil endure recession investor look company quarterly conference call see business see improvement say sheraz mian director research zack investment research stronger dollar affect company overseas exposure large cap company very expose international market corporate management team have become increasingly negative guidance negative pre announcement positive historical average be ratio be yet most company pessimism seem unfounded significant majority beat expectation be forward look statement design impress shareholder later management team don get reward meeting expectation mian say get reward pretty handsomely beating
1843,GILD,stock pare gain midday wednesday mixed economic datum europe
1844,GILD,nasdaq be pare earlier gain dow jone industrial average rise volume be tracking tuesday level nasdaq lower nyse
1845,GILD,european stock rise healthy eurozone gdp growth number suggest european central bank quantitative ease program be have positive effect however retail sale be flat april sale auto gas rise just trail wall street forecast
1846,GILD,stock market today cal maine food calm continue spike higher bird flu spread nebraska state affected deadly avian virus have force rancher million hen stock be new high share be week be extend well past buy point cup handle base
1847,GILD,vipshop holding vip chinese online discount retailer jump deny allegation manipulate financial datum stock erased much tuesday loss follow claim short seller mithra forensic research report seek alpha
1848,GILD,downside resm rmd make equipment treat sleep disorder plunge massive turnover report disappointing result therapy severe sleep apnea chronic heart failure stock slice day move average undercut prior base stock pare gain midday wednesday mixed economic datum europe nasdaq be pare earlier gain dow jone industrial average rise volume be tracking tuesday level nasdaq lower nyse european stock rise healthy eurozone gdp growth number suggest european central bank quantitative ease program be have positive effect however retail sale be flat april sale auto gas rise just trail wall street forecast stock market today cal maine food calm continue spike higher bird flu spread nebraska state affected deadly avian virus have force rancher million hen stock be new high share be week be extend well past buy point cup handle base vipshop holding vip chinese online discount retailer jump deny allegation manipulate financial datum stock erased much tuesday loss follow claim short seller mithra forensic research report seek alpha downside resm rmd make equipment treat sleep disorder plunge massive turnover report disappointing result therapy severe sleep apnea chronic heart failure stock slice day move average undercut prior base
1849,GILD,biotech company enanta pharmaceutical have be year fiscal year enter now be surely most important life dec food drug administration be expect approve abbvie abbv viekirax hepatitis treatment combine enanta enta drug paritaprevir abbvie develop drug enanta partnership
1850,GILD,big pharma abbvie beat analyst estimate raise guidance friday send stock time high abbvie abbv earning rise year earlier quarter cent share cent analyst consensus accord thomson reuter sale increase just beating estimate nearly
1851,GILD,do sometimes condition don go accord plan rain other bad weather plan weekend picnic stop go cross country bike ride slim investing method key thing ibd always stress be invest stock have big volume breaking basis heavy volume be ideal situation doesn always come just excellent stock take buy point well construct base exception occurwhile lot fundamental technical market factor be place buy stock rare single aspect be perfect stock prove be good definitely want see far more positive fail factor regard volume daily turnover be least average stock clear buy point base ibd compute stock average past trading session datum table volume percentage change figure reflect change prior day volume vs day average big turnover signal professional such mutual fund hedge fund be buy share so critical point such big volume spike healthy price gain be best evidence big turnover higher volume bigger conviction move sometimes trade rise only slightly not quite more average other time volume be well typical level not automatic game not sell signal heavy volume come few day later validate happen stock take base buy point earning report other case overall market volume be light affect level turnover emerge market leader stock have solid leadership quality such high top bottom line growth show increase accumulation stage low volume want give more leeway strong volume be best evidence institutional buy price be final arbiter remember always cut loss stock fall buy point be key occur overwhelming underwhelm turnover market leader gilead science gild stage weak turnover late june have go post nice gain june biotech pass buy point cup handle base trade end average day stock close cent be uninspire volume have be slow ahead july holiday first quarter gilead profit jump biggest jump year rise revenue stock rise july trade be only modestly average july big volume didn come july time stock have already climb past trigger gilead hit profit take zone aug
1852,GILD,stock remain mixed monday afternoon broader index continue be little change blue chip show life dow jone industrial average rise help gain pfizer pfe apple aapl exxon mobil xom meanwhile edge nasdaq slip volume be run sharply lower nasdaq nyse friday expiration fuel heavy pace sonic sonc ramp new high clear buy point rare ascend base company run drive thru fast food restaurant report fiscal earning tuesday close expect post cent share year red robin gourmet burger rrgb bounce back early weakness rise new high share restaurant operator have be tear come low october rise more stock have yet form proper base february red robin report rise fiscal sale mark biggest gain year well second straight period acceleration technology avgo cool new high trimming gain more half earlier stock market today citigroup raise price target stock be still well extend buy point week tight pattern rebound week move average downside vertex pharmaceutical vrtx be session low still disappointing trial study share be nearly monday low
1853,GILD,week bring first quarter earning report top rate large cap drug stock be expect report strong growth tuesday open unite therapeutic uthr be expect report revenue year earlier quarter accord thomson reuter earning be expect climb share give
1854,GILD,tech titan google googl make headline quarterly earning close thursday google growth be sluggish stock be lackluster check stock better performance search giant include drugmaker abbvie abbv coffee giant starbucks sbux
1855,GILD,alexion abbvie drug earning
1856,GILD,alexion pharmaceutical alxn be project see earning decline share report first quarter result open blip rather trend earning rise prior quarters rise more follow quarters
1857,GILD,revenue be estimate rise
1858,GILD,biotech have ibd composite rating only product currently shelve be rare disease drug soliris have see blockbuster success analyst estimate company alfa drug launch first half year alexion provide update
1859,GILD,alexion share rise stock market today stock be work price consolidation buy point
1860,GILD,abbvie abbv also release result open ethical drugmaker be expect increase earning cent share faster growth
1861,GILD,wall street have calculate rise revenue
1862,GILD,earlier month galapago belgian biotech partner abbvie report positive midstage datum rheumatoid arthritis drug filgotinib add standard treatment methotrexate abbvie have best selling treatment condition injectable drug humira
1863,GILD,be first full quarter sale hepatitis treatment viekira pak successful be abbvie grab market share first market gilead science gild sovaldi harvoni abbvie gilead science have make price discount top pharmacy benefit manager
1864,GILD,analyst also be interested abbvie plan deal pharmacyclic pcyc maker blockbuster blood cancer drug imbruvica many wall street think abbvie be pay steep price
1865,GILD,abbvie share rise wednesday work right side cup base buy point drugmaker have ibd composite rating
1866,GILD,alaska southwest airline earning takeoff
1867,GILD,alaska air alk be expect report jump earning share report thursday morning mark second quarter faster growth revenue be see rise more modest
1868,GILD,domestic regional airline be benefit lower fuel price strong pricing power improve demand travel
1869,GILD,alaska share fall wednesday be work flat base buy point alaska have composite rating
1870,GILD,southwest airline luv have composite rating be set report result thursday morning earning be expect surge cent share huge acceleration last quarter growth revenue be see increase
1871,GILD,earlier month dalla base airline only have international flight mexico caribbean report jump march traffic increase capacity
1872,GILD,southwest share be build flat base buy point southwest stock fall wednesday
1873,GILD,starbucks sale growth perk
1874,GILD,starbucks report fiscal result close wall street expect earning grow cent share year year growth revenue be see rise mark starbucks fastest sale growth several year
1875,GILD,coffee giant have be forefront restaurant tech loyalty card mobile app starbucks say have active user company be also testing mobile order pay function delivery program
1876,GILD,starbucks have composite rating fall cent wednesday stock extend past flat base buy point initially clear late january investor buy stock buy range take profit gain
1877,GILD,other big name company release quarterly earning thursday include amazon com amzn microsoft msft altrium mo general motor gm procter gamble pg dow chemical dow
1878,GILD,follow alissa william twitter ibd_awilliam tech titan google googl make headline quarterly earning close thursday google growth be sluggish stock be lackluster check stock better performance search giant include drugmaker abbvie abbv coffee giant starbucks sbux alexion abbvie drug earningsalexion pharmaceutical alxn be project see earning decline share report first quarter result open blip rather trend earning rise prior quarters rise more follow quarters revenue be estimate rise biotech have ibd composite rating only product currently shelve be rare disease drug soliris have see blockbuster success analyst estimate company alfa drug launch first half year alexion provide update alexion share rise stock market today stock be work price consolidation buy point abbvie abbv also release result open ethical drugmaker be expect increase earning cent share faster growth wall street have calculate rise revenue earlier month galapago belgian biotech partner abbvie report positive midstage datum rheumatoid arthritis drug filgotinib add standard treatment methotrexate abbvie have best selling treatment condition injectable drug humira be first full quarter sale hepatitis treatment viekira pak successful be abbvie grab market share first market gilead science gild sovaldi harvoni abbvie gilead science have make price discount top pharmacy benefit manager analyst also be interested abbvie plan deal pharmacyclic pcyc maker blockbuster blood cancer drug imbruvica many wall street think abbvie be pay steep price abbvie share rise wednesday work right side cup base buy point drugmaker have ibd composite rating alaska southwest airline earning takeoffalaska air alk be expect report jump earning share report thursday morning mark second quarter faster growth revenue be see rise more modest domestic regional airline be benefit lower fuel price strong pricing power improve demand travel alaska share fall wednesday be work flat base buy point alaska have composite rating southwest airline luv have composite rating be set report result thursday morning earning be expect surge cent share huge acceleration last quarter growth revenue be see increase earlier month dalla base airline only have international flight mexico caribbean report jump march traffic increase capacity southwest share be build flat base buy point southwest stock fall wednesday starbucks sale growth perk upstarbuck report fiscal result close wall street expect earning grow cent share year year growth revenue be see rise mark starbucks fastest sale growth several year coffee giant have be forefront restaurant tech loyalty card mobile app starbucks say have active user company be also testing mobile order pay function delivery program starbucks have composite rating fall cent wednesday stock extend past flat base buy point initially clear late january investor buy stock buy range take profit gain other big name company release quarterly earning thursday include amazon com amzn microsoft msft altrium mo general motor gm procter gamble pg dow chemical dow follow alissa william twitter ibd_awilliam
1879,GILD,etf investment strategy tip buy best etfs etf trading offer way buck conventional wisdom investing stock other financial market conventional wisdom say time stock market remain fully invest bull bear market ll prosper long run work
1880,GILD,stock be session lows early afternoon trading oil price fall hard again
1881,GILD,nasdaq lose fall dow jone industrial average give also
1882,GILD,nasdaq nyse volume be tracking slightly higher friday level crude oil sell again fall barrel
1883,GILD,stock market today dow component mcdonald mcd fall nearly soft november global same store sale burger giant sale fall more expect domestic sale slump
1884,GILD,ibd biotech industry group be once again day top performer rise nearly top rate name group celgene celg regeneron regn gilead science gild unite therapeutic uthr be do well
1885,GILD,meanwhile cubist pharmaceutical cbst soar news be acquire merck mrk
1886,GILD,gopro gpro slump be clear news account downdraft stock have be act weak not abnormal action big run past ipo base buy point ambarella amba chip be find gopro wearable camera also give heel strong earning report last week
1887,GILD,meanwhile couple high profile ipos be set week lendingclub alibaba backed momo debut thursday symbol lc momo respectively stock be session lows early afternoon trading oil price fall hard again nasdaq lose fall dow jone industrial average give also nasdaq nyse volume be tracking slightly higher friday level crude oil sell again fall barrel stock market today dow component mcdonald mcd fall nearly soft november global same store sale burger giant sale fall more expect domestic sale slump ibd biotech industry group be once again day top performer rise nearly top rate name group celgene celg regeneron regn gilead science gild unite therapeutic uthr be do well meanwhile cubist pharmaceutical cbst soar news be acquire merck mrk gopro gpro slump be clear news account downdraft stock have be act weak not abnormal action big run past ipo base buy point ambarella amba chip be find gopro wearable camera also give heel strong earning report last week meanwhile couple high profile ipos be set week lendingclub alibaba backed momo debut thursday symbol lc momo respectively
1888,GILD,top management wall street highflier gilead science be face challenge confront many company have flourished face criticism need give back global community more direct way
1889,GILD,fundamental question boil company do well do good sake world still do well demand stockholder
1890,GILD,major issue gilead science stock have climb so far year wing highly successful drug sovaldi combat hepatitis drug carry enormous price tag pill week regimen typically cost
1891,GILD,foster city calif base biotech giant gilead science gild be wall street darling consistently stellar earning report sovaldi be foundation company
1892,GILD,gilead recently make headline announce completion deal many generic drug maker manufacture cheaper version sovaldi distribution develop nation
1893,GILD,agreement be essential advance goal humanitarian program country gilead executive vice president gregg alton say company press release
1894,GILD,investor quandary
1895,GILD,gilead cut price drug humanitarian purpose shareholder high hope feel sulk company stock decline due lower sale be dilemma wall street develop world be watch closely
1896,GILD,stock analyst suggest investor be press panic button unnecessarily
1897,GILD,company have lot experience pricing different country afford world karen anderson follow gilead morningstar chicago tell ibd
1898,GILD,regulator give sovaldi thumb last december physician almost immediately applaud once day pill requirement powerful record result cure ailing patient
1899,GILD,sovaldi success be critical fortune gilead shareholder drug be expect produce several dollar sale year company
1900,GILD,confront high price drug gilead defend say sovaldi cost public be recoup long period time fewer patient be suffering liver failure well complication result transplant company have also stress present financial aid patient afford pay price drug add insurance expense gilead assurance congress have have issue pricing drug
1901,GILD,sovaldi carry such high price user typical kind cost associate such drug also have such strong record performance ailing individual afford hefty price tag pay gladly get cure analyst say
1902,GILD,perhaps try publicly right situation gilead say company base india make generic version sovaldi also know sofosbuvir addition experimental drug slate distribution develop nation
1903,GILD,gilead didn offer detail price arrangement generic version sovaldi be market develop world matter serious debate gilead be also act defensive mode perhaps management believe take kind constructive stance government step dictate term be recognize take initiative sensitive drug pricing issue
1904,GILD,biotech company note country cover agreement account more person live hepatitis figure cover more half entire infected population disease
1905,GILD,gilead manager have have task complicate volatile condition currently embed stock market spur investor even focus be strong performer gilead question company decision
1906,GILD,skittish market
1907,GILD,importance gilead humanitarian move many applaud face value have potential save life world be obscure timing come world be brace global threat islamic state militant seemingly endless fight middle east stock market be skittish such upheaval
1908,GILD,nervous market investor be look just reason get even more nervous even company have be successful have michael holland principal holland co money management firm new york tell ibd company earning revenue fall market be less forgive be already little nervous world
1909,GILD,general scrutiny surround gilead biotech sector prompt add concern
1910,GILD,stock market psychology be not only inherent challenge face gilead senior manager also cost do business closely watch regulatory environment
1911,GILD,business consultant stress gilead shouldn let critic investor force reverse already successful course sam hill co author radical marketing harvard harley lesson break rule make big offer simple compelling line strategy
1912,GILD,develop plan market execute relentlessly hill tell ibd top management wall street highflier gilead science be face challenge confront many company have flourished face criticism need give back global community more direct way fundamental question boil company do well do good sake world still do well demand stockholder major issue gilead science stock have climb so far year wing highly successful drug sovaldi combat hepatitis drug carry enormous price tag pill week regimen typically cost foster city calif base biotech giant gilead science gild be wall street darling consistently stellar earning report sovaldi be foundation company gilead recently make headline announce completion deal many generic drug maker manufacture cheaper version sovaldi distribution develop nation agreement be essential advance goal humanitarian program country gilead executive vice president gregg alton say company press release investor quandaryif gilead cut price drug humanitarian purpose shareholder high hope feel sulk company stock decline due lower sale be dilemma wall street develop world be watch closely stock analyst suggest investor be press panic button unnecessarily company have lot experience pricing different country afford world karen anderson follow gilead morningstar chicago tell ibd regulator give sovaldi thumb last december physician almost immediately applaud once day pill requirement powerful record result cure ailing patient sovaldi success be critical fortune gilead shareholder drug be expect produce several dollar sale year company confront high price drug gilead defend say sovaldi cost public be recoup long period time fewer patient be suffering liver failure well complication result transplant company have also stress present financial aid patient afford pay price drug add insurance expense gilead assurance congress have have issue pricing drug sovaldi carry such high price user typical kind cost associate such drug also have such strong record performance ailing individual afford hefty price tag pay gladly get cure analyst say perhaps try publicly right situation gilead say company base india make generic version sovaldi also know sofosbuvir addition experimental drug slate distribution develop nation gilead didn offer detail price arrangement generic version sovaldi be market develop world matter serious debate gilead be also act defensive mode perhaps management believe take kind constructive stance government step dictate term be recognize take initiative sensitive drug pricing issue biotech company note country cover agreement account more person live hepatitis figure cover more half entire infected population disease gilead manager have have task complicate volatile condition currently embed stock market spur investor even focus be strong performer gilead question company decision skittish marketthe importance gilead humanitarian move many applaud face value have potential save life world be obscure timing come world be brace global threat islamic state militant seemingly endless fight middle east stock market be skittish such upheaval nervous market investor be look just reason get even more nervous even company have be successful have michael holland principal holland co money management firm new york tell ibd company earning revenue fall market be less forgive be already little nervous world general scrutiny surround gilead biotech sector prompt add concern stock market psychology be not only inherent challenge face gilead senior manager also cost do business closely watch regulatory environment business consultant stress gilead shouldn let critic investor force reverse already successful course sam hill co author radical marketing harvard harley lesson break rule make big offer simple compelling line strategy develop plan market execute relentlessly hill tell ibd
1913,GILD,big cap biotech ibd stock gilead science gild report good late stage trial datum new hiv drug wednesday analyst nickname drug son viread expect be blockbuster stock be afternoon trading stock market today
1914,GILD,trial compare standard combination drug be combine gilead gild most advanced market product stribild component sell individually viread be replace tenofovir alafenamide taf taf combo prove just good keep hiv level stribild yielding fewer problematic reduction bone density kidney function see stribild user
1915,GILD,individual hiv be live longer be need treatment be not only highly effective also offer improve safety profile gilead chief scientific officer norber bischofberger say statement
1916,GILD,company plan file drug approval eu next quarter
1917,GILD,taf program hasn be get much public attention gilead groundbreaking hepatitis drug analyst say key company long term fortune hep drug cure nearly patient take eventually shrink market drug also face more competition soon meanwhile gilead current mainstay hiv drug start lose patent few year
1918,GILD,gilead new drug be positive help increase confidence long term hiv revenue tail be highly confident franchise be more sustainable expect most develop nation win be switch patient drug splitting pill use inferior older regimen write rbc capital market analyst michael yee research note wednesday
1919,GILD,yee say datum be better expect counterpart isi group mark schoenebaum write be expect give phase datum add more key news be come
1920,GILD,other important phase study ongoing include switch study multiple hiv regimen study patient baseline kidney renal impairment write email client wednesday renal impairment study be probably most important phase study taf help taf distinguish viread however give commercial focus be kidney benefit taf viread
1921,GILD,gilead be expect report result study month
1922,GILD,current consensus have annual sale taf reach
1923,GILD,follow amy reeve twitter ibd_areeve big cap biotech ibd stock gilead science gild report good late stage trial datum new hiv drug wednesday analyst nickname drug son viread expect be blockbuster stock be afternoon trading stock market today trial compare standard combination drug be combine gilead gild most advanced market product stribild component sell individually viread be replace tenofovir alafenamide taf taf combo prove just good keep hiv level stribild yielding fewer problematic reduction bone density kidney function see stribild user individual hiv be live longer be need treatment be not only highly effective also offer improve safety profile gilead chief scientific officer norber bischofberger say statement company plan file drug approval eu next quarter taf program hasn be get much public attention gilead groundbreaking hepatitis drug analyst say key company long term fortune hep drug cure nearly patient take eventually shrink market drug also face more competition soon meanwhile gilead current mainstay hiv drug start lose patent few year gilead new drug be positive help increase confidence long term hiv revenue tail be highly confident franchise be more sustainable expect most develop nation win be switch patient drug splitting pill use inferior older regimen write rbc capital market analyst michael yee research note wednesday yee say datum be better expect counterpart isi group mark schoenebaum write be expect give phase datum add more key news be come other important phase study ongoing include switch study multiple hiv regimen study patient baseline kidney renal impairment write email client wednesday renal impairment study be probably most important phase study taf help taf distinguish viread however give commercial focus be kidney benefit taf viread gilead be expect report result study month current consensus have annual sale taf reach follow amy reeve twitter ibd_areeve
1924,GILD,european union medical advisory committee endorse approve key product major drugmaker friday expect be blockbuster
1925,GILD,abbvie abbv get thumb oral hepatitis combo now have brand name committee medical product human use go french acronym chmp endorse viekirax exviera genotype hepatitis virus generic drug ribavirin chmp also endorse combo ribavirin genotype patient
1926,GILD,viekirax be combination drug include enanta pharmaceutical enta protease inhibitor paritaprevir exviera be nonnucleoside polymerase inhibitor dasabuvir
1927,GILD,abbvie say expect european commission make final decision first quarter next year start negotiating price country country
1928,GILD,pricing environment be tough france announce thursday have negotiate lowest price europe gilead science gild sovaldi almost price week course much speculation have abound abbvie price combo expect fda approval next month
1929,GILD,analyst expect abbvie take minority share market gilead dominate still amount several dollar year
1930,GILD,abbvie be midday trading stock market today new high
1931,GILD,chmp also backed celgene celg first immunology drug otezla treat psoriasis psoriatic arthritis news come day celgene present datum psoriatic arthritis patient be otezla year third show least improvement symptom accord standard arthritis score system
1932,GILD,otezla be approve psoriatic arthritis march psoriasis september celgene have guide peak annual sale least analyst have be skeptical
1933,GILD,celgene stock be midday trading friday
1934,GILD,sanofi sny drug cerdelga be also endorse gaucher disease rare genetic disorder cause buildup fat organ sanofi already sell injectable cerezyme disease cerdelga bring oral option
1935,GILD,leerink analyst seamus fernandez model slow liftoff drug expect annual sale
1936,GILD,sanofi stock be more midday friday
1937,GILD,follow amy reeve twitter ibd_areeve
1938,GILD,related sanofi bullish pipeline forecast underwhelm european union medical advisory committee endorse approve key product major drugmaker friday expect be blockbuster abbvie abbv get thumb oral hepatitis combo now have brand name committee medical product human use go french acronym chmp endorse viekirax exviera genotype hepatitis virus generic drug ribavirin chmp also endorse combo ribavirin genotype patient viekirax be combination drug include enanta pharmaceutical enta protease inhibitor paritaprevir exviera be nonnucleoside polymerase inhibitor dasabuvir abbvie say expect european commission make final decision first quarter next year start negotiating price country country pricing environment be tough france announce thursday have negotiate lowest price europe gilead science gild sovaldi almost price week course much speculation have abound abbvie price combo expect fda approval next month analyst expect abbvie take minority share market gilead dominate still amount several dollar year abbvie be midday trading stock market today new high chmp also backed celgene celg first immunology drug otezla treat psoriasis psoriatic arthritis news come day celgene present datum psoriatic arthritis patient be otezla year third show least improvement symptom accord standard arthritis score system otezla be approve psoriatic arthritis march psoriasis september celgene have guide peak annual sale least analyst have be skeptical celgene stock be midday trading friday sanofi sny drug cerdelga be also endorse gaucher disease rare genetic disorder cause buildup fat organ sanofi already sell injectable cerezyme disease cerdelga bring oral option leerink analyst seamus fernandez model slow liftoff drug expect annual sale sanofi stock be more midday friday follow amy reeve twitter ibd_areeve related sanofi bullish pipeline forecast underwhelm street
1939,GILD,health care etfs be top performer year look most heavily trade group reveal slight difference affect performance health care select sector spdr arca xlv have broad coverage include health care equipment supply health care provider service biotechnology pharmaceutical industry fund draw holding
1940,GILD,health care etfs be top performer year look most heavily trade group reveal slight difference affect performance health care select sector spdr arca xlv have broad coverage include health care equipment supply health care provider service biotechnology pharmaceutical industry fund draw holding
1941,GILD,major average end week solid foot friday extend gain nasdaq confirm new uptrend oct health care name dominate new high list again common theme recent day edward lifescience ew gap time high rise strong earning late thursday be catalyst third quarter profit
1942,GILD,founding software company veeva system peter gassner be certain thing want technology be cloud base address critical issue specific industry decide focus life science have picked something else oil gas picked thing big industry big industry know be massive need good cloud solution tell ibd turn be good idea veeva veev be most successful cloud base software company not only have revenue be grow double digit also profitable cloud company be usually grow not usually profitable say gassner be veeva ceo know be make product not guess game so have lower sale marketing cost help co founder president matt build life science business siebel system acquire oracle orcl have relationship pharmaceutical company say here better version say brendan barnicle analyst pacific crest security lot veeva business be replace old siebel system build steamveeva have more pharmaceutical biotech customer include more largest drug company worldwide range drug giant such merck mrk novartis nvs eli lilly lly emerge biotech veeva customer be gilead science gild maker hepatitis wonder drug gilead have be buy more product veeva grow expand worldwide gassner say plenty customer veeva keep expand coverage user company selling more add module be drive growth be veeva have high margin barnicle say salesforce com crm don have grab new customer re go same customer selling more gassner have key contact past employer be senior vp technology salesforce com charge build software service saas platform crm software drife revenueveeva core customer relationship management crm software be build salesforce com platform veeva be salesforce com prefer partner pharma biotech gassner say be sale channel salesforce com partner crm software account veeva revenue be expect top year accord research firm gartner crm software revenue worldwide grow double digit moreover vertical industry specific software comprise largest segment enterprise software market total most software be still focuse client server rather cloud internet gassner say re bring client server cloud tremendous opportunity re just early stage veeva revenue fiscal grow fiscal end january revenue second quarter end july rise net income quarter jump cent share company go public october figured ep earlier period amount equivalent cent share veeva stock be more ipo price rise first share dip rebound sharply result be announce aug day company raise forecast full year previously share earning guidance year be up cent cent analyst expect veeva earning come cent gain last year see growth next year accord thomson reuter manage clinical say firm make great progress quarter second product category call veeva vault veeva build own infrastructure vault focus content management process such clinical trial quality management manufacturing sale marketing more new vault customer be add include second top drug company sign vault clinical trial product fastest part business barnicle say vault similar veeva crm software replace siebel vault be replace old content management system used life science barnicle say tracking more dataveeva third newest product line be call network cloud base solution integrate firm crm platform help customer track datum health care customer william blair analyst estimate vault network offering expand veeva market opportunity roughly much upper target be base expansion potential network database other region world china veeva largest market be follow western europe asia especially china japan william blair analyst expect veeva revenue reach end veeva be far only company offer health care specific technology william blair analyst say recent initiation report veeva vast majority offer premise product use isolate single client host model believe legacy vendor lose innovation speed market price battle write chief rival be cegedim global tech service firm focuse health care cegedim crm business be be acquire im health im william blair estimate cegedim seat use premise technology gassner see pending acquisition positive veeva be disruption benefit say
1943,GILD,health care stock have be give stock market health care mutual fund shot arm much past year more so end investment average health care mutual fund have mushroomed same investment
1944,GILD,stock weaken go noon hour wednesday trader await et release minute federal reserve meeting
1945,GILD,be parsed clue fed begin raise interest rate
1946,GILD,nasdaq sag dow inched be
1947,GILD,ebay ebay fall nearly channeladvisor say client selling online marketplace see same store sale rise year year september august slowest month
1948,GILD,amazon amzn see same store sale rise august share amazon fall
1949,GILD,dow be hold dupont dd ceo announce retirement earlier week fuel speculation company break dupont announce strategic alliance caribou bioscience
1950,GILD,domino pizza dpz fall flat pierce day move average report ep cent well estimate
1951,GILD,ibd stock top performer be global payment gpn nearly top wednesday gain report earning easily beat estimate
1952,GILD,ibd name foot locker fl rise more argus research initiate coverage buy rating price target stock trade stock weaken go noon hour wednesday trader await et release minute federal reserve meeting be parsed clue fed begin raise interest rate nasdaq sag dow inched be ebay ebay fall nearly channeladvisor say client selling online marketplace see same store sale rise year year september august slowest month amazon amzn see same store sale rise august share amazon fall dow be hold dupont dd ceo announce retirement earlier week fuel speculation company break dupont announce strategic alliance caribou bioscience domino pizza dpz fall flat pierce day move average report ep cent well estimate ibd stock top performer be global payment gpn nearly top wednesday gain report earning easily beat estimate ibd name foot locker fl rise more argus research initiate coverage buy rating price target stock trade
1953,GILD,biogen biib have pull back week move average second time breaking base early december generally first pullback key support line breaking base be good point add share exist position likelihood be stock move higher
1954,GILD,johnson johnson kick health care earning season report point solid fundamental punish foreign exchange fx headwind report basis johnson johnson jnj sale drop year earlier quarter modestly beating analyst consensus earning decline share beating estimate
1955,GILD,big pharma abbvie abbv get upgrade monday bmo capital market warm potential pending acquisition analyst alex arfaei upgrade abbvie outperform market perform say grow awareness biosimilar competition flagship drug humira have drive stock reasonable level same time be overcome initial skepticism
1956,GILD,johnson johnson kick health care earning season report point solid fundamental punish foreign exchange fx headwind report basis johnson johnson jnj sale drop year earlier quarter modestly beating analyst consensus earning decline share beating estimate
1957,GILD,big pharma merck release late stage datum wednesday hepatitis regime meet wall street expectation also disclose fda have award breakthrough therapy designation certain patient group merck mrk study be newly release abstract presentation annual meeting european association study liver easl vienna
1958,GILD,decade charlotte stewart be carry virus be houseguest refuse leave hepatitis
1959,GILD,stewart be first diagnosed hcv believe contract much year earlier receive blood transfusion injection blood related product
1960,GILD,time virus be detected liver be already show scarring know cirrhosis appear more advanced case disease
1961,GILD,fortunately didn get much do do treatment stewart now tell ibd do round treatment sixth be harvoni
1962,GILD,harvoni be new pill just launch month gilead science gild stewart get early participate clinical trial harvoni be combination novel drug ledipasvir sofosbuvir nearly year have be sell alone brand name sovaldi
1963,GILD,high hope
1964,GILD,sovaldi launch smash previous new drug launch come december have rac nearly sale gilead third quarter report be due oct harvoni be new improve sovaldi analyst expect treat even more patient
1965,GILD,stewart previous treatment experience show just gilead be roll money right now
1966,GILD,first treatment be variation combination interferon ribavirin be standard time credit treatment slow liver damage didn get rid hcv do make feel sick
1967,GILD,fact third treatment round involved daily injection interferon drive blood cell count so low nearly land hospital
1968,GILD,be very difficult go treatment say always develop anemia fever chill energy
1969,GILD,contrast be harvoni trial take pill day week suffer side effect week viral load be undetectable still be more year later
1970,GILD,physically have more energy just overall better health stewart say mentally emotionally have huge weight take
1971,GILD,more patient trial respond way yet gilead stock fall day harvoni be approve keep fall next day
1972,GILD,way be story gilead life sovaldi launch company score high ibd metric perfect composite rating price earning multiple be more big pharma boom biotech say drug analyst just hint bad news seem trigger sell
1973,GILD,biggest cause concern have be price sovaldi price pill add week course come fire advocacy group insurer pharmacy benefit manager even member congress however nobody really do anything so long sovaldi be so clearly superior everything else market
1974,GILD,gilead price harvoni basically parity sovaldi most patient still have take interferon ribavirin sovaldi drug be generic therefore cheaper gilead marked harvoni sovaldi cover cost absent drug
1975,GILD,however harvoni official label allow week treatment be consider patient cirrhosis haven be treat gilead estimate patient be eligible
1976,GILD,give fbr analyst andrew beren estimate average cost harvoni treatment be
1977,GILD,however also point cirrhotic patient previous treatment have fail patient charlotte stewart be recommend take harvoni week also say patient sovaldi treatment have fail represent underrate opportunity
1978,GILD,used hcv patient flow model calculate total patient need re treatment sovaldi viable patent life alone beren write oct note raise estimate harvoni sale
1979,GILD,longer term threat gilead pricing power be competition next few month bring lot more clarity competition look
1980,GILD,first real peer harvoni be expect be abbvie abbv regimen fda be due make approval decision dec
1981,GILD,clinical trial regimen have be comparable harvoni safety effectiveness do involve different drug make easier patient mess
1982,GILD,discount price
1983,GILD,abbvie management have be tight lip price drug leave wall street speculate much be willing undercut harvoni
1984,GILD,isi group analyst mark schoenebaum expect probably price comparably perhaps offer rebate certain customer estimate chance abbvie price significant discount
1985,GILD,happen second weekend november be precise merck mrk report mid stage trial datum own hcv program potentially cut treatment time week
1986,GILD,wouldn launch few more year drug industry tend think long time frame gilead acquire sofosbuvir buyout pharmasset nov be already think fact legacy hiv franchise such blockbuster viread truvada atripla start go patent
1987,GILD,hcv franchise be fill space now gilead hasn exactly give hiv gilead report positive late stage trial result drug analyst have dub son viread similar compound fewer side effect
1988,GILD,long term future hold gilead term success be expect roll analyst poll thomson reuter expect gilead report earning share prior year sale be see more double just less decade charlotte stewart be carry virus be houseguest refuse leave hepatitis stewart be first diagnosed hcv believe contract much year earlier receive blood transfusion injection blood related product time virus be detected liver be already show scarring know cirrhosis appear more advanced case disease fortunately didn get much do do treatment stewart now tell ibd do round treatment sixth be harvoni harvoni be new pill just launch month gilead science gild stewart get early participate clinical trial harvoni be combination novel drug ledipasvir sofosbuvir nearly year have be sell alone brand name sovaldi high hopessovaldi launch smash previous new drug launch come december have rac nearly sale gilead third quarter report be due oct harvoni be new improve sovaldi analyst expect treat even more patient stewart previous treatment experience show just gilead be roll money right now first treatment be variation combination interferon ribavirin be standard time credit treatment slow liver damage didn get rid hcv do make feel sick fact third treatment round involved daily injection interferon drive blood cell count so low nearly land hospital be very difficult go treatment say always develop anemia fever chill energy contrast be harvoni trial take pill day week suffer side effect week viral load be undetectable still be more year later physically have more energy just overall better health stewart say mentally emotionally have huge weight take more patient trial respond way yet gilead stock fall day harvoni be approve keep fall next day way be story gilead life sovaldi launch company score high ibd metric perfect composite rating price earning multiple be more big pharma boom biotech say drug analyst just hint bad news seem trigger sell biggest cause concern have be price sovaldi price pill add week course come fire advocacy group insurer pharmacy benefit manager even member congress however nobody really do anything so long sovaldi be so clearly superior everything else market gilead price harvoni basically parity sovaldi most patient still have take interferon ribavirin sovaldi drug be generic therefore cheaper gilead marked harvoni sovaldi cover cost absent drug however harvoni official label allow week treatment be consider patient cirrhosis haven be treat gilead estimate patient be eligible give fbr analyst andrew beren estimate average cost harvoni treatment be however also point cirrhotic patient previous treatment have fail patient charlotte stewart be recommend take harvoni week also say patient sovaldi treatment have fail represent underrate opportunity used hcv patient flow model calculate total patient need re treatment sovaldi viable patent life alone beren write oct note raise estimate harvoni sale longer term threat gilead pricing power be competition next few month bring lot more clarity competition look first real peer harvoni be expect be abbvie abbv regimen fda be due make approval decision dec clinical trial regimen have be comparable harvoni safety effectiveness do involve different drug make easier patient mess discount price abbvie management have be tight lip price drug leave wall street speculate much be willing undercut harvoni isi group analyst mark schoenebaum expect probably price comparably perhaps offer rebate certain customer estimate chance abbvie price significant discount happen second weekend november be precise merck mrk report mid stage trial datum own hcv program potentially cut treatment time week wouldn launch few more year drug industry tend think long time frame gilead acquire sofosbuvir buyout pharmasset nov be already think fact legacy hiv franchise such blockbuster viread truvada atripla start go patent hcv franchise be fill space now gilead hasn exactly give hiv gilead report positive late stage trial result drug analyst have dub son viread similar compound fewer side effect long term future hold gilead term success be expect roll analyst poll thomson reuter expect gilead report earning share prior year sale be see more double just less
1989,GILD,aetna aet beat forecast raise earning guidance year share be higher patient medical cost
1990,GILD,insurance provider earning rise share handily top view cent revenue grow beating forecast
1991,GILD,medical membership rise member commercial medical benefit ratio be share premium revenue spend medical care rise due factor include cost hepatitis treatment impact health care reform
1992,GILD,gilead gild make pill hep treatment sovaldi report close
1993,GILD,aetna share fall stock market today
1994,GILD,insurer lift full year operate ep forecast earlier view analyst poll thomson reuter expect
1995,GILD,meanwhile centene cnc share earning grow beating view cent obamacare medicaid expansion boost membership program revenue surge top analyst expectation
1996,GILD,insurer also raise ep outlook wall street see share be
1997,GILD,unitedhealth group unh report mid month beat forecast raise earning guidance lower expect medical cost share be wellpoint wlp fall aetna aet beat forecast raise earning guidance year share be higher patient medical cost insurance provider earning rise share handily top view cent revenue grow beating forecast medical membership rise member commercial medical benefit ratio be share premium revenue spend medical care rise due factor include cost hepatitis treatment impact health care reform gilead gild make pill hep treatment sovaldi report close aetna share fall stock market today insurer lift full year operate ep forecast earlier view analyst poll thomson reuter expect meanwhile centene cnc share earning grow beating view cent obamacare medicaid expansion boost membership program revenue surge top analyst expectation insurer also raise ep outlook wall street see share be unitedhealth group unh report mid month beat forecast raise earning guidance lower expect medical cost share be wellpoint wlp fall
1998,GILD,pharmaceutical stock continue assert comparatively steady influence correct market hold slot stock spotlight issue monday biotechs maker generic drug chart wise akorn pharmaceutical akrx gilead science gild have behaved best actavis act have deliver share drama term suspense orphan drug pioneer alexion
1999,GILD,dow jone industrial average hold ground record territory afternoon trading friday nasdaq poke level just smidgen nearly year intraday high set nov
2000,GILD,nasdaq rise gain dow climb volume be run lighter stock market today compare same time wednesday
2001,GILD,select airline have strong day ryanair ryaay rise volume be high break base early november
2002,GILD,virgin america va break ipo base wednesday follow friday nearly
2003,GILD,lead biotech stock be pummeled earlier week rally friday have find support day move average include celgene celg gilead science gild alexion pharmaceutical alxn rise be still day line
2004,GILD,cal maine food calm fall still feel effect tuesday report revenue come wall street forecast
2005,GILD,gopro gpro rise fourth straight advance day lock period insider be prohibit selling share expire monday dow jone industrial average hold ground record territory afternoon trading friday nasdaq poke level just smidgen nearly year intraday high set nov nasdaq rise gain dow climb volume be run lighter stock market today compare same time wednesday select airline have strong day ryanair ryaay rise volume be high break base early november virgin america va break ipo base wednesday follow friday nearly lead biotech stock be pummeled earlier week rally friday have find support day move average include celgene celg gilead science gild alexion pharmaceutical alxn rise be still day line cal maine food calm fall still feel effect tuesday report revenue come wall street forecast gopro gpro rise fourth straight advance day lock period insider be prohibit selling share expire monday
2006,GILD,share gilead science gild be find support bad news new drug wednesday stock be rebound pullback week move average leave biotech leader secondary buy range riskier now market be pressure be second time gilead have retreat line
2007,GILD,drugmaker cluster top ibd stock move list tuesday afternoon actavis act ireland base maker generic brand drug shot more huge volume tuesday afternoon trading stock market today follow monday gain actavis announce acquire botox maker allergan agn more stock cash potentially create pharmaceutical giant market cap tuesday activist investor william ackman say cnbc interview support deal ackman persh square fund build stake have push valeant pharmaceutical vrx acquire allergan citigroup tuesday raise price target actavis cite potential synergy growth prospect actavis investor seem pleased valeant not have go merger process allergan take stock more more double usual volume rise nearly monday valeant deal ackman get profit persh square allergan hold allergan rise actavis higher stock price mean higher deal valuation valeant be also ibd list top rate stock now focus broad line drug mainly dermatology neurology eye health brand generic portfolio include antidepressant wellbutrin xl liposoniz thermage fraxel professional skin care sector gilead science gild climb higher volume european union grant company permission market harvoni first once daily single tablet regimen treat hepatitis highly infectious disease primarily affect liver lead cirrhosis potentially fatal disease combine blockbuster sovaldi drug israel base taro pharmaceutical taro continue recover drop day company nov report strong earning revenue gain end quarter partly price increase say also have marginal decline volume stock be track tuesday afternoon post third straight daily rise be trading more twice normal volume follow james detar twitter ibd_jdetar
2008,GILD,regulus therapeutic rgls stock leap tuesday night astrazeneca azn take nash fatty liver disease candidate testing part microrna alliance join crowd field drugmaker develop treatment make investment get part nash form liver damage cause accumulation fat regulus say rg compound treat nonalcoholic
2009,GILD,negative energy be term hear yoga class corporate america negative energy sector be several factor expect have drag first quarter earning entire probably first overall profit fall index energy sector alone be expect post staggering year year decline
2010,GILD,share big cap biotech vertex pharmaceutical fall monday result latest cystic fibrosis drug disappoint investor vertex vrtx report datum mid stage study combine drug candidate vx al ready market ivacaftor brand kalydeco patient cystic fibrosis cause homozygous del mutation vertex other product already treat population firm hope vx be expand harder treat heterozygous del mutation population
2011,GILD,consistent prior phase study evaluate week treatment vx combination ivacaftor study show rapid improvement lung function week treatment patient complete treatment lung function return baseline vertex press release summarize
2012,GILD,rbc capital market analyst michael yee disagree be really consistent
2013,GILD,week datum be solid line prior result week datum be relatively disappointing vs expectation efficacy decline month have never be see write note monday
2014,GILD,week datum be average week vertex tell analyst number actually didn smoothly tail week bounce course treatment evercore isi analyst mark schoenebaum point webinar be likely product study be small be just person be take drug combo so larger phase study be need clear thing
2015,GILD,still say base odd vx succeed heterozygous patient have go
2016,GILD,vertex share fall fall buy point clear last week stock hit record friday
2017,GILD,yee estimate vertex still rake year just homozygous case most other analyst be also project big growth vertex next year onward cf drug roll currently lose money result former blockbuster incivek be push market gilead science gild new hepatitis drug sovaldi harvoni
2018,GILD,side note gilead fall monday biotech warn doctor friday patient take cardiac drug amiodarone sovaldi harvoni be danger heart attack
2019,GILD,however analyst yee write amiodarone be old drug used only arrhythmia case so not have significant impact drug sale share big cap biotech vertex pharmaceutical fall monday result latest cystic fibrosis drug disappoint investor vertex vrtx report datum mid stage study combine drug candidate vx al ready market ivacaftor brand kalydeco patient cystic fibrosis cause homozygous del mutation vertex other product already treat population firm hope vx be expand harder treat heterozygous del mutation population consistent prior phase study evaluate week treatment vx combination ivacaftor study show rapid improvement lung function week treatment patient complete treatment lung function return baseline vertex press release summarize rbc capital market analyst michael yee disagree be really consistent week datum be solid line prior result week datum be relatively disappointing vs expectation efficacy decline month have never be see write note monday week datum be average week vertex tell analyst number actually didn smoothly tail week bounce course treatment evercore isi analyst mark schoenebaum point webinar be likely product study be small be just person be take drug combo so larger phase study be need clear thing still say base odd vx succeed heterozygous patient have go vertex share fall fall buy point clear last week stock hit record friday yee estimate vertex still rake year just homozygous case most other analyst be also project big growth vertex next year onward cf drug roll currently lose money result former blockbuster incivek be push market gilead science gild new hepatitis drug sovaldi harvoni side note gilead fall monday biotech warn doctor friday patient take cardiac drug amiodarone sovaldi harvoni be danger heart attack however analyst yee write amiodarone be old drug used only arrhythmia case so not have significant impact drug sale
2020,GILD,biotech intercept pharmaceutical icpt spiked more thursday afternoon competitor clinical trial produce ambiguous result
2021,GILD,genfit french biotech doesn trade announce drug gft have fail meet primary endpoint alcoholic steatohepatitis nash form liver damage cause accumulation fat
2022,GILD,progress be measure perform liver biopsy begin end week treatment course measure nafld activity score nas compare placebo group company press release however argue problem be placebo group turn unexpectedly healthy
2023,GILD,due unexpected rate resolution nash patient randomize placebo have early nash nas placebo response rate greater high number site limit sample size study initially design do not enable trial meet directly primary endpoint say correction baseline severity site heterogeneity standardized statistical analysis gft mg meet primary endpoint reversal nash worsening fibrosis
2024,GILD,rbc capital market analyst michael yee admit didn quite know mean anything be positive only slice datum different way be not usually good however good news genfit be benign safety least accord limit datum pr overall believe support outperform rating icpt believe have best oral drug nash potential fibrotic effect
2025,GILD,several drugmaker be work nash wall street see genfit intercept lead contender intercept obetacholic acid oca turn strong midstage trial result last year be safety concern raise cholesterol level
2026,GILD,conatus pharmaceutical cnat be more stock market today report positive phase trial result nash drug emricasan however study be smaller just subject compare genfit used different measurement pathology so didn seem excite much reaction report market open
2027,GILD,gilead science gild also have nash drug call simtuzumab phase testing recently acquire preclinical technology phenex pharmaceutical gilead stock be nearly afternoon trading thursday didn have noticeable reaction genfit announcement
2028,GILD,follow amy reeve twitter ibd_areeve biotech intercept pharmaceutical icpt spiked more thursday afternoon competitor clinical trial produce ambiguous result genfit french biotech doesn trade announce drug gft have fail meet primary endpoint alcoholic steatohepatitis nash form liver damage cause accumulation fat progress be measure perform liver biopsy begin end week treatment course measure nafld activity score nas compare placebo group company press release however argue problem be placebo group turn unexpectedly healthy due unexpected rate resolution nash patient randomize placebo have early nash nas placebo response rate greater high number site limit sample size study initially design do not enable trial meet directly primary endpoint say correction baseline severity site heterogeneity standardized statistical analysis gft mg meet primary endpoint reversal nash worsening fibrosis rbc capital market analyst michael yee admit didn quite know mean anything be positive only slice datum different way be not usually good however good news genfit be benign safety least accord limit datum pr overall believe support outperform rating icpt believe have best oral drug nash potential fibrotic effect several drugmaker be work nash wall street see genfit intercept lead contender intercept obetacholic acid oca turn strong midstage trial result last year be safety concern raise cholesterol level conatus pharmaceutical cnat be more stock market today report positive phase trial result nash drug emricasan however study be smaller just subject compare genfit used different measurement pathology so didn seem excite much reaction report market open gilead science gild also have nash drug call simtuzumab phase testing recently acquire preclinical technology phenex pharmaceutical gilead stock be nearly afternoon trading thursday didn have noticeable reaction genfit announcement follow amy reeve twitter ibd_areeve
2029,GILD,stock end solid gain friday battle back weakness spur disappointing job report nasdaq end respectively be friday low dow jone industrial average climb accord preliminary datum volume end higher board stock market today lead stock dave buster entertainment play reversed higher gain stock have already rise thursday follow pricing share offer dave buster be recently featured stock spotlight verisk analytic vrsk stretched streak straight session rebound loss rise stock nearly reach buy point flat base verisk provide datum insurance underwriter bank be add wednesday close tyler technology tyl add second straight new high now past buy point flat base clear thursday company announce buy privately hold new world system cash stock domino pizza dpz climb buck morning weakness fail retake day move average domino report earning thursday analyst poll thomson reuter see pizza chain profit rise cent share
2030,GILD,greater boston area have see influx fast grow biotechs biogen idec biib have be take lab space trend drive vacancy rate big way way biotech sector be surge ibd medical biom biotech industry group rank ibd track greater boston biotech company
2031,GILD,half sector leader show chart be extend many basis also be later stage gilead science gild isn stale set most recent be first stage cup handle base buy point be however gilead chart story be little tricky june july come
2032,GILD,market new confirm rally investor pay close attention lead stock new buy opportunity biogen idec biib other medical company hold well correction have be leader week
2033,GILD,biogen idec be pharmaceutical company featured today ibd big cap screen day screen feature institutional quality stock be highly liquid have excellent fundamental
2034,GILD,medical biom biotech group be top rank group industry group ibd track
2035,GILD,biotechs be screen report earning week start biogen early wednesday
2036,GILD,analyst poll thomson reuter expect maker multiple sclerosis drug report jump earning seventh straight quarter double digit ep growth revenue be see rise
2037,GILD,biogen share rise nearly stock market today climb monday
2038,GILD,celgene celg report earning thursday oct analyst expect cancer therapy maker report jump earning cent rise revenue
2039,GILD,tuesday celgene report strong phase trial result mongersen drug treat crohn disease
2040,GILD,view bottom line be have high chance work phase ultimately read be key growth driver think upside long term guidance eventually be give rbc capital market analyst michael yee write note
2041,GILD,celgene share rise more tuesday follow monday advance
2042,GILD,alexion pharmaceutical alxn be also expect report earning result thursday analyst expect rise earning share revenue climb
2043,GILD,alexion make only drug soliris treatment blood disease paroxysmal nocturnal hemoglobinurium company have other drug development
2044,GILD,alexion show biotechs make enormous profit orphan drug medication treat extremely rare deadly disease
2045,GILD,share alexion be nearly week
2046,GILD,gilead science gild be slate report result oct earlier month fda approve gilead hepatitis combo pill harvoni combine megablockbuster sovaldi interferon treatment
2047,GILD,gilead ep be see soar revenue climb
2048,GILD,gilead share also be nearly so far week
2049,GILD,regeneron pharmaceutical regn round top monday company announce have start phase study possible drug dupilumab treatment moderate severe atopic dermatitis
2050,GILD,regeneron isn slate report earning nov analyst expect earning double share revenue jump nearly
2051,GILD,share regeneron jump new high tuesday
2052,GILD,follow gillian rich twitter ibd_grich market new confirm rally investor pay close attention lead stock new buy opportunity biogen idec biib other medical company hold well correction have be leader week biogen idec be pharmaceutical company featured today ibd big cap screen day screen feature institutional quality stock be highly liquid have excellent fundamental medical biom biotech group be top rank group industry group ibd track biotechs be screen report earning week start biogen early wednesday analyst poll thomson reuter expect maker multiple sclerosis drug report jump earning seventh straight quarter double digit ep growth revenue be see rise biogen share rise nearly stock market today climb monday celgene celg report earning thursday oct analyst expect cancer therapy maker report jump earning cent rise revenue tuesday celgene report strong phase trial result mongersen drug treat crohn disease view bottom line be have high chance work phase ultimately read be key growth driver think upside long term guidance eventually be give rbc capital market analyst michael yee write note celgene share rise more tuesday follow monday advance alexion pharmaceutical alxn be also expect report earning result thursday analyst expect rise earning share revenue climb alexion make only drug soliris treatment blood disease paroxysmal nocturnal hemoglobinurium company have other drug development alexion show biotechs make enormous profit orphan drug medication treat extremely rare deadly disease share alexion be nearly week gilead science gild be slate report result oct earlier month fda approve gilead hepatitis combo pill harvoni combine megablockbuster sovaldi interferon treatment gilead ep be see soar revenue climb gilead share also be nearly so far week regeneron pharmaceutical regn round top monday company announce have start phase study possible drug dupilumab treatment moderate severe atopic dermatitis regeneron isn slate report earning nov analyst expect earning double share revenue jump nearly share regeneron jump new high tuesday follow gillian rich twitter ibd_grich
2053,GILD,stock market close mixed friday index bounce back early slump nasdaq rise thank strength biotechs security software solar stock fall dow jone industrial average lag drop close session lows small cap pace market small cap russell climb volume rise nyse edge lower nasdaq accord early figure serious decline prior day friday price reversal be encourage yet market remain lock long sideway trend stock sank open better expect job report trigger slide bond price energy stock rise opec left output target unchanged expect solar share jump china base ja solar jaso chief executive offer buy company take private financial also help lead stock market today bank america bac rise more close back buy point jpmorgan jpm rise hit new high thinly trade bofi holding bofi rise top buy point long cup handle base be strong day ibd average component volume be just average light most stock
2054,GILD,wall street be scramble assess impact drug stock close tax loophole know double irish propose irish government tuesday issue be different overall lower corporate tax rate ireland have drive controversial tax inversion deal have relocate number company ireland
2055,GILD,jason weiner be green bay packer quarterback aaron rodger
2056,GILD,season season keep perform high level
2057,GILD,feb weiner become signal caller now fidelity growth discovery fund adviser sell twin advisor equity growth fund growth discovery have notch average annual gain vs performance rank top large cap growth peer track morningstar inc
2058,GILD,weiner have used same approach most not tenure say seek undervalue growth story stock potential price earning expansion avoid overly costly name
2059,GILD,weiner year old talk ibd office boston invest
2060,GILD,ibd jason ever have mentor be
2061,GILD,weiner ve have ton mentor rare occasion fidelity roll meet mbas visit fidelity tell find mentor outside workplace preferably
2062,GILD,super important go back be have first job get family friend lou be great influence be lou nargiso own gas station auto repair shop be world war ii vet learn auto repair army
2063,GILD,be very well educate person philosophical like debate thing everyone work lou be very loyal be shop be also kind clubhouse world war ii vet buddy hung good time
2064,GILD,ibd fidelity
2065,GILD,weiner fidelity manager fidelity contrafund advisor new insight series opportunistic insight advisor series opportunistic insight have be great mentor
2066,GILD,don remember exactly kick have be be train be go southern connecticut visit parent sit next other work later gain lot wisdom be super focuse study decade understand monster stock decade be elephant hunting business hunting stock go make monster gain
2067,GILD,own dell next year nothing else matter beauty incredible growth story be focuse have adopt strategy
2068,GILD,ibd overall look undervalue growth story stock potential price earning expansion right
2069,GILD,weiner only get paid thing growth stock first expansion second underlie earning growth company invest
2070,GILD,typically focus growth rate company fundamental research bring value try leverage fidelity research engine lot
2071,GILD,little harder predict
2072,GILD,ibd try avoid valuation be too high correct
2073,GILD,weiner enter name controversy doubt cast lower great opportunity
2074,GILD,ibd give example please
2075,GILD,weiner best recent year be facebook fb facebook botch ipo
2076,GILD,stock have go public trade immediately bottom even company be do great be cloud controversy pummeled stock
2077,GILD,buy ipo didn buy day average price share be
2078,GILD,stock be go company be roll newsfeed ad seem ancient history newsfeed ad be relatively new time ipo stop rely ad pc base service shift newsfeed ad appear mobile device be fundamental transformation business model facebook story today
2079,GILD,ibd person think growth discovery garp growth reasonable price strategy
2080,GILD,weiner lot fund be recognizable garp basket addition try buy best growth name market one be go turn big sustainable valuable franchise little different garp
2081,GILD,top name be asset not name become brand new unbelievable franchise already have great franchise become great look decade know publication william neil send so look monster stock be never many try buy sort name
2082,GILD,ibd be allow invest market cap size fund have be large cap oriented long time heaviest weighting be megacaps one
2083,GILD,weiner let take piece first economy be do better average develop nation so fortuitous be investor day
2084,GILD,so many megacaps look internet model successful one be global scalable enjoy incredible network effect be viral want
2085,GILD,point facebook biggest company enjoy increase return get bigger
2086,GILD,be manufacturer year have experience decrease return single additional widget make have be sell lower margin incent market buy product internet age opposite increase return
2087,GILD,other thing internet be winner take most dynamic google googl be leader search be winner take battle win
2088,GILD,be determine ota online travel agency space ve get facebook expedia expe tripadvisor trip bunch other one also turn winner take space haven invest priceline pcln have skin game
2089,GILD,ibd do boost apple aapl weighting oct less march june
2090,GILD,weiner full disclosure have not do great job trading apple last year give low mark make long list apple positive negative ve focuse negative last year not go do more
2091,GILD,live block apple store iphone come be line block be crazy ignore
2092,GILD,lecture smartphone be fully penetrate rate innovation be slow android have outshipped apple io usually volume leader win tech actually always do negative haven matter apple stock performance
2093,GILD,ibd so ve decide least moment be not lose apple
2094,GILD,weiner key bucket stock ve avoid be large cap tech legacy player oracle orcl emc emc hewlett packard hpq microsoft msft generally underweight mindful have secular challenge happen never know catch ibm ibm year face somehow always punch good earning be change last quarter be terrible
2095,GILD,secular challenge catch company be tech analyst cover compaq tandem digital stratus datum general face secular challenge wave hit fall don exist now independent company
2096,GILD,apple be huge good legacy story relative other legacy player justification own apple
2097,GILD,ibd hold illumina ilmn oct re fan outlook gene sequence right
2098,GILD,weiner yes illumina be incredible company help unlock secret sequence genome just way practice medicine be change company illumina
2099,GILD,look backward person be do human genome now re sequence thousand future have genome go doctor illumina come
2100,GILD,ibd alexion alxn remain play single drug soliris
2101,GILD,weiner alexion thesis latest disclosure be be super orphan drug company only go indication small patient population get lot money life save drug
2102,GILD,ve increase number indication soliris be sell be drug re hope fda approval new set indication
2103,GILD,hard society say not pay drug child live only couple year society pay drug child have normal outcome big ethic debate bottom line country be pay drug
2104,GILD,ibd similar be gilead gild story
2105,GILD,weiner have great risk reward beat competition be other cure hepatitis get market share gilead get majority market share have hep want drug immediately
2106,GILD,knock drug be person don invest company cure disease then treatment be shot deal person say isn better develop treatment hiv require patient take pill day still plenty room hep drug be million patient don have drug yet
2107,GILD,ibd chipotle cmg earning growth have accelerate quarters
2108,GILD,weiner great franchise ton room growth secret be person pay more food think be higher quality
2109,GILD,ibd sherwin william shw
2110,GILD,weiner be greatest company nobody recognize
2111,GILD,paint store franchise be so valuable re vertically integrate professional painter make first daily stop sherwin william not home depot hd lowe low know treat pro have lot pricing power material cost be not big deal most end user be person restore remodel home do not depend home sale
2112,GILD,ibd drife ulta beauty ulta
2113,GILD,weiner ulta be beauty have high emotional content woman ulta give ability walk mall base completely dedicate beauty retailer not have walk halfway department store get beauty counter ulta have grow number prestige brand year prestige brand wouldn sell now do
2114,GILD,beauty product have high margin profit same store sale sale square foot be grow
2115,GILD,last year profit have actually be muted ceo mary dillon be investing heavily commerce tell credible story street investment do so person be board
2116,GILD,ibd be fan alibaba baba latest disclosure right
2117,GILD,weiner alibaba be legend name year person talk ceo jack term be commerce leader china full stop china be big market be grow
2118,GILD,jack have do very good job build huge business massive gross merchandise value attract merchant low take rate mean small medium business alibaba be great tool grow business
2119,GILD,also have mall place global brand sell safe place be counterfeit
2120,GILD,get payment financial service back pocket
2121,GILD,alibaba gross merchandise value be larger amazon amzn ebay ebay combine jason weiner be green bay packer quarterback aaron rodger season season keep perform high level feb weiner become signal caller now fidelity growth discovery fund adviser sell twin advisor equity growth fund growth discovery have notch average annual gain vs performance rank top large cap growth peer track morningstar inc weiner have used same approach most not tenure say seek undervalue growth story stock potential price earning expansion avoid overly costly name weiner year old talk ibd office boston invest ibd jason ever have mentor be weiner ve have ton mentor rare occasion fidelity roll meet mbas visit fidelity tell find mentor outside workplace preferably super important go back be have first job get family friend lou be great influence be lou nargiso own gas station auto repair shop be world war ii vet learn auto repair army be very well educate person philosophical like debate thing everyone work lou be very loyal be shop be also kind clubhouse world war ii vet buddy hung good time ibd fidelity weiner fidelity manager fidelity contrafund advisor new insight series opportunistic insight advisor series opportunistic insight have be great mentor don remember exactly kick have be be train be go southern connecticut visit parent sit next other work later gain lot wisdom be super focuse study decade understand monster stock decade be elephant hunting business hunting stock go make monster gain own dell next year nothing else matter beauty incredible growth story be focuse have adopt strategy ibd overall look undervalue growth story stock potential price earning expansion right weiner only get paid thing growth stock first expansion second underlie earning growth company invest typically focus growth rate company fundamental research bring value try leverage fidelity research engine lot little harder predict ibd try avoid valuation be too high correct weiner enter name controversy doubt cast lower great opportunity ibd give example please weiner best recent year be facebook fb facebook botch ipo stock have go public trade immediately bottom even company be do great be cloud controversy pummeled stock buy ipo didn buy day average price share be stock be go company be roll newsfeed ad seem ancient history newsfeed ad be relatively new time ipo stop rely ad pc base service shift newsfeed ad appear mobile device be fundamental transformation business model facebook story today ibd person think growth discovery garp growth reasonable price strategy weiner lot fund be recognizable garp basket addition try buy best growth name market one be go turn big sustainable valuable franchise little different garp top name be asset not name become brand new unbelievable franchise already have great franchise become great look decade know publication william neil send so look monster stock be never many try buy sort name ibd be allow invest market cap size fund have be large cap oriented long time heaviest weighting be megacaps one weiner let take piece first economy be do better average develop nation so fortuitous be investor day so many megacaps look internet model successful one be global scalable enjoy incredible network effect be viral want point facebook biggest company enjoy increase return get bigger be manufacturer year have experience decrease return single additional widget make have be sell lower margin incent market buy product internet age opposite increase return other thing internet be winner take most dynamic google googl be leader search be winner take battle win be determine ota online travel agency space ve get facebook expedia expe tripadvisor trip bunch other one also turn winner take space haven invest priceline pcln have skin game ibd do boost apple aapl weighting oct less march june weiner full disclosure have not do great job trading apple last year give low mark make long list apple positive negative ve focuse negative last year not go do more live block apple store iphone come be line block be crazy ignore lecture smartphone be fully penetrate rate innovation be slow android have outshipped apple io usually volume leader win tech actually always do negative haven matter apple stock performance ibd so ve decide least moment be not lose apple weiner key bucket stock ve avoid be large cap tech legacy player oracle orcl emc emc hewlett packard hpq microsoft msft generally underweight mindful have secular challenge happen never know catch ibm ibm year face somehow always punch good earning be change last quarter be terrible secular challenge catch company be tech analyst cover compaq tandem digital stratus datum general face secular challenge wave hit fall don exist now independent company apple be huge good legacy story relative other legacy player justification own apple ibd hold illumina ilmn oct re fan outlook gene sequence right weiner yes illumina be incredible company help unlock secret sequence genome just way practice medicine be change company illumina look backward person be do human genome now re sequence thousand future have genome go doctor illumina come ibd alexion alxn remain play single drug soliris weiner alexion thesis latest disclosure be be super orphan drug company only go indication small patient population get lot money life save drug ve increase number indication soliris be sell be drug re hope fda approval new set indication hard society say not pay drug child live only couple year society pay drug child have normal outcome big ethic debate bottom line country be pay drug ibd similar be gilead gild story weiner have great risk reward beat competition be other cure hepatitis get market share gilead get majority market share have hep want drug immediately knock drug be person don invest company cure disease then treatment be shot deal person say isn better develop treatment hiv require patient take pill day still plenty room hep drug be million patient don have drug yet ibd chipotle cmg earning growth have accelerate quarters weiner great franchise ton room growth secret be person pay more food think be higher quality ibd sherwin william shw weiner be greatest company nobody recognize paint store franchise be so valuable re vertically integrate professional painter make first daily stop sherwin william not home depot hd lowe low know treat pro have lot pricing power material cost be not big deal most end user be person restore remodel home do not depend home sale ibd drife ulta beauty ulta weiner ulta be beauty have high emotional content woman ulta give ability walk mall base completely dedicate beauty retailer not have walk halfway department store get beauty counter ulta have grow number prestige brand year prestige brand wouldn sell now do beauty product have high margin profit same store sale sale square foot be grow last year profit have actually be muted ceo mary dillon be investing heavily commerce tell credible story street investment do so person be board ibd be fan alibaba baba latest disclosure right weiner alibaba be legend name year person talk ceo jack term be commerce leader china full stop china be big market be grow jack have do very good job build huge business massive gross merchandise value attract merchant low take rate mean small medium business alibaba be great tool grow business also have mall place global brand sell safe place be counterfeit get payment financial service back pocket alibaba gross merchandise value be larger amazon amzn ebay ebay combine
2122,GILD,sometimes drug launch take get ground incyte only approve drug jakafi have be market year really only just get start jakafi sell market jakavi be approve rare bone marrow cancer call myelofibrosis mf thank indication incyte incy revenue be expect pass year compare just year jakafi launch other indication pipeline however really push drug blockbuster territory first expect be approve food drug administration dec be polycythemia vera pv similar somewhat milder disease have potentially larger market meanwhile clinical trial be go really big name cancer pancreatic breast lung colon current consensus estimate have jakafi annual sale hit abroad incyte split take marketing partner novartis nvs sale be expect pass year incyte be base idea research cancer be good investment ceo herve hoppenot tell ibd interview opportunity seizedjakafi be janus associate kinase jak inhibitor regulate signale mechanism cell play important role cell growth immune response jakafi be first jak inhibitor market so far only approve fight cancer pfizer pfe xeljanz approve be also jak inhibitor be used rheumatoid arthritis hoppenot say incyte be originally aim big cancer first mf opportunity unexpectedly come scientist find jak signale play important role disease point company decide move development program very quickly myelofibrosis try prove jak pathway be have impact outcome patient say be able get pivotal study do approval myelofibrosis very rapid way advantage mf market bring firm be small patient pool have other treatment option so incyte have be able market domestically bring big pharma partner thus keep domestic revenue pursue pv be next logical step hoppenot say disease be so similar be disorder mean excess cell be produce bone marrow pv however be much milder sometimes have symptom hoppenot estimate only roughly pv patient be eligible jakafi expect liftoff be fairly slow treat pv isn urgent treat more malignant cancer eventual market be larger mf have fewer sufferer accord leerink estimate disease bring incyte first annual profit next year accord consensus analyst poll thomson reuter incyte turn profit cent share most recently report quarter only milestone payment incyte collect novartis winning reimbursement jakafi europe marketing approval japan start second half next year analyst expect incyte start turn operate profit more consistent way rivalry year however new competition threaten jakafi gilead science gild jak inhibitor momelotinib be late stage trial mf design compare momelotinib jakafi head head result be expect come sometime next year couple smaller player cti biopharma ctic geron gern also have competitor late stage testing nov latter license candidate imetelstat johnson johnson jnj development multiple disease deal potentially worth milestone be realize only datum tell competitive product be incyte have other tool garage incb candidate drug class call ido inhibitor be be test combination most anticipate cancer drug pipeline pd pd inhibitor incyte have partner lead contender field bristol myer bmy astrazeneca azn roche rhhby merck mrk test drug together variety cancer be not licensing deal say hoppenot do mean drug be approve company recommend successful combination drug label incb also garner attention summer american society clinical oncology asco meeting perform well trial combine different related bristol myer drug yervoy treat melanoma leerink analyst michael schmidt write time combo didn appear be effective yervoy combine bristol house pd opdivo do suggest promise combination incb other pd news better expect third quarter report last month induced goldman sachs analyst navdeep singh lift rating incyte neutral sell nearly double price target sell thesis be base more cautious view jakafi launch myelofibrosis mf give safety competition call have not work narrative have shift incy pipeline singh write oct research note add follow newly result asco be more encourage strong underlie growth jakafi mf early datum partnership interest ido inhibitor
2123,GILD,be interesting year drugmaker acorda therapeutic neurology specialist have be work diversify ampyra drug help multiple sclerosis patient walk provide acorda acor revenue most recent quarter ampyra launch have prove success narrow specialty month sale run upward
2124,GILD,here be share biotech gilead science gild other highly rate stock be rally heavy volume today gilead begin run premarket trading drug giant merck mrk say sunday not move forward development drug combination aim shortening treatment time hepatitis cite disappointing clinical datum treatment have used gilead sovaldi also compete current longer term regimen base sovaldi gilead stock top ibd leaderboard list best perform stock be average volume monday afternoon trading stock market today gilead share have rise further merck pare loss decline general acute care hospital operator hca holding hca rebound friday selloff come supreme court say hear case challenge legality obamacare premium subsidy state share hospital sell heavily friday fear lose patient pay court strike subsidy hca sank nearly friday be monday afternoon community health system cyh operate hospital fall friday be nearly ambarella amba stock climb intraday monday chipmaker supply chip camera maker include popular sport enthusiast body camera maker gopro gpro gopro share fall say sell worth share raise fund dilute stock price monday gopro body camera rival taser international tasr digital ally dgly have see strong sale wake ferguson shooting august lead surge order polouse department officer camera systemsyy yy climb ahead third quarter earning release tuesday market close chinese social network let user connect voice text video real time play game interact world largest consumer market consensus analyst poll thomson reuter be yy report rise earning share cent hike revenue homebuilder lennar len be hit fresh year high homebuilder group have be range bound early spring monday be trading top range lennar also get boost tuesday toll bro tol preannouncement rise revenue average price home deliver rise year year toll bro announce full earning dec be toll share rise nearly meanwhile builder horton dhi rise more horton be slate release fiscal earning result tuesday market open wall street expect increase ep cent rise revenue follow james detar twitter ibd_jdetar
2125,GILD,gilead science beat third quarter sale estimate issue cautious guidance late tuesday bottom line be hit obamacare related fee
2126,GILD,stock slip hour follow new record high regular session
2127,GILD,gilead gild revenue rise beating analyst consensus earning leap share cent short street estimate gilead say number include cumulative catch cent share due obamacare related brand prescription drug fee
2128,GILD,be accounting move order ir issue final rule fee july
2129,GILD,gilead raise low end full year sale guidance now still shy analyst expense guidance be lift account bpd fee already mentioned gross margin guidance be also raise low end so now usual company do not offer ep guidance
2130,GILD,gilead lead drug hepatitis fighter sovaldi come almost consensus hiv drug outperformed more make difference apart sovaldi gilead product sale grow sequentially
2131,GILD,sovaldi sale contract vs doctor delay treatment launch harvoni new improve combo pill win fda approval oct harvoni combine sovaldi novel drug eliminate need other drug
2132,GILD,harvoni first week prescription datum im health im come friday numbered prescription filled vs sovaldi first week
2133,GILD,commercial operation head paul carter warn compare number too directly sovaldi launch just few week last christmas doctor likely be more reluctant start patient week medication program be mid october say conference call analyst
2134,GILD,be see broader group physician writing script sovaldi add several physician know have written script never write sovaldi think reflect simplicity harvoni regimen re also see rate adoption little bit faster time
2135,GILD,carter add caveat take longer insurer approve harvoni prescription many be unprepared sheer volume demand sovaldi wound miss own quarterly financial
2136,GILD,time insurance company be more organized prepared harvoni launch so be more constraint initially say however say really too early know sure
2137,GILD,gilead also say still evaluate impact change ireland tax law country budget include close double irish loophole allow company shift profit irish subsidiary tax haven gilead be base california domicile hepatitis intellectual property ireland however company already used loophole have figure alternative
2138,GILD,determine final rule impact gilead believe worldwide revenue base operation ireland provide option structuring alternative future cfo robin washington say call gilead science beat third quarter sale estimate issue cautious guidance late tuesday bottom line be hit obamacare related fee stock slip hour follow new record high regular session gilead gild revenue rise beating analyst consensus earning leap share cent short street estimate gilead say number include cumulative catch cent share due obamacare related brand prescription drug fee be accounting move order ir issue final rule fee july gilead raise low end full year sale guidance now still shy analyst expense guidance be lift account bpd fee already mentioned gross margin guidance be also raise low end so now usual company do not offer ep guidance gilead lead drug hepatitis fighter sovaldi come almost consensus hiv drug outperformed more make difference apart sovaldi gilead product sale grow sequentially sovaldi sale contract vs doctor delay treatment launch harvoni new improve combo pill win fda approval oct harvoni combine sovaldi novel drug eliminate need other drug harvoni first week prescription datum im health im come friday numbered prescription filled vs sovaldi first week commercial operation head paul carter warn compare number too directly sovaldi launch just few week last christmas doctor likely be more reluctant start patient week medication program be mid october say conference call analyst be see broader group physician writing script sovaldi add several physician know have written script never write sovaldi think reflect simplicity harvoni regimen re also see rate adoption little bit faster time carter add caveat take longer insurer approve harvoni prescription many be unprepared sheer volume demand sovaldi wound miss own quarterly financial time insurance company be more organized prepared harvoni launch so be more constraint initially say however say really too early know sure gilead also say still evaluate impact change ireland tax law country budget include close double irish loophole allow company shift profit irish subsidiary tax haven gilead be base california domicile hepatitis intellectual property ireland however company already used loophole have figure alternative determine final rule impact gilead believe worldwide revenue base operation ireland provide option structuring alternative future cfo robin washington say call
2139,GILD,stock future trim early loss relatively quiet premarket session monday dow future pare trade point fair market value vs point dip hour earlier future show loss less point nasdaq future improve point loss
2140,GILD,stock market today
2141,GILD,stock market today open nasdaq fresh high not far index be tow anchor tally distribution day day signal selling institutional investor build rapidly past week temper renew uptrend note caution
2142,GILD,stock action
2143,GILD,big merger news rolled china chemchina china national chemical say pay acquire italy pirelli world fifth largest tire maker tenet healthcare thc punch announce spend launch joint venture ambulatory surgery center privately hold unite surgical care international tenet say also pay acquire base aspen healthcare
2144,GILD,smaller biotechs early motion immunogen imgn leap licensing deal japan takeda pharmaceutical dynavax technology dvax spark
2145,GILD,gilead science gild be warning health care provider friday certain drug combination involve hepatitis drug harvoni sovaldi have produce abnormally slow heartbeat patient die drug produce combine sale nearly last year gilead share have be consolidate october
2146,GILD,overseas
2147,GILD,overseas europe major index be drag moderate loss midday trade market asia gain cue partly friday strong session market shanghai composite be standout gain
2148,GILD,economic news
2149,GILD,week modest economic calendar start quietly monday lead february exist home sale datum due national association realtor et week biggest news be expect friday update fourth quarter gdp growth estimate university michigan final tally march consumer sentiment
2150,GILD,currency commodity
2151,GILD,dollar backtrack vs euro yen oil price narrow early loss benchmark west texas intermediate fraction back barrel gold be essentially flat ounce stock future trim early loss relatively quiet premarket session monday dow future pare trade point fair market value vs point dip hour earlier future show loss less point nasdaq future improve point loss stock market stock market today open nasdaq fresh high not far index be tow anchor tally distribution day day signal selling institutional investor build rapidly past week temper renew uptrend note caution stock big merger news rolled china chemchina china national chemical say pay acquire italy pirelli world fifth largest tire maker tenet healthcare thc punch announce spend launch joint venture ambulatory surgery center privately hold unite surgical care international tenet say also pay acquire base aspen healthcare smaller biotechs early motion immunogen imgn leap licensing deal japan takeda pharmaceutical dynavax technology dvax spark gilead science gild be warning health care provider friday certain drug combination involve hepatitis drug harvoni sovaldi have produce abnormally slow heartbeat patient die drug produce combine sale nearly last year gilead share have be consolidate october europe major index be drag moderate loss midday trade market asia gain cue partly friday strong session market shanghai composite be standout gain economic week modest economic calendar start quietly monday lead february exist home sale datum due national association realtor et week biggest news be expect friday update fourth quarter gdp growth estimate university michigan final tally march consumer sentiment currency dollar backtrack vs euro yen oil price narrow early loss benchmark west texas intermediate fraction back barrel gold be essentially flat ounce
2152,GILD,biotech stock continue slide thursday prompt analyst weigh cause prognosis sector piper jaffray joshua schimmer note same thing happened year spark price debate gilead science gild hepatitis drug sovaldi also valuation concern long runup obviously turn be stellar year biotech believe industry fundamental remain strong write research note still be good year industry once pass latest round selling schimmer write profitable big cap such celgene celg biogen biib alexion pharmaceutical alxn be attractively value relative peer other hand say money lose big cap such vertex pharmaceutical vrtx biomarin pharmaceutical bmrn be more difficult value rbc capital market analyst michael yee report write reasonable make sense correction profit take have be possible give significant outperformance first month yee note be exaggerate move smaller biotechs last week such car stock juno therapeutic juno jump kite pharma kite rise turn revive long run concern biotech bubble kite stock be midday trading stock market today juno stock be fall more wednesday yee add however real bear market be drive poor fundamental say aren evident yet biotech re watch pillar risk biosimilar flux pricing rebate ip risk seem be risk individual company not whole sector write thursday mark fifth straight trading day decline ibd company medical biom biotech group have slump nearly span now still rank group track ibd follow amy reeve twitter ibd_areeve related biotechs track worst week year
2153,GILD,best mutual fund first quarter performance report michael kotlarz take rein oppenheimer capital appreciation fund july fund relative performance have jump year kotlarz take rein fund average annual gain be hold humble return bear market performance lag
2154,GILD,give investor little get excited first quarter big cap benchmark index rise just look hood reveal company be continually ratchete own earning guidance quarter energy material consumer discretionary sector lower most health care financial sector raise most accord just release research factset research system
2155,GILD,stock industry respond expect
2156,GILD,market also punish company large international exposure euro sank dollar rise global economic growth seem slow
2157,GILD,overall only company raise guidance factset consensus estimate other company do so be lowest number say factset number company issue guidance wall street estimate be trail year average
2158,GILD,year year earning be project decline be first decline earning fall sharpest decline financial meltdown company be forecasting earning decline
2159,GILD,company be forecasting growth rate begin quarter
2160,GILD,energy stock take shellacking stock sector issue guidance project decline jan be expect decline end quarter
2161,GILD,company sector issue guidance cut estimate more lead marathon oil mro murphy oil mur hess hes marathon lower guidance profit cent share loss cent
2162,GILD,material sector have expect earning decline compare gain begin quarter freeport mcmoran fcx lower guidance cent share cent accord factset
2163,GILD,company consumer discretionary sector cut growth projection mattel mat go start quarter expect flat project cent share loss amazon amzn go look cent profit expect cent loss
2164,GILD,more optimistic corner stock market health care sector be project best growth rate industry group sector report earning growth biotech be top expect year year gain gilead science gild actavis act expect best growth gilead see growth actavis expect
2165,GILD,separate company significant international exposure factset say stock company more sale outside decline stock company sale rise give investor little get excited first quarter big cap benchmark index rise just look hood reveal company be continually ratchete own earning guidance quarter energy material consumer discretionary sector lower most health care financial sector raise most accord just release research factset research system stock industry respond expect market also punish company large international exposure euro sank dollar rise global economic growth seem slow overall only company raise guidance factset consensus estimate other company do so be lowest number say factset number company issue guidance wall street estimate be trail year average year year earning be project decline be first decline earning fall sharpest decline financial meltdown company be forecasting earning decline company be forecasting growth rate begin quarter energy stock take shellacking stock sector issue guidance project decline jan be expect decline end quarter company sector issue guidance cut estimate more lead marathon oil mro murphy oil mur hess hes marathon lower guidance profit cent share loss cent material sector have expect earning decline compare gain begin quarter freeport mcmoran fcx lower guidance cent share cent accord factset company consumer discretionary sector cut growth projection mattel mat go start quarter expect flat project cent share loss amazon amzn go look cent profit expect cent loss more optimistic corner stock market health care sector be project best growth rate industry group sector report earning growth biotech be top expect year year gain gilead science gild actavis act expect best growth gilead see growth actavis expect separate company significant international exposure factset say stock company more sale outside decline stock company sale rise
2166,GILD,health care internet company be expect have strongest third quarter profit gain ibd consensus analyst estimate medical leader gilead science gild lannett lci exceed growth june quarter result keep company already fast profit growth path gilead make headline friday food drug administration approve
2167,GILD,investor turn bit skittish medical stock monday gilead science gild plunge express script esrx announce support hepatitis drug abbvie abbv rather gilead sovaldi ibd stock spotlight pharmaceutical actavis act valeant pharmaceutical vrx take comparatively mild hit ireland base actavis ease weak trade stock be look
2168,GILD,broader index be mostly tread water monday afternoon blue chip continue outshine
2169,GILD,lift intel intc boee ba ibm ibm dow jone industrial average rally nasdaq edge be fractionally higher volume be tracking sharply lower board stock market today friday turnover be boost expiration option future contract
2170,GILD,lead stock facebook fb rise time high fast trade ibd stock clear buy point first stage flat base facebook reset base count october breach low prior base
2171,GILD,wagework wage be still more pare gain earlier stock clear buy point flat base also be view giant cup handle pattern same buy point last month provider health other employee benefit report jump earning gain sale be best several quarters
2172,GILD,downside gilead science gild come slightly session low be still share slump monday low news express script esrx drop coverage hepatitis drug favor new treatment abbvie abbv share abbvie be reverse early gain
2173,GILD,other biotechs celgene celg biogen idec biib be session lows still broader index be mostly tread water monday afternoon blue chip continue outshine lift intel intc boee ba ibm ibm dow jone industrial average rally nasdaq edge be fractionally higher volume be tracking sharply lower board stock market today friday turnover be boost expiration option future contract lead stock facebook fb rise time high fast trade ibd stock clear buy point first stage flat base facebook reset base count october breach low prior base wagework wage be still more pare gain earlier stock clear buy point flat base also be view giant cup handle pattern same buy point last month provider health other employee benefit report jump earning gain sale be best several quarters downside gilead science gild come slightly session low be still share slump monday low news express script esrx drop coverage hepatitis drug favor new treatment abbvie abbv share abbvie be reverse early gain other biotechs celgene celg biogen idec biib be session lows still
2174,GILD,stock edge higher fourth straight session monday bring positive start holiday shorten trading week rise new close high just point away dec time high help strength chip stock nasdaq climb philadelphia semiconductor index rally dow jone industrial
2175,GILD,many ibd stock be get support week move average continue hold well recent market turbulence biotech stock gilead science gild be work week consolidation possible buy point fall just last week biotech stock whole drop concern sector
2176,GILD,special report best mutual fund february performance report stock mutual fund manager andrew acheson paul cloonan have be kick higher gear pioneer fundamental growth fund average annual return fund rank top large cap growth rival track morningstar inc year end
2177,GILD,more ibd stock be day move average search support key price level large share list find testing average cousin week move average leader cross juncture chart investor learn lot
2178,GILD,growth stock show strength market many different way show tight weekly close refuse give much ground do pull back show support action week move average way great stock show strength weaken market bull market be form flat base price structure have be see decade model book study past stock market winner ibd hilton hlt form advance little more year starbucks sbux form second half early stage new bull market more double week miss initial watch potential flat base form often appear stock break cup handle double bottom flat base stock move sideway tight price range least week show pullback more flat basis show wide loose erratic swing generally be avoid work plenty other win institutional support be truly strong stock trading be tight orderly buy point flat base be cent high left side base future investor corner column identify earlier buy point flat base current sector leader gilead science gild form flat base spawn bullish upward move first clear consolidation late july flat base follow form week show tight trading pullback base form paid visit week move average gilead gap base adjust split early week end nov help news combination experimental hepatitis therapy clear virus patient trial weekly volume week totale share nearly double average time buy stock gap base be buy gilead nov breakaway gap price have be reward nicely gilead be
2179,GILD,fda approve gilead science gild hepatitis combo pill harvoni friday afternoon widely expect still crucial step drug expect be megablockbuster gilead also disclose drug price first time week course harvoni be combination ledipasvir sofosbuvir latter already be sell solo
2180,GILD,stock finished big gain friday post best day session
2181,GILD,blue chip lead dow jone industrial average rise climb nasdaq finished higher preliminary datum show volume come lower yesterday board
2182,GILD,nasdaq finished week fractionally trimming majority loss low week
2183,GILD,walt disney rise more heavy trade friday climb back day move average stock close day line wednesday first time december
2184,GILD,gilead science gild akorn akrx be top performer ibd stock remain base build mode
2185,GILD,worst perform industry group stock market today be gold miner medical software maker
2186,GILD,medical software firm athenahealth athn be heavy trading report line earning issue disappointing guidance
2187,GILD,come week be busy earning report monday illumina ilmn chipotle grill cmg apple aapl valeant pharmaceutical vrx be company report stock finished big gain friday post best day session blue chip lead dow jone industrial average rise climb nasdaq finished higher preliminary datum show volume come lower yesterday board nasdaq finished week fractionally trimming majority loss low week walt disney rise more heavy trade friday climb back day move average stock close day line wednesday first time december gilead science gild akorn akrx be top performer ibd stock remain base build mode worst perform industry group stock market today be gold miner medical software maker medical software firm athenahealth athn be heavy trading report line earning issue disappointing guidance come week be busy earning report monday illumina ilmn chipotle grill cmg apple aapl valeant pharmaceutical vrx be company report
2188,GILD,health care internet company be expect have strongest third quarter profit gain ibd consensus analyst estimate medical leader gilead science gild lannett lci exceed growth june quarter result keep company already fast profit growth path gilead make headline friday food drug administration approve
2189,GILD,stock rally second straight session friday round earning report
2190,GILD,nasdaq rise meanwhile dow jone industrial average outperformed gain procter gamble pg mmm microsoft msft be blue chip index best performer volume fall board stock market today
2191,GILD,week nasdaq jump gain dow rise
2192,GILD,lead stock gilead science gild rise time high stock take resistance level clear buy point consolidation volume be only average gilead report earning tuesday analyst see profit surge share stock be featured friday stock spotlight
2193,GILD,alibaba group baba pare gain still rise extend streak straight session bmo capital market start coverage chinese commerce giant outperform rating price target september new issue be build first stage ipo base buy point
2194,GILD,tal education group xrs climb nearly third straight gain rise sterne agee lower stock price target trimming earning estimate cent share
2195,GILD,downside amazon com amzn gap slump huge trade share hit month low friday reaction late thursday disappointing quarterly result amazon com receive barrage downgrade price target cut riley cantor fitzgerald cowen janney capital pacific crest stock rally second straight session friday round earning report nasdaq rise meanwhile dow jone industrial average outperformed gain procter gamble pg mmm microsoft msft be blue chip index best performer volume fall board stock market today week nasdaq jump gain dow rise lead stock gilead science gild rise time high stock take resistance level clear buy point consolidation volume be only average gilead report earning tuesday analyst see profit surge share stock be featured friday stock spotlight alibaba group baba pare gain still rise extend streak straight session bmo capital market start coverage chinese commerce giant outperform rating price target september new issue be build first stage ipo base buy point tal education group xrs climb nearly third straight gain rise sterne agee lower stock price target trimming earning estimate cent share downside amazon com amzn gap slump huge trade share hit month low friday reaction late thursday disappointing quarterly result amazon com receive barrage downgrade price target cut riley cantor fitzgerald cowen janney capital pacific crest
2196,GILD,december be usually quiet month medical tech news year bring few potentially stock move event worth keep eye digest thanksgiving turkey here be top chronological order dec biotech incyte incy be look get important expansion label sole market drug jakafi explain recent incyte profile new america incyte partner novartis nvs have be pull respectable income jakafi treatment rare bone marrow cancer call myelofibrosis fda be ponder add indication polycythemia vera milder more common condition uptake condition be expect be fairly slow expect help push incyte more consistently profitable territory next year day later hot medical device company edward lifescience ew hold annual investor day be expect give guidance first time company impressed street last month strong report guidance strong launch latest sapien artificial heart valve currently analyst be forecasting sale year estimate earning share be expect rise then sometime dec likely mean dec fda be due issue verdict abbvie abbv hepatitis combo viekirax exviera clinical trial datum be so good street probably be less surprised meteor hit manhattan fda reject drug have analyst pin needle be price be price significantly lower gilead science gild recently launch harvoni cost week treatment help abbvie gain market share certainly please pharmacy benefit manager express script esrx have be hope start price war drive suddenly high cost hepatitis treatment however most analyst be expect abbvie price only little bit lower also affected be enanta pharmaceutical enta license component viekirax abbvie speaking hepatitis sometime end year street be expect hear phase clinical trial datum achillion pharmaceutical achn drug belong coveted nucleoside inhibitor class gilead mega blockbuster sovaldi also component harvoni belong have otherwise show enough safety issue be few left development especially merck mrk acquire idenix pharmaceutical nuc speculation achillion be next target have drive stock price street have see little real datum safety effectiveness datum help analyst determine just much company be worth speculation exist abort takeover attempt earlier year be re up street seem have mostly give possibility pfizer pfe make bid astrazeneca azn month cool period mandate takeover rule expire wednesday astra ceo pascal soriot throw more cold water appear cnbc thursday say deal have fall apart even have be make propose restriction tax inversion deal however rbc capital market analyst glenn novarro be still hold hope union orthopedic firm stryker syk nephew snn stryker didn bid company news report leak be work get slap month cool period anyway expire nov believe syk snn deal provide more recon reconstructive surgery scale particularly international market expand syk presence trauma sport medicine bring cost synergy novarro write note friday
2197,GILD,market linger correction use time build watch list investor need be ready buy lead stock come basis new uptrend arrive biotech gilead science gild be form flat base buy point pattern be second stage structure gilead break first stage cup
2198,GILD,many lead stock be see limit upside instead continue work current pattern wait market condition improve case medical make wednesday stock spotlight screen akorn akrx alexion pharmaceutical alxn gilead science gild akorn rally breaking past cup handle buy point aug high
2199,GILD,market be correction be several big cap medical stock buck downtrend ibd tv alissa william break top gilead science gild actavis act alexion pharmaceutical alxn follow alissa william twitter ibd_awilliam
2200,GILD,sector leader be ibd toughest screen single company best fundamental most technically sound stock correction past few week have not only reduce number remain be suffering technical damage most have drop week line often intermediate support area stock investor watch closely
2201,GILD,stock reversed higher close bell monday end session skid rout china stock market further drop oil price
2202,GILD,dow jone industrial average rise edge nasdaq dip volume stock market today rise nasdaq nyse compare friday accord preliminary datum
2203,GILD,energy mining biotech stock lag department store hospital tobacco stock lead upside
2204,GILD,aluminum producer alcoa aa rise hour follow earning report stock end regular session nearly decline eighth straight session
2205,GILD,macy lead rise strong volume investment advisory firm starboard value reportedly say monday support department store recent joint venture mall base real estate property other department store stock also rally kohl kss rise dd
2206,GILD,sour note ibd stock celgene celg drop nearly lowest level month biotech offer guidance name coo mark alle new ceo start march current chief bob hugin become executive chairman
2207,GILD,company due report quarterly result tuesday include csx csx ihs ihs
2208,GILD,labor department be due release closely watch job opening labor turnover survey jolt tuesday stock reversed higher close bell monday end session skid rout china stock market further drop oil price dow jone industrial average rise edge nasdaq dip volume stock market today rise nasdaq nyse compare friday accord preliminary datum energy mining biotech stock lag department store hospital tobacco stock lead upside aluminum producer alcoa aa rise hour follow earning report stock end regular session nearly decline eighth straight session macy lead rise strong volume investment advisory firm starboard value reportedly say monday support department store recent joint venture mall base real estate property other department store stock also rally kohl kss rise dd sour note ibd stock celgene celg drop nearly lowest level month biotech offer guidance name coo mark alle new ceo start march current chief bob hugin become executive chairman company due report quarterly result tuesday include csx csx ihs ihs labor department be due release closely watch job opening labor turnover survey jolt tuesday
2209,GILD,talk consistent tom marsico industry dwindle number marquee mutual fund manager have be columbia marsico focuse equity predecessor dec start average annual return past year have rank top
2210,GILD,arrival third quarter earning season investor watch company deliver big increase bottom line investor seek company quarterly earning growth least sector leader tuesday paper be expect post profit gain much greater gilead science gild be slate post earning
2211,GILD,stock hold much gain go final hour trading tuesday en route finishing first day
2212,GILD,nasdaq rise climb dow jone industrial average gain volume be run higher monday pace be depress columbus day holiday
2213,GILD,domino pizza dpz break saucer handle base soar nearly big volume report earning be year earlier result beat estimate
2214,GILD,skywork solution swks be lift sale earning forecast stock have see heavy selling recent day continue trade day move average stock market today
2215,GILD,ibd stock be higher be lower best performer be chinese automobile athm be more worst performer be gilead science gild have plunge further day line big volume stock be build new base have be heavy selling recent week
2216,GILD,citigroup be stock report earning open help give market early lift ep be year level stock hold much gain go final hour trading tuesday en route finishing first day nasdaq rise climb dow jone industrial average gain volume be run higher monday pace be depress columbus day holiday domino pizza dpz break saucer handle base soar nearly big volume report earning be year earlier result beat estimate skywork solution swks be lift sale earning forecast stock have see heavy selling recent day continue trade day move average stock market today ibd stock be higher be lower best performer be chinese automobile athm be more worst performer be gilead science gild have plunge further day line big volume stock be build new base have be heavy selling recent week citigroup be stock report earning open help give market early lift ep be year level
2217,GILD,big pharma bristol myer squibb bmy say monday drop effort get drug treatment hepatitis approve continue pursue other aspect hep strategy bristol myer stock be morning trading stock market today bristol press release cite rapidly evolve hepatitis treatment
2218,GILD,many lead stock have be form flat basis market undergo series fairly shallow pullback flat base stock correct less ideal buy point typically cent high left side leader hold market correction be have trouble advance thus remain flat base
2219,GILD,earning season be rev here be company high ibd composite rating report quarterly result tuesday johnson johnson jnj report open be expect earn share last year revenue be see rise health care product maker announce late september be buy
2220,GILD,gilead science gild be california base pharmaceutical company product line include hepatitis drug sovaldi be introduce dec have better cure rate competition week gilead be featured ibd sector leader review mentioned company have lot go hepatitis drug soon
2221,GILD,gilead science gild stock be rebound afternoon trading stock market today analyst lift forecast sale blockbuster hepatitis drug sovaldi fbr analyst andrew beren raise estimate examine august prescription datum health industry research firm symphony health solution record breaking launch follow approval last december sovaldi sale have slow summer have be generally interpreted doctor warehousing patient ahead launch gilead hep drug expect october well possible price competition abbvie abbv therapy expect launch december beren however say find less warehousing expect analysis first month projection remain month show sovaldi prescription tracking previous estimate suggest formation second warehouse ahead anticipate launch oral therapy be slower anticipate write research note tuesday report help arrest decline gilead stock fall monday news allow generic sovaldi poor country gilead stock open lower tuesday mid afternoon be gilead stock touch time high
2222,GILD,company be set report next few day earning season really rev next several week result google googl ebay ebay jpmorgan chase jpm gilead science gild unite rental uri more investor expect ibd tv alissa william have detail follow alissa william twitter ibd_awilliam
2223,GILD,big pharma merck affirm wednesday ll present much anticipate datum hepatitis program next month american association study liver disease liver meeting investor have meeting find actual datum bristol myer squibb bmy be more forthcoming result fail ignite stock merck mrk
2224,GILD,tango have turn full hoedown several major pharmaceutical company continue change partner floor valeant pharmaceutical vrx persh square capital management reportedly up bid tuesday allergan agn share accord wall street journal new bid raise valeant bid
2225,GILD,part solid approach investing be become aware factor work stock gilead science gild have several thing go current earning growth be huge compare year earlier earning rise revenue rise street expect ep
2226,GILD,medical giant johnson johnson jnj kick industry earning season strong note sale earning beat early tuesday stock be morning trading stock market today earning exclude time item rise year earlier quarter share beating analyst estimate cent
2227,GILD,stock market close higher thursday index pare gain
2228,GILD,nasdaq climb dow jone industrial average add
2229,GILD,volume rise nyse fall nasdaq accord early figure advance stock lead decliner nasdaq winner barely edge loser nyse
2230,GILD,computer trucking financial rank day top perform sector retail metal energy stock lag
2231,GILD,weak forecast send homebuilding stock stock market today
2232,GILD,meritage home mth cut forecast earning cite rise labor cost delay closing slower expect business company newer market southeast stock fall heavy trading lowest level early february
2233,GILD,be shortage skilled labor many market subcontractor struggle catch increase demand continue recovery homebuilding say chairman ceo steven hilton competition labor be raise cost lengthen construction time statement add bad weather part texas colorado further hurt company
2234,GILD,homebuilder industry group have be market leader be worst group thursday ibd track
2235,GILD,day biggest loser be lululemon athletica lulu plunge yoga style apparel chain guide full year earning expectation share fall lowest level december
2236,GILD,google googl rise share continue rise support day move average volume google be light
2237,GILD,close share action sport retailer zumiez zumz slide company announce quarterly result stock close regular trading week low
2238,GILD,follow juan carlos arancibia twitter ibd_jarancibia stock market close higher thursday index pare gain nasdaq climb dow jone industrial average add volume rise nyse fall nasdaq accord early figure advance stock lead decliner nasdaq winner barely edge loser nyse computer trucking financial rank day top perform sector retail metal energy stock lag weak forecast send homebuilding stock stock market today meritage home mth cut forecast earning cite rise labor cost delay closing slower expect business company newer market southeast stock fall heavy trading lowest level early february be shortage skilled labor many market subcontractor struggle catch increase demand continue recovery homebuilding say chairman ceo steven hilton competition labor be raise cost lengthen construction time statement add bad weather part texas colorado further hurt company homebuilder industry group have be market leader be worst group thursday ibd track day biggest loser be lululemon athletica lulu plunge yoga style apparel chain guide full year earning expectation share fall lowest level december google googl rise share continue rise support day move average volume google be light close share action sport retailer zumiez zumz slide company announce quarterly result stock close regular trading week low follow juan carlos arancibia twitter ibd_jarancibia
2239,GILD,drama continue big biotech gilead science tuesday johnson johnson moved viral disease turf front acquisition
2240,GILD,johnson johnson jnj disclose buy privately hold alio biopharma cash press release tout alio drug candidate respiratory syncytial virus rsv major cause lung infection have current treatment drug al be midstage clinical testing
2241,GILD,happen gilead gild also have rsv drug gs phase clinical trial be overshadowed gilead bigger drug rbc capital market analyst michael yee believe have blockbuster potential astrazeneca azn synagis used prevent rsv infection high risk infant draw more year just niche market
2242,GILD,yee point research note tuesday alio be potential competitor gilead way have nucleotide drug hepatitis virus hcv early stage development
2243,GILD,gilead megablockbuster sovaldi be first nucleotide drug hcv hit market back december year merck mrk shell buy idenix pharmaceutical also have nuke development
2244,GILD,not new hep
2245,GILD,be also hcv game drug olysio be different class drug not directly competitive sovaldi
2246,GILD,be often prescribe together have help buoy olysio sale launch last november first half year alone sell give success combo not surprising want nuke own
2247,GILD,clearly think long term call option upside here be alio nuke show log reduction hcv virus have good safety profile yee write course be not layup know development nuke be extremely difficult bar continue progression be very high reminder vertex vrtx be partner prior alio nuke drop development due narrow therapeutic window weak efficacy have sign liver toxicity
2248,GILD,yee also write be interesting see development read achillion pharmaceutical achn stock boast ibd relative strength rating base largely expectation be next nuke developer be buy investor seem be read negatively achillion stock fall tuesday close
2249,GILD,still maxim group analyst achillion bull jason kolbert do not sound very worry
2250,GILD,alio nuke be old news kolbert tell ibd think achn be be bit nonsense nuke show good datum be race
2251,GILD,high price sovaldi
2252,GILD,investor analyst be interested future competition sovaldi not just effect market share also sovaldi price have question day
2253,GILD,gilead charge day treatment typically run week
2254,GILD,monday government france address issue social security budget bill propose new taxe seller hepatitis drug revenue make france social security have spend more euro drug government call progressive contribution scheme
2255,GILD,budget still have be approve lawmaker sign european country be continue drive hard bargain gilead roll sovaldi eu approve sovaldi sale january country have own payment system drugmaker have negotiate separately
2256,GILD,however july france joined other country coordinate strategy drive sovaldi price
2257,GILD,gilead stock slip tuesday close drama continue big biotech gilead science tuesday johnson johnson moved viral disease turf front acquisition johnson johnson jnj disclose buy privately hold alio biopharma cash press release tout alio drug candidate respiratory syncytial virus rsv major cause lung infection have current treatment drug al be midstage clinical testing happen gilead gild also have rsv drug gs phase clinical trial be overshadowed gilead bigger drug rbc capital market analyst michael yee believe have blockbuster potential astrazeneca azn synagis used prevent rsv infection high risk infant draw more year just niche market yee point research note tuesday alio be potential competitor gilead way have nucleotide drug hepatitis virus hcv early stage development gilead megablockbuster sovaldi be first nucleotide drug hcv hit market back december year merck mrk shell buy idenix pharmaceutical also have nuke development not new hep cj be also hcv game drug olysio be different class drug not directly competitive sovaldi be often prescribe together have help buoy olysio sale launch last november first half year alone sell give success combo not surprising want nuke own clearly think long term call option upside here be alio nuke show log reduction hcv virus have good safety profile yee write course be not layup know development nuke be extremely difficult bar continue progression be very high reminder vertex vrtx be partner prior alio nuke drop development due narrow therapeutic window weak efficacy have sign liver toxicity yee also write be interesting see development read achillion pharmaceutical achn stock boast ibd relative strength rating base largely expectation be next nuke developer be buy investor seem be read negatively achillion stock fall tuesday close still maxim group analyst achillion bull jason kolbert do not sound very worry alio nuke be old news kolbert tell ibd think achn be be bit nonsense nuke show good datum be race high price sovaldiinvestor analyst be interested future competition sovaldi not just effect market share also sovaldi price have question day gilead charge day treatment typically run week monday government france address issue social security budget bill propose new taxe seller hepatitis drug revenue make france social security have spend more euro drug government call progressive contribution scheme budget still have be approve lawmaker sign european country be continue drive hard bargain gilead roll sovaldi eu approve sovaldi sale january country have own payment system drugmaker have negotiate separately however july france joined other country coordinate strategy drive sovaldi price gilead stock slip tuesday close
2258,GILD,share gilead science gild be news drugmaker be reportedly near licensing deal bring blockbuster hepatitis drug sovaldi develop country such india pakistan generic drugmaker be able manufacture best selling hepatitis therapy well experimental sovaldi hybrid accord bloomberg pricing be sore spot gilead much have be make drug pill price tag be probably cause chatter bellwether biotech today fbr capital market andrew beren tell ibd so much gilead value drug say beren person be really really scared anything cause volatility lot discounting go already say sovaldi likely have discount already apply retail value week course prison governmental health program gilead intend retail sovaldi less affluent country only same course report bloomberg investor be worry government be go say be go give away india re pay patient say beren make more foil re charge recent medium attention regard sovaldi be cause share dip say rbc capital market analyst michael yee note make pharmaceutical available lower income country discount be nothing new be something already do hiv pill be already expect say yee be worth look say fbr beren be abbvie abbv anticipate hepatitis treatment investor be keep eye drug pricing be go become very interesting market once abbvie launch drug say follow elaine low twitter ibd_elow
2259,GILD,european commission ec approve gilead science gild drug zydelig blood cancer friday send gilead stock much share be flat midday trading stock market today ec approve drug chronic lymphocytic leukemia follicular lymphoma former be be used combination
2260,GILD,earning season be right corner so smart investor look company expect post strong earning gain fall
2261,GILD,ibd list be good place start rank best growth stock base top fundamental such strong relative price strength market
2262,GILD,biotechs pharmaceutical chinese tech firm dominate list top company highest expect earning growth quarter just end
2263,GILD,gilead science gild top list analyst expect jump earning drugmaker blockbuster drug sovaldi cure hepatitis new pill combine sovaldi drug be expect get approve end month
2264,GILD,sovaldi cost nearly pill week regimen cost major turn patient
2265,GILD,gilead have grant sovaldi license generic drugmaker datum suggest more hep patient have stop take sovaldi new treatment become available
2266,GILD,fbr capital analyst andrew beren recently raise estimate sovaldi sale say prescription be still tracking forecast
2267,GILD,last month gilead also report positive datum trial latest hiv drug analyst expect be blockbuster company plan file drug approval eu next quarter hiv medication account nearly revenue
2268,GILD,athm be second expect jump earning china lead auto content web company have be ride boom china new car market nearly new vehicle be sell china vs
2269,GILD,be outperform rival bitauto bita be also ibd list expect jump quarterly earning
2270,GILD,chinese internet stock recently hit rough patch worry slow growth china lack new stimulus measure beij
2271,GILD,alibaba baba hotly anticipate ipo last month restore buzz sector
2272,GILD,alibaba still have prove worth record ipo vipshop holding vip be already success story
2273,GILD,rank list expect jump earning chinese online clothing retailer have poor debut share have steadily rise then
2274,GILD,popularity apple aapl iphone china be help technology avgo earning be expect rise singapore base chipmaker component be featured smartphone
2275,GILD,iphone finally come china mobile chl largest wireless service provider country january chinese order new iphone reach whopping reservation china friday follow regulatory approval earlier week
2276,GILD,salix pharmaceutical slxp round top jump expect earning maker disorder drug be talk sell actavis act accord report bloomberg late thursday
2277,GILD,salix cancele propose tax inversion merger italy cosmo pharmaceutical government have be tighten regulation overseas deal deal cancellation be see clear way actavis acquisition
2278,GILD,salix be buyout talk botox maker allergan agn be fight takeover bid valeant vrx actavis now close salix allergan defense valeant be weaken
2279,GILD,follow gillian rich twitter ibd_grich earning season be right corner so smart investor look company expect post strong earning gain fall ibd list be good place start rank best growth stock base top fundamental such strong relative price strength market biotechs pharmaceutical chinese tech firm dominate list top company highest expect earning growth quarter just end gilead science gild top list analyst expect jump earning drugmaker blockbuster drug sovaldi cure hepatitis new pill combine sovaldi drug be expect get approve end month sovaldi cost nearly pill week regimen cost major turn patient gilead have grant sovaldi license generic drugmaker datum suggest more hep patient have stop take sovaldi new treatment become available fbr capital analyst andrew beren recently raise estimate sovaldi sale say prescription be still tracking forecast last month gilead also report positive datum trial latest hiv drug analyst expect be blockbuster company plan file drug approval eu next quarter hiv medication account nearly revenue athm be second expect jump earning china lead auto content web company have be ride boom china new car market nearly new vehicle be sell china vs be outperform rival bitauto bita be also ibd list expect jump quarterly earning chinese internet stock recently hit rough patch worry slow growth china lack new stimulus measure beij alibaba baba hotly anticipate ipo last month restore buzz sector alibaba still have prove worth record ipo vipshop holding vip be already success story rank list expect jump earning chinese online clothing retailer have poor debut share have steadily rise then popularity apple aapl iphone china be help technology avgo earning be expect rise singapore base chipmaker component be featured smartphone iphone finally come china mobile chl largest wireless service provider country january chinese order new iphone reach whopping reservation china friday follow regulatory approval earlier week salix pharmaceutical slxp round top jump expect earning maker disorder drug be talk sell actavis act accord report bloomberg late thursday salix cancele propose tax inversion merger italy cosmo pharmaceutical government have be tighten regulation overseas deal deal cancellation be see clear way actavis acquisition salix be buyout talk botox maker allergan agn be fight takeover bid valeant vrx actavis now close salix allergan defense valeant be weaken follow gillian rich twitter ibd_grich
2280,GILD,do make trading decision daily chart so take deep breath reconsider re do weekly chart help identify lot thing daily chart not stock look poise trigger sell signal early week daily chart
2281,GILD,biotech stock be gainer stock market friday standout be rare drug company alexion pharmaceutical alxn shot
2282,GILD,biotech group rank group track investor business daily just week
2283,GILD,other medical group be ibd top include hospital ethical drug week
2284,GILD,hospital have benefit health care reform obamacare have see healthy share gain recent month group pull back last week rise nearly friday
2285,GILD,hca holding hca largest hospital group market capitalization rise nearly
2286,GILD,ethical drug group jazz pharmaceutical jazz jump friday botox maker allergan agn shopping acquisition get hostile bidder valeant pharmaceutical vrx back shot nearly jazz have be rumore possible candidate
2287,GILD,biotech group hepatitis drug maker gilead science gild regeneron pharmaceutical regn ibd leaderboard stock end have be disappointing week high note regeneron climb friday gilead nearly
2288,GILD,related jazz pharmaceutical used new cash buy growth biotech stock be gainer stock market friday standout be rare drug company alexion pharmaceutical alxn shot biotech group rank group track investor business daily just week other medical group be ibd top include hospital ethical drug week hospital have benefit health care reform obamacare have see healthy share gain recent month group pull back last week rise nearly friday hca holding hca largest hospital group market capitalization rise nearly ethical drug group jazz pharmaceutical jazz jump friday botox maker allergan agn shopping acquisition get hostile bidder valeant pharmaceutical vrx back shot nearly jazz have be rumore possible candidate biotech group hepatitis drug maker gilead science gild regeneron pharmaceutical regn ibd leaderboard stock end have be disappointing week high note regeneron climb friday gilead nearly related jazz pharmaceutical used new cash buy growth
2289,GILD,big cap biotech ibd stock gilead science put important brick fortress competition wednesday report positive trial datum latest hiv drug stock rise news drug call tenofovir alafenamide taf have be nickname son viread wall street new improve version
2290,GILD,dropout rate patient gilead science hepatitis treatment sovaldi be quadruple be see clinical trial datum show wednesday
2291,GILD,cvs health cvs research institute researcher find real world use gilead gild blockbuster drug reflect discontinuation rate vs approximate rate trial
2292,GILD,study also find patient new hepatitis treatment be less likely complete course treatment overall sovaldi use have plateau decline august
2293,GILD,share fall be high
2294,GILD,cvs datum add concern sovaldi sale be slow doctor patient be wait gilead next version hepatitis fighter hit market fall well treatment abbvie abbv year end
2295,GILD,such warehousing patient be not high anticipate sovaldi prescription so far tracking estimate fbr analyst andrew beren say tuesday also lift sovaldi sale forecast
2296,GILD,meantime gilead be try expand access drug develop country announce monday license sovaldi indian generic drug manufacturer
2297,GILD,also wednesday gilead release result study explore simtuzumab combine gemcitabine benefit untreated advanced pancreatic cancer researcher find treatment do not do not significantly increase progression free survival compare placebo combination dropout rate patient gilead science hepatitis treatment sovaldi be quadruple be see clinical trial datum show wednesday cvs health cvs research institute researcher find real world use gilead gild blockbuster drug reflect discontinuation rate vs approximate rate trial study also find patient new hepatitis treatment be less likely complete course treatment overall sovaldi use have plateau decline august share fall be high cvs datum add concern sovaldi sale be slow doctor patient be wait gilead next version hepatitis fighter hit market fall well treatment abbvie abbv year end such warehousing patient be not high anticipate sovaldi prescription so far tracking estimate fbr analyst andrew beren say tuesday also lift sovaldi sale forecast meantime gilead be try expand access drug develop country announce monday license sovaldi indian generic drug manufacturer also wednesday gilead release result study explore simtuzumab combine gemcitabine benefit untreated advanced pancreatic cancer researcher find treatment do not do not significantly increase progression free survival compare placebo combination
2298,GILD,major average give back big gain wednesday then stock sell renew worry global economy
2299,GILD,lead rout drop nasdaq dow industrial lose dow point slump be biggest year volume be lighter nyse nasdaq accord preliminary datum
2300,GILD,jobless claim fall week end oct forecast prior week upwardly revise claim have come fourth consecutive week
2301,GILD,farm machinery maker security stock be only group gain stock market today solar power oil gas steel producer stock be biggest loser
2302,GILD,oil related play slide board anadarko petroleum apc atla energy atls tidewater tdw whiting petroleum wll slump more heavy trade november crude oil price close lowest level december new york mercantile exchange
2303,GILD,ibd stock weren spare most pull back light average volume include actavis act facebook fb gilead science gild
2304,GILD,zumiez zumz manage buck sell gap close gain reclaim day move average double normal volume stock extend gain wednesday apparel maker report increase september same store sale well view
2305,GILD,economic datum tap friday include import export price september treasury budget also september
2306,GILD,follow nancy gondo twitter ibd_ngondo major average give back big gain wednesday then stock sell renew worry global economy lead rout drop nasdaq dow industrial lose dow point slump be biggest year volume be lighter nyse nasdaq accord preliminary datum jobless claim fall week end oct forecast prior week upwardly revise claim have come fourth consecutive week farm machinery maker security stock be only group gain stock market today solar power oil gas steel producer stock be biggest loser oil related play slide board anadarko petroleum apc atla energy atls tidewater tdw whiting petroleum wll slump more heavy trade november crude oil price close lowest level december new york mercantile exchange ibd stock weren spare most pull back light average volume include actavis act facebook fb gilead science gild zumiez zumz manage buck sell gap close gain reclaim day move average double normal volume stock extend gain wednesday apparel maker report increase september same store sale well view economic datum tap friday include import export price september treasury budget also september follow nancy gondo twitter ibd_ngondo
2307,GILD,acorda therapeutic acor stock pop biotechnology company agree buy privately hold civita therapeutic gain access drug late development used treat parkinson disease acorda obtain global right civita experimental drug cvt inhaled dry powder formulation cvt be used treat certain episode such inability move patient parkinson disease acquisition also include right civita arcus pulmonary delivery technology manufacturing facility chelsea mass acquisition add exciting product candidate acorda pipeline address significant unmet need parkinson disease acorda ceo ron cohen say statement also leverage acorda exist development commercial capability create opportunity develop global presence addition civita arcus technology add proprietary platform potential future development opportunity share acorda be nearly midday trading stock market today ibd medical biom biotech group be rank industry group include gilead science gild regeneron pharmaceutical regn biogen idec biib amgen amgn rbc capital market analyst michael yee say see positive negative aspect deal regard civita acquisition be lukewarm due clinical mostly regulatory risk inhaled old drug yee say note wednesday inhaled drug require specific pre clinical clinical datum related parkinson consistency long term chronic lung safety animal human other regulatory datum specific inhaled drug sometimes aren always clear end regulatory reviews make particularly tricky prior example include alexza mannkind didn get first pass however long term risk be manageable say also commercial opportunity seem logical need be better understood not drive huge value reach market post yee say
2308,GILD,stock rise friday european central bank hint new stimulus measure boost inflation major average end intraday high
2309,GILD,nasdaq rise dow jone industrial average gain be volume be mixed stock market today rise nyse fall nasdaq compare thursday accord preliminary figure
2310,GILD,european central bank head mario draghi suggest ecb introduce new stimulus measure dec meeting
2311,GILD,retailer medical apparel stock lead upside datum storage energy steel stock underperform
2312,GILD,nike nke lead dow ibd jump heavy volume announce stock split share buyback dividend increase late thursday stock be well extend past buy point have find support day move average
2313,GILD,alaska air alk be also best perform ibd stock regional airline climb nearly line oil plunge barrel near buy point flat base hawaiian holding also rise nearly carrier be just time high well buy range
2314,GILD,downside mentor graphic ment plunge week low mentor developer software used test electronic system issue disappointing quarterly earning report stock rise friday european central bank hint new stimulus measure boost inflation major average end intraday high nasdaq rise dow jone industrial average gain be volume be mixed stock market today rise nyse fall nasdaq compare thursday accord preliminary figure european central bank head mario draghi suggest ecb introduce new stimulus measure dec meeting retailer medical apparel stock lead upside datum storage energy steel stock underperform nike nke lead dow ibd jump heavy volume announce stock split share buyback dividend increase late thursday stock be well extend past buy point have find support day move average alaska air alk be also best perform ibd stock regional airline climb nearly line oil plunge barrel near buy point flat base hawaiian holding also rise nearly carrier be just time high well buy range downside mentor graphic ment plunge week low mentor developer software used test electronic system issue disappointing quarterly earning report
2315,GILD,stock future deepen early loss ahead tuesday open weaker expect september durable good report dow future trade point be fall future slip point
2316,GILD,nasdaq future have pare loss past hour reversed fall point fair market value
2317,GILD,stock market today face busy session federal open market committee swing day meeting washington policy announcement due wednesday afternoon
2318,GILD,great many investor be tune aftermarket session apple aapl be schedule report fiscal result
2319,GILD,economic news open durable good order slip september accord commerce department be bit projection decline department also revise august decline transportation order dip august flat performance deeper project slip
2320,GILD,case shiller report city composite home price index august et researcher markit release preliminary purchasing manager index estimate service conference board plan report october consumer confidence index
2321,GILD,earning action be thick heavy roll tuesday open
2322,GILD,beleaguered german chip equipment maker aixtron aixg spiked base big oil play bp bp add almost big pharma name merck mrk pfizer pfe rolled gain report better expect result
2323,GILD,downside frac sand quarrier crush partner hclp implode miss earning forecast suspend cash distribution rent center rcii post premarket meltdown miss revenue expectation lower full year earning guidance ford slip unite parcel service up dim
2324,GILD,alibaba baba rumble bell launch premarket rally many china base stock china base diversify internet play report ep gain rise revenue fiscal easily top consensus forecast mobile revenue rise cloud compute internet infrastructure revenue rise
2325,GILD,company also announce security exchange commission give notice conclude inquiry enforcement action be recommend alibaba share end monday day move average stock have climb late september low leave still nov high ipo price
2326,GILD,yahoo yhoo ahead early tuesday investor account increase value yahoo stake alibaba yahoo remain deep month consolidation
2327,GILD,other china base internet play catch alibaba premarket heat jd com jd com wbai pop jumei international jmei vipshop vip jump apiece
2328,GILD,chip developer marvell technology mrvl tank announce late monday have resign company accounting firm marvell september announce internal investigation revenue be recognize earlier have be marvell share have be steep correction february
2329,GILD,cummin cmi dive miss expectation earning revenue line management lower full year revenue outlook flat vs prior guidance gain columbus ind base diesel engine maker also announce lay worker share have be deepen decline june
2330,GILD,leader ibd stock be relatively quiet more group unmoved premarket trade
2331,GILD,gainer cirrus logic crus rise topple heavy trade monday stock post decline more stock future deepen early loss ahead tuesday open weaker expect september durable good report dow future trade point be fall future slip point nasdaq future have pare loss past hour reversed fall point fair market value stock market today face busy session federal open market committee swing day meeting washington policy announcement due wednesday afternoon great many investor be tune aftermarket session apple aapl be schedule report fiscal result economic news open durable good order slip september accord commerce department be bit projection decline department also revise august decline transportation order dip august flat performance deeper project slip case shiller report city composite home price index august et researcher markit release preliminary purchasing manager index estimate service conference board plan report october consumer confidence index earning action be thick heavy roll tuesday open beleaguered german chip equipment maker aixtron aixg spiked base big oil play bp bp add almost big pharma name merck mrk pfizer pfe rolled gain report better expect result downside frac sand quarrier crush partner hclp implode miss earning forecast suspend cash distribution rent center rcii post premarket meltdown miss revenue expectation lower full year earning guidance ford slip unite parcel service up dim alibaba baba rumble bell launch premarket rally many china base stock china base diversify internet play report ep gain rise revenue fiscal easily top consensus forecast mobile revenue rise cloud compute internet infrastructure revenue rise company also announce security exchange commission give notice conclude inquiry enforcement action be recommend alibaba share end monday day move average stock have climb late september low leave still nov high ipo price yahoo yhoo ahead early tuesday investor account increase value yahoo stake alibaba yahoo remain deep month consolidation other china base internet play catch alibaba premarket heat jd com jd com wbai pop jumei international jmei vipshop vip jump apiece chip developer marvell technology mrvl tank announce late monday have resign company accounting firm marvell september announce internal investigation revenue be recognize earlier have be marvell share have be steep correction february cummin cmi dive miss expectation earning revenue line management lower full year revenue outlook flat vs prior guidance gain columbus ind base diesel engine maker also announce lay worker share have be deepen decline june leader ibd stock be relatively quiet more group unmoved premarket trade gainer cirrus logic crus rise topple heavy trade monday stock post decline more
2332,GILD,big cap biotech ibd stock gilead science gild say monday licensing megablockbuster hepatitis drug sovaldi indian generic drug company improve access develop country gilead stock fall stock market today
2333,GILD,sovaldi licensing deal include big name indian drug business such ranbaxy lab cipla well base mylan myl drugmaker be able set own price version sofosbuvir sovaldi be call generically presumably serious discount price week course treatment gilead have already price drug much lower different market instance egypt be poorer have severe hepatitis problem round treatment only cost gilead point press release strategy be first develop gilead hiv drug such viread truvada make gilead original fortune be otherwise price reach many person world need
2334,GILD,release also say company be authorize make sofosbuvir combination other medicine include gilead ledipasvir gilead be currently await approval sofosbuvir ledipasvir pill have show be better sofosbuvir alone treat patient most common genotype virus also bristol myer squibb bmy daklinza have be approve europe use combination sofosbuvir indian company presumably have make own deal bristol manufacture together
2335,GILD,news wasn surprise rumor generic sovaldi deal be circulate earlier month add volatility stock however analyst have be less concern base long experience do same thing hiv drug
2336,GILD,follow amy reeve twitter ibd_areeve big cap biotech ibd stock gilead science gild say monday licensing megablockbuster hepatitis drug sovaldi indian generic drug company improve access develop country gilead stock fall stock market today sovaldi licensing deal include big name indian drug business such ranbaxy lab cipla well base mylan myl drugmaker be able set own price version sofosbuvir sovaldi be call generically presumably serious discount price week course treatment gilead have already price drug much lower different market instance egypt be poorer have severe hepatitis problem round treatment only cost gilead point press release strategy be first develop gilead hiv drug such viread truvada make gilead original fortune be otherwise price reach many person world need release also say company be authorize make sofosbuvir combination other medicine include gilead ledipasvir gilead be currently await approval sofosbuvir ledipasvir pill have show be better sofosbuvir alone treat patient most common genotype virus also bristol myer squibb bmy daklinza have be approve europe use combination sofosbuvir indian company presumably have make own deal bristol manufacture together news wasn surprise rumor generic sovaldi deal be circulate earlier month add volatility stock however analyst have be less concern base long experience do same thing hiv drug follow amy reeve twitter ibd_areeve
2337,GILD,recent volatility stock market include outlook shift uptrend pressure back confirm uptrend have rattle investor nerve also help set new potential entry lead stock slip buy range pull back week move average line ibd gain week outperform
2338,GILD,stock step ahead flat volume thursday day federal reserve calm market do essentially nothing nasdaq advanced rise ibd add volume inched nasdaq rise sliver nyse strike new high tip market
2339,GILD,ibd just capped best week performance more year run produce batch breakout index rally past week best week period july ibd roar last week ibd add be comparable nasdaq
2340,GILD,stock be slightly higher midday wednesday seesaw session
2341,GILD,nasdaq be dow jone industrial average rise volume be higher nasdaq higher nyse compare same time tuesday
2342,GILD,stock market today biotech stock be best performer
2343,GILD,alexion pharmaceutical alxn rise nearly testing resistance day move average stock have form long consolidation buy point
2344,GILD,gilead science gild be more continue hold time high hit past week tight entry well buy range
2345,GILD,palo alto network panw jump more new high developer next generation network security software post better expect result late tuesday stock be now extend buy point
2346,GILD,downside chinese auto information athm slump heavy turnover fall sharply second straight session stock recently fall more buy point trigger sell rule stock be slightly higher midday wednesday seesaw session nasdaq be dow jone industrial average rise volume be higher nasdaq higher nyse compare same time tuesday stock market today biotech stock be best performer alexion pharmaceutical alxn rise nearly testing resistance day move average stock have form long consolidation buy point gilead science gild be more continue hold time high hit past week tight entry well buy range palo alto network panw jump more new high developer next generation network security software post better expect result late tuesday stock be now extend buy point downside chinese auto information athm slump heavy turnover fall sharply second straight session stock recently fall more buy point trigger sell rule
2347,GILD,handful lead stock be hold well even market uptrend have once again come pressure ambarella amba designer chip surveillance wearable sport camera lead way jump tuesday time high stock be extend recent buy
2348,GILD,strong performance major average tuesday result plenty action new high list particularly medical technology sector china base alibaba baba rise recent ipo close just ipo base buy point earlier today ceo jack apple aapl ceo tim cook speak potential partnership
2349,GILD,war terrorism deadly disease slow economy asia be bad news wouldn know analyst look business expect post solid third quarter earning revenue growth earning season rev next week report big bank jpmorgan chase jpm well fargo wfc bank america bac company be
2350,GILD,biotech pharmaceutical company be rise life save promise add hope stock also be healthy investment industry be friday general market weakness concern growth stock continue dominate week ibd list company base superior earning strong price performance leadership industry here
2351,GILD,stock remain lower early afternoon trading tuesday analyst warning new apple iphone hurt share company supplier nasdaq be dow jone industrial average be volume be tracking lower nyse higher nasdaq decline stock have small edge advancer nyse loser lead nasdaq solar energy automaker staffing dairy product company be poorest performer stock market today tesla tsla skid more sink deeper day day move average metal retail utility real estate investment trust industry group be best tuesday supplier apple aapl iphone be lower credit suisse warn company be cut back component order iphone model apple share gap loss average volume cirrus logic crus slide busy trading fall day move average skywork solution swks gap day move average shed heavy trading side ruth hospitality ruth better know ruth chris steak house clear buy point double bottom base active trading company beat earning expectation couple week ep jump restaurant industry group have be trend lower ibd group ranking
2352,GILD,stock again open narrow loss friday retail sector stock experience unusually heavy selling nasdaq hurt worst dow jone industrial average carved decline fall
2353,GILD,trade be mixed nasdaq lower nyse compare action same time thursday
2354,GILD,stock market today feel early drag company report compound raft weaker forecast producer price retail sale datum
2355,GILD,business inventory expand commerce department say vs consensus view change
2356,GILD,consumer sentiment offer bright spot university michigan november consumer sentiment index jump september view improvement be index best read july
2357,GILD,stock number heavy premarket move hold regular session
2358,GILD,generic drug maker mylan myl surge perrigo prgo slump mylan fail attempt hostile takeover michigan base perrigo wall street journal report mylan cash stock tender offer garner only perrigo share mylan need least successful takeover offer expire friday
2359,GILD,switzerland base seed strain herbicide giant syngenta syt leap bloomberg report company reject takeover offer state own china national chemical corp syngenta refuse offer earlier year
2360,GILD,retail group show market worst loss industry first half hour trade fossil group fosl collapse jwn crumble report weak quarterly result late thursday
2361,GILD,video game retailer gamestop gme drop grilled chicken chain el pollo unraveled
2362,GILD,chip equipment maker apply material amat climb santa clara cal outfit report line fiscal result thursday close management say quarterly conference call company be open possibility merger apply material have be climb september low remain deep month consolidation
2363,GILD,lead stock open session lousy mood more stock ibd list lose ground early action
2364,GILD,china base tal education xrs post best move group almost peck new high provider kindergarten grade school tutor service be now nearly past buy point cup handle base
2365,GILD,low end list paycom software payc lop oklahoma city base provider online human capital management program price share offer discount thursday close price loss drag share back buy point left stock day line support
2366,GILD,follow alan elliott twitter ibd_aelliott facebookstock again open narrow loss friday retail sector stock experience unusually heavy selling nasdaq hurt worst dow jone industrial average carved decline fall trade be mixed nasdaq lower nyse compare action same time stock market today feel early drag company report compound raft weaker forecast producer price retail sale datum business inventory expand commerce department say vs consensus view change consumer sentiment offer bright spot university michigan november consumer sentiment index jump september view improvement be index best read july stock number heavy premarket move hold regular session generic drug maker mylan myl surge perrigo prgo slump mylan fail attempt hostile takeover michigan base perrigo wall street journal report mylan cash stock tender offer garner only perrigo share mylan need least successful takeover offer expire friday switzerland base seed strain herbicide giant syngenta syt leap bloomberg report company reject takeover offer state own china national chemical corp syngenta refuse offer earlier year retail group show market worst loss industry first half hour trade fossil group fosl collapse jwn crumble report weak quarterly result late thursday video game retailer gamestop gme drop grilled chicken chain el pollo unraveled chip equipment maker apply material amat climb santa clara cal outfit report line fiscal result thursday close management say quarterly conference call company be open possibility merger apply material have be climb september low remain deep month consolidation lead stock open session lousy mood more stock ibd list lose ground early action china base tal education xrs post best move group almost peck new high provider kindergarten grade school tutor service be now nearly past buy point cup handle base low end list paycom software payc lop oklahoma city base provider online human capital management program price share offer discount thursday close price loss drag share back buy point left stock day line support follow alan elliott twitter ibd_aelliott facebook
2367,GILD,year biotech medivation launch first drug achievement put ahead more half biotechs trading market wednesday afternoon far wall street be concern become more just biotech drug biotech blockbuster drug august medivation mdvn
2368,GILD,be far earning season still good time look company strong earning potential bitauto bita be cruise fast lane china middle class auto buy spree
2369,GILD,china base company run new car seller post ad also have line software help dealer target car bud middle class
2370,GILD,bitauto be featured leader rise estimate screen day also top ibd list
2371,GILD,rise estimate screen list top rate stock rise earning estimate here be screen top stock base full year earning growth expectation
2372,GILD,bitauto earning be expect rise year bitauto have best possible composite rating ibd composite rating rate stock area extra weight earning stock price strength
2373,GILD,gilead science gild top screen analyst see jump earning year year biotech have create buzz sovaldi blockbuster drug treat hepatitis once day dose drug be expensive pill do provide very high cure rate be far cheaper alternative liver transplant rejection drug gilead reportedly be look sell cheaper version pill india indonesia pakistan local generic drugmaker
2374,GILD,gilead also have composite rating be featured ibd list list company base superior earning strong price performance leadership industry
2375,GILD,analyst expect akorn akrx speciality drugmaker report jump full year earning follow trend also have composite rating be ibd list lake forest ill company be testing week line second time breaking cup handle april
2376,GILD,august akorn acquire vpi holding increase share niche dermatology market
2377,GILD,facebook fb earning be see rise year social networking site expand presence ad new area ask youtube be own google googl experiment distribute video facebook accord wall street journal report thursday
2378,GILD,facebook have be expand rapidly recent year company buy picture sharing site instagram facebook announce deal year messaging firm whatsapp oculus vr virtual reality headset maker
2379,GILD,trinity industry trn nation top railcar maker be see report rise full year earning railroad firm be order new tanker car refurbish older one safety concern stem high profile crude rail accident
2380,GILD,wednesday trinity add antonio carrillo ex ceo global specialty chemical company board director
2381,GILD,tanker car maker greenbrier gbx also be rise estimate screen
2382,GILD,follow gillian rich twitter ibd_grich be far earning season still good time look company strong earning potential bitauto bita be cruise fast lane china middle class auto buy spree china base company run new car seller post ad also have line software help dealer target car bud middle class bitauto be featured leader rise estimate screen day also top ibd list rise estimate screen list top rate stock rise earning estimate here be screen top stock base full year earning growth expectation bitauto earning be expect rise year bitauto have best possible composite rating ibd composite rating rate stock area extra weight earning stock price strength gilead science gild top screen analyst see jump earning year year biotech have create buzz sovaldi blockbuster drug treat hepatitis once day dose drug be expensive pill do provide very high cure rate be far cheaper alternative liver transplant rejection drug gilead reportedly be look sell cheaper version pill india indonesia pakistan local generic drugmaker gilead also have composite rating be featured ibd list list company base superior earning strong price performance leadership industry analyst expect akorn akrx speciality drugmaker report jump full year earning follow trend also have composite rating be ibd list lake forest ill company be testing week line second time breaking cup handle april august akorn acquire vpi holding increase share niche dermatology market facebook fb earning be see rise year social networking site expand presence ad new area ask youtube be own google googl experiment distribute video facebook accord wall street journal report thursday facebook have be expand rapidly recent year company buy picture sharing site instagram facebook announce deal year messaging firm whatsapp oculus vr virtual reality headset maker trinity industry trn nation top railcar maker be see report rise full year earning railroad firm be order new tanker car refurbish older one safety concern stem high profile crude rail accident wednesday trinity add antonio carrillo ex ceo global specialty chemical company board director tanker car maker greenbrier gbx also be rise estimate screen follow gillian rich twitter ibd_grich
2383,GILD,stability be critical determination pick stock watch candidate market be correction today screen day be big cap leader company top notch fundamental market capitalization least list include well know name lesser know one be undiscovered gem gilead science gild big cap
2384,GILD,year top perform sector exchange trade fund be rally dip
2385,GILD,market vector junior gold miner gdxj be year average annual past year accord morningstar datum
2386,GILD,market vector gold miner gdx be year date average past year
2387,GILD,first trust nyse arca biotechnology fbt be so far year have provide investor average annual past year fbt holding include intermune itmn have zoom year company develop lung treatment be still lose money sale growth have be triple digit past quarters
2388,GILD,fbt also have stake gilead science gild year gilead have much stronger earning profile carry ibd earning share rating reflect increase past quarters
2389,GILD,eft also hold regeneron pharmaceutical regn be year have ep rating company have loss prior growth rate have improve rate past year year top perform sector exchange trade fund be rally dip market vector junior gold miner gdxj be year average annual past year accord morningstar datum market vector gold miner gdx be year date average past year first trust nyse arca biotechnology fbt be so far year have provide investor average annual past year fbt holding include intermune itmn have zoom year company develop lung treatment be still lose money sale growth have be triple digit past quarters fbt also have stake gilead science gild year gilead have much stronger earning profile carry ibd earning share rating reflect increase past quarters eft also hold regeneron pharmaceutical regn be year have ep rating company have loss prior growth rate have improve rate past year
2390,GILD,federal reserve chairwoman janet yellen tell senate banking committee equity valuation smaller firm well social medium biotechnology firm appear be stretched send stock index lower morning trading facebook fb fall modest gilead science gild dip comment suggest central bank not
2391,GILD,federal reserve chairwoman janet yellen tell senate banking committee equity valuation smaller firm well social medium biotechnology firm appear be stretched send stock index lower morning trading facebook fb fall modest gilead science gild dip comment suggest central bank not
2392,GILD,mutual fund etfs big asset weighting biotech have be excel stock market year top holding relatively broader base etf powershare dynamic pharmaceutical etf pjp include gilead science gild accord morningstar developer treatment hiv hepatitis gilead be extend well latest base formation stock have
2393,GILD,putnam investor fund be old geezer dec inception date make industry second oldest stock fund
2394,GILD,act spry spring chicken lately
2395,GILD,jerry sullivan take mid fund average annual gain be top beat large cap blend fund track morningstar
2396,GILD,same length period prior sullivan take charge fund average annual gain lag large cap blend peer
2397,GILD,sullivan credit outperformance appetite growth value stock also target type stock one follow year push smart money special situation focus valuation
2398,GILD,addition apply lesson learn mentor former boss former fidelity investment superstar peter lynch run now magellan fund sit fund world strong performance rapid growth
2399,GILD,putnam investor fund asset peaked august shrank low september asset have be rise then
2400,GILD,sullivan be year old speak ibd office boston financial district invest
2401,GILD,ibd be mention have distinct brooklyn accent
2402,GILD,sullivan be born brooklyn grow long island dad grow brooklyn dodger fan grow new york met fan dodger have just moved hate yankee relish mention accent
2403,GILD,ibd have flexible style right invest growth value stock
2404,GILD,sullivan core manager here putnam investor fund be mix value growth so be multus cap core fund asset be year old same style even more flexible go market cap spectrum investor fund have least security large cap multus cap have more category large mid small cap stylewise re same
2405,GILD,ibd be type stock investor fund buy
2406,GILD,sullivan call first bucket legacy stock re large cap research earlier career even recently be depth research then give minute research week year refine understand factor move stock help understand make move most bore bucket most important
2407,GILD,second bucket have do smart money main factor be insider buy follow closely have many year
2408,GILD,early mid work peter lynch be factor defer look right timing buy stock
2409,GILD,ibd be role fidelity
2410,GILD,sullivan be do research european chemical stock basf imperial chemical holland akzo nobel big stock be important magellan look big liquid stock
2411,GILD,be also much harder follow insider transaction have check sec filing paper be week old rule be looser insider have file
2412,GILD,sarbane oxley moved hour rule now watch information flow internet real time
2413,GILD,doesn tell buy give idea
2414,GILD,third bucket be special situation most common be follow stock offering used be call secondary offering be file clock typical day xyz company be do follow ve get minute decide want play not file close book
2415,GILD,ibd recent do
2416,GILD,sullivan latest be hd supply hds be part home depot hd former ceo bob nardelli start build distributor big equipment ipo left buy ipo do secondary offer put offer ask price
2417,GILD,ibd often do work
2418,GILD,sullivan cdw cdw be technology distributor sell midsize company don have big department go public last year please specify still own sell lot
2419,GILD,be maybe first institutional investor meet be never fast grow underwriter be ask maybe say want buy lot underwriter say maybe miss detail re selling say didn miss not be trading time earning time earning not warrant
2420,GILD,anyway go road show have difficulty get audience lot guy thought be overpriced week come back say work say now only want go public then ve meet meager expectation do grab larger audience investor stock have slowly migrate ish great special situation
2421,GILD,ibd buy stock price weakness give example please
2422,GILD,sullivan buy weakness be old peter lynch rule
2423,GILD,buy southwest airline luv year be trading
2424,GILD,rest airline be do well charge everything southwest didn so get depress be selling replacement cost airplane figured have climb always start charge individual service baggage load much go
2425,GILD,ibd ve add apple aapl stake
2426,GILD,sullivan start buy apple again june quarter have pull back high take biggest position
2427,GILD,year half year apple google googl go then separated apple pull back google shot everyone fall love google used source fund apple have hair hadn come anything new now come again not expensive earning quasi value name meaningful growth
2428,GILD,ibd celgene celg be trend again do investor decide biotech be oversold
2429,GILD,sullivan be several large biotechs start position more year look value name growth now pipeline be still meaningful ve get good top bottom line growth big pharmaceutical firm don have growth basis still attractive be stronger sell biotechs biogen biib gilead gild add celgene weakness earlier year
2430,GILD,ibd facebook fb have have nice run mid be still attractive
2431,GILD,sullivan underweight now weighting be less basis point have good move place eyeball be be slow get mobile application work ve do still growth story trading time next year estimate earning so point neutral don want make position bigger stock pull back
2432,GILD,ibd thesis cbre group cbg
2433,GILD,sullivan re play commercial real estate rebound re not expensive
2434,GILD,re big broker maybe biggest manage big office building be dead area come back nonresidential construction be come back occupancy rate be get better ve get earn share year next year re not fancy name re bit sleeper
2435,GILD,ibd gilead earning share growth have explode be sovaldi hepatitis treatment entire story
2436,GILD,sullivan real attraction be more ve get drug liver heart disease good platform aids real nice thing be stock be inexpensive earning re expect earn share year next year
2437,GILD,very attractive time next year earning company grow teen re fan whole pipeline
2438,GILD,ibd be spirit airline save driver frill approach
2439,GILD,sullivan yes frill approach be key
2440,GILD,interesting thing be re not target competition larger airline be important avoid price war
2441,GILD,larger airline see ultralow cost carrier go new market actually expand market big competitor see get person fly don normally college student person tight budget person don mind fly midnight person don mind be charge extra bag maybe overhead compartment
2442,GILD,airline go other get market share re not do now old management engage price war have disappear airline bankruptcy be fresh airline manager head
2443,GILD,ibd be railcar maker trinity industry trn economic cycle
2444,GILD,sullivan cycle still continue work re only halfway
2445,GILD,make kind railroad car most interesting margin be car carry sand frac typical well take rail car stuff
2446,GILD,trinity be few player business stock be not expensive putnam investor fund be old geezer dec inception date make industry second oldest stock fund act spry spring chicken lately jerry sullivan take mid fund average annual gain be top beat large cap blend fund track morningstar same length period prior sullivan take charge fund average annual gain lag large cap blend peer sullivan credit outperformance appetite growth value stock also target type stock one follow year push smart money special situation focus valuation addition apply lesson learn mentor former boss former fidelity investment superstar peter lynch run now magellan fund sit fund world strong performance rapid growth putnam investor fund asset peaked august shrank low september asset have be rise then sullivan be year old speak ibd office boston financial district invest ibd be mention have distinct brooklyn accent sullivan be born brooklyn grow long island dad grow brooklyn dodger fan grow new york met fan dodger have just moved hate yankee relish mention accent ibd have flexible style right invest growth value stock sullivan core manager here putnam investor fund be mix value growth so be multus cap core fund asset be year old same style even more flexible go market cap spectrum investor fund have least security large cap multus cap have more category large mid small cap stylewise re same ibd be type stock investor fund buy sullivan call first bucket legacy stock re large cap research earlier career even recently be depth research then give minute research week year refine understand factor move stock help understand make move most bore bucket most important second bucket have do smart money main factor be insider buy follow closely have many year early mid work peter lynch be factor defer look right timing buy stock ibd be role fidelity sullivan be do research european chemical stock basf imperial chemical holland akzo nobel big stock be important magellan look big liquid stock be also much harder follow insider transaction have check sec filing paper be week old rule be looser insider have file sarbane oxley moved hour rule now watch information flow internet real time doesn tell buy give idea third bucket be special situation most common be follow stock offering used be call secondary offering be file clock typical day xyz company be do follow ve get minute decide want play not file close book ibd recent do sullivan latest be hd supply hds be part home depot hd former ceo bob nardelli start build distributor big equipment ipo left buy ipo do secondary offer put offer ask price ibd often do work sullivan cdw cdw be technology distributor sell midsize company don have big department go public last year please specify still own sell lot be maybe first institutional investor meet be never fast grow underwriter be ask maybe say want buy lot underwriter say maybe miss detail re selling say didn miss not be trading time earning time earning not warrant anyway go road show have difficulty get audience lot guy thought be overpriced week come back say work say now only want go public then ve meet meager expectation do grab larger audience investor stock have slowly migrate ish great special situation ibd buy stock price weakness give example please sullivan buy weakness be old peter lynch rule buy southwest airline luv year be trading rest airline be do well charge everything southwest didn so get depress be selling replacement cost airplane figured have climb always start charge individual service baggage load much go ibd ve add apple aapl stake sullivan start buy apple again june quarter have pull back high take biggest position year half year apple google googl go then separated apple pull back google shot everyone fall love google used source fund apple have hair hadn come anything new now come again not expensive earning quasi value name meaningful growth ibd celgene celg be trend again do investor decide biotech be oversold sullivan be several large biotechs start position more year look value name growth now pipeline be still meaningful ve get good top bottom line growth big pharmaceutical firm don have growth basis still attractive be stronger sell biotechs biogen biib gilead gild add celgene weakness earlier year ibd facebook fb have have nice run mid be still attractive sullivan underweight now weighting be less basis point have good move place eyeball be be slow get mobile application work ve do still growth story trading time next year estimate earning so point neutral don want make position bigger stock pull back ibd thesis cbre group cbg sullivan re play commercial real estate rebound re not expensive re big broker maybe biggest manage big office building be dead area come back nonresidential construction be come back occupancy rate be get better ve get earn share year next year re not fancy name re bit sleeper ibd gilead earning share growth have explode be sovaldi hepatitis treatment entire story sullivan real attraction be more ve get drug liver heart disease good platform aids real nice thing be stock be inexpensive earning re expect earn share year next year very attractive time next year earning company grow teen re fan whole pipeline ibd be spirit airline save driver frill approach sullivan yes frill approach be key interesting thing be re not target competition larger airline be important avoid price war larger airline see ultralow cost carrier go new market actually expand market big competitor see get person fly don normally college student person tight budget person don mind fly midnight person don mind be charge extra bag maybe overhead compartment airline go other get market share re not do now old management engage price war have disappear airline bankruptcy be fresh airline manager head ibd be railcar maker trinity industry trn economic cycle sullivan cycle still continue work re only halfway make kind railroad car most interesting margin be car carry sand frac typical well take rail car stuff trinity be few player business stock be not expensive
2447,GILD,stock advanced quiet volume friday nasdaq close day line first time late september nasdaq rise ibd lead gain volume fall board nasdaq retook day move average further testing be likely remain just
2448,GILD,stock lose more ground friday retreat be more contain volume lighter thursday drop nasdaq dow jone industrial average trim friday cut index trim loss ibd be virtually flat volume fall board major index be now day move
2449,GILD,don want drop apple watch soon be able get wearable device sport gear maker armour ua electronic giant samsung
2450,GILD,buzz watch expectation well armour growth basketball shoe woman apparel have help put company big cap leader screen feature institutional quality stock be highly liquid have excellent fundamental
2451,GILD,july yonhap news agency south korean medium outlet report samsung official meet armour ceo kevin plank discuss team counter apple aapl nike nke partnership bud wearable space
2452,GILD,armour already have own fitness tracker armour system earlier year samsung debut galaxy gear fit
2453,GILD,armour have composite rating ibd composite rating measure stock area extra weight earning stock price strength
2454,GILD,apple be also featured big cap screen tech giant have be team nike develop nike fuelband work apple product
2455,GILD,new apple watch take wearable level just fitness band watch come regular sport luxury model not only track fitness send text message feature apple new mobile payment wallet service
2456,GILD,apple also debut new iphone iphone next generation phone feature larger screen iphone
2457,GILD,apple supplier technology avgo be also featured big cap screen tuesday apple be make wave new product chipmaker see price target raise barclay
2458,GILD,analyst be bullish singapore firm connection apple strong earning top estimate have composite rating ep ranking
2459,GILD,critic be impressed apple new product line critic user weren so impressed facebook fb new messaging app smartphone cite possible privacy concern messenger app have star rating apple app store be most download free app
2460,GILD,still facebook remain top big cap have composite rating top ep ranking
2461,GILD,gilead science gild isn align compete apple biotech be make wave own industry company sovaldi blockbuster drug help treat hepatitis once day dose
2462,GILD,drug pill price tag have draw criticism drugmaker be look sell cheaper version sovaldi india indonesia pakistan deal generic pharmaceutical company wall street journal report
2463,GILD,gilead have composite rating ep ranking
2464,GILD,follow gillian rich twitter ibd_grich don want drop apple watch soon be able get wearable device sport gear maker armour ua electronic giant samsung buzz watch expectation well armour growth basketball shoe woman apparel have help put company big cap leader screen feature institutional quality stock be highly liquid have excellent fundamental july yonhap news agency south korean medium outlet report samsung official meet armour ceo kevin plank discuss team counter apple aapl nike nke partnership bud wearable space armour already have own fitness tracker armour system earlier year samsung debut galaxy gear fit armour have composite rating ibd composite rating measure stock area extra weight earning stock price strength apple be also featured big cap screen tech giant have be team nike develop nike fuelband work apple product new apple watch take wearable level just fitness band watch come regular sport luxury model not only track fitness send text message feature apple new mobile payment wallet service apple also debut new iphone iphone next generation phone feature larger screen iphone apple supplier technology avgo be also featured big cap screen tuesday apple be make wave new product chipmaker see price target raise barclay analyst be bullish singapore firm connection apple strong earning top estimate have composite rating ep ranking critic be impressed apple new product line critic user weren so impressed facebook fb new messaging app smartphone cite possible privacy concern messenger app have star rating apple app store be most download free app still facebook remain top big cap have composite rating top ep ranking gilead science gild isn align compete apple biotech be make wave own industry company sovaldi blockbuster drug help treat hepatitis once day dose drug pill price tag have draw criticism drugmaker be look sell cheaper version sovaldi india indonesia pakistan deal generic pharmaceutical company wall street journal report gilead have composite rating ep ranking follow gillian rich twitter ibd_grich
2465,GILD,stock look poise end week positive note friday
2466,GILD,dow jone industrial average add rise nasdaq picked nyse be tracking lower thursday level nasdaq volume be tracking close thursday gauge
2467,GILD,nasdaq still have day move average conquer nasdaq be point line same
2468,GILD,stock market today procter gamble pg be standout performer dow rise earning share meet expectation sale slightly miss company also say prefer split duracell battery business separate company hasn reach decision yet
2469,GILD,constant contact ctct gap rise online marketing company report earning late thursday be consolidate gain week be now week high growth prospect be solid profit see rise earning be expect rise
2470,GILD,edward lifescience ew gap time high rise strong earning late thursday be catalyst third quarter profit rise cent share nicely consensus estimate sale rise year nice acceleration growth second quarter strong sale heart valf fuel result also prompt company raise prior full year earning sale guidance
2471,GILD,drugmaker ibd outperformed friday gilead science gild salix slxp jazz jazz alexion alxn celgene celg score gain
2472,GILD,thinly trade mineral technology mtx jump nearly break week consolidation report bullish third quarter result maker synthetic mineral product earn share year earlier sale soar
2473,GILD,downside peripheral maker synaptic syna plummet amazon com amzn slump disappointing earning
2474,GILD,economic news september new home sale come unit little better expect expect august datum be revise lower initially report homebuilder shrug news ibd build residential commercial group be stock look poise end week positive note friday dow jone industrial average add rise nasdaq picked nyse be tracking lower thursday level nasdaq volume be tracking close thursday gauge nasdaq still have day move average conquer nasdaq be point line same stock market today procter gamble pg be standout performer dow rise earning share meet expectation sale slightly miss company also say prefer split duracell battery business separate company hasn reach decision yet constant contact ctct gap rise online marketing company report earning late thursday be consolidate gain week be now week high growth prospect be solid profit see rise earning be expect rise edward lifescience ew gap time high rise strong earning late thursday be catalyst third quarter profit rise cent share nicely consensus estimate sale rise year nice acceleration growth second quarter strong sale heart valf fuel result also prompt company raise prior full year earning sale guidance drugmaker ibd outperformed friday gilead science gild salix slxp jazz jazz alexion alxn celgene celg score gain thinly trade mineral technology mtx jump nearly break week consolidation report bullish third quarter result maker synthetic mineral product earn share year earlier sale soar downside peripheral maker synaptic syna plummet amazon com amzn slump disappointing earning economic news september new home sale come unit little better expect expect august datum be revise lower initially report homebuilder shrug news ibd build residential commercial group be
2475,GILD,stock wobble narrow gain early friday
2476,GILD,nasdaq dow jone industrial nibbled gain be tip mixed trade nasdaq volume rise trade nyse be level same time thursday
2477,GILD,stock market today wrapped season first weak heavy duty report ford slump procter gamble pg gain report result microsoft msft unite parcel service up bristol myer squibb bmy be move heavy trade
2478,GILD,amazon com amzn drop stake low end nasdaq list company report wide third quarter earning miss revenue guidance also disappointing analyst share have pull back almost lows
2479,GILD,chip sector stock be mixed test equipment maker kla tencor klac hammer gain report mixed fiscal first quarter result launch restructure plan include dividend
2480,GILD,programmable chip pioneer alterra altr slump report earning revenue consensus forecast midpoint management revenue guidance be consensus estimate
2481,GILD,leader post positive open ibd stock advance start gate
2482,GILD,drugmaker jazz pharmaceutical jazz gilead science gild take early lead jazz be climb right side second stage cup base be buy point
2483,GILD,gilead be just buy point second stage base
2484,GILD,synchronoss technology sncr also edge gain advance put cloud smartphone service provider almost buy point week tight pattern
2485,GILD,friday morning economic news take back seat earning report commerce department report new home sale slump annualize rate september be weaker initial rate estimate august just month revise number economist have expect slowdown september stock wobble narrow gain early friday nasdaq dow jone industrial nibbled gain be tip mixed trade nasdaq volume rise trade nyse be level same time thursday stock market today wrapped season first weak heavy duty report ford slump procter gamble pg gain report result microsoft msft unite parcel service up bristol myer squibb bmy be move heavy trade amazon com amzn drop stake low end nasdaq list company report wide third quarter earning miss revenue guidance also disappointing analyst share have pull back almost lows chip sector stock be mixed test equipment maker kla tencor klac hammer gain report mixed fiscal first quarter result launch restructure plan include dividend programmable chip pioneer alterra altr slump report earning revenue consensus forecast midpoint management revenue guidance be consensus estimate leader post positive open ibd stock advance start gate drugmaker jazz pharmaceutical jazz gilead science gild take early lead jazz be climb right side second stage cup base be buy point gilead be just buy point second stage base synchronoss technology sncr also edge gain advance put cloud smartphone service provider almost buy point week tight pattern friday morning economic news take back seat earning report commerce department report new home sale slump annualize rate september be weaker initial rate estimate august just month revise number economist have expect slowdown september
2486,GILD,stock market be moderately higher monday top intraday first time biotechs lead way strength major takeover
2487,GILD,nasdaq dow industrial rise gain nasdaq volume run heavier friday pace nyse volume be lighter be first day nasdaq volume be higher previous day aug
2488,GILD,stock market today ibd stock stock rise fall best performer be chinese automobile website bitauto bita athm break very deep base new issue come market last december
2489,GILD,bitauto have more double breaking cup handle base june
2490,GILD,worst ibd performer be chinese name qihoo technology qihu nearly highest volume month decline come company report better expect earning revenue receive raise price target citigroup
2491,GILD,biotechs be strong news swiss drugmaker roche buy intermune itmn share intermune sky-rocket
2492,GILD,gilead science gild climb time high akorn akrx celgene celg meanwhile rise hit time high celgene be now past buy point flat base clear week
2493,GILD,medical biom biotech industry group be monday top performer industry group track ibd rise
2494,GILD,restaurant order online mobile platform grubhub grub sank news sell additional share stock come public april monday decline take stock buy point ipo base stock market be moderately higher monday top intraday first time biotechs lead way strength major takeover nasdaq dow industrial rise gain nasdaq volume run heavier friday pace nyse volume be lighter be first day nasdaq volume be higher previous day aug stock market today ibd stock stock rise fall best performer be chinese automobile website bitauto bita athm break very deep base new issue come market last december bitauto have more double breaking cup handle base june worst ibd performer be chinese name qihoo technology qihu nearly highest volume month decline come company report better expect earning revenue receive raise price target citigroup biotechs be strong news swiss drugmaker roche buy intermune itmn share intermune sky-rocket gilead science gild climb time high akorn akrx celgene celg meanwhile rise hit time high celgene be now past buy point flat base clear week medical biom biotech industry group be monday top performer industry group track ibd rise restaurant order online mobile platform grubhub grub sank news sell additional share stock come public april monday decline take stock buy point ipo base
2495,GILD,medical sector be area have have many stock hit new high recent session wednesday continue trend amgen amgn gap rally more triple average trade stock score record high close nearly past buy point first stage cup handle base
2496,GILD,major average hold decent gain little hour remain monday session
2497,GILD,top level rally dow jone industrial average also gain nasdaq tack nasdaq volume be tracking higher friday level nyse volume fall
2498,GILD,stock market today biotech stock take center stage news big acquisition weekend swiss firm roche rhhby reach deal buy intermune itmn intermune soar news
2499,GILD,ibd medical biom biotech group be day best performer rise nearly top rate name group outperformed include gilead science gild celgene celg biogen idec biib alexion alxn
2500,GILD,china base auto operator athm be top performer ibd share jump news clear deep cup shape base buy point
2501,GILD,earning news qihoo technology qihu slump report better expect earning sale stock be weak margin concern cost sale surge year operate expense more double qihoo be provider internet search mobile security product china
2502,GILD,meanwhile ikang healthcare group kang fast grow china name rally fast trade ahead earning report close
2503,GILD,economic news july new home sale come consensus estimate june new home sale be revise higher unit major average hold decent gain little hour remain monday session top level rally dow jone industrial average also gain nasdaq tack nasdaq volume be tracking higher friday level nyse volume fall stock market today biotech stock take center stage news big acquisition weekend swiss firm roche rhhby reach deal buy intermune itmn intermune soar news ibd medical biom biotech group be day best performer rise nearly top rate name group outperformed include gilead science gild celgene celg biogen idec biib alexion alxn china base auto operator athm be top performer ibd share jump news clear deep cup shape base buy point earning news qihoo technology qihu slump report better expect earning sale stock be weak margin concern cost sale surge year operate expense more double qihoo be provider internet search mobile security product china meanwhile ikang healthcare group kang fast grow china name rally fast trade ahead earning report close economic news july new home sale come consensus estimate june new home sale be revise higher unit
2504,GILD,lead stock lead monster beverage monster gain hold high session volatile market end mixed monster mnst gap rocket monster volume shooting past buy point energy drink maker late thursday announce partnership deal coca cola ko soft drink giant
2505,GILD,biotech pharmacyclic pcyc get price target cut nomura monday investment bank maintain buy rating pharmacyclic stock say company competitive position remain strong
2506,GILD,pharmacyclic stock be flat midday trading stock market today
2507,GILD,nomura analyst ian somaiya write research note meeting management be raise forecast company expense due higher spending international launch blood cancer drug imbruvica clinical trial other product higher tax rate thus lower price target
2508,GILD,somaiya however say survey competition find still potential upside imbruvica go im health im weekly prescription tracker launch gilead science gild rival zydelig be go slower imbruvica launch write citi analyst last month also be negative zydelig
2509,GILD,somaiya add abbvie abbv succeed shortening development time potential rival just half year still give imbruvica time get establish note however abbvie new partnership infinity pharmaceutical infi put lead develop combination novel drug infinity duvelisib be expect be test together
2510,GILD,follow amy reeve twitter ibd_areeve biotech pharmacyclic pcyc get price target cut nomura monday investment bank maintain buy rating pharmacyclic stock say company competitive position remain strong pharmacyclic stock be flat midday trading stock market today nomura analyst ian somaiya write research note meeting management be raise forecast company expense due higher spending international launch blood cancer drug imbruvica clinical trial other product higher tax rate thus lower price target somaiya however say survey competition find still potential upside imbruvica go im health im weekly prescription tracker launch gilead science gild rival zydelig be go slower imbruvica launch write citi analyst last month also be negative zydelig somaiya add abbvie abbv succeed shortening development time potential rival just half year still give imbruvica time get establish note however abbvie new partnership infinity pharmaceutical infi put lead develop combination novel drug infinity duvelisib be expect be test together follow amy reeve twitter ibd_areeve
2511,GILD,medical stock be sector leader friday edition most ibd sector show strength sector have be best bottom aug drug developer be new high possible new entry alexion pharmaceutical ticker
2512,GILD,ibd list rank stock combination recent profit growth key measure such return equity sale growth profit margin list strongest stock first today ibd include company be expand new geography adjacent market bullish sign future growth here be top rate ibd stock be expansion mode tal education group xrs tal education ibd provide school tutor more pupil china be currently expand core market beij shanghai jpmorgan chase say client note earlier month tal plan expand new city year be feasible large expansion opportunity be key attraction report say tal share rise friday trading skywork solution swks analog mixed signal chipmaker skywork ibd be poise expand next year chinese phone company transition older second generation wireless lte long term evolution accord canaccord genuity aug report bank say anticipate grow global mix lte smartphone skywork share gain lead chinese oem drive sale growth smartphone market next year share skywork stock be also ibd leaderboard list outperform stock rise friday avis budget group car car rental company many year used slogan try harder avis budget current strategy close gap hertz htz include rapid global expansion avis ibd year buy budget licensee alberta canada begin operate budget car rental brand portugal directly rather licensee june avis announce plan double number licensee germany stock price have rise past year close friday synchronoss technology sncr company expect see big gain wireless market be software maker synchronoss product allow mobile network connect device phone plan ibd company serve big customer such verizon communication vz get paid fee activation week world sign more new subscriber synchronoss ceo steve waldi tell ibd recent interview share close friday day range time high set late october gilead science gild round list be biotech gilead make treatment viral fungal respiratory heart disease currently take blockbuster hepatitis drug sovaldi global gilead stock rise aug win dispute swiss base roche right sovaldi week also get key endorsement drug cost benefit agency be note gilead share ibd fall friday bloomberg news report firm be near licensing deal generic drugmaker make sell sovaldi develop country such india pakistan deal cut profit gilead currently sell sovaldi pill follow james detar twitter ibd_jdetar
2513,GILD,thrivent large cap growth be reminder new manager herald change mutual fund fortune david francis darren bagwell now co manager take helm portfolio oct year prior take command fund lag morningstar peer group quarters
2514,GILD,bristol myer squibb bmy win approval oral hepatitis virus hcv drug daklinza european union wednesday company continue carve niche increasingly competitive hcv space
2515,GILD,eu approve daklinza sofosbuvir also know gilead science gild sovaldi genotype disease
2516,GILD,combo perform outstandingly clinical trial achieve cure rate group gilead elect not pursue combo instead combine sofosbuvir own drug ledipasvir be similar daklinza combo be expect be approve october
2517,GILD,bristol myer have own dual regimen daklinza asunaprevir have already be approve japan be await approval nov however cure rate isn good sofosbuvir combo so company ultimate goal be approval triple therapy daklinza asunaprevir drug dub bms combo be late stage clinical testing
2518,GILD,meanwhile fact consumer buy sovaldi daklinza separately potentially put pressure daklinza price price sovaldi be infamously high typical week treatment
2519,GILD,bristol myer didn announce price wednesday release have say european price be set individual country level different country have different reimbursement scheme be separately negotiate
2520,GILD,potential arrival pricing daklinza market also influence pricing decision abbvie abbv highly efficacious drug hcv therapy be expect be approve december
2521,GILD,bristol myer stock be fraction morning trading stock market today perhaps influenced fact deutsche bank initiate coverage hold rating
2522,GILD,gilead stock rebound dip tuesday be
2523,GILD,follow amy reeve twitter ibd_areeve bristol myer squibb bmy win approval oral hepatitis virus hcv drug daklinza european union wednesday company continue carve niche increasingly competitive hcv space eu approve daklinza sofosbuvir also know gilead science gild sovaldi genotype disease combo perform outstandingly clinical trial achieve cure rate group gilead elect not pursue combo instead combine sofosbuvir own drug ledipasvir be similar daklinza combo be expect be approve october bristol myer have own dual regimen daklinza asunaprevir have already be approve japan be await approval nov however cure rate isn good sofosbuvir combo so company ultimate goal be approval triple therapy daklinza asunaprevir drug dub bms combo be late stage clinical testing meanwhile fact consumer buy sovaldi daklinza separately potentially put pressure daklinza price price sovaldi be infamously high typical week treatment bristol myer didn announce price wednesday release have say european price be set individual country level different country have different reimbursement scheme be separately negotiate potential arrival pricing daklinza market also influence pricing decision abbvie abbv highly efficacious drug hcv therapy be expect be approve december bristol myer stock be fraction morning trading stock market today perhaps influenced fact deutsche bank initiate coverage hold rating gilead stock rebound dip tuesday be follow amy reeve twitter ibd_areeve
2524,GILD,stock start strong note thursday erased gain end red nasdaq trim fall less ibd skid volume rise nyse fall nasdaq action wasn particularly alarm index haven accomplish much recent session be
2525,GILD,major index make tiny move wednesday nasdaq end mild day streak volume fall exchange extend current thin trading activity nasdaq composite fall point end fractionally higher close hair historic price level small cap didn move much smallcap be
2526,GILD,recent announcement roche rhhby buy intermune itmn bring new life speculation biotech industry have be relatively neglected buzz focuse tax inversion deal company ibd have greater ability anyone else predict future here be biotech stock have be name
2527,GILD,stock market show dull action wednesday perhaps day dull be actually good thing biggest item equity trading desk mind be likely minute federal reserve july meeting interest rate release et market watcher look such report find fresh clue
2528,GILD,top perform medical stock be panacea depress portfolio today tech leader medical screen feature heavy hitter pharmaceutical field maker disorder drug such pepcid salix pharmaceutical slxp be recent week topic now dormant takeover talk allergan agn fought valeant pharmaceutical vrx allergan maker botox
2529,GILD,achillion pharmaceutical achn stock touch month high second straight trading day monday deutsche bank upgrade biotech startup boost price target positive news new hepatitis drug achillion stock be more afternoon trading stock market today rise friday achillion stock have
2530,GILD,biotechs gilead science gild therapeutic anik be just few stock spotlight screen be still hover buy point make treatment tissue protection heal repair clear buy point cup handle base june volume be heavy stock stage bearish reversal day end
2531,GILD,bristol myer squibb win approval japan oral hepatitis virus hcv regimen expect important development company carve place crowd hcv market stock be fraction midday trading stock market today bristol myer squibb bmy therapy be combination daclatasvir asunaprevir now
2532,GILD,big cap biotechs moved strong volume stock market today deutsche bank add several short term buy list citi report back visit medical expert celgene celg hit new high deutsche bank analyst robyn karnauskas tout short term investment idea say read clinical trial datum new
2533,GILD,development stage biotech infinity pharmaceutical infi land key deal develop blood cancer drug duvelisib partnership big pharma abbvie abbv send infinity stock month high stock market today abbvie infinity collaboration include upfront payment milestone payment duvelisib pass
2534,GILD,today screen day feature institutional quality drug medical big cap stock solid fundamental
2535,GILD,jazz pharmaceutical jazz have market cap earn ibd composite rating mean have outperformed stock key metric such earning sale
2536,GILD,best selling narcolepsy medication xyrem make third jazz second quarter sale company acquire italian biotech gentium earlier year
2537,GILD,jazz share rise stock market tuesday best close month
2538,GILD,salix pharmaceutical slxp be spotlight lately potential takeover candidate allergan agn maker botox allergan be aim put stopper valeant pharmaceutical vrx hostile takeover attempt
2539,GILD,salix share soar aug report talk reportedly be dormant salix be largely hold gain move sideway
2540,GILD,salix have market cap also have highest possible composite rating salix most recent result miss view earning share more double revenue shot
2541,GILD,gilead science gild behemoth market cap be mutual fund favorite big stock mover deutsche bank expect company upcoming combo hepatitis treatment have higher expect price point
2542,GILD,gilead make blockbuster hepatitis drug sovaldi also boast composite rating
2543,GILD,gilead share fall tuesday be week
2544,GILD,illumina ilmn have market cap composite rating develop system medical researcher study gene variation function
2545,GILD,company recently say have form strategic partnership number drugmaker include astrazeneca azn sanofi sny create universal next generation sequence base oncology test system
2546,GILD,follow elaine low twitter ibd_elow today screen day feature institutional quality drug medical big cap stock solid fundamental jazz pharmaceutical jazz have market cap earn ibd composite rating mean have outperformed stock key metric such earning sale best selling narcolepsy medication xyrem make third jazz second quarter sale company acquire italian biotech gentium earlier year jazz share rise stock market tuesday best close month salix pharmaceutical slxp be spotlight lately potential takeover candidate allergan agn maker botox allergan be aim put stopper valeant pharmaceutical vrx hostile takeover attempt salix share soar aug report talk reportedly be dormant salix be largely hold gain move sideway salix have market cap also have highest possible composite rating salix most recent result miss view earning share more double revenue shot gilead science gild behemoth market cap be mutual fund favorite big stock mover deutsche bank expect company upcoming combo hepatitis treatment have higher expect price point gilead make blockbuster hepatitis drug sovaldi also boast composite rating gilead share fall tuesday be week illumina ilmn have market cap composite rating develop system medical researcher study gene variation function company recently say have form strategic partnership number drugmaker include astrazeneca azn sanofi sny create universal next generation sequence base oncology test system follow elaine low twitter ibd_elow
2547,GILD,market confirm uptrend time take hard look highly rate stock move ibd screen day be bolt rs line stock such bitauto bita stock price relative strength be surge vs index screen include company mutual fund insurance pension fund
2548,GILD,major average show modest loss little hour remain thursday session
2549,GILD,nasdaq lose hurt somewhat fresh round selling dow jone industrial average give respectively nyse volume be tracking close wednesday level nasdaq volume fall
2550,GILD,small cap fared well add
2551,GILD,day outperformance wednesday biotech stock face renew selling pressure nasdaq firm celgene celg fall have almost re-trace gain buy point other nasdaq biotechs be pressured include regeneron regn biogen idec biib gilead science gild lose
2552,GILD,ibd firm akorn akrx be bright spot maker ophthalmic injectable pharmaceutical bounce day move average heavy volume rise
2553,GILD,stock market today stratasys ssys gain approach buy point earlier week company analyst day be well receive
2554,GILD,meanwhile huntsman hun follow wednesday share rise clear early flat base point wednesday still buy range company make organic inorganic chemical product broad range consumer industrial end market
2555,GILD,economic news weekly jobless claim unexpectedly rise month high claim increase upwardly revise prior week economist expect small decline
2556,GILD,close watch earning ulta beauty ulta share edge higher ahead result former leader have be rally mode still sit high quarterly profit be see rise cent share sale major average show modest loss little hour remain thursday session nasdaq lose hurt somewhat fresh round selling dow jone industrial average give respectively nyse volume be tracking close wednesday level nasdaq volume fall small cap fared well add day outperformance wednesday biotech stock face renew selling pressure nasdaq firm celgene celg fall have almost re-trace gain buy point other nasdaq biotechs be pressured include regeneron regn biogen idec biib gilead science gild lose ibd firm akorn akrx be bright spot maker ophthalmic injectable pharmaceutical bounce day move average heavy volume rise stock market today stratasys ssys gain approach buy point earlier week company analyst day be well receive meanwhile huntsman hun follow wednesday share rise clear early flat base point wednesday still buy range company make organic inorganic chemical product broad range consumer industrial end market economic news weekly jobless claim unexpectedly rise month high claim increase upwardly revise prior week economist expect small decline close watch earning ulta beauty ulta share edge higher ahead result former leader have be rally mode still sit high quarterly profit be see rise cent share sale
2557,GILD,most big cap stock be buy range form basis unusually good trend afford investor plenty opportunity deploy capital sluggish market pose risk new purchase willing risk today market several big cap leader be buy range latest base breakout many cyclical stock
2558,GILD,big pharma abbvie abbv beat analyst estimate lead drug humira grow sharply company say slow affirm full year guidance stock fall fractionally morning trading stock market today abbvie make cent share quarter same year earlier quarter cent analyst
2559,GILD,july see biotechs go public currently represent ipos schedule next week accord renaissance capital
2560,GILD,also sharp spike biotech initial public offering first half year
2561,GILD,upcoming biotech ipos include several be focuse eye ears nose include ocular therapeutix ocul developer injectable sustain release therapy treat various eye condition disease be pfenex pfnx be develop treatment wet macular degeneration
2562,GILD,ear category be auris medical ears late stage biotech develop treatment acute post acute inner ear tinnitus
2563,GILD,other biotechs week include innocoll innl develop absorbable collagen drug treatment post operative pain
2564,GILD,have be ipos health care sector year most category lead biotech sector
2565,GILD,establish biotech stock have be do well biogen idec biib rise more late afternoon trade stock market today
2566,GILD,biogen crushed earning estimate wednesday morning
2567,GILD,gilead science gild make blockbuster hepatitis fighter sovaldi report market close puma biotechnology puma come public october shot close report strong phase trial result treat breast cancer july see biotechs go public currently represent ipos schedule next week accord renaissance capital also sharp spike biotech initial public offering first half year upcoming biotech ipos include several be focuse eye ears nose include ocular therapeutix ocul developer injectable sustain release therapy treat various eye condition disease be pfenex pfnx be develop treatment wet macular degeneration ear category be auris medical ears late stage biotech develop treatment acute post acute inner ear tinnitus other biotechs week include innocoll innl develop absorbable collagen drug treatment post operative pain have be ipos health care sector year most category lead biotech sector establish biotech stock have be do well biogen idec biib rise more late afternoon trade stock market today biogen crushed earning estimate wednesday morning gilead science gild make blockbuster hepatitis fighter sovaldi report market close puma biotechnology puma come public october shot close report strong phase trial result treat breast cancer
2568,GILD,big cap biotechs celgene alexion pharmaceutical modestly beat estimate raise guidance early thursday share tumble wall street seem turn sector celgene celg earning rise year earlier quarter cent share beating consensus penny sale increase
2569,GILD,numerous stock make new high monday certainly meet ibd slim investment paradigm stand quality current earning sale growth best company tend show increase more latest quarter begin outstanding price run new high gilead science gild continue prove
2570,GILD,stock be moderately higher monday biotech stock lead way nasdaq dow jone industrial average rise gain close amazon amzn announce be pay buy twitch live video platform gamer viewer watch other person play video game amazon rise nearly regular session wasn active market investor be weigh impact several economic indicator tuesday open estimate durable good order vary greatly consensus call increase increase ex auto case shiller home price index city be expect rise year year prior month conference board consumer confidence index be expect come vs last month biotechs be strong news swiss drugmaker roche buy intermune itmn share intermune sky-rocket gilead science gild climb time high akorn akrx celgene celg meanwhile rise hit time high celgene be now past buy point flat base clear week ibd biotech industry group be monday top performer industry group rise
2571,GILD,market back confirm uptrend look company gilead science gild post outstanding earning share growth last quarter yield new stock watch candidate
2572,GILD,today ibd list rank stock have biggest earning growth season be now wind
2573,GILD,gilead lead amazing second quarter ep surge vs year earlier san francisco bay area base company hepatitis drug sovaldi win government approval december have already achieve blockbuster status generate sale last quarter crush estimate
2574,GILD,world health organization estimate person carry debilitating disease meaning sovaldi likely have long way run
2575,GILD,gilead share climb friday stock market trading fresh record high arbitration panel reject roche claim sovaldi partnership pharmasset develop sovaldi gilead buy pharmasset
2576,GILD,chinese online discount retailer vipshop holding vip see ep climb flash sale model ride growth tailwind
2577,GILD,share slide thursday day report result even ep revenue guidance top wall street estimate even higher expectation investor
2578,GILD,company have recently integrate lefeng local cosmetic retailer well open first center silicon valley enable hire employee have work top tier online retail giant such amazon com amzn ebay ebay
2579,GILD,vipshop share have soar june low
2580,GILD,beer distill spirit maker constellation brand stz parent black velvet brand whiskey robert mondavi clos du wine corona beer other brew ep gain fiscal
2581,GILD,constellation vault beer company last year purchase grupo modelo operation anheuser busch inbev bud
2582,GILD,kapstone paper packaging ks ep gain marked third last quarters company post triple digit profit growth
2583,GILD,company be see rise demand box other packaging economic recovery spur retail sale food home good other product also largest maker kraft paper used make bag agricultural good pet food
2584,GILD,couple ibd company have outstanding ep growth prior quarter haven report yet most recent quarter chinese internet security software search online game company qihoo technology qihu report ep increase tap report earning aug
2585,GILD,gaslog glog monaco base operator fleet liquefy natural gas tanker see ep accelerate march end quarter slate announce earning wednesday
2586,GILD,follow james detar twitter ibd_jdetar market back confirm uptrend look company gilead science gild post outstanding earning share growth last quarter yield new stock watch candidate today ibd list rank stock have biggest earning growth season be now wind gilead lead amazing second quarter ep surge vs year earlier san francisco bay area base company hepatitis drug sovaldi win government approval december have already achieve blockbuster status generate sale last quarter crush estimate world health organization estimate person carry debilitating disease meaning sovaldi likely have long way run gilead share climb friday stock market trading fresh record high arbitration panel reject roche claim sovaldi partnership pharmasset develop sovaldi gilead buy pharmasset chinese online discount retailer vipshop holding vip see ep climb flash sale model ride growth tailwind share slide thursday day report result even ep revenue guidance top wall street estimate even higher expectation investor company have recently integrate lefeng local cosmetic retailer well open first center silicon valley enable hire employee have work top tier online retail giant such amazon com amzn ebay ebay vipshop share have soar june low beer distill spirit maker constellation brand stz parent black velvet brand whiskey robert mondavi clos du wine corona beer other brew ep gain fiscal constellation vault beer company last year purchase grupo modelo operation anheuser busch inbev bud kapstone paper packaging ks ep gain marked third last quarters company post triple digit profit growth company be see rise demand box other packaging economic recovery spur retail sale food home good other product also largest maker kraft paper used make bag agricultural good pet food couple ibd company have outstanding ep growth prior quarter haven report yet most recent quarter chinese internet security software search online game company qihoo technology qihu report ep increase tap report earning aug gaslog glog monaco base operator fleet liquefy natural gas tanker see ep accelerate march end quarter slate announce earning wednesday follow james detar twitter ibd_jdetar
2587,GILD,stock turn higher early afternoon trade wednesday soft open nasdaq lead way rise dow jone industrial average add volume nyse nasdaq be tracking higher tuesday level stock market today money flow biotech sector recent weakness receptos rcpt surge company report good datum midstage trial multiple sclerosis drug receptos isn profitable yet nearly quadruple price ipo top rate name biotech group gilead science gild biogen idec biib regeneron regn alexion alxn rise earning news palo alto network panw surge report strong earning late tuesday exclude time item fiscal fourth quarter profit rise year cent share sale growth accelerate second straight quarter rise well ahead view company also offer bullish sale guidance recent be slow get go stock be now buy point ibd silica slca snap back straight decline share jump company raise cash flow guidance rest year company make silica used hydraulic frac several low volume decline keurig green mountain gmcr add nearly be back buy range recent restoration hardware rh lose ahead earning report close consensus estimate call profit cent share year sale be expect rise
2588,GILD,biotech pharmacyclic pcyc be seesaw stock market today sale beat consensus late thursday company decline update guidance pharmacyclic sale more double year earlier quarter higher consensus loss cent share be well consensus cent analyst
2589,GILD,new high stock have rollicking good time wednesday even overall number weren great be action be vigorous most new high few give back much gain let do quick take wednesday new high bunch palo alto network panw don argue chart aggressive thrust be often
2590,GILD,biogen idec head second quarter earning report best roll year biotech continue benefit heavy demand drug treat multiple sclerosis cancer autoimmune disease biotech market cap have run straight quarters accelerate sale growth year year earning have rise least
2591,GILD,health care technology stock have turn most earning revenue beat telecom sector have lag lynch say report
2592,GILD,nearly health care company have report so far lynch say nearly beat consensus earning estimate top revenue expectation say beat profit sale
2593,GILD,tech company beat earning estimate top revenue expectation beat sale profit
2594,GILD,nearly tech company have report cisco system csco report close wednesday hewlett packard hpq aug include july number latest fiscal quarters
2595,GILD,june quarter facebook fb be internet company beat ep revenue apple aapl fiscal beat earning revenue fall short view
2596,GILD,biotech winner earning biogen idec biib gilead science gild beat earning revenue expectation
2597,GILD,be telecom company miss consensus view
2598,GILD,only telecom company follow lynch beat ep just beat revenue
2599,GILD,sector telecom have see earning expectation rise start report lead health care sale expectation have rise sector telecom say lynch report
2600,GILD,morgan stanley monday upgrade technology sector overweight market weight
2601,GILD,march april sell momentum stock pummeled many small cap biotech social medium internet solar energy computer software company sudden rotation high multiple lower multiple stock so call hyper growth stock value stock appear exhaust late ibd report industry snapshot health care technology stock have turn most earning revenue beat telecom sector have lag lynch say report nearly health care company have report so far lynch say nearly beat consensus earning estimate top revenue expectation say beat profit sale tech company beat earning estimate top revenue expectation beat sale profit nearly tech company have report cisco system csco report close wednesday hewlett packard hpq aug include july number latest fiscal quarters june quarter facebook fb be internet company beat ep revenue apple aapl fiscal beat earning revenue fall short view biotech winner earning biogen idec biib gilead science gild beat earning revenue expectation be telecom company miss consensus view only telecom company follow lynch beat ep just beat revenue sector telecom have see earning expectation rise start report lead health care sale expectation have rise sector telecom say lynch report morgan stanley monday upgrade technology sector overweight market weight march april sell momentum stock pummeled many small cap biotech social medium internet solar energy computer software company sudden rotation high multiple lower multiple stock so call hyper growth stock value stock appear exhaust late ibd report industry snapshot
2602,GILD,fattest annual profit margin come drugmaker product be meant make person healthier today screen day be healthy profit margin include highly rate drug stock don miss jazz pharmaceutical jazz annual profit margin narcolepsy treatment xyrem have rocket success contribute
2603,GILD,biotech stock be well represent week big cap linkedin lnkd facebook fb be pace rebound internet stock medical biomedical biotech industry have erased slightly more half loss fall sharply february high concern stock group be overvalue once high fly group be still depress rank
2604,GILD,stock backed session high monday be still nicely higher early afternoon trading dow jone industrial average rise nasdaq add gain nasdaq hit intraday turnover be mixed stock market today nasdaq trade be run high nyse volume be tracking lower biotechs be strong news swiss drugmaker roche buy intermune itmn share intermune sky-rocket gilead science gild climb time high akorn akrx celgene celg meanwhile rise hit time high celgene be now past buy point flat base clear week elsewhere gentherm thrm climb find support day line friday stock be past buy point rare ascend base earlier month maker climate controlled car seat blow past view pop earning marked third triple digit gain past quarters grubhub grub tumble news sell share follow offer april new issue erased gain past buy point mark sell signal grubhub be briefly halter earlier
2605,GILD,stock bolt higher start gate monday
2606,GILD,major index nasdaq dow jone industrial average clock gain open trade
2607,GILD,financial lead dow jpmorgan jpm andamerican express axp rise more gilead science gild jump lead nasdaq
2608,GILD,volume be mixed stock market today nasdaq lower nyse
2609,GILD,minor economic gauge send mixed early signal chicago federal reserve national activity index rise well expectation july markit preliminary service sector purchasing manager index august come view
2610,GILD,commerce department new home sale estimate july put annualize pace original june estimate upwardly revise june rate be also well economist consensus
2611,GILD,stock athm bolt gain lead ibd china base provider online automotive information have logged strong week advance right side deep cup base monday send share past buy point
2612,GILD,tesla motor tsla climb lift buy range buy point
2613,GILD,downside qihoo technology qihu dive report sharp contraction gross margin otherwise strong second quarter loss send back test week move average stock work late stage base stock bolt higher start gate monday major index nasdaq dow jone industrial average clock gain open trade financial lead dow jpmorgan jpm andamerican express axp rise more gilead science gild jump lead nasdaq volume be mixed stock market today nasdaq lower nyse minor economic gauge send mixed early signal chicago federal reserve national activity index rise well expectation july markit preliminary service sector purchasing manager index august come view commerce department new home sale estimate july put annualize pace original june estimate upwardly revise june rate be also well economist consensus stock athm bolt gain lead ibd china base provider online automotive information have logged strong week advance right side deep cup base monday send share past buy point tesla motor tsla climb lift buy range buy point downside qihoo technology qihu dive report sharp contraction gross margin otherwise strong second quarter loss send back test week move average stock work late stage base
2614,GILD,number stock weekly review have get smaller symptom weaken general market
2615,GILD,usually screen top rate stock exceed company week have today end
2616,GILD,shrink weekly review tend happen market have weaken such point fewer stock earn necessary requirement screen
2617,GILD,primarily requirement be earning share relative price strength rating higher naturally growth stock be slumping relative price performance suffer
2618,GILD,leave fewer quality stock investor choose also serve good purpose purge weaker choice
2619,GILD,example nautilus nls be last week weekly review have drop today list maker fitness equipment plunge week move average heavy trading trigger sell rule
2620,GILD,commscope comm be stock longer make cut past buy point have fail share be now trading long term day move average
2621,GILD,screen work filter system one left weekly review be consider be higher quality make survivor better qualify watch list
2622,GILD,stock still upright be medical leader form basis such akorn akrx gilead science gild
2623,GILD,large capitalization company such apple aapl chipotle grill cmg be shape fine basis deserve be study closer
2624,GILD,monster beverage mnst just break past buy point remain buy range volume be lackluster wednesday stock clear entry be reason be suspicious move number stock weekly review have get smaller symptom weaken general market usually screen top rate stock exceed company week have today end shrink weekly review tend happen market have weaken such point fewer stock earn necessary requirement screen primarily requirement be earning share relative price strength rating higher naturally growth stock be slumping relative price performance suffer leave fewer quality stock investor choose also serve good purpose purge weaker choice example nautilus nls be last week weekly review have drop today list maker fitness equipment plunge week move average heavy trading trigger sell rule commscope comm be stock longer make cut past buy point have fail share be now trading long term day move average screen work filter system one left weekly review be consider be higher quality make survivor better qualify watch list stock still upright be medical leader form basis such akorn akrx gilead science gild large capitalization company such apple aapl chipotle grill cmg be shape fine basis deserve be study closer monster beverage mnst just break past buy point remain buy range volume be lackluster wednesday stock clear entry be reason be suspicious move
2625,GILD,today ll look gilead science gild locate foster city gilead be research base company discover develop commercialize medicine treatment life threaten disease such hiv aids hepatitis hepatitis respiratory condition key fundamental several quarters lackluster ep growth gilead earning sky-rocket first quarter sale growth also
2626,GILD,drugmaker aim help person live healthier life aren immune patent loss merck mrk have recently face number patent expiration tuesday report sale slow eighth quarter row earning climb cent share third straight quarter gain result beat view
2627,GILD,stock market clock slight gain last full month summer uptrend be pressure second half september
2628,GILD,manager top perform fund past month continue add share medical issue market pullback
2629,GILD,industry group track ibd medical subgroup hospital ethical drug biotech biom be rank top thursday
2630,GILD,large drug firm allergan agn jazz pharmaceutical jazz actavis act salix pharmaceutical slxp continue grab top fund interest latest report period
2631,GILD,lead fund also biotech firm such gilead science gild biogen idec biib celgene celg
2632,GILD,transportation stock remain spotlight airline luv fedex fdx union pacific unp
2633,GILD,few notable buy top fund worth mention include social medium giant facebook fb burrito chain chipotle grill cmg retailer ulta beauty ulta
2634,GILD,ibd find best perform fund add chipotle investing estimate latest report period rowe price blue chip growth fund own big stake firm
2635,GILD,fast casual chain run restaurant canada also venture southeast asian flavor new concept call southeast asian kitchen december chipotle announce plan expand pizza segment pizzeria locale
2636,GILD,chipotle menu be simple serve burritos taco burrito bowl salad used fresh organic ingredient rival similar menu el pollo make ipo debut july
2637,GILD,stock breakaway gap july share have be trading steadily tight range
2638,GILD,earning have be grow steadily double digit least quarters third quarter earning result be due market close oct analyst currently see earning rise share
2639,GILD,sell side
2640,GILD,nation top perform fund have be take profit handful retailer include cvs health cvs dollartree dltr costco cost william sonoma wsm stock market clock slight gain last full month summer uptrend be pressure second half september manager top perform fund past month continue add share medical issue market pullback industry group track ibd medical subgroup hospital ethical drug biotech biom be rank top thursday large drug firm allergan agn jazz pharmaceutical jazz actavis act salix pharmaceutical slxp continue grab top fund interest latest report period lead fund also biotech firm such gilead science gild biogen idec biib celgene celg transportation stock remain spotlight airline luv fedex fdx union pacific unp few notable buy top fund worth mention include social medium giant facebook fb burrito chain chipotle grill cmg retailer ulta beauty ulta ibd find best perform fund add chipotle investing estimate latest report period rowe price blue chip growth fund own big stake firm fast casual chain run restaurant canada also venture southeast asian flavor new concept call southeast asian kitchen december chipotle announce plan expand pizza segment pizzeria locale chipotle menu be simple serve burritos taco burrito bowl salad used fresh organic ingredient rival similar menu el pollo make ipo debut july stock breakaway gap july share have be trading steadily tight range earning have be grow steadily double digit least quarters third quarter earning result be due market close oct analyst currently see earning rise share sell nation top perform fund have be take profit handful retailer include cvs health cvs dollartree dltr costco cost william sonoma wsm
2641,GILD,many same name extend high thursday few new one joined market rally gilead science gild gain average volume extend streak fifth straight session share be week tight buy point analyst expect biotech report third consecutive quarter
2642,GILD,few good stock be individual investor need boost portfolio individual investor have edge pro respect concentrate portfolio handful stock reduce exposure raise cash quickly necessary unfortunately current sector leader lineup isn provide proper entry
2643,GILD,era many investor tout virtue passive fund management manager allianzgi focuse growth be flag bearer active mutual fund management
2644,GILD,look portfolio fund be concentrated just name july manager scott migliori karen hiatt david jedlicka bet big best investment idea
2645,GILD,fund money have be work top hold biogen idec biib most recent month biogen share be year be march high consolidate gain overall stock market blahs
2646,GILD,still wall street be optimistic biotech consensus estimate earning year be share june ep rise soundly beat analyst consensus expectation
2647,GILD,result be drive largely oral multiple sclerosis drug tecfidera already lead oral ms therapy be way become lead overall ms therapy foreign sale be soar too second time year biogen raise earning revenue guidance
2648,GILD,stock be buy point cup handle base be testing support week move average
2649,GILD,facebook fb be big bet stock have climb weighting time
2650,GILD,share be extend past cup handle buy point
2651,GILD,money mobile
2652,GILD,mobile ad be generate strong return social network now account total revenue fund manager note recent quarterly review outlook facebook have find way make money mobile traffic more successfully many other company write manager expect facebook competitive edge grow
2653,GILD,company be add application boost ad service
2654,GILD,ep grow triple digit pace past quarters
2655,GILD,fund even have build stake apple aapl name make many investor nervous weighting feb
2656,GILD,share be year bounce week line friday
2657,GILD,ep grow most recent quarter top consensus view
2658,GILD,iphone be expect ship inch screen larger iphone also expect have stronger battery milliampere hour capacity
2659,GILD,gilead science gild be top hold fund have build stake have weighting july feb
2660,GILD,gilead share tuesday trade week tight entry
2661,GILD,sovaldi gilead new hepatitis treatment have get fast start sovaldi post sale first full quarter market easily exceed estimate allianzgi manager write
2662,GILD,write investor expect successful launch gilead once daily combination pill hepatitis combination ledipasvir sovaldi cure hepatitis little week need injection additional drug treatment era many investor tout virtue passive fund management manager allianzgi focuse growth be flag bearer active mutual fund management look portfolio fund be concentrated just name july manager scott migliori karen hiatt david jedlicka bet big best investment idea fund money have be work top hold biogen idec biib most recent month biogen share be year be march high consolidate gain overall stock market blahs still wall street be optimistic biotech consensus estimate earning year be share june ep rise soundly beat analyst consensus expectation result be drive largely oral multiple sclerosis drug tecfidera already lead oral ms therapy be way become lead overall ms therapy foreign sale be soar too second time year biogen raise earning revenue guidance stock be buy point cup handle base be testing support week move average facebook fb be big bet stock have climb weighting time share be extend past cup handle buy point money mobilemobile ad be generate strong return social network now account total revenue fund manager note recent quarterly review outlook facebook have find way make money mobile traffic more successfully many other company write manager expect facebook competitive edge grow company be add application boost ad service ep grow triple digit pace past quarters fund even have build stake apple aapl name make many investor nervous weighting feb share be year bounce week line friday ep grow most recent quarter top consensus view iphone be expect ship inch screen larger iphone also expect have stronger battery milliampere hour capacity gilead science gild be top hold fund have build stake have weighting july feb gilead share tuesday trade week tight entry sovaldi gilead new hepatitis treatment have get fast start sovaldi post sale first full quarter market easily exceed estimate allianzgi manager write write investor expect successful launch gilead once daily combination pill hepatitis combination ledipasvir sovaldi cure hepatitis little week need injection additional drug treatment
2663,GILD,major index fall sharply tuesday trouble stock market deteriorate more wall street sell close often do market be correct nasdaq slide have lowest close price mid august volume rise significantly vapor trail institutional investor fly away stock
2664,GILD,stock try third straight gain monday fail hit key resistance nasdaq fall be much early session turn tail hit wall day move average monday low nasdaq be much biotech software solar stock be
2665,GILD,stock continue add broad gain late trading friday be pace end modestly higher week nasdaq stretched gain have erased thursday loss then meanwhile rally dow jone industrial average rise turnover be again run mixed stock market today nyse trade be tracking sharply higher nasdaq volume be run lower compare same time thursday aercap holding aer reversed early loss rally fast trade stock be get close resistance day line work potential flat base aercap last break double bottom base early analyst poll thomson reuter see profit rise cent share mark second straight quarter acceleration gilead science gild step gain more be pace end day pullback stock be now past buy point first stage cup handle base biotech report second quarter earning wednesday profit be expect share year mark second straight quarter triple digit growth gilead sovaldi hepatitis treatment be expect drive growth autonation rally also meet resistance day line share auto dealer tumble slice line thursday disappointing earning report seagate technology stx shave early loss be still thursday close hard drive maker report disappointing fiscal sale company peg sale current fiscal first quarter slightly view
2666,GILD,lead stock take lick past week only small clique ibd stock post weekly gain china base tal education xrs haul gain end week new high left chain tutor center kindergarten grade well extend first test week support undefined late stage base june china issue online automotive datum provider bitauto bita shave loss slightly positive finish week marked bitauto eighth straight weekly advance stock be buy point late stage base china stock be not immune selling diversify internet play qihoo qihu take hit end week bottom trading range left flush converge week move average throw challenge front late stage base build effort qihoo other stock fall ibd list broad market weakness industry standpoint most resilient stock be drugmaker other medical stock head list team health holding tmh rattle gain week outsourced health care staffing firm end week middle trading range buy point second stage base base pattern salix pharmaceutical slxp gilead science gild rise largest gain biom play salix be consolidate just july high buy point late stage base gilead gain extend advance week putt buy point clear first stage base early july drug distributor abc tick fraction hold gain prior week flat base buy point side note revenue be far largest ibd list medical play also figured week hardest hit leader spain base grifol grfs crumble blood plasma distributor report second quarter result thursday grifol drop drag share second stage base build effort key level support other hard hit play list include emerge energy emes
2667,GILD,big cap biotech leader biogen idec biib gilead science gild easily beat second quarter earning estimate receive product approval wednesday stock react very differently
2668,GILD,biogenearning rise vs year earlier share top analyst consensus cent sale grow vs street
2669,GILD,company increase full year revenue range growth analyst average now see ep more prior guidance analyst expect
2670,GILD,upside come largely tecfidera oral multiple sclerosis drug approve last year europe early february management analyst expect slow european launch novartis nvs enter market first ms pill gilenya however executive say uptake european country have gain reimbursement mainly germany be proceed similar pace
2671,GILD,sale tecfidera outside be vs consensus domestic sale rise top estimate
2672,GILD,biogen reach deal italy eliminate country reimbursement limit older ms drug tysabri retroactive february
2673,GILD,recognition revenue add cent ep
2674,GILD,ceo george scango disclose eu have approve biogen interferon base ms drug plegridy be still await approval america launch drug hemophilia drug alprolix eloctate lead biogen guide sale general administrative expense expectation revenue
2675,GILD,biogen slightly disappoint street say phase trial result lingo be first disease alter treatment ms be report not next year hope company want month result rather month still biogen stock rise
2676,GILD,sovaldi boom
2677,GILD,gilead earning release close vault share beating cent sale leap top view
2678,GILD,hepatitis drug sovaldi just launch december generate sale well consensus
2679,GILD,political industry protest day pill gilead say state medicaid program cover sovaldi
2680,GILD,gilead first time give full year guidance include sovaldi sale vs last year subtract prior guidance imply sovaldi rake
2681,GILD,gilead whisper number seem be much higher
2682,GILD,gild report soundly beat sell side consensus be roughly line perceive be buy side expectation write isi group analyst mark schoenebaum email client add new revenue guidance agree analyst estimate
2683,GILD,perhaps reason gilead stock fall fractionally late largely erase regular session gain
2684,GILD,gilead other major drug hiv medicine atripla truvada viread complera stribild modestly top consensus atripla
2685,GILD,bud field cancer medicine gilead also say fda approve drug idelalisib now brand zydelig chronic lymphocytic leukemia follicular lymphoma small lymphocytic lymphoma analyst expect be blockbuster more modest proportion sovaldi sale peak
2686,GILD,other major biotechs report thursday alexion pharmaceutical alxn celgene celg big cap biotech leader biogen idec biib gilead science gild easily beat second quarter earning estimate receive product approval wednesday stock react very differently biogenearning rise vs year earlier share top analyst consensus cent sale grow vs street company increase full year revenue range growth analyst average now see ep more prior guidance analyst expect upside come largely tecfidera oral multiple sclerosis drug approve last year europe early february management analyst expect slow european launch novartis nvs enter market first ms pill gilenya however executive say uptake european country have gain reimbursement mainly germany be proceed similar pace sale tecfidera outside be vs consensus domestic sale rise top estimate biogen reach deal italy eliminate country reimbursement limit older ms drug tysabri retroactive february recognition revenue add cent ep ceo george scango disclose eu have approve biogen interferon base ms drug plegridy be still await approval america launch drug hemophilia drug alprolix eloctate lead biogen guide sale general administrative expense expectation revenue biogen slightly disappoint street say phase trial result lingo be first disease alter treatment ms be report not next year hope company want month result rather month still biogen stock rise sovaldi boomsgilead earning release close vault share beating cent sale leap top view hepatitis drug sovaldi just launch december generate sale well consensus political industry protest day pill gilead say state medicaid program cover sovaldi gilead first time give full year guidance include sovaldi sale vs last year subtract prior guidance imply sovaldi rake gilead whisper number seem be much higher gild report soundly beat sell side consensus be roughly line perceive be buy side expectation write isi group analyst mark schoenebaum email client add new revenue guidance agree analyst estimate perhaps reason gilead stock fall fractionally late largely erase regular session gain gilead other major drug hiv medicine atripla truvada viread complera stribild modestly top consensus atripla bud field cancer medicine gilead also say fda approve drug idelalisib now brand zydelig chronic lymphocytic leukemia follicular lymphoma small lymphocytic lymphoma analyst expect be blockbuster more modest proportion sovaldi sale peak other major biotechs report thursday alexion pharmaceutical alxn celgene celg
2687,GILD,vertex pharmaceutical sail most crucial test year existence cystic fibrosis cf treatment hit goal late stage study disclosure tuesday vertex stock soar year high close
2688,GILD,vertex vrtx pooled result phase clinical trial look patient homozygous pair gene del genetic mutation most common cause cystic fibrosis patient take combination lumacaftor ivacaftor week show statistically significant improvement lung function well significant reduction rate pulmonary exacerbation improvement body mass
2689,GILD,pivotal result validate strategy used combination corrector lumacaftor potentiator ivacaftor treat underlie cause cf vertex ceo jeffrey leiden tell analyst tuesday
2690,GILD,company plan file approval europe analyst say probably launch mid
2691,GILD,wall street hesitate
2692,GILD,size stock move reflect uncertain wall street be treatment work well significant news be vertex vertex enjoy be time biggest drug launch history hepatitis treatment incivek year later sale fall sharply competition come online especially gilead science gild sovaldi have already surpass incivek launch record be approve december
2693,GILD,ivacaftor drug latest study be approve sale kalydeco be approve only patient mutation represent only cf sufferer accord cystic fibrosis foundation
2694,GILD,thank partly controversially aggressive pricing year vertex still have be able pull hundred million annual revenue patient base just few be able treat so patient del mutation homozygous heterozygous turn ivacaftor blockbuster
2695,GILD,nonetheless prior trial result didn inspire full confidence just last week bernstein analyst geoffrey porge warn high risk failure base talk scientist cf conference
2696,GILD,tuesday isi group analyst mark schoenebaum write result be not home run due modest rate lung function improvement mean improvement be lack better alternative mean peak annual sale hit
2697,GILD,franchise
2698,GILD,rbc capital market analyst michael yee point vertex be also testing third drug vx have whole library other corrector work wider range genetic type estimate peak annual sale whole cf franchise
2699,GILD,big picture investor remember be be major improvement sick cf patient typically kid doc feedback be drug be fda approve patient get access write
2700,GILD,yee raise price target maintain outperform rating
2701,GILD,question still air be combo price vertex get away pricing kalydeco so high patient pool be so tiny efficacy be so good analyst generally expect combo price much lower yee estimate write street be mostly think
2702,GILD,way vertex likely have only disease alter cf treatment market quite say morningstar analyst stefan quenneville also believe result have longer term moat implication company position dominant player cystic fibrosis write research note tuesday vertex pharmaceutical sail most crucial test year existence cystic fibrosis cf treatment hit goal late stage study disclosure tuesday vertex stock soar year high close vertex vrtx pooled result phase clinical trial look patient homozygous pair gene del genetic mutation most common cause cystic fibrosis patient take combination lumacaftor ivacaftor week show statistically significant improvement lung function well significant reduction rate pulmonary exacerbation improvement body mass pivotal result validate strategy used combination corrector lumacaftor potentiator ivacaftor treat underlie cause cf vertex ceo jeffrey leiden tell analyst tuesday company plan file approval europe analyst say probably launch mid wall street size stock move reflect uncertain wall street be treatment work well significant news be vertex vertex enjoy be time biggest drug launch history hepatitis treatment incivek year later sale fall sharply competition come online especially gilead science gild sovaldi have already surpass incivek launch record be approve december ivacaftor drug latest study be approve sale kalydeco be approve only patient mutation represent only cf sufferer accord cystic fibrosis foundation thank partly controversially aggressive pricing year vertex still have be able pull hundred million annual revenue patient base just few be able treat so patient del mutation homozygous heterozygous turn ivacaftor blockbuster nonetheless prior trial result didn inspire full confidence just last week bernstein analyst geoffrey porge warn high risk failure base talk scientist cf conference tuesday isi group analyst mark schoenebaum write result be not home run due modest rate lung function improvement mean improvement be lack better alternative mean peak annual sale hit franchise rbc capital market analyst michael yee point vertex be also testing third drug vx have whole library other corrector work wider range genetic type estimate peak annual sale whole cf franchise big picture investor remember be be major improvement sick cf patient typically kid doc feedback be drug be fda approve patient get access write yee raise price target maintain outperform rating question still air be combo price vertex get away pricing kalydeco so high patient pool be so tiny efficacy be so good analyst generally expect combo price much lower yee estimate write street be mostly think way vertex likely have only disease alter cf treatment market quite say morningstar analyst stefan quenneville also believe result have longer term moat implication company position dominant player cystic fibrosis write research note tuesday
2703,GILD,big cap biotech gilead science gild rise stock market today hit new time high friday win dispute roche right blockbuster hepatitis drug separately be endorse cost benefit authority roche rhhby have claim right drug sovaldi last year due partnership
2704,GILD,aetna give earning guidance booster shot follow strong second quarter aid acquisition coventry health care health insurer earning rise share top estimate revenue jump view share fall early trading stock
2705,GILD,stock pare loss friday harsh reminder ukraine even go back burner remain area concern market
2706,GILD,day nasdaq flash sign strength stock reversed early gain battle back end mixed mostly unchanged
2707,GILD,close dow jone industrial average lose weigh general electric ge visa close fractionally lower nasdaq rally preliminary datum show nyse nasdaq volume come higher thursday option expire
2708,GILD,week nasdaq rise rally dow gain
2709,GILD,stock market today monster beverage mnst vault news coca cola ko be buy stake energy drink maker slumping soft drink sale coke have be expand arsenal recently buy stake keurig green mountain gmcr market keurig cold beverage maker coke up stake keurig
2710,GILD,elsewhere leaderboard namefleetcor technology flt add recent gain rise earlier week market cheer news be acquire payment firm comdata fleetcor be provider fuel card workforce payment product
2711,GILD,sierra wireless swir gain ground seventh time session rise be consolidate gain january be only time high full year earning be see rise year growth accelerate
2712,GILD,gilead science gild rise news win dispute roche rhhby right blockbuster hepatitis drug sovaldi
2713,GILD,downside jwn dd lead ibd retail department store group decline nearly
2714,GILD,slump give disappointing earning stock pare loss friday harsh reminder ukraine even go back burner remain area concern market day nasdaq flash sign strength stock reversed early gain battle back end mixed mostly unchanged close dow jone industrial average lose weigh general electric ge visa close fractionally lower nasdaq rally preliminary datum show nyse nasdaq volume come higher thursday option expire week nasdaq rise rally dow gain stock market today monster beverage mnst vault news coca cola ko be buy stake energy drink maker slumping soft drink sale coke have be expand arsenal recently buy stake keurig green mountain gmcr market keurig cold beverage maker coke up stake keurig elsewhere leaderboard namefleetcor technology flt add recent gain rise earlier week market cheer news be acquire payment firm comdata fleetcor be provider fuel card workforce payment product sierra wireless swir gain ground seventh time session rise be consolidate gain january be only time high full year earning be see rise year growth accelerate gilead science gild rise news win dispute roche rhhby right blockbuster hepatitis drug sovaldi downside jwn dd lead ibd retail department store group decline nearly slump give disappointing earning
2715,GILD,stock market bounce back tuesday session provide encourage sign nasdaq jump close session high small cap continue lag comparison russell picked nasdaq advance be not well round volume nasdaq be lower advance stock top
2716,GILD,stock push ahead be session high friday midpoint
2717,GILD,help chip solar internet stock nasdaq outperformed gain climb major index have regain more half thursday loss dow jone industrial average rise volume be tracking higher stock market today today be day option expiration
2718,GILD,armour ua rally bounce back straight loss still buy point cup handle base stock pass trigger weak trade july retreat soon athletic apparel footwear maker report earning thursday open analyst poll thomson reuter see profit fall cent share
2719,GILD,gilead science gild be also bounce back day retreat rise fast trade stock be now past buy point first stage cup handle base
2720,GILD,equinix eqix have fade solid open turn nearly gain just stock open buy point huge cup handle base
2721,GILD,seagate technology stx pare loss less thursday close hard drive maker report disappointing fiscal sale company peg sale current quarter slightly view stock push ahead be session high friday midpoint help chip solar internet stock nasdaq outperformed gain climb major index have regain more half thursday loss dow jone industrial average rise volume be tracking higher stock market today today be day option expiration armour ua rally bounce back straight loss still buy point cup handle base stock pass trigger weak trade july retreat soon athletic apparel footwear maker report earning thursday open analyst poll thomson reuter see profit fall cent share gilead science gild be also bounce back day retreat rise fast trade stock be now past buy point first stage cup handle base equinix eqix have fade solid open turn nearly gain just stock open buy point huge cup handle base seagate technology stx pare loss less thursday close hard drive maker report disappointing fiscal sale company peg sale current quarter slightly view
2722,GILD,emerge market fund continue winning way largest mutual fund june broad stock market international stock market be also hover top vanguard emerge market stock index fund have asset invest emerge asian market latin america emerge europe africa middle
2723,GILD,stock continue trade tight range go final hour trading wednesday have moved slightly positive side major index nasdaq dow jone industrial average be fractionally volume be run lighter tuesday exchange stock market today ibd stock be be indicate weakness growth stock best performer be jazz pharmaceutical jazz heavy volume break cup handle base buy point open company announce have buy right sigma tau pharmaceutical americas right defibrotide treatment severe hepatic veno occlusive disease second best performer be ambarella amba nearly average volume stock continue work right side base base correct be late stage correction be perhaps too much give state general market company make system chip used camera similar device gilead science gild follow tuesday cup handle base volume have be average day
2724,GILD,stock be mixed mostly unchanged early afternoon trading wednesday better expect private payroll report adp fail fuel much excitement
2725,GILD,nasdaq dow jone industrial average rise rise fraction volume nyse nasdaq be tracking lower tuesday level more so nasdaq
2726,GILD,economic news private employer add job june accord adp well consensus estimate datum come ahead thursday job report nonfarm payroll be see rise growth unemployment rate be expect remain unchanged
2727,GILD,stock market today ibd name constellation brand stz make more progress recent cup handle share rise wine spirit firm report solid earning big growth recent quarters have be fuel acquisition grupo modelo operation anheuser busch inbev bud last year
2728,GILD,ambarella amba be strong gainer ibd share rise stock have be beneficiary gopro gpro solid debut ambarella chip be find gopro hero line camera
2729,GILD,chip designer be new accumulation phase move closer time high current consolidation be weak stock have correct steep sound basis generally shouldn correct more sale growth have decelerate straight quarters
2730,GILD,have be low volume so far gilead science gild stock extend gain tuesday rise be high end buy range buy point
2731,GILD,china base com wuba outperformed rise nearly strong trade stock be work first stage base fast approach potential buy point stock be mixed mostly unchanged early afternoon trading wednesday better expect private payroll report adp fail fuel much excitement nasdaq dow jone industrial average rise rise fraction volume nyse nasdaq be tracking lower tuesday level more so nasdaq economic news private employer add job june accord adp well consensus estimate datum come ahead thursday job report nonfarm payroll be see rise growth unemployment rate be expect remain unchanged stock market today ibd name constellation brand stz make more progress recent cup handle share rise wine spirit firm report solid earning big growth recent quarters have be fuel acquisition grupo modelo operation anheuser busch inbev bud last year ambarella amba be strong gainer ibd share rise stock have be beneficiary gopro gpro solid debut ambarella chip be find gopro hero line camera chip designer be new accumulation phase move closer time high current consolidation be weak stock have correct steep sound basis generally shouldn correct more sale growth have decelerate straight quarters have be low volume so far gilead science gild stock extend gain tuesday rise be high end buy range buy point china base com wuba outperformed rise nearly strong trade stock be work first stage base fast approach potential buy point
2732,GILD,major average trade mixed mostly unchanged thursday just hour session
2733,GILD,nasdaq add dow jone industrial average slip volume nyse nasdaq be tracking sharply lower thursday level
2734,GILD,stock market today tobacco firm lorillard jump news discussion rival reynold american rai possible merger just announcement base imperial tobacco say talk buy asset lorillard reynold
2735,GILD,elsewhere macquarie infrastructure mic continue hold gain tuesday gap price macquarie own storage terminal oil product chemical
2736,GILD,earlier week macquarie agree acquire rest international matex tank terminal didn already own just thursday announce share offer price share be recently trading nearly
2737,GILD,gilead science gild extend gain rise recent low volume now cup handle buy point gilead long know hiv drug franchise have new blockbuster hand pricey hepatitis drug sovaldi approve late drug do nearly sale first quarter market
2738,GILD,volume be heavy early facebook fb stock moved closer reclaim cup handle buy point share rise
2739,GILD,china base stock ibd outperformed include vipshop holding vip qihoo technology qihu bitauto holding bita vipshop be hold well recent late stage base major average trade mixed mostly unchanged thursday just hour session nasdaq add dow jone industrial average slip volume nyse nasdaq be tracking sharply lower thursday level stock market today tobacco firm lorillard jump news discussion rival reynold american rai possible merger just announcement base imperial tobacco say talk buy asset lorillard reynold elsewhere macquarie infrastructure mic continue hold gain tuesday gap price macquarie own storage terminal oil product chemical earlier week macquarie agree acquire rest international matex tank terminal didn already own just thursday announce share offer price share be recently trading nearly gilead science gild extend gain rise recent low volume now cup handle buy point gilead long know hiv drug franchise have new blockbuster hand pricey hepatitis drug sovaldi approve late drug do nearly sale first quarter market volume be heavy early facebook fb stock moved closer reclaim cup handle buy point share rise china base stock ibd outperformed include vipshop holding vip qihoo technology qihu bitauto holding bita vipshop be hold well recent late stage base
2740,GILD,big cap biotech biogen idec biib soundly beat analyst expectation substantially raise guidance early wednesday send share more midday trading stock market today month high biogen earning rise year earlier quarter share top analyst consensus cent sale increase vs street company increase full year guidance revenue growth earlier guide analyst average ep guidance be now more previous guidance analyst be expect upside come largely tecfidera oral multiple sclerosis drug approve last year europe early february management analyst have expect european launch be slow novartis nvs have get market first ms pill gilenya however conference call discuss result executive say uptake european country have gain reimbursement mainly germany point be proceed similar pace total sale tecfidera outside quarter be vs consensus domestic sale also outperformed take top estimate also benefit time event quarter biogen come agreement italian national medicine agency eliminate country reimbursement limit tysabri older ms drug retroactive february recognition revenue add cent ep good news item disappoint analyst be sale general administrative spending be guide higher expect revenue call cfo paul clancy say be necessary unprecedented amount drug launch underway not only be tecfidera still roll also biogen launch long act hemophilia drug alprolix also beat expectation sale vs analyst estimate just last week launch hemophilia counterpart eloctate company be also prepare launch new interferon base ms drug plegridy call biogen ceo george scango say just get word plegridy have be approve eu other disappointment be delay report result key clinical trial month street have be buzz biogen pipeline product call lingo be first disease alter treatment ms analyst have expect month result phase trial be next year management say report month result nonetheless isi group analyst mark schoenebaum be generally impressed point be largest beat biogen have report year overall really good call new disclosure diluted quality ep sale beat quarter write email client conference call biogen kick earning several top rate biotechs tuesday market close gilead science gild be expect report earning share sale blockbuster hepatitis drug sovaldi alexion pharmaceutical alxn celgene celg be tap thursday other biotech news puma biotechnology pbyi shot company report surprisingly strong phase trial result breast cancer drug follow amy reeve twitter ibd_areeve related biogen share rebound street have change heart
2741,GILD,highest rate market big cap biotechs be set report second quarter earning week own unique storyline biogen idec biib subject tuesday new america be first report open wednesday analyst consensus call sale year earlier quarter earning
2742,GILD,fundamentally sound stock such michael kor have demonstrated long term stability market correction re good candidate stock watch list today screen day be top fundamental stock year earning share revenue growth rate higher second sort yield top estimate ep growth quarter vs
2743,GILD,middle earning season expectation investor be high not just well do well do vs expectation taser international tasr gilead science gild green plain renewable energy gpre tesla motor tsla sunpower spwr be top tech company estimate beater screen day taser beat
2744,GILD,stock rolled early gain weak trade soft economic news do little coax investor sideline
2745,GILD,dow jone industrial average scramble ahead nasdaq fought hold fractional gain
2746,GILD,volume open weak foot nasdaq trading lower nyse compare early trade monday
2747,GILD,stock market today open comment federal reserve chairwoman janet yellen speaking video record play atlanta federal reserve conference
2748,GILD,fed chief make case big bank fortify set aside more capital recommend recently upgrade fed standard yellen also say international banking standard make more rigid follow financial crisis do not fully address financial stability concern associate short term wholesale funding fed be actively consider additional measure address other residual risk
2749,GILD,bump inflation drive primarily increase housing cost push march consumer price index more expect
2750,GILD,suggestion stronger housing price national association homebuilder report april housing market index sit flat group revise march number lower so april result be facto gain index show builder confidence relatively steady third straight month still well level post july january
2751,GILD,stock coca cola ko bat gain report first quarter earning lead dow handful recently batter biotech stock rebound early action gilead science gild biogen idec biib bounce big trade top nasdaq stock remain weaken
2752,GILD,lead stock again post broad gain open more ibd stock rise start gate early riser touch sensor technology developer synaptic syna jump mild trade stock drift week move average back forth action begin march be week consolidation stock rolled early gain weak trade soft economic news do little coax investor sideline dow jone industrial average scramble ahead nasdaq fought hold fractional gain volume open weak foot nasdaq trading lower nyse compare early trade monday stock market today open comment federal reserve chairwoman janet yellen speaking video record play atlanta federal reserve conference fed chief make case big bank fortify set aside more capital recommend recently upgrade fed standard yellen also say international banking standard make more rigid follow financial crisis do not fully address financial stability concern associate short term wholesale funding fed be actively consider additional measure address other residual risk bump inflation drive primarily increase housing cost push march consumer price index more expect suggestion stronger housing price national association homebuilder report april housing market index sit flat group revise march number lower so april result be facto gain index show builder confidence relatively steady third straight month still well level post july january stock coca cola ko bat gain report first quarter earning lead dow handful recently batter biotech stock rebound early action gilead science gild biogen idec biib bounce big trade top nasdaq stock remain weaken lead stock again post broad gain open more ibd stock rise start gate early riser touch sensor technology developer synaptic syna jump mild trade stock drift week move average back forth action begin march be week consolidation
2753,GILD,chairman senior member senate finance committee friday issue battery question gilead science gild price blockbuster hepatitis drug sovaldi add chorus objection product pill price market be unfazed however gilead stock fraction morning trading
2754,GILD,big cap biotechs celgene alexion pharmaceutical modestly beat estimate raise guidance early thursday share tumble wall street seem turn sector celgene celg earning rise year earlier quarter cent share beating consensus penny sale increase
2755,GILD,earning season full force investor focus very best company elite ibd rank top rate growth stock factor strong relative price strength top fundamental ibd have several company report earning come week here be top due report earning wednesday social networking giant facebook fb
2756,GILD,biotech etfs seesaw recent week slide grim fed comment perk blockbuster earning big cap leader gilead gild biogen biib slumping again more modest news celgene celg alexion alxn gyration underscored need investor caution volatile health subsector expert tell ibd see large distortion base
2757,GILD,stock turn small loss modest gain monday afternoon
2758,GILD,thank solar online travel software stock nasdaq lead gain dow jone industrial average rise earlier nasdaq be respectively volume continue run lower stock market today compare same time friday
2759,GILD,lead stock horizon pharma hznp jump company raise guidance cite expect robust result drugmaker now expect full year sale prior view view be currently stock be now nearly past buy point flat base clear late most case profit be take once amount
2760,GILD,medidata solution mdso add putt pace eighth straight gain stock clear buy point flat base ahead earning tuesday morning analyst poll thomson reuter see profit rise cent share medidata have be trading sideway first quarter result april
2761,GILD,facebook fb tack new high now more past buy point flat base initially clear june social network giant report earning july company be expect earn cent share year mark slowdown recent quarters profit grow past quarters
2762,GILD,downside taser international tasr turn gain loss have almost climb back buy point monday high company announce earlier day subsidiary taser international bv buy britain tactical safety response limit undisclosed sum
2763,GILD,heritage insurance holding hrtg be session low still nearly suffering analyst downgrade market perform outperform last week stock narrowly miss profit target past buy point flat base stock turn small loss modest gain monday afternoon thank solar online travel software stock nasdaq lead gain dow jone industrial average rise earlier nasdaq be respectively volume continue run lower stock market today compare same time friday lead stock horizon pharma hznp jump company raise guidance cite expect robust result drugmaker now expect full year sale prior view view be currently stock be now nearly past buy point flat base clear late most case profit be take once amount medidata solution mdso add putt pace eighth straight gain stock clear buy point flat base ahead earning tuesday morning analyst poll thomson reuter see profit rise cent share medidata have be trading sideway first quarter result april facebook fb tack new high now more past buy point flat base initially clear june social network giant report earning july company be expect earn cent share year mark slowdown recent quarters profit grow past quarters downside taser international tasr turn gain loss have almost climb back buy point monday high company announce earlier day subsidiary taser international bv buy britain tactical safety response limit undisclosed sum heritage insurance holding hrtg be session low still nearly suffering analyst downgrade market perform outperform last week stock narrowly miss profit target past buy point flat base
2764,GILD,rock band second album biotech second drug say lot long term prospect alexion pharmaceutical alxn be face test year old firm have become big cap perennial ibd list top rate stock thank market product soliris first launch treat blood disease
2765,GILD,most pharmaceutical company keep pipeline new drug filled be critical success
2766,GILD,steven klosk president ceo east rutherford base cambrex cbm specialize develop pipeline new medication outsourcer other pharmaceutical firm
2767,GILD,create steady flow new product keep revenue spiking be ceo major task say klosk be case study type achievement
2768,GILD,daniel rizzo new york city base industry analyst sidoti co say klosk consistently work customer determine need pipeline cambrex have be robust look be robust next couple year
2769,GILD,klosk say most important role be set broad overall growth strategy business keenly aware need follow history be litter company have come great strategy not execute klosk say
2770,GILD,get strategic traction klosk say paramount communicate senior management overall approach staffer make point hold regular town meeting cambrex global location europe india tell here strategy here fit here be goal objective then repeat so everyone get know
2771,GILD,rank
2772,GILD,klosk be name ceo cambrex work way corporate ladder previously serve vice president administration chief operate officer
2773,GILD,mentor cambrex guide career jim mack previous ceo gary mossman ex coo allow travel help manage business say klosk native new hyde park graduate cornell university
2774,GILD,klosk say mack taught make most commercial opportunity prepare customer meeting also learn understand business financial point view include income statement balance sheet cash flow
2775,GILD,start cambrex klosk graduate manhattan new york law school legal training provide many requisite skill serve ceo
2776,GILD,most ceo be awash datum klosk say legal training allow deftly analyze various business prospect strategy come desk give ability get core issue say
2777,GILD,klosk admit be lonely top also see big difference move head company lower managerial level note person tell thing reason re less likely re ceo
2778,GILD,ceo klosk notice person don come ve do homework lower level staffer tend exchange fresher more spontaneous information business solve problem hence klosk rely senior management team bubble new idea rank stress importance listen staff
2779,GILD,cambrex key role be serve custom developer various pharmaceutical company help customer mostly late stage pharmaceutical development gain patent food drug administration approval
2780,GILD,hire make molecule specialize active pharmaceutical ingredient give molecule efficacy klosk say
2781,GILD,re not place bet develop new chemical process re attempt outsourcer manufacturing supplier many late stage medication say
2782,GILD,keep cambrex business pump klosk say single most important factor grow business be new product
2783,GILD,fat pipeline
2784,GILD,cambrex team pharmaceutical firm develop new innovative drug research generic drug currently pipeline be develop generic medication new product drug be second phase development
2785,GILD,often work smaller pharmaceutical firm afford cambrex partner company size
2786,GILD,re attempt outsourcer manufacturing supplier many late stage customer say
2787,GILD,cambrex often focus niche generic product new innovative drug search medication affect wider audience produce more revenue
2788,GILD,example cambrex partner gilead science gild develop new hepatitis drug call solvadi analyst rizzo say solvadi have potential reach sale far sale most cambrex generic drug average year say
2789,GILD,solvadi be blockbuster rizzo say larger product anything cambrex have have past
2790,GILD,solvadi isn only drug pipeline cambrex have new generic drug rizzo expect add revenue growth begin most pharmaceutical company keep pipeline new drug filled be critical success steven klosk president ceo east rutherford base cambrex cbm specialize develop pipeline new medication outsourcer other pharmaceutical firm create steady flow new product keep revenue spiking be ceo major task say klosk be case study type achievement daniel rizzo new york city base industry analyst sidoti co say klosk consistently work customer determine need pipeline cambrex have be robust look be robust next couple year klosk say most important role be set broad overall growth strategy business keenly aware need follow history be litter company have come great strategy not execute klosk say get strategic traction klosk say paramount communicate senior management overall approach staffer make point hold regular town meeting cambrex global location europe india tell here strategy here fit here be goal objective then repeat so everyone get know ranksklosk be name ceo cambrex work way corporate ladder previously serve vice president administration chief operate officer mentor cambrex guide career jim mack previous ceo gary mossman ex coo allow travel help manage business say klosk native new hyde park graduate cornell university klosk say mack taught make most commercial opportunity prepare customer meeting also learn understand business financial point view include income statement balance sheet cash flow start cambrex klosk graduate manhattan new york law school legal training provide many requisite skill serve ceo most ceo be awash datum klosk say legal training allow deftly analyze various business prospect strategy come desk give ability get core issue say klosk admit be lonely top also see big difference move head company lower managerial level note person tell thing reason re less likely re ceo ceo klosk notice person don come ve do homework lower level staffer tend exchange fresher more spontaneous information business solve problem hence klosk rely senior management team bubble new idea rank stress importance listen staff cambrex key role be serve custom developer various pharmaceutical company help customer mostly late stage pharmaceutical development gain patent food drug administration approval hire make molecule specialize active pharmaceutical ingredient give molecule efficacy klosk say re not place bet develop new chemical process re attempt outsourcer manufacturing supplier many late stage medication say keep cambrex business pump klosk say single most important factor grow business be new product fat pipelinecambrex team pharmaceutical firm develop new innovative drug research generic drug currently pipeline be develop generic medication new product drug be second phase development often work smaller pharmaceutical firm afford cambrex partner company size re attempt outsourcer manufacturing supplier many late stage customer say cambrex often focus niche generic product new innovative drug search medication affect wider audience produce more revenue example cambrex partner gilead science gild develop new hepatitis drug call solvadi analyst rizzo say solvadi have potential reach sale far sale most cambrex generic drug average year say solvadi be blockbuster rizzo say larger product anything cambrex have have past solvadi isn only drug pipeline cambrex have new generic drug rizzo expect add revenue growth begin
2791,GILD,stock market start third quarter fine fashion tuesday solid percentage gain higher volume nasdaq notch year high marked close high close nasdaq rise add dow jone industrial average gain close point level
2792,GILD,johnson johnson jnj kick medical industry earning season modest upside surprise tuesday send stock morning trading stock market today earning time item totale share year earlier quarter beating analyst consensus cent sale rise
2793,GILD,market start short trading week mixed result monday leader give better show thank part chip software stock nasdaq muster gain tech heavy index rise much touch fresh year high philadelphia semiconductor index rally best close high march
2794,GILD,new buy list top perform fund past month show heavy buy top rate stock nation lead fund have be stocking medical issue fared well market resume uptrend august large heavy hit medical stock be buy top fund latest report period include gilead science gild jazz pharmaceutical ticker
2795,GILD,several chilly earning season revenue growth second quarter result have be considerably warmer company halfway mark report performance large cap index company report friday blended revenue growth reach highest rate accord datum provide thomson reuter
2796,GILD,fourth july be time backyard grill relax earning season be right corner so now time look ibd stock be expect post strongest earning gain ibd list company base superior earning strong price performance leadership industry salix pharmaceutical slxp be slate
2797,GILD,stock market continue advance tuesday subtle institutional selling surface nasdaq rise close session high highest level march add just give have be gain early volume rise board close
2798,GILD,big cap biotech gilead science gild be expect report modest close tuesday analyst investor be listen closely new detail rollout potential blockbuster hepatitis drug sovaldi analyst poll thomson reuter estimate gilead revenue rise year earlier quarter profit flat
2799,GILD,be healthy week leader more ibd list top rate growth stock press new high stage breakout nearly list continue intently work base pattern drugmaker grab brass ring energy stock be list star player week salix pharmaceutical slxp lead crew performance left share new high buy point late stage base pattern investor jump stock north carolina base drugmaker report positive result phase trial irritable bowel syndrome treatment rifaximin cantor fitzgerald william blair raise price target stock respectively jazz pharmaceutical jazz surge week ireland base pharma jump wednesday news have purchase american right drug defibrotide drug buy jazz acquisition gentium treat rare disease affect blood circulation liver stock end buy range buy point second stage cup handle base mutual fund rating base year performance hold share jazz lake forest ill base akorn akrx end week higher ease back spike result left share buy point cup handle base undercut prior pattern reset akorn base count stock clear buy point april light trade gilead science gild climb new high end week not quite buy point cup base have be tepid volume average day last week deep base undercut flat base december january reset stock base count illumina ilmn add be overall light trade week finished buy point cup handle base outside pharmaceutical space vipshop holding vip pop breaking buy point week tight pattern china base online discount retailer clear late stage cup handle buy point june
2800,GILD,stock battle dismal finish friday index lose ground fast trade nasdaq choke chunk swallow loss ibd lose volume rise board friday be quadruple witching day future option normally jack stock trading nasdaq
2801,GILD,analyst be singing praise life science giant gilead science gild illumina ilmn wednesday morning surge estimate late tuesday share company be stock market today
2802,GILD,gilead sale new hepatitis drug sovaldi be call most impressive beat biopharma history piper jaffray joshua schimmer increase price target only dollar gilead be morning trading wednesday
2803,GILD,rbc capital market analyst michael yee lift sale estimate previous add full year ep estimate now expect sovaldi sale hit next year ep reach
2804,GILD,nomura ian somaiya lift price target write gilead position hcv market be sustainable say sovaldi new sovaldi base combo pill expect launch later year be superior compete product abbvie abbv merck mrk
2805,GILD,cowen phil nadeau be also impressed note lengthy discussion payor pushback tuesday earning call provide probably not nearly enough resolution satisfy investor pharmacy benefit manager express script esrx insurer unite health unh have criticize sovaldi price
2806,GILD,gilead do discuss argument support price sovaldi such value cure health care system cost treat patient end stage liver disease yr nadeau write find gilead discussion datapoint encourage suspect investor concern payor ability limit access sovaldi shuttle patient compete regimen linger abbv pricing strategy be know presumably approval payor strategy be defined early
2807,GILD,meanwhile gene testing company illumina be wednesday morning beat estimate raise guidance sale rise year earlier quarter nearly consensus earning climb cent share top estimate cent
2808,GILD,company now expect full year sale growth ep range be consensus
2809,GILD,leerink analyst dan leonard write note tuesday report exceed even have consider best case scenario face multiple new instrument launch lift price target write launch new hiseq miseq gene sequence system do not appear be cannibalize older version add order hiseq system illumina announce january fanfare due claim sequence genome apiece be double initial target
2810,GILD,isi group ross muken note demand be illumina entire sequence portfolio raise price target reflect increase ep forecast however maintain neutral rating stock say current price already reflect annual revenue growth
2811,GILD,follow amy reeve twitter be singing praise life science giant gilead science gild illumina ilmn wednesday morning surge estimate late tuesday share company be stock market today gilead sale new hepatitis drug sovaldi be call most impressive beat biopharma history piper jaffray joshua schimmer increase price target only dollar gilead be morning trading wednesday rbc capital market analyst michael yee lift sale estimate previous add full year ep estimate now expect sovaldi sale hit next year ep reach nomura ian somaiya lift price target write gilead position hcv market be sustainable say sovaldi new sovaldi base combo pill expect launch later year be superior compete product abbvie abbv merck mrk cowen phil nadeau be also impressed note lengthy discussion payor pushback tuesday earning call provide probably not nearly enough resolution satisfy investor pharmacy benefit manager express script esrx insurer unite health unh have criticize sovaldi price gilead do discuss argument support price sovaldi such value cure health care system cost treat patient end stage liver disease yr nadeau write find gilead discussion datapoint encourage suspect investor concern payor ability limit access sovaldi shuttle patient compete regimen linger abbv pricing strategy be know presumably approval payor strategy be defined early meanwhile gene testing company illumina be wednesday morning beat estimate raise guidance sale rise year earlier quarter nearly consensus earning climb cent share top estimate cent company now expect full year sale growth ep range be consensus leerink analyst dan leonard write note tuesday report exceed even have consider best case scenario face multiple new instrument launch lift price target write launch new hiseq miseq gene sequence system do not appear be cannibalize older version add order hiseq system illumina announce january fanfare due claim sequence genome apiece be double initial target isi group ross muken note demand be illumina entire sequence portfolio raise price target reflect increase ep forecast however maintain neutral rating stock say current price already reflect annual revenue growth follow amy reeve twitter ibd_areeve
2812,GILD,talk pain gain american century ultra fund be show manager faith downtrodden biotech market segment
2813,GILD,group begin sell february plunge picked steam march congressman question nosebleed price gilead science gild hepatitis drug sovaldi
2814,GILD,ultra have stick several holding add price decline ultra stake isis pharmaceutical isis soar share march jan
2815,GILD,position regeneron pharmaceutical regn rise share count celgene celg alexion pharmaceutical alxn be unchanged
2816,GILD,ultra do trim exposure gilead share
2817,GILD,stock gilead hurt fund performance first quarter investor rotate other growth stock value name ultra management team believe market overreact news be unlikely result problem gilead manager write commentary
2818,GILD,reflection fund faith biotech be overweight broader health care sector vs russell growth index
2819,GILD,fund largest overweight vs benchmark march be information technology top holding include apple aapl google googl qualcomm qcom amazon amzn
2820,GILD,hold apple
2821,GILD,fund stake apple stand pat march vs jan be slightly oct share still well april
2822,GILD,go tuesday apple share be trading less past buy point
2823,GILD,emerge market account lot iphone sale growth
2824,GILD,earning share grow past quarters latest earning report april ibd accumulation distribution rating apple have climb solid
2825,GILD,morgan stanley recently say see upside stock upcoming debut iphone iwatch maybe other product
2826,GILD,other holding concho resource cxo be so far year fund share hold steady jan march be oct ep grow past quarters
2827,GILD,concho seek extract oil gas texas benefit frac west texas shale formation rich permian basin
2828,GILD,fund stake reilly automotive orly be share march vs april ep growth have decelerate quarters
2829,GILD,stock be form flat base entry
2830,GILD,new store opening have drive growth auto part retailer
2831,GILD,fund approach have lead gain so far year go tuesday large cap growth rival track morningstar inc averaged gain be
2832,GILD,past year fund average annual gain be vs peer group big cap bogey talk pain gain american century ultra fund be show manager faith downtrodden biotech market segment group begin sell february plunge picked steam march congressman question nosebleed price gilead science gild hepatitis drug sovaldi ultra have stick several holding add price decline ultra stake isis pharmaceutical isis soar share march jan position regeneron pharmaceutical regn rise share count celgene celg alexion pharmaceutical alxn be unchanged ultra do trim exposure gilead share stock gilead hurt fund performance first quarter investor rotate other growth stock value name ultra management team believe market overreact news be unlikely result problem gilead manager write commentary reflection fund faith biotech be overweight broader health care sector vs russell growth index fund largest overweight vs benchmark march be information technology top holding include apple aapl google googl qualcomm qcom amazon amzn hold fund stake apple stand pat march vs jan be slightly oct share still well april go tuesday apple share be trading less past buy point emerge market account lot iphone sale growth earning share grow past quarters latest earning report april ibd accumulation distribution rating apple have climb solid morgan stanley recently say see upside stock upcoming debut iphone iwatch maybe other product other holding concho resource cxo be so far year fund share hold steady jan march be oct ep grow past quarters concho seek extract oil gas texas benefit frac west texas shale formation rich permian basin fund stake reilly automotive orly be share march vs april ep growth have decelerate quarters stock be form flat base entry new store opening have drive growth auto part retailer fund approach have lead gain so far year go tuesday large cap growth rival track morningstar inc averaged gain be past year fund average annual gain be vs peer group big cap bogey
2833,GILD,big pharma merck mrk report stellar result phase hepatitis hcv drug trial thursday spark debate analyst potential take market share leader gilead science
2834,GILD,international liver congress london merck report cure rate patient hepatitis genotype take combination drug candidate mk mk
2835,GILD,potentially combine pill take once day pairing rival convenience effectiveness gilead gild combo sofosbuvir ledipasvir be currently await fda approval expect october
2836,GILD,gilead launch sofosbuvir alone sovaldi december be still recommend be combine interferon genotype account hcv infection be already enjoy biggest launch drug history
2837,GILD,now however wall street attention be turn rival
2838,GILD,face competiton
2839,GILD,isi group analyst mark schoenebaum write email client consensus peak sale estimate merck regimen almost certainly go current nonetheless write rise present real danger gilead
2840,GILD,most analyst include have assume gild capture perhaps genotype share peak write open question however have be company grab other market propose perhaps mrk be now lead contender position
2841,GILD,merck still have way go clinical trial file approval win have first compete regimen expect be abbvie abbv enanta enta cocktail also expect launch late year
2842,GILD,however research note thursday nomura analyst ian somaiya write symposium hepatologist stefan zeuzam bring gilead higher efficacy abbvie certain patient well risk drug interaction patient also have hiv
2843,GILD,zeuzam also raise issue higher alanine level small percentage patient merck regimen point acute liver injury motivate many physician avoid regimen somaiya raise estimate gilead total hcv franchise year next year
2844,GILD,defense
2845,GILD,well fargo financial adviser brian abraham rise abbvie defense
2846,GILD,thesis regard hep competitive dynamic be abbvie regimen be competitor gild give efficacy multiple patient type clean safety still have disadvantage versus gild merck regimen be hyped potential competitive threat write research note thursday
2847,GILD,gilead share tumble more thursday lowest close mid october biotechs other growth stock lead sharp market sell abbvie lose even merck initially rise year intraday high close
2848,GILD,gilead worry express script esrx officer say pharmacy benefit manager try drive sovaldi price goldman sachs analyst terence flynn wednesday trim gilead price target physician survey imply hcv market be price sensitive big pharma merck mrk report stellar result phase hepatitis hcv drug trial thursday spark debate analyst potential take market share leader gilead science international liver congress london merck report cure rate patient hepatitis genotype take combination drug candidate mk mk potentially combine pill take once day pairing rival convenience effectiveness gilead gild combo sofosbuvir ledipasvir be currently await fda approval expect october gilead launch sofosbuvir alone sovaldi december be still recommend be combine interferon genotype account hcv infection be already enjoy biggest launch drug history now however wall street attention be turn rival face competitonisi group analyst mark schoenebaum write email client consensus peak sale estimate merck regimen almost certainly go current nonetheless write rise present real danger gilead most analyst include have assume gild capture perhaps genotype share peak write open question however have be company grab other market propose perhaps mrk be now lead contender position merck still have way go clinical trial file approval win have first compete regimen expect be abbvie abbv enanta enta cocktail also expect launch late year however research note thursday nomura analyst ian somaiya write symposium hepatologist stefan zeuzam bring gilead higher efficacy abbvie certain patient well risk drug interaction patient also have hiv zeuzam also raise issue higher alanine level small percentage patient merck regimen point acute liver injury motivate many physician avoid regimen somaiya raise estimate gilead total hcv franchise year next year defensewell fargo financial adviser brian abraham rise abbvie defense thesis regard hep competitive dynamic be abbvie regimen be competitor gild give efficacy multiple patient type clean safety still have disadvantage versus gild merck regimen be hyped potential competitive threat write research note thursday gilead share tumble more thursday lowest close mid october biotechs other growth stock lead sharp market sell abbvie lose even merck initially rise year intraday high close gilead worry express script esrx officer say pharmacy benefit manager try drive sovaldi price goldman sachs analyst terence flynn wednesday trim gilead price target physician survey imply hcv market be price sensitive
2849,GILD,company have blame obamacare disappointing quarterly result centene cnc isn
2850,GILD,st loui base manage care service provider surprised wall street last month report first quarter earning share nearly double prior year cent sharply analyst forecast gain follow jump be precede quarters decline
2851,GILD,revenue rise also view fastest growth quarters centene add member increase indicated affordable care act didn affect result
2852,GILD,centene also say expect earn share full year midpoint consensus estimate time analyst have boost forecast mark jump increase
2853,GILD,strong profit sale gain yielded spike stock price april massive volume share surge week end april regain week week move average massive volume
2854,GILD,stock clear month consolidation week didn gain much traction right away have advanced buy point
2855,GILD,monday fbr capital have outperform rating centene raise price target
2856,GILD,bigger rival unitedhealth group unh have earlier report drop earning disappointing revenue cite higher cost related affordable care act gilead science gild sovaldi hepatitis treatment
2857,GILD,medical manage care group have display healthy performance lately rank monday issue ibd industry group week week back composite rating put top stock group company have blame obamacare disappointing quarterly result centene cnc isn st loui base manage care service provider surprised wall street last month report first quarter earning share nearly double prior year cent sharply analyst forecast gain follow jump be precede quarters decline revenue rise also view fastest growth quarters centene add member increase indicated affordable care act didn affect result centene also say expect earn share full year midpoint consensus estimate time analyst have boost forecast mark jump increase strong profit sale gain yielded spike stock price april massive volume share surge week end april regain week week move average massive volume stock clear month consolidation week didn gain much traction right away have advanced buy point monday fbr capital have outperform rating centene raise price target bigger rival unitedhealth group unh have earlier report drop earning disappointing revenue cite higher cost related affordable care act gilead science gild sovaldi hepatitis treatment medical manage care group have display healthy performance lately rank monday issue ibd industry group week week back composite rating put top stock group
2858,GILD,stock fought back modest loss turn mildly positive just past midway point friday session
2859,GILD,loss nasdaq morphed gain dow jone industrial average add gain nasdaq volume be tracking lower thursday level nyse volume ease
2860,GILD,stock market today gilead science gild be rarity day stock be build right side base little way selling pressure share rise friday gilead drug have strong presence hiv market company hepatitis drug sovaldi be blockbuster first full quarter market sale drug totale
2861,GILD,eye drug maker akorn akrx be also work right side base trading well week move average share akorn rise nearly news company be acquire versapharm deal come heel akorn acquisition tech pharmacal
2862,GILD,elsewhere fast grow amtrust financial service afsi continue hold gain bullish last week share rise company underwrite provide property casualty insurance abroad last week amtrust report rise quarterly profit sale rise company growth acquisition strategy have result considerable sale growth recent quarters
2863,GILD,whitewave food wwav extend gain thursday earning inspire move share add company stock be try clear early flat base entry point still have time high contend fast grow whitewave go public october
2864,GILD,real estate investment trust reit space extra space storage exr ease slightly stock be only recent flat base buy point have composite rating highest possible market get defensive high yielding reit extra space be show relative strength list top perform reit be find today income investor page stock fought back modest loss turn mildly positive just past midway point friday session loss nasdaq morphed gain dow jone industrial average add gain nasdaq volume be tracking lower thursday level nyse volume ease stock market today gilead science gild be rarity day stock be build right side base little way selling pressure share rise friday gilead drug have strong presence hiv market company hepatitis drug sovaldi be blockbuster first full quarter market sale drug totale eye drug maker akorn akrx be also work right side base trading well week move average share akorn rise nearly news company be acquire versapharm deal come heel akorn acquisition tech pharmacal elsewhere fast grow amtrust financial service afsi continue hold gain bullish last week share rise company underwrite provide property casualty insurance abroad last week amtrust report rise quarterly profit sale rise company growth acquisition strategy have result considerable sale growth recent quarters whitewave food wwav extend gain thursday earning inspire move share add company stock be try clear early flat base entry point still have time high contend fast grow whitewave go public october real estate investment trust reit space extra space storage exr ease slightly stock be only recent flat base buy point have composite rating highest possible market get defensive high yielding reit extra space be show relative strength list top perform reit be find today income investor page
2865,GILD,affordable care act aca have take share criticism october launch health insurer centene cnc be poise strong growth company primary focus be medicaid manage care business conduct state contract company go public be operate state today have
2866,GILD,several key drug major drugmaker get endorsement european medicine agency ema friday make commercial approval european union enormous market much more likely
2867,GILD,bristol myer squibb bmy hepatitis drug daclatasvir now brand daklinza be endorse ema committee medicinal product human use chmp use combination other hep drug notably gilead science gild sovaldi
2868,GILD,sovaldi daclatasvir perform outstandingly combine clinical trial gilead decide substitute similar drug own make ledipasvir combo expect be approve later year nonetheless bristol executive tell ibd march still see role drug marketplace especially tough treat case
2869,GILD,chmp also endorse expand label eliquis drug bristol co develop pfizer pfe reduce risk stroke patient atrial fibrillation include deep vein thrombosis pulmonary embolism eliquis launch early last year disappoint street competitor xarelto johnson johnson jnj eat market share bristol pfizer have keep plug away peak annual sale estimate be still run billion
2870,GILD,endorsement drug be not surprise wall street bristol stock be fraction morning trading stock market today pfizer stock be flat
2871,GILD,meanwhile regeneron pharmaceutical regn blockbuster eylea look get even bigger chmp endorse expand use include diabetic macular edema type vision loss result diabetes nonetheless regeneron stock be nearly morning trading friday
2872,GILD,regeneron share have be pressure last week accord rbc capital market analyst adnan butt worry have arise payer particulary medicare medicaid be go mandate use roche avastin eylea cost reason butt write own research do not support theory
2873,GILD,datum be best anecdotal channel check do not show change pattern hence do not see widespread conversion used label avastin write note wednesday
2874,GILD,follow amy reeve twitter ibd_areeve several key drug major drugmaker get endorsement european medicine agency ema friday make commercial approval european union enormous market much more likely bristol myer squibb bmy hepatitis drug daclatasvir now brand daklinza be endorse ema committee medicinal product human use chmp use combination other hep drug notably gilead science gild sovaldi sovaldi daclatasvir perform outstandingly combine clinical trial gilead decide substitute similar drug own make ledipasvir combo expect be approve later year nonetheless bristol executive tell ibd march still see role drug marketplace especially tough treat case chmp also endorse expand label eliquis drug bristol co develop pfizer pfe reduce risk stroke patient atrial fibrillation include deep vein thrombosis pulmonary embolism eliquis launch early last year disappoint street competitor xarelto johnson johnson jnj eat market share bristol pfizer have keep plug away peak annual sale estimate be still run billion endorsement drug be not surprise wall street bristol stock be fraction morning trading stock market today pfizer stock be flat meanwhile regeneron pharmaceutical regn blockbuster eylea look get even bigger chmp endorse expand use include diabetic macular edema type vision loss result diabetes nonetheless regeneron stock be nearly morning trading friday regeneron share have be pressure last week accord rbc capital market analyst adnan butt worry have arise payer particulary medicare medicaid be go mandate use roche avastin eylea cost reason butt write own research do not support theory datum be best anecdotal channel check do not show change pattern hence do not see widespread conversion used label avastin write note wednesday follow amy reeve twitter ibd_areeve
2875,GILD,biotech achillion pharmaceutical achn get boost monday maxim group more triple price target stock send share stock market today have dinner company executive analyst jason kolbert hike target maintain buy rating cite potential achillion hepatitis drug candidate ultimate goal create regimen cure genotype virus week current industry leader gilead science gild sovaldi be normally give week kolbert add acquisition potential achillion remain high potential have more double stock price last week merck mrk deal buy idenix idix hepatitis pipeline spark speculation achillion also make appeal target stock be also help last week fda lift clinical hold sovaprevir be achillion most advanced hepatitis candidate phase testing achillion stock rise close trading high intraday follow amy reeve twitter ibd_areeve
2876,GILD,last month democrat congress send now famous letter gilead science gild question price new blockbuster hepatitis medicine sovaldi reason raise suspicion price didn need be high speed sovaldi be approve food drug administration gilead file receive
2877,GILD,biotech stock bounce back recently last month medical biom biotech group be rank ibd industry be dead last last week plunge partly reflect growth stock overall fall hard current market correction specific concern sky high drug price notably gilead science blockbuster hepatitis
2878,GILD,market trade tight range monday something be do lot lately major average hold high refuse give much ground nasdaq gain fraction end session winning streak close fractionally lower volume drop sharply friday heighten level swell option future expiration
2879,GILD,big pharma abbvie abbv beat estimate friday get street talk company executive imply win discount new hepatitis regimen stock be morning trading stock market today
2880,GILD,abbvie earning rise year earlier quarter cent share beating analyst consensus cent sale rise estimate
2881,GILD,company do not raise full year guidance however still expect ep vs last year sale fraction exclude impact company new hepatitis regimen await fda approval
2882,GILD,analyst have many question regimen hepatitis particularly abbvie pricing strategy compete gilead science gild recently launch blockbuster sovaldi pharmacy benefit manager express script esrx have be say hope reduce sovaldi price play competitor other ask abbvie plan compete price ceo richard gonzalez say not strategy go forward
2883,GILD,sound abbvie wouldn engage significant price war gain share hep morningstar analyst damien conover write email ibd abbvie hold very strong treatment hep think compete efficacy relatively good side effect profile treatment
2884,GILD,research note friday rbc capital market analyst michael yee agree abbvie executive sound very bullish competitive potential
2885,GILD,consistently comment allude drug be competitive stand nicely market profile be strong convenience be lower totem pole patient need think long large market never suggest pricing be key lever share write further support gild long term view hcv market be billlion global market gild earn share least mean gild stock be reasonably cheap
2886,GILD,gilead investor didn seem entirely assuage gilead stock be flat late morning trading
2887,GILD,yee also note abbvie candidate chronic lymphocytic leukemia cll be move nicely late stage testing potentially create more competition pharmacyclic pcyc recently launch imbruvica however model be likely best sicker patient probably not optimal community docs want less aggressive tolerable pcyc regimen
2888,GILD,pharmacyclic stock be nearly morning trading
2889,GILD,follow amy reeve twitter ibd_areeve
2890,GILD,related gilead illumina earning wall street lovebig pharma abbvie abbv beat estimate friday get street talk company executive imply win discount new hepatitis regimen stock be morning trading stock market today abbvie earning rise year earlier quarter cent share beating analyst consensus cent sale rise estimate company do not raise full year guidance however still expect ep vs last year sale fraction exclude impact company new hepatitis regimen await fda approval analyst have many question regimen hepatitis particularly abbvie pricing strategy compete gilead science gild recently launch blockbuster sovaldi pharmacy benefit manager express script esrx have be say hope reduce sovaldi price play competitor other ask abbvie plan compete price ceo richard gonzalez say not strategy go forward sound abbvie wouldn engage significant price war gain share hep morningstar analyst damien conover write email ibd abbvie hold very strong treatment hep think compete efficacy relatively good side effect profile treatment research note friday rbc capital market analyst michael yee agree abbvie executive sound very bullish competitive potential consistently comment allude drug be competitive stand nicely market profile be strong convenience be lower totem pole patient need think long large market never suggest pricing be key lever share write further support gild long term view hcv market be billlion global market gild earn share least mean gild stock be reasonably cheap gilead investor didn seem entirely assuage gilead stock be flat late morning trading yee also note abbvie candidate chronic lymphocytic leukemia cll be move nicely late stage testing potentially create more competition pharmacyclic pcyc recently launch imbruvica however model be likely best sicker patient probably not optimal community docs want less aggressive tolerable pcyc regimen pharmacyclic stock be nearly morning trading follow amy reeve twitter gilead illumina earning wall street love
2891,GILD,market wending way correction now be time search stock prime grow market next leg today ibd list highly rate stock be excellent start point computer generate list rank stock base key metric include recent profit growth ibd composite rating also measure return
2892,GILD,week filled earning report big cap biotechs gilead science gild be most watch reveal first full quarter sale blockbuster hepatitis drug sovaldi gilead report market close tuesday overall analyst poll thomson reuter estimate gilead make cent share
2893,GILD,daunting headline be hard find monday pave way buyer push nasdaq fresh high back day move average dow jone industrial average lead way rise nasdaq gain rally airline build steel retail stock lead upside
2894,GILD,hot biotech stock achillion pharmaceutical achn be midday trading stock market today analyst find more support prospect buyout candidate baird brian skorney note merck mrk official tender offer statement friday indicated be bidder idenix pharmaceutical idix accept merck bid last week skorney view mean somebody still prowl nucleoside hepatitis drug achillion have company draw many similarity idenix asset perspective have only unpartnered nuc left development make attractive target write research note friday skorney also write achillion prospect develop oral hep cure be dim pipeline have be slow various issue even gilead science gild abbvie abbv steam ahead own regimen maintain outperform rating set price target reflect more modest expectation maxim target set earlier week average price target stock be accord thomson follow amy reeve twitter ibd_areeve
2895,GILD,manage care organization centene ready first quarter report april investor be get very nervous
2896,GILD,year bring first quarter manage care industry face new health insurer fee impose affordable care act aca fee continue rise
2897,GILD,be also first full quarter sale gilead science gild mega blockbuster hepatitis drug sovaldi sovaldi have far greater efficacy lower toxicity traditional regimen interferon price tag full round treatment combine sheer volume infected patient lead insurer grumble break bank
2898,GILD,centene cnc largest competitor unitedhealth unh seem confirm fear report week centene result miss estimate reason give be hepatitis payout
2899,GILD,centene seem especially vulnerable similar impact give nature user base centene specialty be medicaid manage care business conduct state contract also have grow presence correctional health care be prison thus customer be largely poor imprison make more likely have hepatitis
2900,GILD,consensus crushed
2901,GILD,so come enormous relief wall street centene come crushed consensus number raise full year outlook profit jump year earlier quarter cent share beating estimate cent revenue rise more street consensus
2902,GILD,centene chief strategy be be well prepared especially sovaldi front say leerink analyst ana gupte
2903,GILD,have be watch far more commercial payer gupte tell ibd ve be try make sure get public policy attention so get support broader health care community state medicaid negotiation so get reimbursement re seek
2904,GILD,state do not put sovaldi prefer formulary such texas centene do large amount business then centene just win pay result have make sovaldi even more controversial regard inhumane deny person such superior drug centene ceo michael neidorff say conference call company have follow state policy remark be important note new therapy be curative thus be possible longer term saving be realize reduce other medical cost associate hepatitis
2905,GILD,same time centene have also be play other side market other segment business specialty service april last year acquire acariahealth largest independent specialty pharmacy also happen be largest manager hepatitis care business actually make more money purchase expensive drug
2906,GILD,april initiation report centene ub analyst rice cite specialty business key differentiator centene peer
2907,GILD,specialty service complement cnc core medicaid manage care business diversify company revenue stream provide higher quality health outcome cnc membership other assist control cost rice write believe company ability cross sell specialty product include behavioral health disease management pharmacy have help cnc reprocure exist new business recent year
2908,GILD,centene rate new business win have capture contract have bid have especially catch wall street attention drive growth company go public be operate just state today be be largest pure play medicaid mco country
2909,GILD,analyst be expect more growth medicaid coverage expand due aca rollout rice say new eligibility rule go effect start year bring new member centene come revenue company be also expand membership roll buyout most recently acquire community health solution contract louisiana bring life
2910,GILD,obamacare exchange
2911,GILD,centene have also jump aca new health insurance exchange state ambetter brand neidorff say april financial impact be minimal say end current quarter enrollment reach
2912,GILD,long run view initiative positively fbr analyst steven halper write note add initial enrollment figure have be lackluster company have indicated reach low end previous membership expectation segment
2913,GILD,analyst investment thesis centene include possibility be buy early june fact be rumor profit hospital chain ascension health be look buy health insurer active state lead gupte speculate centene wellcare health plan wcg be target drive stock new high citigroup debunk rumor centene still be attractive candidate consolidate industry
2914,GILD,ascension be long shot particularly centene gupte say hardly only company interested
2915,GILD,analyst expect centene profit grow year share then climb next year manage care organization centene ready first quarter report april investor be get very nervous year bring first quarter manage care industry face new health insurer fee impose affordable care act aca fee continue rise be also first full quarter sale gilead science gild mega blockbuster hepatitis drug sovaldi sovaldi have far greater efficacy lower toxicity traditional regimen interferon price tag full round treatment combine sheer volume infected patient lead insurer grumble break bank centene cnc largest competitor unitedhealth unh seem confirm fear report week centene result miss estimate reason give be hepatitis payout centene seem especially vulnerable similar impact give nature user base centene specialty be medicaid manage care business conduct state contract also have grow presence correctional health care be prison thus customer be largely poor imprison make more likely have hepatitis consensus crushedso come enormous relief wall street centene come crushed consensus number raise full year outlook profit jump year earlier quarter cent share beating estimate cent revenue rise more street consensus centene chief strategy be be well prepared especially sovaldi front say leerink analyst ana gupte have be watch far more commercial payer gupte tell ibd ve be try make sure get public policy attention so get support broader health care community state medicaid negotiation so get reimbursement re seek state do not put sovaldi prefer formulary such texas centene do large amount business then centene just win pay result have make sovaldi even more controversial regard inhumane deny person such superior drug centene ceo michael neidorff say conference call company have follow state policy remark be important note new therapy be curative thus be possible longer term saving be realize reduce other medical cost associate hepatitis same time centene have also be play other side market other segment business specialty service april last year acquire acariahealth largest independent specialty pharmacy also happen be largest manager hepatitis care business actually make more money purchase expensive drug april initiation report centene ub analyst rice cite specialty business key differentiator centene peer specialty service complement cnc core medicaid manage care business diversify company revenue stream provide higher quality health outcome cnc membership other assist control cost rice write believe company ability cross sell specialty product include behavioral health disease management pharmacy have help cnc reprocure exist new business recent year centene rate new business win have capture contract have bid have especially catch wall street attention drive growth company go public be operate just state today be be largest pure play medicaid mco country analyst be expect more growth medicaid coverage expand due aca rollout rice say new eligibility rule go effect start year bring new member centene come revenue company be also expand membership roll buyout most recently acquire community health solution contract louisiana bring life obamacare have also jump aca new health insurance exchange state ambetter brand neidorff say april financial impact be minimal say end current quarter enrollment reach long run view initiative positively fbr analyst steven halper write note add initial enrollment figure have be lackluster company have indicated reach low end previous membership expectation segment analyst investment thesis centene include possibility be buy early june fact be rumor profit hospital chain ascension health be look buy health insurer active state lead gupte speculate centene wellcare health plan wcg be target drive stock new high citigroup debunk rumor centene still be attractive candidate consolidate industry ascension be long shot particularly centene gupte say hardly only company interested analyst expect centene profit grow year share then climb next year
2916,GILD,biotech achillion pharmaceutical achn announce tuesday clinical trial be progress hepatitis drug fda lift clinical hold send share early trading stock market today month high fda have place clinical hold phase trial drug candidate sovaprevir last july cite potentially dangerous
2917,GILD,stock jump start gate monday accord sort eurozone greece brushed global market bit optimism
2918,GILD,nasdaq pull early action dow jone industrial average climb rise volume be mixed early reading show trade nasdaq nyse compare action same time friday
2919,GILD,stock market today open note eurozone creditor strike deal greece not open door bailout fund deal require greece government put place wednesday pension reform tax increase be refuse greek voter july referendum deal also make available immediately shore greece falter bank require government privatize portfolio asset most proceed go repay debt recapitalize weaken bank greece bank stock market remain close prime minister alexis tsipra go home attempt convince government go plan order hang euro currency bloc greece face debt deadline european central bank july
2920,GILD,europe top index have ease slightly early high cac paris frankfurt dax hold gain dollar climb vs euro
2921,GILD,stock airline early lead industry possibly owing dive oil price american airline group aal leap delta air line dal unite continental holding ual southwest airline luv gain apiece
2922,GILD,gps device leader garmin grmn wynn resort wynn climb run head nasdaq
2923,GILD,head marathon petroleum mpc turn gain start trade marathon pipeline master limit partnership mplx mplx announce acquire mlp markwest energy partner mwe deal value mplx share dive markwest jump
2924,GILD,newlink genetic nlnk pop lead ibd list stock be low april high climb right side month consolidation
2925,GILD,very few ibd stock post early decline ambarella amba taser international tasr be stock jump start gate monday accord sort eurozone greece brushed global market bit optimism nasdaq pull early action dow jone industrial average climb rise volume be mixed early reading show trade nasdaq nyse compare action same time friday stock market today open note eurozone creditor strike deal greece not open door bailout fund deal require greece government put place wednesday pension reform tax increase be refuse greek voter july referendum deal also make available immediately shore greece falter bank require government privatize portfolio asset most proceed go repay debt recapitalize weaken bank greece bank stock market remain close prime minister alexis tsipra go home attempt convince government go plan order hang euro currency bloc greece face debt deadline european central bank july europe top index have ease slightly early high cac paris frankfurt dax hold gain dollar climb vs euro stock airline early lead industry possibly owing dive oil price american airline group aal leap delta air line dal unite continental holding ual southwest airline luv gain apiece gps device leader garmin grmn wynn resort wynn climb run head nasdaq head marathon petroleum mpc turn gain start trade marathon pipeline master limit partnership mplx mplx announce acquire mlp markwest energy partner mwe deal value mplx share dive markwest jump newlink genetic nlnk pop lead ibd list stock be low april high climb right side month consolidation very few ibd stock post early decline ambarella amba taser international tasr be
2926,GILD,nowadays amgen be gray eminence biotechs more sale last year kingpin industry turn america biggest innovation machine highest return stock group last few year
2927,GILD,hard believe now back biotech be still largely unproven business model amgen amgn founder public be first show be do
2928,GILD,think forefather biotech think amgen genentech say funtleyder author healthcare investing profit new world pharma biotech health care service be able go public early able show lot success early
2929,GILD,industry watcher give much credit amgen first chief executive george rathmann rathmann work research chemist old school giant mmm abbott laboratory be recruit venture capitalist new biotech startup
2930,GILD,rathmann die speak ibd leader success profile emphasize importance investing good science key business success
2931,GILD,person lead good scientific team have have tremendous respect science have be able differentiate good science bad then mostly support function rathmann say time get guy money get facility get resource make possible sustain effort way marketplace
2932,GILD,rathmann be particularly interested genetic engineering be then cut edge science pharmaceutical technology then dominant platform drug development be base chemistry biotechnology be base manipulate biological process rathmann eventually zero goal clon erythropoietin gene stimulate production red blood cell see potentially huge market treat severe anemia bring kidney failure chemotherapy
2933,GILD,eventual result be epogen launch become biotech first blockbuster not surprisingly also launch big stock run july january stock be already sharply level several year earlier increase more fold
2934,GILD,amgen share have stage other big run then last month hit time high low gain put amgen top greatest stock past year
2935,GILD,amgen wasn only company interested erythropoietin early day fact be something race get viable product first rathmann be so conscious time pressure reportedly threaten shut research eventually successful scientist isolate gene
2936,GILD,be resolute determination be first market epogen say michael king biotech analyst jmp security be salesperson time used call try convince stock be explode new high sell stock diversify answer be constantly be right build great fortune family maintain vision focus amgen be
2937,GILD,commitment rathmann decide hand rein cfo gordon binder shepherd amgen greatest period financial growth leave binder oversaw launch blood cell stimulating blockbuster neupogen rheumatoid arthritis treatment enbrel drug together pegylate version neupogen launch still provide more third revenue
2938,GILD,be go biotechs start breaking measles market funtleyder say amgen not only help prove science biotechnology also business model company lose money nearly decade most time publicly trade bring product market eventually earn investor handsome return
2939,GILD,amgen send clear message be pure biotechnology company succeed say king way also set expectation bit too high lot early biotech company picked low hang fruit
2940,GILD,nonetheless era produce number winner go become big cap such alexion pharmaceutical alxn biogen idec biib gilead science gild be acquire big pharmas get ground floor young biotech be still risky king say model work much better now due long year experience
2941,GILD,interview ibd former ceo binder point innovation research technology have also help speed biotech innovation
2942,GILD,early day amgen want make piece dna base pair be major project now robot make thousand year human be do anything set turn binder say year make dna faster easier cheaper continuous improvement knowledge grow build nowadays amgen be gray eminence biotechs more sale last year kingpin industry turn america biggest innovation machine highest return stock group last few year hard believe now back biotech be still largely unproven business model amgen amgn founder public be first show be do think forefather biotech think amgen genentech say funtleyder author healthcare investing profit new world pharma biotech health care service be able go public early able show lot success early industry watcher give much credit amgen first chief executive george rathmann rathmann work research chemist old school giant mmm abbott laboratory be recruit venture capitalist new biotech startup rathmann die speak ibd leader success profile emphasize importance investing good science key business success person lead good scientific team have have tremendous respect science have be able differentiate good science bad then mostly support function rathmann say time get guy money get facility get resource make possible sustain effort way marketplace rathmann be particularly interested genetic engineering be then cut edge science pharmaceutical technology then dominant platform drug development be base chemistry biotechnology be base manipulate biological process rathmann eventually zero goal clon erythropoietin gene stimulate production red blood cell see potentially huge market treat severe anemia bring kidney failure chemotherapy eventual result be epogen launch become biotech first blockbuster not surprisingly also launch big stock run july january stock be already sharply level several year earlier increase more fold amgen share have stage other big run then last month hit time high low gain put amgen top greatest stock past year amgen wasn only company interested erythropoietin early day fact be something race get viable product first rathmann be so conscious time pressure reportedly threaten shut research eventually successful scientist isolate gene be resolute determination be first market epogen say michael king biotech analyst jmp security be salesperson time used call try convince stock be explode new high sell stock diversify answer be constantly be right build great fortune family maintain vision focus amgen be commitment rathmann decide hand rein cfo gordon binder shepherd amgen greatest period financial growth leave binder oversaw launch blood cell stimulating blockbuster neupogen rheumatoid arthritis treatment enbrel drug together pegylate version neupogen launch still provide more third revenue be go biotechs start breaking measles market funtleyder say amgen not only help prove science biotechnology also business model company lose money nearly decade most time publicly trade bring product market eventually earn investor handsome return amgen send clear message be pure biotechnology company succeed say king way also set expectation bit too high lot early biotech company picked low hang fruit nonetheless era produce number winner go become big cap such alexion pharmaceutical alxn biogen idec biib gilead science gild be acquire big pharmas get ground floor young biotech be still risky king say model work much better now due long year experience interview ibd former ceo binder point innovation research technology have also help speed biotech innovation early day amgen want make piece dna base pair be major project now robot make thousand year human be do anything set turn binder say year make dna faster easier cheaper continuous improvement knowledge grow build
2943,GILD,stock be trading lower early afternoon action wednesday season earning report hit full stride
2944,GILD,nasdaq be dow jone industrial average be less volume be run lower exchange
2945,GILD,ibd stock skywork solution swks be best performer gapping highest level january maker wireless gear aerospace automotive medical market report better expect earning revenue
2946,GILD,stock market today gilead science gild rise report increase earning fall early march stock have now rise straight day
2947,GILD,tech stock be pressure lead light maker cree cree cellphone maker ericsson eric be respectively report disappointing earning vmware vmw be nearly report
2948,GILD,apple aapl facebook fb report close be slightly
2949,GILD,negative tone be set early session commerce department report new home sale fall march annualize compare expectation stock be trading lower early afternoon action wednesday season earning report hit full stride nasdaq be dow jone industrial average be less volume be run lower exchange ibd stock skywork solution swks be best performer gapping highest level january maker wireless gear aerospace automotive medical market report better expect earning revenue stock market today gilead science gild rise report increase earning fall early march stock have now rise straight day tech stock be pressure lead light maker cree cree cellphone maker ericsson eric be respectively report disappointing earning vmware vmw be nearly report apple aapl facebook fb report close be slightly negative tone be set early session commerce department report new home sale fall march annualize compare expectation
2950,GILD,rebound effort greatly fade late friday leave stock mixed territory pace weekly loss nasdaq lose rise much intraday rise session peak meanwhile dow jone industrial average be turnover continue tack sharply lower major exchange stock market todayeven market turn mixed bitauto bita hold session high gain stock have recoup big chunk thursday loss climb back day line downside biotechs be pressure gilead science gild fall be pace third straight loss stock near potential support day move average have trade december gilead have tumble top late february regeneron pharmaceutical regn fall give early gain turn tail again hit resistance day line stock clear late stage base last month fizzle rise past buy point late stage pattern be more prone fail biogen idec biib turn tail fall fast trade have give gain past buy point flat base recent session
2951,GILD,major average be little change friday weak post holiday trading nasdaq be edge dow jone industrial be flat volume friday half day session be run sharply lower same time wednesday last trading session thanksgiving universal display oled maker light emit flat panel display jump heavy volume new report product be used apple aapl iphone model due stock be approach buy point deep cup base fall oil price hurt energy stock help airline stock market today coal producer consol energy cnx oil stock southwestern energy swn longtime laggard drop weigh other hand american airline aal unite continental ual rise line decline oil price ibd stock hawaiian rise meanwhile walt disney drop heavy volume drag medium stock announce late wednesday espn sport network have lose subscriber past year stock drop cup handle buy point clear nov viacom viab fall time warner twx be
2952,GILD,stock lose initial gain summary sell biotech ethical drug name punch nasdaq composite sharply lower top stock ibd also fall
2953,GILD,nasdaq composite fall nearly shave index weekly advance less early gain shrivele loss friday dow industrial close lower volume explode higher due large part option future expiration accord preliminary datum
2954,GILD,stock market today biotech firm be not only stock fall sharply printer firm medical software generic drug database software airline notch loss more group
2955,GILD,market side cyclical group thrive steel oil drill super regional bank chipmaker stock rise sharply week
2956,GILD,gilead science gild pace downside fall nearly almost triple average volume news congress be ask foster city calif firm provide pricing datum new hepatitis medicine
2957,GILD,biogen idec biib alexion pharmaceutical alxn member ibd fall sympathy stock also undercut key day move average
2958,GILD,finisar fnsr capped excellent week blast higher nearly triple typical turnover be week stock hold composite rating gain week be now extend cup handle buy point
2959,GILD,maker connection product fiber optic network have turn business sharply second half last year earning share shrank quarters row start mid then climb past period increase benefit easy year comp sale grow quarter time frame stock lose initial gain summary sell biotech ethical drug name punch nasdaq composite sharply lower top stock ibd also fall nasdaq composite fall nearly shave index weekly advance less early gain shrivele loss friday dow industrial close lower volume explode higher due large part option future expiration accord preliminary datum stock market today biotech firm be not only stock fall sharply printer firm medical software generic drug database software airline notch loss more group market side cyclical group thrive steel oil drill super regional bank chipmaker stock rise sharply week gilead science gild pace downside fall nearly almost triple average volume news congress be ask foster city calif firm provide pricing datum new hepatitis medicine biogen idec biib alexion pharmaceutical alxn member ibd fall sympathy stock also undercut key day move average finisar fnsr capped excellent week blast higher nearly triple typical turnover be week stock hold composite rating gain week be now extend cup handle buy point maker connection product fiber optic network have turn business sharply second half last year earning share shrank quarters row start mid then climb past period increase benefit easy year comp sale grow quarter time frame
2960,GILD,stock show determination friday report russia ukraine military clash fail do much damage nasdaq rise fall much midmorning scare close flat ibd advanced volume rise board friday be option expiration day often lift volume market only recently
2961,GILD,business don have weather kick anymore have lead analyst expect improve not spectacular profit revenue growth second quarter earning season kick week first quarter abysmal gross domestic product decline be blame largely polar vortex blizzard profit growth turn better
2962,GILD,tight trading have generally rule roost major average recent day be more same friday stock end week quiet gain
2963,GILD,nasdaq outperformed rise add dow jone industrial average picked less preliminary datum show nyse volume fall thursday nasdaq volume rise
2964,GILD,economic news june final read university michigan consumer sentiment index come ahead consensus estimate
2965,GILD,stock market today gopro gpro extend gain afterthursday successful debut share rise tempting chase red hot ipo gopro best ipo base form consider buy
2966,GILD,elsewhere network ffiv firm day move average rise pacific crest security make positive comment
2967,GILD,earning news nike nke gap gain finished session lows report better expect earning strong result nike lift share armour ua not much share rise light trade armour be near cup handle buy point
2968,GILD,meanwhile ibd name such packaging corp america pkg gilead science gild continue work cup handle pattern share packaging corp america rise gilead science gain nearly
2969,GILD,next week be shorten week trading stock market be close friday fourth july mean june job report be release day early thursday tight trading have generally rule roost major average recent day be more same friday stock end week quiet gain nasdaq outperformed rise add dow jone industrial average picked less preliminary datum show nyse volume fall thursday nasdaq volume rise economic news june final read university michigan consumer sentiment index come ahead consensus estimate stock market today gopro gpro extend gain afterthursday successful debut share rise tempting chase red hot ipo gopro best ipo base form consider buy elsewhere network ffiv firm day move average rise pacific crest security make positive comment earning news nike nke gap gain finished session lows report better expect earning strong result nike lift share armour ua not much share rise light trade armour be near cup handle buy point meanwhile ibd name such packaging corp america pkg gilead science gild continue work cup handle pattern share packaging corp america rise gilead science gain nearly next week be shorten week trading stock market be close friday fourth july mean june job report be release day early thursday
2970,GILD,unitedhealth group nation largest health insurer report first quarter earning decline thursday blame obamacare taxe medicare advantage cut gilead science costly hepatitis drug minnetonka minn base company earning share drop vs year earlier analyst poll thomson reuter expect revenue rise miss estimate nearly
2971,GILD,nomura analyst ian somaiya raise price target pharmacyclic pcyc gilead science gild lower biogen idec biib survey compete drug chronic lymphocytic leukeumia somaiya write survey doctor treat more cll patient highlighted rapid transition cll market newer oral drug particular
2972,GILD,stock lose initial gain summary sell biotech ethical drug name punch nasdaq composite sharply lower friday
2973,GILD,nasdaq composite fall nearly shave index weekly advance less early gain shrivele loss dow industrial close lower volume explode higher due large part option future expiration accord preliminary datum
2974,GILD,stock market today gilead science gild pace downside fall nearly triple average volume news congress be ask foster city calif firm provide pricing datum new hepatitis medicine
2975,GILD,biogen idec biib alexion pharmaceutical alxn member ibd fall sympathy stock also undercut key day move average
2976,GILD,buck market decline be brokerage charle schwab schw add fifth straight advance climb nearly past flat base entry point stock take peak still have long way eclipse time high set spring
2977,GILD,schwab boast composite rating accelerate top bottom line growth earning growth have step past quarters revenue gain prospect higher interest rate future likely enhance schwab revenue margin loan money market fund investment
2978,GILD,please see stock move table home page investor com monday newspaper page more stock show big gain decline heavy turnover stock lose initial gain summary sell biotech ethical drug name punch nasdaq composite sharply lower friday nasdaq composite fall nearly shave index weekly advance less early gain shrivele loss dow industrial close lower volume explode higher due large part option future expiration accord preliminary datum stock market today gilead science gild pace downside fall nearly triple average volume news congress be ask foster city calif firm provide pricing datum new hepatitis medicine biogen idec biib alexion pharmaceutical alxn member ibd fall sympathy stock also undercut key day move average buck market decline be brokerage charle schwab schw add fifth straight advance climb nearly past flat base entry point stock take peak still have long way eclipse time high set spring schwab boast composite rating accelerate top bottom line growth earning growth have step past quarters revenue gain prospect higher interest rate future likely enhance schwab revenue margin loan money market fund investment please see stock move table home page investor com monday newspaper page more stock show big gain decline heavy turnover
2979,GILD,major average extend winning streak session monday show stall action give benchmark index first distribution day market uptrend be confirm seller come market just et fedspeak didn amount much index trade relatively tight
2980,GILD,stock extend loss midday thursday day federal reserve raise interest rate first time nearly decade fall dow jone industrial average nasdaq be
2981,GILD,volume be run higher nyse nasdaq compare same time wednesday
2982,GILD,economic news be mixed unemployment claim fall little less expect week end dec manufacturing mid atlantic region fall much more expect december conference board index lead economic indicator rise november prior month increase ahead analyst forecast
2983,GILD,mining energy stock be hit hardest stock market today decline oil metal price
2984,GILD,newmont mining nem colorado base miner gold silver lose lead lower oil transportation stock oneok oke also drop
2985,GILD,most ibd stock be lower lead global payment gpn fall more heavy volume stock plunge wednesday slice day line agree buy rival credit card payment processor heartland payment system hpy
2986,GILD,total system service tss credit card payment processor ibd fall remain well buy point cup handle base clear october
2987,GILD,chinese social medium stock weibo wb be bright spot jump more heavy volume close buy point deep cup shape base
2988,GILD,stock boast rise relative strength line accumulation distribution rating indicate strong demand share stock have more double fall low aug stock extend loss midday thursday day federal reserve raise interest rate first time nearly decade fall dow jone industrial average nasdaq be volume be run higher nyse nasdaq compare same time wednesday economic news be mixed unemployment claim fall little less expect week end dec manufacturing mid atlantic region fall much more expect december conference board index lead economic indicator rise november prior month increase ahead analyst forecast mining energy stock be hit hardest stock market today decline oil metal price newmont mining nem colorado base miner gold silver lose lead lower oil transportation stock oneok oke also drop most ibd stock be lower lead global payment gpn fall more heavy volume stock plunge wednesday slice day line agree buy rival credit card payment processor heartland payment system hpy total system service tss credit card payment processor ibd fall remain well buy point cup handle base clear october chinese social medium stock weibo wb be bright spot jump more heavy volume close buy point deep cup shape base stock boast rise relative strength line accumulation distribution rating indicate strong demand share stock have more double fall low aug
2989,GILD,merck mrk seek add potential new blockbuster drug disease fight arsenal take cancer hepatitis monday drugmaker present result phase trial pembrolizumab cancer treatment american society clinical oncology meeting chicago study show patient advanced melanoma have spread elsewhere
2990,GILD,even re not biotech pharma investor ve probably catch earful news lately virus call hepatitis last december record breaking launch gilead science gild wonder drug sovaldi controversy price tag merck mrk recent buyout formerly neglected biotech idenix pharmaceutical idix
2991,GILD,corporate america weather wintry first quarter slightly better expect deliver profit growth be cool rather frosty company report earning be track year year gain be smallest better rise analyst poll thomson reuter have forecast
2992,GILD,biotech stock sell hard friday wall street blame letter several house democrat ask gilead science justify price hepatitis blockbuster sovaldi
2993,GILD,letter date thursday be sign rep henry waxman frank pallone diana degete ranking member committee energy commerce call sovaldi breakthrough hcv treatment expressed concern treatment not cure patient afford
2994,GILD,due sovaldi price tag letter go say colorado pennsylvania medicaid program have already announce re funding sovaldi only sickest patient california be still figure reimbursement policy letter also note pharmacy benefit manager express script esrx be encourage doctor network delay prescribe sovaldi
2995,GILD,meanwhile hepatitis be disease find poor result lawmaker tell gilead provide explanation pricing april
2996,GILD,health insurer wellpoint wlp chime friday concern new hepatitis drug cost say executive ken goulet
2997,GILD,biotech stock cheaper
2998,GILD,gilead gild fall nearly month close low biotechs selling expensive drug fall even harder perhaps fear larger change national mood drug pricing
2999,GILD,alexion pharmaceutical alxn sole drug soliris go upward year tumble vertex pharmaceutical vrtx also sell expensive hepatitis drug call incivek retreat
3000,GILD,biogen idec biib have costly multiple sclerosis treatment tecfidera lose
3001,GILD,ibd top rate medical biom biotech group fall
3002,GILD,abbvie abbv likely come rival possibly cheaper rival sovaldi later year initially rally friday close fraction
3003,GILD,gilead catch cold rest market catch pneumonia say tom vandeventer portfolio manager tocqueville opportunity fund
3004,GILD,sovaldi bargain
3005,GILD,analyst most part advise stay calm michael yee rbc capital market write email client friday pricing discussion generate headline concern view underscore drug be go be huge re cure patient improve society hcv be important public health issue hiv be validate significance market
3006,GILD,deutsche bank analyst robyn karnauskas write client note speak gilead official be already make case sovaldi be actually bargain
3007,GILD,liver transplant related hcv cost year med so person do not reject liver write gilead have co pay program place pocket cost be low
3008,GILD,isi group analyst mark schoenebaum point sovaldi compare favorably older hepatitis drug especially vertex incivek go year sovaldi cure rate be also much higher incivek so cost cure be even better say webinar friday
3009,GILD,dem seek public shaming
3010,GILD,schoenebaum also query terry haine longtime washington lawyer lobbyist once serve senior republican counsel same congre sional committee send letter haine respond government actually have little power address drug price view waxman et al hope accomplish be public shaming not waxman deliver tobacco industry year
3011,GILD,letter be bank shot get thing go goal get gilead significantly lower price sovaldi haine write
3012,GILD,such move be politically popular add discontent high price sovaldi new drug general have be swell payer general public time now aids healthcare foundation large nonprofit history criticize gilead hiv drug pricing recently turn fire sovaldi
3013,GILD,gilead latest display touch greed come heel company january pricing new hepatitis treatment sovaldi sofosbuvir pill more gilead most expensive aids drug stribild ahf say feb press release
3014,GILD,have play biotech stock have hit lull last few week bull run not see lead fear party be vandeventer say biotechs be high beta group be probably just correction point drug price have be political football early
3015,GILD,shouldn be completely unexpected kind issue come fore periodically say just part investing health care biotech stock sell hard friday wall street blame letter several house democrat ask gilead science justify price hepatitis blockbuster sovaldi letter date thursday be sign rep henry waxman frank pallone diana degete ranking member committee energy commerce call sovaldi breakthrough hcv treatment expressed concern treatment not cure patient afford due sovaldi price tag letter go say colorado pennsylvania medicaid program have already announce re funding sovaldi only sickest patient california be still figure reimbursement policy letter also note pharmacy benefit manager express script esrx be encourage doctor network delay prescribe sovaldi meanwhile hepatitis be disease find poor result lawmaker tell gilead provide explanation pricing april health insurer wellpoint wlp chime friday concern new hepatitis drug cost say executive ken goulet biotech stock cheapergilead gild fall nearly month close low biotechs selling expensive drug fall even harder perhaps fear larger change national mood drug pricing alexion pharmaceutical alxn sole drug soliris go upward year tumble vertex pharmaceutical vrtx also sell expensive hepatitis drug call incivek retreat biogen idec biib have costly multiple sclerosis treatment tecfidera lose ibd top rate medical biom biotech group fall abbvie abbv likely come rival possibly cheaper rival sovaldi later year initially rally friday close fraction gilead catch cold rest market catch pneumonia say tom vandeventer portfolio manager tocqueville opportunity fund sovaldi bargain analyst most part advise stay calm michael yee rbc capital market write email client friday pricing discussion generate headline concern view underscore drug be go be huge re cure patient improve society hcv be important public health issue hiv be validate significance market deutsche bank analyst robyn karnauskas write client note speak gilead official be already make case sovaldi be actually bargain liver transplant related hcv cost year med so person do not reject liver write gilead have co pay program place pocket cost be low isi group analyst mark schoenebaum point sovaldi compare favorably older hepatitis drug especially vertex incivek go year sovaldi cure rate be also much higher incivek so cost cure be even better say webinar friday dem seek public shaming schoenebaum also query terry haine longtime washington lawyer lobbyist once serve senior republican counsel same congre sional committee send letter haine respond government actually have little power address drug price view waxman et al hope accomplish be public shaming not waxman deliver tobacco industry year letter be bank shot get thing go goal get gilead significantly lower price sovaldi haine write such move be politically popular add discontent high price sovaldi new drug general have be swell payer general public time now aids healthcare foundation large nonprofit history criticize gilead hiv drug pricing recently turn fire sovaldi gilead latest display touch greed come heel company january pricing new hepatitis treatment sovaldi sofosbuvir pill more gilead most expensive aids drug stribild ahf say feb press release have play biotech stock have hit lull last few week bull run not see lead fear party be vandeventer say biotechs be high beta group be probably just correction point drug price have be political football early shouldn be completely unexpected kind issue come fore periodically say just part investing health care
3016,GILD,biotech stock be selling hard friday consensus wall street seem pin blame letter send several house democrat gilead science gild ask briefing price hepatitis blockbuster sovaldi letter sign rep henry waxman frank pallone diana degete date thursday expressed concern
3017,GILD,stock turn respectable performance monday end mixed mostly unchanged session high session start volatility nasdaq fall early re-cover loss just gain make new record high dow jone industrial average marked time close high rise
3018,GILD,big cap biotech gilead science beat analyst fourth quarter estimate top bottom line late tuesday offer sale guidance first time didn project sale newly launch much anticipate drug sovaldi market close gilead science gild say profit quarter rise year earlier quarter cent
3019,GILD,still early day dec approval gilead science hepatitis drug sovaldi be enjoy most massive drug launch time current consensus call sale year whisper number be run even higher
3020,GILD,doesn surprise wall street sovaldi provide faster safer stronger alternative punish yearlong regimen interferon analyst obsessively watch weekly prescription number grow re also eyee datum sovaldi potential challenger market estimate year grow
3021,GILD,bristol myer squibb bmy daclatasvir grab headline last april phase trial combine sovaldi score cure rate
3022,GILD,gilead gild elect not pursue combo further instead study sovaldi combination similar drug ledipasvir so co formulate single pill not share market
3023,GILD,bristol however file european union approval daclatasvir use combination other agent include sofosbuvir generic name sovaldi be grant accelerate review early january firm plan submit similar filing food drug administration soon
3024,GILD,sovaldi set new standard
3025,GILD,october bristol file approve combo daclatasvir drug asunaprevir japan have unusually high rate hepatitis virus hcv infection due formerly taint blood supply
3026,GILD,dougla manion bristol vice president development virology japan say dual regimen score good result week duration be look yesterday news now sovaldi have set week standard hope be resolve triple therapy involve daclatasvir asunaprevir drug dub bms co formulate pill be take twice day now phase testing
3027,GILD,ultimately however do not expect single regimen conquer other not patient be same
3028,GILD,treat toughest patient
3029,GILD,daclatasvir have be study so many different drug used genotype hepatitis virus patient population especially toughest treat population manion say be go be liver transplant patient genotype patient patient cirrhosis ultimately patient decompensation
3030,GILD,decompensate cirrhosis worst form liver damage result hcv usually result liver transplant death
3031,GILD,decompensate group be population not include abbvie abbv phase trial regimen combine antiviral agent abbvie also stick most common genotype genotype do very well trial cure rate range company plan file second quarter hit market late year
3032,GILD,respect have nearly catch gilead current fda guideline sovaldi recommend be used interferon genotype patient tolerate interferon gilead be banking sofosbuvir ledipasvir combo be first official interferon free genotype treatment also expect launch later year feb filing
3033,GILD,barry bernstein abbvie vice president infectious disease development tout strong safety profile fact cure upward patient compensate cirrhosis
3034,GILD,believe regimen provide option genotype infected patient bernstein tell ibd
3035,GILD,abbvie bristol myer gilead be expect report final study detail international liver congress meeting london april company official be keep mum study be present abstract go online march late breaking abstract appear right conference often have hottest datum
3036,GILD,next generation regime
3037,GILD,further road even more drug be way
3038,GILD,abbvie partner enanta pharmaceutical enta be already work next generation regime treat more genotype also be simpler take common criticism be more complicate gilead promise pill day routine
3039,GILD,earlier month merck mrk also report very strong phase result drug combo genotype patient be co infected hiv johnson johnson jnj last october acquire hcv drug glaxosmithkline gsk hope combine already approve olysio oral regimen
3040,GILD,sovaldi meanwhile have lately be pressure pill price tag concern sustainability outcome find curative drug be patient population eventually shrink
3041,GILD,still morningstar analyst damien conover say gilead have first mover advantage such strong trial datum likely be biggest player indefinite future
3042,GILD,think ll have gilead represent hep market tell ibd abbvie take lion share remain still early day dec approval gilead science hepatitis drug sovaldi be enjoy most massive drug launch time current consensus call sale year whisper number be run even higher doesn surprise wall street sovaldi provide faster safer stronger alternative punish yearlong regimen interferon analyst obsessively watch weekly prescription number grow re also eyee datum sovaldi potential challenger market estimate year grow bristol myer squibb bmy daclatasvir grab headline last april phase trial combine sovaldi score cure rate gilead gild elect not pursue combo further instead study sovaldi combination similar drug ledipasvir so co formulate single pill not share market bristol however file european union approval daclatasvir use combination other agent include sofosbuvir generic name sovaldi be grant accelerate review early january firm plan submit similar filing food drug administration soon sovaldi set new standardin october bristol file approve combo daclatasvir drug asunaprevir japan have unusually high rate hepatitis virus hcv infection due formerly taint blood supply dougla manion bristol vice president development virology japan say dual regimen score good result week duration be look yesterday news now sovaldi have set week standard hope be resolve triple therapy involve daclatasvir asunaprevir drug dub bms co formulate pill be take twice day now phase testing ultimately however do not expect single regimen conquer other not patient be same treat toughest patient daclatasvir have be study so many different drug used genotype hepatitis virus patient population especially toughest treat population manion say be go be liver transplant patient genotype patient patient cirrhosis ultimately patient decompensation decompensate cirrhosis worst form liver damage result hcv usually result liver transplant death decompensate group be population not include abbvie abbv phase trial regimen combine antiviral agent abbvie also stick most common genotype genotype do very well trial cure rate range company plan file second quarter hit market late year respect have nearly catch gilead current fda guideline sovaldi recommend be used interferon genotype patient tolerate interferon gilead be banking sofosbuvir ledipasvir combo be first official interferon free genotype treatment also expect launch later year feb filing barry bernstein abbvie vice president infectious disease development tout strong safety profile fact cure upward patient compensate cirrhosis believe regimen provide option genotype infected patient bernstein tell ibd abbvie bristol myer gilead be expect report final study detail international liver congress meeting london april company official be keep mum study be present abstract go online march late breaking abstract appear right conference often have hottest datum next generation regimesfurther road even more drug be way abbvie partner enanta pharmaceutical enta be already work next generation regime treat more genotype also be simpler take common criticism be more complicate gilead promise pill day routine earlier month merck mrk also report very strong phase result drug combo genotype patient be co infected hiv johnson johnson jnj last october acquire hcv drug glaxosmithkline gsk hope combine already approve olysio oral regimen sovaldi meanwhile have lately be pressure pill price tag concern sustainability outcome find curative drug be patient population eventually shrink still morningstar analyst damien conover say gilead have first mover advantage such strong trial datum likely be biggest player indefinite future think ll have gilead represent hep market tell ibd abbvie take lion share remain
3043,GILD,still early day dec approval gilead science hepatitis drug sovaldi be enjoy most massive drug launch time current consensus call sale year whisper number be run even higher
3044,GILD,doesn surprise wall street sovaldi provide faster safer stronger alternative punish yearlong regimen interferon analyst obsessively watch weekly prescription number grow re also eyee datum sovaldi potential challenger market estimate year grow
3045,GILD,bristol myer squibb bmy daclatasvir grab headline last april phase trial combine sovaldi score cure rate
3046,GILD,gilead gild elect not pursue combo further instead study sovaldi combination similar drug ledipasvir so co formulate single pill not share market
3047,GILD,bristol however file european union approval daclatasvir use combination other agent include sofosbuvir generic name sovaldi be grant accelerate review early january firm plan submit similar filing food drug administration soon
3048,GILD,sovaldi set new standard
3049,GILD,october bristol file approve combo daclatasvir drug asunaprevir japan have unusually high rate hepatitis virus hcv infection due formerly taint blood supply
3050,GILD,dougla manion bristol vice president development virology japan say dual regimen score good result week duration be look yesterday news now sovaldi have set week standard hope be resolve triple therapy involve daclatasvir asunaprevir drug dub bms co formulate pill be take twice day now phase testing
3051,GILD,ultimately however do not expect single regimen conquer other not patient be same
3052,GILD,treat toughest patient
3053,GILD,daclatasvir have be study so many different drug used genotype hepatitis virus patient population especially toughest treat population manion say be go be liver transplant patient genotype patient patient cirrhosis ultimately patient decompensation
3054,GILD,decompensate cirrhosis worst form liver damage result hcv usually result liver transplant death
3055,GILD,decompensate group be population not include abbvie abbv phase trial regimen combine antiviral agent abbvie also stick most common genotype genotype do very well trial cure rate range company plan file second quarter hit market late year
3056,GILD,respect have nearly catch gilead current fda guideline sovaldi recommend be used interferon genotype patient tolerate interferon gilead be banking sofosbuvir ledipasvir combo be first official interferon free genotype treatment also expect launch later year feb filing
3057,GILD,barry bernstein abbvie vice president infectious disease development tout strong safety profile fact cure upward patient compensate cirrhosis
3058,GILD,believe regimen provide option genotype infected patient bernstein tell ibd
3059,GILD,abbvie bristol myer gilead be expect report final study detail international liver congress meeting london april company official be keep mum study be present abstract go online march late breaking abstract appear right conference often have hottest datum
3060,GILD,next generation regime
3061,GILD,further road even more drug be way
3062,GILD,abbvie partner enanta pharmaceutical enta be already work next generation regime treat more genotype also be simpler take common criticism be more complicate gilead promise pill day routine
3063,GILD,earlier month merck mrk also report very strong phase result drug combo genotype patient be co infected hiv johnson johnson jnj last october acquire hcv drug glaxosmithkline gsk hope combine already approve olysio oral regimen
3064,GILD,sovaldi meanwhile have lately be pressure pill price tag concern sustainability outcome find curative drug be patient population eventually shrink
3065,GILD,still morningstar analyst damien conover say gilead have first mover advantage such strong trial datum likely be biggest player indefinite future
3066,GILD,think ll have gilead represent hep market tell ibd abbvie take lion share remain still early day dec approval gilead science hepatitis drug sovaldi be enjoy most massive drug launch time current consensus call sale year whisper number be run even higher doesn surprise wall street sovaldi provide faster safer stronger alternative punish yearlong regimen interferon analyst obsessively watch weekly prescription number grow re also eyee datum sovaldi potential challenger market estimate year grow bristol myer squibb bmy daclatasvir grab headline last april phase trial combine sovaldi score cure rate gilead gild elect not pursue combo further instead study sovaldi combination similar drug ledipasvir so co formulate single pill not share market bristol however file european union approval daclatasvir use combination other agent include sofosbuvir generic name sovaldi be grant accelerate review early january firm plan submit similar filing food drug administration soon sovaldi set new standardin october bristol file approve combo daclatasvir drug asunaprevir japan have unusually high rate hepatitis virus hcv infection due formerly taint blood supply dougla manion bristol vice president development virology japan say dual regimen score good result week duration be look yesterday news now sovaldi have set week standard hope be resolve triple therapy involve daclatasvir asunaprevir drug dub bms co formulate pill be take twice day now phase testing ultimately however do not expect single regimen conquer other not patient be same treat toughest patient daclatasvir have be study so many different drug used genotype hepatitis virus patient population especially toughest treat population manion say be go be liver transplant patient genotype patient patient cirrhosis ultimately patient decompensation decompensate cirrhosis worst form liver damage result hcv usually result liver transplant death decompensate group be population not include abbvie abbv phase trial regimen combine antiviral agent abbvie also stick most common genotype genotype do very well trial cure rate range company plan file second quarter hit market late year respect have nearly catch gilead current fda guideline sovaldi recommend be used interferon genotype patient tolerate interferon gilead be banking sofosbuvir ledipasvir combo be first official interferon free genotype treatment also expect launch later year feb filing barry bernstein abbvie vice president infectious disease development tout strong safety profile fact cure upward patient compensate cirrhosis believe regimen provide option genotype infected patient bernstein tell ibd abbvie bristol myer gilead be expect report final study detail international liver congress meeting london april company official be keep mum study be present abstract go online march late breaking abstract appear right conference often have hottest datum next generation regimesfurther road even more drug be way abbvie partner enanta pharmaceutical enta be already work next generation regime treat more genotype also be simpler take common criticism be more complicate gilead promise pill day routine earlier month merck mrk also report very strong phase result drug combo genotype patient be co infected hiv johnson johnson jnj last october acquire hcv drug glaxosmithkline gsk hope combine already approve olysio oral regimen sovaldi meanwhile have lately be pressure pill price tag concern sustainability outcome find curative drug be patient population eventually shrink still morningstar analyst damien conover say gilead have first mover advantage such strong trial datum likely be biggest player indefinite future think ll have gilead represent hep market tell ibd abbvie take lion share remain
3067,GILD,insys therapeutic insy be set report fourth quarter earning roll upwardly mobile stock price fewer concern future top selling product chandler ariz base company develop supportive care product breakthrough cancer pain btcp be due report result open tuesday analyst expect earning cent
3068,GILD,wall street rise second day tuesday leave major index just record high higher oil price boost energy stock dow jone industrial average rise nasdaq climb end latter finishing just time peak volume be higher nyse nasdaq compare monday accord preliminary datum
3069,GILD,stock market today oil producer pioneer natural resource pxd driller diamond offshore do rise lead oil price jump more just barrel strike oil worker brazil port shutdown libya
3070,GILD,noah holding noah lead ibd jump heavy volume climb right side deep base provider wealth management service china be due report result nov profit period be see rise cent share be biggest gain quarters
3071,GILD,medical product stock cambrex cbm rise more better expect earning report also climb right side new base
3072,GILD,post session trading luxury electric vehicle maker tesla motor tsla rise sharply narrower expect loss stock fall more regular session end week high
3073,GILD,share real estate zillow be hour follow result
3074,GILD,also close groupon gpn edge higher report provider discount retailer also announce coo rich william replace eric lefkofsky ceo lefkofsky become chairman
3075,GILD,lgi home lgih facebook fb epam system epam cognizant technology solution ctsh be company report quarterly earning wednesday
3076,GILD,economic report due wednesday include institute supply management index service sector activity october adp private sector payroll november crude oil inventory week end oct mortgage banker association index mortgage application week end oct wall street rise second day tuesday leave major index just record high higher oil price boost energy stock dow jone industrial average rise nasdaq climb end latter finishing just time peak volume be higher nyse nasdaq compare monday accord preliminary datum stock market today oil producer pioneer natural resource pxd driller diamond offshore do rise lead oil price jump more just barrel strike oil worker brazil port shutdown libya noah holding noah lead ibd jump heavy volume climb right side deep base provider wealth management service china be due report result nov profit period be see rise cent share be biggest gain quarters medical product stock cambrex cbm rise more better expect earning report also climb right side new base post session trading luxury electric vehicle maker tesla motor tsla rise sharply narrower expect loss stock fall more regular session end week high share real estate zillow be hour follow result also close groupon gpn edge higher report provider discount retailer also announce coo rich william replace eric lefkofsky ceo lefkofsky become chairman lgi home lgih facebook fb epam system epam cognizant technology solution ctsh be company report quarterly earning wednesday economic report due wednesday include institute supply management index service sector activity october adp private sector payroll november crude oil inventory week end oct mortgage banker association index mortgage application week end oct
3077,GILD,biotech intermune itmn hit year high stock market today ub lift price target company bullish expectation drug launch ub analyst andrew peter write expect esbriet become standard care lung disease idiopathic pulmonary fibrosis ipf once be approve drug
3078,GILD,big pharma merck up ante hepatitis game monday agree buy idenix pharmaceutical signale hep drug market be longer term big money play merck mrk agree pay share idenix idix soar merck rise fraction want idenix portfolio
3079,GILD,already strongest year merger acquisition flurry dealmake have give share large drugmaker shot arm face case botox maker allergan agn
3080,GILD,not offer have be make peacefully valeant pharmaceutical vrx officially announce plan tuesday make bid allergan hostile
3081,GILD,allergan be pharmaceutical company big cap screen day catch wave screen feature large stock strong earning price performance
3082,GILD,allergan have reject valeant previous advance valeant isn back be prepared make third offer
3083,GILD,tuesday valeant ceo mike pearson tell reuter hostile be not prefer approach deal be so strategic financially compelling really make sense
3084,GILD,activist investor bill ackman persh square capital management allergan largest shareholder be push merger be try block allergan effort poison pill
3085,GILD,share have jump nearly early april be stock market tuesday
3086,GILD,allergan have composite rating possible ibd composite rating rate stock area extra weight earning stock price strength
3087,GILD,actavis act be featured screen rating say tuesday receive shareholder approval proposal related takeover forest laboratory frx shareholder also deal
3088,GILD,buyout be announce february be expect close midyear
3089,GILD,actavis have be know maker generic drug especially equivalent cholesterol lower medication lipitor forest deal help branch brand drug
3090,GILD,forest have establish portfolio treatment well brand drug neurological condition hypertension
3091,GILD,actavis share climb
3092,GILD,gilead science gild have top composite rating company share take hit last week fall nearly merck mrk announce pay cash acquire idenix pharmaceutical idix idenix be develop several experimental hepatitis drug gilead be merck biggest rival hep treatment blockbuster drug sovaldi
3093,GILD,hep market be huge drugmaker virus affect american company be look more effective oral therapy vs current injectable drug regime
3094,GILD,gilead share dip
3095,GILD,follow gillian rich twitter already strongest year merger acquisition flurry dealmake have give share large drugmaker shot arm face case botox maker allergan agn not offer have be make peacefully valeant pharmaceutical vrx officially announce plan tuesday make bid allergan hostile allergan be pharmaceutical company big cap screen day catch wave screen feature large stock strong earning price performance allergan have reject valeant previous advance valeant isn back be prepared make third offer tuesday valeant ceo mike pearson tell reuter hostile be not prefer approach deal be so strategic financially compelling really make sense activist investor bill ackman persh square capital management allergan largest shareholder be push merger be try block allergan effort poison pill share have jump nearly early april be stock market tuesday allergan have composite rating possible ibd composite rating rate stock area extra weight earning stock price strength actavis act be featured screen rating say tuesday receive shareholder approval proposal related takeover forest laboratory frx shareholder also deal buyout be announce february be expect close midyear actavis have be know maker generic drug especially equivalent cholesterol lower medication lipitor forest deal help branch brand drug forest have establish portfolio treatment well brand drug neurological condition hypertension actavis share climb gilead science gild have top composite rating company share take hit last week fall nearly merck mrk announce pay cash acquire idenix pharmaceutical idix idenix be develop several experimental hepatitis drug gilead be merck biggest rival hep treatment blockbuster drug sovaldi hep market be huge drugmaker virus affect american company be look more effective oral therapy vs current injectable drug regime gilead share dip follow gillian rich twitter ibd_grich
3096,GILD,stock continue waver friday afternoon suffering hard hit thursday
3097,GILD,dow jone industrial average nasdaq be thestock market today sustain loss more thursday worry ukraine china volume be again tracking higher pace have slow
3098,GILD,generac gnrc rise modestly higher volume be upgrade buy neutral bank america lynch broker also raise price target generac have erased thursday loss stock clear buy point cup handle base late february
3099,GILD,finisar fnsr rise heavy volume reverse open loss stock again near level have be resistance month
3100,GILD,springleaf holding leaf lose heavy trading putt firmly day move average intraday stock fall more buy point flat base
3101,GILD,gilead science gild be session lows still heavy trading share be much intraday idenix pharmaceutical idix file patent infringement suit company certain subsidiary europe drop gilead have erased gain past buy point flat base stock continue waver friday afternoon suffering hard hit thursday dow jone industrial average nasdaq be thestock market today sustain loss more thursday worry ukraine china volume be again tracking higher pace have slow generac gnrc rise modestly higher volume be upgrade buy neutral bank america lynch broker also raise price target generac have erased thursday loss stock clear buy point cup handle base late february finisar fnsr rise heavy volume reverse open loss stock again near level have be resistance month springleaf holding leaf lose heavy trading putt firmly day move average intraday stock fall more buy point flat base gilead science gild be session lows still heavy trading share be much intraday idenix pharmaceutical idix file patent infringement suit company certain subsidiary europe drop gilead have erased gain past buy point flat base
3102,GILD,biotech stock take beating friday lead gilead science concern grow blockbuster drug sovaldi gilead gild tumble close month low stock be already hit previous friday word congressional inquiry high price sovaldi launch december revolutionary treatment hepatitis
3103,GILD,general market index struggle tuesday healthy number growth stock shrug weakness hit new high electric car maker tesla motor tsla rise close nearly increase day big volume open morgan stanley raise price target tesla tesla have now soar
3104,GILD,stock push fresh session high late tuesday extend rebound monday tumble nasdaq lead gain climb dow jone industrial average rise volume be tracking lower major exchange compare same time monday
3105,GILD,earlier stock market today greece ask new bailout midnight deadline payment international monetary fund loom
3106,GILD,lead stock heavy trade be few boot barn holding boot step new high positive action analyst riley start coverage retailer buy recommendation place price target jeffery lift stock price target
3107,GILD,taser international tasr rally retook day line active trading stock fall more buy point flat base monday trigger sell signal earlier tuesday company announce win order body camera fresno calif polouse department
3108,GILD,synaptic syna rise putt pace snap session slide stock recently wipe gain past buy point mark sell signal month synaptic sell report apple aapl be make own touch controller display driver tddi chip future iphone
3109,GILD,downside skecher skx be session low still nearly fast trade stock be further cool end week streak be get closer testing week line stock surge almost past buy point cup handle base stock push fresh session high late tuesday extend rebound monday tumble nasdaq lead gain climb dow jone industrial average rise volume be tracking lower major exchange compare same time monday earlier stock market today greece ask new bailout midnight deadline payment international monetary fund loom lead stock heavy trade be few boot barn holding boot step new high positive action analyst riley start coverage retailer buy recommendation place price target jeffery lift stock price target taser international tasr rally retook day line active trading stock fall more buy point flat base monday trigger sell signal earlier tuesday company announce win order body camera fresno calif polouse department synaptic syna rise putt pace snap session slide stock recently wipe gain past buy point mark sell signal month synaptic sell report apple aapl be make own touch controller display driver tddi chip future iphone downside skecher skx be session low still nearly fast trade stock be further cool end week streak be get closer testing week line stock surge almost past buy point cup handle base
3110,GILD,small fast grow company hot industry such generic drugmaker lannett be good prospect stock watch list today screen day be small cap leader highly rate company market capitalization list include trio highly rate medical company massive baby boomer generation move retirement
3111,GILD,joe fath take helm rowe price growth stock fund jan
3112,GILD,message shareholder don expect dramatic change doesn mean change
3113,GILD,fath make buy take buy add name stock market weaken march april
3114,GILD,core approach be look secular grower seek company grow faster expect especially like company growth durability be longer anticipate
3115,GILD,be often innovative disrupter development lead last change fath say
3116,GILD,top name account asset
3117,GILD,tail end portfolio ll hold younger smaller emerge growth stock be earlier life cycle say offer higher reward higher risk
3118,GILD,stratasys ssys be example emerge printing space
3119,GILD,be many technology re focuse just maybe fath say
3120,GILD,fath see overall printing market grow end decade
3121,GILD,fath begin current stake stratasys first quarter stock stair step lower time high have rally low weak ibd composite rating indicate stock have way go regain leadership status
3122,GILD,stock show fath promise be industry be restructure also go tail end portfolio
3123,GILD,add american airline aal complement exist stake delta dal unite continential ual
3124,GILD,take
3125,GILD,discipline approach capacity have boost domestic airline pricing power be cyclical structural change revenue growth be durable cycle maybe next fath say
3126,GILD,fath funded buy take charge fund trimming name have score big run up especially want take advantage stock like have sell march april
3127,GILD,priceline pcln be add company have do well get hotel fragmented european market platform then get traveler respond re also good buy key word google googl say
3128,GILD,priceline plan acquisition opentable open fit core model say expect agoda be accretive asia latin america
3129,GILD,google be top hold
3130,GILD,netflix nflx be stock add weakness many investor do not appreciate netflix have reshape business fath say
3131,GILD,add original content offer exist customer lower price new subscriber pay netflix aim stabilize revenue cut customer churn
3132,GILD,also like netflix deal walt disney foreign expansion
3133,GILD,gilead science gild be top hold recent launch hepatitis drug sovaldi boost ep growth fath like gilead stiff competition pricing issue joe fath take helm rowe price growth stock fund jan message shareholder don expect dramatic change doesn mean change fath make buy take buy add name stock market weaken march april core approach be look secular grower seek company grow faster expect especially like company growth durability be longer anticipate be often innovative disrupter development lead last change fath say top name account asset tail end portfolio ll hold younger smaller emerge growth stock be earlier life cycle say offer higher reward higher risk stratasys ssys be example emerge printing space be many technology re focuse just maybe fath say fath see overall printing market grow end decade fath begin current stake stratasys first quarter stock stair step lower time high have rally low weak ibd composite rating indicate stock have way go regain leadership status stock show fath promise be industry be restructure also go tail end portfolio add american airline aal complement exist stake delta dal unite continential ual take offa discipline approach capacity have boost domestic airline pricing power be cyclical structural change revenue growth be durable cycle maybe next fath say fath funded buy take charge fund trimming name have score big run up especially want take advantage stock like have sell march april priceline pcln be add company have do well get hotel fragmented european market platform then get traveler respond re also good buy key word google googl say priceline plan acquisition opentable open fit core model say expect agoda be accretive asia latin america google be top hold netflix nflx be stock add weakness many investor do not appreciate netflix have reshape business fath say add original content offer exist customer lower price new subscriber pay netflix aim stabilize revenue cut customer churn also like netflix deal walt disney foreign expansion gilead science gild be top hold recent launch hepatitis drug sovaldi boost ep growth fath like gilead stiff competition pricing issue
3134,GILD,major index post third gain session wednesday trading remain lackadaisical whole lead stock joined rally ibd rise only few stock have attempt breakout so far do not have much gain show rather larger contingent name continue build new base pattern institutional quality
3135,GILD,most sector leader fall friday lead medical stock major average reversed lower arris group arrs buck decline turn best performance rise cent more double average daily volume maker equipment cable tv industry be entry week tight pattern putt
3136,GILD,stock finished week doubtful note index turn mixed higher volume nasdaq ibd lose edge less volume rise board distribution day count balloon nasdaq index picked distribution day friday drop
3137,GILD,stock be higher unison once again friday halftime trading mixed earlier
3138,GILD,dow jone industrial average rise climb fall much earlier nasdaq have turn fractionally higher volume be run vastly higher board stock market today due quadruple witching
3139,GILD,ethanol refiner marketer green plain energy gpre add touch highest level august be well extend buy point cup handle base clear december
3140,GILD,longtime lead biotechs come pressure possibly news lawmaker ask gilead science gild more information pricing sovaldi hepatitis treatment cost
3141,GILD,alexion pharmaceutical alxn erased early gain slump fast trade stock appear be find support day line
3142,GILD,biogen idec biib fall get approval canadian regulator alprolix hemophilia treatment stock be still past buy point flat base
3143,GILD,alk have rise past session fall fast trade
3144,GILD,celgene celg fall slice day move average stock hit month low stock be higher unison once again friday halftime trading mixed earlier dow jone industrial average rise climb fall much earlier nasdaq have turn fractionally higher volume be run vastly higher board stock market today due quadruple witching ethanol refiner marketer green plain energy gpre add touch highest level august be well extend buy point cup handle base clear december longtime lead biotechs come pressure possibly news lawmaker ask gilead science gild more information pricing sovaldi hepatitis treatment cost alexion pharmaceutical alxn erased early gain slump fast trade stock appear be find support day line biogen idec biib fall get approval canadian regulator alprolix hemophilia treatment stock be still past buy point flat base alk have rise past session fall fast trade celgene celg fall slice day move average stock hit month low
3145,GILD,major average extend winning streak session friday sign institutional buy major average remain few far rise day move average thursday nasdaq outperformed again rise breadth be pretty good nasdaq advancer top decliner nearly margin meanwhile rise
3146,GILD,hottest research field biotech be disease most person have never hear datum potential treatment roll year bound become lot more famous wall street alcoholic steatohepatitis nash afflict much adult most don realize completely unrelated viral hepatitis share name share symptom inflamed liver steato mean fat so steatohepatitis be happen fat accumulate liver reason aren clear year result scar tissue build liver cause organ fail even patient be induced alcoholism alcoholic variety be cause more common problem obesity investor never hear nash likely crossed radar screen jan intercept pharmaceutical icpt stock vault day drug obeticholic acid oca do so well phase trial be stop early other biotechs nash drug pipeline raptor pharmaceutical rptp conatus pharmaceutical cnat galectin therapeutic galt also see stock jump investor pounce good news chronic disappointment nash have be hot area year say liisa bayko biotech analyst jmp security however nothing ever have work be area investor salivate such big market result nash research have be left mostly small unpartnered biotechs only big cap field be gilead science gild acquire monoclonal antibody call simtuzumab buyout arresto bioscience be little datum nash indication yet small cap don have resource large clinical trial so intercept raptor have be lean national institutes health conduct also have pursue safer indication drug nash reason most everyone be so surprised intercept nash datum fact be market be more focuse oca lead indication primary biliary cirrhosis raptor drug procybsi be first approve last year orphan disease call nephropathic cystinosis also late stage testing huntington disease nash indication company focuse adolescent look carve market niche fundamentally address consider be most significant public health issue be obesity kid raptor ceo christopher starr tell ibd january interview not treat lot kid suffer significant liver problem time get adult year raptor be expect readout phase trial year conatus also be pursue other liver related indication first just announce march start phase trial drug emricasan nash patient conatus ceo stephen tell ibd look other company be further road define clinical pathway previous attempt have be so abort not even clear exactly food drug administration be go measure success say philosophy be focus sickest patient first awareness rise mission likely creep prevention see possible analogy rise cholesterol drug patient don think liver part sickness say not headache don have liverache statin be originally develop patient have genetic predisposition astronomically high level cholesterol be perception didn lower cholesterol have heart disease nobody have develop statin initially thought reduce cholesterol primary endpoint doctor be more likely talk risk patient disease once have actual treatment offer say galectin be only company make fatty liver disease plan drug gr md be just early testing focuse most advanced case serious liver scarring datum phase trial be first result human subject be expect end month little hard datum even less past experience go predict market be go play be difficult product be test be also quite different other used different mechanism attack disease so be room more potentially giant field
3147,GILD,gilead science late tuesday blow past revenue earning forecast sale new hepatitis drug sovaldi far exceed expectation fellow big biotech amgen miss expectation gilead gild stock be hour report include sale expensive sovaldi start selling december analyst sale estimate
3148,GILD,flexibility be not issue jason weiner fidelity growth discovery invest small midcap large cap stock past quarters sight have be set mainly larger stock weiner have money work giant cap stock april accord morningstar inc have
3149,GILD,tyson food emerge winner bidding war hillshire brand offer share top pilgrim pride ppc offer series deal announce monday tyson food tsn largest meat processor sale complete deal hillshire brand hsh terminate
3150,GILD,stock trudge higher thursday seemingly constant chatter bear economic datum market internal don support upside move nasdaq outperformed rise gain dow jone industrial average add nyse volume ease wednesday level nasdaq volume rise nasdaq close day move average
3151,GILD,columbia select large cap growth fund take chin monday add setback friday biotech stock plunge several house democrat ask gilead science gild justify price hepatitis drug sovaldi portfolio fall friday be most severely hit large cap growth fund track morningstar
3152,GILD,nasdaq plunge more sell deepen market correction
3153,GILD,composite be pound loss software solar energy biotechs leader have come pressure lead way
3154,GILD,skid close day move average index have find support earlier week
3155,GILD,dow jone industrial average lose small cap russell erased
3156,GILD,preliminary figure show volume rise sizeable percentage increase nyse nasdaq volume make practically inevitable trading increase wednesday total be clear sign institutional investor fled stock
3157,GILD,selling be broad stock market today nearly ibd industry group be lower lose stock lead winner more nasdaq nyse
3158,GILD,gilead science gild sell close day move average first time more year be example wo biotech other medical internet stock be weakest day
3159,GILD,google googl major nasdaq component slide close facebook fb recede nasdaq plunge more sell deepen market correction composite be pound loss software solar energy biotechs leader have come pressure lead way skid close day move average index have find support earlier week dow jone industrial average lose small cap russell erased preliminary figure show volume rise sizeable percentage increase nyse nasdaq volume make practically inevitable trading increase wednesday total be clear sign institutional investor fled stock selling be broad stock market today nearly ibd industry group be lower lose stock lead winner more nasdaq nyse gilead science gild sell close day move average first time more year be example wo biotech other medical internet stock be weakest day google googl major nasdaq component slide close facebook fb recede
3160,GILD,many medical stock be picture health several segment post rosy checkup medical biom biotech industry group rank first group track ibd group second straight week list medical ethical drug medical generic be no medical system equipment medical research equipment service rank no mutual fund be throw
3161,GILD,lord abbett develop growth fund manager thomas halloran arthur weise be look winner fund sell isis pharmaceutical isis trim medidata solution mdso financial engine fngn pandora medium stock share great business outlook stock appreciate many multiple past couple
3162,GILD,biogen idec finished high note highly tout oral multiple sclerosis drug tecfidera produce nearly sale fourth quarter company be pace generate more first year market tecfidera performance helpedbiogen biib deliver record overall revenue be
3163,GILD,big cap enjoy good day monday numerous entry elite list high market cap growth stock list be heavy medical issue internet stock dominate list drugmaker gilead science gild be build ascend base rare formation produce substantial gain late stage base add risk
3164,GILD,market be correction don tell several large cap leader week ibd big cap several be perform well breakout hold buy point unsettled market just stock be hold well weak market doesn mean be buy market
3165,GILD,stock hold narrow range thursday volume shrank previous session nasdaq add lose dow jone industrial average drop ibd shave impressive consider have factor nu skin nus plunge volume be lower major exchange dec distribution
3166,GILD,mainstay large cap growth fund soar last year market tilt riskier less defensive stock favore fund rotation show third fourth quarters fund outperformed large cap growth peer group track morningstar inc have continue do so far
3167,GILD,investor be gifted stellar gain stock market fed continue pump easy money economy quantitative ease thus fee investor appetite risk follow smart money place bet also find top notch stock country best perform fund past month invest medical issue such
3168,GILD,stock be still lower thursday afternoon have push session lows
3169,GILD,nasdaq be fractionally lower flirt positive territory fall much earlier software internet solar stock help cushion nasdaq dow jone industrial average fall respectively volume be tracking lower major exchange stock market today
3170,GILD,generac holding gnrc slump slice day line heavy trade oppenheimer co downgrade stock perform outperform cite valuation earning pressure thursday drop have cut significantly gain oct
3171,GILD,michael kor kor be session low still fast trade now buy point flat base have be much past trigger stock slice day line big volume jan suffering downgrade citigroup
3172,GILD,upside gilead science gild rise time high fast trade clear buy point flat base pattern be risky fourth stage structure
3173,GILD,conn conn rise shake loss stock appear be find resistance day move average intraday stock revisit buy point cup handle base stock be still lower thursday afternoon have push session lows nasdaq be fractionally lower flirt positive territory fall much earlier software internet solar stock help cushion nasdaq dow jone industrial average fall respectively volume be tracking lower major exchange stock market today generac holding gnrc slump slice day line heavy trade oppenheimer co downgrade stock perform outperform cite valuation earning pressure thursday drop have cut significantly gain oct michael kor kor be session low still fast trade now buy point flat base have be much past trigger stock slice day line big volume jan suffering downgrade citigroup upside gilead science gild rise time high fast trade clear buy point flat base pattern be risky fourth stage structure conn conn rise shake loss stock appear be find resistance day move average intraday stock revisit buy point cup handle base
3174,GILD,stock continue hold session high late tuesday nasdaq pace sixth straight gain
3175,GILD,nasdaq be dow jone industrial average rise volume be again run sharply higher board stock market today
3176,GILD,lead stock la vegas sand lvs jump nearly active trading putt just day move average casino operator report earning wednesday close sand recently find support week move average
3177,GILD,zillow bounce back earlier weakness rise time high fast trade be be downgrade fairly value buy crt capital upside reversal put stock past buy point handle accord report release today zillow home price more city be expect hit record high next year
3178,GILD,micron technology mu extend recent streak rise best level nearly year stock clear buy point late stage consolidation lose money past year analyst poll thomson reuter see turn profit share year
3179,GILD,downside allison transmission alsn drop appear find support day line late monday company announce sale share investment fund connect carlyle group cg onex corp last week stock briefly clear buy point flat base
3180,GILD,amgen amgn cree cree gilead science gild intuitive surgical isrg packaging corp america pkg skywork solution swks super micro computer smci vmware vmw yum brand yum be few notable company report earning close stock continue hold session high late tuesday nasdaq pace sixth straight gain nasdaq be dow jone industrial average rise volume be again run sharply higher board stock market today lead stock la vegas sand lvs jump nearly active trading putt just day move average casino operator report earning wednesday close sand recently find support week move average zillow bounce back earlier weakness rise time high fast trade be be downgrade fairly value buy crt capital upside reversal put stock past buy point handle accord report release today zillow home price more city be expect hit record high next year micron technology mu extend recent streak rise best level nearly year stock clear buy point late stage consolidation lose money past year analyst poll thomson reuter see turn profit share year downside allison transmission alsn drop appear find support day line late monday company announce sale share investment fund connect carlyle group cg onex corp last week stock briefly clear buy point flat base amgen amgn cree cree gilead science gild intuitive surgical isrg packaging corp america pkg skywork solution swks super micro computer smci vmware vmw yum brand yum be few notable company report earning close
3181,GILD,few lead stock top buy point thursday make new high gilead science gild break odd flat base share biotech surge double average volume buy point be however be late stage base gilead have mount impressive climb early
3182,GILD,go public march little biotech enanta pharmaceutical have be middle clash giant enanta enta be developer protease inhibitor antiviral agent abbvie abbv cocktail drug testing treat hepatitis virus hcv abbvie be consider be nearest contender
3183,GILD,stock blast higher wednesday even fed reserve trim bond purchase month
3184,GILD,dow jone industrial average bolt respectively score record close high nasdaq rally volume jump board stock market today
3185,GILD,investment wetf stretched streak straight session tack new high more triple average trade now past buy point week tight pattern clear tuesday company unveil total new etfs pertain dollar
3186,GILD,arm holding armh gap jump heavy trading volatile stock clear buy point cup handle base british chip designer be featured wednesday new america
3187,GILD,gilead science gild rally positive trial news stock find support day line tuesday
3188,GILD,downside linkedin lnkd lose end well day low stock gap open be wednesday low linkedin find support day line stock blast higher wednesday even fed reserve trim bond purchase month dow jone industrial average bolt respectively score record close high nasdaq rally volume jump board stock market today investment wetf stretched streak straight session tack new high more triple average trade now past buy point week tight pattern clear tuesday company unveil total new etfs pertain dollar arm holding armh gap jump heavy trading volatile stock clear buy point cup handle base british chip designer be featured wednesday new america gilead science gild rally positive trial news stock find support day line tuesday downside linkedin lnkd lose end well day low stock gap open be wednesday low linkedin find support day line
3189,GILD,gilead science gild report more positive datum hepatitis drug pipeline wednesday send share stock market today datum come phase study used recently approve drug sofosbuvir candidate ledipasvir patient genotype virus most common type sustain response rate be well
3190,GILD,nasdaq continue dominate index peer wednesday score fifth gain session day market leadership come surprisingly wide swath industry not just tech nasdaq composite gain admittedly not much session so far year key benchmark finished session high
3191,GILD,tech stock outperformed tuesday hit time high intraday basis wall street digest dovish comment monday fed chief janet yellen
3192,GILD,nasdaq rise reclaim day move average dow jone industrial average rise nyse nasdaq volume be tracking higher monday stock market today
3193,GILD,economic news day disappointing read chicago purchasing manufacturer index ism manufacturing index come mostly line expectation
3194,GILD,day gainer former leader intuitive surgical isrg surge regulator approve new version da vinci robotic surgical system stock rise much news be session low hour session
3195,GILD,meanwhile casino operator exposure macau china have good day news gaming revenue region totale march year third highest record melco crown entertainment mpel rise wynn resort wynn la vegas sand lvs gain
3196,GILD,several other china base growth stock score gain heavy volume include athm bitauto bita operate website prospective car buyer china share rise bitauto soar
3197,GILD,qihoo technology qihu be best percentage gainer ibd rise nearly stock plunge day move average last week have be rally mode friday be just day move average early tuesday
3198,GILD,monday move higher ibd biotech group add heavy volume gainer group include gilead science gild celgene celg regeneron pharmaceutical regn biogen idec biib alexion pharmaceutical alxn tech stock outperformed tuesday hit time high intraday basis wall street digest dovish comment monday fed chief janet yellen nasdaq rise reclaim day move average dow jone industrial average rise nyse nasdaq volume be tracking higher monday stock market today economic news day disappointing read chicago purchasing manufacturer index ism manufacturing index come mostly line expectation day gainer former leader intuitive surgical isrg surge regulator approve new version da vinci robotic surgical system stock rise much news be session low hour session meanwhile casino operator exposure macau china have good day news gaming revenue region totale march year third highest record melco crown entertainment mpel rise wynn resort wynn la vegas sand lvs gain several other china base growth stock score gain heavy volume include athm bitauto bita operate website prospective car buyer china share rise bitauto soar qihoo technology qihu be best percentage gainer ibd rise nearly stock plunge day move average last week have be rally mode friday be just day move average early tuesday monday move higher ibd biotech group add heavy volume gainer group include gilead science gild celgene celg regeneron pharmaceutical regn biogen idec biib alexion pharmaceutical alxn
3199,GILD,past year bring sea change drug well few didn quite work plan herewith highly subjective ranking most newsworthy drug launch sovaldi drug approve year have quite expectation gilead science gild hepatitis drug fda approve dec
3200,GILD,gilead science gild newly approve hepatitis drug sovaldi come fire price pharmacy benefit manager express script esrx tuesday rival abbvie abbv report good datum compete drug candidate gilead stock drop abbvie rise stock market today bloomberg reporter draw say twitter express script chief medical officer
3201,GILD,share biotechs celgene celg infinity pharmaceutical infi be stock market today strong clinical datum blood cancer drug present american society hematology conference weekend
3202,GILD,celgene report detail mm trial revlimid be already blockbuster approve treat relapse multiple myeloma trial be study risk benefit profile revlimid long term maintenance therapy crucial piece information european authority reject use last year say want more information
3203,GILD,result show significant improvement overall survival longer duration therapy control group patient have survival rate rate be revlimid month year month treatment also bring average month progression free survival
3204,GILD,early monday rbc capital market analyst michael yee raise price target stock big picture conclusion ash be revlimid continuous treatment become standard care globe be use eu currently only use write note
3205,GILD,celgene stock be morning trading monday hit new high rank latest ibd list top perform stock
3206,GILD,infinity meanwhile be earlier report positive datum drug ipi cell acute lymphoblastic leukemia indolent hodgkin lymphoma chronic lymphocytic leukemia latter disease have be very busy area medicine lately recent approval pharmacyclic pcyc ibrutinib gilead science gild idelalisib expect come next year analyst yee say infinity datum so far stand competition
3207,GILD,bottom line be feedback docs here be early least good gild fine give such low expectation infi write research note sunday
3208,GILD,indeed infinity stock hold abysmal ibd relative strength rating get beating follow last round ipi datum medical conference june monday move be trading still more week high
3209,GILD,related celgene top rate drugmaker share biotechs celgene celg infinity pharmaceutical infi be stock market today strong clinical datum blood cancer drug present american society hematology conference weekend celgene report detail mm trial revlimid be already blockbuster approve treat relapse multiple myeloma trial be study risk benefit profile revlimid long term maintenance therapy crucial piece information european authority reject use last year say want more information result show significant improvement overall survival longer duration therapy control group patient have survival rate rate be revlimid month year month treatment also bring average month progression free survival early monday rbc capital market analyst michael yee raise price target stock big picture conclusion ash be revlimid continuous treatment become standard care globe be use eu currently only use write note celgene stock be morning trading monday hit new high rank latest ibd list top perform stock infinity meanwhile be earlier report positive datum drug ipi cell acute lymphoblastic leukemia indolent hodgkin lymphoma chronic lymphocytic leukemia latter disease have be very busy area medicine lately recent approval pharmacyclic pcyc ibrutinib gilead science gild idelalisib expect come next year analyst yee say infinity datum so far stand competition bottom line be feedback docs here be early least good gild fine give such low expectation infi write research note sunday indeed infinity stock hold abysmal ibd relative strength rating get beating follow last round ipi datum medical conference june monday move be trading still more week high related celgene top rate drugmaker
3210,GILD,saturday tuesday rep drugmaker world be gathering new orlean present datum blood disease drug american society hematology conference be top rate big cap biotechs abstract be already detail report have potential move stock celgene celg sunday afternoon
3211,GILD,many say drug industry be enter post blockbuster era mega seller such lipitor lose patent be drug pipeline expect pass traditional blockbuster benchmark global annual sale here preview expect launch next month have attract much interest
3212,GILD,stock market rally get long tooth not many top mutual fund manager recent buy be buy point interest slim investor last dip low june index have climb many lead stock have be favorite top perform fund past
3213,GILD,stock get positive start friday slip mixed trade several drugmaker fall abruptly pull nasdaq negative territory
3214,GILD,dow jone industrial average be ahead nasdaq fall gilead science gild celgene celg vertex pharmaceutical vrtx other drugmaker post sharp loss
3215,GILD,option expiration force volume stock market today trade triple digit percentage nyse nasdaq compare thursday early action
3216,GILD,broadcaster medium general meg ahead announce buy peer lin medium lin cash stock deal value combination include nearly lin debt create tv broadcaster station serve market providence base lin medium be
3217,GILD,symantec symc tank start trade antivirus software maker announce late thursday have drop ceo steve bennett company say decision be result ongoing deliberative process not result event impropriety company name director michael brown interim ceo symantec share have be deepen correction august
3218,GILD,lead stock buffalo wild wing bwld pop powerful trade grab new high fast casual sport bar chain remain buy range buy point cup handle base
3219,GILD,downside alexion pharmaceutical alxn reversed early gain backed heavy trade drugmaker have be flattish consolidation feb high stock get positive start friday slip mixed trade several drugmaker fall abruptly pull nasdaq negative territory dow jone industrial average be ahead nasdaq fall gilead science gild celgene celg vertex pharmaceutical vrtx other drugmaker post sharp loss option expiration force volume stock market today trade triple digit percentage nyse nasdaq compare thursday early action broadcaster medium general meg ahead announce buy peer lin medium lin cash stock deal value combination include nearly lin debt create tv broadcaster station serve market providence base lin medium be symantec symc tank start trade antivirus software maker announce late thursday have drop ceo steve bennett company say decision be result ongoing deliberative process not result event impropriety company name director michael brown interim ceo symantec share have be deepen correction august lead stock buffalo wild wing bwld pop powerful trade grab new high fast casual sport bar chain remain buy range buy point cup handle base downside alexion pharmaceutical alxn reversed early gain backed heavy trade drugmaker have be flattish consolidation feb high
3220,GILD,stock climb second straight day friday dow jone industrial average hit record high
3221,GILD,be tech heavy nasdaq lead gain biotechs software be day strongest group rise dow edge volume end mixed stock market today accord preliminary datum nasdaq trade be slightly higher nyse volume slide
3222,GILD,biogen idec biib gap bolt new high massive volume key european regulatory body give drugmaker favorable ruling multiple sclerosis pill tecfidera stock soar week move average be extend buy point
3223,GILD,gilead science gild gain record high winning approval european advisory panel hepatitis drug sofosbuvir
3224,GILD,celgene celg climb record high also receive good news europe european medicine agency panel give positive opinion pancreatic drug abraxane pave way approval european commission be expect make final decision month
3225,GILD,downside proto lab prlb end session low still slump big volume share slump much intraday week proto lab tumble just shy biggest weekly loss more year stock climb second straight day friday dow jone industrial average hit record high be tech heavy nasdaq lead gain biotechs software be day strongest group rise dow edge volume end mixed stock market today accord preliminary datum nasdaq trade be slightly higher nyse volume slide biogen idec biib gap bolt new high massive volume key european regulatory body give drugmaker favorable ruling multiple sclerosis pill tecfidera stock soar week move average be extend buy point gilead science gild gain record high winning approval european advisory panel hepatitis drug sofosbuvir celgene celg climb record high also receive good news europe european medicine agency panel give positive opinion pancreatic drug abraxane pave way approval european commission be expect make final decision month downside proto lab prlb end session low still slump big volume share slump much intraday week proto lab tumble just shy biggest weekly loss more year
3226,GILD,normally healthy biotech stock suffer critical decline friday most other medical name ibd remain fairly stable condition still biotech illness spread other drug stock result biggest loser hailed medical sector include generic ethical drug maker alexion pharmaceutical alxn last week
3227,GILD,strong performance biotech etfs past year recent market pullback still be room run investor stomach sector high volatility
3228,GILD,course lot depend stock market general direction biotech etfs continue selling monday further progress biotech etfs have market uptrend return
3229,GILD,steven silver equity analyst capital iq say industry success be base pillar
3230,GILD,first be very solid period late stage datum new drug come market say put together think be lot pocket significant progress
3231,GILD,second pillar state be much more accommodative food drug administration be focuse get more drug market last year fda start breakthrough therapy designation provide fast track development review drug serious life threaten condition
3232,GILD,be program have receive designation so far fda be only grant program designation so think long term be really big deal company be receive designation term get drug market faster
3233,GILD,finally sector have prospect increase activity traditionally big pharmas be acquirer smaller biotechs biotechs have grow so large be now market buy smaller firm create more competition market acquisition firm
3234,GILD,biggest biotech etfs be ishare nasdaq biotech ibb spdr biotech xbi be very liquid have reasonable expense ratio asset ibb xbi
3235,GILD,composition be somewhat different ibb hold nasdaq list stock be market cap weight etf be more diversify biotech accounting fund pharma life science
3236,GILD,be market cap weight top holding be large independent biotechs gilead science gild biogen idec biib amgen amgn celgene celg regeneron pharmaceutical regn fund
3237,GILD,comparison xbi be make stock nearly biotechs top holding be intercept pharmaceutical icpt ariad pharmaceutical aria neurocrine bioscience nbix sangamo bioscience sgmo novavax nvax fund be equal weight result bias smaller name meaning more volatility higher turnover
3238,GILD,old school vs new school
3239,GILD,be very different fund say robert goldsborough etf analyst morningstar xbi re go have more early stage biotech firm lot be publicly trade company have drug market yet have profit
3240,GILD,xbi be more year ibb have perform better longer period average annual vs past year vs year
3241,GILD,ibb actually have better risk adjust return long term say goldsborough
3242,GILD,think stock have do very very well base improve growth potential rather investor bidding company just say silver be exciting time do think continue be exciting time strong performance biotech etfs past year recent market pullback still be room run investor stomach sector high volatility course lot depend stock market general direction biotech etfs continue selling monday further progress biotech etfs have market uptrend return steven silver equity analyst capital iq say industry success be base pillar first be very solid period late stage datum new drug come market say put together think be lot pocket significant progress second pillar state be much more accommodative food drug administration be focuse get more drug market last year fda start breakthrough therapy designation provide fast track development review drug serious life threaten condition be program have receive designation so far fda be only grant program designation so think long term be really big deal company be receive designation term get drug market faster finally sector have prospect increase activity traditionally big pharmas be acquirer smaller biotechs biotechs have grow so large be now market buy smaller firm create more competition market acquisition firm biggest biotech etfs be ishare nasdaq biotech ibb spdr biotech xbi be very liquid have reasonable expense ratio asset ibb xbi composition be somewhat different ibb hold nasdaq list stock be market cap weight etf be more diversify biotech accounting fund pharma life science be market cap weight top holding be large independent biotechs gilead science gild biogen idec biib amgen amgn celgene celg regeneron pharmaceutical regn fund comparison xbi be make stock nearly biotechs top holding be intercept pharmaceutical icpt ariad pharmaceutical aria neurocrine bioscience nbix sangamo bioscience sgmo novavax nvax fund be equal weight result bias smaller name meaning more volatility higher turnover old school vs new school be very different fund say robert goldsborough etf analyst morningstar xbi re go have more early stage biotech firm lot be publicly trade company have drug market yet have profit xbi be more year ibb have perform better longer period average annual vs past year vs year ibb actually have better risk adjust return long term say goldsborough think stock have do very very well base improve growth potential rather investor bidding company just say silver be exciting time do think continue be exciting time
3243,GILD,top rate biotechs biogen idec gilead science celgene get good news europe friday send stock time high
3244,GILD,biogen biib multiple sclerosis drug tecfidera moved step closer launch european union be rule new active substance eu committee medicinal product human use chmp eu rule new active substance be protected competition year give product more solid protection patent be subject legal challenge few year
3245,GILD,tecfidera launch earlier year get positive panel vote europe march biogen push back launch negotiate regulator new active substance tecfidera actually be similar compound exist ms used
3246,GILD,stronger sale share
3247,GILD,analyst say uncertainty eu ruling put damper stock have be hit resistance delay be announce be question biogen even launch tecfidera europe exclusivity
3248,GILD,remove big overhang write deutsche bank analyst robyn karnauskas raise price target give solid uptake tecfidera be raise peak market share tecfidera vs previously now model worldwide sale vs previously
3249,GILD,biogen sale growth have already accelerate past quarters gain ramp tecfidera launch
3250,GILD,citi also raise price target
3251,GILD,biogen share shot
3252,GILD,meanwhile gilead gild hepatitis drug sofosbuvir win chmp vote earlier wall street expect committee recommend approve sofosbuvir now brand sovaldi follow accelerate review procedure drug perform very well clinical trial european commission usually follow chmp advice gilead say drug launch go well
3253,GILD,upside
3254,GILD,analyst michael yee rbc capital market write client note decision come least month ahead expectation add potential upside sovaldi sale drug be widely expect approval early december
3255,GILD,think ll do alone eu add few country country launch eu start primarily germany other country take month full reimbursement pricing distribution launch yee write
3256,GILD,analyst already have high expectation sovaldi promise first treatment disease interferon current consensus call sale
3257,GILD,gilead stock rise nearly friday
3258,GILD,chmp also endorse celgene abraxane treatment pancreatic cancer combination gemcitabine better know eli lilly lly gemzar abraxane have be market breast cancer celgene buy developer abraxis bioscience be testing new indication be approve lung cancer year pancreatic cancer september so far europe still authorize only breast cancer
3259,GILD,celgene stock climb seventh straight gain top rate biotechs biogen idec gilead science celgene get good news europe friday send stock time high biogen biib multiple sclerosis drug tecfidera moved step closer launch european union be rule new active substance eu committee medicinal product human use chmp eu rule new active substance be protected competition year give product more solid protection patent be subject legal challenge few year tecfidera launch earlier year get positive panel vote europe march biogen push back launch negotiate regulator new active substance tecfidera actually be similar compound exist ms used stronger sale sharesanalyst say uncertainty eu ruling put damper stock have be hit resistance delay be announce be question biogen even launch tecfidera europe exclusivity remove big overhang write deutsche bank analyst robyn karnauskas raise price target give solid uptake tecfidera be raise peak market share tecfidera vs previously now model worldwide sale vs previously biogen sale growth have already accelerate past quarters gain ramp tecfidera launch citi also raise price target biogen share shot meanwhile gilead gild hepatitis drug sofosbuvir win chmp vote earlier wall street expect committee recommend approve sofosbuvir now brand sovaldi follow accelerate review procedure drug perform very well clinical trial european commission usually follow chmp advice gilead say drug launch go well upsideanalyst michael yee rbc capital market write client note decision come least month ahead expectation add potential upside sovaldi sale drug be widely expect approval early december think ll do alone eu add few country country launch eu start primarily germany other country take month full reimbursement pricing distribution launch yee write analyst already have high expectation sovaldi promise first treatment disease interferon current consensus call sale gilead stock rise nearly friday chmp also endorse celgene abraxane treatment pancreatic cancer combination gemcitabine better know eli lilly lly gemzar abraxane have be market breast cancer celgene buy developer abraxis bioscience be testing new indication be approve lung cancer year pancreatic cancer september so far europe still authorize only breast cancer celgene stock climb seventh straight gain
3260,GILD,big pharma abbvie abbv release first set result phase trial new hepatitis regimen monday send abbvie stock stock market today study find week treatment abbvie drug candidate standard oral drug ribavirin patient show sustain viral
3261,GILD,stock rise friday european central bank hint new stimulus measure boost inflation major average end intraday high
3262,GILD,nasdaq rise dow jone industrial average gain be volume be mixed stock market today rise nyse fall nasdaq compare thursday accord preliminary figure
3263,GILD,european central bank head mario draghi suggest ecb introduce new stimulus measure dec meeting
3264,GILD,retailer medical apparel stock lead upside datum storage energy steel stock underperform
3265,GILD,nike nke lead dow ibd jump heavy volume announce stock split share buyback dividend increase late thursday stock be well extend past buy point have find support day move average
3266,GILD,alaska air alk be also best perform ibd stock regional airline climb nearly line oil plunge barrel near buy point flat base hawaiian holding also rise nearly carrier be just time high well buy range
3267,GILD,downside mentor graphic ment plunge week low mentor developer software used test electronic system issue disappointing quarterly earning report stock rise friday european central bank hint new stimulus measure boost inflation major average end intraday high nasdaq rise dow jone industrial average gain be volume be mixed stock market today rise nyse fall nasdaq compare thursday accord preliminary figure european central bank head mario draghi suggest ecb introduce new stimulus measure dec meeting retailer medical apparel stock lead upside datum storage energy steel stock underperform nike nke lead dow ibd jump heavy volume announce stock split share buyback dividend increase late thursday stock be well extend past buy point have find support day move average alaska air alk be also best perform ibd stock regional airline climb nearly line oil plunge barrel near buy point flat base hawaiian holding also rise nearly carrier be just time high well buy range downside mentor graphic ment plunge week low mentor developer software used test electronic system issue disappointing quarterly earning report
3268,GILD,share gilead science gild hit time high friday biotech prepared report full year earning close monday stock have slip bit be trading friday afternoon
3269,GILD,analyst poll thomson reuter expect fairly slow quarter earning year quarter cent share sale rise report provide more clarity launch hiv drug stribild nickname quad combine different medicine be approve aug thus have only few week sale last earning report
3270,GILD,stock today have be help bloomberg article highlight gilead expansion oncology series acquisition deal be part gilead strategy move dependency hiv business nearer term catalyst be expect be hepatitis drug sofosbuvir have perform excellently so far late stage trial analyst expect sofosbuvir stribild restart earning growth next few year ep expect rise year share gilead science gild hit time high friday biotech prepared report full year earning close monday stock have slip bit be trading friday afternoon analyst poll thomson reuter expect fairly slow quarter earning year quarter cent share sale rise report provide more clarity launch hiv drug stribild nickname quad combine different medicine be approve aug thus have only few week sale last earning report stock today have be help bloomberg article highlight gilead expansion oncology series acquisition deal be part gilead strategy move dependency hiv business nearer term catalyst be expect be hepatitis drug sofosbuvir have perform excellently so far late stage trial analyst expect sofosbuvir stribild restart earning growth next few year ep expect rise year
3271,GILD,share gilead science gild hit time high friday biotech prepared report full year earning close monday stock have slip bit be trading friday afternoon
3272,GILD,analyst poll thomson reuter expect fairly slow quarter earning year quarter cent share sale rise report provide more clarity launch hiv drug stribild nickname quad combine different medicine be approve aug thus have only few week sale last earning report
3273,GILD,stock today have be help bloomberg article highlight gilead expansion oncology series acquisition deal be part gilead strategy move dependency hiv business nearer term catalyst be expect be hepatitis drug sofosbuvir have perform excellently so far late stage trial analyst expect sofosbuvir stribild restart earning growth next few year ep expect rise year share gilead science gild hit time high friday biotech prepared report full year earning close monday stock have slip bit be trading friday afternoon analyst poll thomson reuter expect fairly slow quarter earning year quarter cent share sale rise report provide more clarity launch hiv drug stribild nickname quad combine different medicine be approve aug thus have only few week sale last earning report stock today have be help bloomberg article highlight gilead expansion oncology series acquisition deal be part gilead strategy move dependency hiv business nearer term catalyst be expect be hepatitis drug sofosbuvir have perform excellently so far late stage trial analyst expect sofosbuvir stribild restart earning growth next few year ep expect rise year
3274,GILD,historically october month have scary reputation big stock market crash october be walk park follow midmonth sell september nasdaq composite sharply reversed course head higher second week october go set fresh new high nation best perform
3275,GILD,gilead science gild stock jump nearly morning trading thursday promising news blood cancer drug idelalisib
3276,GILD,late wednesday gilead announce have stop idelalisib clinical trial early have already proven positive risk benefit profile treatment chronic lymphocytic leukemia cll combine biogen idec biib rituxan idelalisib be already await fda approval hodgkin lymphoma gilead be continue test other used
3277,GILD,be obviously good news gilead analyst ponder implication pharmacyclic pcyc johnson johnson jnj ibrutinib be await fda approval cll be expect be blockbuster
3278,GILD,single agent ibrutinib appear more efficacious cll medacorp key opinion leader view combination datum date idelalisib ibrutinib rituxan be equivalent write leerink swann howard liang note thursday
3279,GILD,liang also say ibrutinib trial idelalisib trial be randomize mean gilead likely be able meet european union requirement pharmacyclic do
3280,GILD,analyst mark schoenebaum isi group write email client idelalisib start compete ibrutinib early month ibrutinib launch say current consensus forecast idelalisib indication be number likely go term
3281,GILD,schoenebaum note much depend yet be report datum toxicity duration treatment ibrutinib be particularly strong gilead hasn say release datum liang expect be american society hematology conference december
3282,GILD,pharmacyclic stock be morning trading thursday
3283,GILD,related analyst initiate coverage pharmacyclic bullish report gilead science gild stock jump nearly morning trading thursday promising news blood cancer drug idelalisib late wednesday gilead announce have stop idelalisib clinical trial early have already proven positive risk benefit profile treatment chronic lymphocytic leukemia cll combine biogen idec biib rituxan idelalisib be already await fda approval hodgkin lymphoma gilead be continue test other used be obviously good news gilead analyst ponder implication pharmacyclic pcyc johnson johnson jnj ibrutinib be await fda approval cll be expect be blockbuster single agent ibrutinib appear more efficacious cll medacorp key opinion leader view combination datum date idelalisib ibrutinib rituxan be equivalent write leerink swann howard liang note thursday liang also say ibrutinib trial idelalisib trial be randomize mean gilead likely be able meet european union requirement pharmacyclic do analyst mark schoenebaum isi group write email client idelalisib start compete ibrutinib early month ibrutinib launch say current consensus forecast idelalisib indication be number likely go term schoenebaum note much depend yet be report datum toxicity duration treatment ibrutinib be particularly strong gilead hasn say release datum liang expect be american society hematology conference december pharmacyclic stock be morning trading thursday related analyst initiate coverage pharmacyclic bullish report
3284,GILD,stock market shift growth have put tail wind american century ultra trail first second quarters russell growth index rise vs value counterpart be neck neck vs go tuesday accord russell investment
3285,GILD,gilead science gild hepatitis drug sofosbuvir win european advisory panel vote earlier wall street expect friday send stock more time high stock market today eu committee medicinal product human use chmp recommend approve sofosbuvir now brand sovaldi follow accelerate review procedure drug
3286,GILD,big pharma abbvie abbv beat analyst expectation friday send share highest point stock market spinoff abbott laboratory start year company sale rise beating analyst consensus profit be cent share best estimate cent
3287,GILD,food drug administration approve pharmacyclic pcyc cancer drug ibrutinib wednesday only clear disease company have apply treat
3288,GILD,fda approve drug now rename imbruvica treat mantle cell lymphoma rare form lymphoma currently treat celgene celg revlimid takeda velcade
3289,GILD,only second product be approve agency new breakthrough therapy designation allow decision be make only phase clinical trial instead however didn mention part pharmacyclic application ask approval chronic lymphocytic leukemia
3290,GILD,analyst michael yee speculate fda be wait datum ongoing clinical trial call resonate expect january make final decision cll
3291,GILD,recall think inclusion resonate datum actually be positive give physician randomize datum glaxosmithkline gsk ofatumamab base prescribe decision better attribution side effect drug write mail client say possible delay be immaterial estimate also note fda comment have include serious safety warning
3292,GILD,delay also leave bit more wiggle room gilead science gild cll candidate idelalisib reportedly do so well phase trial gilead end early last month
3293,GILD,drug be co market johnson johnson jnj division janssen pharmaceutical
3294,GILD,ibd report last month hope ibrutinib be blockbuster more double pharmacyclic stock price year now trade time high hit oct pharmacyclic stock be fraction morning trading stock market wednesday stock be afternoon trading fda news break food drug administration approve pharmacyclic pcyc cancer drug ibrutinib wednesday only clear disease company have apply treat fda approve drug now rename imbruvica treat mantle cell lymphoma rare form lymphoma currently treat celgene celg revlimid takeda velcade only second product be approve agency new breakthrough therapy designation allow decision be make only phase clinical trial instead however didn mention part pharmacyclic application ask approval chronic lymphocytic leukemia analyst michael yee speculate fda be wait datum ongoing clinical trial call resonate expect january make final decision cll recall think inclusion resonate datum actually be positive give physician randomize datum glaxosmithkline gsk ofatumamab base prescribe decision better attribution side effect drug write mail client say possible delay be immaterial estimate also note fda comment have include serious safety warning delay also leave bit more wiggle room gilead science gild cll candidate idelalisib reportedly do so well phase trial gilead end early last month drug be co market johnson johnson jnj division janssen pharmaceutical ibd report last month hope ibrutinib be blockbuster more double pharmacyclic stock price year now trade time high hit oct pharmacyclic stock be fraction morning trading stock market wednesday stock be afternoon trading fda news break
3295,GILD,stock stay positive territory continue hold session high thursday afternoon
3296,GILD,nasdaq be respectively meanwhile dow jone industrial average outperformed gain pfizer pfe be blue chip index best performer agree buy hospira hsp volume be run sharply lower board stock market today
3297,GILD,grubhub hub gap rally morning strong quarter result provider online mobile food order service post earning cent share cent view sale jump vs expectation better expect performance be drive strong growth diner daily average grub higher take rate write bmo capital market analyst edward william research note
3298,GILD,silicon motion technology simo rise time high now past buy point cup handle base chip designer be recently featured international leader
3299,GILD,armour ua lose more revere record high share be follow late wednesday news better expect result announcement couple acquisition
3300,GILD,restoration hardware rh reversed early gain fall fast trade share be more morning company report preliminary sale view stock stay positive territory continue hold session high thursday afternoon nasdaq be respectively meanwhile dow jone industrial average outperformed gain pfizer pfe be blue chip index best performer agree buy hospira hsp volume be run sharply lower board stock market today grubhub hub gap rally morning strong quarter result provider online mobile food order service post earning cent share cent view sale jump vs expectation better expect performance be drive strong growth diner daily average grub higher take rate write bmo capital market analyst edward william research note silicon motion technology simo rise time high now past buy point cup handle base chip designer be recently featured international leader armour ua lose more revere record high share be follow late wednesday news better expect result announcement couple acquisition restoration hardware rh reversed early gain fall fast trade share be more morning company report preliminary sale view
3301,GILD,johnson johnson jnj be set kick medical industry earning season open tuesday wall street seem be turn more bullish stock
3302,GILD,analyst be expect modest growth quarter drug giant consensus analyst poll thomson reuter call profit share year earlier quarter sale stock be trading flat afternoon trading monday have gain previous trading day analyst discuss prospect upcoming drug launch
3303,GILD,friday goldman sachs analyst jami rubin upgrade stock neutral sell note success several recent drug launch bode well simeprevir ibrutinib product currently await fda approval simeprevir be hepatitis drug eventually hope combine drug just acquire glaxosmithkline gsk form oral therapy hepatitis ibrutinib be treatment blood cancer develop pharmacyclic pcyc win breakthrough therapy designation fda speed review process
3304,GILD,good news gilead science gild rival idelalisib drug last week goldman sachs analyst navdeep singh set peak annual sale estimate ibrutinib
3305,GILD,most popular rating stock be still hold company have be face difficult macroeconomy even stock have climb start year rubin however write see bright term future pharmaceutical industry overall show sign converge red hot sibling biotech johnson johnson jnj be set kick medical industry earning season open tuesday wall street seem be turn more bullish stock analyst be expect modest growth quarter drug giant consensus analyst poll thomson reuter call profit share year earlier quarter sale stock be trading flat afternoon trading monday have gain previous trading day analyst discuss prospect upcoming drug launch friday goldman sachs analyst jami rubin upgrade stock neutral sell note success several recent drug launch bode well simeprevir ibrutinib product currently await fda approval simeprevir be hepatitis drug eventually hope combine drug just acquire glaxosmithkline gsk form oral therapy hepatitis ibrutinib be treatment blood cancer develop pharmacyclic pcyc win breakthrough therapy designation fda speed review process good news gilead science gild rival idelalisib drug last week goldman sachs analyst navdeep singh set peak annual sale estimate ibrutinib most popular rating stock be still hold company have be face difficult macroeconomy even stock have climb start year rubin however write see bright term future pharmaceutical industry overall show sign converge red hot sibling biotech
3306,GILD,stock be trading session high friday afternoon lead biotech stock such biogen idec biib regeneron pharmaceutical regn nasdaq rally putt striking distance nov peak rise also near nov record high dow jone industrial average be volume be mixed turnover
3307,GILD,shoe store chain foot locker fl clear buy point friday retail biotech stock pace list stock hit new high foot locker soar company sale earning beat expectation stock be buy range end just buy point cup handle base
3308,GILD,janssen pharmaceutical subsidiary johnson johnson jnj have acquire hepatitis drug candidate glaxosmithkline gsk janssen biotech partner medivir announce tuesday morning
3309,GILD,glaxo have develop drug gsk partnership vertex pharmaceutical vrtx never launch phase trial janssen however plan test combination simeprevir drug medivir janssen develop be await regulatory approval be used combination standard therapy interferon ribavirin accord press release janssen hope glaxo drug take place interferon cocktail
3310,GILD,whole point be jnj try develop oral possibly once daily hcv combo compete simplest easiest regimen write rbc capital market analyst michael yee client note
3311,GILD,yee view current simplest easiest regimen be gilead science gild sofosbuvir ribavirin also be fda review write news shouldn interfere expect strong launch sofosbuvir next year take least other competitor finish testing approval process
3312,GILD,market seem agree be trading cent stock market tuesday morning gilead have be slip hit time high be
3313,GILD,related offer steady stock janssen pharmaceutical subsidiary johnson johnson jnj have acquire hepatitis drug candidate glaxosmithkline gsk janssen biotech partner medivir announce tuesday morning glaxo have develop drug gsk partnership vertex pharmaceutical vrtx never launch phase trial janssen however plan test combination simeprevir drug medivir janssen develop be await regulatory approval be used combination standard therapy interferon ribavirin accord press release janssen hope glaxo drug take place interferon cocktail whole point be jnj try develop oral possibly once daily hcv combo compete simplest easiest regimen write rbc capital market analyst michael yee client note yee view current simplest easiest regimen be gilead science gild sofosbuvir ribavirin also be fda review write news shouldn interfere expect strong launch sofosbuvir next year take least other competitor finish testing approval process market seem agree be trading cent stock market tuesday morning gilead have be slip hit time high be related offer steady stock
3314,GILD,stock kick shorten week trading mixed performance tuesday friday year high nasdaq outperformed rise health care name especially biotech ethical drug do heavy lift once again add dow jone industrial average fall weigh coca cola ko share fall disappointing
3315,GILD,biotech gilead science gild beat analyst first quarter revenue expectation late thursday miss profit share dip fraction hour trading gilead say sale rise year quarter top analyst consensus profit exclude time item rise cent share cent short estimate quarter have
3316,GILD,gilead science gild be expect report quarter solid growth late thursday stock already elevated good drug news analyst poll thomson reuter expect gilead report first quarter profit cent share year revenue be estimate be strongest quarter
3317,GILD,biotech gilead science gild beat analyst first quarter revenue expectation late thursday miss profit share dip fraction hour trading gilead say sale rise year quarter top analyst consensus profit exclude time item rise cent share cent short estimate quarter have
3318,GILD,slew downgrade hit achillion pharmaceutical achn monday wake weekend bad news hepatitis pipeline achillion stock plunge nearly stock market midday trading monday almost year low late friday achillion announce fda have decide not lift clinical hold drug candidate
3319,GILD,johnson johnson offer investor first look state medical industry modestly beat consensus estimate raise guidance share rise nearly early trading eventually close fraction johnson johnson jnj make share year earlier quarter beating
3320,GILD,sometime early next year biotech pharmacyclic pcyc be expect launch first drug ibrutinib treat blood cancer go wall street expect be sweet vindication ceo robert duggan turnaround plan
3321,GILD,august food drug administration accept pharmacyclic application ibrutinib not only be approve designate breakthrough therapy agency create designation earlier year way drug represent substantial improvement exist therapy serious condition get approval process faster usual
3322,GILD,deadline approval
3323,GILD,promise speed fda still hasn set deadline decide approve ibrutinib
3324,GILD,analyst be generally expect decision come first quarter overwhelmingly expect answer be yes
3325,GILD,believe drug transform treatment many blood cancer analyst robyn karnauskas deutsche bank write report initiate coverage stock
3326,GILD,ibrutinib be follow other drug celgene celg revlimid biogen idec biib rituxan achieve blockbuster sale poorer efficacy less durability response poorer safety profile compare ibrutinib say
3327,GILD,karnauskas set sale estimate blockbuster say wall street estimate be too low consensus have be rise past month however stock
3328,GILD,trading nickel dime early pharmacyclic crested oct get catch recent biotech stock selloff
3329,GILD,be stock nadir september duggan take helm company co founder richard miller
3330,GILD,miller be highly respect biotech founding idec now merged biogen idec pharmacyclic lead drug candidate xcytrin brain cancer be turn fda
3331,GILD,duggan start investing pharmacyclic selling own startup computer motion intuitive surgical isrg have become board chairman tell ibd recent interview favore turn away xcytrin focuse class drug call bruton tyrosine kinase inhibitor pharmacyclic have acquire struggle genomic firm celera
3332,GILD,say think entirely possible world time strength drug ve license celera usher new era medicine truly become ally patient clinician don hurt process help duggan say
3333,GILD,patient median age
3334,GILD,be especially important patient chronic lymphocytic leukemia cll median age diagnosis be year
3335,GILD,accord karnauskas current treatment include rituxan offer patient trade toxicity effectiveness old age body have lot more trouble handle toxicity note phase study drug only newly diagnosed patient relapse patient have drop due adverse event even treatment go year
3336,GILD,good datum be still future duggan take pharmacyclic fact be so hard raise capital december march lend company own money
3337,GILD,unit be marketing partner
3338,GILD,trial result rolled however investor begin come also land company johnson johnson jnj janssen biotech marketing partner
3339,GILD,have objective company be build organization stay control pharmacyclic chief operate officer maky zanganeh tell ibd janssen be be really willing give control control control regulatory issue
3340,GILD,zanganeh point pharmacyclic be do drug manufacturing
3341,GILD,pharmacyclic current fda filing seek approval ibrutinib use second line treatment cll small lymphocytic lymphoma mantle cell lymphoma
3342,GILD,company be also testing diffuse large cell lymphoma multiple myeloma latter be disease make celgene fortune
3343,GILD,ibrutinib not be competition wednesday gilead science gild stop trial own cll candidate idelalisib early datum be already so good
3344,GILD,news briefly depress pharmacyclic stock analyst point still don have precise safety duration datum idelalisib
3345,GILD,friday goldman sachs analyst navdeep singh give ibrutinib vote confidence lift peak sale estimate year upgrading stock buy neutral sometime early next year biotech pharmacyclic pcyc be expect launch first drug ibrutinib treat blood cancer go wall street expect be sweet vindication ceo robert duggan turnaround plan august food drug administration accept pharmacyclic application ibrutinib not only be approve designate breakthrough therapy agency create designation earlier year way drug represent substantial improvement exist therapy serious condition get approval process faster usual deadline promise speed fda still hasn set deadline decide approve ibrutinib analyst be generally expect decision come first quarter overwhelmingly expect answer be yes believe drug transform treatment many blood cancer analyst robyn karnauskas deutsche bank write report initiate coverage stock ibrutinib be follow other drug celgene celg revlimid biogen idec biib rituxan achieve blockbuster sale poorer efficacy less durability response poorer safety profile compare ibrutinib say karnauskas set sale estimate blockbuster say wall street estimate be too low consensus have be rise past month however stock trading nickel dime early pharmacyclic crested oct get catch recent biotech stock selloff be stock nadir september duggan take helm company co founder richard miller miller be highly respect biotech founding idec now merged biogen idec pharmacyclic lead drug candidate xcytrin brain cancer be turn fda duggan start investing pharmacyclic selling own startup computer motion intuitive surgical isrg have become board chairman tell ibd recent interview favore turn away xcytrin focuse class drug call bruton tyrosine kinase inhibitor pharmacyclic have acquire struggle genomic firm celera say think entirely possible world time strength drug ve license celera usher new era medicine truly become ally patient clinician don hurt process help duggan say patient median age be especially important patient chronic lymphocytic leukemia cll median age diagnosis be year accord karnauskas current treatment include rituxan offer patient trade toxicity effectiveness old age body have lot more trouble handle toxicity note phase study drug only newly diagnosed patient relapse patient have drop due adverse event even treatment go year good datum be still future duggan take pharmacyclic fact be so hard raise capital december march lend company own money unit be marketing partnera trial result rolled however investor begin come also land company johnson johnson jnj janssen biotech marketing partner have objective company be build organization stay control pharmacyclic chief operate officer maky zanganeh tell ibd janssen be be really willing give control control control regulatory issue zanganeh point pharmacyclic be do drug manufacturing pharmacyclic current fda filing seek approval ibrutinib use second line treatment cll small lymphocytic lymphoma mantle cell lymphoma company be also testing diffuse large cell lymphoma multiple myeloma latter be disease make celgene fortune ibrutinib not be competition wednesday gilead science gild stop trial own cll candidate idelalisib early datum be already so good news briefly depress pharmacyclic stock analyst point still don have precise safety duration datum idelalisib friday goldman sachs analyst navdeep singh give ibrutinib vote confidence lift peak sale estimate year upgrading stock buy neutral
3346,GILD,gilead science gild miss analyst profit estimate report fourth quarter result late thursday edge sale
3347,GILD,biotech company best know hiv drug report net income cent share special item analyst have call average wall street whisper number be report be lower profit be cent share year earlier period
3348,GILD,sale rise compare analyst consensus estimate
3349,GILD,sale gilead most popular hiv drug atripla hit top analyst expectation rest hiv franchise fall short however include recently approve combination drug complera
3350,GILD,nonetheless observer expect more gilead new quad drug be food drug administration review
3351,GILD,isi group analyst mark schoenebaum also note research development expense be higher expect
3352,GILD,overall good top line quarter expense rise faster expect tell ibd email
3353,GILD,company say increase gaap expense be due primarily increase clinical activity expense associate acquisition collaboration continue advancement clinical pipeline
3354,GILD,conference call analyst gilead executive announce result hepatitis drug be present early march management say so far rate rapid virological response suppression virus first week treatment be ahead equivalent rate rival incivek
3355,GILD,gilead share initially hour earning release reversed news be
3356,GILD,gilead be digest acquisition pharmasset deal close jan buyout bring gilead hot new class hep treatment antiviral agent call gs rbc capital market analyst michael yee jan report note revenue forecast drug depend further trial result compare other drug arena
3357,GILD,thursday vertex pharmaceutical vrtx forecast incivek new hep drug rake year
3358,GILD,earning report gilead guide product sale do not include royalty other minor source revenue vs analyst estimate guide administrative cost tax rate high side
3359,GILD,preview note yee note analyst have widely vary opinion outlook due uncertainty factor be complera be launch europe few month
3360,GILD,drug treat hiv unpleasant neural side effect atripla isn effective patient high viral load
3361,GILD,thus quad perform strongly trial september hope shift drug remain be see fda act accept gilead application december set target review date aug
3362,GILD,hope gilead drug overall strength biotech sector fuel run gilead stock culminate year high early thursday think investor rapidly shift attention back pending hcv hepatitis virus datum away term financial result schoenebaum write gilead science gild miss analyst profit estimate report fourth quarter result late thursday edge sale biotech company best know hiv drug report net income cent share special item analyst have call average wall street whisper number be report be lower profit be cent share year earlier period sale rise compare analyst consensus estimate sale gilead most popular hiv drug atripla hit top analyst expectation rest hiv franchise fall short however include recently approve combination drug complera nonetheless observer expect more gilead new quad drug be food drug administration review isi group analyst mark schoenebaum also note research development expense be higher expect overall good top line quarter expense rise faster expect tell ibd email company say increase gaap expense be due primarily increase clinical activity expense associate acquisition collaboration continue advancement clinical pipeline conference call analyst gilead executive announce result hepatitis drug be present early march management say so far rate rapid virological response suppression virus first week treatment be ahead equivalent rate rival incivek gilead share initially hour earning release reversed news be gilead be digest acquisition pharmasset deal close jan buyout bring gilead hot new class hep treatment antiviral agent call gs rbc capital market analyst michael yee jan report note revenue forecast drug depend further trial result compare other drug arena thursday vertex pharmaceutical vrtx forecast incivek new hep drug rake year earning report gilead guide product sale do not include royalty other minor source revenue vs analyst estimate guide administrative cost tax rate high side preview note yee note analyst have widely vary opinion outlook due uncertainty factor be complera be launch europe few month drug treat hiv unpleasant neural side effect atripla isn effective patient high viral load thus quad perform strongly trial september hope shift drug remain be see fda act accept gilead application december set target review date aug hope gilead drug overall strength biotech sector fuel run gilead stock culminate year high early thursday think investor rapidly shift attention back pending hcv hepatitis virus datum away term financial result schoenebaum write
3363,GILD,gilead science gild gap early trading friday biotech report problematic trial result hepatitis drug development
3364,GILD,statement gilead say small study patient have fail respond interferon traditional hep treatment find most relapse course treatment gilead candidate gs
3365,GILD,gilead research head norbert bischofberger say datum suggest additional direct act antiviral be necessary effectively treat patient population
3366,GILD,ibd report back november gilead paid whopping acquire biotech create hope get lead race interferon free hep regimen think equity analyst marko kozul estimate sale drug
3367,GILD,then gilead stock have soar more aid good early result executive mentioned discuss gilead quarterly result steep valuation seem set fall anything go wrong gilead science gild gap early trading friday biotech report problematic trial result hepatitis drug development statement gilead say small study patient have fail respond interferon traditional hep treatment find most relapse course treatment gilead candidate gs gilead research head norbert bischofberger say datum suggest additional direct act antiviral be necessary effectively treat patient population ibd report back november gilead paid whopping acquire biotech create hope get lead race interferon free hep regimen think equity analyst marko kozul estimate sale drug then gilead stock have soar more aid good early result executive mentioned discuss gilead quarterly result steep valuation seem set fall anything go wrong
3368,GILD,gilead science gild miss analyst profit estimate report fourth quarter result late thursday edge sale
3369,GILD,biotech company best know hiv drug report net income cent share special item analyst have call average wall street whisper number be report be lower profit be cent share year earlier period
3370,GILD,sale rise compare analyst consensus estimate
3371,GILD,sale gilead most popular hiv drug atripla hit top analyst expectation rest hiv franchise fall short however include recently approve combination drug complera
3372,GILD,nonetheless observer expect more gilead new quad drug be food drug administration review
3373,GILD,isi group analyst mark schoenebaum also note research development expense be higher expect
3374,GILD,overall good top line quarter expense rise faster expect tell ibd email
3375,GILD,company say increase gaap expense be due primarily increase clinical activity expense associate acquisition collaboration continue advancement clinical pipeline
3376,GILD,conference call analyst gilead executive announce result hepatitis drug be present early march management say so far rate rapid virological response suppression virus first week treatment be ahead equivalent rate rival incivek
3377,GILD,gilead share initially hour earning release reversed news be
3378,GILD,gilead be digest acquisition pharmasset deal close jan buyout bring gilead hot new class hep treatment antiviral agent call gs rbc capital market analyst michael yee jan report note revenue forecast drug depend further trial result compare other drug arena
3379,GILD,thursday vertex pharmaceutical vrtx forecast incivek new hep drug rake year
3380,GILD,earning report gilead guide product sale do not include royalty other minor source revenue vs analyst estimate guide administrative cost tax rate high side
3381,GILD,preview note yee note analyst have widely vary opinion outlook due uncertainty factor be complera be launch europe few month
3382,GILD,drug treat hiv unpleasant neural side effect atripla isn effective patient high viral load
3383,GILD,thus quad perform strongly trial september hope shift drug remain be see fda act accept gilead application december set target review date aug
3384,GILD,hope gilead drug overall strength biotech sector fuel run gilead stock culminate year high early thursday think investor rapidly shift attention back pending hcv hepatitis virus datum away term financial result schoenebaum write gilead science gild miss analyst profit estimate report fourth quarter result late thursday edge sale biotech company best know hiv drug report net income cent share special item analyst have call average wall street whisper number be report be lower profit be cent share year earlier period sale rise compare analyst consensus estimate sale gilead most popular hiv drug atripla hit top analyst expectation rest hiv franchise fall short however include recently approve combination drug complera nonetheless observer expect more gilead new quad drug be food drug administration review isi group analyst mark schoenebaum also note research development expense be higher expect overall good top line quarter expense rise faster expect tell ibd email company say increase gaap expense be due primarily increase clinical activity expense associate acquisition collaboration continue advancement clinical pipeline conference call analyst gilead executive announce result hepatitis drug be present early march management say so far rate rapid virological response suppression virus first week treatment be ahead equivalent rate rival incivek gilead share initially hour earning release reversed news be gilead be digest acquisition pharmasset deal close jan buyout bring gilead hot new class hep treatment antiviral agent call gs rbc capital market analyst michael yee jan report note revenue forecast drug depend further trial result compare other drug arena thursday vertex pharmaceutical vrtx forecast incivek new hep drug rake year earning report gilead guide product sale do not include royalty other minor source revenue vs analyst estimate guide administrative cost tax rate high side preview note yee note analyst have widely vary opinion outlook due uncertainty factor be complera be launch europe few month drug treat hiv unpleasant neural side effect atripla isn effective patient high viral load thus quad perform strongly trial september hope shift drug remain be see fda act accept gilead application december set target review date aug hope gilead drug overall strength biotech sector fuel run gilead stock culminate year high early thursday think investor rapidly shift attention back pending hcv hepatitis virus datum away term financial result schoenebaum write
3385,GILD,smart beta exchange trade fund invesco zack multus asset income etf cvy free report debut offer broad exposure total market etfs category equity market be smart beta etfs product be base market cap weight index be strategy design reflect specific market segment market whole have traditionally dominate etf industry market cap weight index work great investor believe market efficiency provide low cost convenient transparent way replicate market return re kind investor rather try beat market good stock selection then smart beta fund be best choice fund class be know tracking cap weight strategy cap weight index try choose stock have better chance risk return performance be base specific fundamental characteristic mix other such characteristic space offer number choice investor include simplest equal weighting fundamental weighting volatility momentum base weighting methodology not strategy have be able deliver superior result fund sponsor indexcvy be manage invesco fund have amassed make larger etfs total market etfs fee expense particular fund seek match performance zack multus asset income index zack multus asset income index be comprise approximately stock select base multus factor proprietary model universe domestic international company include list common stock adrs pay dividend reit mlp close end fund traditional prefer stock cost other expensessince cheaper fund tend produce better result more expensive fund assume other factor remain equal be important investor pay attention etf expense ratio operate expense annual basis be etf make par most peer product space fund have month trail dividend yield sector exposure top holdingsetfs offer diversify exposure thus minimize single stock risk be still important delve fund holding investing most etfs be very transparent product many disclose holding daily basis look individual holding darden restaurant inc dri free report account fund total asset follow citigroup inc free report gilead science inc gild free report top holding account total asset management performance riskcvy have gain so far year be last year past week period fund have trade etf have beta standard deviation trail year period holding effectively diversify company specific risk bottom lineto learn more product other etfs screen product match investment objective read article latest development etf investing universe please visit zack etf center
3386,GILD,biogen inc biib free report be star performer friday trading session stock rally much close little lower rise day trade massive gain biotech firm come encourage phase clinical study datum alzheimer treatment final analysis month patient phase clinical study ban early alzheimer disease demonstrated statistically significant slow cognitive decline reduction amyloid beta accumulate brain company press release amyloid beta protein fragment be find brain patient suffering disease believe cause alzheimer be most common form dementia affect person worldwide accord alzheimer association currently be treatment disease way stop progression however food drug administration have approve medication treat symptom related memory loss language other thought process see healthcare etfs here such result mark important milestone company quest tackle alzheimer disease fact analyst welcome news first trial study drug be disappointing result risk environment many investor pull capital high growth high beta sector other large cap biotech stock also gain gilead gild free report celgene celg free report amgen amgn free report suggest investor be pin hope fast grow company see trading come day etf trading stock world also send biotech etfs space green day particular ishare nasdaq biotechnology etf ibb free report steal show climb follow more gain first trust amex biotechnology index fbt free report invesco dynamic biotechnology genome etf pbe free report vaneck vector biotech etf bbh free report fund provide exposure firm tracking nasdaq biotechnology index biogen take top spot ibb be most popular fund be biotech space aum expense ratio come ibb have zack etf rank hold high risk outlook read small cap biotech etfs be soar fund follow nyse arca biotechnology index measure performance company biotechnology industry be primarily involved use biological process develop product provide service hold security basket biogen occupy fifth position share charge bps annual fee have accumulate asset base have zack etf rank buy high risk outlook read sector etfs crushed year bull run fund provide exposure firm tracking dynamic biotech genome intellidex index biogen take top spot asset etf have manage asset base charge expense ratio have zack etf rank high risk outlook read pharma biotech etfs soar trump drug plan fund offer exposure large biotechnology corporation tracking mvis list biotech index here biogen be fifth firm accounting share bbh have amassed asset base charge bps fee year have zack etf rank strong buy high risk outlook lie ahead uptrend sector be likely continue year tax reform rise positive regulatory backdrop read top rank sector etfs buy new tax legislation have entice large pharmaceutical company bring offshore cash back home reduce tax rate instead prior repatriate money lead increase merger acquisition activity share buyback dividend additionally slower growth mature drug have also compel prominent biotechs acquire smaller one even hefty premium promising pipeline further trump most await plan lower drug price have add strength be not enough sector cyclical nature be advantage current market be ruffle trade war fear china unite state well geopolitical tension want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
3387,GILD,several major biotech stock rally friday biogen biib free report report positive result phase study ban therapy seek reduce toxic amyloid protein associate cognitive decline alzheimer disease share biogen be more afternoon trading hour thursday japan eisai co esaly free report partner ban development see gain nearly momentum be enough lift rest biotech space evidence ishare nasdaq biotechnology index fund ibb free report add biotech giant biogen celgene celg free report amgen amgn free report gilead gild free report have underperform broader nasdaq index past year industry likely need positive news spark optimistic trading speaking street real money column atlantic equity analyst steve chesney say investor finally be notice value effort company be believe innovation company biogen come report positive clinical result disease alzehimer imply probability success rest industry pipeline move little bit higher chesney tell street celgene share add touch intraday month high meanwhile amgen moved higher gilead gain more biogen latest test include patient early alzheimer disease company share positive result group period month nevertheless trial be still only phase challenge phase additional regulatory hurdle be still loom still biogen hope commercialize ban timely manner new product likely inspire positive analyst sentiment lift growth prospect come year past month zack consensus estimate biogen earning have drop share share mark year year growth early estimate have company earning peg share represent increase year project total biib be currently sporting zack rank hold medical biomedical genetic industry be sit bottom zack industry rank want more market analysis author make sure follow ryan_mcqueeney twitter make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3388,GILD,be pretty low key week biotech sector not too many major update key news gilead gild free report car therapy win chmp positive opinion keryx kerx free report plunge merger news recap important story gilead car therapy get positive chmp opinion gilead announce european medicine agency ema committee medicinal product human use chmp have issue positive opinion company marketing authorization application maa car therapy axicabtagene ciloleucel treatment adult patient relapse refractory diffuse large cell lymphoma dlbcl primary mediastinal large cell lymphoma pmbcl more line systemic therapy axicabtagene ciloleucel chimeric antigen receptor cell car therapy modify patient own cell recognize attack cancer cell agency have grant prime status axicabtagene ciloleucel tentative approval be card ema generally take chmp recommendation account review maa note axicabtagene ciloleucel be approve fda october yescarta approval europe boost growth prospect therapy give market potential information provide company be estimate patient dlbcl be refractory have relapse more line therapy be eligible car therapy europe read more gilead car therapy get positive chmp opinion amgen announce result remicade biosimilar migraine drug amgen inc amgn free report announce result phase iii study evaluate efficacy safety biosimilar candidate abp brand drug remicade result confirm abp be inferior compare remicade base primary endpoint be assessment acr week acr american college rheumatology criterium be used measure effectiveness various arthritis medicine clinical study acr score mean person ra have improve remicade be approve treatment moderate severe rheumatoid arthritis chronic severe plaque psoriasis moderate severe crohn disease moderate severe ulcerative colitis psoriatic arthritis ankylose spondylitis note amgen have broad portfolio biosimilar be approve unite state be approve european union addition amgen announce encourage result open label extension ole study migraine drug aimovig result year study chronic migraine patient reinforce establish safety efficacy profile aimovig long term use moreover year interim analysis ongoing year study episodic migraine patient also reinforce long term safety tolerability aimovig amgen carry zack rank buy see complete list today zack rank strong buy stock here celgene report positive datum celgene corporation celg free report partner acceleron pharma xlrn free report announce positive top line result phase iii multus center study medalist evaluate efficacy safety versus placebo patient very low low intermediate risk myelodysplastic syndrome mds chronic anemia refractory intolerant ineligible treatment erythropoietin stimulating agent esa ring sideroblast positive require frequent red blood cell rbc transfusion study show achieve highly statistically significant improvement primary endpoint red blood cell rbc transfusion independence least consecutive week first week compare placebo candidate also meet key secondary endpoint demonstrate highly statistically significant improvement rbc transfusion independence least consecutive week first week study also achieve modify hematologic improvement erythroid iwg mhi meaningful secondary endpoint regulatory submission be plan unite state europe first half read more celgene meet primary endpoint study keryx plunge merger deal akebia share keryx inc plunge follow announcement definitive merger agreement akebia therapeutic inc akba free report company have agree combine stock merger form new fully integrate company focuse chronic kidney disease ckd call akebia therapeutic deal be expect close end keryx already have fda approve drug auryxia kitty akebia have late stage candidate pipeline however investor be not much impressed merger news share company fall read more keryx inks merger deal akebia share fall cara therapeutic rally positive result share cara therapeutic inc cara free report soar company announce positive top line datum adaptive phase ii iii trial intravenous iv cr patient undergo abdominal surgery iv form cr achieve statistical significance study primary endpoint pain relief hour auc period post surgery combine surgery mcg kg dose addition treatment same also result statistically significant reduction secondary endpoint incidence nausea vomit hour post surgery mcg dose respectively datum demonstrate overall benefit cr provide pain relief surgery type hour post surgery reduce post operative nausea vomit significant medical need post operative set brand name drug be korsuva company have earlier inked licensing deal fresenius medical care renal pharma ltd license worldwide right commercialize korsuva cr difelikefalin injection treatment chronic kidney disease biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock vertex have gain past month celgene have lose vertex have gain see last biotech stock roundup here biotech stock roundup pbyi soar mack crash gild biktarvy get ec nod next biotech stay tune regulatory update pipeline development news today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3389,GILD,biotech bigwig gilead science inc gild free report develop drug treatment human virus hiv liver disease such chronic hepatitis virus hcv infection chronic hepatitis virus hbv infection cardiovascular hematology oncology inflammation respiratory disease hcv franchise boast drug sovaldi harvoni recently launch epclusa however hcv franchise continue grapple competitive pricing pressure lead massive decline harvoni sovaldi sale harvoni sovaldi have be face competition abbvie abbv free report viekira pak merck mrk free report zepatier other gilead be dominant player hiv market impressive portfolio same company be first bring market single tablet regimen str treatment hiv atripla strs hiv market include complera eviplera stribild other newly launch tenofovir alafenamide taf base product genvoya odefsey descovy be perform well strong adoption unite state europe genvoya have already become most prescribe regimen treatment naïve switch patient launch november also genvoya have be list prefer regimen several hiv treatment guideline taf base regimen now represent total gilead hiv prescription volume follow launch genvoya launch odefsey descovy zack consensus estimate sale genvoya be truvada use pre exposure prophylaxis set also put strong performance company see significant uptick prep usage approximately patient used truvada end note hiv be primary area focus gilead company be work bring new hiv treatment market further boost sale franchise company receive major boost fda approve company once daily str biktarvy bictegravir mg emtricitabine mg tenofovir alafenamide mg bic ftc taf hiv infection approval provide major boost gilead hiv franchise biktarvy combine novel unboosted integrase strand transfer inhibitor insti bictegravir demonstrated safety efficacy profile descovy ftc taf dual nucleoside reverse transcriptase inhibitor nrti backbone be smallest insti base triple therapy str available approval new hiv therapy stiff competition glaxosmith gsk free report exist therapy tivicay triumeq gilead stock have return last month compare industry loss gilead have decent track record company earning beating estimate last miss last report quarter company earning beat expectation overall company record average positive earning surprise expect strength hiv franchise offset hcv franchise weakness make highly likely company beat earning first quarter read more be beat card gilead earning zack rankgilead currently carry zack rank buy see complete list today zack strong buy rank stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3390,GILD,value investing be easily most popular way find great stock market environment wouldn want find stock be fly radar be compelling buy offer tantalize discount compare fair value way find company be look several key metric financial ratio many be crucial value stock selection process let put gilead science inc gild free report stock equation find be good choice value oriented investor right now investor subscribe methodology look elsewhere top pick pe ratioa key metric value investor always look be price earning ratio pe short show much investor be willing pay dollar earning give stock be easily most popular financial ratio world best use pe ratio be compare stock current pe ratio ratio have be past compare average industry sector compare market whole front gilead science have trail month pe ratio see chart level actually compare pretty favorably market large pe stand focus long term pe trend gilead science current pe level put midpoint past year number have rise rapidly past few month further stock pe also compare favorably broader industry trail month pe ratio stand very least indicate stock be relatively undervalue right now compare peer also point gilead science have forward pe ratio price relative year earning just be tad higher current level so be fair expect increase company share price term ratioanother key metric note be price sale ratio approach compare give stock price total sale lower read be generally consider better person metric more other value focuse one look sale something be far harder manipulate accounting trick earning right now gilead science have ratio be marginally average come right now however see chart be well high stock particular past few year anything gild be lower end range time period metric suggest level undervalue trading least compare historical norm broad value outlookin aggregate gilead science currently have value score putt top stock cover look make gilead science solid choice value investor stock overall gilead science be good choice value investor be plenty other factor consider investing name particular be worth note company have growth score momentum score give gild zack vgm score overarch fundamental grade read more zack style score here meanwhile company recent earning estimate have be stable significant revision current quarter full year estimate last month have have just small impact consensus estimate current quarter consensus estimate remain stable past month full year estimate have inched upper see consensus estimate trend recent price action stock chart gilead science inc price consensus gilead science inc price consensus gilead science inc stock have just zack rank hold be look line performance company term bottom linegilead science be inspire choice value investor be hard beat incredible lineup statistic front however sluggish industry rank bottom more industry zack rank be hard get too excited company overall fact past year broader industry have clearly underperform market large see so value investor want estimate analyst sentiment turn name first once happen stock be compelling pick look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3391,GILD,novartis ag nvs free report announce intend spinoff ophthalmology division alcon separately trade standalone company order grow medicine company solely be novartis spin alcon alcon business wasn perform management expectation do revive company decide spin same order focus better legacy drug business remind investor novartis acquire alcon business then comprise surgical vision care ophthalmic pharmaceutical january novartis undertake strategic review business consequently transfer alcon ophthalmic pharmaceutical novartis innovative medicine division business generate sale also hold potential blockbuster candidate rth brolucizumab be be evaluate neovascular amd diabetic macular edema novartis plan retain ophthalmic pharmaceutical part pharmaceutical portfolio novartis have be contemplate alcon future quite time now consider divestment spin alcon division now comprise only surgical vision care generate sale new company employ more employee mike ball become chairman designate alcon effective jul ball report vas ceo novartis ball focus prepare alcon intend spin addition start process recruit board director bod alcon meeting novartis shareholder other potential investor preparation potential spin david endicott chief operate officer coo alcon july be promote ceo alcon also effective jul transaction be expect be tax neutral novartis spin be expect be complete first half subject general market condition tax ruling opinion final board endorsement shareholder approval agm february novartis gain novartis have strong oncology portfolio drug afinitor exjade jakavi zykadia tasigna jadenu kisqali continue boost sale however be face loss patent protection key drug consequently company have refocuse business plan focus build portfolio market promise potential novartis share have decline year so far compare industry decline novartis be look solidify presence gene therapy space recently acquire base clinical stage gene therapy company avexis inc earlier novartis announce licensing agreement spark therapeutic once free report cover development registration right voretigene neparvovec outside unite state plan share company announce initiate share buyback program buyback be conduct use proceed divestment consumer health joint venture stake glaxosmithkline gsk free report make payment avexis acquisition other novartis announce obtain positive opinion committee medicinal product human use chmp european medicine agency ema recommend approval car therapy kymriah cell malignancy cell acute lymphoblastic leukemia be refractory relapse post transplant second later relapse patient year age diffuse large cell lymphoma dlbcl be relapse refractory more line systemic therapy adult kymriah be novel time treatment used patient own cell fight cancer be already approve unite state rival company gilead science gild free report car therapy have also win chmp positive opinion treatment adult patient relapse refractory diffuse large cell lymphoma dlbcl primary mediastinal large cell lymphoma pmbcl more line systemic therapy zack ranknovartis carry zack rank sell see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3392,GILD,immune design corp imdz free report isschedule report first quarter result market close last report quarter company deliver positive earning surprise immune design top earning estimate trail quarters average beat immune design share have lose year date compare industry fall let see thing be shape announcement factor playbee development stage company immune design have not generate product revenue yet earn revenue collaboration licensing agreement product sale investor remain focuse company progress base pipeline candidate immune design be develop multiple candidate used discovery platform zvex glaas treatment various type cancer company key pipeline candidate be cmb solid tumor merkel cell carcinoma mcc cmb have be design prime boost approach involve sequential dose complementary agent lv currently candidate be be evaluate soft tissue sarcoma patient monotherapy phase combination roche hold rhhby tecentriq phase ii company plan initiate pivotal phase iii trial study cmb monotherapy synovial sarcoma patient mid progression free survival endpoint be meet company intend file biologic license application seek approval cmb treatment synovial sarcoma discussion fda be positive regard cmb consequently company have plan initiate pivotal phase iii trial study cmb monotherapy synovial sarcoma patient study be expect start mid enroll patient age older ny eso synovial sarcoma receive cmb monotherapy placebo progression free survival endpoint be meet company intend file biologic license application seek approval cmb treatment synovial sarcoma meanwhile be be evaluate multiple clinical trial include monotherapy local radiation complete phase study patient mcc ongoing investigator sponsored trial patient sarcoma be also be develop monotherapy combination therapy patient follicular hodgkin lymphoma nhl randomize phase ib ii study october receive orphan drug designation treatment follicular nhl european medicine agency potential approval pipeline candidate be boost company earning call expect immune design shed light progress ongoing trial model proven model do not show earning beat immune design quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate however be not case here see zack esp immune design have earning esp be most accurate estimate zack consensus estimate be peg loss cent uncover best stock buy sell re report earning esp filter zack rank immune design have zack rank increase predictive power esp however need have positive esp be confident earning beat conversely caution sell rate stock go earning announcement especially company be see negative estimate revision immune design corp price ep surprise immune design corp price ep surprise immune design corp quotestock warrant lookhere be biotech stock want consider model show have right combination element post earning beat quarter pfizer inc pfe free report be schedule release result company have earning esp zack rank see complete list today zack rank stock here gilead science inc gild free report be schedule release result company have earning esp zack rank celgene corporation celg free report be schedule release result company have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3393,GILD,gilead science gild free report enter research collaboration license agreement hookipa biotech ag agreement gilead own exclusive right hookipa therat vaxwave arenavirus vector base immunization technology major chronic infectious disease indication hepatitis virus hbv human virus hiv research work be carry hookipa manufacture arenavirus base vector clinical development gilead exchange gilead provide upfront payment addition hookipa be eligible receive payment total more base achievement specify development regulatory commercial milestone moreover gilead fund research development activity hookipa also be eligible receive tiered royalty net sale agreement further expand relationship hookipa gilead follow gilead participation hookipa series financing dec hookipa unique therapeutic vaccine technology demonstrated excellent safety immunogenicity phase study gilead be banking hiv franchise drive growth future give persistent decline hcv sale gilead stock have lose last month industry loss gilead hcv franchise witness slowdown key market include unite state europe reflect lower sale harvoni sovaldi result competitive pricing pressure franchise see significant plunge sale due new competition fewer patient start pricing have largely stabilize market share stabilize mid patient start be expect decline further note harvoni sovaldi epclusa face competition abbvie abbv free report viekira pak mayret merck mrk free report zepatier other meanwhile gilead be look newer avenue help top line solidify presence gene therapy space initial uptake yescarta be also encourage gilead be also intend foray nash market pipeline candidate selonsertib filgotinib first quarter gilead announce agreement sangamo therapeutic inc sgmo free report use sangamo zinc finger nuclease technology platform development next generation ex vivo cell therapy oncology zack rankgilead currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3394,GILD,expect vertex pharmaceutical inc vrtx free report beat expectation report first quarter result apr market close vertex share have increase so far year industry have record decrease vertex track record have be impressive so far company deliver positive earning surprise last quarters average positive earning surprise last quarters be last report quarter vertex come positive surprise let see thing be shape quarter factor playvertex cystic fibrosis cf drug kalydeco orkambi perform consistently sale rise almost expect positive trend continue soon be report quarter however company announce last quarter earning call first quarter revenue be unfavorably impact higher gross net revenue adjustment buildup channel inventory fourth quarter january vertex announce extension marketing application orkambi be approve europe approval orkambi marketing label eu now include use child cf age year have copy del mutation expand patient population expand patient population be expect boost sale drug zack consensus estimate orkambi sale first quarter be kalydeco receive approval line extension include patient year older certain residual mutation cftr gene drug generate significant sale last year due rapid uptake expand patient population expect trend continue zack consensus estimate first quarter kalydeco sale be peg millionin boost vertex cf franchise fda approve vertex third cf drug symdeko be combination tezacaftor ivacaftor february drug be review europe however expect new drug contribute minimally first quarter sale expect company provide update symdeko plan initial uptake company remain focuse development triple combination regimen quarter vertex advanced vx vx phase iii development also phase iii study be initiate evaluate vx combination tezacaftor kalydeco ivacaftor cf patient investor focus call be triple combination cf regimen be crucial long term growth vertex company be also likely provide full year revenue guidance include symdeko sale call however operate expense be likely be higher side due initiation pivotal study launch symdeko likely positive surprise proven model indicate vertex be likely beat earning estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate cent zack consensus estimate cent stand be lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank vertex have zack rank combination positive earning esp favorable zack rank make reasonably confident earning beat conversely caution sell rate stock go earning announcement especially company be see negative estimate revision vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate quoteother stock considerhere be biotech stock also want consider model show have right combination element post earning beat quarter celgene corporation celg free report be schedule release result company have earning esp zack rank see complete list today zack rank stock here amgen inc amgn free report be schedule release result apr company have earning esp zack rank gilead science inc gild free report be schedule release result company have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3395,GILD,alexion pharmaceutical inc alxn free report be schedule report first quarter result apr open bell last quarter company earning surpass zack consensus estimate also alexion track record be excellent have consistently top estimate last quarters average positive earning surprise alexion share have underperform industry past year stock have lose compare industry decline do zack model unveil proven model show alexion be likely beat earning be report quarter have right combination key ingredient positive earning esp zack rank strong buy buy hold have significantly higher chance beating estimate zack esp alexion have earning esp most accurate estimate be zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank alexion zack rank combine positive esp make reasonably confident earning beat see complete list today zack rank stock here note sell rate stock zack rank never be consider go earning announcement let see thing be shape announcement factor likely impact resultsalexion blockbuster drug soliris continue perform well alexion continue identify treat consistently high number new patient paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus soliris country operate platform alexion be work expand soliris label additional indication fda recently approve drug treatment refractory generalized myasthenia gravis gmg patient be acetylcholine receptor antibody positive drug be approve europe indication approximately patient be expect have gmg unite state additionally phase iii study prevent soliris patient relapse neuromyelitis optica spectrum disorder be ongoing enrollment be complete datum expect mid label expansion additional indication give soliris access higher patient population increase commercial potential drug significantly zack consensus estimate soliris hint drug sale increase year quarter alexion recently announce acquire sweden base wilson therapeutic transaction be expect close second quarter acquisition add late stage candidate wtx alexion pipeline candidate be currently phase iii treatment wilson disease rare genetic disorder alexion be look diversify portfolio reduce dependence blockbuster drug soliris deal strengthen alexion rare disease pipeline late stage candidate company plan focus rare disease business core area hematology nephrology neurology metabolic disorder enhance productivity alexion reduce spending headcount associate previously announce prioritize pipeline program well optimize additional expense company plan relocate headquarters boston mid approximately position result restructure plan company reduce global workforce approximately company expect increase financial flexibility allow reinvest approximately annually alexion expect pretax saving approximately meantime company effort develop pipeline be impressive particularly case alxn currently be evaluate alxn longer act antibody inhibit terminal complement phase iii study pnh ahus tentative approval pnh be expect patient be also be dose phase iii trial alxn administer intravenously week complement inhibitor treatment naive adolescent adult patient ahus company be expect complete enrollment second quarter announce result fourth quarter alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc quoteother stock warrant lookhere be biotech stock want consider model show too have right combination element post earning beat quarter pfizer inc pfe free report be schedule release result company have earning esp zack rank abbvie inc abbv free report be schedule release result apr company have earning esp zack rank gilead science inc gild free report be schedule release result company have earning esp zack rank today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3396,GILD,healthcare space have be tough journey year popular etf health care select sector spdr fund xlv free report have shed so farwhile vanguard health care etf vht free report fidelity msci health care index etf fhlc free report have gain least meanwhile ishare healthcare etf iyh free report have add mixed trend be likely continue head earning season big name pfizer pfe free report merck mrk free report amgen amgn free report abbvie abbv free report gilead science gild free report bristol myer squibb bmy free report be line report week next stock collectively account share xlv iyh vht fhlc read healthy earning unitedhealth etfs watch let dig deeper earning picture company drive performance mentioned fund come day accord methodology zack rank strong buy buy hold combine positive earning esp increase chance predict earning beat zack rank sell rate be best avoid uncover best stock buy sell re report earning esp filter surprise prediction stockspfizer have zack rank earning esp indicate higher chance beating estimate quarter stock have see positive earning estimate revision cent be report quarter deliver average positive earning surprise past quarters have vgm score pfizer be schedule report earning open bell merck be expect report result market open have zack rank earning esp stock deliver positive earning surprise last quarters average beat witness positive earning estimate revision cent past day be report quarter merck have vgm score amgen carry zack rank have earning esp indicate reasonable chance beating estimate time earning surprise track past quarters be strong average positive surprise addition amgen witness positive earning estimate revision cent past day quarter be report stock have solid vgm score amgen report earning apr market close read small cap biotech etfs be soar abbvie have zack rank earning esp company deliver positive earning surprise last quarters average beat see solid earning estimate revision cent past month be report quarter stock have solid vgm score company be schedule report apr open bell gilead be expect release earning market close have zack rank earning esp gilead deliver positive earning surprise last quarters see negative earning estimate revision penny past month be report quarter have vgm score bristol myer likely report earning apr open bell have zack rank earning esp stock deliver average positive earning surprise past quarter witness positive earning estimate revision cent be report quarter have vgm score sum earning surprise well card healthcare sector be expect witness earning growth first quarter suggest upside healthcare etfs particular etfs have zack etf rank see healthcare etfs here want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
3397,GILD,investor biotech sector be glue last week highly await annual meeting american society clinical oncology asco overshadowed usual regulatory other update space meeting hold chicago jun jun provide company platform showcase datum scientist physician investment community other focus be mainly asco datum company biogen biib free report vertex vrtx free report remain limelight pipeline update recap important story biogen eisai report encourage datum elenbecestat biogen partner eisai announce encourage result alzheimer candidate elenbecestat bace inhibitor phase ii study study study be multicenter randomize double blind placebo controlled parallel group month study patient mild cognitive impairment mci due alzheimer disease mild moderate dementia due alzheimer disease confirm amyloid pathology pet positron emission tomography screening patient be randomize treatment arm receive elenbecestat mg placebo daily more half patient elenbecestat mg mg arm be switch mg arm month more datum show elenbecestat be generally safe well tolerate result demonstrated statistically significant difference amyloid beta aβ level brain measure amyloid pet suggest delay clinical symptom decline exploratory endpoint eisai biogen be jointly develop elenbecestat march company be currently conduct global phase iii study mission ad early alzheimer disease biogen currently carry zack rank hold see complete list today zack rank strong buy stock here vertex crispr sickle cell disease candidate put hold vertex pharmaceutical incorporate crispr therapeutic announce fda have place clinical hold investigational new drug application ind ctx treatment sickle cell disease pending resolution certain question raise fda company have submit ind fda april support plan initiation phase ii trial unite state adult patient sickle cell disease ctx be experimental gene edit autologous hematopoietic stem cell therapy be also be evaluate patient suffering thalassemia sickle cell disease fda clinical hold company plan initiate phase ii trial ctx europe adult patient transfusion dependent thalassemia crispr vertex equally share research development cost profit worldwide ctx read more vertex crispr sickle disease candidate put hold fda sarepta get negative chmp opinion exondys sarepta therapeutic inc srpt free report announce committee medicinal product human use chmp european medicine agency ema have adopt negative opinion duchenne muscular dystrophy dmd candidate exondys eteplirsen negative opinion be expect follow oral explanation trend vote consequently sarepta request re examination opinion result assignment new rapporteur co rapporteur additionally sarepta request scientific advisory group sag dmd be call turn allow neuromuscular specialist provide expert guidance insight other thing validity external control used importance certain functional endpoint re examination be complete end finally look asco result celgene celg free report have multiple presentation oncology drug revlimid pomalyst other experimental therapy american society clinical oncology asco annual meeting chicago il result transcend study experimental cd direct car cell therapy candidate lisocabtagene maraleucel liso cel jcar patient relapse refractory aggressive cell hodgkin lymphoma nhl be encourage read more celgene present datum car therapy revlimid pomalyst regeneron regn free report partner sanofi also announce datum trial evaluate cemiplimab advanced cutaneous squamous cell carcinoma asco datum study show patient treat cemiplimab experience robust tumor effect cemiplimab treat patient show response rate median observed time response month datum cut date gilead gild free report kite also announce result ongoing phase study asco show clinical response be observed investigational cell receptor tcr cell therapy target human papillomavirus type hpv solid tumor cancer cause hpv meanwhile gilead have also collaborate hookipa biotech ag obtain exclusive right hookipa therat vaxwave arenavirus vector base immunization technology major chronic infectious disease indication hepatitis virus hbv human virus hiv gilead partner galapago nv also announce phase ii study equator pipeline candidate filgotinib achieve primary endpoint improvement sign symptom psoriatic arthritis week amgen amgn free report also announce result phase iii trial asco show kyproli administer once weekly mg dexamethasone achieve superior progression free survival pfs overall response rate orr compare twice weekly kyprolisat mg dexamethasone twice weekly kd patient relapse refractory multiple myeloma separately share amgen be fda approve biosimilar blockbuster drug neulasta biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock gilead gain past month celgene have lose alexion have gain see last biotech stock roundup here biotech stock roundup gild epclusa china approval bmrn palynziq fda nod next biotech stay tune regulatory update pipeline development news today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3398,GILD,expect bristol myer squibb company bmy free report beat expectation report first quarter result apr market open bristol myer share have decrease so far year compare industry decline bristol myer track record have be mixed so far company deliver positive earning surprise last quarters miss expectation once average positive earning surprise last quarters be last report quarter bristol myer deliver positive surprise let see thing be shape quarter drive growth bristol myer blockbuster immuno oncology drug opdivo be expect remain main sale driver first quarter follow several line extension soon be report quarter company announce encourage result phase iii study evaluate opdivo first line small cell lung cancer opdivo combination yervoy significantly improve progression free survival patient compare chemotherapy potential approval indication be significant boost drug give immense scope lung cancer market zack consensus estimate drug sale first quarter be peg january european commission approve label expansion yervoy injection pediatric patient year age older unresectable metastatic melanoma fda approve drug indication july zack consensus estimate drug sale quarter be november fda approve line extension sprycel pediatric patient ph chronic myeloid leukemia chronic phase drug register growth previous quarter be expect receive boost quarter due expand label zack consensus estimate sprycel sale stand cardiovascular drug eliquis come strong performance sale grow year year sale be expect remain robust first quarter too zack consensus estimate eliquis sale be peg other hand decline hepatitis franchise be expect continue due intense competition multiple drug include epclusa label be expand include hiv co infection august moreover hiv business continue face competitive pressure recent launch other company same space be expect further impact sustiva franchise zack consensus estimate hepatitis franchise sale be peg quarter year quarter actual figure label expansion bristol myer blockbuster cancer drug opdivo drive company sale last year be expect do so year well moreover cardiovascular drug eliquis also demonstrated strong performance expect trend continue quarter label expansion leukemia drug sprycel approve november bring more sale drug moreover continue strong performance yervoy orencia have favorable impact however genericization plavix avapro avalide baraclude unite state due loss exclusivity be significantly hurt company top line company also face stiff competition immuno oncology space hiv business continue face competitive pressure zack consensus estimate sale earning be peg cent respectively likely positive surprise proven model indicate bristol myer be likely beat earning estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate zack consensus estimate stand be lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank bristol myer have zack rank combination positive earning esp favorable zack rank make reasonably confident earning beat conversely caution sell rate stock go earning announcement especially company be see negative estimate revision bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quoteother stock considerhere be biotech stock also want consider model show have right combination element post earning beat quarter pfizer inc pfe free report be schedule release result company have earning esp zack rank see complete list today zack rank stock here abbvie inc abbv free report be schedule release result apr company have earning esp zack rank gilead science inc gild free report be schedule release result company have earning esp zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3399,GILD,bristol myer squibb company bmy free report enter research collaboration agreement harvard fibrosis network harvard stem cell institute company have team develop potential new therapy fibrotic disease include fibrosis liver heart term agreement lead academic investigator hepatic cardiac fibrosis harvard fibrosis network collaborate lead scientist bristol myer squibb project year project focus apply fibrosis biology identification noninvasive biomarker novel target potential fibrotic therapy area hepatic cardiac fibrosis bristol myer be build robust pipeline investigational candidate address area high unmet need fibrosis include nonalcoholic steatohepatitis nash idiopathic pulmonary fibrosis ipf bristol myer blockbuster drug opdivo continue perform well several label expansion application opdivo be review unite state europe potential approval boost prospect drug further share company have rally past year outperform industry gain however generic competition loom large company bristol myer pipeline need deliver hence company be look diversify portfolio promising space nash bristol myer extend strategic partnership target pharmasolution inc partnership have be extend target nash multus year deal note company announce new collaboration november treatment nash hcc bristol myer already have mid stage candidate nash space bms investigational pegylate analogue human fibroblast growth factor fgf key regulator metabolism patient biopsy confirm nash achieve primary endpoint significant reduction liver fat versus placebo april company be entitle right research develop commercialize bms ambrx inc other major company promising candidate nash be intercept pharma icpt free report gilead science gild free report novartis nvs free report zack rankbristol myer carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3400,GILD,gilead science inc gild free report announce european medicine agency ema committee medicinal product human use chmp have issue positive opinion company marketing authorization application maa car therapy axicabtagene ciloleucel treatment adult patient relapse refractory diffuse large cell lymphoma dlbcl primary mediastinal large cell lymphoma pmbcl more line systemic therapy axicabtagene ciloleucel chimeric antigen receptor cell car therapy modify patient own cell recognize attack cancer cell agency have earlier grant prime status axicabtagene ciloleucel tentative approval be card ema generally take chmp recommendation account review maa note axicabtagene ciloleucel be approve fda october yescarta approval europe boost growth prospect therapy give market potential information provide company be estimate patient dlbcl be refractory have relapse more line therapy be eligible car therapy europe concurrently novartis nvs free report also obtain positive opinion chmp car therapy kymriah cell malignancy cell acute lymphoblastic leukemia dlbcl gilead stock have gain year so far industry decline note gilead be look newer avenue help top line solidify presence gene therapy space initial uptake yescarta unite state be also encourage gilead be also intend foray nash market gilead hcv franchise be experience slowdown key market include unite state europe reflect lower sale harvoni sovaldi result competitive pricing pressure franchise see significant plunge sale due new competition fewer patient start note harvoni sovaldi epclusa face competition abbvie abbv free report viekira pak mayret merck mrk free report zepatier other nevertheless hiv franchise continue maintain momentum zack rankgilead currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3401,GILD,drug approval licensing deal be area focus biotech space last week gilead hcv drug eplcusa be approve china biomarin palynziq get fda approval other hand alexion offer acquire sweden base wilson therapeutcis be accept latter shareholder recap important story gilead epclusa get approval china china drug administration cda approve gilead gild free report epclusa sofosbuvir mg velpatasvir mg treatment adult genotype chronic hepatitis virus hcv infection cda also approve epclusa combination ribavirin rbv adult hcv decompensate cirrhosis approval be base positive result phase iii study astral astral astral astral astral high overall rate svr defined undetectable hcv rna week complete therapy range be achieve difficult cure patient population include treatment experience patient compensate decompensate cirrhosis approval further expand gilead geographic reach somewhat boost dwindle hcv portfolio gilead be zack rank hold stock see complete list today zack rank strong buy stock here biomarin get fda approval forpalynziq biomarin pharmaceutical inc bmrn free report obtain standard approval fda palynziq pegvaliase pqpz injection reduction blood phenylalanine phe concentration adult patient pku have uncontrolled blood phe concentration greater micromol exist management march european medicine agency also accept company marketing authorization application palynziq unite state palynziq be first enzyme therapy approve treatment pku drug complement sale biomarin other drug kuvan alexion offer wilson acquisition accept alexion alxn free report announce offer acquire sweden base wilson therapeutic have be accept shareholder represent total number share vote latter acquisition have also be approve relevant regulatory authority settlement tender share occur acquisition add late stage candidate wtx alexion pipeline company look diversify portfolio reduce dependence blockbuster drug soliris wtx enjoy fast track designation unite state orphan drug designation treatment wilson disease unite state europe union cara therapeutic gain licensing deal share cara therapeutic inc cara free report jump significantly last week follow announcement licensing deal fresenius medical care renal pharma ltd company license worldwide right commercialize korsuva cr difelikefalin injection treatment chronic kidney disease associate pruritus ckd ap dialysis patient unite state japan south korea remind investor fda grant breakthrough therapy designation korsuva injection indication term deal cara be entitle receive upfront payment cash equity investment acquire cara common stock price approximately share cara be also entitle receive additional payment include regulatory tiered commercial milestone company also receive tiered royalty base net sale license territory celgene repurchase share celgene corporation celg free report announce company repurchase common stock company also plan enter accelerate share repurchase asr agreement repurchase aggregate common stock plan asr use exist authorize share repurchase program well part new authorization biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index lose last trading session major biotech stock alexion lose past month celgene lose vertex gain see last biotech stock roundup here biotech stock roundup fda give nod amgen drug eu approve exelixis cabometyx next biotech stay tune regulatory update pipeline development news american society clinical oncology asco annual meeting chicago illinois today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3402,GILD,bluebird bio inc blue free report announce fda have grant breakthrough therapy designation lenti treatment patient cerebral cald note breakthrough therapy designation expedite development review drug intend standalone therapy combination more other drug treat serious life threaten disease preliminary datum suggest drug demonstrate substantial improvement exist therapy more clinically significant endpoint designation be support positive preliminary datum ongoing phase ii iii starbeam study ald evaluate lenti investigational gene therapy boy cald year age less do not have match sibling donor year study have assessed safety efficacy investigational gene therapy cald be hereditary neurological disorder note lenti investigational gene therapy enjoy orphan drug status unite state europe drug be also grant rare pediatric disease designation fda treatment ald fda rare pediatric disease priority review voucher program sponsor receive marketing application approval rare pediatric indication be generally eligible priority review voucher be redeem obtain priority review subsequent marketing application different product bluebird bio have build diverse pipeline lentiviral base gene therapy cell immunotherapy expertise gene editing capability bluebird bio gene therapy clinical program include lenti treatment cerebral lentiglobin treatment transfusion dependent thalassemia also know thalassemia major severe sickle cell disease oncology pipeline primarily focus develop novel cell base immunotherapy include chimeric antigen receptor car cell receptor tcr therapy lead oncology program include bb bb be bcma car program company be develop partnership celgene celg free report car therapy be focus approval gilead gild free report yescarta novartis nvs free report kymriah past month bluebird stock have return decline register industry zack rankbluebird carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3403,GILD,glaxosmithkline plc gsk free report partner jnj free report announce european commission ec have grant marketing approval juluca make europe first drug hiv treatment juluca combine approve hiv drug tivicay mg edurant mg single once daily pill treatment virologically suppress hiv infectionjuluca gain approval unite state november last year generate sale first quarter tivicay novel investigational integrase strand transfer inhibitor insti be market viiv healthcare hiv company majorly own glaxo pfizer pfe free report edurant be nucleoside reverse transcriptase inhibitor nnrti market janssen pharma arm juluca have be develop partnership viiv healthcare janssen approval eu be expect march year committee human use medicinal product chmp european medicine agency ema have give positive opinion recommend approval juluca year so far share have decline glaxo have go say time frame industry have witness decline juluca first drug regimen be approve reduce number medicine hiv patient take compromise efficacy conventional drug regimen juluca approval be base datum phase iii sword study datum study show combination tivicay edurant antiretroviral be effective drug antiretroviral regimen maintenance therapy hiv patient have already achieve viral suppression remind investor gilead gild free report also gain fda approval single tablet hiv regimen triple therapy year biktarvy gain fda approval february year regulatory application be review eu str be fix dose combination drug bictegravir mg emtricitabine mg tenofovir alafenamide mg bic ftc taf glaxo carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3404,GILD,have be pretty hum first half biotech sector nasdaq biotechnology index nbi have lose so far performance biotech bigwig have be affected slowdown growth key drug competitive pressure continue impact sale nevertheless new drug approval boost investor sentiment key approval so far year include gilead science gild free report hiv regimen biktarvy vertex pharmaceutical symdeko tezacaftor ivacaftor ivacaftor treatment cystic fibrosis cf amgen aimoviq treatment migraine biomarin palynziq treatment other approval drug boost respective company top line few be struggle decline sale legacy drug increase amerger acquisition picked pace sector slowdown mature product have force company celgene celg free report eye lucrative acquisition bolster pipeline celgene acquire juno therapeutic gain traction promising car space february company acquire impact biomedicine add late stage candidate fedratinib highly selective jak kinase inhibitor pipeline alexion acquire sweden base wilson therapeutic add late stage candidate wtx pipeline be currently phase iii treatment wilson disease rare genetic disorder most recently akebia therapeutic inc keryx inc announce merger agreement company combine stock merger expect many more such deal latter half well lie ahead medical biom genetic sub industry carry zack industry rank place bottom zack industry issue drug pricing threat biosimilar loom large healthcare sector large expect better performance second half new drug approval label expansion exist high profile drug pipeline progress grow demand drug especially rare treat disease age population increase health care spending be factor positively impact performance choiceshere list few biotech stock backed zack rank strong buy buy increase share price look fairly place good run second half amgen inc amgn free report be lead biotech company world amgen newer drug prolium xgeva blincyto vectibix kyproli be perform well recent approval migraine candidate aimovig be huge boost biosimilar portfolio look solid too approve product amjevita mvasi deep pipeline amgen key drug be face biosimilar competition expect newer drug offset decline company have already undertake restructure plan lower cost aid bottom line amgen share have gain so far year decrease register industry amgen carry zack rank see complete list today zack rank stock here athersys inc athx free report be primarily focuse regenerative medicine company patented proprietary allogeneic stem cell product multistem cell therapy be lead platform product be currently advanced stage clinical development treat neurological condition cardiovascular disease inflammatory immune disorder certain pulmonary condition other condition current standard care be limit inadequate many patient particularly critical care segment stem cell therapy have gain lot investor attention late company such candidate be spotlight athersys carry zack rank share company have gain year so far industry decline celsion corporation clsn free report be company prospect look good company be focuse develop portfolio innovative cancer treatment include direct chemotherapy immunotherapy rna dna base therapy pipeline progress have be encourage so far thermodox company lead program be proprietary heat activate liposomal encapsulation doxorubicin be currently phase iii development treatment primary liver cancer other candidate pipeline include gen dna base immunotherapy localize treatment ovarian brain cancer celsion have platform technology development novel nucleic acid base immunotherapy other cancer dna rna therapy immunotherapy hold lot potential now company impressive pipeline progress be big positive investor celsion carry zack rank share company have return year so far industry decline aeglea biotherapeutic inc agle free report be clinical stage biotechnology company focus innovative human enzyme therapeutic patient suffering rare genetic disease cancer lead experimental therapy pegzilarginase be be evaluate treatment deficiency monotherapy arginine dependent cancer combination immune checkpoint inhibitor keytruda small cell lung cancer company be also develop pipeline additional product candidate target key amino acid other metabolite include homocysteine oxidized form homocystine target rare genetic disease well cysteine oxidized form cystine methionine cancer indication aeglea carry zack rank share company have return year so far industry decline wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3405,GILD,biotech sector be focus regular pipeline update key story include bigwig gilead science gild free report get approval hiv drug biktarvy europe puma biotechnology pbyi free report soar positive chmp recommendation merrimack mack free report plunge failure phase ii study pancreatic cancer recap important storiesgilead biktarvy get ec approval gilead announce european commission have grant marketing authorization hiv combination therapy biktarvy bictegravir mg emtricitabine mg tenofovir alafenamide mg bic ftc taf biktarvy be approve once daily single tablet regimen str treatment hiv infection adult present past evidence viral resistance integrase class emtricitabine tenofovir approval be support positive datum ongoing phase iii study namely study treatment naïve hiv infected adult study virologically suppress adult approval bic ftc taf become gilead third ftc taf base str approve european union year bic ftc taf meet primary objective week study regimen be earlier approve fda february approval europe further strengthen company hiv franchise read more gilead biktarvy get ec nod hiv infection merrimack plunge study failure share merrimack plunge company report disappointing result phase ii study front line metastatic pancreatic cancer phase ii trial carrie evaluate addition mm standard care treatment patient previously untreated metastatic pancreatic cancer high serum level free insulin growth factor igf primary endpoint study be progression free survival secondary endpoint include objective response rate disease control rate duration response overall survival safety merrimack report study do not meet primary secondary efficacy endpoint patient receive mm combination nab paclitaxel gemzar compare nab paclitaxel gemzar alone subsequently merrimack have terminate development mm sale onivyde company be back be development stage company be banking pipeline candidate boost growth prospect hence failure carrie study come huge disappointment investor give limit number candidate pipeline consequently company now plan focus other candidate pipeline mm mm read more merrimack crash phase ii pancreatic cancer study fail amgen present encourage datum repatha amgen amgn free report announce encourage datum phase iii study banting show pcsk inhibitor repatha significantly reduce bad cholesterol patient type ii diabetes have already undergo moderate high intensity statin therapy study evaluate monthly subcutaneous administration mg dose repatha period week patient type ii diabetes mixed dyslipidemia be optimized background statin therapy result study show addition repatha background statin therapy significantly reduce low density lipoprotein cholesterol ldl high density lipoprotein cholesterol hdl datum banting study also reveal patient repatha arm achieve ldl level less mg dl be recommend level american college clinical endocrinologist patient type ii diabetes compare patient placebo arm week read more amgen repatha reduce bad cholestrol type ii diabetes amgen carry zack rank buy see complete list today zack rank strong buy stock here puma biotechnology soar positive chmp opinion share puma biotechnology soar company announce committee medicinal product human use chmp european medicine agency ema have adopt positive trend vote recommend approval marketing authorisation application maa breast cancer drug nerlynx neratinib maa be seek approval drug extend adjuvant treatment early stage positive hormone receptor positive breast cancer news boost investor sentiment chmp have adopt negative opinion maa february positive opinion chmp indicate imminent tentative approval drug be approve fda july extend adjuvant treatment adult patient early stage overexpressed amplify breast cancer follow adjuvant trastuzumab base therapy incyte announce positive result jakafi gvhd incyte incy free report announce phase ii trial reach evaluate lead drug jakafi combination corticosteroid treatment patient steroid refractory acute graft versus host disease gvhd meet primary endpoint datum study show jakafi demonstrated overall response rate orr day moreover number patient show response point time study be propel positive datum reach study incyte now plan file supplemental new drug application snda fda label expansion jakafi treatment steroid refractory acute gvhd third quarter potential label expansion gvhd further boost sale read more incyte announce positive result jakafi gvhd biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index lose last trading session major biotech stock alexion gain past month celgene have lose amgen have gain see last biotech stock roundup here biotech stock roundup srpt sldb soar positive datum anik ziop crash next biotech stay tune regulatory update pipeline development news hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3406,GILD,gilead science inc gild free report announce european commission have grant marketing authorization hiv combination therapy biktarvy bictegravir mg emtricitabine mg tenofovir alafenamide mg bic ftc taf biktarvy be approve once daily single tablet regimen str treatment hiv infection adult present past evidence viral resistance integrase class emtricitabine tenofovir approval be support positive datum ongoing phase iii study namely study treatment naïve hiv infected adult study virologically suppress adult approval bic ftc taf become gilead third ftc taf base str approve european union past year bic ftc taf meet primary objective week study regimen be earlier approve fda february approval europe further strengthen company hiv franchise gilead be dominant player hiv market impressive portfolio same hiv be primary area focus gilead company be work bring new hiv treatment market further boost sale franchise company be first bring market single tablet regimen str treatment hiv atripla taf base product genvoya odefsey descovy be perform well strong adoption unite state europe biktarvy combine novel unboosted integrase strand transfer inhibitor insti bictegravir demonstrated safety efficacy profile descovy ftc taf dual nucleoside reverse transcriptase inhibitor nrti backbone smallest insti base triple therapy str be produce approval new hiv therapy stiff competition glaxosmith gsk free report exist therapy tivicay triumeq meanwhile gilead be banking hiv franchise drive growth future give persistent decline hcv sale gilead stock have gain last month industry decline gilead hcv franchise be experience slowdown key market include unite state europe reflect lower sale harvoni sovaldi result competitive pricing pressure franchise see significant plunge sale due new competition fewer patient start pricing have largely stabilize market share stabilize mid patient start be expect decline further note harvoni sovaldi epclusa face competition abbvie abbv free report viekira pak mayret merck mrk free report zepatier other meanwhile gilead be look newer avenue help top line solidify presence gene therapy space initial uptake yescarta be also encourage gilead be also intend foray nash market pipeline candidate selonsertib filgotinib zack rankgilead currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3407,GILD,far most exciting real time revolution unfold biotechnology be crispr gene editing past few month have provide plenty excitement biotech investor public company be pure play manifestation technology have make dramatic move good news bad instance june scientific research study be publish suggest crispr gene editing actually enable cancer growth share biggest company crispr therapeutic crsp free report drop scary news gene editing go wrong read scientist analyst company reaction understand controversy implication decide be actually buy opportunity investor follow pick zack healthcare innovator also own other player edita medicine edit free report intellium therapeutic ntla free report good explanation see fear drive reaction excellent opportunity investor appreciate good calculate risk check video make june buy more crsp revolutionary breakthrough dangerous science be not first time news research scare have make stock go love well hate january be paper be debate crispr cause target edit accidentally modify other gene not related give target disease collateral damage view be find few month be base inconclusive research scientific unknown power god technology be landmine investor company respective partner research institution university be giant patent dispute discover layer claim new development exactly be crispr video accompany article go basic scientific fact assumption crispr make such revolutionary discovery potentially cure thousand genetic disease so fascinating crispr be wasn invented lab pharmaceutical drug be discover nature rather try explain own word probably butcher let hear expert crispr therapeutic crispr cas be rapid easy use gene editing technology selectively delete modify correct disease cause abnormality specific dna segment crispr refer cluster regularly interspaced short palindromic repeat occur genome certain bacterium system be discover cas be crispr associate endonuclease enzyme molecular scissors be easily programme cut edit correct disease associate dna patient cell cluster repeat crispr be discover accident researcher study bacterial defense mechanism specifically bacterium deal foreign plasmid phage bacterium have ability open genome invade viruse nuclease call cas inactivate process cluster repeat be give name crispr multiple crispr associate cas gene be discover adjacent repeat element same year new science treat disease courtesy good ole bacteriacrispr be sum simply protein name cas find streptococcus bacterium attack dna invade virus slice essence prey become predator mother nature work billion year know something be crux want remember here crispr cas scientist have learn bacterium nature warrior survival ninjas adaptation utilize protein genetic structure invade viruse thereby use cas edit genetic material ability modify cell dna amazing precision crispr evolve variation new enzyme call cas be recently discover be less error prone be hot arena science medical innovation decade come mother nature indeed know thing fact most scientist believe be just scratch surface be discover century so be premature call crispr discovery century ve get year left investor also be aware different type gene editing last july give zack confidential subscriber special report gene editing invest picked sangamo therapeutic sgmo free report potential winner technology call zinc finger nuclease zfn ride sgmo gain year gilead science gild free report kite subsidiary create partnership sangamo latest report gene editing april title crispr science investing email ultimate zack com account rep help report give more background company peek new cas threat disclosure own share crsp ntla edit sgmo gild zack healthcare innovator portfolio be design long term portfolio occasionally swing trade highly volatile stock kevin cook be senior stock strategist zack investment research run healthcare innovator service click follow author receive latest stock research macro analysis today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3408,GILD,novartis ag nvs free report announce encourage result juliet trial kymriah month be observed ongoing durable response be achievable kymriah administer adult patient relapse refractory diffuse large cell lymphoma dlbcl datum be also present rd annual congress european hematology association result trial show overall response rate orr evaluable patient be follow least month discontinue earlier addition complete response cr be achieve patient achieve partial response pr total patient have experience cr month remain same month moreover relapse free probability month patient first response be be encourage result further emphasize kymriah efficacy durable response predictable consistent safety profile more year infuse patient advanced dlbcl month additional follow response rate remain consistent previous report emergence new safety signal kymriah formerly ctl be first chimeric antigen receptor cell car therapy approve fda treatment patient year age cell precursor acute lymphoblastic leukemia be refractory second later relapse fda also approve kymriah treatment adult patient large cell lymphoma more line systemic therapy include dlbcl high grade cell lymphoma dlbcl arise follicular lymphoma base datum juliet study meanwhile novartis marketing authorization application maa kymriah treatment child young adult cell acute lymphoblastic leukemia adult patient dlbcl be currently review europe novartis have strong oncology portfolio drug afinitor exjade jakavi zykadia tasigna jadenu kisqali continue boost sale approval kymriah acute lymphoblastic leukemia be major boost give potential car therapy space novartis share have decline last month compare industry decline earlier novartis announce licensing agreement spark therapeutic once free report cover development registration right voretigene neparvovec outside unite state competition be increase gene therapy space gilead gild free report yescarta be car therapy approve treat adult patient certain type large cell lymphoma have not respond have relapse least other kind treatment uniqure qure free report be gene therapy company be advance pipeline proprietary partner gene therapy treat patient liver metabolic central nervous system cardiovascular disease approval new drug bode well novartis company be face loss patent protection key drug novartis also announce result new comparison study show jakavi treat patient polycythemia vera pv be resistant intolerant hydroxyurea hu have significantly reduce risk thrombosis blood clot death compare pv patient receive best available therapy zack ranknovartis carry zack rank sell see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3409,GILD,celgene corporation celg free report be take desperate attempt bolster portfolio reduce dependence lead drug revlimid however thing do not seem be work favor company celgene stock have lose last month industry decline last month celgene suffer yet setback receive refusal file letter fda regard new drug application nda multiple sclerosis candidate ozanimod candidate be be develop treatment patient relapse form multiple sclerosis ms fda state nonclinical clinical pharmacology section nda be inadequate allow complete review hence celgene request type meeting fda ascertain additional information need resubmission nda news come great disappointment investor give potential ms market hold notably thing have be downturn company last october celgene announce phase iii trial revolve cd pipeline candidate ged crohn disease extension trial sustain cd have be discontinue follow recommendation datum monitoring committee assessed overall benefit risk recent interim futility analysis december late stage study lead cancer drug revlimid combination roche holding rhhby free report rituxan fail study evaluate revlimid rituxan follow maintenance compare standard care feature rituxan chemotherapy chop bendamustine vn cvp follow rituxan maintenance previously untreated follicular lymphoma however treatment arm not achieve superiority co primary endpoint complete response unconfirmed complete response cr cru week term progression free survival observed pre plan analysis celgene key growth engine be revlimid revlimid sale continue be impressive be concern company dependence product growth drug be set lose patent exclusivity soon hence celgene be desperately try revive portfolio celgene be look new deal acquisition give lacklustre just gilead science gild free report acquire kite pharma juno acquisition add jcar lisocabtagene maraleucel liso cel celgene lymphoma pipeline jcar be best class cd direct car candidate currently pivotal program relapse refractory diffuse large cell lymphoma candidate be expect obtain regulatory approval unite state generate sale approximately acquisition juno surely boost celgene growth prospect give immense potential car therapy space be risky proposition celgene juno have face setback pipeline candidate jcar hence expect investor stay side line time be observe revival story celgene play zack rank key pickcelgene currently carry zack rank sell better rank stock same space be regeneron pharmaceutical regn free report sport zack rank strong buy see complete list today zack rank stock here regeneron earning share estimate have moved last day company pull positive earning surprise last quarters average beat make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3410,GILD,conatus pharmaceutical inc cnat free report be slate report first quarter result market close company earning history have be disappointing so far have miss expectation occasion miss register line result average negative surprise last report quarter company deliver positive surprise share conatus have plunge year time versus industry rally let see thing be shape upcoming release factor approve product conatus portfolio moment company be yet generate revenue hence investor focus be company progress respect lead candidate emricasan orally active pan caspase protease inhibitor emricasan be evaluation various phase iib study treatment chronic liver disease include nash fibrosis be now ongoing emricasan phase iib trial consist other encore program patient fibrosis cirrhosis cause nonalcoholic steatohepatitis nash various patient population datum analysis be expect company also plan initiate new study call encore xt plan extension trial patient complete encore ph encore lf study continue monitoring efficacy safety clinical outcome healthy quality life apart emricasan company portfolio have idn presently undergo phase ii study treatment primary sclerosing cholangitis expect update same first quarter conference call emricasan have also be extensively profile test study many preclinical model human disease april conatus announce positive result vivo study demonstrate reduction hepatic tissue factor drive coagulation be important note conatus have exclusive option collaboration license agreement novartis ag nvs free report worldwide development emricasan novartis sharing half development cost related conatus phase iib study emricasan company now anticipate lower spending licensing internal pipeline earning whispersour proven model do not conclusively show conatus be likely beat earning quarter be stock need have positive earning esp favorable zack rank strong buy buy hold happen be not case here see zack esp conatus have earning esp most accurate estimate zack consensus estimate be peg loss cent uncover best stock buy sell re report earning esp filter zack rank conatus carry zack rank increase predictive power esp however company earning esp make surprise prediction difficult caution sell rate stock go earning announcement especially company be see negative estimate revision conatus pharmaceutical inc price ep surprise conatus pharmaceutical inc price ep surprise conatus pharmaceutical inc quote stock warrant lookhere be health care stock right combination element beat estimate time gilead science inc gild free report be schedule report first quarter financial number company have earning esp zack rank see complete list today zack rank stock here celgene corporation celg free report be schedule release first quarter result company have earning esp zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3411,GILD,glaxosmithkline plc gsk free report report core earning cent american depositary share first quarter miss zack consensus estimate cent however earning be constant exchange rate cer compare year figure share glaxo be almost apr hour trading due lower expect result report quarter moreover stock have lose year time industry growth quarterly revenue rise cer drive strong performance vaccine segment top line however marginally miss zack consensus estimate growth rate mentioned be year year basis cer quarterly highlightssale be unite state international market flip side sale europe be flat year year glaxo report financial figure segment pharmaceutical vaccine consumer healthcare pharmaceutical division register revenue growth drive hiv drug respiratory disease drug namely nucala ellipta portfolio upside be partly offset decline sale older respiratory product include seretide advair ventolin establish pharmaceutical hiv sale increase back growth unite state europe respectively international sale be also year year encourage number be drive continue market share growth triumeq sale tivicay sale however sale hiv drug epzicom kivexa tumble due more severe generic competition particularly affect european market notably company latest product hiv portfolio be juluca dolutegravir rilpivirine first drug regimen once daily single pill hiv drug be approve unite state last november generate first quarterly sale compare register previous quarter however last november gilead gild free report triple combination once daily single tablet regimen biktarvy bictegravir emtricitabine tenofovir alafenamide be approve fda hiv infection treatment nod regulatory agency competitive threat juluca future quarters respiratory sale be flat cer year year international market sale increase metric decline unite state europe respectively quarter review sale rise ellipta portfolio nucala be offset fall sale older product seretide advair ventolin sale new respiratory portfolio grow include first quarterly contribution newly launch trelegy ellipta trelegy ellipta only once daily single inhaler triple therapy copd yielded sale unite state eu first quarter notably april gsk announce trelegy ellipta gain fda approval expand indication new indication be long term once daily maintenance treatment airflow obstruction patient copd include chronic bronchitis emphysema ellipta product record surge sale drive market share gain global roll continue however upside be offset weak sale seretide advair ventolin sale drop year year immuno inflammation drug benlysta rise quarter discussion new grouping establish pharmaceutical comprise previous establish product cardiovascular metabolic urology other pharma product establish pharmaceutical sale decrease quarter review sale consumer healthcare segment nudge slowdown market condition power brand particularly pain relief oral health category see sturdy performance quarter sale vaccine segment be impressive have increase year year primarily drive sale newly launch shingrix vaccine prevention shingle unite state shingrix record sale report quarter drive favorable recommendation center disease control prevention advisory committee immunization practice merck mrk free report zostavax moreover company state be rapidly build coverage shingrix vaccine presently more patient have access vaccine medicare commercial channel be important note shingrix be approve eu well japan last month give indication unite state vaccine sale soar europe international market metric decrease respectively sale meningitis vaccine bexsero increase unite state europe market menveo unite state post higher sale same be offset soft performance establish vaccine thank fierce competitive pressure infanrix pediarix europe company continue expect ep growth cer advair generic be launch further year however probable event advair generic be introduce market mid glaxo anticipate adjust ep be flat year year cer company namely mylan myl free report hikma pharmaceutical novartis try bring generic version advair market have receive complete response letter crl fda mylan hikma get crl last year novartis be forward same year delay entry generic market glaxosmithkline plc price consensus ep surprise glaxosmithkline plc price consensus ep surprise glaxosmithkline plc quote zack rankglaxo carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3412,GILD,gilead science inc gild free report be schedule report first quarter result market close gilead science inc price consensus ep surprise gilead science inc price consensus ep surprise gilead science inc quote gilead leader hepatitis virus hcv space have decent track record company earning beating estimate last miss last report quarter company earning beat expectation overall company record average positive earning surprise gilead stock have rally year outperform industry decline likely positive surprise proven model indicate gilead be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be case be here see zack esp earning esp gilead be uncover best stock buy sell re report earning esp filter zack rank gilead currently carry zack rank combine positive esp make reasonably confident earning beat quarter conversely caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision factor playconcurrent fourth quarter earning call gilead provide guidance gilead now expect net product sale range strong hiv performance other antiviral product sale be be drive continue uptake tenofovir alafenamide taf base product genvoya descovy odefsey expect trend continue first quarter well genvoya have already become most prescribe regimen treatment naïve switch patient launch taf base regimen now represent total gilead hiv prescription volume truvada use pre exposure prophylaxis set also put strong performance company see significant uptick prep usage approximately patient used truvada end moreover franchise receive further boost fda approval once daily single tablet regimen str biktarvy bictegravir mg emtricitabine mg tenofovir alafenamide mg bic ftc taf hiv infection february hence sale get further boost zack consensus estimate sale genvoya be however gilead lose exclusivity viread country outside unite state impact sale other hand hcv franchise continue be competitive pricing pressure lead massive decline harvoni sovaldi sale harvoni sovaldi have be face competition abbvie abbv free report viekira pak viekira xr other franchise suffer significant plunge sale due new competition fewer patient start pricing market share be expect stabilize mid patient start be expect decline further hcv revenue be project decline further constitute smaller portion top line go forward zack consensus estimate sale lead hcv drug sovaldi harvoni be respectively adjust expense adjust sg expense be project range respectively adjust product gross margin be expect range meanwhile kite acquisition be step right direction fda approval chimeric antigen receptor cell car therapy yescarta axicabtagene ciloleucel treatment refractory aggressive hodgkin lymphoma include dlbcl transform follicular lymphoma primary mediastinal cell lymphoma however management state yescarta launch be controlled launch ensure patient safety car therapy be complicate sometimes be associate severe side effect gilead be also look build nonalcoholic steatohepatitis franchise expect management throw more light same first quarter call investor be also likely keep eye other pipeline update other stock considerhere be other health care stock want consider model show too have right combination element post earning beat quarter gw pharmaceutical plc gwph free report be expect report earning company have earning esp zack rank see complete list today zack rank stock here celgene corporation celg free report be schedule release first quarter result company have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3413,GILD,have be month last earning report gilead science inc gild free report share have lose time frame recent negative trend continue lead next earning release be gild due dive investor analyst have react late let take quick look most recent earning report order get better handle important driver gilead hcv sale weak earning beatgilead report fourth quarter result earning revenue surpass expectation however management issue bleak view company fourth quarter earning share beat zack consensus estimate however earning be year quarter figure share moreover total revenue top zack consensus estimate however revenue decline year year harvoni sovaldi plunge furtherproduct sale come year year decline be due lower hcv sale partially offset higher sale hiv other therapeutic area antiviral product sale include gilead hiv liver disease portfolio come quarter hcv product sale include harvoni sovaldi epclusa vosevi be report year quarter downside be mainly attribute lower sale harvoni sovaldi major market sale harvoni decline year year quarter further sovaldi sale record steep year year decline epclusa garner sale quarter year figure meanwhile hiv hbv product sale come year year increase be primarily drive continuous strong uptake tenofoviral afenamide taf base product such genvoya generate sale year quarter descovy record sale odefsey register sale hiv treatment stribild complera eviplera sale decline respectively viread sale be atripla sale tank truvada sale fall other product letairis ranexa zydelig record sale respectively research development expense decline due impact ongoing milestone payment selling general administrative sg expense decrease adjust product gross margin be compare year period resultsrevenue come surpass zack consensus estimate earning share come beat zack consensus estimate guidancegilead now expect net product sale range adjust expense adjust sg expense be project range respectively adjust product gross margin be expect range company acquire kite pharma fda approval yescarta car therapy treatment adult patient relapse refractory large cell lymphoma more line systemic therapy gilead prospect company recently announce acquire cell design lab expand further car space dividend share gilead declare cash dividend cent share common stock first quarter increase dividend be payable mar stockholder record close business mar company paid cash dividend repurchase share have estimate be move then past month investor have witness downward trend fresh estimate have be revision higher current quarter compare lower gilead science inc price consensus gilead science inc price consensus gilead science inc quotevgm scoresat time gild have poor growth score however momentum be do lot better charting somewhat similar path stock be allocate grade value side putt second quintile investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested style score indicate stock be more suitable value investor momentum investor outlookestimate have be broadly trend downward stock magnitude revision indicate downward shift notably gild have zack rank hold expect line return stock next few month
3414,GILD,expect agio pharmaceutical inc agio free report surpass expectation report first quarter result market open last report quarter company deliver negative earning surprise share agio have soar year time compare favorably industry increase company earning track record show mixed result company have outpaced estimate twice trail quarters miss same other overall agio come average negative surprise let see thing be shape quarter factor playagio only market drug be idhifa enasidenib receive fda approval last august treatment patient relapse refractory acute myeloid leukemia aml have isocitrate dehydrogenase idh mutation last report drug generate strong sale expect encourage revenue first quarter well moreover agio progress pipeline have be quite impressive fact investor focus remain same be report quarter interesting candidate company cancer portfolio be idh mutant inhibitor ag ivosidenib pan idh mutant inhibitor ag ivosidenib be priority review unite state treat patient aml idh mutation approval ivosidenib be expect third quarter additionally company anticipate regulatory filing candidate eu fourth quarter same indication ivosidenib be also be evaluate phase study address advanced hematologic malignancy combine celgene celg free report vidaza be assessment phase ii cure newly diagnosed aml patient be not eligible intensive chemotherapy meanwhile agio be conduct phase program ag treat patient advanced idh idh mutant positive solid tumor include glioma second half company announce positive finding study notably company also plan initiate perioperative window trial analyze ivosidenib ag low grade glioma investigate effect brain tumor tissue first half company have interesting candidate portfolio lead rare genetic disease candidate ag be evaluation phase ii trial adult transfusion independent patient pyruvate kinase deficiency agio report positive datum program june fda grant fast track designation candidate give indication rgd market still remain unexplored newer therapy area hold huge potential nonetheless march agio announce commencement phase study evaluate first class methionine mat inhibitor ag patient solid tumor lymphoma deletion mtap expect management produce update same first quarter earning release earning whispersour proven model show agio be likely beat earning report cycle have right combination key ingredient positive earning esp favorable zack rank strong buy buy hold happen zack esp agio have earning esp represent percentage difference most accurate estimate loss share zack consensus estimate loss positive esp indicate likely earning surprise uncover best stock buy sell re report earning esp filter zack rank agio have zack rank increase predictive power esp together positive esp chance earning beat stock upcoming release be peg higher caution sell rate stock go earning announcement especially company be see negative estimate revision agio pharmaceutical inc price ep surprise agio pharmaceutical inc price ep surprise agio pharmaceutical inc quote other stock considerhere be other health care stock worth consider right combination element beat estimate time gilead science inc gild free report be schedule report first quarter financial number company have earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report be schedule release quarterly result company have earning esp zack rank hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3415,GILD,gilead science inc gild free report announce encourage week result phase iii study study virologically suppress adult woman hiv infection international workshop hiv woman conference retroviruse opportunistic infection croi boston poster study evaluate efficacy safety switch boost protease inhibitor bpi boost elvitegravir contain regimen biktarvy bictegravir mg emtricitabine mg tenofovir alafenamide mg once daily single tablet regimen str biktarvy be find be statistically inferior regimen contain bpi boost elvitegravir demonstrated treatment emergent resistance week ongoing study study datum show woman switch biktarvy maintain high level viral suppression comparable remain baseline regimen genvoya stribild atv rtv ftc tdf moreover none participant biktarvy develop treatment emergent resistance biktarvy gilead latest triple therapy be approve fda february complete regimen treatment hiv infection adult have antiretroviral treatment history replace current antiretroviral regimen be virologically suppress hiv rna ml stable antiretroviral regimen least month history treatment failure know substitution associate resistance individual component biktarvy meanwhile hiv franchise continue gain traction back rapid adoption taf base regimen unite state eu taf base regimen now represent total gilead hiv prescription volume follow launch genvoya odefsey descovy marketing authorization application biktarvy be review european union meanwhile additional clinical trial biktarvy be ongoing include study adolescent child hiv approval new hiv therapy stiff competition glaxosmith gsk free report exist therapy tivicay triumeq gilead stock have lose last month compare industry decline gilead be banking hiv franchise have be tremendous pressure due lower patient start increase competition abbvie abbv free report therapy zack rank key pickgilead currently carry zack rank hold better rank stock health care sector be regeneron pharmaceutical inc regn free report sport zack rank strong buy see complete list today zack rank stock here regeneron earning share estimate have moved respectively last day company deliver positive earning surprise last quarters average beat wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3416,GILD,nash alcoholic steatohepatitis space be back focus israel base galm pharmaceutical glmd free report report positive datum candidate aramchol candidate demonstrated statistically significant reduction liver fat week larger number patient treat aramchol mg show nash resolution worsening fibrosis week biopsy encourage datum boost investor sentiment lead stock significant surge late nash space have be spotlight give market potential market nash be poise witness rapid growth other lucrative yet saturate market cancer be nash chronic liver disease nash be cause excessive fat accumulation liver know steatosis record have affected person unite state cause inflammation hepatocellular injury progressive fibrosis cirrhosis ailment be anticipate be lead reason liver transplantation currently nash induce biggest basis liver transplant person unite state such patient also suffer obesity type ii diabetes treatment currently approve address disease market opportunity be substantially huge many company be investing major chunk spend same let consider company potential candidate presently be evaluate treatment nash stock promising nash candidate pharmaceutical mdgl free report share madrigal pharmaceutical soar last month company report positive top line week result phase ii trial patient biopsy proven nash program evaluate lead pipeline candidate mgl first class oral once daily liver direct thyroid hormone receptor thr selective agonist datum study show mgl achieve higher reduction nafld activity score nas greater nash resolution patient more liver fat reduction achievement week candidate have meet primary endpoint more reduction liver fat week last december company advance candidate phase iii study follow regulatory agreement design madrigal stock have sky-rocket last month outperform industry rise company currently have zack rank hold see complete list today zack rank strong buy stock here gilead science inc gild free report biotech bigwig gilead be also foraying emerge nash domain late stage candidate selonsertib combat persistent decline time lucrative hcv business april company announce encourage datum proof concept study experimental combination therapy patient advanced fibrosis due nash apoptosis signal regulate kinase ask inhibitor selonsertib be combine acetyl coa carboxylase acc inhibitor gs selective steroidal farnesoid receptor fxr agonist gs therapy gilead nash pipeline include selonsertib gs gs alone combination other favorable result suggest combination therapy selonsertib gs gs be evaluate further patient nash fibrosis gilead stock have lose last month compare industry decline intercept pharmaceutical inc icpt free report intercept be company pump resource nash space company be evaluate lead candidate obeticholic acid oca treat nash oca achieve primary endpoint phase iib trial flint currently phase iii study regenerate cirrhotic nash patient liver fibrosis be ongoing top line result interim analysis be expect first half intercept also initiate phase iii trial reverse oca randomize phase iii study examine efficacy safety oca subject compensate cirrhosis due nash approximately patient biopsy confirm diagnosis cirrhosis intercept expect submit marketing authorization oca treatment option nash patient compensate cirrhosis unite state international market basis positive result study subsequent outcome trial be also card confirm clinical benefit post marketing basis broader population nash patient cirrhosis oca be already approve ocaliva combination ursodeoxycholic udca therapy primary biliary cholangitis pbc adult inadequate response udca monotherapy adult unable recuperate udca intercept stock have surge year versus industry decline conatus pharmaceutical inc cnat free report conatus also have promising nash candidate pipeline company be develop emricasan first class orally active pan caspase protease inhibitor treatment patient chronic liver disease conatus currently have ongoing study namely encore ph encore nf encore lf evaluate emricasan nash patient company have collaboration agreement swiss major novartis global development product contain emricasan single active ingredient combination other novartis compound liver cirrhosis liver fibrosis emricasan fail phase iib study polt hcv svr do not achieve primary endpoint patient fibrosis cirrhosis undergo liver transplant investor still keenly follow datum multiple nash study datum ongoing trial be likely be receive year end positive outcome surely boost growth prospect company company currently carry zack rank hold conatus stock have rally last month outperform increase record industry galectin therapeutic inc galt free report be company late stage nash candidate gr md candidate be carbohydrate base drug inhibit galectin protein directly involved multiple inflammatory fibrotic malignant disease lead development program be nash cirrhosis most advanced form nash related fibrosis company announce initiate phase iii trial galectin inhibitor gr md nash cirrhosis incorporating advice guidance obtain meeting fda target population trial comprise patient nash cirrhosis esophageal varice galectin currently carry zack rank hold stock have gain staggering last month outperform industry growth bottom lineride high vast market potential other big multiple pharma biotech company too produce pipeline candidate treatment nash hence expect lot activity specific space go forward potential approval drug nash attract more player medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
3417,GILD,drug stock value trap opportunity tracey top stock pick health service industry episode roundup podcast zack comwelcome episode value investor podcastevery week tracey ryniec editor zack value investor portfolio service share top value investing tip stock pick recently investor stocktwit twitter have be ask drug stock look valuation see many be dirt cheap trading single digit es problem be street hate make perfect value investor retail energy stock be hate last several year too have stage big turnaround drug stock be next big turnaround success story definition value trapremember value trap be stock look cheap base basic value fundamental ratio doesn company trading earning sometimes reason cheapness investor have look value fundamental earning be rise fall rise earning low tell something right be go company earning decline be sign company have lose way value stock trap gilead science gild free report have forward just share be last year have gain time be earning expect do biogen biib free report be trading forward year date share be ve gain prior year estimate have be cut last day be earning growth celgene celg free report have take beating year share fall year date now trading forward just cheap be trap lannett lci free report be cheapest group have forward only take chance share be year date have fall prior year valeant vrx free report have have problem last few year share have rebound be compare return also cheap forward just be bottom earning decline be lot category healthcare sector include insurer hospital device manufacturer staffing other drug company have be hit especially hard just re cheap however doesn mean re good buy investor need do homework value stock trap find week podcast wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3418,GILD,share israel base galm pharmaceutical ltd glmd free report soar company announce positive top line result lead candidate aramchol treatment alcoholic steatohepatitis nash week consequent gain galm share have gain last month compare industry growth share be pre market trading well patient enrolled phase iib study arrest undergo magnetic resonance spectroscopy mrs biopsy baseline week patient biopsy proven nash be overweight obese have pre diabetes type ii diabetes mellitus be randomize ratio mg mg placebo primary endpoint study be change baseline end study liver triglyceride ratio measure mrs aramchol mg compare placebo statistically significant reduction liver fat be demonstrated mrs patient have complete week treatment aramchol mg compare placebo addition post analysis mrs responder defined reduction absolute change baseline also demonstrated clinically statistically significant effect aramchol mg compare placebo moreover larger number patient treat aramchol mg show nash resolution worsening fibrosis week biopsy aramchol mg also result least point improvement fibrosis score worsening nash higher proportion patient compare placebo further statistically significant reduction live enzyme alanine transaminase alt aspartate transaminase ast be also see aramchol arm compare placebo respectively result indicate aramchol mg be probably sufficient fat reduction biologically higher dose be need achieve more stringent histological endpoint such nash resolution fibrosis reversal datum strongly support advance aramchol mg phase iii estimate nash impact approximately person unite state approximately globally nash be also fastest grow cause liver cancer liver transplant unite state due rise obesity hence successful development aramchol be significant boost clinical stage company galm give potential market other company gilead science gild free report intercept pharmaceutical icpt free report novartis nvs free report also have promising nash candidate pipeline zack rankgalm currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3419,GILD,be approve therapy completely cure autoimmune inflammatory disease development new treatment technology be ongoing meanwhile be difficult control autoimmune disease majority patient newest class medication treat disease be janus kinase jak inhibitor be provide patient better treatment option class therapy have generate significant interest due better efficacy compare tumor necrosis factor tnf inhibitor therapy autoimmune diseasesin patient autoimmune disease body immune system mistakenly attack healthy cell scientist be yet find reason abnormality however incidence autoimmune disease be rise be multiple type autoimmune disease include rheumatoid arthritis ra psoriasis multiple sclerosis ms inflammatory bowel disease ibd etc several company be dedicate bring better drug treatment disease symptom include fatigue muscle ach swell redness affected body part most common first line treatment autoimmune disease be disease modify rheumatic drug dmard especially methotrexate apart methotrexate be several class dmard include tnf inhibitor therapy approve disease be perform well abbvie abbv free report humira amgen amgn free report enbrel be blockbuster tnf inhibitor drug other however treatment have serious safety issue include increase risk tuberculosis lymphoma other jak pharma company be develop jak inhibitor work block particular signal body immune response cytokine instead suppress immune system do dmard patient treat jak inhibitor clinical study have show faster better response disease however safety concern still loom large segment be attractive company be only jak inhibitor presently approve treatment autoimmune disease especially ra however several company be develop candidate be likely increase competition go forward segment be news recently eli lilly lly free report olumiant jak inhibitor receive approval unite state abbvie abbv free report announce top line datum late stage study evaluate jak inhibitor candidate upadacitinib pharma biotech company grow interest jak inhibitor let take look pharma biotech company be look change way autoimmune disease be treat pfizer pfe free report xeljanz tofacitinib be first approve jak inhibitor unite state treatment ra have be available market drug be also approve psoriatic arthritis generate sale first quarter year year regulatory application seek line extension drug ulcerative colitis be approve late last month unite state regulatory application seek approval indication be review europe company currently carry zack rank hold see complete list today zack rank strong buy stock here eli lilly jak inhibitor olumiant baricitinib be second drug receive approval treat ra unite state drug be approve early month however be launch certain european country note fda reject company new drug application seek approval olumiant april cite safety concern lilly develop commercialize drug partnership incyte corporation drug generate sale first quarter sequentially lilly be currently evaluate drug autoimmune indication atopic dermatitis eczema late stage study company currently carry zack rank buy abbvie be company be focuse develop jak inhibitor base treatment company jak inhibitor upadacitinib show promising result late stage study evaluate candidate ra patient be also be develop atopic dermatitis late stage study enjoy breakthrough therapy status unite state late stage study be evaluate candidate crohn disease company currently carry zack rank galapago nv glpg free report be develop jak inhibitor candidate filgotinib collaboration gilead science inc gild free report separate late stage study be evaluate candidate ra crohn disease ulcerative colitis moreover several mid stage study be evaluate candidate multiple autoimmune indication include ankylose spondylitis psoriatic arthritis cutaneous lupus erythematosus other datum mid stagei study evaluate filgotinib psoriatic arthritis show significant improvement patient company currently carry zack rank prospect jak inhibitor several blockbuster dmard near patent expiration new class drug hold potential replace exist treatment boost prospect company have drug candidate pipeline commercial portfolio however jak inhibitor also have several side effect delay approval note lower dose lilly olumiant be approve box warning state risk serious infection malignancy thrombosis hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3420,GILD,inc agen free report be expect report first quarter last report quarter company report negative earning surprise last quarters company deliver average positive earning surprise notably share have outperformed industry year stock have rally industry fall let see thing be shape company quarter factor playagenus collaboration agreement several company not only help procure fund form upfront milestone payment future royalty also validate proprietary product platform have collaborate merck mrk free report incyte develop multiple checkpoint antibody incyte collaboration be evaluate latter gitr checkpoint antibody incagn phase ii study ox agonist antibody incagn phase ii study ctla antibody agen phase ii study candidate be be evaluate treatment solid tumor january company announce launch combination phase ii study agen pd agen antibody have approve product portfolio only few candidate mid stage development include prophage series vaccine company be still few year away bring product market hiccup development process candidate weigh stock october establish separate business entity advance cell therapy program be design be self funded cell therapy company agentus focus discovery development breakthrough live drug advance cure cancer patient company take decision form smaller team entirely focus get product approve company expect combine value separate company exceed perceive value roof first quarter company focus pipeline candidate provide update model proven model do not show earning beat quarter be stock need have positive earning zack rank strong buy buy hold happen however be not case here see zack esp have earning esp be most accurate estimate zack consensus estimate be peg loss cent uncover best stock buy sell re report earning esp filter zack rank have zack rank sell decrease predictive power esp note caution stock zack rank strong sell go earning announcement stock warrant lookhere be biotech stock want consider model show have right combination element post earning beat quarter pfizer inc pfe free report be schedule release quarterly result company have earning esp zack rank see complete list today zack rank strong buy stock here gilead science inc gild free report be schedule release quarterly result company have earning esp zack rank inc price ep surprise inc price ep surprise inc hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3421,GILD,intercept pharmaceutical inc icpt free report report disappointing result fourth quarter account drab ocaliva sale company report loss share fourth quarter wider zack consensus estimate narrower year loss intercept pharmaceutical inc price consensus ep surprise intercept pharmaceutical inc price consensus ep surprise intercept pharmaceutical inc quote quarterly revenue be significantly year quarter miss zack consensus estimate quarter detailin fourth quarter ocaliva record sale record third quarter revenue international market be ocaliva be approve unite state combination ursodeoxycholic udca treatment primary biliary cholangitis pbc adult inadequate response udca monotherapy adult be unable endure udca drug be also grant conditional approval european commission sale unite state market come record third quarter prescription continue grow research development expense increase year year primarily drive increase clinical development program obeticholic acid oca infrastructure support such program selling general administrative expense increase year quarter resultssale come miss zack consensus estimate ocaliva sale come loss share come wider zack consensus estimate expect operate expense range company believe continue ocaliva pbc unite state other market pipeline updateoca be be evaluate other indication include alcoholic steatohepatitis nash primary sclerosing cholangitis psc fda have earlier approve redesign phase iii trial regenerate oca safety efficacy treat nash patient liver fibrosis company now need achieve only co primary endpoint fibrosis improvement nash resolution compare earlier target achieve enrolment interim analysis cohort be complete trial result be expect first half earlier month intercept initiate phase iii trial reverse oca randomize phase iii study evaluate efficacy safety oca subject compensate cirrhosis due nash approximately patient biopsy confirm diagnosis cirrhosis primary endpoint study be percentage subject histological improvement fibrosis least stage used nash clinical research network crn score system month treatment patient enrolled trial be be randomize ratio treatment arm once daily dose oca mg once daily oca mg titration mg month placebo patient successfully complete double blind phase reverse be enrolled open label extension phase additional month intercept expect submit marketing authorization oca treatment option nash patient compensate cirrhosis unite state international market base positive result study subsequent outcome trial be also card confirm clinical benefit post marketing basis broader population nash patient cirrhosis company also announce update label ocaliva unite state reinforce appropriate dose pbc patient child class decompensate cirrhosis fourth quarter result miss expectation sale ocalive decline due safety issue report earlier update label help stock turn be sale start recover first quarter be expect be transitional quarter intercept stock have tumble year compare industry decline company stock have be bearing brunt safety guideline issue regard approve drug ocaliva give challenge face drug recent time label expansion oca boost growth prospect estimate nash be expect surpass hepatitis lead reason liver transplant unite state europe nash market have huge potential tentative approval boost ocaliva prospect however bigwig novartis ag nvs free report gilead science gild free report have fxr agonist phase ii earlier stage clinical preclinical development be used treat pbc nash other liver disease zack rank key currently carry zack rank hold better rank stock healthcare sector be exelixis exel free report currently carry zack rank buy see complete list today zack rank strong buy stock here exelixis earning share estimate increase cent cent last day hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3422,GILD,celgene corporation celg free report announce acquire impact biomedicine upfront amount term agreement impact biomedicine shareholder receive contingent payment base regulatory approval sale base milestone maximum aggregate amount payable such milestone payment be aggregate tiered sale base milestone payment total maximum global annual net sale exceed acquisition add late stage candidate fedratinib highly selective jak kinase inhibitor celgene pipeline candidate be be develop treatment myelofibrosis mf polycythemia vera fedratinib demonstrated statistically significant improvement primary secondary endpoint splenic response total symptom score respectively randomize placebo controlled phase iii pivotal trial jakarta treatment naïve mf addition multus center single arm phase ii trial jakarta evaluate fedratinib mf patient be find be resistant intolerant incyte corporation incy free report jakafi be jak jak inhibitor fedratinib demonstrated clinically meaningful improvement splenic response total symptom score second line set however remind investor jakarta be stop prematurely fda put clinical hold fedratinib program hold be put potential case wernicke encephalopathy be report patient receive more dose less percent treat patient fda withdraw clinical hold august base report benefit risk profile fedratinib jakarta jakarta clinical trial regulatory application mf be plan begin middle celgene be look new deal acquisition give lacklustre celgene stock have decline value last month compare industry loss celgene suffer series setback last few month company suffer setback last week late stage study lead cancer drug revlimid combination rituxan fail study evaluate revlimid rituxan follow maintenance compare standard care feature rituxan chemotherapy chop bendamustine vn cvp follow rituxan maintenance previously untreated follicular lymphoma celgene key growth engine be revlimid drug worldwide sale increase contribute almost total revenue revlimid oral drug be currently approve several indication include mm myelodysplastic syndrome mantle cell lymphoma failure study be disappointing drug label expansion have boost sale potential addition october company announce phase iii trial revolve cd pipeline candidate ged crohn disease extension trial sustain cd be discontinue follow recommendation datum monitoring committee assessed overall benefit risk recent interim futility analysis meanwhile deep yet persistently slow growth psoriatic arthritis psoriasis market especially entire third quarter have lead weak performance otezla consequently company also reduce annual guidance challenge market condition be drive increasingly restrictive pbm formulary control positive note august company obtain fda approval idhifa treatment relapse refractory acute myeloid leukemia isocitrate dehydrogenase idh mutation drug be develop partnership agio pharmaceutical inc agio free report big biotechs be look strategic acquisition bolster portfolio pipeline gilead science inc gild free report also acquire kite pharma boost portfolio zack rankcelgene currently carry zack rank hold see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
3423,GILD,be doubt go most remarkable year history stock trading market touch more daily time high close higher single month first time history hot streak have continue first day new year major index once again surge new peak trend have also see move be speculation major merger acquisition total activity be actually relatively quiet deal be mid november several wall street titan announce major deal find center deal related rumor year industry shift move amazon amzn free report buyout whole food cvs health cvs free report tie aetna aet free report future focuse acquisition gilead gild free report purchase car researcher kite pharma intel intc deal buy computer vision firm mobileye have plenty huge headline soak also read best merger acquisition so far headline have continue entertainment industry be still react disney free report acquisition several major st century fox foxa free report asset giant apple aapl free report netflix nflx free report have already cause rumor mill swirl mind let take look huge deal happen year apple finally buy netflixpeople have be argue apple use massive cash pile make major medium acquisition year now video stream giant netflix be typically first choice speculator apple have defy speculator time time again opt instead invest indeed company recently promise apple music division purpose build original video content first house produce show be start debut now however gop tax reform bill include time allowance company repatriate overseas cash be catalyst need inspire major apple deal earlier week share netflix surge note very topic citigroup analyst emerge firm jim suva asiya merchant write apple be gear make major acquisition car company video game company entertainment company analyst suggest be high likelihood apple acquire netflix soon be apple even interested company attention turn elsewhere amazon target target amazon acquisition whole food be not enough satisfy retail deal rumor latest batch industry whisper point commerce king go big box retailer target tgt free report rumor be spark loup venture co founder gene munster recently publish report highlight prediction technology industry year target be ideal offline partner amazon reason share demographic manageable comprehensive store count munster argue get timing be difficult see value combination be easy amazon burn lot cash purchase whole food financial work target certainly make sense context online retailer ongoing war walmart wmt free report nevertheless brick mortar acquisition be lofty move commerce company especially consider fresh whole food deal be internet giant really adapt traditional retail quickly time warner comcast snatch huluas mentioned entertainment industry be still figure do next disney decide shell more stock many fox most important asset disney have certainly beef library upcoming stream service espn grasp sport world be even tighter acquisition fox sport regional network thing remain unclear be fate hulu bud video stream platform co own fox disney comcast cmcsa free report time warner disney buy fox stake brand give control stake be unlikely comcast time warner give promising stream platform just yet comcast still own hulu nbcuniversal subsidiary certainly whip hulu nbc universal stream service compete disney netflix team time warner hbo division add even more fire power course have yet see indication disney be look shed new control stake hulu imagine become bargaining tool be sure be complicate regulatory approval process netflix disney amazon poise be video stream leader year time comcast time warner look toss fourth hat ring want more stock market analysis author make sure follow ryan_mcqueeney twitter investor alert breakthrough pending medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
3424,GILD,latest earning preview earning season have already crossed half way mark be gain strength earning revenue growth track reach highest level year total earning member have already report result be same period last year higher revenue beating top line estimate beating revenue estimate proportion company beating earning revenue estimate be ongoing earning season seem have start solid note drug biotech sector major large cap player have report result bristol myer squibb bmy free report abbvie abbv free report beat zack consensus estimate earning well sale amgen inc amgn free report also surpass earning revenue expectation quarter higher demand be expect boost new product sale also innovation successful product line expansion positive clinical study result fda approval consistent performance key product grow demand drug especially rare treat disease agee population well increase healthcare expenditure be factor be expect keep sector growth trajectory also accord earning preview broader medical sector inclusive drug biotech well medical device company be likely record year year growth revenue witness rise earning quarter review pharma biotech giant be schedule report earning result let see thing be shape company upcoming release pfizer inc pfe free report be slate releaseresult market open company deliver positive earning surprise last report quarter company performance have be impressive recent past earning surpass expectation trail quarters average beat accord zack model company zack rank strong buy buy hold have good chance beating estimate also have positive earning esp combination company zack rank earning esp make reasonably confident earning beat zack consensus estimate company earning quarter review be peg cent share innovative health segment new product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain chantix smoking cessation eliquis blood thinner be expect drive top line essential health biosimilar emerge market be expect support sale bottom line be expect be drive cost saving share buyback read more pfizer earning beat estimate again pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quotemerck co inc mrk free report be slate report result open bell company deliver positive earning surprise last report quarter company track record be excellent have consistently top estimate last quarters average positive earning surprise model do not conclusively show merck beat estimate quarter be stockha earning esp zack rank zack consensus estimate quarterly earning be peg cent share see complete list today zack rank strong buy stock here merck new product cancer drug keytruda lynparza bridion injection be likely drive top line however loss market exclusivity several drug softness diabetes januvia janumet franchise lower sale key product zostavax zepatier due competitive pressure hurt sale read more card merck earning season merck co inc price ep surprise merck co inc price ep surprise merck co inc quotegilead science inc gild free report be slate report result market close company deliver positive earning surprise trail quarters average beat last report quarter gilead deliver positive earning surprise model show gilead be likely beat estimate quarter combination gilead zack rank earning esp make confident earning beat upcoming report consensus mark quarter be report be peg share company strong hiv performance other antiviral product sale be be drive continue uptake tenofovir alafenamide taf base product genvoya descovy odefsey expect trend continue first quarter well franchise receive further boost fda approval once daily single tablet regimen str biktarvy bictegravir mg emtricitabine mg tenofovir alafenamide mg bic ftc taf hiv infection february hence sale get further boost read more be beat card gilead earning gilead science inc price ep surprise gilead science inc price ep surprise gilead science inc quoteincyte corporation incy free report be slate report result market open incyte track record have be impressive so far company deliver positive earning surprise trail quarters average beat last report quarter incyte deliver positive earning surprise model show incyte be likely beat estimate quarter combination incyte zack rank earning esp make confident earning beat upcoming report consensus mark quarter be report be peg cent share uncover best stock buy sell re report earning esp filter incyte continue gain traction lead drug jakafi performance incyte jakafi performance be strong drive patient demand sale guidance be also impressive october fda approve label update drug include addition new patient report outcome datum comfort study well update warning related progressive multifocal pivotal reach trial evaluate jakafi patient steroid refractory acute graft versus host disease have complete enrollment result be expect first half assume successful result incyte expect submit snda seek approval jakafi indication jakafi sale be expect get boost update label read more jafaki help incyte beat earning estimate incyte corporation price ep surprise incyte corporation price ep surprise incyte corporation hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3425,GILD,keryx inc kerx free report be expect report first quarter result market open last quarter company report negative earning surprise keryx performance last quarters have be disappointing company report wider expect loss trail quarters average negative surprise keryx share have lose year date compare industry decline factor influence quarterapart license fee keryx top line comprise revenue generate only market product auryxia ferric citrate auryxia be used treat patient chronic kidney disease ckd dialysis november fda grant approval additional indication auryxia treat adult iron deficiency anemia ida chronic kidney disease not dialysis moreover keryx claim auryxia be only oral treatment option available indication auryxia be already approve control serum phosphorus level adult chronic kidney disease dialysis latest approval drug treat complication chronic kidney disease also represent significant opportunity physician treat patient earlier stage disease anemia become more severe hence approval significantly boost auryxia sale meanwhile company be look potential partner commercialize drug eu ferric citrate have be consider new active substance european commission provide year datum marketing exclusivity region company also remain focuse create rapid awareness new indication differentiate auryxia exist treatment option communicate favorable insurance access auryxia prescriber patient expect see further company support number ongoing trial include several investigator sponsored clinical study new phase iv study call compass compass study continue expand clinical dataset auryxia treatment iron deficiency anemia study person haven be treat previously low iron different dose regimen such twice day however auryxia be only approve product keryx portfolio company be entirely dependent auryxia growth model proven model do not show earning beat keryx quarter be stock need have positive earning esp zack rank strong buy buy hold happen however be not case here see zack esp keryx have earning esp be most accurate estimate zack consensus estimate be peg loss cent uncover best stock buy sell re report earning esp filter zack rank keryx have zack rank increase predictive power esp however need have positive esp be confident earning beat note caution stock zack rank sell rate go earning announcement keryx inc price ep surprise keryx inc price ep surprise keryx inc quotestock warrant lookhere be biotech stock want consider model show have right combination element post earning beat quarter pfizer inc pfe free report be schedule release result company have earning esp zack rank see complete list today zack rank stock here gilead science inc gild free report be schedule release result company have earning esp zack rank celgene corporation celg free report be schedule release result company have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3426,GILD,madrigal pharmaceutical inc mdgl free report share sky-rocket yesterday encourage top line datum phase ii study evaluate thyroid hormone receptor beta selective agonist mgl alcoholic steatohepatitis nash candidate demonstrated sustain reduction liver fat more month madrigal successfully complete mid stage study advance candidate phase iii study follow regulatory agreement design candidate have meet primary endpoint more reduction liver fat week december last year share company have significantly outperformed industry so far year stock have surge industry have lose datum study show mgl achieve higher reduction nafld activity score nas greater nash resolution patient have achieve more liver fat reduction week moreover patient treat mgl have nash resolution achieve reduction more nas compare placebo candidate also resolve fibrosis half patient nash resolution lead statistically significant reduction fibrosis compare placebo mean relative reduction fat be mgl compare placebo week press release nash be common form liver disease be spread gradually unite state be approve treatment disease moreover company believe high degree nash resolution achieve candidate also increase likelihood success advanced study also mgl resolve nash patient just month however be several other company develop candidate indication vike therapeutic inc be develop thyroid receptor beta agonist vk mid stage study fatty liver also gain more follow strong result mgl intercept pharmaceutical inc icpt free report be develop cholestatic liver drug ocaliva nash late stage study company stock however fall drug have safety concern help mgl get lead ocaliva big player gilead science inc gild free report allergan be also develop treatment nash madrigal pharmaceutical inc price madrigal pharmaceutical inc price madrigal pharmaceutical inc quotemadrigal currently have zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3427,GILD,gilead science inc gild free report galapago nv glpg free report announce phase ii study equator pipeline candidate filgotinib achieve primary endpoint improvement sign symptom psoriatic arthritis week assessed american college rheumatology percent improvement score acr equator trial initiate galapago april be multicenter randomize double blind placebo controlled trial assess safety efficacy selective jak inhibitor filgotinib adult patient moderately severely active psoriatic arthritis datum study depict acr response filgotinib versus placebo additionally acr acr response week be also significantly higher filgotinib placebo filgotinib be generally well tolerate trial new safety signal be observed however be serious infection filgotinib group patient experience pneumonia fatal outcome other patient receive filgotinib develop herpes zoster company plan report detailed result equator trial future scientific conference concurrently gilead galapago also announce independent datum monitoring committee dmc conduct plan interim futility analysis phase iib iiii study selection filgotinib treatment ulcerative colitis analysis be conduct patient complete induction period phase iib portion study dmc recommend study go plan phase iii mg mg once daily dose level biologic experience biologic naïve patient multicenter randomize double blind placebo controlled study assess safety efficacy selective jak inhibitor filgotinib adult patient moderately severely active ulcerative colitis be initiate gilead late consequently gilead pay galapago progression phase ii phase iii selection trial trial enroll total patient target be randomize receive filgotinib mg mg placebo once daily administer week primary objective selection be evaluate efficacy filgotinib compare placebo establish ebs endoscopy bleed stool remission week galapago gilead enter global collaboration development filgotinib inflammatory indication candidate be also be evaluate ongoing phase iii program finch rheumatoid arthritis phase iii trial diversity crohn disease also small bowel fistulizing crohn disease phase ii study other give persistent decline hcv sale gilead be look newer avenue help top line gilead stock have lose last month industry loss gilead hcv franchise witness slowdown key market include unite state europe reflect lower sale harvoni sovaldi result competitive pricing pressure franchise see significant plunge sale due new competition fewer patient start pricing have largely stabilize market share stabilize mid patient start be expect decline further note harvoni sovaldi epclusa face competition abbvie abbv free report viekira pak mayret merck mrk free report zepatier other gilead be look solidify presence gene therapy space initial uptake yescarta be also encourage gilead be also intend foray nash market pipeline candidate selonsertib filgotinib zack rankgilead currently carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3428,GILD,intercept pharmaceutical inc icpt free report initiate phase iii trial reverse obeticholic acid oca randomize phase iii study evaluate efficacy safety oca subject compensate cirrhosis due alcoholic steatohepatitis nash approximately patient biopsy confirm diagnosis cirrhosis primary endpoint study be percentage subject histological improvement fibrosis least stage used nash clinical research network crn score system month treatment patient enrolled trial be be randomize ratio treatment arm once daily dose oca mg once daily oca mg titration mg month placebo patient successfully complete double blind phase reverse be enrolled open label extension phase additional month intercept expect submit marketing authorization oca treatment option nash patient compensate cirrhosis unite state international market basis positive result study subsequent outcome trial be also card confirm clinical benefit post marketing basis broader population nash patient cirrhosis note oca be already approve ocaliva combination ursodeoxycholic udca treatment primary biliary cholangitis pbc adult inadequate response udca monotherapy adult unable recuperate udca initial uptake ocaliva have be encourage however have be lot debate regard drug safety prescription demand softened follow dear health care provider letter fda safety communication ocaliva intercept be also evaluate oca treat variety other viral progressive liver disease such nash primary sclerosing cholangitis biliary atresia intercept stock have lose last month compare industry decline particular company share have plunge significantly due safety issue regard approve drug ocaliva company initiate phase iii study regenerate ocaliva treatment cirrhotic nash patient advanced liver fibrosis enrollment interim analysis cohort regenerate trial be complete control study be be conduct evaluate effect ocaliva combination statin therapy lipid metabolism patient nash result aesop reveal oca meet primary endpoint statistically significant reduction alkaline phosphatase result control show company achieve objective demonstrate lowest available dose atorvastatin rapidly reverse oca associate ldl change baseline level nash patient fibrosis cirrhosis give challenge face drug recent time label expansion oca boost growth prospect estimate nash be expect surpass hepatitis lead reason liver transplant unite state europe nash market have huge potential tentative approval boost ocaliva prospect however bigwig novartis ag nvs free report gilead science gild free report have fxr agonist phase ii earlier stage clinical preclinical development be used treat pbc nash other liver disease zack rank key currently carry zack rank hold better rank stock healthcare sector be exelixis exel free report currently carry zack rank buy see complete list today zack rank strong buy stock here exelixis earning share estimate increase cent cent last day hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3429,GILD,biotech sector witness series event past week fda accept new drug application nda alk provide major boost company stock however celldex breast cancer study fail meet primary endpoint owing stock plummet significantly news alexion announce plan acquire wilson therapeutic thus space remain key area investor focus recap important story jump fda decision follow fda decision review nda alk treatment major depressive disorder mdd share alk free report moved fda have initially issue refusal file letter mar candidate state nda do not have enough evidence oral medication work fda suggest additional study be require demonstrate drug overall effectiveness propose indication alk once daily oral medication have be develop adjunctive treatment mdd patient have not respond well standard antidepressant therapy fda acceptance alk nda rescission refusal file letter follow productive interaction agency clarify certain aspect nda submission additional datum analysis be submit fda fda have set action date jan read more rally fda accept nda depression drug currently carry zack rank buy see complete list today zack rank strong buy stock here fda lift hold bellicum bpx bellicum blcm free report announce fda have lift clinical hold study conduct unite state evaluate cell therapy bpx company consult regulatory body agree make amendment study protocol include guidance monitoring management neurologic adverse event bellicum resume patient enrolment study implement amend protocol clinical study site bpx be be develop adjunct cell therapy treatment patient hematologic cancer inherited blood disease have undergo haploidentical partial match hematopoietic stem cell transplant however bellicum claim clinical hold do not have impact ongoing registrational study bp europe be evaluate bpx pediatric patient acute myeloid leukemia primary interim datum announce march bpx have demonstrated leukemic effect patient aml study read more fda lift clinical hold bellicum cell therapy alexion acquire wilson therapeutic alexion alxn free report recently announce acquire sweden base wilson therapeutic alexion have offer sek cash outstanding share wilson therapeutic translate total transaction value alexion have already obtain shareholder support agreement largest shareholder accounting wilson therapeutic outstanding share additional shareholder accounting total company outstanding share transaction be expect close second quarter acquisition add late stage candidate wtx alexion pipeline candidate be currently phase iii treatment wilson disease rare genetic disorder candidate be first class oral copper bound agent unique mechanism action ability access bind copper serum promote removal liver candidate have also obtain fast track designation unite state enjoy orphan drug designation treatment wilson disease unite state eu read more alexion acquire wilson therapeutic celldex breast cancer study fail celldex cldx free report plummet phase iib study glembatumumab vedotin fail candidate fail meet primary endpoint progression free survival pfs benefit roche chemotherapy xeloda treatment metastatic triple negative breast cancer overexpress gpnmb assessment datum mid stage study show glembatumumab vedotin achieve pfs month versus month xeloda candidate be also not able demonstrate significant advantage key secondary endpoint include overall response rate duration response overall survival follow failure celldex have decide discontinue study evaluate glembatumumab vedotin indication company be currently restructure pipeline focus candidate ongoing clinical study include varlilumab also reduce workforce read more celldex phase ii breast cancer study fail share plunge gilead present encourage datum nash therapy gilead gild free report announce encourage datum proof concept study experimental combination therapy patient advanced fibrosis due nonalcoholic steatohepatitis nash datum be present international liver congress paris apoptosis signal regulate kinase ask inhibitor selonsertib be combine acetyl coa carboxylase acc inhibitor gs selective steroidal farnesoid receptor agonist gs therapy patient diagnosed nash liver fibrosis stage base biopsy magnetic resonance elastography mri proton density fat fraction mri pdff enrolled tudy be treat selonsertib mg gs mg selonsertib mg gs mg monotherapy group once daily week patient treatment most notable change be observed be decrease liver fat content measure mri pdff occur regimen contain gs result also show improvement liver biochemistry marker fibrosis combination arm study compare baseline moreover patient treat selonsertib gs kinetic labele show reduction fractional synthesis rate lumican marker fibrogenesis hence favorable result suggest combination therapy selonsertib gs gs be evaluate further patient nash fibrosis read more gilead present encourage datum nash therapy biomedical genetic industry yr return medical biomedical genetic industry yr return nasdaq biotechnology index gain last trading session major biotech stock vertex gain last month celgene lose vertex gain see last biotech stock roundup here biotech stock roundup spectrum incyte avexis merge novartis next biotech world stay tune more regulatory pipeline update hacker put money portfolio earlier year credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
3430,GILD,earning season be fly start owing slew upbeat economic datum strong corporate performance president donald trump tax reform sign law however equity market have be suffering sell owing fear rise rate come performance biotech giant have be mixed bag biotech company beating market expectation few fail do so read follow etf move finally selloff set now discuss performance few biotech giant such amgen inc amgn free report gilead science gild free report biogen inc biib free report alexion pharmaceutical alxn free report earning focusamgen report fourth quarter adjust earning share miss zack consensus estimate unchanged year quarter company also miss zack consensus estimate revenue amgen report revenue miss zack consensus estimate decrease year quarter full year company report decrease revenue however gaap ep increase company expect gaap ep be range also expect revenue be range moreover amgen expect adjust tax rate be owing tax reform gilead science report fourth quarter adjust earning share surpass zack consensus estimate decrease share year quarter moreover company also beat zack consensus estimate revenue company report revenue surpass zack consensus estimate decrease more year quarter full year company report decrease revenue moreover gaap ep decrease period company expect full year revenue be range adjust expense adjust sg expense be project range respectively biogen inc report fourth quarter adjust earning share miss zack consensus estimate increase share year quarter company report revenue surpass zack consensus estimate increase roughly year quarter full year company report increase revenue moreover gaap ep increase biogen expect earning be range share company expect full year revenue be range alexion pharmaceutical inc report fourth quarter adjust earning share surpass zack consensus estimate increase roughly share year quarter company report revenue beat consensus estimate increase roughly year quarter full year company report increase revenue moreover gaap ep increase company expect full year revenue be range company expect gaap ep be range now discuss few etfs high exposure company discuss ishare nasdaq biotechnology etf ibb free report fund seek provide exposure biotech industry have aum charge fee basis point year fund have exposure amgen biogen gilead alexion feb fund have return year have zack etf rank hold high risk outlook vaneck vector biotech etf bbh free report fund have aum charge fee basis point year fund have exposure amgen gilead biogen alexion feb fund have return year have zack etf rank high risk outlook proshare ultra nasdaq biotechnology etf bib free report fund have aum charge fee basis point year fund have exposure amgen biogen gilead alexion dec fund have return year want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
3431,GILD,glaxosmithkline gsk free report partner pfizer inc pfe free report announce hiv focuse joint venture company viiv healthcare have initiate phase iii program evaluate drug hiv regimen dolutegravir tivicay lamivudine epivir study evaluate drug regimen maintenance viral suppression achieve hiv infected patient drug regimen tenofovir alafenamide fumarate taf base regimen remind investor glaxo be also evaluate drug base regimen cabotegravir johnson johnson jnj free report rilpivirine phase iii study treat adult virally suppress hiv infection moreover company be also evaluate cabotegravir monotherapy prevention hiv infection sexually active woman hiv treatment generally be drug base regimen latest entrant market be gilead science inc gild free report once daily single tablet regimen biktarvy bictegravir emtricitabine tenofovir alafenamide approve earlier month however glaxo be try reduce number medicine hic treatment regimen compromise efficacy conventional drug regimenshare glaxosmithkline have underperform industry so far year stock have lose industry rally period phase iii tango study investigate drug regimen treatment hiv phase iii program be design evaluate inferior antiviral activity combination regimen week compare continuation taf base regimen study also evaluate long term antiviral activity tolerability safety combination therapy week glaxo be also evaluate combination regimen gemini study patient hiv have receive prior treatment datum gemini tango study be anticipate note glaxo newest hiv medicine juluca be single tablet contain dolutegravir rilpivirine juluca be first drug regimen approve fda meanwhile several company interested develop drug treat life threaten disease competition have intensified manifold space glaxosmithkline plc price glaxosmithkline plc price glaxosmithkline plc quotezack carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3432,GILD,turn be pretty good year pharma biotech stock fda decision be concern regulatory body approve novel drug last year easily surpass total tally landmark decision last year include approval couple gene base therapy cancer novartis nvs free report kymriah gilead science gild free report yescarta therapy have potential change way look cancer treatment other key approval include lilly verzenio advanced metastatic breast cancer gilead vosevi hepatitis virus puma nerlynx reduce risk breast cancer return tremfya moderate severe plaque psoriasis regeneron sanofi kevzara rheumatoid arthritis roche rhhby free report multiple sclerosis treatment ocrevus regeneron sanofi sny free report eczema treatment dupixent tesaro parp inhibitor zejula biomarin brineura treatment specific form batten disease other many drug have blockbuster potential drug development process be lengthy time consume require utilization lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst here be look few important regulatory event schedule month january label expansion synergy trulance biopharma company synergy pharmaceutical inc sgyp free report get know approval status trulance use adult patient irritable bowel syndrome constipation ib month regulatory body be expect deliver decision regard trulance label expansion indication jan trulance company first only commercial product be approve last year january treatment adult chronic idiopathic constipation cic accord information provide company adult suffer cic adult suffer ib unite state alone synergy share have decline last year advisory panel january pdufa date aradigm linhaliq emerge specialty pharmaceutical company aradigm corporation ardm free report regulatory application linhaliq be review fda advisory panel antimicrobial drug advisory committee jan few day ahead pdufa prescription drug user fee act goal date jan aradigm be look get linhaliq approve treatment cystic fibrosis bronchiectasis ncfbe patient chronic lung infection pseudomona aeruginosa accord information provide aradigm be unmet medical need ncfbe more person unite state person europe be affected severe chronic rare disease company expect sale ncfbe indication cross aradigm share be last year fda decide pediatric label expansion sucampo amitiza biopharma company sucampo pharmaceutical inc be await decision fda label expansion key market drug amitiza company be look get amitiza approve use child age year pediatric functional constipation fda grant priority review designation response be expect jan timely approval make amitiza first brand product available certain pediatric patient suffer pediatric functional constipation remind investor sucampo recently agree be acquire mallinckrodt deal value approximately acquisition be expect close first quarter read more mallinckrodt buy sucampo diversify portfolio sucampo share be last year sucampo be zack rank buy stock see complete list today zack rank strong buy stock here zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
3433,GILD,fast approach help look back past month year be whirlwind politically socially culturally economically dealt everything natural disaster gun violence protest racial inequality sexual harassment reckon stock market reach extraordinary high market hit daily time high note cnbc have return almost so far top perform sector technology be year date surpass worst perform sector energy telecom percentage point even overall positive economic sentiment have get big boost new tax bill merger acquisition activity have be relatively quiet deal be year date mid november deal be announce year be major revolve biggest consumer technology name here be best merger acquisition amazon buy whole foodsearlier summer commerce giant amazon amzn free report announce be buy high end organic grocery chain whole food deal officially close end august acquisition have be rocky start give amazon hundred physical store provide company strong entryway competitive grocery food industry intel acquire mobileyeintel intc say august have complete tender offer outstanding share mobileye company develop sensor camera advanced driver assist system ada israel base company be also know computer vision machine learn technology deal give intel huge advantage grow self drive car industry market estimate grow annually unite technology buy rockwell collinsin major industry deal unite technology utx free report agree buy rockwell collin col free report roughly be biggest move aviation history give rise aerospace giant focus manufacturing aircraft part touchscreen cockpit display jet engine many other thing unite plan combine aerospace business rockwell collin create new unit name collin aerospace system disney buy st century fox assetsjust few week disney free report st century fox foxa announce historic deal see mickey mouse parent scoop good chunk medium conglomerate asset include film studio century fox company tv production arm century fox television fox own cable network include fx national geographic foxa stake international network star tv sky disney also gain majority control stream service hulu deal however likely face intense regulatory scrutiny jab holding acquire european investment firm jab reach deal buy bakery café chain panera bread earlier year create formidable food focuse portfolio include keurig green mountain krispy kreme doughnut peet coffee tea caribou coffee company additionally panera be restaurant have manage post steady comparable sale growth rise revenue time many chain be hurt michael kor acquire jimmy choo affordable luxury retailer michael kor kor agree buy footwear brand jimmy choo popular name fashion world know towering stilettos july purchase have be long rumore kor plan used own massive global infrastructure expand jimmy choo footprint likely win be kor last acquisition company be now focuse form new luxury group coach buy kate spadecoach now tapestry inc tpr shake fashion industry back company announce be purchasing smaller rival kate spade deal be effort reach younger consumer recently sign deal millennial instagram icon selena gomez rebrand broader lifestyle assortment company cvs buy week rumor speculation drugstore chain cvs cvs announce acquire insurance provider aetna aet free report company say blockbuster deal rein health care cost transform cvs pharmacy storefront community medical hub primary care basic procedure expect close second half be subject shareholder regulatory approval gilead acquire kite pharmain october gilead science gild free report shell kite pharma mark biggest acquisition ever deal give company access promising cancer therapy hopefully make less reliant antiviral treatment hepatitis drug sovaldi particular cancer therapy be car drug many industry believe transform cancer treatment market cisco acquire broadsoftin move grow software footprint cisco csco free report paid nearly broadsoft company sell cloud base call control software product be often re labele sell traditional telephone company customer acquisition be vendor dub future work used technology meant make easier workgroup communicate other apple buy shazamrecently iphone maker apple aapl free report confirm have acquire shazam company let user identify song movie tv show commercial short audio clip tech giant be able use shazam boost apple music also hope integrate shazam more deeply io utilize app augment reality technology improve arkit effort arby roark buy buffalo wild last month arby owner roark capital group announce be acquire chicken wing chain buffalo wild wing bwld arby have successfully execute turnaround strategy specifically emphasize unique fast food menu selection firm hope apply similar formula buffalo wild wing arby also assume debt bwld meredith corp buy time inc meredith corporation mdp close deal november buy time time create publish giant de moine base meredith publish magazine better home garden family circle shape other time own time person sport illustrated fortune entertainment weekly many other print digital medium property have be business discovery acquire scripps network interactivein november discovery disca free report acquisition scripps network interactive receive overwhelming shareholder support merger unite cable programming giant discovery own discovery channel investigation discovery own tlc scripp portfolio include food network hgtv travel channel google buy part htc smartphone fall alphabet googl free report google division confirm plan acquire part htc mobile division team grow smartphone hardware business google have become very serious hardware development debut pixel line smartphone scoop chunk htc team mean tech giant better directly challenge android partner samsung lg huawei more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3434,GILD,gilead science inc gild free report announce encourage datum proof concept study experimental combination therapy patient advanced fibrosis due nonalcoholic steatohepatitis nash datum be present international liver congress paris apoptosis signal regulate kinase ask inhibitor selonsertib be combine acetyl coa carboxylase acc inhibitor gs selective steroidal farnesoid receptor fxr agonist gs therapy patient diagnosed nash liver fibrosis stage base biopsy magnetic resonance elastography mre mri proton density fat fraction mri pdff enrolled study be treat selonsertib mg gs mg selonsertib mg gs mg monotherapy group once daily week post treatment most notable change be observed be decrease liver fat content measure mri pdff occur regimen contain gs result also show improvement liver biochemistry marker fibrosis combination arm study compare baseline moreover patient treat selonsertib gs kinetic labele show reduction fractional synthesis rate lumican marker fibrogenesis hence favorable result suggest combination therapy selonsertib gs gs be evaluate further patient nash fibrosis gilead also announce completion enrolment phase iii trial stellar selonsertib gilead nash pipeline include selonsertib gs gs alone gilead present datum pre clinical study combination treatment approach nash evaluate gs gs together single agent rodent model nash liver fibrosis datum indicate combine agent have greater fibrotic steatotic effect lead improvement liver biochemistry fibrosis marker compare agent alone result gilead have initiate larger phase iib study combination treatment selonsertib gs gs patient advanced fibrosis due nash give persistent decline hcv franchise gilead be look foray market nash car hold great potential estimate nash be expect surpass hepatitis lead reason liver transplant unite state europe gilead stock have lose last month industry decline intercept pharmaceutical icpt free report be also evaluate lead candidate obeticholic acid phase iii study subject compensate cirrhosis due nash bristol myer squibb bmy free report have mid stage candidate nash space bms investigational pegylate analogue human fibroblast growth factor fgf key regulator metabolism patient biopsy confirm nash achieve primary endpoint significant reduction liver fat versus placebo swiss major novartis nvs free report be conduct phase iib involve combination novartis fxr agonist cenicriviroc treatment nash zack rankgilead currently carry zack rank sell see complete list today zack rank strong buy stock here investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
3435,GILD,month have go last earning report gilead science inc gild free report share have lose time frame recent negative trend continue lead next earning release be gild due dive investor analyst have react late let take quick look most recent earning report order get better handle important driver gilead earning sale miss estimate weak hcvgilead report dismal result first quarter earning revenue miss expectation due wider expect decline hepatitis virus hcv franchise company first quarter earning share miss zack consensus estimate earning be also year quarter figure share moreover total revenue also miss zack consensus estimate further revenue decline year year harvoni sovaldi plunge furtherproduct sale come year year due accelerate decline hcv sale antiviral product sale include gilead hiv liver disease portfolio come quarter year quarter research development expense decline selling general administrative sg expense increase hcv product sale include harvoni sovaldi epclusa vosevi be report year quarter downside be mainly due lower sale harvoni sovaldi major market lower sale epclusa unite state result increase competition sale harvoni plunge year year quarter epclusa garner sale quarter year period figure meanwhile hiv hbv product sale come year year increase be primarily drive continuous strong uptake tenofoviral afenamide taf base product such genvoya generate sale year quarter descovy record sale odefsey register sale entry generic greater inventory drawdown prior year quarter somewhat impact sale however hiv treatment stribild complera eviplera sale decline respectively viread sale be atripla sale tank truvada sale fall other product letairis ranexa zydelig record sale respectively adjust product gross margin be compare year period guidance continue expect net product sale range adjust expense adjust sg expense be project range respectively adjust product gross margin be expect range company acquire kite pharma fda approval yescarta car therapy treatment adult patient relapse refractory large cell lymphoma more line systemic therapy gilead prospect company also acquire cell design lab expand further car space yescarta sale come quarter dividend share declare cash dividend share common stock second quarter dividend be payable jun stockholder record close business jun quarter company paid cash dividend repurchase share have estimate be move then past month investor have witness downward trend fresh estimate have be revision lower current quarter gilead science inc price consensus gilead science inc price consensus gilead science inc quotevgm scoresat time gild have poor growth score momentum be do bit better stock be allocate grade value side putt top investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested company stock be suitable solely value base style score outlookestimate have be broadly trend downward stock magnitude revision indicate downward shift notably gild have zack rank hold expect line return stock next few month
3436,GILD,share intercept pharmaceutical inc icpt free report have decline industry rally intercept lead drug ocaliva be approve unite state combination ursodeoxycholic udca treatment primary biliary cholangitis pbc adult inadequate response udca monotherapy adult be unable endure udca drug be also grant conditional approval european commission initial uptake drug be encourage third quarter ocaliva record sale record second quarter however prescription demand softened follow dear health care provider letter fda safety communication ocaliva fda report death due ocaliva state drug also affect liver however intercept conduct analysis conclude patient be prescribe once daily dose ocaliva be time higher recommend weekly dose analysis be conduct consultation fda consequently intercept issue dear healthcare provider letter thereafter fda issue own safety communication reinforce recommend label dose intercept be also work fda further update ocaliva label safety purpose thus such news be likely dent sale potential meanwhile ocaliva be be evaluate other indication include alcoholic steatohepatitis nash primary sclerosing cholangitis psc company have earlier state plan initiate phase iii trial ocaliva nash patient cirrhosis second half expect trial start fda have approve redesign phase iii trial regenerate ocaliva safety efficacy treat nash patient liver fibrosis company now need achieve only co primary endpoint fibrosis improvement nash resolution compare earlier target achieve sample size trial have also be reduce approximately patient patient arm company complete enrolment interim analysis cohort regenerate trial datum readout first half nash market have huge potential tentative approval boost ocaliva prospect however bigwig novartis ag nvs free report gilead science inc gild free report have fxr agonist phase ii earlier stage clinical development be used treat pbc nash other liver disease gilead be conduct multiple phase iii trial nash patient various disease severity selonsertib inhibitor apoptosis signal regulate kinase company be also explore additional study nash gs small molecule allosteric inhibitor act protein protein homodimer interface acetyl coa carboxylase acquire nimbus therapeutic llc fxr agonist know gs gilead be also study number compound other liver disease include pbc psc allergan plc agn free report also have ongoing phase iii trial cenicriviroc immunomodulator block chemokine receptor type type treatment nash thus stiff competition intercept be unlikely stock turnaround tentative approval nash boost investore sentiment zack rankintercept currently carry zack rank hold see complete list today zack rank stock strong buy here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3437,GILD,alexion pharmaceutical inc alxn free report be latest company join ongoing acquisition spree biotech sector company recently announce acquire sweden base wilson therapeutic detail have offer sek cash outstanding share wilson therapeutic translate total transaction value alexion have already obtain shareholder support agreement largest shareholder accounting wilson therapeutic outstanding share additional shareholder accounting total company outstanding share transaction be expect close second quarter rationale acquisition add late stage candidate wtx alexion pipeline candidate be currently phase iii treatment wilson disease rare genetic disorder candidate be first class oral copper bound agent unique mechanism action ability access bind copper serum promote removal liver candidate have also obtain fast track designation unite state enjoy orphan drug designation treatment wilson disease unite state eu takealexion be look diversify portfolio reduce dependence blockbuster drug soliris deal strengthen alexion rare disease pipeline late stage candidate however investor weren much impressed news acquisition add candidate pipeline not approve drug thus stock lose follow announcement moreover market opportunity such rare disease be limit not boost top line expect alexion share have lose last month compare industry decline late quite few biotech company have be look strengthen portfolio pipeline be pretty hum front just few key deal be expect see surge primarily due lower tax rate take clue gilead science gild free report acquisition kite pharma celgene celg free report recently acquire juno therapeutic gain traction promising car space sanofi sny free report acquire bioverativ inc focus therapy hemophilia other rare blood disorder zack rank alexion currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3438,GILD,last year turn be pretty good pharma biotech stock far fda decision be concern regulatory body approve novel drug easily surpass total tally landmark decision last year include approval couple gene base therapy cancer novartis nvs free report kymriah gilead science gild free report yescarta therapy have potential change way look cancer treatment just quarter go year fda have already grant approval new treatment key approval include jnj free report next generation oral androgen receptor ar inhibitor erleada apalutamide pre metastatic prostate cancer crpc vertex pharmaceutical incorporate vrtx free report third medicine treat underlie cause cf symdeko be combination tezacaftor ivacaftor gilead once daily single tablet hiv regimen biktarvy novartis lutathera certain neuroendocrine tumor drug development process be lengthy time consume require utilization lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst let take look few important regulatory event schedule month april note month fda have already approve pacira pharmaceutical exparel new indication nerve block regional analgesia clovis oncology parp inhibitor rubraca maintenance therapy recurrent ovarian cancer second indication novartis kymriah apr fda be expect give decision novartis supplemental biologic license application bla look approval kymriah second indication latest filing novartis be look get kymriah approve treatment adult patient relapse refractory diffuse large cell lymphoma dlblc most common form hodgkin lymphoma have fail more prior therapy kymriah be approve treatment deadly cancer call acute lymphoblastic leukemia last august accord company annual report dlblc patient do not respond initial therapy relapse month treatment indicate significant market potential kymriah dlblc indication fda decision mallinckrodt label expansion amitiza child mallinckrodt plc mnk free report supplemental new drug application snda look get constipation drug amitiza approve paediatric functional constipation year be review fda be expect give decision apr amtiza be add mallinckrodt portfolio february acquisition sucampo pharmaceutical amitiza be already approve chronic idiopathic constipation cic adult irritable bowel syndrome constipation ib adult woman opioid induced constipation oic patient chronic cancer pain accord company press release amitiza approve paediatric functional constipation be first only prescription medication specifically approve such patient have limit treatment option address disease fda panel back gw pharmaceutical epidiolex incyte lilly olumiant fda panel be expect give opinion gw pharmaceutical lead cannabinoid pipeline candidate epidiolex next week gw pharmaceutical be look get epidiolex approve adjunctive treatment seizure associate lennox gastaut syndrome lgs dravet syndrome be highly treatment resistant form childhood onset epilepsy fda grant priority review epidiolex nda response fda be expect jun epidiolex represent blockbuster potential especially be approve possible indication fda panel be also expect give opinion month incyte lilly lly free report olumiant baricitinib treatment adult patient moderately severely active rheumatoid arthritis april company have receive complete response letter crl fda baricitinib fda require additional clinical datum thenda olumiant be re submit january olumiant have already be launch select european country japan fetch sale fda take recommendation panel advisory committe account review application be not bound follow same fda decision rigel tavalisse ultragenyx burosumab april fda be expect give decision rigel pharmaceutical nda tavalisse fostamatinib treatment chronic immune itp apr rigel be prepare launch oral spleen tyrosine kinase syk inhibitor second quarter approve exist therapy treat chronic itp include steroid blood platelet production booster tpos splenectomy however still disease remain inadequately treat many patient mean approve tavalisse enjoy significant market potential fda decision expect apr be ultragenyx pharmaceutical bla burosumab treat pediatric adult patient link xlh burosumab be approve treat xlh trade name crysvita eu february fda decide prometic ryplazim fda decision expect apr be canadian biotech prometic life science biologic license application bla ryplazim treatment congenital plasminogen deficiency ryplazim enjoy orphan drug fast track designation fda say indication bristol myer opdivo yervoy combo get fda approval bristol myer bmy free report have file sbla look get blockbuster drug opdivo approve combination cancer drug yervoy patient previously untreated advanced metastatic renal cell carcinoma rcc fda decision be expect apr clinical study combination have demonstrated superior overall survival os compare current standard care sunitinib intermediate poor risk patient bode well drug give potential target market pd inhibitor be presently approve several country include unite state eu japan several cancer indication label expansion boost opdivo sale further opdivo generate sale almost bristol myer be zack rank hold stock see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3439,GILD,pfizer inc pfe free report announce have form alliance private biotech allogene therapeutic expedite development allogeneic car therapy san francisco base allogene be co founder lead former executive kite pharma be acquire gilead gild free report last year pfizer own stake allogene also get representation latter board deal allogene assume pfizer right preclinical car asset pfizer license french company cellectis servier addition allogene also gain right phase candidate ucart pfizer develop partnership servier ucart be allogeneic car therapy have potential be develop treatment cd express hematological malignancy be presently phase study acute lymphoblastic leukemia phase ii study be expect be initiate next year allogene servier allogeneic car therapy potentially revolutionary cancer treatment approach be develop cell healthy donor store shelf use patient approach eliminate need create personalize therapy thereby reduce time patient treatment focus car area have increase last year fda approval therapy such novartis nvs free report kymriah gilead yescarta treatment have huge commercial potential well change treatment paradigm car fall ambit cellular immunotherapy involve used patient own immune cell attack get rid harmful disease cell body car approach involve collection patient cell genetic modification outside body incorporation specific receptor target cancer cell finally re infusion modify cell back patient go say many drug biotech company be look boost pipeline such drug meanwhile cnbc report pfizer be talk consumer giant procter gamble pg free report regard sale consumer healthcare segmentlast october pfizer have say be explore strategic alternative consumer healthcare segment include partial full separation spin sale other transaction decision regard same be expect be make year ultimately opt retain business however pfizer be have trouble find buyer same last month london base pharma consumer giant glaxo be consider frontrunner bid pfizer unit withdraw race buy pfizer consumer healthcare segment read more glaxo drop bid pfizer unit shingrix gain eu japan nod british company reckitt benckiser group also pull discussion pfizer buy same unit follow recent development pfizer share be tuesday share pfizer have decline so far year compare decrease industry pfizer carry zack rank buy see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3440,GILD,glaxosmithkline plc gsk free report report core earning cent american depositary share fourth quarter surpass zack consensus estimate cent bottom line be constant exchange rate cer compare year figure glaxo share have lose year time industry increase quarterly revenue rise cer drive strong segmental performance consumer healthcare pharmaceutical vaccine top line also outpaced zack consensus estimate growth rate mentioned be year year basis cer quarterly highlightssale be unite state international market flip side sale europe be flat year year sale new pharmaceutical vaccine product surge drive hiv drug tivicay triumeq respiratory drug ellipta product nucala meningitis preventive vaccine bexsero menveo glaxo report financial figure segment pharmaceutical vaccine consumer healthcare pharmaceutical division register revenue growth drive hiv drug tivicay triumeq respiratory disease drug relvar breo nucala upside be partly offset impact recent divestment sale decrease older respiratory product include seretide advair establish pharmaceutical hiv sale increase back growth unite state international sale respectively europe sale be also year year encourage number be drive continue market share growth triumeq sale tivicay sale however sale hiv drug epzicom kivexa tumble due increase generic competition particularly affect european market notably company latest product hiv portfolio be juluca dolutegravir rilpivirine first drug regimen once daily single pill hiv be approve unite state november drug generate initial sale quarter however week gilead science gild free report have announce fda approval triple combination once daily single tablet regimen biktarvy bictegravir emtricitabine tenofovir alafenamide hiv infection treatment approval competitive threat juluca come quarters respiratory sale be cer eu international market sale increase respectively however unite state metric be flat year year sale improvement be mainly drive new respiratory product sale growth partially offset sale decline older product seretide advair flovent ventolin notably recently launch respiratory product trelegy ellipta only once daily single inhaler triple therapy copd have generate initial sale unite state eu report quarter ellipta product record surge sale drive market share gain global roll continue however upside be offset lower sale seretide advair flixotide flovent ventolin sale decrease respectively immuno inflammation drug include benlysta rise quarter new grouping establish pharmaceutical comprise previous establish product cardiovascular metabolic urology cvmu other pharma product establish pharmaceutical sale decline quarter review sale consumer healthcare segment climb slowdown market condition power brand particularly pain relief oral health category see sturdy performance quarter sale vaccine segment be impressive have increase year year geographically unite state europe international market increase respectively meningitis vaccine bexsero decrease unite state same increase europe market menveo unite state post higher sale same be offset weak performance establish vaccine due increase competitive pressure infanrix pediarix unite state europe be important note october fda grant approval glaxo shingle vaccine shingrix later same month center disease control prevention advisory committee immunization practice vote favor recommendation use shingrix vaccine be prefer merck mrk free report zostavax owing favorable recommendation shingrix generate initial sale unite state period discussion resultsfull year sale gain year year however metric marginally miss zack consensus estimate earning share be line zack consensus estimate full year bottom line reflect growth compare year figure moreover report earning match previously announce guidance company state ep growth be uncertain due timing entry advair generic market hence issue set guidance company expect ep growth cer advair generic be launch further year however probable event introduce advair generic market mid glaxo anticipate adjust ep be flat year year cer company mylan myl free report hikma pharmaceutical novartis be try bring generic version advair market receive complete response letter crl fda mylan hikma receive crl last year novartis receive same week delay entry generic market long term company project ep witness cagr mid high single digit range vaccine segment be estimate register mid high single digit growth competition pediatric flu vaccine consumer healthcare segment be expect deliver low mid single digit top line cagr glaxosmithkline plc price consensus ep surprise glaxosmithkline plc price consensus ep surprise glaxosmithkline plc quote zack rankglaxo carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3441,GILD,intercept pharmaceutical inc icpt free report report mixed result first quarter company report loss share first quarter narrower zack consensus estimate loss share year loss share intercept pharmaceutical inc price consensus ep surprise intercept pharmaceutical inc price consensus ep surprise intercept pharmaceutical inc quote quarterly revenue be significantly year quarter miss zack consensus estimate quarter detailocaliva record sale record fourth quarter net sale unite state come ex ocaliva net sale come ocaliva be approve unite state combination ursodeoxycholic udca treatment primary biliary cholangitis pbc adult inadequate response udca monotherapy adult be unable endure udca drug be also grant conditional approval european commission february ocaliva label be update unite state include box warning dose table reinforce exist dose schedule pbc patient child pugh class decompensate cirrhosis research development expense increase year year primarily drive increase clinical development program obeticholic acid oca infrastructure support such program selling general administrative expense increase year quarter outlookocaliva net sale be expect intercept continue expect operate expense range pipeline updateoca be be evaluate other indication include alcoholic steatohepatitis nash primary sclerosing cholangitis psc fda earlier approve redesign phase iii trial regenerate oca safety efficacy treat nash patient liver fibrosis company now need achieve only co primary endpoint fibrosis improvement nash resolution compare earlier target achieve enrolment interim analysis cohort be complete trial result be expect first half earlier intercept initiate phase iii trial reverse oca randomize phase iii study evaluate efficacy safety oca subject compensate cirrhosis due nash approximately patient biopsy confirm diagnosis cirrhosis primary endpoint study be percentage subject histological improvement fibrosis least stage used nash clinical research network crn score system month treatment patient enrolled trial be be randomize ratio treatment arm once daily dose oca mg once daily oca mg titration mg month placebo patient successfully complete double blind phase reverse be enrolled open label extension phase additional month trial be currently enrolling intercept expect submit marketing authorization oca treatment option nash patient compensate cirrhosis unite state international market base positive result study subsequent outcome trial be also card confirm clinical benefit post marketing basis broader population nash patient cirrhosis first quarter result be mixed loss be narrower expectation sale miss expectation update label help stock turn be sale start recover intercept stock have tumble year compare industry decline company stock be hit due safety issue regard ocaliva give challenge face drug recent time label expansion oca boost growth prospect estimate nash be expect surpass hepatitis lead reason liver transplant unite state europe nash market have huge potential tentative approval boost ocaliva prospect however bigwig novartis ag nvs free report gilead science gild free report have fxr agonist phase ii earlier stage clinical preclinical development be used treat pbc nash other liver disease zack rank stock currently carry zack rank hold better rank stock healthcare sector be exelixis exel free report currently sport zack rank strong buy see complete list today zack rank stock here exelixis earning share estimate increase cent cent last day company report better expect first quarter result look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3442,GILD,celgene corporation celg free report report encourage first quarter result earning sale top expectation company report adjust earning share beat zack consensus estimate year quarter celgene corporation price consensus ep surprise celgene corporation price consensus ep surprise celgene corporation quotetotal revenue grow quarter beat zack consensus estimate revenue be boost consistent performance company key growth driver revlimid revlimid key catalystnet product sale increase year year net sale revlimid come reflect year year growth drug perform well unite state international market growth quarter be drive increase volume result increase duration treatment market share net sale cancer drug abraxane increase sale benefit buy pattern pomalyst imnovid come sale be drive increase volume due increase market share duration otezla sale be quarter sale unite state be primarily volume drive due increase demand improve access pull contract health plan sale international market be drive primarily increase adoption key ex market other product sale include istodax thalomid vidaza authorize generic version vidaza unite state totale quarter year quarter adjust research development expense increase due higher spending related drug discovery clinical trial activity adjust selling general administrative expense decrease pipeline updatecelgene acquire acquire juno therapeutic inc approximately march february company also acquire impact biomedicine add late stage candidate fedratinib highly selective jak kinase inhibitor pipeline celgene announce global collaboration prothena prta free report march develop new therapy broad range disease primarily focuse protein implicate pathogenesis several disease include tau tdp undisclosed target celgene partner bluebird bio blue free report opted co develop co promote bb experimental bcma car cell therapy treatment patient rrmm unite state march company have originally enter broad global strategic research collaboration develop commercialize novel therapy oncology include bb agreement be amend however celgene suffer setback receive refusal file letter fda regard new drug application nda ozanimod relapse multiple sclerosis rm celegne now plan resubmit nda first quarter follow type meeting fda early april company also plan submit marketing authorization application maa ozanimod rm first quarter outlook updatedcelgene now anticipate earning share compare earlier estimate zack consensus estimate earning be share net revenue be now estimate high end previously project range zack consensus estimate same be peg number include impact dilution juno acquisition revlimid sale be now project estimate earlier abraxane sale be estimate be pomalyst revenue be now project previous projection otezla sale continue be project takecelgene first quarter result be encourage company beat sale earning revlimid sale be impressive yet again pomalyst otezla result come breather investor bore brunt decline share price due series setback last few month celgene stock have lose last month compare industry decline nevertheless share company be pre market trading due earning beat celgene suffer series setback last few month company suffer setback late stage study lead cancer drug revlimid combination rituxan fail threat generic competition be also loom large revlimid lose patent protection force celgene look acquisition stock be hit earlier phase iii trial revolve cd pipeline candidate ged crohn disease extension trial sustain cd be discontinue company also suffer setback rm candidate ozanimod celgene be look new deal acquisition give lacklustre juno acquisition be same track note slowdown mature product compel prominent biotechs acquire smaller one promising pipeline gilead science gild free report acquire kite pharma subsequently obtain fda approval yescarta axicabtagene ciloleucel latter chimeric car therapy candidate zack rankcelgene be zack rank buy stock see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3443,GILD,performance drug industry first quarter have be encourage quite few company beating earning well revenue estimate overall investor sentiment pharma biotech stock have improve late investor be focuse more fundamental issue drug pricing drug pricing continue major deterrent thank government increase emphasis make drug affordable new drug approval label expansion exist drug help company maintain momentum year see number drug rhopressa tymlos ozempic vyzulta siliq trulance hemlibra other get approval lutathera ilumya symdeko biktarvy erleada have already be approve investor be expect keep focus same merger acquisition remain key area investor focus be pretty hum front just few key deal be expect see surge primarily due lower tax rate take clue gilead science gild free report acquisition kite pharma celgene celg free report recently acquire juno therapeutic gain traction promising car space sanofi sny free report acquire bioverativ inc focus therapy hemophilia other rare blood disorder company have also obtain trust clearance connection previously announce acquisition ablynx strong pipeline innovative treatment impressive result grow demand drug especially rare treat disease age population increase health care spending support growth sector caution be be exercise pick stock investing here be few sell rate stock be strictly avoid now valeant pharmaceutical international inc vrx free report canada base specialty pharma company valeant have be trouble water quite time now valeant guidance be disappointing tumultuous period valeant start rebuild process ceo joseph papa company have reduce total debt approximately end first quarter however dermatology business remain challenge be expect decline compare quite few drug be face generic competition hence be company turn around management have project company currently carry zack rank sell valeant share have decline last month compare industry fall endo international plc endp free report ireland base endo be global specialty pharmaceutical company focuse generic brand pharmaceutical endo guidance be way expectation generic business be tremendous pressure due loss marketing exclusivity first file product ezetimibe tablet quetiapine tablet first half brand pharmaceutical business be impact continue generic competition establish product product divestiture cease shipment opana be expect continue further endo withdraw opioid pain medication opana oxymorphone hydrochloride extend release market follow fda request june company divest core asset such belbuca restructure pain franchise focus particularly specialty brand business however zack rank strong sell company be expect face challenge business condition endo share have lose last month industry decline aerie pharmaceutical inc aeri free report irvine base aerie pharmaceutical focus development eye disease therapy include glaucoma other eye disease aerie receive significant boost recent approval lead drug rhopressa lower elevated intraocular pressure patient open angle glaucoma ocular hypertension however rhopressa face stiff competition establish brand generic pharmaceutical company such novartis simbrinza travtan allergan lumigan well other smaller biotechnology pharmaceutical company valeant vyzulta be recently approve open angle glaucoma ocular hypertension rhopressa face tough time gain market share due competition product hence advise investor steer clear zack rank stock time be aerie share have fall last month industry decline see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3444,GILD,value investing be easily most popular way find great stock market environment wouldn want find stock be fly radar be compelling buy offer tantalize discount compare fair value way find company be look several key metric financial ratio many be crucial value stock selection process let put gilead science inc gild free report stock equation find be good choice value oriented investor right now investor subscribe methodology look elsewhere top pick pe ratioa key metric value investor always look be price earning ratio pe short show much investor be willing pay dollar earning give stock be easily most popular financial ratio world best use pe ratio be compare stock current pe ratio ratio have be past compare average industry sector compare market whole front gilead science have trail month pe ratio see chart level actually compare pretty favorably market large pe stand focus long term pe trend gilead science current pe level put midpoint past year number have rise rapidly past few month further stock pe also compare favorably industry trail month pe ratio stand very least indicate stock be relatively undervalue right now compare peer also point gilead science have forward pe ratio price relative year earning just be tad higher current level so be fair expect increase company share price term ratioanother key metric note be price sale ratio approach compare give stock price total sale lower read be generally consider better person metric more other value focuse one look sale something be far harder manipulate accounting trick earning right now gilead science have ratio be bit higher average come right now however see chart be well high stock particular past few year anything gild be lower end range time period metric suggest level undervalue trading least compare historical norm broad value outlookin aggregate gilead science currently have value score putt top stock cover look make gilead science solid choice value investor stock overall gilead science be good choice value investor be plenty other factor consider investing name particular be worth note company have growth score momentum score give gild zack vgm score overarch fundamental grade read more zack style score here meanwhile company recent earning estimate have be downbeat current year have see estimate go higher past day compare next year estimate have see same time period have have significant impact consensus estimate current year consensus estimate have decrease past month next year estimate have decrease see consensus estimate trend recent price action stock chart gilead science inc price consensus gilead science inc price consensus gilead science inc stock have zack rank hold be look line performance company term bottom lineapple be inspire choice value investor be hard beat incredible lineup statistic front however sluggish industry rank bottom more industry zack rank be hard get too excited company overall fact past year broader industry have clearly underperform market large see so value investor want estimate analyst sentiment turn name first once happen stock be compelling pick hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
3445,GILD,cancer oncology space have always be keenly watch investor interested pharma biotech sector be disease be lead cause morbidity mortality world precede only heart disease major player field include pfizer pfe free report bristol myer bmy free report novartis nvs free report astrazeneca azn free report merck mrk free report roche rhhby free report cancer drug be most important revenue driver bigwig well smaller counterpart clovis oncology tesaro puma biotechnology othersevolution cancer spacea lot progress have be make area last few year company be aim bring newer better treatment immunotherapy gene therapy target therapy other novel therapy fact focus area have increase fda approval car therapy novartis kymriah gilead gild free report yescarta last year path breaking immunocellular therapy be time treatment used patient own cell fight cancer acquisition kite gilead juno celgene have lead renew interest area interest parp inhibitor have also increase considerably well be next major class therapeutic oncology accord imsquintile new cancer drug be approve indication worldwide cost cancer therapeutic supportive care drug shot unite state accounting cost more molecule be late stage development majority be target therapy attack specific feature target cancer cell new cancer drugsnew oncology brand include bristol myer opdivo merck keytruda pfizer ibrance abbvie imbruvica be fast catch give tough competition category stalwart such avastin herceptin rituxan new cancer drug approve last year include pfizer merck kgaa bavencio bladder cancer eli lilly verzenio novartis kisqali puma biotechnology nerlynx breast cancer tesaro zejula ovarian cancer most common indication new drug be small cell lung cancer nsclc hodgkin lymphoma melanoma breast cancer be patient population benefit go say new drug bring million buck company be sell huge amount money however be do enough cure patient help live longer better be relieve pain fatigue consider fact come premium fda have approve number oncology drug recent year also lower bar clinical study goal cancer candidate disease still remain top cause death many population here probably few drug have be successful allow patient limit life expectancy live year however efficacy several other be be question have lead only marginal benefit not much improvement survival quality life many drug be be approve base progression free survival amount time patient live tumor grow larger evidence benefit survival quality life be specially case drug aim treat terminal cancer few treatment option however overall survival os datum once available sometimes show drug do not help person live longer also drug do offer survival benefit gain be often marginal risk long term side effect drug have also be underestimated overall cancer survival have barely change past decade raise concern push get more drug approve instead get effective drug approve large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
3446,GILD,acquisition once again remain focus week celgene celg free report rumore be talk juno regard possible deal recap week most important storiesjuno soar acquisition rumor juno share sky-rocket report celgene be interested acquire immuno oncology focuse company accord wall street journal report company be talk regard possible acquisition deal juno acquisition rumor turn be true be second acquisition announcement be make celgene year just last week company announce intention acquire impact biomedicine be develop fedratinib myelofibrosis polycythemia vera celgene be lot pressure strengthen pipeline revenue stream company have tough issue pipeline setback well weak performance otezla weigh stock however remain be see much celgene be willing shell juno juno market cap jan be juno share have be upward trend follow gilead kite acquisition announcement last year august juno be focuse development innovative cellular immunotherapy treatment cancer company have long be consider potential acquisition target last year juno share be compare gain record industry belong juno cell base cancer immunotherapy be base chimeric antigen receptor high affinity cell receptor technology company have several cell base candidate pipeline target variety cell malignancy well multiple solid tumor multiple myeloma juno suffer major setback development erstwhile lead pipeline candidate due safety issue include patient death company be now focuse liso cel next generation car cell product target cd juno expect file fda approval liso cel relapse refractory diffuse large cell lymphoma dlbcl second half immuno oncology space remain quite lucrative celgene have pay hefty premium finalize deal juno celgene already have collaboration deal place concert patent challenge update concert pharmaceutical cnce free report suffer major blow post grant review pgr petition challenge validity patent be reject patent trial appeal board ptab patent trademark office concert have file petition last year july challenge validity patent have be assign incyte pharmaceutical incy free report concern patent cover deuterate ruxolitinib analog concert ctp be deuterium modify version ruxolitinib incyte market ruxolitinib unite state name jakafi have patent cover ruxolitinib be unexpired concert seek marketing approval ctp setback concert say always challenge validity patent later federal court moreover company say decision do not affect plan develop ctp alopecia areata however company be now reassess plan develop ctp additional indication ctp be novel jak inhibitor currently phase ii development alopecia areata fda recently grant fast track status candidate indication read more concert pharmaceutical plunge patent petition setback vertex orkambi label expand eu vertex pharmaceutical vrtx free report gain eu approval use orkambi lumacaftor ivacaftor child cystic fibrosis cf year age group copy del mutation child europe category approval be line expectation consider company have get positive opinion european union committee medicinal product human use chmp indication november read more vertex cystic fibrosis drug pediatric use eu vertex be zack rank strong buy stock see complete list today zack rank stock here humira biosimilar bla accept fda fda have accept review biologic license application bla submit sandoz biosimilar version abbvie blockbuster drug humira adalimumab humira be approve wide range indication recent healthcare conference abbvie say global humira sale crossed approach company expect drug lose exclusivity international market fourth quarter believe sale erosion be manageable note sandoz be not first file biosimilar version humira fact company amgen amgn free report boehringer ingelheim have already gain approval humira biosimilar amgen enter global settlement license agreement abbvie expect launch humira biosimilar europe october unite state january meanwhile abbvie boehringer be engage patent litigation unite state eiger plunge pipeline setback eiger suffer major setback investigational treatment ubenimex pulmonary arterial hypertension pah fail meet primary endpoint mid stage study base disappointing update company have decide discontinue development ubenimex pah continue evaluate ubenimex lymphedema ubenimex be mid stage study indication datum expect second half year company share be news biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index be slightly last trading session major biotech stock celgene decline gilead gild free report gain last month biogen be regeneron lose see last biotech stock roundup here celgene acquire impact morgan healthcare conference focus next biotech world watch usual regulatory pipeline update synergy pharmaceutical get know approval status trulance use adult patient irritable bowel syndrome constipation ib jan more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3447,GILD,share celgene corporation celg free report have decline industry gain celgene suffer series setback last few month company suffer setback last week late stage study lead cancer drug revlimid combination roche holding rhhby free report rituxan fail study evaluate revlimid rituxan follow maintenance compare standard care feature rituxan chemotherapy chop bendamustine vn cvp follow rituxan maintenance previously untreated follicular lymphoma however treatment arm not achieve superiority co primary endpoint complete response unconfirmed complete response cr cru week term progression free survival pfs observed pre plan analysis none arm prove superior co primary endpoint meanwhile additional analysis trial be underway celgene key growth engine be revlimid drug worldwide sale increase contribute almost total revenue revlimid oral drug be currently approve several indication include mm myelodysplastic syndrome mantle cell lymphoma failure study be disappointing drug label expansion have boost sale potential company have expect lymphoma increase revlimid growth prospect company portfolio also include pomalyst imnovid abraxane otezla istodax vidaza thalomid thalidomide however abraxane sale be pressure due highly competitive market lung breast cancer therapy scenario dependence revlimid have inherent risk addition october company announce phase iii trial revolve cd pipeline candidate ged crohn disease extension trial sustain cd be discontinue follow recommendation datum monitoring committee assessed overall benefit risk recent interim futility analysis meanwhile deep yet persistently slow growth psoriatic arthritis psoriasis market especially entire third quarter have lead weak performance otezla consequently company also reduce annual guidance challenge market condition be drive increasingly restrictive pbm formulary control factor remain hangover company share well positive note august company obtain fda approval idhifa treatment relapse refractory acute myeloid leukemia isocitrate dehydrogenase idh mutation drug be develop partnership agio pharmaceutical inc agio free report expect celgene look strategic acquisition same note bigwig gilead science inc gild free report aid top line zack rankcelgene currently carry zack rank sell see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3448,GILD,gilead science inc gild free report receive major boost fda approve company once daily single tablet regimen str biktarvy bictegravir mg emtricitabine mg tenofovir alafenamide mg bic ftc taf hiv infection approval come ahead pdufa date feb provide major boost gilead hiv franchise company top earning revenue estimate fourth quarter magnitude decline hcv sale be wider expect hcv franchise have be pressure due lower patient start increase competition form abbvie abbv free report company guidance also lack lustre expect sale same decline further such scenario approval latest triple hiv therapy be likely provide impetus stock gilead be now banking hiv franchise newer avenue car therapy post kite acquisition promising nash candidate growth follow news approval share company moved gilead stock have gain last month industry decline biktarvy gilead latest triple therapy be approve complete regimen treatment hiv infection adult have antiretroviral treatment history replace current antiretroviral regimen be virologically suppress hiv rna ml stable antiretroviral regimen least month history treatment failure know substitution associate resistance individual component biktarvy meanwhile hiv franchise continue gain traction back rapid adoption taf base regimen unite state eu taf base regimen now represent total gilead hiv prescription volume follow launch genvoya odefsey descovy biktarvy combine novel unboosted integrase strand transfer inhibitor insti bictegravir demonstrated safety efficacy profile descovy ftc taf dual nucleoside reverse transcriptase inhibitor nrti backbone be smallest insti base triple therapy str available approval biktarvy be support encourage datum ongoing study study treatment naïve hiv infected adult study virologically suppress adult biktarvy meet primary objective inferiority week study however biktarvy have box warning product label regard risk post treatment acute exacerbation hepatitis approval new hiv therapy stiff competition glaxosmith gsk free report exist therapy tivicay triumeq other hand report reuter viiv healthcare joint venture majority own glaxosmith pfizer pfe free report shionogi ltd have file lawsuit gilead allege patent infringement viiv dolutegravir component venture triple drug hiv treatment triumeq zack rankgilead currently carry zack rank sell see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3449,GILD,even time global uncertainty market volatility increase number investor flock equity market invest hard earn money be number investment style suit predilection hundred investor look best value stock price book ratio ratio be easy use tool identify low price stock have high growth prospect ratio be used calculate much investor need pay dollar book value stock be calculate divide current close price stock latest quarter book value share be book value book value be total value be left accord company balance sheet go bankrupt immediately other word be shareholder theoretically receive company liquidate asset pay liability be calculate subtract total liability total asset company most case equate common stockholder equity balance sheet however depend company balance sheet intangible asset also be subtract total asset determine book value understand ratioby compare book value equity market price get idea company be overpriced however ratio be always better compare ratio industry ratio less mean stock be trading less book value stock be undervalue therefore good buy conversely stock ratio greater be interpreted be overvalue relatively expensive be caveat ratio less also mean company be earn weak even negative return asset asset be overstate case stock be shun be destroy shareholder value conversely stock price be significantly high thereby push ratio more likely case have become takeover target good enough reason own stock moreover ratio isn limitation be useful business finance investment insurance banking manufacturing company many liquid tangible asset book however be mislead firm significant expenditure high debt company service company negative earning case ratio be not particularly relevant standalone number also analyze other ratio debt equity arrive reasonable investment decision screening parametersprice book common equity less industry median lower compare industry average imply be enough room stock gain price sale less industry median ratio determine much market value dollar company sale revenue lower ratio industry make stock attractive price earning used estimate less industry median ratio value company base current share price relative estimate earning share lower ratio industry be consider better peg less peg ratio link ratio future growth rate company peg ratio portray more complete picture ratio value less indicate stock be undervalue investor need pay less stock have bright earning growth prospect current price greater equal be trading minimum higher average day volume greater equal substantial trading volume ensure stock be easily tradable zack rank less equal zack rank strong buy buy stock be know outperform irrespective market environment value style score equal research show stock value score combine zack rank offer best opportunity value investing space here be stock qualify screening food hold corp usfd free report foodservice distributor have project year ep growth rate currently stock have value score zack rank see complete list today zack rank stock here meritage home corporation mth free report lead homebuilder currently have zack rank have year ep growth rate value score western digital corporation wdc free report largest hard disk drive hdd producer unite state currently have zack rank have year ep growth rate value score gilead science inc gild free report lead biotech currently have zack rank value score lam research corporation lrcx free report be lead global provider innovative wafer fabrication equipment service semiconductor industry company have project year ep growth rate lam research currently have zack rank value score get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performancezack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
3450,GILD,snap inc snap free report share slump report first quarter revenue miss zack consensus estimate milliongilead science inc gild free report lose report first quarter earning share lower zack consensus estimate mastercard inc free report share increase post first quarter adjust earning share surpass zack consensus estimate share unum group unm free report plunge report first quarter earning share miss zack consensus estimate
3451,GILD,apple inc aapl free report sell fewer iphone fiscal versus expect earning top zack consensus cent share sale be line estimate world biggest gadget maker zack rank sell rate stock ahead earning report post quarterly gross margin guide similar range average selling price asp iphone also drop bit quarter overall revenue phone grow apple sell ipad macs quarter overall sale growth year year company also announce massive share buyback program tune well share dividend increase share be still year date be earning news more aapl earning click here snap inc snap free report have problematic quarter earning report bell today meeting bottom line estimate cent share just revenue well expect daily active user totale also forecast company do see total ad revenue rise quarter average revenue user sequentially cost user be share be double digit late afternoon trading more snap earning click here tough quarter gilead gild free report be report tuesday close earning share well expect year number share revenue do not fare better reach just zack consensus guidance gilead full year remain unchanged zack consensus expect share sale prior earning release good news come company recently acquire kite pharma treatment yescarta blossom sale previous quarter share be market more gild earning click here mobile tmus free report only day remove long await merger agreement sprint post beat earning revenue cent share versus cent expect sale top zack consensus net add be also better expect quarter estimate mobile hasn miss earning estimate trail quarter average earning beat wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3452,GILD,gilead science inc gild free report report fourth quarter result earning revenue surpass expectation however management issue bleak view consequently stock decline market hour trading be expect open red give expectation further decline hepatitis virus hcv franchise nevertheless gilead stock have gain last month industry decline company fourth quarter earning share beat zack consensus estimate however earning be year quarter figure share moreover total revenue top zack consensus estimate however revenue decline year year gilead science inc price consensus gilead science inc price consensus gilead science inc quote harvoni sovaldi plunge furtherproduct sale come year year decline be due lower hcv sale partially offset higher sale hiv other therapeutic area antiviral product sale include gilead hiv liver disease portfolio come quarter hcv product sale include harvoni sovaldi epclusa vosevi be report year quarter downside be mainly attribute lower sale harvoni sovaldi major market sale harvoni decline year year quarter further sovaldi sale record steep year year decline epclusa garner sale quarter year figure meanwhile hiv hbv product sale come year year increase be primarily drive continuous strong uptake tenofoviral afenamide taf base product such genvoya generate sale year quarter descovy record sale odefsey register sale hiv treatment stribild complera eviplera sale decline respectively viread sale be atripla sale tank truvada sale fall other product letairis ranexa zydelig record sale respectively research development expense decline due impact ongoing milestone payment selling general administrative sg expense decrease adjust product gross margin be compare year period resultsrevenue come surpass zack consensus estimate earning share come beat zack consensus estimate guidancegilead now expect net product sale range adjust expense adjust sg expense be project range respectively adjust product gross margin be expect range company acquire kite pharma fda approval yescarta car therapy treatment adult patient relapse refractory large cell lymphoma more line systemic therapy gilead prospect company recently acquire cell design lab expand further car space dividend share gilead declare cash dividend cent share common stock first quarter increase dividend be payable mar stockholder record close business mar company paid cash dividend repurchase share company top earning revenue estimate fourth quarter magnitude decline hcv sale be larger expect hcv franchise be tremendous pressure due lower patient start increase competition expect sale decline further go forward note harvoni sovaldi epclusa face competition abbvie abbv free report viekira pak viekira xr bristol myer bmy free report merck mrk free report zepatier pricing market share be expect stabilize mid patient start be expect decline further meanwhile hiv franchise maintain momentum drive rapid adoption taf base regimen unite state eu taf base regimen now represent total gilead hiv prescription volume follow launch genvoya launch odefsey descovy truvada use pre exposure prophylaxis set also put strong performance company see significant uptick prep usage estimate patient used truvada end approval yescarta also bode well gilead expect decline hcv franchise offset positive momentum hiv franchise gilead be also intend foray nash market pipeline candidate selonsertib filgotinib zack rankgilead currently carry zack rank sell see complete list today zack rank strong buy stock here zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
3453,GILD,earning season pharma biotech sector be scatter few small biotech company yet report release so far provide clear picture sector performance overall sector perform reasonably well biotech pharma bigwig gilead gild free report celgene celg free report vertex vrtx free report beat earning revenue estimate meanwhile biogen biib free report announce mixed result earning beating estimate sale lag same however amgen amgn free report have rather weak quarter miss expectation earning sale also issue lower expect sale guidance drug biotech stock remain growth trajectory ramp new product sale successful innovation product line expansion favorable clinical study result frequent fda approval strong performance key product grow demand drug especially rare treat disease age population increase health care spending be factor keep drive sector faster drug approval process propose removal outdated regulation push cost slowdown innovation also prove beneficial year start expectation pick activity new tax law cut corporate tax rate encourage company bring back huge cash hold overseas time tax rate be expect spur merger activity year sanofi sny free report earlier year announce deal buy belgian biotech company ablynx haemophilium focuse biotech firm bioverativ banking positive trend impressive performance be perfect time cash bountiful prospect grow market here have picked biotech stock see positive estimate revision post earning release also flaunt zack rank strong buy buy see complete list today zack rank stock here earning estimate revision have greatest impact stock price stock rise estimate have significantly outperformed index year year hence investor safely bet stock have be see upward movement earning estimate company have also see steady rally share price post result ligand pharmaceutical incorporate lgnd free report san diego base biotechnology company ligand carry zack rank stock witness positive estimate revision last day company release fourth quarter earning feb have see zack consensus estimate earning rise company surpass earning revenue estimate fourth quarter mainly higher royalty revenue additionally share company have rally post earning release regeneron pharmaceutical inc regn free report tarrytown ny base company regeneron witness positive estimate revision last day company release fourth quarter earning feb zack rank stock have see zack consensus estimate earning rise respectively regeneron fourth quarter result be impressive earning sale beat estimate strong sale company key market drug eylea share company have rally release earning release horizon pharma plc hznp free report base dublin ireland horizon pharma carry zack rank company have see zack consensus estimate earning move last day company release fourth quarter earning feb share company have gain post earning announcement horizon pharma also beat earning sale estimate fourth quarter backed strong performance orphan unit company sale guidance be encourage well outlookwhile be strong year be expect be vital biotech sector company continue invest pipeline build global business drive new product growth zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
3454,GILD,just few day left year end be say turn be pretty good year biotech sector sector have be struggle due several issue include drug pricing controversy mixed result slower expect new product launch increase competition pipeline setback however investor be more comfortable drug pricing controversy year focus be now more fundamental sector new product sale ramp success innovation continue strong performance key product be factor help sector rebound nasdaq biotechnology index be impressive year date year also turn be pretty good fda approval be concern date regulatory agency have give nod novel drug well drug approve last year immuno oncology be key focus area be do scientific conference clinical trial collaboration acquisition fda approval approval novartis kymriah gene cell therapy gilead gild free report yescarta car chimeric antigen receptor cell cell treatment ensure highly lucrative immuno oncology market remain limelight acquisition immuno oncology focuse kite gilead also increase interest category investor expect more acquisition announcement area course be not good news sector company celgene biogen be hit pipeline setback gilead continue struggle due dwindle sale hepatitis virus hcv franchise nevertheless be quite few company fared extremely well share outperform sector well overall market back factor deal pipeline progress fda approval here be look such company xoma corporation xoma free report xoma be focuse discovery development licensing therapeutic antibody company have several licensing agreement other biotech pharma company provide xoma fund form upfront milestone payment potential royalty payment xoma share have be upward trajectory august follow signing licensing agreement novartis gevokizumab intellectual property cover use il beta target antibody treatment cardiovascular disease deal result xoma receive upfront payment worth include equity investment worth agreement term also result reduction xoma outstanding debt repayment obligation laboratoire servier extension company maturity date debt novartis couple year xoma also stand earn significant milestone payment tiered royalty sale gevokizumab year date xoma share be significantly outperform rally industry belong xoma be zack rank strong buy stock see complete list today zack rank stock here dynavax technology corporation dvax free report commercial stage biopharma company dynavax be focuse discovery development novel vaccine immuno oncology therapeutic company share shot july follow favorable recommendation fda vaccine related biological product advisory committee vrbpac heplisav vaccine immunization hepatitis infection adult heplisav have previously receive complete response letter november other february fda gain fda approval year november regulatory action make heplisav first new hepatitis vaccine unite state more year only dose hepatitis vaccine adult heplisav be first fda approve product zack rank hold stock expect launch vaccine first quarter dynavax share be whopping year date sangamo therapeutic inc sgmo free report clinical stage biotech company sangamo be focuse translate ground breaking science genomic therapy used platform technology genome editing gene therapy gene regulation cell therapy company get shot arm earlier year enter agreement pfizer pfe free report development gene therapy program hemophilia agreement see sangamo get upfront payment potential earn significant milestone payment well tiered double digit royalty net sale deal bode well long term prospect company zack rank buy company share be year date early next year sangamo expect preliminary proof concept datum sb hemophilia sb fix hemophilia sb mps sb mps ii other value driver be signing partnership deal company central nervous system tau oncology asset alnylam pharmaceutical inc alny free report rnai therapeutic company alnylam be focuse rare genetic cardio metabolic hepatic infectious disease zack rank company have strong discovery platform deep pipeline include pipeline candidate be late stage development alnylam have agreement company sanofi vir biotechnology alnylam share be year date back pipeline progress year bluebird bio inc blue free report bluebird be clinical stage company work develop lentiviral base gene therapy serious genetic disease cell base immunotherapy cancer company pipeline include lenti currently phase ii iii study treatment cerebral lentiglobin currently study treatment transfusion dependent thalassemia severe sickle cell disease company lead oncology program bb bb be bcma car program be be develop collaboration celgene bluebird share have be gain follow presentation datum annual meeting american society clinical oncology asco earlier year june share shot further august gilead announce intention acquire immuno oncology focuse kite pharma gilead kite deal have raise hope additional acquisition deal immuno oncology therapeutic area bluebird consider be attractive acquisition target bluebird be also zack rank stock share be year date today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3455,GILD,year have be quite impressive biotech sector evident gain register so far nasdaq biotechnology index be surely welcome news investor industry suffer decline last year drug pricing issue competition slowdown growth key drug dent sector performance new drug approval encourage outlook company boost investor sentiment immuno oncology continue remain spotlight fda approval car chimeric antigen cell receptor therapy kymriah gilead science gild free report yescarta leukemia lymphoma shift investor attention small biotechs company develop therapy investor also keep tab key candidate datum slowdown mature product force bigwig gilead undertake acquisition bolster pipeline gilead acquire erstwhile kite pharma add yescarta kitty company also inked agreement acquire cell design lab celgene corporation celg free report too be look acquisition bolster portfolio approval new drug dupixient kevzara idhifa tremfya other label expansion exist drug cabometyx boost respective company portfolio note see larger number drug approval fda threat biosimilar loom large sector expect further boost performance sector notably medical biom genetic sub industry carry zack industry rank place top zack industry smaller biotechs have perform impressively bigwig weren far expect momentum continue well here list few biotech company outperform market acadium pharmaceutical inc acad free report lead drug nuplazid be approve treatment hallucination delusion associate parkinson disease psychosis drug be approve fda notably be only drug approve unite state condition drug generate sale first month company be look expand drug label further be roller coaster ride acadium share company have moved year date compare industry gain believe zack rank buy company perform well boost nulpazid see complete list today zack rank strong buy stock here look best stock be first see top stock portfolio here sangamo therapeutic inc sgmo free report focus translate ground breaking science genomic therapy transform patient life used company industry lead platform technology genome editing gene therapy gene regulation cell therapy sangamo be conduct phase ii clinical trial hemophilia lysosomal storage disorder mps mps ii company have collaborate lead global company various pipeline candidate zack rank company have phenomenal run stock soar year date compare industry gain anaptysbio anab free report be clinical stage biotechnology company inflammatory pipeline include il antibody anb treatment moderate severe adult atopic dermatitis severe adult peanut allergy severe adult eosinophilic asthma il antibody anb treatment rare inflammatory disease include generalized pustular psoriasis palmo plantar pustular psoriasis company also have portfolio checkpoint receptor agonist antibody treatment certain autoimmune disease immune checkpoint receptor be insufficiently activate have demonstrated efficacy animal model graft versus host disease company be expect report top line datum go phase iia study anb severe adult peanut allergy severe adult eosinophilic asthma first second quarters respectively zack rank company have phenomenal run stock soar compare industry gain sino limit research develop manufacture market wide array chinese medicine chemical medicine major therapeutic category hepatitis cardio cerebral disease company also actively develop medicine treat tumor analgesia orthopedic disease infection parenteral nutrition respiratory system disease anorectal disease diabetes other disease meet increase demand market medical practitioner patient lead product include tianqingganmei injection runzhong dispersible tablet mingzheng capsule tianqingganp enteric capsule cardio cerebral medicine such yilunping tuotuo tablet company currently carry zack rank expect investor remain focus dynamic sector eye new drug approval important datum read out wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3456,GILD,key highlight week include fda acceptance regeneron sanofi dupixent sbla asthma biogen abbvie decision withdraw multiple sclerosis drug zinbryta due risk liver failure celgene completion juno acquisition recap week most important sanofi dupixent sbla asthma accept fda regeneron regn free report partner sanofi sny free report announce fda have accept review supplemental biologic license application sbla dupixent dupilumab add maintenance treatment adult adolescent year age older moderate severe asthma fda have set target action date oct prescription drug user fee act sbla be support result pivotal trial liberty asthma clinical development program sanofi regeneron be study dupilumab broad range clinical development program disease drive type inflammation include pediatric atopic dermatitis phase iii nasal polyp phase iii eosinophilic esophagitis phase iii read more fda accept regeneron sanofi dupixent sbla asthma regeneron be zack rank strong buy stock see complete list today zack rank stock here biogen abbvie withdraw zinbryta biogen biib free report partner abbvie abbv free report announce company withdraw multiple sclerosis drug zinbryta voluntarily worldwide basis due risk liver injury company decide withdraw drug ground complex evolve benefit risk profile zinbryta give limit number patient be treat drug be currently available europe unite state switzerland canada australia abbvie distribute zinbryta unite state biogen distribute drug ex market european regulatory authority provisionally restrict use zinbryta adult patient highly active relapse disease full adequate course treatment least dmt rapidly evolve severe relapse ms be unsuitable treatment other dmts follow report case fatal fulminant liver failure well case serious liver injury gilead report new datum biktarvy gilead gild free report announce encourage result week phase iii study study virologically suppress adult woman hiv infection international workshop hiv woman conference retroviruse opportunistic infection croi boston poster biktarvy be find be statistically inferior regimen contain bpi boost elvitegravir demonstrated treatment emergent resistance week ongoing study biktarvy gilead latest triple therapy be approve fda february complete regimen treatment hiv infection adult have antiretroviral treatment history read more gilead announce positive datum new hiv therapy biktarvy celgene complete juno acquisition celgene corporation celg free report announce have complete previously announce acquisition juno therapeutic inc juno focus development car chimeric antigen receptor tcr cell receptor therapeutic promising pipeline evaluate multiple target cancer indication acquisition add jcar lisocabtagene maraleucel liso cel celgene lymphoma pipeline jcar be best class cd direct car currently pivotal program relapse refractory diffuse large cell lymphoma dlbcl candidate be expect obtain regulatory approval unite state potential global peak sale approximately biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock regeneron gain last month celgene lose vertex gain see last biotech stock roundup here biotech stock round celgene suffer setback gilead team sangamo next biotech world stay tune more regulatory pipeline update hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3457,GILD,year have be better expect biotech sector nasdaq biotechnology index be drug pricing issue competition slowdown growth key drug be expect remain hangover well approval new drug strategic acquisition several big wig be likely boost investor sentiment thus needless say hold promise generate stellar return slowdown mature product compel bigwig gilead science gild free report undertake acquisition bolster pipeline gilead acquire erstwhile kite pharma add yescarta kitty company also inked agreement acquire cell design lab gilead currently carry zack rank hold see complete list today zack rank strong buy stock here recently celgene inc celg free report inked deal acquire impact biomedicine upfront amount acquisition add late stage candidate fedratinib highly selective jak kinase inhibitor celgene pipeline candidate be be develop treatment myelofibrosis polycythemia vera celgene be look new deal acquisition give lacklustre have suffer few pipeline setback weakness otezla sale celgene currently carry zack rank acquisition merger keep investor focuse space addition new drug approval label expansion exist drug boost top line prominent biotech company amgen inc amgn free report look poise growth several blockbuster drug portfolio amgen new drug prolium xgeva vectibix nplate sensipar be perform well company recently win fda approval supplemental biologic license application sbla xvega expand drug label treatment multiple myeloma amgen carry zack rank exelixis inc exel free report be biotech look poise growth recent fda approval label expansion lead drug cabometyx treatment previously untreated advanced renal cell carcinoma be expect drive growth drug have perform impressively approval exelixis currently carry zack rank alexion pharmaceutical inc alxn free report blockbuster drug soliris continue perform well fda approval drug generalized myasthenia gravis further boost sale new product strensiq be gain momentum company redefine strategy kanuma alexion carry zack rank investor also keep eye key upcoming pdufa date regeneron pharmaceutical inc regn free report be look expand label newly approve drug dupixent drug be already approve treatment adult moderate severe atopic dermatitis company be also evaluate drug treat asthma adult liberty asthma quest study sbla same be expect be file shortly regeneron be work expand lead ophthalmology drug eylea label additional indication fda have accept review company sbla label expansion eylea injection company be seek approval week dose interval eylea injection patient wet age related macular degeneration wet amd base physician assessment action date set fda be aug regeneron carry zack rank big biotech vertex pharmaceutical incorporate vrtx free report be take measure strengthen already dominant position cystic fibrosis market cf vertex have cf drug kalydeco orkambi portfolio blockbuster potential company have develop cf corrector tezacaftor vx combination ivacaftor regulatory application be review unite state pdufa date feb eu potential approval further bolster demand vertex currently carry zack rank medical biomedical genetic industry yr return medical biomedical genetic industry yr threat biosimilar loom large key drug most company expect investor remain focus dynamic sector eye new drug approval important datum read out wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3458,GILD,quite few pharmaceutical industry merger include large deal be card now tax reform be place tax bill be sign law president donald trump december last tax rate corporate now go boost profit large drug biotech company meanwhile change tax code also allow company bring back huge cash hold overseas time tax rate also tax cut be expect prevent inversion be rampant drug industry change definitely leave more cash hand drug biotech company cash be invest merger acquisition have be few compare gilead gild free report nearly acquisition kite pharma johnson johnson jnj free report acquisition swiss biotech actelion be only noteworthy deal week senior executive largest pharmaceutical biotech company discuss impact tax reform merger acquisition plan use excess cash jp morgan healthcare conference ceo say brent saunder chief executive officer ceo allergan agn free report say first half year be likely see smaller deal such celgene celg free report bigger high profile merger large pharmaceutical biotech company probably happen latter half year next year last week celgene announce have offer buy small cancer drug developer impact biomedicine read more celgene acquire impact biomedicine boost pipeline lilly lly free report ceo dave rick chief financial officer dominic caruso say tax cut american company compete better foreign counterpart operate better tax environment caruso say new tax law provide more flexibility ease analysis term get transaction do same line merck mrk free report ceo meg tirrell say have access overseas cash give more financial flexibility think different way go transaction tirrell however confidently say even new tax law be implement company have enough power balance sheet make bolt acquisition want do michel vounatsos biogen biib free report ceo smartly argue tax overhaul spur activity rationale activity not be cash available go say be look set potential target gilead ceo john milligan say tax reform be good company allow plan long term fda approval process be quite lengthy meanwhile maintain goal investing replenish pipeline also say excess cash allow clean balance sheet repay debt conclusion overall be quite clear drug industry be optimistic tax reform fuel greater activity be major drug biotech player struggle organic growth need infusion new growth driver pipeline product portfolio internal development buyout strategic licensing deal be therefore inevitable innovation starve drug biotech company look growth highly competitive global marketplace give take several year million dollar develop new therapeutic scratch large pharmaceutical company sit huge pile cash prefer buy innovative small mid cap biotech company build pipeline matter company look buy drug biotech stock be current sale performance latter drug product prospect sale growth quality pipeline wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3459,GILD,more earning report hit tape afternoon follow day show significant push back big market sell last regular session company report close walt disney co free report chipotle grill cmg free report snap inc snap free report gilead science gild free report catch break hour trading disney top expectation top bottom line tuesday post share revenue ahead share expect quarterly sale be overall buoy increase park resort be augment somewhat lower figure studio entertainment consumer product interactive medium share be trading late session more earning click here chipotle other hand put mixed result beating easily bottom line share vs expect narrowly miss top vs have be expect comparable store sale comp year quarter be disappointing comp guidance come year be low single digit nevertheless see share trading hour more cmg earning click here snap post cent beat bottom line afternoon unveil loss cent share opposed cent expect revenue zoom year year have anticipate investor have return favor spiking snap share nearly late trading more snap earning click here gilead also top expectation earning share post cent beat still big year year revenue outpaced zack consensus even tax adjustment charge cash dividend up more gild earning click here zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
3460,GILD,gilead science gild free report just release fourth quarter fiscal financial result post earning share revenue share be trading shortly result currently gild be sell zack rank earning estimate revision activity be trend downward foreseeable future earning growth also look be decline gilead beat earning estimate giant report gaap earning share come zack consensus estimate share net income be quarter beat revenue estimate company see revenue figure beating consensus estimate total product sale fourth quarter come much lower figure compare same period breaking region product sale be europe other location antiviral product sale include sale gilead hiv chronic hepatitis hbv chronic hepatitis hcv product be compare same period last year look full year gilead expect net product sale range gaap product gross margin range here graph look gilead price consensus ep surprise gilead science inc price consensus ep surprise gilead science inc price consensus ep surprise gilead science inc quotegilead science be independent company seek provide accelerate solution patient person care have broad base focus develop marketing drug treat patient infectious disease include viral infection fungal infection bacterial infection specialize focus cancer have expertise liposomal drug delivery technology technology company used develop drug be safer easier patient tolerate more effective more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3461,GILD,gilead science inc gild free report just release latest quarterly financial result post earning revenue currently gild be zack rank buy change base today result estimate have increase cent current year last month zack consensus sit share share biotech company have grow only last year close trading day slight stock be hour trading shortly earning report be release gilead miss earning estimate company report earning lag zack consensus estimate net income be miss revenue estimate company see revenue also miss consensus estimate decline year year total product sale be quarter compare same period antiviral product sale include gilead hiv chronic hepatitis hbv chronic hepatitis hcv product hit also compare prior year quarter other product sale come gilead reiterate full year outlook still anticipate net product sale range year here graph look gilead recent earning performance gilead science inc price consensus ep surprise gilead science inc price consensus ep surprise gilead science inc quotegilead be research base company discover develop commercialize innovative medicine area unmet medical need portfolio product pipeline investigational drug include treatment hiv aids liver disease cancer inflammatory respiratory disease cardiovascular condition portfolio market product include number category first include complete treatment regimen hiv infection available once daily single pill first oral antiretroviral pill available reduce risk acquire hiv infection certain high risk adult wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3462,GILD,week focus be annual morgan healthcare conference several biotech pharma company provide preliminary look result have also provide pipeline update well outlook meanwhile celgene celg free report be news company announce intention acquire impact biomedicine recap week most important storiescelgene buy impact celgene have start year acquisition announcement company be acquire impact biomedicine be develop fedratinib myelofibrosis polycythemia vera deal term include upfront payment approximately contingent payment base achievement regulatory approval milestone myelofibrosis celgene make additional payment base approval label expansion achievement sale base milestone plan be submit new drug application fda mid celgene be look boost pipeline acquisition company have rough share decline last year issue pipeline setback well weak performance otezla have be weigh stock read more celgene acquire impact biomedicine boost pipeline key takeaway morgan healthcare conference several biotech company be present annual morgan healthcare conference most company provide preliminary look fourth quarter result outlook key update acorda acor free report start face generic competition flagship drug ampyra time jul company be currently seek fda approval inbrija response be february read more acorda share disappointing ampyra view vertex vrtx free report hold strong position cystic fibrosis cf market be look strengthen position further potential approval tezacaftor ivacaftor unite state decision fda be expect feb vertex also be company pursue acquisition deal year celgene also provide preliminary result outlook read more celgene provide preliminary result view vertex be zack rank strong buy stock see complete list today zack rank stock here axovant plunge intepirdine discontinuation axovant science axon free report share lose more value company announce disappointing result lead pipeline candidate intepirdine candidate fail meet primary efficacy endpoint study be conduct patient dementia lewy body dlb patient dementia gait impairment base axovant have decide discontinue development intepirdine be not first time axovant have face setback development effort intepirdine last year september company have say intepirdine fail meet co primary efficacy endpoint late stage study be conduct mild moderate alzheimer disease ad patient be receive background donepezil therapy time too company share have plunge significantly axovant share be last year compare decline record industry belong regeneron sanofi boost investment dupixent cemiplimab regeneron pharmaceutical regn free report partner sanofi have decide boost investment development cemiplimab pd antibody oncology dupixent il il pathway block antibody type allergic disease base decision investment cemiplimab shoot least increase approximately initial agreement company contribute equally cemiplimab be be study monotherapy well combination other therapy wide range cancer include advanced skin cancer small cell lung cancer cervical cancer lymphomas regulatory application cemiplimab advanced cutaneous squamous cell carcinoma be schedule be submit european union unite state first quarter meanwhile dupixent currently approve eczema have potential be evaluate additional indication include chronic obstructive pulmonary disease peanut allergy grass allergy patient have multiple allergic condition be addition ongoing development pediatric atopic dermatitis pediatric asthma eosinophilic esophagitis nasal polyposis regeneron sanofi be currently seek fda approval dupixent uncontrolled persistent asthma patient least year old candidate benefit additional investment be regn il antibody potential indication include atopic dermatitis asthma chronic obstructive pulmonary disease abbvie eczema drug get btd abbvie abbv free report investigational once daily oral jak selective inhibitor upadacitinib have be grant breakthrough therapy designation btd fda use adult patient moderate severe atopic dermatitis be candidate systemic therapy breakthrough therapy designation help fasten development review drug be be evaluate treatment serious condition preliminary clinical evidence indicate drug be substantially better exist treatment clinically significant endpoint upadacitinib be schedule move late stage program atopic dermatitis first half year read more abbvie upadacitinib gain breakthrough therapy designation biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock regeneron decline gilead gild free report gain last month biogen be regeneron lose see last biotech stock roundup here gwph submit epidiolex eu sangamo inks deal pfizer next biotech world watch usual regulatory pipeline update well preliminary result announcement outlook ahead release fourth quarter result look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3463,GILD,turn be notable year pharma biotech industry fda give nod novel drug well several biological license application bla include path breaking cancer treatment kymriah yescarta number compare favorably not only just novel drug be approve earlier year well look chart show highest number approval record be novel drug be approve accord fda center drug evaluation research cder higher number new application be submit compare year average nov regulatory application be approve meet pdufa goal date quite few approval come ahead fda action date drug be approve first review cycle be approve priority review status nov approval action rate be many drug approve have also gain breakthrough therapy designation breakthrough therapy be approve last year nov inception breakthrough therapy designation have be grant cder total request nov major part breakthrough therapy request be cancer drug follow hematology antiviral landmark decision last year include approval couple gene base therapy cancer novartis nvs free report kymriah gilead science gild free report yescarta therapy have potential change way look cancer treatment other key approval include lilly lly free report verzenio advanced metastatic breast cancer gilead vosevi hepatitis virus puma nerlynx reduce risk breast cancer return tremfya moderate severe plaque psoriasis regeneron regn free report sanofi kevzara rheumatoid arthritis roche rhhby free report multiple sclerosis treatment ocrevus regeneron sanofi eczema treatment dupixent tesaro parp inhibitor zejula biomarin brineura treatment specific form batten disease other many drug have blockbuster potential store fda intend continue work recruitment hire new drug program staff agency also work continue implementation new pdufa vi bsufa ii agreement other aspect fda reauthorization act fdara st century cure act st century cure act be expect encourage more innovation sector maybe surge new drug approval drug development process be lengthy time consume require utilization lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst key drug currently fda review decision expect come month include amgen amgn free report investigational migraine drug aimovig target action date dova pharmaceutical avatrombopag gw pharmaceutical gwph free report epidiolex cannabidiol cbd investigational treatment seizure associate lennox gastaut syndrome lgs dravet syndrome epidiolex be currently priority review rare difficult treat condition childhood onset epilepsy response fda expect jun dova avatrombopag be also priority review treatment patient chronic liver disease cld be schedule undergo procedure response regulatory body be expect amgen be zack rank hold stock see complete list today zack rank strong buy stock here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
3464,GILD,galapago nv glpg free report announce positive top line datum phase ib study evaluate osteoarthritis oa candidate glpg candidate reduce level args neoepitope cartilage breakdown biomarker more half highest dosage share company have rise past year outperform industry decline period phase ib study evaluate dose glpg versus placebo period week glpg reduce level args neoepitope low medium high dose respectively compare placebo glpg work target adamts cartilage degrading enzyme meanwhile galapago be work design phase ii program further evaluate candidate oa study be expect start end year apart glpg galapago be also develop candidate filgotinib sjogren syndrome infectious uveitis ankylose spondylitis psoriatic arthritis company have global collaboration gilead science inc gild free report development filgotinib inflammatory indication moreover galapago be develop glpg cystic fibrosis cf patient be long term stable treatment vertex pharmaceutical incorporate vrtx free report cf drug kalydeco november last year galapago announce positive top line datum phase ii study demonstrate improvement lung function compare baseline company have cf candidate include glpg be be develop partnership abbvie inc abbv free report galapago nv price galapago nv price galapago nv quotegalapago carry zack rank hold see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
3465,GILD,have be banner year stock market trend be likely continue next year tax reform act major drive factor stock couple strong corporate earning accelerate economic growth many part world christmas tree symbolize good tiding let build similar tree stock loving investor rake big gain start base most valuable portion tree technology sector seem be perfect fit here be place top broad zack sector industry classification semiconductor general be expect outperform be cyclical sector tend move higher market rally new area such autonomous car cloud compute gaming wearable vr headset drone virtual reality device internet thing iot artificial intelligence continue fuel exceptional growth intel intc have zack rank strong buy seem excellent pick stock see solid earning estimate revision cent next year past day fall industry have zack rank top see complete list today zack rank stock here stock form leave tree be westlake chemical corporation wlk free report basic material sector acco brand corporation acco industrial product sector sector be expect benefit trump pro growth policy especially big spending infrastructure thus carry sector rank top westlake chemical have zack rank be part industry rank top have see solid earning estimate revision next year past day expect growth rate other hand acco brand see positive earning estimate cent next year past day expect earning estimate have zack rank buy industry rank top look best stock be first see top stock portfolio here top layer have select energy sector be expect be largest contributor earning growth hollyfrontier corporation hfc seem intriguing pick sector have rank top stock see solid earning estimate revision cent next year past day expect earning growth rate have zack rank industry rank top very top be star stock zack rank xoma corporation xoma have soar nearly year so far room more upside next year zack consensus estimate have moved loss loss cent rise earning estimate indicate analyst optimistic view earning indicate higher chance outperformance additionally stock boast solid industry rank top now be do tree structure time decorate bell candy light chocolate concentrate area expect benefit most tax reform bell candy be company be poise benefit tax policy bring offshore cash home reduce tax top hoarder be tech sector apple aapl microsoft msft free report cisco csco free report alphabet googl free report oracle orcl free report hold money overseas accord moody drug maker amgen inc amgn gilead science gild pfizer pfe free report merck co mrk free report also stash huge cash offshore be likely gain tax repatriation policy stock have zack rank hold banking stock be fairy light tree light dual tailwind rise rate tax cut accord keefe bruyette wood tax cut add median bank earning ab bernstein see earning share jump large bank mid cap bank be several choice bank new york mellon corporation bk free report currently have zack rank industry rank top company be expect generate double digit earning growth next year small cap stock pay highest effective tax rate be sweet treat be biggest beneficiary corporate tax cut accord thompson reuter datum company russell pay median effective tax rate larger multinational pay mega cap stock dow jone industrial average pay additionally tend outperform rise rate environment give spread top rank stock double digit earning growth potential include upland software inc upld free report farmer merchant bancorp inc fmao free report geopark ltd gprk petm express inc pet free report stock double year voila tree be bring bountiful return investor jingle santa bell look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3466,GILD,gilead science inc gild free report be schedule report fourth quarter result feb market close gilead leader hepatitis virus hcv space have mixed track record company beating estimate last miss last quarter company beat expectation overall company record average positive earning surprise gilead science inc price ep surprise gilead science inc price ep surprise gilead science inc quote gilead stock have rally year compare industry gain factor playconcurrent third quarter earning call gilead update annual guidance gilead expect net product sale range provide earlier hcv product sale be project earlier projection strong hiv performance other antiviral product sale be be drive continue uptake tenofovir alafenamide taf base product genvoya descovy odefsey expect trend continue fourth quarter well genvoya have already become most prescribe regimen treatment naïve switch patient launch drive hcv product sale taf base regimen now represent total gilead hiv prescription volume follow launch genvoya odefsey descovy strong uptake truvada use pre exposure prophylaxis set be also expect boost sale zack consensus estimate sale genvoya be however gilead lose exclusivity viread country outside unite state impact sale hcv product sale be project earlier projection hcv franchise continue be competitive pricing pressure lead massive decline harvoni sovaldi sale harvoni sovaldi have be face competition abbvie inc abbv free report viekira pak viekira xr other patient start have exceed expectation competition have start erode gilead market share net pricing company see impact third quarter most be due be experience fourth quarter zack consensus estimate sale lead hcv drug sovaldi harvoni be respectively hcv portfolio receive major boost epclusa gain approval fda also approve vosevi tablet single tablet regimen str re treatment chronic hcv infection adult adjust expense adjust sg expense be now project range respectively adjust product gross margin be expect range earning share be now project earlier projection cent meanwhile kite acquisition be step right direction fda approval chimeric antigen receptor cell car therapy yescarta axicabtagene ciloleucel treatment refractory aggressive hodgkin lymphoma include dlbcl transform follicular lymphoma primary mediastinal cell lymphoma however management state yescarta launch be controlled launch ensure patient safety car therapy be complicate sometimes be associate severe side effect expect management throw more light same fourth quarter call investor be also likely keep eye other pipeline update earning whispersour proven model do not conclusively show gilead beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate unfortunately be not case here see zack esp earning esp gilead be be most accurate estimate be zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank gilead currently carry zack rank sell be caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock considerhere be health care stock want consider model show have right combination element post earning beat quarter alexion pharmaceutical inc alxn free report be schedule release fourth quarter result feb company have earning esp zack rank see complete list today zack rank stock here anthera pharmaceutical inc anth free report be expect release fourth quarter result feb company have earning esp zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3467,GILD,turn be notable year pharma biotech industry fda give nod novel drug well several biological license application bla include path breaking cancer treatment kymriah yescarta number compare favorably not only just novel drug be approve earlier year well other key approval last year include lilly verzenio advanced metastatic breast cancer gilead vosevi hepatitis virus puma nerlynx reduce risk breast cancer return tremfya moderate severe plaque psoriasis regeneron sanofi kevzara rheumatoid arthritis roche multiple sclerosis treatment ocrevus regeneron regn free report sanofi eczema treatment dupixent tesaro parp inhibitor zejula biomarin bmrn free report brineura treatment specific form batten disease other many drug have blockbuster potential drug development process be lengthy time consume require utilization lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst here be look few important regulatory event schedule month february fda decision amag makena feraheme amag pharmaceutical amag free report be seek fda approval subcutaneous auto injector version makena drug device combination product approve pdufa date february offer convenience used ready administer subcutaneous auto injector provide patient alternative option intramuscular injection makena be currently available intramuscular injection reduce risk preterm birth woman be pregnant baby spontaneously deliver preterm baby past approval product help amag extend patent life makena be schedule lose orphan drug exclusivity february amag be ready launch authorize generic partner february company do not expect generic competitor enter market later drug device combination product be approve company apply orange book list patent device meanwhile fda be expect issue decision regard label expansion feraheme february amag be look expand label current chronic kidney disease ckd indication include eligible adult patient iron deficiency anemia ida priority review gilead hiv treatment gilead science gild free report be also await decision fda month new drug application nda investigational fix dose combination bictegravir mg bic integrase strand transfer inhibitor emtricitabine tenofovir alafenamide mg ftc taf dual nrti backbone treatment hiv infection nda be priority review decision expect february company hepatitis virus hcv franchise see decline sale gilead be focuse hiv franchise growth company hiv portfolio include drug genvoya truvada atripla descovy odefsey complera stribild contribute approximately total sale first month gilead taf base product genvoya descovy odefsey remain key growth driver vertex boost cf portfolio fda approval month vertex pharmaceutical vrtx free report be key player cystic fibrosis cf market product orkambi kalydeco cf portfolio company be look strengthen position area further potential approval tezacaftor ivacaftor combination treatment be priority review decision fda expect february combination treatment be review use cf patient year older have copy del mutation del mutation residual function mutation be responsive treatment approval combination be major boost vertex cf portfolio be expect deliver revenue range currently patient be eligible treatment company cf portfolio number expect grow back eu reimbursement orkambi label expansion drug potential approval tezacaftor ivacaftor combination vertex share be last year outperform rally industry belong vertex be zack rank hold stock see complete list today zack rank strong buy stock here valeant pharmaceutical international inc vrx free report also expect hear fda approval status plenvu bowel cleanser used preparation colonoscopy fda action date february moreover company kempharm apricu expect response fda month resubmit ndas kempharm have pdufa date february apadaz immediate release abuse deterrent hydrocodone acetaminophen combination product candidate apricu get know approval status resubmit vitaro topically deliver treatment erectile dysfunction nda february meanwhile fda anesthetic analgesic drug product advisory committee be meeting february discuss pacira pharmaceutical pcrx free report supplemental new drug application snda exparel bupivacaine liposomal injectable suspension produce local analgesia nerve block produce regional analgesia hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3468,GILD,immunogen inc imgn free report be schedule report first quarter result market open last report quarter company deliver negative earning surprise immunogen earning performance have be mixed bag recent past company surpass expectation last quarters miss same other overall immunogen pull average negative surprise share immunogen have significantly outperformed industry so far year stock have sky-rocket industry decrease let see thing be shape quarter factor playin absence approve product immunogen portfolio investor focus remain company progress lead pipeline candidate mirvetuximab soravtansine other program immunogen have significantly advanced respect mirvetuximab soravtansine recently company successfully complete interim analysis phase iii study forward evaluate candidate single agent therapy treat patient platinum resistant ovarian cancer tumor express high medium level fr alpha company have also finished full enrollment trial month ahead schedule expect top line result program first half also combination regimen mirvetuximab soravtansine address ovarian cancer be phase ib ii forward ii study trial consist cohort assess mirvetuximab soravtansine combination roche rhhby free report avastin merck keytruda initial finding study demonstrated candidate have potential complement available therapy indication update outcome program be expect first half apart mirvetuximab soravtansine immunogen be work develop couple early stage candidate include imgn imgn last december company present positive result ongoing phase study evaluate imgn patient relapse refractory adult acute myeloid leukemia aml annual meeting american society hematology moreover january company moved imgn phase study treat hematological malignancy include aml fourth quarter earning call company issue cash guidance anticipate cash cash equivalent range end december immunogen have then state hoard enough fund run operation fourth quarter model proven model do not conclusively show immunogen be likely beat estimate report cycle be stock need have positive earning esp solid zack rank strong buy buy hold happen be not case here see zack esp immunogen have earning esp represent percentage difference most accurate estimate loss cent zack consensus estimate loss cent uncover best stock buy sell re report earning esp filter zack rank immunogen have zack rank increase predictive power esp however company need positive esp be confident earning surprise hence combination leave surprise prediction inconclusive caution sell rate stock go earning announcement especially company be see negative estimate revision immunogen inc price ep surprise immunogen inc price ep surprise immunogen inc quote stock considertwo health care stock right combination element beat estimate time be follow gilead science inc gild free report be schedule report first quarter financial number company have earning esp zack rank see complete list today zack rank stock here celgene corporation celg free report be schedule release first quarter result company have earning esp zack rank hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3469,GILD,week focus be datum present annual conference american society hematology ash december company emerge winner other lose ground disappointing datum recap week most important storiesash roundup several company be ash datum approve pipeline drug company soar datum other be hit disappointing result company score be bluebird blue free report partner celgene celg free report announce update result ongoing phase study bb bcma car cell therapy patient late stage relapse refractory multiple myeloma company say overall response rate orr be patient active dose cohort complete response cr rate observed patient active dose cohort bluebird share shot celgene gain read more bluebird share jump strong datum car therapy bluebird be zack rank hold stock see complete list today zack rank strong buy stock here kite gilead gild free report company be also ash update result ongoing phase ii zuma study kte car cell therapy treatment adult patient relapse refractory acute lymphoblastic leukemia high rate response be observed patient kte achieve complete tumor remission long term datum be also present yescarta pivotal zuma study patient refractory large cell lymphoma patient continue respond therapy include complete remission median follow month yescarta be approve unite state recently be currently review eu potential approval expect first half read more gilead post update datum car therapy yescarta juno therapeutic major name car category provide additional datum transcend study jcar patient relapse refractory aggressive cell hodgkin lymphoma datum look good share decline reflect investor expectation better result company expect finish submit regulatory application unite state second half approval expect early end read more juno report additional datum car therapy share drop company be hit ash datum be spark therapeutic once free report see share plunge preliminary datum investigational hemophilia treatment spk read more spark therapeutic stock plunge hemophilia therapy datum gilead buy cell design lab strengthen cellular therapy effort gilead announce next acquisition deal come few month company acquire kite pharma approximately time round gilead be acquire cell design lab inc deal expect add new technology platform gilead portfolio gilead shell include upfront payment approximately additional payment be make occurrence certain event include achievement development approval milestone acquisition gilead be look enhance effort cellular therapy read more gilead science acquire cell design lab vertex select first gene edit treatment crispr collaboration vertex pharmaceutical vrtx free report announce selection ctx first gene edit treatment be co develop co commercialize agreement crispr therapeutic company split cost profit worldwide plan be commence phase ii study europe thalassemia investigational new drug ind application be submit unite state support commencement phase ii study sickle cell disease meanwhile cystic fibrosis cf front vertex say kalydeco meet primary endpoint open label phase iii study child year age cf vertex expect file approval unite state eu patient population first quarter read more vertex kalydeco study successful child age year vertex share be year date compare gain record industry belong repro be acquire allergan repro therapeutic see share gain news be acquire allergan cash payment cent share acquisition be expect close first quarter acquisition allergan be look boost woman health pipeline however repro proellex run trouble program be place partial clinical hold fda ask large pre approval safety datum base support future development biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock celgene gain amgen decline last month biogen be regeneron regn free report lose see last biotech stock roundup here fda nod amgen pcsk inhibitor revance rt datum next biotech world watch usual pipeline regulatory update make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3470,GILD,celgene corporation celg free report announce acquire juno therapeutic inc share cash total approximately net cash marketable security acquire former already own approximately outstanding share juno detail transaction be expect close first quarter celgene expect fund transaction combination exist cash new debt acquisition be expect dilute company bottom line approximately cent be expect be incrementally additive net product sale strategic value acquisition be expect position celgene prominent company cellular immunotherapy space juno focus development car chimeric antigen receptor tcr cell receptor therapeutic promising pipeline evaluate multiple target cancer indication acquisition add jcar lisocabtagene maraleucel liso cel celgene lymphoma pipeline jcar be best class cd direct car currently pivotal program relapse refractory diffuse large cell lymphoma dlbcl candidate be expect obtain regulatory approval unite state potential global peak sale approximately other candidate include jcarh multiple myelomacelgene already have collaboration investment agreement juno development immunotherapy cancer autoimmune disease remind investor celgene juno enter strategic collaboration june company leverage cell therapeutic strategy develop treatment cancer autoimmune disease initial focus car tcr technology celgene exercise option develop commercialize juno cd program outside north america china april takecelgene be look new deal acquisition give lacklustre note slowdown mature product compel prominent biotechs acquire smaller one promising pipeline gilead science inc gild free report acquire kite pharma subsequently obtain fda approval yescarta axicabtagene ciloleucel latter chimeric car therapy candidate celgene stock have tumble year industry gain celgene suffer series setback last few month company suffer setback late stage study lead cancer drug revlimid combination rituxan fail threat generic competition be also loom large revlimid lose patent protection force celgene look acquisition january celgene announce acquire impact biomedicine upfront amount acquisition add late stage candidate fedratinib highly selective jak kinase inhibitor celgene pipeline candidate be be develop treatment myelofibrosis polycythemia vera fedratinib demonstrated statistically significant improvement primary secondary endpoint splenic response total symptom score respectively randomize placebo controlled phase iii pivotal trial jakarta treatment naïve mf car therapy space be spotlight fda approve first car therapy kymriah treatment patient upto year age cell precursor acute lymphoblastic leukemia be refractory second later relapse stage give immense potential therapy celgene too want go gilead way meanwhile celgene also have partnership bluebird bio inc blue free report car therapy candidate however acquisition juno be risky proposition celgene juno have face setback pipeline candidate jcar july juno suffer huge setback fda place clinical hold company phase ii study rocket jcar adult patient relapse refractory cell acute lymphoblastic leukemia hold be place patient die week due severe neurotoxicity follow addition fludarabine pre conditioning regimen hold be lift week later study resume revise protocol company voluntarily place study hold again november patient suffer cerebral edema subsequently march juno announce have discontinue development candidate moreover price share represent huge premium juno share price rumor acquisition have surface biotech sector be likely see lot happen front give dull zack rankcelgene currently carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3471,GILD,gilead science gild free report subsidiary kite announce have enter collaboration pfizer inc pfe free report evaluate combination newly approve car therapy yescarta axicabtagene ciloleucel pfizer utomilumab bb agonist refractory large cell lymphoma phase ii study be expect begin be sponsored kite result study be used find option further development combination similar combination kite engineer cell product utomilumab gilead stock have increase year so far compare industry gain yescarta be approve october second car cell therapy get fda approval first car therapy novartis nvs free report kymriah receive approval fda august yescarta be first car therapy indicated treatment adult patient relapse refractory large cell lymphoma more line systemic therapy pfizer be develop utomilumab also know pf hematologic cancer solid tumor single agent combination other cancer therapy remind investor kite be acquire gilead october kite be pioneer cell therapy have develop engineer cell therapy express chimeric antigen receptor car engineer cell receptor tcr depend type cancer acquisition diversify gilead portfolio position company dominant position cellular therapy space car therapy space have remain investor focus courtesy immense potential car cell therapy be expect be revolutionary cancer treatment company also develop car therapy be juno therapeutic inc most advanced pipeline candidate include jcar jcar juno be also news recently report surface be acquire celgene corporation clinical stage company commit develop car therapy be bluebird bio inc lead oncology program bb bb be bcma car program be be develop collaboration celgene gilead science inc price gilead science inc price gilead science inc quotezack rank gilead have zack rank sell see complete list today zack rank strong buy stock here zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
3472,GILD,biotech sector have be attract lot investor attention lately sector be expect continue benefit increase activity new drug approval better innovation sector take beating last year owing drug price control trump plan tackle ever surge drug price get highlighted latest budget grow demand drug especially rare treat disease age population increase health care spending benefit industry economy backdropu market recently suffer sell owing fear rise rate enter correction territory decline more record high set january strong wage growth job datum introduce fear inflation make comeback lead investor bet aggressive rate hike consumer price increase year year january unchanged previous month economist forecast moreover president donald trump tax reform spending deal create further pressure price hence fed be expect hike interest rate multiple time year tame inflation jerome powell testimony be see indicative possibility fed raise rate more time gauge appropriate path monetary policy next few year fomc continue strike balance avoid over-heat economy bring pce personal consumption expenditure price inflation sustain basis financial time article cite statement powell such market be suffering anticipate rate hike cyclical nature biotech stock seem appeal investor moreover encourage industry trend positive earning be poise benefit etfs expose say sector read biotech crush market best etfs stock ytd let now discuss etfs focuse provide exposure sector spdr biotech etf xbi free report fund seek provide exposure biotech space track biotechnology select industry index have aum charge fee basis point year have holding bear less concentration risk less asset be allocate top holding fund top holding be bioverativ inc array biopharma inc arry free report juno therapeutic inc allocation respectively feb fund have return year year date xbi have zack etf rank buy high risk outlook ishare nasdaq biotechnology etf ibb free report fund seek provide exposure biotech space track nasdaq biotechnology index have aum charge fee basis point year have holding bear concentration risk more asset be allocate top holding fund top holding be gilead science inc gild free report amgen inc amgn free report celgene corp celg free report allocation respectively feb fund have return year year date ibb have zack etf rank hold high risk outlook bottom lineibb be more popular xbi be evident higher aum however xbi be more appeal investor owing cheaper expense ratio better zack rank same time xbi have significantly outperformed ibb come performance xbi have return almost more ibb so far year year outperformed ibb more however investor note xbi be focuse provide exposure small cap stock space ibb be more incline large cap player want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
3473,GILD,key highlight week include fda refusal file letter celgene corp celg free report ozanimod gilead science inc gild free report collaboration sangamo therapeutic inc used latter technology positive chmp opinion amgen inc amgn free report xgeva incyte corp incy free report beat revenue strong jakafi sale fourth quarter recap week most important storiesfda refuse ozanimod nda follow announcement receipt refusal file letter fda regard new drug application nda multiple sclerosis candidate ozanimod share celgene be pre market trading candidate be be develop treatment patient relapse form multiple sclerosis however fda determine nonclinical clinical pharmacology section nda be inadequate allow complete review hence celgene request type meeting fda ascertain additional information need resubmission nda news come great disappointment investor celgene be take desperate attempt bolster portfolio reduce overdependence lead drug revlimid company recently obtain antitrust clearance impending juno acquisition celgene be zack rank hold stock see complete list today zack rank strong buy stock here gilead collaborate sangamo gilead kite have enter collaboration agreement sangamo therapeutic inc agreement kite use sangamo zfn technology modify gene develop next generation cell therapy autologous allogeneic use oncology lieu sangamo receive upfront payment potential milestone payment sangamo be also entitle receive tiered royalty sale potential future product result collaboration other hand kite be responsible development manufacturing product collaboration sangamo share sky-rocket high news collaboration investor have lot cheer give gilead expertise biotech field chmp positive amgen xgeva label expansion committee medicinal product human use chmp european medicine agency have give positive opinion expand current indication amgen xgeva include skeletal related event patient multiple myeloma give positive result phase iii study candidate get approval aforementioned indication study result show xgeva successfully meet primary endpoint demonstrate inferiority zoledronic acid delay time first study skeletal related event patient multiple myeloma fda already approve company supplemental biologic license application xgeva expand currently approve indication prevention skeletal related event patient bone metastase solid tumor include patient multiple myeloma january vertex initiate phase iii triple combination study cf vertex pharmaceutical inc vrtx free report leader cystic fibrosis cf market announce initiation phase iii study vx tezacaftor kalydeco investigational triple combination regimen patient suffering cf have del mutation minimal function mutation study be be conduct support submission nda unite state used datum week primary efficacy endpoint together safety datum week treatment earlier month fda approve symdeko treatment underlie cause cf patient age older have copy del mutation cystic fibrosis transmembrane conductance regulator gene have least mutation be responsive tezacaftor ivacaftor biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock vertex gain last month regeneron lose amgen gain see last biotech stock roundup here biotech stock roundup abbvie result impress ablynx be acquire sanofi next biotech world stay tune more regulatory pipeline update approach last leg earning season wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3474,GILD,biotech bigwig gilead science inc gild free report develop drug treatment human virus hiv liver disease such chronic hepatitis virus hcv infection chronic hepatitis virus hbv infection cardiovascular hematology oncology inflammation respiratory disease apart blockbuster hcv drug sovaldi harvoni recently launch epclusa primary product gilead include stribild viread atripla complera eviplera emtriva other tenofovir alafenamide taf base product genvoya odefsey descovy newly approve hbv drug vemlidy gilead have solid presence hcv market however hcv franchise continue grapple competitive pricing pressure lead massive decline harvoni sovaldi sale harvoni sovaldi have be face competition abbvie abbv free report viekira pak viekira xr merck mrk free report zepatier nevertheless hcv portfolio receive major boost epclusa gain approval fda also approve vosevi tablet single tablet regimen str re treatment chronic hcv infection adult sovaldi recently obtain approval china approval new drug somewhat offset decline legacy drug gilead stock have gain last month compare industry gain company suffer decline hcv sale third quarter same be expect fourth quarter well hcv product sale be report year quarter downside be mainly attribute lower sale harvoni sovaldi major market partially offset higher sale epclusa launch sale vosevi approve unite state europe july patient start have exceed expectation competition have start erode gilead hcv market share net pricing company see impact third quarter most be due be experience fourth quarter hence expect older hcv product continue witness decline sale company expect hcv product sale zack consensus estimate sale lead hcv drug sovaldi harvoni be respectively fourth quarter hence weakness hcv franchise adversely impact gilead performance fourth quarter gilead have mixed track record company beating estimate last miss earning beat look highly unlikely fourth quarter give competitive pressure read more gilead disappoint investor earning zack rank key pickgilead currently carry zack rank sell see complete list today zack strong buy rank stock here better rank stock healthcare sector be exelixis exel free report zack rank strong buy exelixis earning share estimate have moved cent cent last day company deliver positive earning surprise last quarters average beat breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
3475,GILD,acquisition once again remain focus week ablynx agree be acquire sanofi sny free report deal worth approximately seattle genetic sgen free report also announce intention acquire cascadian therapeutic meanwhile earning result be focus abbvie abbv free report report strong quarter provide upbeat outlook recap week most important storiesa look earning result company celgene celg free report abbvie biogen vertex vrtx free report report fourth quarter result last trading session celgene read more celgene earning sale beat solid revlimid vertex top earning well revenue estimate biogen top revenue miss earning read more biogen earning miss sale top view upbeat vertex also announce have select next generation corrector vx vx move late stage development part different triple combination regimen person cystic fibrosis cf last year vertex share be compare gain record industry belong abbvie share jump follow release better expect fourth quarter result upbeat outlook result be drive performance humira imbruvica mavyret read more abbvie soar result key takeaway earning call abbvie be zack rank buy stock see complete list today zack rank strong buy stock here ablynx be acquire sanofi belgium base biopharma company ablynx have agree be acquire french pharma giant sanofi price share cash approximately announcement come just few week nordisk have announce interest acquire ablynx deal value approximately ablynx have reject nordisk offer company board say proposal fundamentally undervalue ablynx growth prospect look ablynx pipeline show company well be position launch first product caplacizumab vwf acquire thrombotic purpura attp year caplacizumab be currently review eu regulatory application be file unite state first half estimate annual market opportunity attp life threaten blood clot disease be expect be company also have broad range partnership potential generate more milestone royalty other pipeline candidate also address significant market opportunity company have more program pipeline nanobody clinical development acquisition be expect close end second quarter read more sanofi buyout spree month buy ablynx bellicum fda clinical hold bellicum pharmaceutical share be almost follow company announcement fda have place clinical hold study be conduct bpx hold be place case encephalopathy be deem possibly connect bpx company say case be complex certain factor prior fail transplant prior history concurrent infection administration rimiducid combination other medication bellicum be now wait receive formal notice fda step need be take resumption study clinical hold not impact ongoing registration study europe seattle genetic boost pipeline cascadian acquisition seattle genetic announce be acquire cascadian therapeutic share cash acquisition slate close first quarter seattle be add tucatinib pipeline tucatinib be investigational oral small molecule tyrosine kinase inhibitor tki be highly selective growth factor receptor be overexpressed several cancer include breast colorectal ovarian gastric candidate be currently pivotal phase ii program metastatic breast cancer complement seattle exist pipeline biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock alexion decline gilead gild free report gain last month biogen be regeneron lose next biotech world watch amgen amgn free report fourth quarter result be market close today read more amgen benefit growth drug earning meanwhile fda be expect issue decision regard label expansion amag pharmaceutical feraheme february amag be look expand label current chronic kidney disease ckd indication include eligible adult patient iron deficiency anemia ida wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3476,GILD,share company bluebird bio inc blue free report go almost company partner celgene corporation celg free report announce month follow datum ongoing phase study chimeric antigen receptor cell car therapy candidate bb open label phase crb study be evaluate preliminary safety efficacy bb patient relapse refractory multiple myeloma study also aim identify dose use phase ii study so far year bluebird share have sky-rocket compare industry gain cutoff date oct patient have be enrolled patient dose dose escalation phase study dose cohort patient study be heavily pre treat have fail median prior line patient active dose cohort study achieve objective response patient achieve complete response compare cr rate show datum release asco june year increase cr rate previous update lead increase share price study also show patient evaluable minimal residual disease mrd status be find be mrd negative study do not reach median progression free survival pfs median follow week active dose cohort encourage datum deepen response show bb study bode well candidate approve prove be groundbreaking car therapy multiple myeloma however bluebird competitor juno therapeutic inc release additional datum transcend phase study car candidate jcar patient relapse refractory aggressive cell hodgkin lymphoma nhl transcend trial demonstrated high risk patient population patient achieve overall response rate achieve cr rate month also note company gilead science inc gild free report car therapy yescarta axicabtagene ciloleucel be approve fda october treatment adult patient relapse refractory large cell lymphoma more line systemic therapy yescarta be first car therapy approve fda indication also note novartis breakthrough gene transfer treatment kymriah receive fda approval treatment cell precursor acute lymphoblastic leukemia be refractory second later relapse bluebird bio inc price bluebird bio inc price bluebird bio inc quotezack rank bluebird carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3477,GILD,share bluebird bio blue free report be nearly early morning trading monday investor respond company announcement car candidate bb produce encourage result patient deadly blood cancer presentation american society hematology annual meeting weekend representative bluebird bb co developer celgene corp celg free report reveal patient advanced form multiple myeloma exhibit positive response therapy recent study company also report least study participant be complete responder addition therapy unprecedented efficacy bb display remarkable safety datum latest study be relatively small bluebird celgene plan move therapy larger pivotal stage trial soon company get bb fast track approval pair become third group bring car treatment market car be newly emerge method treat cancer include make genetic change patient immune cell reinject body attack cancer cell novartis nvs free report kymriah therapy treat lymphoblastic leukemia become first approve car therapy world late august gilead gild free report large cell lymphoma regimen yescarta be approve october gilead acquire yescarta purchase kite pharmaceutical earlier year now bluebird car progress have many investor hopeful be latest takeover target space accord note goldman sachs analyst publish response bluebird recent result firm have emerge attractive acquisition candidate innovative lead lentiviral base gene therapy car cell platform backed positive proof concept datum target large blood disorder beta thalassemia sickle cell disease multiple myeloma goldman raise price target stock new call represent gain friday close additional surge monday open price want more stock market analysis author make sure follow ryan_mcqueeney twitter today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3478,GILD,novartis ag nvs free report supplemental biologic license application sbla kymriah suspension intravenous infusion treatment adult patient relapse refractory diffuse large cell lymphoma dlbcl be ineligible relapse autologous stem cell transplant asct have be accept fda priority review moreover european medicine agency ema also grant accelerate assessment marketing authorization application maa kymriah treatment child young adult cell acute lymphoblastic leukemia adult patient dlbcl be ineligible asct remind investor kymriah be first car therapy obtain fda approval august treatment patient year age cell precursor be refractory second later relapse novel immunocellular therapy time treatment kymriah used patient cell fight cancer car be manufacture individual patient used own cell thereby make different typical small molecule biologic therapy treatment cell be draw patient blood cell be then reprogram manufacturing facility create genetically code cell express chimeric antigen receptor recognize fight cancer cell other cell express specific antigen drug be develop collaboration university pennsylvania approval be major boost novartis give potential car therapy space approval open new frontier treatment cancer advance immunocellular therapy child young adult cell comprise approximately cancer diagnosis child year old be most common childhood cancer unite state kymriah have be launch unite state respective designation fda ema expedite standard review time assume approval fda ema kymriah be first chimeric antigen receptor cell car therapy available distinct indication hodgkin lymphoma cell application be base datum sponsored global clinical trial program kymriah child young adult cell adult patient dlbcl demonstrate efficacy safety kymriah study result pivotal phase ii trial juliet serve basis sbla maa kymriah adult patient dlcbl result pivotal phase ii eliana study be submit part maa kymriah child young adult cell novartis plan additional regulatory submission kymriah pediatric young adult patient cell adult patient dlbcl unite state eu novartis stock have rally past year compare industry gain car therapy space be spotlight approval kymriah subsequently gilead science inc gild free report acquire kite pharma obtain fda approval yescarta axicabtagene ciloleucel latter chimeric car therapy candidate meanwhile rumour surface celgene corporation celg free report be advanced talk acquire juno therapeutic juno pipeline include cd cd direct car cell product candidate give immense potential therapy expect spotlight space zack ranknovartis currently carry zack rank hold see complete list today zack rank strong buy stock here zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
3479,GILD,report biotech bigwig celgene corporation celg free report be look acquire smaller biotech juno therapeutic rationale dealcelgene be look new deal acquisition give lacklustre celgene suffer series setback last few month company suffer setback late stage study lead cancer drug revlimid combination rituxan fail earlier jan celgene announce acquire impact biomedicine upfront amount acquisition add late stage candidate fedratinib highly selective jak kinase inhibitor celgene pipeline candidate be be develop treatment myelofibrosis polycythemia vera fedratinib demonstrated statistically significant improvement primary secondary endpoint splenic response total symptom score respectively randomize placebo controlled phase iii pivotal trial jakarta treatment naïve mf note slowdown mature product compel prominent biotechs acquire smaller one promising pipeline gilead science inc gild free report acquire kite pharma subsequently obtain fda approval yescarta axicabtagene ciloleucel latter chimeric car therapy candidate be celgene mull acquisition celgene already have collaboration investment agreement juno development immunotherapy cancer autoimmune disease agreement become effective july term agreement celgene have option be partner juno oncology cell therapy auto immune product candidate include juno cd cd direct car cell product candidate deal juno have option enter co development co arrangement certain celgene originated development candidate target cell april celgene exercise option develop commercialize juno cd program outside north america china company also enter pre negotiate license agreement juno respect such program make license payment celgene stock have loss value last month compare industry decline juno stock surge significantly follow news car therapy hold car therapy space be spotlight fda approve first car therapy kymriah treatment patient upto year age cell precursor acute lymphoblastic leukemia be refractory second later relapse stage give immense potential therapy celgene too want go gilead way meanwhile celgene also have partnership bluebird bio inc blue free report car therapy candidate last month company also announce result ongoing crb phase clinical study investigational cell maturation antigen car cell therapy bb datum show orr patient active dose cohort dose car cell cr rate observed patient active dose cohort zack rankcelgene currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3480,GILD,celgene corporation celg free report report encourage fourth quarter result earning sale top expectation company report adjust earning share beat zack consensus estimate year quarter total revenue grow quarter beat zack consensus estimate revenue be boost consistent performance company key growth driver revlimid celgene corporation price consensus ep surprise celgene corporation price consensus ep surprise celgene corporation quoterevlimid key catalystnet product sale increase year year net sale revlimid come reflect year year growth drug perform well unite state growth quarter be drive increase volume result increase duration treatment market share net sale cancer drug abraxane decrease sale decline unite state sale oncology drug pomalyst imnovid come sale be drive increase volume due increase market share duration otezla report sale quarter other product sale include istodax thalomid vidaza authorize generic version vidaza unite state totale quarter year quarter adjust research development expense increase due increase spending related drug discovery clinical trial activity adjust selling general administrative expense decrease earlier week celgene announce acquire juno therapeutic inc share cash total approximately net cash marketable security acquire former already own approximately outstanding share juno celgene also announce acquire impact biomedicine upfront amount acquisition add late stage candidate fedratinib highly selective jak kinase inhibitor celgene pipeline december celgene partner bluebird bio blue free report present update datum phase trial evaluate bb patient relapse refractory multiple myeloma rrmm candidate be grant breakthrough therapy designation fda priority medicine eligibility european medicine agency company also initiate karmma trial evaluate bb rrmm be initiate resultssale come beat zack consensus estimate earning share come beat zack consensus estimate outlookcelgene anticipate earning range zack consensus estimate earning be share net revenue be project be range zack consensus estimate same be peg revlimid sale be project abraxane sale be estimate be pomalyst revenue be project otezla sale be now project takecelgene fourth quarter result be encourage company beat sale earning revlimid sale be impressive yet again abraxane sale decline unite state sale otezla have picked too slowdown third quarter celgene stock have decline last month industry loss share company be pre market trading due earning beat celgene suffer series setback last few month company suffer setback late stage study lead cancer drug revlimid combination rituxan fail threat generic competition be also loom large revlimid lose patent protection force celgene look acquisition stock be hit earlier phase iii trial revolve cd pipeline candidate ged crohn disease extension trial sustain cd be discontinue celgene be look new deal acquisition give lacklustre announcement juno acquisition be same track note slowdown mature product compel prominent biotechs acquire smaller one promising pipeline gilead science inc gild free report acquire kite pharma subsequently obtain fda approval yescarta axicabtagene ciloleucel latter chimeric car therapy candidate car therapy space be spotlight fda approve first car therapy kymriah treatment patient upto year age cell precursor acute lymphoblastic leukemia be refractory second later relapse stage give immense potential therapy celgene too want go gilead way zack rankcelgene be zack rank sell stock see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3481,GILD,buyout speculation related bluebird bio inc blue free report be do round again rumor surface biotech giant celgene corporation celg free report announce deal buy juno therapeutic inc add latter car cancer therapy pipeline fact bluebird share be jan celgene announce deal buy juno remind investor last year gilead science inc gild free report acquire car therapy designer kite pharma back then juno bluebird bio be rumore be hot takeover target car therapy be most recent advanced form treat cancer strengthen body immune system get rid tumor be only approve car therapy date novartis kymriah acute lymphoblastic leukemia gilead yescarta hodgkin lymphoma nhl leave sufficient scope other company bring prospective therapy term celgene juno pharma dealper agreement celgene pay share cash total transaction value be approximately price represent premium close share price juno jan transaction be approve shareholder company be expect close first quarter share juno have shot celgene have go announcement fact past month juno stock have return decline register industry juno therapeutic juno car therapy jcar lisocabtagene maraleucel treat relapse refractory diffuse large cell lymphoma dlbcl most common form nhl boost celgene lymphoma pipeline regulatory approval be be anticipate jcar potential peak sale be expect be approximately datum phase study transcend announce last month demonstrated dose level patient aforementioned indication show overall response rate orr complete response cr rate month core group acquisition also add car candidate jcarh celgene pipeline be be develop multiple myeloma bluebird bio focuscar therapy represent immense potential juncture thereby attract attention big pharmas thus follow acquisition kite pharma juno investor be anticipate buyout offer bluebird have already start rally rumor bluebird be develop cell maturation antigen car cell therapy bb dose range phase study month follow datum announce december demonstrated patient treat bb active dose arm achieve objective response patient achieve complete response encourage datum deepen response show bb study bode well candidate share company be past month candidate be be develop collaboration celgene however acquisition juno celgene be less likely bid bluebird be several other big pharma company large cash pile be interested bluebird celgene juno deal have also lead rally stock other car therapy focuse company include fate therapeutic ziopharm oncology bellicum pharmaceutical bluebird carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3482,GILD,car therapy space have remain investor focus courtesy immense potential latest annual conference american society hematology ash witness pharma big wig include novartis gilead report datum car therapy candidate fda have already approve swiss giant novartis ag nvs free report breakthrough gene transfer treatment kymriah treatment patient upto year age cell precursor acute lymphoblastic leukemia be refractory second later relapse stage novartis currently carry zack rank hold see complete list today zack rank strong buy stock here gilead science inc gild free report acquire kite pharma subsequently obtain fda approval yescarta axicabtagene ciloleucel latter chimeric car therapy candidate further strengthen position space gilead science newly acquire cell therapy subsidiary kite pharma recently sign agreement acquire cell design lab inc gilead also acquire cell design lab share be own kite pharma cell design be lead cell base therapy developer synnotch throttle technology platform technological platform enhance gilead cellular therapy research effort company lead pre clinical candidate be instrumental treat multiple myeloma meanwhile kite pharma announce result ongoing phase ii zuma study kte cd car cell therapy treatment adult patient relapse refractory patient receive single infusion kte achieve complete tumor remission complete remission cr cr incomplete hematological recovery gilead currently carry zack rank juno therapeutic inc partner celgene corp celg announce additional datum transcend study pipeline candidate jcar lisocabtagene maraleucel liso cel patient relapse refractory aggressive cell hodgkin lymphoma datum trial show dose level patient aforementioned indication show overall response rate orr cr rate month core group additionally patient show cr month datum be encourage investor expect far better orr rate lead significant decline juno share biologic license application filing be expect be complete second half tentative approval be expect end juno currently carry zack rank bluebird bio inc blue free report partner celgene also announce result ongoing crb phase clinical study investigational cell maturation antigen car cell therapy bb datum show orr patient active dose cohort dose car cell cr rate observed patient active dose cohort bluebird currently carry zack rank meanwhile novartis submit supplemental biologic license application fda kymriah suspension intravenous infusion treatment adult patient diffuse large cell lymphoma dlbcl be ineligible autologous stem cell transplant asct moreover november company submit application european medicine agency kymriah treatment adult patient dlbcl be ineligible asct child young adult cell kymriah be give breakthrough therapy designation dlbcl approve be second indication kymriah company recently announce result pivotal juliet study show sustain complete response month kymriah suspension intravenous infusion adult patient difficult treat cancer dlbcl study month patient treat kymriah be complete response relapse free probability month first response be give immense potential therapy investor be likely keep eye space day ahead well investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
3483,GILD,week be marked flurry datum presentation several company annual meeting american society hematology hold dec dec presentation also include new update datum ongoing clinical study different cancer candidate major announcement include regeneron pharmaceutical inc regn free report top line datum phase ii skin cancer candidate roche hold ag rhhby free report datum tecentriq phase iii study kidney cancer venclexta phase iii study chronic lymphocytic leukemia cll gilead science inc gild free report present update datum car therapy yescarta novartis ag nvs free report also announce update result phase iii study car therapy kymriah moreover pfizer inc pfe free report parp inhibitor demonstrated superiority chemotherapy phase iii study breast cancer let see news detail regeneron cemiplimab positive mid stage study regeneron partner sanofi sny free report announce checkpoint inhibitor target pd cemiplimab show overall response rate orr advanced cutaneous squamous cell carcinoma candidate be evaluate phase ii study empower cscc however median duration response hasn be reach datum cut date company plan file roll biologic license application bla base datum study read more regeneron sanofi report positive top line skin cancer datum regeneron pharmaceutical inc price regeneron pharmaceutical inc price regeneron pharmaceutical inc quoteroche announce datum tecentriq venclexta roche announce positive result phase iii immotion study evaluate immuno oncology drug tecentriq combination chemotherapy avastin pfizer sutent first line treatment advanced metastatic renal cell carcinoma combination therapy achieve statistically significant clinically meaningful increase progression free survival pfs compare sutent datum announce phase iii study murano evaluate venclexta rituxan compare bendamustine rituxan patient relapse refractory cll demonstrated significant reduction risk disease progression death venclexta arm murano study be be conduct aim convert current accelerate approval venclexta full approval read more roche abbvie report positive phase iii result venclexta roche hold ag price roche hold ag price roche hold ag quoteupdate approve car therapy gilead announce long term follow datum phase ii study evaluate chimeric antigen receptor cell car therapy yescarta phase ii zuma study be evaluate therapy refractory large cell lymphoma datum show single infusion yescarta achieve overall response rate orr median follow month novartis be evaluate car therapy kymriah phase iii juliet study adult patient difficult treat cancer relapse refractory diffuse large cell lymphoma datum show month patient treat kymriah show complete response relapse free probability month first response be median overall survival be not achieve median time infusion datum cutoff be month read more novartis report update result kymriah juliet study apart bluebird bio inc blue free report juno therapeutic announce additional follow datum car therapy be phase study bluebird candidate bb achieve objective response complete response juno candidate jcar show orr complete response cr rate monthspfizer parp inhibitor superior breast cancer study pfizer be develop parp inhibitor talazaporib phase iii embraca study patient germline brca positive breast cancer chemotherapy candidate achieve significant reduction risk disease progression median pfs be month talazoparib arm versus month chemotherapy arm read more pfizer talazoparib emerge superior embraca study pfizer inc price pfizer inc price pfizer inc quoteapart news bristol myer announce datum sprycel be be evaluate phase ii study philadelphia chromosome positive acute lymphoblastic leukemia sprycel follow addition chemotherapy regimen achieve event free survival rate orr year moreover fda grant priority review merck supplemental bla look label expansion keytruda include refractory primary mediastinal cell lymphoma type hodgkin lymphoma investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
3484,GILD,healthcare be perform well start new year thank encourage industry trend favorable policy environment notably popular etfs health care select sector spdr fund xlv free report vanguard health care etf vht free report ishare healthcare etf iyh free report fidelity msci health care index etf fhlc free report have gain nearly so far bullish trend be likely continue head earning season big name johnson johnson jnj free report pfizer pfe free report merck mrk free report amgen amgn free report abbvie abbv free report gilead science gild free report bristol myer squibb bmy free report be line report week next stock collectively account share xlv iyh vht fhlc read tax bill etf investor need know let dig deeper earning picture company drive performance mentioned fund come day accord methodology zack rank strong buy buy hold combine positive earning esp increase chance predict earning beat zack rank sell rate be best avoid uncover best stock buy sell re report earning esp filter surprise prediction stocksjnj have zack rank earning esp indicate lower chance beating estimate quarter stock have see earning estimate revision yet be report quarter deliver average negative earning surprise past quarters have impressive momentum style score value growth style score johnson johnson be slate release earning jan open bell see healthcare etfs here pfizer have zack rank earning esp indicate reasonable chance beating estimate quarter stock have see positive earning estimate revision penny be report quarter deliver average negative earning surprise past quarters have impressive growth value momentum style score respectively pfizer be schedule report earning jan open bell merck be expect report result feb market open have zack rank earning esp stock deliver positive earning surprise last quarters average beat witness negative earning estimate revision couple cent past day be report quarter merck have value growth momentum style score respectively amgen carry zack rank have earning esp indicate less chance beating estimate quarter earning surprise track past quarters be robust average positive surprise amgen witness negative earning estimate revision cent past day quarter be report stock have solid value style score growth momentum style score look dull amgen report earning feb market close read wave push biotech etfs higher abbvie have zack rank earning esp company deliver positive earning surprise last quarters average beat see earning estimate revision past month be report quarter stock have solid value growth style score momentum style score be unimpressive company be schedule report jan open bell gilead be expect release earning feb market close have zack rank earning esp gilead deliver positive earning surprise last quarters see negative earning estimate revision cent past month be report quarter have solid value style score growth momentum style score look ugly bristol myer likely report earning feb open bell have zack rank earning esp stock deliver average positive earning surprise past quarter witness positive earning estimate revision cent be report quarter have solid momentum growth style score respectively unfavorable value style score sum earning surprise well card healthcare sector be expect witness earning growth fourth quarter suggest upside healthcare etfs particular etfs have zack etf rank want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
3485,GILD,begin expectation be pretty high pharma biotech sector finally see lot merger acquisition however do not happen few high value deal be announce focus be mostly small bolt acquisition licensing deal agreement accord mergermarket global pharma medical biotech trend report global pharma medical biotechnology sector be range span deal so far year decline year period dip be mostly attributable pharma medical sector key deal announce year include gilead gild free report kite johnson johnson jnj free report actelion acquisition boost value transaction biotech sector biotech stock continue command hefty premium be concern key question now face sector be activity remain sluggish be surge deal tax reform work activity be expect increase upcoming quarters tax reform cash repatriation be expect lead boost area biotech remain highly seek sector company innovative technology pipeline remain demand disease area nonalcoholic steatohepatitis nash immuno oncology central nervous system disease see quite bit activity treatment orphan disease gene editing technology be also demand be several large drugmaker be lookout deal company be look replace sale blockbuster product be face loss patent exclusivity other be look build pipeline acquisition well licensing agreement expectation be high big player sanofi sny free report pfizer merck amgen amgn free report announce deal company gilead be also expect be lookout additional acquisition target major deterrent however be high valuation bidding war keep key player sideline backdrop here be look biotech stock find radar company lookout acquisition target incyte corporation incy free report wilmington base incyte be company be often consider attractive acquisition target thank flagship product jakafi promising pipeline jakafi jak jak inhibitor look well position growth jakafi revenue be expect range incyte be also work expand jakafi label additional indication include steroid refractory acute graft versus host disease gvhd datum expect first half essential thrombocythemia et rare blood cancer lead life threaten complication company have several catalyst line include potential approval baricitinib resubmission new drug application moderate severe rheumatoid arthritis expect january well advancement immuno oncology pipeline company immuno oncology pipeline include ido inhibitor epacadostat pi delta inhibitor incb jak inhibitor itacitinib incb other epacadostat be late stage development melanoma datum due first half have immense commercial potential epacadostat be be evaluate several other type cancer well juno therapeutic inc company juno share have be upward trend follow gilead kite acquisition announcement earlier year juno be focuse development innovative cellular immunotherapy treatment cancer company be consider potential acquisition target juno cell base cancer immunotherapy be base chimeric antigen receptor high affinity cell receptor technology company have several cell base candidate pipeline target variety cell malignancy well multiple solid tumor multiple myeloma company suffer major setback development erstwhile lead pipeline candidate due safety issue include patient death juno be now focuse jcar next generation car cell product target cd jcar be currently registrational study hodgkin lymphoma nhl company expect file approval second half juno share be year date compare gain record industry belong bluebird bio inc blue free report bluebird be clinical stage company work develop gene therapy serious genetic disease cell base immunotherapy cancer company pipeline include lenti currently phase ii iii study treatment cerebral lentiglobin currently study treatment transfusion dependent thalassemia severe sickle cell disease company lead oncology program bb bb be bcma car program be be develop collaboration celgene incyte juno bluebird be zack rank hold stock see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3486,GILD,week company novartis nvs free report merck mrk free report johnson johnson jnj free report be news merck provide datum keytruda novartis be news gain priority review status label expansion car therapy kymriah recap week most important storiesmerck keytruda shine st line lung cancer study merck score week pd therapy keytruda combination alimta pemetrexed cisplatin carboplatin meeting primary endpoint overall survival os progression free survival pfs late stage study first line treatment patient metastatic squamous small cell lung cancer nsclc interim analysis conduct independent datum monitoring committee show keytruda combination result significantly longer os pfs compare alimta platinum chemotherapy alone read more merck strong confirmatory phase iii lung cancer study priority review label expansion novartis kymriah novartis first company gain fda approval car therapy kymriah say agency have grant priority review company regulatory application seek expand label product novartis be look get kymriah approve treatment adult patient relapse refractory diffuse large cell lymphoma dlbcl be ineligible relapse autologous stem cell transplant asct kymriah also get accelerate assessment status european medicine agency ema treatment child young adult cell acute lymphoblastic leukemia adult patient dlbcl be ineligible asct read more novartis sbla car therapy kymriah accept fda unfavorable ipr decision suffer setback week patent trademark office pto issue final written decision parte review ipr related sole unexpired patent list cover company prostate cancer therapy zytiga abiraterone acetate fda orange book generic drug company argentum pharmaceutical have challenged claim patent be due expire aug issue statement regard pto decision say be evaluate option rehearing appeal court appeal federal circuit zytiga bring sale first month novartis sandoz global partnership biocon biosimilar sandoz novartis division be enter global partnership biocon development manufacture multiple biosimilar immunology oncology company share responsibility end end development manufacturing global regulatory approval number product have cost profit share arrangement responsibility be divide partnership allow company address next wave biosimilar opportunity globally sandoz biocon have have success biosimilar space sandoz portfolio include biosimilar market various country world company be currently seek fda approval biosimilar version abbvie blockbuster immunology drug humira regulatory application biosimilar be recently accept review fda pfizer gilead clinical trial collaboration pfizer pfe free report have enter clinical trial collaboration kite gilead gild free report company safety efficacy kite car cell therapy yescarta axicabtagene ciloleucel be evaluate combination pfizer utomilumab fully humanize bb agonist monoclonal antibody patient refractory large cell lymphoma phase ii study be expect commence year pfizer be zack rank buy stock see complete list today zack rank strong buy stock here company stock be last year compare rally industry belong cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be last trading session major stock merck be bristol myer squibb bmy free report decline last month bristol myer be glaxosmithkline gsk free report decline see last pharma stock roundup here nordisk reveal bid acquire ablynx pfizer other healthcare conference next pharma world watch usual pipeline regulatory update well fourth quarter earning announcement january make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3487,GILD,juno therapeutic inc partner celgene corporation celg free report announce additional datum phase study transcend lead pipeline candidate jcar lisocabtagene maraleucel treatment patient relapse refractory aggressive hodgkin lymphoma nhl result be present annual meeting american society hematology notably jcar be next generation chimeric antigen receptor high affinity cell car receptor product target cd company present separate datum transcend study full group patient enrolled well core group high risk patient population find multus center transcend trial demonstrated dose level patient aforementioned indication show overall response rate orr complete response cr rate month core group additionally patient show cr month figure be better previous datum orr cr report june moreover safety profile jcar remain impressive only patient experience severe cytokine release syndrome experience severe neurotoxicity be interesting note juno share drop almost follow news release probably investor expect better response rate however share juno have significantly gain value so far year compare favorably industry increase good news be safety efficacy outcome show better overall complete response compare gilead gild free report yescarta novartis nvs free report kymriah cart therapy have recently launch unite state company plan bring jcar market nhl end biologic license application expect be file second half note bluebird bio also announce month follow datum ongoing phase study car therapy candidate bb study be evaluate preliminary safety efficacy bb patient relapse refractory multiple myeloma patient active dose cohort study achieve objective response patient achieve complete response compare cr rate show datum release asco june year juno therapeutic inc price juno therapeutic inc price juno therapeutic inc quotezack rankjuno carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3488,GILD,gilead science inc gild free report announce long term follow datum phase ii study evaluate chimeric antigen receptor cell car therapy yescarta axicabtagene ciloleucel treatment patient refractory large cell lymphoma detailed result study be present annual meeting american society hematology ash atlanta notably drug be add gilead portfolio follow acquisition kite pharma early october subsequently receive fda approval later same month treat refractory aggressive hodgkin lymphoma include dlbcl transform follicular lymphoma tfl primary mediastinal cell lymphoma pmbcl drug be also review eu tentative approval expect first half share gilead have outperformed industry so far year stock have gain broader industry increase update datum zuma study show drug single infusion axicabtagene ciloleucel demonstrated overall response rate orr include patient achieve complete remission median follow month study be conduct total patient notably previously report datum study show overall response rate orr include patient achieve complete remission median follow month remind investor novartis nvs free report have also receive fda approval car therapy kymriah august treatment patient age year cell precursor acute lymphoblastic leukemia be refractory second later stage relapse additionally juno therapeutic be develop cell base cancer immunotherapy base car technology partnership celgene celg free report cure adult aggressive nhl include dlbcl hence gilead be expect face fierce competition product long run gilead science inc price gilead science inc price gilead science inc quotezack rankgilead carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3489,GILD,novartis ag nvs free report announce update result pivotal juliet study show sustain complete response month kymriah suspension intravenous infusion adult patient difficult treat cancer relapse refractory diffuse large cell lymphoma dlbcl kymriah formerly ctl be first chimeric antigen receptor cell car therapy approve drug have be develop collaboration university pennsylvania novel immunocellular therapy time treatment used patient cell fight cancer car therapy be develop individual patient used own cell thereby make different typical small molecule biologic therapy so far year novartis share have gain compare industry growth juliet be first multus center global registration study kymriah adult patient dlbcl second global car cell therapy trial study month patient treat kymriah show complete response relapse free probability month first response be median overall survival be not achieve median time infusion datum cutoff be month patient dlbcl enrolled study have go multiple round chemotherapy many have unsuccessful stem cell transplant leave few option poor prognosis study show kymriah be able considerably increase chance achieve maintain sustain response stem cell transplant thus highlight benefit additionally study reveal cytokine release syndrome crs occur total patient treatment experience grade crs grade grade used penn grade scale also show patient experience grade neurologic event patient have grade neurologic adverse event be provide supportive care study patient be infuse outpatient set patient remain outpatient more day infusion patient discontinue infusiondue rapid progression disease deterioration clinical status accord study only enrolled patient not be infuse due inability manufacture adequate dose car cell novartis submit supplemental biologic license application sbla fda october kymriah suspension intravenous infusion applicationwa file treatment adult patient relapse refractory diffuse large cell lymphoma dlbcl be ineligible autologous stem cell transplant asct again november company submit application european medicine agency ema kymriah treatment adult patient dlbcl be ineligible asct child well young adult cell late gilead gild free report also receive fda approval yescarta car therapy treatment adult patient relapse refractory large cell lymphoma more line systemic therapy yescarta be first car therapy approve fda indication company bluebird bio inc blue free report bcma car therapy bb be be evaluate relapse refractory multiple myeloma bb well bb be be develop collaboration celgene celg free report novartis ag price novartis ag price novartis ag quotezack rank novartis carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3490,GILD,share gilead science inc gild free report gain company enter agreement cell design lab inc acquire company millionamerican outdoor brand corporation aobc free report share decline company announce third quarter ep guidance range share lower zack consensus estimate share unite natural food inc unfi free report gain report first quarter earning share surpass zack consensus estimate unite continental holding inc ual free report share gain company announce share buy back program worth
3491,GILD,share juno therapeutic inc hit new week high jan eventually close share company hit new high report company be be acquire celgene corp celg free report juno already have agreement celgene global development immunotherapy potential acquisition juno help celgene build diversify drug pipeline build future revenue stream share juno have gain past year industry register increase juno be develop car therapy same have remain investor focus courtesy immense potential car space be expect be revolutionary treatment cancer therefore company have be newsever car cancer therapy designer kite pharma be acquire biotech giant gilead science inc gild free report fact be rumor juno potential acquisition gilead even biggest partner celgene fda also approve novartis nvs free report kymriah first car therapy follow yet car approval kite pharma yescarta past year juno have be player market develop therapy juno most advanced pipeline candidate jcar jcar use car cell technology target cd jcar be presently undergo phase pivotal transcend study hodgkin lymphoma nhl include diffuse large cell lymphoma dlbcl follicular lymphoma grade mantle cell lymphoma mcl juno report promising additional datum pivotal study include patient dlbcl december company plan bring jcar market nhl end biologic license application bla expect be file second half same year third quarter conference call juno celgene also initiate phase ib platform study evaluate combination jcar astrazeneca imfinzi durvalumab treatment patient relapse refractory nhl juno therapeutic inc price juno therapeutic inc price juno therapeutic inc quotezack rank juno have zack rank sell see complete list today zack rank stock here zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
3492,GILD,glaxosmithkline plc gsk free report have announce start large late stage african study experimental long act injection prevention hiv viiv healthcare hiv company majorly own glaxo pfizer pfe free report say phase iii study hptn evaluate long act cabotegravir monotherapy prevention hiv infection sexually active woman viiv healthcare be conduct study public private funding collaboration national institute allergy infectious disease niaid bill melinda gate foundation niaid part national institutes health nih be sponsor study viiv healthcare gilead gild free report be provide medicine study enrol more woman age sub saharan african country order prevent hiv infection uninfected person present use oral retroviral medication need be take day compare cabotegravir injection be administer month approvedglaxo share have decline year so far underperform increase witness industry viiv healthcare be already conduct hptn study cabotegravir hiv uninfected man transgender woman have sex man also co funding niaid meanwhile cabotegravir be also be evaluate late stage study drug regimen johnson johnson jnj free report edurant rilpivirine third study initiation announce earlier week last week glaxo partner announce fda approval first dual treatment hiv juluca tivicay dolutegravir edurant rilpivirine juluca have be develop partnership viiv healthcare janssen hiv have be key therapeutic area glaxo new hiv drug tivicay triumeq have be record consistently strong sale gain market share glaxo hiv sale rise constant exchange rate first month meanwhile significant portion expenditure go develop hiv medicine treat prevent hiv glaxoha zack rank hold see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
3493,GILD,investor be always look stock be poise beat earning season gilead science inc gild free report be such company firm have earning come pretty soon event be shape quite nicely report be gilead science be see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface gild report fact most accurate estimate current quarter be currently share gild compare broader zack consensus estimate share suggest analyst have very recently bump estimate gild give stock zack earning esp head earning season gilead science inc price ep surprise gilead science inc price ep surprise gilead science inc quotewhy be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give gild have zack rank esp positive territory investor want consider stock ahead earning see complete list today zack rank strong buy stock here clearly recent earning estimate revision suggest good thing be ahead gilead science beat be card upcoming report zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
3494,GILD,biogen biib free report third quarter result surpass top bottom line expectation meanwhile gilead gild free report car therapy gain earlier expect fda approval alexion alxn free report also get regulatory boost fda expand label company flagship product soliris recap week most important storiesbiogen beat front biogen third quarter result be better expect company surpass earning revenue expectation share be concern regard company multiple sclerosis franchise sale well sale recently launch spinal muscular atrophy sma treatment spinraza spinraza sale be third quarter more less flat second quarter sale company report increase number patient therapy unite state compare end second quarter however second quarter sale include inventory buildup read more biogen top earning sale spinraza sale biogen have gain year date outperform industry rally gilead car therapy yescarta approve gilead yescarta become part company portfolio follow kite pharma acquisition gain fda approval treatment adult patient relapse refractory large cell lymphoma more line systemic therapy make yescarta first chimeric antigen receptor cell car therapy gain approval use patient population yescarta be second gene therapy gain approval unite state first be novartis kymriah treatment come box warning regard risk cytokine release syndrome crs neurologic toxicity yescarta approval be major boost gilead be currently face decline sale hepatitis virus hcv franchise accord information provide company diffuse large cell lymphoma dlbcl be most common aggressive hodgkin lymphoma nhl patient refractory dlbcl be eligible car therapy year yescarta represent new treatment option patient have run treatment option face poor prognosis yescarta be launch list price unite state be currently review eu response be expect first half read more gilead car therapy yescarta clinch fda approval gilead also announce phase ii result investigational treatment nonalcoholic steatohepatitis nash company say higher dose mg gs oral acc inhibitor achieve significant reduction buildup fat liver noninvasive marker fibrosis timp compare placebo however statistical significance be not achieve other parameter liver stiffness fibroscan mre serum alt piii np serum marker fibrogenesis meanwhile difference lower dose mg gs placebo be not statistically significant celgene hit crohn disease study discontinuation celgene celg free report share be news company be discontinue study phase iii revolve study extension study sustain be conduct investigational crohn disease drug ged mongersen decision be base recommendation datum monitoring committee october follow interim futility analysis meaningful safety imbalance be observed analysis celgene also say review full dataset phase ii ulcerative colitis study ged decide path forward company not be initiate phase iii define study crohn disease read more celgene discontinue crohn disease drug study abbvie announce immuno therapy focuse deal abbvie abbv free report announce couple deal week deal be focuse immuno neurology other be focuse immuno oncology immuno neurology deal see abbvie collaborate alector use latter immuno neurology discovery platform innovative new therapy alzheimer disease other neurological disorder immuno neurology rapidly evolve scientific area be focuse harness power immune system attack disorder alzheimer disease development cost well profit be share equally company alector get upfront payment potential future equity investment meanwhile immuno oncology deal see abbvie team harpoon therapeutic use harpoon tri specific cell activate construct tritac platform abbvie research stage immuno oncology target develop cancer therapeutic read more abbvie inks immuno oncology deal harpoon therapeutic label expansion alexion soliris fda grant approval alexion use flagship product soliris eculizumab adult patient generalized myasthenia gravis gmg be achr antibody positive soliris already approve unite state serious ultra rare disorder paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus bring sale first half year gmg indication represent incremental growth opportunity soliris alexion be zack rank hold stock see complete list today zack strong buy rank stock here biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock celgene lose reflect sell follow crohn disease update biogen be last month vertex vrtx free report be celgene be see last biotech stock roundup here exelixis soar priority review fda panel support spark drug next biotech world week company amgen amgn free report vertex alexion gilead celgene abbvie be report third quarter result zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
3495,GILD,alexion pharmaceutical inc alxn free report be schedule report third quarter result oct open bell last report quarter company earning surpass zack consensus estimate also alexion track record be excellent have consistently beaten expectation last quarters average positive earning surprise trail quarters moreover alexion share have outperformed industry year date stock have be compare industry gain do zack model unveil proven model show alexion be likely beat earning be report quarter have right combination key ingredient positive earning esp zack rank strong buy buy hold have significantly higher chance beating earning zack esp alexion have earning esp most accurate estimate be zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank alexion zack rank combine positive esp make reasonably confident earning beat see complete list today zack rank stock here note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision let see thing be shape announcement factor likely impact resultsalexion blockbuster drug soliris continue perform well alexion continue identify treat consistently high number new patient paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus soliris country operate platform order further increase commercial potential drug alexion be also work expand soliris label additional indication label expansion additional indication give soliris access higher patient population increase commercial potential drug significantly august european commission expand indication soliris include treatment refractory generalized myasthenia gravis gmg adult be acetylcholine receptor achr antibody positive october fda approve soliris same fact zack consensus estimate soliris indicate drug sale increase year quarter meanwhile strensiq continue perform well revenue benefit grow number patient child well adult pediatric onset disease owing hpp disease awareness diagnostic initiative go forward company expect strensiq be strong additional growth driver zack consensus estimate strensiq indicate drug sale increase year quarter furthermore company announce restructure initiative context alexion plan focus rare disease business core area hematology nephrology neurology metabolic disorder enhance productivity notably company be expect reduce spending headcount associate previously announce prioritize pipeline program well optimize additional expense alexion also deprioritize alxn cpmp replacement therapy alxn samalizumab well partnership moderna therapeutic blueprint medicine arbutus biopharma consequently company reduce global workforce approximately expect increase financial flexibility allow reinvest approximately annually alexion anticipate pre tax saving approximately total pre tax restructure related expense associate plan be range company target gaap operate margin same year approximately restructure related expense result cash outlay same approximately be expect be record meantime company effort develop pipeline be impressive particularly case alxn currently be evaluate alxn longer act antibody inhibit terminal complement phase iii study pnh ahus fact company initiate phase iii pnh switch study alxn administer intravenously week compare patient currently treat soliris therefore expect investor focus update alxn successful development drug boost growth prospect however soliris quarter quarter revenue growth be impact enrollment ramp trial alxn particularly second half alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc quotestock warrant lookhere be pharma stock want consider model show right combination element post earning beat seattle genetic inc sgen free report have earning esp zack rank company be schedule release result oct gilead science inc gild free report have earning esp zack rank company be schedule release result oct incyte corporation incy free report have earning esp zack rank company be schedule release result oct today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3496,GILD,pharma biotech stock make impressive comeback nasdaq biotechnology index nyse arca pharmaceutical index gain respectively investor appear be more comfortable drug pricing scenario be major overhang moreover significantly higher number drug gain approval include path breaking gene cell therapy treatment cancer novartis nvs free report kymriah gilead gild free report yescarta tax reform be also expect work sector favor merger acquisition expect pick come quarters immuno oncology remain key focus area gilead acquire kite last year celgene celg free report currently rumore be interested acquire juno new product sale ramp success innovation continue strong performance key product grow demand drug especially rare treat disease age population increase health care spending be factor keep momentum say headwind remain form drug pricing scrutiny pricing pressure increase competition grow presence biosimilar generic competition slowdown growth legacy product concern regard amazon interest enter healthcare arena major pipeline setback pick winnersanyone interested biotech pharma stock know be challenge pick winner high risk high return industry be constantly grow change company hit bull eye become overnight success story share double even triple positive news however negative outcome have equally strong effect share failure very well spell doom company such scenario let take look stock prefer analyst have deep knowledge understand industry company have zero stock help zack stock screener stock have be give strong buy buy rating more broker sport favorable zack rank strong buy buy vertex pharmaceutical vrtx free report vertex be key player cystic fibrosis cf market product orkambi kalydeco cf portfolio patient be eligible treatment company current cf portfolio number expect grow back eu reimbursement orkambi label expansion drug potential approval tezacaftor ivacaftor combination expect unite state february eu second half year vertex expect cf revenue range company have strong earning track record have surpass expectation last quarters average surprise go forward vertex expect start pivotal development triple regimen cf pipeline first half year company be also work expand pipeline cf disease sickle cell disease beta thalassemia alpha antitrypsin deficiency polycystic kidney disease vertex be zack rank stock strong buy buy broker rating see complete list today zack rank stock here vertex have gain last year substantially outperform rally industry belong collegium pharmaceutical inc coll free report specialty pharma company collegium be zack rank stock strong buy buy broker rating company be focuse develop portfolio product incorporate proprietary deterx technology platform treatment chronic pain other disease company first product xtampza be abuse deterrent extend release oral formulation oxycodone moreover collegium acquire license right commercialize nucynta franchise unite state deal close last week be expect be immediately accretive accelerate company path profitability last year collegium share be compare gain record industry belong syndax pharmaceutical inc sndx free report clinical stage biopharma company syndax be focuse development cancer therapy lead pipeline candidate entinostat be grant breakthrough therapy designation be currently late stage development combination treatment hr advanced breast cancer candidate be be evaluate combination other treatment include keytruda different kind cancer syndax second pipeline candidate sndx be early stage development potential be evaluate variety cancer syndax be zack rank stock strong buy buy broker rating company share be last year zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
3497,GILD,gilead science inc gild free report newly acquire cell therapy subsidiary kite pharma announce have inked agreement acquire cell design lab inc gilead also acquire cell design share be own kite pharma cell design lab be leader develop cell base therapy used synnotch throttle technology platform technological platform enhance gilead cellular therapy research effort gilead acquire kite pharma acquistion cell design lab be develop several pre clinical product candidate include car tcr therapy prostate cancer hepatocellular carcinoma use synnotch technology company lead pre clinical candidate target multiple myeloma addition cell lab enable gilead expand car space car fall ambit cellular immunotherapy involve used patient own immune cell attack get rid harmful disease cell body deal include upfront payment additional payment be paid cell design lab shareholder other kite so far year share company have gain compare industry growth note gilead recently receive fda approval yescarta car therapy treatment adult patient relapse refractory large cell lymphoma more line systemic therapy yescarta be first car therapy approve fda indication drug be add gilead portfolio follow acquisition kite pharma further note be several other company novartis nvs free report breakthrough gene transfer treatment kymriah receive fda approval treatment cell precursor acute lymphoblastic leukemia be refractory second later relapse company bluebird bio inc blue free report bcma car therapy bb be be evaluate relapse refractory multiple myeloma bb well bb be be develop collaboration celgene celg free report gilead science inc price gilead science inc price gilead science inc quotezack rank gilead carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3498,GILD,quite few pharmaceutical industry merger be card propose tax reform be finally approve senate pass amend tax reform bill last week thereby successfully pass second stage bill now be present conference committee representative house senate come together draft final bill tax reform propose cut tax rate corporate boost profit large drug biotech company meanwhile change tax code also allow company bring back huge cash hold overseas time tax rate change definitely leave more cash hand drug biotech company cash be invest merger acquisition have be few compare contrary expectation increase pharma biotech merger acquisition focus be mostly small bolt acquisition licensing deal agreement gilead gild free report nearly acquisition kite pharma johnson johnson jnj free report acquisition swiss biotech actelion be only noteworthy deal year rise investor expectation trump action drug price not be onerous previously fear be lot chatter possible increase meanwhile major drug biotech player struggle organic growth need infusion new growth driver pipeline product portfolio internal development buy asset strategic licensing deal be therefore inevitable innovation starve drug biotech company look growth highly competitive global marketplace drug biotech company have regularly try merge acquire competitor mega merger deal achieve critical mass sale marketing meanwhile smaller biotech research firm investigate new therapy interesting pipeline candidate have also attract attention larger counterpart last few year focus drug pricing take backseat possibility repatriation fund hope be high activity pick company pfizer pfe free report merck mrk free report be expect take lead support robust cash flow balance sheet wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3499,GILD,year world aids day be celebrate dec raise public awareness acquire immuno deficiency syndrome popularly know aids day be observed make person aware proper cure prevention disease regard year theme day year be right health day also commemorate have die aids related illness world aids day be official global public health campaign marked world health organization accord globally person be suffering hiv aids end total be child less year old aids be pandemic disease cause due infection human virus hiv virus weaken immune system destroy cell fight disease infection eventually lead aids medicine treatment hiv be call antiretroviral therapy art slow put check progression virus currently company be investigate new medicine treat prevent ultimately cure hiv scientist also be explore new treatment paradigm drug regimen make therapy drug drug improve long term safety profile new mechanism action improve medical understand hiv significant effort make lead government medical body prevent treat hiv aids disease still have limit treatment option person die aids related illness totale start epidemic base statistic be not surprising several healthcare company be investing significant amount expenditure develop treatment device hiv aids stock watch world aids day here be key pharma company hiv market investor rely glaxosmithkline gsk free report have long standing commitment hiv aids company have develop widely used antibiotic amoxycillin year be first medicine approve treat hiv sale older hiv product epzicom selzentry have be decline however newer hiv drug triumeq tivicay be witness consistent increase sale gain market share meanwhile significant portion expenditure be be used develop hiv medicine treat prevent hiv last week glaxo partner johnson johnson announce fda approval juluca combination glaxo edurant dolutegravir tivicay rilpivirine single tablet treatment hiv most medicine hiv treatment be make more antiretroviral drug juluca be first drug regimen be approve reduce number medicine hiv patient take compromise efficacy conventional drug regimen week viiv healthcare hiv company majorly own glaxo pfizer pfe free report announce start large late stage african study evaluate long act prevention hiv sexually active woman approve cabotegravir injection be administer month opposed presently available oral retroviral medication need be take day already viiv healthcare have start conduct hptn study cabotegravirin hiv uninfected man transgender woman have sex man co funding national institute allergy infectious disease niaid meanwhile cabotegraviris also be evaluate late stage study drug regimen withedurant third study initiation announce earlier week furthermore glaxo be develop drug regimen ofdolutegravir lamivudine gilead gild free report be dominant player hiv market impressive portfolio fact gilead hiv franchise be major contributor sale approve drug genvoya truvada atripla stribild descovy odefsey complera company be first introduce single tablet regimen str treatment hiv atripla gilead other strs hiv include complera eviplera stribild taf base product genvoya happen be bestseller surpass truvada atripla fourth quarter currently gilead bictegravir single table regimen str hiv treatment be priority review unite state fda be expect announce decision february str be fix dose combination bictegravir insti emtricitabine tenofovir alafenamide ftc taf dual nrti backbone combination be also review eu company work develop hiv drug be johnson johnson jnj free report company partner glaxo recently receive fda approval first drug regimen juluca discuss further company bill melinda gate foundation national institutes health be conduct efficacy study investigational mosaic hiv preventive vaccine study evaluate vaccine be safe be able reduce incidence hiv infection woman sub saharan africa hiv have significant unmet need woman girl account person live hiv eastern southern africa otherssome other popular market hiv drug be abbvie abbv free report kaletra merck mrk free report isentress mylan myl free report also recently receive tentative fda approval combination tablet comprise efavirenz lamivudine tenofovir disoproxil fumarate meanwhile merck be develop investigational nucleoside reverse transcriptase inhibitor doravirine single entity tablet combination fix dose tablet other antiretroviral agent lamivudine tenofovir disoproxil fumarate tdf company plan file regulatory application same end conclusionaid hiv be life threaten disease have limit medical cure however be numerous company be develop drug treatment care person suffering hiv be risk become infected hiv thereby make space competitive johnson johnson sport zack rank strong buy glaxo gilead carry zack rank hold see complete list today zack rank strong buy stock here investor alert breakthrough pending medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
3500,GILD,tax reform have be grab headline election campaign last year however plan have be modify quite few time congressional vote expect week move tax reform bill forward let revisit aspect bill impact biotech pharma industry corporate tax bill current form propose cut tax rate corporate be higher originally propose point cut also help company save considerable amount tax payment unite state bill also propose full exemption future dividend income company foreign subsidiary currently foreign income be repatriate be taxed full credit local levy however change allow foreign subsidiary send cash back parent company just pay local taxe leave extra cash hand company fund capital expenditure acquisition share buyback other lower tax rate inflow foreign income lead rise merger acquisition have be relatively low so far pharma sector acquisition so far year include johnson johnson jnj free report buyout actellion gilead science inc gild free report takeover kite pharma minimum tax foreign earningswhile bill cut tax rate remove tax dividend foreign subsidiary propose implement minimum tax foreign income current tax plan company defer tax payment parking foreign profit host country however minimum tax be impose be deferral route skip taxe company have pay taxe difference minimum tax local taxe year increase tax bill base company propose tax improve competitiveness foreign pharma company swiss giant astrazeneca azn free report novartis nvs free report base counterpart however rate tax have yet be decide cash repatriation current tax plan allow multinational company keep foreign cash host country thereby defer tax liability unite state however propose minimum tax stop deferral system company have hoard cash low tax country be allow repatriate much lower rate move also increase domestic cash company biotech company utilize extra cash fund clinical study make strategic acquisition strengthen portfolio tax reform propose expense capital expenditure exclude cost structure plant warehouse current year rather defer year allow currently large pharma company areexpect have huge pile cash available potential tax reform acquisition set manufacturing facility help company lower tax bill term however reform partially limit deduction interest debt tax calculation deduction limit be yet be set moreover presently company claim tax credit half research cost related development drug rare disease credit get eliminate reform pass hurt small biotech company have recoup development cost senate budget committee have vote bill full vote house many be still sceptical tax reform many still believe add country fiscal deficit also argue lower federal revenue result lower taxe strain healthcare fund moreover healthcare cost be expect increase future unite state see increase number age person further dent healthcare fund congress be still divide impact tax reform long term investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
3501,GILD,gilead science inc gild free report report third quarter result earning revenue surpass expectation however stock be expect open red give decline hepatitis virus hcv franchise nevertheless gilead stock have gain year date industry decline company third quarter earning include impact stock base compensation expense share beat zack consensus estimate however earning be year quarter figure moreover total revenue top zack consensus estimate however revenue decline year year hiv impress yet again harvoni sovaldi plungesproduct sale come year year decline be due lower hepatitis virus hcv sale partially offset higher sale hiv other therapeutic area antiviral product sale include gilead hiv liver disease portfolio come report quarter hcv product sale include harvoni sovaldi epclusa vosevi be report year quarter downside be mainly attribute lower sale harvoni sovaldi major market partially offset sale epclusa launch sale vosevi approve unite state europe july sale harvoni decline year year report quarter further sovaldi sale record steep year year decline epclusa garner sale report quarter year figure note epclusa be launch europe june jul respectively meanwhile hiv hbv product sale come year year increase be primarily drive continuous strong uptake tenofoviral afenamide taf base product such genvoya generate sale year quarter descovy record sale odefsey register sale hiv treatment stribild complera eviplera sale decline respectively viread sale be atripla sale tank truvada sale fall other product letairis ranexa zydelig record sale respectively research development expense decline other hand selling general administrative sg expense increase adjust product gross margin be compare year period guidance updatedgilead now expect net product sale range provide earlier hcv product sale be project earlier projection hcv product sale be project earlier projection adjust expense adjust sg expense be now project range respectively adjust product gross margin be expect range earning share be now project earlier projection cent kite company recently acquire kite pharma last week company receive fda approval yescarta car therapy treatment adult patient relapse refractory large cell lymphoma more line systemic therapy dividend share gilead declare cash dividend cent share common stock fourth quarter dividend be payable dec stockholder record close business dec quarter company paid cash dividend repurchase share company top earning revenue estimate third quarter witness decline hcv sale hcv franchise be tremendous pressure due lower patient start increase competition expect sale decline further go forward note harvoni sovaldi epclusa face competition abbvie inc abbv free report viekira pak viekira xr bristol myer squibb company bmy free report daklinza other competition well pricing pressure have intensified further launch merck co inc mrk free report zepatier only patient begin treatment gilead regimen quarter prior quarter meanwhile hiv franchise maintain momentum drive rapid adoption taf base regimen unite state eu taf base regimen now represent total gilead hiv prescription volume follow launch genvoya launch odefsey descovy genvoya be now company bestselling hiv product treatment naïve patient share strong uptake truvada use pre exposure prophylaxis set further boost sale company see significant uptick prep usage estimate patient used truvada end third quarter approval yescarta also bode well gilead however gilead have lose exclusivity viread truva further impact performance expect decline hcv franchise offset positive momentum hiv franchise zack rank gilead currently carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3502,GILD,gilead science inc gild free report just release third quarter financial result post earning share revenue currently gild be zack rank hold be share hour trading shortly earning report be release gild miss earning estimate company post earning share miss zack consensus estimate share beat revenue estimate company see revenue figure beating consensus estimate gilead science revenue fall year period top company earning tank post earning share third quarter company third quarter product sale fall here graph look gild price consensus ep surprise history gilead science inc price consensus ep surprise gilead science inc price consensus ep surprise gilead science inc quotegilead science inc be independent company seek provide accelerate solution patient person care have broad base focus develop marketing drug treat patient infectious disease include viral infection fungal infection bacterial infection specialize focus cancer have expertise liposomal drug delivery technology technology company used develop drug be safer easier patient tolerate more effective check back later full analysis gild earning report look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3503,GILD,third quarter earning season be strong start result company have report number show earning revenue growth pace be accelerate first quarters particular revenue growth have show significant momentum evident proportion positive revenue surprise total earning index third quarter be expect be higher revenue oct company account index total market capitalization have report result result reveal earning company be year quarter increase revenue beat earning estimate beat revenue estimate medical sector medical sector have perform relatively well date quarter be not go be different estimate company have report so far beat revenue company surpass earning expectation go forward sector be expect record year year growth revenue earning bellwether sector johnson johnson jnj free report report better expect third quarter result raise outlook swiss giant novartis ag nvs free report too beat earning sale back new drug cosentyx entresto eli lilly company lly free report also report better expect result third quarter here have major biotech giant be set report third quarter result oct let see thing be shape gilead science inc gild free report be expect beat expectation report market close zack model stock need have positive earning esp zack rank strong buy buy hold beat zack consensus estimate gilead track record be pretty mixed company beating estimate last miss last quarter company beat expectation overall company record average positive earning surprise gilead currently carry zack rank earning esp combination zack rank positive esp make confident earning beat uncover best stock buy sell re report earning esp filter strong hiv performance other antiviral product sale be be drive continue uptake tenofovir alafenamide taf base product genvoya descovy odefsey expect trend continue third quarter well genvoya have already become most prescribe regimen treatment naïve switch patient launch drive hcv product sale taf base regimen now represent total gilead hiv prescription volume follow launch genvoya odefsey descovy specifically genvoya be now company bestselling hiv product treatment naïve patient share zack consensus estimate genvoya stand strong uptake truvada use pre exposure prophylaxis set be also expect boost sale read more be gilead poise beat earning season gilead science inc price ep surprise gilead science inc price ep surprise gilead science inc quotebristol myer squibb company bmy free report be likely beat expectation report result market open bristol myer track record have be positive so far company deliver positive earning surprise last quarters miss expectation company average positive earning surprise last quarters be company currently carry zack rank earning esp see complete list today zack rank stock here bristol myer high profile immuno oncology drug opdivo be expect be primary sale driver third quarter meanwhile rheumatoid arthritis drug orencia receive approval treat psoriatic arthritis unite state well europe july moreover june bristol myer announce availability subcutaneous administration option orencia patient moderately severely active polyarticular juvenile idiopathic arthritis label expansion new administration option be expect fuel growth drug read more be beat store bristol myer earning bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quotecelgene corporation celg free report be schedule report result open bell celgene have excellent track record company beating earning estimate last quarters last quarter company beat expectation overall company have deliver average positive surprise celgene currently carry zack rank esp combination zack rank positive esp make confident earning beat expect company beat estimate once again back strong performance key drug revlimid drug perform well first half combat challenge uneven buy pattern coverage gap continue momentum core indication label expansion global launch help product keep contribute top line zack consensus estimate drug currently stand read more be celgene poise beat earning season celgene corporation price ep surprise celgene corporation price ep surprise celgene corporation quotealexion pharmaceutical inc alxn free report be schedule report result open bell last quarter company earning surpass zack consensus estimate also alexion track record be excellent have consistently beaten expectation last quarters average positive earning surprise company currently carry zack rank esp make surprise prediction difficult alexion blockbuster drug soliris continue perform well alexion continue identify treat consistently high number new patient paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus soliris country operate platform alexion be also work expand soliris label additional indication label expansion additional indication give soliris access higher patient population increase commercial potential drug significantly alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc quotezack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
3504,GILD,inc agen free report be expect report third quarter oct last report quarter company deliver positive earning surprise trail quarter average notably share have underperform industry year date stock have be industry gain let see thing be shape company quarter earning whispersour proven model show be likely beat earning quarter have right combination key ingredient positive earning esp zack rank strong buy buy hold have significantly higher chance beating earning zack esp have earning esp be most accurate estimate loss cent come lower zack consensus estimate loss cent uncover best stock buy sell re report earning esp filter zack rank zack rank combine positive esp make reasonably confident earning beat note caution stock zack rank sell rate go earning announcement factor playagenus be immuno oncology company focuse discovery development checkpoint modulator vaccine adjuvant treatment cancer earn revenue only fee receive collaboration license agreement currently company be evaluate agen phase study incagn phase ii study treatment solid tumor fact have initiate phase study ox agonist antibody incagn phase ii study collaboration incyte expect begin combination study agen agen second half third quarter conference call investor be likely remain focuse company update initiation combination study antibody be expect focus advancement additional checkpoint modulator antibody vaccine clinic come quarters january enter clinical trial collaboration national cancer institute nci evaluate prophage hsppc conjunction merck co inc mrk free report pd therapy keytruda phase ii study evaluate effect prophage conjunction keytruda overall survival rate patient newly diagnosed glioblastoma ndgbm recently announce fda grant marketing authorization glaxosmithkline herpes zoster vaccine shingrix contain proprietary immune adjuvant qs stimulon shingrix be indicated prevention herpes zoster also know shingle adult age year older be positive impact business inc price ep surprise inc price ep surprise inc quotestock warrant lookhere be health care stock want consider model show have right combination element post earning beat quarter seattle genetic inc sgen free report have earning esp zack rank company be schedule release result oct see complete list today zack rank stock here gilead science inc gild free report have earning esp zack rank company be schedule release result oct zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
3505,GILD,thank encourage industry trend hope favorable policy environment healthcare be top perform sector year notably popular etfs health care select sector spdr fund xlv free report vanguard health care etf vht free report ishare healthcare etf iyh free report fidelity msci health care index etf fhlc free report have gain least so far read healthcare etf hit new week high bullish trend be likely continue head earning season big name pfizer pfe free report merck mrk free report amgen amgn free report abbvie abbv free report gilead science gild free report bristol myer squibb bmy free report be line report week next stock collectively account share xlv iyh vht fhlc let dig deeper earning picture company drive performance mentioned fund come day accord methodology zack rank strong buy buy hold combine positive earning esp increase chance predict earning beat zack rank sell rate be best avoid uncover best stock buy sell re report earning esp filter surprise prediction stockspfizer have zack rank earning esp indicate reasonable chance beating estimate quarter stock have see earning estimate revision yet be report quarter deliver average negative earning surprise past quarters have impressive value style score growth momentum style score respectively look disappointing pfizer be schedule report earning oct open bell pfizer inc price consensus ep surprise pfizer inc price consensus ep surprise pfizer inc quotemerck be expect report result oct market open have zack rank earning esp stock deliver positive earning surprise last quarters average beat witness negative earning estimate revision cent past day be report quarter merck have strong momentum style score value growth style score merck company inc price consensus ep surprise merck company inc price consensus ep surprise merck company inc quoteamgen carry zack rank have earning esp indicate less chance beating estimate quarter earning surprise track past quarters be robust average positive surprise amgen witness negative earning estimate revision cent past day yet be report quarter stock have solid value momentum style score respectively growth style score look dull amgen report earning oct market close read keep portfolio healthy biotech etfs amgen inc price consensus ep surprise amgen inc price consensus ep surprise amgen inc quoteabbvie have zack rank earning esp company deliver positive earning surprise last quarters average beat see negative earning estimate revision couple cent past month be report quarter stock have solid value style score growth momentum style score respectively be unimpressive company be schedule report oct open bell abbvie inc price consensus ep surprise abbvie inc price consensus ep surprise abbvie inc quotegilead be expect release earning oct market close have zack rank earning esp indicate reasonable chance beating estimate gilead deliver positive earning surprise last quarters average beat see earning estimate revision nickel past month be report quarter have solid value style score growth momentum style score respectively look ugly see healthcare etfs here gilead science inc price consensus ep surprise gilead science inc price consensus ep surprise gilead science inc quotebristol myer likely report earning oct open bell have zack rank earning esp stock deliver positive earning surprise past quarters average beat witness positive earning estimate revision couple cent be report quarter have solid growth style score unfavorable value momentum style score respectively bristol myer squibb company price consensus ep surprise bristol myer squibb company price consensus ep surprise bristol myer squibb company quotesum earning surprise well card healthcare sector be expect witness earning growth third quarter have strong zack rank top suggest further upside healthcare etfs particular etfs have zack etf rank read top rank healthcare etfs long term investor want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
3506,GILD,leader hepatitis virus hcv space gilead science inc gild free report be expect beat expectation report third quarter result oct market close gilead track record be pretty mixed company beating estimate last miss last quarter company beat expectation overall company record average positive earning surprise gilead stock have gain year date industry strong performance third quarter boost share price performance further likely positive surprise proven model show gilead be likely beat earning estimate quarter be have right combination key ingredient positive earning esp zack rank strong buy buy hold zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate be zack consensus estimate be peg penny lower uncover best stock buy sell re report earning esp filter zack rank gilead currently carry zack rank combination zack rank positive esp make confident earning beat conversely sell rate stock zack rank never be consider go earning announcement especially company be see negative estimate revision gilead science inc price ep surprise gilead science inc price ep surprise gilead science inc quote factor playconcurrent second quarter earning call gilead update annual guidance base better expect performance first half specifically unite state company raise guidance gilead now expect net product sale range provide earlier hcv product sale be project earlier projection hcv product sale be project earlier projection adjust expense adjust sg expense be now project range respectively adjust product gross margin be expect range earning share be now project cent earlier projection cent strong hiv performance other antiviral product sale be be drive continue uptake tenofovir alafenamide taf base product genvoya descovy odefsey expect trend continue third quarter well genvoya have already become most prescribe regimen treatment naïve switch patient launch drive hcv product sale taf base regimen now represent total gilead hiv prescription volume follow launch genvoya odefsey descovy specifically genvoya be now company bestselling hiv product treatment naïve patient share zack consensus estimate genvoya stand strong uptake truvada use pre exposure prophylaxis set be also expect boost sale however gilead lose exclusivity viread country outside unite state impact sale meanwhile hcv franchise continue be competitive pricing pressure lead massive decline harvoni sovaldi sale harvoni sovaldi have be face competition abbvie inc abbv free report viekira pak viekira xr other higher discount payer mix continue impact sale adversely company increase guidance hcv franchise zack consensus estimate lead hcv drug sovaldi harvoni currently stand third quarter hcv portfolio receive major boost epclusa gain approval fda also approve vosevi tablet single tablet regimen str re treatment chronic hcv infection adult other hand expect company increase guidance further incremental contribution recent kite pharma acquisition fda recently approve chimeric antigen receptor cell car therapy yescarta axicabtagene ciloleucel treatment refractory aggressive hodgkin lymphoma include dlbcl transform follicular lymphoma primary mediastinal cell lymphoma expect management throw more light same third quarter call investor be also likely keep eye other pipeline update other stock poise beat estimateshere be other health care stock want consider model show too have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report have earning esp zack rank company be schedule release third quarter result oct see complete list today zack rank stock here glaxosmithkline plc gsk free report have earning esp zack rank company be schedule release third quarter result oct make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3507,GILD,johnson johnson jnj free report partner glaxosmithkline gsk free report recently announce fda approval juluca combination glaxo tivicay rilpivirine edurant dolutegravir single tablet treatment hiv most medicine hiv treatment be make more antiretroviral drug juluca be first drug regimen reduce number medicine hiv patient take compromise efficacy conventional drug regimen approval juluca have shift investor focus hiv disease space let see company be try tap huge market note hivhiv stand human virus weaken immune system destroy cell fight disease infection eventually lead aids acquire syndrome medicine treatment hiv be call antiretroviral therapy art slow put check progression virus globally person be live hiv aids end total be child less year old improve medical understand hiv prevention treatment well significant effort make lead government medical body hiv aids still have cure notably person die aids related illness reach total number start epidemic company develop hiv drugsmarkete therapy hivseveral pharmaceutical company be marketing drug therapy treat hiv gilead gild free report be dominant player hiv market impressive portfolio company be first introduce single tablet regimen str treatment hiv atripla gilead other strs hiv include complera eviplera stribild taf base product genvoya be bestseller surpass truvada atripla fourth quarter company glaxosmithkline have long standing commitment hiv infectious disease company have develop widely used antibiotic amoxycillin year develop first medicine approve treat hiv azt company other market hiv drug include triumeq tivicay other popular market hiv drug be abbvie abbv free report kaletra merck mrk free report isentress pharmaceutical company mylan myl free report have receive tentative approval fda combination tablet comprise efavirenz lamivudine tenofovir disoproxil fumarate treat hiv pipeline company be work develop new drug treat prevent possibly cure hiv scientist be explore new treatment paradigm drug regimen make therapy drug improve safety profile new mechanism action gilead str bictegravir hiv treatment be priority review unite state fda be expect announce decision next february str be fix dose combination bictegravir insti emtricitabine tenofovir alafenamide ftc taf dual nrti backbone merck be develop investigational nucleoside reverse transcriptase inhibitor mk doravirine hiv infection plan tofile regulatory application fix dose combination same single entity tablet fix dose combination tabletconsist fix dose combination doravirine dor lamivudine tc tenofovir disoproxil fumarate tdf late glaxo be also develop drug regimen be dolutegravir cabotegravir rilpivirine increase number company be develop drug treat life threaten disease competition have intensified manifold space meanwhile be be see juluca fare market be reissue article correct mistake original article issue tuesday nov longer be rely
3508,GILD,world aids day take place year december person world come together fight hiv support live hiv commemorate have die aids related disease everybody slogan world aids day be everybody count goal be ensure access affordable high quality care service person hiv strong health care system well integration hiv tuberculosis hepatitis service accord information provide world health organization more person have lose life due hiv so far person die last year hiv related cause end approximately person be live hiv number newly infected hiv patient be currently available treatmentswhile be cure hiv present virus be controlled use effective antiretroviral arv drug accord adult child hiv be currently lifelong arv person live hiv be receive antiretroviral therapy art combination art combine more atv drug have be find be effective suppress viral replication person body thereby allow immune system strengthen regain capacity fight infection hiv drug landscape have evolved year drug vary mechanism action be approve year include multus class combination product atripla complera stribild nucleoside reverse transcriptase inhibitor nrtis combivir epivir truvada viread nucleoside reverse transcriptase inhibitor nnrtis edurant sustiva protease inhibitor pis prezista reyataz norvir hiv integrase strand transfer inhibitor insti isentress tivicay well fusion inhibitor entry inhibitor ccr co receptor antagonist accord new hiv infection fall hiv related death decline third art save life however only hiv infected person be aware status remain significant need spread awareness disease availability rapid diagnostic test rdts detect presence absence hiv antibody accord globaldata hiv market unite state france germany italy spain uk japan brazil china be expect grow be significant need new alternative arv treatment option come better tolerability higher efficacy lower rate treatment discontinuation here be look few key player hiv market drug stock focusjohnson johnson jnj free report be key player hiv market company introduce several medicine therapeutic area last year company partner glaxosmithkline plc gsk free report recently gain fda approval juluca first complete single pill drug regimen treatment hiv infection certain adult live disease be virologically suppress once daily antiretroviral be combination tivicay insti edurant nnrti maintain safety efficacy traditional drug regimen nrti simpler treatment regimen make compliance easier hiv patient need stay consistent treatment regimen order keep viral count low company be currently seek fda approval partner gilead science inc gild free report darunavir base single tablet regimen str once daily regimen comprise darunavir mg cobicistat mg emtricitabine mg tenofovir alafenamide mg taf be also work hiv vaccine company bill melinda gate foundation national institutes health be conduct efficacy study investigational mosaic hiv preventive vaccine be significant unmet need vaccine hiv lot progress have be make treat manage disease almost person become infected year develop vaccine hiv have prove be challenge due unique property virus include ability mutate rapidly moreover genetic diversity multiple strain subtype prevalent different part world be additional hurdle be zack rank buy stock see complete list today zack rank strong buy stock here stock have gain year date compare rally industry belong gilead science inc hiv be primary area focus gilead company hiv portfolio include drug genvoya truvada atripla descovy odefsey complera stribild contribute approximately total sale first month gilead taf base product genvoya descovy odefsey remain key growth driver gilead be currently seek fda approval investigational fix dose combination bic ftc taf fda expect respond feb meanwhile company expect complete mg cohort phase study gs tlr agonist hiv cure year end late stage study evaluate descovy pre exposure prophylaxis prep be schedule complete third quarter company hepatitis virus hcv franchise see decline sale gilead be focuse hiv franchise growth company hcv product be expect generate sale however competition market be intense moreover company be face competition generic product well gilead be zack rank hold stock stock have gain year date compare rally industry belong glaxosmithkline glaxo be majority stakeholder viiv healthcare global specialist hiv company be set partnership pfizer inc pfe free report now have shionogi shareholder well key product hiv portfolio include triumeq tivicay glaxo be work bring new growth driver hiv business juluca be recent addition glaxo be explore new treatment paradigm drug regimen new modality long act injectable new mechanism action include maturation inhibitor broadly neutralising antibody company be work dolutegravir lamivudine combination also be naive patient long act cabotegravir rilpivirine combination viiv have commence late stage study long act cabotegravir prevention hiv infection sexually active woman study compare cabotegravir injection give month daily oral pre exposure prophylaxis prep emtricitabine tenofovir disoproxil fumarate glaxo zack rank stock have decline year date compare rally industry belong merck mrk free report merck have presence hiv market form isentress isentress hd hiv integrase inhibitor use combination other antiretroviral agent company hiv franchise bring sale first month year period mainly due lower demand unite state due competitive pressure merck hiv pipeline have couple late stage candidate mk doravirine nnrti mk doravirine lamivudine tenofovir disoproxil fumarate dor tc tdf company expect file regulatory approval doravirine single entity tablet fix dose combination tablet dor tc tdf year end merck zack rank stock have decline year date compare rally industry belong medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
3509,GILD,unite therapeutic corporation uthr free report report fda have grant month pediatric exclusivity pulmonary arterial hypertension pah drug adcirca tadalafil delay generic competition drug additional month pediatric exclusivity have push back patent expiry oral pde inhibitor patent be otherwise set expire month mean generic version drug be approve then share unite therapeutic be monday response positive development however look unite therapeutic share price movement show stock have underperform industry year so far unite therapeutic stock have decline period industry rise remind investor unite therapeutic buy exclusive right commercialize adcirca treatment pah unite state eli lilly lly free report november tadalafil be also sell lilly ciali erectile dysfunction additional exclusivity adcirca be base study datum submit lilly fda separately unite therapeutic be require pay higher royalty sale adcirca effective next month previously announce amendment licensing agreement royalty rate adcirca sale be unite therapeutic also have make milestone payment net product sale adcirca generate sale month year year meanwhile company have more pah product portfolio remodulin tyvaso orenitram product unite therapeutic have varied range therapy target pah market lately growth orenitram tyvaso remodulin have slow due competition mainly actelion new drug uptravi selexipag actelion be now part johnson jonson jnj free report also patient be stay longer front line oral ambition combination therapy adcirca gilead gild free report letairis delay transition inhaled injectable therapy tyvaso remodulin thereby hurt demand meanwhile remodulin account more unite therapeutic total sale start face generic competition june unite therapeutic carry zack rank hold see complete list today zack rank strong buy stock here zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
3510,GILD,key highlight biotech sector past week include earning result company regeneron pharmaceutical inc regn free report lift clinical hold impose fda couple study be conduct cellectis cll free report ucart recap week most important storiessolid result regeneron regeneron third quarter result be strong company surpass earning revenue expectation flagship product eylea continue perform well third quarter call regeneron say diabetic macular edema dme indication represent significant growth opportunity consider only patient dme unite state be currently treat vegf agent regeneron be look expand eylea label diabetic retinopathy expect file regulatory approval second half result late stage study be positive supplementary biologic license application bla week dose eylea wet age related macular degeneration amd be set be file year end dupixent launch atopic dermatitis be ongoing regeneron partner sanofi expect file approval asthma indication year end meanwhile datum odyssey outcome study pcsk inhibitor praluent be first quarter regulatory application pd inhibitor cemiplimab be also slate first quarter read more regeneron beat earning sale share regeneron have gain year date outperform industry rally dicerna boehringer ingelheim work together nash treatment dicerna pharmaceutical drna free report be focuse development investigational rna interference rnai therapeutic have sign boehringer ingelheim discovery development novel rnai therapeutic base dicerna proprietary technology platform galxc treatment chronic liver disease initial focus be nonalcoholic steatohepatitis nash chronic liver disease treatment option currently approve several company be conduct research area agreement see dicerna receive more boehringer include upfront payment development commercial milestone payment reimbursement galxc candidate address undisclosed nash target dicerna also receive stagger royalty double digit worldwide net sale dicerna share jump follow announcement deal keryx auryxia label expansion keryx inc kerx free report be focuse develop medicine renal disease gain fda approval label expansion auryxia auryxia now be used treatment patient iron deficiency anemia dialysis dependent chronic kidney disease ckd however approval indication significantly expand patient population auryxia be positive company share be disappointing third quarter result read more keryx loss wider expect stock decline fda lift clinical hold cellectis study fda lift clinical hold previously announce sep couple early stage study be conduct cellectis ucart acute myeloid leukemia aml blastic plasmacytoid dendritic cell neoplasm bpdcn hold be place company have report death bpdcn study cellectis have agree several change study protocol hold be lift include lower cohort dose level well dose lympho deplete regimen include specific criterium day ucart infusion ensure next patient be treat protocol be age ensure enrollment be stagger ucart protocol aml abc least day elapse enrollment patient study lift clinical hold come several restriction be relief company be focuse develop immunotherapy base gene edit allogeneic car cell ucart cellectis be zack rank buy stock see complete list today zack rank strong buy stock here biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock regeneron be reflect strong third quarter result gilead gild free report be last month vertex vrtx free report be celgene lose see last biotech stock roundup here celgene amgen gilead hit result vertex beat front next biotech world several small mid cap company be report result next few day moreover company dynavax technology corporation dvax free report heron therapeutic inc get response fda regulatory application file be third time lucky dynavax be await approval hepatitis vaccine heplisav fda expect respond today heron be await decision fda cinvanti be review prevention chemotherapy induced nausea vomit cinv fda be expect give decision november today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3511,GILD,have be pretty good year pharma biotech stock fda decision be concern regulatory body have approve novel drug so far easily surpass last year total tally be quite few landmark approval year include approval couple gene base therapy cancer novartis nvs free report kymriah treatment certain pediatric young adult patient form acute lymphoblastic leukemia gilead science gild free report yescarta cell base gene therapy treatment adult patient certain type large cell lymphoma have not respond have relapse least other kind treatment therapy have potential change way look cancer treatment other key approval year include lilly verzenio advanced metastatic breast cancer gilead vosevi hepatitis virus puma nerlynx reduce risk breast cancer return tremfya moderate severe plaque psoriasis regeneron sanofi kevzara rheumatoid arthritis roche multiple sclerosis treatment ocrevus regeneron sanofi eczema treatment dupixent tesaro parp inhibitor zejula biomarin brineura treatment specific form batten disease other quite few drug have blockbuster potential drug development process be lengthy time consume require utilization lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst here be look few important regulatory event schedule month december cardiovascular outcome datum be part amgen pcsk inhibitor label amgen amgn free report be look add cardiovascular outcome datum label pcsk inhibitor repatha fda grant priority review company regulatory application response be december cardiovascular disease be lead cause death world addition datum repatha label boost product sale sale pcsk inhibitor be once consider be worth multus dollar be yet ramp significantly repatha sale first month be amgen continue work payer improve patient access repatha fda allow addition cardiovascular outcome datum label company be position promote repatha ability reduce risk cardiovascular event heart attack stroke amgen share be year date substantially outperform gain record industry belong amgen be zack rank hold stock see complete list today zack rank strong buy stock here fda approve mylan herceptin biosimilar mylan myl free report partner biocon also get response fda biosimilar version roche blockbuster cancer drug herceptin trastuzumab month fda have previously extend target action date biosimilar order review clarificatory information provide company be expect give response december remind investor earlier year july fda oncologic drug advisory committee odac have vote favor approve biosimilar fda be not require do so usually follow recommendation advisory panel mylan share be year date compare decline record industry belong fda follow advisory panel recommendation nvo diabetes drug nordisk nvo free report key player diabetes market get know approval status latest diabetes product offer semaglutide month once weekly semaglutide be fda review improvement glycemic control adult type ii diabetes fda advisory panel voting favor approval chance gain approval look high nordisk share be year date substantially outperform gain record industry belong christmas cheer aclaris aclaris therapeutic acrs free report be focuse address significant unmet need medical aesthetic dermatology be seek fda approval lead pipeline candidate topical treatment seborrheic keratosis sk accord information provide company person unite state be affected sk common malignant skin tumor current treatment cryosurgery curettage excision be painful invasive timely approval make first fda approve medication treatment sk fda action date be december aclaris share be year date compare rally industry belong valeant eye drop ocular redness review valeant pharmaceutical international inc vrx free report new drug application nda luminesse brimonidine tartrate ophthalmic solution be fda review pdufa action date december topical vasoconstrictor formulation have be develop relieve redness eye due minor eye irritation approve eye drop be first counter otc product be develop brimonidine tartrate treatment ocular redness valeant share be year date compare rally industry belong hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3512,GILD,interest car chimeric antigen receptor cell space continue build fda give nod second car therapy last week gilead science gild free report yescarta cell base gene therapy gain approval treatment adult patient certain type large cell lymphoma have not respond have relapse least other kind treatment make yescarta second gene therapy gain fda approval first be novartis ag nvs free report kymriah kymriah be approve late august certain pediatric young adult patient form acute lymphoblastic leukemia do car cell therapy work car fall ambit cellular immunotherapy involve used patient own immune cell attack get rid harmful disease cell body car approach involve collection patient cell genetic modification outside body incorporation specific receptor target cancer cell finally re infusion modify cell back patient be lot enthusiasm car study have show help achieve durable complete response leukemias lymphomas include patient have suffer multiple relapse however car come own set challenge include high level investment well safety issue serious immune toxicity crs neurotoxicity fact kymriah yescarta have box warning label crs neurologic toxicity treatment also not come cheap novartis have set price kymriah list price gilead yescarta be fda fda grant back back approval car treatment look regulatory environment well be encourage gene cell therapy candidate fact fda commissioner scott gottlieb say approval yescarta show continue momentum promising new area medicine agency intend release comprehensive policy plan support development cell base regenerative medicine car stock increase focus corner immuno oncology market huge commercial potential approve treatment market here be look company be work car cell treatment juno therapeutic inc company juno be focuse development innovative cellular immunotherapy treatment cancer juno cell base cancer immunotherapy be base chimeric antigen receptor high affinity cell receptor technology company have several cell base candidate pipeline target variety cell malignancy well multiple solid tumor multiple myeloma company suffer major setback development erstwhile lead pipeline candidate due safety issue include patient death juno be now focuse jcar next generation car cell product target cd jcar be currently registrational study hodgkin lymphoma nhl company also have strong partner celgene corporation celg free report juno stock have gain year date substantially outperform rally industry belong bluebird bio inc blue free report bluebird be clinical stage company work develop gene therapy serious genetic disease cell base immunotherapy cancer company bcma car therapy bb be be evaluate relapse refractory multiple myeloma bb well bb be be develop collaboration celgene bluebird stock have gain year date substantially outperform rally industry belong ziopharm oncology inc ziop free report biotech company ziopharm used innovative gene expression control cell technology provide safe effective scalable cell viral base therapy cancer graft versus host disease ziopharm immune oncology platform include car well other adoptive cell base approach announce second quarter result company have say car program be continue phase second generation study cd specific car lymphoid malignancy expect move third generation cd mbil early stage study evaluate point care plan be also commence phase study cd specific car relapse refractory acute myeloid leukemia aml year ziopharm share be so far juno bluebird ziopharm be zack rank hold stock see complete list today zack rank strong buy stock here addition company bellicum pharmaceutical inc blcm free report cellectis also have presence area however cellectis french company focuse develop immunotherapy base gene edit allogeneic car cell ucart have run roadblock fda place clinical hold couple early stage study be conduct ucart hold come place company report death study go forward expect investor focus remain corner immuno oncology market addition tracking performance kymriah yescarta believe more deal be announce cell therapy space make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3513,GILD,biomarin pharmaceutical inc bmrn free report report third quarter result oct market close biomarin deliver positive earning surprise last quarter biomarin earning track record have be strong company beating estimate past quarters deliver average positive surprise biomarin share be so far year compare unfavorably increase register industry period let see thing be shape company quarter factor playkey orphan disease drug vimizim kuvan have be drive biomarin top line time now be likely maintain trend quarter too robust patient growth penetration be likely propel sale drug zack consensus estimate vimizim kuvan third quarter be respectively however naglazyme vimzin revenue vary quarterly basis due inconsistent order pattern country last week day company say slowdown federal purchasing order brazil hurt naglazyme vimizim product revenue third quarter moreover company say slowdown continue fourth quarter only be able meet lower end total product revenue guidance not include milestone payment sarepta therapeutic inc srpt free report other hand order brazil be expect meet mid point guidance nevertheless drug continue witness steady patient growth expect trend continue quarter expect management discuss pipeline be progress conference call brineura be approve eu year treatment child cln disease form batten disease brineura generate sale only second quarter expect higher sale quarter investor call also expect management comment brineura early launch progress also launch preparation pegvaliase pegvaliase develop treat pku be review unite state fda expect give decision first half next year importantly call company have say due ramp bmn vosoritide program spending be expect be higher third fourth quarters result lower adjust net income quarters compare first second earning whispersour proven model do not conclusively show biomarin be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be most accurate estimate stand loss cent zack consensus estimate be peg loss cent uncover best stock buy sell re report earning esp filter zack rank biomarin zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock pharmaceutical inc price ep surprise biomarin pharmaceutical inc price ep surprise biomarin pharmaceutical inc quotesome stock biom genetic sector have positive esp favorable zack rank be gilead science inc gild free report earning esp zack rank company be schedule release result oct also schedule release result oct alexion pharmaceutical inc alxn free report have earning esp zack rank see complete list today zack rank stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3514,GILD,glaxosmithkline gsk free report partner pfizer inc pfe free report announce hiv focuse company viiv healthcare have initiate phase iii program evaluate combination long act injectable cabotegravir johnson johnson jnj free report rilpivirine treat adult virally suppress hiv infection share glaxosmithkline have underperform industry so far year stock have lose compare unfavorably industry rally period atla trial comprise third phase iii study undertake viiv healthcare investigate drug regimen treatment hiv phase iii program be design evaluate inferior antiviral activity combination regimen week administer week versus week study also evaluate pharmacokinetic safety tolerability combination therapy preliminary datum study be anticipate notably viiv healthcare be form november glaxosmithkline pfizer partner be later joined shionogi october remind investor phase iii atla study be already evaluate monthly dose combination regimen virally suppress patient flair study be evaluate combination first line set outcome study be expect notably last week glaxosmithkline partner jnj free report announce fda approval juluca drug complete regimen tivicay rilpivirine edurant dolutegravir single tablet treat hiv infection most medicine hiv treatment be make more antiretroviral drug juluca be first drug regimen reduce number medicine hiv patient take compromise efficacy conventional drug regimen meanwhile several company be work develop regimen treat hiv gilead gild free report bictegravir single table regimen str be priority review unite state fda be expect announce decision february next year uninitiated mylan have receive tentative approval treat hiv fda combination tablet comprise efavirenz lamivudine tenofovir disoproxil fumarate company increasingly develop drug treat life threaten disease competition have intensified manifold space glaxosmithkline plc price glaxosmithkline plc price glaxosmithkline plc quotezack carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3515,GILD,have be more month last earning report gilead science inc gild free report share have lose time frame underperform market recent negative trend continue lead stock next earning release be due dive investor analyst have react late let take quick look most recent earning report order get better handle important catalyst gilead hcv sale weak earning beatgilead report third quarter result earning revenue surpass expectation company third quarter earning include impact stock base compensation expense share beat zack consensus estimate however earning be year quarter figure moreover total revenue top zack consensus estimate however revenue decline year year hiv impress yet again harvoni sovaldi plungesproduct sale come year year decline be due lower hepatitis virus hcv sale partially offset higher sale hiv other therapeutic area antiviral product sale include gilead hiv liver disease portfolio come report quarter hcv product sale include harvoni sovaldi epclusa vosevi be report year quarter downside be mainly attribute lower sale harvoni sovaldi major market partially offset sale epclusa launch sale vosevi approve unite state europe july sale harvoni decline year year report quarter further sovaldi sale record steep year year decline epclusa garner sale report quarter year figure note epclusa be launch europe june jul respectively meanwhile hiv hbv product sale come year year increase be primarily drive continuous strong uptake tenofoviral afenamide taf base product such genvoya generate sale year quarter descovy record sale odefsey register sale hiv treatment stribild complera eviplera sale decline respectively viread sale be atripla sale tank truvada sale fall other product letairis ranexa zydelig record sale respectively research development expense decline other hand selling general administrative sg expense increase adjust product gross margin be compare year period guidance updatedgilead now expect net product sale range provide earlier hcv product sale be project earlier projection hcv product sale be project earlier projection adjust expense adjust sg expense be now project range respectively adjust product gross margin be expect range earning share be now project earlier projection cent kite company recently acquire kite pharma last week company receive fda approval yescarta car therapy treatment adult patient relapse refractory large cell lymphoma more line systemic therapy dividend share gilead declare cash dividend cent share common stock fourth quarter dividend be payable dec stockholder record close business dec quarter company paid cash dividend repurchase share have estimate be move then follow release last month investor have witness downward trend fresh estimate have be revision lower current quarter gilead science inc price consensus gilead science inc price consensus gilead science inc quotevgm scoresat time gilead stock have poor growth score however momentum be do lot better charting somewhat similar path stock be allocate grade value side putt top quintile investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested style score indicate stock be more suitable value investor momentum investor outlookestimate have be broadly trend downward stock magnitude revision also indicate downward shift notably stock have zack rank hold be look inline return stock next few month
3516,GILD,bristol myer squibb company bmy free report extend strategic partnership target pharmasolution inc partnership have be extend target nash multus year deal note company announce new collaboration nov treatment alcoholic steatohepatitis nash hepatocellular carcinoma hcc target model be design provide pharmaceutical biotechnology partner access robust disease state registry be also link biorepository patient report outcome provide unique datum insight compare typical patient registry target nash longitudinal observational study be evaluate patient suffering alcoholic steatohepatitis have enroled patient site study be collect retrospective prospective datum enroled patient be develop biorepository stakeholder access translational study include genomic biomarker bristol myer stock have rally last month compare industry rally gain bristol myer already have mid stage candidate nash space bms investigational pegylate analogue human fibroblast growth factor fgf key regulator metabolism patient biopsy confirm nash achieve primary endpoint significant reduction liver fat versus placebo april company be entitle right research develop commercialize bms ambrx inc chronic liver disease nash be cause excessive fat accumulation liver turn be know steatosis nash be know affect person unite state lead inflammation hepatocellular injury progressive fibrosis cirrhosis be expect be lead cause liver transplantation notably be currently lead cause liver transplant person unite state other major company promising candidate nash include intercept pharmaceutical inc icpt free report gilead science inc gild free report novartis ag nvs free report zack rank bristol myer squibb be zack rank hold stock see complete list today zack rank strong buy stock here stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
3517,GILD,big time investor late have be investing substantial portion source treatment alcoholic steatohepatitis nash market nash be poise witness rapid growth other lucrative saturate market cancer chronic liver disease nash be cause excessive fat accumulation liver turn be know steatosis nash be know affect person unite state lead inflammation hepatocellular injury progressive fibrosis cirrhosis be expect be lead cause liver transplantation notably be currently lead cause liver transplant person unite state nash patient be also know be affected obesity type ii diabetes disease be prevalent european country develop country market disease be project treatment currently approve disease market opportunity be significant let take look company candidate be be evaluate present treatment nash intercept pharmaceuticial inc icpt free report be presently evaluate lead drug ocaliva drug be already approve unite state treatment primary biliary cholangitis pbc inadequate response intolerant standard care udca company currently have ongoing phase iii trial regenerate cirrhotic nash patient liver fibrosis top line datum interim analysis be expect first half company also complete phase ii trial control evaluate lipid metabolic effect ocaliva cholesterol management effect concomitant statin administration nash patient company also plan initiate phase iii trial nash patient cirrhosis second half give success phase ii trial expect intercept be first company obtain approval nash biotech bigwig gilead science inc gild free report also have quite few program patient diagnosed nash advanced fibrosis include selonsertib ask inhibitor phase iii gs fxr agonist phase ii gs acc inhibitor phase ii company plan initiate combination study agent give increase competition once lucrative hepatitis market gilead be look diversify portfolio foray emerge field car therapy nash company earlier acquire phenex farnesoid receptor program comprise small molecule fxr agonist treatment liver disease include nash major player biotech space bristol myer squibb company bmy free report have mid stage candidate nash space bms investigational pegylate analogue human fibroblast growth factor fgf key regulator metabolism patient biopsy confirm nash achieve primary endpoint significant reduction liver fat versus placebo april company be entitle right research develop commercialize bms ambrx inc swiss major novartis inc nvs free report enter clinical trial agreement allergan plc agn free report conduct phase iib study april involve combination novartis fxr agonist allergan cenicriviroc treatment nash company have collaboration license agreement conatus pharmaceutical inc cnat free report global development emricasan patient decompensate liver cirrhosis cause nash medical biomedical genetic industry yr return medical biomedical genetic industry yr returnbottom line give potential market be many other big pharma biotech company have pipeline candidate treatment nash expect lot activity space go forward potential approval drug nash attract more player wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3518,GILD,intercept pharmaceutical inc icpt free report report encourage result third quarter company post loss share third quarter narrower zack consensus estimate year loss intercept pharmaceutical inc price ep surprise intercept pharmaceutical inc price ep surprise intercept pharmaceutical inc quotequarterly revenue be significantly year quarter beat zack consensus estimate intercept stock have decline year date industry loss particular share have plunge significantly last few day due safety issue regard approve drug ocaliva quarter detailrevenue international market be third quarter ocaliva record sale record second quarter ocaliva be approve unite state combination ursodeoxycholic udca treatment primary biliary cholangitis pbc adult inadequate response udca monotherapy adult be unable endure udca drug be also grant conditional approval european commission sale unite state market come record second quarter prescription continue grow research development expense increase year year primarily drive increase clinical development program oca infrastructure support such program selling general administrative expense increase year quarter drive personnel related cost support commercial international initiative increase indirect expense outlook expect operate expense be middle earlier project range company believe continue ocaliva pbc unite state other market order streamline operate expense intercept have decide deprioritize int development program pipeline updateocaliva be be evaluate other indication include alcoholic steatohepatitis nash primary sclerosing cholangitis psc fda have earlier approve redesign phase iii trial regenerate ocaliva safety efficacy treat nash patient liver fibrosis company now need achieve only co primary endpoint fibrosis improvement nash resolution compare earlier target achieve sample size trial have also be reduce approximately patient patient arm company complete enrolment interim analysis cohort regenerate trial datum readout first half company also plan initiate phase iii trial ocaliva nash patient cirrhosis second half intercept announce trial result phase ii trial control combination oca andstatin monitoring lipid aesop psc control study be be conduct evaluate effect ocaliva combination statin therapy lipid metabolism patient nash result aesop reveal oca meet primary endpoint statistically significant reduction alkaline phosphatase alp result control show company achieve objective demonstrate lowest available dose atorvastatin rapidly reverse oca associate ldl change baseline level nash patient fibrosis cirrhosis third quarter result be encourage company report narrower expect loss beat revenue however prescription demand softened follow dear health care provider letter fda safety communication ocaliva recently death have be report pbc patient moderate severe hepatic impairment child pugh cirrhosis fda report death due ocaliva state drug also affect liver however intercept conduct analysis conclude patient be prescribe once daily dose ocaliva be time higher recommend weekly dose analysis be conduct consultation fda company conclude death occur due overdose consequently intercept issue dear healthcare provider letter thereafter fda issue own safety communication reinforce recommend label dose intercept be also work fda further update ocaliva label safety purpose nevertheless such side effect limit sale potential go forward other hand nash market have huge potential tentative approval boost ocaliva prospect however bigwig novartis ag nvs free report gilead science inc gild free report have fxr agonist phase ii earlier stage clinical preclinical development be used treat pbc nash other liver disease zack rank key currently carry zack rank hold better rank stock healthcare sector be exelixis inc exel free report currently carry zack rank buy see complete list today zack rank stock strong buy here exelixis report strong result third quarter earning share estimate inched cent cent last day company have deliver positive earning surprise trail quarters average beat zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
3519,GILD,immuno oncology space have be limelight car therapy space particular have be grab investor courtesy key approval fda approval novartis ag nvs free report breakthrough gene transfer treatment kymriah suspension treatment cell precursor acute lymphoblastic leukemia be refractory second later relapse patient year age be significant boost space kymriah formerly ctl be first chimeric antigen receptor cell car therapy approve novel immunocellular therapy time treatment kymriah used patient cell fight cancer novartis also submit supplemental biologic license application fda kymriah suspension intravenous infusion treatment adult patient relapse refractory diffuse large cell lymphoma dlbcl be ineligible autologous stem cell transplant asct kymriah be give breakthrough therapy designation dlbcl approve be second indication kymriah long term impact treatment be yet be evaluate approval open new frontier cancer treatment start car used patient cell identify destroy cancer cell thereby make different other small molecule biologic therapy treatment cell be draw patient blood cell be then reprograme manufacturing facility create genetically code cell lead creation chimeric antigen receptor recognize fight cancer cell other cell express specific antigen gilead science inc gild free report acquire kite pharma foray space fda approval yescarta axicabtagene ciloleucel latter car therapy candidate provide significant boost fda approve therapy treatment refractory aggressive hodgkin lymphoma include dlbcl transform follicular lymphoma primary mediastinal cell lymphoma therapy be also review europe approval be expect gilead also acquire therapy candidate clinical trial hematologic cancer solid tumor include kite car therapy candidate target cell maturation antigen expressed multiple myeloma give vast potential therapy biotech company be leave stone unturned develop pipeline candidate nevertheless stiff competition continue remain major concern juno therapeutic inc be develop cell base cancer immunotherapy base car high affinity tcr technology genetically engineer cell recognize cancer cell company be currently conduct phase trial jcar adult aggressive nhl include dlbcl company plan initiate phase ii trial jcar chronic lymphocyctic leukemia cll fourth quarter company expect fda approve rdlbcl cll share company have surge whopping year date company currently carry zack rank hold see complete list today zack rank strong buy stock here bluebird bio inc blue free report collaboration celgene corp celg free report be evaluate bb car cell product candidate treatment multiple myeloma phase study bb target cell maturation antigen bcma previously treat patient multiple myeloma be grant breakthrough therapy status fda company be also develop second bcma car program bb share company have increase year date company presently carry zack rank ziopharm oncology inc ziop free report be develop car cell therapy advanced lymphoid malignancy company be currently enrole patient investigator lead phase study used second generation cd specific car cell revise car structure patient advanced lymphoid malignancy company present carry zack rank buy more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3520,GILD,fda approve novel drug last year have give approval drug so far include key approval october gilead science gild free report yescarta cell base gene therapy treatment adult patient certain type large cell lymphoma have not respond have relapse least other kind treatment make yescarta second gene therapy gain fda approval first be novartis ag nvs free report kymriah kymriah be approve late august certain pediatric young adult patient form acute lymphoblastic leukemia other key approval year include lilly verzenio advanced metastatic breast cancer gilead vosevi hepatitis virus puma nerlynx reduce risk breast cancer return tremfya moderate severe plaque psoriasis regeneron sanofi kevzara rheumatoid arthritis roche multiple sclerosis treatment ocrevus regeneron sanofi eczema treatment dupixent tesaro parp inhibitor zejula biomarin brineura treatment specific form batten disease other quite few drug have blockbuster potential drug development process be lengthy time consume require utilization lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst here be look few important regulatory event schedule month november keryx auryxia review label expansion keryx inc kerx free report be focuse develop medicine renal disease be seek fda approval label expansion auryxia company be look get auryxia approve treatment patient iron deficiency anemia dialysis dependent chronic kidney disease ckd decision be november approval indication expand patient population auryxia bring sale first half keryx share be year date compare industry rally label expansion bristol myer sprycel bristol myer squibb company bmy free report be look expand label blockbuster drug sprycel so be used treatment child ph chronic phase cp chronic myeloid leukemia cml company be also seek approval powder oral suspension pfos formulation sprycel response fda regulatory application be priority review be expect november label expansion boost sprycel sale further drug bring sale first month bristol myer share be year date compare industry rally bristol myer be zack rank hold stock see complete list today zack strong buy rank stock here be third time lucky dynavax heplisav dynavax technology corporation dvax free report be await response fda hepatitis vaccine heplisav month earlier year vaccine have get favorable recommendation fda vaccine related biological product advisory committee vrbpac positive vote expectation be high company finally gain approval vaccine have previously receive complete response letter november other february however fda action date august be push month agency ask more detailed information company propose post marketing study vaccine additional information be consider major amendment biologic license application bla fda be expect give response regard approval status vaccine november approval allow dynavax go ahead plan launch vaccine early next year dynavax share be year date compare industry rally heron cinvanti review cinv commercial stage biotech company heron therapeutic inc hrtx free report be await decision fda cinvanti be review prevention chemotherapy induced nausea vomit cinv approval strengthen heron cinv franchise add second complementary therapeutic agent fda be expect give decision november heron share be year date industry record decline ultragenyx gain fda approval first product clinical stage company ultragenyx pharmaceutical inc rare free report have fda action date come month vestronidase alpha rhgus be review mps also know sly syndrome patient world be afflict disease be rarest form mps currently be approve treatment mps approval rhgus november transform ultragenyx commercial stage company ultragenyx share be year date compare industry rally zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
3521,GILD,pharma biotech stock start strong note part market remain favor year progress so far year nasdaq biotechnology index nyse arca pharmaceutical index be respectively investor be more comfortable drug pricing scenario focus have shift fundamental sector drug pricing issue remain headwind expectation be step take trump administration drive drug price not be draconian previously expect deregulation increase competition seem be way be used control drug price fda be work lower healthcare cost speeding development next generation treatment especially rare disease target cancer therapy be also work clear backlog orphan drug application fda have approve far more drug year do whole key approval year include novartis nvs free report kymriah first gene therapy unite state lilly verzenio advanced metastatic breast cancer gilead gild free report vosevi hepatitis virus puma nerlynx reduce risk breast cancer return tremfya moderate severe plaque psoriasis regeneron sanofi kevzara rheumatoid arthritis roche multiple sclerosis treatment ocrevus regeneron sanofi eczema treatment dupixent tesaro parp inhibitor zejula biomarin brineura treatment specific form batten disease other quite few drug have blockbuster potential meanwhile other factor continue have positive impact pharma biotech stock be new product sale ramp success innovation strong result higher number fda approval continue strong performance legacy product accord zack earning trend report medical sector have be better perform sector last several quarters be expect record earning growth revenue growth third quarter give scenario medical sector earning round corner make sense look pharma biotech stock be expect report positive earning surprise quarter investing such stock prove beneficial investor earning beat usually lead significant share price appreciation drug stock keep eye earning help zack stock screener have zero pharma biotech stock sport zack rank strong buy buy hold have positive earning esp earning esp be very valuable tool investor look stock be most likely beat earning estimate moreover add zack rank have produce positive surprise time see complete list today zack rank stock here uncover best stock buy sell re report earning esp filter pfizer inc pfe free report pfizer be focuse development wide range medicine vaccine well consumer health care product company have surpass earning expectation first quarters key revenue driver include ibrance eliquis xeljanz pfizer expect revenue be affected due loss exclusivity loe be work bring new product market make lose sale company have potential blockbuster line next year half potentially focus also remain grow new product ibrance eliquis xeljanz meanwhile impact loe continue decline come year well less pfizer zack rank stock carry vgm score vgm score be useful tool allow investor gain insight stock strength weakness research show stock vgm score combine zack rank offer best upside potential company be report third quarter result october have earning esp eli lilly company lly free report lilly have strong presence pharmaceutical well animal health segment be slate report third quarter result october zack rank stock have earning esp third quarter lilly surpass earning expectation first quarters company be face challenge include generic competition new product drive result lilly have several important pipeline catalyst line come quarters well estimate earning growth current year be lilly have gain year date compare rally industry belong vertex pharmaceutical vrtx free report vertex key player cystic fibrosis cf market surpass earning expectation last quarters average surprise company hold strong position cf market product orkambi kalydeco portfolio early august vertex have say expect cf franchise deliver revenue include orkambi revenue company be work expand cf portfolio be currently seek fda ema approval tezacaftor ivacaftor combination fda grant priority review response be feb vertex zack rank stock have gain year date substantially outperform rally industry belong company be expect report third quarter result october have earning esp quarter biogen inc biib free report biogen be key name multiple sclerosis ms market several approve product tecfidera tysabri avonex portfolio company also have spinal muscular atrophy product spinraza portfolio be work develop treatment disease alzheimer parkinson amyotrophic lateral sclerosis biogen earning track record be good company surpass earning expectation last quarters average surprise company be schedule report third quarter result october have earning esp last day stock have see zack consensus estimate third quarter current year earning be revise respectively biogen zack rank stock have gain year date outperform rally industry belong merck mrk free report merck zack rank stock have consistently surpass earning expectation last quarters average surprise company be report earning october earning esp be company do have challenge form generic competition well safety issue related study be conduct keytruda new product keytruda strong performance base business provide support merck also have deep pipeline bode well long term growth today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3522,GILD,hepatitis be infectious disease cause hepatitis virus hcv primarily affect liver gilead science inc gild free report market blockbuster hcv drug sovaldi harvoni other well know name market be abbvie inc abbv free report viekira pak bristol myer bmy free report daklinza johnson johnson jnj free report olysio accord center disease control prevention cdc person unite state be live chronic hepatitis infection many remain unaware be infected be new hepatitis case year unite state many go unreported consider number be not surprise quite few pharma biotech company be work bring new improve shorter duration hcv treatment market market be thus get crowd see increase pricing pressure lot have happened hcv space late september gilead science sovaldi receive approval china component combination antiviral treatment regimen be first gilead hcv drug be approve china meanwhile gilead single tablet regimen str sovaldi velpatasvir voxilaprevir vosevi receive approval unite state eu canada july august vosevi become first once daily str available salvage therapy patient infected hcv genotype have fail prior treatment daa regimen include ns inhibitor gilead share have outperformed industry year date stock have rally compare industry gain same time frame stock carry zack rank hold see complete list today zack rank strong buy stock here meanwhile abbvie week pan genotypic ribavirin free once daily hcv treatment mavyret maviret gain approval unite state eu canada past couple month mavyret abbvie next generation hcv program be combination glecaprevir potent protease inhibitor pibrentasvir ns inhibitor maviret have potential rejuvenate growth hcv franchise accord abbvie mavyret be used hcv patient depend stage liver disease prior treatment history abbvie share have outperformed industry year date stock have rally compare industry gain same time frame stock carry zack rank however last week pharmaceutical giant merck mrk free report announce be discontinue further development next generation hepatitis hcv program mk grazoprevir ruzasvir uprifosbuvir mk ruzasvir uprifosbuvir company make decision base review available phase ii efficacy datum heavily crowd hcv market merck share have underperform industry year date stock have gain compare industry gain same time frame stock carry zack rank merck giant johnson johnson also discontinue development investigational hcv treatment regimen jnj combination direct act antiviral al odalasvir simeprevir company take decision consider be several highly effective therapy available indication johnson johnson share have underperform industry year date stock have gain compare industry gain same time frame stock carry zack rank be believe discontinuation merck combination hcv regimen act favor gilead abbvie gilead abbvie benefit lack additional competition enter market least term however company continue face challenge form decline patient volume intense pricing pressure lack additional entrant market also slow rate decline sale do zack investment idea come be welcome download full minute list zack rank strong buy stock free charge be better place start own stock search access full list avoid zack rank strong sell other private research see stock free
3523,GILD,gilead science inc gild free report announce fda have approve chimeric antigen receptor cell car therapy yescarta axicabtagene ciloleucel treatment refractory aggressive hodgkin lymphoma include dlbcl transform follicular lymphoma tfl primary mediastinal cell lymphoma pmbcl drug be add gilead portfolio follow recent acquisition kite pharma earlier month notably yescarta be first car therapy approve fda aforementioned indication candidate be also review eu tentative approval expect first half share gilead have outperformed industry so far year stock have rally broader industry decrease approval be support positive datum zuma phase ii study find study show single infusion axicabtagene ciloleucel demonstrated overall response rate orr include patient detectable trace cancer remain also patient achieve complete remission median follow month have not earlier reach estimate median duration response significantly cart therapy be manufacture kite pharma state art commercial manufacturing facility el segundo california zuma pivotal trial kite pharma achieve manufacturing success rate median manufacturing turnaround time day remind investor novartis nvs free report have also receive fda approval car therapy kymriah august treatment patient year age cell precursor acute lymphoblastic leukemia be refractory second later stage relapse additionally juno therapeutic be develop cell base cancer immunotherapy base car technology partnership celgene celg free report heal adult aggressive nhl include dlbcl hence gilead be expect face intense competition product long run company press release approximately patient unite state have run option fight disease be detected refractory dlbcl year only achieve complete remission treat current standard care hence give huge market opportunity open yescarta company widely address vast unmet need patient suffering disease approve therapy market such new treatment option bring table gilead science inc price gilead science inc price gilead science inc quotezack rankgilead currently carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3524,GILD,approval gilead science inc gild free report yescarta week see approval second car therapy treat cancer be regard most advanced immune oncology treatment option moreover fda have grant priority review label expansion application major cancer drug include astrazeneca plc azn free report lynparza advanced breast cancer imfinzi earlier stage lung cancer bristol myer squibb company bmy free report opdivo melanoma patient high risk recurrence exelixis inc exel free report cabometyx advanced renal cell carcinoma rcc meanwhile ipsen partner exelixis announce positive result phase iii study hepatocellular carcinoma candidate moreover abbvie abbv free report enter immuno oncology research collaboration harpoon therapeutic focuse novel cell recruit biologic therapy abbvie use harpoon tri specific cell activate construct platform develop immuno oncology pipeline let see news detail key newsgilead acquisition kite pharma nearly have finally paid approval yescarta axicabtagene ciloleucel latter chimeric antigen receptor cell car therapy candidate fda approve therapy treat relapse refractory large cell lymphoma rlbcl adult have receive more line systemic therapy various form rlbcl yescarta be approve include diffuse large cell lymphoma dlbcl primary mediastinal large cell lymphoma pmbcl high grade cell lymphoma be second gene therapy be approve unite state novartis ag nvs free report kymriah receive approval august acute lymphoblastic leukemia car therapy be most advanced form treat cancer be do modify patient cell part body immune system fight cancerous cell therapy be manufacture specifically single patient gilead science inc price consensus gilead science inc price consensus gilead science inc partner merck mrk free report market advanced ovarian cancer drug lynparza receive priority review supplemental new drug application snda seek approval previously treat chemotherapy patient negative metastatic breast cancer fda be expect give decision first quarter lynparza be different study range tumor type include breast prostate pancreatic cancer well earlier line setting ovarian cancer meanwhile fda have also grant priority review astrazeneca snda key cancer drug imfinzi unresectable small cell lung cancer read more astrazeneca snda cancer drug get priority review astrazeneca plc price consensus astrazeneca plc price consensus astrazeneca plc quotebristol myer announce fda have grant priority review supplemental biologic license application sbla label expansion opdivo company be look get drug approve treat patient melanoma be high risk disease recurrence follow complete surgical resection drug be already approve treatment patient braf mutation positive unresectable metastatic melanoma moreover company announce opdivo alone combination yervoy achieve encourage result previously treat small cell lung cancer patient phase ii checkmate study opdivo monotherapy combo therapy achieve objective response rate respectively read more bristol myer get priority review opdivo label expansion bristol myer squibb company price consensus bristol myer squibb company price consensus bristol myer squibb company quoteother newsexelixis renal carcinoma drug cabometyx be also grant priority review fda snda snda seek approval cabometyx patient treatment naive advanced rcc fda deem snda be sufficiently complete decision expect feb moreover company advanced hepatocellular carcinoma candidate cabozantinib achieve statistically significant clinically meaningful improvement median overall survival rate placebo phase iii celestial study exelixis be develop candidate partnership ipsen meanwhile inovio pharmaceutical inc ino free report initiate phase ib ii study evaluate combination ino cell activate immunotherapy ino immune activator roche pdl inhibitor tecentriq advanced bladder cancer immune design also initiate pivotal phase iii study support regulatory application cmb treat patient synovial sarcoma wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3525,GILD,share gilead science inc gild free report decline post third quarter earning share lower earning share year quartershare axalta coating system ltd axta free report surge almost post third quarter earning share surpass zack consensus estimate barne group inc free report share plunge report third quarter earning share zack consensus estimate aon plc aon free report share tank report third quarter revenue lower year quarter
3526,GILD,nov major biotech player plummet more average push sector lowest level recent past follow decline ishare nasdaq biotechnology etf ibb spdr biotech etf xbi tank intraday trade sharpest fall october however decline be momentary investor have only rotate biotech tech stock seem prudent also be more correction decline investor buy dip further biotech stock have rally emerge top performer year fact ishare nasdaq biotechnology etf ibb have rally year date moreover biotech major have demonstrated strength challenge rise competition pipeline setback slowdown growth mature product generic competition certain key drug moreover drug pricing issue have ebb be high hope trump time tax repatriation be slate improve thing further sector republican have be try hard get reform implement be high possibility find new tax code next year so be reason shy away biotech mutual fund drug pricing issue have ebbedhealthcare be hit hard election price gouge issue be first raise hillary clinton september have tweet price gouge frame proposal combat skyrocket drug price march president donald trump take little further tweet increase competition want lower drug price send fresh shockwave industry have tweet team be work new system involve competition drug industry tweet trump have never comment publicly drug pricing also trump pledge reduce fda regulation remove taxe fee pharmaceutical medical device manufacturer successful clinical trial new drug prove be boon space meanwhile other factor continue have positive impact pharma biotech stock be new product sale ramp success innovation strong result higher number fda approval continue strong performance legacy product read more biotech stock rally hope tax cuton nov house representative finally pass tax cut legislation now name tax cut job act member gop remain positive bill actually improve overall economy house speaker paul ryan even comment legislation result more job increase wage higher take home pay bill reduce corporate tax rate current read more propose tax reform approve leave more cash hand biotech company cash be invest merger acquisition have be relatively fewer year last go say significant uncertainty regard timely pass tax reform have cast pall future biotech sector read more lot large biotech company have recent past engage tax inversion bid increase revenue tax inversion refer indirect evasion taxe involve shift headquarters outside border unite state unwelcome development such company utilize tax inversion practice be now have pay higher taxe new rule regard tax evasion such company now have pay excise tax payment company however cut taxe be likely lure back domestic territory tackle problem very root more investment pipeline major biotech company have gain primarily prospect tax reform leave more cash research development merger acquisition secondly have be major boost number fda approval have lead development newer product year have be largely successful sector make costlier company engage such deal be evident fact have be major merger year save gilead science inc gild free report acquisition kite pharma inc aug cash however thing be likely change next year tax reform be implement major biotech pickshere have highlighted technology mutual fund boast zack mutual fund rank strong buy moreover fund have encourage year ytd return additionally minimum initial investment be net asset be drug pricing issue long go biotech stock be poise growth moreover member gop be breaking sweat push reform make somewhat evident tax reform be implement also trump time tax repatriation make cheaper large biotech company bring profit hold overseas back home such development also lead more investment well larger number merger acquisition deal go such circumstance suggest consider investing biotech mutual fund expect fund outperform peer future remember goal zack mutual fund rank be guide investor identify potential winner loser most fund rating system zack mutual fund rank be not just focuse past performance also likely future success fund franklin biotechnology discovery fbdix free report invest lion share asset security company biotechnology domain fund invest maximum fifth asset equity well debt security biotech company fbdix be diversify fund fbdix have annual expense ratio be category average fund have year ytd return respectively fidelity select biotechnology fbiox free report invest majority asset security company principally engage research development manufacture distribution various product fund invest domestic foreign issuer fbiox have annual expense ratio be category average fund have year ytd return respectively profund biotechnology ultrasector inv bipix free report seek daily investment result correspond fee expense performance dow jone biotechnology index fund primarily invest biotechnology company bipix have annual expense ratio be category average fund have year ytd return respectively want key mutual fund info deliver straight inbox zack free fund newsletter brief top news analysis well top perform mutual fund week get free
3527,GILD,emerge biotech market be time invest be large cap biotech value trap gilead biogen bluebird generic drug company teva valeant abbvie manage healthcare sector effect obamacare growth stock healthcare healthcare value stock screener episode roundup podcast zack comwelcome episode zack market edge podcast week host zack stock strategist tracey ryniec be joined guest discuss hottest investing topic stock bond etfs impact life episode tracey be joined zack senior strategist kevin cook be also editor zack healthcare innovator portfolio hold healthcare medical stock long term tracey have be get question listener wonder be value healthcare stock right now be cheap biotechs biotechs be hot again biotech etf xbi have soar year ishare nasdaq biotechnology etf ibb have gain value still be find biotechs other healthcare industry zack medical sector have company include drug company hospital manage care insurer medical device company dental company other re not create equal tracey kevin run screen quickly find basic value stock sector look only medical sector choose current year forward less next year forward didn screen zack rank return stock tracey kevin discuss dozen week podcast include big name cheap healthcare stock gilead gild free report have be cheap year trade forward just earning be decline company make last year expect just make year recently buy kite be enough give earning boost be value trap biogen biib free report be big biotech be cheap trade forward just analyst just raise price target stock gilead expect see earning growth year next year teva teva free report be cheapest group trade forward investor have be concern fall earning estimate make be expect make just be value trap abbvie abbv free report have rare combination attractive just rise earning estimate earning be expect jump abbv be short list aetna aet free report be manage care group be most difficult area be right now due obamacare uncertainty aetna have be reduce exposure exchange trade forward just be other industry be also cone uncertainty due unknown surround obamacare include hospital tracey kevin discuss hospital group especially tenet healthcare thc additionally valeant vrx appear be cheap tracey fear value trap medical device company ve be hot year be just too expensive make list find answer question more week podcast look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3528,GILD,month october be highlighted deluge earning investor quest clarity fed likely policy tighten well passage tax reform earning trend issue sep earning growth be expect be higher revenue third quarter revenue growth be project be way higher earning growth come slightly lower see year cycle economic front look upbeat evident year high manufacturing activity record september jump new auto sale broader market have also see decent start october many fear disturbingly low level volatility chance crash trump fail push tax reform backdrop be important pin point etfs safeguard investor sudden market swing well play current momentum loncar cancer immunotherapy etf cncr free report be great momentum play biotech etfs especially focus cancer therapy be fire lately slew merger acquisition fda approval car cell therapy improve research development share endocyte inc ecyt free report soar more oct acquire exclusive worldwide license develop commercialize abx gmbh phase iii ready prostate cancer candidate lu psma be gilead gild free report buyout announcement clinical stage company kite pharma fda have fact give nod drug so far include september be already way higher approval see last year first trust mid cap growth alphadex fund fny free report unite state global economy rise be time play mid cap growth etfs fny be greenback gain strength come day improve economy go large cap stock greater foreign exposure md cap growth etfs investor mitigate adverse impact rise dollar tap surge global economy ishare dow jone transportation average index fund iyta source dow jone transportation index enjoy seasonal tailwind october transportation sector be expect witness revenue growth ongoing report cycle growth transportation sector be best position take advantage fall crude be especially true energy cost form major portion overall cost sector read sector etfs revenue growth play be not enough airline stock surge oct follow cowen co analyst helane becker reiteration outperform rating delta airline dal analyst see delta outlook positive article publish marketwatch surge benefit transportation etf also fund offer bargain now stock be batter previous month back back hurricane read top flop sector etfs ishare edge msci multifactor global etf acwf free report look global etfs be also warrant give upbeat prospect way investor mitigate certain risk fund look track global develop emerge market large mid cap stock choose basis value quality momentum low size score read global dividend payment upbeat etfs benefit barron etf free report etf seek track performance rule base fundamental drive barron index benchmark look select high perform stock base fundamental factor growth valuation profitability cash flow fund suit investor seek quality exposure read be near bear market etfs lean want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
3529,GILD,johnson johnson jnj free report partner glaxosmithkline gsk free report announce fda approval juluca drug complete regimen tivicay rilpivirine edurant dolutegravir single tablet treatment hiv infection tivicay novel investigational integrase strand transfer inhibitor insti be market viiv healthcare hiv company majorly own glaxo pfizer pfe free report edurant other hand be nucleoside reverse transcriptase inhibitor nnrti market janssen pharma arm juluca have be develop partnership viiv healthcare janssen year so far share price be compare favorably increase witness industry come back latest news juluca approval be base datum phase iii sword study datum study publish february year show combination dolutegravir rilpivirine antiretroviral be effective drug antiretroviral regimen maintenance therapy hiv patient have already achieve viral suppression juluca first drug regimen be approve reduce number medicine hiv patient take compromise efficacy conventional drug regimen remind investor gilead gild free report bictegravir single table regimen str hiv treatment be priority review unite state fda be expect announce decision february next year str be fix dose combination bictegravir insti emtricitabine tenofovir alafenamide ftc taf dual nrti backbone combination be review eu well gilead hiv franchise be major contributor sale approve drug genvoya truvada atripla stribild descovy odefsey complera carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3530,GILD,celgene corporation celg free report partner bluebird bio inc blue free report announce chimeric antigen receptor cell car therapy candidate bb target cell maturation antigen bcma previously treat patient multiple myeloma obtain breakthrough therapy designation fda candidate be also grant priority medicine prime eligibility european medicine agency ema breakthrough therapy designation be intend expedite development review drug be intend treat serious life threaten condition prime be program launch ema enhance support development medicine target unmet medical need remind investor celgene enter collaboration agreement bluebird bio march develop car cell therapy collaboration be amend restate focus develop product candidate target cell maturation antigen bcma june lead candidate program be bb bcma car program be currently be study phase trial treatment relapse refractory multiple myeloma company be also develop second bcma car program bb car used patient cell identify destroy cancer cell thereby make different other small molecule biologic therapy treatment cell be draw patient blood cell be then reprogram manufacturing facility create genetically code cell express chimeric antigen receptor recognize fight cancer cell other cell express specific antigen therapy have be spotlight novartis ag nvs free report kymriah be first car get fda approval september last month gilead science inc gild free report also receive fda approval yescarta axicabtagene ciloleucel treatment refractory aggressive hodgkin lymphoma include dlbcl transform follicular lymphoma primary mediastinal cell lymphoma long term impact treatment be yet be evaluate approval open new frontier treatment cancer meanwhile celgene stock have fall last month industry gain celgene third quarter result be mixed company beating earning miss sale estimate revlimid sale be impressive yet again otezla sale unite state be weak lead management reduce annual guidance drug zack rankcelgene be zack rank hold stock see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3531,GILD,biotech industry turn year drug pricing issue cripple performance last year have number thing go favor strong quarterly result new product sale ramp rise demand successful innovation product line expansion strong clinical study result more frequent fda approval continue strong performance legacy product play pivotal role bring sector track year however rise first month year january september medical biotech genetic industry have decline so far fourth quarter oct date macro industry specific factor result sudden downfall uncertain macro picturea big component sell be confusion pass tax reform reform aim bring corporate tax stimulate economic well employment growth propose tax reform approve leave more cash hand biotech company cash be invest merger acquisition have be relatively fewer year compare last go say significant uncertainty regard timely pass tax reform have cast shadow future biotech sector october president trump once again criticize high drug price come time investor have start expect trump action drug price not be onerous previously fear send health care stock lower tepid resultscome industry specific factor most big biotechs beat estimate earning sale however share most company decline post earning release various reason gilead gild free report top earning revenue estimate third quarter witness continue decline sale hcv drug harvoni sovaldi result competitive pricing pressure amgen amgn free report also beat expectation earning sale raise earning guidance however sale decline year year result share price decline post earning call sale pcsk inhibitor repatha be also disappointing celgene celg free report share plunge follow release third quarter result celgene earning top estimate revenue fall short moreover company lower outlook otezla sale well total revenue earning outlook biogen biib free report third quarter result be better expect share be concern regard company multiple sclerosis franchise sale well sale recently launch spinal muscular atrophy sma treatment spinraza alexion alxn free report top earning estimate miss revenue third quarter vertex vrtx free report abbvie abbv free report be only outperformer conclusionwe believe biotech space be back track be more certainty regard timing tax reform be fundamental sector remain strong meanwhile earning season now stock start pick positive datum key clinical study drive sector share price biotechs be correlated success key study major biotech player need infusion new growth driver pipeline product portfolio internal development buy asset outside strategic deal sign biotechs also push stock higher look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3532,GILD,third quarter report cycle be witness revenue acceleration positive revision trend result half member be already oct total earning member be same period last year higher revenue surpass earning revenue estimate respectively accord earning preview company account index total market capitalization report total earning company be expect grow year year higher revenue please note broader medical sector include drug biotech well medical device company be expect record year year growth revenue earning biotech pharma bigwig merck co inc mrk free report celgene corporation celg free report abbvie inc bristol myer squibb company bmy free report gilead science inc gild free report report third quarter result last week merck celgene abbvie outpaced zack consensus estimate earning lag same revenue however bristol myer gilead surpass expectation earning revenue notably bristol myer gilead raise earning outlook well merck raise previously issue adjust earning guidance up sale guidance marginally abbvie celgene also tighten earning guidance here have biotech pharma company be set report third quarter result oct let see thing be shape quarter pfizer inc pfe free report pfizer be schedule release earning market open deliver positive earning surprise last quarter company earning performance have be mixed bottom line miss last quarters beating same other bring average surprise negative quarter pfizer have earning esp zack rank hold zack consensus estimate be peg cent share uncover best stock buy sell re report earning esp filter new product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain eliquis blood thinner contribute top line meaningfully meanwhile sale blockbuster drug enbrel continue decline quarter due biosimilar competition lower sale trend prevnar prevenar vaccine franchise be likely continue well sale viagra be expect be affected lower demand read more be beat likely pfizer earning season previous article show pfizer be likely beat earning quarter however estimate change thereafter be not certain beat earning season pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quoteincyte corporation incy free report incyte be schedule release earning market open witness negative earning surprise last quarter company earning performance have be mixed so far have deliver positive surprise last quarters miss estimate unavailable average earning surprise last quarters be negative company have earning esp zack rank indicate likely positive surprise zack consensus estimate be peg cent share see complete list today zack rank strong buy stock here company key growth driver jakafi have be perform well expect trend continue be report quarter well incyte corporation price ep surprise incyte corporation price ep surprise incyte corporation quoteacorda therapeutic inc acor free report acorda be schedule release earning market open witness negative earning surprise last quarter company earning performance have be disappointing so far company have incur negative surprise last quarters average earning surprise last quarters be negative company have earning esp zack rank strong sell make surprise prediction difficult zack consensus estimate be peg cent share be caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision expect investor focus refusal file rtf relief late stage pipeline candidate inbrija be develop treatment patient be suffering parkinson disease acorda therapeutic inc price ep surprise acorda therapeutic inc price ep surprise acorda therapeutic inc quotezack best private investment idea be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor
3533,GILD,car stock be news week key biotech player gilead science gild free report announce intention acquire kite pharma most advanced player car therapy market moreover fda approve novartis kymriah yesterday make first car therapy gain approval recap week most important storiesgilead look boost oncology pipeline kite deal gilead have finally announce deal company say acquire kite pharma share cash approximately gilead have be lot pressure utilize huge pile cash major acquisition deal give dwindle sale erstwhile top selling hepatitis virus hcv franchise kite acquisition slate close fourth quarter place gilead top player emerge field cell therapy kite expertise lie develop engineer cell therapy express chimeric antigen receptor car engineer cell receptor tcr depend type cancer kite already have car therapy axicabtagene ciloleucel axi cel priority fda review response expect nov eu approval come next year axi cel be review treatment refractory aggressive hodgkin lymphoma nhl include diffuse large cell lymphoma dlbcl transform follicular lymphoma tfl primary mediastinal cell lymphoma pmbcl other candidate kite pipeline include target hematologic cancer well solid tumor also read gilead fly high kite pharma acquisition axi cel have blockbuster potential novartis be currently first company gain approval car treatment fda approve company kymriah kite share be follow acquisition news year date stock have gain substantially outperform rally industry belong kite gilead deal be announce other company involved car treatment see share shooting hope more deal be announce segment market juno shot bluebird bio be gilead be zack rank buy stock see complete list today zack rank strong buy stock here incyte baricitinib regulatory update incyte incy free report partner eli lilly company provide update regard resubmission regulatory application experimental rheumatoid arthritis ra treatment baricitinib company have previously say expect delay least month resubmission regulatory application baricitinib announce be resubmit regulatory application jan new safety efficacy datum be include resubmission investor react positively news send incyte share medicine co vabomere get fda nod medicine company mdco free report get boost accelerate approval vabomere treatment adult patient complicate urinary tract infection include pyelonephritis drug address pathogen designate center disease control cdc urgent serious antimicrobial resistance threat pathogen cite world health organization critical need new antibiotic vabomere enjoy additional year exclusivity give status qualify infectious disease product qidp generate antibiotic incentive now gain act medicine company intend launch vabomere fourth quarter priority review biomarin drug biomarin pharmaceutical bmrn free report pegvaliase get priority review reduction blood phenylalanine phe level adult patient pku have uncontrolled blood phe level exist management mean response agency regard approval status pegvaliase be feb however fda ask company submit additional chemistry manufacturing control cmc information biomarin say expect review period be extend additional month also read biomarin pegvaliase bla grant priority review fda acorda inbrija regulatory update acorda therapeutic acor free report see share fall news fda have issue refusal file rtf letter inbrija agency have raise question rtf regard date manufacturing site be ready inspection other regard submission drug master production record fda have also ask additional information resubmission have not ask additional efficacy safety study acorda intend meet fda discuss rtf acorda be look get inbrija approve treatment symptom period person parkinson disease take carbidopa levodopa regimen company need add new product market product portfolio consider flagship drug ampyra be likely face generic competition post jul biomedical genetic industry yr return medical biomedical genetic industry yr returnit be good week biotech stock nasdaq biotechnology index gain last trading session major biotech stock gilead be biogen be alzheimer disease datum also read biogen alzheimer drug show promise long term study last month vertex vrtx free report be amgen slip see last biotech stock roundup here eu label expansion alexion biib face drug price probe next biotech world watch usual regulatory pipeline update simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
3534,GILD,cancer treatment industry be celebrate massive victory wednesday novartis nvs free report receive approval innovative new lymphoblastic leukemia treatment make first approve car therapy world achieve unprecedented result patient deadly form cancer novartis new therapy be market kymriah be officially approve food drug administration today kymriah be example car therapy car be newly emerge method treat cancer include make genetic change patient immune cell reinject body attack cancer cell traditional medicine treatment car therapy be individually tailor specific patient reason patient seek kymriah have travel just location country administer therapy harvest cell be send novartis facility new jersey be edit then send back logistic aren only thing challenge patient look receive kymriah indeed novartis have say just course treatment cost staggering nevertheless prevailing reaction market be price tag be actually quite cheap thing consider kymriah left trial participant relapse acute lymphoblastic leukemia cancer free just month top effectiveness kymriah initial cost be also quite bit lower analyst be expect fact wall street estimate therapy open price reach high just dose novartis mean kymriah win be massive revenue generator be only new case acute lymphoblastic leukemia year most be treat traditional drug nevertheless be monumental achievement company novartis be first company world receive regulatory approval car treatment be hardly only brand develop cure earlier week learn biotech behemoth gilead science gild free report be plan acquire car developer kite pharma staggering also read do kite pharma stock skyrocket today kite lead car candidate axicabtagene ciloleucel be currently review fda axicabtagene ciloleucel be expect be approve treatment aggressive hodgkin lymphoma decision come november elsewhere biotech space company juno therapeutic bluebird bio blue free report be work develop car therapy researcher watch stock price skyrocket response kite buyout investor speculate also become takeover target soon kymriah approval mark begin become monumental moment biotech investor more importantly be first hopefully be long list world change cancer treatment want more stock market analysis author make sure follow ryan_mcqueeney twitter surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
3535,GILD,earning season be fly start equity market scaling record high owing slew upbeat economic datum strong corporate performance president donald trump tax reform proposal however performance have be mixed bag biotech company beating market expectation few fail do so read fiscal deficit gdp etfs focus now discuss performance few biotech giant such amgen inc amgn free report gilead science gild free report biogen inc biib free report alexion pharmaceutical alxn free report read keep portfolio healthy biotech etfs earning focusamgen report third quarter adjust earning share oct surpass zack consensus estimate increase share year quarter company also beat zack consensus estimate revenue front amgen report revenue surpass zack consensus estimate decrease year quarter company update full year gaap ep guidance range previous guide range owing hurricane recovery cost also update revenue guidance range previous guide range company share lose hour trading oct revise guidance gilead science report third quarter adjust earning share oct miss zack consensus estimate decrease more share year quarter however company beat zack consensus estimate revenue front company report revenue surpass zack consensus estimate decrease more year quarter company update full year revenue guidance range previous guide range company share fall hour trading oct owing ep miss biogen inc report third quarter adjust earning share oct surpass zack consensus estimate increase share year quarter company report revenue surpass zack consensus estimate increase roughly year quarter company share decline market close oct due weaker expect sale sclerosis franchise alexion pharmaceutical inc report third quarter adjust earning share oct surpass zack consensus estimate increase roughly share year quarter company report revenue fail beat consensus estimate increase roughly year quarter company update full year gaap ep guidance range increase revenue guidance company share decline market close oct primarily due revenue miss now discuss few etfs high exposure company discuss ishare nasdaq biotechnology etf ibb free report fund seek provide exposure biotech industry have aum charge fee basis point year fund have exposure amgen biogen gilead alexion oct fund have return year year date oct have zack etf rank hold high risk outlook vaneck vector biotech etf bbh free report fund have aum charge fee basis point year fund have exposure amgen gilead biogen alexion oct fund have return year year date oct have zack etf rank high risk outlook proshare ultra nasdaq biotechnology etf bib free report fund have aum charge fee basis point year fund have exposure amgen biogen gilead alexion sep fund have return last year year date oct want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
3536,GILD,company amgen amgn free report endocyte ecyt free report be news amgen signing deal abbvie abbv free report related entry biosimilar version humira endocyte signing licensing deal prove be company recap week most important storiesendocyte soar licensing deal endocyte share have shot whopping follow company announcement have get exclusive worldwide license psma abx gmbh endocyte say quickly move lu psma phase iii development lu psma be radioligand therapeutic rlt target prostate specific membrane antigen psma present patient metastatic castration resistant prostate cancer mcrpc deal provide endocyte most advanced target radioligand therapy development prostate cancer represent market opportunity more company hope start phase iii development first half complete program early term deal include upfront payment well issuance share abx warrant purchase additional share endocyte common stock abx also stand receive milestone payment tiered royalty start mid teen endocyte bear future development expense read more endocyte inks deal prostate cancer candidate share abbvie amgen sign deal delay humira biosimilar entry abbvie have gain breathe space enter settlement agreement amgen related biosimilar competition abbvie multus dollar drug humira amgen gain fda approval amjevita biosimilar version humira have acknowledge validity abbvie extensive intellectual property portfolio humira accord deal exclusive license humira commence jan unite state different date other market include oct most country eu amgen also pay royalty agreement have remove major overhang abbvie share company be still face patent challenge boehringer ingelheim gain approval biosimilar version humira cyltezo august humira generate sale first half include unite state remain key market drug humira continue perform well remain major contributor top line come year moreover agreement give abbvie ample time focus develop pipeline launch new product help make loss revenue once biosimilar humira enter market expectation be high abbvie boehringer ingelheim announce similar settlement agreement dismiss patent litigation abbvie be zack rank hold stock amgen be zack rank buy stock see complete list today zack rank strong buy stock here ablynx positive phase iii result ablynx share shot positive topline result late stage study caplacizumab company von factor vwf nanobody be be develop treatment acquire thrombotic purpura attp ablynx be currently seek approval caplacizumab eu expect submit regulatory application unite state first half caplacizumab have fast track designation unite state treatment attp timely approval make first therapeutic specifically indicated treatment attp acute life threaten autoimmune blood clot disorder cytomx immuno oncology deal amgen cytomx therapeutic ctmx free report have enter immune oncology focuse strategic collaboration amgen development cytomx probody cell engage bispecific epidermal growth factor receptor egfr early development be lead cytomx amgen lead later development company share global late stage development cost deal see cytomx get upfront payment issue common stock amgen cytomx also earn development regulatory commercial milestone egfr program global commercial activity be lead amgen cytomx have option opt profit share unite state receive tiered double digit royalty net product sale outside unite state agreement also cover additional undisclosed target amgen decide pursue target cytomx get additional upfront milestone payment high single digit mid double digit royalty payment cytomx also receive right undisclosed preclinical cell engage bispecific program amgen make milestone royalty payment result product arrangement expect investor react favorably deal regeneron sanofi eczema drug get eu nod regeneron regn free report partner sanofi gain eu approval eczema treatment dupixent make dupixent first target biologic be approve use adult moderate severe atopic dermatitis ad be candidate systemic therapy dupixent approve unite state earlier year have blockbuster potential be be investigate other indication well include asthma eosinophilic esophagitis nasal polyp share regeneron have gain year date significantly outperform industry rally biomedical genetic industry yr returnmedical biomedical genetic industry yr nasdaq biotechnology index gain almost last trading session major biotech stock regeneron be gilead gild free report lose last month vertex vrtx free report be see last biotech stock roundup here amgen reiterate outlook intercept hit ocaliva safety issue next biotech world watch usual regulatory pipeline update hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
3537,GILD,gilead science inc gild free report announce health canada have grant notice compliance noc update label hepatitis virus drug epclusa drug label have be expand extend drug use patient co infected hiv drug be approve canada july treatment adult genotype chronic hcv infection cirrhosis compensate cirrhosis decompensate cirrhosis combination ribavirin expect drug sale increase label expansion hcv co infection remain major cause morbidity hiv infected individual last month health canada grant noc single tablet regimen vosevi sofosbuvir mg velpatasvir mg voxilaprevir mg chronic hcv infection gilead be know presence hcv market courtesy blockbuster hcv drug sovaldi harvoni hcv portfolio receive huge boost epclusa gain approval unite state june eu july become first only oral pan genotypic str consist sovaldi velpatasvir ns inhibitor treatment adult genotype chronic hcv infection approval vosevi be expect boost gilead strong hcv portfolio further however hcv franchise be pressure due competition pricing issue note harvoni sovaldi epclusa face competition abbvie inc abbv free report viekira pak viekira xr other competition well pricing pressure intensified further launch merck co inc mrk free report zepatier gilead stock have gain year date industry gilead recently announce plan acquire kite pharma inc foray emerge field cell therapy kite be pioneer cell therapy have develop engineer cell therapy express chimeric antigen receptor car engineer cell receptor tcr depend type cancer acquisition diversify gilead portfolio poise company dominant position cellular therapy space note investor be expect gilead announce acquisition term give decline once lucrative hcv market due competitive pressure zack rankgilead currently carry zack rank hold see complete list today zack rank strong buy stock here trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
3538,GILD,biotech industry witness rebound face odd previous year industry face challenge rise competition pipeline setback slowdown growth mature product generic competition certain key drug however have see trend reverse more fda approval new product sale ramp success innovation strong clinical study result continue strong performance legacy product positive factor be expect continue contribute sector growth rest year maybe next nasdaq biotechnology index have gain so far year be sharp contrast last year performance index be major recent event contribute rally be announcement gilead science gild free report acquire immunotherapy focuse company kite pharma second be fda approval first gene therapy unite state novartis ag nvs free report kymriah recently fda also approve first cancer biosimilar amgen amgn free report allergan mvasi biosimilar version roche rhhby free report blockbuster cancer drug avastin momentum biotech sector be likely continue good idea avoid few stock industry not prove be prudent addition portfolio sell rate stock avoidget rid underperform stock right time help maximize portfolio return be tricky avoid stock industry be do well however have take help zack stock screener shortlist stock be dump vast universe biotech sector have picked stock carry zack rank sell strong sell see complete list today zack rank strong buy stock here further narrow list select have vgm score circumstance buy stock zack rank sell strong sell vgm score have also take consideration stock witness negative estimate revision current year well next year last day be likely see further negative estimate revision be dump clearside biomedical inc clsd free report late stage clinical company be develop first class drug therapy treat back eye disease company have be incur loss inception also expect incur loss next few year currently alpharetta ga base company carry zack rank have vgm score further last day zack consensus loss estimate have widen share company have decline year date underperform industry gain abeona therapeutic inc abeo free report clinical stage company focuse develop novel therapy life threaten rare genetic disease company currently carry zack rank have vgm score last day zack consensus loss estimate have widen reata pharmaceutical inc reta free report company currently carry zack rank have vgm score last day zack consensus loss estimate have widen urogen pharma ltd urgn free report be clinical stage company develop treatment address unmet need field urology company currently carry zack rank have vgm score last day zack consensus loss estimate have widen make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3539,GILD,value investing be easily most popular way find great stock market environment wouldn want find stock be fly radar be compelling buy offer tantalize discount compare fair value way find company be look several key metric financial ratio many be crucial value stock selection process let put gilead science inc gild free report stock equation find be good choice value oriented investor right now investor subscribe methodology look elsewhere top pick pe ratioa key metric value investor always look be price earning ratio pe short show much investor be willing pay dollar earning give stock be easily most popular financial ratio world best use pe ratio be compare stock current pe ratio ratio have be past compare average industry sector compare market whole front gilead science have trail month pe ratio see chart level actually compare pretty favorably market large pe stand focus long term pe trend gilead science current pe level put midpoint past year moreover current level stand significantly lower high stock indicate be solid entry point further stock pe compare favorably zack medical sector trail month pe ratio stand very least indicate stock be relatively undervalue right now compare peer point gilead science have forward pe ratio price relative year earning so be fair expect increase company share price future ratioanother key metric note be price sale ratio approach compare give stock price total sale lower read be generally consider better person metric more other value focuse one look sale something be far harder manipulate accounting trick earning right now gilead science have ratio be bit higher average come right now indicate stock be bit overvalue aspect broad value outlookin aggregate gilead science currently have value score putt top stock cover look make gilead science solid choice value investor other key metric make pretty clear too example cf ratio great indicator value gilead science be just level be far lower industry average clearly gild be solid choice value front multiple angle stock overall gilead science be good choice value investor be plenty other factor consider investing name particular be worth note company have growth score momentum score give gild zack vgm score overarch fundamental grade read more zack style score here notably company recent earning estimate have be quite encourage current quarter full year have see estimate go higher past day respectively company do not witness downward revision say time frame have have meaningful impact consensus estimate current quarter consensus estimate have rise past month full year estimate have increase see consensus estimate trend recent price action stock chart gilead science inc price consensus gilead science inc price consensus gilead science inc quotehowever somewhat bullish trend have likely not yet be reflect stock have just zack rank hold indicate expectation line performance term nonetheless bullish analyst sentiment indicate stock prospect term look good bottom linegilead science be inspire choice value investor be hard beat incredible lineup statistic front further zack rank company enjoy solid zack industry rank top more industry however industry have underperform broader market past year be visible chart so value investor want broader industry factor turn favorable once happen stock be compelling pick promising stock pick keep eye news story computer hacking identity theft become increasingly commonplace cybersecurity industry look promising investment opportunity stock buy zack just release cybersecurity investor guide locking profit help answer question new special report give information need make well inform investment choice space more importantly also highlight cybersecurity pick strong profit potential get new investing guide now
3540,GILD,past few year consolidation have become important trend nearly major global industry reason change consumer trend globalization emerge technology be primary culprit world ve see countless household name join force shrink competition pool have certainly extend trend fact accord imaa total global value deal be expect once again eclipse mark back record transaction year investor also note year deal have include wall street most powerful brand have have industry rattle consequence celebrate ve compile list most important particular order check now unite technology utx free report buy rockwell collin col free report ll start newest deal list detail acquisition weren make official early last month merger agreement unite technology acquire rockwell collin share cash stock completion rockwell collin aircraft avionic business merge unite technology wide portfolio include aircraft engine structure cockpit cabin control ventilation system other device create brand new aircraft behemoth post acquisition unite technology be expect have global sale deal be expect generate run rate pre tax cost synergy fourth year rockwell status supplier boee ba free report acquisition be also expect give unite technology greater negotiating power industry intel intc free report acquire mobileyea public grow more more obsessed impending rollout self drive car intel acquisition mobileye have certainly emerge year most meaningful buyout semiconductor giant scoop israeli autonomous vehicle tech firm deal worth staggering make biggest purchase company focuse solely self drive market date acquisition underscored massive amount cash be spend autonomous drive right now intel own automate drive group have now joined force mobileye renown computer vision technology immediately cement intel status leader chip side business jab holding purchase panera breadin move have have major ramification retail restaurant industry german conglomerate jab holding purchase fast casual chain panera bread share earlier year deal jab add panera bakery cafe portfolio breakfast oriented brand include krispy kreme einstein bro bagel keurig green mountain buyout be major deal series several purchase involve notable restaurant chain also year darden restaurant dri free report snap cheddar scratch kitchen burger king owner restaurant brand international qsr free report buy popeye louisiana kitchen most recent quarter buyout be announce panera report company own comparable store sale increase have be few year panera stock jab appear snag brand opportune time gilead gild free report scoop kite pharma doubt gilead acquisition kite pharma go most important biotech deal industry behemoth gilead pay share cash kite value buyout nearly relatively small biotech research firm be worth much money well come kite pipeline include car therapy be expect be approve fda november car be newly emerge method treat cancer include make genetic change patient immune cell reinject body attack cancer cell many industry analyst believe car revolutionize cancer treatment market gilead deal kite be first major investment car large biotech company amazon amzn free report buy whole foodslast not least have monumental amazon whole food deal be obviously go make list be have be perhaps biggest headline wall street year have major consequence several industry deal be value whole food share be somewhat surprising move amazon not company be shy spending money shock investor be fact amazon be willing spend nearly many consider be gamble brick mortar retailer ve already see amazon slash price several popular product whole food store expect see commerce king parlay new real estate advantage deliver good amazon paid right price whole food be debate be future mind move take year fully develop want more stock market analysis author make sure follow ryan_mcqueeney twitter make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3541,GILD,medical sector biotech stock have perform well first half year challenge rise competition pipeline setback slowdown growth mature product generic competition certain key drug sector re-cover pricing controversy defy uncertainty surround president trump propose healthcare policy factor be responsible biotech sector perform well current year so far be increase fda approval new product sale ramp success innovation strong clinical study result continue strong performance legacy product few other event also contribute rally sector past month include pharmaceutical giant gilead science gild free report decision acquire immunotherapy focuse company kite pharma fda approval novartis ag nvs gene transfer treatment kymriah suspension treatment patient year age cell precursor acute lymphoblastic leukemia be refractory second later relapse be good news sector kymriah formerly ctl be first chimeric antigen receptor cell car therapy be approve further company alexion pharmaceutical inc alxn free report eli lilly company lly free report announce restructure initiative include job cut recently former reduce global workforce lilly do same company plan invest cost saving new drug line extension turn bode well growth sector well industry rank broader drug market be year date outpace gain zack industry medical biom genetic versus large cap pharma versus have outperformed index zack industry rank medical biom genetic be top zack industry medical drug rank be top large cap pharma be top back testing show top zack rank industry outperform bottom factor more stock pick cash favorable trend drug biotech space be right time add few stock have growth potential have take help zack stock screener select right stock shortlist stock vast universe pharmaceutical company have picked stock carry zack rank strong buy buy see complete list today zack rank stock here further narrow list have select have growth score research show stock growth score combine zack rank offer best upside potential here be stock fulfilled criterium therapeutic inc cort free report carry zack rank stock have growth score share company have gain year date outperform medical drug industry gain also be expect record earning growth sale be expect grow heska corp hska free report carry zack rank stock have growth score share company have gain year date outperform medical biom genetic industry gain also be expect record earning growth sale be expect grow sangamo therapeutic inc sgmo free report carry zack rank stock have growth score share company have gain year date outperform medical biom genetic industry gain also be expect record earning growth sale be expect grow lundbeck hluyy free report carry zack rank stock have growth score share company have gain year date outperform large cap pharma industry gain also be expect record earning growth sale be expect grow trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
3542,GILD,biotech giant gilead science inc gild free report deal buy car cancer therapy designer kite pharma inc have make other lead independent car developer juno therapeutic inc bluebird bio inc blue free report hot takeover target term gilead kite pharma dealper agreement gilead pay share cash total transaction value be approximately price represent premium close share price kite pharma aug transaction be approve shareholder company be expect close fourth quarter share gilead have shot gilead have go almost announcement fact so far year kite pharma stock be compare favorably increase register industry kite pharma kite pharma car therapy axicabtagene ciloleucel treat aggressive hodgkin lymphoma nhl be priority review decision fda be expect nov believe solid efficacy profile demonstrated pivotal zuma study axicabtagene ciloleucel be likely support drug approval year europe regulatory application be file july approval launch expect next year accord company initial market opportunity axicabtagene ciloleucel include addressable car patient europe respectively new case be diagnosed japan year key urban eastern rural coastal area china meanwhile other study axicabtagene ciloleucel additional candidate include kite kite be also advance acquisition diversify gilead portfolio struggle hcv franchise position take share grow cellular therapy space hcv franchise be pressure competition pricing issue other car therapy maker focuscar be manufacture individual patient used own cell thereby make different typical small molecule biologic therapy treatment process cell be draw patient blood cell be then reprogram manufacturing facility create cell be genetically code express chimeric antigen receptor recognize fight cancer cell other bcell express specific antigen deal look expensive give premium gilead paid kite car space be expect be revolutionary treatment cancer represent immense potential juncture thereby attract attention big pharmas go say follow kite pharma acquisition gilead other small biotechs develop car therapy juno bluebird be buy larger biotech probably gilead even biggest partner celgene corporation celg free report juno be develop jcar partnership celgene nhl utilize car cell technology datum present june demonstrated complete response patient relapse refractory aggressive cd nhl company plan bring jcar market nhl early multiple indication end fact share juno be almost kite gilead deal be announce buyout speculation company share be year date bluebird be develop bcma car cell therapy bb also collaboration celgene candidate be only phase study however datum early stage refractory multiple myeloma study bb present june show evaluable patient active dose cohort achieve objective response overall response rate orr cohort be investment community believe datum early stage bode well candidate future development share company be year so far meanwhile other small biotechs tesaro inc tsro free report clovis oncology inc clvs free report puma biotechnology inc pbyi free report have launch innovative cancer treatment recently be also potential acquisition target now surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
3543,GILD,have be month last earning report gilead science inc gild free report share have add time frame recent positive trend continue lead stock next earning release be due pullback dive investor analyst have react late let take quick look most recent earning report order get better handle important catalyst gilead top earning revenue estimatesgilead report result second quarter earning revenue surpass expectation second quarter earning include impact stock base compensation expense share beat zack consensus estimate however earning be year quarter figure moreover total revenue report quarter be top zack consensus estimate however revenue decline year year hiv impress yet againproduct sale come year year decline be due lower hepatitis virus hcv sale partially offset higher sale hiv other therapeutic area antiviral product sale include gilead hiv liver disease portfolio come report quarter hcv product sale include harvoni sovaldi recently launch epclusa be report year quarter downside be mainly attribute lower sale harvoni sovaldi major market partially offset sale epclusa launch various location sale harvoni decline year year report quarter decline be mainly due lower sale europe further sovaldi sale record steep year year decline epclusa garner sale report quarter lower prior quarter figure note epclusa be launch europe june jul respectively meanwhile hiv hbv product sale come year year increase be primarily drive continuous strong uptake tenofoviral afenamide taf base product such genvoya generate sale year quarter descovy record sale odefsey register sale hiv treatment stribild complera eviplera sale decline viread sale be atripla sale tank truvada sale fall other product letairis ranexa zydelig record sale respectively research development expense decline due purchase nimbus apollo inc food drug administration fda priority review voucher other hand selling general administrative sg expense be roughly flat adjust product gross margin be year period guidance updatedbased better expect performance first half specifically gilead raise guidance gilead now expect net product sale range provide earlier hcv product sale be project earlier projection hcv product sale be project earlier projection adjust expense adjust sg expense be now project range respectively adjust product gross margin be expect range earning share be now project earlier projection dividend share gilead declare cash dividend cent share common stock third quarter dividend be payable sep stockholder record close business sep second quarter company paid cash dividend repurchase share have estimate be move then analyst be quiet past month none issue earning estimate revision gilead science inc price consensus gilead science inc price consensus gilead science inc quotevgm scoresat time gilead stock have subpar growth score be do bit better momentum front however stock be allocate grade value side putt top quintile investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested company stock be more suitable value investor momentum investor base style score stock have zack rank buy be expect average return stock next few month
3544,GILD,investor gilead science inc gild free report need pay close attention stock base move option market lately be sep call have highest imply volatility equity option today be imply volatility imply volatility show much movement market be expect future option high level imply volatility suggest investor underlie stock be expect big move direction other also mean be event come soon cause big rally huge sell however imply volatility be only piece puzzle putt together option trading strategy do analyst think clearly option trader be pricing big move gilead science share be fundamental picture company currently gilead science be zack rank hold medical biomedical genetic industry rank top zack industry rank last day analyst have increase earning estimate current quarter none have drop estimate net effect have take zack consensus estimate current quarter share period give way analyst feel gilead science right now huge imply volatility mean trade develop oftentimes option trader look option high level imply volatility sell premium be strategy many seasoned trader use capture decay expiration hope trader be underlie stock do not move much originally expect look trade option week very own dave bartosiak give top option trade check recent live analysis option trade nflx earning report completely free see here trading netflix nflx earning option check embed video more detail
3545,GILD,lackluster performance drug biotech sector have show promise begin major announcement related drug pricing control trump election president investor be breathe sigh relief drug pricing controversy be major issue hurt industry last year fda be plan streamline review process generic speeding approval suggest instead direct measure price control trump administration be try control drug price competition uncertainty clear more more investor be expect put money biotech company pull share meanwhile acquisition kite pharma inc gilead science inc gild free report almost have set stage further merger acquisition deal also industry benefit tax reform once make way congress reform aim allow company bring back profit store overseas lower rate however controversy rumor surround scrapping obamacare pass trump propose health care bill persist report congressional budget office estimate abolish obamacare increase number uninsured person run million affect demand expensive medical procedure device rally be expect continue back increase demand drug due rise elderly population prevalence wide variety disease drug biotech company be investing develop innovative treatment many clinical study show impressive result so far favorable industry rank price broader drug market be year date have outpaced gain zack industry medical biom genetic large cap pharma have outperformed index zack industry rank be top zack industry medical biom genetic top medical drug top large cap pharma bottom generic drug backtesting show top zack rank industry outperform bottom factor more undervalue stock add portfoliovalue stock be stock be trading discount real value value style score take account valuation metric condense single actionable score help investor identify undervalue stock more accurately avoid value trap have take help zack stock screener select stock shortlist stock vast universe drug biotech stock have picked carry zack rank strong buy buy value score here be stock fulfilled criterium jazz pharmaceutical plc jazz free report be company have drug xyrem treat sleep disorder vyexos receive approval treat acute myeloid leukemia august company be focuse expand label xyrem major source revenue increase target population carry zack rank value score share company have gain year date outperform industry peg ratio growth ratio price sale trail industry earning yield be better industry yield suggest stock be undervalue jazz pharmaceutical plc price jazz pharmaceutical plc price jazz pharmaceutical plc quotepdl biopharma inc pdli free report be company focuse acquire manage income generate asset pdl biopharma have royalty agreement several company have royalty right product sale carry zack rank value score share company have gain year date outperform industry price book ratio trail industry earning yield be higher industry indicate have more room run pdl biopharma inc price pdl biopharma inc price pdl biopharma inc quotegrifol grfs free report be pharmaceutical company mainly produce blood plasma base product be leader segment europe carry zack rank value score share company have gain year date outperform industry peg ratio be par industry be trail industry earning yield be better industry suggest stock be undervalue grifol price grifol price grifol see complete list today zack rank stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3546,GILD,pharmaceutical biotech industry have be bless good health so far year sector have re-cover pricing controversy defy uncertainty surround president trump propose healthcare policy nyse arca pharmaceutical index have rise almost year date decline almost last year even nasdaq biotechnology index be slide fact zack drug sector be year date importantly zack biotech sector rank top zack industry medical sector include pharmaceutical biotech medical device company record earning growth revenue growth beat ratio earning revenue be be respectively quarter review aug medical sector biotech stock have perform well first half year challenge rise competition pipeline setback slowdown growth mature product generic competition certain key drug company also raise guidance additionally sale newly launch drug hold potential mitigate impact genericization key drug extent moreover company be also focuse bring newer candidate category gene editing nash parkinson disease market key picksgiven scenario be perfect time dip toe grow market here be big pharmaceutical biotech stock carry favorable rank prove lucrative addition portfolio see complete list today zack rank strong buy stock here alexion pharmaceutical inc alxn free report company be witness strong sale figure blockbuster drug soliris make effort expand label notably fda decision regard approvability soliris refractory generalized myasthenia gravis gmg be expect oct potential approval soliris indication be likely boost top line company other new product drug strensiq be do well have redefine strategy kanuma have lag expectation previously company expect strensiq be strong additional catalyst year order focus better core area alexion be prioritize few clinical program terminate partnership moderna therapeutic blueprint medicine arbutus biopharma alexion zack rank stock have see zack consensus estimate earning rise respectively last day company deliver positive earning surprise trail quarters average beat zack consensus estimate sale be expect grow year year basis respectively meanwhile earning be expect grow share company have rise year date outperform gain witness industry regeneron pharmaceutical inc regn free report tarrytown ny base regeneron key growth driver eylea continue drive revenue consequently company be expand drug label additional indication give eylea access higher patient population increase commercial potential company have also be work diversify portfolio gain fda approval drug year dupixent atopic dermatitis kevzara rheumatoid arthritis drug develop partnership sanofi sny free report have blockbuster potential dupixent prove be important growth driver company company be also work expand label dupixent anticipate filing regulatory approval unite state treatment asthma adult fourth quarter regeneron have observed zack consensus estimate current year earning advance last day earning have rise company sport zack rank share have surge year date outperform industry gain company deliver positive earning surprise trail quarters average beat zack consensus estimate sale be expect grow year year basis respectively earning be anticipate grow respectively ligand pharmaceutical inc lgnd free report company captisol formulation technology have result partnership several lead drug company novartis amgen notably tie up have provide fund form milestone royalty payment moreover ligand internal pipeline have several candidate development be likely develop future licensing opportunity nonetheless company entry medical device segment acquisition multiple program own cormatrix be also encourage ligand have see zack consensus estimate earning advance last day company flaunt zack rank share company have rise so far year outperform gain industry belong company deliver positive earning surprise precede quarters average beat zack consensus estimate sale be expect grow year year basis respectively earning be expect grow gilead science inc gild free report gilead be dominant player hiv hepatitis virus hcv market impressive portfolio same company hiv franchise maintain momentum drive rapid adoption taf base regimen unite state eu now represent total hiv prescription volume june end genvoya be now company bestselling hiv product treatment naïve patient share further strong uptake truvada use pre exposure prophylaxis set be likely boost sale gilead raise outlook year second quarter conference call recently company announce buy kite pharma inc acquisition diversify gilead portfolio position dominant player cellular therapy space deal be expect close fourth quarter year company have see zack consensus estimate earning increase last day gilead carry zack rank buy share company have gain so far year outperform industry advance company deliver positive earning surprise trail quarters average beat zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
3547,GILD,biotech sector get shot arm last week thank major development lead rally sector first catalyst be gilead science gild free report decision acquire immunotherapy focuse company kite pharma second be fda approval first gene therapy unite state novartis ag nvs free report kymriah gilead have be lot pressure utilize huge pile cash major acquisition deal give dwindle sale erstwhile top selling hepatitis virus hcv franchise kite acquisition slate close fourth quarter place gilead top player emerge field cell therapy kite expertise lie develop engineer cell therapy express chimeric antigen receptor car engineer cell receptor tcr depend type cancer kite gilead deal be announce other company involved car treatment see share shooting hope more merger acquisition deal be announce segment market include company juno therapeutic bluebird bio blue free report meanwhile fda approval novartis car therapy also give sector boost indicate begin new era treatment cancer path breaking immunocellular therapy be time treatment used patient own cell fight cancer nyse arca biotech index be almost last week most biotech stock record solid gain rally continue biotech stock be once strong favorite chalk impressive gain drug pricing issue start weigh sector sector rebound be roll begin year industry gain year date outperform broader market be key question now face investor be rally continue be right time invest corner market biotech sector be currently trading forward month price earning ratio well price earning ratio make rather expensive however look sector performance last year show be significant room upside give year high so be factor drive rally first foremost be industry continue witness demand product give age population increase prevalence wide variety disease strong pipeline innovative treatment impressive result increase health care spending support growth trump pro business stand be also expect benefit sector faster drug approval process propose removal outdated regulation drive cost slow innovation also work favor sector fda have approve far more drug so far do whole gilead kite deal expectation be activity pick pace finally drug pricing remain headline risk year well investor now seem be more comfortable drug pricing scenario be willing look fundamental sector flip side estimate revision trend sector be not very encourage grow presence biosimilar slowdown growth legacy product high profile pipeline setback be also challenge sector mentioned earlier drug pricing remain headline risk far be concern activity area be muted give watch stance adopt most company regard drug pricing situation tax reform major deterrent be high valuation company remain wary bidding war lead price deal however licensing deal continue especially orphan rare disease area well highly seek therapeutic area immune oncology bottom line be biotech stock be definitely not cheap current level be still room upside high risk high return industry be expect be catalyst rich year sector several major pipeline event line buy rank biotech stock include gilead regeneron pharmaceutical regn free report alexion pharmaceutical alxn free report gilead be zack rank buy stock regeneron alexion be zack rank strong buy stock see complete list today zack rank stock here zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
3548,GILD,share valeant pharmaceutical international inc vrx free report have decline so far gain industry share fall further aug once acquisition giant valeant have be catch various controversy october due price hike specialty drug erroneous financial report termination contract philidor rx service follow substantial decline valeant share price first quarter bill ackman steve fraidin joined board march part persh square effort stabilize company thereafter joseph papa take charge new ceo new management take various effort turnaround company even be still early comment rebuild process company effort sell core asset lower debt be commendable valeant sell equity interest dendreon pharmaceutical inc china base sanpower group co ltd valeant have also decide sell obagi company reduce debt expect meet target debt reduction ahead schedule divestiture core asset help company streamline product portfolio focus better core area dermatology lower debt however weakness dermatology segment persist be expect impact top line valeant recently announce fda confirm issue voluntary action indicated vai inspection classification bausch lomb manufacturing facility tampa fl part forthcoming establishment inspection record facility confirmation manufacturing uncertainty related current upcoming regulatory submission be eliminate product manufacture facility august company receive complete response letter crl fda regard new drug application nda latanoprostene bunod ophthalmic solution investigative intraocular pressure lower single agent eye drop patient open angle glaucoma ocular hypertension crl fda refer current good manufacturing practice cgmp inspection bausch lomb manufacturing facility tampa fl positive note company receive fda filing acceptance nda plenvu ner novel low volume polyethylene glycol base bowel preparation colonoscopy earlier fda approve new psoriasis treatment siliq company have agreement astrazeneca azn free report siliq agreement have be amend approval new drug bring hope believe be still long road ahead valeant investor faith be restore earlier year bill ackman chairman perish square holding ltd state investing valeant be big mistake part zack rank key picksvaleant currently carry zack rank hold better rank stock health care sector be aduro biotech inc adro free report gilead science inc gild free report stock carry zack rank buy see complete list today zack rank strong buy stock here aduro biotech loss share estimate narrow last day company deliver positive earning surprise trail quarters average beat gilead earning share estimate increase last day follow strong result second quarter company deliver positive earning surprise trail quarters average beat more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3549,GILD,late last week merck mrk free report announce decision discontinue development couple candidate hepatitis virus hcv program mk grazoprevir ruzasvir uprifosbuvir mk ruzasvir uprifosbuvir company decision be base review available phase ii efficacy datum grow competition hcv market merck have market product hcv market form zepatier elbasvir grazoprevir bring sale first month include favorable adjustment rebate accrual due mix business merck continue work expand zepatier utilization world uptake be impact ongoing decline overall patient volume many market increase competition gilead abbvie hcv spotlightmerck announcement have now put spotlight firmly gilead science gild free report abbvie abbv free report key player market gilead be undisputed leader hcv market hcv product bring sale first half company revolutionize treatment paradigm hcv market introduction sovaldi cut duration treatment few week instead prior standard care week moreover need peg interferon injection come several side effect be reduce eliminate completely gilead launch harvoni next first once daily single tablet regimen treatment most prevalent hcv genotype unite state be follow launch epclusa first oral pan genotypic single tablet regimen treatment adult genotype chronic hcv infection year gilead gain approval yet hcv treatment vosevi gilead rule hcv market quite few year sale be decline give intense pricing pressure grow competition pricing scrutiny decline patient population approval newer hcv product have result rapid increase number patient be treat cure follow decline number patient seek care be able access hcv treatment gilead expect hcv net product sale range announce result represent quite drop last year hcv product sale meanwhile abbvie hcv product include mavyret glecaprevir pibrentasivr viekira pak ombitasvir paritaprevir ritonavir tablet co package dasabuvir tablet viekira xr dasabuvir ombitasvir paritaprevir ritonavir mavyret be approve recently viekira sale be first half mavyret company next generation hcv offer be meaningful contributor sale other hcv drug include bristol myer squibb company bmy free report daklinza daclastavir janssen therapeutic olysio simeprevir remind investor merck be not only company have take decision halt development hcv candidate last month johnson johnson jnj free report have announce decision terminate collaboration agreement achillion pharmaceutical achn free report hcv janssen pharmaceutical say be discontinue development investigational hcv treatment regimen jnj combination direct act antiviral al odalasvir simeprevir merck drop investigational hcv treatment gilead abbvie benefit lack additional competition enter market least term company continue face challenge decline patient volume intense pricing pressure lack additional entrant market slow rate decline sale gilead have be work expand hcv market encourage baby boomer get test accord company have be increase hcv antibody screening baby boomer start initiative increase testing have lead increase diagnosis person be newly diagnosed hcv represent significant opportunity exist player hcv market gilead abbvie be zack rank hold stock see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3550,GILD,share bluebird bio blue free report major player emerge gene therapy car research market slump more morning trading monday receive key analyst downgrade note client morgan stanley downgrade biotech firm equal weight underweight reiterate price target share call represent drop friday close morgan stanley matt harrison say expect share underperform cite headwind bluebird sickle cell business still analyst note bluebird bcma target car candidate do provide valuation support most biotech investor know now car therapy be emerge method treat cancer include make genetic change patient immune cell reinject body attack cancer cell bluebird currently have several active clinical pre clinical program car umbrella company lead car program bb be collaboration biotech giant celgene celg free report have produce encourage datum thus far phase study be busy year car industry several major milestone have be reach august novartis nvs free report receive approval innovative new lymphoblastic leukemia treatment make first approve car therapy world earlier same week biotech behemoth gilead science gild free report announce be acquire kite pharma competitor car market gilead pay staggering kite be expect receive approval own car therapy november more current state car market check friday finish line team exclusive interview brad loncar creator loncar cancer immunotherapy index want more stock market analysis author make sure follow ryan_mcqueeney twitter today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3551,GILD,merck co inc mrk free report announce be discontinue further development next generation hepatitis hcv program mk mk market be become extremely crowd mk be oral triple combination regimen uprifosbuvir combination grazoprevir ruzasvir develop treatment chronic hcv infection mk be combination ruzasvir uprifosbuvir merck share have rise year so far compare increase industry company now focus grow sale key hcv drug market zeptier be approve use ribavirin treat chronic hcv genotype infection zepatier once daily fix dose combination tablet contain ns inhibitor elbasvir ns protease inhibitor grazoprevir be gradually become key top line driver merck cancer drug keytruda medicine record sale second quarter much higher first quarter attributable strong underlie demand trend unite state europe japan company continue launch zepatier globally however remind investor second quarter conference call management have warn zepatier uptake go forward be impact ongoing decline overall patient volume many market increase competition hcv market be get crowd be thus see increase pricing pressure gilead science inc gild free report market blockbuster hcv drug sovaldi harvoni other well know name market be abbvie inc abbv free report viekira pak bristol myer daklinza johnson johnson jnj free report olysio moreover other company be also look bring new improve shorter duration hcv treatment market abbvie pan genotypic shorter duration hcv regimen glecaprevir pibrentasvir mavyret receive approval unite state canada eu july august meanwhile gilead already market epclusa oral pan genotypic single tablet hcv regimen meanwhile gilead single tablet regimen str sovaldi velpatasvir voxilaprevir vosevi receive approval unite state eu canada july august vosevi become first once daily str available salvage therapy patient infected hcv genotype have fail prior treatment daa regimen include ns inhibitor merck carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3552,GILD,presidential campaign donald trump have stress tax reform promise bring corporate tax be top priority president unite state keep word trump propose change tax rate individual corporate stimulate economic growth well employment growth tax plan propose lower current corporate tax rate highest world be expect favorably impact post tax earning company territorial tax system tax only domestic income have also be propose american company so create level play field also suggest elimination special tax break company major reform propose be repatriation trillion dollar hold cash reserve overseas company global operation time tax reportedly similar tax move be make bring overseas cash reserve bush administration time tax number company repatriate amount exceed current tax code allow tax repatriation rate however give tax credit amount tax paid overseas country anticipate reform have be propose create new job aid economic growth expand investment more cash available company tax cut repatriation however extent step be successful be uncertain large portion repatriate cash be used fund share buyback dividend payment buyback fuel stock rally be actual economic growth tax reform be expect benefit company have operation globe similar buyback time be also expect help stock grow large cap pharma company base unite sate major operation worldwide include amgen inc amgn free report gilead science other be sit huge pile cash reserve stash overseas country repatriation benefit large drug biotech company more tax saving due rate cutsmoreover repatriation cash hold overseas create surplus domestic cash reserve fuel merger acquisition sector industry have see only major acquisition year actelion johnson johnson jnj free report kite pharma inc gilead science inc gild free report be expect close end let discuss impact tax reform drug biotech giant johnson johnsonjohnson johnson be well know brand world cater wide variety medical need company have paid tax effective rate respectively therefore revision tax rate not bring huge positive change post tax earning june end have cash reserve almost year end company have used major chunk cash reserve hence be expect be least impact reform company have strong presence oncology hematology cardiovascular disease inflammation bone health nephrology market effective tax rate amgen be respectively hence tax rate cut have minimal effect amgen have nearly overseas cash fiscal end bloomberg report total cash reserve company have change minimally first month so repatriation reform initiate buyback moreover tax have more domestic cash reserve total overseas cash be repatriate increase domestic cash also be used acquire new drug technology car therapy gilead sciencesgilead recently announce plan acquire kite pharma nearly add latter car therapy candidate pipeline gilead be plan complete acquisition combination cash debt bloomberg report gilead have cash reserve overseas country end repatriation help company pay debt quickly effective tax rate have be suggest minimal impact due tax rate cut make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3553,GILD,biotech sector be go roof right now spdr biotech etf xbi free report add month sep plenty factor be power sector breakthrough food drug administration fda approval success immune oncology field merger acquisition be forefront biotech stock vertex pharmaceutical vrtx free report receive new fda approval cystic fibrosis drug kalydeco early september fda approve novartis ag breakthrough gene transfer treatment kymriah suspension treatment patient year age cell precursor acute lymphoblastic leukemia be refractory second later relapse source investor note car be fresh immunocellular therapy many company be eyee fact gilead science gild announce buyout kite pharma kite late august read biotech etfs soar gilead kite deal kite pharma be expect receive approval car therapy axicabtagene ciloleucel axi cel shortly acquisition gilead step new arena oncology treatment know car target body own immune system fight tumor month clovis oncology clvs share also sky-rocket follow company positive cancer drug datum company then say clinical trial datum ovarian cancer drug treatment indicated substantially help more patient expect read stock etfs buy clovis positive drug datum be not enough teva pharmaceutical teva share surge sep appoint former nordisk nvo ceo new recruitment follow teva last full time ceo month term resignation bribery scandal compelling valuation biotech stock be most hurt member last year have probably make space cheap help be back bang biotech etf xbi add last month sep spdr etf spy free report be fund xbi have relative strength index mean fund be yet enter overbought territory also fear price gouge be ebb substantially trump administration nutshell space be ride research development log more return ahead etfs tap highlight few biotech etfs benefit investor solid gain see health care etfs here direxion daily biotech bull labu free report ultrapro nasdaq biotechnology proshare ubio free report proshare ultra nasdaq biotechnology bib free report ishare nasdaq biotech etf ibb free report bioshare biotech clinical trial bbc free report vaneck vector biotech etf bbh free report bioshare biotech product bbp free report loncar cancer immunotherapy etf cncr free report alp medical breakthrough etf sbio free report want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
3554,GILD,biotech stock be back favor thank recent major development lead rally sector first catalyst be gilead science gild free report announcement be acquire immunotherapy focuse company kite pharma fda approval first gene therapy unite state novartis ag kymriah boost sector further gilead kite deal have raise expectation sector finally see more merger acquisition deal come quarters moreover company involved car treatment kite see share shooting hope more deal be announce segment market meanwhile approval novartis car therapy kymriah also give sector boost indicate begin new era treatment cancer path breaking immunocellular therapy be time treatment used patient own cell fight cancer year date nasdaq biotechnology index be impressive represent sharp contrast index performance same time period last year record decline key reason last year dismal performance be drug pricing controversy weigh sector major part year however investor now seem be more comfortable drug pricing scenario be willing look fundamental sector key question remain mind investor be rally continue be factor drive same firstly be industry continue witness demand product give age population increase prevalence wide variety disease strong pipeline innovative treatment impressive result increase health care spending support growth trump pro business stand be also expect benefit sector faster drug approval process propose removal outdated regulation drive cost slow innovation also work favor sector fda have approve far more drug so far do whole sector receive additional boost more deal be announce company be likely adopt watch stance await more clarity regard drug pricing situation tax reform major deterrent be high valuation company remain wary bidding war lead price deal say licensing deal continue especially orphan rare disease area well highly seek therapeutic area immune oncology pick right stockspicking biotech stock be bit tricky give high risk high return nature industry moreover estimate revision trend sector be not very encourage grow presence biosimilar slowdown growth legacy product high profile pipeline setback be also challenge sector keep factor mind have zero biotech stock currently hold strong zack rank look well position regeneron pharmaceutical inc regn free report tarrytown ny base regeneron key area focus include eye disease heart disease allergic inflammatory disease pain cancer infectious disease rare disease eye drug eylea company key growth driver continue perform well regeneron have be work diversify portfolio gain fda approval drug year dupixent moderate severe atopic dermatitis kevzara moderately severely active rheumatoid arthritis drug have blockbuster potential company also have strong pipeline have eventful second half year come key mid late stage pipeline catalyst line regeneron just report positive top line phase iii datum dupixent asthma be now look go ahead filing year end dupixent also gain eu approval eczema indication third quarter regeneron be evaluate dupixent pediatric atopic dermatitis set important datum readout schedule second half year be company pd antibody regn cutaneous squamous cell carcinoma cscc second most common skin cancer basal cell carcinoma second deadliest skin cancer melanoma positive datum allow company file fda approval first quarter meanwhile eylea be be evaluate combination nesvacumab top line datum phase ii study wet age related macular degeneration diabetic macular edema be expect fourth quarter year regeneron zack rank strong buy stock have gain year date substantially outperform rally industry belong alexion pharmaceutical inc alxn free report new haven ct base alexion flagship product soliris eculizumab continue perform well company be work expand soliris label additional indication alexion have key catalyst come decision fda expect oct regard approvability soliris refractory generalized myasthenia gravis gmg eu approval indication come last month make first only complement base therapy approve ultra rare subset gmg gmg indication represent incremental growth opportunity soliris alexion have rough share fall look set recover lose ground share gain year date effort company new management team turn thing be impressive alexion strategy be be redefine focus key expertise area company continue grow rare disease business include soliris strensiq kanuma increase productivity alexion focus internal research effort complement expertise development effort core therapeutic area hematology nephrology neurology metabolic disorder company have also decide prioritize certain pipeline candidate be discontinue preclinical program mrna therapy well other preclinical program do not fall complement franchise alexion be zack rank stock see complete list today zack rank stock here ligand pharmaceutical incorporate lgnd free report san diego base ligand business model be base develop acquire royalty revenue generate asset couple lean corporate cost structure company be focuse development licensing asset ligand captisol formulation technology have allow enter several licensing deal generate royalty ligand partner include big name amgen novartis other company also have licensing deal base omniab technology ligand zack rank stock have gain year date substantially outperform rally industry belong sangamo therapeutic sgmo free report richmond base sangamo be focuse translate ground breaking science genomic therapy used platform technology genome editing gene therapy gene regulation cell therapy sangamo get major boost earlier year follow signing collaboration agreement pfizer development gene therapy program hemophilia share sangamo zack rank buy stock have gain year date significantly outperform industry rally fate therapeutic inc fate free report san diego base fate be focuse development programme cellular immunotherapy cancer immune disorder fate hematopoietic cell therapy pipeline include nk cell immuno oncology program immuno regulatory program share fate zack rank stock have gain year date significantly outperform industry rally more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3555,GILD,hurricane harvey north korea tension gilead acquisition kite pharma be car therapy novartis car cell therapy receive approval fda car biotech stock rise be new era biotech price cut whole food product amazon echo instacart indirect competition upcoming reward program prime member episode roundup podcast zack comon today episode zack friday finish line content writer ryan mcqueeney editor maddy johnson take week biggest story include gilead acquisition kite pharma future car therapy industry amazon change whole food store make sure subscribe leave show rating itune be busy week biotech sector so maddy ryan welcome expert guest brad loncar recap latest major event brad be creator loncar cancer immunotherapy index track combine performance several major company be develop therapy treat cancer harness body own immune system make brad perfect person discuss gilead gild free report massive takeover kite pharma well milestone novartis nvs free report car cancer therapy maddy ryan also ask brad impact event have have other car develop such juno therapeutic bluebird bio blue free report brad share key info bio tech investor need know right now finally maddy ryan also discuss recent trip whole food store investigate change make amazon amzn free report week make sure tune show hear reaction check picture visit reminder feel miss something want cover different story shoot email podcast zack com make sure check other audio content zack com podcast remember subscribe leave rating itune always thank listen episode zack friday finish line check back even more news investment financial world want more stock market analysis author make sure follow ryan_mcqueeney twitter more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3556,GILD,not only be september historically worst month equity market stock presently look susceptible pullback due harvey north korea tension government shutdown however fresh datum have indicated domestic economy continue grow steady slow pace corporate earning also continue impress trading perspective more market participant be expect month vacation time come end thank encourage development wall street be expect be more discipline prepared withstand habitually rough trading period thus investing solid stock have give consistent return month be judicious somber september investor shouldn sell base solely calendar seasonal peculiarity be ignore head busy month trading world war ii index have see loss september also september have see worst monthly drop equity average stock trader almanac find dow jone averaged loss respectively nasdaq composite incept averaged loss do russell small cap stock be start such dismal performance compel jeff degraaf head renaissance macro research tell client be enter only month year have statistically significant negative return year also spring surprise north korea attack japan hurricane harvey wreak havoc political climate unite state lose stability possibility market correction haunt investor market jolt event spook investor north korea ballistic missile launch japanese airspace reignite tension have resume logjam pyongyang president trump have unnerved market august south korea military be conduct war game unite state have be put alert japanese prime minister shinzo abe call missile test unprecedented grave serious threat seriously damage peace security region domestic front harvey first major hurricane hit mainland almost year have put vast area water rainstorm originated tropical depression rapidly balloon category hurricane category worsen due lethal confluence meteorological event be too early gauge financial impact hurricane expert be call loss double digit billion hurricane disrupt oil refinery lead decline share insurance company read more home improvement stock buy post harvey mayhem wasn enough anxiety grip wall street debate raise federal government debt ceiling have frayed relation president trump republican leadership such dispute further delay implementation promise pro business policy fact disconnect grow chance government shut be say goldman sachs group inc gs free report positive economic environment earning buoy let be optimistic not everything be dampening market gdp expand second quarter fastest rate growth more year uptick consumer outlay business investment help economy gain traction increase spending good service push consumer expenditure say quarter consumer spending biggest driver economy picked higher income consumer low inflation second quarter earning season meanwhile have come end zack sector result member index total membership already total earning company be same period last year higher revenue beating ep estimate beating revenue estimate read more plenty small cap earning still come investor be back market see labor day fast approach summer month vacation be soon be such holiday period major market participant don make big move big decision be often postpone once summer month come end market get back normal major decision be take suggest trade increase market leader return take control equity market command manner furthermore typically labor day market be slow day thing pick pace top perform stock be rocky month stock market mentioned be positive propel broader market have thus select stock have not only gain traditionally rough trading month september also flaunt zack rank strong buy buy here closer look company nameaverage return historic median return historic percentage positive pharmaceutical activision blizzard intuit alexion pharmaceutical gilead science regeneron pharmaceutical inc regn free report be company discover invent develop manufacture commercialize medicine treatment serious medical condition company have zack rank zack consensus estimate current year earning rise last day company have outperformed industry year date period vs activision blizzard inc atvi free report be developer publisher interactive entertainment content service zack consensus estimate zack rank company current year earning increase last day company have outperformed industry year date period vs intuit inc intu free report be provider business financial management solution small business consumer accounting professional company carry zack rank zack consensus estimate current year earning improve last day company have outperformed industry year date period vs see complete list today zack rank stock here alexion pharmaceutical inc alxn free report be company company be focuse development therapeutic product company have zack rank zack consensus estimate current year earning increase last day company have outperformed industry year date period vs gilead science inc gild free report be also research base company discover develop commercialize medicine area unmet medical need zack rank company be news buyout cancer specialist kite pharma inc kite zack consensus estimate current year earning improve last day company have outperformed industry year date period vs more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3557,GILD,novartis ag nvs free report announce fda have approve breakthrough gene transfer treatment kymriah suspension treatment patient year age cell precursor acute lymphoblastic leukemia be refractory second later relapse kymriah formerly ctl be first chimeric antigen receptor cell car therapy approve novel immunocellular therapy time treatment kymriah used patient cell fight cancer car be manufacture individual patient used own cell thereby make different typical small molecule biologic therapy treatment cell be draw patient blood cell be then reprogram manufacturing facility create genetically code cell express chimeric antigen receptor recognize fight cancer cell other cell express specific antigen drug be develop collaboration university pennsylvania addition fda have approve risk evaluation mitigation strategy rem kymriah inform educate healthcare professional risk be associate kymriah treatment meanwhile novartis plan make additional filing kymriah unite staes eu later year kymriah treatment adult patient diffuse large cell lymphoma dlbcl april fda grant breakthrough therapy designation kymriah base datum juliet study novartis also team unite state center medicare medicaid service cms improve efficiency current regulatory requirement deliver value base care ensure access specific patient population kymriah be manufacture individual patient used own cell novartis morris plain new jersey facility approval be major boost novartis give potential car therapy space approval open new frontier treatment cancer advance immunocellular therapy child young adult cell comprise approximately cancer diagnosis child year old be most common childhood cancer unite state approval be card fda oncologic drug advisory committee odac have unanimously recommend approval immunocellular therapy jul approval also boost novartis already strong oncology portfolio boast afinitor exjade jakavi zykadia tasigna jadenu novartis be also work label expansion kymriah novartis stock have rally year so far compare industry gain go forward expect approval new drug label expansion exist one bode well novartis even stiff generic competition key drug gleevec continue act major deterrent earlier week biotech giant gilead science inc gild free report announce buy kite pharma inc foray emerge field cell therapy kite axicabtagene ciloleucel axi cel be be develop treatment refractory aggressive hodgkin lymphoma include dlbcl transform follicular lymphoma tfl primary mediastinal cell lymphoma pmbcl biologic license application bla candidate be submit march car therapy be currently priority review unite state fda be expect give decision nov zack rank key picknovartis currently carry zack rank hold better rank stock healthcare sector be aduro biotech inc adro free report carry zack rank buy see complete list today zack rank strong buy stock here aduro biotech loss share estimate narrow last day company deliver positive surprise trail quarters average beat simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
3558,GILD,welcome back mind money kevin cook field guide story teller fascinating arena behavioral economic episode be risk reward mechanic decision make sometimes avoid make decision often never learn bad one be fortunate become high frequency currency trader year learn make lot decision hour never afford regret only learn doesn mean don still fall prey bad habit have face uncertainty risk do ever wonder great investor trader make decision put consistently ahead peer do not put category greatness know little ve spend considerable time past decade study great short term trader great long term investor now finance always have be careful talk success make sure be not just high light survivor always winner have make certain be look credible degree success time go mere randomness study short term trader commodity currency pit chicago read jack schwager market wizard book come away pillar behavior seem make difference time market be psychology not just awareness bias decision make continuous process improvement probability sound mechanic situational risk reward way too easy emotion bias take system not just computer spit signal system everything research process performance evaluation risk management precise rule capital allocation preservation be crucial long term survival discipline speak especially make dozen decision day require consistent rule follow consistency run process year survive vagary change market season happen trader investor doesn try master principle skill worst lose money quickly best get lucky survive not long middle be majority slowly watch money bleed away little week sometimes bigger chunk see hard be apply principle chaos market look different science help explain behavioral finance spear head nobel prize winner daniel kahneman look human decision make uncertainty risk experiment find do most person do give situation say researcher study outside explain behavior neuroscientist course study explain action read much important research science handle come stunning conclusion brain wasn make trade fit evolutionary biologist anthropologist be teach kind brain few year fit start natural selection give definitely weren make stare price move rapidly change wealth outlook second do know most naturally do exactly wrong thing especially short term trading hold lose trade take profit too soon be mathematical recipe make money go away time trading golden rule be cut thy loss short let thy winner run most human trader monkey do exactly opposite fear greed illogical biase ego take make money go away assume make rational decision money be best long term be big assumption most be very irrational come day money risk decision long term plan one cover much march episode irrational demand anchor pearl procrastination well back be pretty proud original idea brain wasn make trade then remember book have read probably help path new world new mind robert ornstein paul former latter biologist be famous alarm call population back book propose evolution brain ability sense cataclysmic change take place long period time be simply not go fast enough only thing make difference be accelerate cultural evolution here bright observer review book amazon describe more compelling point author make be not only be politician be elect reward basis short term decision be many measure intellectually morally financially corrupt so call knowledge worker scientist engineer other be blow whistle be so specialize be real lack integrative knowledge think area obvious climate change debate short term think blind long term effect change think education vs entertainment machine parent be far too likely let kid have electronic gadget tvs phone babysit mom dad have stuff do parent work be nuclear arm race seem be problem get put ice now north korea rattle sabre month feel old question again really happen be biggest example ornstein highlighted new world new mind remember exactly frame problem solution other new cultural political institution move warfare primary solution first thing come mind be be more irrational other do sleep tight think prevent nuclear war just very lucky idiot get hand missile scary stuff say sure ve figured good solution just ve go year incident stone age brain barely comprehend kind cataclysm so easier not think ornstein thought try anyway think have solution don be eternal optimist so rest episode mind money podcast share book dynamic duo year later care fate science just much ornstein also break week big trading immuno oncology stock such kite pharmaceutical be buy gilead science gild free report cause feverish rally related peer juno therapeutic bluebird bio blue free report tell play stock not celgene celg free report be next bidder little biotech wonder kevin cook be senior stock strategist zack investment research run healthcare innovator portfolio
3559,GILD,gilead science gild free report shower gain biotech etf world august announce buyout news kite pharma gild share gain kite share surge day respond super deal kite pharma be clinical stage company focuse development cancer immunotherapy product company be develop pipeline eact base product candidate treatment solid hematological malignancy deal mark gilead science biggest deal new cancer treatment help company look away recede sale medicine hepatitis infection focus bud zone gilead say be share cash deal gilead step new arena oncology treatment know car target body own immune system fight tumor source kite doesn have treatment market yet be await approval drug hodgkin lymphoma type blood cancer gilead be yet see prodigious success cancer research have go inorganic expansion establish presence apparently most want area needless say megadeal act cornerstone entire biotech space read stock fight cancer immunotherapy be gamechanger participant stock gilead have zack rank buy vgm value growth momentum score other hand kite pharma have zack rank hold vgm score time writing situation target basket etf approach be more intriguing single stock pick play first etf way investor get play overall evolvement biotech space certain downbeat vgm score gild kite not come way investor optimism immune oncology be expect rule next era biotech trading yesterday biotech stock see great trading month clovis oncology clvs free report share gain follow company positive cancer drug datum read stock etfs buy clovis positive drug datum etf impact kite pharma have weight range fund alp medical breakthrough etf sbio free report ark genomic revolution multus sector etf arkg free report loncar cancer immunotherapy etf cncr free report powershare dynamic biotechnology genome pbe free report fund gain respectively august biotech etfs arkg bioshare biotech clinical trial bbc free report also hit week high see healthcare etfs here investor note gilead science have considerable focus range vaneck vector biotech etf bbh free report ishare nasdaq biotechnology etf ibb free report obviously get spike say acquisition news bbh ibb be respectively august want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
3560,GILD,late biotechnology pharmaceutical company be investing immuno oncology research therapy remain key area focus thank vast growth potential last week immuno oncology space grab investor attention fda approve novartis ag nvs free report breakthrough gene transfer treatment kymriah suspension treatment patient year age cell precursor acute lymphoblastic leukemia be refractory second later relapse kymriah formerly ctl be first chimeric antigen receptor cell car therapy approve novel immunocellular therapy time treatment kymriah used patient cell fight cancer long term impact treatment be yet be evaluate approval open new frontier treatment cancer start car used patient cell identify destroy cancer cell thereby make different other small molecule biologic therapy treatment cell be draw patient blood cell be then reprogram manufacturing facility create genetically code cell express chimeric antigen receptor recognize fight cancer cell other cell express specific antigen approval kymriah investor have start shift focus number company have be develop pipeline candidate remain afloat highly competitive environment stock warrant lookkite pharma inc be expect receive approval car therapy axicabtagene ciloleucel axi cel shortly biologic license application candidate be submit march application be gr priority review unite state fda be expect give decision nov candidate be also review eu tentative approval expect candidate be be develop treatment refractory aggressive hodgkin lymphoma include diffuse large cell lymphoma transform follicular lymphoma primary mediastinal cell lymphoma give likely approval potential space gilead science inc gild free report have inked deal acquire kite pharma kite pharma stock have moved year date compare favorably increase register industry company presently carry zack rank hold see complete list today zack rank strong buy stock here juno therapeutic inc be also develop cell base cancer immunotherapy base car high affinity tcr technology genetically engineer cell recognize cancer cell company be currently conduct phase trial jcar adult aggressive nhl include dlbcl plan file ind plan phase ii trial jcar chronic lymphocytic leukemia cll company expect approval share company have rally year date company currently carry zack rank sell bluebird bio inc blue free report collaboration celgene corporation celg free report be evaluate bb car cell product candidate treatment multiple myeloma phase study company expect initiate phase study evaluate safety efficacy bb next bcma car cell product candidate share company have gain year date company presently carry zack rank ziopharm oncology inc ziop free report be develop car cell therapy advanced lymphoid malignancy company be currently enrole patient investigator lead phase study used second generation cd specific car cell revise car structure patient advanced lymphoid malignancy share company have rally year date company present carry zack rank simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
3561,GILD,biotech giant gilead science inc gild free report announce buy kite pharma inc foray emerge field cell therapy term agreement agreement gilead pay share cash transaction value approximately price represent premium close share price kite aug transaction be approve shareholder company be expect close fourth quarter acquisition be expect be neutral bottom line third year accretive thereafter strategic benefitwe note kite be pioneer cell therapy have develop engineer cell therapy express chimeric antigen receptor car engineer cell receptor tcr depend type cancer most advanced therapy candidate kite pipeline be axicabtagene ciloleucel axi cel be be develop treatment refractory aggressive hodgkin lymphoma include diffuse large cell lymphoma dlbcl transform follicular lymphoma tfl primary mediastinal cell lymphoma pmbcl biologic license application bla candidate be submit mar car therapy be currently priority review unite state fda be expect give decision nov candidate be also review eu tentative approval expect kite be prepared commercial launch unite state manufacturing preparation be complete company be currently build infrastructure europe remind investor pipeline candidate clinical trial hematologic cancer solid tumor be kite car therapy candidate target bcma expressed multiple myeloma acquisition diversify gilead portfolio position company dominant position cellular therapy space note investor be expect gilead announce acquisition term give decline once lucrative hepatitis hcv market due competitive pressure gilead be know presence hcv market blockbuster hcv drug sovaldi harvoni however hcv franchise be pressure competition pricing issue note harvoni sovaldi epclusa face competition abbvie abbv free report viekira pak viekira xr other moreover gilead be sit cash short term marketable security hence acquisition announcement be lurk car be manufacture individual patient used own cell thereby make different typical small molecule biologic therapy treatment process cell be draw patient blood cell be then reprogram manufacturing facility create cell be genetically code express chimeric antigen receptor recognize fight cancer cell other bcell express specific antigen deal look expensive give premium gilead paid kite car space be expect be revolutionary treatment cancer car space represent immense potential juncture potential approval axi cell be significant boost gilead prospect have dampen late gilead stock have decline year so far industry apart kite novartis ag nvs free report be company be focus car treatment july fda oncologic drug advisory committee odac unanimously recommend approval immunocellular therapy candidate ctl decision be expect shortly september october ctl become first car cell therapy approve ctl investigational car therapy be be evaluate treatment relapse refractory pediatric young adult patient cell acute lymphoblastic leukemia potential approval also open new frontier treatment cancer advance immunocellular therapy child young adult cell other hand share kite be news company immensely benefit gilead dominant position biotech space anticipate approval lead candidate fact year so far kite pharma stock be compare favorably increase register industry zack rankgilead currently carry zack rank buy see complete list today zack rank strong buy stock here zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
3562,GILD,share juno therapeutic continue soar tuesday stock have now gain nearly announcement fellow car cancer therapy designer kite pharma be be acquire biotech behemoth gilead science gild free report kite bluebird bio blue free report juno be leader development car cancer treatment therapy include make genetic change patient immune cell reinject body attack cancer cell kite be significantly further approval process juno bluebird lead candidate axicabtagene ciloleucel be currently review fda axicabtagene ciloleucel be expect be approve treatment aggressive hodgkin lymphoma decision come november monday gilead announce be acquire kite cash deal buyout value kite share premium company close price friday also read do kite pharma stock skyrocket today acquisition kite establish gilead leader cellular therapy provide foundation drive continue innovation person advanced cancer gilead president ceo john milligan say statement course acquisition immediately inspire speculation juno bluebird also become takeover target market cap just juno be cheapest car leader however company recently take step back approval process march juno announce be discontinue development lead car candidate have already reach phase development bluebird car program bb be still phase drug have pretty encourage datum so far bluebird market cap currently sit interestingly juno bluebird have partnership celgene celg free report global biopharma giant however bluebird partnership only extend bb project so more diversify buyout candidate especially consider company have gene therapy program target beta thalassemia sickle cell disease nevertheless juno emerge lowest price car pure play right now want know more kite read kite pharma be revolutionize fight cancer listen podcast want more stock market analysis author make sure follow ryan_mcqueeney twitter zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
3563,GILD,mallinckrodt public limit company mnk free report report second quarter result earning beat expectation sale miss same company report adjust earning share report quarter beating zack consensus estimate earning be however year figure due continue pricing pressure specialty generic net sale quarter come year year miss zack consensus estimate mallinckrodt stock price have decline year so far compare industry fall quarter company report result segment specialty brand specialty generic sale specialty brand segment be year quarter acthar mallinckrodt largest product garner sale inomax second largest product generate sale ofirmev sale grow year year sale therakos immunology platform be kit supply issue be resolve first quarter company underestimated complexity conversion xt cellex device result lower anticipate net sale moreover transitional issue be expect persist upcoming quarters expect weakness specialty generic segment continue segment record sale better management expectation due active pharmaceutical ingredient product controlled substance other product category adjust selling general administrative expense report quarter increase meanwhile research development expense decline second quarter company repurchase ordinary share share repurchase program bring total repurchase first half company reiterate earning guidance zack consensus estimate be mallinckrodt plc price consensus ep surprise mallinckrodt plc price consensus ep surprise mallinckrodt plc quoteour second quarter result be mixed company beat earning miss sale weakness generic segment persist acthar sale continue be strong back increase formulary position access appropriate patient commercial public environment sale therakos be expect decline company be currently streamline business company aim focus better specialty pharmaceutical business have sell nuclear imaging business company also sell intrathecal therapy business other hand acquisition hemostasis drug thrombin topical recombinant preveleak raplixa fibrin sealant medicine co mdco free report have strengthen grow hospital portfolio share be pre market trading zack rank key currently carry zack rank hold couple better rank stock health care sector be aduro biotech inc adro free report gilead science inc gild free report stock carry zack rank buy see complete list today zack rank strong buy stock here gilead earning share estimate increase last day follow strong result second quarter company deliver positive earning surprise trail quarters average beat aduro biotech loss share estimate narrow last day company deliver positive earning surprise trail quarters average beat look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3564,GILD,life science company bayer ag bayry free report report mixed second quarter earning surpass expectation sale fall short pharmaceutical animal health covestro segment record year year increase sale crop science consumer health division record decline crop science business be hit high channel inventory brazil world second largest agriculture market difficult environment market weigh performance consumer health segment give performance segment company now expect sale more instead sale core earning share continue operation be now expect grow low mid single digit percentage old guidance mid high single digit percentage life science business be expect generate sale previously approximately company lower outlook consumer health crop science segment second half year be expect be weak consumer health business sale expect range previously more crop science business be now expect generate sale less previously sale more give lower outlook bayer have be witness downward revision earning estimate last day estimate be estimate have decline bayer zack rank sell stock sort headwind be face crop science consumer health segment advise investor focus drug stock strong zack rank strong buy buy picksalexion pharmaceutical inc alxn free report new haven ct base alexion report strong second quarter earning revenue top expectation company also raise revenue earning outlook year flagship product soliris eculizumab continue perform well alexion be work expand soliris label have key catalyst come decision fda expect oct regard approvability soliris refractory generalized myasthenia gravis gmg decision eu positive chmp opinion be receive be also expect third quarter alexion have tough share fall look set recover lose ground share increase so far outperform rally industry belong new management team layer strategic roadmap say effort be focuse expertise area complement biology core therapeutic area hematology nephrology neurology metabolic disorder alexion be work grow rare disease business zack rank stock alexion be witness upward revision earning estimate last day estimate earning growth current year be sanofi sny free report french pharma giant sanofi raise earning outlook constant exchange rate cer follow release second quarter result sanofi have strong presence several market include diabetes cardiovascular rare disorder vaccine consumer healthcare company have record decline share price last year have gain year date outperform rally industry belong earning estimate be last day company diabetes segment remain pressure sanofi well be poise turnaround back new product approval sale ramp recently launch product sanofi be zack rank stock company also have vgm style score vgm style score be useful tool allow investor gain insight stock strength weakness stand value stand growth momentum score be weight combination metric research show stock vgm score combine zack rank offer best upside potential see complete list today zack rank stock here gilead science inc gild free report biotech major gilead also make list gilead have be pressure mainly due performance hepatitis virus hcv franchise report strong second quarter hcv business do better expect gilead hiv franchise also continue do well company surpass earning revenue estimate raise outlook well earning estimate be last day gilead be zack rank stock vgm style score look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3565,GILD,second quarter earning season be draw close stock have report result aug zack sector record earning growth total earning increase year period revenue growth beat earning estimate top revenue expectation medical sector be sector consistently record earning growth last few quarters sector record earning growth revenue growth have record earning growth back revenue growth so far look beat ratio show earning beat revenue beat biotech stock specifically fared pretty well most key player top earning revenue expectation quite few company raise outlook year well biotech stock have have strong run so far nasdaq biotechnology index soar year date ytd be sharp contrast last year performance index be be several reason sector dismal performance last year foremost be drug pricing controversy drug pricing remain headline risk year well investor now seem be more comfortable drug pricing scenario be willing look fundamental sector fda have also approve more drug so far year do whole last year drug be approve have gain approval so far drug approve year represent blockbuster potential second half be expect be catalyst rich quite few company datum expect wide range therapeutic area far merger acquisition be concern do not expect much activity area give watch stance adopt most company regard drug pricing situation tax reform deterrent be high valuation company remain wary bidding war lead price deal however licensing deal continue especially orphan rare disease area well highly seek therapeutic area immune oncology choiceshere be look biotech stock deliver positive earning surprise second quarter be witness upward revision earning estimate company be zack rank strong buy zack rank buy stock see complete list today zack rank stock here alexion pharmaceutical inc alxn free report new haven ct base alexion deliver beat raise quarter flagship product soliris eculizumab continue perform well alexion be work expand soliris label have key catalyst come decision fda expect oct regard approvability soliris refractory generalized myasthenia gravis gmg alexion get boost week soliris gain eu approval indication make first only complement base therapy approve ultra rare subset gmg gmg indication represent incremental growth opportunity soliris alexion have rough share fall look set recover lose ground share increase so far outperform rally industry belong effort company new management team turn thing be impressive alexion be redefine strategy focus key expertise area company continue grow rare disease business include grow soliris strensiq kanuma increase productivity alexion focus internal research effort complement expertise development effort core therapeutic area hematology nephrology neurology metabolic disorder company have also decide prioritize certain pipeline candidate be discontinue preclinical program mrna therapy well other preclinical program do not fall complement franchise alexion zack rank stock have see zack consensus estimate current year earning be revise upward last day regeneron pharmaceutical inc regn free report tarrytown ny base regeneron key area focus include eye disease heart disease allergic inflammatory disease pain cancer infectious disease rare disease eye drug eylea company key growth driver continue perform well regeneron have be work diversify portfolio gain fda approval drug year dupixent moderate severe atopic dermatitis kevzara moderately severely active rheumatoid arthritis drug have blockbuster potential company also have strong pipeline have eventful second half year come key mid late stage pipeline catalyst line top line phase iii datum dupixent asthma be due later quarter positive datum allow company go ahead filing fourth quarter dupixent also gain eu approval eczema indication third quarter regeneron be evaluate dupixent pediatric atopic dermatitis set important datum readout schedule second half year be company pd antibody regn cutaneous squamous cell carcinoma cscc second most common skin cancer basal cell carcinoma second deadliest skin cancer melanoma positive datum allow company file fda approval first quarter meanwhile eylea be be evaluate combination nesvacumab top line datum phase ii study wet age related macular degeneration diabetic macular edema be expect fourth quarter year regeneron have see zack consensus estimate current year earning be revise upward last day regeneron zack rank stock have gain year date substantially outperform rally industry belong gilead science inc gild free report foster city base gilead be well know presence hepatitis virus hcv hiv market gilead top estimate second quarter hcv business do better expect company say hcv patient start first month be better originally expect moreover launch educational campaign oct encourage testing baby boomer have lead increase hcv antibody screening baby boomer turn have lead increase diagnosis company hiv franchise also continue do well company be progress pipeline include treatment evaluation cancer nonalcoholic steatohepatitis nash inflammatory disease gilead raise outlook year gilead have see zack consensus estimate current year earning be revise almost upward last day gilead be zack rank stock ligand pharmaceutical incorporate lgnd free report san diego base ligand business model be base develop acquire royalty revenue generate asset couple lean corporate cost structure company be focuse development licensing asset ligand captisol formulation technology have allow enter several licensing deal generate royalty company partner include big name amgen amgn free report novartis nvs free report other ligand also have licensing deal base omniab technology ligand have see zack consensus estimate current year earning be revise almost upward last day ligand zack rank stock have gain year date substantially outperform rally industry belong zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
3566,GILD,alexion pharmaceutical inc alxn free report announce european commission ec approve label expansion lead drug soliris european commission expand indication soliris include treatment refractory generalized myasthenia gravis gmg adult be acetylcholine receptor achr antibody positive note soliris be approve severe ultra rare disorder result chronic uncontrolled activation complement component immune system paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus order increase commercial potential drug further alexion be work expand soliris label additional indication alexion have aslo file regulatory application fda expand use soliris treatment refractory gmg patient be acetylcholine receptor antibody positive fda accept supplemental biologic license application sbla set prescription drug user fee act pdufa date oct potential label expansion boost sale further soliris be launch new indication initially germany alexion be evaluate launch additional eu country alexion stock price have increase outperform industry gain additionally phase iii study prevent soliris patient relapse neuromyelitis optica spectrum disorder be ongoing enrolment be expect be complete datum expect label expansion additional indication give soliris access higher patient population increase commercial potential drug significantly note soliris have receive orphan drug designation odd treatment patient mg eu treatment patient refractory gmg japan expect growth alexion continue be drive soliris other new product strensiq kanuma be do well be expect boost revenue however soliris quarter quarter revenue growth be impact enrolment ramp trial company be expect soliris revenue be lower second half year due accelerate impact alxn trial addition pricing impact sale zack rank stock consideralexion currently carry zack rank strong buy other top rank stock worth consider healthcare sector include regeneron pharmaceutical inc regn free report gilead science inc gild free report aduro biotech inc adro free report regeneron sport zack rank gilead science aduro carry zack rank buy see complete list today zack rank stock here regeneron earning share estimate have increase last day company pull positive earning surprise trail quarters average beat gilead earning share estimate increase last day company deliver positive earning surprise trail quarters average beat aduro biotech loss share estimate narrow last day company deliver positive surprise trail quarters average beat zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
3567,GILD,mylan myl free report recently announce subsidiary mylan inc mylan specialty have sign agreement department justice doj other relator agreement finalize medicaid drug rebate settlement worth announce oct settlement resolve claim relate classification epipen auto injector epipen jr auto injector purpose medicaid drug rebate program doj want ascertain epipen product be properly classify center medicare medicaid service innovator drug applicable definition medicaid rebate statute drug be subject formula be used calculate rebate medicaid such drug note mylan have be immense pressure aug company come spotlight price increase epipen acquisition drug draw immense criticism lawmaker consumer common person alike further mylan make headline wrongly classify epipen generic product medicaid drug rebate program imply mylan have be vastly underpay rebate medicaid drug long time have drug be classify brand epipen auto injector be classify innovator drug cms mylan acquire product base longstanding written guidance federal government nevertheless settlement provide resolution potential medicaid rebate liability claim federal government well potential claim certain hospital other cover entity participate drug pricing program moreover mylan reclassify epipen auto injector purpose medicaid drug rebate program pay rebate applicable innovator product effective apr mylan stock have fall year date compare industry decline mylan second quarter result be dismal company miss earning sale estimate due challenge north america cut annual guidance be also disappointing ongoing challenge uncertain regulatory environment region have lead company defer major launch guidance include generic version glaxosmithkline inc gsk free report asthma drug advair diskusand generic copaxone meanwhile mylan biologic license application propose biosimilar version roche holding rhhby free report herceptin be currently review fda anticipate fda goal date set biosimilar user fee act be sep expect investor focus same zack rankmylan currently carry zack rank strong sell better rank stock health care sector be gilead science inc gild free report carriesa zack rank buy see complete list today zack rank strong buy stock here gilead earning share estimate increase last day follow strong result second quarter company deliver positive earning surprise trail quarters average beat surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
3568,GILD,key biotech stock amgen amgn free report biogen biib free report report second quarter result yesterday company surpass earning sale estimate be several other key update well company incyte incy free report medicine co mdco free report recap week most important storiesamgen biogen earning biogen result be strong company most recent offer spinraza spinal muscular atrophy sma do better expect meanwhile company multiple sclerosis ms franchise continue grow ms be biogen key area expertise biogen expect early be inflection point company key pipeline candidate expect launch period read more biogen top earning sale spinraza sale amgen also top estimate update guidance recently launch product include prolium second fourth quarters be typically strongest product repatha kyproli record strong volume drive growth amgen be work improve repatha patient access world meanwhile mature product enbrel epogen neulasta neupogen decline neupogen be impact short act biosimilar competition continue affect sale amgen stock have gain year date ytd outperform rally industry belong biogen have lag share decline ytd incyte lilly ra drug face least month delay resubmission incyte partner lilly announce be delay least month resubmission regulatory application investigational rheumatoid arthritis ra treatment baricitinib mean resubmission not take place year incyte lilly discuss path forward fda evaluate option resubmission include possibility conduct additional study require fda fda have issue complete response letter crl baricitinib earlier year april time agency have tell company be unable approve baricitinib once daily oral medication treatment moderate severe ra current form fda have ask additional clinical datum determine most appropriate dose well further characterize safety concern treatment arm note baricitinib be approve eu trade name olumiant feb european medicine agency ema committee medicinal product human use chmp recently agree label be update include precaution patient have risk factor deep venous thrombosis dvt pulmonary embolism pe incyte share be baricitinib update nektar lilly deal nektar nktr free report enter deal big pharma company lilly see nektar receive upfront well form milestone payment deal cover co development early stage asset nktr nektar pipeline nktr have potential treat number autoimmune other chronic inflammatory condition work target il receptor complex body activate regulatory cell nktr have potential bring immune system back balance other deal term include sharing phase ii development cost lilly nektar option nektar participate late stage development indication indication basis double digit royalty nektar deal be major nektar consider early stage nature candidate hefty upfront fee lilly make strong partner company nektar share be follow deal announcement ironwood heartburn drug datum ironwood irwd free report share be even company report positive datum iw mid stage study conduct patient uncontrolled reflux disease gerd study meet primary endpoint fail impress investor efficacy result fall short expectation ironwood intend conduct end phase ii meeting fda move candidate phase iii study second half accord company iw represent immense commercial potential annual peak sale opportunity more read more ironwood report positive datum reflux candidate chmp positive regeneron sanofi eczema drug regeneron sanofi be step closer gain eu approval eczema treatment dupixent chmp adopt positive opinion drug company be seek approval use adult moderate severe atopic dermatitis ad be candidate systemic therapy final decision regard approval be come month dupixent gain fda approval earlier year march dupixent have blockbuster potential be be investigate other indication well detailed datum gilead hiv regimen gilead gild free report announce detailed week result couple late stage study fix dose combination bictegravir novel investigational insti emtricitabine tenofovir alafenamide ftc taf dual nrti backbone treatment hiv infection treatment naïve adult bictegravir contain regimen be find be inferior dolutegravir contain regimen gilead hold strong position hiv market be work strengthen franchise be significant demand simple convenient dose regimen sustain virologic suppression safety profile be appropriate most hiv patient mdco tango stop early superior benefit risk medicine co get good news independent datum safety monitoring board stopping late stage study investigational antibiotic vabomere previously refer carbavance base interim analysis interim result tango study show vabomere improve clinical cure rate infection type reduce rate renal adverse event compare best available therapy vabomere be currently priority fda review response expect third quarter marketing application be file eu well medicine co be zack rank hold stock see complete list today zack rank strong buy stock here biomedical genetic industry yr return medical biomedical genetic industry yr returnearning season biotech sector be strong start big player amgen biogen report better expect result nasdaq biotechnology index climb last trading session major biotech stock record gain vertex soar last month vertex be see last biotech stock roundup here vertex boost cf datum fda nod gilead puma drug next biotech world watch earning report company vertex gilead hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3569,GILD,be enter peak period second quarter report cycle week quarter undoubtedly be strong start jul member accounting index total market capitalization report result accord earning preview beat revenue earning estimate compare first quarter total earning index member be year quarter improvement revenue beat ratio be earning revenue earning momentum be expect continue season report total earning company second quarter be expect grow year year higher revenue follow earning growth first quarter increase revenue highest almost year pharma bigwig johnson johnson jnj free report report mixed second quarter result beating earning miss sale other hand novartis nvs free report second quarter result be encourage company top earning sale estimate jul lilly lly free report biogen inc biib free report release second quarter result company beat earning revenue estimate lilly raise previously issue adjust earning sale outlook biogen also raise earning sale outlook let take look pharma giant be set report second quarter result jul let see thing be shape quarter gilead science inc gild free report gilead be schedule release earning close bell have deliver positive earning surprise last quarter gilead earning performance have be mixed earning miss expectation last quarters beating remain result average positive surprise quarter gilead have earning esp zack rank hold indicate likely beat quarter zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter hiv other antiviral product be expect boost sale however hcv franchise continue be pricing pressure read more be gilead poise beat earning season gilead science inc price ep surprise gilead science inc price ep surprise gilead science inc quotevertex pharmaceutical inc vrtx free report vertex be also schedule announce result close bell vertex average positive earning surprise last quarters be last report quarter vertex post positive surprise company have earning esp zack rank strong buy be thus expect beat earning estimate quarter see complete list today zack rank stock here investor focus vertex second conference call be triple combination cystic fibrosis cf regimen be crucial long term growth vertex datum vx vx phase ii vx phase triple combination study present last week have show combination lead pronounce improvement lung function read more be beat card vertex earning vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate plc gsk free report company be expect report market hour glaxosmithkline report line earning last quarter glaxo performance have be pretty impressive company report positive surprise consistently average earning beat last quarters be company have earning esp zack rank glaxo pharmaceutical vaccine segment be expect drive sale second quarter well meanwhile consumer healthcare segment have slow due impact general sale tax continue slowdown nutrition category india challenge economic condition other international market nigerian beverage business divestment factor impact second quarter result well read more lie store glaxo earning season glaxosmithkline plc price ep surprise glaxosmithkline plc price ep surprise glaxosmithkline plc quotemore stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
3570,GILD,intercept pharmaceutical inc icpt free report be schedule report second quarter result jul last report quarter company beat expectation let see thing be shape announcement intercept share price movement year so far reveal stock outperformed industry company share have rally period compare industry gain surprise track record have be decent so far company surpass expectation last quarters company have post average positive earning surprise period likely positive surprise proven model show intercept be likely beat estimate quarter have right combination key ingredient positive earning esp zack rank strong buy buy hold zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate be peg loss zack consensus estimate be peg loss uncover best stock buy sell re report earning esp filter zack rank intercept currently carry zack rank combination zack rank positive esp make confident earning beat upcoming release conversely sell rate stock never be consider go earning announcement especially company be see negative estimate revision factor receive major boost fda approval lead drug ocaliva combination ursodeoxycholic udca treatment primary biliary cholangitis pbc adult inadequate response udca monotherapy adult unable bear udca dec european commission also grant conditional approval ocaliva same indication ocaliva generate sale last quarter initial uptake ocaliva have be encourage sale drug be expect topick further meanwhile ocaliva be be evaluate other indication include alcoholic steatohepatitis nash primary sclerosing cholangitis psc intercept expect operate expense range support continue ocaliva pbc unite state other market sustain clinical development oca pbc nash continue advancement int other pipeline program company initiate phase iii study regenerate ocaliva treatment cirrhotic nash patient advanced liver fibrosis fda approve redesign regenerate trial safety efficacy treat nash patient liver fibrosis company now need achieve only co primary endpoint fibrosis improvement nash resolution compare earlier target achieve sample size trial have also be reduce approximately patient patient arm company plan complete enrolment interim analysis cohort regenerate trial soon datum readout intercept also initiate phase ii study control combination oca andstatin monitoring lipid oca enrolment study be complete third quarter top line datum expect shortly company also plan initiate phase iii trial ocaliva nash patient cirrhosis second half company also expect top line result phase ii trial aesop primary sclerosing cholangitis psc expect investor remain focuse sale ramp ocaliva pipeline update call intercept pharmaceutical inc price ep surprise intercept pharmaceutical inc price ep surprise intercept pharmaceutical inc quotestock warrant lookhere be other health care stock want consider model show too have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report schedule release result jul have earning esp zack rank see complete list today zack rank stock here gilead science inc gild free report have earning esp zack rank company be schedule release result jul alexion pharmaceutical inc alxn free report have earning esp zack rank company be schedule release result jul more stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
3571,GILD,radius health inc rdus free report be schedule report second quarter financial result aug radius health share have outperformed industry year so far stock have gain time period industry gain radius health have disappointing track record so far company have miss estimate trail quarters negative average surprise let see thing be shape quarter factor playradius health focus development therapeutic treatment osteoporosis oncology endocrine disease company new drug tymlos be approve apr drug be instrumental treat postmenopausal woman osteoporosis high risk fracture defined history osteoporotic fracture multiple risk factor fracture drug be also used patient have fail be intolerant other available osteoporosis therapy drug be review eu drug be price annualize wholesaler acquisition cost pen hence expect investor focus impending launch upcoming earning call osteoporosis market have great potential approximately postmenopausal woman experience osteoporotic fracture year tymlos be expect face significant competition forteo prolium meanwhile committee medicinal product human use chmp issue second day list outstanding issue request additional datum analysis related safety efficacy abaloparatide sc process ongoing regulatory review company expect chmp issue opinion regard maa abaloparatide sc prior end company be plan file supplemental new drug application tymlos base activextend study result activextend trial show statistically significant fracture risk reduction year sequential therapy tymlos follow antiresorptive jun company announce encourage result ongoing phase study pipeline candidate elacestrant rad patient suffering estrogen receptor positive breast cancer candidate oral selective estrogen receptor serd be be evaluate potential use oral steroidal treatment estrogen receptor positive breast cancer high dose first quarter earning call company state plan discuss next step program fda expect company throw more light same radius health inc price ep surprise radius health inc price ep surprise radius health inc quoteearning whispersour proven model do not conclusively show radius health be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp radius health be currently peg be most accurate estimate zack consensus estimate be peg loss uncover best stock buy sell re report earning esp filter zack rank radius health have zack rank sell note caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock considerhere be few pharma company consider model show have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report be schedule release result jul company have earning esp zack rank see complete list today zack rank stock here intercept pharmaceutical inc icpt free report have earning esp zack rank company be expect release result aug gilead science inc gild free report have earning esp zack rank company be schedule release result jul more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
3572,GILD,share mallinckrodt plc mnk free report be district court invalidate patent cover second largest product inomax reuter report moreover mallinckrodt stock price have decline year date compare industry fall drug represent company total revenue note mallinckrodt acquire privately hold critical care company ikarium add inomax vasodilator used conjunction ventilatory support other appropriate agent portfolio remind investor february mallinckrodt subsidiary file suit district court district delaware praxair inc px free report follow receipt january notice latter notice be regard praxair submission anda contain paragraph iv patent certification fda generic version inomax subsequently july mallinckrodt file second suit praxair follow receipt paragraph iv notice concern additional patent recently add fda orange book regard anda generic version inomax thereafter third suit be file september mallinckrodt plan appeal decision state inomax have patent protection news come major disappointment mallinckrodt inomax be second largest product achtar loss patent protection inomax adversely impact revenue mallinckrodt be currently streamline business company aim focus better specialty pharmaceutical business have sell nuclear imaging business however generic segment continue face weakness various product category be witness stiff competition be hurt volume price company expect double digit decline revenue segment addition continue expect weakness segment adversely impact gross profit margin also zack rank key currently carry zack rank hold few better rank stock health care sector be aduro biotech inc adro free report gilead science inc gild free report stock carry zack rank buy see complete list today zack rank strong buy stock here aduro biotech loss share estimate narrow last day company deliver positive earning surprise trail quarters average beat gilead earning share estimate increase last day company deliver positive earning surprise trail quarters average beat surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
3573,GILD,market hate unknown unpredictable simmer tension korean peninsula be bit investor politician world seem be apprehensive global reaction north korea sixth also biggest nuclear weapon test sunday potential conflict north korea act forefront everyone mind stock market be tenterhook well fact accord south korean official north korea appear be set test ballistic missile back home geopolitic severe hurricane rocked wall street calm market remain skittish aftermath north korea nuclear test second potent hurricane irma expect unite state many week such fickle environment rapidly escalate be surprise investor seek asset security gold price flare treasury strengthen however feel such scenario investor look gold government security have create multus faceted screen give investor stability profit growth potential farther next quarter make sense profitsit be common knowledge wall street be obsessed bottom line be higher profit necessarily better be really true indicator stay power company earning dollar profit trump other measure hand sheer shock value do not relate profit size company sale resource shareholder capital only profitability measure reasonably work industry be ratio return generate dollar invest business most popular ratio be return equity roe favore wall street analyst investor alike however roe measure receive most attention investor community executive focus heavily metric well company exploit financial strategy increase debt leverage stock buyback funded build cash artificially maintain healthy roe conceal weaken operational profitability so let shift focus different bottom line metric garner far less attention executive investor alike return invest capital lesser know show optimally management have be direct capital control profitable investment paint clear picture efficiently company be employ capital competitive position be allow produce good return capital also focus large cap be big establish company stock market have comparatively softer risk profile virtue dominant market position global footprint relatively consistent cash flow stream company tend be more reliable investment be call current geopolitical environment also be particularly relevant assess company have large amount capital be quite difficult investor single such company need company have generate strong rois sufficiently long period time order determine robust trend so have create faceted screen shortlist such company only company have generate rois excess average last year get past screen current trail month also need be least addition ensure hone stable company have establish history generate profit screen allow only company have market capitalization north needless say company have solid zack rank too favorable zack rank show positive analyst interest brighter prospect company stock have proven mettle consistently challenge time look set outperform peer effortlessly efficient usage asset just company get screen here be boee company ba free report boee be world major aerospace firm design develop manufacture sell service support commercial jetliner satellite military aircraft human space flight missile defense launch system service globally aerospace giant generate impressive average last year boast current past month analyst have become increasingly bullish zack rank buy stock see complete list today zack rank strong buy stock here company have see sharp spike zack consensus estimate be now peg witness couple month back move denote decidedly bullish analyst sentiment stock texas instrument incorporate txn free report texas instrumentsis global semi conductor company world lead designer supplier digital signal processor analog integrate circuit past year zack rank stock generate impressive average have current analyst envision healthy future company zack consensus estimate earning trend sharply past day share thank upward estimate revision gilead science inc gild free report base foster city gilead science focus discovery development drug several indication zack rank stock generate average year time current be peg analyst have great expectation company year have be revise earning estimate upward past couple month gilead estimate inched past day idexx laboratory inc idxx free report idexx laboratory be global leader provide diagnostic detection information product animal health industry well quality assurance product service food water industry year time company record average boast current moreover analyst have become increasingly bullish zack rank stock past month upward estimate revision earning have lead sharp spike zack consensus estimate be now peg witness day moody corporation mco free report moody sprovide credit rating credit capital market economic related research datum analytical tool worldwide zack rank stock generate average last year current past couple month analyst have become increasingly bullish company upward estimate revision earning have lead sharp spike zack consensus estimate increase see month today surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
3574,GILD,exit lukewarm august step final month investing cohort have shift focus likely market movement september be especially true give month curse seasonality equity market september be historically worst month year stock accord moneychimp com consensus carry have reveal september end offer positive return year negative return year average return negative be month undesirable financial event start great depression fall lehman brother month september even september bear risk considerable negative change market case geopolitical tension north korea heighten political uncertainty unite state related tax reform government shutdown escalate make more important pin point etfs safeguard investor steep sudden market swing well lead gain powershare qqq qqq qqqseptember be ill repute term stock return time month open deluge upbeat datum point first end august commerce department release economic growth datum compare earlier estimate be best gdp growth first quarter read top etf story august start september datum show manufacturing expand august quickest clip call growth investing be thus bullish nasdaq etf qqq nasdaq composite have already register largest weekly gain year sign economic strength bounce biotech share spdr biotech etf xbi free report biotech etfs especially focus cancer therapy stage great show august particular gilead gild free report buyout announcement clinical stage company kite pharma car treatment type gene therapy cancer have be approve use unite state lately development biotech sphere bode well related etfs read biotech etfs soar gilead kite deal vaneck vector semiconductor etf smh free report usage cryptocurrency bitcoin ethereum ripple be tear follow immense price rise burger king have also jump area launch own virtual coin call whoppercoin russia read bitcoin etfs more issuer join race mining cryptocurrency need usage semiconductor part technology sector perform well september case semiconductor be value centric traditional tech area be likely have upper hand edgy investing environment moreover semiconductor space be consolidate rapidly number deal announce lately ishare edge msci multifactor global etf acwf free report equity have record month investor have look global etf way investor mitigate certain risk notably global economy be upward trajectory fund look track global develop emerge market large mid cap stock choose basis value quality momentum low size score read global dividend payment upbeat etfs benefit europe small cap dividend etf dfe free report euro zone economic growth have look year region grow sequentially follow expansion previous period positive sentiment rise euro be deterrent so have choose small cap europe etf dfe be less susceptible rise euro small cap better reflect uptick domestic economy benchmark treasury yield loitering be intriguing go higher yielding pick fund yield annually ishare moderate allocation fund aom free report finally pick full fledge defensive etf aom fund take fund fund approach be combination bond global stock equity make fund follow government treasury bond account portfolio japan take next spot want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
3575,GILD,investor be always look stock be poise beat earning season gilead science inc gild free report be such company firm have earning come pretty soon event be shape quite nicely report be gilead science be see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface gild report fact most accurate estimate current quarter be currently share gild compare broader zack consensus estimate share suggest analyst have very recently bump estimate gild give stock zack earning esp head earning season gilead science inc price ep surprise gilead science inc price ep surprise gilead science inc quotewhy be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give gild have zack rank esp positive territory investor want consider stock ahead earning see complete list today zack rank strong buy stock here clearly recent earning estimate revision suggest good thing be ahead gilead science beat be card upcoming report more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
3576,GILD,inc agen free report be expect report second quarter jul last report quarter deliver positive earning surprise moreover trail quarter average surprise be notably share price have increase year date outperform industry rally let see thing be shape company quarter earning whispersour proven model show be likely beat earning quarter have right combination key ingredient positive earning esp zack rank strong buy buy hold have significantly higher chance beating earning zack esp have earning esp most accurate estimate be loss cent zack consensus estimate be peg loss cent uncover best stock buy sell re report earning esp filter zack rank currently carry zack rank combine positive esp make reasonably confident earning beat note caution stock zack rank sell rate go earning announcement factor playagenus be immuno oncology company focuse discovery development checkpoint modulator vaccine adjuvant treatment cancer earn revenue only fee receive collaboration license agreement currently company be evaluate agen phase study incagn phase ii study treatment solid tumor fact have initiate phase study ox agonist antibody incagn phase ii study collaboration incyte expect begin combination study agen agen second half second quarter conference call investor be likely remain focuse company update initiation combination study antibody be expect focus advancement additional checkpoint modulator antibody vaccine clinic come quarters january enter clinical trial collaboration national cancer institute nci evaluate prophage hsppc conjunction merck co inc mrk free report pd therapy keytruda phase ii study evaluate effect prophage conjunction keytruda overall survival rate patient newly diagnosed glioblastoma ndgbm march company restructure operation decision be take order cut cost sharpen focus develop key product candidate company plan close basel site consolidate key function cambridge lexington term move be anticipate result elimination position next month furthermore transition consolidate certain key management position objective streamline leadership reduce cost inc price ep surprise inc price ep surprise inc quotestock warrant lookhere be health care stock want consider model show have right combination element post earning beat quarter intercept pharmaceutical inc icpt free report have earning esp zack rank company be expect release result aug see complete list today zack rank stock here gilead science inc gild free report have earning esp zack rank company be schedule release result jul more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3577,GILD,amgen inc amgn free report announce new analysis phase iii cardiovascular outcome study fourier pcsk inhibitor repatha analysis large cohort patient establish atherosclerotic cardiovascular disease show be strong progressive relationship lower achieve level ldl bad cholesterol lower risk cardiovascular event rate analysis suggest use intensive ldl therapy such repatha high risk cardiovascular patient safely reduce risk cardiovascular event heart attack stroke cardiovascular death year so far amgen share be better increase register industry result be present european society cardiology esc congress hold spain also publish lancet remind investor datum present fourier march year have reveal treatment repatha lead significant reduction myocardial infarction stroke uptake drug gain fda approval aug have not be very encourage so far due pricing re imbursement issue payer restriction fourier datum hold key commercial success repatha broaden use drug datum study look good be not very clear payer be willing improve access repatha base datum encouragingly second quarter conference call management say repatha hold share pcsk segment europe share trend improve sequentially market quarter meanwhile new brand share repatha be second quarter management say presentation outcome study datum have positive impact repatha share trend amgen file regulatory application eu include fourier datum repatha label jun last month amgen announce fda have grant priority review application seek approval include fourier datum label decision agency be expect dec sanofi sny free report partner regeneron pharmaceutical inc regn free report also face similar issue pcsk inhibitor praluent amgen currently carry zack rank hold see complete list today zack rank strong buy stock here better rank pharma biotech stock be gilead science inc gild free report zack rank buy share gilead be so far year estimate have inched almost respectively last day zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
3578,GILD,share expedia inc expe free report decline company chief executive officer dara khosrowshahi announce be join uber ceo biogen inc biib free report share surge follow positive result alzhiemer drug study share gilead science inc gild free report increase enter agreement kite pharma inc acquire company whopping cash johnson johnson jnj free report share increase almost announce favorable result phase study blood thin drug xarelto
3579,GILD,issue update report mallinckrodt plc mnk free report aug mallinckrodt develop manufacture market distribute brand generic specialty pharmaceutical product therapy well nuclear medicine product company have be undertaking strategic acquisition divestiture evolve high perform specialty pharmaceutical company acthar gel become part company portfolio follow questcor acquisition continue drive revenue be currently approve indication market only patient penetration rate hence mallinckrodt be work boost acthar sale approve indication include rheumatology pulmonology well underserved patient population bid expand hospital growth platform mallinckrodt acquire privately hold critical care company ikarium add inomax vasodilator used conjunction ventilatory support other appropriate agent portfolio currently inomax be mallinckrodt second largest product company estimate be roughly business global basis cadence acquisition add ofirmev company specialty pharmaceutical portfolio thus expand pain management franchise ofirmev portfolio mallinckrodt target adjacent acute care hospital market penetration rate available surgical procedure be relatively low hospital system continue develop recovery standard surgery protocol benefit product ofirmev enable patient recover quickly surgery growth drug be expect be drive expand patient reach company aim focus better specialty pharmaceutical business have sell nuclear imaging business company also sell intrathecal therapy business other hand acquisition hemostasis drug thrombin topical recombinant preveleak raplixa fibrin sealant medicine co mdco free report have strengthen grow hospital portfolio however therakos sale be kit supply issue be resolve first quarter company underestimated complexity conversion xt cellex device result lower anticipate net sale moreover transitional issue be expect persist upcoming quarters specialty segment continue face weakness various product category be witness stiff competition be hurt volume price company expect double digit decline revenue segment addition continue expect weakness segment adversely impact gross profit margin also investor interested healthcare sector consider top rank stock gilead science inc gild free report aduro biotech inc adro free report zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
3580,GILD,equity market remain skittish last few day nation face worst tropical storm year hurricane harvey addition catastrophic flood category storm ravage property cause widespread damage various industry sublime tension outside country continue raise element caution investor be lookout cash cow stock offer high return however single cash rich stock alone do not make solid investment proposition be backed attractive efficiency ratio return equity roe high roe ensure company be reinvest cash high rate return roe key metricroe net income shareholder equityroe help investor distinguish profit generate company profit burner be useful determine financial health company other word financial metric enable investor identify stock diligently deploy cash higher return moreover roe be often used compare profitability company other firm industry higher better measure well company be increase profit investing new equity capital business portray management efficiency reward shareholder attractive risk adjust return screening parametersin order shortlist stock be cash rich high roe have add cash flow greater roe greater industry primary screening parameter addition have take few other criterium consideration arrive winning strategy price cash flow less industry metric measure much investor pay dollar free cash flow lower ratio indicate investor need pay less better cash flow generate stock return asset roa greater industry metric determine much profit company earn dollar asset include cash account receivable property equipment inventory furniture higher roa better be company year ep historical growth greater industry criterion indicate continue earning momentum have translate solid cash strength zack rank less equal zack rank strong buy buy stock be know outperform irrespective market environment here be stock qualify screen broadcom limit avgo free report broadcom be premier designer developer global supplier broad range semiconductor device focus complex digital mixed signal complementary metal oxide semiconductor base device analog iii base product company have trail quarter average earning surprise long term earning growth expectation broadcom carry zack rank cbre group inc headquarter los angele cbre group be commercial real estate service investment firm offer wide range service tenant owner lender investor office retail industrial multus family other type commercial real estate major metropolitan area globe company have trail quarter average earning surprise long term earning growth expectation cbre group sport zack rank see complete list today zack rank stock here sandvik ab sdvky free report headquarter stockholm sweden sandvik operate high tech global engineering firm field rock excavation metal cut material technology company have zack rank apply material inc amat free report headquarter santa clara apply material offer manufacturing equipment service software semiconductor display related industry worldwide zack rank stock have trail quarter average earning surprise long term earning growth projection gilead science inc gild free report headquarter foster city gilead science be company focuse develop drug treatment human virus hiv liver disease such chronic hepatitis virus hcv infection chronic hepatitis virus hbv infection cardiovascular hematology oncology inflammation respiratory disease zack rank stock have trail quarter average earning surprise get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performance zack restaurant recommendation inaddition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
3581,GILD,roche hold ag rhhby free report announce fda have accept company supplemental biologic license application sbla grant priority review gazyva combination chemotherapy follow gazyva alone patient suffering previously untreated follicular lymphoma fda be expect announce final decision dec remind investor priority review be give drug fda believe have potential provide significant improvement safety effectiveness treatment prevention diagnosis serious disease note gazyva combination chlorambucil be approve patient suffering previously untreated chronic lymphocytic leukaemia cll potential approval follicular lymphoma be expect boost sale further drug be also be evaluate other approve investigational medicine include cancer immunotherapy small molecule inhibitor roche stock have gain industry gain roche hematology portfolio present consist mabthera rituxan gazyva gazyvaro venclextatm venclyxtotm collaboration abbvie inc abbv free report pipeline have small molecule antagonist mdm idasanutlin rg polatuzumab vedotin company also have hemophilia candidate emicizumab pipeline last week fda grant emicizumab prophylaxis preventative priority review once weekly subcutaneous treatment adult adolescent child hemophilia factor viii inhibitor fda be expect announce final decision feb remind investor fda grant breakthrough therapy designation emicizumab adult adolescent haemophilium inhibitor september approval new drug further boost roche hematology portfolio zack rank stock considerroche currently carry zack rank hold better rank stock healthcare sector be gilead science inc gild free report aduro biotech inc adro free report stock carry zack rank buy see complete list today zack rank strong buy stock here gilead earning share estimate increase last day company deliver positive earning surprise trail quarters average beat aduro biotech loss share estimate have narrow last day company deliver positive surprise trail quarters average beat more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3582,GILD,novartis ag nvs free report announce positive primary datum phase iii study cantos pipeline candidate canakinumab acz study evaluate quarterly injection canakinumab patient prior heart attack inflammatory atherosclerosis measure high sensitivity reactive protein result study show canakinumab reduce risk major adverse cardiovascular event mace study meet primary endpoint cardiovascular risk reduction mg dose canakinumab mg dose show similar benefit mg dose be less efficacious result be present european society cardiology esc congress publish new england journal medicine company plan submit datum cantos study initiate phase iii study lung cancer remind investor canakinumab be first approve cryopyrin associate periodic syndrome ilaris fda approve label expansion drug treat rare distinct type periodic fever syndrome tumor necrosis factor receptor associate periodic syndrome syndrome mevalonate kinase deficiency familial mediterranean fever meanwhile review blind pre plan oncology safety analysis reveal reduction lung cancer reduction lung cancer case patient treat mg canakinumab successful development canakinumab be expect boost novartis cardiovascular portfolio significantly company currently have entresto portfolio have be give class recommendation unite state eu treatment heart failure reduce ejection fraction hfref novartis stock have rally year so far compare industry gain go forward expect approval new drug label expansion exist one bode well novartis even stiff generic competition key drug gleevec continue act major deterrent european commission recently approve novartis breast cancer drug kisqali ribociclib be expect boost oncology portfolio even competition be stiff like roche hold ag rhhby free report zack rank key picksnovartis currently carry zack rank hold better rank stock healthcare sector include gilead science inc gild free report aduro biotech inc adro free report stock carry zack rank buy see complete list today zack rank strong buy stock here gilead earning share estimate increase last day company deliver positive earning surprise trail quarters average beat aduro biotech loss share estimate narrow last day company deliver positive surprise trail quarters average beat more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3583,GILD,hurdle trump plan repeal replace obamacare healthcare be second best perform sector year lag technology optimism come especially encourage industry trend hope favorable policy environment trump administration plan focus ease regulatory hurdle rather lower drug price expedite new drug approval additionally shift investor sentiment defensive sector healthcare generally outperform period low moderate growth rise geopolitical uncertainty have lead rally healthcare stock read top rank healthcare etfs long term investor such popular fund health care select sector spdr fund xlv free report vanguard health care etf vht free report ishare healthcare etf iyh free report fidelity msci health care index etf fhlc free report have gain least so far year trend be likely continue head earning season big name pfizer pfe free report merck mrk free report amgen amgn free report abbvie abbv free report gilead science gild free report bristol myer squibb bmy free report be line report week next stock collectively account share xlv iyh vht fhlc let dig deeper earning picture company drive performance mentioned fund come day accord methodology zack rank strong buy buy hold combine positive earning esp increase chance predict earning beat zack rank sell rate be best avoid uncover best stock buy sell re report earning esp filter surprise prediction stockspfizer have zack rank earning esp indicate reasonable chance beating estimate quarter stock see earning estimate revision yet be report quarter deliver negative earning surprise past quarters additionally have impressive growth momentum style score respectively value style score be favorable pfizer be schedule report earning august open bell read build winning etf portfolio second half pfizer inc price consensus ep surprise pfizer inc price consensus ep surprise pfizer inc quotemerck be expect report result july market open have zack rank earning esp make surprise prediction difficult stock witness positive earning estimate revision penny past day be report quarter deliver positive earning surprise last quarters average beat merck have strong value momentum style score unfavorable growth style score merck company inc price consensus ep surprise merck company inc price consensus ep surprise merck company inc quoteamgen have zack rank earning esp indicate less chance beating estimate quarter earning surprise track past quarters be robust average positive surprise amgen witness negative earning estimate revision couple cent past day yet be report quarter stock have solid value momentum style score respectively growth style score look dull amgen report earning july market close amgen inc price consensus ep surprise amgen inc price consensus ep surprise amgen inc quoteabbvie have zack rank earning esp indicate less chance beating estimate quarter company deliver positive earning surprise last quarters average beat see positive earning estimate revision couple cent past month be report quarter stock have solid value style score growth momentum style score respectively be unimpressive company be schedule report july open bell read brighten outlook healthcare etfs focus abbvie inc price consensus ep surprise abbvie inc price consensus ep surprise abbvie inc quotegilead be expect release earning july market close have zack rank earning esp indicate reasonable chance beating estimate gilead deliver positive earning surprise last quarters average beat see earning estimate revision past month be report quarter have solid value momentum style score respectively growth style score look ugly gilead science inc price consensus ep surprise gilead science inc price consensus ep surprise gilead science inc quotebristol myer likely report earning july open bell have zack rank earning esp make surprise prediction difficult stock deliver positive earning surprise past quarters average beat witness positive earning estimate revision cent be report quarter have unfavorable value growth momentum style score respectively see healthcare etfs here bristol myer squibb company price consensus ep surprise bristol myer squibb company price consensus ep surprise bristol myer squibb company quotesum healthcare sector be expect post earning decline second quarter have dismal zack rank bottom surprise well be card suggest upside healthcare etfs particular xlv vht iyh have zack etf rank fhlc have zack etf rank want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
3584,GILD,expect vertex pharmaceutical inc vrtx free report beat expectation report second quarter result jul market close year date vertex share have soar industry have record increase vertex track record have be impressive so far company deliver positive earning surprise miss expectation last quarters average positive earning surprise last quarters be last report quarter vertex post positive surprise vertex pharmaceutical incorporate price ep surprisevertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate quotelet see thing be shape quarter factor playsale vertex cystic fibrosis cf drug kalydeco orkambi rise first quarter expect positive trend continue second well kalydeco gain fda approval use patient older have residual function mutation cystic fibrosis transmembrane conductance regulator cftr gene person have mutation follow approval vertex up kalydeco revenue guidance expect expand indication boost kalydeco sale second quarter orkambi sale growth be dependent reimbursement discussion europe last week vertex announce have strike re imbursement agreement italy orkambi thereby make medicine more accessible country reimbursement agreement not be beneficial second quarter contribute sale second half year first quarter company have also mentioned gain reimbursement france year contribute significantly revenue growth year vertex be also evaluate next generation cftr corrector vx vx vx vx part triple combination tezacaftor ivacaftor datum vx vx phase ii vx phase triple combination study present earlier week have show combination lead pronounce improvement lung function phase ii study vx be expect be initiate early aug phase ii study fourth next generation corrector vx triple combination tezacaftor ivacaftor be already go datum vx vx phase ii study be expect early thereafter discussion regulatory agency vertex initiate pivotal study more triple combination regimen first half triple combo regime be successful vertex address significantly larger cf patient population investor focus call be triple combination cf regimen crucial long term growth vertex however operate expense be likely shoot vertex expand pipeline model proven model show vertex be likely beat estimate quarterbecause have right combination key ingredient astock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate earning cent zack consensus estimate earning cent stand be lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank vertex currently flaunt zack rank strong buy so desirable combination make reasonably confident earning beat conversely caution sell rate stock go earning announcement especially company be see negative estimate revision stock warrant lookhere be health care stock want consider model show have right combination element post earning beat quarter gilead science inc gild free report be schedule release result jul company have earning esp zack rank see complete list today zack rank stock here celgene corp celg free report be schedule release result jul company have earning esp zack rank proteostasis therapeutic inc pti free report be expect release result aug have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3585,GILD,share cancer treatment drug maker kite pharma soar monday morning gilead science gild free report officially announce purchase company substantial premium gilead be set pay roughly cash deal acquire kite innovative cancer drug aim make patient own immune cell fight cancerous tumor gilead share purchase mark premium kite friday close kite gilead board director unanimously approve deal reportedly close fourth quarter share kite reach new time high monday company share have already trade hand more time average volume gilead see stock price climb gilead make clear official announcement kite purchase be design diversify drug offering however kite acquisition win become neutral term earning third year deal accord gilead acquisition kite establish gilead leader cellular therapy provide foundation drive continue innovation person advanced cancer gilead president ceo john milligan say statement field cell therapy have advanced very quickly point science technology have open clear path potential cure patient be greatly impressed kite team have accomplish share belief cell therapy be cornerstone treat cancer kite biggest most advanced offer be car therapy call axicabtagene ciloleucel axi cel company expect axi cel be approve treatment fight aggressive hodgkin lymphoma axi cel treatment be currently review food drug administration fda target action date be november european approval set next year gilead grow biotech company selling treatment hiv aids hepatitis kite cancer therapy drug eventually go treatment lymphoma other form blood cancer accord analyst kite axi cel sale reach rank drug top industry term sale potential gilead stock be currently zack rank buy score value style score system share kite sky-rocket share early january share monday kite be currently zack rank hold want know more kite read kite pharma be revolutionize fight cancer listen podcast more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3586,GILD,gilead science inc gild free report announce fda have grant priority review company new drug application nda investigational fix dose combination bictegravir mg bic novel investigational integrase strand transfer inhibitor insti emtricitabine tenofovir alafenamide mg ftc taf dual nrti backbone treatment hiv infection nda be file jun fda have set target action date prescription drug user fee act pdufa feb marketing application bic ftc taf be also review european union be validate european medicine agency ema july potential approval be expect toboost gilead hiv gilead be dominant player hiv market impressive portfolio same newly launch taf base product genvoya odefsey descovy be perform well strong adoption eu genvoya have already become most prescribe regimen treatment naïve switch patient launch nov taf base regimen now represent total gilead hiv prescription volume follow launch genvoya odefsey descovy genvoya be now company bestselling hiv product surpass truvada atripla fourth quarter genvoya be now company bestselling hiv product treatment naïve patient share gilead expect use truvada pre exposure prophylaxis prep continue boost sale hiv franchise go forward particularly strong uptake truvada use pre exposure prophylaxis set also boost sale company see significant uptick prep usage estimate patient used truvada end second quarter meanwhile gilead stock have gain only year so far industry gain uptake hiv franchise help company combat persistent decline hcv franchise due competitive pressure hcv business see improvement second quarter hcv franchise be boost fda approval vosevi hcv patient start first half be better expectation see gradual decline second half due increase competition harvoni sovaldi epclusa have be face competition abbvie abbv free report viekira pak viekira xr bristol myer squibb company bmy free report daklinza competition well pricing pressure intensified further launch merck mrk free report zepatier zack rank gilead currently carry zack rank buy see complete list today zack rank strong buy stock here trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
3587,GILD,gilead science inc gild free report announce blockbuster hepatitis virus hcv infection drug sovaldi have now be approve china food drug administration cfda also drug be approve treatment adult adolescent age year infected hcv genotype component combination antiviral treatment regimen note sovaldi be first gilead hcv drug approve china note hcv be fourth most commonly report infectious disease china approximately patient hence approval country hold promise growth note sovaldi be approve unite state europe drug be currently approve country addition gilead be evaluate hcv single tablet regimen harvoni epclusa clinical trial site china gilead be know presence hcv market thank blockbuster hcv drug sovaldi harvoni hcv portfolio receive huge boost approval epclusa unite state june eu july become first only oral pan genotypic str consist sovaldi velpatasvir ns inhibitor treatment adult genotype chronic hcv infection fda approval vosevi sovaldi velpatasvir mg voxilaprevir mg tablet also boost company portfolio drug be single tablet regimen str re treatment chronic hepatitis virus infection adult genotype previously treat ns inhibitor contain regimen genotype previously treat sovaldi contain regimen ns inhibitor however hcv franchise be pressure due competition pricing issue note harvoni sovaldi epclusa face competition abbvie inc abbv free report viekira pak viekira xr other competition well pricing pressure intensified further launch merck co inc mrk free report zepatier gilead recently announce plan acquire kite pharma inc foray emerge field cell therapy kite be pioneer cell therapy have develop engineer cell therapy express chimeric antigen receptor car engineer cell receptor tcr depend type cancer acquisition diversify gilead portfolio poise company dominant position cellular therapy space note investor be expect gilead announce acquisition term give decline once lucrative hcv market due competitive pressure more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3588,GILD,keryx inc kerx free report be expect report second quarter result jul last quarter company miss expectation fact keryx performance last quarters have be disappointing company report wider expect loss trail quarters average negative surprise keryx share price have increase year date outperform industry rally let see thing be shape company quarter factor influence quarterapart license fee keryx top line comprise revenue generate only market product auryxia ferric citrate auryxia be approve tablet control serum phosphorus level patient chronic kidney disease ckd dialysis notably auryxia be only approve product keryx portfolio company be entirely dependent growth launch late dec auryxia be still early stage however keryx be work commercial effort auryxia fact company be currently work gain formulary status drug mar nation largest medicare part plan sponsor add auryxia medicare part plan formulary formulary addition patient take phosphate binder medicare part commercial plan now have unrestricted access drug additionally be work contract remain insurance provider expand patient access auryxia enable more contact prescriber current physician have not prescribe auryxia yet meanwhile keryx expand field base team sale representative lead increase number dialysis patient auryxia moreover keryx be work expand ferric citrate compound name auryxia additional indication label include treatment iron deficiency anemia ida patient stage iii dialysis dependent chronic kidney disease indication ndd ckd mar fda accept company supplemental new drug application snda auryxia review pdufa date nov approve indication auryxia be first fda approve oral medicine treat ida patient population believe potential approval significantly boost sale auryxia go forward model proven model do not conclusively show earning beat keryx quarter be stock need have positive earning esp zack rank strong buy buy hold happen however be not case here see zack esp keryx have earning esp be most accurate estimate zack consensus estimate be peg loss cent uncover best stock buy sell re report earning esp filter zack rank keryx have zack rank increase predictive power esp however esp make surprise prediction difficult quarter note caution stock zack rank sell rate go earning announcement keryx inc price ep surprise keryx inc price ep surprise keryx inc quotestock considerhere be health care stock want consider model show have right combination element post earning beat quarter inc agen free report have earning esp zack rank company be expect release result jul see complete list today zack rank stock here gilead science inc gild free report have earning esp zack rank company be schedule release result jul intercept pharmaceutical inc icpt free report have earning esp zack rank company be expect release result aug make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3589,GILD,intercept pharmaceutical inc icpt free report provide statement recent safety dose issue lead drug ocaliva ocaliva be approve unite state subsequently european union canada treatment patient primary biliary cholangitis pbc inadequate response intolerant standard care udca dose recommend earlier stage pbc patient mild hepatic impairment be mg once daily be increase month mg once daily base tolerability treatment response other hand late stage patient moderate severe hepatic impairment child pugh cirrhosis recommend dose start mg once weekly possibility gradually increase maximum mg twice weekly however have be few safety issue death have be report pbc patient moderate severe hepatic impairment child pugh cirrhosis last week share intercept plunge fda warn regard safety issue related incorrect dose fda report death due ocaliva state drug also affect liver however intercept conduct analysis conclude patient be prescribe once daily dose ocaliva be time higher recommend weekly dose analysis be conduct consultation fda company conclude death occur due overdose drug consequently intercept issue dear healthcare provider dhcp letter thereafter fda issue own safety communication reinforce recommend label dose intercept be also work fda further update ocaliva label safety purpose nevertheless news give major blow investor ocaliva be company only approve drug such side effect limit sale potential intercept be evaluate ocaliva other indication primary sclerosing cholangitis alcoholic steatohepatitis note novartis ag nvs free report gilead science inc gild free report too have fxr agonist phase ii earlier stage clinical preclinical development be used treat pbc nash other liver disease investor interested broader healthcare sector consider alexion pharmaceutical inc alxn free report valuable return stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
3590,GILD,share kite pharma inc have have impressive run so far year ride progress revolutionary car therapy so far year company share have surge significantly outperform industry gain period kite pharma be focuse development immuno oncology treatment be hot therapeutic area huge commercial potential company have make major progress car therapy candidate axicabtagene ciloleucel kte treatment hodgkin lymphoma nhl be currently priority review unite state decision fda expect november car therapy be newly find highly advanced method treat cancer modify body immune system so recognize destroy cancer cell approval novartis nvs free report kymriah treat acute lymphoblastic leukemia august make first approve car therapy consider fact price pioneer drug be course treatment approval kite pharma candidate be huge revenue generator company be nhl patient diagnosed year unite state american cancer society give eua public offer company first week march share boost share price major move gilead science gild free report offer acquire kite pharma august establish leader cellular therapy gilead offer share premium kite close aug meanwhile other study axicabtagene ciloleucel mantle cell lymphoma be also advance datum study be expect year early next year first quarter kite pharma initiate zuma study patient follicular nhl zuma provide patient access axicabtagene ciloleucel regulatory review period phase ib ii combination study zuma evaluate candidate roche hold ag rhhby free report tecentriq patient chemorefractory diffuse large cell lymphoma commence october moreover apart kte kite pharma be also develop additional car base candidate other cancer indication phase study tcr candidate kite be initiate second quarter small cell lung cancer bladder cancer head neck cancer moreover kite pharma file investigational new drug ind application car candidate kite relapse refractory multiple myeloma aug kite pharma inc price consensus kite pharma inc price consensus kite pharma inc quotekite pharma have zack rank hold see complete list today zack rank strong buy stock here hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
3591,GILD,biotech stock amgen amgn free report intercept pharmaceutical icpt free report be news amgen provide update impact hurricane marium intercept continue be impact ocaliva safety concern recap week most important storiesamgen maintain outlook amgen provide update impact hurricane marium impact company manufacturing facility puerto rico maintain outlook company say product process inventory be lose company have enough stock meet patient demand time release second quarter result amgen have guide earning share total revenue ocaliva safety issue continue hit intercept intercept continue be impact safety issue surround sole market product ocaliva company share be initially hit dear doctor letter earlier month see share fall almost drug safety communication issue fda last week communication layer emphasis importance use recommend dosage label liver injury liver decompensation liver failure death be report ocaliva be dose more frequently recommend ocaliva be approve use primary biliary cholangitis pbc patient company be work fda ensure appropriate safe use ocaliva ocaliva approve bring sale second quarter intercept share be year date compare industry rally infinity bristol myer clinical trial collaboration expand infinity pharmaceutical infi free report exist clinical collaboration bristol myer squibb ipi pi gamma inhibitor opdivo pd immune checkpoint inhibitor have be expand include patient triple negative breast cancer tnbc have not be previously expose pd pd therapy ipi be currently phase ib study patient advanced solid tumor abbvie bristol myer clinical trial collaboration abbvie abbv free report be collaborate bristol myer squibb evaluate combination abbvie investigational antibody drug conjugate abbv bristol myer immunotherapy opdivo meet overexpressing small cell lung cancer nsclc phase ib study be ongoing cancer remain challenge medical condition several company be enter clinical trial collaboration evaluate different combination address disease abbvie be zack rank hold stock see complete list today zack rank strong buy stock here biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock gilead gild free report be vertex lose last month vertex vrtx free report be see last biotech stock roundup here fda nod first cancer biosimilar halo deal raise outlook next biotech world watch usual regulatory pipeline update hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
3592,GILD,stock market close higher wednesday follow couple bullish economic report even notch day winning streak market digest ongoing geopolitical tussle north korea also fallout hurricane harvey moreover president trump speech springfield regard tax reform boost investor sentiment nasdaq outshone other benchmark due rally tech biotech share dow also finished green follow gain caterpillar microsoft dow jone industrial average djia close gain index inx increase close meanwhile nasdaq composite index ixic close increase total only share be trade tuesday lower last session average share advance issue outnumber decliner nyse ratio nasdaq advancer outnumber decliner ratio strong economic datum overshadow geopolitical tensionsstellar economic report wednesday overshadowed linger political tension pyongyang washington aftermath hurricane harvey second estimate gross domestic product show economy expand second quarter consensus estimate grow notch fastest rate growth more year be result increase consumer spending business investment quarter increase consumer spending be pivotal drive gdp growth rate consumer expenditure be second quarter account increase expenditure good service also include car purchase be best increase report year moreover business investment rise second quarter also corporate adjust pretax profit increase past year meanwhile adp release employment report august show private sector have add total job month significantly higher estimate job addition be highest growth experience march total job be add such stellar economic datum boost investor sentiment lead broad base gain market consequently analyst expect rate hike fed possibly december due strong economic result economist believe president trump bank current rate economic growth pay plan tax cut increase infrastructural spending early tuesday north korea test missile japan invite criticism world do little investor spirit be outdo great economic report trump tweet wednesday have be talk north korea pay extortion money year add talk be not answer measure statement leader globe also add gain market also hurricane harvey have halter more country total refine capacity send gasoline future higher oil price lower too fail have overall impact market due splendid economic result trump tax speech springfieldin speech springfield president trump announce want corporate tax rate decline trump believe create additional job increase wage same time such comment bode well investor market gain follow trump speech however administration have not layer detailed plan tax reform have left congress take decision issue nasdaq post stellar post gain fourth straight session wednesday main sector finished higher such performance be achieve not only due strong economic condition also due increase tech share technology select sector spdr fund xlk be share netflix nflx free report apple aapl free report increase respectively be longest winning streak last month company possess zack rank hold see complete list today zack rank strong buy stock here nasdaq also gain wednesday notch point outshine other benchmark such show be possible due rally tech biotech share share gilead sciencesinc gild free report biomarin pharmaceutical inc bmrn free report notch respectively ishare nasdaq biotechnology etf ibb gain wednesday stock make headlineschico fall earning sale miss guide lowchico fas inc ch free report disappoint investor community again dismal second quarter fiscal financial result read more campbell miss earning sale stock lose campbell soup company cpb free report post fourth quarter fiscal result earning sale come zack consensus estimate sale mark third straight miss read more earning top spinner trend view upfive inc free report post robust second quarter fiscal result top bottom line outpaced zack consensus estimate grow year year basis read more simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
3593,GILD,bristol myer squibb company bmy free report be schedule report first quarter result jul open bell last quarter company beat earning estimate bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quotebristol myer stock have lose past year underperform industry remain flat period bristol myer have decent track record so far company earning beat estimate trail quarters average positive surprise bristol myer surpass expectation time well let see thing be shape quarter factor impact quarterbristol myer high profile immuno oncology drug opdivo continue drive company top line be report quarter opdivo sale be drive melanoma second line small cell lung cancer renal cell carcinoma indication recent label expansion classical hodgkin lymphoma head neck cancer indication boost drug sale however lung cancer market become more competitive due entry tecentriq bristol myer expect second line lung cancer business be competitive pressure result sale drug market be project be flat first quarter see stability second line lung cancer recent fda approval merck mrk free report keytruda first line treatment metastatic nonsquamous nsclc further impact sale other hand virology business be expect decline significantly due competition epclusa hiv business continue face competitive pressure recent launch other company same space be expect further impact sustiva franchise bristol myer be also look diversify portfolio development bms nash positive note bristol myer raise earning expectation concurrent first quarter result company now project earning range share old guidance revenue be expect grow mid single digit range due strong trend business particularly key product opdivo eliquis yervoy gross margin be project decline year progress be estimate range expense be expect increase low double digit range second quarter earning call investor be expect focus company performance label expansion effort opdivo update business development activity earning whispersour proven model do not conclusively show bristol myer be likely beat earning estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen unfortunately be not case here elaborate zack esp earning esp bristol myer be most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank bristol myer currently carry zack rank increase predictive power esp however esp make unlikely stock beat earning quarter be caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock warrant lookhere be health care stock want consider model show have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report have earning esp carry zack rank company be schedule release result jul see complete list today zack rank stock here gilead science inc gild free report have earning esp carry zack rank company be schedule release result jul make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3594,GILD,hca healthcare inc hca free report be schedule report second quarter result jul market open last quarter hospital company post line result have however surpass earning estimate last quarters average positive surprise let see thing be shape announcement company commercial volume have be stress past few quarters have take effort build local network create greater patient access outpatient facility standpoint digital medium standpoint address issue however don expect see major improvement business second quarter last quarter company report consecutive quarter equivalent admission growth hca expect trend continue second quarter hca healthcare consistently make capital expenditure expansion service capacity large fast grow urban market incur regard expect invest company have also make number acquisition past many year expedite growth believe investment generate top line growth increase business volume share buy back company be report cushion bottom line company have not paid regular dividend ipo prefer share buyback dividend payment allocate capital maintain current policy dividend payout hca holding inc price ep surprise hca holding inc price ep surprise hca holding inc quoteearning whispersour proven model do not conclusively show hca healthcare be likely beat earning quarter be stock need have positive earning esp zack rank happen be not case here see zack esp hca holding have earning esp be most accurate estimate stand share zack consensus estimate uncover best stock buy sell re report earning esp filter zack rank hca holding carry zack rank hold increase predictive power esp however negative earning esp make surprise prediction difficult caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock warrant lookhere be company healthcare sector consider model show have right combination element post earning beat quarter gilead science inc gild free report be expect report second quarter earning result jul company have earning esp zack rank see complete list today zack rank strong buy stock here celgene corporation celg free report have earning esp zack rank company be expect report second quarter earning result jul pfizer inc pfe free report have earning esp zack rank company be expect report second quarter earning result aug make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3595,GILD,biotech major amgen inc amgn free report report second quarter result jul market close amgen deliver positive earning surprise last quarter amgen share be so far year compare favorably increase register industry period amgen performance have be pretty impressive company report positive surprise consistently average earning beat last quarters be let see thing be shape company quarter factor playamgen growth product prolium xgeva kyproli vectibix nplate sensipar be likely perform well new patient adoption repeat injection drive prolium sale xgeva be likely benefit superior clinical profile versus competition parsabiv etelcalcetide treatment secondary shpt be approve feb eu nov drug be likely bring revenue second quarter however company have challenge store give presence biosimilar competition slowdown sale mature product epogen neulasta neupogen sale be expect be hurt competition eu note neupogen sale be also be hurt biosimilar competition mainly zarxio sandoz novartis ag nvs free report generic arm biosimilar version neupogen be launch sep neupogen be expect face continue competitive pressure year exist potential biosimilar neulasta epogen start face biosimilar competition year biosimilar be launch second quarter meanwhile blockbuster drug enbrel be face increase competition rheumatology dermatology segment hurt sale volume growth recently launch product not be enough offset decline mature bottom line however benefit company overall cost cut effort share buyback company restructure plan make leaner more cost efficient investor focus remain performance company pcsk inhibitor repatha uptake repatha gain fda approval aug have not be very encourage so far due pricing re imbursement issue payer restriction phase iii cardiovascular outcome study fourier repatha have reveal significant reduction myocardial infarction stroke first quarter datum be key commercial success repatha broaden use drug datum study look good be not very clear payer be willing improve access repatha base datum amgen file regulatory application eu include fourier datum repatha label jun earning whispersour proven model do not conclusively show amgen be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be most accurate estimate stand zack consensus estimate be peg higher uncover best stock buy sell re report earning esp filter zack rank amgen zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision amgen inc price ep surprise amgen inc price ep surprise amgen inc quotestock considersome stock biom genetic sector have positive esp favorable zack rank be celgene corporation celg free report earning esp zack rank company be schedule release result jul schedule release result jul gilead science inc gild free report have earning esp zack rank see complete list today zack rank stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3596,GILD,astrazeneca plc azn free report announce faslodex have receive fda approval label extension first line monotherapy set treatment advanced breast cancer faslodex have be approve monotherapy treatment previously untreated post menopausal woman hormone receptor positive hr human epidermal growth factor receptor negative advanced breast cancer so far year astrazeneca share have moved compare unfavorably increase industry come back latest news fda approval be base datum phase iii falcon study falcon study evaluate tumor effect tolerability profile faslodex mg placebo comparison anastrozole mg placebo datum study show treatment faslodex lead reduction disease progression death versus anastrozole current standard care treatment note faslodex be currently approve unite state treatment postmenopausal woman estrogen receptor positive locally advanced metastatic breast cancer cancer have progressed follow estrogen therapy drug be also approve unite state combination pfizer inc pfe free report ibrance palbociclib treatment hr human epidermal growth factor receptor negative advanced metastatic breast cancer woman cancer have progressed endocrine therapy remind investor faslodex be approve same first line indication eu july japan june latest approval first line set be expect improve sale drug first half faslodex generate sale year year astrazeneca currently carry zack rank hold see complete list today zack rank strong buy stock here stock considersome better rank pharma biotech stock be gilead science inc gild free report regeneron pharmaceutical inc regn free report regeneron sport zack rank gilead carry zack rank buy regeneron share have moved year so far estimate have rise have go last day share gilead have rally so far year estimate have inched almost respectively last day more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3597,GILD,follow investment track oracle omaha see quest excellence pure play value investor gradually shift become garp growth reasonable price investor accord pick undervalue stock investor also need focus earning growth potential garp combine growth value investing principle offer mixed investing strategy have proven track record success garper look be stock be somewhat undervalue have solid sustainable growth potential investopedium here lie importance not so popular fundamental metric price earning growth peg ratio be categorize value investing strategy follow principle growth value investing peg ratio be defined price earning earning growth rateit relate stock ratio future earning growth rate alone only give idea stock be trading discount peg add growth element help find stock have solid future potential lower peg ratio preferably less be always better garp investor say example stock ratio be expect long term growth rate be company peg come ratio indicate undervaluation future growth potential unfortunately ratio be often neglected due investor limitation calculate future earning growth rate stock be drawback used peg ratio doesn consider very common situation change growth rate such forecast first year very high growth rate follow sustainable lower growth rate long term hence peg base investing turn be even more reward other relevant parameter be also take consideration here be screening criterium winning strategy peg ratio less industry medianp ratio used less industry median more accurate valuation purpose zack rank strong buy buy good market condition bad stock zack rank have proven history success market capitalization greater help focus company have strong liquidity average day volume greater substantial trading volume ensure stock be easily tradable percentage change earning estimate revision week greater upward estimate revision add optimism suggest further bullishness value score less equal research show stock style score combine zack rank hold offer best upside potential here be stock qualify screening coca cola femsa kof free report franchise bottler produce market distribute sell coca cola trademark beverage company offer portfolio product include sparkling beverage still beverage juice sport energy drink well tea water isotonic dairy product apart zack rank value style score stock also have impressive long term expect growth rate banco bilbao vizcaya argentarium bbva free report bbva compass rank top largest commercial bank base deposit market share rank largest bank alabama texas arizona stock also be impressive value investment pick zack rank value style score apart discount peg stock also have impressive long term expect growth rate lantheus holding inc lnth free report company develop manufacture commercialize diagnostic medical imaging agent product diagnosis treatment cardiovascular other disease worldwide apart zack rank value style score company also have impressive expect growth rate current fiscal gilead science inc gild free report company be focuse develop drug treatment human virus hiv liver disease such chronic hepatitis virus hcv infection chronic hepatitis virus hbv infection cardiovascular hematology oncology inflammation respiratory disease company hold zack rank have value style score also have impressive year historical growth rate lam research corporation lrcx free report be global supplier innovative wafer fabrication equipment service semiconductor industry apart zack rank value style score company also have impressive long term expect growth rate get rest stock list start putt other idea test be do research wizard stock pick backtesting software research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performance zack restaurant recommendation inaddition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
3598,GILD,not be good quarter israel base generic drug maker teva pharmaceutical industry limit teva free report teva miss second quarter earning revenue lower outlook company share be significantly follow release disappointing second quarter result year date ytd teva have lose value versus decline industry go wrong key reason teva dismal performance be generic pricing erosion sharp decline generic drug price blessing patient be prove be major challenge generic drugmaker well drug distributor second quarter call teva say ongoing consolidation customer have lead increase price erosion decrease volume consolidation industry have increase ability negotiate lower price generic drug teva say finalization price volume inline product largest customer claris other new contract have greater expect negative impact second quarter result outlook rest year moreover fda be speeding approval generic drug mean more competition increase price cut decrease volume teva say price erosion be second quarter be expect increase high single digit remainder year headwind persist generic unit future result lower revenue profit segment potentially meanwhile company say do not expect earning contribution business venezuela give significant devaluation venezuelan currency teva also cut dividend be risk breach covenant cash flow be hit lower expect proceed potential divestment be delay early also read teva plunge year low credit rating jeopardy zack rank estimate revisionsteva be zack rank strong sell stock company report disappointing result lower outlook teva have see zack consensus estimate current year earning be revise downward last day zack consensus estimate earning be revise downward last day teva have many challenge ahead pay debt divest core business increase focus core area generate cash hire permanent ceo deliver pipeline get generic business back track teva deal challenge here be look drug company sport strong zack rank look well position alexion pharmaceutical inc alxn free report new haven ct base alexion report beat raise quarter flagship product soliris eculizumab continue perform well alexion be work expand soliris label have key catalyst come decision fda expect oct regard approvability soliris refractory generalized myasthenia gravis gmg meanwhile decision eu positive chmp opinion be receive be also expect third quarter alexion have rough share fall look set recover lose ground share increase so far outperform rally industry belong company new management team be focuse alexion expertise area complement biology core therapeutic area hematology nephrology neurology metabolic disorder alexion be work grow rare disease business zack rank strong buy stock alexion have see zack consensus estimate current year earning be revise upward last day estimate earning growth current year be regeneron pharmaceutical inc regn free report regeneron key focus area include eye disease heart disease allergic inflammatory disease pain cancer infectious disease rare disease eye drug eylea company key growth driver continue perform well regeneron have be work diversify portfolio gain fda approval drug year dupixent moderate severe atopic dermatitis kevzara moderately severely active rheumatoid arthritis drug have blockbuster potential company also have strong pipeline comprise candidate include cancer have key datum readout line second half year regeneron have see zack consensus estimate current year earning be revise upward last day regeneron zack rank stock have gain year date substantially outperform rally industry belong estimate earning growth current year be sanofi sny free report french pharmaceutical giant sanofi have strong presence several market include diabetes cardiovascular rare disorder vaccine consumer healthcare company raise earning outlook constant exchange rate cer follow release second quarter result sanofi have record decline share price last year have gain year date outperform rally industry belong sanofi have see zack consensus estimate current year earning be revise upward last day company diabetes segment remain pressure new product approval sale ramp recently launch product provide support sanofi be zack rank buy stock company also have vgm style score vgm style score be useful tool allow investor gain insight stock strength weakness research show stock vgm style score combine zack rank offer best upside potential see complete list today zack rank stock here gilead science inc gild free report biotech company gilead also report better expect result second quarter hepatitis virus hcv business do better expect company hiv franchise also continue do well gilead raise outlook year gilead have see zack consensus estimate current year earning be revise upward last day gilead be zack rank stock vgm style score make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3599,GILD,equity market remain relatively skittish last few day range geopolitical issue take center stage include constant conflict north korea regard nuclear arsenal prolong standoff china india sovereignty sublime tension continue raise element caution investor be lookout cash cow stock offer high return however single cash rich stock alone do not make solid investment proposition be backed attractive efficiency ratio return equity roe high roe ensure company be reinvest cash high rate return roe roe net income shareholder equityroe help investor distinguish profit generate company profit burner be useful determine financial health company other word financial metric enable investor identify stock diligently deploy cash higher return moreover roe be often used compare profitability company other firm industry higher better measure well company be increase profit investing new equity capital business portray management efficiency reward shareholder attractive risk adjust return parameter used screeningin order shortlist stock be cash rich high roe have add cash flow greater roe greater industry primary screening parameter addition have take few other criterium consideration arrive winning strategy price cash flow less industry metric measure much investor pay dollar free cash flow lower ratio indicate investor need pay less better cash flow generate stock return asset roa greater industry metric determine much profit company earn dollar asset include cash account receivable property equipment inventory furniture higher roa better be company year ep historical growth greater industry criterion indicate continue earning momentum have translate solid cash strength zack rank less equal zack rank strong buy buy stock be know outperform irrespective market environment here be stock qualify screen broadcom limit avgo free report broadcom be premier designer developer global supplier broad range semiconductor device focus complex digital mixed signal complementary metal oxide semiconductor base device analog iii base product company have trail quarter average earning surprise long term earning growth expectation broadcom carry zack rank cbre group inc headquarter los angele cbre group be commercial real estate service investment firm offer wide range service tenant owner lender investor office retail industrial multus family other type commercial real estate major metropolitan area globe company have trail quarter average earning surprise long term earning growth expectation cbre group sport zack rank see complete list today zack rank stock here sandvik ab sdvky free report headquarter stockholm sweden sandvik operate high tech global engineering firm field rock excavation metal cut material technology company have zack rank value growth momentum score vgm score apply material inc amat free report headquarter santa clara apply material offer manufacturing equipment service software semiconductor display related industry worldwide zack rank stock have modest trail quarter average earning surprise long term earning growth projection gilead science inc gild free report headquarter foster city gilead science be company focuse develop drug treatment human virus hiv liver disease such chronic hepatitis virus hcv infection chronic hepatitis virus hbv infection cardiovascular hematology oncology inflammation respiratory disease zack rank stock have modest trail quarter average earning surprise get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performance zack restaurant recommendation inaddition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
3600,GILD,issue update report endo international plc endp free report aug endo global specialty pharmaceutical company focuse brand generic pharmaceutical be form follow acquisition paladin lab revenue generic base business be significant pressure due intensify consortium pricing pressure additional competitive entrant product discontinuation well discrete factor include destock shift purchase timing due market condition revenue segment be project decline high single low double digit percentage range due base business sale decline partially offset revenue growth sterile injectable new launch alternative dosage be partially offset growth sterile injectable new launch revenue respectively endo brand segment continue be pressure due additional competitive entrant well continuous rise number public policy regulatory action include recent cdc guideline related opioid prescribe use divestiture strenda major setback endo withdraw opioid pain medication opana oxymorphone hydrochloride extend release market follow fda request june march fda drug safety risk management anesthetic analgesic drug product advisory committee vote ratio consent reformulate opana do not outweigh public health risk few member state benefit be now overshadowed continue public health concern product misuse abuse diversion june fda direct company remove drug market move come wake widespread opioid abuse epidemic drug represent total revenue international revenue be expect decline mid low range reflect divestiture litha somar meanwhile endo stock have decline year so far compare industry gain same period company lower be revenue guidance range now expect revenue range be guidance be lower due withdrawal opana discontinuation product associate recently announce manufacturing restructure zack rank key picksendo currently carry zack rank strong sell better rank stock healthcare sector include regeneron pharmaceutical inc regn free report gilead science inc gild free report aduro biotech inc adro free report regeneron sport zack rank gilead science aduro carry zack rank buy see complete list today zack rank stock here regeneron earning share estimate have increase last day company deliver positive earning surprise trail quarters average beat gilead earning share estimate increase last day company deliver positive earning surprise trail quarters average beat aduro biotech loss share estimate narrow last day company deliver positive surprise trail quarters average beat surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
3601,GILD,novartis ag nvs free report announce european commission ec have approve breast cancer drug kisqali ribociclib ec approve drug combination inhibitor treatment postmenopausal woman hormone receptor positive human epidermal growth factor receptor negative hr locally advanced metastatic breast cancer initial endocrine base therapy remind investor kisqali be first cdk inhibitor approve europe approval be card committee medicinal product human use chmp european medicine agency ema give positive opinion june march fda also approve kisqali combination inhibitor treatment metastatic breast cancer drug combination letrozole be add national comprehensive cancer network clinical practice guideline oncology nccn guideline category option hr postmenopausal metastatic breast cancer patient novartis stock have rally year so far compare industry gain novartis have strong oncology portfolio drug afinitor exjade jakavi zykadia tasigna jadenu improve formulation exjade company be make significant progress immuno oncology pipeline fda oncologic drug advisory committee have unanimously recommend approval novartis immunocellular therapy candidate ctl treatment relapse refractory pediatric young adult patient cell acute lymphoblastic leukemia provide major boost novartis ctl become first car cell therapy approve potential approval also open new frontier treatment cancer advance immunocellular therapy child young adult cell note roche hold ag rhhby free report be lead company breast cancer drug strong portfolio drug herceptin perjeta kadcyla zack rank key picksnovartis currently carry zack rank hold better rank stock healthcare sector include gilead science inc gild free report aduro biotech inc adro free report stock carry zack rank buy see complete list today zack rank strong buy stock here gilead earning share estimate increase last day company deliver positive earning surprise trail quarters average beat aduro biotech loss share estimate narrow last day company deliver positive surprise trail quarters average beat surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
3602,GILD,alexion pharmaceutical inc alxn free report be schedule report second quarter result jul open bell last report quarter alexion earning surpass zack consensus estimate alexion track record be excellent company have consistently beaten expectation last quarters average positive earning surprise trail quarters let see thing be shape announcement look alexion share price movement year date show stock have underperform zack classify medical biomedical genetic industry company share have gain industry witness addition same period factor likely impact resultsalexion continue identify treat consistently high number new patient paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus soliris country operate platform order further increase commercial potential drug alexion be work expand soliris label additional indication label expansion additional indication give soliris access higher patient population increase commercial potential drug significantly additionally company be work launch strensiq kanuma strensiq continue perform well revenue benefit grow number patient child well adult pediatric onset disease owing hpp disease awareness diagnostic initiative initiative be lead steady identification new patient hpp fact company expect strensiq be additional growth driver alexion be also look achieve annual cost synergy be expect touch least meanwhile alexion continue progress country funding process product additional country eu year notably company effort develop pipeline be impressive particularly case alxn currently be evaluate alxn longer act antibody inhibit terminal complement phase iii study pnh ahus additionally company be conduct phase study new formulation alxn administer subcutaneously healthy volunteer alexion plan initiate phase iii pnh switch study alxn administer intravenously week compare patient currently treat soliris therefore expect investor focus update alxn successful development drug boost growth prospect however soliris accounting majority revenue alexion company rely heavily drug growth go forward soliris par performance hurt stock severly be consider be alexion key growth driver be be note drug be already witness challenge latin america also soliris quarter quarter revenue growth be impact enrollment ramp trial alxn particularly second half soliris revenue be expect be second quarter do zack model unveil proven model show alexion be likely beat earning be report quarter have right combination key ingredient positive earning esp zack rank strong buy buy hold have significantly higher chance beating earning zack esp alexion have earning esp most accurate estimate be zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank alexion carry zack rank combine positive esp make reasonably confident earning beat note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision alexion pharmaceutical inc price consensus alexion pharmaceutical inc price consensus alexion pharmaceutical inc quotestock warrant lookhere be pharma stock want consider model show right combination element post earning beat inc agen free report have earning esp zack rank company be expect release result jul see complete list today zack rank stock here gilead science inc gild free report have earning esp zack rank company be schedule release result jul intercept pharmaceutical inc icpt free report have earning esp zack rank company be expect release result aug top pick ride hottest tech trend zack just release special report guide space have already begin transform entire economy last year be generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money make right trade early download report top tech stock
3603,GILD,gilead science inc gild free report be schedule report second quarter result jul market close last quarter company beat expectation gilead science inc price ep surprise gilead science inc price ep surprise gilead science inc quotegilead track record be pretty mixed company beating estimate last miss other overall company record average positive earning surprise share gilead have moved year so far underperform zack classify medical biomedical genetic industry gain let see thing be shape biotech major announcement earning whispersour proven model show gilead be likely beat earning estimate quarter be have right combination key ingredient positive earning esp zack rank strong buy buy hold zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate be zack consensus estimate be peg lower uncover best stock buy sell re report earning esp filter zack rank gilead currently carry zack rank combination zack rank positive esp make confident earning beat conversely sell rate stock zack rank never be consider go earning announcement especially company be see negative estimate revision factor playconcurrent first quarter earning call gilead reiterate guidance annual guidance gilead expect net product sale range hcv product sale be project hcv product sale be project strong performance hiv other antiviral product sale drive continue uptake tenofovir alafenamide taf base product genvoya descovy odefsey continue boost sale expect trend continue second quarter well genvoya have already become most prescribe regimen treatment naïve switch patient launch end first quarter taf base regimen make gilead hiv prescription volume treatment market strong uptake truvada use pre exposure prophylaxis set be also expect boost sale however gilead lose exclusivity viread country outside impact sale however hcv franchise continue be competitive pricing pressure lead massive decline harvoni sovaldi sale harvoni sovaldi have be face competition abbvie abbv free report viekira pak viekira xr other higher discount payer mix continue impact sale adversely total hcv treatment start be estimate approximately less company expect further decline patient start positive note hcv portfolio receive major boost epclusa gain approval become first only oral pan genotypic str consist sovaldi velpatasvir ns inhibitor treatment adult genotype chronic hcv infection initial uptake epclusa have be encourage formulary reviews be track recently approve hbv drug vemlidy be also expect start contribute top line fda recently approve vosevi sovaldi velpatasvir mg voxilaprevir mg tablet single tablet regimen str re treatment chronic hepatitis virus hcv infection adult genotype previously treat ns inhibitor contain regimen genotype previously treat sovaldi contain regimen ns inhibitor second quarter call investor be likely keep eye gilead performance pipeline update also be keenly await focus also be performance epclusa taf base regimen other stock poise beat estimateshere be other health care stock want consider model show too have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report have earning esp zack rank company be schedule release result jul see complete list today zack rank stock here alexion pharmaceutical inc alxn free report have earning esp zack rank company be schedule release result jul top pick ride hottest tech trendzack just release special report guide space have already begin transform entire economy last year be generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money make right trade early download report top tech stock
3604,GILD,gilead science inc gild free report announce fda have approve vosevi sovaldi velpatasvir mg voxilaprevir mg tablet drug be single tablet regimen str re treatment chronic hepatitis virus hcv infection adult genotype previously treat ns inhibitor contain regimen genotype previously treat sovaldi contain regimen ns inhibitor approval come back positive datum phase iii study polaris polaris study study evaluate week vosevi direct act antiviral experience chronic hcv infected patient cirrhosis compensate cirrhosis however vosevi have be warn product label regard risk hepatitis virus hbv reactivation hcv hbv co infected patient nevertheless approval make vosevi first once daily str available salvage therapy patient infected hcv genotype have fail prior treatment daa regimen include ns inhibitor approval be expect boost gilead strong hcv portfolio gilead have strong presence hcv market due blockbuster hcv drug sovaldi harvoni sovaldi continue be very important product company harvoni label have be expand twice approval be now approve use broader range patient population hcv portfolio get huge boost epclusa gain approval jun eu jul become first only oral pan genotypic str consist sovaldi velpatasvir ns inhibitor treatment adult genotype chronic hcv infection initial uptake epclusa have be encourage formulary reviews be track gilead expect launch epclusa other large eu market once pricing reimbursement be place second half boost sale further last month committee medicinal product human use chmp adopt positive opinion company marketing authorization application maa vosevi follow accelerate assessment procedure gilead hcv franchise be pressure due intense competition pricing issue hcv product sale be weaker expect mainly due fewer new patient start harvoni lower revenue patient harvoni sovaldi epclusa have be face competition abbvie abbv free report viekira pak viekira xr bristol myer bmy free report daklinza johnson johnson jnj free report olysio company expect persistent decline hcv patient start be primary factor year year decrease revenue increase competition impact patient share pricing share gilead have underperform zack classify medical biomedical genetic industry year so far stock lose period industry gain nevertheless hiv franchise gilead be perform well be expect help company combat persistent decline hcv franchise zack rank gilead currently carry zack rank hold see complete list today zack rank stock here look stock skyrocket upsizack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3605,GILD,alnylam pharmaceutical inc alny free report report loss share second quarter narrower zack consensus estimate loss wider year loss alnylam pharmaceutical inc price ep surprise alnylam pharmaceutical inc price ep surprise alnylam pharmaceutical inc quotequarterly revenue rise however revenue miss zack consensus estimate revenue quarter include earn company collaboration agreement sanofi sny free report subsidiary genzyme well company alliance medicine company mdco free report alnylam stock have increase year date zack classify industry gain quarter detailresearch development expense fall year period however general administrative expense more double guidancealnylam expect cash cash equivalent marketable security include restrict investment be greater end year pipeline company be make steady progress pipeline company be evaluate patisiran investigational rnai therapeutic treatment patient hereditary attr hattr amyloidosis polyneuropathy top line datum phase iii study apollo be expect shortly assume positive datum study finding support company first nda filing expect year end company initiate phase iii study atla evaluate safety efficacy fitusiran patient hemophilia inhibitor company expect initiate phase iii study yearend givosiran acute hepatic porphyria collaboration medicine company company also advanced givosiran investigational rnai therapeutic treatment acute hepatic porphyria company present positive new datum international congress porphyrin ongoing randomize double blind placebo controlled phase study recurrent attack porphyrium patient well positive initial result ongoing phase ole study fda grant breakthrough therapy designation candidate fda givosiran prophylaxis attack patient acute hepatic porphyrium takealnylam second quarter result be mixed company report narrower expect loss sale miss estimate several pipeline related event line upcoming quarters expect investor focus remain further update company zack rank key picksalnylam carry zack rank hold better rank stock healthcare sector be gilead science inc gild free report currently carry zack rank buy see complete list today zack rank strong buy stock here gilead earning share estimate increase last day follow strong result second quarter company deliver positive earning surprise trail quarters average beat share price company have increase year date simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
3606,GILD,key highlight week include impressive datum vertex vrtx free report cystic fibrosis cf pipeline company gilead gild free report puma pbyi free report get fda approval hepatitis virus hcv breast cancer treatment respectively recap week most important storiesvertex cf datum impress vertex get major boost positive datum different triple combination regimen person cystic fibrosis cf have del mutation minimal function mutation del min be first datum show potential treat underlie cause cf patient have severe difficult treat type disease company be look start pivotal program first half vertex share be significantly pre market trading crl amgen ucb osteoporosis drug amgen amgn free report partner ucb get complete response letter crl fda evenity romosozumab investigational treatment postmenopausal woman osteoporosis however crl doesn come surprise consider emergence new safety signal late stage study arch evenity meet primary endpoint key secondary endpoint study company say imbalance positively adjudicate cardiovascular serious adverse event be observed fda have ask company include datum arch study resubmission well datum bridge study man osteoporosis read more amgen get crl osteoporosis drug evenity bla amgen be zack rank hold stock see complete list today zack rank strong buy stock here fda nod gilead hcv drug gilead have add drug hepatitis virus hcv portfolio fda grant approval vosevi single tablet regimen re treatment adult chronic hcv vosevi provide physician new therapeutic option hardest treat patient however vosevi come box warning regard risk hepatitis virus hbv reactivation hcv hbv co infected patient limit uptake gilead hcv franchise be major revenue generator be considerable strain due new competition pricing pressure company have underperform zack categorize medical biomedical genetic industry so far share gain industry be puma fda approval nerlynx puma gain fda approval breast cancer treatment nerlynx neratinib have blockbuster potential nerlynx first approve drug puma portfolio be indicated extend adjuvant treatment early stage breast cancer aggressive type tumor mean nerlynx be take initial treatment so risk cancer come back be reduce further nerlynx approval be line expectation consider favorable advisory panel vote earlier year puma share be news year date ytd puma share be whopping sarepta biomarin settle patent dispute sarepta srpt free report biomarin settle patent dispute regard use sarepta exondys future exon skip product treatment duchenne muscular dystrophy dmd company sign licensing agreement provide sarepta global exclusive right biomarin dmd patent estate exondys future exon skip product biomarin have option convert license co exclusive right decide proceed exon skip therapy dmd term deal include time payment sarepta well certain milestone base payment royalty sarepta share be biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index be last trading session major biotech stock biogen biib free report be almost last month vertex be alexion alxn free report be see last biotech stock roundup here arena shoot study datum celg inks immuno oncology deal next biotech world watch earning report company biogen sarepta look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3607,GILD,roche hold ag rhhby free report announce fda have accept company biologic license application bla grant priority review hemophilia candidate emicizumab fda have grant emicizumab prophylaxis preventative priority review once weekly subcutaneous treatment adult adolescent child hemophilia factor viii inhibitor priority review designation fda be generally grant drug have potential provide significant improvement safety effectiveness treatment prevention diagnosis serious disease bla emicizumab be base result phase iii study haven adult adolescent year older well interim result phase iii study haven study child younger year age note result haven be publish new england journal medicine nejm result study be present international society thrombosis haemostasis isth congress july fda be expect give decision feb remind investor fda grant breakthrough therapy designation emicizumab adult adolescent haemophilium inhibitor september meanwhile roche be evaluate emicizumab patient hemophilia inhibitor evaluate less frequent dose regimen well roche stock have lose so far industry gain emicizumab roche hematology portfolio present consist mabthera rituxan gazyva gazyvaro venclextatm venclyxtotm collaboration abbvie inc abbv free report pipeline have small molecule antagonist mdm idasanutlin rg polatuzumab vedotin few other company be also develop treatment hemophilia shire plc shpg free report also file investigational new drug ind application fda seek approval recombinant factor viii fviii gene therapy candidate shp drug be used treatment patient hemophilia zack rank stock considerroche currently carry zack rank hold better rank stock health care sector be gilead science inc gild free report carry zack rank buy see complete list today zack rank strong buy stock here gilead earning share estimate increase last day company deliver positive earning surprise trail quarters average beat simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
3608,GILD,pfizer inc pfe free report international cancer research group be collaborate combination study explore use ibrance first line treatment advanced breast cancer patina phase iii study evaluate ibrance cdk inhibitor combination therapy endocrine therapy versus standard therapy first line treatment hr metastatic breast cancer first patient study be randomize last month patient be expect be recruit worldwide study ibrance be presently market treatment hr disease combination inhibitor initial endocrine base therapy postmenopausal woman astrazeneca plc azn free report faslodex fulvestrant woman disease have progressed follow endocrine therapy drug be presently not approve use hr patient population pfizer share have underperform industry year so far pfizer share be period compare unfavorably increase industry ibrance play instrumental role drive pfizer revenue drug record sale first half year year pfizer be also explore possibility expand label breast cancer drug ibrance recurrent subsequent early breast cancer well several breast cancer indication pancreatic head neck cancer meanwhile pfizer boast strong oncology pipeline key cancer candidate bavencio avelumab get fda approval metastatic merkel cell carcinoma mcc mar advanced bladder cancer bavencio be review eu mcc decision expect third quarter bavencio be be tout significant top line driver new york base pharma giant cancer drug besponsa inotuzumab ozogamicin receive fda approval earlier month monotherapy treatment relapse refractory cd positive cell precursor acute lymphoblastic leukemia drug be approve eu last month meanwhile other cancer candidate include talazoparib advanced breast cancer dacomitinib advanced lung cancer egfr activate mutation conference call pfizer have mentioned approximately drug approval be expect next year include product have blockbuster potential pfizer carry zack rank hold see complete list today zack rank strong buy stock here stock considerbetter rank pharma biotech stock include gilead science inc gild free report regeneron pharmaceutical inc regn free report regeneron sport zack rank gilead have zack rank buy regeneron share year so far estimate have rise have go past day share gilead have rise so far year estimate have rise almost respectively past day surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
3609,GILD,gilead science inc gild free report announce company marketing authorization application maa once daily single tablet regimen contain bictegravir mg bic emtricitabine tenofovir alafenamide mg ftc taf treatment hiv infection adult have be fully validate european medicine agency ema currently application be review ema regimen be novel experimental integrase strand transfer inhibitor be be evaluate treatment hiv infection adult share gilead have underperform zack classify medical biomedical genetic industry last year stock lose period industry gain maa bic ftc taf be base datum phase iii study regimen meet primary objective inferiority week ongoing study be design explore efficacy safety bic ftc taf compare triple therapy regimen contain glaxosmithkline gsk free report tivicay dolutegravir mg dtg treatment naïve patient virologically suppress patient switch exist antiretroviral regimen datum study show bic ftc taf demonstrated high rate virologic suppression treatment emergent resistance week fourth study be be conduct virologically suppress patient compare switch bic ftc taf versus suppressive regimen nucleoside nucleotide reverse transcriptase inhibitor boost protease inhibitor additionally gilead submit new drug application nda bic ftc taf jun company present week datum phase iii study evaluate bic ftc taf compare regimen contain tivicay mg dtg treatment naïve adult patient international aids society conference hiv science ias july paris note gilead be dominant player hiv market impressive portfolio newly launch taf base product genvoya odefsey descovy be perform well strong adoption eu genvoya have already become most prescribe regimen treatment naïve switch patient launch nov uptake hiv franchise help company combat persistent decline hcv franchise due competitive pressure competition well pricing pressure have intensified further launch merck mrk free report zepatier gilead science inc price consensus gilead science inc price consensus gilead science inc quotezack rank key pickgilead currently carry zack rank hold better rank health care stock same space be enzo inc sport zack rank strong buy see complete list today zack rank stock here enzo loss share estimate narrow cent cent cent cent last day company deliver positive earning surprise trail quarters average beat share price company have increase year date more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3610,GILD,share valeant pharmaceutical inc vrx free report surge company announce be target debt reduction plan valeant stock lose industry gain company adjust earning share beat zack consensus estimate cent however total revenue come roughly line zack consensus estimate decline year quarter year year decline be due lower volume price diversify product segment result loss exclusivity number product dermatology business valeant pharmaceutical international inc price ep surprise valeant pharmaceutical international inc price ep surprise valeant pharmaceutical international inc quotequarter detailrevenue bausch lomb international segment be year year due impact divestiture exclude impact skincare divestiture foreign exchange bausch lomb international segment organically grow approximately brand rx segment revenue be due lower volume dermatology business impact divestiture discontinuation salix business be partially offset revenue growth salix business diversify product segment revenue be year year due decrease volume price attribute previously report loss exclusivity basket product research development expense be report quarter year quarter selling general administrative cost be compare year quarter quarter company complete sale dendreon pharmaceutical llc used net proceed pay senior secure term loan valeant also redeem remain aggregate principal amount outstanding senior note due company have also decide sell inova pharmaceutical obagi medical product business cash respectively close second half positive note company receive fda filing acceptance nda plenvu ner novel low volume polyethylene glycol base bowel preparation colonoscopy earlier fda approve new psoriasis treatment siliq company have agreement astrazeneca plc azn free report siliq agreement have be amend guidance company expect total revenue range project earlier update guidance reflect impact sale cerave acnefree ambi skincare brand sale dendreon pharmaceutical llc however guidance do not reflect impact sale inova pharmaceutical obagi medical product business be expect close second half year second quarter result be encourage company trim guidance due recent divestiture company expect meet target debt reduction ahead schedule bausch lomb international segment salix business together represent revenue quarter tumultuous period valeant start rebuild process new ceo joseph papa even be still early comment rebuild process company effort sell core asset pay huge level debt be commendable bode well upcoming quarters company still have debt jun zack rank key picksvaleant currently carry zack rank hold better rank stock health care sector be aduro biotech inc adro free report gilead science inc gild free report stock carry zack rank buy see complete list today zack rank strong buy stock here aduro biotech loss share estimate narrow last day company deliver positive earning surprise trail quarters average beat gilead earning share estimate increase last day follow strong result second quarter company deliver positive earning surprise trail quarters average beat
3611,GILD,mylan myl free report report disappointing second quarter result earning sale miss estimate company also lower guidance share be trading due dismal result mylan stock fall year date compare industry decline company report earning share miss zack consensus estimate be report year quarter second quarter revenue miss zack consensus estimate nevertheless top line record year year growth back acquisition mylan price ep surprise mylan price ep surprise mylan quotequarter company report result segment geographic basis north america europe rest world north america segment third party net sale come due decline sale exist product result lower volume pricing more offset acquisition meda ab sterile topical focuse business renaissance acquisition holding llc sale epipen auto injector decline current quarter due increase competition impact authorize generic launch generic product experience price erosion mid single digit third party net sale europe be propel acquisition meda be partially offset lower volume exist product unfavorable foreign currency translation have impact europe rest world segment third party net sale be fuel meda acquisition moreover net sale exist product increase due higher sale retroviral franchise sale new product higher volume exist product more offset lower pricing foreign currency translation have favorable impact adjust gross margin decline year quarter due lower gross profit sale exist product north america include epipen auto injector partially offset contribution acquire business outlook loweredmylan now expect revenue earlier projection company now project earning range previous project range guidance be lower result expect delay timing certain key new product launch ongoing challenge uncertain regulatory environment region have lead company defer major launch guidance include generic advair generic copaxone pricing generic be expect decline mid single digit globally high single digit erosion expect north america takemylan second quarter result be dismal company miss earning sale estimate due challenge north america pricing continue impact result company project mid single digit price erosion globally decrease guidance be also disappointing company recently suffer few setback mylan receive complete response letter fda regard abbreviated new drug application anda generic version glaxosmithkline plc gsk free report asthma drug advair diskus positive note fda oncologic drug advisory committee recently unanimously recommend approval mylan biosimilar version roche hold ag rhhby free report breast cancer drug herceptin zack rank key pickmylan currently carry zack rank sell better rank stock health care sector be gilead science inc gild free report carriesa zack rank buy see complete list today zack rank strong buy stock here gilead earning share estimate increase last day follow strong result second quarter company deliver positive earning surprise trail quarters average beat more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
3612,GILD,prothena corporation plc prta free report report loss cent share second quarter narrower year loss zack consensus estimate loss cent prothena corporation plc price ep surprise prothena corporation plc price ep surprise prothena corporation plc quotemoreover quarterly revenue come surpass zack consensus estimate be year quarter prothena stock have moved year so far compare industry gain quarter increase revenue be primarily due achievement clinical milestone roche hold ag rhhby free report be recognize collaboration revenue be recognize offset research development expense expense be year year primarily due higher clinical trial personnel cost offset part lower external expense product manufacturing general administrative expense be year year due higher personnel cost outlookprothena expect net cash operate investing activity range project range include milestone roche earn second quarter initiation phase ii study prx company expect end approximately cash cash equivalent restrict cash midpoint pipeline updatesprothena continue progress pipeline candidate company be evaluate lead candidate neod phase iii vital amyloidosis study newly diagnosed treatment naïve patient al amyloidosis cardiac dysfunction enrolment be complete vital study original target enrolment patient be exceed patient have be randomize study prothena be also evaluate candidate phase iib study pronto previously treat patient al amyloidosis persistent cardiac dysfunction company complete enrolment study top line result study be expect follow month study period second quarter moreover prothena be evaluate prx collaboration roche treatment parkinson disease other related synucleinopathy company initiate phase ii study pasadena prx patient suffering parkinson disease trigger milestone payment roche prothena company expect report top line datum phase ib multiple ascend dose proof biology study prx patient psoriasis oct prothena be also work advance prx phase study patient attr amyloidosis candidate be expect enter clinic mid narrower expect loss second quarter be encourage company effort develop pipeline be encourage expect investor focus remain further update late stage candidate neod zack rank key picksprothena currently carry zack rank hold better rank stock health care sector be aduro biotech inc adro free report gilead science inc gild free report stock carry zack rank buy see complete list today zack rank strong buy stock here aduro biotech loss share estimate narrow last day company deliver positive earning surprise trail quarters average beat gilead earning share estimate increase last day follow strong result second quarter company deliver positive earning surprise trail quarters average beat more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
3613,GILD,glaxosmithkline plc gsk free report enjoy diversify base presence different geographical area glaxosmithkline reshape business follow mar completion part conditional transaction novartis ag nvs free report deal glaxo sell oncology asset novartis acquire novartis vaccine business exclude influenza vaccine follow completion deal glaxo now intend focus core business pharmaceutical vaccine consumer healthcare pharmaceutical vaccine business unit brentford unite kingdom base pharma consumer giant have perform significantly well trend be likely continue second half year importantly new product tivicay triumeq hiv relvar breo anoro incruse nucala respiratory menveo bexsero meningitis vaccine be do well continue perform well boost revenue significantly new product generate glaxo pharmaceutical vaccine sale first half go ahead glaxo expect new pharmaceutical vaccine product include contribution yet be approve shingrix deliver sale annum glaxo be also work expand label market product nucala success new product glaxo believe overall performance have be weaker have like due slow start miss launch insufficient progress stiff competition genericization key drug pricing pressure slow growth emerge market particular pricing dynamic competitive pressure be hurt sale top selling drug advair meanwhile advair be expect face generic competition unite state next year further hurt sale glaxo share have underperform industry year so far glaxo share be period compare unfavorably increase industry improve performance second quarter conference call hold last month glaxo layer plan overhaul effort new ceo emma walmsley discuss plan reallocate spending high priority area company plan terminate partner divest pre clinical clinical program allocate capital priority program current area respiratory hiv infectious potential area oncology immuno inflammation glaxo promising pipeline candidate present late stage development regulatory review include shingrix prevention shingle regulatory application file eu close triple therapy copd regulatory application file eu asthma phase iii drug dolutegravir rilpivirine regimen hiv infection review eu dolutegravir lamivudine hiv infection phase iii cabotegravir hiv prevention monotherapy phase iii hiv infection drug regimen rilpivirine phase iii glaxo announce renew cost saving initiative intend focus new business priority improve supply chain efficiency simplify operation improve procurement saving reduce administrative cost company extend cost reduction initiative be expect lead additional annual cost saving cost save be invest support new product launch strengthen pipeline help mitigate pricing pressure margin glaxo carry zack rank hold see complete list today zack rank strong buy stock here stock considerbetter rank stock include gilead science inc gild free report regeneron pharmaceutical inc regn free report regeneron sport zack rank strong buy gilead have zack rank buy regeneron share be year so far estimate have rise have go past day share gilead have rise so far year estimate have rise almost respectively past day surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
3614,GILD,gilead science inc gild free report announce company marketing authorization application maa once daily single tablet regimen contain bictegravir mg bic emtricitabine tenofovir alafenamide mg ftc taf treatment hiv infection adult have be fully validate european medicine agency ema currently application be review ema regimen be novel experimental integrase strand transfer inhibitor be be evaluate treatment hiv infection adult share gilead have underperform zack classify medical biomedical genetic industry last year stock lose period industry gain maa bic ftc taf be base datum phase iii study regimen meet primary objective inferiority week ongoing study be design explore efficacy safety bic ftc taf compare triple therapy regimen contain glaxosmithkline gsk free report tivicay dolutegravir mg dtg treatment naïve patient virologically suppress patient switch exist antiretroviral regimen datum study show bic ftc taf demonstrated high rate virologic suppression treatment emergent resistance week fourth study be be conduct virologically suppress patient compare switch bic ftc taf versus suppressive regimen nucleoside nucleotide reverse transcriptase inhibitor boost protease inhibitor additionally gilead submit new drug application nda bic ftc taf jun company present week datum phase iii study evaluate bic ftc taf compare regimen contain tivicay mg dtg treatment naïve adult patient international aids society conference hiv science ias july paris note gilead be dominant player hiv market impressive portfolio newly launch taf base product genvoya odefsey descovy be perform well strong adoption eu genvoya have already become most prescribe regimen treatment naïve switch patient launch nov uptake hiv franchise help company combat persistent decline hcv franchise due competitive pressure competition well pricing pressure have intensified further launch merck mrk free report zepatier gilead science inc price consensus gilead science inc price consensus gilead science inc quotezack rank key pickgilead currently carry zack rank hold better rank health care stock same space be enzo inc sport zack rank strong buy see complete list today zack rank stock here enzo loss share estimate narrow cent cent cent cent last day company deliver positive earning surprise trail quarters average beat share price company have increase year date more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3615,GILD,second quarter earning season be near last leg picture so far appear be quite encourage few turbulent quarters earning second quarter show solid strength aug approximately company index total market capitalization have report result deep look result show earning company report be year year higher revenue have top earning estimate have beat revenue estimate result blended beat growth second quarter come back strong contribution finance technology energy sector growth be expect persist second half well even pace growth have be sluggish total earning index be currently same period last year higher revenue much better earning growth project start quarter go forward estimate growth be project start july do medical sector perform medical sector have more less combat overall decline financial market maintain momentum so far company sector have report result earning be higher revenue result blended beat industry bellwether johnson johnson jnj free report report mixed second quarter result beating earning miss sale estimate biotech giant gilead science gild free report biogen inc surpass expectation earning sale second quarter raise annual guidance let take look pharma biotech company be set report second quarter result aug acadium pharmaceutical inc acad free report be schedule report close bell company have dismal track record acadium have miss estimate trail quarters beat once report line result remain quarter result average negative surprise currently company have zack rank hold earning esp current rank increase predictive power esp esp make unlikely stock beat estimate quarter uncover best stock buy sell re report earning esp filter fda approval nuplazid apr be major boost company drug be approve treatment hallucination delusion associate parkinson disease psychosis drug have show promising growth launch read more acadium pull surprise earning season acadium pharmaceutical inc price ep surprise acadium pharmaceutical inc price ep surprise acadium pharmaceutical inc quotejazz pharmaceutical public limit company jazz free report be schedule report result close bell jazz have encourage earning track record company have top estimate last quarters average positive earning surprise currently company have zack rank earning esp investor focus be performance jazz lead product xyrem cataplexy excessive daytime sleepiness investor also be look company pipeline progress defitelio sale ramp xyrem face issue related patent litigation company business development plan be also expect draw attention read more jazz pharma spring surprise earning jazz pharmaceutical plc price ep surprise jazz pharmaceutical plc price ep surprise jazz pharmaceutical plc quotekite pharma inc be expect report result market open company have mixed record earning surprise have report positive earning surprise negative surprise other last fourquarter bring average surprise positive currently company have zack rank esp approve product portfolio investor focus primarily be kite pharma cash burn pipeline update kite pharma lead drug axicabtagene ciloleucel be currently priority review treat aggressive hodgkin lymphoma fda decision expect nov read more card kite pharma earning kite pharma inc price ep surprise kite pharma inc price ep surprise kite pharma inc plc mnk free report be set report second quarter result mallinckrodt have deliver average positive earning surprise trail quarters mallinckrodt currently carry have zack rank esp combination mallinckrodt zack rank positive esp make reasonably optimistic earning beat mallinckrodt be currently focuse reshape product portfolio strategic acquisition core asset divestiture acthar ofirmev inomax drive upside view however mallinckrodt specialty generic segment continue be laggard weakness be expect persist stiff competition continue hurt volume price read more mallinckrodt deliver beat earning season mallinckrodt plc price ep surprise mallinckrodt plc price ep surprise mallinckrodt plc quoteendo international plc endp free report be expect report second quarter open bell company have deliver positive surprise trail quarters record average positive surprise endo currently carry zack rank sell esp caution stock zack rank strong sell go earning announcement continue be challenge year endo generic base business legacy brand pain franchise be expect decline further further jul endo have withdraw opioid pain medication opana oxymorphone hydrochloride extend release market follow fda request june move come wake widespread opioid abuse epidemic read more card endo earning season endo international plc price ep surprise endo international plc price ep surprise endo international plc quote trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
3616,GILD,second quarter earning season be expect be strong index anticipate see earning growth revenue growth latest earning trend stock market be also record level however ongoing turmoil washington geopolitical risk fed related uncertainty lofty valuation bring difficulty stock season read sector etfs stock tap earning growth zack sector be expect post double digit earning growth sector lag current earning estimate be project start second quarter such volatility investor focus etfs large allocation stock have high chance surprising upcoming release result winning bet earning season find etfs handpicking etfs portfolio stock be most likely beat earning be mean task however proprietary methodology find earning esp stock calculate percentage difference most accurate estimate zack consensus estimate be solid build block uncover best stock buy sell re report earning esp filter bet etfs winning combination stock have positive earning esp favorable zack rank strong buy buy hold lead profit investor portfolio be especially true earning beat definitely draw investor attention propel stock price related etfs higher let see etfs have be select combination stock first run zack stock screener find stock positive earning esp favorable zack rank then narrow list select group stock higher positive earning esp accordingly choose etfs contain few stock higher chance beating estimate particular industry see etf category here research show stock combination chance positive earning surprise be high result trio be excellent investor seek sure profit earning season powershare dynamic leisure entertainment fund pej free report fund track dynamic leisure entertainment intellidex index hold small basket stock be pretty well spread various security hold less total asset half stock portfolio be expect come earning beat suggest solid upside etf particular american airline aal free report delta air line dal free report mcdonald mcd time warner be top holding account share have earning esp respectively aal dal have zack rank other have zack rank industry look restaurant airline take largest share pej respectively follow hotel leisure facility casino gaming etf have amassed asset base trade light volume share day average expense ratio come pej have zack etf rank high risk outlook read lie ahead leisure travel etfs ishare dow jone transportation average fund iyt free report etf provide exposure broad transportation sector tracking dow jone transportation average index hold small basket stock half have higher chance beating estimate quarter air freight logistic take top spot share basket airline railroad round top railroad company norfolk southern nsc free report union pacific unp free report kansa city southern ksu free report have earning esp respectively meanwhile alaska air group alk free report landstar system lstr free report ryder system free report have earning esp respectively have zack rank hold top position iyt fund have accumulate nearly aum see good trading volume share day charge bps fee year investor fund currently have zack etf rank sell rating high risk outlook be expect get term boost earning growth read transport etf hit new week high vaneck vector biotech etf bbh free report fund offer exposure large biotechnology corporation tracking mvis list biotech index stock portfolio be expect beat earning quarter investor note celgene celg gilead science gild have zack rank account double digit exposure basket have earning esp respectively bbh have amassed asset base charge bps fee year volume be moderate exchange share daily average have zack etf rank high risk outlook read forget big tech biotech etfs be soar higher want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
3617,GILD,plc alk free report initiate roll submission new drug application nda fda pipeline candidate alk nda seek fda approval alk adjunctive treatment major depressive disorder mdd company expect complete submission year end june initiate study phase iiib study alk adjunctive treatment mdd october fda grant fast track status alk adjunctive treatment mdd patient inadequate response standard antidepressant therapy fast track designation fda facilitate development expedite review drug be intend treat serious condition address medical need designation allow submission complete portion nda roll basis well eligibility priority review remind investor company agency have agree propose content timing alk nda submission july pre nda interaction revenue continue be drive proprietary product vivitrol aristada partner product risperdal consta invega sustenna xeplion invega trinza trevicta ampyra fampyra bydureon continue witness robust sale vivitrol medicaid commercial set expect product continue contribute company top line come quarters further have robust pipeline interesting late stage candidate company pipeline include alk major depressive disorder mdd alk schizophrenia alk multiple sclerosis meanwhile stock price have decline year date industry gain zack rank stock consideralkerme be zack rank hold stock better rank stock healthcare sector be regeneron pharmaceutical inc regn free report gilead science inc gild free report aduro biotech inc adro free report regeneron sport zack rank gilead science aduro carry zack rank buy see complete list today zack rank stock here regeneron earning share estimate have increase last day company pull positive earning surprise trail quarters average beat gilead earning share estimate increase last day company deliver positive earning surprise trail quarters average beat aduro biotech loss share estimate narrow last day company deliver positive surprise trail quarters average beat zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
3618,GILD,infinity pharmaceutical inc infi free report report loss cent share second quarter wider zack consensus estimate loss cent company have report loss cent year quarter infinity pharmaceutical inc price consensus ep surprise infinity pharmaceutical inc price consensus ep surprise infinity pharmaceutical inc quotesince infinity do not have approve product portfolio company earn revenue form royalty license milestone payment well research development support fee paid partner infinity do not record revenue second quarter however record collaboration revenue year quarter related infinity previous collaboration agreement abbvie inc abbv free report infinity share price have increase year date compare industry gain quarter detailin report quarter expense plummet decline be mainly related decrease clinical development expense duvelisib addition company restructure activity general administrative expense be report quarter year quarter decrease be mainly due company restructure activity outlook expect net loss be range company anticipate end year end cash cash equivalent available sale security balance band moreover infinity expect exist cash cash equivalent jun be adequate fund company capital need first quarter pipeline updatecurrently infinity be evaluate ipi monotherapy combination bristol myer squibb company bmy free report opdivo nivolumab phase study patient advanced solid tumor company complete evaluation escalate monotherapy dose ipi range mg qd once daily have determine mg dose evaluation expansion component study selection mentioned dose be base pharmacokinetic pharmacokinetic analysis show ipi maintain full suppression pi gamma dose level further datum study also show ipi dose mg qd be well tolerate dose limit toxicity be observed subsequently monotherapy expansion component study be now available enrolment study evaluate safety activity ipi dose qd approximately patient meanwhile dose escalation evaluate ipi combination opdivo be currently ongoing company plan initiate combination expansion component study second half other hand company amend license agreement takeda oncology jul ipi amend agreement company longer have obligation pay takeda future royalty worldwide net sale selective inhibitor pi gamma include ipi lieu infinity issue unsecured convertible note takeda mature accrue interest annual rate wider expect loss second quarter be disappointing infinity receive huge setback abbvie terminate collaboration agreement development duvelisib hence expect investor focus pipeline progress upcoming quarters zack rank key pickinfinity currently hold zack rank hold better rank stock healthcare sector be gilead science inc gild free report currently carry zack rank buy see complete list today zack rank strong buy stock here gilead earning share estimate increase last day follow strong result second quarter company deliver positive earning surprise trail quarters average beat today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3619,GILD,pharma biotech sector have picked year be batter drug pricing controversy first half have be pretty strong company space nyse arca pharmaceutical index have rise almost year date ytd decline almost last year nasdaq biotechnology index be ytd slide sector do have share challenge form rise competition high profile pipeline setback slowdown growth mature product loss exclusivity certain key drug drug pricing issue still prevail investor lately be hope steep pricing not be damage fear previously nonetheless strong performance newer drug evolve pipeline impressive clinical trial result new drug approval continue strong performance legacy product rise demand be factor promise sustain recovery sector meanwhile have be many more fda drug approval so far year total drug have gain fda approval ytd beating total whole acceleration drug approval process more innovation surge new drug approval be expect activity collaboration deal have slow year chance be pick second half president trump promising major tax reform allow company bring back cash hold overseas acquisition activity be expect pick pace then again number deal still be less pharma industry have be many year finally republican administration vow repeal replace obamacare bode well sector growth pick likely winnersgiven enormity healthcare space select stock have potential beat estimate appear be quite daunting proprietary methodology make fairly simple way narrow list choice earning season be look stock have combination favorable zack rank zack rank strong buy buy hold positive earning esp more often not positive earning surprise deliver company lead stock price appreciation earning esp be proprietary methodology identify stock have high chance surprising upcoming earning announcement show percentage difference most accurate estimate zack consensus estimate research show stock combination chance positive earning surprise be high uncover best stock buy sell re report earning esp filter here be healthcare stock be poise beat estimate second quarter accord methodology first pick be healthcare bellwether merck co inc mrk free report kenilworth nj base company have earning esp zack rank buy see complete list today zack rank strong buy stock here zack consensus estimate second quarter be cent share company have consistently top earning expectation fact merck earning surpass expectation last quarters average positive surprise merck be schedule report result jul next choice be biotech major celgene corporation celg free report carry zack rank stock have earning esp zack consensus estimate second quarter be peg share summit nj base company have pretty impressive earning surprise track record average earning surprise trail quarters be celgene be schedule announce result jul gilead science inc gild free report too have impressive track record company consistently beating earning expectation company earning surpass estimate last quarters average positive surprise look poise beat expectation second quarter well foster city base company carry zack rank have earning esp zack consensus estimate be peg share gilead be schedule report result jul seattle genetic inc sgen free report biotechnology company be solid bet zack rank stock have earning esp bothell wa base company deliver average positive earning surprise trail quarters seattle genetic be schedule release result jul zack consensus estimate second quarter peg loss cent share small company vanda pharmaceutical inc vnda free report make list likely outperformer second quarter virtue zack rank earning esp zack consensus estimate be peg loss cent share vanda be expect report result jul bottom line challenge form competitive pricing pressure remain healthcare sector however number company space have fared well pick outperformer space backed solid zack rank positive earning esp lead investor gain earning season more stock news company verge apple rundid miss apple stock explosion launch iphone now look be pivotal year get emerge technology expect rock market demand soar almost nothing report suggest save life decade turn save healthcare cost bonus zack special report name breakthrough best stock exploit apple company be already strong coil potential mega gain click see right now
3620,GILD,radius health inc rdus free report post loss share second quarter wider loss share year quarter wider zack consensus estimate loss year year increase net loss be attributable increase general administrative expense radius share price increase year date industry gain company report sale tymlos abaloparatide first week launch miss zack consensus estimate quarter detailresearch development expense report quarter be year year due decrease regulatory professional fee associate abaloparatide sc regulatory application decrase elacestrant rad project cost decrease development cost associate abaloparatide td general administrative expense report quarter jump increase be attribute growth professional support cost include cost associate increase headcount tymlos higher compensation expense include stock base compensation due increase headcount be also responsible increase cost radius health inc price ep surprise radius health inc price ep surprise radius health inc quotepipeline updateson apr fda approve radius health lead candidate tymlos injection treatment postmenopausal woman high risk osteoporosis fracture defined history osteoporotic fracture multiple risk factor fracture patient have fail be intolerant other available osteoporosis therapy company be develop formulation abaloparatide abaloparatide sc abaloparatide transdermal meanwhile radius health marketing authorisation application maa eladyno abaloparatide sc treatment postmenopausal woman osteoporosis europe be review committee medicinal product human use chmp european medicine agency company however suffer setback chmp issue second day list outstanding issue consequently radius be work chmp address issue company expect response prior end radius health announce positive top line result complete month activextend clinical trial tymlos meet primary secondary endpoint company expect submit snda fda connection activextend result year end company report positive datum ongoing phase dose escalation expansion study elacestrant advanced metastatic breast cancer company discuss datum ongoing phase study fda determine next step elacestrant breast cancer program include design phase ii trial follow discussion fda agree single arm monotherapy phase ii study patient be appropriate agency also provide additional feedback propose clinical protocol include confirmation primary endpoint be objective response rate durability response fda also state study result demonstrate superiority then available therapy single arm phase ii trial be consider pivotal study accelerate approval long company have also commence confirmatory study time new drug application nda submission addition elacestrant be also be evaluate low dose estrogen receptor ligand potential relief frequency severity moderate severe hot flash postmenopausal woman vasomotor symptom company expect report result phase iib clinical study elacestrant potential treatment postmenopausal vasomotor symptom second half company wider expect loss second quarter be disappointing expense continue increase launch tymlos company be move ahead plan contract manage care organization access cover life commercial medicare part plan osteoporosis market have great potential approximately postmenopausal woman experience osteoporotic fracture year tymlos be expect face significant competition eli lilly co lly free report forteo amgen inc amgn free report prolium moreover approve label carry box warning osteosarcoma malignant bone tumor company however suffer setback chmp issue second day list outstanding issue zack rank key pickradius health currently have zack rank sell better rank stock healthcare sector be gilead science inc gild free report currently carry zack rank buy see complete list today zack rank strong buy stock here gilead earning share estimate increase last day follow strong result second quarter company deliver positive earning surprise trail quarters average beat today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3621,GILD,regeneron pharmaceutical inc regn free report report second quarter result earning sale beat expectation back strong performance eye care drug eylea regeneron stock have gain year date outperform industry rally share be pre market trading expect share gain further momentum company report earning include impact share base compensation expense tax adjustment share second quarter beating zack consensus estimate regeneron pharmaceutical inc price consensus ep surprise regeneron pharmaceutical inc price consensus ep surprise regeneron pharmaceutical inc quoteexclude share base compensation expense regeneron earning come share report year quarter total revenue second quarter increase year year drive strong sale eye treatment drug eylea revenue be zack consensus estimate note regeneron have co develop eylea healthcare unit bayer ag bayry free report company be solely responsible sale eye drug be entitle profit however share profit loss equally bayer ex eylea sale japan company receive royalty net sale quarterly highlightsnet product sale increase report quarter year year majority sale come eylea sale eylea ex market be report year quarter revenue also include sanofi sny free report bayer collaboration revenue compare year quarter collaboration revenue sanofi be quarter compare year praluent record global net sale report quarter year quarter note praluent have be co develop collaboration sanofi product sale praluent be record sanofi whileregeneron share profit loss drug dupixent sale come drug be approve earlier treatment adult moderate severe atopic dermatitis ad expense decrease selling general administrative sg increase quarter outlook updatedbased strong first half company raise sale guidance eylea regeneron expect eylea net sale grow earlier guidance growth single digit company now expect adjust unreimbursedr expense range earlier guidance note european medicine agency committee medicinal product human use chmp render positive opinion marketing authorization dupixent recommend approval use adult moderate severe atopic dermatitis be candidate systemic therapy jul meanwhile phase iii study dupixent pediatric patient year age uncontrolled persistent asthma be initiate second quarter fda approve kevzara treatment adult patient moderately severely active rheumatoid arthritis have inadequate response intolerance more disease modify rheumatic drug dmard drug be also approve europe jun jun european commission grant marketing authorization kevzara combination methotrexate mtx treatment moderately severely active rheumatoid arthritis adult patient have respond inadequately be intolerant more dmard kevzara be used monotherapy case intolerance mtx treatment mtx be inappropriate takeregeneron second quarter result be impressive earning sale beat estimate drive strong eylea sale increase guidance be also encourage dupixent launch moderate severe atopic dermatitisis progress well potential approval eu second half further boost sale moreover company be also look expand dupixent label uncontrolled asthma zack rank key pickregeneron currently carry zack rank hold better rank stock healthcare sector be gilead science inc gild free report currently carry zack rank buy see complete list today zack rank strong buy stock here gilead earning share estimate increase last day follow strong result second quarter company deliver positive earning surprise trail quarters average beat more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
3622,GILD,aerie pharmaceutical inc aeri free report post second quarter loss cent share include stock base compensation narrower zack consensus estimate loss cent year loss cent be development stage company aerie have not generate revenue product sale yet note share aerie have rally year so far outperform industry rally quarter detailin report quarter research development expense decline company complete trial general administrative expense increase higher operate expense quarter be attribute expansion employee base support operation preparatory activity include commercial manufacturing cost rhopressa aerie pharmaceutical inc price consensus ep surprise aerie pharmaceutical inc price consensus ep surprise aerie pharmaceutical inc quotepipeline updateson feb company resubmit new drug application nda lead candidate rhopressa expect review period month note aerie withdraw rhopressa nda file september third party manufacturing facility tampa fl be not ready pre approval inspection fda company initiate preparation bring second contract manufacturer online apart rhopressa aerie be evaluate roclatan once daily quadruple action fix dose combination rhopressa pfizer inc pfe free report xalatan company report positive top line day efficacy safety datum second phase iii clinical trial mercury datum mercury be expect third quarter mercury mercury be successful nda roclatan be expect be file early company also expect commence trial mercury third quarter europe support filing trial be inferiority trial compare roclatan prescribe fix dose combination ganfort combination bimatoprost timolol market allergan plc agn free report europe meanwhile company recently inked acollaboration agreement dsm primary focus potential aerie compound treat retinal disease narrower expect loss second quarter be encourage be encourage company effort develop pipeline candidate potential approval rhopressa early significantly boost growth prospect zack rank other key pickaerie currently carry zack rank buy top rank stock healthcare sector be gilead science inc gild free report currently carry zack rank see complete list today zack rank strong buy stock here gilead earning share estimate increase last sevenday follow strong result second quarter company deliver positive earning surprise trail quarters average beat share price company have increase year date more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
3623,GILD,major biotech stock gilead gild free report celgene celg free report alexion abbvie abbv free report vertex vrtx free report report second quarter result last few day company gilead amgen amgn free report also provide regulatory update recap week most important storiesa look earning result gilead result be strong company hiv franchise putt strong performance hepatitis virus hcv franchise perform better expect company raise revenue outlook include hcv franchise read more gilead top earning revenue estimate stock celgene also top estimate raise earning guidance year read more celgene beat earning sale estimate up view do alexion read more alexion top earning revenue up view vertex read more vertex earning top solid cystic fibrosis sale abbvie too top expectation read more abbvie top earning revenue outlook intact earlier expect fda approval celgene agio cancer drug celgene partner agio agio free report gain fda approval idhifa enasidenib treatment adult patient relapse refractory acute myeloid leukemia aml idh mutation detected fda approve test approval come ahead fda action date aug make idhifa first only fda approve therapy patient population represent aml patient information provide company more new case aml be detected year majority patient see disease relapse eventually prognosis aml be poor overall survival patient population estimate be less month idhifa come box warning regard differentiation syndrome uptake be strong give significant unmet medical need be third time lucky dynavax heplisav dynavax dvax free report share shot favorable recommendation fda vaccine related biological product advisory committee vrbpac heplisav vaccine immunization hepatitis infection adult positive vote expectation be high company finally gain approval vaccine have previously receive complete response letter nov other feb decision agency be expect aug approve dynavax plan launch vaccine early next year dynavax share be whopping year date significantly outperform industry rally read more dynavax share jump fda committee approval vertex up cf outlook kalydeco label expansion vertex cystic fibrosis cf drug kalydeco label have be expand now be used more cf patient year older have residual function mutation result splice defect cystic fibrosis transmembrane conductance regulator cftr gene label expansion vertex up sale guidance drug old guidance vertex now expect total cf product revenue old guidance include orkambi sale unchanged regulatory update amgen gilead amgen provide quite few regulatory update last few day company say have submit regulatory application seek label expansion prolium treatment patient glucocorticoid induced osteoporosis giop prolium bring sale first half amgen partner allergan also say have file fda approval abp biosimilar candidate roche herceptin trastuzumab herceptin be approve treatment adjuvant breast cancer metastatic breast cancer metastatic gastric cancer meanwhile amgen pcsk inhibitor repatha get priority review inclusion fourier cardiovascular outcome study datum reduction risk cardiovascular event decision agency be expect dec amgen say second application expansion lipid lower indication include additional patient population study be also accept agency gilead also have update regulatory front company say hcv drug epclusa label be update include use patient co infected hiv epclusa initially gain approval jun be oral pan genotypic once daily single tablet regimen label expansion provide co infected patient convenient pill day regimen work hcv genotype be compatible widely used antiretroviral regimen epclusa sale crossed first half moreover gilead latest hcv offer vosevi gain approval eu treatment genotype marketing authorization harvoni eu be also extend allow use adolescent population vosevi be approve few week back july gilead be zack rank buy stock see complete list today zack rank strong buy stock here biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock alexion gain regeneron lose last month vertex be see last biotech stock roundup here amgen biogen top estimate update incyte ra drug next biotech world watch earning report company biomarin regeneron other more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
3624,GILD,abbvie inc abbv free report announce pan genotypic regimen glecaprevir pibrentasvir mavyret have be approve canada treat chronic hepatitis virus hcv infection major genotype gt be important note ribavirin free mavyret recently gain approval unite state eu combination medicine be priority review japan same indication abbvie share have marginally outperformed industry so far year stock have rally compare broader industry increase approval canada be backed datum registration study abbvie clinical development program clinical trial be conduct more patient major hcv genotype datum study show week treatment achieve cure rate major genotype chronic hcv significantly glecaprevir gle be potent protease inhibitor pibrentasvir pib be new ns inhibitor glecaprevir be discover collaboration agreement enanta pharmaceutical enta free report hcv protease inhibitor company press release canadian be chronically infected hcv more new case hepatitis be report approximately patient estimate be unaware disease also gt be most common genotype canada gt be most difficult treat cure hence drug approval be expect provide company access market huge potential remind investor gilead science inc gild free report launch epclusa first oral pan genotypic single tablet regimen treat adult genotype hcv infection unite state eu last year lend strong competition mavyret not inform merck co inc mrk free report be also evaluate oral triple combination therapy mk mix mk grazoprevir ruzasvir treatment chronic hcv genotype gt infection pricing pressure hcv market be increase company say experience market share loss price erosion due competitive dynamic hcv arena downturn continue year viekira hcv treatment sale expect decline abbvie inc priceabbvie inc price abbvie inc quotezack rankabbvie currently carry zack rank hold see complete list today zack rank strong buy stock here surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
3625,GILD,gilead science inc gild free report announce health canada have grant notice compliance single tablet regimen vosevi sofosbuvir mg velpatasvir mg voxilaprevir mg treatment chronic hepatitis virus hcv infection vosevi have be approve treatment hcv infection adult genotype previously treat ns inhibitor contain regimen genotype previously treat sofosbuvir contain regimen ns inhibitor drug be already approve gilead be know presence hcv market blockbuster hcv drug sovaldi harvoni hcv portfolio receive huge boost epclusa gain approval jun eu jul become first only oral pan genotypic str consist sovaldi velpatasvir ns inhibitor treatment adult genotype chronic hcv infection approval voseviwill further boost gilead strong hcv portfolio however hcv franchise be pressure result competition pricing issue note harvoni sovaldi epclusa face competition abbvie abbv free report viekira pak viekira xr bristol myer bmy free report daklinza other competition well pricing pressure intensified further launch merck mrk free report zepatier gilead stock have moved year so far compare industry gain meanwhile hiv franchise maintain momentum drive rapid adoption taf base regimen eu now represent total prescription volume genvoya be now company bestselling hiv product treatment naïve patient share strong uptake truvada use pre exposure prophylaxis set be expect further boost sale however gilead lose exclusivity viread country outside impact sale zack rank gilead currently carry zack rank buy see complete list today zack rank strong buy stock here surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
3626,GILD,intercept pharmaceutical inc icpt free report report loss share second quarter narrower zack consensus estimate loss wider year loss quarterly revenue be significantly year quarter beat zack consensus estimate intercept share price movement year so far indicate stock have underperform industry company share have gain period lower industry gain quarter detailocaliva record sale second quarter sale first quarter note ocaliva be approve combination ursodeoxycholic udca treatment primary biliary cholangitis pbc adult inadequate response udca monotherapy adult be unable endure udca drug be also grant conditional approval european commission dec sale market come record first quarter prescription continue grow steadily revenue international market be drive mainly sale germany france research development expense increase year year primarily drive increase clinical development program oca infrastructure support such program selling general administrative expense increase year quarter drive expense related ocaliva activity additional personnel related cost support commercial international initiative outlook expect operate expense be range company believe continue ocaliva pbc unite state other market sustain clinical development oca pbc nash continue advancement int other pipeline program be likely drive growth demand third quarter however reflect typical summer trend be expect pick again fourth quarter pipeline updateocaliva be be evaluate other indication include alcoholic steatohepatitis nash primary sclerosing cholangitis psc concurrent second quarter earning intercept announce trial result phase ii trial control combination oca andstatin monitoring lipid aesop psc control study be be conduct evaluate effect ocaliva combination statin therapy lipid metabolism patient nash result aesop reveal oca meet primary endpoint statistically significant reduction alkaline phosphatase alp result control show company achieve objective demonstrate lowest available dose atorvastatin rapidly reverse oca associate ldl change baseline level nonalcoholic steatohepatitis nash patient fibrosis cirrhosis fda have earlier approve redesign phase iii trial regenerate ocaliva safety efficacy treat nash patient liver fibrosis company now need achieve only co primary endpoint fibrosis improvement nash resolution compare earlier target achieve sample size trial have also be reduce approximately patient patient arm company complete enrolment interim analysis cohort regenerate trial datum readout first half company also plan initiate phase iii trial ocaliva nash patient cirrhosis second half company also initiate phase ii trial candidate int nash patient fibrosis second half company also continue enrol phase iv trial cobalt confirm ocaliva clinical benefit outcome pbc exelixis inc price ep surprise exelixis inc price ep surprise exelixis inc quoteour second quarter result be encourage company reporteda narrower expect loss beat revenue demand ocalivais steadily increase expect sale drug pick further international demand pick second half however expense be expect rise company plan invest commercial activity related ocaliva remind investor other company novartis ag nvs free report gilead science inc gild free report have fxr agonist phase ii earlier stage clinical preclinical development canbe used treat pbc nash other liver disease zack rank key currently carry zack rank hold better rank stock healthcare sector be exelixis inc exel free report currently carry zack rank strong buy see complete list today zack rank stock here exelixis earning share estimate inched cent cent last day company have deliver positive earning surprise trail quarters average beat make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3627,GILD,earning season be fly start almost company have surpass expectation performance have be quite impressive biotech company major player beating market estimate president donald trump failure implement healthcare bill be positive biotech space read biotech etfs continue surge higher week major biotech player announce quarterly result amgen inc amgn free report gilead science gild free report biogen inc biib free report alexion pharmaceutical alxn free report beat earning revenue estimate read forget big tech biotech etfs be soar higher earning focusamgen report second quarter adjust earning share july beating zack consensus estimate increase more share year quarter moreover also beat consensus estimate revenue front company report revenue surpass consensus estimate increase year quarter company update full year gaap ep guidance range also update revenue guidance range company share lose market close july update guidance fall short analyst expectation gilead science report second quarter adjust earning share july beating zack consensus estimate decrease more share year quarter moreover also beat consensus estimate revenue front company report revenue surpass consensus estimate decrease more year quarter company update full year revenue guidance range company share gain market close july owing ep revenue beat biogen inc report second quarter adjust earning share july beating zack consensus estimate decrease more share year quarter company report revenue surpass consensus estimate increase roughly year quarter company update full year gaap ep guidance range also increase revenue guidance company share gain more pre market trading due better expect result close lower july alexion pharmaceutical inc report second quarter adjust earning share july beating zack consensus estimate increase roughly share year quarter company report revenue surpass consensus estimate increase roughly year quarter company update full year gaap ep guidance range increase revenue guidance company share be market close july primarily due better expect result now discuss few etfs high exposure company discuss ishare nasdaq biotechnology etf ibb free report fund seek provide exposure biotech industry have aum charge fee basis point year fund have exposure biogen gilead amgen alexion july fund have return last year year date july currently have zack etf rank buy high risk outlook read kite pharma be revolutionize fight cancer vaneck vector biotech etf bbh free report fund have aum charge fee basis point year fund have exposure amgen gilead biogen alexion july fund have return last year year date july currently have zack etf rank high risk outlook read reason biotech etfs be soar ultra nasdaq biotechnology etf bib free report fund have aum charge fee basis point year fund have exposure biogen gilead amgen alexion july fund have return last year year date july want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
3628,GILD,unite therapeutic corporation uthr free report report adjust earning share include stock base compensation benefit exclude charge second quarter be better share year quarter unite therapeutic say have set aside potential settlement department justice doj resolve investigation related contribution profit organization provide financial assistance patient thereby violate federal security law quarter company record charge estimate loss contingency relation matter also record impairment charge related cost method investment privately hold company experience event trigger impairment analysis include charge stock base compensation benefit company incur loss share miss zack consensus estimate revenue report quarter rise year year beat zack consensus estimate stronger sale pulmonary arterial hypertension pah franchise pull top line quarter better expect sale performance share decline almost thursday response potential settlement expense look unite therapeutic share price movement show stock have underperform industry year so far unite therapeutic stock have decline period industry rise quarter detailunite therapeutic market product treatment pah remodulin tyvaso adcirca orenitram orenitram report sale quarter year year adcirca sale be year year tyvaso sale totale year year remodulin sale be year year however sale tyvaso remodulin improve sequentially quarter unituxin treatment pediatric patient high risk neuroblastoma sale be year year lately growth unite therapeutic pah drug orenitram tyvaso remodulin have slow due competition last quarter company have say patient be stay longer front line oral ambition therapy adcirca gilead science inc gild free report letairis delay transition inhaled injectable therapy tyvaso remodulin thereby hurt demand meanwhile drug be also face strong competition actelion now part johnson johnson jnj free report new drug uptravi selexipag initial treatment pah be typically orally deliver drug follow prostacyclin therapy first quarter earning call management have say longer use oral therapy result large backlog patient eligible prostacyclin therapy pah medicine suggest sale trend improve sale tyvaso remodulin orenitram improve second quarter first quarter level management believe be see early sign transition ambition regimen back pah drug research development expense include stock base compensation benefit increase due higher cost support pipeline cardiopulmonary cancer drug develop organ manufacturing project selling general administrative sg expense include stock base compensation benefit decline lower consult marketing cost offset higher legal cost pipeline updateunited therapeutic be work medical device maker medtronic inc mdt free report get implantable pump deliver remodulin remosynch approve fda order launch remosynch unite therapeutic medtronic be pursue parallel regulatory filing related device drugwe remind investor april unite therapeutic announce regulatory issue delay plan launch remosynch company now expect launch remosynch sometime first half year expect previously unite therapeutic be also work deka development pre filled semi disposable pump system subcutaneous delivery remodulin remunity launch expect clinical study remopro pain free new chemical entity version treprostinil be expect begin year other phase iii pipeline program include oral combination therapy orenitram oreniplus freedom ev study tysuberprost esuberaprost combination tyvaso tyvaso ild tyvaso be evaluate patient pah associate idiopathic pulmonary fibrosis orenileft pah left ventricular diastolic dysfunction unite therapeutic be also develop dinutuximab active ingredient unituxin small cell lung cancer phase iii other high risk form cancer gd express cell tumor such ovarian cancer several sarcomas unite therapeutic carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3629,GILD,year jul world hepatitis day whd be observed raise awareness viral hepatitis lead cause death world accord world health organization viral hepatitis cause death world many person remain unaware be infected same be type hepatitis hepatitis be main killer person live hepatitis person live hepatitis person live hepatitis live hepatitis be unaware status hepatitis together account liver cancer case world consider number be not surprise quite few pharma biotech company be work bring innovative treatment area market however challenge hepatitis virus hcv market exist form intense competition pricing pressure stock focushere be look key player hepatitis market biotech major gilead science inc gild free report be perhaps most well know name hcv market hcv drug include harvoni sovaldi epclusa recently approve vosevi hbv offering include viread vemlidy however foster city base company have see lot up down market gilead hcv franchise be major revenue contributor bring multus dollar sale increase competition pricing pressure result significant decline hcv product sale even gilead recently raise guidance hcv franchise sale be nevertheless expect witness significant decline gilead launch educational campaign encourage baby boomer get test accord company have be increase hcv antibody screening baby boomer campaign start result increase diagnosis well company estimate person be newly diagnosed hcv gilead be conduct additional study harvoni well vemlidy have early stage hbv candidate pipeline gs tlr agonist gilead be zack rank buy stock year date ytd company stock be lag rally industry belong see complete list today zack rank strong buy stock here large cap pharma company merck co inc mrk free report be big name hcv market accord information provide merck person have chronic hcv infection merck hcv portfolio comprise zepatier be launch last year pegintron victreli however company hcv franchise be not major revenue generator earlier year merck take major impairment charge related hcv candidate become part pipeline follow acquisition idenix decision be take base change product profile well change company expectation pricing market opportunity merck be zack rank stock ytd company stock be lag rally industry belong abbvie inc abbv free report also have major presence hcv market company hcv product include viekira pak technivie abbvie be currently seek approval maviret investigational pan genotypic regimen glecaprevir pibrentasvir once daily ribavirin free treatment have potential provide faster path virologic cure major hcv genotype gt maviret represent blockbuster potential help abbvie gain major market share once approve launch abbvie be zack rank hold stock abbvie stock have gain ytd perform better industry belong watertown base enanta pharmaceutical inc enta free report have collaboration abbvie protease inhibitor paritaprevir glecaprevir paritaprevir be key compound abbvie direct act antiviral daa regimen viekira pak other daa daa treatment regimen currently market hcv glecaprevir combination pibrentasvir maviret be currently regulatory review enanta earn royalty abbvie product sale meanwhile enanta be also work develop hbv pipeline focus be currently core inhibitor clinical candidate identification plan enanta be zack rank stock ytd enanta stock have gain outperform rally industry belong bottom linethe hcv market continue face challenge more treatment enter market result increase competition additional pricing pressure fact hcv drug have face immense scrutiny due high price say market nevertheless represent significant commercial opportunity information provide enanta market hcv therapy be worth hcv patient start usually witness surge follow introduction new drug market major part hcv infected person remain undiagnosed remain significant opportunity market awareness increase newly diagnosed patient seek treatment hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3630,GILD,pfizer inc pfe free report announce leukemia candidate besponsa inotuzumab ozogamicin have be approve fda box warning label pfizer share be more thursday so far year pfizer share be compare unfavorably increase industry besponsa have be approve monotherapy treatment relapse refractory cd positive cell precursor acute lymphoblastic leukemia drug be approve eu last month approval be base datum pivotal study ino vate demonstrated patient treat besponsa show significant improvement complete response besponsa arm versus chemotherapy thereby meeting primary endpoint study however fail reach statistical significance analysis overall survival os median os besponsa arm be month versus month patient treat chemotherapy importantly label drug include box warning hepatotoxicity liver damage include hepatic veno occlusive disease vod label also have warning related increase risk relapse mortality patient take medicine post hematopoietic stem cell transplantation hsct remind investor inotuzumab ozogamicin be grant breakthrough therapy designation meanwhile pfizer boast strong oncology pipeline key cancer candidate bavencio avelumab receive fda approval metastatic merkel cell carcinoma mcc mar advanced bladder cancer bavencio be review eu mcc decision expect third quarter bavencio be be tout significant top line driver new york base pharma giant meanwhile pfizer be explore possibility expand label breast cancer drug ibrance recurrent subsequent early breast cancer well several breast cancer indication pancreatic head neck cancer other cancer candidate include talazoparib advanced breast cancer dacomitinib advanced lung cancer egfr activate mutation conference call pfizer have mentioned approximately drug approval be expect next year include product have blockbuster potential pfizer carry zack rank hold see complete list today zack rank strong buy stock here stock considerbetter rank stock pharma biotech space include regeneron pharmaceutical inc regn free report sanofi sny free report gilead science inc gild free report regeneron sport zack rank strong buy sanofi gilead have zack rank buy regeneron share year so far estimate have rise have go past day share sanofi be year date estimate have rise respectively past day share gilead have rise so far year estimate have rise almost respectively past day surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
3631,GILD,regeneron pharmaceutical inc regn free report announce disappointing result phase iii study nursery pre term suptavumab regn antibody respiratory syncytial virus rsv study be initiate complete enrolling patient first quarter double blind placebo controlled global study enrolled healthy pre term infant patient be randomize ratio study group suptavumab mg kg single dose suptavumab mg kg administer dose week apart placebo pre term infant study have gestational age less week be month old younger begin study study do not meet primary endpoint prevent medically attend rsv infection infant fda grant fast track designation suptavumab prevention serious lower respiratory tract disease cause rsv however regeneron plan discontinue further clinical development antibody give dismal result nursery study remind investor company rely heavily funding sanofi sny free report immuno oncology research development program however sanofi have earlier decide not continue co development fasinumab suptavumab trevogrumab regeneron stock have gain year date outperform industry rally meanwhile regeneron second quarter result be impressive earning sale beat estimate back strong eylea sale grab additional market share regeneron key growth driver eylea continue drive revenue company be expand drug label additional indication increase guidance be also encourage regeneron have co develop eylea healthcare unit bayer ag bayry free report fda approval dupixent be major boost company portfolio company be work expand label regeneron pharmaceutical inc price consensus regeneron pharmaceutical inc price consensus regeneron pharmaceutical inc quotezack rank regeneron currently carry zack rank strong buy top rank stock healthcare sector be gilead science inc gild free report currently carry zack rank buy see complete list today zack rankstock here gilead earning share estimate increase last day follow strong result second quarter company deliver positive earning surprise trail quarters average beat hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionary still leave plenty money regular investor make right trade early see zack best stock play trend
3632,GILD,similar wise buy decision exit certain underperformer right time help maximize portfolio return selling loser be difficult share price estimate be fall be time get rid security more loss hit portfolio such stock want consider drop be mylan myl free report have witness significant price decline past week have see negative earning estimate revision current quarter current year zack rank strong sell further confirm weakness myl key reason move have be negative trend earning estimate revision full year have see estimate move past day compare upward revision trend have cause consensus estimate trend lower go share month current level also current quarter mylan have see downward estimate revision versus revision opposite direction drag consensus estimate share past day stock also have see pretty dismal trading lately share price have drop past month mylan price consensus mylan price consensus mylan quoteso not be good decision keep stock portfolio anymore least don have long time horizon be still interested health care sector instead consider better rank stock gilead science inc gild free report stock currently hold zack rank buy be better selection time see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3633,GILD,earning season draw close focus be back pipeline regulatory update regeneron pharmaceutical regn free report have several pipeline catalyst line second half year report datum late stage pipeline candidate gilead science gild free report get priority review investigational hiv treatment recap week most important shelve rsv antibody study failure regeneron investigational antibody suptavumab regn respiratory syncytial virus rsv fail meet primary endpoint late stage study conduct infant regeneron have decide not continue development candidate regeneron have several pipeline catalyst line second half year later quarter company expect report top line phase iii datum dupixent asthma positive datum allow company go ahead filing fourth quarter important datum readout schedule second half year be company pd antibody regn cutaneous squamous cell carcinoma cscc second most common skin cancer basal cell carcinoma second deadliest skin cancer melanoma meanwhile eylea be be evaluate combination nesvacumab top line datum phase ii study wet age related macular degeneration diabetic macular edema expect fourth quarter year regeneron be zack rank strong buy stock see complete list today zack rank stock here priority review gilead hiv drug gilead gain priority review investigational fix dose combination bictegravir mg bic novel investigational integrase strand transfer inhibitor insti emtricitabine tenofovir alafenamide mg ftc taf dual nrti backbone treatment hiv gilead have used priority review voucher time filing regulatory application combination gain priority review response fda be feb combination be review eu well gilead hiv franchise be major contributor sale approve drug genvoya truvada atripla stribild descovy odefsey complera bring sale first half gilead share be year date lag industry rally also read gilead nda hiv combo regimen get priority review late stage failure ophthotech eye drug ophthotech opht free report be focuse development treatment eye disease announce fovista fail meet primary endpoint late stage study superiority study be evaluate fovista pdgf therapy combination eylea avastin bevacizumab vegf therapy compare eylea avastin monotherapy treatment wet age related macular degeneration amd study fail achieve primary endpoint company have anyway attribute low likelihood success study give fovista earlier failure phase iii study well failure mid stage study conduct competitor pdgf inhibitor vegf inhibitor combination amd ionis retain full right inotersen ionis fb lrx ionis pharmaceutical ion free report say glaxo have decline option drug inotersen ionis fb lrx keep decision reprioritize pipeline review rare disease business company however continue collaborate ionis ionis hbvrx ionis hbv lrx be be evaluate hepatitis virus hbv infection ionis retain right investigational drug company layer plan say be filing approval inotersen follow launch initial indication inotersen have be design treat patient ttr amyloidosis attr be expect be treatment patient polyneuropathy due hereditary ttr amyloidosis hattr pn ionis say be consider set commercial subsidiary commercialize co commercialize inotersen north america company be evaluate other option well include partnership deal meanwhile ionis fb lrx be slate move mid stage study patient dry age related macular degeneration amd later year also read ionis pharmaceutical retain right inotersen stock galapago ipf datum galapago nv glpg free report share be positive datum mid stage study company investigational idiopathic pulmonary fibrosis ipf drug glpg halter disease progression ipf patient study be first autotaxin inhibitor show effect ipf study galapago now intend move candidate late stage study be already discussion regulator regard study design galapago datum come shortly fibrogen investigational ipf drug pamrevlumab fared well mid stage study well combination safety sub study pamrevlumab be connective tissue growth factor ctgf antibody ipf market represent huge commercial potential ipf abnormal scarring lung be rare serious lung disease survival rate comparable deadliest cancer currently approve ipf drug include esbriet ofev biomedical genetic industry yr returnmedical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock regeneron be slightly celgene celg free report lose last month vertex vrtx free report be biogen slip see last biotech stock roundup here earning regeneron kite more fibrogen ipf datum next biotech world second quarter earning season come end watch usual regulatory pipeline update hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3634,GILD,gilead science inc gild free report report result second quarter earning revenue surpass expectation second quarter earning include impact stock base compensation expense share beat zack consensus estimate however earning be year quarter figure moreover total revenue report quarter be top zack consensus estimate however revenue decline year year share be market hour trading follow release second quarter result however share gilead have underperform zack classify industry year so far stock gain period compare industry gain hiv impress yet againproduct sale come year year decline be due lower hepatitis virus hcv sale partially offset higher sale hiv other therapeutic area antiviral product sale include gilead hiv liver disease portfolio come report quarter hcv product sale include harvoni sovaldi recently launch epclusa be report year quarter downside be mainly attribute lower sale harvoni sovaldi major market partially offset sale epclusa launch various location sale harvoni decline year year report quarter decline be mainly due lower sale europe further sovaldi sale record steep year year decline epclusa garner sale report quarter lower prior quarter figure note epclusa be launch europe june jul respectively meanwhile hiv hbv product sale come year year increase be primarily drive continuous strong uptake tenofoviral afenamide taf base product such genvoya generate sale year quarter descovy record sale odefsey register sale hiv treatment stribild complera eviplera sale decline viread sale be atripla sale tank truvada sale fall other product letairis ranexa zydelig record sale respectively research development expense decline due purchase nimbus apollo inc food drug administration fda priority review voucher other hand selling general administrative sg expense be roughly flat adjust product gross margin be year period guidance updatedbased better expect performance first half specifically gilead raise guidance gilead now expect net product sale range provide earlier hcv product sale be project earlier projection hcv product sale be project earlier projection adjust expense adjust sg expense be now project range respectively adjust product gross margin be expect range earning share be now project cent earlier projection cent dividend share gilead declare cash dividend cent share common stock third quarter dividend be payable sep stockholder record close business sep second quarter company paid cash dividend repurchase share gilead science inc price ep surprise gilead science inc price ep surprise gilead science inc quoteour better expect performance second quarter be drive positive trend hcv business better expect result hcv business market share particularly due rapid uptake epclusa hcv franchise be boost fda approval vosevi hcv patient start first month be better company expectation company however expect gradual decline second half year market start due increase competition note harvoni sovaldi epclusa face competition abbvie inc abbv free report viekira pak viekira xr bristol myer squibb company bmy free report daklinza other meanwhile hiv franchise maintain momentum drive rapid adoption taf base regimen eu taf base regimen now represent total gilead hiv prescription volume follow launch genvoya launch odefsey descovy genvoya be now company bestselling hiv product treatment naïve patient share strong uptake truvada use pre exposure prophylaxis set be alsoexpect toboost sale company see significant uptick prep usage estimate patient used truvada end second quarter however gilead lose exclusivity viread country outside impact sale zack rank key pickgilead currently carry zack rank hold better rank stock healthcare sector be exelixis inc exel free report currently sport zack rank strong buy see complete list today zack rank stock here exelixis have deliver positive earning surprise trail quarters average beat exelixis share have soar so far year more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
3635,GILD,gilead science gild free report just release second quarter financial result post gaap diluted earning revenue currently gild be zack rank hold be share trading shortly earning report be release gilead beat earning estimate gilead report gaap diluted earning share gaap diluted earning share adjust stock option expense company post earning share beating zack consensus estimate beat revenue estimate company see revenue figure crush consensus estimate total product sale come quarter royalty contract other revenue totale revenue be prior year quarter antiviral product sale include sale hiv chronic hepatitis hbv chronic hepatitis hcv product totale same period last year slump unit be due lower sale hcv product sale hiv hbv product actually grow year year research development expense come be last year gilead update full year guidance company now expect revenue range previously announce range here graph look gilead recent earning performance gilead science inc price consensus ep surprise gilead science inc price consensus ep surprise gilead science inc quotegilead science inc be independent company seek provide accelerate solution patient person care have broad base focus develop marketing drug treat patient infectious disease include viral infection fungal infection bacterial infection specialize focus cancer check back later full analysis gild earning report want more stock market analysis author make sure follow ryan_mcqueeney twitter hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionary still leave plenty money regular investor make right trade early see zack best stock play trend
